

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:48:15 ; Search time 1 Seconds  
(without alignments)  
1.148 Million cell updates/sec

Title: US-09-745-763-35  
Perfect score: 1851  
Sequence: 1 GGCTAGCCGCGAGCTTAGT.....CTGAAAAA.....1851

Scoring table: IDENTITY NUC  
Gapop 10.0, Gapext 0.5

Searched: 19 seqs, 310 residues

Total number of hits satisfying chosen parameters: 38

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 19 summaries

Database : rst35.seq:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	18.8	1.0	22	1	CA587453 ACCESSION:CA587453
C 2	17	0.9	22	1	CR786821 ACCESSION:CR786821
C 3	16.4	0.9	18	1	AJ725584 ACCESSION:AJ725584
C 4	16	0.9	16	1	CR786853 ACCESSION:CR786853
C 5	16	0.9	18	1	CR786637 ACCESSION:CR786637
C 6	15.4	0.8	20	1	AZ352278 ACCESSION:AZ352278
C 7	15	0.8	16	1	CR786609 ACCESSION:CR786609
C 8	14.8	0.8	19	1	AJ650841 ACCESSION:AJ650841
C 9	13.4	0.7	15	1	CF291030 ACCESSION:CF291030
C 10	13.4	0.7	15	1	CR789161 ACCESSION:CR789161
C 11	13.4	0.7	16	1	AJ569544 ACCESSION:AJ569544
C 12	13.4	0.7	16	1	AJ592205 ACCESSION:AJ592205
C 13	12.8	0.7	16	1	RA937877 ACCESSION:RA937877
C 14	12.4	0.7	14	1	CF301021 ACCESSION:CF301021
C 15	12	0.6	12	1	AJ739036 ACCESSION:AJ739036
C 16	11.8	0.6	15	1	BM658732 ACCESSION:BM658732
C 17	11.4	0.6	13	1	AJ655484 ACCESSION:AJ655484
C 18	11.4	0.6	13	1	CF291168 ACCESSION:CF291168
C 19	11.4	0.6	14	1	AJ600105 ACCESSION:AJ600105

ALIGNMENTS

RESULT 1  
CA587453/c CA587453 22 bp mRNA linear EST 12-JAN-2004  
LOCUS LBE12P58 cDNA from mouse aorta Mus musculus cdna, mRNA sequence.  
DEFINITION CA587453  
ACCESSION CA587453  
VERSION CA587453.1 GI:40792715  
KEYWORDS EST.  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus

REFERENCE  
AUTHORS Borang, S., Anderson, T., Thelin, A., Odeberg, J. and Lundberg, J.  
TITLE Vascular gene expression in atherosclerotic plaque prone regions  
analysed by representational difference analysis  
JOURNAL Unpublished (2002)  
COMMENT Contact: Andersson Tove  
Department of Biotechnology  
KTH  
Teknikringen 34, plan 6, 100 44 Stockholm, Sweden  
Tel: +46 8 790 71 29  
Fax: +46 8 245452  
Email: tovebiochem.kth.se  
Representations (amplified cDNA) from plaque prone regions  
Seq primer: CTA TGA CCA TGA TTA CGC CAA G.  
Location/Qualifiers

FEATURES  
source

1..22  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="ApoE-/- and LDLR-/- on C57BL/6x 129 background"  
/db\_xref="taxon:10090"  
/sex="male"  
/dev\_stage="8 weeks old"  
/clone\_lib="cDNA from mouse aorta"  
/notes="Organ: aorta; Site 1: DpnII; Site 2: DpnII; CDNA was prepared from whole aorta divided in atherosclerotic plaque prone regions (aortic arch and abdominal aorta proximal part) and less plaque prone regions (descending thoracic aorta and abdominal aorta distal part). CDNA was fragmented with DpnII, linker ligated and amplified to generated starting material for representational difference analysis (RDA). The two cDNA pools were subjected to iterative RDA subtraction and amplification to enrich for gene fragments differentially expressed at early stages of atherosclerosis."

Query Match 1.0%; Score 18.8; DB 1; Length 22;  
Best Local Similarity 90.9%; Pred. No. 1.3;  
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 900 TCCTTCAACTCTGACGAGAGA 921  
Db 22 TCCTTCAACTCTGACGAGAGA 1

RESULT 2

CR786821 22 bp mRNA linear EST 01-OCT-2004  
DEFINITION DKFZp468F2431 r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone  
LOCUS DKFZp468F2431 5', mRNA sequence.  
ACCESSION CR786821  
VERSION CR786821.1 GI:53705818  
KEYWORDS EST.  
SOURCE Pongo pygmaeus (orangutan)  
ORGANISM Pongo pygmaeus  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.  
REFERENCE 1 (bases 1 to 22)  
AUTHORS Koehrer, K., Beyer, A., Mewes, H.W., Weil, B., Amid, C., Osanger, A.,  
Fobo, G., Han, M. and Wiemann, S.  
TITLE Pongo pygmaeus mRNA (Koehrer, K., Beyer, A., Mewes, H.W., et al.)  
JOURNAL Unpublished (2004)  
COMMENT Contact: MIPS

MIPS  
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany  
This is the 5' sequence of the clone insert. Clone from S. Wiemann,  
Molecular Genome Analysis, German Cancer Research Center (DKFZ);  
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,  
Germany. Please contact RZPD for ordering:  
http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468F2431  
Further information about the clone and the sequencing project is  
available at http://mips.gsf.de/projects/cdna/.

```

FEATURES
source
  Location/Qualifiers
    1..22
      /organism="Pongo pygmaeus"
      /mol_type="mRNA"
      /db_xref="taxon:9600"
      /clone="DKFZp468F2431"
      /tissue_type="heart"
      /dev_stage="adult"
      /lab_host="DH10B"
      /notes="Vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match
Best Local Similarity 0.9%; Score 17; DB 1; Length 22;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1834 TGAAGAAAAAAGAAAAA 1850
Db 6 GAAAAAAGAAAAA 22

RESULT 3
AJ725584
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Gallus gallus
  Gallus gallus (chicken)
  Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
  Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
  Phasianinae; Gallus.
REFERENCE
  1 (bases 1 to 18)
  Caldwell, R.B., Kierzek, A.M., Arakawa, H., Bezzubov, Y., Zaim, J.,
  Fiedler, P., Kutter, S., Blagodatski, A., Kostovska, D., Koter, M.,
  Plachy, J., Carninci, P., Hayashizaki, Y. and Buerstedde, J.M.
  Full-length cDNAs from bursal lymphocytes to facilitate gene
  function analysis
  Unpublished (2004)
  Contact: Caldwell RB
  GSf - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie
  Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.

FEATURES
source
  Location/Qualifiers
    1..18
      /organism="Gallus gallus"
      /mol_type="mRNA"
      /db_xref="taxon:9031"
      /clone="2c16r4"
      /cell_type="bursal lymphocyte"
      /dev_stage="2-3 weeks old"
      /clone_lib="rikenl"
      /notes="CB inbred strain"

Query Match
Best Local Similarity 0.9%; Score 16.4; DB 1; Length 18;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1833 TGAAGAAAAAAGAAAAA 1850
Db 1 TCAAGAAAAAAGAAAAA 18

RESULT 4
CR786853
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Pongo pygmaeus (orangutan)
  Pongo pygmaeus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE
  1 (bases 1 to 18)
  Koehrer, K., Beyer, A., Mewes, H.W., Weil, B., Amid, C., Osanger, A.,
  Fobo, G., Han, M. and Wiemann, S.
  Pongo pygmaeus mRNA (Koehrer, K., Beyer, A., Mewes, H.W., et al.)
  Unpublished (2004)
  Contact: MIPS
  MIPS
  Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
  This is the 5' sequence of the clone insert. Clone from S. Wiemann,
  Molecular Genome Analysis, German Cancer Research Center (DKFZ);
  Email s.wiemann@kfz-heidelberg.de; mforschung GmbH in Berlin,
  Germany. Please contact RZPD for ordering:
  http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468J2331
  Further information about the clone and the sequencing project is
  available at http://mips.gsf.de/projects/cdna/.

FEATURES
source
  Location/Qualifiers
    1..18
      /organism="Pongo pygmaeus"
      /mol_type="mRNA"
      /db_xref="taxon:9600"
      /clone="DKFZp468J2331"
      /tissue_type="heart"
      /dev_stage="adult"

```

---

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
1 (bases 1 to 16)
Koehrer, K., Beyer, A., Mewes, H.W., Weil, B., Amid, C., Osanger, A.,
Fobo, G., Han, M. and Wiemann, S.
Pongo pygmaeus mRNA (Koehrer, K., Beyer, A., Mewes, H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@kfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468E2231
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.

FEATURES
source
  Location/Qualifiers
    1..16
      /organism="Pongo pygmaeus"
      /mol_type="mRNA"
      /db_xref="taxon:9600"
      /clone="DKFZp468E2231"
      /tissue_type="heart"
      /dev_stage="adult"
      /lab_host="DH10B"
      /clone_lib="468 (synonym: phrt1)"
      /note="Vector: pSport1_Sfi; Site_1: SfiI; Site_2: SfiIb"

Query Match
Best Local Similarity 0.9%; Score 16; DB 1; Length 16;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAGAAAAA 1850
Db 1 AAAAAAAGAAAAA 16

RESULT 5
CR786637
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
  Pongo pygmaeus (orangutan)
  Pongo pygmaeus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
REFERENCE
  1 (bases 1 to 18)
  Koehrer, K., Beyer, A., Mewes, H.W., Weil, B., Amid, C., Osanger, A.,
  Fobo, G., Han, M. and Wiemann, S.
  Pongo pygmaeus mRNA (Koehrer, K., Beyer, A., Mewes, H.W., et al.)
  Unpublished (2004)
  Contact: MIPS
  MIPS
  Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
  This is the 5' sequence of the clone insert. Clone from S. Wiemann,
  Molecular Genome Analysis, German Cancer Research Center (DKFZ);
  Email s.wiemann@kfz-heidelberg.de; mforschung GmbH in Berlin,
  Germany. Please contact RZPD for ordering:
  http://www.rzpd.de/cgi-bin/products/cl.cgi?CloneID=DKFZp468J2331
  Further information about the clone and the sequencing project is
  available at http://mips.gsf.de/projects/cdna/.

FEATURES
source
  Location/Qualifiers
    1..18
      /organism="Pongo pygmaeus"
      /mol_type="mRNA"
      /db_xref="taxon:9600"
      /clone="DKFZp468J2331"
      /tissue_type="heart"
      /dev_stage="adult"

```



```

/lab_host="DH10B"
/clone_lib="468 (synonym: phrt1)"
/notes="Vector: pSport1_Sfi; Site_1: SfiIa; Site_2: SfiIb"

Query Match      0.8%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1850
Db 1 AAAAAAAAAAAAAAAAAA 16

RESULT 6
AZ352278/c
LOCUS      20 bp      DNA      linear      GSS 29-SEP-2000
DEFINITION 1M0090K08R Mouse 10kb plasmid UGCM library Mus musculus genomic
Clone UGCM1M0090K08 R, genomic survey sequence.
ACCESSION  AZ352278
VERSION     AZ352278.1 GI:10431515
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barbet,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausen,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0090 row: K column: 08
Seq primer: CACACGAGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.

FEATURES             source
1..20
Location/Qualifiers
    /organism="Mus musculus"
    /mol_type="genomic DNA"
    /strain="C57BL/6J"
    /db_xref="taxon:10090"
    /clone="UGCM1M0090K08"
    /sex="Male"
    /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
    /clone_lib="Mouse 10kb plasmid UGCM library"
    /notes="Vector: pWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptor DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 [gi|4732114|gb|AF129072.1], a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptor mouse DNA was annealed to
adaptor vector DNA, and transformed into

```

---

```

chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 4.5;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1128 TTCCAGTATTATCAGTT 1144
Db 17 TTCCATTATTATCAGTT 1

RESULT 7
CR786609
LOCUS      16 bp      mRNA      linear      EST 01-OCT-2004
DEFINITION DKFZp468C2031_r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
DKFZp468C2031_5', mRNA sequence.
ACCESSION  CR786609
VERSION     CR786609.1 GI:53705606
KEYWORDS    EST.
SOURCE      Pongo pygmaeus (orangutan)
ORGANISM    Pongo pygmaeus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Pongo.
1 (bases 1 to 16)
Koehler,K., Beyer,A., Mewes,H.W., Weil,B., Amid,C., Osanger,A.,
Fobo,G., Han,M. and Wiemann,S.
Pongo pygmaeus mRNA (Koehler,K., Beyer,A., Mewes,H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/cl.cgi?cloneid=DKFZp468C2031
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.

FEATURES             source
1..16
Location/Qualifiers
    /organism="Pongo pygmaeus"
    /mol_type="mRNA"
    /db_xref="taxon:9600"
    /clone="DKFZp468C2031"
    /tissue_type="heart"
    /dev_stage="adult"
    /lab_host="DH10B"
    /clone_lib="468 (synonym: phrt1)"
    /notes="Vector: pSport1_Sfi; Site_1: SfiIa; Site_2: SfiIb"

Query Match      0.8%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1849
Db 2 AAAAAAAAAAAAAAAAAA 16

RESULT 8
AJ650841
LOCUS      19 bp      mRNA      linear      EST 07-JUL-2004
DEFINITION AJ650841 CSEQRAN19 Sus scrofa cDNA clone C0003276_H22, mRNA
sequence.
ACCESSION  AJ650841
VERSION     AJ650841.1 GI:49327686
KEYWORDS    EST.
SOURCE      Sus scrofa (pig)
ORGANISM    Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
1 (bases 1 to 19)

```

**AUTHORS** Anderson, S.I., Finlayson, H.A. and Archibald, A.L.  
**TITLE** Development of cDNA and EST resources for studying reproduction and embryo development in pigs and cattle  
**JOURNAL** Unpublished (2004)  
**COMMENT** Contact: Anderson SI  
 Genomics and Bioinformatics  
 Roslin Institute  
 Roslin, Midlothian, EH25 9PS, UNITED KINGDOM

Single pass sequencing. Bases called and trimmed with phred v0.020425.c. Vector identified by cross\_match with the -minscore 20 and -mismatch 12 options. Vector: pBlueScriptII(KS) R. Site1: EcoRI R. Site2: NotI 5' Seq Primer M13F Normalised library constructed from pooled ovaries. Clones available from UK Centre for Functional Genomics in Farm Animals, Roslin Institute, Roslin, Midlothian, UK, EH25 9PS, [www.ark-genomics.org](http://www.ark-genomics.org).

**FEATURES**

source

1. .19  
 /organism="Sus scrofa"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9823"  
 /clone="C0003276\_H22"  
 /tissue\_type="ovary"  
 /clone\_lib="CSEQUAN19"  
 /notes="Vector: pBlueScriptII(KS+); Site 1: EcoRI; Site 2: NotI; Single pass sequencing; Normalised library constructed from pooled ovaries"

**Query Match** 0.8%; Score 14.8; DB 1; Length 19;  
**Best Local Similarity** 88.9%; Pred. No. 5.1;  
**Matches** 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1259 GGTATGAGCCTCTGCA 1276

DB 2 GGTTTGAGCCTACTGCA 19

**RESULT 9**

LOCUS

CF291030 15 bp mRNA linear EST 14-AUG-2003  
**DEFINITION** 14ROOT--01-E19.g1 Rice root plasmid cDNA library (14ROOT) Oryza sativa (japonica cultivar-group) cDNA clone 14ROOT--01-E19, mRNA sequence.

ACCESSION CF291030

VERSION CF291030.1 GI:33660063

KEYWORDS EST.

SOURCE Oryza sativa (japonica cultivar-group)

**ORGANISM** Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzeae; Oryza.

REFERENCE 1 (bases 1 to 15)

AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

COMMENT Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University  
 Yongin, Gyeonggi, Korea  
 Tel: 82 31 330 6193  
 Fax: 82 31 321 6355

Email: [bnahm@gbio.com](mailto:bnahm@gbio.com), [bnahm@bio.myongji.ac.kr](mailto:bnahm@bio.myongji.ac.kr).**FEATURES**

source

1. .15  
 /organism="Oryza sativa (japonica cultivar-group)"  
 /mol\_type="mRNA"  
 /cultivar="Nackdong"  
 /db\_xref="taxon:39947"  
 /clone="14ROOT--01-E19"  
 /tissue\_type="root"  
 /dev\_stage="14 days after germination"  
 /lab\_host="E.coli DH10B"  
 /clone\_lib="Rice root plasmid cDNA library (14ROOT)"

/note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

**Query Match** 0.7%; Score 13.4; DB 1; Length 15;  
**Best Local Similarity** 93.3%; Pred. No. 5.7;  
**Matches** 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

DB 1 AAAAAAAAAAAAAA 15

**RESULT 10**

LOCUS

CR789161 15 bp mRNA linear EST 01-OCT-2004  
**DEFINITION** DKFZp468J1632 r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone DKFZp468J1632 5', mRNA sequence.

ACCESSION CR789161

VERSION CR789161.1 GI:53708043

KEYWORDS EST.

SOURCE Pongo pygmaeus (orangutan)

**ORGANISM**

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Pongo.

REFERENCE 1 (bases 1 to 15)

AUTHORS Ansorge, W., Krieger, S., Regiert, T., Rittmueller, C., Schwager, B.,

Mewes, H.W., Weil, B., Amid, C., Osanger, A., Pobo, G., Han, M. and

Wiemann, S.

Pongo pygmaeus mRNA (Ansorge, W., Krieger, S., Regiert, T., et al.)

Unpublished (2004)

COMMENT Contact: MIPS

MIPS

Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany

This is the 5' sequence of the clone insert. Clone from S. Wiemann, Molecular Genome Analysis, German Cancer Research Center (DKFZ); Email [s.wiemann@dkfz-heidelberg.de](mailto:s.wiemann@dkfz-heidelberg.de); RZPD for ordering;

<http://www.rzpd.de/cgi-bin/products/cl.cgi?cloneID=DKFZp468J1632>  
 Further information about the clone and the sequencing project is available at <http://mips.gsf.de/projects/cdna/>.

**FEATURES**

source

1. .15  
 /organism="Pongo pygmaeus"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9600"  
 /clone="DKFZp468J1632"  
 /tissue\_type="heart"  
 /dev\_stage="adult"  
 /lab\_host="DH10B"  
 /clone\_lib="468 (synonym: phrt1)"

/note="Vector: pSport1\_Sfi; Site\_1: SfiI; Site\_2: SfiIb"

**Query Match** 0.7%; Score 13.4; DB 1; Length 15;  
**Best Local Similarity** 93.3%; Pred. No. 5.7;  
**Matches** 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

DB 1 AAAAAAAAAAAAAA 15

**RESULT 11**

LOCUS

AI569544 16 bp mRNA linear EST 12-MAY-1999  
**DEFINITION** to28d10.x1 NCI CGAP Ut4 Homo sapiens cDNA clone IMAGE:2180371 3', similar to TR:Q18444 Q18444 COSMID C34D4.; contains MSRI.b2 MSRI repetitive element.; mRNA sequence.

ACCESSION AI569544

VERSION AI569544.1 GI:4532918

KEYWORDS EST.

SOURCE Homo sapiens (human)

**ORGANISM**

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 16)  
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.  
National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index  
Unpublished (1997)  
Contact: Robert Strausberg, Ph.D.  
Email: [cgapsb-remail.nih.gov](mailto:cgapsb-remail.nih.gov)  
Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.  
cDNA Library Preparation: Life Technologies, Inc.  
cDNA Library Arrayed by: Greg Lennon, Ph.D.  
DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: [www-bio.llnl.gov/bbrp/image/image.html](http://www-bio.llnl.gov/bbrp/image/image.html)  
Trace considered overall poor quality  
Insert Length: 1683 Std Error: 0.00  
Seq primer: -40UP from Gibco  
High quality sequence stop: 1  
POLYA=No.

FEATURES  
source  
1..16  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:2180371"  
/tissue\_type="serous papillary carcinoma, high grade, 2 pooled tumors"  
/lab\_host="DH10B"  
/clone\_lib="NCI CGAP Ut4"  
/note="Organ: uterus; Vector: pCMV-SPORT6; Site 1: SalI; Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.48 kb. Life Technologies catalog #: 11542-016"

Query Match 0.7%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 6.5;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACC 1719  
Db 1 CCCCTCCCTCCACC 15

RESULT 12  
AJ592205/c  
LOCUS  
DEFINITION  
368G08, genomic survey sequence.  
ACCESSION  
AJ592205  
VERSION  
AJ592205.1 GI:37941829  
KEYWORDS  
GSS; left border; T-DNA flanking sequence.  
SOURCE  
Arabidopsis thaliana (thale cress)  
ORGANISM  
Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.

REFERENCE  
1  
Brunaud, V., Balzergue, S., Dubreucq, B., Aubourg, S., Samson, F., Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G., Lepiniec, L., Caboche, M. and Lecharry, A.  
T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites  
EMBO Rep. 3 (12), 1152-1157 (2002)  
JOURNAL  
MEDLINE  
22363535  
PUBMED  
12446565  
REFERENCE  
2 (bases 1 to 16)  
AUTHORS  
Balzergue, S.  
TITLE  
Direct Submission  
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue

Gaston Cremieux, 91057 Evry cedex, FRANCE  
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.inbio.gen.fr>).  
Location/Qualifiers  
1..16  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/cultivar="Wassillewskija"  
/db\_xref="taxon:3702"  
/clone="368G08"  
/clone\_lib="Arabidopsis thaliana T-DNA insertion lines"  
misc\_feature 1..16  
/note="T-DNA flanking sequence left border"

Query Match 0.7%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 6.5;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 79 AAAACCACTGGAAA 93  
Db 15 AAAACCACTGGAAA 1

RESULT 13  
AA937877/c  
LOCUS  
DEFINITION  
AA937877 16 bp mRNA linear EST 30-APR-1998  
similar to TR:Q35989 Q35989 CYTOCHROME C OXIDASE SUBUNIT 1; mRNA sequence.  
AA937877  
ACCESSION  
AA937877.1 GI:3095988  
KEYWORDS  
EST.  
SOURCE  
Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 16)  
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.  
National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index  
Unpublished (1997)  
Contact: Robert Strausberg, Ph.D.  
Email: [cgapsb-remail.nih.gov](mailto:cgapsb-remail.nih.gov)  
Tissue Procurement: W. Douglas Figg, Ph.D., Paul H. Duray, M.D., Rodrigo F. Chuqui, M.D., Michael R. Emmert-Buck, M.D., Ph.D.  
cDNA Library Preparation: David B. Krizman, Ph.D.  
cDNA Library Arrayed by: Greg Lennon, Ph.D.  
DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: [www-bio.llnl.gov/bbrp/image/image.html](http://www-bio.llnl.gov/bbrp/image/image.html)  
Trace considered overall poor quality  
Seq primer: -40ml3 fwd. ET from Amersham  
High quality sequence stop: 1.  
Location/Qualifiers  
1..16  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:1253890"  
/sex="male"  
/tissue\_type="metastatic prostate bone lesion"

```

/lab_host="DH10B"
/clone_lib="NCI_CGAP_Pr12"
/note="Vector: pAMP10; mRNA made from metastatic prostate
lesion of the bone, cDNA made by oligo-dT priming.
Non-directionally cloned. Size-selected on agarose gel,
average insert size 600 bp. Library made by D. Krizman,
NIH."

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 8.2;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850
Db 16 AAAAAATAAAAAACAA 1

RESULT 14
CF301021      14 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--05-L10-g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
sativa (japonica cultivar-group) cDNA clone 7LEAF--05-L10, mRNA
sequence.
ACCESSION CF301021
VERSION CF301021.1 GI:33672782
KEYWORDS EST.
SOURCE Oryza sativa (japonica cultivar-group)
ORGANISM Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzeae; Oryza.
1 (bases 1 to 14)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
source
1..14
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--05-L10"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match      0.7%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 7.5;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAATAAAAAAA 14

RESULT 15
AJ739036
LOCUS AJ739036
DEFINITION AJ739036 riken1 Gallus gallus cDNA clone 16p11r3, mRNA sequence.
ACCESSION AJ739036
VERSION AJ739036.1 GI:53904414

```

```

KEYWORDS EST.
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 12)
Caldwell,R.B., Kierzek,A.M., Arakawa,H., Bezubov,Y., Zaim,J.,
Fiedler,P., Kutter,S., Blagodatski,A., Kostovska,D., Kotet,M.,
Plachy,J., Carninci,P., Hayashizaki,Y. and Buerstedde,J.M.
Full-length cDNAs from bursal lymphocytes to facilitate gene
function analysis
Unpublished (2004)
Contact: Caldwell RB
GSF - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie
Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.

FEATURES
source
1..12
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
/clone="16p11r3"
/cell_type="bursal lymphocyte"
/dev_stage="2-3 weeks old"
/clone_lib="riken1"
/note="CB inbred strain"

Query Match      0.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 6.5;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1846
Db 1 AAAAAAAAAAAAAA 12

RESULT 16
BM658732/c
LOCUS BM658732
DEFINITION LZV602768445.R1 CSEQFXL37 pig adrenal Sus scrofa cDNA, mRNA
sequence.
ACCESSION BM658732
VERSION BM658732.1 GI:18959003
KEYWORDS EST.
SOURCE Sus scrofa (pig)
ORGANISM Sus scrofa
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE 1 (bases 1 to 15)
AUTHORS Adelson,D.L. and Gill,C.A.
TITLE Porcine ESTs
JOURNAL Unpublished (2002)
COMMENT Contact: David L. Adelson
Animal Breeding and Genetics
Texas A&M University
Animal Science Dept., TAMU-2471, College Station, TX 77843-2471,
USA
Tel: 9798452616
Fax: 9798456970
Email: david.adelson@tamu.edu.

FEATURES
source
1..15
/organism="Sus scrofa"
/mol_type="mRNA"
/db_xref="taxon:9823"
/clone_lib="CSEQFXL37 pig adrenal"
/note="Organ: adrenal gland; Vector: pBluescript SK+;
Site 1: NotI; Site 2: EcoRI; sequence 5' of the insert
(5'-NNN...NNNinbert)
GGCAATGTGAGCTCCACCGCGGTGGCGCGCGGCTCGAG. Sequence 3' of
the inserts (AAGAATTCGATATCAAGCTTATCGATACCGTGCACCTCGAG.
non-normalized library, sequenced 3' with M13R primer."

```

1. (bases 1 to 13)  
 Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,  
 Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.  
 Large-scale Sequencing Analysis of Rice ESTs  
 Unpublished (2003)  
 Contact: Nahm B.H.  
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division  
 of Bioscience and Bioinformatics, Myongji University  
 Yongin, Kyeonggi, Korea  
 Tel: 82 31 330 6193  
 Fax: 82 31 321 6355  
 Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.  
 Location/Qualifiers  
 1. 13  
 /organism="Oryza sativa (japonica cultivar-group)"  
 /mol\_type="mRNA"  
 /cultiivar="Nackdong"  
 /db\_xref="taxon:39947"  
 /clone="14ROOT--01-H20"  
 /tissue\_type="root"  
 /dev\_stage="14 days after germination"  
 /lab\_host="E.coli DH10B"  
 /clone\_lib="Rice root Plasmid cDNA library (14ROOT)"  
 /note="Vector: PCR4-TOP0; Site 1: EcoRI; mRNA was capped  
 with oligoribonucleotides and then used as templates for  
 RT-PCR."

Query Match 0.6%; Score 11.4; DB 1; Length 13;  
 Best Local Similarity 92.3%; Pred No. 9.6;  
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0

QY 1835 AAAAAAAAAAAAAA 1847  
 ||||| |||||  
 Db 1 AAAAAATAAAAAAA 13

RESULT 19  
 AJ600105/c  
 LOCUS  
 DEFINITION  
 ACCESSION  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM

AJ600105 14 bp DNA linear GSS 15-JAN-2004  
 Arabidopsis thaliana T-DNA flanking sequence, right border, clone  
 500B09, genomic survey sequence.  
 AJ600105  
 AJ600105.1 GI:37949733  
 GSS; right border; T-DNA flanking sequence.  
 Arabidopsis thaliana (thale cress)  
 Arabidopsis thaliana  
 Arabidopsis thaliana  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.  
 1

REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 MEDLINE  
 PUBMED  
 REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 COMMENT

Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,  
 Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Palletier, G.,  
 Lepiniec, L., Caboche, N. and Lecharny, A.  
 T-DNA integration into the Arabidopsis genome depends on sequences  
 of pre-insertion sites  
 EMBO Rep. 3 (12), 1152-1157 (2002)  
 2363535  
 1246565  
 2 (bases 1 to 14)  
 Balzerque, S.  
 Direct Submission  
 Submitted (23-OCT-2003) Balzerque S., UMRGV, INRA/CNRS, 2 rue  
 Gaston Cremieux, 91057 Evry cedex, FRANCE  
 PCR was performed on DNA from transformants of Arabidopsis thaliana  
 plants from INRA (Versailles). The DNA fragment(s) resulting from  
 the PCR were directly sequenced from the left of the right border  
 to determine the genomic sequence flanking the insertion. T-DNA  
 derived sequences were removed. Information to order the  
 corresponding mutant line and a link to a database providing a  
 graphical display of the insertion site are available at  
<http://dbgap.versailles.inra.fr/publiclines/>. This sequence has  
 been generated in the framework of the French plant genomics  
 program 'Genoplante' (<http://www.genoplante.com>) and

```

FEATURES             http://genoplante-info.inbio.gen.fr).
Source              Location/Qualifiers
    1. .14
        /organism="Arabidopsis thaliana"
        /mol_type="genomic DNA"
        /cultivar="Wassillewskija"
        /db_xref="taxon:3702"
        /clone="500309"
        /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature        1. .14
                    /note="T-DNA flanking sequence
                    right border"

Query Match          0.6%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 11;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 476 AATTCATAAGATA 488
Db 13 AATTCATAAGATA 1

```

Search completed: July 12, 2005, 10:48:16  
 Job time : 1 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:44:49 ; Search time 10 Seconds  
(without alignments)  
3.652 Million cell updates/sec

Title: US-09-745-763-35  
Perfect score: 1851  
Sequence: 1 GGCTAGGCCGCGAGCTTAGT.....CTGAAAAAAAAAAAAAAAAA 1851

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 504 seqs, 9864 residues

Total number of hits satisfying chosen parameters: 1008

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 504 summaries

Database : rnpb35.seq.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	28	1.5	29	1	US-09-745-763-54
C 2	25	1.4	25	1	US-10-719-900-527131
C 3	25	1.4	25	1	US-10-956-157-44562
C 4	25	1.4	25	1	US-10-956-157-44563
C 5	25	1.4	25	1	US-10-956-157-44564
C 6	25	1.4	25	1	US-10-956-157-44565
C 7	25	1.4	25	1	US-10-956-157-44566
C 8	25	1.4	25	1	US-10-956-157-44567
C 9	25	1.4	25	1	US-10-956-157-44568
C 10	25	1.4	25	1	US-10-956-157-44569
C 11	25	1.4	25	1	US-10-956-157-44570
C 12	25	1.4	25	1	US-10-956-157-44571
C 13	25	1.4	25	1	US-10-956-157-44572
C 14	25	1.4	25	1	US-10-956-157-44573
C 15	25	1.4	25	1	US-10-956-157-44574
C 16	25	1.4	25	1	US-10-956-157-44575
C 17	25	1.4	25	1	US-10-956-157-44576
C 18	25	1.4	25	1	US-10-956-157-44577
C 19	25	1.4	25	1	US-10-956-157-44578
C 20	25	1.4	25	1	US-10-956-157-44579
C 21	25	1.4	25	1	US-10-956-157-44580
C 22	25	1.4	25	1	US-10-956-157-44581
C 23	25	1.4	25	1	US-10-956-157-44582
C 24	25	1.4	25	1	US-10-956-157-44583
C 25	25	1.4	25	1	US-10-956-157-44584
C 26	25	1.4	25	1	US-10-956-157-44585
C 27	25	1.4	25	1	US-10-956-157-124005
C 28	25	1.4	25	1	US-10-956-157-124207
C 29	25	1.4	25	1	US-10-956-157-127217
C 30	25	1.4	25	1	US-10-956-157-129079
C 31	25	1.4	25	1	US-10-956-157-136211
C 32	25	1.4	25	1	US-10-956-157-137039
C 33	25	1.4	25	1	US-10-956-157-152266

Sequence 161580,  
Sequence 162447,  
Sequence 169555,  
Sequence 178856,  
Sequence 182012,  
Sequence 182211,  
Sequence 182627,  
Sequence 187410,  
Sequence 189946,  
Sequence 193114,  
Sequence 198539,  
Sequence 218907,  
Sequence 218550,  
Sequence 225436,  
Sequence 241762,  
Sequence 251130,  
Sequence 256776,  
Sequence 260715,  
Sequence 260866,  
Sequence 261245,  
Sequence 290004,  
Sequence 295664,  
Sequence 296148,  
Sequence 297155,  
Sequence 302256,  
Sequence 312448,  
Sequence 312779,  
Sequence 315180,  
Sequence 325522,  
Sequence 103390,  
Sequence 127130,  
Sequence 129011,  
Sequence 181479,  
Sequence 212376,  
Sequence 103389,  
Sequence 209370,  
Sequence 456064,  
Sequence 623295,  
Sequence 917234,  
Sequence 106985,  
Sequence 209369,  
Sequence 456065,  
Sequence 585846,  
Sequence 623294,  
Sequence 664932,  
Sequence 752325,  
Sequence 764443,  
Sequence 917233,  
Sequence 298572,  
Sequence 298573,  
Sequence 36103, A  
Sequence 917267,  
Sequence 456190,  
Sequence 607010,  
Sequence 970578,  
Sequence 127295,  
Sequence 443028,  
Sequence 732505,  
Sequence 36101, A  
Sequence 33, Appl  
Sequence 7, Appl  
Sequence 34, Appl  
Sequence 28, Appl  
Sequence 29727, A  
Sequence 29728, A  
Sequence 3, Appl  
Sequence 32, Appl  
Sequence 45, Appl  
Sequence 21, Appl  
Sequence 23, Appl  
Sequence 913, App  
Sequence 939, App  
Sequence 150, App

c 107	17	0.9	18	1	US-10-674-159A-112	Sequence 112, App	c 180	16.4	0.9	20	1	US-10-289-762-3072	Sequence 3072, Ap
c 108	17	0.9	18	1	US-10-776-917-141	Sequence 141, App	181	16.4	0.9	20	1	US-10-831-901A-26525	Sequence 26525, A
c 109	17	0.9	18	1	US-10-766-096-9	Sequence 9, Appli	182	16.4	0.9	20	1	US-10-831-901A-26526	Sequence 26526, A
c 110	17	0.9	18	1	US-10-638-141-10	Sequence 10, Appl	183	16.4	0.9	20	1	US-10-831-901A-26527	Sequence 26527, A
c 111	17	0.9	18	1	US-10-776-934-741	Sequence 741, App	c 184	16.4	0.9	20	1	US-10-831-901A-29726	Sequence 29726, A
c 112	17	0.9	18	1	US-10-601-140A-24	Sequence 24, Appl	185	16.4	0.9	21	1	US-09-828-034-10	Sequence 10, Appl
c 113	17	0.9	18	1	US-10-884-617-2	Sequence 2, Appli	186	16.2	0.9	21	1	US-09-765-111A-32	Sequence 32, Appl
c 114	17	0.9	18	1	US-10-669-962-27	Sequence 27, Appl	187	16.2	0.9	21	1	US-10-072-012-1128	Sequence 1128, Ap
c 115	17	0.9	18	1	US-10-669-962-29	Sequence 29, Appl	c 188	16.2	0.9	21	1	US-10-792-280-220	Sequence 220, App
c 116	17	0.9	18	1	US-10-503-120-1	Sequence 1, Appli	189	16.2	0.9	21	1	US-10-751-736-7618	Sequence 7618, Ap
c 117	17	0.9	18	1	US-10-503-120-8	Sequence 8, Appli	190	16.2	0.9	21	1	US-10-751-736-7619	Sequence 7619, Ap
c 118	17	0.9	18	1	US-10-503-120-9	Sequence 9, Appli	c 191	16.2	0.9	21	1	US-10-751-736-17864	Sequence 17864, A
c 119	17	0.9	18	1	US-10-503-120-10	Sequence 10, Appl	192	16.2	0.9	21	1	US-10-751-736-23615	Sequence 23615, A
c 120	17	0.9	18	1	US-10-503-120-21	Sequence 21, Appl	193	16.2	0.9	21	1	US-10-847-918-9328	Sequence 9328, Ap
c 121	17	0.9	18	1	US-11-024-428-7	Sequence 7, Appli	c 194	16.2	0.9	21	1	US-10-847-918-9330	Sequence 9330, Ap
c 122	17	0.9	19	1	US-10-760-940-1	Sequence 1, Appli	c 195	16.2	0.9	21	1	US-10-847-918-9570	Sequence 9570, Ap
c 123	17	0.9	19	1	US-10-913-246-22	Sequence 22, Appl	196	16.2	0.9	21	1	US-10-847-918-12368	Sequence 12368, A
c 124	17	0.9	19	1	US-10-913-246-24	Sequence 24, Appl	c 197	16.2	0.9	21	1	US-10-847-918-12887	Sequence 12887, A
c 125	17	0.9	19	1	US-10-934-890-22	Sequence 22, Appl	c 198	16.2	0.9	21	1	US-10-847-918-13478	Sequence 13478, A
c 126	17	0.9	19	1	US-10-934-890-24	Sequence 24, Appl	c 199	16	0.9	16	1	US-10-755-118-94	Sequence 94, Appl
c 127	17	0.9	19	1	US-10-700-884-23	Sequence 23, Appl	c 200	16	0.9	17	1	US-10-608-863-4	Sequence 4, Appli
c 128	17	0.9	19	1	US-10-800-487-162	Sequence 162, App	c 201	16	0.9	18	1	US-10-872-984-6	Sequence 6, Appli
c 129	17	0.9	19	1	US-10-800-487-328	Sequence 328, App	c 202	16	0.9	21	1	US-10-751-736-19139	Sequence 19139, A
c 130	17	0.9	19	1	US-10-940-360-1	Sequence 1, Appli	203	15.8	0.9	19	1	US-10-871-222-150	Sequence 150, App
c 131	17	0.9	20	1	US-09-976-900A-55	Sequence 55, Appl	c 204	15.8	0.9	19	1	US-10-871-222-300	Sequence 300, App
c 132	17	0.9	20	1	US-10-661-415-12	Sequence 12, Appl	205	15.8	0.9	19	1	US-10-840-731-34	Sequence 34, Appl
c 133	17	0.9	20	1	US-10-661-415-15	Sequence 15, Appl	c 206	15.8	0.9	19	1	US-10-840-731-129	Sequence 129, App
c 134	17	0.9	20	1	US-10-831-778-226	Sequence 226, App	c 207	15.8	0.9	20	1	US-09-987-025-8	Sequence 8, Appli
c 135	17	0.9	20	1	US-10-831-778-556	Sequence 556, App	c 208	15.8	0.9	20	1	US-10-108-164-125	Sequence 125, App
c 136	17	0.9	20	1	US-10-831-778-560	Sequence 560, App	c 209	15.8	0.9	20	1	US-10-139-604-2	Sequence 2, Appli
c 137	17	0.9	20	1	US-10-728-078-14	Sequence 14, Appl	210	15.8	0.9	20	1	US-10-261-706-4	Sequence 4, Appli
c 138	17	0.9	20	1	US-10-728-078-23	Sequence 23, Appl	c 211	15.8	0.9	20	1	US-10-289-762-6169	Sequence 6169, Ap
c 139	17	0.9	20	1	US-10-601-140A-1	Sequence 1, Appli	212	15.8	0.9	20	1	US-10-831-901A-8646	Sequence 8646, Ap
c 140	17	0.9	20	1	US-10-601-140A-2	Sequence 2, Appli	213	15.8	0.9	20	1	US-10-831-901A-8647	Sequence 8647, Ap
c 141	17	0.9	20	1	US-10-601-140A-3	Sequence 3, Appli	214	15.8	0.9	20	1	US-10-699-362A-4	Sequence 4, Appli
c 142	17	0.9	20	1	US-10-601-140A-4	Sequence 4, Appli	215	15.8	0.9	20	1	US-10-966-829-8	Sequence 8, Appli
c 143	17	0.9	20	1	US-10-601-140A-6	Sequence 6, Appli	c 216	15.8	0.9	21	1	US-10-792-280-376	Sequence 376, App
c 144	17	0.9	20	1	US-10-601-140A-7	Sequence 7, Appli	c 217	15.8	0.9	21	1	US-10-751-736-23903	Sequence 23903, A
c 145	17	0.9	20	1	US-10-601-140A-8	Sequence 8, Appli	c 218	15.8	0.9	21	1	US-10-751-736-29406	Sequence 29406, A
c 146	17	0.9	20	1	US-10-601-140A-9	Sequence 9, Appli	c 219	15.8	0.9	21	1	US-10-831-819-12	Sequence 12, Appl
c 147	17	0.9	20	1	US-10-601-140A-10	Sequence 10, Appl	220	15.8	0.9	21	1	US-10-479-472A-7	Sequence 7, Appli
c 148	17	0.9	20	1	US-10-601-140A-23	Sequence 23, Appl	c 221	15.4	0.8	17	1	US-09-877-478-266	Sequence 266, App
c 149	17	0.9	20	1	US-10-601-140A-34	Sequence 34, Appl	c 222	15.4	0.8	17	1	US-10-342-903-266	Sequence 266, App
c 150	17	0.9	20	1	US-10-601-140A-40	Sequence 40, Appl	c 223	15.4	0.8	17	1	US-10-669-841-266	Sequence 266, App
c 151	17	0.9	20	1	US-10-601-140A-44	Sequence 44, Appl	c 224	15.4	0.8	18	1	US-09-969-373-3693	Sequence 3693, Ap
c 152	17	0.9	20	1	US-10-876-086-49	Sequence 49, Appl	c 225	15.4	0.8	18	1	US-10-436-231-2	Sequence 1, Appli
c 153	17	0.9	20	1	US-10-620-642-32	Sequence 32, Appl	c 226	15.4	0.8	18	1	US-10-436-231-1	Sequence 6, Appli
c 154	17	0.9	20	1	US-10-831-901A-29729	Sequence 29729, A	c 227	15.4	0.8	19	1	US-09-916-136A-6	Sequence 420, App
c 155	17	0.9	20	1	US-10-831-901A-29730	Sequence 29730, A	c 228	15.4	0.8	19	1	US-10-444-925-420	Sequence 404, App
c 156	17	0.9	20	1	US-10-831-901A-29731	Sequence 29731, A	c 229	15.4	0.8	19	1	US-10-871-222-404	Sequence 404, App
c 157	17	0.9	20	1	US-10-831-901A-29732	Sequence 29732, A	c 230	15.4	0.8	19	1	US-10-871-222-508	Sequence 508, App
c 158	17	0.9	20	1	US-10-831-901A-29733	Sequence 29733, A	c 231	15.4	0.8	19	1	US-10-881-118-121	Sequence 121, App
c 159	17	0.9	20	1	US-10-831-901A-29734	Sequence 29734, A	c 232	15.4	0.8	19	1	US-10-881-118-284	Sequence 284, App
c 160	17	0.9	20	1	US-10-831-901A-29735	Sequence 29735, A	c 233	15.4	0.8	19	1	US-10-840-731-32	Sequence 32, Appl
c 161	17	0.9	20	1	US-10-831-901A-29736	Sequence 29736, A	c 234	15.4	0.8	19	1	US-10-840-731-33	Sequence 33, Appl
c 162	17	0.9	20	1	US-10-789-831-22	Sequence 22, Appl	c 235	15.4	0.8	19	1	US-10-840-731-127	Sequence 127, App
c 163	17	0.9	20	1	US-10-789-831-23	Sequence 23, Appl	c 236	15.4	0.8	19	1	US-10-840-731-128	Sequence 128, App
c 164	17	0.9	20	1	US-10-789-831-24	Sequence 24, Appl	c 237	15.4	0.8	19	1	US-10-863-973-389	Sequence 389, App
c 165	17	0.9	21	1	US-10-831-778-912	Sequence 912, App	c 238	15.4	0.8	19	1	US-10-863-973-589	Sequence 589, App
c 166	17	0.9	21	1	US-10-751-736-19135	Sequence 19135, A	c 239	15.4	0.8	20	1	US-09-242-772-55	Sequence 55, Appl
c 167	17	0.9	21	1	US-10-751-736-19136	Sequence 19136, A	c 240	15.4	0.8	20	1	US-10-058-423-14	Sequence 14, Appl
c 168	17	0.9	21	1	US-10-751-736-19138	Sequence 19138, A	c 241	15.4	0.8	20	1	US-10-289-762-6103	Sequence 6103, Ap
c 169	17	0.9	21	1	US-10-913-246-23	Sequence 23, Appl	242	15.4	0.8	20	1	US-10-766-185-47	Sequence 47, Appl
c 170	17	0.9	21	1	US-10-934-890-23	Sequence 23, Appl	243	15.4	0.8	20	1	US-10-380-049-11	Sequence 11, Appl
c 171	17	0.9	21	1	US-10-830-287A-7	Sequence 7, Appli	244	15.4	0.8	20	1	US-10-831-901A-26524	Sequence 26524, A
c 172	17	0.9	21	1	US-10-601-140A-43	Sequence 43, Appl	245	15.4	0.8	20	1	US-10-831-901A-26528	Sequence 26528, A
c 173	16.8	0.9	21	1	US-09-263-981-4	Sequence 4, Appli	c 246	15.4	0.8	20	1	US-10-831-901A-29725	Sequence 29725, A
c 174	16.8	0.9	21	1	US-10-843-938-4	Sequence 4, Appli	c 247	15.4	0.8	20	1	US-10-317-869A-54	Sequence 54, Appl
c 175	16.8	0.9	21	1	US-10-751-736-25521	Sequence 25521, A	c 248	15.4	0.8	20	1	US-10-317-869A-103	Sequence 103, App
c 176	16.8	0.9	22	1	US-10-027-632-52359	Sequence 52359, A	c 249	15.2	0.8	17	1	US-10-872-645-29	Sequence 29, Appl
c 177	16.8	0.9	22	1	US-10-027-632-52359	Sequence 52359, A	c 250	15.2	0.8	20	1	US-09-768-917-9	Sequence 9, Appli
c 178	16.4	0.9	18	1	US-10-349-143-4101	Sequence 4101, Ap	c 251	15.2	0.8	20	1	US-09-888-326-410	Sequence 410, App
c 179	16.4	0.9	18	1	US-10-872-984-5	Sequence 5, Appli	c 252	15.2	0.8	20	1	US-09-802-640-74	Sequence 74, Appl



C 253	15.2	0.8	20	1	US-09-776-479-243.	Sequence 243, App	C 326	15	0.8	17	1	US-10-724-270-1285	Sequence 1285, Ap
C 254	15.2	0.8	20	1	US-09-776-479-243	Sequence 243, App	C 327	15	0.8	20	1	US-10-644-052A-376	Sequence 376, App
C 255	15.2	0.8	20	1	US-09-932-419-5	Sequence 5, Appli	C 328	15	0.8	20	1	US-10-644-052A-376	Sequence 377, App
C 256	15.2	0.8	20	1	US-09-915-814-184	Sequence 184, App	C 329	14.8	0.8	18	1	US-10-479-472A-9	Sequence 8, Appli
C 257	15.2	0.8	20	1	US-09-965-101-57	Sequence 57, Appli	C 330	14.8	0.8	18	1	US-10-479-472A-9	Sequence 9, Appli
C 258	15.2	0.8	20	1	US-10-112-663-235	Sequence 235, App	C 331	14.8	0.8	18	1	US-10-479-472A-9	Sequence 6888, Ap
C 259	15.2	0.8	20	1	US-10-017-995-243	Sequence 243, App	C 332	14.8	0.8	19	1	US-10-349-143-6888	Sequence 7139, Ap
C 260	15.2	0.8	20	1	US-10-067-076-10	Sequence 10, Appl	C 333	14.8	0.8	19	1	US-10-349-143-6888	Sequence 307, App
C 261	15.2	0.8	20	1	US-10-314-578-243	Sequence 243, App	C 334	14.8	0.8	19	1	US-10-830-569-307	Sequence 614, App
C 262	15.2	0.8	20	1	US-10-403-902A-74	Sequence 74, Appl	C 335	14.8	0.8	19	1	US-10-830-569-307	Sequence 35, Appli
C 263	15.2	0.8	20	1	US-10-175-499-39	Sequence 39, Appl	C 336	14.8	0.8	19	1	US-10-840-731-35	Sequence 130, App
C 264	15.2	0.8	20	1	US-10-289-762-4294	Sequence 4294, Ap	C 337	14.8	0.8	19	1	US-10-840-731-35	Sequence 130, App
C 265	15.2	0.8	20	1	US-10-210-556-35	Sequence 35, Appl	C 338	14.8	0.8	19	1	US-10-863-973-694	Sequence 694, App
C 266	15.2	0.8	20	1	US-10-210-556-158	Sequence 158, App	C 339	14.4	0.8	16	1	US-10-863-973-694	Sequence 694, App
C 267	15.2	0.8	20	1	US-10-280-183A-69	Sequence 69, Appl	C 340	14.4	0.8	17	1	US-10-164-915-3	Sequence 3, Appli
C 268	15.2	0.8	20	1	US-10-303-326-30	Sequence 30, Appl	C 341	14.4	0.8	17	1	US-09-866-108-8364	Sequence 8364, Ap
C 269	15.2	0.8	20	1	US-10-303-326-60	Sequence 60, Appl	C 342	14.4	0.8	17	1	US-09-866-108-8364	Sequence 8365, Ap
C 270	15.2	0.8	20	1	US-10-304-125-30	Sequence 30, Appl	C 343	14.4	0.8	17	1	US-09-866-108-10030	Sequence 10030, A
C 271	15.2	0.8	20	1	US-10-304-125-100	Sequence 100, App	C 344	14.4	0.8	17	1	US-09-866-108-10030	Sequence 10031, A
C 272	15.2	0.8	20	1	US-10-688-706-2869	Sequence 2869, App	C 345	14.4	0.8	17	1	US-09-877-478-265	Sequence 1622, Ap
C 273	15.2	0.8	20	1	US-10-304-019-23	Sequence 23, Appl	C 346	14.4	0.8	17	1	US-09-877-478-265	Sequence 265, App
C 274	15.2	0.8	20	1	US-10-304-019-94	Sequence 94, Appl	C 347	14.4	0.8	17	1	US-09-877-478-267	Sequence 267, App
C 275	15.2	0.8	20	1	US-10-318-819A-64	Sequence 64, Appl	C 348	14.4	0.8	17	1	US-09-848-754A-2911	Sequence 2911, Ap
C 276	15.2	0.8	20	1	US-10-318-819A-120	Sequence 120, App	C 349	14.4	0.8	17	1	US-09-848-754A-3506	Sequence 3506, Ap
C 277	15.2	0.8	20	1	US-10-712-795-261	Sequence 261, App	C 350	14.4	0.8	17	1	US-09-780-164-1033	Sequence 1033, Ap
C 278	15.2	0.8	20	1	US-10-712-795-627	Sequence 627, App	C 351	14.4	0.8	17	1	US-09-740-332-1266	Sequence 1266, Ap
C 279	15.2	0.8	20	1	US-10-712-795-835	Sequence 835, App	C 352	14.4	0.8	17	1	US-09-740-332-1414	Sequence 1414, Ap
C 280	15.2	0.8	20	1	US-10-712-795-880	Sequence 880, App	C 353	14.4	0.8	17	1	US-09-740-332-3289	Sequence 3289, Ap
C 281	15.2	0.8	20	1	US-10-831-778-243	Sequence 243, App	C 354	14.4	0.8	17	1	US-09-817-879-1266	Sequence 1266, Ap
C 282	15.2	0.8	20	1	US-10-920-612-261	Sequence 261, App	C 355	14.4	0.8	17	1	US-09-817-879-1414	Sequence 1414, Ap
C 283	15.2	0.8	20	1	US-10-920-612-827	Sequence 827, App	C 356	14.4	0.8	17	1	US-09-817-879-3289	Sequence 3289, Ap
C 284	15.2	0.8	20	1	US-10-920-612-835	Sequence 835, App	C 357	14.4	0.8	17	1	US-10-238-700-1286	Sequence 1286, Ap
C 285	15.2	0.8	20	1	US-10-920-612-880	Sequence 880, App	C 358	14.4	0.8	17	1	US-10-342-902-265	Sequence 265, App
C 286	15.2	0.8	20	1	US-10-838-659-57	Sequence 57, Appl	C 359	14.4	0.8	17	1	US-10-342-902-267	Sequence 267, App
C 287	15.2	0.8	20	1	US-10-831-901A-22	Sequence 22, Appl	C 360	14.4	0.8	17	1	US-10-138-674-4471	Sequence 4471, Ap
C 288	15.2	0.8	20	1	US-10-831-901A-1686	Sequence 1686, Ap	C 361	14.4	0.8	17	1	US-10-138-674-7673	Sequence 7673, Ap
C 289	15.2	0.8	20	1	US-10-831-901A-1687	Sequence 1687, Ap	C 362	14.4	0.8	17	1	US-10-138-674-7673	Sequence 8905, Ap
C 290	15.2	0.8	20	1	US-10-831-901A-8645	Sequence 8645, Ap	C 363	14.4	0.8	17	1	US-10-287-949A-4471	Sequence 4471, Ap
C 291	15.2	0.8	20	1	US-10-831-901A-8648	Sequence 8648, Ap	C 364	14.4	0.8	17	1	US-10-287-949A-7673	Sequence 7673, Ap
C 292	15.2	0.8	20	1	US-10-831-901A-11564	Sequence 11564, A	C 365	14.4	0.8	17	1	US-10-287-949A-8905	Sequence 8905, Ap
C 293	15.2	0.8	20	1	US-10-831-901A-11564	Sequence 11565, A	C 366	14.4	0.8	17	1	US-10-669-841-265	Sequence 265, App
C 294	15.2	0.8	20	1	US-10-831-901A-11565	Sequence 21448, A	C 367	14.4	0.8	17	1	US-10-669-841-267	Sequence 267, App
C 295	15.2	0.8	20	1	US-10-831-901A-21448	Sequence 23367, A	C 368	14.4	0.8	17	1	US-10-669-841-3859	Sequence 3859, Ap
C 296	15.2	0.8	20	1	US-10-831-901A-23367	Sequence 25435, A	C 369	14.4	0.8	17	1	US-10-669-841-4007	Sequence 4007, Ap
C 297	15.2	0.8	20	1	US-10-831-901A-25435	Sequence 25436, A	C 370	14.4	0.8	17	1	US-10-669-841-5882	Sequence 5882, Ap
C 298	15.2	0.8	20	1	US-10-663-451-166	Sequence 166, App	C 371	14.4	0.8	17	1	US-10-723-361-8364	Sequence 8364, Ap
C 299	15.2	0.8	20	1	US-10-182-049-151	Sequence 151, App	C 372	14.4	0.8	17	1	US-10-723-361-8365	Sequence 8365, Ap
C 300	15	0.8	15	1	US-10-830-484-4	Sequence 4, Appli	C 373	14.4	0.8	17	1	US-10-723-361-10030	Sequence 10030, A
C 301	15	0.8	15	1	US-10-755-118-3	Sequence 3, Appli	C 374	14.4	0.8	17	1	US-10-723-361-10031	Sequence 10031, A
C 302	15	0.8	15	1	US-10-755-118-4	Sequence 4, Appli	C 375	14.4	0.8	17	1	US-10-712-633-729	Sequence 729, App
C 303	15	0.8	15	1	US-10-755-118-31	Sequence 31, Appli	C 376	14.4	0.8	17	1	US-10-712-633-4103	Sequence 4103, Ap
C 304	15	0.8	15	1	US-10-755-118-32	Sequence 32, Appli	C 377	14.4	0.8	17	1	US-10-724-270-1286	Sequence 1286, Ap
C 305	15	0.8	15	1	US-10-755-118-36	Sequence 36, Appli	C 378	14.4	0.8	18	1	US-09-263-959-1276	Sequence 1276, Ap
C 306	15	0.8	15	1	US-10-755-118-38	Sequence 38, Appli	C 379	14.4	0.8	18	1	US-09-955-529-189	Sequence 189, App
C 307	15	0.8	15	1	US-10-755-118-39	Sequence 39, Appli	C 380	14.4	0.8	18	1	US-10-214-670-29	Sequence 29, Appl
C 308	15	0.8	15	1	US-10-755-118-40	Sequence 40, Appli	C 381	14.4	0.8	18	1	US-10-277-216-327	Sequence 327, App
C 309	15	0.8	15	1	US-10-755-118-43	Sequence 43, Appli	C 382	14.4	0.8	18	1	US-10-126-022-327	Sequence 327, App
C 310	15	0.8	15	1	US-10-755-118-44	Sequence 44, Appli	C 383	14.4	0.8	18	1	US-10-416-708A-8	Sequence 8, Appli
C 311	15	0.8	15	1	US-10-755-118-45	Sequence 45, Appli	C 384	14.4	0.8	19	1	US-10-604-944-221	Sequence 221, App
C 312	15	0.8	15	1	US-10-755-118-48	Sequence 48, Appli	C 385	14.4	0.8	19	1	US-10-840-731-31	Sequence 31, Appl
C 313	15	0.8	15	1	US-10-755-118-49	Sequence 49, Appli	C 386	14.4	0.8	19	1	US-10-840-731-126	Sequence 126, App
C 314	15	0.8	15	1	US-10-770-989-9	Sequence 9, Appli	C 387	14.2	0.8	17	1	US-10-671-034-5	Sequence 5, Appli
C 315	15	0.8	15	1	US-10-833-502-9	Sequence 9, Appli	C 388	14	0.8	14	1	US-10-830-484-3	Sequence 3, Appli
C 316	15	0.8	15	1	US-10-939-214-54	Sequence 54, Appli	C 389	14	0.8	14	1	US-10-764-393-11	Sequence 11, Appl
C 317	15	0.8	15	1	US-10-939-214-55	Sequence 55, Appli	C 390	14	0.8	14	1	US-10-764-393-11	Sequence 11, Appl
C 318	15	0.8	15	1	US-10-601-140A-5	Sequence 5, Appli	C 391	14	0.8	14	1	US-10-855-595-21	Sequence 21, Appl
C 319	15	0.8	15	1	US-10-601-140A-16	Sequence 16, Appli	C 392	14	0.8	14	1	US-10-763-076-11	Sequence 11, Appl
C 320	15	0.8	15	1	US-10-601-140A-19	Sequence 19, Appli	C 393	14	0.8	14	1	US-10-855-532-21	Sequence 21, Appl
C 321	15	0.8	15	1	US-10-239-919A-4	Sequence 4, Appli	C 394	14	0.8	14	1	US-10-764-388-11	Sequence 11, Appl
C 322	15	0.8	15	1	US-10-938-661A-22	Sequence 22, Appli	C 395	14	0.8	14	1	US-10-096-076-11	Sequence 11, Appl
C 323	15	0.8	17	1	US-10-238-700-1285	Sequence 1285, Ap	C 396	14	0.8	17	1	US-09-866-108-2590	Sequence 2590, Ap
C 324	15	0.8	17	1	US-10-608-863-3	Sequence 3, Appli	C 397	14	0.8	17	1	US-09-866-108-2591	Sequence 2591, Ap
C 325	15	0.8	17	1	US-10-608-863-5	Sequence 5, Appli	C 398	14	0.8	17	1	US-09-866-108-2592	Sequence 2592, Ap



TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617) 498-8284  
TELEFAX: (617) 876-5851  
INFORMATION FOR SEQ ID NO: 54:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 29 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid  
DESCRIPTION: /desc = "oligonucleotide"  
SEQUENCE DESCRIPTION: SEQ ID NO: 54:  
US-09-745-763-54

Query Match 1.5%; Score 28; DB 1; Length 29;  
Best Local Similarity 96.6%; Pred. No. 14;  
Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 295 GATTGGCACTTCTGGTTGATCACTGTGGA 323  
DB 29 GATTGGCACTTCTGGTTGATCACTGTGGA 1

RESULT 2  
US-10-719-900-527131/c  
; Sequence 527131, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Yue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002-11-20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 527131  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-527131

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1426 TGGATCCAAAGCAGATGAATGTCG 1450  
DB 25 TGGATCCAAAGCAGATGAATGTCG 1

RESULT 3  
US-10-956-157-44562  
; Sequence 44562, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44562  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44562

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 618 AACCAACCTTACATCAACTACTCAA 642  
DB 1 AACCAACCTTACATCAACTACTCAA 25

RESULT 4  
US-10-956-157-44563  
; Sequence 44563, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44563  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44563

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1125 GCCTTCCAGTATTATCAGTTACACA 1149  
DB 1 GCCTTCCAGTATTATCAGTTACACA 25

RESULT 5  
US-10-956-157-44564  
; Sequence 44564, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44564  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44564

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1124 TGCTTCCAGTATTATCAGTTACAC 1148  
DB 1 TGCTTCCAGTATTATCAGTTACAC 25

RESULT 6  
US-10-956-157-44565  
; Sequence 44565, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44565
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44565

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1123 GTGCTTCCAGTATTATCAGTTACA 1147
Db      1 GTGCTTCCAGTATTATCAGTTACA 25

RESULT 7
US-10-956-157-44566
; Sequence 44566, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44566
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44566

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      617 TAACCAACCTTACATCAACTACTCA 641
Db      1 TAACCAACCTTACATCAACTACTCA 25

RESULT 8
US-10-956-157-44567
; Sequence 44567, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44567
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44567

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      619 ACCAACCTTACATCAACTACTCAAG 643
Db      1 ACCAACCTTACATCAACTACTCAAG 25

RESULT 11
US-10-956-157-44570
; Sequence 44570, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1129 TCAGTATTATCAGTTACCAAGGT 1153
Db      1 TCAGTATTATCAGTTACCAAGGT 25

RESULT 9
US-10-956-157-44568
; Sequence 44568, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44568
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44568

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1122 GTGCTTCCAGTATTATCAGTTAC 1146
Db      1 GTGCTTCCAGTATTATCAGTTAC 25

RESULT 10
US-10-956-157-44569
; Sequence 44569, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44569
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44569

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      619 ACCAACCTTACATCAACTACTCAAG 643
Db      1 ACCAACCTTACATCAACTACTCAAG 25

RESULT 11
US-10-956-157-44570
; Sequence 44570, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44570  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44570

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 892 ATACTGATTCCTTCAACACTGAGC 916  
Db 1 ATACTGATTCCTTCAACACTGAGC 25

RESULT 12  
US-10-956-157-44571  
; Sequence 44571, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44571  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44571

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 616 ATACCAACCTTACATCAACTACTC 640  
Db 1 ATACCAACCTTACATCAACTACTC 25

RESULT 13  
US-10-956-157-44572  
; Sequence 44572, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44572  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44572

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1128 TTCCAGTATTATCAGTTACACAGG 1152  
Db 1 TTCCAGTATTATCAGTTACACAGG 25

RESULT 14  
US-10-956-157-44573  
; Sequence 44573, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44573  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44573

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1126 CTTCCAGTATTATCAGTTACACAA 1150  
Db 1 CTTCCAGTATTATCAGTTACACAA 25

RESULT 15  
US-10-956-157-44574  
; Sequence 44574, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44574  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44574

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 890 AGATACGTATTCCTTCAACACTGTA 914  
Db 1 AGATACGTATTCCTTCAACACTGTA 25

RESULT 16  
US-10-956-157-44575  
; Sequence 44575, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44575  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44575

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 891 GATACTGATTCCTTCAACACTGTAG 915  
Db 1 GATACTGATTCCTTCAACACTGTAG 25  
|||||

## RESULT 17

US-10-956-157-44576  
; Sequence 44576, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44576  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44576

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 889 CAGATACTGATTCCTTCAACACTGT 913  
Db 1 CAGATACTGATTCCTTCAACACTGT 25  
|||||

## RESULT 18

US-10-956-157-44577  
; Sequence 44577, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44577  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44577

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 625 CTTACATCAACTCAAGGACGGT 649  
Db 1 CTTACATCAACTCAAGGACGGT 25  
|||||

## RESULT 19

US-10-956-157-44578  
; Sequence 44578, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44578  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44578

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1130 CCAGTATTATCAGTTACACAAGSTA 1154  
Db 1 CCAGTATTATCAGTTACACAAGSTA 25  
|||||

## RESULT 20

US-10-956-157-44579  
; Sequence 44579, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44579  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-44579

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 893 TACTGATTCCTTCAACACTGTAGCA 917  
Db 1 TACTGATTCCTTCAACACTGTAGCA 25  
|||||

## RESULT 21

US-10-956-157-44580  
; Sequence 44580, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; FILE REFERENCE: 031896-043000 (AM 101081)

```

; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44580
; LENGTH: 25
; TYPE: DNA
; ORGANISM: probe Sequence
US-10-956-157-44580

```

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 626 TTACATCAACTACTCAAGGACGGTG 650  
|||||  
Db 1 TTACATCAACTACTCAAGGACGGTG 25

```

RESULT 22
US-10-956-157-44581
; Sequence 44581, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS
; FILE REFERENCE: 031895-043000 (AM 1010)
; CURRENT APPLICATION NUMBER: US/10/956.1
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44581
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44581

```

```
Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 888 CCAGATACTGATTCTTCAACACTG 912  
|||  
Db 1 CCAGATACTGATTCTTCAACACTG 25

```

RESULT 23
US-10-956-157-44582
; Sequence 44582, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS
; FILE REFERENCE: 031896-043000 (AM 10108)
; CURRENT APPLICATION NUMBER: US/10/956,1
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44582
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44582

```

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 732 ATCTACAGTCCTCACACAGGTATC 756

Db  
1 ATCTACAGTCCTCACACAGGTATTC 25

```

RESULT 24
US - 10-956-157-44583
; Sequence 44583, Application US/10956157
; Publication NO. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAY
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS
; FILE REFERENCE: 031896-043000 (AM 1010)
; CURRENT APPLICATION NUMBER: US/10/956,
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44583
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44583

```

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 898 ATTCCTTCAACACTGTAGCAGAGAT 922  
 Db 1 ATTCCTTCAACACTGTAGCAGAGAT 25

```

RESULT 25
US-10-956-157-44584
; Sequence 44584, Application US/10956157
; Publication NO. US20050118625a1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS
; TITLE OF INVENTION: HUMAN OSTEOSTATHIRIN
; FILE REFERENCE: 031896-043000 (AM 101010)
; CURRENT APPLICATION NUMBER: US/10/956,
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44584
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-44584

```

```
Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy	731	CATCTACAGTCCTCACACAGGTATT	755
D <sub>b</sub>	1	CATCTACAGTCCTCACACAGGTATT	25

RESULT 26  
US-10-956-157-44585  
; Sequence 44585, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Wyeth  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS  
; TITLE OF INVENTION: HUMAN OSTEOCARTRIL  
; FILE REFERENCE: 031896-043000 (AM 10108)  
; CURRENT APPLICATION NUMBER: US/10/956-

; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 44585  
; TYPE: DNA  
; LENGTH: 25  
; ORGANISM: Probe Sequence  
US-10-956-157-44585

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1712 CTCGCCACCATAGATCAACATAT 1736  
|||||  
DB 1 CTCGCCACCATAGATCAACATAT 25

## RESULT 27

US-10-956-157-124005  
; Sequence 124005, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 124005  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-124005

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1610 ATTCACTTCAAAGCACAACTCTAT 1634  
|||||  
DB 1 ATTCACTTCAAAGCACAACTCTAT 25

## RESULT 28

US-10-956-157-124207  
; Sequence 124207, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 124207  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-124207

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1744 ATTACAGTGGGGCATTTCTTTATA 1768  
|||||

DB 1 ATTACAGTGGGGCATTTCTTTATA 25

## RESULT 29

US-10-956-157-127217  
; Sequence 127217, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 127217  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-127217

Query Match 1.4%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1594 ATAACAATTTCAATTCATCTT 1618  
|||||  
DB 1 ATAACAATTTCAATTCATCTT 25

## RESULT 30

US-10-956-157-129079  
; Sequence 129079, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 129079  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-129079

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1614 ATCTTCAAAGCACAACTCTATTCA 1638  
|||||  
DB 1 ATCTTCAAAGCACAACTCTATTCA 25

## RESULT 31

US-10-956-157-136211  
; Sequence 136211, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04



; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 136211  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-136211

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1740 AGGATTACAGTGGGGGCAATTCCT 1764  
|||||  
Db 1 AGGATTACAGTGGGGGCAATTCCT 25

## RESULT 32

US-10-956-157-137039  
; Sequence 137039, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 137039  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-137039

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1749 AGTGGGGGCATTCCTTTATATACCC 1773  
|||||  
Db 1 AGTGGGGGCATTCCTTTATATACCC 25

## RESULT 33

US-10-956-157-152266  
; Sequence 152266, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 152266  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-152266

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1747 ACATGGGGGCATTCCTTTATATCA 1771  
|||||  
Db 1 ACATGGGGGCATTCCTTTATATCA 25

## RESULT 34

US-10-956-157-161580  
; Sequence 161580, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 161580  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-161580

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1529 AAGAAAGCTTTTCATGCTTCTGGCC 1553  
|||||  
Db 1 AAGAAAGCTTTTCATGCTTCTGGCC 25

## RESULT 35

US-10-956-157-162447  
; Sequence 162447, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 162447  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-162447

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1621 AAGCACAACTCTATTTTCATGCTTC 1645  
|||||  
Db 1 AAGCACAACTCTATTTTCATGCTTC 25

## RESULT 36

US-10-956-157-168555  
; Sequence 168555, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 168555
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-168555

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1608 CAATTTCATCTTCAAGCACAACTCT 1632
Db 1 CAATTCATCTTCAAGCACAACTCT 25

RESULT 37
US-10-956-157-178856
; Sequence 178856, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 178856
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-178856

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1637 CATGCTTCTGTTATTATCTTTCTT 1661
Db 1 CATGCTTCTGTTATTATCTTTCTT 25

RESULT 38
US-10-956-157-182012
; Sequence 182012, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 182012
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-182012

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1616 CTTCAAGACCAACTCTATTTCATG 1640
Db 1 CTTCAAGACCAACTCTATTTCATG 25

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 168555
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-182211

Query Match      1.4%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1712 CTCCCACCACATAGATCAACATAT 1736
Db 1 CTCCCACCACATAGATCAACATAT 25

RESULT 41
US-10-956-157-187410
; Sequence 187410, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
```

; SEQ ID NO 187410  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-187410

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAACTCTCTTC 1591  
|||||  
Db 1 CTGCAACTTTGGAAACTCTCTTC 25

## RESULT 42

US-10-956-157-189946  
; Sequence 189946, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 189946  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-189946

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1561 CTGGGCTGCAACTTTGGAAACTC 1585  
|||||  
Db 1 CTGGGCTGCAACTTTGGAAACTC 25

## RESULT 43

US-10-956-157-193114  
; Sequence 193114, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 193114  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-193114

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1714 CCCACCACATAGATCAACATATGG 1738  
|||||  
Db 1 CCCACCACATAGATCAACATATGG 25

## RESULT 44

US-10-956-157-198539  
; Sequence 198539, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 198539  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-198539

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1711 CCTCCACCATAGATCAACATA 1735  
|||||  
Db 1 CCTCCACCATAGATCAACATA 25

## RESULT 45

US-10-956-157-216907  
; Sequence 216907, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 216907  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-216907

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1569 GCAACTTTGGAAACTCTCTTCAC 1593  
|||||  
Db 1 GCAACTTTGGAAACTCTCTTCAC 25

## RESULT 46

US-10-956-157-218550  
; Sequence 218550, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 218550

; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-218550

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1725 GAATCAACATATGCTAGGATTACA 1749  
|||||  
Db 1 GAATCAACATATGCTAGGATTACA 25

## RESULT 47

US-10-956-157-225436  
; Sequence 225436, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 225436  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-225436

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1527 GAAAGAAACGTTTCATGCTTCGG 1551  
|||||  
Db 1 GAAAGAAACGTTTCATGCTTCGG 25

## RESULT 48

US-10-956-157-241762  
; Sequence 241762, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 241762  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-241762

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1743 GATTACAGTGGGGCATTTCTTTAT 1767  
|||||  
Db 1 GATTACAGTGGGGCATTTCTTTAT 25

## RESULT 49

US-10-956-157-251130  
; Sequence 251130, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 251130  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-251130

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1565 GTCTGCAACTTTGGAAACTCTCT 1589  
|||||  
Db 1 GTCTGCAACTTTGGAAACTCTCT 25

## RESULT 50

US-10-956-157-256776  
; Sequence 256776, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 256776  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-256776

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1750 GTGGGGGCATTTCTTTATATCACCT 1774  
|||||  
Db 1 GTGGGGGCATTTCTTTATATCACCT 25

## RESULT 51

US-10-956-157-260715  
; Sequence 260715, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 260715  
; LENGTH: 25

```
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-260715

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1563 GGGTCTGCAACTTTGGAAACTCTC 1587
      |||||
Db 1 GGGTCTGCAACTTTGGAAACTCTC 25

RESULT 52
US-10-956-157-260866
; Sequence 260866, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 260866
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-260866

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1741 GGGATTACAGTGGGGCAATTCCTT 1765
      |||||
Db 1 GGGATTACAGTGGGGCAATTCCTT 25

RESULT 53
US-10-956-157-261245
; Sequence 261245, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 261245
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-261245

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1564 GGTCTGCAACTTTGGAAACTCTC 1588
      |||||
Db 1 GGTCTGCAACTTTGGAAACTCTC 25

RESULT 54
US-10-956-157-290004
```

```
; Sequence 290004, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 290004
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-290004

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1559 TCCTGGGCTCTGCAACTTTGGAAAC 1583
      |||||
Db 1 TCCTGGGCTCTGCAACTTTGGAAAC 25

RESULT 55
US-10-956-157-295664
; Sequence 295664, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 295664
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-295664

Query Match
Best Local Similarity 1.4%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1658 TCTTGATACCTTCCAAATTCCTGA 1682
      |||||
Db 1 TCTTGATACCTTCCAAATTCCTGA 25

RESULT 56
US-10-956-157-296148
; Sequence 296148, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 296148
; LENGTH: 25
; TYPE: DNA
```

; ORGANISM: Probe Sequence  
US-10-956-157-296148

Query Match 1.4%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 25; Conservative 0; Mismatches 0; Indels

Qy 1612 TCATCTTCAAGCACAACCTCTATTT 1636  
|||  
Db 1 TCATCTTCAAGCACAACCTCTATTT 25

## RESULT 57

US-10-956-157-297155  
; Sequence 297155, Application US/10956157  
; Publication No. US20050118625A1

GENERAL INFORMATION:

APPLICANT: Wveth

APPLICANT: Mounts. William

APPLICANT: MOUNITS, WILLIAM  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

FILE OF INVENTOR: ROYAL GREGORIANI  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-1-

; NUMBER OF SEQ ID NOS: 319805

: SOFTWARE: Patent

; SOF INARE: F  
; SEO ID NO 29

SEQ	ID	NO	2	3
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30				
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				
61				
62				
63				
64				
65				
66				
67				
68				
69				
70				
71				
72				
73				
74				
75				
76				
77				
78				
79				
80				
81				
82				
83				
84				
85				
86				
87				
88				
89				
90				
91				
92				
93				
94				
95				
96				
97				
98				
99				
100				

```

; LENGTH: 25
; TYPE: DATA

```

; TYPE: DNA

3-10-956-157-297155

Qy	Matches	25; Conservative	0; Mismatch
1618	TCAAAGCACAACTCTATTTTCATGCT	1642	

RESULT 58  
US-10-956-157-302256

; Sequence 302256, App

; Publication No. U.

; GENERAL INFORMATION:

APPLICANT: Wyeth  
APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR  
 ;  
 ; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS

; FILE REFERENCE: 031896-04300

; CURRENT APPLICATION NUMBER: US

; CURRENT FILING I

NUMBER OF S

: SOFTWARE:

: SEO ID NO 302256

```

; SEQ ID NO 302236
; LENGTH: 25

```

TYPE: DNA  
ORGANISM: Probe Sequence  
5-10-956-157-302256

Query Match 1.4%; score 25;  
Best Local Similarity 100.0%; Pred. No.  
Matches 25; Conservative 0; Mismatch

25

DD  
DECUT F E O  
T TACAGTGGGGCATTTCTTTATAATC 2

US-10-719-900-527130/c  
; Sequence 527130, Application US/10719900  
; Publication No. US20050026164A1

Query Match 1.3%; Score 23.4; DB 1; Length 25;  
Best Local Similarity 96.0%; Pred. No. 39;  
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 CTTCTGGCCAGGAATCCTGGGTCTG 1569  
|||||  
Db 1 CTTCTGGCCAGGATCCTGGGTCTG 25

## RESULT 67

US-10-956-157-212376  
; Sequence 212376, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 212376

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-212376

Query Match 1.3%; Score 23.4; DB 1; Length 25;  
Best Local Similarity 96.0%; Pred. No. 39;  
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1544 GCTTCTGGCCAGGAATCCTGGGTCT 1568  
|||||  
Db 1 GCTTCTGGCCAGGATCCTGGGTCT 25

## RESULT 68

US-10-719-900-103389/c  
; Sequence 103389, Application US/10719900  
; Publication No. US20050026164A1

## ; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 103389

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-103389

Query Match 1.2%; Score 21.8; DB 1; Length 25;  
Best Local Similarity 92.0%; Pred. No. 62;  
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1399 ACTCCACGGAGACACCATGACTGT 1423  
|||||  
Db 25 ATTCCACGGAGTCACCATGACTGT 1

## RESULT 69

US-10-719-900-209370

; Sequence 209370, Application US/10719900

; Publication No. US20050026164A1

## ; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 209370  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-209370

Query Match 1.2%; Score 21.8; DB 1; Length 25;  
Best Local Similarity 92.0%; Pred. No. 62;  
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1381 AGTATTTCTTCTCCATCATCTCCA 1405  
|||||  
Db 1 AGTATTTCTTTTCCATCATCTCCA 25

## RESULT 70

US-10-719-900-456064/c  
; Sequence 456064, Application US/10719900  
; Publication No. US20050026164A1

## ; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 456064

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-456064

Query Match 1.2%; Score 21.8; DB 1; Length 25;  
Best Local Similarity 92.0%; Pred. No. 62;  
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1489 ACATGGAAGAAATGCTGCCTAGTGC 1513  
|||||  
Db 25 ACATGATGAAATGCTGCCAGTGC 1

## RESULT 71

US-10-719-900-623295  
; Sequence 623295, Application US/10719900  
; Publication No. US20050026164A1

## ; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 623295

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-623295



Query Match 1.2%; Score 21.8; DB 1; Length 25;  
Best Local Similarity 92.0%; Pred. No. 62;  
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1463 GCGCTGTTGTTCTTATGTTGCA 1487  
Db 1 GCGCTGTTGCTTAIGTTGCA 25

RESULT 72  
US-10-719-900-917234  
; Sequence 917234, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 917234  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-917234

Query Match 1.2%; Score 21.8; DB 1; Length 25;  
Best Local Similarity 92.0%; Pred. No. 62;  
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1324 TCACTTTTGATCCAACTGAGT 1348  
Db 1 TTACTTCTGATCCAACTGAGT 25

RESULT 73  
US-10-719-900-106985  
; Sequence 106985, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 106985  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-106985

Query Match 1.1%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 1e+02;  
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1438 AGATGAATGTTGCTGCTGCTTTG 1462  
Db 1 ACATGGATGTTGCTGATGCTGTTG 25

RESULT 74  
US-10-719-900-209369  
; Sequence 209369, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 209369  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-209369

Query Match 1.1%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 1e+02;  
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1381 AGTATTTCTTCTCCATCATCTCCA 1405  
Db 1 AGTATTTCTTTACCATCATCTCCA 25

RESULT 75  
US-10-719-900-456065/c  
; Sequence 456065, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 456065  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-456065

Query Match 1.1%; Score 20.2; DB 1; Length 25;  
Best Local Similarity 88.0%; Pred. No. 1e+02;  
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy 1489 ACATGGAAGAAATGCTCCCTAGGTC 1513  
Db 25 ACATGGATGAAAGACTGCCCAGGTC 1

RESULT 76  
US-10-719-900-585846  
; Sequence 585846, Application US/10719900  
; Publication No. US20050026164A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
; FILE REFERENCE: 3528.1  
; CURRENT APPLICATION NUMBER: US/10/719,900  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,808  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 982914  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 585846  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-10-719-900-585846

Query Match 1.1%; Score 20.2; DB 1; Length 25;



Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1324 TCAACTTTTGGATCAAGCTGGAGT 1348  
 Db 1 TTAACCTTCTGGAACCAAGCTGGAGT 25

## RESULT 82

US-10-719-900-298572  
 ; Sequence 298572, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1  
 ; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002-11-20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 298572  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-719-900-298572

Query Match 1.1%; Score 19.8; DB 1; Length 25;  
 Best Local Similarity 91.3%; Pred. No. 1.1e+02;  
 Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1236 AAGCCAGGGCCATCATGAGGA 1258  
 Db 2 AAGCCAGGGCCATCATGAGGA 24

## RESULT 83

US-10-719-900-298573  
 ; Sequence 298573, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1  
 ; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002-11-20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 298573  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-719-900-298573

Query Match 1.1%; Score 19.8; DB 1; Length 25;  
 Best Local Similarity 91.3%; Pred. No. 1.1e+02;  
 Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1236 AAGCCAGGGCCATCATGAGGA 1258  
 Db 2 AAGCCAGGGCCATCATGAGGA 24

## RESULT 84

US-10-809-189-36103/c  
 ; Sequence 36103, Application US/10809189  
 ; Publication No. US20050048531A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Michael Mittmann  
 ; APPLICANT: David Mack  
 ; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.  
 ; TITLE OF INVENTION: Methods of Genetic Analysis  
 ; FILE REFERENCE: 3101.1  
 ; CURRENT APPLICATION NUMBER: US/10/809,189  
 ; CURRENT FILING DATE: 2004-03-25  
 ; PRIOR APPLICATION NUMBER: US/09/396,196  
 ; PRIOR FILING DATE: 1999-09-15  
 ; PRIOR APPLICATION NUMBER: 60/100,678  
 ; PRIOR FILING DATE: 1998-09-17  
 ; NUMBER OF SEQ ID NOS: 127806  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 36103  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-809-189-36103

Query Match 1.1%; Score 19.8; DB 1; Length 25;  
 Best Local Similarity 91.3%; Pred. No. 1.1e+02;  
 Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 961 GTGACATCTGGACAGCTGGGAT 983  
 Db 25 GTGACATCTGGACAGCTGGGAT 3

## RESULT 85

US-10-719-900-917267/c  
 ; Sequence 917267, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1  
 ; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002-11-20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 917267  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus  
 US-10-719-900-917267

Query Match 1.0%; Score 19.4; DB 1; Length 25;  
 Best Local Similarity 95.2%; Pred. No. 1.3e+02;  
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1457 TGTTCGGCTGTTGTTCTTA 1477  
 Db 22 TGTTCGGCTGTTGTTCTTA 2

## RESULT 86

US-10-719-900-456190/c  
 ; Sequence 456190, Application US/10719900  
 ; Publication No. US20050026164A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Xue Mei Zhou  
 ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse  
 ; FILE REFERENCE: 3528.1  
 ; CURRENT APPLICATION NUMBER: US/10/719,900  
 ; CURRENT FILING DATE: 2003-11-20  
 ; PRIOR APPLICATION NUMBER: 60/427,808  
 ; PRIOR FILING DATE: 2002-11-20  
 ; NUMBER OF SEQ ID NOS: 982914  
 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
 ; SEQ ID NO 456190  
 ; LENGTH: 25  
 ; TYPE: DNA  
 ; ORGANISM: Mus musculus

US-10-719-900-456190

Query Match 1.0%; Score 19.2; DB 1; Length 25;  
Best Local Similarity 87.5%; Pred. No. 1.3e+02;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1275 CAGCCCTCAATATCACTCAGGTC 1298

Db 24 CAGCCACTCAATATGACACAGGTC 1

RESULT 87

US-10-719-900-607010/c

; Sequence 607010, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 607010

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-607010

Query Match 1.0%; Score 19.2; DB 1; Length 25;  
Best Local Similarity 87.5%; Pred. No. 1.3e+02;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1538 TTTGATGCTTCTGGCCAGGAATCC 1561

Db 24 TTTGATGCTTCTGGCCAGGAATCC 1

RESULT 88

US-10-719-900-970578/c

; Sequence 970578, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 970578

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-970578

Query Match 1.0%; Score 19.2; DB 1; Length 25;  
Best Local Similarity 87.5%; Pred. No. 1.3e+02;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 559 CCTCTTCGATGAATCCAGAGAA 582

Db 25 CCTCGTTCGATGAGCTCCAGAGAA 2

RESULT 89

US-10-809-189-127295

; Sequence 127295, Application US/10809189

; Publication No. US20050048531A1

; GENERAL INFORMATION:

; APPLICANT: Michael Mitmann

; APPLICANT: David Mack

; APPLICANT: David Lockhart

; APPLICANT: Affymetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis

; FILE REFERENCE: 3101.1

; CURRENT APPLICATION NUMBER: US/10/809,189

; CURRENT FILING DATE: 2004-03-25

; PRIOR APPLICATION NUMBER: US/09/396,196

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 127295

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-809-189-127295

Query Match 1.0%; Score 19.2; DB 1; Length 25;  
Best Local Similarity 87.5%; Pred. No. 1.3e+02;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 138 CTTTATCCCTGCTCTGGGAA 161

Db 1 CTTTATCCCTGCTCTGGGAA 24

RESULT 90

US-10-719-900-443028/c

; Sequence 443028, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 443028

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-443028

Query Match 1.0%; Score 18.8; DB 1; Length 25;  
Best Local Similarity 90.9%; Pred. No. 1.5e+02;  
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 833 GGCTTCTCATGGATCAAAATT 854

Db 23 GGCTTCTCATGGATCAAAATT 2

RESULT 91

US-10-719-900-732505

; Sequence 732505, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

```
; SEQ ID NO 732505
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-732505

Query Match      1.0%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1128 TTCCAGTATTATCAGTTACACA 1149
Db 2 TTGCAGCATTATCAGTTACACA 23

RESULT 92
US-10-809-189-36101/c
; Sequence 36101, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36101
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-36101

Query Match      1.0%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 1.5e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 962 TGGACATCTGGACAGCTGGGAT 983
Db 25 TGGACATCTGGCTGAGCTGGGAT 4

RESULT 93
US-10-620-642-33/c
; Sequence 33, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Kristina M.
; APPLICANT: Bosselman, Robert A.
; APPLICANT: Suggs, Sidney V.
; APPLICANT: Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-620-642-33

Query Match      1.0%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1832 CTGAAAAA1851
Db 20 CTA1851

RESULT 94
US-10-872-984-7/c
; Sequence 7, Application US/10872984
; Publication No. US20040265889A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-7

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1833 TGAAGAAAAAAGAAAAA 1850
Db 18 TGAAGAAAAAAGAAAAA 1

RESULT 95
US-10-669-962-28/c
; Sequence 28, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Bruggiera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: P8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-669-962-28

Query Match      1.0%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 89;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAGAAAAAAGAAAA 1851
Db 18 GAAAAAAGAAAAAAGAAAA 1

RESULT 96
US-10-620-642-34/c
; Sequence 34, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; APPLICANT: Bosseelman, Robert A.
; APPLICANT: Suggs, Sidney V.
; APPLICANT: Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/10/620,642
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-620-642-34

Query Match      1.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 11e-02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAGAAAAAAGAAAA 1851
Db 19 GAAAAAAGAAAAAAGAAAA 2

RESULT 97
US-10-831-901A-29727/c
; Sequence 29727, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (S10L0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
```

;; PRIOR APPLICATION NUMBER: 60/466,426  
;; PRIOR FILING DATE: 2003-04-28  
;; PRIOR APPLICATION NUMBER: 60/468,562  
;; PRIOR FILING DATE: 2003-05-06  
;; PRIOR APPLICATION NUMBER: 60/467,770  
;; PRIOR FILING DATE: 2003-04-30  
;; PRIOR APPLICATION NUMBER: 60/468,627  
;; PRIOR FILING DATE: 2003-05-06  
;; PRIOR APPLICATION NUMBER: 60/477,637  
;; PRIOR FILING DATE: 2003-06-10  
;; PRIOR APPLICATION NUMBER: 60/483,579  
;; PRIOR FILING DATE: 2003-06-27  
;; NUMBER OF SEQ ID NOS: 30063  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 29727  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Antisense compound  
US-10-831-901A-29727

Query Match 0.9%; Score 17.4; DB 1; Length 20;  
Best Local Similarity 94.7%; Pred. No. 1.3e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1833 TGAAGAAAAAAGAAAAA 1851  
||| ||||| ||||| |||||  
Db 19 TGACAAAAAAGAAAAA 1

RESULT 98  
US-10-831-901A-29728/c  
;; Sequence 29728, Application US/10831901A  
;; Publication No. US20050100885A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Crooke, Stanley T.  
;; APPLICANT: Ecker, David J.  
;; APPLICANT: Sampath, Rangarajan  
;; APPLICANT: Freier, Susan M.  
;; APPLICANT: Massire, Christian  
;; APPLICANT: Hofstadler, Steven A.  
;; APPLICANT: Lowery, Kristin Sannes  
;; APPLICANT: Swayze, Eric  
;; APPLICANT: Baker, Brenda F.  
;; APPLICANT: Bennett, C. Frank  
;; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
;; FILE REFERENCE: ISIS0083-100 (BIOL000808)  
;; CURRENT APPLICATION NUMBER: US/10/831,901A  
;; CURRENT FILING DATE: 2004-04-26  
;; PRIOR APPLICATION NUMBER: 60/466,426  
;; PRIOR FILING DATE: 2003-04-28  
;; PRIOR APPLICATION NUMBER: 60/468,562  
;; PRIOR FILING DATE: 2003-05-06  
;; PRIOR APPLICATION NUMBER: 60/467,770  
;; PRIOR FILING DATE: 2003-04-30  
;; PRIOR APPLICATION NUMBER: 60/468,627  
;; PRIOR FILING DATE: 2003-05-06  
;; PRIOR APPLICATION NUMBER: 60/477,637  
;; PRIOR FILING DATE: 2003-06-10  
;; PRIOR APPLICATION NUMBER: 60/483,579  
;; PRIOR FILING DATE: 2003-06-27  
;; NUMBER OF SEQ ID NOS: 30063  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 29728  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Antisense compound  
US-10-831-901A-29728

Query Match 0.9%; Score 17.4; DB 1; Length 20;  
Best Local Similarity 94.7%; Pred. No. 1.3e+02;  
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1833 TGAAGAAAAAAGAAAAA 1851  
||| ||||| ||||| |||||  
Db 20 TGACAAAAAAGAAAAA 2

RESULT 99  
US-10-664-000-3/c  
;; Sequence 3, Application US/10664000  
;; Publication No. US20040248144A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Mir, Kalim  
;; TITLE OF INVENTION: Arrays and Methods of Use  
;; FILE REFERENCE: 8654/2182  
;; CURRENT APPLICATION NUMBER: US/10/664,000  
;; CURRENT FILING DATE: 2003-09-16  
;; PRIOR APPLICATION NUMBER: PCT/GB02/01245  
;; PRIOR FILING DATE: 2002-03-18  
;; PRIOR APPLICATION NUMBER: GB0106635.6  
;; PRIOR FILING DATE: 2001-03-16  
;; PRIOR APPLICATION NUMBER: GB0118879.6  
;; PRIOR FILING DATE: 2001-08-02  
;; NUMBER OF SEQ ID NOS: 3  
;; SOFTWARE: PatentIn version 3.2  
;; SEQ ID NO 3  
;; LENGTH: 22  
;; TYPE: DNA  
;; ORGANISM: Artificial  
;; FEATURE:  
;; OTHER INFORMATION: Anchored capture oligonucleotide  
;; FEATURE:  
;; NAME/KEY: misc feature  
;; LOCATION: (22)..(22)  
;; OTHER INFORMATION: n is a, c, g, or t  
US-10-664-000-3

Query Match 0.9%; Score 17.2; DB 1; Length 22;  
Best Local Similarity 94.4%; Pred. No. 1.8e+02;  
Matches 17; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAGAAAAAAGAAAA 1851  
: ||||| ||||| |||||  
Db 21 BAAAAAAGAAAAAAGAAAA 4

RESULT 100  
US-10-601-140A-32/c  
;; Sequence 32, Application US/10601140A  
;; Publication No. US20050053942A1  
;; GENERAL INFORMATION:  
;; APPLICANT: KAUPPINEN, SAKARI  
;; APPLICANT: JACOBSEN, NANA  
;; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
;; FILE REFERENCE: 57764(71994)  
;; CURRENT APPLICATION NUMBER: US/10/601,140A  
;; CURRENT FILING DATE: 2003-06-20  
;; PRIOR APPLICATION NUMBER: US 60/390,928  
;; PRIOR FILING DATE: 2002-06-24  
;; NUMBER OF SEQ ID NOS: 45  
;; SOFTWARE: PatentIn Ver. 3.2  
;; SEQ ID NO 32  
;; LENGTH: 22  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
;; OTHER INFORMATION: oligonucleotide  
;; FEATURE:  
;; NAME/KEY: modified\_base

```
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (22)
; OTHER INFORMATION: a, t, c or g
US-10-601-140A-32
```

```
Query Match 0.9%; Score 17.2; DB 1; Length 22;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1834 GAAAAAAAAAAAAAAAAAAAA 1851
Db 21 BAAAAAAAAAAAAAAAAAAAA 4
```

```
RESULT 101
US-10-601-140A-45/c
; Sequence 45, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764 (71994)
; CURRENT APPLICATION NUMBER: US/10/601.140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 45
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (22)
; OTHER INFORMATION: a, t, c or g
US-10-601-140A-45
```

```
Query Match 0.9%; Score 17.2; DB 1; Length 22;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1834 GAAAAAAAAAAAAAAAAAAAA 1851
Db 21 BAAAAAAAAAAAAAAAAAAAA 4
```

```
RESULT 102
US-10-849-072-21
; Sequence 21, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; TITLE OF INVENTION: used
; FILE REFERENCE: 4780/00/WO
; CURRENT APPLICATION NUMBER: US/10/849,072
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-21
```

```
Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAAAAA 17
```

```
RESULT 103
US-10-849-072-23/c
; Sequence 23, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; TITLE OF INVENTION: used
; FILE REFERENCE: 4780/00/WO
; CURRENT APPLICATION NUMBER: US/10/849,072
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```



; OTHER INFORMATION: Description of Artificial Sequence: second  
; OTHER INFORMATION: fragment of SEQ ID NO: 6  
US-10-849-072-23

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 18 AAAAAAAAAAAAAAAAAA 2

## RESULT 104

US-10-831-778-913/c  
; Sequence 913, Application US/10831778  
; Publication No. US20040235774A1  
; GENERAL INFORMATION:  
; APPLICANT: Bratzler, Robert L.  
; APPLICANT: Petersen, Deanna M.  
; APPLICANT: Fouron, Yves  
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the  
; FILE REFERENCE: C1037/7013 (HCL/MAT)  
; CURRENT APPLICATION NUMBER: US/10/831,778  
; CURRENT FILING DATE: 2004-04-23  
; PRIOR APPLICATION NUMBER: US 60/179,991  
; PRIOR FILING DATE: 2000-02-03  
; NUMBER OF SEQ ID NOS: 1093  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 913  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Sequence  
US-10-831-778-913

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 18 AAAAAAAAAAAAAAAAAA 2

## RESULT 105

US-10-831-778-939/c  
; Sequence 939, Application US/10831778  
; Publication No. US20040235774A1  
; GENERAL INFORMATION:  
; APPLICANT: Bratzler, Robert L.  
; APPLICANT: Petersen, Deanna M.  
; APPLICANT: Fouron, Yves  
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the  
; FILE REFERENCE: C1037/7013 (HCL/MAT)  
; CURRENT APPLICATION NUMBER: US/10/831,778  
; CURRENT FILING DATE: 2004-04-23  
; PRIOR APPLICATION NUMBER: US 60/179,991  
; PRIOR FILING DATE: 2000-02-03  
; NUMBER OF SEQ ID NOS: 1093  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 939  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Sequence  
US-10-831-778-939

Query Match 0.9%; Score 17; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 18 AAAAAAAAAAAAAAAAAA 2

## RESULT 106

US-10-776-933-150/c  
; Sequence 150, Application US/10776933  
; Publication No. US20040241717A1  
; GENERAL INFORMATION:  
; APPLICANT: HANSEN, BO  
; APPLICANT: THURUE, CHARLOTTE ALBAEK  
; APPLICANT: WESTERGAARD, MAJKEN  
; APPLICANT: PETERSEN, KANILLE DUMONG  
; APPLICANT: WISENBACH, MARGIT  
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN  
; FILE REFERENCE: 58614(71432)  
; CURRENT APPLICATION NUMBER: US/10/776,933  
; CURRENT FILING DATE: 2004-02-10  
; PRIOR APPLICATION NUMBER: 60/446,374  
; PRIOR FILING DATE: 2003-02-10  
; NUMBER OF SEQ ID NOS: 150  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 150  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: poly-T oligonucleotide  
; FEATURE:  
; OTHER INFORMATION: This sequence may encompass 12-18 nucleotides  
; OTHER INFORMATION: according to the specification as filed  
US-10-776-933-150

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 18 AAAAAAAAAAAAAAAAAA 2

## RESULT 107

US-10-674-159A-112/c  
; Sequence 112, Application US/10674159A  
; Publication No. US20040242518A1  
; GENERAL INFORMATION:  
; APPLICANT: Chen, Jianzhu  
; APPLICANT: Ge, Qing  
; APPLICANT: Eisen, Herman  
; TITLE OF INVENTION: Influenza Therapeutic  
; FILE REFERENCE: 0492611-0506  
; CURRENT APPLICATION NUMBER: US/10/674,159A  
; CURRENT FILING DATE: 2003-09-29  
; NUMBER OF SEQ ID NOS: 271  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 112  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: mRNA  
US-10-674-159A-112

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;



Publication No. US20050014712A1  
GENERAL INFORMATION:  
APPLICANT: HANSEN, BO  
APPLICANT: THURU, CHARLOTTE ALBAEK  
APPLICANT: WESTERGAARD, MAJKEN  
APPLICANT: PETERSEN, KAMILLE DUMONG  
APPLICANT: WISENBACH, MARGIT  
TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION  
CURRENT APPLICATION NUMBER: US/10/776,934  
FILE REFERENCE: 58610(71432)  
CURRENT FILING DATE: 2004-02-10  
PRIOR APPLICATION NUMBER: 60/446,372  
PRIOR FILING DATE: 2003-02-10  
PRIOR APPLICATION NUMBER: 60/523,591  
PRIOR FILING DATE: 2003-11-19  
NUMBER OF SEQ ID NOS: 741  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 741  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial sequence  
FEATURE:  
OTHER INFORMATION: poly-T oligonucleotide  
FEATURE:  
OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the  
US-10-776-934-741

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 112  
US-10-601-140A-24/c  
Sequence 24, Application US/10601140A  
Publication No. US20050053942A1  
GENERAL INFORMATION:  
APPLICANT: KAUPPINEN, SAKARI  
APPLICANT: JACOBSEN, NANA  
TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
FILE REFERENCE: 57764(71994)  
CURRENT APPLICATION NUMBER: US/10/601,140A  
CURRENT FILING DATE: 2003-06-20  
PRIOR APPLICATION NUMBER: US 60/390,928  
PRIOR FILING DATE: 2002-06-24  
NUMBER OF SEQ ID NOS: 45  
SOFTWARE: PatentIn Ver. 3.2  
SEQ ID NO 24  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Primer  
NAME/KEY: misc feature  
LOCATION: (1)..(18)  
OTHER INFORMATION: this sequence may encompass 12-18 nucleotides  
US-10-601-140A-24

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 113  
US-10-884-617-2/c  
Sequence 2, Application US/10884617  
Publication No. US20050054730A1  
GENERAL INFORMATION:  
APPLICANT: Fu, Jin  
APPLICANT: Gaetani, Silvana  
APPLICANT: Picomelli, Daniele  
TITLE OF INVENTION: Compounds, Compositions and Treatments of  
FILE REFERENCE: Oleoylcholanamide-Like Modulators of PPARalpha  
CURRENT APPLICATION NUMBER: US/10/884,617  
CURRENT FILING DATE: 2004-07-01  
PRIOR APPLICATION NUMBER: US 60/279,542  
PRIOR FILING DATE: 2001-03-27  
PRIOR APPLICATION NUMBER: US 60/336,289  
PRIOR FILING DATE: 2001-10-31  
PRIOR APPLICATION NUMBER: US 10/112,509  
PRIOR FILING DATE: 2002-03-27  
PRIOR APPLICATION NUMBER: US 60/485,062  
PRIOR FILING DATE: 2003-07-02  
NUMBER OF SEQ ID NOS: 23  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 2  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence:Oligo(dt)-12-18  
OTHER INFORMATION: primer for reverse transcription of total RNA  
NAME/KEY: modified base  
LOCATION: (13)..(18)  
OTHER INFORMATION: t at positions 13-18 may be present or absent  
US-10-884-617-2

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 114  
US-10-669-962-27/c  
Sequence 27, Application US/10669962  
Publication No. US20050081264A1  
GENERAL INFORMATION:  
APPLICANT: Bruggiera, Filippa  
APPLICANT: Holton, Timothy A.  
APPLICANT: Michael, Michael Z.  
TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES  
FILE REFERENCE: 11658  
CURRENT APPLICATION NUMBER: US/10/669,962  
CURRENT FILING DATE: 2003-09-24  
PRIOR APPLICATION NUMBER: US/09/142,108C  
PRIOR FILING DATE: 1998-09-01  
PRIOR APPLICATION NUMBER: PN8386  
PRIOR FILING DATE: 1996-03-01  
NUMBER OF SEQ ID NOS: 45  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 27  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide  
US-10-669-962-27

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
DB 17 AAAAAAAAAAAAAAAAAA 1

RESULT 115  
US-10-669-962-29/c  
; Sequence 29, Application US/10669962  
; Publication No. US20050081264A1  
; GENERAL INFORMATION:  
; APPLICANT: Brugliera, Filippa  
; APPLICANT: Holton, Timothy A.  
; APPLICANT: Michael, Michael Z.  
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES  
; TITLE OF INVENTION: AND USES THEREFOR  
; FILE REFERENCE: 11658  
; CURRENT APPLICATION NUMBER: US/10/669,962  
; CURRENT FILING DATE: 2003-09-24  
; PRIOR APPLICATION NUMBER: US/09/142,108C  
; PRIOR FILING DATE: 1998-09-01  
; PRIOR APPLICATION NUMBER: PN8386  
; PRIOR FILING DATE: 1996-03-01  
; NUMBER OF SEQ ID NOS: 45  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 29  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide  
US-10-669-962-29

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
DB 17 AAAAAAAAAAAAAAAAAA 1

RESULT 116  
US-10-503-120-1/c  
; Sequence 1, Application US/10503120  
; Publication No. US20050142535A1  
; GENERAL INFORMATION:  
; APPLICANT: MCGILL UNIVERSITY ET AL.  
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF  
; FILE REFERENCE: 85827-63  
; CURRENT APPLICATION NUMBER: US/10/503,120  
; CURRENT FILING DATE: 2004-07-30  
; PRIOR APPLICATION NUMBER: US 60/352,873  
; PRIOR FILING DATE: 2002-02-01  
; NUMBER OF SEQ ID NOS: 22  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Oligonucleotide  
US-10-503-120-1

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851

DB 18 AAAAAAAAAAAAAAAAAA 2  
|||||

RESULT 117  
US-10-503-120-8/c  
; Sequence 8, Application US/10503120  
; Publication No. US20050142535A1  
; GENERAL INFORMATION:  
; APPLICANT: MCGILL UNIVERSITY ET AL.  
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF  
; FILE REFERENCE: 85827-63  
; CURRENT APPLICATION NUMBER: US/10/503,120  
; CURRENT FILING DATE: 2004-07-30  
; PRIOR APPLICATION NUMBER: US 60/352,873  
; PRIOR FILING DATE: 2002-02-01  
; NUMBER OF SEQ ID NOS: 22  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 8  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Oligonucleotide  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (1)..(17)  
; OTHER INFORMATION: Residues 1, 3, 5, 7, 9, 11, 13, 15 and 17 are 2'-O-methyl-D-uridi  
US-10-503-120-8

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
DB 18 AAAAAAAAAAAAAAAAAA 2

RESULT 118  
US-10-503-120-9/c  
; Sequence 9, Application US/10503120  
; Publication No. US20050142535A1  
; GENERAL INFORMATION:  
; APPLICANT: MCGILL UNIVERSITY ET AL.  
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF  
; FILE REFERENCE: 85827-63  
; CURRENT APPLICATION NUMBER: US/10/503,120  
; CURRENT FILING DATE: 2004-07-30  
; PRIOR APPLICATION NUMBER: US 60/352,873  
; PRIOR FILING DATE: 2002-02-01  
; NUMBER OF SEQ ID NOS: 22  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 9  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Oligonucleotide  
; NAME/KEY: misc feature  
; LOCATION: (1)..(15)  
; OTHER INFORMATION: Residues 1-3, 7-9, and 13-15 are 2'-O-methyl-D-uridine  
US-10-503-120-9

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
DB 18 AAAAAAAAAAAAAAAAAA 2

RESULT 119  
US-10-503-120-10/c  
; Sequence 10, Application US/10503120  
; Publication No. US2005014235A1  
; GENERAL INFORMATION:  
; APPLICANT: MCGILL UNIVERSITY ET AL.  
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF  
; FILE REFERENCE: 85827-63  
; CURRENT APPLICATION NUMBER: US/10/503,120  
; CURRENT FILING DATE: 2004-07-30  
; PRIOR APPLICATION NUMBER: US 60/352,873  
; PRIOR FILING DATE: 2002-02-01  
; NUMBER OF SEQ ID NOS: 22  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 10  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Oligonucleotide  
; NAME/KEY: misc\_feature  
; LOCATION: (1)..(18)  
; OTHER INFORMATION: Residues 1-6 and 13-18 are 2'-O-methyl-D-uridine  
US-10-503-120-10

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 120  
US-10-503-120-21  
; Sequence 21, Application US/10503120  
; Publication No. US2005014253A1  
; GENERAL INFORMATION:  
; APPLICANT: MCGILL UNIVERSITY ET AL.  
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF  
; FILE REFERENCE: 85827-63  
; CURRENT APPLICATION NUMBER: US/10/503,120  
; CURRENT FILING DATE: 2004-07-30  
; PRIOR APPLICATION NUMBER: US 60/352,873  
; PRIOR FILING DATE: 2002-02-01  
; NUMBER OF SEQ ID NOS: 22  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 21  
; LENGTH: 18  
; TYPE: RNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Target RNA oligonucleotide  
US-10-503-120-21

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 121  
US-11-024-428-7/c  
; Sequence 7, Application US/11024428  
; Publication No. US20050106676A1  
; GENERAL INFORMATION:

; APPLICANT: NAGAI, HIROSHI  
; APPLICANT: KURODA, KYOKO  
; APPLICANT: NAKAJIMA, TERUMI  
; TITLE OF INVENTION: NOVEL PROTEINS HAVING HEMOLYTIC ACTIVITY AND GENES  
; TITLE OF INVENTION: ENCODING THE PROTEIN  
; FILE REFERENCE: 037181.50611US  
; CURRENT APPLICATION NUMBER: US/11/024,428  
; CURRENT FILING DATE: 2004-12-30  
; PRIOR APPLICATION NUMBER: US/09/979,275  
; PRIOR FILING DATE: 2003-05-27  
; PRIOR APPLICATION NUMBER: PCT/JP01/02209  
; PRIOR FILING DATE: 2001-03-21  
; PRIOR APPLICATION NUMBER: JP 2000-78967  
; PRIOR FILING DATE: 2000-03-21  
; NUMBER OF SEQ ID NOS: 12  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 7  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: oligonucleotide  
; FEATURE:  
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides  
US-11-024-428-7

Query Match 0.9%; Score 17; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 122  
US-10-760-940-1/c  
; Sequence 1, Application US/10760940  
; Publication No. US20040219577A1  
; GENERAL INFORMATION:  
; APPLICANT: Ravikumar, Vasulinga  
; APPLICANT: Manoharan, Muthiah  
; APPLICANT: Capaldi, Daniel C.  
; APPLICANT: Krotz, Achim  
; APPLICANT: Cole, Douglas L.  
; APPLICANT: Guzaev, Andrei  
; TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS  
; FILE REFERENCE: ISIS-5422  
; CURRENT APPLICATION NUMBER: US/10/760,940  
; CURRENT FILING DATE: 2004-01-20  
; PRIOR APPLICATION NUMBER: US 10/232,881  
; PRIOR FILING DATE: 2002-08-30  
; PRIOR APPLICATION NUMBER: US 09/288,679  
; PRIOR FILING DATE: 1999-04-09  
; PRIOR APPLICATION NUMBER: US 60/118,564  
; PRIOR FILING DATE: 1999-02-04  
; NUMBER OF SEQ ID NOS: 5  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Construct  
US-10-760-940-1

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||

Db 19 AAAAAAAAAAAAAAAAAA 3

## RESULT 123

US-10-913-246-22  
; Sequence 22, Application US/10913246  
; Publication No. US20050003441A1  
; GENERAL INFORMATION:  
; APPLICANT: Kurn, Nurith  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; FILE REFERENCE: 492692000500  
; CURRENT APPLICATION NUMBER: US/10/913,246  
; CURRENT FILING DATE: 2004-08-05  
; PRIOR APPLICATION NUMBER: US/10/100,321  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 60/274,550  
; PRIOR FILING DATE: 2001-03-09  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
; NAME/KEY: misc\_feature  
; LOCATION: 1  
; OTHER INFORMATION: n = A,T,C or G  
US-10-913-246-22

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 2 AAAAAAAAAAAAAAAAAA 18

## RESULT 124

US-10-913-246-24  
; Sequence 24, Application US/10913246  
; Publication No. US20050003441A1  
; GENERAL INFORMATION:  
; APPLICANT: Kurn, Nurith  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; FILE REFERENCE: 492692000500  
; CURRENT APPLICATION NUMBER: US/10/913,246  
; CURRENT FILING DATE: 2004-08-05  
; PRIOR APPLICATION NUMBER: US/10/100,321  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 60/274,550  
; PRIOR FILING DATE: 2001-03-09  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 24  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-913-246-24

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 1 AAAAAAAAAAAAAAAAAA 17

## RESULT 125

US-10-934-890-22  
; Sequence 22, Application US/10934890  
; Publication No. US20050014192A1  
; GENERAL INFORMATION:  
; APPLICANT: Kurn, Nurith  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; FILE REFERENCE: 492692000500  
; CURRENT APPLICATION NUMBER: US/10/934,890  
; CURRENT FILING DATE: 2004-09-03  
; PRIOR APPLICATION NUMBER: US/10/100,321  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 60/274,550  
; PRIOR FILING DATE: 2001-03-09  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
; NAME/KEY: misc\_feature  
; LOCATION: 1  
; OTHER INFORMATION: n = A,T,C or G  
US-10-934-890-22

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 2 AAAAAAAAAAAAAAAAAA 18

## RESULT 126

US-10-934-890-24  
; Sequence 24, Application US/10934890  
; Publication No. US20050014192A1  
; GENERAL INFORMATION:  
; APPLICANT: Kurn, Nurith  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; FILE REFERENCE: 492692000500  
; CURRENT APPLICATION NUMBER: US/10/934,890  
; CURRENT FILING DATE: 2004-09-03  
; PRIOR APPLICATION NUMBER: US/10/100,321  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 60/274,550  
; PRIOR FILING DATE: 2001-03-09  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 24  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-934-890-24

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
Db 1 AAAAAAAAAAAAAAAAAA 17

```
RESULT 127
US-10-700-884-23/c
; Sequence 23, Application US/10700884
; Publication No. US20050118605A9
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Eldrup, Anne B.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bhat, Balkrishen
; APPLICANT: Griffey, Richard
; APPLICANT: Swayze, Eric E.
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Prakash, Thazha P.
; APPLICANT: Rajeev, Kallanthottathil G.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE
; FILE REFERENCE: ISIS-5317
; CURRENT APPLICATION NUMBER: US/10/700,884
; PRIOR FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: US 10/635,380
; PRIOR FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: US 60/423,760
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 09/479,949
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/479,783
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 08/870,608
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: US 08/659,440
; PRIOR FILING DATE: 1996-06-06
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-O-[2-(methoxy)ethyl]-2-thio-5-methyluridine
US-10-700-884-23

Query Match          0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 128
US-10-800-487-162/c
; Sequence 162, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
; LENGTH: 19
```

```
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-800-487-162

Query Match          0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1850
Db 19 GAAAAAAAAAAAAAAAAA 3

RESULT 129
US-10-800-487-328
; Sequence 328, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-800-487-328

Query Match          0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAAAAAAAAAAAAAA 1850
Db 1 GAAAAAAAAAAAAAAAAA 17

RESULT 130
US-10-940-360-1/c
; Sequence 1, Application US/10940360
; Publication No. US20050137391A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/10/940,360
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: US/09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Novel Sequence
US-10-940-360-1

Query Match          0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 131
US-09-976-900A-55
; Sequence 55, Application US/09976900A
; Publication No. US20040219520A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Eighanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-123
; CURRENT APPLICATION NUMBER: US/09/976,900A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
```

```
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
US-09-976-900A-55

Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 132
US-10-661-415-12
; Sequence 12, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-661-415-12

Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 133
US-10-661-415-15/c
; Sequence 15, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
```



; FILE REFERENCE: 029849/0205  
; CURRENT APPLICATION NUMBER: US/10/661,415  
; CURRENT FILING DATE: 2003-09-12  
; PRIOR APPLICATION NUMBER: PCT/IB03/04573  
; PRIOR FILING DATE: 2003-09-11  
; PRIOR APPLICATION NUMBER: 60/430,934  
; PRIOR FILING DATE: 2002-12-05  
; PRIOR APPLICATION NUMBER: 60/410,264  
; PRIOR FILING DATE: 2002-09-13  
; NUMBER OF SEQ ID NOS: 36  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 15  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-10-661-415-15

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 20 AAAAAAAAAAAAAAAAAA 4

## RESULT 134

US-10-831-778-226/c  
; Sequence 226, Application US/10831778  
; Publication No. US20040235774A1  
; GENERAL INFORMATION:  
; APPLICANT: Bratzler, Robert L.  
; APPLICANT: Petersen, Deanna M.  
; APPLICANT: Fouron, Yves  
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the  
; TITLE OF INVENTION: Treatment of Asthma and Allergy  
; FILE REFERENCE: C1037/7013 (HCL/MAT)  
; CURRENT APPLICATION NUMBER: US/10/831,778  
; CURRENT FILING DATE: 2004-04-23  
; PRIOR APPLICATION NUMBER: US 60/179,991  
; PRIOR FILING DATE: 2000-02-03  
; NUMBER OF SEQ ID NOS: 1093  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 226  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Sequence  
US-10-831-778-226

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 20 AAAAAAAAAAAAAAAAAA 4

## RESULT 135

US-10-831-778-556/c  
; Sequence 556, Application US/10831778  
; Publication No. US20040235774A1  
; GENERAL INFORMATION:  
; APPLICANT: Bratzler, Robert L.  
; APPLICANT: Petersen, Deanna M.  
; APPLICANT: Fouron, Yves  
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the  
; TITLE OF INVENTION: Treatment of Asthma and Allergy

; FILE REFERENCE: C1037/7013 (HCL/MAT)  
; CURRENT APPLICATION NUMBER: US/10/831,778  
; CURRENT FILING DATE: 2004-04-23  
; PRIOR APPLICATION NUMBER: US 60/179,991  
; PRIOR FILING DATE: 2000-02-03  
; NUMBER OF SEQ ID NOS: 1093  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 556  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Sequence  
US-10-831-778-556

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 20 AAAAAAAAAAAAAAAAAA 4

## RESULT 136

US-10-831-778-560  
; Sequence 560, Application US/10831778  
; Publication No. US20040235774A1  
; GENERAL INFORMATION:  
; APPLICANT: Bratzler, Robert L.  
; APPLICANT: Petersen, Deanna M.  
; APPLICANT: Fouron, Yves  
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the  
; TITLE OF INVENTION: Treatment of Asthma and Allergy  
; FILE REFERENCE: C1037/7013 (HCL/MAT)  
; CURRENT APPLICATION NUMBER: US/10/831,778  
; CURRENT FILING DATE: 2004-04-23  
; PRIOR APPLICATION NUMBER: US 60/179,991  
; PRIOR FILING DATE: 2000-02-03  
; NUMBER OF SEQ ID NOS: 1093  
; SOFTWARE: FastSEQ for Windows Version 3.0  
; SEQ ID NO 560  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Sequence  
US-10-831-778-560

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 1 AAAAAAAAAAAAAAAAAA 17

## RESULT 137

US-10-728-078-14  
; Sequence 14, Application US/10728078  
; Publication No. US20050038229A1  
; GENERAL INFORMATION:  
; APPLICANT: Lipovsek, Dasa  
; APPLICANT: Wagner, Richard W  
; APPLICANT: Kuimelis, Robert G  
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS  
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS  
; FILE REFERENCE: 50036/021004  
; CURRENT APPLICATION NUMBER: US/10/728,078  
; CURRENT FILING DATE: 2003-12-03  
; PRIOR APPLICATION NUMBER: US/09/688,566  
; PRIOR FILING DATE: 2000-10-16

```
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Puromycin linker oligonucleotide
US-10-728-078-14
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 1 AAAAAAAAAAAAAAAAAA 17
```

```
RESULT 138
US-10-728-078-23/c
; Sequence 23, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-728-078-23
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 20 AAAAAAAAAAAAAAAAAA 4
```

```
RESULT 139
US-10-601-140A-1/c
; Sequence 1, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
```

```
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: Patentin Ver. 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-1
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1835 AAAAAAAAAAAAAAAAAA 1851
    |||||
Db 20 AAAAAAAAAAAAAAAAAA 4
```

```
RESULT 140
US-10-601-140A-2/c
; Sequence 2, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: Patentin Ver. 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
```

```
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-2
```

```
Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4
```

## RESULT 141

```
US-10-601-140A-3/c
; Sequence 3, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 3
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-3
```

```
Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4
```

## RESULT 142

```
US-10-601-140A-4/c
; Sequence 4, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
```

```
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (16)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-4
```

```
Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAAAAAA 4
```

## RESULT 143

```
US-10-601-140A-6/c
; Sequence 6, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 6
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
```

```
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-6
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAA 4
```

## RESULT 144

```
US-10-601-140A-7/c
; Sequence 7, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-7
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAA 4
```

## RESULT 145

```
US-10-601-140A-8/c
; Sequence 8, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-8
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1851
Db 20 AAAAAAAAAAAAAA 4
```

## RESULT 146

```
US-10-601-140A-9/c
; Sequence 9, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (3)..(4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
US-10-601-140A-9
```

```
Query Match          0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```





```
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/10/620,642
  FILING DATE: 16-Jul-2003
  CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
  APPLICATION NUMBER: US/10/175,608
  FILING DATE: 16-Oct-2002
  APPLICATION NUMBER: 09/635,249
  FILING DATE: 07-Aug-2000
  APPLICATION NUMBER: 09/486,546
  FILING DATE: 24-May-1995
  APPLICATION NUMBER: 08/172,329
  FILING DATE: 21-Dec-1993
  APPLICATION NUMBER: 07/982,255
  FILING DATE: 25-Nov-1992
  APPLICATION NUMBER: 07/684,535
  FILING DATE: 10-Apr-1991
  APPLICATION NUMBER: 09/589,701
  FILING DATE: 10-Oct-1991
  APPLICATION NUMBER: 07/573,616
  FILING DATE: 24-Aug-1990
  APPLICATION NUMBER: 07/537,198
  FILING DATE: 11-Jun-1990
  APPLICATION NUMBER: 07/422,383
  FILING DATE: 16-Oct-1989
ATTORNEY/AGENT INFORMATION:
  NAME: Clough, David W.
  REGISTRATION NUMBER: 36,107
  REFERENCE/DOCKET NUMBER: 01017/35199
  TELECOMMUNICATION INFORMATION:
    TELEPHONE: 312/474-6300
    TELEFAX: 312/474-0448
    TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 32:
  SEQUENCE CHARACTERISTICS:
    LENGTH: 20 base pairs
    TYPE: nucleic acid
    STRANDEDNESS: single
    TOPOLOGY: linear
  MOLECULE TYPE: DNA
  SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-10-620-642-32
Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 154
US-10-831-901A-29729/c
; Sequence 29729, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian A.
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; PRIOR APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-Aug-2000
; PRIOR APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-May-1995
; PRIOR APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-Dec-1993
; PRIOR APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-Nov-1992
; PRIOR APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-Apr-1991
; PRIOR APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-Oct-1991
; PRIOR APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-Aug-1990
; PRIOR APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-Jun-1990
; PRIOR APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-Oct-1989
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
```

```
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
  APPLICATION NUMBER: US/10/831,901A
  FILING DATE: 2004-04-26
  PRIOR APPLICATION NUMBER: 60/466,426
  FILING DATE: 2003-04-28
  PRIOR APPLICATION NUMBER: 60/468,562
  FILING DATE: 2003-05-06
  PRIOR APPLICATION NUMBER: 60/467,770
  FILING DATE: 2003-04-30
  PRIOR APPLICATION NUMBER: 60/468,627
  FILING DATE: 2003-05-06
  PRIOR APPLICATION NUMBER: 60/477,637
  FILING DATE: 2003-06-10
  PRIOR APPLICATION NUMBER: 60/483,579
  FILING DATE: 2003-06-27
  NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29729
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29729
Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 155
US-10-831-901A-29730/c
; Sequence 29730, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian A.
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29730
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
```

US-10-831-901A-29730

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
DB 18 AAAAAAAAAAAAAAAAAA 2

RESULT 156

US-10-831-901A-29731/c  
; Sequence 29731, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank  
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 29731  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-29731

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
DB 19 AAAAAAAAAAAAAAAAAA 3

RESULT 157

US-10-831-901A-29732/c  
; Sequence 29732, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.

; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank  
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; PRIOR FILING DATE: 2003-06-27  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 29732  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-29732

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
DB 20 AAAAAAAAAAAAAAAAAA 4

RESULT 158

US-10-831-901A-29733/c  
; Sequence 29733, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank  
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; PRIOR FILING DATE: 2003-06-27  
; NUMBER OF SEQ ID NOS: 30063



; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 29733  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-29733

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 AAAAAAAAAAAAAAAAAA 4

## RESULT 159

US-10-831-901A-29734/c  
; Sequence 29734, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:

; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank

; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)

; CURRENT APPLICATION NUMBER: US/10/831.901A  
; CURRENT FILING DATE: 2004-04-26

; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; PRIOR FILING DATE: 2003-06-27  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 29734  
; LENGTH: 20

; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound

US-10-831-901A-29734

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 AAAAAAAAAAAAAAAAAA 4

## RESULT 160

US-10-831-901A-29735/c  
; Sequence 29735, Application US/10831901A  
; Publication No. US20050100885A1

## ; GENERAL INFORMATION:

; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank

; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)

; CURRENT APPLICATION NUMBER: US/10/831.901A  
; CURRENT FILING DATE: 2004-04-26

; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; PRIOR FILING DATE: 2003-06-27  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 29735  
; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense compound

US-10-831-901A-29735

## Query Match

0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 AAAAAAAAAAAAAAAAAA 4

## RESULT 161

US-10-831-901A-29736/c  
; Sequence 29736, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:

; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank

; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)

; CURRENT APPLICATION NUMBER: US/10/831.901A  
; CURRENT FILING DATE: 2004-04-26

; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30

;  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; PRIOR FILING DATE: 2003-06-27  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 29736  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-29736

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 162  
US-10-789-831-22  
; Sequence 22, Application US/10789831  
; Publication No. US20050130174A1  
; GENERAL INFORMATION:  
; APPLICANT: Bao, Yijia P.  
; APPLICANT: Muller, Uwe R.  
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH UNIVERSAL NANOPARTICLE  
; FILE REFERENCE: 03-214-A  
; CURRENT APPLICATION NUMBER: US/10/789,831  
; PRIOR FILING DATE: 2004-02-27  
; PRIOR APPLICATION NUMBER: US 60/450,268  
; PRIOR FILING DATE: 2003-02-27  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 22  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; FEATURE:  
; OTHER INFORMATION: detection probe  
; NAME/KEY: unsure  
; LOCATION: (1)-(1)  
; OTHER INFORMATION: a comprises an epiandrosterone disulfide group  
US-10-789-831-22

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 163  
US-10-789-831-23/c  
; Sequence 23, Application US/10789831  
; Publication No. US20050130174A1  
; GENERAL INFORMATION:  
; APPLICANT: Bao, Yijia P.  
; APPLICANT: Muller, Uwe R.  
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH UNIVERSAL NANOPARTICLE  
; FILE REFERENCE: 03-214-A  
; CURRENT APPLICATION NUMBER: US/10/789,831

;  
; CURRENT FILING DATE: 2004-02-27  
; PRIOR APPLICATION NUMBER: US 60/450,268  
; PRIOR FILING DATE: 2003-02-27  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 23  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: detection probe  
; NAME/KEY: unsure  
; LOCATION: (1)-(1)  
; OTHER INFORMATION: t comprises an epiandrosterone disulfide group  
US-10-789-831-23

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
| | | | | | | | | | | | | | | | | | | | | |  
Db 20 AAAAAAAAAAAAAAAAAA 4

RESULT 164  
US-10-789-831-24  
; Sequence 24, Application US/10789831  
; Publication No. US20050130174A1  
; GENERAL INFORMATION:  
; APPLICANT: Bao, Yijia P.  
; APPLICANT: Muller, Uwe R.  
; TITLE OF INVENTION: LABEL-FREE GENE EXPRESSION PROFILING WITH UNIVERSAL NANOPARTICLE  
; FILE REFERENCE: 03-214-A  
; CURRENT APPLICATION NUMBER: US/10/789,831  
; CURRENT FILING DATE: 2004-02-27  
; PRIOR APPLICATION NUMBER: US 60/450,268  
; PRIOR FILING DATE: 2003-02-27  
; NUMBER OF SEQ ID NOS: 24  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 24  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: detection probe  
US-10-789-831-24

Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
| | | | | | | | | | | | | | | | | | | | | |  
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 165  
US-10-831-778-912/c  
; Sequence 912, Application US/10831778  
; Publication No. US20040235774A1  
; GENERAL INFORMATION:  
; APPLICANT: Bratzler, Robert L.  
; APPLICANT: Petersen, Deanna M.  
; APPLICANT: Fouron, Yves  
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the  
; FILE REFERENCE: C1037/7013 (HCL/NAT)  
; CURRENT APPLICATION NUMBER: US/10/831,778  
; CURRENT FILING DATE: 2004-04-23  
; PRIOR APPLICATION NUMBER: US 60/179,991

; PRIOR FILING DATE: 2000-02-03  
; NUMBER OF SEQ ID NOS: 1093  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 912  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURES:  
; OTHER INFORMATION: Synthetic Sequence  
US-10-831-778-912

Query Match 0.9%; Score 17; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 21 AAAAAAAAAAAAAAAAAA 5

## RESULT 166

US-10-751-736-19135  
; Sequence 19135, Application US/10751736  
; Publication No. US2004026230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751.736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19135  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-19135

Query Match 0.9%; Score 17; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGTT 1460  
Db 4 ATGTTGCTGCTGCTGTT 20

## RESULT 167

US-10-751-736-19136  
; Sequence 19136, Application US/10751736  
; Publication No. US2004026230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751.736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19136  
; LENGTH: 21

; TYPE: RNA  
; ORGANISM: RNAI  
US-10-751-736-19136

Query Match 0.9%; Score 17; DB 1; Length 21;  
Best Local Similarity 52.9%; Pred. No. 1.7e+02;  
Matches 9; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGTT 1460  
Db 2 AUGUUGCUGCUGCUGUU 18

## RESULT 168

US-10-751-736-19138  
; Sequence 19138, Application US/10751736  
; Publication No. US2004026230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751.736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 19138  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: homo sapiens  
US-10-751-736-19138

Query Match 0.9%; Score 17; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGTT 1460  
Db 2 ATGTTGCTGCTGCTGTT 18

## RESULT 169

US-10-913-246-23  
; Sequence 23, Application US/10913246  
; Publication No. US2005003441A1  
; GENERAL INFORMATION:  
; APPLICANT: Kurn, Nurith  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; FILE REFERENCE: 49262000500  
; CURRENT APPLICATION NUMBER: US/10/913.246  
; CURRENT FILING DATE: 2004-08-05  
; PRIOR APPLICATION NUMBER: US/10/100.321  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 60/274,550  
; PRIOR FILING DATE: 2001-03-09  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURES:  
; OTHER INFORMATION: Primer  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: 1  
; OTHER INFORMATION: n = A,T,C or G

## US-10-913-246-23

Query Match 0.9%; Score 17; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
DB 2 AAAAAAAAAAAAAAAAAA 18

## RESULT 170

US-10-934-890-23  
; Sequence 23, Application US/10934890  
; Publication No. US20050014192A1  
; GENERAL INFORMATION:  
; APPLICANT: Kurn, Nurith  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; FILE REFERENCE: AMPLIFICATION OF RNA SEQUENCES  
; CURRENT APPLICATION NUMBER: US/10/934,890  
; CURRENT FILING DATE: 2004-09-03  
; PRIOR APPLICATION NUMBER: US/10/100,321  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 60/274,550  
; PRIOR FILING DATE: 2001-03-09  
; NUMBER OF SEQ ID NOS: 25  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: 1  
; OTHER INFORMATION: n = A,T,C or G  
US-10-934-890-23

Query Match 0.9%; Score 17; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
DB 2 AAAAAAAAAAAAAAAAAA 18

## RESULT 171

US-10-830-287A-7/c  
; Sequence 7, Application US/10830287A  
; Publication No. US20050038238A1  
; GENERAL INFORMATION:  
; APPLICANT: Kriesel, John D.  
; APPLICANT: Jones, Brandt B.  
; APPLICANT: Grissom, Charles B.  
; APPLICANT: Herpin, Geoff  
; APPLICANT: Glazer, Peter M.  
; TITLE OF INVENTION: OLIGONUCLEOTIDE COMPLEXES FOR USE AS ANTI-VIRAL THERAPEUTICS  
; FILE REFERENCE: 007180-19  
; CURRENT APPLICATION NUMBER: US/10/830,287A  
; CURRENT FILING DATE: 2004-04-21  
; PRIOR APPLICATION NUMBER: 60/464,270  
; PRIOR FILING DATE: 2003-04-21  
; NUMBER OF SEQ ID NOS: 12  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Variola virus  
US-10-830-287A-7

Query Match 0.9%; Score 17; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
DB 21 AAAAAAAAAAAAAAAAAA 5

## RESULT 172

US-10-601-140A-43  
; Sequence 43, Application US/10601140A  
; Publication No. US20050053942A1  
; GENERAL INFORMATION:  
; APPLICANT: KAUPPINEN, SAKARI  
; APPLICANT: JACOBSEN, NANA  
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
; FILE REFERENCE: NUCLEOTIDE SEQUENCE  
; FILE REFERENCE: 57764(71994)  
; CURRENT APPLICATION NUMBER: US/10/601,140A  
; CURRENT FILING DATE: 2003-06-20  
; PRIOR APPLICATION NUMBER: US 60/390,928  
; PRIOR FILING DATE: 2002-06-24  
; NUMBER OF SEQ ID NOS: 45  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 43  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-601-140A-43

Query Match 0.9%; Score 17; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||  
DB 1 AAAAAAAAAAAAAAAAAA 17

## RESULT 173

US-09-263-981-4/c  
; Sequence 4, Application US/09263981  
; Patent No. US20020155437A1  
; GENERAL INFORMATION:  
; APPLICANT: Fisher, Paul B.  
; TITLE OF INVENTION: Use of Prostate Tumor Inducing Gene for Detection of  
; FILE REFERENCE: Cancer Cells  
; FILE REFERENCE: 51950-A-PCT-US/JML  
; CURRENT APPLICATION NUMBER: US/09/263,981  
; CURRENT FILING DATE: 1999-03-05  
; PRIOR APPLICATION NUMBER: PCT/US97/15645  
; PRIOR FILING DATE: 1997-09-05  
; PRIOR APPLICATION NUMBER: 08/708,208  
; PRIOR FILING DATE: 1996-09-06  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: primer  
US-09-263-981-4

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 1.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGTT 1460  
|||||

Db 20 TGAATGTTGCTGCTGCTGTT 1

RESULT 174  
US-10-843-938-4/c  
; Sequence 4, Application US/10843938  
; Publication No. US20040203063A1  
; GENERAL INFORMATION:  
; APPLICANT: Fisher, Paul B.  
; TITLE OF INVENTION: USE OF PROSTATE TUMOR INDUCING GENE FOR  
; FILE REFERENCE: A34609-A-PCT-USA-A (070050.2578)  
; CURRENT APPLICATION NUMBER: US/10/843,938  
; CURRENT FILING DATE: 2004-05-12  
; PRIOR APPLICATION NUMBER: 09/263,981  
; PRIOR FILING DATE: 1999-03-05  
; PRIOR APPLICATION NUMBER: PCT/US97/15645  
; PRIOR FILING DATE: 1997-09-05  
; PRIOR APPLICATION NUMBER: 08/708,208  
; PRIOR FILING DATE: 1996-09-06  
; PRIOR APPLICATION NUMBER: 08/371,377  
; PRIOR FILING DATE: 1995-01-11  
; NUMBER OF SEQ ID NOS: 11  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic oligonucleotide  
US-10-843-938-4

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 1.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1441 TGAATGTTGCTGCTGCTGTT 1460

Db 20 TGAATGTTGCTGCTGCTGTT 1

RESULT 175  
US-10-751-736-25521  
; Sequence 25521, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25521  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI  
US-10-751-736-25521

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 50.0%; Pred. No. 1.8e+02;  
Matches 10; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 123 TTCGTGGTGTTCACCTTTT 142

Db 1 UUCGGUGAGUUCACCGUU 20

RESULT 176  
US-10-027-632-52359  
; Sequence 52359, Application US/10027632  
; Publication No. US20020198371A1  
; GENERAL INFORMATION:  
; APPLICANT: Wang, David G.  
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide  
; FILE REFERENCE: 108827.129  
; CURRENT APPLICATION NUMBER: US/10/027,632  
; CURRENT FILING DATE: 2002-04-30  
; PRIOR APPLICATION NUMBER: US 60/218,006  
; PRIOR FILING DATE: 2000-07-12  
; PRIOR APPLICATION NUMBER: US 60/198,676  
; PRIOR FILING DATE: 2000-04-20  
; PRIOR APPLICATION NUMBER: US 60/193,483  
; PRIOR FILING DATE: 2000-03-29  
; PRIOR APPLICATION NUMBER: US 60/185,218  
; PRIOR FILING DATE: 2000-02-24  
; PRIOR APPLICATION NUMBER: US 60/167,363  
; PRIOR FILING DATE: 1999-11-23  
; PRIOR APPLICATION NUMBER: US 60/156,358  
; PRIOR FILING DATE: 1999-09-28  
; PRIOR APPLICATION NUMBER: US 60/146,002  
; PRIOR FILING DATE: 1999-08-09  
; NUMBER OF SEQ ID NOS: 325720  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 52359  
; LENGTH: 22  
; TYPE: DNA  
; ORGANISM: Human  
US-10-027-632-52359

Query Match 0.9%; Score 16.8; DB 1; Length 22;  
Best Local Similarity 90.0%; Pred. No. 2e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 789 ACAGCCTGTATTACGGTGA 808

Db 1 ACAACCTGTATTACGGTGA 20

RESULT 177  
US-10-027-632-52359  
; Sequence 52359, Application US/10027632  
; Publication No. US20030204075A9  
; GENERAL INFORMATION:  
; APPLICANT: Wang, David G.  
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide  
; FILE REFERENCE: 108827.129  
; CURRENT APPLICATION NUMBER: US/10/027,632  
; CURRENT FILING DATE: 2002-04-30  
; PRIOR APPLICATION NUMBER: US 60/218,006  
; PRIOR FILING DATE: 2000-07-12  
; PRIOR APPLICATION NUMBER: US 60/198,676  
; PRIOR FILING DATE: 2000-04-20  
; PRIOR APPLICATION NUMBER: US 60/193,483  
; PRIOR FILING DATE: 2000-03-29  
; PRIOR APPLICATION NUMBER: US 60/185,218  
; PRIOR FILING DATE: 2000-02-24  
; PRIOR APPLICATION NUMBER: US 60/167,363  
; PRIOR FILING DATE: 1999-11-23  
; PRIOR APPLICATION NUMBER: US 60/156,358  
; PRIOR FILING DATE: 1999-09-28  
; PRIOR APPLICATION NUMBER: US 60/146,002  
; PRIOR FILING DATE: 1999-08-09  
; NUMBER OF SEQ ID NOS: 325720  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 52359  
; LENGTH: 22  
; TYPE: DNA

```
; ORGANISM: Human
US-10-027-632-52359

Query Match          0.9%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 789 ACAGCCTGTATTACGGTGA 808
Db 1 ACAACCTGTATTACGGTGAA 20

RESULT 178
US-10-349-143-4101/c
; Sequence 4101, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020C91
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4101
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-13272 for SEQ 167,
US-10-349-143-4101

Query Match          0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 730 CCATCTACAGTCTCTACA 747
Db 18 CCATCTACATCTCTACA 1

RESULT 179
US-10-872-984-5/c
; Sequence 5, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
```

```
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-5

Query Match          0.9%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1851
Db 18 GCAAAAAAAAAAAAAAAAA 1

RESULT 180
US-10-289-762-3072/c
; Sequence 3072, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Grifais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3072
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-3072

Query Match          0.9%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1612 TCATCTTCAAGCACCAAC 1629
Db 19 TCATCTTCAAGCACGAC 2

RESULT 181
US-10-831-901A-26525
; Sequence 26525, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
```

;; PRIOR FILING DATE: 2003-06-10  
;; PRIOR APPLICATION NUMBER: 60/483,579  
;; PRIOR FILING DATE: 2003-06-27  
;; NUMBER OF SEQ ID NOS: 30063  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 26525  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Antisense compound  
US-10-831-901A-26525

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 1.8e+02;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 366 ATTATGTACCAAAACCTG 383  
|||||||

Db 1 ATTATGTACCAAAACCTG 18

RESULT 182  
US-10-831-901A-26526  
;; Sequence 26526, Application US/10831901A  
;; Publication No. US20050100885A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Crooke, Stanley T.  
;; APPLICANT: Ecker, David J.  
;; APPLICANT: Sampath, Rangarajan  
;; APPLICANT: Freier, Susan M.  
;; APPLICANT: Massire, Christian  
;; APPLICANT: Hofstadler, Steven A.  
;; APPLICANT: Lowery, Kristin Sannes  
;; APPLICANT: Swayze, Eric  
;; APPLICANT: Baker, Brenda F.  
;; APPLICANT: Bennett, C. Frank  
;; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
;; FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
;; CURRENT APPLICATION NUMBER: US/10/831,901A  
;; CURRENT FILING DATE: 2004-04-26  
;; PRIOR APPLICATION NUMBER: 60/466,426  
;; PRIOR FILING DATE: 2003-04-28  
;; PRIOR APPLICATION NUMBER: 60/468,562  
;; PRIOR FILING DATE: 2003-05-06  
;; PRIOR APPLICATION NUMBER: 60/467,770  
;; PRIOR FILING DATE: 2003-05-06  
;; PRIOR APPLICATION NUMBER: 60/477,637  
;; PRIOR FILING DATE: 2003-06-10  
;; PRIOR APPLICATION NUMBER: 60/483,579  
;; NUMBER OF SEQ ID NOS: 30063  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 26526  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Antisense compound

US-10-831-901A-26526

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 1.8e+02;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 366 ATTATGTACCAAAACCTG 383  
|||||||

Db 2 ATTATGTACCAAAACCTG 19

RESULT 183  
US-10-831-901A-26527  
;; Sequence 26527, Application US/10831901A  
;; Publication No. US20050100885A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Crooke, Stanley T.  
;; APPLICANT: Ecker, David J.  
;; APPLICANT: Sampath, Rangarajan  
;; APPLICANT: Freier, Susan M.  
;; APPLICANT: Massire, Christian  
;; APPLICANT: Hofstadler, Steven A.  
;; APPLICANT: Lowery, Kristin Sannes  
;; APPLICANT: Swayze, Eric  
;; APPLICANT: Baker, Brenda F.  
;; APPLICANT: Bennett, C. Frank  
;; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
;; FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
;; CURRENT APPLICATION NUMBER: US/10/831,901A  
;; CURRENT FILING DATE: 2004-04-26  
;; PRIOR APPLICATION NUMBER: 60/466,426  
;; PRIOR FILING DATE: 2003-04-28  
;; PRIOR APPLICATION NUMBER: 60/468,562  
;; PRIOR FILING DATE: 2003-05-06  
;; PRIOR APPLICATION NUMBER: 60/467,770  
;; PRIOR FILING DATE: 2003-04-30  
;; PRIOR APPLICATION NUMBER: 60/468,627  
;; PRIOR FILING DATE: 2003-05-06  
;; PRIOR APPLICATION NUMBER: 60/477,637  
;; PRIOR FILING DATE: 2003-06-10  
;; PRIOR APPLICATION NUMBER: 60/483,579  
;; NUMBER OF SEQ ID NOS: 30063  
;; SOFTWARE: FastSeq for Windows Version 4.0  
;; SEQ ID NO 26527  
;; LENGTH: 20  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Antisense compound

US-10-831-901A-26527

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 1.8e+02;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 366 ATTATGTACCAAAACCTG 383  
|||||||

Db 3 ATTATGTACCAAAACCTG 20

RESULT 184  
US-10-831-901A-29726/c  
;; Sequence 29726, Application US/10831901A  
;; Publication No. US20050100885A1  
;; GENERAL INFORMATION:  
;; APPLICANT: Crooke, Stanley T.  
;; APPLICANT: Ecker, David J.  
;; APPLICANT: Sampath, Rangarajan  
;; APPLICANT: Freier, Susan M.  
;; APPLICANT: Massire, Christian  
;; APPLICANT: Hofstadler, Steven A.  
;; APPLICANT: Lowery, Kristin Sannes  
;; APPLICANT: Swayze, Eric  
;; APPLICANT: Baker, Brenda F.  
;; APPLICANT: Bennett, C. Frank  
;; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
;; FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
;; CURRENT APPLICATION NUMBER: US/10/831,901A  
;; CURRENT FILING DATE: 2004-04-26  
;; PRIOR APPLICATION NUMBER: 60/466,426  
;; PRIOR FILING DATE: 2003-04-28

US-10-831-901A-29726/c

; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; PRIOR FILING DATE: 2003-06-27  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 29726  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-29726

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 1.8e+02;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1833 TGAAGAAAAAAGAAAAA 1850  
DB 18 TGACAAAAAAGAAAAA 1

RESULT 185  
US-09-828-034-10  
; Sequence 10, Application US/09828034  
; Patent No. US20020064771A1  
; GENERAL INFORMATION:  
; APPLICANT: Zhong, Weidong  
; APPLICANT: Hong, Zhi  
; APPLICANT: Ferrari, Eric  
; TITLE OF INVENTION: HCV REPLICASE COMPLEXES  
; FILE REFERENCE: IN01165  
; CURRENT APPLICATION NUMBER: US/09/828,034  
; CURRENT FILING DATE: 2001-04-06  
; PRIOR APPLICATION NUMBER: U.S. 60/195,852  
; PRIOR FILING DATE: 2000-04-06  
; NUMBER OF SEQ ID NOS: 33  
; SOFTWARE: PatentIn ver. 2.1  
; SEQ ID NO 10  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic RNA  
US-09-828-034-10

Query Match 0.9%; Score 16.2; DB 1; Length 21;  
Best Local Similarity 85.7%; Pred. No. 2.1e+02;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 28 GCCGCTTCCTGCGCGCGTC 48  
DB 1 GCCGCGCGCGCGCGCGCGC 21

RESULT 186  
US-09-765-111A-32  
; Sequence 32, Application US/09765111A  
; Patent No. US20020106796A1  
; GENERAL INFORMATION:  
; APPLICANT: Fletcher, Jonathan A.  
; APPLICANT: Kroll, Todd G.  
; TITLE OF INVENTION: FAX8-PPARGamma NUCLEIC ACID MOLECULES  
; AND POLYPEPTIDES AND USES THEREOF  
; FILE REFERENCE: B0801/7196/ERP/MAT  
; CURRENT APPLICATION NUMBER: US/09/765,111A

; CURRENT FILING DATE: 2001-01-18  
; PRIOR APPLICATION NUMBER: US 60/177,109  
; PRIOR FILING DATE: 2000-01-20  
; PRIOR APPLICATION NUMBER: US 60/225,079  
; PRIOR FILING DATE: 2000-08-14  
; NUMBER OF SEQ ID NOS: 47  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 32  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Homo Sapiens  
US-09-765-111A-32

Query Match 0.9%; Score 16.2; DB 1; Length 21;  
Best Local Similarity 85.7%; Pred. No. 2.1e+02;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 886 ACCGAGATACGTTCCTTCA 906  
DB 1 ACCGAGAAAGCATTCCTTCA 21

RESULT 187  
US-10-072-012-1128  
; Sequence 1128, Application US/10072012  
; Publication No. US20040033493A1  
; GENERAL INFORMATION:  
; APPLICANT: Tchernev, Velizar  
; APPLICANT: Spytek, Kimberly  
; APPLICANT: Zerhusen, Bryan  
; APPLICANT: Patturajan, Meera  
; APPLICANT: Shinkets, Richard  
; APPLICANT: Li, Li  
; APPLICANT: Gangolli, Esha  
; APPLICANT: Padigaru, Muralidhara  
; APPLICANT: Anderson, David W.  
; APPLICANT: Rastelli, Luca  
; APPLICANT: Miller, Charles E.  
; APPLICANT: Gerlach, Valerie  
; APPLICANT: Taupier Jr, Raymond J.  
; APPLICANT: Gusev, Vladimir Y.  
; APPLICANT: Colman, Steven D.  
; APPLICANT: Wolenc, Adam R.  
; APPLICANT: Pena, Carol E. A  
; APPLICANT: Furtak, Katarzyna  
; APPLICANT: Grosse, William M.  
; APPLICANT: Alsobrook II, John P.  
; APPLICANT: Lepley, Denise M.  
; APPLICANT: Rieger, Daniel K.  
; APPLICANT: Burgess, Catherine E.  
; TITLE OF INVENTION: Proteins and Nucleic Acids Encoding Same  
; FILE REFERENCE: 21402-258  
; CURRENT APPLICATION NUMBER: US/10/072,012  
; CURRENT FILING DATE: 2002-01-31  
; PRIOR APPLICATION NUMBER: 60/265,102  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: 60/265,514  
; PRIOR FILING DATE: 2001-01-31  
; PRIOR APPLICATION NUMBER: 60/265,517  
; PRIOR FILING DATE: 2001-01-31  
; PRIOR APPLICATION NUMBER: 60/265,412  
; PRIOR FILING DATE: 2001-01-31  
; PRIOR APPLICATION NUMBER: 60/265,395  
; PRIOR FILING DATE: 2001-01-31  
; PRIOR APPLICATION NUMBER: 60/266,406  
; PRIOR FILING DATE: 2001-02-02  
; PRIOR APPLICATION NUMBER: 60/266,767  
; PRIOR FILING DATE: 2001-02-05  
; PRIOR APPLICATION NUMBER: 60/267,057  
; PRIOR FILING DATE: 2001-02-07  
; PRIOR APPLICATION NUMBER: 60/266,975  
; PRIOR FILING DATE: 2001-02-07  
; PRIOR APPLICATION NUMBER: 60/267,459



```
; PRIOR FILING DATE: 2001-02-08
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1391
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1128
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Ag712 Reverse
US-10-072-012-1128
```

```
Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1441 TGAATGTTGCTGCTGCTGTTT 1461
      |||||
Db 1 TGGATGTTGCTGCTACTGCT 21
```

## RESULT 188

```
US-10-792-280-220/c
; Sequence 220, Application US/10792280
; Publication No. US20040234517A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Bowman, Michael
; APPLICANT: Follettie, Maximillian
; APPLICANT: Chen, Heng
; APPLICANT: Williams, Cara
; APPLICANT: Ellis, Debra
; APPLICANT: Winkler, Aaron
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ASTHMA OR
; FILE REFERENCE: AM1023-2
; CURRENT APPLICATION NUMBER: US/10/792,280
; CURRENT FILING DATE: 2004-03-04
; NUMBER OF SEQ ID NOS: 1535
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 220
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl-sense strand
US-10-792-280-220
```

```
Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1690 AAAAGGAATCATTCTCCCTC 1710
      |||||
Db 21 AAAAGGAATCATTCTGAGCTC 1
```

## RESULT 189

```
US-10-751-736-7618
; Sequence 7618, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7618
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-7618
```

```
Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1662 GATACTTTCCAAATTCCTCTGA 1682
      |||||
Db 1 GATCCTTTCCAAATACTTTGA 21
```

## RESULT 190

```
US-10-751-736-7619
; Sequence 7619, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7619
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-7619
```

```
Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 42.9%; Pred. No. 2.1e+02;
Matches 9; Conservative 9; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1664 TACTTTCCAAATTCCTCTGATT 1684
      :|:::|
Db 1 UCCUUUCCAAAUACUUUGAUU 21
```

## RESULT 191

```
US-10-751-736-17864/c
; Sequence 17864, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17864
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAl
US-10-751-736-17864
```

```
Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 451 AATCAGCTGTGATGCTGGAGC 471
Db 21 AATCATAAAGTGATGCTGGAGC 1

RESULT 192
US-10-751-736-23615/c
; Sequence 23615, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23615
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai
US-10-751-736-23615

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 207 AAAGAGAAATAGCCAGCTCT 227
Db 21 AAAGAGAAAGAGCCAGCTGT 1

RESULT 193
US-10-847-918-9328
; Sequence 9328, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9328
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-847-918-9328

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 AAAGGAATCATTTCTCCCTCC 1711
Db 1 AAAGGAGTCATTTCTCTACTCC 21

RESULT 194
US-10-847-918-9330/c
; Sequence 9330, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9330
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-847-918-9330

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 AAAGGAATCATTTCTCCCTCC 1711
Db 21 AAAGGAGTCATTTCTCTACTCC 1

RESULT 195
US-10-847-918-9570/c
; Sequence 9570, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9570
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-847-918-9570

Query Match      0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1690 AAAAGGAATCATTTCTCCCTC 1710
Db 21 AAAAGGAGTCATTTCTCTACTC 1

RESULT 196
US-10-847-918-12368/c
; Sequence 12368, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
```

```
QY 1691 AAAGGAATCATTTCTCCCTCC 1711
Db 1 AAAGGAGTCATTTCTCTACTCC 21
```

; APPLICANT: Wyeth  
; APPLICANT: Be, Xiaobing  
; APPLICANT: Liu, Wei  
; APPLICANT: Slonim, Donna  
; APPLICANT: Howes, Steve  
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers  
; FILE REFERENCE: 031896-026000 (AM101264)  
; CURRENT APPLICATION NUMBER: US/10/847,918  
; PRIOR FILING DATE: 2004-05-19  
; PRIOR APPLICATION NUMBER: US 60/471,729  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 12368  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI-sense strand  
US-10-847-918-12368

Query Match 0.9%; Score 16.2; DB 1; Length 21;  
Best Local Similarity 85.7%; Pred. No. 2.1e+02;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1599 AATTCATCCCAATTCCTTC 1619  
Db 21 AATTCCTCCATTCACCTTC 1

RESULT 197  
US-10-847-918-12887/c  
; Sequence 12887, Application US/10847918  
; Publication No. US20050119210A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Be, Xiaobing  
; APPLICANT: Liu, Wei  
; APPLICANT: Slonim, Donna  
; APPLICANT: Howes, Steve  
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers  
; FILE REFERENCE: 031896-026000 (AM101264)  
; CURRENT APPLICATION NUMBER: US/10/847,918  
; CURRENT FILING DATE: 2004-05-19  
; PRIOR FILING DATE: 2003-05-20  
; PRIOR APPLICATION NUMBER: US 60/471,729  
; NUMBER OF SEQ ID NOS: 14937  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 12887  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI-sense strand  
US-10-847-918-12887

Query Match 0.9%; Score 16.2; DB 1; Length 21;  
Best Local Similarity 85.7%; Pred. No. 2.1e+02;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 240 AAAGCAATCATCAACCTAGCT 260  
Db 21 AAAGCAATGGTCAACCTGGCT 1

RESULT 198  
US-10-847-918-13478/c  
; Sequence 13478, Application US/10847918  
; Publication No. US20050119210A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Be, Xiaobing  
; APPLICANT: Liu, Wei  
; APPLICANT: Slonim, Donna  
; APPLICANT: Howes, Steve  
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers  
; FILE REFERENCE: 031896-026000 (AM101264)

; CURRENT APPLICATION NUMBER: US/10/847,918  
; CURRENT FILING DATE: 2004-05-19  
; PRIOR APPLICATION NUMBER: US 60/471,729  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 14937  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 13478  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI-sense strand  
US-10-847-918-13478

Query Match 0.9%; Score 16.2; DB 1; Length 21;  
Best Local Similarity 85.7%; Pred. No. 2.1e+02;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 240 AAAGCAATCATCAACCTAGCT 260  
Db 21 AAAGCAATGGTCAACCTGGCT 1

RESULT 199  
US-10-755-118-94/c  
; Sequence 94, Application US/10755118  
; Publication No. US2005009041A1  
; GENERAL INFORMATION:  
; APPLICANT: Buchardt, Ole  
; APPLICANT: Egholm, Michael  
; APPLICANT: Nielsen, Peter Eigil  
; APPLICANT: Berg, Rolf Henrik  
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR  
; FILE REFERENCE: ISIS-5427  
; CURRENT APPLICATION NUMBER: US/10/755,118  
; CURRENT FILING DATE: 2004-01-09  
; PRIOR APPLICATION NUMBER: US 08/462,977  
; PRIOR FILING DATE: 1995-06-05  
; PRIOR APPLICATION NUMBER: US 08/108,591  
; PRIOR FILING DATE: 1993-11-22  
; PRIOR APPLICATION NUMBER: PCT/EP92/01219  
; PRIOR FILING DATE: 1992-05-22  
; PRIOR APPLICATION NUMBER: DN 510/92  
; PRIOR FILING DATE: 1992-04-15  
; PRIOR APPLICATION NUMBER: DN 987/91  
; PRIOR FILING DATE: 1991-05-24  
; PRIOR APPLICATION NUMBER: DN 986/91  
; PRIOR FILING DATE: 1991-05-24  
; NUMBER OF SEQ ID NOS: 157  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 94  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Construct  
US-10-755-118-94

Query Match 0.9%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1850  
Db 16 AAAAAAAAAAAAAA 1

RESULT 200  
US-10-608-863-4/c  
; Sequence 4, Application US/10608863  
; Publication No. US20040214192A1  
; GENERAL INFORMATION:  
; APPLICANT: Hashida, Ryoichi  
; APPLICANT: Kagaya, Shinji  
; APPLICANT: Yayoi, Yoshihiro

```
; APPLICANT: Sugita, Yuji
; APPLICANT: Saito, Hirohisa
; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREA
; TITLE OF INVENTION: ALLERGIC DISEASES
; FILE REFERENCE: 3462.1003-000
; CURRENT APPLICATION NUMBER: US/10/608.863
; CURRENT FILING DATE: 2003-06-27
; PRIOR APPLICATION NUMBER: JP 2002-188490
; PRIOR FILING DATE: 2002-06-27
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Artificially
; OTHER INFORMATION: Synthesized Primer Sequence
US-10-608-863-4

Query Match          0.9%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAAAAAAAAAAAAAA 1849
Db 17 GAAAAAAAAAAAAAAAAA 2

RESULT 201
US-10-872-984-6/c
; Sequence 6, Application US/10872984
; Publication No. US20040265889A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-6

Query Match          0.9%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1850
Db 16 AAAAAAAAAAAAAAAAAA 1

RESULT 202
US-10-751-736-19139
; Sequence 19139, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```

```
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19139
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-19139

Query Match          0.9%; Score 16; DB 1; Length 21;
Best Local Similarity 50.0%; Pred. No. 2.2e+02;
Matches 8; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGTGCTGCTGTT 1460
Db 1 UGUUGCUGCUGCUGU 16

RESULT 203
US-10-871-222-150
; Sequence 150, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Raebertl, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
; TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
; TITLE OF INVENTION: Nucleic Acid (SINA)
; FILE REFERENCE: 400/164 (MHB04-487)
; CURRENT APPLICATION NUMBER: US/10/871,222
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 150
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/sina sense r
US-10-871-222-150

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.1e+02;
```

Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1833 TGAATAAAAAAAAAAAAAA 1851  
:|||||||

Db 1 UGUAAAAAAAAAAAAAAAAA 19

RESULT 204  
US-10-871-222-300/c  
; Sequence 300, Application US/10871222  
; Publication No. US20050119212A1  
; GENERAL INFORMATION:  
; APPLICANT: Sirna Therapeutics, Inc.  
; APPLICANT: Haeberli, Peter  
; TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids  
; TITLE OF INVENTION: Synthese Ligand (FASL) Gene Expression Using Short Interfering  
; TITLE OF INVENTION: Nucleic Acid (siNA)  
; FILE REFERENCE: 400/164 (MBHB04-487)  
; CURRENT APPLICATION NUMBER: US/10/871,222  
; PRIOR FILING DATE: 2004-06-18  
; PRIOR APPLICATION NUMBER: PCT/US04/16390  
; PRIOR FILING DATE: 2004-05-24  
; PRIOR APPLICATION NUMBER: US10/826966  
; PRIOR FILING DATE: 2004-04-16  
; PRIOR APPLICATION NUMBER: US10/757803  
; PRIOR FILING DATE: 2004-01-14  
; PRIOR APPLICATION NUMBER: US10/720448  
; PRIOR FILING DATE: 2003-11-24  
; PRIOR APPLICATION NUMBER: US10/693059  
; PRIOR FILING DATE: 2003-10-23  
; PRIOR APPLICATION NUMBER: PCT/US03/05028  
; PRIOR FILING DATE: 2003-05-23  
; PRIOR APPLICATION NUMBER: PCT/US03/05346  
; PRIOR FILING DATE: 2003-02-20  
; PRIOR APPLICATION NUMBER: US60/358580  
; PRIOR FILING DATE: 2002-02-20  
; PRIOR APPLICATION NUMBER: US60/363124  
; PRIOR FILING DATE: 2002-03-11  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 706  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 300  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region  
US-10-871-222-300

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 1.9e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1833 TGAATAAAAAAAAAAAAAA 1851  
|||

Db 19 TGGTAAAAAAAAAAAAAAAA 1

RESULT 205  
US-10-840-731-34  
; Sequence 34, Application US/10840731  
; Publication No. US20050137153A1  
; GENERAL INFORMATION:  
; APPLICANT: Sirna Therapeutics, Inc.  
; APPLICANT: McSwiggen, James  
; APPLICANT: Robin, Howard  
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)  
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)  
; FILE REFERENCE: 400/155 (MBHB04-410)  
; CURRENT APPLICATION NUMBER: US/10/840,731

; CURRENT FILING DATE: 2004-05-06  
; PRIOR FILING DATE: 2004-04-16  
; PRIOR APPLICATION NUMBER: US 10/826,966  
; PRIOR FILING DATE: 2004-01-14  
; PRIOR APPLICATION NUMBER: US 10/757,803  
; PRIOR FILING DATE: 2003-11-24  
; PRIOR APPLICATION NUMBER: US 10/720,448  
; PRIOR FILING DATE: 2003-10-23  
; PRIOR APPLICATION NUMBER: US 10/693,059  
; PRIOR FILING DATE: 2003-05-23  
; PRIOR APPLICATION NUMBER: US 10/444,853  
; PRIOR FILING DATE: 2003-08-29  
; PRIOR APPLICATION NUMBER: US 10/652,791  
; PRIOR FILING DATE: 2003-04-24  
; PRIOR APPLICATION NUMBER: US 10/422,704  
; PRIOR FILING DATE: 2003-04-16  
; PRIOR APPLICATION NUMBER: US 10/417,012  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: PCT/US03/05346  
; PRIOR FILING DATE: 2003-02-20  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 296  
; SOFTWARE: PatentIn version 3.3  
; SEQ ID NO 34  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r  
US-10-840-731-34

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 47.4%; Pred. No. 1.9e+02;  
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1813 AATAATTTTGGAGATCT 1831  
:|||||

Db 1 AUAUUUUUGAGGAUGU 19

RESULT 206  
US-10-840-731-129/c  
; Sequence 129, Application US/10840731  
; Publication No. US20050137153A1  
; GENERAL INFORMATION:  
; APPLICANT: Sirna Therapeutics, Inc.  
; APPLICANT: McSwiggen, James  
; APPLICANT: Robin, Howard  
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)  
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)  
; FILE REFERENCE: 400/155 (MBHB04-410)  
; CURRENT APPLICATION NUMBER: US/10/840,731  
; CURRENT FILING DATE: 2004-05-06  
; PRIOR APPLICATION NUMBER: US 10/826,966  
; PRIOR FILING DATE: 2004-04-16  
; PRIOR APPLICATION NUMBER: US 10/757,803  
; PRIOR FILING DATE: 2004-01-14  
; PRIOR APPLICATION NUMBER: US 10/720,448  
; PRIOR FILING DATE: 2003-11-24  
; PRIOR APPLICATION NUMBER: US 10/693,059  
; PRIOR FILING DATE: 2003-10-23  
; PRIOR APPLICATION NUMBER: US 10/444,853  
; PRIOR FILING DATE: 2003-05-23  
; PRIOR APPLICATION NUMBER: US 10/652,791  
; PRIOR FILING DATE: 2003-08-29  
; PRIOR APPLICATION NUMBER: US 10/422,704  
; PRIOR FILING DATE: 2003-04-24  
; PRIOR APPLICATION NUMBER: US 10/417,012  
; PRIOR FILING DATE: 2003-04-16  
; PRIOR APPLICATION NUMBER: US 10/427,160  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: PCT/US03/05346

```
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 129
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-129

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGATCT 1831
Db 19 ATAAATTTTGGAGGATGT 1

RESULT 207
US-09-987-025-8
; Sequence 8, Application US/09987025
; Patent No. US20020108148A1
; GENERAL INFORMATION:
; APPLICANT: Boronat, Albert
; APPLICANT: Campos, Narcisco
; APPLICANT: Kishore, Ganesh M.
; TITLE OF INVENTION: Nucleic Acid Sequences Involved in
; FILE REFERENCE: 17142/02/US
; CURRENT APPLICATION NUMBER: US/09/987,025
; CURRENT FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: 09/549,787
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/129,899
; PRIOR FILING DATE: 1999-04-15
; PRIOR APPLICATION NUMBER: 60/146,461
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-09-987-025-8

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1244 GGCCATCATGGAGGAGTT 1262
Db 1 GGCCATGCTGGAGGAGTT 19

RESULT 208
US-10-108-164-125
; Sequence 125, Application US/10108164
; Publication No. US20030104356A1
; GENERAL INFORMATION:
; APPLICANT: Berger, Shelley L.
; APPLICANT: Fraser, Nigel W.
; APPLICANT: Tal-Singer, Ruth
; APPLICANT: Leary, Jeffrey J.
; TITLE OF INVENTION: Compounds And Methods For Treating And
; FILE REFERENCE: Screening Viral Reactivation
; CURRENT APPLICATION NUMBER: US/10/108,164
; CURRENT FILING DATE: 2002-03-26
```

```
; PRIOR APPLICATION NUMBER: 09/424,348
; PRIOR FILING DATE: 1999-07-01
; PRIOR APPLICATION NUMBER: PCT/US98/13733
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/051,633
; PRIOR FILING DATE: 1997-07-03
; PRIOR APPLICATION NUMBER: 60/054,515
; PRIOR FILING DATE: 1997-08-01
; PRIOR APPLICATION NUMBER: 60/080,352
; PRIOR FILING DATE: 1998-04-01
; NUMBER OF SEQ ID NOS: 145
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 125
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-108-164-125

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 AGAAGCAAGGAGGAGATT 608
Db 2 AAAAGCAAGGAGGAGATT 20

RESULT 209
US-10-139-604-2
; Sequence 2, Application US/10139604
; Publication No. US20030124551A1
; GENERAL INFORMATION:
; APPLICANT: METRIS THERAPEUTICS LIMITED
; APPLICANT: LNIENICEK, Mirna
; APPLICANT: PAPPA, Helen
; TITLE OF INVENTION: AGENTS IMPLICATED IN ENDOMETRIOSIS
; FILE REFERENCE: 1396-1-006
; CURRENT APPLICATION NUMBER: US/10/139,604
; CURRENT FILING DATE: 2002-08-23
; PRIOR APPLICATION NUMBER: GB 9926081.2
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926074.7
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926079.6
; PRIOR FILING DATE: 1999-11-03
; PRIOR APPLICATION NUMBER: GB 9926076.2
; PRIOR FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: SeqWin99, version 1.02
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 5' RT-PCR primer for Elongation factor-1
US-10-139-604-2

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGCTGT 1459
Db 2 TGATTGTTGCTGCTGCTGT 20

RESULT 210
US-10-261-706-4
; Sequence 4, Application US/10261706
; Publication No. US20040001830A1
; GENERAL INFORMATION:
; APPLICANT: Freskgaard, Per-Ola
; APPLICANT: Clausen, Jes T
```

```
; APPLICANT: Sorensen, Brit B
; APPLICANT: Kjalke, Marianne
; TITLE OF INVENTION: Human Tissue Factor Antibodies
; FILE REFERENCE: 6264.200-US
; CURRENT APPLICATION NUMBER: US/10/261,706
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: Danish Application PA 2001 01437
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 60/329,775
; PRIOR FILING DATE: 2001-10-16
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-706-4

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1172 TCTGTGTGAGTGTGAC 1190
Db      2 TCTGTGTGAGGCTGAC 20

RESULT 211
US-10-289-762-6169/c
; Sequence 6169, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6169

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1440 ATGAATGTTGCTGCTGCTG 1458
Db      19 ATGATTGTTGCTGCTGCCG 1

RESULT 212
US-10-831-901A-8646
; Sequence 8646, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8647
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
```

```
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8646
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-8646

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 815 AGAATGATGTCAGAGATG 833
Db      1 AGAATGATGTCACGAGTG 19

RESULT 213
US-10-831-901A-8647
; Sequence 8647, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8647
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
```

```
US-10-831-901A-8647
Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 815 AGAAATGATGTCAGGAATG 833
Db 2 AGAAATGATGTCAGGATG 20

RESULT 214
US-10-699-362A-4
; Sequence 4, Application US/10699362A
; Publication No. US20050106139A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk A/S
; APPLICANT: Svendsen, Ivan
; APPLICANT: Kjaergaard, Kristian
; APPLICANT: Zahn, Stefan
; TITLE OF INVENTION: Humanized Tissue Factor Antibodies
; FILE REFERENCE: 6600.200-US
; CURRENT APPLICATION NUMBER: US/10/699,362A
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: Danish Application No. 2002 01661
; PRIOR FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: US Application No. 60/427,157
; PRIOR FILING DATE: 2002-11-18
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-699-362A-4

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1172 TCTGGTGATGAGTCTGAC 1190
Db 2 TCTGGTGATGACGCTGAC 20

RESULT 215
US-10-966-829-8
; Sequence 8, Application US/10966829
; Publication No. US20050120406A1
; GENERAL INFORMATION:
; APPLICANT: Boronot, Albert
; APPLICANT: Campos, Narciso
; APPLICANT: Kishore, Ganesh M.
; TITLE OF INVENTION: Nucleic Acid Sequences Involved in
; FILE REFERENCE: 17142/02/US
; CURRENT APPLICATION NUMBER: US/10/966,829
; CURRENT FILING DATE: 2004-10-15
; PRIOR APPLICATION NUMBER: US/09/987,025
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: 09/549,787
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/129,899
; PRIOR FILING DATE: 1999-04-15
; PRIOR APPLICATION NUMBER: 60/146,461
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA

US-10-831-901A-8647
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-966-829-8

Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 2.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1244 GGCCATCATGAGGAGGTT 1262
Db 1 GGCCATGCTGGAGAGGTT 19

RESULT 216
US-10-792-280-376/c
; Sequence 376, Application US/10792280
; Publication No. US20040234517A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Bowman, Michael
; APPLICANT: Follettie, Maximillian
; APPLICANT: Chen, Heng
; APPLICANT: Williams, Cara
; APPLICANT: Ellis, Debra
; APPLICANT: Winkler, Aaron
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ASTHMA OR
; FILE REFERENCE: AM101023-2
; CURRENT APPLICATION NUMBER: US/10/792,280
; CURRENT FILING DATE: 2004-03-04
; NUMBER OF SEQ ID NOS: 1535
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 376
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-792-280-376

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 2.3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1164 AACTACAGTCTGGTGATGG 1182
Db 21 AACTCCAGCTGGTGATGG 3

RESULT 217
US-10-751-736-23903/c
; Sequence 23903, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23903
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-23903
```



Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 2.3e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 211 AAGAAATAGCCAGCTGTGG 229  
||||| ||||||| |||  
Db 21 AAGAAAGAGCCAGCTGTGG 3

RESULT 218  
US-10-751-736-29406/c  
; Sequence 29406, Application US/10751736  
; Publication No. US20040265230A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Martinez, Robert  
; APPLICANT: Brown, Eugene  
; APPLICANT: Liu, Wei  
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
; FILE REFERENCE: AM100927 (031896-002000)  
; CURRENT APPLICATION NUMBER: US/10/751,736  
; CURRENT FILING DATE: 2003-01-06  
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
; PRIOR FILING DATE: 2003-01-06  
; NUMBER OF SEQ ID NOS: 54873  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 29406  
; LENGTH: 21  
; TYPE: RNA  
; ORGANISM: RNAI  
US-10-751-736-29406

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 2.3e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 801 ACGGTGAAGATGCAGAA 819  
||||| ||||||| |||  
Db 19 ACGGTGAAGATGAAGAA 1

RESULT 219  
US-10-831-819-12/c  
; Sequence 12, Application US/10831819  
; Publication No. US20050112613A1  
; GENERAL INFORMATION:  
; APPLICANT: KRAHE, RALF  
; APPLICANT: ZHANG, SHANXIANG  
; TITLE OF INVENTION: METHODS AND REAGENTS FOR PREDICTING THE LIKELIHOOD OF  
; FILE REFERENCE: 18525/04053  
; CURRENT APPLICATION NUMBER: US/10/831,819  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR APPLICATION NUMBER: 60/320,146  
; PRIOR FILING DATE: 2003-04-25  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 12  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Probe  
US-10-831-819-12

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 2.3e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTCCGTCCGCCGCG 46  
||||| ||| |||||||

Db 19 GCCGCGCGCGCGCGCGCG 1

RESULT 220  
US-10-479-472A-7  
; Sequence 7, Application US/10479472A  
; Publication No. US20050118581A1  
; GENERAL INFORMATION:  
; APPLICANT: DEL-FAVERO, JURGEN PETER LODE  
; APPLICANT: VAN BROECKHOVEN, CHRISTINE  
; TITLE OF INVENTION: NOVEL BRAIN EXPRESSED GENE AND PROTEIN ASSOCIATED WITH  
; FILE REFERENCE: JAB-1711  
; CURRENT APPLICATION NUMBER: US/10/479,472A  
; CURRENT FILING DATE: 2003-12-01  
; PRIOR APPLICATION NUMBER: PCT/EP02/06316  
; PRIOR FILING DATE: 2002-06-06  
; PRIOR APPLICATION NUMBER: EP 01202214.1  
; PRIOR FILING DATE: 2001-06-11  
; NUMBER OF SEQ ID NOS: 12  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 7  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Unknown Organism  
; FEATURE:  
; OTHER INFORMATION: Description of Unknown Organism: Illustrative  
US-10-479-472A-7

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 2.3e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTCCGTCCGCCGCG 46  
||||| ||| |||||||  
Db 3 GCCGCGCGCGCGCGCGCG 21

RESULT 221  
US-09-877-478-266/c  
; Sequence 266, Application US/09877478  
; Publication No. US20030068301A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication  
; FILE REFERENCE: MHB00-845-H (400/029)  
; CURRENT APPLICATION NUMBER: US/09/877,478  
; CURRENT FILING DATE: 2001-12-31  
; PRIOR APPLICATION NUMBER: US 07/882,712  
; PRIOR FILING DATE: 1992-05-14  
; PRIOR APPLICATION NUMBER: US 09/531,025  
; PRIOR FILING DATE: 2000-03-20  
; PRIOR APPLICATION NUMBER: US 09/636,385  
; PRIOR FILING DATE: 2000-08-09  
; PRIOR APPLICATION NUMBER: US 09/696,347  
; PRIOR FILING DATE: 2000-10-24  
; PRIOR APPLICATION NUMBER: US 08/193,627  
; PRIOR FILING DATE: 1994-02-07  
; PRIOR APPLICATION NUMBER: US 08/433,993  
; PRIOR FILING DATE: 1995-05-04  
; PRIOR APPLICATION NUMBER: US 08/434,504  
; PRIOR FILING DATE: 1995-05-04  
; PRIOR APPLICATION NUMBER: US 09/436,430  
; PRIOR FILING DATE: 1999-11-08  
; NUMBER OF SEQ ID NOS: 6586  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 266  
; LENGTH: 17

```

; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-266

Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGGCATTACAGCAGAA 545
Db 17 AAGGCATTAAAGCAGAA 1

RESULT 222
US-10-342-902-266/c
; Sequence 266, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBH00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-266

Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGGCATTACAGCAGAA 545
Db 17 AAGGCATTAAAGCAGAA 1

RESULT 223
US-10-669-841-266/c
; Sequence 266, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPN

```

```

; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 266
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-266

Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.7e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGGCATTACAGCAGAA 545
Db 17 AAGGCATTAAAGCAGAA 1

RESULT 224
US-09-969-373-3693/c
; Sequence 3693, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Eifert, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3693
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3693

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 465 CTGGAGCCCAAGATTCA 481
Db 18 CTGGAGCCCAAGATTCA 2

```



```
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 404
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-871-222-404

Query Match          0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 3 AAAAAAAAAAAAAAAAAA 19

RESULT 230
US-10-871-222-508/c
; Sequence 508, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
; TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
; TITLE OF INVENTION: Nucleic Acid (SINA)
; FILE REFERENCE: 400/164 (MEHB04-487)
; CURRENT APPLICATION NUMBER: US/10/871,222
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 508
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-871-222-508

Query Match          0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAAAAAAAAAAAAAAAAA 1

RESULT 231
US-10-881-118-121
; Sequence 121, Application US/10881118
; Publication No. US20050130181A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Mediated Inhibition of Wingless Gene Expression Using Short
; TITLE OF INVENTION: Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400-197 (MEHB04-546)
; CURRENT APPLICATION NUMBER: US/10/881,118
; CURRENT FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 452
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 121
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-881-118-121

Query Match          0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.8%; Pred. No. 2.1e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 11 CGAGCTTAGTCCTGGGA 27
Db 3 CAAGCUUAGUCCUGGA 19

RESULT 232
US-10-881-118-284/c
```

```
; Sequence 284, Application US/10881118
; Publication No. US20050130181A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; TITLE OF INVENTION: RNA Mediated Inhibition of Wingless Gene Expression Using Short
; FILE REFERENCE: 400-197 (MEHB04-546)
; CURRENT FILING DATE: 2004-06-30
; PRIOR APPLICATION NUMBER: US/10/891,118
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 452
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 284
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-881-118-284

Query Match 0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 11 CGAGCTTAGTCTCGGA 27
Db 17 CAAGCTTAGTCTCGGA 1

RESULT 233
US-10-840-731-32
; Sequence 32, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US/10/840,731
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
```

```
; Sequence 33, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 32
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-840-731-32

Query Match 0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.9%; Pred. No. 2.1e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

Qy 1813 ATAAATTTTTCGAAGAT 1829
Db 3 AUAUUUUUUGGAGAU 19

RESULT 234
US-10-840-731-33
; Sequence 33, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-840-731-33
```

```
Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.94; Pred. No. 2.1e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGAT 1829
   :|||||:|||||:|
Db 2 AUAUUUUUGGAGAU 18

RESULT 235
US-10-840-731-127/c
; Sequence 127, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; PRIOR FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 127
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-127

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 52.94; Pred. No. 2.1e+02;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGAT 1829
   :|||||:|||||:|
Db 2 AUAUUUUUGGAGAU 18

RESULT 236
US-10-840-731-128/c
; Sequence 128, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; PRIOR FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 127
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-127

Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGAGAT 1829
   :|||||:|||||:|
Db 17 ATAAATTTTGGAGAT 1

RESULT 237
US-10-863-973-389/c
; Sequence 389, Application US/10863973
; Publication No. US20050143333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 389
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense x
US-10-863-973-389
Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 2.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      689 GGGGGCTTTGGCATCTC 705
Db      19  GGGGGCTTTGGCATCTC 3

RESULT 238
US-10-863-973-589
; Sequence 589, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: Polisky, Barry
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBH803-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 589
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-863-973-589
Query Match      0.8%; Score 15.4; DB 1; Length 19;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
```

```
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      689 GGGGGCTTTGGCATCTC 705
Db      1  GGGGGCTTUGGCAUGUC 17

RESULT 239
US-09-242-772-55/c
; Sequence 55, Application US/09242772
; Publication No. US20020009720A1
; GENERAL INFORMATION:
; APPLICANT: Vlaams Interuniversitair Instituut voor Biotechnologie
; TITLE OF INVENTION: PLAG gene family and tumorigenesis
; FILE REFERENCE: VIB-011-US
; CURRENT APPLICATION NUMBER: US/09/242,772
; CURRENT FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: EP 96202229.6
; PRIOR FILING DATE: 1996-08-22
; PRIOR APPLICATION NUMBER: EP 97200130.9
; PRIOR FILING DATE: 1997-01-17
; PRIOR APPLICATION NUMBER: PCT/EP97/04759
; PRIOR FILING DATE: 1997-08-22
; NUMBER OF SEQ ID NOS: 139
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
; NAME/KEY: misc feature
; OTHER INFORMATION: sense primer EM156
US-09-242-772-55
Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1441 TGAATGTGCTGCTGCT 1457
Db      20  TGACTGTGCTGCTGCT 4

RESULT 240
US-10-058-422-14/c
; Sequence 14, Application US/10058422
; Publication No. US20030108881A1
; GENERAL INFORMATION:
; APPLICANT: Hyeoung Lee, Hye Eun Bang, Sang-Nae Cho, Gill-Han BAI,
; APPLICANT: Sang-Jae Kim
; TITLE OF INVENTION: A method for identifying Micobacteria tuberculosis and
; TITLE OF INVENTION: non-tuberculosis Micobacteria, together with detecting resistance
; TITLE OF INVENTION: to an antituberculosis drug of Micobacteria obtained by mutation
; FILE REFERENCE: 0217-0008
; CURRENT APPLICATION NUMBER: US/10/058,422
; CURRENT FILING DATE: 2002-01-30
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: KopatentIn 1.71
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligomer probe for M. abscessus
US-10-058-422-14
Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 126 GGTGGTGTTCACCTTTT 142
Db 17 GGTGGTGTTCACCTTTT 1

RESULT 241
US-10-289-762-6103
; Sequence 6103, Application US/10289762
; Publication No. US2004006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-6103

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 150 TGCTCTGGGAAGCTAT 166
Db 2 TGCTCTGGGAAGCTAT 18

RESULT 242
US-10-766-185-47
; Sequence 47, Application US/10766185
; Publication No. US20040152655A1
; GENERAL INFORMATION:
; APPLICANT: Yoon, Heejeong
; APPLICANT: Ahn, Chang Ho
; APPLICANT: Lee, Young Bok
; APPLICANT: Mao, Lingjun
; APPLICANT: Jiang, Xiaoming
; TITLE OF INVENTION: Antisense oligonucleotides that inhibit expression of HIF-1
; FILE REFERENCE: RX 7034
; CURRENT APPLICATION NUMBER: US/10/766,185
; CURRENT FILING DATE: 2004-01-28
; NUMBER OF SEQ ID NOS: 130
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-766-185-47

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1134 TATATCAGTTACACAA 1150
Db 4 TAATATCAGTTACACAA 20

RESULT 243
US-10-380-049-11
; Sequence 11, Application US/10380049
; Publication No. US20050013804A1
; GENERAL INFORMATION:
; APPLICANT: KATO Yukio
; TITLE OF INVENTION: Method for culturing bone marrow mesenchymal stem cells
```

```
; FILE REFERENCE: FP1021
; CURRENT APPLICATION NUMBER: US/10/380,049
; CURRENT FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: JP2000-276971
; PRIOR FILING DATE: 2000-09-12
; NUMBER OF SEQ ID NOS: 14
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-380-049-11

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1403 CCACGGAGACACCATGA 1419
Db 1 CCACGGAGACACCATGA 17

RESULT 244
US-10-831-901A-26524
; Sequence 26524, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian A.
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26524
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-26524

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 367 TTATGTACCAAAACCTG 383
Db 1 TTATGTACCAAAACCTG 17
```



```
RESULT 245
US-10-831-901A-26528
; Sequence 26528, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26528
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-26528

Query Match          0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 366 ATTATGTACCAAAACCT 382
Db 4 ATTATGTACAAAAACCT 20

RESULT 246
US-10-831-901A-29725/c
; Sequence 29725, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
```

```
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29725
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29725

Query Match          0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1833 TGAATAAAAAAAAAA 1849
Db 17 TGACAAAAAAAAAAAAA 1

RESULT 247
US-10-317-869A-54
; Sequence 54, Application US/10317869A
; Publication No. US20050101000A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF PHOSPHODIESTERASE 4B EXPRESSION
; FILE REFERENCE: RTS-0429
; CURRENT APPLICATION NUMBER: US/10/317,869A
; CURRENT FILING DATE: 2002-12-11
; NUMBER OF SEQ ID NOS: 113
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-869A-54

Query Match          0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 446 AGAAGATCATCTGTGA 462
Db 3 AGAAGATCATCTGTGA 19

RESULT 248
US-10-317-869A-103/c
; Sequence 103, Application US/10317869A
; Publication No. US20050101000A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF PHOSPHODIESTERASE 4B EXPRESSION
; FILE REFERENCE: RTS-0429
; CURRENT APPLICATION NUMBER: US/10/317,869A
; CURRENT FILING DATE: 2002-12-11
; NUMBER OF SEQ ID NOS: 113
; SEQ ID NO 103
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-317-869A-103

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 446 AGAAGATCAGCTGTGA 452
Db 18 AGAAGATCATCTGTGA 2

RESULT 249
US-10-872-645-29/c
; Sequence 29, Application US/10872645
; Publication No. US20050100887A1
; GENERAL INFORMATION:
; APPLICANT: AXXIMA Pharmaceuticals AG
; APPLICANT: Salasidis, Konstadinos
; APPLICANT: Schubart, Daniel
; APPLICANT: Laasidis, Konstadinos
; APPLICANT: Gutbrod, Heidrun
; APPLICANT: Mueller, Stefan
; APPLICANT: Kraetzer, Friedrich
; APPLICANT: Oert, Sabine
; TITLE OF INVENTION: Targets for Hepatitis C Virus Infections
; FILE REFERENCE: AXM-014.1 US
; CURRENT APPLICATION NUMBER: US/10/872,645
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: PCT/EP02/14578
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: US 60/341,757
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 29
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: v = a or g or c
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: n=a or g or t or c
US-10-872-645-29

Query Match      0.8%; Score 15.2; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.8e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAAAGAAAAA 1849
Db 16 BAAAAAAGAAAAA 1

RESULT 250
US-09-768-917-9
; Sequence 9, Application US/09768917
; Patent No. US20020034494A1
; GENERAL INFORMATION:
; APPLICANT: Vicari, Alain P.
; APPLICANT: Caux, Christophe
; APPLICANT: LaFace, Drake
; TITLE OF INVENTION: Chemokines as Adjuvants of Immune Response
; FILE REFERENCE: SF0896K US
; CURRENT APPLICATION NUMBER: US/09/768,917
; CURRENT FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: EP 0 974 357
```

```
; PRIOR FILING DATE: 1998-07-16
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-768-917-9

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1083 CGGCTGGTCTCTGGACTGC 1102
Db 1 CTGCTGGTCTCTGGACTTC 20

RESULT 251
US-09-888-326-410/c
; Sequence 410, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; CURRENT FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 410
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (0)..(0)
; OTHER INFORMATION: phosphodiester backbone
US-09-888-326-410

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CGGCTCTCGTCGCGCGCTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 252
US-09-802-640-74
; Sequence 74, Application US/09802640
; Publication No. US20030036057A1
; GENERAL INFORMATION:
; APPLICANT: Braun, Andreas
; APPLICANT: Kley, Patrick
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ASSOCIATED WITH
; FILE REFERENCE: 24736-2048
; CURRENT APPLICATION NUMBER: US/09/802,640
; CURRENT FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 122
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 74
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial sequence
US-09-802-640-74

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1265 GAGCCTGCTGCAGCCCTCA 1284
Db 1 GTGACTTCTGCAGCCCTCA 20

RESULT 253
US-09-776-479-243/c
; Sequence 243, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; PRIOR FILING DATE: 2001-02-02
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-243

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTCGCGCGCGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 254
US-09-776-479-243/c
; Sequence 243, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-243

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTCGCGCGCGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 255
US-09-932-419-5/c
; Sequence 5, Application US/09932419
; Publication No. US20030096238A1
; GENERAL INFORMATION:
; APPLICANT: Salceda, Susana
; APPLICANT: Cafferkey, Robert
; TITLE OF INVENTION: COMPOSITIONS AND METHODS RELATING TO GYNECOLOGIC CANCER
; FILE REFERENCE: DEX-0216
; CURRENT APPLICATION NUMBER: US/09/932,419
; PRIOR FILING DATE: 2001-08-16
; PRIOR APPLICATION NUMBER: 60/225,857
; PRIOR FILING DATE: 2000-08-17
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-932-419-5

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1445 TGTGCTGCTGCTGTTGGG 1464
Db 20 TCTTGATGCTGCTGTTGGG 1

RESULT 256
US-09-915-814-184
; Sequence 184, Application US/09915814
; Publication No. US20030096771A1
; GENERAL INFORMATION:
; APPLICANT: Madeline M. Butler
; APPLICANT: Andrew T. Watt
; APPLICANT: Susan M. Freier
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF HORMONE-SENSITIVE LIPASE EXPRESSION
; FILE REFERENCE: ISPH-0587
; CURRENT APPLICATION NUMBER: US/09/915,814
; PRIOR FILING DATE: 2001-07-26
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 184
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-915-814-184

Query Match
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 524 TCCAGAGGCATTACAGCAG 543
Db 1 TCCAGAGGCTTCCAGAG 20

RESULT 257
```

```
US-09-965-101-57/c
; Sequence 57, Application US/09965101
; Publication No. US20040186067A1
; GENERAL INFORMATION:
; APPLICANT: Davis, Heather L.
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schorr, Joachim
; APPLICANT: Wu, Tong
; TITLE OF INVENTION: Vectors and Methods for Immunization or
; TITLE OF INVENTION: Therapeutic Protocols
; FILE REFERENCE: C1039/7057 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/965,101
; CURRENT FILING DATE: 2001-09-26
; PRIOR APPLICATION NUMBER: US 05/082,649
; PRIOR FILING DATE: 1998-05-20
; PRIOR APPLICATION NUMBER: US 60/047,233
; PRIOR FILING DATE: 1997-05-20
; PRIOR APPLICATION NUMBER: US 60/047,209
; PRIOR FILING DATE: 1997-05-20
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-09-965-101-57

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGGTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 258
US-10-112-653-235/c
; Sequence 235, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Berg, Daniel J.
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
; TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
; FILE REFERENCE: C01039/70060 (AMS)
; CURRENT APPLICATION NUMBER: US/10/112,653
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/279,642
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 235
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-235

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGGTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 259
US-10-017-995-243/c
; Sequence 243, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-243

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGGTC 48
Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 260
US-10-067-076-10
; Sequence 10, Application US/10067076
; Publication No. US20030104404A1
; GENERAL INFORMATION:
; APPLICANT: Wise, Carol A.
; TITLE OF INVENTION: Genetic Markers for Autoimmune Disorder
; FILE REFERENCE: TEX871/4-006US/36000
; CURRENT APPLICATION NUMBER: US/10/067,076
; CURRENT FILING DATE: 2002-02-04
; PRIOR APPLICATION NUMBER: 60/287,893
; PRIOR FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: 09/710,693
; PRIOR FILING DATE: 2000-11-08
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Human Nucleic Acid
US-10-067-076-10

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 989 GCAGGTGCGCATGGATG 1008
Db 1 GCAGTGTCAAGGATG 20

RESULT 261
US-10-314-578-243/c
; Sequence 243, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jorg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
```

; PRIOR FILING DATE: 1999-09-25  
; PRIOR APPLICATION NUMBER: US 60/156,135  
; PRIOR FILING DATE: 1999-09-27  
; PRIOR APPLICATION NUMBER: US 60/227,436  
; PRIOR FILING DATE: 2000-08-23  
; NUMBER OF SEQ ID NOS: 1145  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 243  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic Sequence  
US-10-314-578-243

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
Qy 29 CCGCCTCGTGCAGCCGCTC 48  
||||| ||| |||||  
Db 20 CCGCGCGCGCGCGCGCC 1

RESULT 262  
US-10-403-902A-74  
; Sequence 74, Application US/10403902A  
; Publication No. US20030224418A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun, Andreas  
; APPLICANT: Bansal, Aruna  
; APPLICANT: Kleyn, Patrick  
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ASSOCIATED WITH  
; TITLE OF INVENTION: CARDIOVASCULAR DISEASE AND THEIR USE  
; FILE REFERENCE: 24736-2048B  
; CURRENT APPLICATION NUMBER: US/10/403,902A  
; CURRENT FILING DATE: 2003-07-21  
; PRIOR APPLICATION NUMBER: 09/802,640  
; PRIOR FILING DATE: 2001-03-09  
; NUMBER OF SEQ ID NOS: 122  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 74  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
US-10-403-902A-74

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
Qy 1265 GAGCCTGCTGCAGCCCTCA 1284  
||||| ||| |||||  
Db 1 GTGACTTCTGAGCCCTCA 20

RESULT 263  
US-10-175-499-39/c  
; Sequence 39, Application US/10175499  
; Publication No. US2003023977A1  
; GENERAL INFORMATION:  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Kenneth W. Dobie  
; APPLICANT: Susan J. Myers  
; TITLE OF INVENTION: ANTISENSE MODULATION OF SPLICING FACTOR R/S-RICH 10 EXPRESSION  
; FILE REFERENCE: HTS-0018  
; CURRENT APPLICATION NUMBER: US/10/175,499  
; CURRENT FILING DATE: 2002-06-17  
; NUMBER OF SEQ ID NOS: 62  
; SEQ ID NO 39  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence

; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-175-499-39

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
Qy 1411 ACACCATGACTGTCATGGAT 1430  
||||| ||| |||||  
Db 20 ACACATACCTGTCATGGAT 1

RESULT 264  
US-10-289-762-4294  
; Sequence 4294, Application US/10289762  
; Publication No. US20040006218A1  
; GENERAL INFORMATION:  
; APPLICANT: Grifflais, R.  
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments  
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention  
; FILE REFERENCE: 9710-003-999  
; CURRENT APPLICATION NUMBER: US/10/289,762  
; CURRENT FILING DATE: 2003-03-27  
; NUMBER OF SEQ ID NOS: 6849  
; SEQ ID NO 4294  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Chlamydia pneumoniae  
US-10-289-762-4294

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
Qy 1428 GATCCAAAGCAGATGAATG 1447  
||||| ||| |||||  
Db 1 GCTCCGAACCAAGATGAATG 20

RESULT 265  
US-10-210-556-35/c  
; Sequence 35, Application US/10210556  
; Publication No. US20040023904A1  
; GENERAL INFORMATION:  
; APPLICANT: Lex M. Cowbert  
; APPLICANT: Susan M. Freier  
; APPLICANT: Kenneth W. Dobie  
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPRA EXPRESSION  
; FILE REFERENCE: PTS-0015  
; CURRENT APPLICATION NUMBER: US/10/210,556  
; CURRENT FILING DATE: 2002-07-31  
; NUMBER OF SEQ ID NOS: 227  
; SEQ ID NO 35  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-210-556-35

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
  
Qy 888 CCAGATACGATTCCTTCAA 907  
||||| ||| |||||  
Db 20 CCAGATTCGATTACATCAA 1

RESULT 266  
US-10-210-556-158

```
; Sequence 158, Application US/10210556
; Publication No. US20040023904A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; APPLICANT: Susan M. Freier
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTTPRA EXPRESSION
; FILE REFERENCE: PFS-0015
; CURRENT APPLICATION NUMBER: US/10/210,556
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 227
; SEQ ID NO 158
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-210-556-158

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      888 CCAGATACGATGATTCCTTCAA 907
Db      1 CCAGATTCGATTACATCAA 20
||||| ||||| ||||| |||||

RESULT 267
US-10-280-183A-69/c
; Sequence 69, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Chatterjee, Aubroindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shanru
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; FILE REFERENCE: PC18306A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794
; PRIOR FILING DATE: 2000-04-28
; NUMBER OF SEQ ID NOS: 652
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Mouse
US-10-280-183A-69

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      685 AGGTGGGGGCTTTGGCATCT 704
Db      20 AGGTGAGGGTTTGGCTCT 1
||||| ||||| ||||| |||||

RESULT 268
US-10-303-326-30/c
; Sequence 30, Application US/10303326
; Publication No. US20040101849A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SELENOPROTEIN W EXPRESSION
; FILE REFERENCE: HTS-0033
; CURRENT APPLICATION NUMBER: US/10/303,326
; CURRENT FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
US-10-303-326-30

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      37 GTGCGCGCGCTCAGAGCCGC 56
Db      20 GTGCGCGCCATCAAGCCGC 1
||||| ||||| ||||| |||||

RESULT 269
US-10-303-326-60
; Sequence 60, Application US/10303326
; Publication No. US20040101849A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SELENOPROTEIN W EXPRESSION
; FILE REFERENCE: HTS-0033
; CURRENT APPLICATION NUMBER: US/10/303,326
; CURRENT FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 71
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-303-326-60

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      37 GTGCGCGCGCTCAGAGCCGC 56
Db      1 GTGCGCGCCATCAAGCCGC 20
||||| ||||| ||||| |||||

RESULT 270
US-10-304-125-30
; Sequence 30, Application US/10304125
; Publication No. US20040102405A1
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF SQUALENE SYNTHASE EXPRESSION
; FILE REFERENCE: PFS-0056
; CURRENT APPLICATION NUMBER: US/10/304,125
; CURRENT FILING DATE: 2002-11-23
; NUMBER OF SEQ ID NOS: 145
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

## US-10-304-125-30

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 973 ACAGCTGGGATGTGGGCGAG 992  
||| ||||| ||||| |||||  
Db 1 ACATCTGGGATGTGGTGCAG 20

## RESULT 271

US-10-304-125-100/c  
; Sequence 100, Application US/10304125  
; Publication No. US20040102405A1  
; GENERAL INFORMATION:

; APPLICANT: Susan M. Freier  
; APPLICANT: C. Frank Bennett  
; APPLICANT: Nicholas M. Dean  
; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF SQUALENE SYNTHASE EXPRESSION

; FILE REFERENCE: PTS-0056

; CURRENT APPLICATION NUMBER: US/10/304,125

; CURRENT FILING DATE: 2002-11-23

; NUMBER OF SEQ ID NOS: 145

; SEQ ID NO 100

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-304-125-100

## Query Match

Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 973 ACAGCTGGGATGTGGGCGAG 992  
||| ||||| ||||| |||||  
Db 20 ACATCTGGGATGTGGTGCAG 1

## RESULT 272

US-10-688-706-2869  
; Sequence 2869, Application US/10688706  
; Publication No. US20040102412A1  
; GENERAL INFORMATION:

; APPLICANT: Pharmacia Corp.

; APPLICANT: Broeschat, Kay

; TITLE OF INVENTION: ANTISENSE MODULATION OF GFAT EXPRESSION

; FILE REFERENCE: 01393/1

; CURRENT APPLICATION NUMBER: US/10/688,706

; CURRENT FILING DATE: 2003-10-17

; PRIOR APPLICATION NUMBER: 60/419,268

; PRIOR FILING DATE: 2002-10-17

; NUMBER OF SEQ ID NOS: 3071

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 2869

; LENGTH: 20

; TYPE: DNA

; ORGANISM: artificial

; FEATURE:

; OTHER INFORMATION: human GFAT antisense

US-10-688-706-2869

## Query Match

Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 845 GATCAAAATTCATTTCAGC 864  
||| ||||| ||||| |||||  
Db 1 GATAAATATGTCATTTCAGC 20

## RESULT 273

US-10-304-019-23/c  
; Sequence 23, Application US/10304019  
; Publication No. US20040102622A1  
; GENERAL INFORMATION:

; APPLICANT: Nicholas M. Dean

; APPLICANT: C. Frank Bennett

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF HEPATOCYTE GROWTH FACTOR RECEPTOR EXPRESSION

; FILE REFERENCE: PTS-0043

; CURRENT APPLICATION NUMBER: US/10/304,019

; CURRENT FILING DATE: 2002-11-23

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 23

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-304-019-23

## Query Match

Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1664 TACTTCCAAATTCCTGTGAT 1683  
||| ||||| ||||| |||||  
Db 20 TCCTTCCAAATACTTTGAT 1

## RESULT 274

US-10-304-019-94  
; Sequence 94, Application US/10304019  
; Publication No. US20040102622A1  
; GENERAL INFORMATION:

; APPLICANT: Nicholas M. Dean

; APPLICANT: C. Frank Bennett

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF HEPATOCYTE GROWTH FACTOR RECEPTOR EXPRESSION

; FILE REFERENCE: PTS-0043

; CURRENT APPLICATION NUMBER: US/10/304,019

; CURRENT FILING DATE: 2002-11-23

; NUMBER OF SEQ ID NOS: 147

; SEQ ID NO 94

; LENGTH: 20

; TYPE: DNA

; ORGANISM: H. sapiens

; FEATURE:

US-10-304-019-94

## Query Match

Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1664 TACTTCCAAATTCCTGTGAT 1683  
||| ||||| ||||| |||||  
Db 1 TCCTTCCAAATACTTTGAT 20

## RESULT 275

US-10-318-819A-64/c  
; Sequence 64, Application US/10318819A  
; Publication No. US20040115645A1  
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF DRK2 EXPRESSION

; FILE REFERENCE: PTS-0069

; CURRENT APPLICATION NUMBER: US/10/318,819A

; CURRENT FILING DATE: 2002-12-12

; NUMBER OF SEQ ID NOS: 133

; SEQ ID NO 64

; LENGTH: 20

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-318-819A-64

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 501 CTTGGCAGCAGCATTTGGGAC 520
Db 20 CTTGGCTACAGCAGTGGGAC 1

RESULT 276
US-10-318-819A-120
; Sequence 120, Application US/10318819A
; Publication No. US20040115645A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DRAX2 EXPRESSION
; FILE REFERENCE: PTS-0069
; CURRENT APPLICATION NUMBER: US/10/318,819A
; CURRENT FILING DATE: 2002-12-12
; NUMBER OF SEQ ID NOS: 133
; SEQ ID NO 120
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-318-819A-120

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 501 CTTGGCAGCAGCATTTGGGAC 520
Db 1 CTTGGCTACAGCAGTGGGAC 20

RESULT 277
US-10-712-795-261/c
; Sequence 261, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 261
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-712-795-261

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 780 AAAATTCCAAACAGCCTGTAT 799
Db 20 AAAATTCAAACAGCCTATAT 1

RESULT 278
US-10-712-795-627
; Sequence 627, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 627
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-712-795-627

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 780 AAAATTCCAAACAGCCTGTAT 799
Db 1 AAAATTCAAACAGCCTATAT 20

RESULT 279
US-10-712-795-835
; Sequence 835, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/426,234
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: PCT/US03/15493
; PRIOR FILING DATE: 2003-05-13
; NUMBER OF SEQ ID NOS: 892
; SEQ ID NO 835
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-712-795-835

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 ATGCAAGAAATGGCATCTCTA 186
Db 1 ATGGAAGACTGGCAGCTCTA 20

RESULT 280
US-10-712-795-880/c
; Sequence 880, Application US/10712795
; Publication No. US20040214325A1
; GENERAL INFORMATION:
; APPLICANT: Crooke et al.
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
; FILE REFERENCE: 30566/39662
; CURRENT APPLICATION NUMBER: US/10/712,795
```





US-10-920-612-835

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 167 ATGCAGATGGCATCTCTA 186  
|||||  
Db 1 ATGGAAGACTGGCAGCTCTA 20

RESULT 285

US-10-920-612-890/c  
; Sequence 880, Application US/10920612  
; Publication No. US2005009088A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke et al.  
; TITLE OF INVENTION: ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION  
; FILE REFERENCE: 30566/39634A  
; CURRENT APPLICATION NUMBER: US/10/920,612  
; CURRENT FILING DATE: 2004-08-17  
; PRIOR APPLICATION NUMBER: PCT/US03/15493  
; PRIOR FILING DATE: 2003-11-15  
; PRIOR APPLICATION NUMBER: US 10/712,795  
; PRIOR FILING DATE: 2003-11-13  
; PRIOR APPLICATION NUMBER: US 60/426,234  
; PRIOR FILING DATE: 2002-11-13  
; NUMBER OF SEQ ID NOS: 892  
; SEQ ID NO 880  
; LENGTH: 20  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-920-612-880

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 941 AGAACAGGTTGTACTGTCTA 960  
|||||  
Db 20 AGAACAGGAGTCTGTCTA 1

RESULT 286

US-10-838-659-57/c  
; Sequence 57, Application US/10838659  
; Publication No. US20050032734A1  
; GENERAL INFORMATION:  
; APPLICANT: Davis, Heather L.  
; APPLICANT: Krieg, Arthur M.  
; APPLICANT: Schorr, Joachim  
; APPLICANT: Wu, Tong  
; TITLE OF INVENTION: Vectors and Methods for Immunization or  
; FILE REFERENCE: C1039.70057US01  
; CURRENT APPLICATION NUMBER: US/10/838,659  
; CURRENT FILING DATE: 2004-05-03  
; PRIOR APPLICATION NUMBER: US 09/965,101  
; PRIOR FILING DATE: 2001-09-26  
; PRIOR APPLICATION NUMBER: US 09/082,649  
; PRIOR FILING DATE: 1998-05-20  
; PRIOR APPLICATION NUMBER: US 60/047,233  
; PRIOR FILING DATE: 1997-05-20  
; PRIOR APPLICATION NUMBER: US 60/047,209  
; PRIOR FILING DATE: 1997-05-20  
; NUMBER OF SEQ ID NOS: 84  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 57  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence

FEATURE:  
; OTHER INFORMATION: synthetic oligonucleotide  
US-10-838-659-57

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CGCCTTCCTCGCGCCGTC 48  
|||||  
Db 20 CGCGCGCGCGCGCGCC 1

RESULT 287

US-10-831-901A-22/c  
; Sequence 22, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank  
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; PRIOR FILING DATE: 2003-06-27  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-22

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 346 ACCAGAAAAGCCATCCAA 365  
|||||  
Db 20 ACCAGAAAAGCCACCAA 1

RESULT 288

US-10-831-901A-1686  
; Sequence 1686, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.

```
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1686
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1686

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      809 AGATGCGAAGATGATGCA 828
      ||||| ||||| ||||| |||||
Db      1 AGATGCCAAATGATGCCA 20

RESULT 289
US-10-831-901A-1687
; Sequence 1687, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8645
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-8645

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      809 AGATGCGAAGATGATGCA 828
      ||||| ||||| ||||| |||||
Db      1 AGATGCCAAATGATGCCA 20

RESULT 289
US-10-831-901A-1687
; Sequence 1687, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8645
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-8645
```

```
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1687
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1687

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      808 AAGATGCGAAGATGATGCA 827
      ||||| ||||| ||||| |||||
Db      1 AAGATGCCAAATGATGCCA 20

RESULT 290
US-10-831-901A-8645
; Sequence 8645, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8645
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-8645

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      816 GAAATGATGTCAGATGCG 835
      ||||| ||||| ||||| |||||
Db      1 GAAATGATGTCAGATGAC 20

RESULT 291
US-10-831-901A-8648
```

```
; Sequence 8648, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8648
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-8648

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      813 GCAGAAATGATGTCACGAAT 832
Db      1 GTAGAAATGATGTCACGAGT 20

RESULT 292
US-10-831-901A-11564/c
; Sequence 11564, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11564
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-11564
```

```
; Sequence 8648, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11564
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-11564

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1445 TGTTCCTGCTGCTGTTGGG 1464
Db      20 TGTTCCTGCTGCTACTTTGG 1

RESULT 293
US-10-831-901A-11565/c
; Sequence 11565, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT FILING DATE: 2004-04-26
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11565
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-11565

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Qy 1446 GTTCTGCTGCTGTTGGGC 1465  
Db 20 GTTCTGCTGCTACTTGGC 1

## RESULT 294

US-10-831-901A-21448  
; Sequence 21448, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank  
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-27  
; PRIOR APPLICATION NUMBER: 60/483,579  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 21448  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-21448

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1616 CTTCAAGCACTCTATT 1635  
Db 1 CTTGAACCACTCTGTT 20

## RESULT 295

US-10-831-901A-23367  
; Sequence 23367, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank  
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 25435  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-21448

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1616 CTTCAAGCACTCTATT 1635  
Db 1 CTTGAACCACTCTGTT 20

## RESULT 295

US-10-831-901A-23367  
; Sequence 23367, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank  
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 25435  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-21448

FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; PRIOR FILING DATE: 2003-06-27  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 23367  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-23367

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 2.5e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1774 TCTTAAAAACATTGTTCCA 1793  
Db 1 TCTGGAATACATTGTTCCA 20

## RESULT 296

US-10-831-901A-25435  
; Sequence 25435, Application US/10831901A  
; Publication No. US20050100885A1  
; GENERAL INFORMATION:  
; APPLICANT: Crooke, Stanley T.  
; APPLICANT: Ecker, David J.  
; APPLICANT: Sampath, Rangarajan  
; APPLICANT: Freier, Susan M.  
; APPLICANT: Massire, Christian  
; APPLICANT: Hofstadler, Steven A.  
; APPLICANT: Lowery, Kristin Sannes  
; APPLICANT: Swayze, Eric  
; APPLICANT: Baker, Brenda F.  
; APPLICANT: Bennett, C. Frank  
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe  
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)  
; CURRENT APPLICATION NUMBER: US/10/831,901A  
; CURRENT FILING DATE: 2004-04-26  
; PRIOR APPLICATION NUMBER: 60/466,426  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/468,562  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/467,770  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: 60/468,627  
; PRIOR FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 60/477,637  
; PRIOR FILING DATE: 2003-06-10  
; PRIOR APPLICATION NUMBER: 60/483,579  
; NUMBER OF SEQ ID NOS: 30063  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 25435  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense compound  
US-10-831-901A-21448

```
; OTHER INFORMATION: Antisense compound
US-10-831-901A-25435

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1820 TTTGGAAGATCTCTGAAAA 1839
      ||||| || ||||| |||||
Db 1 TTTGGTAGCGCTCTGAAAAA 20

RESULT 297
US-10-831-901A-25436
; Sequence 25436, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL00008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25436
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-25436

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1819 TTTTGAAGATCTCTGAAAA 1838
      ||||| || ||||| |||||
Db 1 TTTTGGTAGCGCTCTGAAAA 20

RESULT 298
US-10-663-451-166
; Sequence 166, Application US/10663451
; Publication No. US20050101555A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 7 EXPRESSION
; FILE REFERENCE: RTS-0201
; CURRENT APPLICATION NUMBER: US/10/663,451
```

```
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US/09/659,860A
; PRIOR FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-663-451-166

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1528 AAAGAAACGTTTTCATGCTT 1547
      ||||| ||||| ||||| |||||
Db 1 AAGGAAACCTTTTCATGCCT 20

RESULT 299
US-10-182-049-151/c
; Sequence 151, Application US/10182049
; Publication No. US2005011322A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: C. Frank Bennett
; APPLICANT: Nicholas M. Dean
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION
; FILE REFERENCE: RTSP-0360
; CURRENT APPLICATION NUMBER: US/10/182,049
; CURRENT FILING DATE: 2002-07-27
; PRIOR APPLICATION NUMBER: 09/490,208
; PRIOR FILING DATE: 2000-01-24
; NUMBER OF SEQ ID NOS: 182
; SEQ ID NO 151
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-182-049-151

Query Match          0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 385 AGCAAGATGGCTGGAGAA 404
      ||||| ||||| ||||| |||||
Db 20 ACCAAGATGGCTGGAGAA 1

RESULT 300
US-10-830-484-4/c
; Sequence 4, Application US/10830484
; Publication No. US20040220397A1
; GENERAL INFORMATION:
; APPLICANT: Leuck, Michael
; APPLICANT: Wolter, Andreas
; TITLE OF INVENTION: Solid Support For The Synthesis Of 3' Amino Oligonucleotides
; FILE REFERENCE: PRO13
; CURRENT APPLICATION NUMBER: US/10/830,484
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,269
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial
```

```
; FEATURE:
; OTHER INFORMATION: Synthetic Nucleic Acid Ligand
US-10-830-484-4

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 301
US-10-755-118-3/c
; Sequence 3, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755.118
; PRIOR FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acr1
US-10-755-118-4

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 303
US-10-755-118-31/c
; Sequence 31, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755.118
; PRIOR FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 31
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
US-10-755-118-3

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 302
US-10-755-118-4/c
; Sequence 4, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligodeoxyribonucleotide
US-10-755-118-31
Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 304
US-10-755-118-32
; Sequence 32, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: BHA resin
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: tert-butoxycarbonyl
US-10-755-118-36
Query Match      0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 306
US-10-755-118-38/c
; Sequence 38, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
```



```
;; FEATURE:
;; OTHER INFORMATION: Synthetic Construct
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(1)
;; OTHER INFORMATION: BHA resins
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(15)
;; OTHER INFORMATION: (2'-aminoethyl)glycine
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (15)..(15)
;; OTHER INFORMATION: tert-butoxycarbonyl
US-10-755-118-38
```

```
Query Match
Best Local Similarity 0.8%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
```

## RESULT 307

```
US-10-755-118-39/c
; Sequence 39, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Buchardt, Ole
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
```

```
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
```

```
; FILE REFERENCE: ISIS-5427
```

```
; CURRENT APPLICATION NUMBER: US/10/755,118
```

```
; CURRENT FILING DATE: 2004-01-09
```

```
; PRIOR APPLICATION NUMBER: US 08/462,977
```

```
; PRIOR FILING DATE: 1995-06-05
```

```
; PRIOR APPLICATION NUMBER: US 08/108,591
```

```
; PRIOR FILING DATE: 1993-11-22
```

```
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
```

```
; PRIOR FILING DATE: 1992-05-22
```

```
; PRIOR APPLICATION NUMBER: DN 510/92
```

```
; PRIOR FILING DATE: 1992-04-15
```

```
; PRIOR APPLICATION NUMBER: DN 987/91
```

```
; PRIOR FILING DATE: 1991-05-24
```

```
; PRIOR APPLICATION NUMBER: DN 986/91
```

```
; PRIOR FILING DATE: 1991-05-24
```

```
; NUMBER OF SEQ ID NOS: 157
```

```
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 39
```

```
; LENGTH: 15
```

```
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
```

```
; OTHER INFORMATION: Synthetic Construct
```

```
; FEATURE:
```

```
; NAME/KEY: misc_feature
```

```
; LOCATION: (1)..(1)
```

```
; OTHER INFORMATION: BHA resin
```

```
; FEATURE:
```

```
; NAME/KEY: misc_feature
```

```
; LOCATION: (1)..(15)
```

```
; OTHER INFORMATION: (2'-aminoethyl)glycine
```

```
; FEATURE:
```

```
; NAME/KEY: misc_feature
```

```
; LOCATION: (15)..(15)
```

```
; OTHER INFORMATION: Acrl
```

```
US-10-755-118-39
```

```
Query Match
0.8%; Score 15; DB 1; Length 15;
```

```
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
```

## RESULT 308

```
US-10-755-118-40/c
```

```
; Sequence 40, Application US/10755118
```

```
; Publication No. US20050009041A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Buchardt, Ole
```

```
; APPLICANT: Nielsen, Peter Eigil
```

```
; APPLICANT: Berg, Rolf Henrik
```

```
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
```

```
; FILE REFERENCE: ISIS-5427
```

```
; CURRENT APPLICATION NUMBER: US/10/755,118
```

```
; CURRENT FILING DATE: 2004-01-09
```

```
; PRIOR APPLICATION NUMBER: US 08/462,977
```

```
; PRIOR FILING DATE: 1995-06-05
```

```
; PRIOR APPLICATION NUMBER: US 08/108,591
```

```
; PRIOR FILING DATE: 1993-11-22
```

```
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
```

```
; PRIOR FILING DATE: 1992-05-22
```

```
; PRIOR APPLICATION NUMBER: DN 510/92
```

```
; PRIOR FILING DATE: 1992-04-15
```

```
; PRIOR APPLICATION NUMBER: DN 987/91
```

```
; PRIOR FILING DATE: 1991-05-24
```

```
; PRIOR APPLICATION NUMBER: DN 986/91
```

```
; PRIOR FILING DATE: 1991-05-24
```

```
; NUMBER OF SEQ ID NOS: 157
```

```
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 40
```

```
; LENGTH: 15
```

```
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
```

```
; OTHER INFORMATION: Synthetic Construct
```

```
; FEATURE:
```

```
; NAME/KEY: misc_feature
```

```
; LOCATION: (1)..(1)
```

```
; OTHER INFORMATION: BHA resin
```

```
; FEATURE:
```

```
; NAME/KEY: misc_feature
```

```
; LOCATION: (1)..(15)
```

```
; OTHER INFORMATION: (2'-aminoethyl)glycine
```

```
; FEATURE:
```

```
; NAME/KEY: misc_feature
```

```
; LOCATION: (15)..(15)
```

```
; OTHER INFORMATION: Hydrogen
```

```
US-10-755-118-40
```

```
Query Match
0.8%; Score 15; DB 1; Length 15;
```

```
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
```

## RESULT 309

```
US-10-755-118-43/c
```

```
; Sequence 43, Application US/10755118
```

```
; Publication No. US20050009041A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Buchardt, Ole
```

```
; APPLICANT: Egholm, Michael
```

```
; APPLICANT: Nielsen, Peter Eigil
```

```
; APPLICANT: Berg, Rolf Henrik
```

```
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acrl
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: NH2
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
; US-10-755-118-43

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 310
US-10-755-118-44/c
; Sequence 44, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Clz)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys-NH2
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Acrl
; US-10-755-118-44

Query Match          0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 311
US-10-755-118-45/c
; Sequence 45, Application US/10755118
; Publication No. US2005009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; PRIOR FILING DATE: 1991-05-24
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Clz)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; FEATURE:
; NAME/KEY: misc_feature
```

```

; LOCATION: (15)..(15)
; OTHER INFORMATION: tert-butoxycarbonyl
US-10-755-118-45

Query Match
Best Local Similarity 0.8%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
DB 15 AAAAAAAAAAAAAA 1

RESULT 312
US-10-755-118-48/c
; Sequence 48, Application US/10755118
; Publication No. US20050009041A1
; GENERAL INFORMATION:
; APPLICANT: Buchardt, Ole
; APPLICANT: Egholm, Michael
; APPLICANT: Nielsen, Peter Eigil
; APPLICANT: Berg, Rolf Henrik
; TITLE OF INVENTION: PEPTIDE NUCLEIC ACIDS AND SYNTHETIC PROCEDURES THEREFOR
; FILE REFERENCE: ISIS-5427
; CURRENT APPLICATION NUMBER: US/10/755,118
; PRIOR FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US 08/462,977
; PRIOR FILING DATE: 1995-06-05
; PRIOR APPLICATION NUMBER: US 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: DN 510/92
; PRIOR FILING DATE: 1992-04-15
; PRIOR APPLICATION NUMBER: DN 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: DN 986/91
; NUMBER OF SEQ ID NOS: 157
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 48
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: Lys (Cl2)-BHA resin
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: (2'-aminoethyl)glycine
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: Hydrogen
; US-10-755-118-49

Query Match
Best Local Similarity 0.8%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
DB 15 AAAAAAAAAAAAAA 1

RESULT 314
US-10-770-989-9/c
; Sequence 9, Application US/10770989
; Publication No. US20050019789A1
; GENERAL INFORMATION:
; APPLICANT: Ankenbauer, Waltraud
; APPLICANT: Schmitz-Agheguyan, Gudrun
; APPLICANT: Bonch-Osmolovskaya, Elizaveta
; APPLICANT: Svetlichny, Vitaly
; APPLICANT: Markau, Ursula
; APPLICANT: Angerer, Bernhard
; APPLICANT: Reiser, Astrid
; APPLICANT: Roche Molecular Systems, Inc.
; TITLE OF INVENTION: Thermostable DNA Polymerase from Anaerocellum
; FILE REFERENCE: 022101-000610US
; CURRENT APPLICATION NUMBER: US/10/770,989
; CURRENT FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: EP 96115877.1
; PRIOR FILING DATE: 1996-10-03
; PRIOR APPLICATION NUMBER: WO PCT/EP97/05390

```

; PRIOR FILING DATE: 1997-10-01  
; PRIOR APPLICATION NUMBER: US 09/269,858  
; PRIOR FILING DATE: 1999-06-10  
; NUMBER OF SEQ ID NOS: 9  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 9  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: (dt) -15,  
; OTHER INFORMATION: oligo dt primer  
US-10-770-989-9

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849  
Db 15 AAAAAAAAAAAAAA 1

RESULT 315  
US-10-833-502-9/c  
; Sequence 9, Application US/10833502  
; Publication No. US20050026279A1  
; GENERAL INFORMATION:  
; APPLICANT: ESPANA, EDGAR M.  
; TITLE OF INVENTION: SURGICAL GRAFTS AND METHODS OF PREPARATION  
; FILE REFERENCE: TIS-107  
; CURRENT APPLICATION NUMBER: US/10/833,502  
; PRIOR FILING DATE: 2002-04-28  
; PRIOR APPLICATION NUMBER: 60/465,989  
; PRIOR FILING DATE: 2003-04-28  
; PRIOR APPLICATION NUMBER: 60/473,007  
; PRIOR FILING DATE: 2003-05-22  
; NUMBER OF SEQ ID NOS: 10  
; SOFTWARE: PatentIn Ver. 3.2  
; SEQ ID NO 9  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-833-502-9

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849  
Db 15 AAAAAAAAAAAAAA 1

RESULT 316  
US-10-939-214-54/c  
; Sequence 54, Application US/10939214  
; Publication No. US20050026817A1  
; GENERAL INFORMATION:  
; APPLICANT: UHLMANN, EUGEN  
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR  
; TITLE OF INVENTION: PREPARATION AND USE  
; FILE REFERENCE: 02481.1437-02  
; CURRENT APPLICATION NUMBER: US/10/939,214  
; CURRENT FILING DATE: 2004-09-10  
; PRIOR APPLICATION NUMBER: US/09/793,146  
; PRIOR FILING DATE: 2001-02-27  
; PRIOR APPLICATION NUMBER: P 44 08 528.1  
; PRIOR FILING DATE: 1994-03-14

; PRIOR APPLICATION NUMBER: 08/402,838  
; PRIOR FILING DATE: 1995-03-13  
; NUMBER OF SEQ ID NOS: 70  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 54  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA  
US-10-939-214-54

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849  
Db 15 AAAAAAAAAAAAAA 1

RESULT 317  
US-10-939-214-55/c  
; Sequence 55, Application US/10939214  
; Publication No. US20050026817A1  
; GENERAL INFORMATION:  
; APPLICANT: UHLMANN, EUGEN  
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR  
; TITLE OF INVENTION: PREPARATION AND USE  
; FILE REFERENCE: 02481.1437-02  
; CURRENT APPLICATION NUMBER: US/10/939,214  
; CURRENT FILING DATE: 2004-09-10  
; PRIOR APPLICATION NUMBER: US/09/793,146  
; PRIOR FILING DATE: 2001-02-27  
; PRIOR APPLICATION NUMBER: P 44 08 528.1  
; PRIOR FILING DATE: 1994-03-14  
; PRIOR APPLICATION NUMBER: 08/402,838  
; PRIOR FILING DATE: 1995-03-13  
; NUMBER OF SEQ ID NOS: 70  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 55  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA  
US-10-939-214-55

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849  
Db 15 AAAAAAAAAAAAAA 1

RESULT 318  
US-10-601-140A-5/c  
; Sequence 5, Application US/10601140A  
; Publication No. US20050053942A1  
; GENERAL INFORMATION:  
; APPLICANT: KAUPPINEN, SAKARI  
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A  
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE  
; FILE REFERENCE: 57764(71994)  
; CURRENT APPLICATION NUMBER: US/10/601,140A  
; CURRENT FILING DATE: 2003-06-20  
; PRIOR APPLICATION NUMBER: US 60/390,928  
; PRIOR FILING DATE: 2002-06-24  
; NUMBER OF SEQ ID NOS: 45

```
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(15)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-5
```

```
Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
```

## RESULT 319

```
US-10-601-140A-16/c
; Sequence 16, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601.140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-16
```

```
Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
```

## RESULT 320

```
US-10-601-140A-19/c
; Sequence 19, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601.140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
```

```
; SEQ ID NO 19
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-19
```

```
Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
```

## RESULT 321

```
US-10-239-919A-4/c
; Sequence 4, Application US/10239919A
; Publication No. US20050054831A1
; GENERAL INFORMATION:
; APPLICANT: HWANG, IN-HWAN
; APPLICANT: LIM, JEONG-HWA
; APPLICANT: PIH, KYOUNG-TAE
; TITLE OF INVENTION: AN OSMOTIC STRESS-INDUCIBLE PROTEIN FUNCTIONING AS A
; TITLE OF INVENTION: NEGATIVE REGULATOR IN OSMOTIC STRESS SIGNALING PATHWAY
; FILE REFERENCE: 7022-0004
; CURRENT APPLICATION NUMBER: US/10/239,919A
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/KR02/00152
; PRIOR FILING DATE: 2002-02-01
; PRIOR APPLICATION NUMBER: KR 2001/5097
; PRIOR FILING DATE: 2001-02-02
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-239-919A-4
```

```
Query Match 0.8%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1
```

## RESULT 322

US-10-938-661A-22/c

; Sequence 22, Application US/10938661A

; Publication No. US20050070000A1

; GENERAL INFORMATION:

; APPLICANT: Pecker, Iris

; APPLICANT: Michal, Israel

; APPLICANT: Itzhaki, Hanan

; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY DISTANTLY

; FILE REFERENCE: 3462.1003-000

; CURRENT APPLICATION NUMBER: US/10/938,661A

; PRIOR FILING DATE: 2004-09-13

; NUMBER OF SEQ ID NOS: 25

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 22

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Artificial sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide

US-10-938-661A-22

Query Match 0.8%; Score 15; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1835 AAAAAAAAAAAAAA 1849

|||||

16 AAAAAAAAAAAAAA 1

## RESULT 323

US-10-238-700-1285/c

; Sequence 1285, Application US/10238700

; Publication No. US2003013521A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level

; FILE REFERENCE: 400/057 (MHB01-1158-A)

; CURRENT APPLICATION NUMBER: US/10/238,700

; CURRENT FILING DATE: 2002-09-18

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: PCT/US 02/16840

; PRIOR FILING DATE: 2001-09-10

; NUMBER OF SEQ ID NOS: 4666

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1285

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-238-700-1285

Query Match

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1443 AATGTCGCTGCTGCT 1457

|||||

16 AATGTCGCTGCTGCT 2

## RESULT 324

US-10-608-863-3/c

; Sequence 3, Application US/10608863

; Publication No. US20040214192A1

; GENERAL INFORMATION:

; APPLICANT: Hashida, Ryoichi

; APPLICANT: Kagaya, Shinji

; APPLICANT: Yayoi, Yoshihiro

; APPLICANT: Sugita, Yuji

; APPLICANT: Saito, Hirohisa

; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREAT

; FILE REFERENCE: 3462.1003-000

; CURRENT APPLICATION NUMBER: US/10/608,863

; PRIOR FILING DATE: 2003-06-27

; PRIOR APPLICATION NUMBER: JP 2002-188490

; NUMBER OF SEQ ID NOS: 18

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 3

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence:Artificially

; OTHER INFORMATION: Synthesized Primer Sequence

US-10-608-863-3

Query Match 0.8%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1835 AAAAAAAAAAAAAA 1849

|||||

16 AAAAAAAAAAAAAA 2

## RESULT 325

US-10-608-863-5/c

; Sequence 5, Application US/10608863

; Publication No. US20040214192A1

; GENERAL INFORMATION:

; APPLICANT: Hashida, Ryoichi

; APPLICANT: Kagaya, Shinji

; APPLICANT: Yayoi, Yoshihiro

; APPLICANT: Sugita, Yuji

; APPLICANT: Saito, Hirohisa

; TITLE OF INVENTION: METHODS FOR EXAMINATION FOR ALLERGIC DISEASES, AND DRUGS FOR TREAT

; FILE REFERENCE: 3462.1003-000

; CURRENT APPLICATION NUMBER: US/10/608,863

; CURRENT FILING DATE: 2003-06-27

; PRIOR APPLICATION NUMBER: JP 2002-188490

; PRIOR FILING DATE: 2002-06-27

; NUMBER OF SEQ ID NOS: 18

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 5

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence:Artificially

; OTHER INFORMATION: Synthesized Primer Sequence

US-10-608-863-5

Query Match

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

1835 AAAAAAAAAAAAAA 1849

|||||

16 AAAAAAAAAAAAAA 2

## RESULT 326

US-10-724-270-1285/c

; Sequence 1285, Application US/10724270

; Publication No. US20050080031A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1285
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-724-270-1285

Query Match          0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1443 AATGTTGCTGCTGCT 1457
Db 16 AATGTTGCTGCTGCT 2

RESULT 327
US-10-644-052A-376/c
; Sequence 376, Application US/10644052A
; Publication No. US20050059619A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M
; APPLICANT: Samulowitz, Ulrike
; APPLICANT: Vollmer, Joerg
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Jurk, Marlon
; APPLICANT: Lipford, Grayson
; APPLICANT: Rankin, Robert
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
; FILE REFERENCE: C1037.70048US00
; CURRENT APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/404,820
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/429,701
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: US 60/447,377
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1285
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-377

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 20 AAAAAAAAAAAAAA 6

RESULT 329
US-10-479-472A-8/c
; Sequence 8, Application US/10479472A
; Publication No. US20050118581A1
; GENERAL INFORMATION:
; APPLICANT: DEL-FAVERO, JURGEN PETER LODE
; APPLICANT: VAN BROECKHOVEN, CHRISTINE
; TITLE OF INVENTION: NOVEL BRAIN EXPRESSED GENE AND PROTEIN ASSOCIATED WITH
; FILE REFERENCE: JAB-1711
; CURRENT APPLICATION NUMBER: US/10/479,472A
; CURRENT FILING DATE: 2003-12-01
; PRIOR APPLICATION NUMBER: PCT/EP02/06316
; PRIOR FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 376
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-376

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 20 AAAAAAAAAAAAAA 6

RESULT 328
US-10-644-052A-377/c
; Sequence 377, Application US/10644052A
; Publication No. US20050059619A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M
; APPLICANT: Samulowitz, Ulrike
; APPLICANT: Vollmer, Joerg
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Jurk, Marlon
; APPLICANT: Lipford, Grayson
; APPLICANT: Rankin, Robert
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACIDS
; FILE REFERENCE: C1037.70048US00
; CURRENT APPLICATION NUMBER: US/10/644,052A
; CURRENT FILING DATE: 2003-08-19
; PRIOR APPLICATION NUMBER: US 60/404,479
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/404,820
; PRIOR FILING DATE: 2002-08-19
; PRIOR APPLICATION NUMBER: US 60/429,701
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: US 60/447,377
; PRIOR FILING DATE: 2003-02-14
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 377
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligodeoxynucleotide
US-10-644-052A-377

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 20 AAAAAAAAAAAAAA 6

RESULT 329
US-10-479-472A-8/c
; Sequence 8, Application US/10479472A
; Publication No. US20050118581A1
; GENERAL INFORMATION:
; APPLICANT: DEL-FAVERO, JURGEN PETER LODE
; APPLICANT: VAN BROECKHOVEN, CHRISTINE
; TITLE OF INVENTION: NOVEL BRAIN EXPRESSED GENE AND PROTEIN ASSOCIATED WITH
; FILE REFERENCE: JAB-1711
; CURRENT APPLICATION NUMBER: US/10/479,472A
; CURRENT FILING DATE: 2003-12-01
; PRIOR APPLICATION NUMBER: PCT/EP02/06316
; PRIOR FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 388
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 377
; LENGTH: 20
; TYPE: DNA
```

```
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Illustrative
; OTHER INFORMATION: oligonucleotide
US-10-479-472A-8

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGCG 46
Db 18 CCGCGCGCGCGCGCGCG 1

RESULT 330
US-10-479-472A-9
; Sequence 9, Application US/10479472A
; Publication No. US20050118581A1
; GENERAL INFORMATION:
; APPLICANT: DEL-FAVERO, JURGEN PETER LODE
; APPLICANT: VAN BROECKHOVEN, CHRISTINE
; TITLE OF INVENTION: NOVEL BRAIN EXPRESSED GENE AND PROTEIN ASSOCIATED WITH
; TITLE OF INVENTION: BIPOLAR DISORDER
; FILE REFERENCE: JAB-1711
; CURRENT APPLICATION NUMBER: US/10/479,472A
; CURRENT FILING DATE: 2003-12-01
; PRIOR APPLICATION NUMBER: PCT/EP02/06316
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: EP 01202214.1
; PRIOR FILING DATE: 2001-06-11
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Illustrative
; OTHER INFORMATION: oligonucleotide
US-10-479-472A-9

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGCG 46
Db 1 CCGCGCGCGCGCGCGCG 18

RESULT 331
US-10-479-472A-9
; Sequence 9, Application US/10479472A
; Publication No. US20050118581A1
; GENERAL INFORMATION:
; APPLICANT: COHEN, DANIEL
; APPLICANT: CHUMAKOV, ILIYA
; TITLE OF INVENTION: BIALLELIC MARKERS FOR USE IN CONSTRUCTING A HIGH DENSITY...
; FILE REFERENCE: GENSET.020Cp1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: 1999-04-21
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
```

```
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6888
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-21057 for SEQ 2954,
US-10-349-143-6888

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 GTGTGTTCTTATGCTTGT 1484
Db 19 GTTCCTTCTTATGCTTGT 2

RESULT 332
US-10-349-143-7139/C
; Sequence 7139, Application US/10349143
; Publication No. US2004000584A1
; GENERAL INFORMATION:
; APPLICANT: COHEN, DANIEL
; APPLICANT: BLUMENFELD, MARTA
; APPLICANT: CHUMAKOV, ILIYA
; TITLE OF INVENTION: BIALLELIC MARKERS FOR USE IN CONSTRUCTING A HIGH DENSITY...
; FILE REFERENCE: GENSET.020Cp1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7139
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..19
; OTHER INFORMATION: upstream amplification primer 99-24768 for SEQ 3205,
US-10-349-143-7139

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1629 CTCATTTCATGCTTCT 1646
Db 19 CTCCTTCTTCTGCTTCT 2

RESULT 333
US-10-830-569-307
; Sequence 307, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: SIRNA THERAPEUTICS, INC.
; APPLICANT: MCSWIGGEN, JAMES
; TITLE OF INVENTION: RNA INTERFERENCE MEDIATED INHIBITION OF HAIRLESS (HR) GENE
; TITLE OF INVENTION: Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/153 (MBHB04-378-A)
```



```
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 307
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-830-569-307

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 2.5e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1829 TCTCTGAAAAA 1846
Db 2 UUGUGAAAAA 19

RESULT 334
US-10-830-569-614/c
; Sequence 614, Application US/10830569
; Publication No. US20050054598A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hairless (HR) Gene
; FILE REFERENCE: 400/153 (MBHB04-378-A)
; CURRENT APPLICATION NUMBER: US/10/830,569
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/825,485
; PRIOR FILING DATE: 2004-04-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
```

```
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 821
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 614
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-830-569-614

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1829 TCTCTGAAAAA 1846
Db 18 TTTCTGAAAAA 1

RESULT 335
US-10-840-731-35
; Sequence 35, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 35
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-840-731-35

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 44.4%; Pred. No. 2.5e+02;
Matches 8; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 1814 TAAATTTTGGAGATCT 1831
Db 1 UAAAUUUUGAGGAUGU 18
```

```
RESULT 336
US-10-840-731-130/c
; Sequence 130, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/155 (MBHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 130
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-840-731-130

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1814 TAAATTTTGGAGATCT 1831
Db 19 TAAATTTTGGAGATCT 2

RESULT 337
US-10-863-973-694
; Sequence 694, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
```

```
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 694
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-863-973-694

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 55.6%; Pred. No. 2.5e+02;
Matches 10; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 820 TGAATCTCAAGAAATGGCTT 837
Db 1 UGAUGUCAAAAAUGUCUU 18

RESULT 338
US-10-863-973-765/c
; Sequence 765, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 765
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1na antisense region
US-10-863-973-765

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 820 TGATGTCGAAGTGCCTT 837
Db 19 TGATGTCGAAGTGCCTT 2

RESULT 339
US-10-164-915-3
; Sequence 3, Application US/10164915
; Publication No. US20030148391A1
; GENERAL INFORMATION:
; APPLICANT: Salafsky, Joshua S.
; TITLE OF INVENTION: Method Using a Surface-Selective No. US20030148391A1linear Optica
; FILE REFERENCE: For Detection of Interactions Involving a Conformational Change
; CURRENT APPLICATION NUMBER: US/10/164,915
; CURRENT FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: 60/253,862
; PRIOR FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: 60/260,249
; PRIOR FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: 60/265,775
; PRIOR FILING DATE: 2001-02-01
; PRIOR APPLICATION NUMBER: 60/278,941
; PRIOR FILING DATE: 2001-01-27
; NUMBER OF SEQ ID NOS: 6
; SEQ ID NO 3
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Oligonucleotide structure fo
US-10-164-915-3

Query Match          0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1834 GAAAAAACAACAAAAA 1849
Db 1 GAAAAAACAACAAAAA 16

RESULT 340
US-09-866-108-8364
; Sequence 8364, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8364
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8364

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAGTTCAC 410
Db 2 GCTGGAGAAAGTTCAC 17

RESULT 341
US-09-866-108-8365
; Sequence 8365, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 8365  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-8365

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 395 GCTGGAGAAAGTTCAC 410  
|||||  
Db 1 GCTGGAGAAAGTGCAC 16

## RESULT 342

US-09-866-108-10030/c  
; Sequence 10030, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-01-30  
; NUMBER OF SEQ ID NOS: 15752

; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 10030  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-10030

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGAGACTC 1080  
|||||  
Db 17 CGTCCACAGAGACTC 2

## RESULT 343

US-09-866-108-10031/c  
; Sequence 10031, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharon G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752

```

; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10031
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10031

```

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. NO. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 344  
US-09-927-046-1622/c  
; Sequence 1622, Application US/09927046  
; Publication No. US20030064946A1

Query Match	0.8%	Score 14.4;	DB 1;
Best Local Similarity	93.8%	Pred. No. 2.2e+02;	
Matches 15;	Conservative	0;	Mismatches 1;
			Indels 0;
			Gaps 0;

RESULT 345  
US-09-877-478-265/c  
; Sequence 265, Application US/09877478  
; Publication No. US20030068301A1

```

/ AFFILIATION: Morrissey, Dave
/ TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
/ FILE REFERENCE: MBH800-845-H (400/029)
/ CURRENT APPLICATION NUMBER: US/09/877,478
/ CURRENT FILING DATE: 2001-12-31
/ PRIOR APPLICATION NUMBER: US 07/882,712
/ PRIOR FILING DATE: 1992-05-14
/ PRIOR APPLICATION NUMBER: US 09/531,025
/ PRIOR FILING DATE: 2000-03-20
/ PRIOR APPLICATION NUMBER: US 09/636,385
/ PRIOR FILING DATE: 2000-08-09
/ PRIOR APPLICATION NUMBER: US 09/696,347
/ PRIOR FILING DATE: 2000-10-24
/ PRIOR APPLICATION NUMBER: US 08/193,627

```

RESULT 347  
US-09-848-754A-2911

```

; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 265
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-265

```

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 346  
US-09-877-478-267/c  
; Sequence 267, Application US/09877478  
; Publication No. US20030068301A1

```
Query Match      0.8%;      Score 14.4;  DB 1;      Length 17;
Best Local Similarity 93.8%;  Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels
```

```
; Sequence 2911, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MH800-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2911
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2911

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.2e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1327 ACTTTGGATCCCAAGC 1342
      ||:::|||||
Db      1 ACCUUGGAUCCAAGC 16

RESULT 348
US-09-848-754A-3506
; Sequence 3506, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Epidermal Growth Factor Receptors
; FILE REFERENCE: MH800-958-1 (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3506
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-3506

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.2e+02;
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1327 ACTTTGGATCCCAAGC 1342
      ||:::|||||
Db      2 ACCUUGGAUCCAAGC 17

RESULT 349
US-09-780-164-1033
; Sequence 1033, Application US/09780164
; Publication No. US20030092646A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1033
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Homo sapiens
US-09-780-164-1033

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      202 AAATAAAGAGAAAT 217
      ||:::|||||
Db      1 AAATAAAGAGAAAGU 16

RESULT 350
US-09-740-332-1266/c
; Sequence 1266, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1266
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1266

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1005 GATGGCGGTGGAGCCT 1020
      |||||
Db      17 GATGGGGGTGGAGCCT 2

RESULT 351
US-09-740-332-1414/c
; Sequence 1414, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1414
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1414

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1173 CTGGTGATGAGTCTG 1188
      |||||
```

```
Db      16 CTGGTGATGGAGGCTG 1
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1414
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1414

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1173 CTGGTGATGGAGGCTG 1188
      |||||
Db      16 CTGGTGATGGAGGCTG 1

RESULT 355
US-09-817-879-3289
; Sequence 3289, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3289
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3289

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      1005 GATGGCGGTGGAGCCT 1020
      |||||
Db      2 GAUGGGGUGGAGCCU 17

RESULT 356
US-09-817-879-1266/c
; Sequence 1266, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1266
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1266

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1005 GATGGCGGTGGAGCCT 1020
      |||||
Db      17 GATGGGGGTGGAGCCT 2

RESULT 354
US-09-817-879-1414/c
; Sequence 1414, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
```

```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1414
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1414

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1173 CTGGTGATGGAGGCTG 1188
      |||||
Db      16 CTGGTGATGGAGGCTG 1

RESULT 355
US-09-817-879-3289
; Sequence 3289, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3289
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3289

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy      1005 GATGGCGGTGGAGCCT 1020
      |||||
Db      2 GAUGGGGUGGAGCCU 17

RESULT 356
US-10-238-700-1286/c
; Sequence 1286, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
```

```
; NUMBER OF SEQ ID NOS: 4566
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1286
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-1286

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1440 ATGAATGTCGCTGCTG 1455
Db 16 ATTAATGTCGCTGCTG 1

RESULT 357
US-10-342-902-265/c
; Sequence 265, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 265
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-265

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 530 AGGCATTACAGCAGAA 545
Db 17 AGGCATTAAAGCAGAA 2

RESULT 358
US-10-342-902-267/c
; Sequence 267, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
```

```
; FILE REFERENCE: 400/075 (MBHB00-845-1)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 267
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-267

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 529 AAGGCATTACAGCAGA 544
Db 16 AAGGCATTAAAGCAGA 1

RESULT 359
US-10-138-674-4471
; Sequence 4471, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-4471

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1204 TACCCACTGGGCTGCA 1219
Db 2 UACCCACUGGGCAGCA 17

RESULT 360
US-10-138-674-7673/c
; Sequence 7673, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
```



```
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7673
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-7673

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1280 CCTCAATATCACTCAG 1295
Db 17 CCTCAATCACTCAG 2

RESULT 361
US-10-138-674-8905
; Sequence 8905, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8905

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1566 TCTGCAACTTTGGAAA 1581
Db 2 UCUGCAAAUUGGAAA 17

RESULT 362
US-10-287-949A-4471
; Sequence 4471, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
```

```
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-4471

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1204 TACCACTGGGCTCCA 1219
Db 2 UACCCACUGGGCAGCA 17

RESULT 363
US-10-287-949A-7673/c
; Sequence 7673, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7673
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7673

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1280 CCTCAATATCACTCAG 1295
Db 17 CCTCAATCACTCAG 2

RESULT 364
US-10-287-949A-8905
; Sequence 8905, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8905

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1566 TCTGCAACTTTGGAAA 1581
Db 2 UCUGCAAAUUGGAAA 17

RESULT 365
US-10-287-949A-7673/c
; Sequence 7673, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7673
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-7673

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.2e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1204 TACCACTGGGCTCCA 1219
Db 2 UACCCACUGGGCAGCA 17

RESULT 366
US-10-287-949A-8905
; Sequence 8905, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8905

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1566 TCTGCAACTTTGGAAA 1581
Db 2 UCUGCAAAUUGGAAA 17
```



; PRIOR APPLICATION NUMBER: US 60/337,055  
; PRIOR FILING DATE: 2001-12-05  
; PRIOR APPLICATION NUMBER: US 60/358,580  
; PRIOR FILING DATE: 2002-02-20  
; PRIOR APPLICATION NUMBER: US 60/363,124  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 09/817,879  
; PRIOR FILING DATE: 2001-03-26  
; PRIOR APPLICATION NUMBER: US 09/740,332  
; PRIOR FILING DATE: 2000-12-18  
; PRIOR APPLICATION NUMBER: US 09/611,931  
; PRIOR FILING DATE: 2000-07-07  
; PRIOR APPLICATION NUMBER: US 09/504,321  
; PRIOR FILING DATE: 2000-02-15  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 16207  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3859  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-3859

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1005 GATGGCGGTGGAGCT 1020  
|||||  
Db 17 GATGGCGGTGGAGCT 2

RESULT 368  
US-10-669-841-4007/c  
; Sequence 4007, Application US/10669841  
; Publication No. US20040127446A1  
; GENERAL INFORMATION:  
; APPLICANT: Sirna Therapeutics, Inc.  
; APPLICANT: Lawrence, Blatt  
; APPLICANT: Dennis, Macejak  
; APPLICANT: James, McSwiggen  
; APPLICANT: David, Morrissey  
; APPLICANT: Pamela, Pavco  
; APPLICANT: Patrice, Lee  
; APPLICANT: Kenneth, Draper  
; APPLICANT: Elisabeth, Roberts  
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP  
; TITLE OF INVENTION: VIRUS REPLICATION  
; FILE REFERENCE: 400/042US (MBH02-249-E)  
; CURRENT APPLICATION NUMBER: US/10/669,841  
; CURRENT FILING DATE: 2003-09-23  
; PRIOR APPLICATION NUMBER: PCT/US02/09187  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: US 60/296,876  
; PRIOR FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 60/335,059  
; PRIOR FILING DATE: 2001-10-24  
; PRIOR APPLICATION NUMBER: US 60/363,124  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 09/817,879  
; PRIOR FILING DATE: 2001-03-26  
; PRIOR APPLICATION NUMBER: US 09/740,332  
; PRIOR FILING DATE: 2000-12-18  
; PRIOR APPLICATION NUMBER: US 09/611,931  
; PRIOR FILING DATE: 2000-07-07  
; PRIOR APPLICATION NUMBER: US 09/504,321  
; PRIOR FILING DATE: 2000-02-15  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 16207  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5882  
; LENGTH: 17  
; TYPE: RNA

; PRIOR APPLICATION NUMBER: US 09/611,931  
; PRIOR FILING DATE: 2000-07-07  
; PRIOR APPLICATION NUMBER: US 09/504,321  
; PRIOR FILING DATE: 2000-02-15  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 16207  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4007  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-4007

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 2.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1173 CTGCTGATGGAGTCTG 1188  
|||||  
Db 16 CTGCTGATGGAGTCTG 1

RESULT 369  
US-10-669-841-5882  
; Sequence 5882, Application US/10669841  
; Publication No. US20040127446A1  
; GENERAL INFORMATION:  
; APPLICANT: Sirna Therapeutics, Inc.  
; APPLICANT: Lawrence, Blatt  
; APPLICANT: Dennis, Macejak  
; APPLICANT: James, McSwiggen  
; APPLICANT: David, Morrissey  
; APPLICANT: Pamela, Pavco  
; APPLICANT: Patrice, Lee  
; APPLICANT: Kenneth, Draper  
; APPLICANT: Elisabeth, Roberts  
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP  
; TITLE OF INVENTION: VIRUS REPLICATION  
; FILE REFERENCE: 400/042US (MBH02-249-E)  
; CURRENT APPLICATION NUMBER: US/10/669,841  
; CURRENT FILING DATE: 2003-09-23  
; PRIOR APPLICATION NUMBER: PCT/US02/09187  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: US 60/296,876  
; PRIOR FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 60/335,059  
; PRIOR FILING DATE: 2001-10-24  
; PRIOR APPLICATION NUMBER: US 60/337,055  
; PRIOR FILING DATE: 2001-12-05  
; PRIOR APPLICATION NUMBER: US 60/358,580  
; PRIOR FILING DATE: 2002-02-20  
; PRIOR APPLICATION NUMBER: US 60/363,124  
; PRIOR FILING DATE: 2002-03-11  
; PRIOR APPLICATION NUMBER: US 09/817,879  
; PRIOR FILING DATE: 2001-03-26  
; PRIOR APPLICATION NUMBER: US 09/740,332  
; PRIOR FILING DATE: 2000-12-18  
; PRIOR APPLICATION NUMBER: US 09/611,931  
; PRIOR FILING DATE: 2000-07-07  
; PRIOR APPLICATION NUMBER: US 09/504,321  
; PRIOR FILING DATE: 2000-02-15  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 16207  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5882  
; LENGTH: 17  
; TYPE: RNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5882
```

```
Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.2e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1005 GATGGGGTGGAGCCT 1020
Db      2 GAUGGGGGGAGGCCU 17
      ||:||:||:||:||:
```

## RESULT 370

```
US-10-723-361-8364
; Sequence 8364, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8364
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8365
```

```
Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      395 GCTGGAGAAAGTTCAC 410
Db      1 GCTGGAGAAAGTGCAC 16
      |||||
```

## RESULT 372

```
US-10-723-361-10030/c
; Sequence 10030, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
```

```
Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      395 GCTGGAGAAAGTTCAC 410
Db      2 GCTGGAGAAAGTGCAC 17
      |||||
```

## RESULT 371

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10030
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10030

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1065 CGTCCAAAGAGGACTC 1080
Db      17  CGTCCACAGAGGACTC 2

RESULT 373
US-10-723-361-10031/c
; Sequence 10031, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
```

```
; SEQ ID NO 10031
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10031

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1065 CGTCCAAAGAGGACTC 1080
Db      16  CGTCCACAGAGGACTC 1

RESULT 374
US-10-712-633-729/c
; Sequence 729, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 729
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-729

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1280 CCTCAATATCACTCAG 1295
Db      17  CCTCAACATCACTCAG 2

RESULT 375
US-10-712-633-4103
; Sequence 4103, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
```

```
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; FILE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR APPLICATION NUMBER: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4103
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-4103

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.2e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY      1566 TCCTGCAACTTGGAAA 1581
DB      2 UCUGCAAAUUGGAAA 17

RESULT 376
US-10-724-270-1286/c
; Sequence 1286, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; TITLE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1286
; LENGTH: 17
```

```
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1286

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.2e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1440 ATGAATGTTGCTGCTG 1455
DB      16 ATTAATGTTGCTGCTG 1

RESULT 377
US-09-263-959-1276/c
; Sequence 1276, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 1276:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-1276

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1335 ATCCAAGCTGGAGTGC 1350
DB      17 ATCCAGGCTGGAGTGC 2

RESULT 378
US-09-995-529-189
; Sequence 189, Application US/09995529
; Publication No. US2003009655A1
; GENERAL INFORMATION:
; APPLICANT: Watkins, Jeffrey D.
; APPLICANT: Huse, William D.
; APPLICANT: Tang, Ying
; TITLE OF INVENTION: Humanized Collagen Antibodies and
; TITLE OF INVENTION: Related Methods
```

; FILE REFERENCE: P-IX 4976  
; CURRENT APPLICATION NUMBER: US/09/995,529  
; CURRENT FILING DATE: 2001-11-26  
; NUMBER OF SEQ ID NOS: 358  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 189  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-09-995-529-189

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 75.0%; Pred. No. 2.5e+02;  
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGT 1459  
Db 1 RTRTSCGTGCTGCTRT 16

## RESULT 379

; Sequence 189, Application US/99995529  
; Publication No. US20040091482A9  
; GENERAL INFORMATION:  
; APPLICANT: Watkins, Jeffrey D.  
; APPLICANT: Huse, William D.  
; APPLICANT: Tang, Ying  
; TITLE OF INVENTION: Humanized Collagen Antibodies and  
; TITLE OF INVENTION: Related Methods  
; FILE REFERENCE: P-IX 4976  
; CURRENT APPLICATION NUMBER: US/09/995,529  
; CURRENT FILING DATE: 2001-11-26  
; NUMBER OF SEQ ID NOS: 358  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 189  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-09-995-529-189

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 75.0%; Pred. No. 2.5e+02;  
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1444 ATGTTGCTGCTGCTGT 1459  
Db 1 RTRTSCGTGCTGCTRT 16

## RESULT 380

US-10-214-670-29/c  
; Sequence 29, Application US/10214670  
; Publication No. US20030180715A1  
; GENERAL INFORMATION:  
; APPLICANT: Tibotec Pharmaceuticals Ltd.  
; TITLE OF INVENTION: Methods and means for assessing HIV envelope inhibitor  
; TITLE OF INVENTION: therapy  
; FILE REFERENCE: VIP-0021 seq listing  
; CURRENT APPLICATION NUMBER: US/10/214,670  
; CURRENT FILING DATE: 2002-08-08  
; PRIOR APPLICATION NUMBER: EP 01203011.0  
; PRIOR FILING DATE: 2001-08-08  
; PRIOR APPLICATION NUMBER: US 60/310497  
; PRIOR FILING DATE: 2001-08-08  
; NUMBER OF SEQ ID NOS: 62  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 29  
; LENGTH: 18

; TYPE: DNA  
; ORGANISM: Human immunodeficiency virus  
US-10-214-670-29

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1104 GAAGAACAAAGTGGAG 1119  
Db 18 GAAGAGAGAGTGGAG 3

## RESULT 381

US-10-277-216-327  
; Sequence 327, Application US/10277216  
; Publication No. US20040002470A1  
; GENERAL INFORMATION:  
; APPLICANT: KEITH, TIM  
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,  
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE  
; FILE REFERENCE: 2976-4051  
; CURRENT APPLICATION NUMBER: US/10/277,216  
; CURRENT FILING DATE: 2002-10-17  
; PRIOR APPLICATION NUMBER: 10/126,022  
; PRIOR FILING DATE: 2002-04-19  
; PRIOR APPLICATION NUMBER: 09/834,597  
; PRIOR FILING DATE: 2001-04-13  
; PRIOR APPLICATION NUMBER: 09/548,797  
; PRIOR FILING DATE: 2000-04-13  
; NUMBER OF SEQ ID NOS: 420  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 327  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-277-216-327

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 2.5e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 453 TCAGCTGTGATGCTGG 468  
Db 3 TCAGCTGTGCTGGTGG 18

## RESULT 382

US-10-126-022-327  
; Sequence 327, Application US/10126022  
; Publication No. US20040023215A1  
; GENERAL INFORMATION:  
; APPLICANT: KEITH, TIM  
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,  
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE  
; FILE REFERENCE: 2976-4039US2  
; CURRENT APPLICATION NUMBER: US/10/126,022  
; CURRENT FILING DATE: 2002-04-19  
; PRIOR APPLICATION NUMBER: 09/834,597  
; PRIOR FILING DATE: 2001-04-13  
; PRIOR APPLICATION NUMBER: 09/548,797  
; PRIOR FILING DATE: 2000-04-13  
; NUMBER OF SEQ ID NOS: 420  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 327  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Primer  
US-10-126-022-327

```
Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 453 TCAGCTGTGATGGTGG 468
Db      ||||| ||||| |||||
3 TCAGCTGTGCTGGTGG 18

RESULT 383
US-10-416-708A-8/c
; Sequence 8, Application US/10416708A
; Publication No. US20040161753A1
; GENERAL INFORMATION:
; APPLICANT: Wise, John G.
; APPLICANT: Fromknecht, Katja
; TITLE OF INVENTION: CREATION AND IDENTIFICATION OF PROTEINS HAVING NEW DNA BINDING
; TITLE OF INVENTION: SPECIFICITIES
; FILE REFERENCE: 37779-0004
; CURRENT APPLICATION NUMBER: US/10/416,708A
; CURRENT FILING DATE: 2004-01-28
; NUMBER OF SEQ ID NOS: 89
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Cauliflower mosaic virus derived sequence
US-10-416-708A-8

Query Match      0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 97 AAATGAAATTCCTAT 112
Db      ||||| ||||| |||||
16 AAATGAATTCCTAT 1

RESULT 384
US-10-604-944-221/c
; Sequence 221, Application US/10604944
; Publication No. US20040219515A1
; GENERAL INFORMATION:
; APPLICANT: ROSETTA GENOMICS LTD
; TITLE OF INVENTION: BIOINFORMATIALLY DETECTABLE GROUP OF NOVEL HIV REGULATORY GENES
; TITLE OF INVENTION: AND USES THEREOF
; FILE REFERENCE: 55008
; CURRENT APPLICATION NUMBER: US/10/604,944
; CURRENT FILING DATE: 2003-08-28
; NUMBER OF SEQ ID NOS: 406
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 221
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Human immunodeficiency virus 1
US-10-604-944-221

Query Match      0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 692 GCCTTTGGCATCTCTC 707
Db      | ||||| ||||| |||||
19 GCCTTTGGCATCTCTC 4

RESULT 385
US-10-840-731-31
; Sequence 31, Application US/10840731
; Publication No. US20050137153A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 31
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-840-731-31

Query Match      0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 56.2%; Pred. No. 2.8e+02;
Matches 9; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1813 ATAAATTTTGGGAAGA 1828
Db      |:|:|:|:|:|:|:|:|:|
4 AUAUAUUUUUGGAGGA 19

RESULT 386
US-10-840-731-126/c
; Sequence 126, Application US/10840731
; Publication No. US20050137153A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Robin, Howard
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Alpha-1 Antitrypsin (AAT)
; FILE REFERENCE: 400/155 (MEHB04-410)
; CURRENT APPLICATION NUMBER: US/10/840,731
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/652,791
```



```
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/422,704
; PRIOR FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 296
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 126
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-840-731-126

Query Match      0.8%; Score 14.4; DB 1; Length 19;
Best Local Similarity 93.8%; Pred. No. 2.8e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1813 ATAAATTTTGGAGCA 1828
Db 16 ATAAATTTTGGAGCA 1

RESULT 387
US-10-671-034-5/c
; Sequence 5, Application US/10671034
; Publication No. US20050096268A1
; GENERAL INFORMATION:
; APPLICANT: Wynn, Thomas
; Chiaromonte, Monica
; Collins, Mary
; Donaldson, Debra
; Fitz, Lori
; Neben, Tamlyn
; Whitters, Matthew
; Wood, Clive
; TITLE OF INVENTION: TREATMENT OF FIBROSIS BY ANTAGONISM OF IL-13
; AND IL-13 RECEPTOR CHAINS
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 Cambridgepark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/671,034
; FILING DATE: 25-Sep-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/301,808
; FILING DATE: 1999-11-29
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268A2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
```

```
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-671-034-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.3e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTCCTGGAGCCA 1359
Db 17 TGGAGYGMVTGGAGYSM 1

RESULT 388
US-10-830-484-3/c
; Sequence 3, Application US/10830484
; Publication No. US20040220397A1
; GENERAL INFORMATION:
; APPLICANT: Leuck, Michael
; APPLICANT: Wolter, Andreas
; TITLE OF INVENTION: Solid Support For The Synthesis Of 3' Amino Oligonucleotides
; FILE REFERENCE: PRO13
; CURRENT APPLICATION NUMBER: US/10/830,484
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,269
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Nucleic Acid Ligand
; NAME/KEY: misc feature
; LOCATION: (1)..(14)
; OTHER INFORMATION: 3' NH2
US-10-830-484-3

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1848
Db 14 AAAAAAAAAAAAAA 1

RESULT 389
US-10-764-393-11
; Sequence 11, Application US/10764393
; Publication No. US20040229248A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,393
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-393-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAAAAAAAAAA 14

RESULT 390
US-10-764-389-11
; Sequence 11, Application US/10764389
; Publication No. US20040230036A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,389
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-389-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAAAAAAAAAA 14

RESULT 391
US-10-855-595-21/c
; Sequence 21, Application US/10855595
; Publication No. US20040235057A1
; GENERAL INFORMATION:
; APPLICANT: Petkovich, P. Martin, White, Jay A.,
; Beckett, Barbara R., Jones, Glenville
; TITLE OF INVENTION: Retinoid Metabolizing Protein
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Blake, Cassels & Graydon
; STREET: Box 25, Commerce Court West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5L 1A9
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
; COMPUTER: COMPAQ, IBM PC compatible
; OPERATING SYSTEM: MS-DOS 5.1
; SOFTWARE: WORD PERFECT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/855,595
; FILING DATE: 28-May-2004
; PRIOR APPLICATION DATA:

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-393-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAAAAAAAAAA 14

RESULT 392
US-10-763-076-11
; Sequence 11, Application US/10763076
; Publication No. US20040254355A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/763,076
; CURRENT FILING DATE: 2004-01-22
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-763-076-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1833 TGAATAAAAAAAAA 1846
Db 14 TGAATAAAAAAAAA 1

RESULT 393
US-10-763-076-11
; Sequence 11, Application US/10763076
; Publication No. US20040254355A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABBANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/763,076
; CURRENT FILING DATE: 2004-01-22
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-763-076-11

Query Match      0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848
Db 1 AAAAAAAAAAAAAA 14

RESULT 393
US-10-855-532-21/c
; Sequence 21, Application US/10855532
; Publication No. US20040259074A1
; GENERAL INFORMATION:
; APPLICANT: Petkovich, P. Martin, White, Jay A.,
```

```
; Beckett, Barbara R., Jones, Glenville
; TITLE OF INVENTION: Retinoid Metabolizing Protein
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Blake, Cassels & Graydon
; STREET: Box 25, Commerce Court West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5L 1A9
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
; COMPUTER: COMPAQ, IBM PC compatible
; OPERATING SYSTEM: MS-DOS 5.1
; SOFTWARE: WORD PERFECT
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/855,532
; FILING DATE: 28-May-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/668,482
; FILING DATE: 25-Sep-2000
; APPLICATION NUMBER: 08/882,164
; FILING DATE: June 25, 1997
; APPLICATION NUMBER: 08/667,546
; FILING DATE: June 21, 1996
; APPLICATION NUMBER: 08/724,466
; FILING DATE: October 1, 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Hunt, John C.
; REGISTRATION NUMBER: 36,424
; REFERENCE/DOCKET NUMBER: 50767/00010
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 863-4344
; TELEFAX: (416) 863-2653
; INFORMATION FOR SEQ ID NO: 21
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 21
US-10-855-532-21
; SEQUENCE DESCRIPTION: SEQ ID NO: 21
Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1833 TCAAAAAAAAAA 1846
DB 14 TCAAAAAAAAAA 1
RESULT 394
US-10-764-388-11
; Sequence 11, Application US/10764388
; Publication No. US20050004350A1
; GENERAL INFORMATION:
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: RABANI, ELAZAR
; TITLE OF INVENTION: LABELING REAGENTS AND LABELED TARGETS, TARGET LABELING
; TITLE OF INVENTION: PROCESSES AND OTHER PROCESSES FOR USING SAME IN NUCLEIC
; TITLE OF INVENTION: ACID DETERMINATIONS AND ANALYSES
; FILE REFERENCE: ENZ-61
; CURRENT APPLICATION NUMBER: US/10/764,388
; CURRENT FILING DATE: 2004-01-23
; PRIOR APPLICATION NUMBER: US/10/096,075
; PRIOR FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-388-11
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-764-388-11
Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAA 1848
DB 1 AAAAAAAAAA 14
RESULT 395
US-10-096-076-11
; Sequence 11, Application US/10096076
; Publication No. US20050137388A1
; GENERAL INFORMATION:
; APPLICANT: RABANI, ELAZAR
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: DONEGAN, JAMES J.
; APPLICANT: COLEMAN, JACK
; APPLICANT: LIU, DAKAI
; TITLE OF INVENTION: REAL-TIME NUCLEIC ACID DETECTION PROCESSES AND
; TITLE OF INVENTION: COMPOSITIONS
; FILE REFERENCE: ENZ-62
; CURRENT APPLICATION NUMBER: US/10/096,076
; CURRENT FILING DATE: 2002-03-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 14
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-096-076-11
Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAA 1848
DB 1 AAAAAAAAAA 14
RESULT 396
US-09-866-108-2590
; Sequence 2590, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 2590  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-2590

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003  
|||||  
Db 4 CAGGGTGCCATGGA 17

RESULT 397  
US-09-866-108-2591  
; Sequence 2591, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05  
; NUMBER OF SEQ ID NOS: 15752  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 2591  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108-2591

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003  
|||||  
Db 3 CAGGGTGCCATGGA 16

RESULT 398  
US-09-866-108-2592  
; Sequence 2592, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21  
; PRIOR APPLICATION NUMBER: US 60/266,860  
; PRIOR FILING DATE: 2001-02-05



```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2842
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2842

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGAACAGAT 285
Db 1 AGCCGAGAACAGAU 14

RESULT 403
US-10-156-306-3723
; Sequence 3723, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3723
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3723

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 2.5e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGAACAGAT 285
Db 3 AGCCGAGAACAGAU 16

RESULT 404
US-10-723-361-2590
; Sequence 2590, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2591
```

```
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2590

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003
Db 4 CAGGGTGCCATGGA 17

RESULT 405
US-10-723-361-2591
; Sequence 2591, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2591
```

; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-723-361-2591

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003  
|||||

Db 3 CAGGGTGCCATGGA 16  
|||||

## RESULT 406

US-10-723-361-2592  
; Sequence 2592, Application US/107233361  
; Publication No. US20040137589A1  
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
; FILE REFERENCE: PB0105  
; CURRENT APPLICATION NUMBER: US/10/723,361  
; CURRENT FILING DATE: 2003-11-26  
; PRIOR APPLICATION NUMBER: US 09/866,108  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 2592  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-723-361-2592

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003  
|||||

Db 2 CAGGGTGCCATGGA 15  
|||||

## RESULT 407

US-10-723-361-2593  
; Sequence 2593, Application US/107233361  
; Publication No. US20040137589A1  
; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART A  
; FILE REFERENCE: PB0105  
; CURRENT APPLICATION NUMBER: US/10/723,361  
; CURRENT FILING DATE: 2003-11-26  
; PRIOR APPLICATION NUMBER: US 09/866,108  
; PRIOR FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 2593  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-723-361-2593

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGGTGCCATGGA 1003  
|||||

Db 1 CAGGGTGCCATGGA 14  
|||||

## RESULT 408

US-10-494-343-165/c  
; Sequence 165, Application US/10494343  
; Publication No. US20040248138A1  
; GENERAL INFORMATION:  
; APPLICANT: Pham, Thuy  
; APPLICANT: Shanon, Mark  
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1  
; FILE REFERENCE: PB0184  
; CURRENT APPLICATION NUMBER: US/10/494,343  
; CURRENT FILING DATE: 2004-04-30  
; PRIOR APPLICATION NUMBER: US to be assigned  
; PRIOR FILING DATE: to be assigned  
; PRIOR APPLICATION NUMBER: PCT/US2002/035129  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: US 60/334,773  
; PRIOR FILING DATE: 2001-11-01  
; NUMBER OF SEQ ID NOS: 870  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 165  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-494-343-165

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458  
|||||  
Db 17 TGTGCTGCTGCTG 4

## RESULT 409

US-10-494-343-166/c  
; Sequence 166, Application US/10494343  
; Publication No. US20040248138A1  
; GENERAL INFORMATION:  
; APPLICANT: Shannon, Mark  
; APPLICANT: Phan, Thuymy  
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1  
; FILE REFERENCE: PB0184  
; CURRENT APPLICATION NUMBER: US/10/494,343  
; PRIOR FILING DATE: 2004-04-30  
; PRIOR APPLICATION NUMBER: US to be assigned  
; PRIOR FILING DATE: to be assigned  
; PRIOR APPLICATION NUMBER: PCT/US2002/035129  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: US 60/334,773  
; PRIOR FILING DATE: 2001-11-01  
; NUMBER OF SEQ ID NOS: 870  
; SOFTWARE: Aeonica Sequence Listing Engine  
; SEQ ID NO 166  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-494-343-166

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458  
|||||  
Db 16 TGTGCTGCTGCTG 3

## RESULT 410

US-10-494-343-167/c  
; Sequence 167, Application US/10494343  
; Publication No. US20040248138A1  
; GENERAL INFORMATION:  
; APPLICANT: Shannon, Mark  
; APPLICANT: Phan, Thuymy  
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1  
; FILE REFERENCE: PB0184  
; CURRENT APPLICATION NUMBER: US/10/494,343  
; PRIOR FILING DATE: 2004-04-30  
; PRIOR APPLICATION NUMBER: US to be assigned  
; PRIOR FILING DATE: to be assigned  
; PRIOR APPLICATION NUMBER: PCT/US2002/035129  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: US 60/334,773  
; PRIOR FILING DATE: 2001-11-01  
; NUMBER OF SEQ ID NOS: 870  
; SOFTWARE: Aeonica Sequence Listing Engine  
; SEQ ID NO 167  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-494-343-167

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458  
|||||  
Db 15 TGTGCTGCTGCTG 2

## RESULT 411

US-10-494-343-168/c  
; Sequence 188, Application US/10494343  
; Publication No. US20040248138A1  
; GENERAL INFORMATION:  
; APPLICANT: Shannon, Mark  
; APPLICANT: Phan, Thuymy  
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1  
; FILE REFERENCE: PB0184  
; CURRENT APPLICATION NUMBER: US/10/494,343  
; PRIOR FILING DATE: 2004-04-30  
; PRIOR APPLICATION NUMBER: US to be assigned  
; PRIOR FILING DATE: to be assigned  
; PRIOR APPLICATION NUMBER: PCT/US2002/035129  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: US 60/334,773  
; PRIOR FILING DATE: 2001-11-01  
; NUMBER OF SEQ ID NOS: 870  
; SOFTWARE: Aeonica Sequence Listing Engine  
; SEQ ID NO 168  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-494-343-168

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458  
|||||  
Db 14 TGTGCTGCTGCTG 1

## RESULT 412

US-10-494-343-182  
; Sequence 182, Application US/10494343  
; Publication No. US20040248138A1  
; GENERAL INFORMATION:  
; APPLICANT: Shannon, Mark  
; APPLICANT: Phan, Thuymy  
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1  
; FILE REFERENCE: PB0184  
; CURRENT APPLICATION NUMBER: US/10/494,343  
; PRIOR FILING DATE: 2004-04-30  
; PRIOR APPLICATION NUMBER: US to be assigned  
; PRIOR FILING DATE: to be assigned  
; PRIOR APPLICATION NUMBER: PCT/US2002/035129  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: US 60/334,773  
; PRIOR FILING DATE: 2001-11-01  
; NUMBER OF SEQ ID NOS: 870  
; SOFTWARE: Aeonica Sequence Listing Engine  
; SEQ ID NO 182  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-494-343-182

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 662 GCAGGGGGCGGTGG 675  
|||||  
Db 4 GCAGGGGGCGGTGG 17



RESULT 413  
US-10-494-343-183  
; Sequence 183, Application US/10494343  
; Publication No. US20040248138A1  
; GENERAL INFORMATION:  
; APPLICANT: Shannon, Mark  
; APPLICANT: Phan, Thuymy  
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1  
; FILE REFERENCE: PB0184  
; CURRENT APPLICATION NUMBER: US/10/494,343  
; CURRENT FILING DATE: 2004-04-30  
; PRIOR APPLICATION NUMBER: US to be assigned  
; PRIOR FILING DATE: to be assigned  
; PRIOR APPLICATION NUMBER: PCT/US2002/035129  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: US 60/334,773  
; PRIOR FILING DATE: 2001-11-01  
; NUMBER OF SEQ ID NOS: 870  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 183  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-494-343-183

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGGCGGTGG 675  
Db 3 GCAGGGGGCGGTGG 16  
RESULT 414  
US-10-494-343-184  
; Sequence 184, Application US/10494343  
; Publication No. US20040248138A1  
; GENERAL INFORMATION:  
; APPLICANT: Shannon, Mark  
; APPLICANT: Phan, Thuymy  
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1  
; FILE REFERENCE: PB0184  
; CURRENT APPLICATION NUMBER: US/10/494,343  
; CURRENT FILING DATE: 2004-04-30  
; PRIOR APPLICATION NUMBER: US to be assigned  
; PRIOR FILING DATE: to be assigned  
; PRIOR APPLICATION NUMBER: PCT/US2002/035129  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: US 60/334,773  
; PRIOR FILING DATE: 2001-11-01  
; NUMBER OF SEQ ID NOS: 870  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 184  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-494-343-184

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGGCGGTGG 675  
Db 2 GCAGGGGGCGGTGG 15  
RESULT 415  
US-10-494-343-185  
; Sequence 185, Application US/10494343  
; Publication No. US20040248138A1  
; GENERAL INFORMATION:

; APPLICANT: Shannon, Mark  
; APPLICANT: Phan, Thuymy  
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1  
; FILE REFERENCE: PB0184  
; CURRENT APPLICATION NUMBER: US/10/494,343  
; CURRENT FILING DATE: 2004-04-30  
; PRIOR APPLICATION NUMBER: US to be assigned  
; PRIOR FILING DATE: to be assigned  
; PRIOR APPLICATION NUMBER: PCT/US2002/035129  
; PRIOR FILING DATE: 2002-11-01  
; PRIOR APPLICATION NUMBER: US 60/334,773  
; PRIOR FILING DATE: 2001-11-01  
; NUMBER OF SEQ ID NOS: 870  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 185  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-494-343-185

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.5e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGGCGGTGG 675  
Db 1 GCAGGGGGCGGTGG 14

RESULT 416  
US-09-866-108-1536  
; Sequence 1536, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00662  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00661  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00670  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 60/234,687  
; PRIOR FILING DATE: 2000-09-21

```

; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-8666-108-1536

```

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels

Qy 1081 TCGGGCTGGTCTCTGG 1097  
Db 1 TGGGGCTGGTGCCCTGG 17

```

RESULT 417
US-09-866-108-1537
; Sequence 1537, Application US/09866108
; Patent No. US2002004800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

```

```
Query Match      0.78; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No. 2.6e+00;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

RESULT 418  
US-09-866-108-8360  
; Sequence 8360, Application US/09866108  
; Patent No. US20020048800A1  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Shaaron G.  
; APPLICANT: HANZEL, David K.

Query Match	0.7%	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	89.2%;	Pred. No. 2.6e+03;		
Matches 15;	Conservative 0;	Mismatches 2;	Indels 0;	Gaps 0;
Qy	390	GATGGGCTGGAGAAAGT	406	
Db	1	GAGGAGCTGGAGAAAGT	17	

## RESULT 419

```

; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 9572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9572

Query Match 0.7% Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred.No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTCGACAGCTGGGATGT 985
Db 17 CTCGACAGCGGGATGT 1
||| ||||| |||||
||| ||||| |||||

RESULT 421
US-09-730-289B-153/c
; Sequence 153, Application US/09730289B
; Publication No. US20030050259A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCES: MBH800-864-A (400/006)
; CURRENT APPLICATION NUMBER: US/09/730,289B
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 153
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-153

```

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1795 TTTTAAAGTAACACTT 1811

Db 17 TTTTAAACTAACTCTT 1

## RESULT 422

US-09-780-533A-2550  
; Sequence 2550, Application US/09780533A  
; Publication No. US20030060611A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Chowrira, Bharat  
; APPLICANT: Haeblerli, Pete  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
; FILE REFERENCE: MEHB00,878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780,533A  
; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2550  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-2550

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 2.6e+02;

Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAATAAAGAGAAAT 217

Db 1 GGAUAAGGAGAAAU 17

## RESULT 423

US-09-927-046-198/c  
; Sequence 198, Application US/09927046  
; Publication No. US20030064946A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Thompson, Jim  
; APPLICANT: McKenzie, Tim  
; APPLICANT: Ayers, Dave  
; APPLICANT: Grupe, Andrew  
; APPLICANT: Szymkowski, Edmund  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1  
; FILE REFERENCE: 249/021  
; CURRENT APPLICATION NUMBER: US/09/927,046  
; CURRENT FILING DATE: 2001-08-09  
; NUMBER OF SEQ ID NOS: 5450  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 198  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-927-046-198

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1722 ATAGAATCAACATATGG 1738

Db 17 ATAGAATCAACATGTTG 1

## RESULT 424

US-09-927-046-264  
; Sequence 264, Application US/09927046  
; Publication No. US20030064946A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Thompson, Jim  
; APPLICANT: McKenzie, Tim  
; APPLICANT: Ayers, Dave  
; APPLICANT: Grupe, Andrew  
; APPLICANT: Szymkowski, Edmund  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1  
; FILE REFERENCE: 249/021  
; CURRENT APPLICATION NUMBER: US/09/927,046  
; CURRENT FILING DATE: 2001-08-09  
; NUMBER OF SEQ ID NOS: 5450  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 264  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-927-046-264

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 2.6e+02;

Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 210 GAAGAAATAGCCAGCTG 226

Db 1 GAAGAAUAUCCAACUG 17

## RESULT 425

US-09-848-754A-431  
; Sequence 431, Application US/09848754A  
; Publication No. US20030073207A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors  
; FILE REFERENCE: MEHB00-958-1 (400/018)  
; CURRENT APPLICATION NUMBER: US/09/848,754A  
; CURRENT FILING DATE: 2001-05-03  
; NUMBER OF SEQ ID NOS: 9645  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 431  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-848-754A-431

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 64.7%; Pred. No. 2.6e+02;

Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 174 AATGGCATCTCTAAGAG 190

Db 1 A AUGGCAUCUUAAGGG 17

## RESULT 426

US-09-848-754A-2212/c  
; Sequence 2212, Application US/09848754A  
; Publication No. US20030073207A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors

; TITLE OF INVENTION: Levels of Epidermal Growth Factor Receptors  
; FILE REFERENCE: MBH00-958-1 (400/018)  
; CURRENT APPLICATION NUMBER: US/09/848,754A  
; CURRENT FILING DATE: 2001-05-03  
; NUMBER OF SEQ ID NOS: 9645  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2212  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-848-754A-2212

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 674 GGAAGCTGCCAGGTGG 690  
Db 17 GGCAGTGCCTCAGGTGG 1

RESULT 427  
US-09-776-474-20/c  
; Sequence 20, Application US/09776474  
; Publication No. US20030087847A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Jarvis, Thale  
; APPLICANT: Boohar, Robert  
; APPLICANT: Holman, Patricia  
; APPLICANT: Fattaeey, Ali  
; APPLICANT: McSwiggen, Jim  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Checkpoint Kinase-1 (CHK1)  
; FILE REFERENCE: MBH00-958-A (400/008)  
; CURRENT APPLICATION NUMBER: US/09/776,474  
; CURRENT FILING DATE: 2001-02-02  
; PRIOR APPLICATION NUMBER: US 60/179,983  
; PRIOR FILING DATE: 2000-03-02  
; NUMBER OF SEQ ID NOS: 2992  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 20  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-776-474-20

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1654 TCTTCTTGATCTTC 1670  
Db 17 TCTTCTTAATATTC 1

RESULT 428  
US-09-827-395A-6/c  
; Sequence 6, Application US/09827395A  
; Publication No. US20030113891A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowhira  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G  
; FILE REFERENCE: MBH00-878-C (400/017)  
; CURRENT APPLICATION NUMBER: US/09/827,395A  
; CURRENT FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-827-395A-6

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAAGATGGGCTG 398  
Db 17 TGCAGCAAGATGGGCTG 1

RESULT 429  
US-09-827-395A-540  
; Sequence 540, Application US/09827395A  
; Publication No. US20030113891A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowhira  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G  
; FILE REFERENCE: MBH00-878-C (400/017)  
; CURRENT APPLICATION NUMBER: US/09/827,395A  
; CURRENT FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 540  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-827-395A-540

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1085 GCTGGTCTCTGGACTG 1101  
Db 1 GCUGGUGCUGGACAG 17

RESULT 430  
US-09-740-332-1531  
; Sequence 1531, Application US/09740332  
; Publication No. US20030125270A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: RPI 400/003  
; CURRENT APPLICATION NUMBER: US/09/740,332  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9704  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1531  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:

; OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-1531

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1287 ATCACTCAGTCTCTGAG 1303  
|:|||||:|:|:|  
Db 1 AUCACUCAGCUGCUGAG 17

RESULT 431

US-09-740-332-3141  
; Sequence 3141, Application US/09740332  
; Publication No. US20030125270A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: RPI 400/003  
; CURRENT APPLICATION NUMBER: US/09/740,332  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9704  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3141  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-3141

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1171 GTCGTGGTGGAGTCT 1187  
|:|||||:|:|:|  
Db 1 GGCUGGUGAGGAGGCU 17

RESULT 432

US-09-817-879-1531  
; Sequence 1531, Application US/09817879  
; Publication No. US20030171311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: MBH00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1531  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-1531

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1287 ATCACTCAGTCTCTGAG 1303  
|:|||||:|:|:|

Db 1 AUCACUCAGCUGCUGAG 17

RESULT 433

US-09-817-879-3141  
; Sequence 3141, Application US/09817879  
; Publication No. US20030171311A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals Inc.  
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related  
; FILE REFERENCE: MBH00-801-F  
; CURRENT APPLICATION NUMBER: US/09/817,879  
; CURRENT FILING DATE: 2001-03-26  
; NUMBER OF SEQ ID NOS: 9703  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3141  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: artificial sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION:  
; OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-3141

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1171 GTCGTGGTGGAGTCT 1187  
|:|||||:|:|:|  
Db 1 GGCUGGUGAGGAGGCU 17

RESULT 434

US-10-060-830-43  
; Sequence 43, Application US/10060830  
; Publication No. US20030032154A1  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN  
; FILE REFERENCE: PB0169  
; CURRENT APPLICATION NUMBER: US/10/060,830  
; CURRENT FILING DATE: 2002-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 09/864,761  
; PRIOR FILING DATE: 2001-05-23  
; PRIOR APPLICATION NUMBER: US 60/325,062  
; PRIOR FILING DATE: 2001-09-25  
; NUMBER OF SEQ ID NOS: 1123  
; SOFTWARE: Acomica Sequence Listing Engine  
; SEQ ID NO 43  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-060-830-43

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1518 AACACGTAAGAAAGAAA 1534  
|||||  
Db 1 AACACGTAAGAAAGAAA 17

## RESULT 435

US-10-060-830-44  
; Sequence 44, Application US/10060830  
; Publication No. US20030032154A1  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; APPLICANT: Nguyen, Cung-Tuong  
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN  
; FILE REFERENCE: PB0169  
; CURRENT APPLICATION NUMBER: US/10/060,830  
; PRIOR FILING DATE: 2002-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 09/864,761  
; PRIOR FILING DATE: 2001-05-23  
; PRIOR APPLICATION NUMBER: US 60/325,062  
; PRIOR FILING DATE: 2001-09-25  
; NUMBER OF SEQ ID NOS: 1123  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 44  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-060-830-44

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1519 AACAGTAAGAAAGAAC 1535  
|||||  
Db 1 AACAGTAAGAAAGAAC 17

## RESULT 436

US-10-060-756A-4251/c  
; Sequence 4251, Application US/10060756A  
; Publication No. US20030046717A1  
; GENERAL INFORMATION:  
; APPLICANT: Zhang, Jian  
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN  
; FILE REFERENCE: PB0177  
; CURRENT APPLICATION NUMBER: US/10/060,756A  
; PRIOR FILING DATE: 2002-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 09/864,761

; PRIOR FILING DATE: 2001-05-23  
; PRIOR APPLICATION NUMBER: US 60/327,898  
; PRIOR FILING DATE: 2001-10-09  
; NUMBER OF SEQ ID NOS: 4804  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 4251  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-060-756A-4251

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 ATTATCTTAACAAGAAA 81  
|||||  
Db 17 ATATCATATAACAAGAAA 1

## RESULT 437

US-10-060-998-715/c  
; Sequence 715, Application US/10060998  
; Publication No. US20030104530A1  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1  
; FILE REFERENCE: PB01108  
; CURRENT APPLICATION NUMBER: US/10/060,998  
; PRIOR FILING DATE: 2002-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 09/864,761  
; PRIOR FILING DATE: 2001-05-23  
; PRIOR APPLICATION NUMBER: US 60/343,331  
; PRIOR FILING DATE: 2001-12-21  
; NUMBER OF SEQ ID NOS: 3056  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 715  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-060-998-715

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 911 TGTAGCAGATCACTG 927  
|||||  
Db 17 TGTAGCAGATCACTG 1

## RESULT 438

US-10-060-998-716/c  
; Sequence 716, Application US/10060998  
; Publication No. US20030104530A1  
; GENERAL INFORMATION:  
; APPLICANT: Gu, Yizhong  
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1  
; FILE REFERENCE: PB01108  
; CURRENT APPLICATION NUMBER: US/10/060,998  
; PRIOR FILING DATE: 2002-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 09/864,761  
; PRIOR FILING DATE: 2001-05-23  
; PRIOR APPLICATION NUMBER: US 60/343,331  
; PRIOR FILING DATE: 2001-12-21  
; NUMBER OF SEQ ID NOS: 3056  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO 716  
; LENGTH: 17

```

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-716

Query Match      0.7%  Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 910 CTGTAGCAGAGATCACT 926
Db 17 CTGTAGCAGACATCAGT 1
      |||||
RESULT 439
US-10-156-306-368
; Sequence 368, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 368
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-368

Query Match      0.7%  Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1822 TGGAAAGATCTCTGAAAA 1838
Db 1 UGUACAUCUCUGAAAA 17
      :|||:|:|:|
RESULT 440
US-10-156-306-1548
; Sequence 1548, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1548
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-1548

Query Match      0.7%  Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.6e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 1823 GGAAGATCTCTGAAAA 1839
Db 1 GUACAUCUCUGAAAA 17
      |||||
RESULT 441
US-10-238-700-2801/G

```



; Sequence 540, Application US/10430882  
; Publication No. US20030203870A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Lawrence Blatt  
; APPLICANT: James McSwiggen  
; APPLICANT: Bharat Chowhri  
; APPLICANT: Peter Haeberli  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor  
; FILE REFERENCE: MBH00-878-H (400/112)  
; CURRENT APPLICATION NUMBER: US/10/430,882  
; CURRENT FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: 09/827,395  
; PRIOR FILING DATE: 2001-04-05  
; PRIOR APPLICATION NUMBER: 09/780,533  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: PCT/US01/04273  
; PRIOR FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: PCT/US02/10512  
; PRIOR FILING DATE: 2002-04-03  
; NUMBER OF SEQ ID NOS: 2617  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 540  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-430-882-540

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1085 GCTGCTCTCTGGACTG 1101  
Db 1 GCUGGUGCUGUGGACAG 17

## RESULT 444

US-10-674-1931  
; Sequence 1931, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1931  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-1931

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCACTTTGGAAAC 1583  
Db 1 CUGCAAAUUGGAAACC 17

## RESULT 445

US-10-138-674-1932

; Sequence 1932, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1932  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-1932

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 2.6e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCAACTTTGGAAACT 1584  
Db 1 UGCAAAUUGGAAACCU 17

## RESULT 446

US-10-138-674-2017/c  
; Sequence 2017, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2017  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-2017

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTCCAA 1165  
Db 17 AAGGAAATATTTCCCA 1

## RESULT 447

US-10-138-674-2613  
; Sequence 2613, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2613

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583
Db 1 CUGCAAGUUUGAAACC 17

RESULT 448
US-10-138-674-2614
; Sequence 2614, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2614

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.6e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCAACTTTGGAAACT 1584
Db 1 UGCAAGUUUGAAACCU 17

RESULT 449
US-10-138-674-3602/c
; Sequence 3602, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
```

```
; ORGANISM: Mus musculus
US-10-138-674-3602

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAA 1851
Db 17 AAACAAACAAACAAAAA 1

RESULT 450
US-10-138-674-3603/c
; Sequence 3603, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-3603

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAA 1851
Db 17 AAACAAACAAACAAAAA 1

RESULT 451
US-10-138-674-6261/c
; Sequence 6261, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6261
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6261

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1470 GTTCTTATGTTGTC 1486
|||||
```

Db 17 GTTCTTATGCTGATGC 1

## RESULT 452

US-10-138-674-7493/c  
; Sequence 7493, Application US/10138674  
; Publication No. US20040077565A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7493  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-7493

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1643 TTCTGTTATTATCTTTC 1659

Db 17 TTCTGTTATTAACTGTC 1

## RESULT 453

US-10-287-949A-1931  
; Sequence 1931, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1931  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-1931

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAAC 1583

Db 1 CUGCAAAUUGGAAACC 17

## RESULT 454

US-10-287-949A-1932  
; Sequence 1932, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/138,674  
; CURRENT FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 7493  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-138-674-7493

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1643 TTCTGTTATTATCTTTC 1659

Db 17 TTCTGTTATTAACTGTC 1

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1643 TTCTGTTATTATCTTTC 1659

Db 17 TTCTGTTATTAACTGTC 1

## RESULT 453

US-10-287-949A-1931  
; Sequence 1931, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1931  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-1931

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAAC 1583

Db 1 CUGCAAAUUGGAAACC 17

## RESULT 454

US-10-287-949A-1932  
; Sequence 1932, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1932  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-1932

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 2.6e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCAACTTTGGAAACT 1584

Db 1 UGCAAAUUGGAAACCU 17

## RESULT 455

US-10-287-949A-2017/c  
; Sequence 2017, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2017  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-2017

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGGTAAATATTTCCAA 1165

Db 17 AAGGAAATATTTCCCA 1

## RESULT 456

US-10-287-949A-2613  
; Sequence 2613, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MBH00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11

; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2613  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-287-949A-2613

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 2.6e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAC 1583  
|:||||:|||||  
DB 1 CUGCAAGUUUGGAACC 17

RESULT 457  
US-10-287-949A-2614  
; Sequence 2614, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2614  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-287-949A-2614

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 2.6e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCACCTTTGGAAC 1584  
:||||:|||||  
DB 1 UGCAAGUUUGGAACCU 17

RESULT 458  
US-10-287-949A-3602/c  
; Sequence 3602, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3602  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-287-949A-3602

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAA 1851  
||| ||||| |||||  
DB 17 AAACAAACAAAAAA 1

RESULT 459  
US-10-287-949A-3603/c  
; Sequence 3603, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3603  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus musculus  
US-10-287-949A-3603

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAA 1851  
||| ||||| |||||  
DB 17 AAACAAACAAAAAA 1

RESULT 460  
US-10-287-949A-6261/c  
; Sequence 6261, Application US/10287949A  
; Publication No. US20040102389A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel  
; FILE REFERENCE: MHB00-876-N (400/049)  
; CURRENT APPLICATION NUMBER: US/10/287,949A  
; CURRENT FILING DATE: 2003-04-11  
; NUMBER OF SEQ ID NOS: 20822  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6261  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-287-949A-6261

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1470 GTTCTTATGTTGTC 1486  
||| ||||| |||||  
DB 17 GTTCTTATGTCGATGC 1

RESULT 461

```

; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS D VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-4124

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred.No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY    1287 ATCACTCAGGTCCTGAG 1303
Db          1 AUCACUCAGCGUCUGAG 17
           |:|::|||: |:|::|

RESULT 464
US-10-669-841-5734
; Sequence 5734, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS D VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4124
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
; US-10-669-841-4124

```

```
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5734
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5734

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.6e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1171 GTCTGGTGAGTGCT 1187
Db 1 GCGUGGUGAGGAGGCU 17

RESULT 465
US-10-723-361-1536
; Sequence 1536, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1537
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1536

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1081 TGGCGCTGGTGCTGG 1097
Db 1 TGGGGCTGGTGCCCTGG 17

RESULT 466
US-10-723-361-1537
; Sequence 1537, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1537
```

```
Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1082 GCGGCTGCTGCTCGGA 1098
Db 1 GGGGCTGGTGCCTTGA 17

RESULT 467
US-10-723-361-8360
; Sequence 8360, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8360
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8363

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 393 GGGCTGGAGAAAGTTCA 409
Db 1 GAGCTGGAGAAAGTGCA 17

RESULT 469
US-10-723-361-9572/c
; Sequence 9572, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8360
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8360

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 390 GATGGCTGGAGAAAGT 406
Db 1 GAGGAGCTGGAGAAAGT 17

RESULT 468
US-10-723-361-8363
; Sequence 8363, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
```

```
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8363
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8363

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 393 GGGCTGGAGAAAGTTCA 409
Db 1 GAGCTGGAGAAAGTGCA 17

RESULT 469
US-10-723-361-9572/c
; Sequence 9572, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 8363
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8363
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 9572
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9572

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTCGACAGCTGGGATGT 985
Db 17 CTCGACAGCGGGATGT 1

RESULT 470
US-10-712-633-479/c
; Sequence 479, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-479

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1643 TTCTGTTATTATCTTTC 1659
Db 17 TTCTGTTATTAACTGTC 1

RESULT 471
US-10-712-633-479/c
; Sequence 479, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-479

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1643 TTCTGTTATTATCTTTC 1659
Db 17 TTCTGTTATTAACTGTC 1

RESULT 471
US-10-712-633-479/c
; Sequence 479, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-479

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1470 GTTCTTATGTTGTTGC 1486
Db 17 GTTCTTATGCTGATGC 1

RESULT 472
US-10-712-633-4212/c
; Sequence 4212, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-4212/c
; Sequence 4212, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 479
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-3660/c
; Sequence 3660, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; FILE REFERENCE: MBH02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3660
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-3660

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1470 GTTCTTATGTTGTTGC 1486
Db 17 GTTCTTATGCTGATGC 1
```



; PRIOR FILING DATE: 2001-11-30  
; PRIOR APPLICATION NUMBER: US 10/138,674  
; PRIOR FILING DATE: 2002-05-03  
; NUMBER OF SEQ ID NOS: 5989  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4212  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo Sapiens  
US-10-712-633-4212

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGGTAAATATTCCAA 1165  
Db 17 AAGGAAATATTCCCA 1

RESULT 473  
US-10-444-765-39  
; Sequence 39, Application US/10444765  
; Publication No. US20040248097A1  
; GENERAL INFORMATION:  
; APPLICANT: Chang, Ming-Shi  
; TITLE OF INVENTION: INTERLEUKIN-20 VARIANTS AND PROMOTERS  
; FILE REFERENCE: 15846-002001  
; CURRENT APPLICATION NUMBER: US/10/444,765  
; CURRENT FILING DATE: 2003-05-23  
; NUMBER OF SEQ ID NOS: 46  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 39  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-444-765-39

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 778 CCAAAATTCACACGCC 794  
Db 1 CCACAATTCACACTGCC 17

RESULT 474  
US-10-498-462-2053/c  
; Sequence 2053, Application US/10498462  
; Publication No. US20040259175A1  
; GENERAL INFORMATION:  
; APPLICANT: Guo, Jinjiao  
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1  
; FILE REFERENCE: PB01102  
; CURRENT APPLICATION NUMBER: US/10/498,462  
; CURRENT FILING DATE: 2004-06-10  
; PRIOR APPLICATION NUMBER: US 60/339,764  
; PRIOR FILING DATE: 2001-12-10  
; PRIOR APPLICATION NUMBER: PCT/US02/37506  
; PRIOR FILING DATE: 2002-11-22  
; NUMBER OF SEQ ID NOS: 3320  
; SOFTWARE: Aeomica Sequence Listing Engine  
; SEQ ID NO 2053  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-498-462-2053

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 511 GCATTGGGACTCTCCCA 527  
Db 17 GCATTGGGACTCTCTTA 1

RESULT 475  
US-10-724-270-1480/c  
; Sequence 1480, Application US/10724270  
; Publication No. US20050080031A1  
; GENERAL INFORMATION:  
; APPLICANT: McSwigen, James  
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level  
; FILE REFERENCE: 400/046-US (MBHB02-326-A)  
; CURRENT APPLICATION NUMBER: US/10/724,270  
; CURRENT FILING DATE: 2003-11-26  
; PRIOR APPLICATION NUMBER: PCT/US02/16840  
; PRIOR FILING DATE: 2002-05-29  
; PRIOR APPLICATION NUMBER: US 60/318,471  
; PRIOR FILING DATE: 2001-09-10  
; PRIOR APPLICATION NUMBER: US 60/296,249  
; PRIOR FILING DATE: 2001-06-06  
; PRIOR APPLICATION NUMBER: US 60/294,140  
; PRIOR FILING DATE: 2001-05-29  
; PRIOR APPLICATION NUMBER: US 10/238,700  
; PRIOR FILING DATE: 2002-09-10  
; PRIOR APPLICATION NUMBER: US 10/163,552  
; PRIOR FILING DATE: 2002-06-06  
; PRIOR APPLICATION NUMBER: US 10/157,580  
; PRIOR FILING DATE: 2002-05-29  
; PRIOR APPLICATION NUMBER: US 10/693,059  
; PRIOR FILING DATE: 2002-10-23  
; PRIOR APPLICATION NUMBER: US 10/444,853  
; PRIOR FILING DATE: 2003-05-23  
; PRIOR APPLICATION NUMBER: US 10/417,012  
; PRIOR FILING DATE: 2003-04-16  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 6810  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1480  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-10-724-270-1480

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 30 CGCCTCGTCGCGCGCG 46  
Db 17 CGCGCGCGCGCGCGCG 1

RESULT 476  
US-10-890-776A-4251/c  
; Sequence 4251, Application US/10890776A  
; Publication No. US20050129683A1  
; GENERAL INFORMATION:  
; APPLICANT: Zhang, Jian  
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN  
; FILE REFERENCE: PB0177  
; CURRENT APPLICATION NUMBER: US/10/890,776A  
; CURRENT FILING DATE: 2004-07-14  
; PRIOR APPLICATION NUMBER: US 10/060,756  
; PRIOR FILING DATE: 2002-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30

```

; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 4251
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-4251

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 ATTATCTTACACAGAAA 81
Db 17 AATATCATAACAGAAA 1

RESULT 477
US-08-983-605-93
; Sequence 93, Application US/08983605A
; Publication No. US20020066118A1
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
; TITLE OF INVENTION: Triticum aestivum and Tribe Triticace and the Use of
; TITLE OF INVENTION: Said Markers
; FILE REFERENCE: 2936.10400
; CURRENT APPLICATION NUMBER: US/08/983,605A
; CURRENT FILING DATE: 1998-05-01
; EARLIER APPLICATION NUMBER: DE 195 25 284.5
; EARLIER FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 93
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Triticum aestivum
US-08-983-605-93

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1696 AATCATTCTCCCTCCC 1712
Db 2 AATCATTCTCCCTCCC 18

RESULT 478
US-09-735-787-31
; Sequence 31, Application US/09735787
; Patent No. US20010036910A1
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Grethe
; NAME/KEY: Mikkelsen, Jan Moller
; OTHER INFORMATION: Schulein, Martin
; OTHER INFORMATION: Patkar, Shankant A.
; OTHER INFORMATION: Hagen, Fred
; TITLE OF INVENTION: A Cellulase Preparation Comprising an
; NUMBER OF SEQUENCES: 33
; Endoglucanase Enzyme
```

```

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. US20010036910A1o No. US20010036910A1disk of No. US2001003691
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/735,787
; FILING DATE: 13-Dec-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/189,028
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Lambiris, Elias J.
; REGISTRATION NUMBER: 33,728
; REFERENCE/DOCKET NUMBER: 3469.214-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-09-735-787-31

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 633 AACTACTCAAGGACGGT 649
Db 1 AGCTTCTCAAGGACGGT 17

RESULT 479
US-09-736-863-19
; Sequence 19, Application US/09736863
; Patent No. US20020037507A1
; GENERAL INFORMATION:
; APPLICANT: WalkerPeach, Cindy
; APPLICANT: Xiyuan, Hu
; TITLE OF INVENTION: Compositions, Methods and Kits for Allele Discrimination
; FILE REFERENCE: 25436/1730
; CURRENT APPLICATION NUMBER: US/09/736,863
; CURRENT FILING DATE: 2000-12-14
; PRIOR APPLICATION NUMBER: 60/171,126
; PRIOR FILING DATE: 1999-12-16
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: SDF1 forward PCR primer
; NAME/KEY: misc feature
; OTHER INFORMATION: SDF1 forward PCR primer
US-09-736-863-19

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY	Db	722	CTCCTCTCCATCTACA	738	Best Local Similarity	88.2%	Pred. No. 2.9e+02;	Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	Db	1	CCCCCTCTCCATCCACA	17													
<p>RESULT 480</p> <p>US-09-500-700-68/c</p> <p>Sequence 68, Application US/09500700</p> <p>Publication No. US20030059767A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: THE SCRIPPS RESEARCH INSTITUTE</p> <p>APPLICANT: BARBAS III, Carlos F.</p> <p>APPLICANT: GOTTESFELD, Joel M.</p> <p>APPLICANT: WRIGHT, Peter E.</p> <p>TITLE OF INVENTION: ZINC FINGER PROTEIN DERIVATIVES AND METHODS THEREFOR</p> <p>FILE REFERENCE: SCRIPI160-4</p> <p>CURRENT APPLICATION NUMBER: US/09/500,700</p> <p>CURRENT FILING DATE: 2003-01-10</p> <p>PRIOR APPLICATION NUMBER: US 08/863,813</p> <p>PRIOR FILING DATE: 1997-05-27</p> <p>PRIOR APPLICATION NUMBER: US 08/676,318</p> <p>PRIOR FILING DATE: 1996-12-30</p> <p>PRIOR APPLICATION NUMBER: PCT/US95/00829</p> <p>PRIOR FILING DATE: 1995-01-18</p> <p>PRIOR APPLICATION NUMBER: US 08/312,604</p> <p>PRIOR FILING DATE: 1994-09-28</p> <p>PRIOR APPLICATION NUMBER: US 08/183,119</p> <p>PRIOR FILING DATE: 1994-01-18</p> <p>NUMBER OF SEQ ID NOS: 127</p> <p>SOFTWARE: PatentIn version 3.1</p> <p>SEQ ID NO 68</p> <p>LENGTH: 18</p> <p>TYPE: DNA</p> <p>ORGANISM: Artificial Sequence</p> <p>FEATURE:</p> <p>OTHER INFORMATION: (GCG)6 probe</p> <p>US-09-500-700-68</p>																	
<p>Query Match</p> <p>Best Local Similarity 88.2%; Pred. No. 2.9e+02;</p> <p>Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>																	
QY	Db	30	CGCCTCCGTCGCGCGCG 46														
Db		18	CGCGCGCGCGCGCGCGCG 2														
<p>RESULT 481</p> <p>US-10-181-603-45</p> <p>Sequence 45, Application US/10181603</p> <p>Publication No. US20030049662A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Brett P. Monia</p> <p>APPLICANT: Lex M. Cowsett</p> <p>TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION</p> <p>FILE REFERENCE: RTSP-0342</p> <p>CURRENT APPLICATION NUMBER: US/10/181,603</p> <p>CURRENT FILING DATE: 2002-07-17</p> <p>PRIOR APPLICATION NUMBER: PCT/US01/01165</p> <p>PRIOR FILING DATE: 2001-01-12</p> <p>PRIOR APPLICATION NUMBER: 09/487,444</p> <p>PRIOR FILING DATE: 2000-01-19</p> <p>NUMBER OF SEQ ID NOS: 49</p> <p>SEQ ID NO 45</p> <p>LENGTH: 18</p> <p>TYPE: DNA</p> <p>ORGANISM: Artificial Sequence</p> <p>FEATURE:</p> <p>OTHER INFORMATION: Antisense Oligonucleotide</p> <p>US-10-181-603-45</p>																	
<p>Query Match</p> <p>Best Local Similarity 88.2%; Pred. No. 2.9e+02;</p> <p>Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>																	
QY	Db	30	CGCCTCCGTCGCGCGCG 46														
Db		18	CGCGCGCGCGCGCGCGCG 2														
<p>RESULT 482</p> <p>US-10-314-405-45/c</p> <p>Sequence 45, Application US/10314405</p> <p>Publication No. US20030108940A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Hidetoshi, Inoko</p> <p>APPLICANT: Gen, Tamiya</p> <p>APPLICANT: Yasunari, Matsuzaka</p> <p>TITLE OF INVENTION: NOVEL POLYMORPHIC MICROSATELLITE MARKERS IN THE HUMAN MHC CLASS I</p> <p>FILE REFERENCE: 06501-069001</p> <p>CURRENT APPLICATION NUMBER: US/10/314,405</p> <p>CURRENT FILING DATE: 2002-12-06</p> <p>PRIOR APPLICATION NUMBER: US/09/713,616</p> <p>PRIOR FILING DATE: 2000-11-15</p> <p>NUMBER OF SEQ ID NOS: 46</p> <p>SOFTWARE: PatentIn version 3.0</p> <p>SEQ ID NO 45</p> <p>LENGTH: 18</p> <p>TYPE: DNA</p> <p>ORGANISM: Homo sapiens</p> <p>US-10-314-405-45</p>																	
<p>Query Match</p> <p>Best Local Similarity 88.2%; Pred. No. 2.9e+02;</p> <p>Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>																	
QY	Db	30	CGCCTCCGTCGCGCGCG 46														
Db		18	CGCGCGCGCGCGCGCGCG 2														
<p>RESULT 483</p> <p>US-10-138-870-31</p> <p>Sequence 31, Application US/10138870</p> <p>Publication No. US20030119167A1</p> <p>GENERAL INFORMATION:</p> <p>APPLICANT: Rasmussen, Grethe</p> <p>APPLICANT: Mikkelson, Jan Moller</p> <p>APPLICANT: Schulein, Martin</p> <p>APPLICANT: Patkar, Shankant A.</p> <p>APPLICANT: Hagen, Fred</p> <p>TITLE OF INVENTION: A Cellulase Preparation Comprising an Endoglucanase Enzyme</p> <p>NUMBER OF SEQUENCES: 33</p> <p>CORRESPONDENCE ADDRESS:</p> <p>ADDRESSEE: No. US20030119167A10 No. US20030119167A1disk of No. US20030119167A1</p> <p>STREET: 405 Lexington Avenue, 64th Floor</p> <p>CITY: New York</p> <p>STATE: New York</p> <p>COUNTRY: United States of America</p> <p>ZIP: 10174-6401</p> <p>COMPUTER READABLE FORM:</p> <p>MEDIUM TYPE: Floppy disk</p> <p>COMPUTER: IBM PC compatible</p> <p>OPERATING SYSTEM: PC-DOS/MS-DOS</p> <p>SOFTWARE: PatentIn Release #1.0, Version #1.30</p> <p>CURRENT APPLICATION DATA:</p> <p>APPLICATION NUMBER: US/10/138,870</p> <p>FILING DATE: 03-May-2002</p> <p>CLASSIFICATION: &lt;Unknown&gt;</p> <p>PRIOR APPLICATION DATA:</p> <p>APPLICATION NUMBER: US/09/735,787</p> <p>FILING DATE: 13-Dec-2000</p> <p>APPLICATION NUMBER: 09/189,028</p> <p>FILING DATE: &lt;Unknown&gt;</p>																	
<p>Query Match</p> <p>Best Local Similarity 88.2%; Pred. No. 2.9e+02;</p> <p>Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>																	

```
/
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Lambiris, Elias J.
/ REGISTRATION NUMBER: 33,728
/ REFERENCE/DOCKET NUMBER: 3469,214-US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 212-867-0123
/ TELEFAX: 212-878-9655
/ INFORMATION FOR SEQ ID NO: 31:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: cDNA
/ SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-10-138-870-31

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      633 AACTACTCAAGGACGGT 649
Db      1 AGCTTCTCAGGACGGT 17

RESULT 484
US-10-133-779-9/c
; Sequence 9, Application US/10133779
; Publication No. US20030165884A1
; GENERAL INFORMATION:
; APPLICANT: Chow, Robert
; APPLICANT: Tonai, Richard
; APPLICANT: StemCytex, Inc.
; TITLE OF INVENTION: High Throughput Methods of HLA Typing
; FILE REFERENCE: 020035-000210US
; CURRENT APPLICATION NUMBER: US/10/133,779
; CURRENT FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US/09/747,391
; PRIOR FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: US 60/172,768
; PRIOR FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 278
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-133-779-9

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      382 TGCAGCAAGATGGGCTG 398
Db      17 TGCAGCACGAGGGGCTG 1

RESULT 485
US-10-133-779-125/c
; Sequence 125, Application US/10133779
; Publication No. US20030165884A1
; GENERAL INFORMATION:
; APPLICANT: Chow, Robert
; APPLICANT: Tonai, Richard
; APPLICANT: StemCytex, Inc.
; TITLE OF INVENTION: High Throughput Methods of HLA Typing
; FILE REFERENCE: 020035-000210US
; CURRENT APPLICATION NUMBER: US/10/133,779
; CURRENT FILING DATE: 2002-04-25
; PRIOR APPLICATION NUMBER: US/09/747,391
; PRIOR FILING DATE: 2001-07-13
US-10-133-779-125

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      382 TGCAGCAAGATGGGCTG 398
Db      17 TGCAGCACGAGGGGCTG 1

RESULT 486
US-10-289-845-19/c
; Sequence 19, Application US/10289845
; Publication No. US20030170679A1
; GENERAL INFORMATION:
; APPLICANT: Wood, Linda
; APPLICANT: Wagner, Susanne
; APPLICANT: Parodi, Luis
; TITLE OF INVENTION: Single Nucleotide Polymorphisms in GH-1
; FILE REFERENCE: 00791.US1
; CURRENT APPLICATION NUMBER: US/10/289,845
; CURRENT FILING DATE: 2002-11-07
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 18
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-289-845-19

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1554 AGGAATCTCTGGTCTGC 1570
Db      17 AGGACTCTCTGGGTCTGC 1

RESULT 487
US-10-289-845-48/c
; Sequence 48, Application US/10289845
; Publication No. US20030170679A1
; GENERAL INFORMATION:
; APPLICANT: Wood, Linda
; APPLICANT: Wagner, Susanne
; APPLICANT: Parodi, Luis
; TITLE OF INVENTION: Single Nucleotide Polymorphisms in GH-1
; FILE REFERENCE: 00791.US1
; CURRENT APPLICATION NUMBER: US/10/289,845
; CURRENT FILING DATE: 2002-11-07
; NUMBER OF SEQ ID NOS: 51
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 48
; LENGTH: 18
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-289-845-48

Query Match      0.7%; Score 13.8; DB 1; Length 18;
```



Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1101 GCAGAGACAAGGTGG 1117  
Db 2 GCAGAGGAGCAAGGTGG 18

```

RESULT 491
US-10-126-022-101
; Sequence 101, Application US/10126022
; Publication No. US20040023215A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 2976-4039US2
; CURRENT APPLICATION NUMBER: US/10/126,022
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; PRIOR FILING DATE: 2000-04-13
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 101
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-126-022-101

```

```
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels
```

Qy 1101 GCAGAGAACCAAGGTGG 1117  
Db 2 GCAGAGGAGCAAGGTGG 18

```

RESULT 492
US-10-333-429-261/c
; Sequence 261, Application US/10333429
; Publication No. US20040048265A1
; GENERAL INFORMATION:
; APPLICANT: GENSET
; TITLE OF INVENTION: Obesity Associated Biallelic Marker Maps
; FILE REFERENCE: G-083US02PCT
; CURRENT APPLICATION NUMBER: US/10/333,429
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: PCT/IB01/01477
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: US 60/219,704
; PRIOR FILING DATE: 2000-07-18
; NUMBER OF SEQ ID NOS: 579
; SOFTWARE: Patent.pm
; SEQ ID NO 261
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-32166 f
US-10-333-429-261

```

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels

QY 224 CTGTGGAGATGTTGCTA 240

Db 17 CTGTGAAGATGATGCTA 1

```

RESULT 493
US-10-376-770-205
; Sequence 205, Application US/10376770
; Publication No. US20040106102A1
; GENERAL INFORMATION:
; APPLICANT: Dhallan, Ravinder S.
; TITLE OF INVENTION: RAPID ANALYSIS OF VARIATIONS IN A GENOME
; FILE REFERENCE: 543312000320
; CURRENT APPLICATION NUMBER: US/10/376,770
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; NUMBER OF SEQ ID NOS: 262
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 205
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)...(8)
; OTHER INFORMATION: These nucleotides may be absent
US-10-376-770-205

```

Query Match	0.7%	Score 13.8;	DB 1;	Length 18;
Best Local Similarity	88.2%	Pred. No. 2.9e+02;		
Matches	15: Conservative	0: Mismatches	2: Indels	Gaps

Qy 201 GAAATAAAAGAAGAAAT 217  
|||  
Db 1 GAAATAAAAGAAGAAAT 17

```

RESULT 494
US-10-745-377-138/c
; Sequence 138, Application US/10745377
; Publication No. US20040137423A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 760050-109
; CURRENT APPLICATION NUMBER: US/10745,377
; CURRENT FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 138
; LENGTH: 18

```

```
; TYPE: DNA
; ORGANISM: homo sapien
US-10-745-377-138

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1641 CTTTCTGTATATATCTT 1657
Db 18 CTTTCTGATATCTCTT 2

RESULT 495
US-10-661-165-205
; Sequence 205, Application US/10661165
; Publication No. US20040137470A1
; GENERAL INFORMATION:
; APPLICANT: Dhallan, Ravinder S.
; TITLE OF INVENTION: METHODS FOR DETECTION OF GENETIC
; FILE REFERENCE: 543312000420
; CURRENT APPLICATION NUMBER: US/10/661,165
; CURRENT FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: PCT/US03/06198
; PRIOR FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/378,354
; PRIOR FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: US 10/093,618
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/360,232
; PRIOR FILING DATE: 2002-03-01
; PRIOR APPLICATION NUMBER: PCT/US03/27308
; PRIOR FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US 10/376,770
; PRIOR FILING DATE: 2003-02-28
; NUMBER OF SEQ ID NOS: 628
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 205
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (5)...(8)
; OTHER INFORMATION: These nucleotides may be absent
US-10-661-165-205

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAGAGAAAT 217
Db 1 GAAATAAAGAGAAAGAT 17

RESULT 496
US-10-327-598-836
; Sequence 836, Application US/10327598
; Publication No. US20040181039A1
; GENERAL INFORMATION:
; APPLICANT: Krah, Eugene
; APPLICANT: Guo, Honliang
; APPLICANT: Aliyappa, Ashok
; APPLICANT: Lawton, Robert
; TITLE OF INVENTION: Canine Immunoglobulin Variable Domains, Caninized Antibodies, and
; TITLE OF INVENTION: for Making and Using Them
; FILE REFERENCE: 01-799-A
; CURRENT APPLICATION NUMBER: US/10/327,598
; CURRENT FILING DATE: 2002-12-20
; PRIOR APPLICATION NUMBER: US 60/344,874
; PRIOR FILING DATE: 2001-12-21
```

```
; NUMBER OF SEQ ID NOS: 1139
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 836
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION:
US-10-327-598-836

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1069 CAAAGAGGACTCTGCGG 1085
Db 1 CTAAGAGCACTCTGCGG 17

RESULT 497
US-10-758-307-208/c
; Sequence 208, Application US/10758307
; Publication No. US20040209290A1
; GENERAL INFORMATION:
; APPLICANT: GENOMIC HEALTH, INC.
; APPLICANT: RUSH UNIVERSITY MEDICAL CENTER
; APPLICANT: Cobleigh, Melody
; APPLICANT: Shak, Steven
; APPLICANT: Baker, Joffre
; APPLICANT: Cronin, Maureen
; TITLE OF INVENTION: GENE EXPRESSION MARKERS FOR BREAST
; FILE REFERENCE: 39740/0008 US
; CURRENT APPLICATION NUMBER: US/10/758,307
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 60/440,861
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 440
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 208
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: probe
US-10-758-307-208

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 673 TGGAGCTGCCAAGTG 689
Db 17 TGGCAGCTGCCCAGTG 1

RESULT 498
US-10-872-113-138/c
; Sequence 138, Application US/10872113
; Publication No. US20040229275A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne W.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; FILE REFERENCE: 760050-138
; CURRENT APPLICATION NUMBER: US/10/872,113
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
```

```
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 138
; TYPE: DNA
; LENGTH: 18
; ORGANISM: homo sapien
US-10-872-113-138

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1641 CTTCTGTTATTATCTT 1657
Db 18 CTTCTGATATCTCTT 2

RESULT 499
US-10-714-195-213/c
; Sequence 213, Application US/10714195
; Publication No. US20050019785A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Joffre
; APPLICANT: Cronin, Maureen
; APPLICANT: Shak, Steve
; APPLICANT: Baselga, Jose
; TITLE OF INVENTION: GENE EXPRESSION PROFILING OF EGFR
; FILE REFERENCE: 39740-0005
; CURRENT APPLICATION NUMBER: US/10/714,195
; CURRENT FILING DATE: 2003-11-14
; PRIOR APPLICATION NUMBER: 60/427090
; PRIOR FILING DATE: 2003-11-15
; NUMBER OF SEQ ID NOS: 372
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 213
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-714-195-213

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 673 TGAAGCTGCCAAGGTG 689
Db 17 TGGCAGCTGCCCAGGTG 1

RESULT 500
US-10-852-797-102/c
; Sequence 102, Application US/10852797
; Publication No. US20050064455A1
; GENERAL INFORMATION:
; APPLICANT: Genomic Health, Inc.
; APPLICANT: Baker, Joffre
; APPLICANT: Miller, Kathy D.
; APPLICANT: Shak, Steven
; APPLICANT: Sledge, George

; APPLICANT: Soule, Sharon
; TITLE OF INVENTION: Gene Expression Markers for Predicting
; FILE REFERENCE: 39740-0010
; CURRENT APPLICATION NUMBER: US/10/852,797
; CURRENT FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: 60/473,970
; PRIOR FILING DATE: 2003-05-28
; NUMBER OF SEQ ID NOS: 372
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 102
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: probe
US-10-852-797-102

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 673 TGAAGCTGCCAAGGTG 689
Db 17 TGGCAGCTGCCCAGGTG 1

RESULT 501
US-10-941-069-68/c
; Sequence 68, Application US/10941069
; Publication No. US2005008485A1
; GENERAL INFORMATION:
; APPLICANT: THE SCRIPPS RESEARCH INSTITUTE
; APPLICANT: BARBAS III, Carlos F.
; APPLICANT: GOTTESFELD, Joel M.
; APPLICANT: WRIGHT, Peter E.
; TITLE OF INVENTION: ZINC FINGER PROTEIN DERIVATIVES AND METHODS THEREFOR
; FILE REFERENCE: SCRIPT1160-4
; CURRENT APPLICATION NUMBER: US/10/941,069
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: US/09/500,700
; PRIOR FILING DATE: 2000-02-09
; PRIOR APPLICATION NUMBER: US 08/863,813
; PRIOR FILING DATE: 1997-05-27
; PRIOR APPLICATION NUMBER: US 08/676,318
; PRIOR FILING DATE: 1996-12-30
; PRIOR APPLICATION NUMBER: PCT/US95/00829
; PRIOR FILING DATE: 1995-01-18
; PRIOR APPLICATION NUMBER: US 08/312,604
; PRIOR FILING DATE: 1994-09-28
; PRIOR APPLICATION NUMBER: US 08/183,119
; PRIOR FILING DATE: 1994-01-18
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: (GCG)6 probe
US-10-941-069-68

Query Match          0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 2.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCCTCCGTCGCGCGG 46
Db 18 CGCGCGCGCGCGCGCG 2

RESULT 502
US-10-481-613-152
```



; Sequence 152, Application US/10481613  
; Publication No. US20050085627A1  
; GENERAL INFORMATION:  
; APPLICANT: Zhang, Youming  
; APPLICANT: Moffatt, Miriam  
; APPLICANT: Cookson, William  
; APPLICANT: Tinsley, Jon  
; TITLE OF INVENTION: Atopy  
; FILE REFERENCE: 16721-0003US1 / P32688WO/KVC  
; CURRENT APPLICATION NUMBER: US/10/481,613  
; CURRENT FILING DATE: 2003-12-19  
; PRIOR APPLICATION NUMBER: PCT/GB02/02859  
; PRIOR FILING DATE: 2002-06-21  
; PRIOR APPLICATION NUMBER: GB 0115211.5  
; PRIOR FILING DATE: 2001-06-21  
; PRIOR APPLICATION NUMBER: GB 0115212.3  
; PRIOR FILING DATE: 2001-06-21  
; PRIOR APPLICATION NUMBER: GB 0115213.1  
; PRIOR FILING DATE: 2001-06-21  
; NUMBER OF SEQ ID NOS: 326  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 152  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-481-613-152

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 939 CCAGAACAGGTTGTACT 955  
||| ||||| |||||  
Db 1 CCTGAACAGGCTGTACT 17

RESULT 503  
US-10-485-508B-51  
; Sequence 51, Application US/10485508B  
; Publication No. US20050106134A1  
; GENERAL INFORMATION:  
; APPLICANT: NIE, Quiying  
; APPLICANT: SALAMONSEN, Lois Adrienne  
; APPLICANT: FINDLAY, John Kerr  
; TITLE OF INVENTION: Pregnancy-related enzyme activity  
; FILE REFERENCE: 28943-0007  
; CURRENT APPLICATION NUMBER: US/10/485,508B  
; CURRENT FILING DATE: 2004-02-02  
; PRIOR APPLICATION NUMBER: PCT/AU02/01020  
; PRIOR FILING DATE: 2002-07-31  
; PRIOR APPLICATION NUMBER: AU PR 6730  
; PRIOR FILING DATE: 2001-07-31  
; NUMBER OF SEQ ID NOS: 51  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 51  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic nucleotide - primer  
US-10-485-508B-51

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 509 CAGCATTGGGACTCTC 525  
||| ||||| |||||  
Db 2 CAGCATTGGGACTCTC 18

RESULT 504  
US-10-498-794-77  
; Sequence 77, Application US/10498794  
; Publication No. US20050142552A1  
; GENERAL INFORMATION:  
; APPLICANT: Gurling, Hugh MD  
; TITLE OF INVENTION: Susceptibility locus for schizophrenia  
; FILE REFERENCE: 620-312  
; CURRENT APPLICATION NUMBER: US/10/498,794  
; CURRENT FILING DATE: 2004-06-14  
; PRIOR APPLICATION NUMBER: PCT/GB2002/005630  
; PRIOR FILING DATE: 2002-12-12  
; PRIOR APPLICATION NUMBER: GB 0129758.9  
; PRIOR FILING DATE: 2001-12-12  
; NUMBER OF SEQ ID NOS: 103  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 77  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-498-794-77

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 2.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1514 CTAGAAACAGTAAGAAA 1530  
||| ||||| |||||  
Db 1 CTAGTAAGTAAGAAA 17

Search completed: July 12, 2005, 10:45:02  
Job time : 13 secs

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:42:36 ; Search time 7 Seconds  
(without alignments)  
3.454 Million cell updates/sec

Title: US-09-745-763-35  
Perfect score: 1851  
Sequence: 1 GGCTAGGCGCGAGCTAGT.....CTGAAAAA.....1851

Scoring table: IDENTITY NUC  
Gap 10.0, Gapext 0.5

Searched: 378 seqs, 6532 residues

Total number of hits satisfying chosen parameters: 756

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 384 summaries

Database : rni35.seq.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19.8	1.1	25	1	US-09-396-196G-36103
C 2	19.2	1.0	25	1	US-09-396-196G-127295
C 3	18.8	1.0	25	1	US-09-396-196G-36101
C 4	17	0.9	17	1	US-09-766-253-132
C 5	17	0.9	17	1	US-09-685-664B-1075
C 6	17	0.9	18	1	US-09-809-545A-84
C 7	17	0.9	18	1	US-10-352-704-12
C 8	17	0.9	18	1	US-10-352-704-18
C 9	17	0.9	20	1	US-09-976-618A-55
C 10	17	0.9	20	1	US-09-976-618A-55
C 11	17	0.9	20	1	US-10-234-764-10
C 12	17	0.9	20	1	US-09-975-059A-55
C 13	17	0.9	20	1	US-09-859-736-3
C 14	17	0.9	20	1	US-09-859-736-4
C 15	17	0.9	21	1	US-09-859-736-6
C 16	16.4	0.9	18	1	US-09-422-978-4101
C 17	16.4	0.9	20	1	US-09-198-452A-3072
C 18	16.2	0.9	21	1	US-08-863-639A-67
C 19	16.2	0.9	21	1	US-08-863-639A-71
C 20	16.2	0.9	21	1	US-08-416-214A-11
C 21	16.2	0.9	21	1	US-09-765-111A-32
C 22	16	0.9	16	1	US-09-766-253-131
C 23	16	0.9	17	1	US-09-685-664B-1074
C 24	16	0.9	17	1	US-09-685-664B-1076
C 25	16	0.9	17	1	US-09-090-672B-107
C 26	16	0.9	18	1	US-09-904-744-1
C 27	16	0.9	19	1	US-09-696-791-479
C 28	15.8	0.9	19	1	US-09-037-990B-79
C 29	15.8	0.9	19	1	US-09-475-947A-12
C 30	15.8	0.9	19	1	US-09-696-791-3050
C 31	15.8	0.9	19	1	US-09-696-791-3051
C 32	15.8	0.9	20	1	US-08-215-138B-16
C 33	15.8	0.9	20	1	US-08-407-344-16
C 34	15.8	0.9	20	1	US-09-198-452A-6169
C 35	15.8	0.9	21	1	US-08-863-639A-52
C 36	15.8	0.9	21	1	US-08-863-639A-55
C 37	15.8	0.9	21	1	US-08-863-639A-56
C 38	15.8	0.9	21	1	US-08-863-639A-68
C 39	15.4	0.8	17	1	US-09-685-664B-1077
C 40	15.4	0.8	18	1	US-08-282-197C-28
C 41	15.4	0.8	18	1	US-08-857-946-8
C 42	15.4	0.8	18	1	US-08-970-740-8
C 43	15.4	0.8	18	1	US-09-710-794-8
C 44	15.4	0.8	20	1	US-09-198-452A-6103
C 45	15.4	0.8	20	1	US-10-058-422A-14
C 46	15.2	0.8	20	1	US-08-182-172-7
C 47	15.2	0.8	20	1	US-09-418-641-57
C 48	15.2	0.8	20	1	US-09-484-345-75
C 49	15.2	0.8	20	1	US-09-000-092-11
C 50	15.2	0.8	20	1	US-09-030-701-65
C 51	15.2	0.8	20	1	US-09-082-649B-57
C 52	15.2	0.8	20	1	US-09-198-452A-4294
C 53	15.2	0.8	20	1	US-09-710-693-10
C 54	15.2	0.8	20	1	US-09-965-101-57
C 55	15	0.8	15	1	US-10-352-704-10
C 56	15	0.8	15	1	US-10-352-704-16
C 57	15	0.8	17	1	US-09-685-664B-1073
C 58	15	0.8	17	1	US-09-090-672B-105
C 59	15	0.8	17	1	US-09-090-672B-106
C 60	15	0.8	18	1	US-09-904-744-2
C 61	15	0.8	19	1	US-09-696-791-478
C 62	15	0.8	20	1	US-09-344-914-53
C 63	15	0.8	20	1	US-09-344-914-54
C 64	15	0.8	20	1	US-09-344-914-55
C 65	15	0.8	20	1	US-09-344-914-56
C 66	15	0.8	20	1	US-09-344-914-57
C 67	15	0.8	20	1	US-09-344-914-58
C 68	14.8	0.8	19	1	US-08-215-138-9
C 69	14.8	0.8	19	1	US-08-407-344-9
C 70	14.8	0.8	19	1	US-09-422-978-6888
C 71	14.8	0.8	19	1	US-09-422-978-7139
C 72	14.8	0.8	19	1	US-09-938-077-19
C 73	14.8	0.8	19	1	US-09-696-791-2728
C 74	14.8	0.8	19	1	US-09-696-791-3559
C 75	14.4	0.8	16	1	US-08-753-147-188
C 76	14.4	0.8	17	1	US-09-371-772B-4471
C 77	14.4	0.8	17	1	US-09-866-108A-8364
C 78	14.4	0.8	17	1	US-09-866-108A-8365
C 79	14.4	0.8	17	1	US-09-866-108A-10030
C 80	14.4	0.8	17	1	US-09-866-108A-10031
C 81	14.4	0.8	17	1	US-09-685-664B-1078
C 82	14.4	0.8	18	1	US-09-289-377-28
C 83	14.4	0.8	18	1	US-09-282-147-17
C 84	14.4	0.8	18	1	US-09-696-791-4229
C 85	14.4	0.8	19	1	US-09-696-791-3052
C 86	14.2	0.8	17	1	US-08-609-572-5
C 87	14.2	0.8	17	1	US-08-841-751-5
C 88	14.2	0.8	17	1	US-08-846-340-5
C 89	14.2	0.8	17	1	US-08-846-344-5
C 90	14.2	0.8	17	1	US-09-301-808-5
C 91	14	0.8	14	1	US-09-859-736-7
C 92	14	0.8	15	1	US-09-491-356C-19
C 93	14	0.8	17	1	US-09-866-108A-2590
C 94	14	0.8	17	1	US-09-866-108A-2591
C 95	14	0.8	17	1	US-09-866-108A-2592
C 96	14	0.8	17	1	US-09-866-108A-2593
C 97	14	0.8	17	1	US-09-685-664B-1072
C 98	14	0.8	18	1	US-08-143-219-10
C 99	14	0.8	18	1	US-10-271-065-1
C 100	13.8	0.7	17	1	US-08-985-162-431
C 101	13.8	0.7	17	1	US-08-987-574-46
C 102	13.8	0.7	17	1	US-08-535-168-46
C 103	13.8	0.7	17	1	US-09-017-974-46
C 104	13.8	0.7	17	1	US-08-682-255A-46
C 105	13.8	0.7	17	1	US-08-584-040-4164
C 106	13.8	0.7	17	1	US-08-584-040-4165

Sequence 6169, Ap  
Sequence 52, Appl  
Sequence 55, Appl  
Sequence 56, Appl  
Sequence 68, Appl  
Sequence 1077, Ap  
Sequence 28, Appl  
Sequence 8, Appl  
Sequence 8, Appl  
Sequence 6103, Ap  
Sequence 14, Appl  
Sequence 7, Appl  
Sequence 75, Appl  
Sequence 11, Appl  
Sequence 65, Appl  
Sequence 57, Appl  
Sequence 4294, Ap  
Sequence 10, Appl  
Sequence 57, Appl  
Sequence 16, Appl  
Sequence 1073, Ap  
Sequence 105, App  
Sequence 106, App  
Sequence 2, Appl  
Sequence 478, App  
Sequence 53, Appl  
Sequence 54, Appl  
Sequence 55, Appl  
Sequence 56, Appl  
Sequence 57, Appl  
Sequence 58, Appl  
Sequence 59, Appl  
Sequence 9, Appl  
Sequence 9, Appl  
Sequence 6888, Ap  
Sequence 7139, Ap  
Sequence 19, Appl  
Sequence 2728, Ap  
Sequence 3559, Ap  
Sequence 188, App  
Sequence 4471, Ap  
Sequence 8364, Ap  
Sequence 8365, Ap  
Sequence 10030, A  
Sequence 10031, A  
Sequence 1078, Ap  
Sequence 28, Appl  
Sequence 17, Appl  
Sequence 4229, Ap  
Sequence 3052, Ap  
Sequence 5, Appl  
Sequence 5, Appl  
Sequence 5, Appl  
Sequence 5, Appl  
Sequence 7, Appl  
Sequence 13, Appl  
Sequence 2590, Ap  
Sequence 2591, Ap  
Sequence 2592, Ap  
Sequence 2593, Ap  
Sequence 1072, Ap  
Sequence 10, Appl  
Sequence 1, Appl  
Sequence 431, App  
Sequence 46, Appl  
Sequence 46, Appl  
Sequence 46, Appl  
Sequence 4164, Ap  
Sequence 4165, Ap

c 107	13.8	0.7	17	1	US-08-584-040-4250	Sequence 4250, Ap	180	13.4	0.7	17	1	US-09-866-108A-8366	Sequence 8366, Ap
c 108	13.8	0.7	17	1	US-08-584-040-5734	Sequence 5734, Ap	181	13.4	0.7	17	1	US-09-866-108A-8587	Sequence 8587, Ap
c 109	13.8	0.7	17	1	US-08-584-040-5735	Sequence 5735, Ap	182	13.4	0.7	17	1	US-09-866-108A-8588	Sequence 8588, Ap
c 110	13.8	0.7	17	1	US-08-584-040-5820	Sequence 5820, Ap	183	13.4	0.7	17	1	US-09-866-108A-8589	Sequence 8589, Ap
c 111	13.8	0.7	17	1	US-08-584-040-7818	Sequence 7818, Ap	c 184	13.4	0.7	17	1	US-09-866-108A-10029	Sequence 10029, A
c 112	13.8	0.7	17	1	US-08-584-040-7819	Sequence 7819, Ap	c 185	13.4	0.7	17	1	US-09-866-108A-10032	Sequence 10032, A
c 113	13.8	0.7	17	1	US-09-429-130-46	Sequence 46, Appl	c 186	13.4	0.7	17	1	US-09-940-244-418	Sequence 418, App
c 114	13.8	0.7	17	1	US-09-371-7728-1931	Sequence 1931, Ap	c 187	13.4	0.7	17	1	US-09-685-6648-2018	Sequence 2018, Ap
c 115	13.8	0.7	17	1	US-09-371-7728-1932	Sequence 1932, Ap	c 188	13.4	0.7	17	1	PCT-US91-03680-7	Sequence 7, Appli
c 116	13.8	0.7	17	1	US-09-371-7728-2017	Sequence 2017, Ap	c 189	13.2	0.7	15	1	US-08-702-665A-8	Sequence 8, Appli
c 117	13.8	0.7	17	1	US-09-371-7728-2613	Sequence 2613, Ap	c 190	13	0.7	15	1	US-08-292-620A-370	Sequence 370, App
c 118	13.8	0.7	17	1	US-09-371-7728-2614	Sequence 2614, Ap	c 191	13	0.7	15	1	US-09-071-845-370	Sequence 370, App
c 119	13.8	0.7	17	1	US-09-371-7728-3602	Sequence 3602, Ap	c 192	13	0.7	15	1	US-09-701-947A-20	Sequence 20, Appl
c 120	13.8	0.7	17	1	US-09-371-7728-3603	Sequence 3603, Ap	c 193	13	0.7	15	1	US-09-701-947A-21	Sequence 21, Appl
c 121	13.8	0.7	17	1	US-09-371-7728-6261	Sequence 6261, Ap	c 194	13	0.7	15	1	US-09-701-947A-22	Sequence 22, Appl
c 122	13.8	0.7	17	1	US-09-401-063-431	Sequence 431, App	c 195	13	0.7	17	1	US-08-985-162-333	Sequence 333, App
c 123	13.8	0.7	17	1	US-09-866-108A-1536	Sequence 1536, Ap	c 196	13	0.7	17	1	US-09-017-974-74	Sequence 74, Appl
c 124	13.8	0.7	17	1	US-09-866-108A-1537	Sequence 1537, Ap	c 197	13	0.7	17	1	US-09-017-974-78	Sequence 78, Appl
c 125	13.8	0.7	17	1	US-09-866-108A-8360	Sequence 8360, Ap	c 198	13	0.7	17	1	US-09-098-628-8	Sequence 8, Appli
c 126	13.8	0.7	17	1	US-09-866-108A-8363	Sequence 8363, Ap	c 199	13	0.7	17	1	US-08-682-255A-74	Sequence 74, Appl
c 127	13.8	0.7	17	1	US-09-866-108A-9572	Sequence 9572, Ap	c 200	13	0.7	17	1	US-08-682-255A-78	Sequence 78, Appl
c 128	13.8	0.7	17	1	US-09-685-664B-1079	Sequence 1079, Ap	c 201	13	0.7	17	1	US-09-429-130-74	Sequence 74, Appl
c 129	13.8	0.7	17	1	US-09-685-664B-1931	Sequence 1931, Ap	c 202	13	0.7	17	1	US-09-429-130-78	Sequence 78, Appl
c 130	13.8	0.7	17	1	US-09-685-664B-1932	Sequence 1932, Ap	c 203	13	0.7	17	1	US-09-401-063-333	Sequence 333, App
c 131	13.8	0.7	17	1	US-09-685-664B-2017	Sequence 2017, Ap	c 204	13	0.7	17	1	US-09-866-108A-2589	Sequence 2589, Ap
c 132	13.8	0.7	17	1	US-09-685-664B-2613	Sequence 2613, Ap	c 205	13	0.7	17	1	US-09-866-108A-2594	Sequence 2594, Ap
c 133	13.8	0.7	17	1	US-09-685-664B-2614	Sequence 2614, Ap	c 206	13	0.7	17	1	US-09-404-912-265	Sequence 265, App
c 134	13.8	0.7	17	1	US-09-685-664B-3602	Sequence 3602, Ap	c 207	13	0.7	17	1	US-09-685-664B-1071	Sequence 1071, Ap
c 135	13.8	0.7	17	1	US-09-685-664B-3603	Sequence 3603, Ap	c 208	13	0.7	17	1	PCT-US91-02186-12	Sequence 12, Appl
c 136	13.8	0.7	17	1	PCT-US96-11786-46	Sequence 46, Appl	c 209	13	0.7	17	1	5514566-19	Patent No. 5514566
c 137	13.8	0.7	18	1	US-08-050-232-12	Sequence 12, Appl	c 210	12.8	0.7	16	1	US-08-239-256-4	Sequence 4, Appli
c 138	13.8	0.7	18	1	US-08-661-767-12	Sequence 12, Appl	c 211	12.8	0.7	16	1	US-08-485-692-1	Sequence 1, Appli
c 139	13.8	0.7	18	1	US-08-468-580-17	Sequence 17, Appl	c 212	12.8	0.7	16	1	US-08-419-519-1	Sequence 1, Appli
c 140	13.8	0.7	18	1	US-08-384-324-2	Sequence 2, Appli	c 213	12.8	0.7	16	1	US-08-770-235A-22	Sequence 22, Appl
c 141	13.8	0.7	18	1	US-08-244-597-14	Sequence 14, Appl	c 214	12.8	0.7	16	1	US-08-757-024-273	Sequence 273, App
c 142	13.8	0.7	18	1	US-08-389-423-31	Sequence 31, Appl	c 215	12.8	0.7	16	1	US-08-987-574-47	Sequence 47, Appl
c 143	13.8	0.7	18	1	US-09-205-860-46	Sequence 46, Appl	c 216	12.8	0.7	16	1	US-08-535-168-47	Sequence 47, Appl
c 144	13.8	0.7	18	1	US-08-857-946-14	Sequence 14, Appl	c 217	12.8	0.7	16	1	US-09-017-974-47	Sequence 47, Appl
c 145	13.8	0.7	18	1	US-08-370-740-14	Sequence 14, Appl	c 218	12.8	0.7	16	1	US-08-682-255A-47	Sequence 47, Appl
c 146	13.8	0.7	18	1	US-09-487-444-45	Sequence 45, Appl	c 219	12.8	0.7	16	1	US-09-429-130-47	Sequence 47, Appl
c 147	13.8	0.7	18	1	US-09-189-028-31	Sequence 31, Appl	c 220	12.8	0.7	16	1	US-09-371-772B-7075	Sequence 7075, Ap
c 148	13.8	0.7	18	1	US-09-197-224-14	Sequence 14, Appl	c 221	12.8	0.7	16	1	US-09-756-301B-22	Sequence 22, Appl
c 149	13.8	0.7	18	1	US-09-197-221-14	Sequence 14, Appl	c 222	12.8	0.7	16	1	US-09-152-059-1	Sequence 1, Appli
c 150	13.8	0.7	18	1	US-09-572-392A-14	Sequence 14, Appl	c 223	12.8	0.7	16	1	US-09-152-059-57	Sequence 57, Appl
c 151	13.8	0.7	18	1	US-09-723-756-14	Sequence 14, Appl	c 224	12.8	0.7	16	1	US-09-152-059-59	Sequence 59, Appl
c 152	13.8	0.7	18	1	US-09-532-840-14	Sequence 14, Appl	c 225	12.8	0.7	16	1	US-09-152-059-63	Sequence 63, Appl
c 153	13.8	0.7	18	1	US-09-747-391-9	Sequence 9, Appli	c 226	12.8	0.7	16	1	US-09-093-972C-273	Sequence 273, App
c 154	13.8	0.7	18	1	US-08-983-605-93	Sequence 93, Appl	c 227	12.8	0.7	16	1	US-09-958-163A-1	Sequence 1, Appli
c 155	13.8	0.7	18	1	PCT-US93-12600-17	Sequence 68, Appl	c 228	12.8	0.7	16	1	PCT-US96-11786-47	Sequence 47, Appl
c 156	13.8	0.7	18	1	PCT-US95-03731-17	Sequence 17, Appl	c 229	12.8	0.7	16	1	5177193-9	Patent No. 5177193
c 157	13.8	0.7	18	1	PCT-US96-01473-2	Sequence 2, Appli	c 230	12.8	0.7	16	1	5177193-9	Patent No. 5177193
c 158	13.8	0.7	18	1	US-09-180-437-104	Sequence 104, App	c 231	12.8	0.7	17	1	US-08-985-162-333	Sequence 333, App
c 159	13.8	0.7	15	1	US-09-371-7728-5840	Sequence 5840, Ap	c 232	12.8	0.7	17	1	US-09-098-628-8	Sequence 8, Appli
c 160	13.4	0.7	16	1	US-09-017-974-66	Sequence 66, Appl	c 233	12.8	0.7	17	1	US-09-401-063-333	Sequence 333, App
c 161	13.4	0.7	17	1	US-09-017-974-73	Sequence 73, Appl	c 234	12.8	0.7	17	1	PCT-US91-02186-12	Sequence 12, Appl
c 162	13.4	0.7	17	1	US-09-017-974-76	Sequence 76, Appl	c 235	12.8	0.7	17	1	5514566-19	Patent No. 5514566
c 163	13.4	0.7	17	1	US-09-017-974-77	Sequence 77, Appl	c 236	12.8	0.7	17	1	US-08-145-704-33	Sequence 33, Appl
c 164	13.4	0.7	17	1	US-09-017-974-76	Sequence 76, Appl	c 237	12.8	0.7	17	1	US-08-469-177-7	Sequence 7, Appli
c 165	13.4	0.7	17	1	US-08-682-255A-66	Sequence 66, Appl	c 238	12.8	0.7	17	1	US-08-390-850-635	Sequence 635, App
c 166	13.4	0.7	17	1	US-08-682-255A-73	Sequence 73, Appl	c 239	12.8	0.7	17	1	US-08-290-978A-9	Sequence 9, Appli
c 167	13.4	0.7	17	1	US-08-682-255A-76	Sequence 76, Appl	c 240	12.8	0.7	17	1	US-08-373-124A-192	Sequence 192, App
c 168	13.4	0.7	17	1	US-08-682-255A-77	Sequence 77, Appl	c 241	12.8	0.7	17	1	US-08-373-124A-278	Sequence 278, App
c 169	13.4	0.7	17	1	US-08-682-255A-77	Sequence 77, Appl	c 242	12.8	0.7	17	1	US-08-373-124A-512	Sequence 512, App
c 170	13.4	0.7	17	1	US-08-584-040-4251	Sequence 4251, Ap	c 243	12.8	0.7	17	1	US-08-373-124A-514	Sequence 514, App
c 171	13.4	0.7	17	1	US-08-584-040-5821	Sequence 5821, Ap	c 244	12.8	0.7	17	1	US-08-373-124A-960	Sequence 960, App
c 172	13.4	0.7	17	1	US-09-429-130-66	Sequence 66, Appl	c 245	12.8	0.7	17	1	US-08-373-124A-1192	Sequence 1192, Ap
c 173	13.4	0.7	17	1	US-09-429-130-73	Sequence 73, Appl	c 246	12.8	0.7	17	1	US-08-373-124A-2325	Sequence 2325, Ap
c 174	13.4	0.7	17	1	US-09-429-130-76	Sequence 76, Appl	c 247	12.8	0.7	17	1	US-08-462-917-3	Sequence 3, Appli
c 175	13.4	0.7	17	1	US-09-429-130-77	Sequence 77, Appl	c 248	12.8	0.7	17	1	US-08-435-634-635	Sequence 635, App
c 176	13.4	0.7	17	1	US-09-371-7728-2018	Sequence 2018, Ap	c 249	12.8	0.7	17	1	US-08-653-740-20	Sequence 20, Appl
c 177	13.4	0.7	17	1	US-09-866-108A-1538	Sequence 1538, Ap	c 250	12.8	0.7	17	1	US-08-758-306-379	Sequence 379, App
c 178	13.4	0.7	17	1	US-09-866-108A-1539	Sequence 1539, Ap	c 251	12.8	0.7	17	1	US-08-758-306-381	Sequence 381, App
c 179	13.4	0.7	17	1	US-09-866-108A-1539	Sequence 1539, Ap	c 252	12.8	0.7	17	1	US-08-435-628-192	Sequence 192, App

c 253 12.8 0.7 17 1 US-08-435-628-278 Sequence 278, App  
 c 254 12.8 0.7 17 1 US-08-435-628-512 Sequence 512, App  
 c 255 12.8 0.7 17 1 US-08-435-628-514 Sequence 514, App  
 c 256 12.8 0.7 17 1 US-08-435-628-960 Sequence 960, App  
 c 257 12.8 0.7 17 1 US-08-435-628-1192 Sequence 1192, App  
 c 258 12.8 0.7 17 1 US-08-435-628-2325 Sequence 2325, App  
 c 259 12.8 0.7 17 1 US-08-780-869-9 Sequence 9, Appli  
 c 260 12.8 0.7 17 1 US-09-073-594-20 Sequence 20, Appl  
 c 261 12.8 0.7 17 1 US-08-757-024-236 Sequence 236, App  
 c 262 12.8 0.7 17 1 US-08-757-024-272 Sequence 272, App  
 c 263 12.8 0.7 17 1 US-08-985-162-42 Sequence 42, Appl  
 c 264 12.8 0.7 17 1 US-08-985-162-665 Sequence 665, App  
 c 265 12.8 0.7 17 1 US-09-275-925-20 Sequence 20, Appl  
 c 266 12.8 0.7 17 1 US-08-987-574-33 Sequence 33, Appl  
 c 267 12.8 0.7 17 1 US-08-535-168-33 Sequence 33, Appl  
 c 268 12.8 0.7 17 1 US-08-720-625-9 Sequence 9, Appli  
 c 269 12.8 0.7 17 1 US-09-017-974-33 Sequence 33, Appl  
 c 270 12.8 0.7 17 1 US-09-017-974-58 Sequence 58, Appl  
 c 271 12.8 0.7 17 1 US-09-017-974-59 Sequence 59, Appl  
 c 272 12.8 0.7 17 1 US-09-017-974-68 Sequence 68, Appl  
 c 273 12.8 0.7 17 1 US-09-017-974-72 Sequence 72, Appl  
 c 274 12.8 0.7 17 1 US-09-017-974-80 Sequence 80, Appl  
 c 275 12.8 0.7 17 1 US-09-017-974-81 Sequence 81, Appl  
 c 276 12.8 0.7 17 1 US-09-017-974-87 Sequence 87, Appl  
 c 277 12.8 0.7 17 1 US-08-682-255A-33 Sequence 33, Appl  
 c 278 12.8 0.7 17 1 US-08-682-255A-58 Sequence 58, Appl  
 c 279 12.8 0.7 17 1 US-08-682-255A-59 Sequence 59, Appl  
 c 280 12.8 0.7 17 1 US-08-682-255A-68 Sequence 68, Appl  
 c 281 12.8 0.7 17 1 US-08-682-255A-72 Sequence 72, Appl  
 c 282 12.8 0.7 17 1 US-08-682-255A-80 Sequence 80, Appl  
 c 283 12.8 0.7 17 1 US-08-682-255A-81 Sequence 81, Appl  
 c 284 12.8 0.7 17 1 US-08-682-255A-87 Sequence 87, Appl  
 c 285 12.8 0.7 17 1 US-08-584-040-1788 Sequence 1788, Ap  
 c 286 12.8 0.7 17 1 US-08-584-040-1932 Sequence 1932, Ap  
 c 287 12.8 0.7 17 1 US-08-584-040-2938 Sequence 3938, Ap  
 c 288 12.8 0.7 17 1 US-08-584-040-5806 Sequence 5806, Ap  
 c 289 12.8 0.7 17 1 US-08-584-040-7820 Sequence 7820, Ap  
 c 290 12.8 0.7 17 1 US-09-429-130-33 Sequence 33, Appl  
 c 291 12.8 0.7 17 1 US-09-429-130-58 Sequence 58, Appl  
 c 292 12.8 0.7 17 1 US-09-429-130-59 Sequence 59, Appl  
 c 293 12.8 0.7 17 1 US-09-429-130-68 Sequence 68, Appl  
 c 294 12.8 0.7 17 1 US-09-429-130-72 Sequence 72, Appl  
 c 295 12.8 0.7 17 1 US-09-429-130-80 Sequence 80, Appl  
 c 296 12.8 0.7 17 1 US-09-429-130-81 Sequence 81, Appl  
 c 297 12.8 0.7 17 1 US-09-429-130-87 Sequence 87, Appl  
 c 298 12.8 0.7 17 1 US-09-474-432B-558 Sequence 558, App  
 c 299 12.8 0.7 17 1 US-09-474-432B-559 Sequence 559, App  
 c 300 12.8 0.7 17 1 US-09-474-432B-677 Sequence 677, App  
 c 301 12.8 0.7 17 1 US-09-474-432B-876 Sequence 876, App  
 c 302 12.8 0.7 17 1 US-09-371-772B-333 Sequence 333, App  
 c 303 12.8 0.7 17 1 US-09-371-772B-477 Sequence 477, App  
 c 304 12.8 0.7 17 1 US-09-371-772B-1705 Sequence 1705, Ap  
 c 305 12.8 0.7 17 1 US-09-371-772B-2671 Sequence 2671, Ap  
 c 306 12.8 0.7 17 1 US-09-371-772B-3604 Sequence 3604, Ap  
 c 307 12.8 0.7 17 1 US-09-371-772B-4280 Sequence 4280, Ap  
 c 308 12.8 0.7 17 1 US-09-371-772B-4407 Sequence 4407, Ap  
 c 309 12.8 0.7 17 1 US-09-371-772B-4766 Sequence 4766, Ap  
 c 310 12.8 0.7 17 1 US-09-371-772B-4869 Sequence 4869, Ap  
 c 311 12.8 0.7 17 1 US-09-371-772B-5113 Sequence 5113, Ap  
 c 312 12.8 0.7 17 1 US-09-371-772B-5139 Sequence 5139, Ap  
 c 313 12.8 0.7 17 1 US-09-371-772B-5170 Sequence 5170, Ap  
 c 314 12.8 0.7 17 1 US-09-371-772B-5171 Sequence 5171, Ap  
 c 315 12.8 0.7 17 1 US-09-371-772B-5340 Sequence 5340, Ap  
 c 316 12.8 0.7 17 1 US-09-371-772B-5341 Sequence 5341, Ap  
 c 317 12.8 0.7 17 1 US-09-371-772B-5349 Sequence 5349, Ap  
 c 318 12.8 0.7 17 1 US-09-371-772B-6331 Sequence 6331, Ap  
 c 319 12.8 0.7 17 1 US-09-371-772B-6591 Sequence 6591, Ap  
 c 320 12.8 0.7 17 1 US-09-476-387-557 Sequence 557, App  
 c 321 12.8 0.7 17 1 US-09-476-387-558 Sequence 558, App  
 c 322 12.8 0.7 17 1 US-09-476-387-676 Sequence 676, App  
 c 323 12.8 0.7 17 1 US-09-476-387-875 Sequence 875, App  
 c 324 12.8 0.7 17 1 US-09-401-063-42 Sequence 42, Appl  
 c 325 12.8 0.7 17 1 US-09-401-063-665 Sequence 665, App

326 12.8 0.7 17 1 US-09-827-998-1724 Sequence 1724, Ap  
 327 12.8 0.7 17 1 US-09-827-998-1725 Sequence 1725, Ap  
 328 12.8 0.7 17 1 US-09-866-108A-1535 Sequence 1535, Ap  
 c 329 12.8 0.7 17 1 US-09-866-108A-2360 Sequence 2360, Ap  
 c 330 12.8 0.7 17 1 US-09-866-108A-2361 Sequence 2361, Ap  
 c 331 12.8 0.7 17 1 US-09-866-108A-6976 Sequence 6976, Ap  
 c 332 12.8 0.7 17 1 US-09-866-108A-6977 Sequence 6977, Ap  
 c 333 12.8 0.7 17 1 US-09-866-108A-7126 Sequence 7126, Ap  
 c 334 12.8 0.7 17 1 US-09-866-108A-7126 Sequence 7126, Ap  
 c 335 12.8 0.7 17 1 US-09-866-108A-8359 Sequence 8359, Ap  
 c 336 12.8 0.7 17 1 US-09-866-108A-8361 Sequence 8361, Ap  
 c 337 12.8 0.7 17 1 US-09-866-108A-8362 Sequence 8362, Ap  
 c 338 12.8 0.7 17 1 US-09-866-108A-9536 Sequence 9536, Ap  
 c 339 12.8 0.7 17 1 US-09-866-108A-9537 Sequence 9537, Ap  
 c 340 12.8 0.7 17 1 US-09-866-108A-9571 Sequence 9571, Ap  
 c 341 12.8 0.7 17 1 US-09-866-108A-9573 Sequence 9573, Ap  
 c 342 12.8 0.7 17 1 US-09-866-108A-10256 Sequence 10256, A  
 c 343 12.8 0.7 17 1 US-09-866-108A-10257 Sequence 10257, A  
 c 344 12.8 0.7 17 1 US-09-404-912-155 Sequence 155, App  
 c 345 12.8 0.7 17 1 US-09-155-885A-101 Sequence 101, App  
 c 346 12.8 0.7 17 1 US-10-029-598-30 Sequence 30, Appl  
 c 347 12.8 0.7 17 1 US-09-685-664B-333 Sequence 333, App  
 c 348 12.8 0.7 17 1 US-09-685-664B-477 Sequence 477, App  
 c 349 12.8 0.7 17 1 US-09-685-664B-1080 Sequence 1080, Ap  
 c 350 12.8 0.7 17 1 US-09-685-664B-1705 Sequence 1705, Ap  
 c 351 12.8 0.7 17 1 US-09-685-664B-2671 Sequence 2671, Ap  
 c 352 12.8 0.7 17 1 US-09-685-664B-3604 Sequence 3604, Ap  
 c 353 12.8 0.7 17 1 US-09-093-972C-236 Sequence 236, App  
 c 354 12.8 0.7 17 1 US-09-093-972C-272 Sequence 272, App  
 c 355 12.8 0.7 17 1 PCT-US96-11786-33 Sequence 33, Appl  
 c 356 12.6 0.7 15 1 US-08-431-048A-151 Sequence 151, App  
 c 357 12.4 0.7 14 1 US-08-294-424-46 Sequence 46, Appl  
 c 358 12.4 0.7 14 1 US-09-152-059-116 Sequence 116, App  
 c 359 12.4 0.7 14 1 US-08-875-553D-14 Sequence 14, Appl  
 c 360 12.4 0.7 14 1 US-09-981-803-32 Sequence 32, Appl  
 c 361 12.4 0.7 14 1 US-09-981-803-48 Sequence 48, Appl  
 c 362 12.4 0.7 14 1 US-09-699-295-130 Sequence 130, App  
 c 363 12.4 0.7 15 1 US-08-334-847-92 Sequence 92, Appl  
 c 364 12.4 0.7 15 1 US-08-334-847-615 Sequence 615, App  
 c 365 12.4 0.7 15 1 US-08-908-724-1 Sequence 1, Appli  
 c 366 12.4 0.7 15 1 US-08-173-489C-87 Sequence 87, Appl  
 c 367 12.4 0.7 15 1 US-09-115-446-3 Sequence 3, Appli  
 c 368 12.4 0.7 15 1 US-08-584-040-8462 Sequence 8462, Ap  
 c 369 12.4 0.7 15 1 US-09-475-947A-304 Sequence 304, App  
 c 370 12.4 0.7 15 1 US-09-371-772B-4117 Sequence 4117, Ap  
 c 371 12.4 0.7 15 1 US-09-565-590-3 Sequence 3, Appli  
 c 372 12.4 0.7 15 1 US-09-685-664B-4117 Sequence 4117, Ap  
 c 373 12.4 0.7 15 1 PCT-US93-12600-18 Sequence 18, Appl  
 c 374 12.4 0.7 15 1 5182195-33 Patent No. 5182195  
 c 375 12.4 0.7 15 1 5182195-33 Patent No. 5182195  
 c 376 12.4 0.7 16 1 US-08-419-414-13 Sequence 13, Appl  
 c 377 12.4 0.7 16 1 US-09-564-805-92 Sequence 92, Appl  
 c 378 12.4 0.7 16 1 US-09-060-299-443 Sequence 443, App  
 c 379 12.4 0.7 16 1 US-09-402-923A-443 Sequence 443, App  
 c 380 12.4 0.7 16 1 US-09-371-772B-5841 Sequence 5841, Ap  
 c 381 12.4 0.7 16 1 US-09-371-772B-5864 Sequence 5864, Ap  
 c 382 12.4 0.7 16 1 US-09-750-401-6 Sequence 6, Appli  
 c 383 12.4 0.7 16 1 US-09-479-005A-332 Sequence 332, App  
 c 384 12 0.6 15 1 US-08-173-489C-87 Sequence 87, Appl

## ALIGNMENTS

RESULT 1  
 US-09-396-196G-36103/c  
 ; Sequence 36103, Application US/09396196G  
 ; Patent No. 6821724  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Michael Mittmann  
 ; APPLICANT: David Mack  
 ; APPLICANT: David Lockhart  
 ; APPLICANT: Affymetrix, Inc.

; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; CURRENT FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 36103  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-09-396-196G-36103

Query Match 1.1%; Score 19.8; DB 1; Length 25;  
Best Local Similarity 91.3%; Pred. No. 19;  
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 GTGGACATCTGGACAGCTGGGAT 983  
Db 25 GTGGACATCTGGTCTGAGCTGGGGT 3

RESULT 2  
US-09-396-196G-127295  
; Sequence 127295, Application US/09396196G  
; Patent No. 6821724  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; CURRENT FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 127295  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: mus musculus  
US-09-396-196G-127295

Query Match 1.0%; Score 19.2; DB 1; Length 25;  
Best Local Similarity 87.5%; Pred. No. 25;  
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 138 CTTTATCCCTGCTGCTGGAAA 161  
Db 1 CTTTATCCCTGCTGCTGGAAA 24

RESULT 3  
US-09-396-196G-36101/c  
; Sequence 36101, Application US/09396196G  
; Patent No. 6821724  
; GENERAL INFORMATION:  
; APPLICANT: Michael Mittmann  
; APPLICANT: David Mack  
; APPLICANT: David Lockhart  
; APPLICANT: Affymetrix, Inc.  
; TITLE OF INVENTION: Methods of Genetic Analysis  
; FILE REFERENCE: 3101.1  
; CURRENT APPLICATION NUMBER: US/09/396,196G  
; CURRENT FILING DATE: 1999-09-15  
; PRIOR APPLICATION NUMBER: 60/100,678  
; PRIOR FILING DATE: 1998-09-17  
; NUMBER OF SEQ ID NOS: 127806  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 36101

; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Mus musculus  
US-09-396-196G-36101

Query Match 1.0%; Score 18.8; DB 1; Length 25;  
Best Local Similarity 90.9%; Pred. No. 29;  
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 962 TGGACATCTGGACAGCTGGGAT 983  
Db 25 TGGACATCTGGTCTGAGCTGGGGT 4

RESULT 4  
US-09-766-253-132/c  
; Sequence 132, Application US/09766253  
; Patent No. 6808880  
; GENERAL INFORMATION:  
; APPLICANT: Cech, Thomas R.  
; Lingner, Joachim  
; Nakamura, Toru  
; Chapman, Karen B.  
; Morin, Gregg B.  
; Harley, Calvin  
; Andrews, William H.  
; TITLE OF INVENTION: No. 6808880el Telomerase  
; NUMBER OF SEQUENCES: 171  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, 8th Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: United States of America  
; ZIP: 94111  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/766,253  
; FILING DATE: 19-Jan-2001  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/846,017  
; FILING DATE: 1997-04-25  
; APPLICATION NUMBER: US 08/724,643  
; FILING DATE: 01-OCT-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Apple, Randolph T.  
; REGISTRATION NUMBER: 36,429  
; REFERENCE/DOCKET NUMBER: 015389-002920US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 132:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; SEQUENCE DESCRIPTION: SEQ ID NO: 132:  
US-09-766-253-132

Query Match 0.9%; Score 17; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 33;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAA 1851  
Db 17 AAAAAAAAAAAAAAAA 1

## RESULT 5

US-09-685-664B-1075/c  
 ; Sequence 1075, Application US/09685664B  
 ; Patent No. 6818447  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
 ; APPLICANT: Pavco, Pam  
 ; APPLICANT: McSwiggen, Jim  
 ; APPLICANT: Stinchcomb, Dan  
 ; APPLICANT: Escobedo, Jaime  
 ; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to  
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
 ; FILE REFERENCE: MBH00-876-K (400/021)  
 ; CURRENT APPLICATION NUMBER: US/09/685,664B  
 ; CURRENT FILING DATE: 2000-10-10  
 ; PRIOR APPLICATION NUMBER: US 60/005,974  
 ; PRIOR FILING DATE: 1995-10-26  
 ; PRIOR APPLICATION NUMBER: US 08/584,040  
 ; PRIOR FILING DATE: 1996-01-08  
 ; PRIOR APPLICATION NUMBER: US 09/371,772  
 ; PRIOR FILING DATE: 1999-08-10  
 ; NUMBER OF SEQ ID NOS: 8231  
 ; SOFTWARE: PatentIn version 3.0  
 ; SEQ ID NO 1075  
 ; LENGTH: 17  
 ; TYPE: RNA  
 ; ORGANISM: Homo sapiens  
 US-09-685-664B-1075

Query Match 0.9%; Score 17; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 33;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1850  
 Db 17 GAAAAAAAAAAAAAAAAA 1

## RESULT 6

US-09-809-545A-84/c  
 ; Sequence 84, Application US/09809545A  
 ; Patent No. 6800455  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Stanton, Lawrence W.  
 ; APPLICANT: White, R. Tyler  
 ; TITLE OF INVENTION: SECRETED FACTORS  
 ; FILE REFERENCE: SCIOS.017A  
 ; CURRENT APPLICATION NUMBER: US/09/809,545A  
 ; CURRENT FILING DATE: 2001-03-14  
 ; NUMBER OF SEQ ID NOS: 84  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 84  
 ; LENGTH: 18  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Oligos corresponding to polylinker sequence.  
 US-09-809-545A-84

Query Match 0.9%; Score 17; DB 1; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 37;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
 Db 18 AAAAAAAAAAAAAAAAAA 2

## RESULT 7

US-10-352-704-12/c  
 ; Sequence 12, Application US/10352704  
 ; Patent No. 6825339

## GENERAL INFORMATION:

APPLICANT: Chatelain, Francois  
 ; Kumarev, Viktor  
 ; TITLE OF INVENTION: Process for Preparing Polynucleotides on  
 ; a Solid Support and Apparatus Permitting its  
 ; Implementation  
 ; NUMBER OF SEQUENCES: 31  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Jacobson, Price, Holman & Stern  
 ; STREET: 400 Seventh St. N.W.  
 ; CITY: Washington D.C.  
 ; STATE: D.C.  
 ; COUNTRY: U.S.A.  
 ; ZIP: 20004  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/10/352,704  
 ; FILING DATE: 28-Jan-2003  
 ; CLASSIFICATION: 536  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/358,556A  
 ; FILING DATE: 14-DEC-1994  
 ; APPLICATION NUMBER: FR 9315164  
 ; FILING DATE: 16-DEC-1993  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Player, William E.  
 ; REGISTRATION NUMBER: 31,409  
 ; REFERENCE/DOCKET NUMBER: 10577/P58418  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (202) 638-6666  
 ; TELEFAX: (202) 393-5350  
 ; TELEX: RCA 248593 IDEA UR  
 ; INFORMATION FOR SEQ ID NO: 12:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 18 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (genomic)  
 ; HYPOTHETICAL: NO  
 ; ANTI-SENSE: NO  
 ; FRAGMENT TYPE: N-terminal  
 ; FEATURE:  
 ; NAME/KEY: CDS  
 ; LOCATION: 1..18  
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 12:  
 US-10-352-704-12  
 Query Match 0.9%; Score 17; DB 1; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 37;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
 Db 18 AAAAAAAAAAAAAAAAAA 2  
 RESULT 8  
 US-10-352-704-18  
 ; Sequence 18, Application US/10352704  
 ; Patent No. 6825339  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Chatelain, Francois  
 ; Kumarev, Viktor  
 ; TITLE OF INVENTION: Process for Preparing Polynucleotides on  
 ; a Solid Support and Apparatus Permitting its  
 ; Implementation  
 ; NUMBER OF SEQUENCES: 31  
 ; CORRESPONDENCE ADDRESS:

```
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C
; STATE: D.C
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704
; FILING DATE: 28-Jan-2003
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/358,556A
; FILING DATE: 14-DEC-1994
; APPLICATION NUMBER: FR 9315164
; FILING DATE: 16-DEC-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)638-6666
; TELEFAX: (202) 393-5350
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-352-704-18

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 9
US-09-976-618A-55
; Sequence 55, Application US/09976618A
; Patent No. 6812334
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-121
; CURRENT APPLICATION NUMBER: US/09/976,618A
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 1999-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-976-618A-55

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 10
US-09-976-968A-55
; Sequence 55, Application US/09976968A
; Patent No. 6818753
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-117
; CURRENT APPLICATION NUMBER: US/09/976,968A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; OTHER INFORMATION: synthetic sequence
US-09-976-968A-55

Query Match 0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 1 AAAAAAAAAAAAAAAAAA 17
```



```
Db      1 AAAAAAAAAAAAAAAAAA 17

RESULT 11
US-10-234-764-10/c
; Sequence 10, Application US/10234764
; Patent No. 6825331
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Lounberg, Harri
; APPLICANT: Salo, Harri
; APPLICANT: Vitta, Pasi
; TITLE OF INVENTION: Aminoxy Functionalized Oligomers
; FILE REFERENCE: ISIS5089
; CURRENT APPLICATION NUMBER: US/10/234,764
; CURRENT FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 09/344,260
; PRIOR FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-234-764-10

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
      |||
Db      20 AAAAAAAAAAAAAAAAAA 4

RESULT 12
US-09-975-059A-55
; Sequence 55, Application US/09975059A
; Patent No. 6828432
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Strohoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-115
; CURRENT APPLICATION NUMBER: US/09/975,059A
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
US-09-975-059A-55

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
      |||
Db      20 AAAAAAAAAAAAAAAAAA 4

RESULT 13
US-09-859-736-3/c
; Sequence 3, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-859-736-3

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1835 AAAAAAAAAAAAAAAAAA 1851
      |||
Db      20 AAAAAAAAAAAAAAAAAA 4

RESULT 14
US-09-859-736-4/c
; Sequence 4, Application US/09859736
; Patent No. 6838244
; GENERAL INFORMATION:
; APPLICANT: LI, WAN-LIANG ROBERT
; APPLICANT: ZHOU, JIAN S.
; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
; FILE REFERENCE: 16517.248
; CURRENT APPLICATION NUMBER: US/09/859,736
; CURRENT FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: 60/205,452
; PRIOR FILING DATE: 2000-05-19
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-859-736-4

Query Match      0.9%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 44;
```

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 20 AAAAAAAAAAAAAAAAAA 4

## RESULT 15

US-09-859-736-6/c

; Sequence 6, Application US/09859736

; Patent No. 6838244

; GENERAL INFORMATION:

; APPLICANT: LI, WAN-LIANG ROBERT

; APPLICANT: ZHOU, JIAN S.

; TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF

; FILE REFERENCE: 16517.248

; CURRENT APPLICATION NUMBER: US/09/859,736

; CURRENT FILING DATE: 2001-05-18

; PRIOR APPLICATION NUMBER: 60/205,452

; PRIOR FILING DATE: 2000-05-19

; NUMBER OF SEQ ID NOS: 7

; SOFTWARE: Patentin Ver. 2.1

; SEQ ID NO 6

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: dt oligonucleotide

US-09-859-736-6

Query Match 0.9%; Score 17; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 48;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851

Db 21 AAAAAAAAAAAAAAAAAA 5

## RESULT 16

US-09-422-978-4101/c

; Sequence 4101, Application US/09422978

; Patent No. 6537751

; GENERAL INFORMATION:

; APPLICANT: Cohen, Daniel

; APPLICANT: Blumenfeld, Marta

; APPLICANT: Chumakov, Ilya

; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

; FILE REFERENCE: GENSET 020CP1

; CURRENT APPLICATION NUMBER: US/09/422,978

; CURRENT FILING DATE: 1999-10-20

; EARLIER APPLICATION NUMBER: US 09/298,850

; EARLIER FILING DATE: 1999-04-21

; EARLIER APPLICATION NUMBER: US 60/109,732

; EARLIER FILING DATE: 1998-11-23

; EARLIER APPLICATION NUMBER: US 60/082,614

; EARLIER FILING DATE: 1998-04-21

; NUMBER OF SEQ ID NOS: 11796

; SEQ ID NO 4101

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Homo Sapiens

; FEATURE:

; NAME/KEY: primer\_bind

; LOCATION: 1..18

; OTHER INFORMATION: upstream amplification primer 99-13272 for SEQ 167,

US-09-422-978-4101

Query Match

Best Local Similarity 0.9%; Score 16.4; DB 1; Length 18;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 730 CCATCTACAGTCTCTCACA 747

Db 18 CCATCTACATCTCTCACA 1

## RESULT 17

US-09-198-452A-3072/c

; Sequence 3072, Application US/09198452A

; Patent No. 6559294

; GENERAL INFORMATION:

; APPLICANT: Grifffais, R.

; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments

; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention

; TITLE OF INVENTION: and treatment of infection

; FILE REFERENCE: 9710-003-999

; CURRENT APPLICATION NUMBER: US/09/198,452A

; CURRENT FILING DATE: 1998-11-24

; NUMBER OF SEQ ID NOS: 6849

; SEQ ID NO 3072

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Chlamydia pneumoniae

US-09-198-452A-3072

Query Match 0.9%; Score 16.4; DB 1; Length 20;

Best Local Similarity 94.4%; Pred. No. 57;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1612 TCATCTTCAAAGCACAAC 1629

Db 19 TCATCTTCAAAGCAGAC 2

## RESULT 18

US-08-863-639A-67

; Sequence 67, Application US/08863639A

; Patent No. 5981185

; GENERAL INFORMATION:

; APPLICANT: Matson, Robert S.

; APPLICANT: Coassin, Peter J.

; APPLICANT: Rampal, Jang B.

; APPLICANT: Caskey, C. T.

; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS

; NUMBER OF SEQUENCES: 95

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Sheldon & Mak

; STREET: 225 South Lake Avenue, 9th Floor

; CITY: Pasadena

; STATE: CA

; COUNTRY: USA

; ZIP: 91101

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage

; COMPUTER: IBM compatible

; OPERATING SYSTEM: Windows 95

; SOFTWARE: Corel WordPerfect 8 version

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/863,639A

; FILING DATE: May 28, 1997

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Joseph E. Mueth

; REGISTRATION NUMBER: 20,532

; REFERENCE/DOCKET NUMBER: 11859-1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (626) 796-4000

; TELEFAX: (626) 795-6321

; INFORMATION FOR SEQ ID NO: 67:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 21 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

```
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-67

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 67;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 28 GCGGCTCCGTCGCGCGCGTC 48
    ||||| ||||| ||||| |||||
Db 1 GCGGCGCGCGCGCGCGCGCC 21

RESULT 19
US-08-863-639A-71/c
; Sequence 71, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel WordPerfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863.639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 71:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-71

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 67;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 28 GCGGCTCCGTCGCGCGCGTC 48
    ||||| ||||| ||||| |||||
Db 21 GCGGCGCGCGCGCGCGCGCC 1

RESULT 20
US-08-416-214A-11/c
; Sequence 11, Application US/08416214A
; Patent No. 5998596
; GENERAL INFORMATION:
; APPLICANT: Bergan, Raymond; Neckers, Len
; TITLE OF INVENTION: Inhibition Of Protein
; TITLE OF INVENTION: Kinase Activity By Aptameric Action Of
; TITLE OF INVENTION: Oligonucleotides
```

```
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/416,214A
; FILING DATE: 04-APR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Kathryn M.
; REGISTRATION NUMBER: 34,556
; REFERENCE/DOCKET NUMBER: 2026-4166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; TELEX: 421792
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: Nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; MOLECULE TYPE: Other nucleic acid
; HYPOTHETICAL: Yes
; ANTI-SENSE: NO
US-08-416-214A-11

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 67;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 28 GCGGCTCCGTCGCGCGCGTC 48
    ||||| ||||| ||||| |||||
Db 21 GCGGCGCGCGCGCGCGCGCC 1

RESULT 21
US-09-765-111A-32
; Sequence 32, Application US/09765111A
; Patent No. 6723506
; GENERAL INFORMATION:
; APPLICANT: Fletcher, Jonathan A.
; APPLICANT: Kroll, Todd G.
; TITLE OF INVENTION: PAX8-PPARGgamma NUCLEIC ACID MOLECULES
; FILE REFERENCE: B0801/7196/ERP/MAT
; CURRENT APPLICATION NUMBER: US/09/765,111A
; CURRENT FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: US 60/177,109
; PRIOR FILING DATE: 2000-01-20
; PRIOR APPLICATION NUMBER: US 60/225,079
; PRIOR FILING DATE: 2000-08-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 32
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-765-111A-32

Query Match          0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 67;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 886 ACCAGACTACTGATTCCTTCA 906
```

Db 1 ACCCAGAAAGCGATTCCTTCA 21  
||||||| | |||||||||

## RESULT 22

US-09-766-253-131  
; Sequence 131, Application US/09766253  
; Patent No. 6808880

## GENERAL INFORMATION:

; APPLICANT: Cech, Thomas R.  
; Lingner, Joachim  
; Nakamura, Toru  
; Chapman, Karen B.  
; Morin, Gregg B.  
; Harley, Calvin  
; Andrews, William H.

; TITLE OF INVENTION: No. 6808880el Telomerase

; NUMBER OF SEQUENCES: 171

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, 8th Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: United States of America  
; ZIP: 94111

## COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/766,253

; FILING DATE: 19-Jan-2001

; CLASSIFICATION: <Unknown>

## PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/846,017

; FILING DATE: 1997-04-25

; APPLICATION NUMBER: US 08/724,643

; FILING DATE: 01-OCT-1996

## ATTORNEY/AGENT INFORMATION:

; NAME: Apple, Randolph T.

; REGISTRATION NUMBER: 36,429

; REFERENCE/DOCKET NUMBER: 015389-002920US

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 576-0200

; TELEFAX: (415) 576-0300

; INFORMATION FOR SEQ ID NO: 131:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 16 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; SEQUENCE DESCRIPTION: SEQ ID NO: 131:

US-09-766-253-131

Query Match 0.9%; Score 16; DB 1; Length 16;

Best Local Similarity 100.0%; Pred. No. 46;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850

Db 1 AAAAAAAAAAAAAA 16  
|||||||

## RESULT 23

US-09-685-664B-1074/c

; Sequence 1074, Application US/09685664B

; Patent No. 6818447

## GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-K (400/021)

; CURRENT APPLICATION NUMBER: US/09/685,664B

; CURRENT FILING DATE: 2000-10-10

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/005,974

; PRIOR FILING DATE: 1996-01-08

; PRIOR APPLICATION NUMBER: US 09/371,772

; PRIOR FILING DATE: 1999-08-10

; NUMBER OF SEQ ID NOS: 8231

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1074

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-685-664B-1074

Query Match 0.9%; Score 16; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 51;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850

Db 17 AAAAAAAAAAAAAA 2  
|||||||

## RESULT 24

US-09-685-664B-1076/c

; Sequence 1076, Application US/09685664B

; Patent No. 6818447

## GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH00-876-K (400/021)

; CURRENT APPLICATION NUMBER: US/09/685,664B

; CURRENT FILING DATE: 2000-10-10

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1996-01-08

; PRIOR APPLICATION NUMBER: US 09/371,772

; PRIOR FILING DATE: 1999-08-10

; NUMBER OF SEQ ID NOS: 8231

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1076

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-685-664B-1076

Query Match 0.9%; Score 16; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 51;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1834 GAAAAAAAAAAAAA 1849

Db 16 GAAAAAAAAAAAAA 1  
|||||||

## RESULT 25

US-09-090-672B-107/c

; Sequence 107, Application US/09090672B

; Patent No. 6828428

## GENERAL INFORMATION:

; APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura,

APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,  
APPLICANT: Shigemasa; Takei, Masami  
TITLE OF INVENTION: IGA Nephropathy-Related Genes  
NUMBER OF SEQUENCES: 111  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto  
STREET: 30 Rockefeller Plaza  
CITY: New York  
STATE: New York  
ZIP: 10112-3801  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
COMPUTER: Compaq PC  
OPERATING SYSTEM: Windows 95  
SOFTWARE: WordPerfect 8.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/090,672B  
FILING DATE: 04-JUNE-1998  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/JP97/04468  
FILING DATE: 05-DEC-1997  
APPLICATION NUMBER: JP-8-325763  
FILING DATE: 05-DEC-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Perry, Lawrence S.  
REGISTRATION NUMBER: 31865  
REFERENCE/DOCKET NUMBER: 766.21  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 218-2100  
TELEFAX: (212) 218-2200  
INFORMATION FOR SEQ ID NO: 107:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid, synthetic DNA  
US-09-090-672B-107

Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 51;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1849  
Db 17 GAAAAAAAAAAAAAAAAA 2

RESULT 26  
US-09-904-744-1  
Sequence 1, Application US/09904744  
Patent No. 6828142  
GENERAL INFORMATION:  
APPLICANT: Barbera-Guillem, Emilio  
APPLICANT: Nelson, M. Bud  
APPLICANT: Castro, Stephanie  
TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form  
TITLE OF INVENTION: dendrimers in a signal amplification system  
FILE REFERENCE: B-73  
CURRENT APPLICATION NUMBER: US/09/904,744  
CURRENT FILING DATE: 2001-07-13  
PRIOR APPLICATION NUMBER: 09/437076  
PRIOR FILING DATE: 1999-11-09  
PRIOR APPLICATION NUMBER: 60/107828  
PRIOR FILING DATE: 1998-11-10  
NUMBER OF SEQ ID NOS: 6  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:

APPLICANT: Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada,  
APPLICANT: Shigemasa; Takei, Masami  
TITLE OF INVENTION: IGA Nephropathy-Related Genes  
NUMBER OF SEQUENCES: 111  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto  
STREET: 30 Rockefeller Plaza  
CITY: New York  
STATE: New York  
ZIP: 10112-3801  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
COMPUTER: Compaq PC  
OPERATING SYSTEM: Windows 95  
SOFTWARE: WordPerfect 8.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/090,672B  
FILING DATE: 04-JUNE-1998  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/JP97/04468  
FILING DATE: 05-DEC-1997  
APPLICATION NUMBER: JP-8-325763  
FILING DATE: 05-DEC-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Perry, Lawrence S.  
REGISTRATION NUMBER: 31865  
REFERENCE/DOCKET NUMBER: 766.21  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 218-2100  
TELEFAX: (212) 218-2200  
INFORMATION FOR SEQ ID NO: 107:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid, synthetic DNA  
US-09-090-672B-107

Query Match 0.9%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 51;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1849  
Db 17 GAAAAAAAAAAAAAAAAA 2

RESULT 26  
US-09-904-744-1  
Sequence 1, Application US/09904744  
Patent No. 6828142  
GENERAL INFORMATION:  
APPLICANT: Barbera-Guillem, Emilio  
APPLICANT: Nelson, M. Bud  
APPLICANT: Castro, Stephanie  
TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form  
TITLE OF INVENTION: dendrimers in a signal amplification system  
FILE REFERENCE: B-73  
CURRENT APPLICATION NUMBER: US/09/904,744  
CURRENT FILING DATE: 2001-07-13  
PRIOR APPLICATION NUMBER: 09/437076  
PRIOR FILING DATE: 1999-11-09  
PRIOR APPLICATION NUMBER: 60/107828  
PRIOR FILING DATE: 1998-11-10  
NUMBER OF SEQ ID NOS: 6  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:

OTHER INFORMATION: synthesized  
US-09-904-744-1

Query Match 0.9%; Score 16; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 56;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAAAAAAAAAAAAA 1849  
Db 3 GAAAAAAAAAAAAAAAAA 18

RESULT 27  
US-09-696-791-479/c  
Sequence 479, Application US/09696791.  
Patent No. 6770633  
GENERAL INFORMATION:  
APPLICANT: Robbins, Joan M.  
APPLICANT: Tritz, Richard  
TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE  
TITLE OF INVENTION: SKIN AND EYE DISEASES  
FILE REFERENCE: 480124.407  
CURRENT APPLICATION NUMBER: US/09/696,791  
CURRENT FILING DATE: 2000-10-25  
NUMBER OF SEQ ID NOS: 4523  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 479  
LENGTH: 19  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
OTHER INFORMATION: Cdk4 ribozyme binding site  
US-09-696-791-479

Query Match 0.9%; Score 16; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 62;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1095 TGGACTGCAGAGAAC 1110  
Db 19 TGGACTGCAGAGAAC 4

RESULT 28  
US-09-037-990B-79  
Sequence 79, Application US/09037990B  
Patent No. 6248519.  
GENERAL INFORMATION:  
APPLICANT: ENGEL, Stacia R.  
DESCENZO, Richard A.  
MORENZONI, Richard A.  
IRELAN, Nancy A.  
TITLE OF INVENTION: DETECTION OF FERMENTATION-RELATED  
MICROORGANISMS  
NUMBER OF SEQUENCES: 100  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun  
STREET: 6300 Sears Tower, 233 South Wacker Drive  
CITY: Chicago  
STATE: Illinois  
COUNTRY: United States of America  
ZIP: 60606-6402  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/037,990B  
FILING DATE: 11-Mar-1999  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: <Unknown>

```
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sharp, Jeffrey S.
; REGISTRATION NUMBER: 31,879
; REFERENCE/DOCKET NUMBER: 29520/30001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 79:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 79:
US-09-037-990B-79

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1696 AATCATTCCTCCCTCCCTC 1714
Db 1 AATCATTCCTCCCTCACTC 19

RESULT 29
US-09-475-947A-12/c
; Sequence 12, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-12

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1516 AGAACAAGTAAGAAGAAA 1534
Db 19 AGAACAAGTAAGAAGAAA 1

RESULT 30
US-09-696-791-3050/c
; Sequence 3050, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3050
; LENGTH: 19

; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Sharp, Jeffrey S.
; REGISTRATION NUMBER: 31,879
; REFERENCE/DOCKET NUMBER: 29520/30001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 79:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 79:
US-09-037-990B-79

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1696 AATCATTCCTCCCTCCCTC 1714
Db 1 AATCATTCCTCCCTCACTC 19

RESULT 29
US-09-475-947A-12/c
; Sequence 12, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-12

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1516 AGAACAAGTAAGAAGAAA 1534
Db 19 AGAACAAGTAAGAAGAAA 1

RESULT 30
US-09-696-791-3050/c
; Sequence 3050, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3050
; LENGTH: 19

; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin A1 ribozyme binding site
US-09-696-791-3050

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 436 GGGAGAGGGGAGGAATC 454
Db 19 GGGAGAGGGAGAGATGAATC 1

RESULT 31
US-09-696-791-3051/c
; Sequence 3051, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3051
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin A1 ribozyme binding site
US-09-696-791-3051

Query Match          0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 434 CTGGGAGAGGGGAGAGAA 452
Db 19 CTGGGAGAGGGAGAGATGAA 1

RESULT 32
US-08-215-138-16
; Sequence 16, Application US/08215138
; Patent No. 5470719
; GENERAL INFORMATION:
; APPLICANT: Meng, Shi-Yuan
; APPLICANT: Morris, Charles F.
; APPLICANT: Tsai, Larry B.
; TITLE OF INVENTION: Enhanced Secretion of Polypeptides
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/215,138
; FILING DATE:
; CLASSIFICATION: 530
; INFORMATION FOR SEQ ID NO: 16:
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-215-138-16

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAGGAAT 1698
Db 2 TGATTCTAGAGGAGGAAT 20

RESULT 33
US-08-407-344-16
; Sequence 16, Application US/08407344
; Patent No. 5608036
; GENERAL INFORMATION:
; APPLICANT: Meng, Shi-Yuan
; APPLICANT: Morris, Charles F.
; APPLICANT: Tsai, Larry B.
; TITLE OF INVENTION: Enhanced Secretion of Polypeptides
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/407,344
; FILING DATE:
; CLASSIFICATION: 530
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-407-344-16

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAGGAAT 1698
Db 2 TGATTCTAGAGGAGGAAT 20

RESULT 34
US-09-198-452A-6169/c
; Sequence 6169, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24

; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 6169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-6169

Query Match          0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 73;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1440 ATGAATGTTGCTGCTGCTG 1458
Db 19 ATGATTGTTGCTGCTGCGC 1

RESULT 35
US-08-863-639A-52
; Sequence 52, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel Wordperfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
US-08-863-639A-52

Query Match          0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 79;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCCCTCGTCGCCGCCG 46
Db 3 GCCGCCGCCGCCGCCGCCG 21

RESULT 36
US-08-863-639A-55
; Sequence 55, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
```

APPLICANT: Matson, Robert S.  
APPLICANT: Coassin, Peter J.  
APPLICANT: Rampal, Jang B.  
APPLICANT: Caskey, C. T.  
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS  
NUMBER OF SEQUENCES: 95  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Sheldon & Mak  
STREET: 225 South Lake Avenue, 9th Floor  
CITY: Pasadena  
STATE: CA  
COUNTRY: USA  
ZIP: 91101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: Windows 95  
SOFTWARE: Corel WordPerfect 8 version  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/863,639A  
FILING DATE: May 28, 1997  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Joseph E. Mueth  
REGISTRATION NUMBER: 20,532  
REFERENCE/DOCKET NUMBER: 11859-1  
TELEPHONE: (626) 796-4000  
TELEFAX: (626) 795-6321  
INFORMATION FOR SEQ ID NO: 55:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 21 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: Other nucleic acid  
US-08-863-639A-55

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCTCGTCGCCGCCG 46  
Db 2 GCCGCGCCGCCGCCGCCG 20

RESULT 37  
US-08-863-639A-56/c  
Sequence 56, Application US/08863639A  
Patent No. 5981185  
GENERAL INFORMATION:  
APPLICANT: Matson, Robert S.  
APPLICANT: Coassin, Peter J.  
APPLICANT: Rampal, Jang B.  
APPLICANT: Caskey, C. T.  
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS  
NUMBER OF SEQUENCES: 95  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Sheldon & Mak  
STREET: 225 South Lake Avenue, 9th Floor  
CITY: Pasadena  
STATE: CA  
COUNTRY: USA  
ZIP: 91101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: Windows 95  
SOFTWARE: Corel WordPerfect 8 version  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/863,639A  
FILING DATE: May 28, 1997

CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Joseph E. Mueth  
REGISTRATION NUMBER: 20,532  
REFERENCE/DOCKET NUMBER: 11859-1  
TELEPHONE: (626) 796-4000  
TELEFAX: (626) 795-6321  
INFORMATION FOR SEQ ID NO: 56:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 21 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: Other nucleic acid  
US-08-863-639A-56

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCTCGTCGCCGCCG 46  
Db 19 GCCGCGCCGCCGCCGCCG 1

RESULT 38  
US-08-863-639A-68/c  
Sequence 68, Application US/08863639A  
Patent No. 5981185  
GENERAL INFORMATION:  
APPLICANT: Matson, Robert S.  
APPLICANT: Coassin, Peter J.  
APPLICANT: Rampal, Jang B.  
APPLICANT: Caskey, C. T.  
TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS  
NUMBER OF SEQUENCES: 95  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Sheldon & Mak  
STREET: 225 South Lake Avenue, 9th Floor  
CITY: Pasadena  
STATE: CA  
COUNTRY: USA  
ZIP: 91101  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
COMPUTER: IBM compatible  
OPERATING SYSTEM: Windows 95  
SOFTWARE: Corel WordPerfect 8 version  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/863,639A  
FILING DATE: May 28, 1997  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Joseph E. Mueth  
REGISTRATION NUMBER: 20,532  
REFERENCE/DOCKET NUMBER: 11859-1  
TELEPHONE: (626) 796-4000  
TELEFAX: (626) 795-6321  
INFORMATION FOR SEQ ID NO: 68:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 21 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: Other nucleic acid  
US-08-863-639A-68

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 79;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;



QY 28 GCGGCTCGTCGCGCGCG 46  
|||||  
Db 20 GCGGCGCGCGCGCGCG 2

## RESULT 39

US-09-685-664B-1077/c  
; Sequence 1077, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-878-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; PRIOR FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1077  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-1077

Query Match 0.8%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 66;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1833 TGAATAAAAAAAAAAAAA 1849  
|||  
Db 17 TGAATAAAAAAAAAAAAA 1

## RESULT 40

US-08-282-197C-28  
; Sequence 28, Application US/08282197C  
; Patent No. 5871730  
; GENERAL INFORMATION:  
; APPLICANT: Brzezinski, Ryszard  
; APPLICANT: Dery, Claude V  
; APPLICANT: Beaulieu, Carole  
; TITLE OF INVENTION: Thermostable Xylanase DNA, Protein and Methods of Use  
; NUMBER OF SEQUENCES: 67  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox P.L.L.C.  
; STREET: 1100 New York Ave., NW  
; CITY: Washington  
; STATE: DC  
; COUNTRY: USA  
; ZIP: 20005  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/282,197C  
; FILING DATE: 29-JUL-1994  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Cimbala, Michele A  
; REGISTRATION NUMBER: 33,851

; REFERENCE/DOCKET NUMBER: 1050.0410000  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-371-2600  
; TELEFAX: 202-371-2540  
; INFORMATION FOR SEQ ID NO: 28:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: both  
; TOPOLOGY: both  
US-08-282-197C-28

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 82.4%; Pred. No. 73;  
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 443 GGGAGAGAAATCAGCTG 459  
|||||  
Db 2 GGGAGAGAAUACAGAU 18

## RESULT 41

US-08-857-946-8/c  
; Sequence 8, Application US/08857946  
; Patent No. 5994075  
; GENERAL INFORMATION:  
; APPLICANT: Goodfellow, P.N.  
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A GENE  
; TITLE OF INVENTION: GENE OF INTEREST  
; NUMBER OF SEQUENCES: 162  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Banner & Witcoff, Inc.  
; STREET: 75 State Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109-1807  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: WordPerfect 6.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/857,946  
; FILING DATE: 16-MAY-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/60/017,824  
; FILING DATE: 17-MAY-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kathleen M. Williams  
; REGISTRATION NUMBER: 34,380  
; REFERENCE/DOCKET NUMBER: 3529/05573  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-345-9100  
; TELEFAX: 617-345-9111  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 bases  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: other nucleic acid  
US-08-857-946-8

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 73;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GCGCTCGTCGCGCGCG 46  
|||||  
Db 18 GCGCGCGTCGCGCGCG 2

RESULT 42  
US-08-970-740-8/c  
; Sequence 8, Application US/08970740  
; Patent No. 6015670  
; GENERAL INFORMATION:  
; APPLICANT: Goodfellow, P.N.  
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A  
; TITLE OF INVENTION: GENE OF INTEREST  
; NUMBER OF SEQUENCES: 162  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Banner & Witcoff, Inc.  
; STREET: 28 State Street, 28th Floor  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: USA  
; ZIP: 02109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: WordPerfect 6.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/970,740  
; FILING DATE: 14-NOV-1997  
; PRIOR APPLICATION NUMBER: 08/857,946  
; FILING DATE: 16-MAY-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/017,824  
; FILING DATE: 17-MAY-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Kathleen M. Williams  
; REGISTRATION NUMBER: 34,380  
; REFERENCE/DOCKET NUMBER: 3529/59829  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-227-7111  
; TELEFAX: 617-227-4399  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 bases  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: other nucleic acid  
US-08-970-740-8

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 73;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 30 CGCCTCGTCGCGCGCG 46  
Db 18 CGCGCGCGTCGCGCGCG 2

RESULT 43  
US-09-710-794-8  
; Sequence 8, Application US/09710794  
; Patent No. 6573069  
; GENERAL INFORMATION:  
; APPLICANT: Holloway, James L.  
; APPLICANT: Gao, Zeren  
; TITLE OF INVENTION: NOVEL CRIB PROTEIN ZMSEI  
; FILE REFERENCE: 99-76  
; CURRENT APPLICATION NUMBER: US/09/710,794  
; CURRENT FILING DATE: 2000-11-09  
; PRIOR APPLICATION NUMBER: US 60/164,685  
; PRIOR FILING DATE: 1999-11-10  
; NUMBER OF SEQ ID NOS: 31  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 8

; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Oligonucleotide primer ZC18860  
US-09-710-794-8

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 73;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 714 TCCGTGGCCTCTTCTC 730  
Db 1 TCCGGGGCCTCTTCTC 17

RESULT 44  
US-09-198-452A-6103  
; Sequence 6103, Application US/09198452A  
; Patent No. 6559294  
; GENERAL INFORMATION:  
; APPLICANT: Grifffais, R.  
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments  
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention  
; TITLE OF INVENTION: and treatment of infection  
; FILE REFERENCE: 9710-003-999  
; CURRENT APPLICATION NUMBER: US/09/198,452A  
; CURRENT FILING DATE: 1998-11-24  
; NUMBER OF SEQ ID NOS: 6849  
; SEQ ID NO 6103  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Chlamydia pneumoniae  
US-09-198-452A-6103

Query Match 0.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 87;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 150 TGCTCTGGGAAAGCTAT 166  
Db 2 TGCTCTGGGAAAGCTAT 18

RESULT 45  
US-10-058-422A-14/c  
; Sequence 14, Application US/10058422A  
; Patent No. 6815165  
; GENERAL INFORMATION:  
; APPLICANT: LEE, HyeYoung  
; APPLICANT: CHO, Sang-Nae  
; TITLE OF INVENTION: A method for identifying Mycobacterium tuberculosis and  
; TITLE OF INVENTION: non-tuberculosis Mycobacteria, together with detecting resistance  
; TITLE OF INVENTION: to an antituberculosis drug of Mycobacteria obtained by mutation  
; TITLE OF INVENTION: of rpoB gene  
; FILE REFERENCE: 912-27  
; CURRENT APPLICATION NUMBER: US/10/058,422A  
; CURRENT FILING DATE: 2002-01-30  
; NUMBER OF SEQ ID NOS: 31  
; SOFTWARE: KopatentIn 1.71  
; SEQ ID NO 14  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Oligomer probe for M. abscessus  
US-10-058-422A-14

Query Match 0.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 87;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 126 GGTGTGTTCACCTTTT 142

Db 17 GGTGGGTGCACCTTT 1

RESULT 46  
US-08-182-172-7/c  
; Sequence 7, Application US/08182172  
; Patent No. 5714318  
; GENERAL INFORMATION:  
; APPLICANT: Sagner, Gregor  
; APPLICANT: Kessler, Christoph  
; APPLICANT: Blum, Helmut  
; APPLICANT: Domdey, Horst  
; TITLE OF INVENTION: SIMULTANEOUS SEQUENCING OF NUCLEIC ACIDS  
; NUMBER OF SEQUENCES: 17  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Nikaido, Marmelstein, Murray & Oram  
; STREET: 655 Fifteenth Street N.W. Suite 330  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: U.S.A.  
; ZIP: 20005-5701  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/182,172  
; FILING DATE:  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Murray, Robert B.  
; REGISTRATION NUMBER: 22,980  
; REFERENCE/DOCKET NUMBER: P564-4006  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202)638-5000  
; TELEFAX: (202)638-4810  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 20 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-08-182-172-7

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 94;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 620 CCAACCTTACACTACT 639  
Db 20 CCAACCTTACACTACT 1

RESULT 47  
US-09-418-641-57  
; Sequence 57, Application US/09418641A  
; Patent No. 6124133  
; GENERAL INFORMATION:  
; APPLICANT: Jennifer K. Taylor  
; APPLICANT: Lex M. Cowser  
; TITLE OF INVENTION: ANTISENSE MODULATION OF FRA-1 EXPRESSION  
; FILE REFERENCE: RTS-0105  
; CURRENT APPLICATION NUMBER: US/09/418,641A  
; CURRENT FILING DATE: 1999-10-15  
; NUMBER OF SEQ ID NOS: 89  
; SEQ ID NO 57  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-418-641-57

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 94;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 1270 TGCTGCAGCCCTCAATATC 1289  
Db 1 TTCTGCAGCTCTCAATCTC 20

RESULT 48  
US-09-484-345-75/c  
; Sequence 75, Application US/09484345  
; Patent No. 6159734  
; GENERAL INFORMATION:  
; APPLICANT: Robert McKay  
; APPLICANT: Alexander H. Borchers  
; APPLICANT: Brenda F. Baker  
; TITLE OF INVENTION: ANTISENSE MODULATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR  
; FILE REFERENCE: RTS-0104  
; CURRENT APPLICATION NUMBER: US/09/484,345  
; CURRENT FILING DATE: 2000-01-18  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 75  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-484-345-75

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 94;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 887 CCCAGATACCTGATTCCTTCA 906  
Db 20 CCCAGAAAGCGATTCCTTCA 1

RESULT 49  
US-09-000-092-11  
; Sequence 11, Application US/09000092  
; Patent No. 6160203  
; GENERAL INFORMATION:  
; APPLICANT: Ferri, Stefano  
; APPLICANT: Toguri, Toshihiro  
; TITLE OF INVENTION: DNA STRANDS CODING FOR  
; TITLE OF INVENTION: GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE  
; NUMBER OF SEQUENCES: 27  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: FOLEY & LARDNER  
; STREET: 3000 K Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: U.S.A.  
; ZIP: 20007-5109  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/000,092  
; FILING DATE: 26-JAN-1998  
; CLASSIFICATION: 800  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: WO PCT/JP96/01844  
; FILING DATE: 03-JUL-1996  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 192123/1995

```
; FILING DATE: 27-JUL-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Bent, Stephen A.
; REGISTRATION NUMBER: 29,768
; REFERENCE/DOCKET NUMBER: 16887/916
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Primer"
US-09-000-092-11

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1480 TTGTTGCAGACATGGAAGAA 1499
||| ||||| ||||| |||||
Db 1 TTGCTGCAGGAGTGAAGAA 20

RESULT 50
US-09-030-701-65/c
; Sequence 65, Application US/09030701B
; Patent No. 6214806
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schwartz, David A.
; TITLE OF INVENTION: USE OF NUCLEIC ACIDS CONTAINING
; TITLE OF INVENTION: UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF
; TITLE OF INVENTION: LPS-ASSOCIATED DISORDERS
; FILE REFERENCE: C1039/7011
; CURRENT APPLICATION NUMBER: US/09/030,701B
; CURRENT FILING DATE: 1998-02-25
; PRIOR FILING DATE: 1997-02-28
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-09-030-701-65

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCCGTCGCCGCCGTC 48
||||| ||||| ||||| |||||
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 51
US-09-082-649B-57/c
; Sequence 57, Application US/09082649B
; Patent No. 6339068
; GENERAL INFORMATION:
; APPLICANT: Davis, Heather L.
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schorr, Joachim
; APPLICANT: Wu, Tong
; TITLE OF INVENTION: Vectors and Methods for Immunization or
; TITLE OF INVENTION: Therapeutic Protocols
; FILE REFERENCE: C1039/7009
```

```
; CURRENT APPLICATION NUMBER: US/09/082,649B
; CURRENT FILING DATE: 1998-05-20
; PRIOR APPLICATION NUMBER: US 60/047,233
; PRIOR FILING DATE: 1997-05-20
; PRIOR APPLICATION NUMBER: US 60/047,209
; PRIOR FILING DATE: 1997-05-20
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic oligonucleotide
US-09-082-649B-57

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCCGTCGCCGCCGTC 48
||||| ||||| ||||| |||||
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 52
US-09-198-452A-4294
; Sequence 4294, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Griflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; TITLE OF INVENTION: and treatment of infection
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 4294
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-4294

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1428 GATCCAAAGCAGATGAATGT 1447
||||| ||||| ||||| |||||
Db 1 GCTCCGACACAGATGAATGT 20

RESULT 53
US-09-710-693-10
; Sequence 10, Application US/09710693
; Patent No. 6642370
; GENERAL INFORMATION:
; APPLICANT: WISE, CAROL A
; TITLE OF INVENTION: GENETIC MARKER FOR AUTOIMMUNE DISORDER
; FILE REFERENCE: SEQ FOR TEX871
; CURRENT APPLICATION NUMBER: US/09/710,693
; CURRENT FILING DATE: 2000-11-08
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-710-693-10

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 94;
```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 989 GCAGGTGCGATGATG 1008  
|||||  
Db 1 GCAGGTGCTCAAGGATG 20

## RESULT 54

US-09-965-101-57/c  
; Sequence 57, Application US/09965101  
; Patent No. 6821957  
; GENERAL INFORMATION:  
; APPLICANT: Davis, Heather L.  
; APPLICANT: Krieger, Arthur M.  
; APPLICANT: Schorr, Joachim  
; APPLICANT: Wu, Tong  
; TITLE OF INVENTION: Vectors and Methods for Immunization or  
; FILE REFERENCE: C1039/7057 (HCL/WAT)  
; CURRENT APPLICATION NUMBER: US/09/965,101  
; CURRENT FILING DATE: 2001-09-26  
; PRIOR APPLICATION NUMBER: US 09/082,649  
; PRIOR FILING DATE: 1998-05-20  
; PRIOR APPLICATION NUMBER: US 60/047,233  
; PRIOR FILING DATE: 1997-05-20  
; PRIOR APPLICATION NUMBER: US 60/047,209  
; PRIOR FILING DATE: 1997-05-20  
; NUMBER OF SEQ ID NOS: 84  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 57  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: synthetic oligonucleotide  
US-09-965-101-57

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 94;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CGCGCTCGTCCGCGCGTC 48  
|||||  
Db 20 CGCGCGCGCGCGCGCGCC 1

## RESULT 55

US-10-352-704-10/c  
; Sequence 10, Application US/10352704  
; Patent No. 6825339  
; GENERAL INFORMATION:  
; APPLICANT: Chatelain, Francois  
; Kumarev, Viktor  
; TITLE OF INVENTION: Process for Preparing Polynucleotides on  
; a Solid Support and Apparatus Permitting its  
; Implementation  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Jacobson, Price, Holman & Stern  
; STREET: 400 Seventh St. N.W.  
; CITY: Washington D.C.  
; STATE: D.C.  
; COUNTRY: U.S.A.  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/352,704  
; FILING DATE: 28-Jan-2003  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/358,556A  
; FILING DATE: 14-DEC-1994  
; APPLICATION NUMBER: FR 9315164  
; FILING DATE: 16-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Player, William E.  
; REGISTRATION NUMBER: 31,409

;;  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/358,556A  
;; FILING DATE: 14-DEC-1994  
;; APPLICATION NUMBER: FR 9315164  
;; FILING DATE: 16-DEC-1993  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Player, William E.  
;; REGISTRATION NUMBER: 31,409  
;; REFERENCE/DOCKET NUMBER: 10577/P58418  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (202) 638-6666  
;; TELEFAX: (202) 393-5350  
;; TELEX: RCA 248593 IDEA UR  
;; INFORMATION FOR SEQ ID NO: 10:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 15 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA (genomic)  
;; HYPOTHETICAL: NO  
;; ANTI-SENSE: NO  
;; FRAGMENT TYPE: N-terminal  
;; FEATURE:  
;; NAME/KEY: CDS  
;; LOCATION: 1..15  
;; SEQUENCE DESCRIPTION: SEQ ID NO: 10:  
US-10-352-704-10

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 64;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849  
|||||  
Db 15 AAAAAAAAAAAAAA 1

## RESULT 56

US-10-352-704-16  
; Sequence 16, Application US/10352704  
; Patent No. 6825339  
; GENERAL INFORMATION:  
; APPLICANT: Chatelain, Francois  
; Kumarev, Viktor  
; TITLE OF INVENTION: Process for Preparing Polynucleotides on  
; a Solid Support and Apparatus Permitting its  
; Implementation  
; NUMBER OF SEQUENCES: 31  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Jacobson, Price, Holman & Stern  
; STREET: 400 Seventh St. N.W.  
; CITY: Washington D.C.  
; STATE: D.C.  
; COUNTRY: U.S.A.  
; ZIP: 20004  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/10/352,704  
; FILING DATE: 28-Jan-2003  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/358,556A  
; FILING DATE: 14-DEC-1994  
; APPLICATION NUMBER: FR 9315164  
; FILING DATE: 16-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Player, William E.  
; REGISTRATION NUMBER: 31,409

REFERENCE/DOCKET NUMBER: 10577/P58418  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (202) 638-6666  
TELEFAX: (202) 393-5350  
TELEX: RCA 248593 IDEA UR  
INFORMATION FOR SEQ ID NO: 16:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
FRAGMENT TYPE: N-terminal  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 1..15  
SEQUENCE DESCRIPTION: SEQ ID NO: 16:  
US-10-352-704-16

Query Match 0.8%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 64;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

Db 1 AAAAAAAAAAAAAA 15

## RESULT 57

US-09-685-664B-1073/C  
Sequence 1073, Application US/09685664B  
Patent No. 6818447  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to  
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MBHB00-876-K (400/021)  
CURRENT APPLICATION NUMBER: US/09/685,664B  
CURRENT FILING DATE: 2000-10-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/594,040  
PRIOR FILING DATE: 1996-01-08  
PRIOR APPLICATION NUMBER: US 09/371,772  
PRIOR FILING DATE: 1999-08-10  
NUMBER OF SEQ ID NOS: 8231  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1073  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-685-664B-1073

Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 79;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

Db 17 AAAAAAAAAAAAAA 3

## RESULT 58

US-09-090-672B-105/c  
Sequence 105, Application US/09090672B  
Patent No. 6828428  
GENERAL INFORMATION:

APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura, Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada, Shigemasa; Takei, Masami  
TITLE OF INVENTION: Iga Nephropathy-Related Genes  
NUMBER OF SEQUENCES: 111  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto  
STREET: 30 Rockefeller Plaza  
CITY: New York  
STATE: New York  
ZIP: 10112-3801  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
COMPUTER: Compaq PC  
OPERATING SYSTEM: Windows 95  
SOFTWARE: WordPerfect 8.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/090,672B  
FILING DATE: 04-JUNE-1998  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/JP97/04468  
FILING DATE: 05-DEC-1997  
APPLICATION NUMBER: JP-8-325763  
FILING DATE: 05-DEC-1996  
ATTORNEY/AGENT INFORMATION:  
NAME: Perry, Lawrence S.  
REGISTRATION NUMBER: 31865  
REFERENCE/DOCKET NUMBER: 766.21  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 218-2100  
TELEFAX: (212) 218-2200  
INFORMATION FOR SEQ ID NO: 105:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid, synthetic DNA  
US-09-090-672B-105

Query Match 0.8%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 79;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849

Db 16 AAAAAAAAAAAAAA 2

## RESULT 59

US-09-090-672B-106/c  
Sequence 106, Application US/09090672B  
Patent No. 6828428  
GENERAL INFORMATION:

APPLICANT: Ishiwata, Tetsuyoshi; Sakurada, Mikiko; Nishimura, Ayako; Nakagawa, Satoshi; Nishi, Tatsunari; Kuga, Tetsuro; Sawada, Shigemasa; Takei, Masami  
TITLE OF INVENTION: Iga Nephropathy-Related Genes  
NUMBER OF SEQUENCES: 111  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fitzpatrick, Cella, Harper & Scinto  
STREET: 30 Rockefeller Plaza  
CITY: New York  
STATE: New York  
ZIP: 10112-3801  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage  
COMPUTER: Compaq PC  
OPERATING SYSTEM: Windows 95  
SOFTWARE: WordPerfect 8.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/090,672B

```
; FILING DATE: 04-JUNE-1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP97/04468
; FILING DATE: 05-DEC-1997
; APPLICATION NUMBER: JP-8-325763
; FILING DATE: 05-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Perry, Lawrence S.
; REGISTRATION NUMBER: 31865
; REFERENCE/DOCKET NUMBER: 766.21
; TELEPHONE: (212) 218-2100
; TELEFAX: (212) 218-2200
; INFORMATION FOR SEQ ID NO: 106:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid, synthetic DNA
US-09-090-672B-106

Query Match          0.8%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 79;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 16 AAAAAAAAAAAAAA 2

RESULT 60
US-09-904-744-2/c
; Sequence 2, Application US/09904744
; Patent No. 6828142
; GENERAL INFORMATION:
; APPLICANT: Barbera-Gulien, Emilio
; APPLICANT: Nelson, M. Bud
; APPLICANT: Castro, Stephanie
; TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
; TITLE OF INVENTION: dendrimers in a signal amplification system
; FILE REFERENCE: B-73
; CURRENT APPLICATION NUMBER: US/09/904,744
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/437076
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/107828
; PRIOR FILING DATE: 1998-11-10
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized
US-09-904-744-2

Query Match          0.8%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 86;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1849
Db 18 AAAAAAAAAAAAAA 4

RESULT 61
US-09-696-791-478/c
; Sequence 478, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
```

```
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696.791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 478
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdk4 ribozyme binding site
US-09-696-791-478

Query Match          0.8%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 94;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1096 GGACTGCAGAGAAC 1110
Db 19 GGACTGCAGAGAAC 5

RESULT 62
US-09-344-914-53
; Sequence 53, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-53

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 1 TTGCTGCTGCTGTTT 15

RESULT 63
US-09-344-914-54
; Sequence 54, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-54
```

```
Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
DB 2 TTGCTGCTGCTGTTT 16

RESULT 64
US-09-344-914-55
; Sequence 55, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-55

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
DB 3 TTGCTGCTGCTGTTT 17

RESULT 65
US-09-344-914-56
; Sequence 56, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-56

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
DB 4 TTGCTGCTGCTGTTT 18

RESULT 66
US-09-344-914-57
; Sequence 57, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
```

```
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-57

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
DB 5 TTGCTGCTGCTGTTT 19

RESULT 67
US-09-344-914-58
; Sequence 58, Application US/09344914
; Patent No. 6110664
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-S1 EXPRESSION
; FILE REFERENCE: RTS-0068
; CURRENT APPLICATION NUMBER: US/09/344,914
; CURRENT FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-914-58

Query Match          0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
DB 6 TTGCTGCTGCTGTTT 20

RESULT 68
US-08-215-138-9
; Sequence 9, Application US/08215138
; Patent No. 5470719
; GENERAL INFORMATION:
; APPLICANT: Meng, Shi-Yuan
; APPLICANT: Morris, Charles F.
; APPLICANT: Tsai, Larry B
; TITLE OF INVENTION: Enhanced Secretion of Polypeptides
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO
; STREET: 1840 Dehavilland Drive
; CITY: Thousand Oaks
; STATE: CA
; COUNTRY: USA
; ZIP: 91320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/215,138
; FILING DATE:
```



; CLASSIFICATION: 530  
; INFORMATION FOR SEQ ID NO: 9:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 19 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
US-08-215-138-9

Query Match 0.8%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2;

Qy 1680 TGATTCTAGAAAAGGAA 1697  
|||||  
Db 2 TGATTCTAGAAAGGAGAA 19

RESULT 69  
US-08-407-344-9  
; Sequence 9, Application US/08407344  
; Patent No. 5608036  
; GENERAL INFORMATION:  
; APPLICANT: Meng, Shi-Yuan  
; APPLICANT: Morris, Charles F.  
; APPLICANT: Tsai, Larry B  
; TITLE OF INVENTION: Enhanced Secretion of Polypeptides  
; NUMBER OF SEQUENCES: 23  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Amgen Inc., U.S. Patent Operations/NAO  
; STREET: 1840 Dehavilland Drive  
; CITY: Thousand Oaks  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 91320  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; FILING DATE:  
; APPLICATION NUMBER: US/08/407,344  
; CLASSIFICATION: 530  
; INFORMATION FOR SEQ ID NO: 9:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 19 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
US-08-407-344-9

Query Match 0.8%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2;

Qy 1680 TGATTCTAGAAAAGGAA 1697  
|||||  
Db 2 TGATTCTAGAAAGGAGAA 19

RESULT 70  
US-09-422-978-6888/c  
; Sequence 6888, Application US/09422978  
; Patent No. 6537751  
; GENERAL INFORMATION:  
; APPLICANT: Cohen, Daniel  
; APPLICANT: Blumenfeld, Marta  
; APPLICANT: Chumakov, Ilya  
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...  
; FILE REFERENCE: GENSET.020CPI

; CURRENT APPLICATION NUMBER: US/09/422,978  
; CURRENT FILING DATE: 1999-10-20  
; EARLIER APPLICATION NUMBER: US 09/298,850  
; EARLIER FILING DATE: 1999-04-21  
; EARLIER APPLICATION NUMBER: US 60/109,732  
; EARLIER FILING DATE: 1998-11-23  
; EARLIER APPLICATION NUMBER: US 60/082,614  
; EARLIER FILING DATE: 1998-04-21  
; NUMBER OF SEQ ID NOS: 11796  
; SEQ ID NO 6888  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Homo Sapiens  
; FEATURE:  
; NAME/KEY: primer\_bind  
; LOCATION: 1..19  
; OTHER INFORMATION: upstream amplification primer 99-21057 for SEQ 2954,  
US-09-422-978-6888

Query Match 0.8%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2;

Qy 1467 GTTCTTTCTTATGTTGT 1484  
|||  
Db 19 GTTCTTTCTTATGTTGT 2

RESULT 71  
US-09-422-978-7139/c  
; Sequence 7139, Application US/09422978  
; Patent No. 6537751  
; GENERAL INFORMATION:  
; APPLICANT: Cohen, Daniel  
; APPLICANT: Blumenfeld, Marta  
; APPLICANT: Chumakov, Ilya  
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...  
; FILE REFERENCE: GENSET.020CPI  
; CURRENT APPLICATION NUMBER: US/09/422,978  
; CURRENT FILING DATE: 1999-10-20  
; EARLIER APPLICATION NUMBER: US 09/298,850  
; EARLIER FILING DATE: 1999-04-21  
; EARLIER APPLICATION NUMBER: US 60/109,732  
; EARLIER FILING DATE: 1998-11-23  
; EARLIER APPLICATION NUMBER: US 60/082,614  
; EARLIER FILING DATE: 1998-04-21  
; NUMBER OF SEQ ID NOS: 11796  
; SEQ ID NO 7139  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Homo Sapiens  
; FEATURE:  
; NAME/KEY: primer\_bind  
; LOCATION: 1..19  
; OTHER INFORMATION: upstream amplification primer 99-24768 for SEQ 3205,  
US-09-422-978-7139

Query Match 0.8%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 1e+02; Indels 0; Gaps 0;  
Matches 16; Conservative 0; Mismatches 2;

Qy 1629 CTCTATTTCATGCTTTCT 1646  
|||||  
Db 19 CTCTTTCTTGTCTTCT 2

RESULT 72  
US-09-938-077-19/c  
; Sequence 19, Application US/09938077  
; Patent No. 6730500  
; GENERAL INFORMATION:  
; APPLICANT: Lok, Si  
; TITLE OF INVENTION: Methods for Generating a Continuous

```
; TITLE OF INVENTION: Nucleotide Sequence from No. 6730500contiguous Nucleotide Sequen
; Patent No. 6730500
; FILE REFERENCE: 00-68
; CURRENT APPLICATION NUMBER: US/09/938,077
; CURRENT FILING DATE: 2001-08-23
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 19
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Illustrative nucleotide sequence.
US-09-938-077-19

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1065 CGTCCAAGAGGACTCTG 1082
Db      19  CTTCATAGAGGACTCTG 2

RESULT 73
US-09-696-791-2728/c
; Sequence 2728, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 2728
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin G1 ribozyme binding site
US-09-696-791-2728

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1326 AACTTTGGATCCAGCT 1343
Db      18  AACATTTGGATACAAGCT 1

RESULT 74
US-09-696-791-3559/c
; Sequence 3559, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 3559
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cdc25 hs ribozyme binding site
US-09-696-791-3559

Query Match          0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      963 GGACATCTGGACAGCTGG 980
Db      19  GGACATCTGGACAGACGG 2

RESULT 75
US-08-753-147-188/c
; Sequence 188, Application US/08753147
; Patent No. 5770372
; GENERAL INFORMATION:
; APPLICANT: Concannon, Patrick
; TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene
; NUMBER OF SEQUENCES: 196
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson and Kindness
; STREET: 1420 5th Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/753,147
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sheiness, Diana K.
; REGISTRATION NUMBER: 35,356
; REFERENCE/DOCKET NUMBER: VMRC-1-9714
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 743-4387
; TELEFAX: (206) 224 0779
; INFORMATION FOR SEQ ID NO: 188:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-08-753-147-188

Query Match          0.8%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 92;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      81 AACCAACTGGAAAAA 96
Db      16  AACCAACTGGAGAAA 1

RESULT 76
US-09-371-772B-4471
; Sequence 4471, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
```

```
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 4471
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4471

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1204 TACCACCTGGCTGCA 1219
Db 2 UACCCACUGGCAGCA 17

RESULT 77
US-09-866-108A-8364
; Sequence 8364, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8364
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-8364

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1e+02;
Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1204 TACCACCTGGCTGCA 1219
Db 2 UACCCACUGGCAGCA 17

RESULT 78
US-09-866-108A-8365
; Sequence 8365, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8365
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-8365

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAGTTCAC 410
Db 2 GCTGGAGAAAGTGCAC 17

RESULT 79
US-09-866-108A-10030/c
; Sequence 10030, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

```
US-09-866-108A-8364

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAGTTCAC 410
Db 2 GCTGGAGAAAGTGCAC 17

RESULT 78
US-09-866-108A-8365
; Sequence 8365, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8365
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-8365

Query Match      0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 395 GCTGGAGAAAGTTCAC 410
Db 1 GCTGGAGAAAGTGCAC 16

RESULT 79
US-09-866-108A-10030/c
; Sequence 10030, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
```

; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 10030  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-10030

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGGAGGACTC 1080  
||||| |||||||  
DB 17 CGTCCACAGAGGACTC 2

RESULT 80  
US-09-866-108A-10031/c  
; Sequence 10031, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 10031  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-10031

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGGAGGACTC 1080  
||||| |||||||  
DB 16 CGTCCACAGAGGACTC 1

RESULT 81  
US-09-685-664B-1078/c  
; Sequence 1078, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Methods and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH800-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1078  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-1078

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1833 TGAATAAAAAAAAAA 1848  
||||| |||||||  
DB 16 TGAATAAAAAAAAAA 1

RESULT 82  
US-09-289-377-28/c  
; Sequence 28, Application US/09289377  
; Patent No. 6046321  
; GENERAL INFORMATION:

; APPLICANT: Lex M. Cowseert  
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-I1 EXPRESSION  
; FILE REFERENCE: RTS-0058  
; CURRENT APPLICATION NUMBER: US/09/289,377  
; CURRENT FILING DATE: 1999-04-09  
; NUMBER OF SEQ ID NOS: 47  
; SEQ ID NO 28  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-289-377-28

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 807 GAAGATGAGAAATGA 822  
Db 16 GAAGATGAGAAATGA 1

RESULT 83  
US-09-282-147-17  
; Sequence 17, Application US/09282147  
; Patent No. 6274147  
; GENERAL INFORMATION:  
; APPLICANT: VAKHARIA, Vikram  
; APPLICANT: YAO, Kun  
; TITLE OF INVENTION: METHOD FOR GENERATING NONPATHOGENIC, INFECTIOUS  
; TITLE OF INVENTION: PANCREATIC NECROSIS VIRUS (IPNV) FROM SYNTHETIC RNA  
; FILE REFERENCE: 8288-9023  
; CURRENT APPLICATION NUMBER: US/09/282,147  
; CURRENT FILING DATE: 1999-03-31  
; EARLIER APPLICATION NUMBER: US/60/080,278  
; EARLIER FILING DATE: 1998-03-31  
; EARLIER APPLICATION NUMBER: PCT/US97/12955  
; EARLIER FILING DATE: 1998-03-31  
; NUMBER OF SEQ ID NOS: 51  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 17  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: synthetic  
US-09-282-147-17

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 450 GAATCAGCTGTGATGC 465  
Db 3 GAATCAGCTGTGATGC 18

RESULT 84  
US-09-696-791-4229/c  
; Sequence 4229, Application US/09696791  
; Patent No. 6770633  
; GENERAL INFORMATION:  
; APPLICANT: Robbins, Joan M.  
; APPLICANT: Tritz, Richard  
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE  
; TITLE OF INVENTION: SKIN AND EYE DISEASES  
; FILE REFERENCE: 480124.407  
; CURRENT APPLICATION NUMBER: US/09/696,791  
; CURRENT FILING DATE: 2000-10-25  
; NUMBER OF SEQ ID NOS: 4523  
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 4229  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: Hammerhead ribozyme recognition site for cdc 2 kinase  
US-09-696-791-4229

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1376 ATCAAGTATTCTTC 1391  
Db 16 ATCAAGTATTCTTC 1

RESULT 85  
US-09-696-791-3052/c  
; Sequence 3052, Application US/09696791  
; Patent No. 6770633  
; GENERAL INFORMATION:  
; APPLICANT: Robbins, Joan M.  
; APPLICANT: Tritz, Richard  
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE  
; TITLE OF INVENTION: SKIN AND EYE DISEASES  
; FILE REFERENCE: 480124.407  
; CURRENT APPLICATION NUMBER: US/09/696,791  
; CURRENT FILING DATE: 2000-10-25  
; NUMBER OF SEQ ID NOS: 4523  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 3052  
; LENGTH: 19  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; OTHER INFORMATION: Cyclin A1 ribozyme binding site  
US-09-696-791-3052

Query Match 0.8%; Score 14.4; DB 1; Length 19;  
Best Local Similarity 93.8%; Pred. No. 1.2e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 433 ACTGGGAGAGGGGAGA 448  
Db 17 ACTGGGAGAGGGGAGA 2

RESULT 86  
US-08-609-572-5/c  
; Sequence 5, Application US/08609572  
; Patent No. 5710023  
; GENERAL INFORMATION:  
; APPLICANT: Collins, Mary  
; APPLICANT: Donaldson, Debra  
; APPLICANT: Fitz, Lori  
; APPLICANT: Neben, Tamlyn  
; APPLICANT: Whitters, Matthew  
; APPLICANT: Wood, Clive  
; TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN  
; NUMBER OF SEQUENCES: 9  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genetics Institute, Inc.  
; STREET: 87 CambridgePark Drive  
; CITY: Cambridge  
; STATE: MA  
; COUNTRY: USA  
; ZIP: 02140  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/609,572
; FILING DATE:
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-609-572-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTGGAGYSM 1

RESULT 87
US-08-841-751-5/c
; Sequence 5, Application US/08841751
; Patent No. 6214559
; GENERAL INFORMATION:
; APPLICANT: Collins, Mary
; APPLICANT: Donaldson, Debra
; APPLICANT: Fitz, Lori
; APPLICANT: Neben, Tamlyn
; APPLICANT: Whitters, Matthew
; APPLICANT: Wood, Clive
; TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/841,751
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/609,572
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-841-751-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTGGAGYSM 1

RESULT 88
US-08-846-340-5/c
; Sequence 5, Application US/08846340
; Patent No. 6248714
; GENERAL INFORMATION:
; APPLICANT: Collins, Mary
; APPLICANT: Donaldson, Debra
; APPLICANT: Fitz, Lori
; APPLICANT: Neben, Tamlyn
; APPLICANT: Whitters, Matthew
; APPLICANT: Wood, Clive
; TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/846,340
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/609,572
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-846-340-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTGGAGYSM 1

RESULT 89
US-08-846-344-5/c
; Sequence 5, Application US/08846344
```

```
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-841-751-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTGGAGYSM 1

RESULT 88
US-08-846-340-5/c
; Sequence 5, Application US/08846340
; Patent No. 6248714
; GENERAL INFORMATION:
; APPLICANT: Collins, Mary
; APPLICANT: Donaldson, Debra
; APPLICANT: Fitz, Lori
; APPLICANT: Neben, Tamlyn
; APPLICANT: Whitters, Matthew
; APPLICANT: Wood, Clive
; TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genetics Institute, Inc.
; STREET: 87 CambridgePark Drive
; CITY: Cambridge
; STATE: MA
; COUNTRY: USA
; ZIP: 02140
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/846,340
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/609,572
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: G15268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 498-8224
; TELEFAX: (617) 876-5851
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
US-08-846-340-5

Query Match      0.8%; Score 14.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.1e+02;
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359
Db 17 TGGAGYGMVTGGAGYSM 1

RESULT 89
US-08-846-344-5/c
; Sequence 5, Application US/08846344
```

Patent No. 6268480  
GENERAL INFORMATION:  
APPLICANT: Collins, Mary  
APPLICANT: Donaldson, Debra  
APPLICANT: Fitz, Lori  
APPLICANT: Neben, Tamlyn  
APPLICANT: Whitters, Matthew  
APPLICANT: Wood, Clive  
TITLE OF INVENTION: CYTOKINE RECEPTOR CHAIN  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Genetics Institute, Inc.  
STREET: 87 CambridgePark Drive  
CITY: Cambridge  
STATE: MA  
COUNTRY: USA  
ZIP: 02140  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/846.344  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION NUMBER: 08/609,572  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Brown, Scott A.  
REGISTRATION NUMBER: 32,724  
REFERENCE/DOCKET NUMBER: G15268  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617) 498-8224  
TELEFAX: (617) 876-5851  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: oligonucleotide  
US-08-846-344-5

Query Match 0.8%; Score 14.2; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.1e+02;  
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359  
Db 17 TGGAGYGMVTTGGAGYSM 1

RESULT 90  
US-09-301-808-5/c  
Sequence 5, Application US/09301808  
Patent No. 6664227  
GENERAL INFORMATION:  
APPLICANT: Wynn, Thomas  
APPLICANT: Chiaramonte, Monica  
APPLICANT: Collins, Mary  
APPLICANT: Donaldson, Debra  
APPLICANT: Fitz, Lori  
APPLICANT: Neben, Tamlyn  
APPLICANT: Whitters, Matthew  
APPLICANT: Wood, Clive  
TITLE OF INVENTION: TREATMENT OF FIBROSIS BY ANTAGONISM OF IL-13  
NUMBER OF SEQUENCES: 9  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Genetics Institute, Inc.  
STREET: 87 CambridgePark Drive

CITY: Cambridge  
STATE: MA  
COUNTRY: USA  
ZIP: 02140  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/301,808  
FILING DATE:  
CLASSIFICATION:  
ATTORNEY/AGENT INFORMATION:  
NAME: Brown, Scott A.  
REGISTRATION NUMBER: 32,724  
REFERENCE/DOCKET NUMBER: G15268A2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617) 498-8224  
TELEFAX: (617) 876-5851  
INFORMATION FOR SEQ ID NO: 5:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: oligonucleotide  
US-09-301-808-5

Query Match 0.8%; Score 14.2; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.1e+02;  
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGCCA 1359  
Db 17 TGGAGYGMVTTGGAGYSM 1

RESULT 91  
US-09-859-736-7/c  
Sequence 7, Application US/09859736  
Patent No. 6838244  
GENERAL INFORMATION:  
APPLICANT: LI, WAN-LIANG ROBERT  
APPLICANT: ZHOU, JIAN S.  
TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF  
FILE REFERENCE: 18517.248  
CURRENT APPLICATION NUMBER: US/09/859,736  
CURRENT FILING DATE: 2001-05-18  
PRIOR APPLICATION NUMBER: 60/205,452  
PRIOR FILING DATE: 2000-05-19  
NUMBER OF SEQ ID NOS: 7  
SOFTWARE: Patent in Ver. 2.1  
SEQ ID NO 7  
LENGTH: 14  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
OTHER INFORMATION: dt oligonucleotide  
US-09-859-736-7

Query Match 0.8%; Score 14; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 87;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1848  
Db 14 AAAAAAAAAAAAAA 1

RESULT 92  
US-09-491-356C-19/c

```
; Sequence 19, Application US/09491356C
; Patent No. 6566061
; GENERAL INFORMATION:
; APPLICANT: Philibert, Robert A.
; APPLICANT: Ginns, Edward I.
; APPLICANT: Delisi, Lynn
; TITLE OF INVENTION: IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF XQ13
; FILE REFERENCE: 9465.6US11
; CURRENT APPLICATION NUMBER: US/09/491,356C
; CURRENT FILING DATE: 2000-01-26
; PRIOR APPLICATION NUMBER: PCT/US99/09365
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 60/083,465
; PRIOR FILING DATE: 1998-04-29
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 19
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-491-356C-19

Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
Db 14 TGTGCTGCTGCTG 1

RESULT 93
US-09-866-108A-2590
; Sequence 2590, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2591

Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
Db 14 TGTGCTGCTGCTG 1

RESULT 94
US-09-866-108A-2591
; Sequence 2591, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2591
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2591

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003
Db 4 CAGGGTGCCATGGA 17

RESULT 95
US-09-866-108A-2592
; Sequence 2592, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: Philibert, Robert A.
; APPLICANT: Ginns, Edward I.
; APPLICANT: Delisi, Lynn
; TITLE OF INVENTION: IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF XQ13
; FILE REFERENCE: 9465.6US11
; CURRENT APPLICATION NUMBER: US/09/491,356C
; CURRENT FILING DATE: 2000-01-26
; PRIOR APPLICATION NUMBER: PCT/US99/09365
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 60/083,465
; PRIOR FILING DATE: 1998-04-29
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 19
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-491-356C-19

Query Match      0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 98;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458
Db 14 TGTGCTGCTGCTG 1

RESULT 93
US-09-866-108A-2590
; Sequence 2590, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2590
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2591

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003
Db 3 CAGGGTGCCATGGA 16

RESULT 95
US-09-866-108A-2592
; Sequence 2592, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```



APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
PRIORITY FILING DATE: 2001-05-25  
PRIORITY FILING DATE: US 60/207,456  
PRIORITY FILING DATE: 2000-05-26  
PRIORITY FILING DATE: GB 24263.6  
PRIORITY FILING DATE: 2000-10-04  
PRIORITY FILING DATE: US 60/236,359  
PRIORITY FILING DATE: 2000-09-27  
PRIORITY FILING DATE: PCT/US01/00666  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY FILING DATE: PCT/US01/00667  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY FILING DATE: PCT/US01/00664  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY FILING DATE: PCT/US01/00669  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY FILING DATE: PCT/US01/00665  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY FILING DATE: PCT/US01/00668  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY FILING DATE: PCT/US01/00663  
PRIORITY FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecmica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 2592  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-2592

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGTCGCATGGA 1003  
|||||

Db 2 CAGGTCGCATGGA 15  
|||||

RESULT 96  
US-09-866-108A-2593  
Sequence 2593, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AECMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
PRIORITY FILING DATE: 2001-05-25  
PRIORITY FILING DATE: US 60/207,456  
PRIORITY FILING DATE: 2000-05-26  
PRIORITY FILING DATE: GB 24263.6  
PRIORITY FILING DATE: 2000-10-04  
PRIORITY FILING DATE: US 60/236,359  
PRIORITY FILING DATE: 2000-09-27  
PRIORITY FILING DATE: PCT/US01/00666

PRIORITY FILING DATE: 2001-01-30  
PRIORITY APPLICATION NUMBER: PCT/US01/00667  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY APPLICATION NUMBER: PCT/US01/00664  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY APPLICATION NUMBER: PCT/US01/00669  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY APPLICATION NUMBER: PCT/US01/00665  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY APPLICATION NUMBER: PCT/US01/00668  
PRIORITY FILING DATE: 2001-01-30  
PRIORITY APPLICATION NUMBER: PCT/US01/00663  
PRIORITY FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecmica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 2593  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-2593

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGTCGCATGGA 1003  
|||||

Db 1 CAGGTCGCATGGA 14  
|||||

RESULT 97  
US-09-685-664B-1072/C  
Sequence 1072, Application US/09685664B  
Patent No. 6818447  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pam  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
FILE REFERENCE: MEHB00-876-K (400/021)  
CURRENT APPLICATION NUMBER: US/09/685,664B  
PRIORITY FILING DATE: 2000-10-10  
PRIORITY APPLICATION NUMBER: US 60/005,974  
PRIORITY FILING DATE: 1995-10-26  
PRIORITY APPLICATION NUMBER: US 08/584,040  
PRIORITY FILING DATE: 1996-01-08  
PRIORITY APPLICATION NUMBER: US 09/371,772  
PRIORITY FILING DATE: 1999-08-10  
NUMBER OF SEQ ID NOS: 8231  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1072  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-685-664B-1072

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1848  
|||||

Db 17 AAAAAAAAAAAAAA 4  
|||||

RESULT 98  
US-08-143-219-10  
Sequence 10, Application US/08143219

Patent No. 5670330  
GENERAL INFORMATION:  
APPLICANT: Sonenberg, Nahum  
APPLICANT: Katze, Michael G.  
APPLICANT: Roy, Sophie  
APPLICANT: Koromilas, Antonis E.  
APPLICANT: Barber, Glen N.  
TITLE OF INVENTION: TUMOR-CELL ASSAY METHOD AND KIT  
NUMBER OF SEQUENCES: 27  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 611 West Sixth Street  
CITY: Los Angeles  
STATE: CA  
COUNTRY: USA  
ZIP: 90017  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM compatible  
OPERATING SYSTEM: PC-DOS (Version 5.0)  
SOFTWARE: WordPerfect (Version 5.1)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/143,219  
FILING DATE: October 25, 1993  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
PRIOR APPLICATION DATA: including application  
PRIOR APPLICATION DATA: described below:  
APPLICATION NUMBER: 08/141,244  
FILING DATE: October 22, 1993  
APPLICATION NUMBER: 07/953,681  
FILING DATE: September 29, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Douglas E. Olson  
REGISTRATION NUMBER: 22,798  
REFERENCE/DOCKET NUMBER: 204/139  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 10:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
HYPOTHETICAL: NO  
ORIGINAL SOURCE:  
INDIVIDUAL ISOLATE: COMPLEMENTARY SEQUENCE TO R8 PRIMER,  
INDIVIDUAL ISOLATE: FIGURE 5  
US-08-143-219-10

Query Match 0.8%; Score 14; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 272 AGCCGAGAACAGAT 285  
Db 1 AGCCGAGAACAGAT 14

RESULT 99  
US-10-271-065-1  
Sequence 1, Application US/10271065  
Patent No. 6759580  
GENERAL INFORMATION:  
APPLICANT: Charles Thomas Cunningham  
TITLE OF INVENTION: Inbred Maize Line PH87H  
FILE REFERENCE: 1467  
CURRENT APPLICATION NUMBER: US/10/271.065  
CURRENT FILING DATE: 2002-10-15  
PRIOR APPLICATION NUMBER: US 60/352,291

PRIOR FILING DATE: 2002-01-28  
NUMBER OF SEQ ID NOS: 4  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 1  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Lprimer for PH1279122  
US-10-271-065-1  
Query Match 0.8%; Score 14; DB 1; Length 18;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1084 GGCTGGTCTCTGG 1097  
Db 4 GGCTGGTCTCTGG 17  
RESULT 100  
US-08-985-162-431  
Sequence 431, Application US/08985162  
Patent No. 6057156  
GENERAL INFORMATION:  
APPLICANT: Akhtar, Saghir  
APPLICANT: Fell, Patricia  
APPLICANT: McSwiggen, James  
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT  
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
TITLE OF INVENTION: FACTOR RECEPTORS  
NUMBER OF SEQUENCES: 1877  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq for Windows 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/985,162  
FILING DATE: 04 December 1997  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/036,476  
FILING DATE: 31 January 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 230/107  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 431:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-985-162-431  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.3e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

QY 174 AATGGCATCTCTTAAGAG 190
Db 1 AAUGGCAUCUUUAGGG 17

RESULT 101
US-08-987-574-46/c
; Sequence 46, Application US/08987574
; Patent No. 6150339
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Pennewald, Susan
; APPLICANT: Zendegui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/987,574
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/651-5151
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-987-574-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCCTCCCTCCACCAC 1721
Db 17 CCCACCCACCACCAC 1

RESULT 102
US-08-535-168-46/c
; Sequence 46, Application US/08535168
; Patent No. 6184369
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Pennewald, Susan

```

```

; APPLICANT: Zendegui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,168
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/651-5151
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-535-168-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCCTCCCTCCACCAC 1721
Db 17 CCCACCCACCACCAC 1

RESULT 103
US-09-017-974-46/c
; Sequence 46, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cosum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912

```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-09-017-974-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCTCCCTCCACCAC 1721
Db 17 CCCACCACCACCAC 1

RESULT 104
US-08-682-255A-46/c
; Sequence 46, Application US/08682255A
; Patent No. 632185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-682-255A-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCTCCCTCCACCAC 1721
Db 17 CCCACCACCACCAC 1

RESULT 105
US-08-584-040-4164
; Sequence 4164, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.

```

REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 4164:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-4164

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.3e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAAC 1583  
Db 1 CUGCAAAUUGGAAACC 17

RESULT 106

US-08-584-040-4165  
; Sequence 4165, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 4165:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

US-08-584-040-4164

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.3e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAAC 1583  
Db 1 CUGCAAAUUGGAAACC 17

RESULT 107

US-08-584-040-4250/c  
; Sequence 4250, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 4250:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

US-08-584-040-4250

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTCCAA 1165  
Db 17 AAGTAAATATTTCCCA 1

RESULT 108

US-08-584-040-4165

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.3e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCACCTTTGGAAACT 1584  
Db 1 UGCAAAUUGGAAACCU 17

RESULT 107

US-08-584-040-4250/c  
; Sequence 4250, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 4250:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

US-08-584-040-4250

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTCCAA 1165  
Db 17 AAGTAAATATTTCCCA 1

RESULT 108

```
US-08-584-040-5734
; Sequence 5734, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5734:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5735
; Query Match 0.7%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 64.7%; Pred. No. 1.3e+02;
; Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTCGAACCTTGGAAAC 1583
Db 1 CUGCAAGUUGGAAC 17

RESULT 109
US-08-584-040-5735
; Sequence 5735, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

US-08-584-040-5734
; Sequence 5734, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5734:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-5735
; Query Match 0.7%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 64.7%; Pred. No. 1.3e+02;
; Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTCGAACCTTGGAAAC 1583
Db 1 CUGCAAGUUGGAAC 17

RESULT 110
US-08-584-040-5820/C
; Sequence 5820, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
```

MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 5820:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-5820

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTCCAA 1165  
Db 17 AAGGAAATATTCCCA 1

RESULT 111  
US-08-584-040-7818/c  
Sequence 7818, Application US/08584040  
Patent No. 6346398  
GENERAL INFORMATION:  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: TREATMENT OF DISEASES OR  
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
NUMBER OF SEQUENCES: 8502  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 7818:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-584-040-7818

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAA 1851  
Db 17 AACAAAAAACAAAAAA 1

RESULT 112  
US-08-584-040-7819/c  
Sequence 7819, Application US/08584040  
Patent No. 6346398  
GENERAL INFORMATION:  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
TITLE OF INVENTION: TREATMENT OF DISEASES OR  
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
NUMBER OF SEQUENCES: 8502  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
STREET: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/584,040  
FILING DATE: January 11, 1996  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/005,974  
FILING DATE: October 26, 1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 218/064  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 7819:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single

```
;
; TOPOLOGY: linear
; US-08-584-040-7819

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAAAAAAAAACAAAAA 1

RESULT 113
US-09-429-130-46/c
; Sequence 46, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; Fennewald, Susan
; Zendequi, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pommier, Eyves
; Mazumder, Abhijit
; 60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/429,130
; FILING DATE: 28-Oct-1999
; CLASSIFICATION: <Unknown>
; 19-JULY-95
; 25-MARCH-96
; 19-MARCH-96
; 17-APRIL-96
; 23-APRIL-96
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/682,255
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 46:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
```

```
;
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 46:
; US-09-429-130-46

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCCTCCCTCCACCAC 1721
Db 17 CCCCAACCCACCACCAC 1

RESULT 114
US-09-371-772B-1931
; Sequence 1931, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH800.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1931
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-1931

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTCGCACTTTGGAAAC 1583
Db 1 CUGCAAAUUUGGAACC 17

RESULT 115
US-09-371-772B-1932
; Sequence 1932, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBH800.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1932
; LENGTH: 17
; TYPE: RNA
;
```



; ORGANISM: Homo sapiens  
US-09-371-772B-1932

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.3e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
Qy 1568 TGCACACTTTGGAAACT 1584  
:||||:|||||:  
Db 1 UGCAAAUUGGAAACC 17

## RESULT 116

US-09-371-772B-2017/c  
; Sequence 2017, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2017  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-2017

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1149 AAGTAATATTTCCTCA 1165  
:||||:|||||:  
Db 17 AAGGAATATTTCCTCA 1

## RESULT 117

US-09-371-772B-2613  
; Sequence 2613, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2613  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.

US-09-371-772B-2613

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.3e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
Qy 1567 CTGCAACTTTGGAAAC 1583  
:||||:|||||:  
Db 1 CUGCAAGUUGGAAACC 17

## RESULT 118

US-09-371-772B-2614  
; Sequence 2614, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2614  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-2614

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.3e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
Qy 1568 TGCACACTTTGGAAACT 1584  
:||||:|||||:  
Db 1 UGCAAGUUGGAAACC 17

## RESULT 119

US-09-371-772B-3602/c  
; Sequence 3602, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3602  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-3602

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
||| ||||| |||||  
Db 17 AAAAAAAAAACAAAAA 1

RESULT 120  
US-09-371-772B-3603/c  
; Sequence 3603, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 3603  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-3603

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
||| ||||| |||||  
Db 17 AAAAAAAAAACAAAAA 1

RESULT 121  
US-09-371-772B-6261/c  
; Sequence 6261, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 6261  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-6261

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1470 GTTCTTATGTTGTC 1486  
||| ||||| |||||  
Db 17 GTTCTTATGTCGATGC 1

RESULT 122  
US-09-401-063-431  
; Sequence 431, Application US/09401063  
; Patent No. 6623962  
; GENERAL INFORMATION:  
; APPLICANT: Akhtar, Saghir  
; APPLICANT: Fell, Patricia  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT  
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
; NUMBER OF SEQUENCES: 1877  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSEQ for Windows 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/401,063  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION NUMBER: 08/985,162  
; FILING DATE: 04 December 1997  
; APPLICATION NUMBER: 60/036,476  
; FILING DATE: 31 January 1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 230/107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 431:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-09-401-063-431

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.3e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 174 AATGCATCTCTAAGAG 190  
||:||||:|:  
Db 1 A AUGGCAUCUUUAGGG 17

RESULT 123  
US-09-866-108A-1536  
; Sequence 1536, Application US/09866108A

```
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1536

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1081 TCGGCTGGTGTCTGG 1097
Db 1 TGGGCTGGTGTCTGG 17

RESULT 124
US-09-866-108A-1537
; Sequence 1537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1536

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1081 TCGGCTGGTGTCTGG 1097
Db 1 TGGGCTGGTGTCTGG 17

RESULT 124
US-09-866-108A-1537
; Sequence 1537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
```

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1537

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1082 GCGGCTGGTGTCTGGA 1098
Db 1 GGGGCTGGTGTCTGGA 17

RESULT 125
US-09-866-108A-8360
; Sequence 8360, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
```

; Patent No. 6686188  
; SEQ ID NO 8360  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-8360

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 GATGGCTGGAGAAAGT 406  
||| ||||| ||||| |||||  
Db 1 GAGGAGCTGGAGAAAGT 17

## RESULT 126

US-09-866-108A-8363  
; Sequence 8363, Application US/09866108A  
; Patent No. 6686188

; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 8363

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-8363

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 393 GGGCTGGAGAAAGTTCA 409  
||| ||||| ||||| |||||  
Db 1 GAGCTGGAGAAAGTGCA 17

## RESULT 127

US-09-866-108A-9572/c

; Sequence 9572, Application US/09866108A  
; Patent No. 6686188

; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US/09/866,108A

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 15755

; SOFTWARE: Aecomica Sequence Listing Engine

; Patent No. 6686188

; SEQ ID NO 9572

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108A-9572

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTGCACAGCTGGGATGT 985  
||| ||||| ||||| |||||  
Db 17 CTCGACAGCGGGATGT 1

## RESULT 128

US-09-685-664B-1079/c

; Sequence 1079, Application US/09685664B

; Patent No. 6818447

; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related

; FILE REFERENCE: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH900-876-K (400/021)

; CURRENT APPLICATION NUMBER: US/09/685,664B

; CURRENT FILING DATE: 2000-10-10

; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040

; PRIOR FILING DATE: 1996-01-08

; PRIOR APPLICATION NUMBER: US 09/371,772

; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1079  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-1079

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1831 TCTGAAAAAATAAAAA 1847  
||| ||||| |||||  
Db 17 TTTGAAAAAATAAAAAA 1

## RESULT 129

US-09-685-664B-1931  
; Sequence 1931, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1931  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-1931

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.3e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTGGAAC 1583  
||| ||||| |||||  
Db 1 CUGCAAAUUUGGAAC 17

## RESULT 130

US-09-685-664B-1932  
; Sequence 1932, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26

; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1932  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-1932

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.3e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 1568 TGCACCTTTGAAACT 1584  
:||| ||||| |||||  
Db 1 UGCAAAUUUGGAACCU 17

## RESULT 131

US-09-685-664B-2017/c  
; Sequence 2017, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 2017  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-2017

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTCCAA 1165  
||| ||||| |||||  
Db 17 AAGGAAATATTTCCCA 1

## RESULT 132

US-09-685-664B-2613  
; Sequence 2613, Application US/09685664B  
; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBHB00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B

```
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2613
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2613

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.3e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583
Db 1 CUGCAAGUUGGAAACC 17

RESULT 133
US-09-685-664B-2614
; Sequence 2614, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2614

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 1.3e+02;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCAACTTTGGAAACT 1584
Db 1 UGCAAGUUGGAAACCU 17

RESULT 134
US-09-685-664B-3602/c
; Sequence 3602, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
```

```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3602
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3602

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAACAAACAAACAAAAA 1

RESULT 135
US-09-685-664B-3603/c
; Sequence 3603, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3603
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3603

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 17 AAACAAACAAACAAAAA 1

RESULT 136
PCT-US96-11786-46/c
; Sequence 46, Application PC/TUS9611786
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
```

APPLICANT: Hogan, Michael E.  
APPLICANT: Pommer, Yves  
APPLICANT: Mazunder, Abhijit  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Oligonucleotides  
NUMBER OF SEQUENCES: 52  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1850  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/11786  
FILING DATE: 17-JULY-1996  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;  
APPLICATION NUMBER: 60/015,714; 60/016,271  
FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-  
FILING DATE: APRIL-96; 17-APRIL-96  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06214  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 46:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
PCT-US96-11786-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACCAC 1721  
Db 17 CCCACCACCCACCAC 1

RESULT 137  
US-08-050-232-12  
Sequence 12, Application US/08050232  
Patent No. 5525492  
GENERAL INFORMATION:  
APPLICANT:  
TITLE OF INVENTION: Process for Amplifying Nucleic Acid  
NUMBER OF SEQUENCES: 14  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Marks & Murase  
STREET: 2001 L Street, N.W., Suite 750  
CITY: Washington  
STATE: D.C.  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS-DOS  
SOFTWARE: Wordstar  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/050,232  
FILING DATE: 14-MAY-1993

APPLICANT: Hogan, Michael E.  
APPLICANT: Pommer, Yves  
APPLICANT: Mazunder, Abhijit  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Oligonucleotides  
NUMBER OF SEQUENCES: 52  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1850  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/11786  
FILING DATE: 17-JULY-1996  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;  
APPLICATION NUMBER: 60/015,714; 60/016,271  
FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-  
FILING DATE: APRIL-96; 17-APRIL-96  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06214  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 46:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
PCT-US96-11786-46

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACCAC 1721  
Db 17 CCCACCACCCACCAC 1

RESULT 137  
US-08-050-232-12  
Sequence 12, Application US/08050232  
Patent No. 5525492  
GENERAL INFORMATION:  
APPLICANT:  
TITLE OF INVENTION: Process for Amplifying Nucleic Acid  
NUMBER OF SEQUENCES: 14  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Marks & Murase  
STREET: 2001 L Street, N.W., Suite 750  
CITY: Washington  
STATE: D.C.  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS-DOS  
SOFTWARE: Wordstar  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/050,232  
FILING DATE: 14-MAY-1993

CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9024005.2  
FILING DATE: 05-NOV-1990  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: WO PCT/GB91/01935  
FILING DATE: 05-NOV-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Michael D. Bednarek  
REGISTRATION NUMBER: 32,329  
REFERENCE/DOCKET NUMBER: SH-PCT-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-955-4900  
TELEFAX: 202-955-4932  
TELEX: 248749  
INFORMATION FOR SEQ ID NO: 12:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 1..18  
US-08-050-232-12

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 504 GGCAGCAGCATTGGGAC 520  
Db 2 GGCAGCAGCATTGGGAC 18

RESULT 138  
US-08-661-767-12  
Sequence 12, Application US/08661767  
Patent No. 5824515  
GENERAL INFORMATION:  
APPLICANT: Adrian Vivian Sinton HILL  
TITLE OF INVENTION: Process for Amplifying Nucleic Acid  
NUMBER OF SEQUENCES: 14  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: WENDEROOTH, LIND & PONACK  
STREET: 805 Fifteenth Street, Suite 700  
CITY: Washington  
STATE: D.C.  
COUNTRY: U.S.A.  
ZIP: 20005  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette, 3.5 inch, 1.44 mb  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS-DOS  
SOFTWARE: Wordperfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/661,767  
FILING DATE: June 11, 1996  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9024005.2  
FILING DATE: 05-NOV-1990  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: WO PCT/GB91/01935  
FILING DATE: 05-NOV-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Warren M. Cheek, Jr.  
REGISTRATION NUMBER: 33,367  
REFERENCE/DOCKET NUMBER: 263/KPM1540US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 202-371-8850  
TELEFAX: 202-371-8856

```
;
; TELEX:
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; US-08-661-767-12

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 504 GGCAGCAGCATTTGGGAC 520
Db 2 GCGCGAGCATTTGGGAC 18

RESULT 139
US-08-468-580-17/c
; Sequence 17, Application US/08468580
; Patent No. 5824642
; GENERAL INFORMATION:
; APPLICANT: Attie, Kenneth
; APPLICANT: Carlsson, Lena
; APPLICANT: Gesundheit, Neil
; APPLICANT: Goddard, Audrey
; TITLE OF INVENTION: Treatment of Partial Growth Hormone Insensitivity Syndrome
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/468,580
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/410452
; FILING DATE: 24-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/224982
; FILING DATE: 07-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Hasak, Janet E.
; REGISTRATION NUMBER: 28,616
; REFERENCE/DOCKET NUMBER: P0884P1C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1896
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-468-580-17

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 264 TATGTTAAAGCCCGAGAA 280
Db 17 TAAGGTTAAAGCCCGAGCA 1

RESULT 140
US-08-384-324-2/c
; Sequence 2, Application US/08384324
; Patent No. 5844110
; GENERAL INFORMATION:
; APPLICANT: Gold, Barry I.
; TITLE OF INVENTION: Synthetic Triple Helix-Forming Compounds
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dann, Dorfman, Herrell and Skillman
; STREET: 1601 Market Street, Suite 720
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/384,324
; FILING DATE: 31-JAN-1995
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Reed, Janet E.
; REGISTRATION NUMBER: 36,252
; REFERENCE/DOCKET NUMBER: 63076
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 563-4100
; TELEFAX: (215) 563-4044
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: not relevant
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: YES
; ANTI-SENSE: YES
; US-08-384-324-2

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1834 GAAAAAAGAAAAA 1850
Db 17 GAAAAAAGAAAAA 1

RESULT 141
US-08-244-597-14
; Sequence 14, Application US/08244597
; Patent No. 585793
; GENERAL INFORMATION:
; APPLICANT: Griffiths, Andrew David
; APPLICANT: Hoogenboom, Hendricus RJM
; APPLICANT: Marks, James David
; APPLICANT: McCafferty, John
; APPLICANT: Winter, Gregory Paul
; APPLICANT: Grigg, Geoffrey Walter
; TITLE OF INVENTION: Production of anti-self antibodies from
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
```



ADDRESSEE: David W. Clough  
STREET: Marshall, O'Toole, Gerstein, Murray & Borun  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60606-6402  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.25 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/244,597  
FILING DATE: 01-JUN-1994  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9125579.4  
FILING DATE: 02-DEC-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9125582.8  
FILING DATE: 02-DEC-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9206318.9  
FILING DATE: 24-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9206372.6  
FILING DATE: 24-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/GB92/01755  
FILING DATE: 23-SEP-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Clough, David W  
REGISTRATION NUMBER: 36,107  
REFERENCE/DOCKET NUMBER: 28111/32094  
TELEPHONE: 312-474-6300  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-244-597-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGGTGGAGA 811  
|||||  
Db 2 TGTATTACTGTGCAAGA 18

RESULT 142  
US-08-389-423-31  
Sequence 31, Application US/08389423  
Patent No. 5948672  
GENERAL INFORMATION:  
APPLICANT: Rasmussen, Grethe  
APPLICANT: Mikkelsen, Jan Moller  
APPLICANT: Schuelein, Martin  
APPLICANT: Patkar, Shankant A.  
APPLICANT: Hagen, Fred  
TITLE OF INVENTION: A Cellulase Preparation Comprising an  
TITLE OF INVENTION: Endoglucanase Enzyme  
NUMBER OF SEQUENCES: 33  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: No. 5948672 of No. 5948672 disk of No. 5948672th America, Inc.  
STREET: 405 Lexington Avenue, 64th Floor  
CITY: New York  
STATE: New York

COUNTRY: United States of America  
ZIP: 10174-6401  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/389,423  
FILING DATE: 14-FEB-1995  
CLASSIFICATION: 435  
ATTORNEY/AGENT INFORMATION:  
NAME: Lamdiris, Elias J.  
REGISTRATION NUMBER: 33,728  
REFERENCE/DOCKET NUMBER: 3469.214-US  
TELEPHONE: 212-867-0123  
TELEFAX: 212-878-9655  
INFORMATION FOR SEQ ID NO: 31:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-389-423-31

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 633 AACTACTCAAGGACGGT 649  
|||||  
Db 1 AGCTTCTCAAGGACGGT 17

RESULT 143  
US-09-205-860-46  
Sequence 46, Application US/09205860  
Patent No. 5981732  
GENERAL INFORMATION:  
APPLICANT: Lex M. Cowsert  
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION  
FILE REFERENCE: RTS-0031  
CURRENT APPLICATION NUMBER: US/09/205,860  
CURRENT FILING DATE: 1998-12-04  
NUMBER OF SEQ ID NOS: 87  
SEQ ID NO 46  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-09-205-860-46

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1778 AAAAACATTCTTTCCAC 1794  
|||||  
Db 2 AAAACCTTGTTCAC 18

RESULT 144  
US-08-857-946-14/c  
Sequence 14, Application US/08857946  
Patent No. 5994075  
GENERAL INFORMATION:  
APPLICANT: Goodfellow, P.N.  
TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A  
TITLE OF INVENTION: GENE OF INTEREST  
NUMBER OF SEQUENCES: 162

```
;
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 75 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1807
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/857,946
; FILING DATE: 16-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/60/017,824
; FILING DATE: 17-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/05573
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-345-9100
; TELEFAX: 617-345-9111
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-857-946-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGC 44
Db 17 GCCGCCGCCGCCGCCGC 1

RESULT 145
US-08-970-740-14/c
; Sequence 14, Application US/08970740
; Patent No. 6015670
; GENERAL INFORMATION:
; APPLICANT: Goodfellow, P. N.
; TITLE OF INVENTION: METHODS FOR IDENTIFYING A MUTATION IN A
; TITLE OF INVENTION: GENE OF INTEREST
; NUMBER OF SEQUENCES: 162
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: 28 State Street, 28th Floor
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/970,740
; FILING DATE: 14-NOV-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/857,946
; FILING DATE: 16-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/017,824
```

```
;
; FILING DATE: 17-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 3529/59829
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-227-7111
; TELEFAX: 617-227-4399
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-970-740-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGC 44
Db 17 GCCGCCGCCGCCGCCGC 1

RESULT 146
US-09-487-444-45
; Sequence 45, Application US/09487444
; Patent No. 6159697
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
; FILE REFERENCE: RTS-0133
; CURRENT APPLICATION NUMBER: US/09/487,444
; CURRENT FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 45
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-487-444-45

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 196 TTGAAGAAATAAAGAA 212
Db 2 TAGAAGAAATAAAGAA 18

RESULT 147
US-09-189-028-31
; Sequence 31, Application US/09189028
; Patent No. 6423524
; GENERAL INFORMATION:
; APPLICANT: Rasmussen, Grethe
; APPLICANT: Mikkelsen, Jan Moller
; APPLICANT: Schulein, Martin
; APPLICANT: Patkar, Shankant A.
; APPLICANT: Hagen, Fred
; TITLE OF INVENTION: A Cellulase Preparation Comprising an
; TITLE OF INVENTION: Endoglucanase Enzyme
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 6423524o No. 6423524disk of No. 6423524th America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
```

COUNTRY: United States of America  
ZIP: 10174-6401  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/189,028  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/389,423  
FILING DATE: 14-FEB-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Lambiris, Elias J.  
REGISTRATION NUMBER: 33,728  
REFERENCE/DOCKET NUMBER: 3469,214-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0123  
TELEFAX: 212-878-9655  
INFORMATION FOR SEQ ID NO: 31:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cdNA  
US-09-189-028-31

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 633 AACTACTCAAGGACGGT 649  
Db 1 AGCTTCTCAAGGACGGT 17

RESULT 148  
US-09-197-224-14  
Sequence 14, Application US/09197224  
Patent No. 6521404  
GENERAL INFORMATION:  
APPLICANT: Griffiths, Andrew David  
APPLICANT: Hoogenboom, Hendricus RJM  
APPLICANT: Marks, James David  
APPLICANT: McCafferty, John  
APPLICANT: Winter, Gregory Paul  
TITLE OF INVENTION: Production of anti-self antibodies from  
TITLE OF INVENTION: antibody segment repertoires and displayed on phage  
NUMBER OF SEQUENCES: 21  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: David W. Clough  
STREET: Marshall, O'Toole, Gerstein, Murray & Borun  
STREET: 6300 Sears Tower, 233 South Wacker Drive  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60606-6402  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/197,224  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/244,597  
FILING DATE: 01-JUN-1994

APPLICATION NUMBER: GB 9125579.4  
FILING DATE: 02-DEC-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9125582.8  
FILING DATE: 02-DEC-1991  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9206318.9  
FILING DATE: 24-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: GB 9206372.6  
FILING DATE: 24-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/GB92/01755  
FILING DATE: 23-SEP-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Clough, David W  
REGISTRATION NUMBER: 36,107  
REFERENCE/DOCKET NUMBER: 28111/32094  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 312-474-6300  
INFORMATION FOR SEQ ID NO: 14:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-197-224-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGTTGGAAGA 811  
Db 2 TGTATTACTGTGCAAGA 18

RESULT 149  
US-09-197-221-14  
Sequence 14, Application US/09197221  
Patent No. 6544731  
GENERAL INFORMATION:  
APPLICANT: Griffiths, Andrew David  
APPLICANT: Hoogenboom, Hendricus RJM  
APPLICANT: Marks, James David  
APPLICANT: McCafferty, John  
APPLICANT: Winter, Gregory Paul  
TITLE OF INVENTION: Production of anti-self antibodies from  
TITLE OF INVENTION: antibody segment repertoires and displayed on phage  
NUMBER OF SEQUENCES: 21  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: David W. Clough  
STREET: Marshall, O'Toole, Gerstein, Murray & Borun  
STREET: 6300 Sears Tower, 233 South Wacker Drive  
CITY: Chicago  
STATE: Illinois  
COUNTRY: USA  
ZIP: 60606-6402  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/197,221  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/244,597  
FILING DATE: 01-JUN-1994  
APPLICATION NUMBER: GB 9125579.4  
FILING DATE: 02-DEC-1991

```
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9125582.8
/ FILING DATE: 02-DEC-1991
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9206318.9
/ FILING DATE: 24-MAR-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9206372.6
/ FILING DATE: 24-MAR-1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/GB92/01755
/ FILING DATE: 23-SEP-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clough, David W
/ REGISTRATION NUMBER: 36,107
/ REFERENCE/DOCKET NUMBER: 28111/32094
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312-474-6300
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-09-197-221-14
/
/ Query Match 0.7%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 1.4e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 795 TGTATTACGGTGAAGA 811
/ Db 2 TGTATTACTGTGCAAGA 18
/
/ RESULT 150
/ US-09-572-392A-14
/ Sequence 14, Application US/09572392A
/ Patent No. 655313
/ GENERAL INFORMATION:
/ APPLICANT: Griffiths, Andrew
/ APPLICANT: Hoogenboom, Hendricus
/ APPLICANT: Marks, James
/ APPLICANT: McCafferty, John
/ APPLICANT: Winter, Gregory
/ APPLICANT: Griff99, Geoffrey
/ TITLE OF INVENTION: Production of Anti-Self Antibodies from Antibody Segment Reperto
/ FILE REFERENCE: 28111/32094A
/ CURRENT APPLICATION NUMBER: US/09572,392A
/ CURRENT FILING DATE: 2000-05-16
/ PRIOR APPLICATION NUMBER: US 09/197,224
/ PRIOR FILING DATE: 1998-11-20
/ PRIOR APPLICATION NUMBER: PCT/GB92/02240
/ PRIOR FILING DATE: 1992-12-02
/ NUMBER OF SEQ ID NOS: 21
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 14
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: oligonucleotide CDRBACK
/
/ US-09-572-392A-14
/
/ Query Match 0.7%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 1.4e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 795 TGTATTACGGTGAAGA 811
/ Db 2 TGTATTACTGTGCAAGA 18
/
/ RESULT 151
/ US-09-723-756-14
/ Sequence 14, Application US/09723756
/ Patent No. 6582915
/ GENERAL INFORMATION:
/ APPLICANT: Griffiths, Andrew David
/ APPLICANT: Hoogenboom, Hendricus RJM
/ APPLICANT: Marks, James David
/ APPLICANT: McCafferty, John
/ APPLICANT: Winter, Gregory Paul
/ APPLICANT: Griff99, Geoffrey Walter
/ TITLE OF INVENTION: Production of anti-self antibodies from
/ antibody segment repertoires and displayed on phage
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: David W. Clough
/ STREET: Marshall, O'Toole, Gerstein, Murray & Borun
/ 6300 Sears Tower, 233 South Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: USA
/ ZIP: 60606-6402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
/ CURRENT APPLICATION DATA: US/09/723,756
/ APPLICATION NUMBER: GB 9125579.4
/ FILING DATE: 02-DEC-1991
/ APPLICATION NUMBER: GB 9125582.8
/ FILING DATE: 02-DEC-1991
/ APPLICATION NUMBER: GB 9206318.9
/ FILING DATE: 24-MAR-1992
/ APPLICATION NUMBER: GB 9206372.6
/ FILING DATE: 24-MAR-1992
/ APPLICATION NUMBER: PCT/GB92/01755
/ FILING DATE: 23-SEP-1992
/ APPLICATION NUMBER: PCT/GB92/02240
/ FILING DATE: 02-DEC-1992
/ APPLICATION NUMBER: US 08/244,597
/ FILING DATE: 26-OCT-1994
/ APPLICATION NUMBER: US 09/197,224
/ FILING DATE: 20-NOV-1998
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clough, David W
/ REGISTRATION NUMBER: 36,107
/ REFERENCE/DOCKET NUMBER: 28111/32094E
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312-474-6300
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ SEQUENCE DESCRIPTION: SEQ ID NO: 14:
/
/ US-09-723-756-14
/
/ Query Match 0.7%; Score 13.8; DB 1; Length 18;
/ Best Local Similarity 88.2%; Pred. No. 1.4e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 795 TGTATTACGGTGAAGA 811
/ Db 2 TGTATTACTGTGCAAGA 18
/
/ RESULT 152
/ US-09-532-840-14
```

; Sequence 14, Application US/09532840  
; Patent No. 6593081  
; GENERAL INFORMATION:  
; APPLICANT: Griffiths, Andrew  
; APPLICANT: Hoogenboom, Hendricus  
; APPLICANT: Marks, James  
; APPLICANT: McCafferty, John  
; APPLICANT: Winter, Gregory  
; APPLICANT: Grigg, Geoffrey  
; TITLE OF INVENTION: Production of Anti-Self Antibodies from Antibody Segment Repet  
; FILE REFERENCE: 28111/32094D  
; CURRENT APPLICATION NUMBER: US/09/532,840  
; CURRENT FILING DATE: 2000-03-21  
; PRIOR APPLICATION NUMBER: US 08/244,597  
; PRIOR FILING DATE: 1994-06-01  
; PRIOR APPLICATION NUMBER: GB 9125582.8  
; PRIOR FILING DATE: 1991-12-02  
; PRIOR APPLICATION NUMBER: GB 9206318.9  
; PRIOR FILING DATE: 1992-03-24  
; PRIOR APPLICATION NUMBER: GB 9206372.6  
; PRIOR FILING DATE: 1992-03-24  
; PRIOR APPLICATION NUMBER: GB 9125579.4  
; PRIOR FILING DATE: 1991-12-02  
; PRIOR APPLICATION NUMBER: PCT/GB92/01755  
; PRIOR FILING DATE: 1992-09-23  
; NUMBER OF SEQ ID NOS: 21  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 14  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: oligonucleotide CDRBACK  
US-09-532-840-14

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGGTGGAGA 811  
Db 2 TGTATTACTGTGCAAGA 18  
|||||

RESULT 153  
US-09-747-391-9/c  
; Sequence 9, Application US/09747391  
; Patent No. 6670124  
; GENERAL INFORMATION:  
; APPLICANT: Chow, Robert  
; APPLICANT: Tonai, Richard  
; APPLICANT: StemCye, Inc.  
; TITLE OF INVENTION: High Throughput Methods of HLA Typing  
; FILE REFERENCE: 020035-000210US  
; CURRENT APPLICATION NUMBER: US/09/747,391  
; CURRENT FILING DATE: 2001-07-13  
; PRIOR APPLICATION NUMBER: US 60/172,768  
; PRIOR FILING DATE: 1999-12-20  
; NUMBER OF SEQ ID NOS: 278  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 9  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-747-391-9

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAGATGGGCTG 398  
Db 17 TGCAGCAGGGGGCTG 1  
|||||

RESULT 154  
US-09-747-391-125/c  
; Sequence 125, Application US/09747391  
; Patent No. 6670124  
; GENERAL INFORMATION:  
; APPLICANT: Chow, Robert  
; APPLICANT: Tonai, Richard  
; APPLICANT: StemCye, Inc.  
; TITLE OF INVENTION: High Throughput Methods of HLA Typing  
; FILE REFERENCE: 020035-000210US  
; CURRENT APPLICATION NUMBER: US/09/747,391  
; CURRENT FILING DATE: 2001-07-13  
; PRIOR APPLICATION NUMBER: US 60/172,768  
; PRIOR FILING DATE: 1999-12-20  
; NUMBER OF SEQ ID NOS: 278  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 125  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-747-391-125

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAGATGGGCTG 398  
Db 17 TGCAGCAGGGGGCTG 1  
|||||

RESULT 155  
US-08-983-605-93  
; Sequence 93, Application US/08983605A  
; Patent No. 6720137  
; GENERAL INFORMATION:  
; APPLICANT: Roder, Marion  
; TITLE OF INVENTION: Microsatellite Markers for plants of the Species  
; TITLE OF INVENTION: Triticum Aestivum and Tribe Triticeae and the Use of  
; FILE REFERENCE: 2936.10400  
; CURRENT APPLICATION NUMBER: US/08/983,605A  
; CURRENT FILING DATE: 1998-05-01  
; EARLIER APPLICATION NUMBER: DE 195 25 284.5  
; EARLIER FILING DATE: 1995-06-28  
; NUMBER OF SEQ ID NOS: 466  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 93  
; LENGTH: 18  
; TYPE: DNA  
; ORGANISM: Triticum aestivum  
US-08-983-605-93

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1696 AATCATTCCTCCCTCCC 1712  
Db 2 AATCATTCCTCCCTCCC 18  
|||||

RESULT 156  
US-09-500-700-68/c  
; Sequence 68, Application US/09500700  
; Patent No. 6790941  
; GENERAL INFORMATION:  
; APPLICANT: THE SCRIPPS RESEARCH INSTITUTE  
; APPLICANT: BARBAS III, Carlos F.  
; APPLICANT: GOTTESFELD, Joel M.  
; APPLICANT: WRIGHT, Peter E.  
; TITLE OF INVENTION: ZINC FINGER PROTEIN DERIVATIVES AND METHODS THEREFOR

```
; FILE REFERENCE: SCRIP1160-4
; CURRENT APPLICATION NUMBER: US/09/500,700
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: US 08/863,813
; PRIOR FILING DATE: 1997-05-27
; PRIOR APPLICATION NUMBER: US 08/676,318
; PRIOR FILING DATE: 1996-12-30
; PRIOR APPLICATION NUMBER: PCT/US95/00829
; PRIOR FILING DATE: 1995-01-18
; PRIOR APPLICATION NUMBER: US 08/312,604
; PRIOR FILING DATE: 1994-09-28
; PRIOR APPLICATION NUMBER: US 08/183,119
; PRIOR FILING DATE: 1994-01-18
; NUMBER OF SEQ ID NOS: 127
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 68
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: (GCG)6 probe
; US-09-500-700-68

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      30 CGCCTCGTCGCGCGCG 46
        ||||| |||||
Db      18 CGCGCGCGCGCGCGCG 2

RESULT 157
PCT-US93-12600-17/c
; Sequence 17, Application PC/TUS9312600
; GENERAL INFORMATION:
; APPLICANT: Denner, Larry A.
; APPLICANT: Rege, Ajay A.
; APPLICANT: Dixon, Richard A.F.
; TITLE OF INVENTION: ANTISENSE MOLECULES DIRECTED AGAINST A
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR RECEPTOR GENE FAMILY
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dressler, Goldsmith, Shore &
; ADDRESSEE: Minamow, Ltd.
; STREET: 180 North Stetson, Suite 4700
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/12600
; FILING DATE: 28-DEC-1993
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/999,706
; FILING DATE: December 31, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Katz, Martin L.
; REGISTRATION NUMBER: 25,011
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)616-5400
; TELEFAX: (312)616-5460
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
```

```
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US93-12600-17

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      977 CTGGGATGTGGCAGG 993
        ||||| |||||
Db      17 CTGGGATGTGGGCTGG 1

RESULT 158
PCT-US95-03731-17/c
; Sequence 17, Application PC/TUS9503731
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc.
; TITLE OF INVENTION: Treatment of Partial Growth Hormone Insensitivity Syndrome
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/03731
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/224982
; FILING DATE: 07-APR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Hasak, Janet E.
; REGISTRATION NUMBER: 28,616
; REFERENCE/DOCKET NUMBER: 884P1PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1896
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US95-03731-17

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      264 TATGGTAAAGCCAGAA 280
        ||||| |||||
Db      17 TAAGGTAAAGCCAGCA 1

RESULT 159
PCT-US96-01473-2/c
; Sequence 2, Application PC/TUS9601473
; GENERAL INFORMATION:
; APPLICANT: University of Nebraska, Board of Regents
; APPLICANT: Gold, Barry I.
; TITLE OF INVENTION: Synthetic Triple Helix-Forming Compounds
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
```

ADDRESSEE: Dann, Dorfman, Herrell and Skillman  
STREET: 1601 Market Street Suite 720  
CITY: Philadelphia  
STATE: PA  
COUNTRY: USA  
ZIP: 19103-2307  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US96/01473  
FILING DATE: 29-JAN-1996  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/384,324  
FILING DATE: 01-FEB-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Reed, Janet E.  
REGISTRATION NUMBER: 36,252  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (215) 563-4100  
TELEFAX: (215) 563-4044  
INFORMATION FOR SEQ ID NO: 2:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: not relevant  
MOLECULE TYPE: other nucleic acid  
HYPOTHETICAL: YES  
ANTI-SENSE: YES  
PCT-US96-01473-2

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1834 GAAAAAAGAAAAA 1850  
DB 17 GAAAAAAGAAAAA 1

RESULT 160  
US-09-180-437-104/c  
Sequence 104, Application US/09180437  
Patent No. 6251873  
GENERAL INFORMATION:  
APPLICANT: FUKUSAKO, Shioji  
APPLICANT: MORISAWA, Yoshifumi  
APPLICANT: KUSUYAMA, Takeshi  
TITLE OF INVENTION: Antisense Compounds to CD14  
FILE REFERENCE: 1110-209P  
CURRENT APPLICATION NUMBER: US/09/180,437  
CURRENT FILING DATE: 1998-11-06  
EARLIER APPLICATION NUMBER: PCT/JP98/00953  
EARLIER FILING DATE: 1998-03-09  
EARLIER APPLICATION NUMBER: 09-053518 JAPAN  
EARLIER FILING DATE: 1997-03-07  
NUMBER OF SEQ ID NOS: 289  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 104  
LENGTH: 15  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: other nucleic acid  
US-09-180-437-104

Query Match 0.7%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.3e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1446 GTTGCTGCTGCTGT 1460  
DB 15 GTTGCTGCTGCTGCT 1

## RESULT 161

US-09-371-772B-5840/c  
Sequence 5840, Application US/09371772B  
Patent No. 6566127  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Pavco, Pan  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Escobedo, Jaime  
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
FILE REFERENCE: MBH00,876-J (237/198)  
CURRENT APPLICATION NUMBER: US/09/371,772B  
CURRENT FILING DATE: 1999-08-10  
PRIOR APPLICATION NUMBER: US 60/005,974  
PRIOR FILING DATE: 1995-10-26  
PRIOR APPLICATION NUMBER: US 08/584,040  
PRIOR FILING DATE: 1996-01-08  
NUMBER OF SEQ ID NOS: 14225  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5840  
LENGTH: 16  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-371-772B-5840

Query Match 0.7%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1281 CTCATATCACTCAG 1295  
DB 16 CTCATCACTCAG 2

## RESULT 162

US-09-017-974-66/c  
Sequence 66, Application US/09017974  
Patent No. 6288042  
GENERAL INFORMATION:  
APPLICANT: Rando, Robert F.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Wallace, Thomas L.  
APPLICANT: Cossum, Paul A.  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
NUMBER OF SEQUENCES: 88  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1800  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/017,974  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 66:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 13
; OTHER INFORMATION: /note= "C-5 propynl dU"
;
US-09-017-974-66

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCNCCACCACCAC 1

RESULT 163
US-09-017-974-73/c
; Sequence 73, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 76:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
;

; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 73:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 13
; OTHER INFORMATION: /note= "5-bromo dU"
;
US-09-017-974-73

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCNCCACCACCAC 1

RESULT 164
US-09-017-974-76/c
; Sequence 76, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 76:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
;
```



; LOCATION: 9  
; OTHER INFORMATION: /note= "5-iodo dU"  
US-09-017-974-76

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCAC 1

## RESULT 165

US-09-017-974-77/c

; Sequence 77, Application US/09017974  
; Patent No. 6288042

; GENERAL INFORMATION:

; APPLICANT: Rando, Robert F.

; APPLICANT: Ojwang, Joshua O.

; APPLICANT: Hogan, Michael E.

; APPLICANT: Wallace, Thomas L.

; APPLICANT: Cossum, Paul A.

; TITLE OF INVENTION: Anti-Viral Guanosine-Rich

; TITLE OF INVENTION: Tetrad Forming Oligonucleotides.

; NUMBER OF SEQUENCES: 88

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Conley, Rose & Tayon, P.C.

; STREET: 600 Travis, Suite 1800

; CITY: Houston

; STATE: Texas

; COUNTRY: U.S.A.

; ZIP: 77002-2912

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: MS Word 97 (saved as .txt file)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/017,974

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/037,374

; FILING DATE: 04-FEB-97

; APPLICATION NUMBER:

; FILING DATE: 09-DEC-97

; ATTORNEY/AGENT INFORMATION:

; NAME: McDaniel, C. Steven

; REGISTRATION NUMBER: 33,962

; REFERENCE/DOCKET NUMBER: 1472-06223

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 713/238-8010

; TELEFAX: 713/238-8008

; INFORMATION FOR SEQ ID NO: 77:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)

; FEATURE:

; NAME/KEY: misc\_feature

; LOCATION: 13

; OTHER INFORMATION: /note= "5-iodo dU"

US-09-017-974-77

## Query Match

Best Local Similarity 87.5%; Score 13.4; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721

Db 16 CCCACCCACCAC 1

Db 16 CCCNCCCACCACCAC 1

## RESULT 166

US-08-682-255A-66/c

; Sequence 66, Application US/08682255A

; Patent No. 6323185

; GENERAL INFORMATION:

; APPLICANT: Rando, Robert F.

; APPLICANT: Pennewald, Susan

; APPLICANT: Zendegui, Joseph G.

; APPLICANT: Ojwang, Joshua O.

; APPLICANT: Hogan, Michael E.

; APPLICANT: Pommier, Yves

; APPLICANT: Mazumder, Abhijit

; TITLE OF INVENTION: Anti-Viral Guanosine-Rich

; TITLE OF INVENTION: Oligonucleotides

; NUMBER OF SEQUENCES: 87

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Conley, Rose & Tayon, P.C.

; STREET: 600 Travis, Suite 1850

; CITY: Houston

; STATE: Texas

; COUNTRY: U.S.A.

; ZIP: 77002-2912

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: MS Windows 95

; SOFTWARE: MS Word 97 (saved as .txt file)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/682,255A

; FILING DATE: 17-JULY-1996

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/535,168

; FILING DATE: 23-OCT-95

; APPLICATION NUMBER: 60/001,505

; FILING DATE: 19-JULY-95

; APPLICATION NUMBER: 60/014,007

; FILING DATE: 25-MARCH-96

; APPLICATION NUMBER: 60/013,688

; FILING DATE: 19-MARCH-96

; APPLICATION NUMBER: 60/015,714

; FILING DATE: 17-APRIL-96

; APPLICATION NUMBER: 60/016,271

; FILING DATE: 23-APRIL-96

; ATTORNEY/AGENT INFORMATION:

; NAME: McDaniel, C. Steven

; REGISTRATION NUMBER: 33,962

; REFERENCE/DOCKET NUMBER: 1472-06214

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 713/238-8010

; TELEFAX: 713/238-8008

; INFORMATION FOR SEQ ID NO: 66:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: DNA (genomic)

; FEATURE:

; NAME/KEY: misc\_feature

; LOCATION: 13

; OTHER INFORMATION: /note= "C-5 propynl dU"

US-08-682-255A-66

## Query Match

Best Local Similarity 87.5%; Score 13.4; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721

Db 16 CCCNCCCACCACCAC 1

Db 16 CCNCCCACCACCAC 1

RESULT 167  
US-08-682-255A-73/c  
; Sequence 73, Application US/08682255A  
; Patent No. 6323185  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Fennewald, Susan  
; APPLICANT: Zendequi, Joseph G.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Pommier, Yves  
; APPLICANT: Mazumder, Abhijit  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Oligonucleotides  
; NUMBER OF SEQUENCES: 87  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tavyon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/682,255A  
; FILING DATE: 17-JULY-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/535,168  
; FILING DATE: 23-OCT-95  
; APPLICATION NUMBER: 60/001,505  
; FILING DATE: 19-JULY-95  
; APPLICATION NUMBER: 60/014,007  
; FILING DATE: 25-MARCH-96  
; APPLICATION NUMBER: 60/013,688  
; FILING DATE: 19-MARCH-96  
; APPLICATION NUMBER: 60/015,714  
; FILING DATE: 17-APRIL-96  
; APPLICATION NUMBER: 60/016,271  
; FILING DATE: 23-APRIL-96  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06214  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 73:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: 13  
; OTHER INFORMATION: /note= "5-bromo dU"  
US-08-682-255A-73

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1706 CCCTCCCTCCACCAC 1721  
||| ||| |||||

Db 16 CCNCCCACCACCAC 1

RESULT 168  
US-08-682-255A-76/c  
; Sequence 76, Application US/08682255A  
; Patent No. 6323185  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Fennewald, Susan  
; APPLICANT: Zendequi, Joseph G.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Pommier, Yves  
; APPLICANT: Mazumder, Abhijit  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Oligonucleotides  
; NUMBER OF SEQUENCES: 87  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tavyon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/682,255A  
; FILING DATE: 17-JULY-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/535,168  
; FILING DATE: 23-OCT-95  
; APPLICATION NUMBER: 60/001,505  
; FILING DATE: 19-JULY-95  
; APPLICATION NUMBER: 60/014,007  
; FILING DATE: 25-MARCH-96  
; APPLICATION NUMBER: 60/013,688  
; FILING DATE: 19-MARCH-96  
; APPLICATION NUMBER: 60/015,714  
; FILING DATE: 17-APRIL-96  
; APPLICATION NUMBER: 60/016,271  
; FILING DATE: 23-APRIL-96  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06214  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 76:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: 9  
; OTHER INFORMATION: /note= "5-iodo dU"  
US-08-682-255A-76

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1706 CCCTCCCTCCACCAC 1721  
||| ||| |||||

Db 16 CCCACCCCCACCAC 1

## RESULT 169

US-08-682-255A-77/c  
; Sequence 77, Application US/08682255A  
; Patent No. 6323185

## GENERAL INFORMATION:

; APPLICANT: Rando, Robert F.  
; APPLICANT: Fennwald, Susan  
; APPLICANT: Zendequi, Joseph G.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Pommier, Yves  
; APPLICANT: Mazunder, Abhijit  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Oligonucleotides  
; NUMBER OF SEQUENCES: 87

## CORRESPONDENCE ADDRESS:

; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912

## COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)

## CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/682,255A  
; FILING DATE: 17-JULY-1996

## CLASSIFICATION: 435

## PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/535,168

## FILING DATE: 23-OCT-95

; APPLICATION NUMBER: 60/001,505

## FILING DATE: 19-JULY-95

; APPLICATION NUMBER: 60/014,007

## FILING DATE: 25-MARCH-96

; APPLICATION NUMBER: 60/013,688

## FILING DATE: 19-MARCH-96

; APPLICATION NUMBER: 60/015,714

## FILING DATE: 17-APRIL-96

; APPLICATION NUMBER: 60/016,271

## FILING DATE: 23-APRIL-96

## ATTORNEY/AGENT INFORMATION:

; NAME: McDaniel, C. Steven

## REGISTRATION NUMBER: 33,962

; REFERENCE/DOCKET NUMBER: 1472-06214

## TELECOMMUNICATION INFORMATION:

; TELEPHONE: 713/238-8010

## TELEFAX: 713/238-8008

## INFORMATION FOR SEQ ID NO: 77:

## SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

## MOLECULE TYPE: DNA (genomic)

## FEATURE:

; NAME/KEY: misc\_feature

; LOCATION: 13

; OTHER INFORMATION: /note= "5-iodo dU"

US-08-682-255A-77

Query Match 0.7%; Score 13.4; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721

|||||

Db 16 CCCNCCACCACCAC 1

## RESULT 170

US-08-584-040-4251/c  
; Sequence 4251, Application US/08584040  
; Patent No. 6346398

## GENERAL INFORMATION:

; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502

## CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Suite 4700  
; STATE: Los Angeles  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066

## COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1

## CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996

## CLASSIFICATION: 514

## PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/005,974

## FILING DATE: October 26, 1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 218/064

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 4251:

## SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-584-040-4251

Query Match 0.7%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 1.5e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTC 1163

|||||

15 AAGGAAATATTTC 1

## RESULT 171

US-08-584-040-5821/c  
; Sequence 5821, Application US/08584040  
; Patent No. 6346398

## GENERAL INFORMATION:

; APPLICANT: Pavco, Pamela

; APPLICANT: McSwiggen, James

; APPLICANT: Stinchcomb, Dan T.

; APPLICANT: Escobedo, Jaime

;; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
;; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
;; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
;; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
;; NUMBER OF SEQUENCES: 8502  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Lyon & Lyon  
;; STREET: 633 West Fifth Street  
;; CITY: Los Angeles  
;; STATE: California  
;; COUNTRY: U.S.A.  
;; ZIP: 90071-2066  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
;; MEDIUM TYPE: storage  
;; COMPUTER: IBM Compatible  
;; OPERATING SYSTEM: IBM P.C. DOS 5.0  
;; SOFTWARE: Word Perfect 5.1  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/584,040  
;; FILING DATE: January 11, 1996  
;; CLASSIFICATION: 514  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 60/005,974  
;; FILING DATE: October 26, 1995  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Warburg, Richard J.  
;; REGISTRATION NUMBER: 32,327  
;; REFERENCE/DOCKET NUMBER: 218/064  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: (213) 489-1600  
;; TELEFAX: (213) 955-0440  
;; TELEX: 67-3510  
;; INFORMATION FOR SEQ ID NO: 5821:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; US-08-584-040-5821

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.31; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1149 AAGGTAATATTTC 1163  
Db 15 AAGGAATATTTC 1

RESULT 172  
US-09-429-130-66/c  
; Sequence 66, Application US/09429130  
; Patent No. 6355785

;; GENERAL INFORMATION:  
;; APPLICANT: Rando, Robert F.  
;; Fennewald, Susan  
;; Zengedui, Joseph G.  
;; Ojwang, Joshua O.  
;; Hogan, Michael E.  
;; Pommer, Eyles  
;; Mazumder, Abhijit  
;; 60/015,714  
;; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
;; Oligonucleotides  
;; NUMBER OF SEQUENCES: 87  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Conley, Rose & Tayon, P.C.  
;; STREET: 600 Travis, Suite 1850  
;; CITY: Houston  
;; STATE: Texas

;; COUNTRY: U.S.A.  
;; ZIP: 77002-2912  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: MS Windows 95  
;; SOFTWARE: MS Word 97 (saved as .txt file)  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/09/429,130  
;; FILING DATE: 28-Oct-1999  
;; CLASSIFICATION: <Unknown>  
;; 19-JULY-95  
;; 25-MARCH-96  
;; 19-MARCH-96  
;; 17-APRIL-96  
;; 23-APRIL-96

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: 08/682,255  
;; FILING DATE: <Unknown>  
;; APPLICATION NUMBER: 60/001,505  
;; FILING DATE: 19-JULY-95  
;; APPLICATION NUMBER: 60/014,007  
;; FILING DATE: 25-MARCH-96  
;; APPLICATION NUMBER: 60/013,688  
;; FILING DATE: 19-MARCH-96  
;; APPLICATION NUMBER: 60/016,271  
;; FILING DATE: 17-APRIL-96  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: McDaniel, C. Steven  
;; REGISTRATION NUMBER: 33,962  
;; REFERENCE/DOCKET NUMBER: 1472-06214  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 713/238-8010  
;; TELEFAX: 713/238-8008

;; INFORMATION FOR SEQ ID NO: 66:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA (genomic)  
;; FEATURE:  
;; NAME/KEY: misc\_feature  
;; LOCATION: 13

;; OTHER INFORMATION: /note= "C-5 propynl du"  
;; SEQUENCE DESCRIPTION: SEQ ID NO: 66:  
US-09-429-130-66

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCNCCTCCACCACCAC 1

RESULT 173  
US-09-429-130-73/c  
; Sequence 73, Application US/09429130  
; Patent No. 6355785

;; GENERAL INFORMATION:  
;; APPLICANT: Rando, Robert F.  
;; Fennewald, Susan  
;; Zengedui, Joseph G.  
;; Ojwang, Joshua O.  
;; Hogan, Michael E.  
;; Pommer, Eyles  
;; Mazumder, Abhijit  
;; 60/015,714  
;; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
;; Oligonucleotides  
;; NUMBER OF SEQUENCES: 87

; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/429,130  
; FILING DATE: 28-Oct-1999  
; CLASSIFICATION: <Unknown>  
; 19-JULY-95  
; 25-MARCH-96  
; 19-MARCH-96  
; 17-APRIL-96  
; 23-APRIL-96  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/682,255  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 60/001,505  
; FILING DATE: 19-JULY-95  
; APPLICATION NUMBER: 60/014,007  
; FILING DATE: 25-MARCH-96  
; APPLICATION NUMBER: 60/013,688  
; FILING DATE: 19-MARCH-96  
; APPLICATION NUMBER: 60/016,271  
; FILING DATE: 17-APRIL-96  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06214  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 73:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: 13  
; OTHER INFORMATION: /note= "5-bromo du"  
; SEQUENCE DESCRIPTION: SEQ ID NO: 73:  
US-09-429-130-73

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCNCCACCACCAC 1

RESULT 174  
US-09-429-130-76/c  
; Sequence 76, Application US/09429130  
; Patent No. 6355785  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; Pennewald, Susan  
; Zendequi, Joseph G.  
; Olwang, Joshua O.  
; Hogan, Michael E.  
; Pommier, Eyes

; Mazumder, Abhijit  
; 60/015,714  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; Oligonucleotides  
; NUMBER OF SEQUENCES: 87  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/429,130  
; FILING DATE: 28-Oct-1999  
; CLASSIFICATION: <Unknown>  
; 19-JULY-95  
; 25-MARCH-96  
; 19-MARCH-96  
; 17-APRIL-96  
; 23-APRIL-96  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/682,255  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 60/001,505  
; FILING DATE: 19-JULY-95  
; APPLICATION NUMBER: 60/014,007  
; FILING DATE: 25-MARCH-96  
; APPLICATION NUMBER: 60/013,688  
; FILING DATE: 19-MARCH-96  
; APPLICATION NUMBER: 60/016,271  
; FILING DATE: 17-APRIL-96  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06214  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 76:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: 9  
; OTHER INFORMATION: /note= "5-iodo du"  
; SEQUENCE DESCRIPTION: SEQ ID NO: 76:  
US-09-429-130-76

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCNCCACCACCAC 1

RESULT 175  
US-09-429-130-77/c  
; Sequence 77, Application US/09429130  
; Patent No. 6355785  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.

```

1 Fennewald, Susan
2 Zendequi, Joseph G.
3 Ojwang, Joshua O.
4 Hogan, Michael E.
5 Pommier, Yves
6 Mazumder, Abhijit
7 60/015,714
8
9 TITLE OF INVENTION: Anti-Viral Guanosine-Rich
10 Oligonucleotides
11
12 NUMBER OF SEQUENCES: 87
13 CORRESPONDENCE ADDRESS:
14 ADDRESSEE: Conley, Rose & Tayon, P.C.
15 STREET: 600 Travis, Suite 1850
16 CITY: Houston
17 STATE: Texas
18 COUNTRY: U.S.A.
19 ZIP: 77002-2912
20
21 COMPUTER READABLE FORM:
22 MEDIUM TYPE: Floppy disk
23 COMPUTER: IBM PC compatible
24 OPERATING SYSTEM: MS Windows 95
25 SOFTWARE: MS Word 97 (saved as .txt file)
26
27 CURRENT APPLICATION DATA:
28 APPLICATION NUMBER: US/09/429,130
29 FILING DATE: 28-Oct-1999
30 CLASSIFICATION: <Unknown>
31 19-JULY-95
32 25-MARCH-96
33 19-MARCH-96
34 17-APRIL-96
35 23-APRIL-96
36
37 PRIOR APPLICATION DATA:
38 APPLICATION NUMBER: 08/682,255
39 FILING DATE: <Unknown>
40 APPLICATION NUMBER: 60/001,505
41 FILING DATE: 19-JULY-95
42 APPLICATION NUMBER: 60/014,007
43 FILING DATE: 25-MARCH-96
44 APPLICATION NUMBER: 60/013,688
45 FILING DATE: 19-MARCH-96
46 APPLICATION NUMBER: 60/016,271
47 FILING DATE: 17-APRIL-96
48
49 ATTORNEY/AGENT INFORMATION:
50 NAME: McDaniel, C. Steven
51 REGISTRATION NUMBER: 33,962
52 REFERENCE/DOCKET NUMBER: 1472-06214
53
54 TELECOMMUNICATION INFORMATION:
55 TELEPHONE: 713/238-8010
56 TELEFAX: 713/238-8008
57
58 INFORMATION FOR SEQ ID NO: 77:
59 SEQUENCE CHARACTERISTICS:
60 LENGTH: 17 base pairs
61 TYPE: nucleic acid
62 STRANDEDNESS: single
63 TOPOLOGY: linear
64 MOLECULE TYPE: DNA (genomic)
65 FEATURE:
66 NAME/KEY: misc_feature
67 LOCATION: 13
68
69 OTHER INFORMATION: /note= "5-iodo dU"
70
71 SEQUENCE DESCRIPTION: SEQ ID NO: 77:
72 US-09-429-130-77

```

Patent No. 686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 686188  
SEQ ID NO 1538  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-1538

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1084 GGCTGGTGGCTCTGGA 1098  
Db 2 GGCTGGTGGCTCTGGA 16

RESULT 179  
US-09-866-108A-1539  
Sequence 1539, Application US/09866108A  
Patent No. 686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine

PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 686188  
SEQ ID NO 1539  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-1539

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1084 GGCTGGTGGCTCTGGA 1098  
Db 1 GGCTGGTGGCTCTGGA 15

RESULT 180  
US-09-866-108A-8366  
Sequence 8366, Application US/09866108A  
Patent No. 686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine

; Patent No. 6686188  
; SEQ ID NO 8366  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-8366

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 396 CTGAGAAAGTTCAC 410  
Db 1 CTGAGAAAGTGCAC 15

## RESULT 181

US-09-866-108A-8587  
; Sequence 8587, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aemica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 8587  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-8588

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAGAACACAGG 1114  
Db 3 TGCAGAGACACAGG 17

US-09-866-108A-8587

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAGAACACAGG 1114  
Db 3 TGCAGAGACACAGG 17

## RESULT 182

US-09-866-108A-8588

; Sequence 8588, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aemica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 8588  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-8588

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAGAACACAGG 1114  
Db 2 TGCAGAGACACAGG 16

## RESULT 183

US-09-866-108A-8589  
; Sequence 8589, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04



```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8589
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8589

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1100 TGCAGAGCAACAGG 1114
Db      1 TGCAGAGCAACAGG 15

RESULT 184
US-09-866-108A-10029/c
; Sequence 10029, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8589
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8589

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1100 TGCAGAGCAACAGG 1114
Db      1 TGCAGAGCAACAGG 15

RESULT 184
US-09-866-108A-10029/c
; Sequence 10029, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10029
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10029

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1066 GTCCAAAGAGGACTC 1080
Db      17 GTCCACAGAGGACTC 3

RESULT 185
US-09-866-108A-10032/c
; Sequence 10032, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10032
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10032

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGGACT 1079
Db      15 CGTCCACAGAGGACT 1

RESULT 186
```

```
US-09-940-244-418/c
; Sequence 418, Application US/09940244
; Patent No. 6692917
; GENERAL INFORMATION:
; APPLICANT: Neri, Bruce P.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Smith, Lloyd M.
; TITLE OF INVENTION: Reactions on Dendrimers
; FILE REFERENCE: FORS-06478
; CURRENT APPLICATION NUMBER: US/09/940,244
; CURRENT FILING DATE: 2002-05-06
; NUMBER OF SEQ ID NOS: 422
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 418
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-940-244-418

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 566 CGATGAACCTGCAGAG 580
Db 16 CGATGACCTGCAGAG 2

RESULT 187
US-09-685-664B-2018/c
; Sequence 2018, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2018
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-2018

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1149 AAGGTAAATATTTCC 1163
Db 15 AAGGAAATATTTCC 1

RESULT 188
PCT-US91-03680-7/c
; Sequence 7, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 8
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "N4,N4-ethanocytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 14
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 17
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "1,3-propanediol"
; PCT-US91-03680-7

Query Match          0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850
Db 16 AAGAAAAAANAANA 1

RESULT 189
US-08-702-665A-8/c
; Sequence 8, Application US/08702665A
; Patent No. 6274708
; GENERAL INFORMATION:
; APPLICANT: Hilton, Douglas J.
; TITLE OF INVENTION: A NOVEL HAEMOPOIETIN RECEPTOR
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 Garden City Plaza
```

```

; CITY: Garden City
; STATE: New York
; COUNTRY: United States of America
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702,665A
; FILING DATE: 20-DEC-1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Presser, Leopold
; REGISTRATION NUMBER: 19,827
; REFERENCE/DOCKET NUMBER: 10296
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 203 901 SANS UR
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..2
; OTHER INFORMATION: /note= "R at Position 1 is A or G"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 7..8
; OTHER INFORMATION: /note= "N at Position 7 is N"
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 10..11
; OTHER INFORMATION: /note= "R at Position 10 is A or G"
; US-08-702-665A-8

```

```

Query Match      0.7%; Score 13.2; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy      1343 TGGAGTGCCTGAGC 1357
Db      15 TGGAGYGCNTGGAGY 1

```

```

RESULT 190
US-08-292-620A-370/c
; Sequence 370, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

```

```

; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 370:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-370

```

```

Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      1829 TCTCTGAAAAAAA 1841
Db      13 TCTCTGAAAAAAA 1

```

```

RESULT 191
US-09-071-845-370/c
; Sequence 370, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0

```

```
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA: US/09/071,845
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 370:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-370

Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1829 TCTCTGAAAAAA 1841
Db 13 TCTCTGAAAAAA 1

RESULT 192
US-09-701-947A-20/c
; Sequence 20, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; TYPE: DNA
; LENGTH: 15
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-20

Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAAGAT 487
Db 15 GAATTCATAAGAT 3

RESULT 193
US-09-701-947A-20/c
; Sequence 20, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; TYPE: DNA
; LENGTH: 15
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-20

Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAAGAT 487
Db 15 GAATTCATAAGAT 3

RESULT 194
US-09-701-947A-22/c
; Sequence 22, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: 60/112,150
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; TYPE: DNA
; LENGTH: 15
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-22

Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAAGAT 487
Db 15 GAATTCATAAGAT 3

RESULT 195
US-08-985-162-333
; Sequence 333, Application US/08985162
; Patent No. 6057156
```

```
US-09-701-947A-21/c
; Sequence 21, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: 60/112,150
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-21

Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAAGAT 487
Db 15 GAATTCATAAGAT 3

RESULT 194
US-09-701-947A-22/c
; Sequence 22, Application US/09701947A
; Patent No. 6818611
; GENERAL INFORMATION:
; APPLICANT: Altman, Elliot
; TITLE OF INVENTION: STABILIZED BIOACTIVE PEPTIDES AND METHODS OF
; FILE REFERENCE: 235.00010101
; CURRENT APPLICATION NUMBER: US/09/701,947A
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: 60/104,013
; PRIOR FILING DATE: 1998-10-13
; PRIOR APPLICATION NUMBER: 60/112,150
; PRIOR FILING DATE: 1998-12-14
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; TYPE: DNA
; LENGTH: 15
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; OTHER INFORMATION: fragment
US-09-701-947A-22

Query Match      0.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GAATTCATAAGAT 487
Db 15 GAATTCATAAGAT 3

RESULT 195
US-08-985-162-333
; Sequence 333, Application US/08985162
; Patent No. 6057156
```

GENERAL INFORMATION:  
APPLICANT: Akhtar, Saghir  
APPLICANT: Fell, Patricia  
APPLICANT: McSwiggen, James  
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT  
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
TITLE OF INVENTION: FACTOR RECEPTORS  
NUMBER OF SEQUENCES: 1877  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
STATE: Los Angeles  
COUNTRY: California  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Fast-SEQ for Windows 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/985,162  
FILING DATE: 04 December 1997  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/036,476  
FILING DATE: 31 January 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 230/107  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 333:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-985-162-333

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 69.2%; Pred. No. 1.8e+02;  
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1330 TTGGATCCAGC 1342  
Db 2 UUUGGAUCCAGC 14  
:::|||||

RESULT 196  
US-09-017-974-74/c  
Sequence 74, Application US/09017974  
Patent No. 6288042  
GENERAL INFORMATION:  
APPLICANT: Rando, Robert F.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Wallace, Thomas L.  
APPLICANT: Cossum, Paul A.  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
NUMBER OF SEQUENCES: 88  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1800  
CITY: Houston  
STATE: Texas

COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/017,974  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/037,374  
FILING DATE: 04-FEB-97  
APPLICATION NUMBER:  
FILING DATE: 09-DEC-97  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06223  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 74:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc feature  
LOCATION: 5,9,13  
OTHER INFORMATION: /note= "5-bromo dU"  
US-09-017-974-74

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 81.2%; Pred. No. 1.8e+02;  
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACCAC 1721  
Db 16 CCCNCCNCCNCCAC 1  
||| ||| ||| |||

RESULT 197  
US-09-017-974-78/c  
Sequence 78, Application US/09017974  
Patent No. 6288042  
GENERAL INFORMATION:  
APPLICANT: Rando, Robert F.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Wallace, Thomas L.  
APPLICANT: Cossum, Paul A.  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
NUMBER OF SEQUENCES: 88  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1800  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/017,974  
FILING DATE:

```
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA: 60/037,374
/ APPLICATION NUMBER: 60/037,374
/ FILING DATE: 04-FEB-97
/ APPLICATION NUMBER:
/ FILING DATE: 09-DEC-97
/ ATTORNEY/AGENT INFORMATION:
/ NAME: McDaniel, C. Steven
/ REGISTRATION NUMBER: 33,962
/ REFERENCE/DOCKET NUMBER: 1472-06223
/ TELEPHONE: 713/238-8010
/ TELEFAX: 713/238-8008
/ INFORMATION FOR SEQ ID NO: 78:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ MOLECULE TYPE: DNA (genomic)
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: 5,9,13
/ OTHER INFORMATION: /note="5-iodo dU"
US-09-017-974-78

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCNCCNCCNCCAC 1

RESULT 198
US-09-098-628-8/c
Sequence 8, Application US/09098628
Patent No. 6294359
GENERAL INFORMATION:
APPLICANT: FIDDES, J.C.
APPLICANT: ABRAHAM, J.D.
TITLE OF INVENTION: HUMAN BASIC FIBROBLAST GROWTH
TITLE OF INVENTION: FACTOR ANALOG
NUMBER OF SEQUENCES: 69
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 755 PAGE MILL ROAD
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304-1018
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows
SOFTWARE: FastSeq for Windows Version 2.0b
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/098,628
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Lehnhardt, Susan K
REGISTRATION NUMBER: 33,943
REFERENCE/DOCKET NUMBER: 21900-20089.10
TELEPHONE: 650-813-5600
TELEFAX: 650-494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 8:
```

```
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-09-098-628-8

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1329 TTTTGGATCCAAG 1341
Db 14 TTTTGGATCCAAG 2

RESULT 199
US-08-682-255A-74/c
Sequence 74, Application US/08682255A
Patent No. 6323185
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Fennewald, Susan
APPLICANT: Zendequi, Joseph G.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Pommer, Byves
APPLICANT: Mazumder, Abhijit
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/682,255A
FILING DATE: 17-JULY-1996
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/535,168
FILING DATE: 23-OCT-95
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/015,714
FILING DATE: 17-APRIL-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 23-APRIL-96
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 74:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
```

```
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 5,9,13
; OTHER INFORMATION: /note= "5-bromo dU"
US-08-682-255A-74

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCCAC 1721
Db 16 CCNCCNCCNCCNCCAC 1

RESULT 200
US-08-682-255A-78/c
; Sequence 78, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zengdegui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Eyves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 78:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 5,9,13
; OTHER INFORMATION: /note= "5-iodo dU"
US-08-682-255A-78

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCCAC 1721
Db 16 CCNCCNCCNCCNCCAC 1

RESULT 201
US-09-429-130-74/c
; Sequence 74, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zengdegui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Eyves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/429,130
; FILING DATE: 28-Oct-1999
; CLASSIFICATION: <Unknown>
; 19-JULY-95
; 25-MARCH-96
; 19-MARCH-96
; 17-APRIL-96
; 23-APRIL-96
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/682,255
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
;   NAME/KEY: misc feature
;   LOCATION: 5,9,13
;   OTHER INFORMATION: /note= "5-bromo dU"
;   SEQUENCE DESCRIPTION: SEQ ID NO: 74:
US-09-429-130-74
;
; Query Match          0.7%; Score 13; DB 1; Length 17;
; Best Local Similarity 81.2%; Pred. No. 1.8e+02;
; Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
QY 1706 CCCTCCCTCCACAC 1721
Db 16 CCCNCCNCCNCCAC 1

RESULT 202
US-09-429-130-78/c
; Sequence 78, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
;   APPLICANT: Rando, Robert F.
;   Fennewald, Susan
;   Zendequi, Joseph G.
;   Ojwang, Joshua O.
;   Hogan, Michael E.
;   Pomnier, Byves
;   Mazumder, Abhijit
;   60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
;   Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE: Conley, Rose & Tayon, P.C.
;   STREET: 600 Travis, Suite 1850
;   CITY: Houston
;   STATE: Texas
;   COUNTRY: U.S.A.
;   ZIP: 77002-2912
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: Floppy disk
;   COMPUTER: IBM PC compatible
;   OPERATING SYSTEM: MS Windows 95
;   SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/429,130
;   FILING DATE: 28-Oct-1999
;   CLASSIFICATION: <Unknown>
;   19-JULY-95
;   25-MARCH-96
;   19-MARCH-96
;   17-APRIL-96
;   23-APRIL-96
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 08/682,255
;   FILING DATE: <Unknown>
;   APPLICATION NUMBER: 60/001,505
;   FILING DATE: 19-JULY-95
;   APPLICATION NUMBER: 60/014,007
;   FILING DATE: 25-MARCH-96
;   APPLICATION NUMBER: 60/013,688
;   FILING DATE: 19-MARCH-96
;   APPLICATION NUMBER: 60/016,271
;   FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
;   NAME: McDaniel, C. Steven
;   REGISTRATION NUMBER: 33,962
;   REFERENCE/DOCKET NUMBER: 1472-06214
;
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: 713/238-8010
;   TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 78:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   FEATURE:
;     NAME/KEY: misc feature
;     LOCATION: 5,9,13
;     OTHER INFORMATION: /note= "5-iodo dU"
;     SEQUENCE DESCRIPTION: SEQ ID NO: 78:
US-09-429-130-78
;
; Query Match          0.7%; Score 13; DB 1; Length 17;
; Best Local Similarity 81.2%; Pred. No. 1.8e+02;
; Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
;
QY 1706 CCCTCCCTCCACAC 1721
Db 16 CCCNCCNCCNCCAC 1

RESULT 203
US-09-401-063-333
; Sequence 333, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
;   APPLICANT: Akhtar, Saghir
;   APPLICANT: Fell, Patricia
;   TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
;   TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
;   TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
;   TITLE OF INVENTION: FACTOR RECEPTORS
;   NUMBER OF SEQUENCES: 1877
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE: Lyon & Lyon
;     STREET: 633 West Fifth Street
;     CITY: Suite 4700
;     CITY: Los Angeles
;     STATE: California
;     COUNTRY: U.S.A.
;     ZIP: 90071-2066
; COMPUTER READABLE FORM:
;   MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;   COMPUTER: IBM compatible
;   OPERATING SYSTEM: IBM P.C. DOS 5.0
;   SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER: US/09/401,063
;   FILING DATE:
;   CLASSIFICATION:
; PRIOR APPLICATION DATA:
;   APPLICATION NUMBER: 08/985,162
;   FILING DATE: 04 December 1997
;   APPLICATION NUMBER: 60/036,476
;   FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
;   NAME: Warburg, Richard J.
;   REGISTRATION NUMBER: 32,327
;   REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (213) 489-1600
;   TELEFAX: (213) 955-0440
;   TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 333:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 17 base pairs
```



; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-09-401-063-333

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 69.2%; Pred. No. 1.8e+02;  
Matches 9; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1330 TTGGATCCAAAGC 1342  
Db 2 UUUGGAUCCNAGC 14  
:::|||||

## RESULT 204

US-09-866-108A-2589  
; Sequence 2589, Application US/09866108A  
; Patent No. 6686188

## GENERAL INFORMATION:

; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663

; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 2589  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-2589

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGTGCCATGG 1002  
Db 5 CAGGTGCCATGG 17  
|||||

; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-2589

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGTGCCATGG 1002  
Db 5 CAGGTGCCATGG 17  
|||||

## RESULT 205

US-09-866-108A-2594  
; Sequence 2594, Application US/09866108A  
; Patent No. 6686188

## GENERAL INFORMATION:

; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663

; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 2594  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-866-108A-2594

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 991 AGGTGCCATGGA 1003  
Db 1 AGGTGCCATGGA 13  
|||||

## RESULT 206

US-09-404-912-265  
; Sequence 265, Application US/09404912  
; Patent No. 6703228

## GENERAL INFORMATION:

; APPLICANT: John Landers  
; APPLICANT: David Houseman  
; APPLICANT: Barbara Jordan  
; APPLICANT: Alain Charest  
; TITLE OF INVENTION: Methods and Products Related to  
; FILE REFERENCE: M0656/7045(HCL/MAT)  
; CURRENT APPLICATION NUMBER: US/09/404,912  
; CURRENT FILING DATE: 1999-09-24  
; PRIOR APPLICATION NUMBER: US 60/101,757  
; PRIOR FILING DATE: 1998-09-25  
; PRIOR APPLICATION NUMBER: PCT/US99/22283  
; PRIOR FILING DATE: 1999-09-24  
; NUMBER OF SEQ ID NOS: 691  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 265  
; LENGTH: 17

```
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-265

Query Match          0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1594 ATAACAATTTCAT 1606
Db 5 ATAACAATTTCAT 17

RESULT 207
US-09-685-664B-1071/c
; Sequence 1071, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/371,772
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1071
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1071

Query Match          0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1847
Db 17 AAAAAAAAAAAAAA 5

RESULT 208
PCT-US91-02186-12/c
; Sequence 12, Application PC/TUS9102186
; GENERAL INFORMATION:
; APPLICANT: California Biotechnology Inc.
; APPLICANT: Inventors: Thompson, Stewart A.
; APPLICANT: Abraham, Judith A.
; TITLE OF INVENTION: High Level Expression of Basic Fibroblast Growth Factor Having a Homogeneous N-terminus
; TITLE OF INVENTION: Fibroblast Growth Factor Having a Homogeneous N-terminus
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Irell & Manella
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025-3471
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/02186
; FILING DATE: 19910702
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 1900-0275.41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
PCT-US91-02186-12

Query Match          0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1329 TTTTGGATCCAAG 1341
Db 14 TTTTGGATCCAAG 2

RESULT 209
5514566-19/c
; Patent No. 5514566
; APPLICANT: FIDDES, JOHN C.; ABRAHAM, JUDITH A.
; TITLE OF INVENTION: METHODS OF PRODUCING RECOMBINANT FIBROBLASTS GROWTH FACTORS
; NUMBER OF SEQUENCES: 21
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/417,022
; FILING DATE: 05-APR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 809,163
; FILING DATE: 16-DEC-1985
; APPLICATION NUMBER: 775,521
; FILING DATE: 12-SEP-1985
; SEQ ID NO:19:
; LENGTH: 17
5514566-19

Query Match          0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1329 TTTTGGATCCAAG 1341
Db 14 TTTTGGATCCAAG 2

RESULT 210
US-08-239-256-4
; Sequence 4, Application US/08239256
; Patent No. 5585345
; GENERAL INFORMATION:
; APPLICANT: BOIME, IRVING
; APPLICANT: MATZUK, MARTIN M.
; APPLICANT: KEENE, JEFFREY L.
; TITLE OF INVENTION: CTP EXTENDED FORM OF LH
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Ave. N.W.
; CITY: Washington, D.C.
; COUNTRY: USA
; ZIP: 20006-1812
```

```
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/239,256
; FILING DATE: 06-MAY-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 29500-20030.12
; TELEPHONE: (202) 887-1500
; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..12
; US-08-239-256-4

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
Db 1 GAAATGAAGAGATAAA 16

RESULT 211
US-08-485-692-1
; Sequence 1, Application US/08485692
; Patent No. 5759818
; GENERAL INFORMATION:
; APPLICANT: BOIME, IRVING
; TITLE OF INVENTION: MODIFIED PROTEIN AND PEPTIDE
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Ave. N.W.
; CITY: Washington, D.C.
; COUNTRY: USA
; ZIP: 20006-1812
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,692
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/049,869
; FILING DATE: 20-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 29500-20030.21
; TELEPHONE: (202) 887-1500
; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..12
; US-08-485-692-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
Db 1 GAAATGAAGAGATAAA 16

RESULT 211
US-08-485-692-1
; Sequence 1, Application US/08485692
; Patent No. 5759818
; GENERAL INFORMATION:
; APPLICANT: BOIME, IRVING
; TITLE OF INVENTION: MODIFIED PROTEIN AND PEPTIDE
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Ave. N.W.
; CITY: Washington, D.C.
; COUNTRY: USA
; ZIP: 20006-1812
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,692
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/049,869
; FILING DATE: 20-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 29500-20030.21
; TELEPHONE: (202) 887-1500
; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..12
; US-08-485-692-1
```

```
;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..12
; US-08-485-692-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
Db 1 GAAATGAAGAGATAAA 16

RESULT 212
US-08-419-519-1
; Sequence 1, Application US/08419519
; Patent No. 5792460
; GENERAL INFORMATION:
; APPLICANT: BOIME, IRVING
; TITLE OF INVENTION: MODIFIED PROTEIN AND PEPTIDE
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Ave. N.W.
; CITY: Washington, D.C.
; COUNTRY: USA
; ZIP: 20006-1812
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/419,519
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/049,869
; FILING DATE: 20-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 29500-20030.21
; TELEPHONE: (202) 887-1500
; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..12
; US-08-419-519-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
Db 1 GAAATGAAGAGATAAA 16

RESULT 212
US-08-419-519-1
; Sequence 1, Application US/08419519
; Patent No. 5792460
; GENERAL INFORMATION:
; APPLICANT: BOIME, IRVING
; TITLE OF INVENTION: MODIFIED PROTEIN AND PEPTIDE
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Ave. N.W.
; CITY: Washington, D.C.
; COUNTRY: USA
; ZIP: 20006-1812
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/419,519
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/049,869
; FILING DATE: 20-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 29500-20030.21
; TELEPHONE: (202) 887-1500
; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..12
; US-08-419-519-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 201 GAAATAAAAGAGAAA 216
Db 1 GAAATGAAGAGATAAA 16
```

```
RESULT 213
US-08-770-235A-22
; Sequence 22, Application US/08770235A
; Patent No. 5939538
; GENERAL INFORMATION:
; APPLICANT: Leavitt, Markley C.
; APPLICANT: Tritz, Richard
; APPLICANT: Feng, Yu
; APPLICANT: Barber, Jack
; APPLICANT: Yu, Mang
; TITLE OF INVENTION: Methods and Compositions for Inhibiting
; TITLE OF INVENTION: HIV Infection of Cells By Cleaving HIV Co-receptor RNA
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/770,235A
; FILING DATE: 19-DEC-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/027,875
; FILING DATE: 25-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: QUINE, Jonathan A.
; REGISTRATION NUMBER: P-41,261
; REFERENCE/DOCKET NUMBER: 016556-001610US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-770-235A-22

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 484 AGATAGCCATCCTGGG 499
Db 1 AGAAGUCAUCUUGG 16

RESULT 214
US-08-757-024-273
; Sequence 273, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
```

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 273:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-273

Query Match 0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTGGACAGCTGGGATG 984
Db 1 CTGGAAGCTGAGATG 16

RESULT 215
US-08-987-574-47/c
; Sequence 47, Application US/08987574
; Patent No. 6150339
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/987,574
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
```

TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/651-5151  
TELEFAX: 713/651-5246  
TELEX: 762829  
INFORMATION FOR SEQ ID NO: 47:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-987-574-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

## RESULT 216

US-08-535-168-47/c  
Sequence 47, Application US/08535168  
Patent No. 6184369

## GENERAL INFORMATION:

APPLICANT: Rando, Robert F.  
APPLICANT: Fennwald, Susan  
APPLICANT: Zendegeu, Joseph G.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Oligonucleotides  
NUMBER OF SEQUENCES: 52

## CORRESPONDENCE ADDRESS:

ADDRESSEE: Fulbright & Jaworski  
STREET: 1301 McKinney, Suite 5100  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77010-3095

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION NUMBER: US/08/535.168

## FILING DATE:

CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/US94/04529  
FILING DATE: 28-OCT-1993  
APPLICATION NUMBER: US-08/053.027  
FILING DATE: 23-APR-1993

## ATTORNEY/AGENT INFORMATION:

NAME: Paul, Thomas D.  
REGISTRATION NUMBER: 32,714  
REFERENCE/DOCKET NUMBER: D-5574-CIP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/651-5151  
TELEFAX: 713/651-5246  
TELEX: 762829

## INFORMATION FOR SEQ ID NO: 47:

SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-08-535-168-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

## RESULT 217

US-09-017-974-47/c  
Sequence 47, Application US/09017974  
Patent No. 6288042

## GENERAL INFORMATION:

APPLICANT: Rando, Robert F.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Wallace, Thomas L.  
APPLICANT: Cossum, Paul A.  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
NUMBER OF SEQUENCES: 88

## CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1800  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912

## COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/017,974

## FILING DATE:

CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/037,374  
FILING DATE: 04-FEB-97  
APPLICATION NUMBER:  
FILING DATE: 09-DEC-97

## ATTORNEY/AGENT INFORMATION:

NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06223  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008

## INFORMATION FOR SEQ ID NO: 47:

SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-09-017-974-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

## RESULT 218

US-08-682-255A-47/c  
Sequence 47, Application US/08682255A  
Patent No. 6323185

## GENERAL INFORMATION:

; APPLICANT: Rando, Robert F.  
; APPLICANT: Fennwald, Susan  
; APPLICANT: Zengdegui, Joseph G.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Pommier, Yves  
; APPLICANT: Mazumder, Abhijit  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Oligonucleotides  
; NUMBER OF SEQUENCES: 87  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/682,255A  
; FILING DATE: 17-JULY-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/535,168  
; FILING DATE: 23-OCT-95  
; APPLICATION NUMBER: 60/001,505  
; FILING DATE: 19-JULY-95  
; APPLICATION NUMBER: 60/014,007  
; FILING DATE: 25-MARCH-96  
; APPLICATION NUMBER: 60/013,688  
; FILING DATE: 19-MARCH-96  
; APPLICATION NUMBER: 60/015,714  
; FILING DATE: 17-APRIL-96  
; APPLICATION NUMBER: 60/016,271  
; FILING DATE: 23-APRIL-96  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06214  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 47:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 16 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; US-08-682-255A-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCCACCACCACCAC 1

## RESULT 219

US-09-429-130-47/c  
; Sequence 47, Application US/09429130  
; Patent No. 6355785  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; Fennwald, Susan  
; Zengdegui, Joseph G.  
; Ojwang, Joshua O.

; Hogan, Michael E.  
; Pommier, Yves  
; Mazumder, Abhijit  
; 60/015,714  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Oligonucleotides  
; NUMBER OF SEQUENCES: 87  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/429,130  
; FILING DATE: 28-Oct-1999  
; CLASSIFICATION: <Unknown>  
; 19-JULY-95  
; 25-MARCH-96  
; 19-MARCH-96  
; 17-APRIL-96  
; 23-APRIL-96  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/682,255  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: 60/001,505  
; FILING DATE: 19-JULY-95  
; APPLICATION NUMBER: 60/014,007  
; FILING DATE: 25-MARCH-96  
; APPLICATION NUMBER: 60/013,688  
; FILING DATE: 19-MARCH-96  
; APPLICATION NUMBER: 60/016,271  
; FILING DATE: 17-APRIL-96  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06214  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 47:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 16 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; SEQUENCE DESCRIPTION: SEQ ID NO: 47:  
; US-09-429-130-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCCACCACCACCAC 1

## RESULT 220

US-09-371-772B-7075  
; Sequence 7075, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim

```

; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7075
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-7075

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      1007 TGGCGGTGGAGCTTT 1022
      :||| |:||| |:::
Db      1   UGGCGGUGGUCUUU 16

RESULT 221
US-09-756-301B-22
; Sequence 22, Application US/09756301B
; Patent No. 6790444
; GENERAL INFORMATION:
; APPLICANT: Le, Junning
; APPLICANT: Vilcek, Jan
; APPLICANT: Daddona, Peter
; APPLICANT: Grayeb, John
; APPLICANT: Knight, David M.
; APPLICANT: Siegel, Scott
; TITLE OF INVENTION: Anti-TNF Antibodies and Peptides of
; FILE REFERENCE: 0975.1005-008
; CURRENT APPLICATION NUMBER: US/09/756,301B
; CURRENT FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: U.S. 09/133,119
; PRIOR FILING DATE: 1998-08-12
; PRIOR APPLICATION NUMBER: U.S. 08/570,674
; PRIOR FILING DATE: 1995-12-11
; PRIOR APPLICATION NUMBER: U.S. 08/324,799
; PRIOR FILING DATE: 1994-10-18
; PRIOR APPLICATION NUMBER: U.S. 08/192,102
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/192,861
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/192,093
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/010,406
; PRIOR FILING DATE: 1993-01-29
; PRIOR APPLICATION NUMBER: U.S. 08/013,413
; PRIOR FILING DATE: 1993-02-02
; PRIOR APPLICATION NUMBER: U.S. 07/943,852
; PRIOR FILING DATE: 1992-09-11
; PRIOR APPLICATION NUMBER: U.S. 07/853,606
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Partial sequence of pH707

US-09-756-301B-22
Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy      1007 TGGCGGTGGAGCTTT 1022
      :||| |:||| |:::
Db      1   UGGCGGUGGUCUUU 16

RESULT 221
US-09-756-301B-22
; Sequence 22, Application US/09756301B
; Patent No. 6790444
; GENERAL INFORMATION:
; APPLICANT: Le, Junning
; APPLICANT: Vilcek, Jan
; APPLICANT: Daddona, Peter
; APPLICANT: Grayeb, John
; APPLICANT: Knight, David M.
; APPLICANT: Siegel, Scott
; TITLE OF INVENTION: Anti-TNF Antibodies and Peptides of
; FILE REFERENCE: 0975.1005-008
; CURRENT APPLICATION NUMBER: US/09/756,301B
; CURRENT FILING DATE: 2001-01-08
; PRIOR APPLICATION NUMBER: U.S. 09/133,119
; PRIOR FILING DATE: 1998-08-12
; PRIOR APPLICATION NUMBER: U.S. 08/570,674
; PRIOR FILING DATE: 1995-12-11
; PRIOR APPLICATION NUMBER: U.S. 08/324,799
; PRIOR FILING DATE: 1994-10-18
; PRIOR APPLICATION NUMBER: U.S. 08/192,102
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/192,861
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/192,093
; PRIOR FILING DATE: 1994-02-04
; PRIOR APPLICATION NUMBER: U.S. 08/010,406
; PRIOR FILING DATE: 1993-01-29
; PRIOR APPLICATION NUMBER: U.S. 08/013,413
; PRIOR FILING DATE: 1993-02-02
; PRIOR APPLICATION NUMBER: U.S. 07/943,852
; PRIOR FILING DATE: 1992-09-11
; PRIOR APPLICATION NUMBER: U.S. 07/853,606
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Partial sequence of pH707

US-09-756-301B-22
Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      746 CACAGGTATTCAGGAA 761
      ||||| |||||
Db      1 CACAGGTATTCAGGCA 16

RESULT 222
US-09-152-059-1/c
; Sequence 1, Application US/09152059
; Patent No. 6794499
; GENERAL INFORMATION:
; APPLICANT: WENGEL, JESPER
; APPLICANT: NIELSEN, POUL
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
; FILE REFERENCE: 49165 (71994)
; CURRENT APPLICATION NUMBER: US/09/152,059
; CURRENT FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/058,541
; PRIOR FILING DATE: 1997-09-12
; PRIOR APPLICATION NUMBER: 60/068,293
; PRIOR FILING DATE: 1997-12-19
; PRIOR APPLICATION NUMBER: 60/071,682
; PRIOR FILING DATE: 1998-01-16
; PRIOR APPLICATION NUMBER: 60/076,591
; PRIOR FILING DATE: 1998-03-03
; PRIOR APPLICATION NUMBER: 60/083,507
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/088,309
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/094,355
; PRIOR FILING DATE: 1998-07-28
; NUMBER OF SEQ ID NOS: 146
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(15)
; OTHER INFORMATION: LNA monomer
; OTHER INFORMATION: Description of Artificial Sequence: LNA modified
; OTHER INFORMATION: oligonucleotide
US-09-152-059-1

Query Match          0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1594 ATACAAATTTTCATCCA 1609
      ||||| |||||
Db      16 ATACAAATTTTCACACA 1

RESULT 223
US-09-152-059-57/c
; Sequence 57, Application US/09152059
; Patent No. 6794499
; GENERAL INFORMATION:
; APPLICANT: WENGEL, JESPER
; APPLICANT: NIELSEN, POUL
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES
; FILE REFERENCE: 49165 (71994)
; CURRENT APPLICATION NUMBER: US/09/152,059
; CURRENT FILING DATE: 1998-09-11
; PRIOR APPLICATION NUMBER: 60/058,541
; PRIOR FILING DATE: 1997-09-12
; PRIOR APPLICATION NUMBER: 60/068,293
```

; PRIOR FILING DATE: 1997-12-19  
; PRIOR APPLICATION NUMBER: 60/071,682  
; PRIOR FILING DATE: 1998-01-16  
; PRIOR APPLICATION NUMBER: 60/076,591  
; PRIOR FILING DATE: 1998-03-03  
; PRIOR APPLICATION NUMBER: 60/083,507  
; PRIOR FILING DATE: 1998-04-29  
; PRIOR APPLICATION NUMBER: 60/088,309  
; PRIOR FILING DATE: 1998-06-05  
; PRIOR APPLICATION NUMBER: 60/094,355  
; PRIOR FILING DATE: 1998-07-28  
; NUMBER OF SEQ ID NOS: 146  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 57  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; NAME/KEY: modified base  
; LOCATION: (1)..(15)  
; OTHER INFORMATION: LNA monomer  
; OTHER INFORMATION: Description of Artificial Sequence: LNA modified  
; OTHER INFORMATION: oligonucleotide  
US-09-152-059-57

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 ATAACAATTTTCATCCA 1609  
Db 16 ATAACAATTTTCACACA 1

RESULT 224  
US-09-152-059-59/c  
; Sequence 59, Application US/09152059  
; Patent No. 6794499  
; GENERAL INFORMATION:  
; APPLICANT: WENGEL, JESPER  
; APPLICANT: NIELSEN, POUL  
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES  
; FILE REFERENCE: 49165 (71994)  
; CURRENT APPLICATION NUMBER: US/09/152,059  
; CURRENT FILING DATE: 1998-09-11  
; PRIOR APPLICATION NUMBER: 60/058,541  
; PRIOR FILING DATE: 1997-09-12  
; PRIOR APPLICATION NUMBER: 60/068,293  
; PRIOR FILING DATE: 1997-12-19  
; PRIOR APPLICATION NUMBER: 60/071,682  
; PRIOR FILING DATE: 1998-01-16  
; PRIOR APPLICATION NUMBER: 60/076,591  
; PRIOR FILING DATE: 1998-03-03  
; PRIOR APPLICATION NUMBER: 60/083,507  
; PRIOR FILING DATE: 1998-04-29  
; PRIOR APPLICATION NUMBER: 60/088,309  
; PRIOR FILING DATE: 1998-06-05  
; PRIOR APPLICATION NUMBER: 60/094,355  
; PRIOR FILING DATE: 1998-07-28  
; NUMBER OF SEQ ID NOS: 146  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 59  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; NAME/KEY: modified base  
; LOCATION: (1)..(15)  
; OTHER INFORMATION: LNA monomer  
; OTHER INFORMATION: Description of Artificial Sequence: LNA modified  
; OTHER INFORMATION: oligonucleotide  
US-09-152-059-59

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 ATAACAATTTTCATCCA 1609  
Db 16 ATAACAATTTTCACACA 1

RESULT 225  
US-09-152-059-63/c  
; Sequence 63, Application US/09152059  
; Patent No. 6794499  
; GENERAL INFORMATION:  
; APPLICANT: WENGEL, JESPER  
; APPLICANT: NIELSEN, POUL  
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES  
; FILE REFERENCE: 49165 (71994)  
; CURRENT APPLICATION NUMBER: US/09/152,059  
; CURRENT FILING DATE: 1998-09-11  
; PRIOR APPLICATION NUMBER: 60/058,541  
; PRIOR FILING DATE: 1997-09-12  
; PRIOR APPLICATION NUMBER: 60/068,293  
; PRIOR FILING DATE: 1997-12-19  
; PRIOR APPLICATION NUMBER: 60/071,682  
; PRIOR FILING DATE: 1998-01-16  
; PRIOR APPLICATION NUMBER: 60/076,591  
; PRIOR FILING DATE: 1998-03-03  
; PRIOR APPLICATION NUMBER: 60/083,507  
; PRIOR FILING DATE: 1998-04-29  
; PRIOR APPLICATION NUMBER: 60/088,309  
; PRIOR FILING DATE: 1998-06-05  
; PRIOR APPLICATION NUMBER: 60/094,355  
; PRIOR FILING DATE: 1998-07-28  
; NUMBER OF SEQ ID NOS: 146  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 63  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; NAME/KEY: modified base  
; LOCATION: (1)..(15)  
; OTHER INFORMATION: LNA monomer  
; OTHER INFORMATION: Description of Artificial Sequence: LNA modified  
; OTHER INFORMATION: oligonucleotide  
US-09-152-059-63

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1594 ATAACAATTTTCATCCA 1609  
Db 16 ATAACAATTTTCACACA 1

RESULT 226  
US-09-093-972C-273  
; Sequence 273, Application US/09093972C  
; Patent No. 6825174  
; GENERAL INFORMATION:  
; APPLICANT: NYCE, Jonathan W.  
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION  
; NUMBER OF SEQUENCES: 996  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
; STREET: 7 Clarke Drive  
; CITY: Cranbury  
; STATE: New Jersey  
; COUNTRY: USA



; ZIP: 08512  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ;  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/09/093,972C  
 ; FILING DATE: 09-Jun-1998  
 ; CLASSIFICATION: <Unknown>  
 ;  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/472,527  
 ; FILING DATE: 7-June-1995  
 ; APPLICATION NUMBER: US 08/757,024  
 ; FILING DATE: 26-11-1996  
 ; APPLICATION NUMBER: US 08/472,527  
 ; FILING DATE: 7-June-1995  
 ; APPLICATION NUMBER: US 09/016,464  
 ; FILING DATE: 30-January-1998  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Amzel, Viviana  
 ; REGISTRATION NUMBER: 30,930  
 ; REFERENCE/DOCKET NUMBER: EPI-00672  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 609-409-3035  
 ; TELEFAX: 413-254-9245  
 ; TELEX: <Unknown>  
 ;  
 ; INFORMATION FOR SEQ ID NO: 273:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 16 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (genomic)  
 ; SEQUENCE DESCRIPTION: SEQ ID NO: 273:  
 ; US-09-093-972C-273

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Oy 969 CTGGACAGCTGGGATG 984  
 Db 1 CTGGAAAGCTGAGATG 16

RESULT 227  
 US-09-958-163A-1  
 ; Sequence 1, Application US/09958163A  
 ; Patent No. 6831071  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Sergeev, Pavel  
 ; TITLE OF INVENTION: Synthesis of biologically active compounds in cells  
 ; FILE REFERENCE: sergeev  
 ; CURRENT APPLICATION NUMBER: US/09/958.163A  
 ; CURRENT FILING DATE: 2001-10-03  
 ; NUMBER OF SEQ ID NOS: 44  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 1  
 ; LENGTH: 16  
 ; TYPE: DNA  
 ; ORGANISM: Human immunodeficiency virus type 1  
 ; PUBLICATION INFORMATION:  
 ; DATABASE ACCESSION NUMBER: X01762  
 ; DATABASE ENTRY DATE: 1985-01-01  
 ; PATENT DOCUMENT NUMBER: US 5,571,937  
 ; PATENT FILING DATE: 1994-05-13  
 ; PUBLICATION DATE: 1996-01-11  
 ; RELEVANT RESIDUES: (1)..(16)  
 ; US-09-958-163A-1

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Oy 198 GAAGAAATAAAGAG 213  
 Db 1 GAAGAAATAGAGAG 16

RESULT 228  
 PCT-US96-11786-47/c  
 ; Sequence 47, Application PC/TUS9611786  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Rando, Robert F.  
 ; APPLICANT: Fennewald, Susan  
 ; APPLICANT: Zengdegui, Joseph G.  
 ; APPLICANT: Ojwang, Joshua O.  
 ; APPLICANT: Hogan, Michael E.  
 ; APPLICANT: Pommier, Eyles  
 ; APPLICANT: Mazumder, Abhijit  
 ; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
 ; TITLE OF INVENTION: Oligonucleotides  
 ; NUMBER OF SEQUENCES: 52  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Conley, Rose & Tayon, P.C.  
 ; STREET: 600 Travis, Suite 1850  
 ; CITY: Houston  
 ; STATE: Texas  
 ; COUNTRY: U.S.A.  
 ; ZIP: 77002-2912  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US96/11786  
 ; FILING DATE: 17-JULY-1996  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;  
 ; APPLICATION NUMBER: 60/015,714; 60/016,271  
 ; FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-  
 ; FILING DATE: APRIL-96; 17-APRIL-96  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: McDaniel, C. Steven  
 ; REGISTRATION NUMBER: 33,962  
 ; REFERENCE/DOCKET NUMBER: 1472-06214  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 713/238-8010  
 ; TELEFAX: 713/238-8008  
 ; INFORMATION FOR SEQ ID NO: 47:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 16 base pairs  
 ; TYPE: nucleic acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: DNA (genomic)  
 ; PCT-US96-11786-47

Query Match 0.7%; Score 12.8; DB 1; Length 16;  
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Oy 1706 CCTCTCCCTCCACCAC 1721  
 Db 16 CCACCCACCACCAC 1

RESULT 229  
 5177193-9  
 ; Patent No. 5177193  
 ; APPLICANT: BOIME, IRVING; MATZUK, MARTIN M.  
 ; TITLE OF INVENTION: MODIFIED FORMS OF REPRODUCTIVE HORMONES  
 ; NUMBER OF SEQUENCES: 26

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/532,254
; FILING DATE: 01-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 313,646
; FILING DATE: 21-FEB-1989
; SEQ ID NO:9:
; LENGTH: 16
5177193-9

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      201 GAAATAAAAGAGAAA 216
      ||||| ||||| |||||
Db      1 GAAATGAAGAGATAAA 16

RESULT 230
5177193-9
; Patent No. 5177193
; APPLICANT: BOIME, IRVING; MATZUK, MARTIN M.
; TITLE OF INVENTION: MODIFIED FORMS OF REPRODUCTIVE HORMONES
; NUMBER OF SEQUENCES: 26
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/532,254
; FILING DATE: 01-JUN-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 313,646
; FILING DATE: 21-FEB-1989
; SEQ ID NO:9:
; LENGTH: 16
5177193-9

Query Match      0.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      201 GAAATAAAAGAGAAA 216
      ||||| ||||| |||||
Db      1 GAAATGAAGAGATAAA 16

RESULT 231
US-08-985-162-333/c
; Sequence 333, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
```

```
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 333:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-333

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1421 TGTCTGATGGATCCAAAG 1436
      ||||| ||||| |||||
Db      16 TGGCTTGGATCCAAAG 1

RESULT 232
US-09-098-628-8
; Sequence 8, Application US/09098628
; Patent No. 6294359
; GENERAL INFORMATION:
; APPLICANT: FIDDES, J.C.
; APPLICANT: ABRAHAM, J.D.
; TITLE OF INVENTION: HUMAN BASIC FIBROBLAST GROWTH
; TITLE OF INVENTION: FACTOR ANALOG
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 PAGE MILL ROAD
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/098,628
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lehnhardt, Susan K
; REGISTRATION NUMBER: 33,943
; REFERENCE/DOCKET NUMBER: 21900-20089.10
; TELEPHONE: 650-813-5600
; TELEFAX: 650-494-0792
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

US-09-098-628-8

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1424 CATGGATCCAAAGCAG 1439  
Db 2 CTTGGATCCAAACAG 17

RESULT 233

US-09-401-063-333/c  
Sequence 333, Application US/09401063  
Patent No. 6623962

GENERAL INFORMATION:  
APPLICANT: Akhtar, Saghir  
APPLICANT: Fell, Patricia  
APPLICANT: McSwiggen, James  
TITLE OF INVENTION: ENZYMIC NUCLEIC ACID TREATMENT  
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
TITLE OF INVENTION: FACTOR RECEPTORS  
NUMBER OF SEQUENCES: 1877

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq for Windows 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/401,063  
FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/985,162  
FILING DATE: 04 December 1997  
APPLICATION NUMBER: 60/036,476  
FILING DATE: 31 January 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Wardburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 230/107  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 333:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear

US-09-401-063-333

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1421 TGTGATGGATCCAAAG 1436  
Db 16 TGGCTTGGATCCAAAG 1

RESULT 234

PCT-US91-02186-12

Sequence 12, Application PC/TUS9102186  
GENERAL INFORMATION:  
APPLICANT: California Biotechnology Inc.  
APPLICANT: Inventors: Thompson, Stewart A.  
APPLICANT: Abraham, Judith A.  
TITLE OF INVENTION: High Level Expression of Basic  
TITLE OF INVENTION: Fibroblast Growth Factor Having a Homogeneous  
TITLE OF INVENTION: N-terminus  
NUMBER OF SEQUENCES: 26

CORRESPONDENCE ADDRESS:

ADDRESSEE: Irell & Manella  
STREET: 545 Middlefield Road, Suite 200  
CITY: Menlo Park  
STATE: California  
COUNTRY: USA  
ZIP: 94025-3471

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US91/02186  
FILING DATE: 19910702

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Murashige, Kate H.  
REGISTRATION NUMBER: 29,959  
REFERENCE/DOCKET NUMBER: 1900-0275.41  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 415-327-7250

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: NUCLEIC ACID

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

PCT-US91-02186-12

Query Match

Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1424 CATGGATCCAAAGCAG 1439

Db 2 CTTGGATCCAAACAG 17

RESULT 235

5514566-19

Patent No. 5514566

APPLICANT: FIDDES, JOHN C.; ABRAHAM, JUDITH A.

TITLE OF INVENTION: METHODS OF PRODUCING RECOMBINANT

FIBROBLASTS GROWTH FACTORS

NUMBER OF SEQUENCES: 21

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/417,022

FILING DATE: 05-APR-1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 809,163

FILING DATE: 16-DEC-1985

APPLICATION NUMBER: 775,521

FILING DATE: 12-SEP-1985

SEQ ID NO:19:

LENGTH: 17

5514566-19

Query Match

Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 1424 CATGGATCCAAAGCAG 1439
Db 2 CTTGGATCCAAAGCAG 17

RESULT 236
US-08-145-704-33/c
; Sequence 33, Application US/08145704
; Patent No. 5567604
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Joshua O. Ojwang
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/145,704
; FILING DATE: 28-OCT-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/651-5151
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: /note= "Amine moiety attached to 3'
; OTHER INFORMATION: end"
US-08-145-704-33

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCACCACCAC 1

```

```

RESULT 237
US-08-469-177-7/c
; Sequence 7, Application US/08469177
; Patent No. 5607924
; GENERAL INFORMATION:
; APPLICANT: MAGDA, Darren

```

```

; APPLICANT: SESSLER, Jonathan L.
; APPLICANT: IVERSON, Brent L.
; APPLICANT: SANSON, Petra I.
; APPLICANT: WRIGHT, Meredith
; TITLE OF INVENTION: DNA PHOTOCLEAVAGE USING TEXAPHYRINS
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pharmacyclics, Inc.
; STREET: 995 East Arques Avenue
; CITY: Sunnyvale
; STATE: California
; COUNTRY: United States of America
; ZIP: 94086
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/469,177
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Jacqueline S.
; REGISTRATION NUMBER: 30,279
; REFERENCE/DOCKET NUMBER: PHAY:057
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 774-3363
; TELEFAX: (408) 774-0340
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "RNA"
US-08-469-177-7

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 199 AAGAAATAAAGAAGA 214
Db 16 AAGAAAGAAGAAGA 1

```

```

RESULT 238
US-08-390-850-635/c
; Sequence 635, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwigen, James
; APPLICANT: Gustofson, John T.
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible

```

```

; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390.850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 635:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-390-850-635

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 197 TGAAGAAATAAAAGAA 212
Db 17 TGAAGAAATAGAAAA 2

```

## RESULT 239

```

US-08-290-978A-9/c
; Sequence 9, Application US/08290978A
; Patent No. 5624834
; GENERAL INFORMATION:
; APPLICANT: KUSTERS-VAN SOMEREN, MARGO A.
; APPLICANT: MULLER, YVONNE
; APPLICANT: KESTER, HERMANUS C.M.
; APPLICANT: VISSER, JACOB
; APPLICANT: VAN OYEN, ALBERT J.J.
; APPLICANT: ROLIN, CLAUD
; TITLE OF INVENTION: CLONING AND EXPRESSION OF THE
; TITLE OF INVENTION: EXO-POLY GALACTURONASE GENE FROM ASPERGILLUS
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Avenue N.W.
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20006-1812
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/290,978A
; FILING DATE: 17-OCT-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: MURASHIGE, KATE H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4615-0044.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 887-1500

```

```

; TELEFAX: (202) 887-0763
; TELEX: 90-4030
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: pgaX NcoI antisense
; US-08-290-978A-9

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 1303 GCCATGGAGGAGGCAC 1318
Db 17 GCCATGGAGATGGCAC 2

```

## RESULT 240

```

US-08-373-124A-192
; Sequence 192, Application US/08373124A
; Patent No. 5645042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 192:
; SEQUENCE CHARACTERISTICS:

```

; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-373-124A-192

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 62.5%; Pred. No. 1.9e+02;  
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 716 CGTGGCCTCTCTCTCC 731  
||:||||:|  
Db 1 CGUGACCUCCUCC 16

## RESULT 241

US-08-373-124A-278/c  
; Sequence 278, Application US/08373124A  
; Patent No. 5646042  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071

COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/373,124A  
; FILING DATE: January 13, 1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 278:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-373-124A-278

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 AACTTTGGATCAAG 1341  
|||||  
Db 17 AACTTCTGGATCAAG 2

## RESULT 242

US-08-373-124A-512/c  
; Sequence 512, Application US/08373124A  
; Patent No. 5646042  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071

COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/373,124A  
; FILING DATE: January 13, 1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 512:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-373-124A-512

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GGTCTTAGAAACAGTA 1525  
|||||  
Db 17 GGTCTTAAAAACAGTA 2

## RESULT 243

US-08-373-124A-514/c  
; Sequence 514, Application US/08373124A

Patent No. 5646042  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth  
APPLICANT: McSwiggen, James  
APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
TREATMENT OF RESTENOSIS AND  
CANCER USING RIBOZYMES  
NUMBER OF SEQUENCES: 2627  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/373,124A  
FILING DATE: January 13, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/245,466  
FILING DATE: May 18, 1994  
APPLICATION NUMBER: 08/192,943  
FILING DATE: February 7, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
APPLICATION NUMBER: 07/936,422  
FILING DATE: August 26, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/035  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 514:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-373-124A-514

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1510 GGCTCTAGAACAGTA 1525  
Db 16 GGTCTTAACACAGTA 1

RESULT 244  
US-08-373-124A-960/c  
Sequence 960, Application US/08373124A  
Patent No. 5646042  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth  
APPLICANT: McSwiggen, James  
APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
TREATMENT OF RESTENOSIS AND  
CANCER USING RIBOZYMES

NUMBER OF SEQUENCES: 2627  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/373,124A  
FILING DATE: January 13, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/245,466  
FILING DATE: May 18, 1994  
APPLICATION NUMBER: 08/192,943  
FILING DATE: February 7, 1994  
APPLICATION NUMBER: 07/987,132  
FILING DATE: December 7, 1992  
APPLICATION NUMBER: 07/936,422  
FILING DATE: August 26, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 209/035  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 960:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-373-124A-960

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1375 TATACAAAGTATTTCTT 1390  
Db 17 TATAAAACTATTTCTT 2

RESULT 245  
US-08-373-124A-1192  
Sequence 1192, Application US/08373124A  
Patent No. 5646042  
GENERAL INFORMATION:  
APPLICANT: Stinchcomb, Dan T.  
APPLICANT: Draper, Kenneth  
APPLICANT: McSwiggen, James  
APPLICANT: Jarvis, Thale  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
TREATMENT OF RESTENOSIS AND  
CANCER USING RIBOZYMES  
NUMBER OF SEQUENCES: 2627  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1192:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-373-124A-1192

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.9e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1559 TCCTGGGTCGTGCAACT 1574
DB 1 UCCUGUGUUUGCAACU 16

```

```

RESULT 246
US-08-373-124A-2325/c
; Sequence 2325, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2325:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-373-124A-2325

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1326 AACTTTGGATCCAAG 1341
DB 17 AACTTTGGATCCAAG 2

```

```

RESULT 247
US-08-462-917-3
; Sequence 3, Application US/08462917
; Patent No. 5661008
; GENERAL INFORMATION:
; APPLICANT: ALMSTEDT, Annelie B
; APPLICANT: GRAY (HELLSTROM), Eva Maria
; APPLICANT: LIND, Peter
; APPLICANT: LJUNG, Catherine
; APPLICANT: SANDBERG, Helena Inga
; APPLICANT: SPIRA, Jack
; APPLICANT: SYDOW-BACKMAN, Mona
; APPLICANT: WIMAN, Helena
; TITLE OF INVENTION: RECOMBINANT HUMAN FACTOR VIII
; TITLE OF INVENTION: DERIVATIVES
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Burns, Doane, Swecker & Mathis
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
;
COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25.
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,917
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/934,495
; FILING DATE: 17-DEC-1992
; APPLICATION NUMBER: SE 9100799-7
; FILING DATE: 15-MAR-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Crane-Feury, Sharon E

```



```
;
; REGISTRATION NUMBER: 36,113
; REFERENCE/DOCKET NUMBER: 003300-283
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 836-6620
; TELEFAX: (703) 836-2021
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-462-917-3

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1594 ATAACAATTTCATCCA 1609
Db 2 ATAACAATTTCACACA 17

RESULT 248
US-08-435-634-635/c
; Sequence 635, Application US/08435634
; Patent No. 5731295
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,634
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/390,850
; FILING DATE: February 17, 1995
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5731295 September 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 635:
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-634-635

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 197 TGAAGAAATAAAGAA 212
Db 17 TGAAGAAATAAAGAAA 2

RESULT 249
US-08-653-740-20
; Sequence 20, Application US/08653740
; Patent No. 5792850
; GENERAL INFORMATION:
; APPLICANT: James W. Baumgartner
; APPLICANT: Donald C. Foster
; APPLICANT: Frank J. Grant
; APPLICANT: Cindy A. Sprecher
; TITLE OF INVENTION: HEMATOPOIETIC CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/653,740
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, Gary E
; REGISTRATION NUMBER: 31,648
; REFERENCE/DOCKET NUMBER: 95-31
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6673
; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: 9559
US-08-653-740-20

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAGC 1357
Db 3 TGGAGYGMNTGGAGY 17

RESULT 250
US-08-758-306-379/c
; Sequence 379, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
```

```
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 379:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-758-306-379

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 774 GTGCCCAAAATTCCAA 789
Db 17 GGCACAAAATTCCAA 2

RESULT 251
US-08-306-381/c
; Sequence 381, Application US/08/58306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
```



; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 512:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-435-628-512

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GGTCCTAGAAACAGTA 1525  
Db 17 GGTTCTAAAAACAGTA 2

## RESULT 255

US-08-435-628-514/c  
; Sequence 514, Application US/08435628  
; Patent No. 5817796  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,628  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/373,124  
; FILING DATE: January 13, 1995  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 514:

; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-435-628-514

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GGTCCTAGAAACAGTA 1525  
Db 16 GGTTCTAAAAACAGTA 1

## RESULT 256

US-08-435-628-960/c  
; Sequence 960, Application US/08435628  
; Patent No. 5817796  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,628  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/373,124  
; FILING DATE: January 13, 1995  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 960:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-435-628-960

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1375 TATACAACTATTTCCT 1390  
|||||  
DB 17 TATAAACTATTTCCT 2

RESULT 257  
US-08-435-628-1192  
; Sequence 1192, Application US/08435628  
; Patent No. 5817796  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,628  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/373,124  
; FILING DATE: January 13, 1995  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 1192:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

US-08-435-628-1192  
Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 56.2%; Pred. No. 1.9e+02;  
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1559 TCCTGGGCTGCAACT 1574

Db 1 UCCUGUGUUGCAACU 16  
:||:|:|:|:|:|:|

RESULT 258  
US-08-435-628-2325/c  
; Sequence 2325, Application US/08435628  
; Patent No. 5817796  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Draper, Kenneth  
; APPLICANT: McSwiggen, James  
; APPLICANT: Jarvis, Thale  
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR  
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND  
; TITLE OF INVENTION: CANCER USING RIBOZYMES  
; NUMBER OF SEQUENCES: 2627  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,628  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/373,124  
; FILING DATE: January 13, 1995  
; APPLICATION NUMBER: 08/245,466  
; FILING DATE: May 18, 1994  
; APPLICATION NUMBER: 08/192,943  
; FILING DATE: February 7, 1994  
; APPLICATION NUMBER: 07/987,132  
; FILING DATE: December 7, 1992  
; APPLICATION NUMBER: 07/936,422  
; FILING DATE: August 26, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 209/035  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 2325:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

US-08-435-628-2325  
Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 AACTTTTGGATCCAAAG 1341  
|||||

DB 17 AACTTCTGGATTCAAG 2  
|||||

RESULT 259  
US-08-780-869-9/c

; Sequence 9, Application US/08780869  
; Patent No. 5830737  
; GENERAL INFORMATION:  
; APPLICANT: KUSTERS-VAN SOMEREN, MARGO A.  
; APPLICANT: MULLER, YVONNE  
; APPLICANT: KESTER, HERMANUS C.M.  
; APPLICANT: VISSER, JACOB  
; APPLICANT: VAN OYEN, ALBERT J.J.  
; APPLICANT: ROLIN, CLAUDE  
; TITLE OF INVENTION: CLONING AND EXPRESSION OF THE  
; TITLE OF INVENTION: EXO-POLYGALACTURONASE GENE FROM ASPERGILLUS  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORRISON & FOERSTER  
; STREET: 2000 Pennsylvania Avenue N.W.  
; CITY: Washington  
; STATE: DC  
; COUNTRY: USA  
; ZIP: 20006-1812  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/780,869  
; FILING DATE: 24-JAN-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/290,978  
; FILING DATE: 17-OCT-1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: MURASHIGE, KATE H.  
; REGISTRATION NUMBER: 29,959  
; REFERENCE/DOCKET NUMBER: 4615-0044.00  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 887-1500  
; TELEFAX: (202) 887-0763  
; TELEX: 90-4030  
; INFORMATION FOR SEQ ID NO: 9:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; HYPOTHETICAL: NO  
; ANTI-SENSE: YES  
; ORIGINAL SOURCE:  
; INDIVIDUAL ISOLATE: pgaX NcoI antisense  
; US-08-780-869-9  
  
Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1303 GCCATGGAGAGGCAC 1318  
Db 17 GCCATGGAGATGGCAC 2  
  
RESULT 260  
US-09-073-594-20  
; Sequence 20, Application US/09073594  
; Patent No. 5925735  
; GENERAL INFORMATION:  
; APPLICANT: James W. Baumgartner  
; APPLICANT: Donald C. Foster  
; APPLICANT: Frank J. Grant  
; APPLICANT: Cindy A. Sprecher  
; TITLE OF INVENTION: HEMATOPOIETIC CYTOKINE RECEPTOR  
; NUMBER OF SEQUENCES: 42  
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: ZymoGenetics, Inc.  
; STREET: 1201 Eastlake Avenue East  
; CITY: Seattle  
; STATE: WA  
; COUNTRY: USA  
; ZIP: 98102  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/073,594  
; FILING DATE:  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Parker, Gary E  
; REGISTRATION NUMBER: 31,648  
; REFERENCE/DOCKET NUMBER: 95-31  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 206-442-6673  
; TELEFAX: 206-442-6678  
; INFORMATION FOR SEQ ID NO: 20:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; CLONE: 9559  
; US-09-073-594-20  
  
Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 73.3%; Pred. No. 1.9e+02;  
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
  
Qy 1343 TGGAGTGCTGGGAGC 1357  
Db 3 TGGAGYGMNTGGAGY 17  
  
RESULT 261  
US-08-757-024-236  
; Sequence 236, Application US/08757024  
; Patent No. 6025339  
; GENERAL INFORMATION:  
; APPLICANT: Nyce, Jonathan W.  
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA  
; NUMBER OF SEQUENCES: 952  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON  
; STREET: P.O. Drawer 34009  
; CITY: Charlotte  
; STATE: No. 6025339th Carolina  
; COUNTRY: USA  
; ZIP: 28234  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/757,024  
; FILING DATE: 26-NOV-1996  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Sibley, Kenneth D.  
; REGISTRATION NUMBER: 31,665  
; REFERENCE/DOCKET NUMBER: 5218-41  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 919-881-3140  
; TELEFAX: 919-881-3175  
; TELEX: 575102

INFORMATION FOR SEQ ID NO: 236:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA (genomic)  
 US-08-757-024-236

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTGGACAGCTGGGATG 984  
 ||||| ||||| |||||  
 Db 2 CTGGAAGCTGAGATG 17

## RESULT 262

US-08-757-024-272  
 ; Sequence 272, Application US/08757024  
 ; Patent No. 6025339

GENERAL INFORMATION:  
 APPLICANT: NYCE, Jonathan W.  
 TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA  
 NUMBER OF SEQUENCES: 952  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: BELL, SELTZER, PARK & GIBSON  
 STREET: P.O. Drawer 34009  
 CITY: Charlotte  
 STATE: No. 6025339th Carolina  
 COUNTRY: USA  
 ZIP: 28234

COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent In Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/757,024  
 FILING DATE: 26-NOV-1996  
 CLASSIFICATION: 514  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Sibley, Kenneth D.  
 REGISTRATION NUMBER: 31,665  
 REFERENCE/DOCKET NUMBER: 5218-41  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 919-881-3140  
 TELEX: 919-881-3175

INFORMATION FOR SEQ ID NO: 272:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA (genomic)  
 US-08-757-024-272

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTGGACAGCTGGGATG 984  
 ||||| ||||| |||||  
 Db 1 CTGGAAGCTGAGATG 16

## RESULT 263

US-08-985-162-42/c  
 ; Sequence 42, Application US/08985162  
 ; Patent No. 6057156  
 ; GENERAL INFORMATION:

APPLICANT: Akhtar, Saghir  
 APPLICANT: Fell, Patricia  
 APPLICANT: McSwiggen, James  
 TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT  
 TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
 TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
 TITLE OF INVENTION: FACTOR RECEPTORS  
 NUMBER OF SEQUENCES: 1877  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Lyon & Lyon  
 STREET: 633 West Fifth Street  
 STREET: Suite 4700  
 CITY: Los Angeles  
 STATE: California  
 COUNTRY: U.S.A.  
 ZIP: 90071-2066

COMPUTER READABLE FORM:  
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 MEDIUM TYPE: storage  
 COMPUTER: IBM Compatible  
 OPERATING SYSTEM: IBM P.C. DOS 5.0  
 SOFTWARE: FastSEQ for Windows 2.0  
 CURRENT APPLICATION DATA:  
 APPLICATION NUMBER: US/08/985,162  
 FILING DATE: 04 December 1997  
 CLASSIFICATION: 514

PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: 60/036,476  
 FILING DATE: 31 January 1997  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Warburg, Richard J.  
 REGISTRATION NUMBER: 32,327  
 REFERENCE/DOCKET NUMBER: 230/107  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: (213) 489-1600  
 TELEX: (213) 955-0440  
 TELE: 67-3510

INFORMATION FOR SEQ ID NO: 42:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear

US-08-985-162-42

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1664 TACTTTCCTCAATTCCTC 1679  
 ||||| ||||| |||||  
 Db 17 TAATTTCCTCAATTCCTC 2

## RESULT 264

US-08-985-162-665/c  
 ; Sequence 665, Application US/08985162  
 ; Patent No. 6057156  
 ; GENERAL INFORMATION:

APPLICANT: Akhtar, Saghir  
 APPLICANT: Fell, Patricia  
 APPLICANT: McSwiggen, James  
 TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT  
 TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED  
 TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH  
 TITLE OF INVENTION: FACTOR RECEPTORS  
 NUMBER OF SEQUENCES: 1877  
 CORRESPONDENCE ADDRESS:  
 ADDRESSEE: Lyon & Lyon  
 STREET: 633 West Fifth Street  
 STREET: Suite 4700  
 CITY: Los Angeles  
 STATE: California

```

; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 665:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-665

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAGAGAAA 216
DB 16 GAAGTAAAGAGAAA 1

RESULT 265
US-09-275-925-20
; Sequence 20, Application US/09275925
; Patent No. 6080406
; GENERAL INFORMATION:
; APPLICANT: James W. Baumgartner
; APPLICANT: Donald C. Foster
; APPLICANT: Frank J. Grant
; APPLICANT: Cindy A. Sprecher
; TITLE OF INVENTION: HEMATOPOIETIC CYTOKINE RECEPTOR
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/275,925
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, Gary E
; REGISTRATION NUMBER: 31,648
; REFERENCE/DOCKET NUMBER: 95-31
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-442-6673

```

```

; TELEFAX: 206-442-6678
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: 9559
; US-09-275-925-20

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1343 TGGAGTGCCTGGAGC 1357
DB 3 TGGAGYGMNTGGAGY 17

RESULT 266
US-08-987-574-33/c
; Sequence 33, Application US/08987574
; Patent No. 6150339
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendegeui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/987,574
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/651-5151
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: /note= "Amine moiety

```



```
OTHER INFORMATION: attached to 3' end"
US-08-987-574-33

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCCAC 1721
    ||| ||| ||| ||| ||| |||
    16 CCCACCCACCCACCCAC 1

RESULT 267
US-08-535-168-33/c
; Sequence 33, Application US/08535168
; Patent No. 6184369
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennwald, Susan
; APPLICANT: Zendegeui, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 52
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fulbright & Jaworski
; STREET: 1301 McKinney, Suite 5100
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77010-3095
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,168
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04529
; FILING DATE: 28-OCT-1993
; APPLICATION NUMBER: US 08/053,027
; FILING DATE: 23-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Paul, Thomas D.
; REGISTRATION NUMBER: 32,714
; REFERENCE/DOCKET NUMBER: D-5574-CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/651-5151
; TELEFAX: 713/651-5246
; TELEX: 762829
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: /note="Amine moiety
; OTHER INFORMATION: attached to 3' end"
US-08-535-168-33

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCCAC 1721
```

```
||| ||| ||| ||| ||| |||
16 CCCACCCACCCACCCAC 1

RESULT 268
US-08-720-625-9
; Sequence 9, Application US/08720625
; Patent No. 6242587
; GENERAL INFORMATION:
; APPLICANT: Naik, Ulhas P.
; APPLICANT: Parise, Leslie V.
; TITLE OF INVENTION: CALCIUM-INTEGRIN BINDING PROTEIN
; NUMBER OF SEQUENCES: 10
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bell, Seltzer, Park & Gibson
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6242587th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,625
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5470-138
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-420-2200
; TELEFAX: 919-881-3175
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA primer"
US-08-720-625-9

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1055 TCTTGGGCTCGTCCA 1070
    ||| ||| ||| ||| ||| |||
    2 TCGTTGGCTCGTCCA 17

RESULT 269
US-09-017-974-33/c
; Sequence 33, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossum, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
```

```
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; TOPOLOGY: linear
; STRANDEDNESS: single
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: /note= "Amine moiety
; OTHER INFORMATION: attached to 3' end"
US-09-017-974-33

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 270
US-09-017-974-58/c
; Sequence 58, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
```

```
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06223
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 58:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; TOPOLOGY: linear
; STRANDEDNESS: single
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 11
; OTHER INFORMATION: /note= "the base is
; OTHER INFORMATION: removed from this nucleotide"
US-09-017-974-58

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 271
US-09-017-974-59/c
; Sequence 59, Application US/09017974
; Patent No. 6288042
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Wallace, Thomas L.
; APPLICANT: Cossam, Paul A.
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1800
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/017,974
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/037,374
; FILING DATE: 04-FEB-97
; APPLICATION NUMBER:
; FILING DATE: 09-DEC-97
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
```

REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06223  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 59:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: RNA (genomic)  
US-09-017-974-59

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 272  
US-09-017-974-68/c  
Sequence 68, Application US/09017974  
Patent No. 6288042  
GENERAL INFORMATION:  
APPLICANT: Rando, Robert F.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Wallace, Thomas L.  
APPLICANT: Cossum, Paul A.  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
NUMBER OF SEQUENCES: 88  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1800  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/017,974  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/037,374  
FILING DATE: 04-FEB-97  
APPLICATION NUMBER:  
FILING DATE: 09-DEC-97  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06223  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 68:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc\_feature

LOCATION: 2  
OTHER INFORMATION: /note= "the base is  
TELECOMMUNICATION INFORMATION: removed from this nucleotide"  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 5,13  
OTHER INFORMATION: /note= "C-5 propynl dU"  
US-09-017-974-68

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 273  
US-09-017-974-72/c  
Sequence 72, Application US/09017974  
Patent No. 6288042  
GENERAL INFORMATION:  
APPLICANT: Rando, Robert F.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Wallace, Thomas L.  
APPLICANT: Cossum, Paul A.  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
NUMBER OF SEQUENCES: 88  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1800  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/017,974  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/037,374  
FILING DATE: 04-FEB-97  
APPLICATION NUMBER:  
FILING DATE: 09-DEC-97  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06223  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 72:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 13  
OTHER INFORMATION: /note= "3' cholesterol via  
OTHER INFORMATION: triglycyl linker"  
US-09-017-974-72

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 274  
US-09-017-974-80/c  
; Sequence 80, Application US/09017974  
; Patent No. 6288042  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Wallace, Thomas L.  
; APPLICANT: Cossum, Paul A.  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1800  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/017,974  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/037,374  
; FILING DATE: 04-FEB-97  
; APPLICATION NUMBER:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06223  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 80:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
US-09-017-974-80

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 275  
US-09-017-974-81/c  
; Sequence 81, Application US/09017974  
; Patent No. 6288042  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Wallace, Thomas L.  
; APPLICANT: Cossum, Paul A.  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1800  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/017,974  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/037,374  
; FILING DATE: 04-FEB-97  
; APPLICATION NUMBER:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06223  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 81:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
US-09-017-974-81

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 276  
US-09-017-974-87/c  
; Sequence 87, Application US/09017974  
; Patent No. 6288042  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Wallace, Thomas L.  
; APPLICANT: Cossum, Paul A.  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1800  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/017,974  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/037,374  
; FILING DATE: 04-FEB-97  
; APPLICATION NUMBER:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06223  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 87:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
US-09-017-974-87

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

APPLICANT: Rando, Robert F.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Wallace, Thomas L.  
APPLICANT: Cossum, Paul A.  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
NUMBER OF SEQUENCES: 88  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1800  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/017,974  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/037,374  
FILING DATE: 04-FEB-97  
APPLICATION NUMBER:  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06223  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 81:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-09-017-974-81

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 277  
US-09-017-974-87/c  
; Sequence 87, Application US/09017974  
; Patent No. 6288042  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Wallace, Thomas L.  
; APPLICANT: Cossum, Paul A.  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1800  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/017,974  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/037,374  
; FILING DATE: 04-FEB-97  
; APPLICATION NUMBER:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06223  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 81:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
US-09-017-974-81

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 278  
US-09-017-974-87/c  
; Sequence 87, Application US/09017974  
; Patent No. 6288042  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Wallace, Thomas L.  
; APPLICANT: Cossum, Paul A.  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1800  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/017,974  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/037,374  
; FILING DATE: 04-FEB-97  
; APPLICATION NUMBER:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06223  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 81:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
US-09-017-974-81

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 279  
US-09-017-974-87/c  
; Sequence 87, Application US/09017974  
; Patent No. 6288042  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Wallace, Thomas L.  
; APPLICANT: Cossum, Paul A.  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Tetrad Forming Oligonucleotides  
; NUMBER OF SEQUENCES: 88  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1800  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/017,974  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/037,374  
; FILING DATE: 04-FEB-97  
; APPLICATION NUMBER:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06223  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 81:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
US-09-017-974-81

ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/017,974  
FILING DATE:  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 60/037,374  
FILING DATE: 04-FEB-97  
APPLICATION NUMBER:  
FILING DATE: 09-DEC-97  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06223  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 87:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
US-09-017-974-87

Query Match 0.7% Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 277  
US-08-682-255A-33/c  
Sequence 33, Application US/08682255A  
Patent No. 6323185  
GENERAL INFORMATION:  
APPLICANT: Rando, Robert F.  
APPLICANT: Fennwald, Susan  
APPLICANT: Zendegeui, Joseph G.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Pommier, Yves  
APPLICANT: Mazumder, Abhijit  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Oligonucleotides  
NUMBER OF SEQUENCES: 87  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1850  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS Windows 95  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/682,255A  
FILING DATE: 17-JULY-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION NUMBER: US 08/535,168

FILING DATE: 23-OCT-95  
APPLICATION NUMBER: 60/001,505  
FILING DATE: 19-JULY-95  
APPLICATION NUMBER: 60/014,007  
FILING DATE: 25-MARCH-96  
APPLICATION NUMBER: 60/013,688  
FILING DATE: 19-MARCH-96  
APPLICATION NUMBER: 60/015,714  
FILING DATE: 17-APRIL-96  
APPLICATION NUMBER: 60/016,271  
FILING DATE: 23-APRIL-96  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06214  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 33:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 17  
OTHER INFORMATION: /note= "Amine moiety  
OTHER INFORMATION: attached to 3' end"  
US-08-682-255A-33

Query Match 0.7% Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1

RESULT 278  
US-08-682-255A-58/c  
Sequence 58, Application US/08682255A  
Patent No. 6323185  
GENERAL INFORMATION:  
APPLICANT: Rando, Robert F.  
APPLICANT: Fennwald, Susan  
APPLICANT: Zendegeui, Joseph G.  
APPLICANT: Ojwang, Joshua O.  
APPLICANT: Hogan, Michael E.  
APPLICANT: Pommier, Yves  
APPLICANT: Mazumder, Abhijit  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
TITLE OF INVENTION: Oligonucleotides  
NUMBER OF SEQUENCES: 87  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1850  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS Windows 95  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/682,255A  
FILING DATE: 17-JULY-1996  
CLASSIFICATION: 435  
PRIOR APPLICATION NUMBER: US 08/535,168

```
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 58:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 11
; OTHER INFORMATION: /note= "the base is
; OTHER INFORMATION: removed from this nucleotide"
US-08-682-255A-58

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 279
US-08-682-255A-59/c
; Sequence 59, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 59:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA (genomic)
US-08-682-255A-59

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCACCAC 1

RESULT 280
US-08-682-255A-68/c
; Sequence 68, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennewald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommier, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tavon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
```

;; FILING DATE: 19-JULY-95  
;; APPLICATION NUMBER: 60/014,007  
;; FILING DATE: 25-MARCH-96  
;; APPLICATION NUMBER: 60/013,688  
;; FILING DATE: 19-MARCH-96  
;; APPLICATION NUMBER: 60/015,714  
;; FILING DATE: 17-APRIL-96  
;; APPLICATION NUMBER: 60/016,271  
;; FILING DATE: 23-APRIL-96  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: McDaniel, C. Steven  
;; REGISTRATION NUMBER: 33,962  
;; REFERENCE/DOCKET NUMBER: 1472-06214  
;; TELEPHONE: 713/238-8010  
;; TELEFAX: 713/238-8008  
;; INFORMATION FOR SEQ ID NO: 68:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA (genomic)  
;; FEATURE:  
;; NAME/KEY: misc\_feature  
;; LOCATION: 2  
;; OTHER INFORMATION: /note="the base is  
;; OTHER INFORMATION: removed from this nucleotide"  
;; FEATURE:  
;; NAME/KEY: misc\_feature  
;; LOCATION: 5,13  
;; OTHER INFORMATION: /note="C-5 propynl dU"  
US-08-682-255A-68

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCAC 1

RESULT 281  
US-08-682-255A-72/c  
; Sequence 72, Application US/08682255A  
; Patent No. 6323185  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Fennwald, Susan  
; APPLICANT: Zengdegui, Joseph G.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Pommer, Byves  
; APPLICANT: Mazumder, Abhijit  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Oligonucleotides  
; NUMBER OF SEQUENCES: 87  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/682,255A  
; FILING DATE: 17-JULY-1996

;; CLASSIFICATION: 435  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/535,168  
;; FILING DATE: 23-OCT-95  
;; APPLICATION NUMBER: 60/001,505  
;; FILING DATE: 19-JULY-95  
;; APPLICATION NUMBER: 60/014,007  
;; FILING DATE: 25-MARCH-96  
;; APPLICATION NUMBER: 60/013,688  
;; FILING DATE: 19-MARCH-96  
;; APPLICATION NUMBER: 60/015,714  
;; FILING DATE: 17-APRIL-96  
;; APPLICATION NUMBER: 60/016,271  
;; FILING DATE: 23-APRIL-96  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: McDaniel, C. Steven  
;; REGISTRATION NUMBER: 33,962  
;; REFERENCE/DOCKET NUMBER: 1472-06214  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 713/238-8010  
;; TELEFAX: 713/238-8008  
;; INFORMATION FOR SEQ ID NO: 72:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA (genomic)  
;; FEATURE:  
;; NAME/KEY: misc\_feature  
;; LOCATION: 13  
;; OTHER INFORMATION: /note="3' cholesterol via  
;; OTHER INFORMATION: triglycyl linker"  
US-08-682-255A-72

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCAC 1

RESULT 282  
US-08-682-255A-80/c  
; Sequence 80, Application US/08682255A  
; Patent No. 6323185  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Fennwald, Susan  
; APPLICANT: Zengdegui, Joseph G.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Pommer, Byves  
; APPLICANT: Mazumder, Abhijit  
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
; TITLE OF INVENTION: Oligonucleotides  
; NUMBER OF SEQUENCES: 87  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Conley, Rose & Tayon, P.C.  
; STREET: 600 Travis, Suite 1850  
; CITY: Houston  
; STATE: Texas  
; COUNTRY: U.S.A.  
; ZIP: 77002-2912  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS Windows 95  
; SOFTWARE: MS Word 97 (saved as .txt file)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/682,255A

```
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-682-255A-80

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACAC 1721
DB 16 CCCACCCGCCACAC 1

RESULT 283
US-08-682-255A-81/c
; Sequence 81, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennelwald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommer, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
```

```
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-682-255A-81

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACAC 1721
DB 16 CCCGCCACCCACAC 1

RESULT 284
US-08-682-255A-87/c
; Sequence 87, Application US/08682255A
; Patent No. 6323185
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; APPLICANT: Fennelwald, Susan
; APPLICANT: Zendequi, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommer, Yves
; APPLICANT: Mazumder, Abhijit
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
```



; FILING DATE: 25-MARCH-96  
; APPLICATION NUMBER: 60/013,688  
; FILING DATE: 19-MARCH-96  
; APPLICATION NUMBER: 60/015,714  
; FILING DATE: 17-APRIL-96  
; APPLICATION NUMBER: 60/016,271  
; FILING DATE: 23-APRIL-96  
; ATTORNEY/AGENT INFORMATION:  
; NAME: McDaniel, C. Steven  
; REGISTRATION NUMBER: 33,962  
; REFERENCE/DOCKET NUMBER: 1472-06214  
; TELEPHONE: 713/238-8010  
; TELEFAX: 713/238-8008  
; INFORMATION FOR SEQ ID NO: 87:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
US-08-682-255A-87

Query Match 0.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCCTCCCTCCACCAC 1721  
DB 16 CCCACCCACCAC 1

## RESULT 285

US-08-584-040-1788/c  
; Sequence 1788, Application US/08584040  
; Patent No. 6346398

; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 1932:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-584-040-1932

Query Match

0.7%; Score 12.8; DB 1; Length 17;

; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 1788:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-584-040-1788

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 TCTGTTATTATCTTC 1659  
DB 17 TCTGTTATTAACTGC 2

## RESULT 286

US-08-584-040-1932  
; Sequence 1932, Application US/08584040  
; Patent No. 6346398

; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066

; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 1932:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-584-040-1932

```
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1154 AAATATTTCACATC 1169
Db 1 AAAACUCUCCACUAC 16
||||:|||||:|

RESULT 287
US-08-584-040-3938/c
; Sequence 3938, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3938:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3938

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 823 TGTCAAGATGGCTTC 838
Db 16 TGTCAAAATGGCTTC 1
|||||:|||||

RESULT 289
US-08-584-040-7820/c
; Sequence 7820, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3938:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3938

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1736 TGTGACGATACAGT 1751
Db 16 TGTGACGATACAGT 1
|||||:|||||

RESULT 288
US-08-584-040-5806/c
; Sequence 5806, Application US/08584040
; Patent No. 6346398
```

```

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7820:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-7820

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 1835 AAAAAAAAAAAAAA 1850
Db 16 AAAAAAAAAAAAAA 1

```

```

RESULT 290
US-09-429-130-33/c
; Sequence 33 Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; Fennewald, Susan
; Zendequi, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pommier, Eyves
; Mazumder, Abhijit
; 60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/429,130
; FILING DATE: 28-Oct-1999
; CLASSIFICATION: <Unknown>
; 19-JULY-95
; 25-MARCH-96
; 19-MARCH-96
; 17-APRIL-96
; 23-APRIL-96
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/682,255
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 17-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: McDaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 17
; OTHER INFORMATION: /note= "Amine moiety
; attached to 3' end"
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-429-130-33

```

```

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 1706 CCTCCTCCACCAC 1721
Db 16 CCCACCACCACCAC 1

```

```

RESULT 291
US-09-429-130-58/c
; Sequence 58, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; Fennewald, Susan
; Zendequi, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pommier, Eyves
; Mazumder, Abhijit
; 60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.

```

```

ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:

```

23-APRIL-96  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/682,255  
FILING DATE: <Unknown>  
APPLICATION NUMBER: 60/001,505  
FILING DATE: 19-JULY-95  
APPLICATION NUMBER: 60/014,007  
FILING DATE: 25-MARCH-96  
APPLICATION NUMBER: 60/013,688  
FILING DATE: 19-MARCH-96  
APPLICATION NUMBER: 60/016,271  
FILING DATE: 17-APRIL-96  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06214  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels

```

RESULT 292
US-09-429-130-59/c
; Sequence 59, Application US/09429130
; Patent No. 6355785
; GENERAL INFORMATION:
; APPLICANT: Rando, Robert F.
; Fennewald, Susan
; Zendequi, Joseph G.
; Ojwang, Joshua O.
; Hogan, Michael E.
; Pommier, Yves
; Mazumder, Abhijit
; 60/015,714
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich
; Oligonucleotides
; NUMBER OF SEQUENCES: 87
;

```

CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1850  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS Windows 95  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/429,130  
FILING DATE: 28-Oct-1999  
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/682,255  
FILING DATE: <Unknown>  
APPLICATION NUMBER: 60/001,505  
FILING DATE: 19-JULY-95  
APPLICATION NUMBER: 60/014,007  
FILING DATE: 25-MARCH-96  
APPLICATION NUMBER: 60/013,688  
FILING DATE: 19-MARCH-96  
APPLICATION NUMBER: 60/016,271  
FILING DATE: 17-APRIL-96  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06214  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14: Conservative 0; Mismatches 2; Indels 0; Gaps 0;

RESULT 293	
US-09-429-130-68/c	
; Sequence 68, Application US/09429130	
; Patent No. 6355785	
; GENERAL INFORMATION:	
; APPLICANT: Rando, Robert F.	
; Fennewald, Susan	
; Zendequi, Joseph G.	
; Ojwang, Joshua O.	
; Hogan, Michael E.	
; Pommier, Yves	
; Mazumder, Abhijit	
; 60/015,714	
; TITLE OF INVENTION: Anti-Viral Guanosine-Rich	
; Oligonucleotides	

NUMBER OF SEQUENCES: 87  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1850  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS Windows 95  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/429,130  
FILING DATE: 28-Oct-1999  
CLASSIFICATION: <Unknown>  
19-JULY-95  
25-MARCH-96  
19-MARCH-96  
17-APRIL-96  
23-APRIL-96  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/682,255  
FILING DATE: <Unknown>  
APPLICATION NUMBER: 60/001,505  
FILING DATE: 19-JULY-95  
APPLICATION NUMBER: 60/014,007  
FILING DATE: 25-MARCH-96  
APPLICATION NUMBER: 60/013,688  
FILING DATE: 19-MARCH-96  
APPLICATION NUMBER: 60/016,271  
FILING DATE: 17-APRIL-96  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06214  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 68:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 2  
OTHER INFORMATION: /note= "the base is removed from this nucleotide"  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 5,13  
OTHER INFORMATION: /note= "C-5 propynyl dU"  
SEQUENCE DESCRIPTION: SEQ ID NO: 68:  
US-09-429-130-68

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCACCCACCACCAC 1

## RESULT 294

US-09-429-130-72/c  
Sequence 72, Application US/09429130  
Patent No. 6355785  
GENERAL INFORMATION:

APPLICANT: Rando, Robert F.  
Fennwald, Susan  
Zendegeui, Joseph G.  
Ojwang, Joshua O.  
Hogan, Michael E.  
Pommier, Byves  
Mazumder, Abhijit  
60/015,714  
TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
Oligonucleotides  
NUMBER OF SEQUENCES: 87  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Conley, Rose & Tayon, P.C.  
STREET: 600 Travis, Suite 1850  
CITY: Houston  
STATE: Texas  
COUNTRY: U.S.A.  
ZIP: 77002-2912  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: MS Windows 95  
SOFTWARE: MS Word 97 (saved as .txt file)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/429,130  
FILING DATE: 28-Oct-1999  
CLASSIFICATION: <Unknown>  
19-JULY-95  
25-MARCH-96  
19-MARCH-96  
17-APRIL-96  
23-APRIL-96  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/682,255  
FILING DATE: <Unknown>  
APPLICATION NUMBER: 60/001,505  
FILING DATE: 19-JULY-95  
APPLICATION NUMBER: 60/014,007  
FILING DATE: 25-MARCH-96  
APPLICATION NUMBER: 60/013,688  
FILING DATE: 19-MARCH-96  
APPLICATION NUMBER: 60/016,271  
FILING DATE: 17-APRIL-96  
ATTORNEY/AGENT INFORMATION:  
NAME: McDaniel, C. Steven  
REGISTRATION NUMBER: 33,962  
REFERENCE/DOCKET NUMBER: 1472-06214  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 713/238-8010  
TELEFAX: 713/238-8008  
INFORMATION FOR SEQ ID NO: 72:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION: 13  
OTHER INFORMATION: /note= "3' cholesterol via triglycyl linker"  
SEQUENCE DESCRIPTION: SEQ ID NO: 72:  
US-09-429-130-72

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCACCCACCACCAC 1

## RESULT 295

US-09-429-130-80/c  
; Sequence 80, Application US/09429130  
; Patent No. 6355785

## GENERAL INFORMATION:

APPLICANT: Rando, Robert F.  
; Fennewald, Susan  
; Zendegeui, Joseph G.  
; Ojwang, Joshua O.  
; Hogan, Michael E.  
; Pommier, Eyles  
; Mazumder, Abhijit  
60/015,714

TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
Oligonucleotides

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.

STREET: 600 Travis, Suite 1850

CITY: Houston

STATE: Texas

COUNTRY: U.S.A.

ZIP: 77002-2912

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: MS Windows 95

SOFTWARE: MS Word 97 (saved as .txt file)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/429,130

FILING DATE: 28-Oct-1999

CLASSIFICATION: <Unknown>

19-JULY-95

25-MARCH-96

19-MARCH-96

17-APRIL-96

23-APRIL-96

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/682,255

FILING DATE: <Unknown>

APPLICATION NUMBER: 60/001,505

FILING DATE: 19-JULY-95

APPLICATION NUMBER: 60/014,007

FILING DATE: 25-MARCH-96

APPLICATION NUMBER: 60/013,688

FILING DATE: 19-MARCH-96

APPLICATION NUMBER: 60/016,271

FILING DATE: 17-APRIL-96

ATTORNEY/AGENT INFORMATION:

NAME: McDaniel, C. Steven

REGISTRATION NUMBER: 33,962

REFERENCE/DOCKET NUMBER: 1472-06214

TELECOMMUNICATION INFORMATION:

TELEPHONE: 713/238-8010

TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 80:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 80:

US-09-429-130-80

Query Match

Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

1706 CCCTCCCTCCACCAC 1721

16 CCCACCGCCACCAC 1

Db

## RESULT 296

US-09-429-130-81/c  
; Sequence 81, Application US/09429130  
; Patent No. 6355785

## GENERAL INFORMATION:

APPLICANT: Rando, Robert F.  
; Fennewald, Susan  
; Zendegeui, Joseph G.  
; Ojwang, Joshua O.  
; Hogan, Michael E.  
; Pommier, Eyles  
; Mazumder, Abhijit  
60/015,714

TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
Oligonucleotides

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.

STREET: 600 Travis, Suite 1850

CITY: Houston

STATE: Texas

COUNTRY: U.S.A.

ZIP: 77002-2912

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: MS Windows 95

SOFTWARE: MS Word 97 (saved as .txt file)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/429,130

FILING DATE: 28-Oct-1999

CLASSIFICATION: <Unknown>

19-JULY-95

25-MARCH-96

19-MARCH-96

17-APRIL-96

23-APRIL-96

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/682,255

FILING DATE: <Unknown>

APPLICATION NUMBER: 60/001,505

FILING DATE: 19-JULY-95

APPLICATION NUMBER: 60/014,007

FILING DATE: 25-MARCH-96

APPLICATION NUMBER: 60/013,688

FILING DATE: 19-MARCH-96

APPLICATION NUMBER: 60/016,271

FILING DATE: 17-APRIL-96

ATTORNEY/AGENT INFORMATION:

NAME: McDaniel, C. Steven

REGISTRATION NUMBER: 33,962

REFERENCE/DOCKET NUMBER: 1472-06214

TELECOMMUNICATION INFORMATION:

TELEPHONE: 713/238-8010

TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 81:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 81:

US-09-429-130-81

Query Match

Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

1706 CCCTCCCTCCACCAC 1721

1706 CCCTCCCTCCACCAC 1721

Db

Db 16 CCCGCCACCACCAC 1

## RESULT 297

US-09-429-130-87/c

; Sequence 87, Application US/09429130

; Patent No. 6355785

; GENERAL INFORMATION:

APPLICANT: Rando, Robert F.  
Fennwald, Susan  
Zendequi, Joseph G.  
Oiwang, Joshua O.  
Hogan, Michael E.  
Pomnier, Yves  
Mazunder, Abhijit  
60/015,714

TITLE OF INVENTION: Anti-Viral Guanosine-Rich

Oligonucleotides

NUMBER OF SEQUENCES: 87

CORRESPONDENCE ADDRESS:

ADDRESSEE: Conley, Rose & Tayon, P.C.

STREET: 600 Travis, Suite 1850

CITY: Houston

STATE: Texas

COUNTRY: U.S.A.

ZIP: 77002-2912

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: MS Windows 95

SOFTWARE: MS Word 97 (saved as .txt file)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/429,130

FILING DATE: 28-Oct-1999

CLASSIFICATION: <Unknown>

19-JULY-95

23-MARCH-96

19-MARCH-96

17-APRIL-96

23-APRIL-96

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/682,255

FILING DATE: <Unknown>

APPLICATION NUMBER: 60/001,505

FILING DATE: 19-JULY-95

APPLICATION NUMBER: 60/014,007

FILING DATE: 25-MARCH-96

APPLICATION NUMBER: 60/013,688

FILING DATE: 19-MARCH-96

APPLICATION NUMBER: 60/016,271

FILING DATE: 17-APRIL-96

ATTORNEY/AGENT INFORMATION:

NAME: McDaniel, C. Steven

REGISTRATION NUMBER: 33,962

REFERENCE/DOCKET NUMBER: 1472-06214

TELECOMMUNICATION INFORMATION:

TELEPHONE: 713/238-8010

TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 87:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 87:

US-09-429-130-87

Query Match 0.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721

Db 16 CCCGCCACCACCAC 1

## RESULT 298

US-09-474-432B-558/c

; Sequence 558, Application US/09474432B

; Patent No. 6528640

; GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.  
Beigelman, Leo  
Burgin, Alex  
Beaudry, Amber  
Karpeisky, Alex  
Adamc, Jasenka  
Sweedler, David  
Zinnen, Shawn

TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot

FILE REFERENCE: MEHB00-831-B (247/276)

CURRENT APPLICATION NUMBER: US/09/474,432B

CURRENT FILING DATE: 1999-12-19

PRIOR APPLICATION NUMBER: US 60/064,866

PRIOR FILING DATE: 1997-11-05

PRIOR APPLICATION NUMBER: US 60/084,727

PRIOR FILING DATE: 1998-04-29

PRIOR APPLICATION NUMBER: US 09/186,675

PRIOR FILING DATE: 1998-11-04

PRIOR APPLICATION NUMBER: US 09/301,511

PRIOR FILING DATE: 1999-04-28

NUMBER OF SEQ ID NOS: 1526

SOFTWARE: PatentIn version 3.0

SEQ ID NO 558

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-474-432B-558

Query Match 0.7%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1850

Db 17 AACACAAACCAAAAAA 2

## RESULT 299

US-09-474-432B-559/c

; Sequence 559, Application US/09474432B

; Patent No. 6528640

; GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.  
Beigelman, Leo  
Burgin, Alex  
Beaudry, Amber  
Karpeisky, Alex  
Adamc, Jasenka  
Sweedler, David  
Zinnen, Shawn

TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot

FILE REFERENCE: MEHB00-831-B (247/276)

CURRENT APPLICATION NUMBER: US/09/474,432B

CURRENT FILING DATE: 1999-12-19

PRIOR APPLICATION NUMBER: US 60/064,866

PRIOR FILING DATE: 1997-11-05

PRIOR APPLICATION NUMBER: US 60/084,727

PRIOR FILING DATE: 1998-04-29

PRIOR APPLICATION NUMBER: US 09/186,675

PRIOR FILING DATE: 1998-11-04

PRIOR APPLICATION NUMBER: US 09/301,511

PRIOR FILING DATE: 1999-04-28

NUMBER OF SEQ ID NOS: 1526

SOFTWARE: PatentIn version 3.0

```
; SEQ ID NO 559
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-559

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAA...AAAAA 1850
Db 16 AAAAAA...AACAA 1

RESULT 300
US-09-474-432B-677
; Sequence 677, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH800-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 677
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-677

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.9e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 951 GTACTGGTCAGTGGAC 966
Db 2 GAACUGGCGACUGGAC 17

RESULT 301
US-09-474-432B-876/c
; Sequence 876, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH800-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
```

```
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 876
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-876

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 578 GAGAGGGGCTCAGAA 593
Db 17 GGGCAGGGGCTCAGAA 2

RESULT 302
US-09-371-772B-333/c
; Sequence 333, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Relating to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH800,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-333

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1644 TCTGTATTATCTTTC 1659
Db 17 TCTGTATTAACTGTC 2

RESULT 303
US-09-371-772B-477
; Sequence 477, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Relating to Vascular Endothelial Growth Factor Receptor
```



```
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-477

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1154 AAATATTCCAACTAC 1169
    |||: :|||:|
Db 1 AAACUCUCCAAACUAC 16

RESULT 304
US-09-371-772B-1705/c
; Sequence 1705, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1705
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1705

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1736 TGGTAGGATACACT 1751
    ||||| |||||
Db 16 TGGTAAGCATGCAGT 1

RESULT 305
US-09-371-772B-2671/c
; Sequence 2671, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
```

```
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2671
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2671

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 823 TGTCAGAATGGCTTC 838
    ||||| |||||
Db 16 TGTCAAAAATGGTTTC 1

RESULT 306
US-09-371-772B-3604/c
; Sequence 3604, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3604

Query Match          0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAA 1850
    ||||| |||||
Db 16 AAAACAAAAAACAAAA 1

RESULT 307
US-09-371-772B-4280/c
; Sequence 4280, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBHB00,876-J (237/198)
```

```
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4280
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4280

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 889 CAGATACCTGATTCCTT 904
Db 16 CAGATTCGTTCCTT 1

RESULT 308
US-09-371-772B-4407
; Sequence 4407, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4407
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4407

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 237 GCTAAAGCAATCATCA 252
Db 1 GAUAAAGCAUUCAUCA 16

RESULT 309
US-09-371-772B-4766
; Sequence 4766, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
```

```
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4766
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4766

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1154 AAATATTTCCAACTAC 1169
Db 2 AAAUCUCUCCAAUAC 17

RESULT 310
US-09-371-772B-4869
; Sequence 4869, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4869
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4869

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 186 AAGAGGACTTTTGAAG 201
Db 1 AUGAGGACUUCUUCAG 16

RESULT 311
US-09-371-772B-5113
; Sequence 5113, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
```

; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: Patentin version 3.0  
; SEQ ID NO 5113  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5113

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 75.0%; Pred. No. 1.9e+02;  
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 427 TACCCCACTGGGAGAG 442  
Db 1 UACCCACUGGCCAG 16

## RESULT 312

US-09-371-772B-5139/c  
; Sequence 5139, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: Patentin version 3.0  
; SEQ ID NO 5139  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5139

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 229 GAGATGTTGCTAAAGC 244  
Db 16 GAGATGTTGCTCAGGC 1

## RESULT 313

US-09-371-772B-5170/c  
; Sequence 5170, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974

; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: Patentin version 3.0  
; SEQ ID NO 5170  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5170

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1306 ATCGAGAGGACAGAGA 1321  
Db 17 ATGTAGAAGGGTCAGA 2

## RESULT 314

US-09-371-772B-5171/c  
; Sequence 5171, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: Patentin version 3.0  
; SEQ ID NO 5171  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5171

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1306 ATCGAGAGGACAGAGA 1321  
Db 16 ATGTAGAAGGGTCAGA 1

## RESULT 315

US-09-371-772B-5340  
; Sequence 5340, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26



RESULT 321  
US-09-476-387-558/c  
: Sequence 558, Application US/09476387  
: Patent No. 6617438  
: GENERAL INFORMATION:  
: APPLICANT: Ribozyme Pharmaceuticals, Inc.  
: APPLICANT: Beigelman, Leo  
: APPLICANT: Beaudry, Amber  
: APPLICANT: Karpesky, Alex  
: APPLICANT: Adamic, Jasenka Matulic  
: APPLICANT: Sweedler, Dave  
: APPLICANT: Zinnen, Shawn

Query Match	0.7%	Score 12.8;	DB 1;	Length 17;
Best Local Similarity	75.0%	Pred. NO. 1.9e+02;		
Matches 12;	Conservative 2;	Mismatches 2;	Indels 0;	Gaps 0;
QY	951	GTACTGTCAGTGGAC	966	
Db	2	GAACUGGCAGUGGAC	17	

```
RESULT 323
US-09-476-387-875/c
; Sequence 875, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleob
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 875
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-875

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      578 GAGAGGGGCTCAGAA 593
Db      17 GGCAGGGGCTCAGAA 2

RESULT 324
US-09-401-063-42/c
; Sequence 42, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1664 TACTTTCCTCAATTC 1679
Db      17 TAATTTCCAAATTC 2

RESULT 325
US-09-401-063-665/c
; Sequence 665, Application US/09401063
; Patent No. 6623962
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/401,063
; FILING DATE:

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1664 TACTTTCCTCAATTC 1679
Db      17 TAATTTCCAAATTC 2

CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/985,162
; FILING DATE: 04 December 1997
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-42
```

```
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 665:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-401-063-665

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAGAGAGAAA 216
DB 16 GAAGTAAAGAGAGAAA 1

RESULT 326
US-09-827-998-1724
; Sequence 1724, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDIMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 1724
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-827-998-1724

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTGTT 1460
DB 2 TGTGCTGCTGCTGTT 17

RESULT 327
US-09-827-998-1725
; Sequence 1725, Application US/09827998
; Patent No. 6656700
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: NOVEL ISOFORMS OF HUMAN PREGNANCY-ASSOCIATED PROTEIN E
; FILE REFERENCE: MDIMORF-8
; CURRENT APPLICATION NUMBER: US/09/827,998
; CURRENT FILING DATE: 2001-04-06
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; NUMBER OF SEQ ID NOS: 1881
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6656700
; SEQ ID NO 1725
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-09-827-998-1725

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTGTT 1460
DB 1 TGTGCTGCTGCTGTT 16

RESULT 328
US-09-866-108A-1535
; Sequence 1535, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1535
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1535

Query Match
Best Local Similarity 0.7%; Score 12.8; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1081 TGGGGCTGGTCTGCTG 1096
DB 2 TGGGGCTGGTCTGCTG 17

RESULT 329
US-09-866-108A-2360/c
; Sequence 2360, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2360
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2360

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 ATCAGCTGTGATCGTG 467
Db 17 AGCAGCTGTGATCGG 2

RESULT 330
US-09-866-108A-2361/c
; Sequence 2361, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2360
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2360

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 ATCAGCTGTGATCGTG 467
Db 17 AGCAGCTGTGATCGG 2

RESULT 330
US-09-866-108A-2361/c
; Sequence 2361, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2361
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2361

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 452 ATCAGCTGTGATCGTG 467
Db 16 AGCAGCTGTGATCGG 1

RESULT 331
US-09-866-108A-6976
; Sequence 6976, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6976
; LENGTH: 17
```



```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6976

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1437 CAGATGAATGTTGCTG 1452
Db 2 CAGAAGAATGGGCTG 17

RESULT 332
US-09-866-108A-6977
; Sequence 6977, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7125
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7125

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1671 CAAATTCCTGATTC 1686
Db 17 CAATTCCTGATTT 2

RESULT 334
US-09-866-108A-7126/c
; Sequence 7126, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6977

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1437 CAGATGAATGTTGCTG 1452
Db 1 CAGAAGAATGGGCTG 16

RESULT 333
US-09-866-108A-7125/c
; Sequence 7125, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7126
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-7126

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1671 CAAATTCCTGATTC 1686
Db 16 CAACTTCCTGATTT 1

RESULT 335
US-09-866-108A-8359
; Sequence 8359, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8359
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8359

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1671 CAAATTCCTGATTC 1686
Db 16 CAACTTCCTGATTT 1

RESULT 336
US-09-866-108A-8361
; Sequence 8361, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8361
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8361

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 391 ATGGGCTGGAGAAAGT 406
Db 1 AGGAGCTGGAGAAAGT 16

RESULT 337
US-09-866-108A-8362
; Sequence 8362, Application US/09866108A
; Patent No. 6686188
; SEQ ID NO 8359
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8359

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 GATGGCTGGAGAAAG 405
Db 2 GAGGAGCTGGAGAAAG 17

RESULT 336
US-09-866-108A-8361
; Sequence 8361, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8361
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-8361

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 391 ATGGGCTGGAGAAAGT 406
Db 1 AGGAGCTGGAGAAAGT 16

RESULT 337
US-09-866-108A-8362
; Sequence 8362, Application US/09866108A
; Patent No. 6686188
; SEQ ID NO 8359
```

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8362
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8362

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 393 GGGCTGGAGAAAGTTC 408
DB 2 GAGCTGGAGAAAGTGC 17

RESULT 338
US-09-866-108A-9536/c
; Sequence 9536, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8362
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9536/c

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 441 AGGGGAGAGAAATCAG 456
DB 17 AGGGGAGAGAAATCAG 2

RESULT 339
US-09-866-108A-9537/c
; Sequence 9537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
```

```
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9536

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 441 AGGGGAGAGAAATCAG 456
DB 17 AGGGGAGAGAAATCAG 2

RESULT 339
US-09-866-108A-9537/c
; Sequence 9537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
```

; SEQ ID NO 9537  
 ; LENGTH: 17  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-09-866-108A-9537

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 441 AGGGGAGGAATCAG 456  
 ||||| ||||| |||||  
 DB 16 AGGGGAGGAAGCAG 1

RESULT 340  
 US-09-866-108A-9571/c  
 ; Sequence 9571, Application US/09866108A  
 ; Patent No. 6686188  
 ; GENERAL INFORMATION:  
 ; APPLICANT: GU, Yizhong  
 ; APPLICANT: JI, Yonggang  
 ; APPLICANT: PENN, Sharron G.  
 ; APPLICANT: HANZEL, David K.  
 ; APPLICANT: RANK, David R.  
 ; APPLICANT: CHEN, Wensheng  
 ; APPLICANT: SHANNON, Mark  
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
 ; FILE REFERENCE: AEOMICA-7  
 ; CURRENT APPLICATION NUMBER: US/09/866,108A  
 ; CURRENT FILING DATE: 2001-05-25  
 ; PRIOR APPLICATION NUMBER: US 60/207,456  
 ; PRIOR FILING DATE: 2000-05-26  
 ; PRIOR APPLICATION NUMBER: GB 24263.6  
 ; PRIOR FILING DATE: 2000-10-04  
 ; PRIOR APPLICATION NUMBER: US 60/236,359  
 ; PRIOR FILING DATE: 2000-09-27  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663  
 ; PRIOR FILING DATE: 2001-01-30  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 15755  
 ; SOFTWARE: Aeomica Sequence Listing Engine  
 ; Patent No. 6686188  
 ; SEQ ID NO 9573  
 ; LENGTH: 17  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-09-866-108A-9573

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTGCACAGCTGGGATG 984  
 ||||| ||||| |||||  
 DB 16 CTCGACAGCGGGATG 1

RESULT 342  
 US-09-866-108A-10256/c  
 ; Sequence 10256, Application US/09866108A  
 ; Patent No. 6686188  
 ; GENERAL INFORMATION:  
 ; APPLICANT: GU, Yizhong  
 ; APPLICANT: JI, Yonggang  
 ; APPLICANT: PENN, Sharron G.  
 ; APPLICANT: HANZEL, David K.  
 ; APPLICANT: RANK, David R.  
 ; APPLICANT: CHEN, Wensheng  
 ; APPLICANT: SHANNON, Mark  
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
 ; FILE REFERENCE: AEOMICA-7  
 ; CURRENT APPLICATION NUMBER: US/09/866,108A  
 ; CURRENT FILING DATE: 2001-05-25  
 ; PRIOR APPLICATION NUMBER: US 60/207,456  
 ; PRIOR FILING DATE: 2000-05-26  
 ; PRIOR APPLICATION NUMBER: GB 24263.6  
 ; PRIOR FILING DATE: 2000-10-04  
 ; PRIOR APPLICATION NUMBER: US 60/236,359  
 ; PRIOR FILING DATE: 2000-09-27  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663  
 ; PRIOR FILING DATE: 2001-01-30  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 15755  
 ; SOFTWARE: Aeomica Sequence Listing Engine  
 ; Patent No. 6686188  
 ; SEQ ID NO 9571  
 ; LENGTH: 17  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-09-866-108A-9571

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
 Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 970 TGCACAGCTGGGATGT 985  
 ||||| ||||| |||||  
 DB 17 TCGACAGCGGGATGT 2

RESULT 341  
 US-09-866-108A-9573/c  
 ; Sequence 9573, Application US/09866108A  
 ; Patent No. 6686188  
 ; GENERAL INFORMATION:  
 ; APPLICANT: GU, Yizhong  
 ; APPLICANT: JI, Yonggang  
 ; APPLICANT: PENN, Sharron G.  
 ; APPLICANT: HANZEL, David K.  
 ; APPLICANT: RANK, David R.  
 ; APPLICANT: CHEN, Wensheng  
 ; APPLICANT: SHANNON, Mark  
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
 ; FILE REFERENCE: AEOMICA-7  
 ; CURRENT APPLICATION NUMBER: US/09/866,108A  
 ; CURRENT FILING DATE: 2001-05-25  
 ; PRIOR APPLICATION NUMBER: US 60/207,456  
 ; PRIOR FILING DATE: 2000-05-26  
 ; PRIOR APPLICATION NUMBER: GB 24263.6  
 ; PRIOR FILING DATE: 2000-10-04  
 ; PRIOR APPLICATION NUMBER: US 60/236,359  
 ; PRIOR FILING DATE: 2000-09-27  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00666  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00667  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00664  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00669  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00665  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00668  
 ; PRIOR FILING DATE: 2001-01-30  
 ; PRIOR APPLICATION NUMBER: PCT/US01/00663  
 ; PRIOR FILING DATE: 2001-01-30  
 ; Remaining Prior Application data removed - See File Wrapper or PALM.  
 ; NUMBER OF SEQ ID NOS: 15755  
 ; SOFTWARE: Aeomica Sequence Listing Engine  
 ; Patent No. 6686188  
 ; SEQ ID NO 9571  
 ; LENGTH: 17  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-09-866-108A-9571

```
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10256
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10256

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1195 GAACCTTCTTACCCAC 1210
      ||||| ||||| |||||
Db      17 GAACCGTCTTGCCAC 2

RESULT 343
US-09-866-108A-10257/c
; Sequence 10257, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
```

```
; Patent No. 6686188
; SEQ ID NO 10257
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10257

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1195 GAACCTTCTTACCCAC 1210
      ||||| ||||| |||||
Db      16 GAACCGTCTTGCCAC 1

RESULT 344
US-09-404-912-155
; Sequence 155, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; PRIOR FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 155
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-155

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1670 CCAAAATCTCTGATTC 1685
      ||||| ||||| |||||
Db      1 CCAAATATCTGATTC 16

RESULT 345
US-09-155-885A-101/c
; Sequence 101, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; APPLICANT: ROSSAU, RUDI
; APPLICANT: MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHUYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
```

```
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/155,885A
; FILING DATE: 08-Oct-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/02002
; FILING DATE: 21-APR-1997
; APPLICATION NUMBER: EP 96870053.4
; FILING DATE: 19-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 101:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 101:
US-09-155-885A-101
```

```
Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 246 ATCATCAACCTAGCTG 261
Db 17 ATCATCCACATAGCTG 2
```

```
RESULT 346
US-10-029-598-30/c
; Sequence 30, Application US/10029598
; Patent No. 6747014
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E.
; APPLICANT: Ecker, David J.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions And Methods For No. 6747014-Parental Delivery Of Oli
; FILE REFERENCE: IS184945
; CURRENT APPLICATION NUMBER: US/10/029,598
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 08/082,624
; PRIOR FILING DATE: 1998-05-21
; PRIOR APPLICATION NUMBER: 09/315,298
; PRIOR FILING DATE: 1999-05-20
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 30
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Sequence
US-10-029-598-30
```

```
Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1706 CCTCTCCCTCCACCAC 1721
Db 16 CCCACCCACCCACCAC 1
```

## RESULT 347

```
US-09-685-664B-333/c
; Sequence 333, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 333
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-333
```

```
Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1644 TCTGTATTATCTTTC 1659
Db 17 TCTGTATTATCTGTC 2
```

## RESULT 348

```
US-09-685-664B-477
; Sequence 477, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 477
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-477
```

```
Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 1154 AATATTTCCTCAACTAC 1169
Db 1 AAACUCUCCACACUAC 16

RESULT 349
US-09-685-664B-1080/c
; Sequence 1080, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1080
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1080

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1831 TCTGAAAAAATAAAAA 1846
Db 16 TTTCGAAAAAATAAAAA 1

RESULT 350
US-09-685-664B-1705/c
; Sequence 1705, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1705
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1705

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1154 AATATTTCCTCAACTAC 1169
Db 1 AAACUCUCCACACUAC 16

RESULT 349
US-09-685-664B-1080/c
; Sequence 1080, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1080
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1080

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1831 TCTGAAAAAATAAAAA 1846
Db 16 TTTCGAAAAAATAAAAA 1

RESULT 350
US-09-685-664B-1705/c
; Sequence 1705, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1705
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-1705

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1736 TGGTAGGATTACAGT 1751
Db 16 TGGTAAGATGACAGT 1

RESULT 351
US-09-685-664B-2671/c
; Sequence 2671, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2671
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2671

Query Match 0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 823 TGTCAAGAATGGCTTC 838
Db 16 TGTCAAAATGGTTTC 1

RESULT 352
US-09-685-664B-3604/c
; Sequence 3604, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR FILING DATE: 1996-01-08
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3604
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3604
```

US-09-685-664B-3604

Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAA 1850  
Db 16 AAAAAAAAAAAAAA 1

RESULT 353

US-09-093-972C-236  
; Sequence 236, Application US/09093972C  
; Patent No. 6825174  
; GENERAL INFORMATION:  
; APPLICANT: Nyce, Jonathan W.  
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION

NUMBER OF SEQUENCES: 996  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
STREET: 7 Clarke Drive  
CITY: Cranbury  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 08512

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/093,972C  
FILING DATE: 09-June-1998  
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 08/757,024  
FILING DATE: 26-11-1996  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 09/016,464  
FILING DATE: 30-January-1998  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930  
REFERENCE/DOCKET NUMBER: EPI-00672  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 609-409-3035  
TELEFAX: 413-254-9245  
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 236:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 236:

US-09-093-972C-236  
Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTGACAGCTGGGATG 984  
Db 2 CTGAAAGCTGAGATG 17

RESULT 354

US-09-093-972C-272  
; Sequence 272, Application US/09093972C  
; Patent No. 6825174  
; GENERAL INFORMATION:  
; APPLICANT: Nyce, Jonathan W.  
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION

NUMBER OF SEQUENCES: 996  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
STREET: 7 Clarke Drive  
CITY: Cranbury  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 08512

COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent in Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/093,972C  
FILING DATE: 09-June-1998  
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 08/757,024  
FILING DATE: 26-11-1996  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 09/016,464  
FILING DATE: 30-January-1998  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930  
REFERENCE/DOCKET NUMBER: EPI-00672  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 609-409-3035  
TELEFAX: 413-254-9245  
TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 272:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 272:

US-09-093-972C-272  
Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTGACAGCTGGGATG 984  
Db 1 CTGAAAGCTGAGATG 16

RESULT 355

PCT-US96-11786-33/c  
; Sequence 33, Application PC/TUS9611786  
; GENERAL INFORMATION:  
; APPLICANT: Rando, Robert F.  
; APPLICANT: Fennewald, Susan  
; APPLICANT: Zendequi, Joseph G.  
; APPLICANT: Ojwang, Joshua O.  
; APPLICANT: Hogan, Michael E.  
; APPLICANT: Pommier, Yves  
; APPLICANT: Mazumder, Abhijit



;; TITLE OF INVENTION: Anti-Viral Guanosine-Rich  
;; TITLE OF INVENTION: Oligonucleotides  
;; NUMBER OF SEQUENCES: 52  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: Conley, Rose & Tayon, P.C.  
;; STREET: 600 Travis, Suite 1850  
;; CITY: Houston  
;; STATE: Texas  
;; COUNTRY: U.S.A.  
;; ZIP: 77002-2912  
;;  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: PCT/US96/11786  
;; FILING DATE: 17-JULY-1996  
;; CLASSIFICATION:  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 08/535,168; 60/001,505; 60/014,007; 60/013,688;  
;; APPLICATION NUMBER: 60/015,714; 60/016,271  
;; FILING DATE: 23-OCT-95; 17-JULY-96; 25-MARCH-96; 19-MARCH-96; 23-  
;; FILING DATE: APRIL-96; 17-APRIL-96  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: McDaniel, C. Steven  
;; REGISTRATION NUMBER: 33,962  
;; REFERENCE/DOCKET NUMBER: 1472-06214  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 713/238-8010  
;; TELEFAX: 713/238-8008  
;; INFORMATION FOR SEQ ID NO: 33:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 17 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA (genomic)  
;; FEATURE:  
;; NAME/KEY: misc\_feature  
;; LOCATION: 17  
;; OTHER INFORMATION: /note="Amine moiety"  
;; OTHER INFORMATION: attached to 3' end"  
PCT-US96-11786-33  
  
Query Match 0.7%; Score 12.8; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1706 CCCTCCCTCCACCAC 1721  
Db 16 CCCACCCACCACCAC 1  
  
RESULT 356  
US-08-431-048F-151/c  
; Sequence 151, Application US/08431048F  
; Patent No. 6531586  
; GENERAL INFORMATION:  
; APPLICANT: ST. GEORGE-HYSLOP, PETER H  
; ROMMENS, JOHANNA M  
; FRASER, PAUL E  
; TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED  
; TO ALZHEIMER'S DISEASE  
; NUMBER OF SEQUENCES: 155  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DARBY & DARBY P.C.  
; STREET: 805 THIRD AVENUE  
; CITY: NEW YORK  
; STATE: N.Y.  
; COUNTRY: U.S.A.  
; ZIP: 10022-7513  
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.30  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/431,048F  
;; FILING DATE: 28-Apr-1995  
;; CLASSIFICATION: <Unknown>  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: FEHLNER, PAUL F.  
;; REGISTRATION NUMBER: 35135  
;; REFERENCE/DOCKET NUMBER: 1034/0F808  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 212-527-7700  
;; TELEFAX: 212-527-6237  
;; INFORMATION FOR SEQ ID NO: 151:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 15 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: DNA  
;; SEQUENCE DESCRIPTION: SEQ ID NO: 151:  
US-08-431-048F-151  
  
Query Match 0.7%; Score 12.6; DB 1; Length 15;  
Best Local Similarity 92.3%; Pred. No. 1.7e+02;  
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 328 GACTGAGTGGCTC 340  
Db 13 GACTGAGTGGCTC 1  
  
RESULT 357  
US-08-294-424-46  
; Sequence 46, Application US/08294424  
; Patent No. 5800984  
; GENERAL INFORMATION:  
; APPLICANT: Vary, Calvin  
; TITLE OF INVENTION: NUCLEIC ACID SEQUENCE DETECTION BY  
; TITLE OF INVENTION: TRIPLE HELIX FORMATION  
; NUMBER OF SEQUENCES: 49  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3 1/2" Diskette, 1.44 Mb storage  
; COMPUTER: IBM PS/2 Model 50Z or 55SX  
; OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)  
; SOFTWARE: WordPerfect (Version 5.0)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/294,424  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/000,922  
; FILING DATE: 16 JAN 1993  
; APPLICATION NUMBER: US/07/629,601B  
; FILING DATE: 17-DEC-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Freeman, John W.  
; REGISTRATION NUMBER: 29,066  
; REFERENCE/DOCKET NUMBER: 00088-037001  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 542-5070  
; TELEFAX: (617) 542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 46 :

; SEQUENCE CHARACTERISTICS:  
; LENGTH: 14  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-294-424-46

Query Match 0.7%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 722 CTCCTTCTCCATCT 735  
Db 1 CTCCTTCTCTTCT 14

## RESULT 358

US-09-152-059-116  
; Sequence 116, Application US/09152059  
; Patent No. 6794499  
; GENERAL INFORMATION:  
; APPLICANT: WENGEL, JESPER  
; APPLICANT: NIELSEN, POUL  
; TITLE OF INVENTION: OLIGONUCLEOTIDE ANALOGUES  
; FILE REFERENCE: 49165 (71994)  
; CURRENT APPLICATION NUMBER: US/09/152,059  
; CURRENT FILING DATE: 1998-09-11  
; PRIOR APPLICATION NUMBER: 60/058,541  
; PRIOR FILING DATE: 1997-09-12  
; PRIOR APPLICATION NUMBER: 60/068,293  
; PRIOR FILING DATE: 1997-12-19  
; PRIOR APPLICATION NUMBER: 60/071,682  
; PRIOR FILING DATE: 1998-01-16  
; PRIOR APPLICATION NUMBER: 60/076,591  
; PRIOR FILING DATE: 1998-03-03  
; PRIOR APPLICATION NUMBER: 60/083,507  
; PRIOR FILING DATE: 1998-04-29  
; PRIOR APPLICATION NUMBER: 60/088,309  
; PRIOR FILING DATE: 1998-06-05  
; PRIOR APPLICATION NUMBER: 60/094,355  
; PRIOR FILING DATE: 1998-07-28  
; NUMBER OF SEQ ID NOS: 146  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 116  
; LENGTH: 14  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
; OTHER INFORMATION: oligonucleotide  
US-09-152-059-116

Query Match 0.7%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1848  
Db 1 AAAAAAAAAAAAAA 14

## RESULT 359

US-08-875-553D-14/c  
; Sequence 14, Application US/08875553D  
; Patent No. 6811972  
; GENERAL INFORMATION:  
; APPLICANT: Paul B. Fisher and Ruochuan Shen  
; TITLE OF INVENTION: DEVELOPMENT OF DNA PROBES AND IMMUNOLOGICAL REAGENTS SPECIFIC FOR  
; TITLE OF INVENTION: SURFACE-EXPRESSED MOLECULES AND TRANSFORMATION-ASSOCIATED GENES  
; FILE REFERENCE: 0667/37590-C-PCT-US  
; CURRENT APPLICATION NUMBER: US/08/875,553D  
; CURRENT FILING DATE: 1998-05-26  
; NUMBER OF SEQ ID NOS: 43

; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 14  
; LENGTH: 14  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (1..1)  
; OTHER INFORMATION: Primer  
US-08-875-553D-14

Query Match 0.7%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1834 GAAAAAAAAAAAAA 1847  
Db 14 GCAAAAAAAAAAAAAA 1

## RESULT 360

US-09-981-803-32  
; Sequence 32, Application US/09981803  
; Patent No. 6825012  
; GENERAL INFORMATION:  
; APPLICANT: Joel CROUZET  
; APPLICANT: Daniel SCHERMAN  
; APPLICANT: Beatrice CAMERON  
; APPLICANT: Pierre WILS  
; APPLICANT: Anne-Marie DARQUET  
; TITLE OF INVENTION: DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY  
; FILE REFERENCE: MINICIRCLE  
; CURRENT APPLICATION NUMBER: US/09/981,803  
; CURRENT FILING DATE: 2001-10-19  
; NUMBER OF SEQ ID NOS: 50  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 32  
; LENGTH: 14  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: Description of the artificial sequence:  
; OTHER INFORMATION: oligonucleotide  
US-09-981-803-32

Query Match 0.7%; Score 12.4; DB 1; Length 14;  
Best Local Similarity 92.9%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 199 AAGAAATAAAGAA 212  
Db 1 AAGAAATAAAGAA 14

## RESULT 361

US-09-981-803-48/c  
; Sequence 48, Application US/09981803  
; Patent No. 6825012  
; GENERAL INFORMATION:  
; APPLICANT: Joel CROUZET  
; APPLICANT: Daniel SCHERMAN  
; APPLICANT: Beatrice CAMERON  
; APPLICANT: Pierre WILS  
; APPLICANT: Anne-Marie DARQUET  
; TITLE OF INVENTION: DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY  
; FILE REFERENCE: MINICIRCLE  
; CURRENT APPLICATION NUMBER: US/09/981,803  
; CURRENT FILING DATE: 2001-10-19  
; NUMBER OF SEQ ID NOS: 50  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 48  
; LENGTH: 14  
; TYPE: DNA

```

; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-334-847-92
;
; Query Match 0.7%; Score 12.4; DB 1; Length 15;
; Best Local Similarity 64.3%; Pred. No. 1.9e+02;
; Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
;
; QY 1360 GTCTACTTCATGAC 1373
; DB 1 GCUACUAGAUGAC 14
;
; RESULT 364
; US-08-334-847-615/c
; Sequence 615, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.

```

```
;
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 615:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-334-847-615
;
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1728 TCAACATATGGTAG 1741
Db 14 TCAATATATGGTAG 1

RESULT 365
US-08-908-724-1/c
; Sequence 1, Application US/08908724
; Patent No. 5840728
; GENERAL INFORMATION:
; APPLICANT: Marquez, Victor E.
; APPLICANT: Nicklaus, Marc C.
; APPLICANT: Barchi, Joseph J.
; APPLICANT: Rodriguez, Juan B.
; APPLICANT: Siddiqui, Maqbool A.
; TITLE OF INVENTION: CONFORMATIONALLY LOCKED NUCLEOSIDE
; TITLE OF INVENTION: ANALOGS AS ANTIHERPATIC AGENTS
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive, 16th Floor
; CITY: Newport Beach
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/908,724
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Bartfield, Neil S
; REGISTRATION NUMBER: 39,901
; REFERENCE/DOCKET NUMBER: NIH130.001PR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-235-8550
; TELEFAX: 619-235-0176
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE:

;
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 615:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-334-847-615
;
Query Match 0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1728 TCAACATATGGTAG 1741
Db 14 TCAATATATGGTAG 1

RESULT 366
US-08-173-489C-87/c
; Sequence 87, Application US/08173489C
; Patent No. 5861244
; GENERAL INFORMATION:
; APPLICANT: WANG, C. -G.
; APPLICANT: HEPBURN, A. G.
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.
; NUMBER OF SEQUENCES: 365
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,
; STREET: 510 EAST 73RD STREET,
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10021.
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage
; COMPUTER: IBM PC/XT/AT
; OPERATING SYSTEM: MS-DOS version 6.2
; SOFTWARE: Wordperfect version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/173,489C
; FILING DATE: 22 DEC 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/968,436
; FILING DATE: 29 OCT 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Handelman, Joseph H.
; REGISTRATION NUMBER: 26,179
; REFERENCE/DOCKET NUMBER: U9518-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (attorney) (212) 708-1880
; TELEFAX: (attorney) (212) 246-8959
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: double stranded
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; DESCRIPTION: retinoblastoma gene (Accession #
; DESCRIPTION: M33647, J02994) nucleotides 4062 to 4076
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: chromosome 13
; MAP POSITION: 13q14.2
; PUBLICATION INFORMATION:
; AUTHORS: Friend, S H, Horowitz, J M, Gerber, M R,
; AUTHORS: Wang X F, Bogenmann, E, Li, F P, Weinberg,
; AUTHORS: R A.
; TITLE: Deletions of a DNA sequence
; TITLE: in retinoblastomas and mesenchymal tumors:
; TITLE: Organization of the sequence and its encoded
; TITLE: protein
; JOURNAL: Proceedings of the National Academy of
```

```
; JOURNAL: Sciences, USA
; VOLUME: 84
; PAGES: 9059-9063
; DATE: 1987
; RELEVANT RESIDUES IN SEQ ID NO: 87 :FROM 1 TO 15
US-08-173-489C-87

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 437 GGAGAGGGGAGAG 450
Db 14 GGGAGGGGAGAG 1

RESULT 367
US-09-115-446-3/c
; Sequence 3, Application US/09115446
; Patent No. 6165719
; GENERAL INFORMATION:
; APPLICANT: Chandy, George K.
; APPLICANT: Gargus, Jay J.
; APPLICANT: Gutran, George
; APPLICANT: Fantino, Emmanuelle
; APPLICANT: Kalman, Katarin
; TITLE OF INVENTION: hKCA3/KCNN3 SMALL CONDUCTANCE CALCIUM
; TITLE OF INVENTION: ACTIVATED POTASSIUM CHANNEL: A DIAGNOSTIC
; TITLE OF INVENTION: MARKER AND THERAPEUTIC TARGET
; FILE REFERENCE: 07306/014001
; CURRENT APPLICATION NUMBER: US/09/115,446
; CURRENT FILING DATE: 1998-07-14
; EARLIER APPLICATION NUMBER: 60/052,556
; EARLIER FILING DATE: 1997-07-15
; EARLIER APPLICATION NUMBER: 60/070,741
; EARLIER FILING DATE: 1998-01-08
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-115-446-3

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1834 GAAAAAAGAAAAA 1847
Db 14 GAAAAAAGAAAAA 1

RESULT 368
US-08-584-040-8462
; Sequence 8462, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles

; JOURNAL: Sciences, USA
; VOLUME: 84
; PAGES: 9059-9063
; DATE: 1987
; RELEVANT RESIDUES IN SEQ ID NO: 87 :FROM 1 TO 15
US-08-173-489C-87

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1568 TGCACCTTTGGAAA 1581
Db 1 UGCAAAUUGGAAA 14

RESULT 369
US-09-475-947A-304/c
; Sequence 304, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 304
; LENGTH: 15
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-304

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGT 1460
Db 15 TTGCTGCTGCTGT 2

RESULT 370
US-09-371-772B-4117
; Sequence 4117, Application US/09371772B
```

; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00.876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4117  
; LENGTH: 15  
; TYPE: RNA  
; ORGANISM: Mus sp.  
US-09-371-772B-4117

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 64.3%; Pred. No. 1.9e+02;  
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1568 TGCACACTTTGGAAA 1581  
:||||| :|||  
Db 1 UGC AAAUUUGAAA 14

RESULT 371  
US-09-565-590-3/c  
; Sequence 3, Application US/09565590  
; Patent No. 6653100  
; GENERAL INFORMATION:  
; APPLICANT: Chandry, George K.  
; APPLICANT: Gargus, Jay J.  
; APPLICANT: Gutman, George  
; APPLICANT: Fantino, Emmanuelle  
; APPLICANT: Kalman, Katarin  
; TITLE OF INVENTION: hKCA3/KCN3 SMALL CONDUCTANCE CALCIUM  
; TITLE OF INVENTION: ACTIVATED POTASSIUM CHANNEL: A DIAGNOSTIC  
; FILE REFERENCE: 07306/014001  
; CURRENT APPLICATION NUMBER: US/09/565,590  
; CURRENT FILING DATE: 2000-05-04  
; PRIOR APPLICATION NUMBER: 09/115,446  
; PRIOR FILING DATE: 1998-07-14  
; PRIOR APPLICATION NUMBER: 60/070,741  
; PRIOR FILING DATE: 1998-01-08  
; NUMBER OF SEQ ID NOS: 15  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 15  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-09-565-590-3

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.9e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1834 GAAAAAAGAAAAA 1847  
:||||| :|||||  
Db 14 GAAAAAAGAAAAA 1

RESULT 372  
US-09-685-664B-4117  
; Sequence 4117, Application US/09685664B

; Patent No. 6818447  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MBH00-876-K (400/021)  
; CURRENT APPLICATION NUMBER: US/09/685,664B  
; CURRENT FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; PRIOR APPLICATION NUMBER: US 09/371,772  
; PRIOR FILING DATE: 1999-08-10  
; NUMBER OF SEQ ID NOS: 8231  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 4117  
; LENGTH: 15  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-685-664B-4117

Query Match 0.7%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 64.3%; Pred. No. 1.9e+02;  
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1568 TGCACACTTTGGAAA 1581  
:||||| :|||  
Db 1 UGC AAAUUUGAAA 14

RESULT 373  
PCT-US93-12600-18/c  
; Sequence 18, Application PC/TUS9312600  
; GENERAL INFORMATION:  
; APPLICANT: Denner, Larry A.  
; APPLICANT: Rege, Ajay A.  
; APPLICANT: Dixon, Richard A.F.  
; TITLE OF INVENTION: ANTISENSE MOLECULES DIRECTED AGAINST A  
; TITLE OF INVENTION: FIBROBLAST GROWTH FACTOR RECEPTOR GENE FAMILY  
; NUMBER OF SEQUENCES: 29  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Dressler, Goldsmith, Shore &  
; ADDRESSEE: Milnamow, Ltd.  
; STREET: 180 North Stetson, Suite 4700  
; CITY: Chicago  
; STATE: Illinois  
; COUNTRY: USA  
; ZIP: 60601  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: PCT/US93/12600  
; FILING DATE: 28-DEC-1993  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/999,706  
; FILING DATE: December 31, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Katz, Martin L.  
; REGISTRATION NUMBER: 25,011  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 616-5400  
; TELEFAX: (312) 616-5460  
; INFORMATION FOR SEQ ID NO: 18:  
; SEQUENCE CHARACTERISTICS:

```
;
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US93-12600-18

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 977 CTGGGATGTTGGGC 990
Db 14 CTGGGATGTTGGGC 1

RESULT 374
5182195-33/c
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO; KAISHO, YOSHIHIKO; YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO: 33:
; LENGTH: 15
5182195-33

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTT 1460
Db 14 TTGCTGATGCTGTT 1

RESULT 375
5182195-33/c
; Patent No. 5182195
; APPLICANT: NAKAHAMA, KAZUO; KAISHO, YOSHIHIKO; YOSHIMURA, KOJI
; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
; DEFICIENT YEASTS
; NUMBER OF SEQUENCES: 71
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/269,140
; FILING DATE: 09-NOV-1988
; SEQ ID NO: 33:
; LENGTH: 15
5182195-33

Query Match          0.7%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTT 1460
Db 14 TTGCTGATGCTGTT 1

RESULT 376
US-08-419-414-13/c
; Sequence 13, Application US/08419414
; Patent No. 5753787
; GENERAL INFORMATION:
; APPLICANT: Hawdon, John M.
; APPLICANT: Hotez, Peter J.
; APPLICANT: Jones, Brian F.
; TITLE OF INVENTION: Hookworm Vaccine
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:

;
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US93-12600-18

ADDRESSSEE: Patrea L. Pabst
STREET: 2800 One Atlantic Center
STREET: 1201 West Peachtree Street
CITY: Atlanta
STATE: Georgia
COUNTRY: USA
ZIP: 30309-3450
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/419,414
FILING DATE:
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Pabst, Patrea L.
REGISTRATION NUMBER: 31,284
REFERENCE/DOCKET NUMBER: YU113
TELECOMMUNICATION INFORMATION:
TELEPHONE: (404) 873-8795
TELEFAX: (404) 873-8795
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA primer"
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-419-414-13

Query Match          0.7%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1078 CTCGCGGCTGGTG 1091
Db 15 CTCGCGGCTGGTG 2

RESULT 377
US-09-564-805-92/c
; Sequence 92, Application US/09564805
; Patent No. 6333403
; GENERAL INFORMATION:
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Teng, David H.F.
; APPLICANT: Simard, Jacques
; APPLICANT: Rommens, Johanna M.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: Chromosome 17p-Linked Prostate Cancer Susceptibility
; FILE REFERENCES: 2318-258
; CURRENT APPLICATION NUMBER: US/09/564,805
; CURRENT FILING DATE: 2000-05-05
; PRIOR APPLICATION NUMBER: US 60/107,468
; PRIOR FILING DATE: 1998-11-06
; PRIOR APPLICATION NUMBER: 09/434,382
; PRIOR FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 92
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-564-805-92

Query Match          0.7%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 2.1e+02;
```

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 571 AACTGCAGACG 584  
Db 15 AACTGCGGAGG 2

## RESULT 378

US-09-060-299-443

; Sequence 443, Application US/09060299

; Patent No. 6545137

; GENERAL INFORMATION:

; APPLICANT: Todd, John A

; APPLICANT: Hess, John W

; APPLICANT: Caskey, Charles T

; APPLICANT: Cox, Roger D

; APPLICANT: Gerhold, David

; APPLICANT: Hammond, Holly

; APPLICANT: Hey, Patricia

; APPLICANT: Kawaguchi, Yoshihiko

; APPLICANT: Merriman, Tony R

; APPLICANT: Metzker, Michael L

; TITLE OF INVENTION: No. 6545137el Receptor

; NUMBER OF SEQUENCES: 455

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Nixon and Vanderhye

; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor

; CITY: Arlington

; STATE: Virginia

; COUNTRY: US

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25 (BPO)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/060,299

; FILING DATE: 15-APR-1998

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 60/043,553

; FILING DATE: 15-APR-1997

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 60/048,740

; FILING DATE: 05-JUN-1997

; ATTORNEY/AGENT INFORMATION:

; NAME: B.J.Sadoff

; REGISTRATION NUMBER: 36,663

; REFERENCE/DOCKET NUMBER: 620-35

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (703)816-4091

; TELEFAX: (703)816-4100

; INFORMATION FOR SEQ ID NO: 443:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 16 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

; US-09-060-299-443

Query Match 0.7%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.le+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 499 GTCTTGCAGCAGC 512  
Db 1 GTCTTGCAGCAGC 14

## RESULT 379

US-09-402-923A-443

; Sequence 443, Application US/09402923A

; Patent No. 6555654

## GENERAL INFORMATION:

; APPLICANT: Todd, John A

; APPLICANT: Hess, John W

; APPLICANT: Caskey, Charles T

; APPLICANT: Cox, Roger D

; APPLICANT: Gerhold, David

; APPLICANT: Hammond, Holly

; APPLICANT: Hey, Patricia

; APPLICANT: Kawaguchi, Yoshihiko

; APPLICANT: Merriman, Tony R

; APPLICANT: Metzker, Michael L

; TITLE OF INVENTION: No. 6555654el LDL-Receptor

; NUMBER OF SEQUENCES: 455

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Nixon and Vanderhye

; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor

; CITY: Arlington

; STATE: Virginia

; COUNTRY: US

; ZIP: VA 22201-4714

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: Patent In Release #1.0, Version #1.25 (BPO)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/402,923A

; FILING DATE: 14-Feb-2001

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: PCT/GB98/01102

; FILING DATE: 15-APR-1998

; APPLICATION NUMBER: US 60/043,553

; FILING DATE: 15-APR-1997

; APPLICATION NUMBER: US 60/048,740

; FILING DATE: 05-JUN-1997

; ATTORNEY/AGENT INFORMATION:

; NAME: B.J.Sadoff

; REGISTRATION NUMBER: 36,663

; REFERENCE/DOCKET NUMBER: 620-81

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (703)816-4091

; TELEFAX: (703)816-4100

; INFORMATION FOR SEQ ID NO: 443:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 16 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: double

; TOPOLOGY: linear

; SEQUENCE DESCRIPTION: SEQ ID NO: 443:

; US-09-402-923A-443

Query Match 0.7%; Score 12.4; DB 1; Length 16;

Best Local Similarity 92.9%; Pred. No. 2.le+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 499 GTCTTGCAGCAGC 512  
Db 1 GTCTTGCAGCAGC 14

## RESULT 380

US-09-371-772B-5841/c

; Sequence 5841, Application US/09371772B

; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH800,876-J (237/198)



; CURRENT APPLICATION NUMBER: US/09/371,772B  
; PRIOR FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5841  
; LENGTH: 16  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5841

Query Match 0.7%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2.1e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1280 CCTCAATATCACTC 1293  
Db 14 CCTCAATCACTC 1

RESULT 381  
US-09-371-772B-5864  
; Sequence 5864, Application US/09371772B  
; Patent No. 6566127  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; APPLICANT: Pavco, Pam  
; APPLICANT: McSwiggan, Jim  
; APPLICANT: Stinchcomb, Dan  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re  
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor  
; FILE REFERENCE: MHB00,876-J (237/198)  
; CURRENT APPLICATION NUMBER: US/09/371,772B  
; CURRENT FILING DATE: 1999-08-10  
; PRIOR APPLICATION NUMBER: US 60/005,974  
; PRIOR FILING DATE: 1995-10-26  
; PRIOR APPLICATION NUMBER: US 08/584,040  
; PRIOR FILING DATE: 1996-01-08  
; NUMBER OF SEQ ID NOS: 14225  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 5864  
; LENGTH: 16  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-371-772B-5864

Query Match 0.7%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 64.3%; Pred. No. 2.1e+02;  
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
Qy 188 GAGGACTTTTGAAG 201  
Db 1 GAGGACUUGCAG 14

RESULT 382  
US-09-750-401-6/c  
; Sequence 6, Application US/09750401  
; Patent No. 6635422  
; GENERAL INFORMATION:  
; APPLICANT: Keene, Jack D.  
; APPLICANT: Carson, Craig C.  
; APPLICANT: Tenenbaum, Scott A.  
; TITLE OF INVENTION: Methods for isolating and characterizing endogenous mRNA-protein  
; TITLE OF INVENTION: complexes  
; FILE REFERENCE: REN-001  
; CURRENT APPLICATION NUMBER: US/09/750,401  
; CURRENT FILING DATE: 2000-12-28  
; PRIOR APPLICATION NUMBER: US 60/173,338

; PRIOR FILING DATE: 1999-12-28  
; NUMBER OF SEQ ID NOS: 37  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 6  
; LENGTH: 16  
; TYPE: RNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: 3'-UTR sequence of HOX 2.5  
US-09-750-401-6

Query Match 0.7%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2.1e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1808 ACTTAATAAATTTT 1821  
Db 14 ACTTAATAAATTT 1

RESULT 383  
US-09-479-005A-332/c  
; Sequence 332, Application US/09479005A  
; Patent No. 6656731  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyne Pharmaceuticals, Inc.  
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity  
; FILE REFERENCE: MHB00-884-C  
; CURRENT APPLICATION NUMBER: US/09/479,005A  
; CURRENT FILING DATE: 2000-01-07  
; PRIOR APPLICATION NUMBER: US 09/444,209  
; PRIOR FILING DATE: 1999-11-19  
; PRIOR APPLICATION NUMBER: US 09/159,274  
; PRIOR FILING DATE: 1998-09-22  
; PRIOR APPLICATION NUMBER: US 60/059,473  
; PRIOR FILING DATE: 1997-09-22  
; NUMBER OF SEQ ID NOS: 1208  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 332  
; LENGTH: 16  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-479-005A-332

Query Match 0.7%; Score 12.4; DB 1; Length 16;  
Best Local Similarity 92.9%; Pred. No. 2.1e+02;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1589 TTCACATAACAATT 1602  
Db 15 TTCACATAGCAATT 2

RESULT 384  
US-08-173-489C-87  
; Sequence 87, Application US/08173489C  
; Patent No. 5861244  
; GENERAL INFORMATION:  
; APPLICANT: WANG, C.-G.  
; APPLICANT: HEPBURN, A. G.  
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA  
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.  
; NUMBER OF SEQUENCES: 365  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,  
; STREET: 510 EAST 73RD STREET,  
; CITY: NEW YORK  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 10021.  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 inch, 1.44Mb storage  
; COMPUTER: IBM PC/XT/AT

OPERATING SYSTEM: MS-DOS version 6.2  
SOFTWARE: Wordperfect Version 5.1  
CURRENT APPLICATION DATA: /08/173,489C  
APPLICATION NUMBER: US/08/173,489C  
FILING DATE: 22 DEC 1993  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/968,436  
FILING DATE: 29 OCT 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Handelman, Joseph H.  
REGISTRATION NUMBER: 26,179  
REFERENCE/DOCKET NUMBER: U9518-6  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (attorney) (212) 708-1880  
TELEFAX: (attorney) (212) 246-8959  
INFORMATION FOR SEQ ID NO: 87:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: Nucleic Acid  
STRANDEDNESS: double stranded  
TOPOLOGY: linear  
MOLECULE TYPE: Genomic DNA  
DESCRIPTION: retinoblastoma gene (Accession #  
M33647, J02994) nucleotides 4062 to 4076  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
POSITION IN GENOME:  
CHROMOSOME/SEGMENT: chromosome 13  
MAP POSITION: 13q14.2  
PUBLICATION INFORMATION:  
AUTHORS: Friend, S H, Horowitz, J M, Gerber, M R,  
Wang X F, Bogenmann, E, Li, F P, Weinberg,  
R A.  
TITLE: Deletions of a DNA sequence  
TITLE: in retinoblastomas and mesenchymal tumors:  
TITLE: Organization of the sequence and its encoded  
TITLE: protein  
JOURNAL: Proceedings of the National Academy of  
Sciences, USA  
VOLUME: 84  
PAGES: 9059-9063  
DATE: 1987  
RELEVANT RESIDUES IN SEQ ID NO: 87 :FROM 1 TO 15  
US-08-173-489C-87

Query Match 0.6% Score 12; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 2.2e+02;  
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1701 TTCTCCCTCCC 1712  
|||||  
Db 2 TTCTCCCTCCC 13

Search completed: July 12, 2005, 10:42:44  
Job time : 8 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:37:23 ; Search time 7 Seconds  
(without alignments)  
3.416 Million cell updates/sec

Title: US-09-745-763-35  
Perfect score: 1851  
Sequence: 1 GGCTAGCCCGAGCTAGT.....CTGAAAAA.....AAAAA 1851

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 364 seqs, 6460 residues

Total number of hits satisfying chosen parameters: 728

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 369 summaries

Database : rge35.seq.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	28	1.5	29	1	BD106421
C 2	18.4	1.0	20	1	AR562157
C 3	18	1.0	20	1	AR562158
C 4	17.8	1.0	23	1	AG9549
C 5	17.2	0.9	19	1	AR528447
C 6	17	0.9	19	1	AR541350
C 7	17	0.9	19	1	AR541351
C 8	17	0.9	19	1	AR541352
C 9	17	0.9	19	1	AR541353
C 10	17	0.9	19	1	AR541361
C 11	17	0.9	20	1	AR532682
C 12	17	0.9	20	1	AR532682
C 13	17	0.9	20	1	AR532682
C 14	17	0.9	20	1	AR532682
C 15	17	0.9	20	1	AR532682
C 16	17	0.9	20	1	AR532682
C 17	16.4	0.9	18	1	AR532682
C 18	16.4	0.9	20	1	AR532682
C 19	16.4	0.9	20	1	AR532682
C 20	16.4	0.9	20	1	AR532682
C 21	16.4	0.9	21	1	AR532682
C 22	16.2	0.9	21	1	AR532682
C 23	16.2	0.9	21	1	AR532682
C 24	16.2	0.9	21	1	AR532682
C 25	16.2	0.9	21	1	AR532682
C 26	16	0.9	16	1	AR561628
C 27	16	0.9	16	1	AR561693
C 28	16	0.9	19	1	AR561693
C 29	15.8	0.9	19	1	AR241724
C 30	15.8	0.9	19	1	AR241724
C 31	15.8	0.9	19	1	AR241724
C 32	15.8	0.9	20	1	BD272150
C 33	15.8	0.9	20	1	BD272150

ACCESSION: I36684	20	1	I36684	0.9	15.8	34
ACCESSION: AR315632	20	1	AR315632	0.9	15.8	C 35
ACCESSION: AX040095	20	1	AX040095	0.9	15.8	C 36
ACCESSION: AX956227	20	1	AX956227	0.9	15.8	C 37
ACCESSION: AR084563	21	1	AR084563	0.9	15.8	C 38
ACCESSION: AR084566	21	1	AR084566	0.9	15.8	C 39
ACCESSION: AR084567	21	1	AR084567	0.9	15.8	C 40
ACCESSION: AR084579	21	1	AR084579	0.9	15.8	C 41
ACCESSION: Q0830490	21	1	Q0830490	0.9	15.8	C 42
ACCESSION: Q0830491	21	1	Q0830491	0.9	15.8	C 43
ACCESSION: Q0830492	21	1	Q0830492	0.9	15.8	C 44
ACCESSION: AR203496	21	1	AR203496	0.9	15.8	C 45
ACCESSION: BD056667	21	1	BD056667	0.9	15.8	C 46
ACCESSION: AX725153	17	1	AX725153	0.8	15.4	C 47
ACCESSION: AX727863	17	1	AX727863	0.8	15.4	C 48
ACCESSION: AX733002	17	1	AX733002	0.8	15.4	C 49
ACCESSION: A67588	18	1	A67588	0.8	15.4	C 50
ACCESSION: AR035168	18	1	AR035168	0.8	15.4	C 51
ACCESSION: AR089726	18	1	AR089726	0.8	15.4	C 52
ACCESSION: Q0786327	18	1	Q0786327	0.8	15.4	C 53
ACCESSION: AR340812	18	1	AR340812	0.8	15.4	C 54
ACCESSION: AX141245	18	1	AX141245	0.8	15.4	C 55
ACCESSION: BD142414	20	1	BD142414	0.8	15.4	C 56
ACCESSION: AR315566	20	1	AR315566	0.8	15.4	C 57
ACCESSION: AX149057	20	1	AX149057	0.8	15.4	C 58
ACCESSION: AX554362	20	1	AX554362	0.8	15.4	C 59
ACCESSION: AR121539	20	1	AR121539	0.8	15.2	C 60
ACCESSION: AR121992	20	1	AR121992	0.8	15.2	C 61
ACCESSION: Q0786367	20	1	Q0786367	0.8	15.2	C 62
ACCESSION: Q0796907	20	1	Q0796907	0.8	15.2	C 63
ACCESSION: I83426	20	1	I83426	0.8	15.2	C 64
ACCESSION: AR182885	20	1	AR182885	0.8	15.2	C 65
ACCESSION: AR313757	20	1	AR313757	0.8	15.2	C 66
ACCESSION: AR429256	20	1	AR429256	0.8	15.2	C 67
ACCESSION: AX104051	20	1	AX104051	0.8	15.2	C 68
ACCESSION: AX298435	20	1	AX298435	0.8	15.2	C 69
ACCESSION: AX355382	20	1	AX355382	0.8	15.2	C 70
ACCESSION: AX458688	20	1	AX458688	0.8	15.2	C 71
ACCESSION: AX547104	20	1	AX547104	0.8	15.2	C 72
ACCESSION: AX556882	20	1	AX556882	0.8	15.2	C 73
ACCESSION: BD069976	20	1	BD069976	0.8	15.2	C 74
ACCESSION: BD088317	20	1	BD088317	0.8	15.2	C 75
ACCESSION: AB068428	20	1	AB068428	0.8	15.2	C 76
ACCESSION: AX129260	19	1	AX129260	0.8	15	C 77
ACCESSION: AR107613	20	1	AR107613	0.8	15	C 78
ACCESSION: AR107614	20	1	AR107614	0.8	15	C 79
ACCESSION: AR107615	20	1	AR107615	0.8	15	C 80
ACCESSION: AR107616	20	1	AR107616	0.8	15	C 81
ACCESSION: AR107617	20	1	AR107617	0.8	15	C 82
ACCESSION: AR107618	20	1	AR107618	0.8	15	C 83
ACCESSION: I15672	19	1	I15672	0.8	14.8	C 84
ACCESSION: I36677	19	1	I36677	0.8	14.8	C 85
ACCESSION: AR295153	19	1	AR295153	0.8	14.8	C 86
ACCESSION: AR295404	19	1	AR295404	0.8	14.8	C 87
ACCESSION: AR533334	19	1	AR533334	0.8	14.8	C 88
ACCESSION: AX131510	19	1	AX131510	0.8	14.8	C 89
ACCESSION: AX132341	19	1	AX132341	0.8	14.8	C 90
ACCESSION: AX149169	19	1	AX149169	0.8	14.8	C 91
ACCESSION: Q0623624	17	1	Q0623624	0.8	14.4	C 92
ACCESSION: Q0623625	17	1	Q0623625	0.8	14.4	C 93
ACCESSION: Q0625290	17	1	Q0625290	0.8	14.4	C 94
ACCESSION: Q0625291	17	1	Q0625291	0.8	14.4	C 95
ACCESSION: Q0625291	17	1	Q0625291	0.8	14.4	C 96
ACCESSION: AR327069	17	1	AR327069	0.8	14.4	C 97
ACCESSION: AR464687	17	1	AR464687	0.8	14.4	C 98
ACCESSION: AR464688	17	1	AR464688	0.8	14.4	C 99
ACCESSION: AR466353	17	1	AR466353	0.8	14.4	C 100
ACCESSION: AR466354	17	1	AR466354	0.8	14.4	C 101
ACCESSION: AX218292	17	1	AX218292	0.8	14.4	C 102
ACCESSION: AX579784	17	1	AX579784	0.8	14.4	C 103
ACCESSION: AX722986	17	1	AX722986	0.8	14.4	C 104
ACCESSION: AX723927	17	1	AX723927	0.8	14.4	C 105
ACCESSION: AX724619	17	1	AX724619	0.8	14.4	C 106
ACCESSION: AX725224	17	1	AX725224	0.8	14.4	C 107

C 107	14.4	0.8	17	1	AX726651	ACCESSION:AX726651	180	13.8	0.7	17	1	AX475498	ACCESSION:AX475498
108	14.4	0.8	17	1	AX735552	ACCESSION:AX735552	C 181	13.8	0.7	17	1	AX502944	ACCESSION:AX502944
109	14.4	0.8	17	1	AX736376	ACCESSION:AX736376	C 182	13.8	0.7	17	1	AX578360	ACCESSION:AX578360
110	14.4	0.8	18	1	AR164526	ACCESSION:AR164526	183	13.8	0.7	17	1	AX578426	ACCESSION:AX578426
C 111	14.4	0.8	18	1	AX133011	ACCESSION:AX133011	184	13.8	0.7	17	1	AX615236	ACCESSION:AX615236
112	14.4	0.8	18	1	AX327131	ACCESSION:AX327131	185	13.8	0.7	17	1	AX615237	ACCESSION:AX615237
C 113	14.4	0.8	18	1	AX697910	ACCESSION:AX697910	C 186	13.8	0.7	17	1	AX648875	ACCESSION:AX648875
C 114	14.4	0.8	19	1	AX131834	ACCESSION:AX131834	C 187	13.8	0.7	17	1	AX648876	ACCESSION:AX648876
C 115	14.2	0.8	17	1	181221	ACCESSION:181221	C 188	13.8	0.7	17	1	AX693083	ACCESSION:AX693083
C 116	14.2	0.8	17	1	AR438875	ACCESSION:AR438875	C 189	13.8	0.7	17	1	AX724533	ACCESSION:AX724533
C 117	14	0.8	15	1	AR322168	ACCESSION:AR322168	C 190	13.8	0.7	17	1	AX728002	ACCESSION:AX728002
118	14	0.8	17	1	CQ617850	ACCESSION:CQ617850	191	13.8	0.7	17	1	AX730762	ACCESSION:AX730762
119	14	0.8	17	1	CQ617851	ACCESSION:CQ617851	192	13.8	0.7	17	1	AX734915	ACCESSION:AX734915
120	14	0.8	17	1	CQ617852	ACCESSION:CQ617852	193	13.8	0.7	17	1	AX736157	ACCESSION:AX736157
121	14	0.8	17	1	CQ617853	ACCESSION:CQ617853	C 194	13.8	0.7	17	1	AX736485	ACCESSION:AX736485
122	14	0.8	17	1	AR458913	ACCESSION:AR458913	195	13.8	0.7	17	1	AX737865	ACCESSION:AX737865
123	14	0.8	17	1	AR458914	ACCESSION:AR458914	C 196	13.8	0.7	17	1	AX783722	ACCESSION:AX783722
124	14	0.8	17	1	AR458915	ACCESSION:AR458915	197	13.8	0.7	17	1	BD067591	ACCESSION:BD067591
125	14	0.8	17	1	AR458916	ACCESSION:AR458916	C 198	13.8	0.7	18	1	AI4295	ACCESSION:AI4295
126	14	0.8	17	1	AX217415	ACCESSION:AX217415	C 199	13.8	0.7	18	1	AI8146	ACCESSION:AI8146
C 127	14	0.8	17	1	AX688102	ACCESSION:AX688102	C 200	13.8	0.7	18	1	A65728	ACCESSION:A65728
C 128	14	0.8	17	1	AX688103	ACCESSION:AX688103	C 201	13.8	0.7	18	1	A67594	ACCESSION:A67594
C 129	14	0.8	17	1	AX688104	ACCESSION:AX688104	202	13.8	0.7	18	1	AR049397	ACCESSION:AR049397
C 130	14	0.8	17	1	AX688105	ACCESSION:AX688105	C 203	13.8	0.7	18	1	AR049649	ACCESSION:AR049649
C 131	14	0.8	17	1	AX733399	ACCESSION:AX733399	C 204	13.8	0.7	18	1	AR063241	ACCESSION:AR063241
C 132	14	0.8	17	1	AX733818	ACCESSION:AX733818	205	13.8	0.7	18	1	AR072949	ACCESSION:AR072949
C 133	14	0.8	17	1	AX733819	ACCESSION:AX733819	C 206	13.8	0.7	18	1	AR085610	ACCESSION:AR085610
C 134	14	0.8	17	1	AX733820	ACCESSION:AX733820	C 207	13.8	0.7	18	1	AR089732	ACCESSION:AR089732
C 135	14	0.8	17	1	AX733821	ACCESSION:AX733821	208	13.8	0.7	18	1	AR121149	ACCESSION:AR121149
136	14	0.8	17	1	AX733825	ACCESSION:AX733825	209	13.8	0.7	18	1	BD171756	ACCESSION:BD171756
137	14	0.8	17	1	AX733836	ACCESSION:AX733836	210	13.8	0.7	18	1	BD171760	ACCESSION:BD171760
138	14	0.8	17	1	AX733837	ACCESSION:AX733837	C 211	13.8	0.7	18	1	CQ795193	ACCESSION:CQ795193
139	14	0.8	17	1	AX733838	ACCESSION:AX733838	C 212	13.8	0.7	18	1	CQ807790	ACCESSION:CQ807790
140	14	0.8	17	1	166351	ACCESSION:166351	C 213	13.8	0.7	18	1	CQ876358	ACCESSION:CQ876358
141	14	0.8	18	1	AR564469	ACCESSION:AR564469	C 214	13.8	0.7	18	1	E29787	ACCESSION:E29787
C 142	13.8	0.7	17	1	AR168820	ACCESSION:AR168820	215	13.8	0.7	18	1	I21931	ACCESSION:I21931
C 143	13.8	0.7	17	1	BD198938	ACCESSION:BD198938	216	13.8	0.7	18	1	AR220082	ACCESSION:AR220082
C 144	13.8	0.7	17	1	BD201322	ACCESSION:BD201322	217	13.8	0.7	18	1	AR281858	ACCESSION:AR281858
145	13.8	0.7	17	1	CQ616796	ACCESSION:CQ616796	218	13.8	0.7	18	1	AR303208	ACCESSION:AR303208
146	13.8	0.7	17	1	CQ616797	ACCESSION:CQ616797	219	13.8	0.7	18	1	AR308314	ACCESSION:AR308314
147	13.8	0.7	17	1	CQ623620	ACCESSION:CQ623620	220	13.8	0.7	18	1	AR344645	ACCESSION:AR344645
148	13.8	0.7	17	1	CQ623621	ACCESSION:CQ623621	221	13.8	0.7	18	1	AR353533	ACCESSION:AR353533
C 149	13.8	0.7	17	1	CQ624832	ACCESSION:CQ624832	C 222	13.8	0.7	18	1	AR442110	ACCESSION:AR442110
150	13.8	0.7	17	1	AR188676	ACCESSION:AR188676	C 223	13.8	0.7	18	1	AR442224	ACCESSION:AR442224
151	13.8	0.7	17	1	AR188677	ACCESSION:AR188677	224	13.8	0.7	18	1	AR493061	ACCESSION:AR493061
C 152	13.8	0.7	17	1	AR188762	ACCESSION:AR188762	C 225	13.8	0.7	18	1	AX092726	ACCESSION:AX092726
153	13.8	0.7	17	1	AR190246	ACCESSION:AR190246	226	13.8	0.7	18	1	AX113887	ACCESSION:AX113887
154	13.8	0.7	17	1	AR190247	ACCESSION:AR190247	227	13.8	0.7	18	1	AX326905	ACCESSION:AX326905
C 155	13.8	0.7	17	1	AR190332	ACCESSION:AR190332	C 228	13.8	0.7	18	1	AX378472	ACCESSION:AX378472
C 156	13.8	0.7	17	1	AR192330	ACCESSION:AR192330	229	13.8	0.7	18	1	AX699211	ACCESSION:AX699211
C 157	13.8	0.7	17	1	AR192331	ACCESSION:AR192331	C 230	13.8	0.7	18	1	AX785466	ACCESSION:AX785466
C 158	13.8	0.7	17	1	AR200289	ACCESSION:AR200289	C 231	13.8	0.7	18	1	AX959634	ACCESSION:AX959634
C 159	13.8	0.7	17	1	AR262421	ACCESSION:AR262421	C 232	13.8	0.7	18	1	BD002174	ACCESSION:BD002174
160	13.8	0.7	17	1	AR324529	ACCESSION:AR324529	C 233	13.8	0.7	18	1	BD002275	ACCESSION:BD002275
161	13.8	0.7	17	1	AR324530	ACCESSION:AR324530	234	13.8	0.7	18	1	BD010879	ACCESSION:BD010879
C 162	13.8	0.7	17	1	AR324615	ACCESSION:AR324615	235	13.4	0.7	15	1	BD244856	ACCESSION:BD244856
163	13.8	0.7	17	1	AR325211	ACCESSION:AR325211	C 236	13.4	0.7	16	1	BD248438	ACCESSION:BD248438
164	13.8	0.7	17	1	AR325212	ACCESSION:AR325212	C 237	13.4	0.7	16	1	AX928000	ACCESSION:AX928000
C 165	13.8	0.7	17	1	AR326200	ACCESSION:AR326200	C 238	13.4	0.7	17	1	AR168840	ACCESSION:AR168840
C 166	13.8	0.7	17	1	AR326201	ACCESSION:AR326201	C 239	13.4	0.7	17	1	AR168847	ACCESSION:AR168847
C 167	13.8	0.7	17	1	AR328859	ACCESSION:AR328859	C 240	13.4	0.7	17	1	AR168850	ACCESSION:AR168850
168	13.8	0.7	17	1	AR402091	ACCESSION:AR402091	C 241	13.4	0.7	17	1	AR168851	ACCESSION:AR168851
169	13.8	0.7	17	1	AR457859	ACCESSION:AR457859	C 242	13.4	0.7	17	1	BD198937	ACCESSION:BD198937
170	13.8	0.7	17	1	AR457860	ACCESSION:AR457860	C 243	13.4	0.7	17	1	BD201049	ACCESSION:BD201049
171	13.8	0.7	17	1	AR464683	ACCESSION:AR464683	C 244	13.4	0.7	17	1	BD201115	ACCESSION:BD201115
172	13.8	0.7	17	1	AR464685	ACCESSION:AR464685	C 245	13.4	0.7	17	1	BD254875	ACCESSION:BD254875
C 173	13.8	0.7	17	1	AR465895	ACCESSION:AR465895	C 246	13.4	0.7	17	1	CQ616798	ACCESSION:CQ616798
174	13.8	0.7	17	1	AX217108	ACCESSION:AX217108	247	13.4	0.7	17	1	CQ616799	ACCESSION:CQ616799
C 175	13.8	0.7	17	1	AX226648	ACCESSION:AX226648	248	13.4	0.7	17	1	CQ623626	ACCESSION:CQ623626
C 176	13.8	0.7	17	1	AX255600	ACCESSION:AX255600	249	13.4	0.7	17	1	CQ623847	ACCESSION:CQ623847
C 177	13.8	0.7	17	1	AX421858	ACCESSION:AX421858	250	13.4	0.7	17	1	CQ623848	ACCESSION:CQ623848
C 178	13.8	0.7	17	1	AX423222	ACCESSION:AX423222	251	13.4	0.7	17	1	CQ623849	ACCESSION:CQ623849
C 179	13.8	0.7	17	1	AX423319	ACCESSION:AX423319	C 252	13.4	0.7	17	1	CQ625289	ACCESSION:CQ625289

C 253 13.4 0.7 17 1 C0625292  
 C 254 13.4 0.7 17 1 E32474  
 C 255 13.4 0.7 17 1 AR188763  
 C 256 13.4 0.7 17 1 AR190333  
 C 257 13.4 0.7 17 1 AR200309  
 C 258 13.4 0.7 17 1 AR200316  
 C 259 13.4 0.7 17 1 AR200319  
 C 260 13.4 0.7 17 1 AR200320  
 C 261 13.4 0.7 17 1 AR200320  
 C 262 13.4 0.7 17 1 AR200320  
 C 263 13.4 0.7 17 1 AR200320  
 C 264 13.4 0.7 17 1 AR200320  
 C 265 13.4 0.7 17 1 AR200320  
 C 266 13.4 0.7 17 1 AR200320  
 C 267 13.4 0.7 17 1 AR200320  
 C 268 13.4 0.7 17 1 AR200320  
 C 269 13.4 0.7 17 1 AR200320  
 C 270 13.4 0.7 17 1 AR200320  
 C 271 13.4 0.7 17 1 AR200320  
 C 272 13.4 0.7 17 1 AR200320  
 C 273 13.4 0.7 17 1 AR200320  
 C 274 13.4 0.7 17 1 AR200320  
 C 275 13.4 0.7 17 1 AR200320  
 C 276 13.4 0.7 17 1 AR200320  
 C 277 13.4 0.7 17 1 AR200320  
 C 278 13.4 0.7 17 1 AR200320  
 C 279 13.4 0.7 17 1 AR200320  
 C 280 13.4 0.7 17 1 AR200320  
 C 281 13.4 0.7 17 1 AR200320  
 C 282 13.4 0.7 17 1 AR200320  
 C 283 13.4 0.7 17 1 AR200320  
 C 284 13.4 0.7 17 1 AR200320  
 C 285 13.4 0.7 17 1 AR200320  
 C 286 13.4 0.7 17 1 AR200320  
 C 287 13.4 0.7 17 1 AR200320  
 C 288 13.4 0.7 17 1 AR200320  
 C 289 13.4 0.7 17 1 AR200320  
 C 290 13.4 0.7 17 1 AR200320  
 C 291 13.4 0.7 17 1 AR200320  
 C 292 13.4 0.7 17 1 AR200320  
 C 293 13.4 0.7 17 1 AR200320  
 C 294 13.4 0.7 17 1 AR200320  
 C 295 13.4 0.7 17 1 AR200320  
 C 296 13.4 0.7 17 1 AR200320  
 C 297 13.4 0.7 17 1 AR200320  
 C 298 13.4 0.7 17 1 AR200320  
 C 299 13.4 0.7 17 1 AR200320  
 C 300 13.4 0.7 17 1 AR200320  
 C 301 13.4 0.7 17 1 AR200320  
 C 302 13.4 0.7 17 1 AR200320  
 C 303 13.4 0.7 17 1 AR200320  
 C 304 13.4 0.7 17 1 AR200320  
 C 305 13.4 0.7 17 1 AR200320  
 C 306 13.4 0.7 17 1 AR200320  
 C 307 13.4 0.7 17 1 AR200320  
 C 308 13.4 0.7 17 1 AR200320  
 C 309 13.4 0.7 17 1 AR200320  
 C 310 13.4 0.7 17 1 AR200320  
 C 311 13.4 0.7 17 1 AR200320  
 C 312 13.4 0.7 17 1 AR200320  
 C 313 13.4 0.7 17 1 AR200320  
 C 314 13.4 0.7 17 1 AR200320  
 C 315 13.4 0.7 17 1 AR200320  
 C 316 13.4 0.7 17 1 AR200320  
 C 317 13.4 0.7 17 1 AR200320  
 C 318 13.4 0.7 17 1 AR200320  
 C 319 13.4 0.7 17 1 AR200320  
 C 320 13.4 0.7 17 1 AR200320  
 C 321 13.4 0.7 17 1 AR200320  
 C 322 13.4 0.7 17 1 AR200320  
 C 323 13.4 0.7 17 1 AR200320  
 C 324 13.4 0.7 17 1 AR200320  
 C 325 13.4 0.7 17 1 AR200320

C 326 13 0.7 17 1 AR168852  
 C 327 13 0.7 17 1 BD241318  
 C 328 13 0.7 17 1 BD254874  
 C 329 13 0.7 17 1 CQ617849  
 C 330 13 0.7 17 1 CQ617854  
 C 331 13 0.7 17 1 AR200317  
 C 332 13 0.7 17 1 AR200321  
 C 333 13 0.7 17 1 AR262448  
 C 334 13 0.7 17 1 AR262452  
 C 335 13 0.7 17 1 AR365612  
 C 336 13 0.7 17 1 AR401993  
 C 337 13 0.7 17 1 AR458912  
 C 338 13 0.7 17 1 AR458917  
 C 339 13 0.7 17 1 AR482819  
 C 340 13 0.7 17 1 AR482819  
 C 341 13 0.7 17 1 AR482819  
 C 342 13 0.7 17 1 AR482819  
 C 343 13 0.7 17 1 AR482819  
 C 344 13 0.7 17 1 AR482819  
 C 345 13 0.7 17 1 AR482819  
 C 346 13 0.7 17 1 AR482819  
 C 347 13 0.7 17 1 AR482819  
 C 348 13 0.7 17 1 AR482819  
 C 349 13 0.7 17 1 AR482819  
 C 350 13 0.7 17 1 AR482819  
 C 351 13 0.7 17 1 AR482819  
 C 352 13 0.7 17 1 AR482819  
 C 353 13 0.7 17 1 AR482819  
 C 354 13 0.7 17 1 AR482819  
 C 355 13 0.7 17 1 AR482819  
 C 356 13 0.7 17 1 AR482819  
 C 357 13 0.7 17 1 AR482819  
 C 358 13 0.7 17 1 AR482819  
 C 359 13 0.7 17 1 AR482819  
 C 360 13 0.7 17 1 AR482819  
 C 361 13 0.7 17 1 AR482819  
 C 362 13 0.7 17 1 AR482819  
 C 363 13 0.7 17 1 AR482819  
 C 364 13 0.7 17 1 AR482819  
 C 365 12.8 0.7 17 1 AR482819  
 C 366 12.8 0.7 17 1 AR482819  
 C 367 12.8 0.7 17 1 AR482819  
 C 368 12.8 0.7 17 1 AR482819  
 C 369 12.8 0.7 17 1 AR482819

## ALIGNMENTS

RESULT 1  
 BD106421/c  
 LOCUS  
 DEFINITION  
 ACCESSION  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM  
 REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 COMMENT

BD106421 29 bp DNA linear PAT 18-SEP-2002  
 Secreter proteins and polynucleotides encoding them.  
 BD106421 GI:23201239  
 JP 2002503955-A/12.  
 Chlamydia sp.  
 Bacteria; Chlamydiales; Chlamydiales; Chlamydia.  
 1 (bases 1 to 29)  
 Jacobs, K., Mccoy, J.M., Lavallie, E.R., Racie, L.A., Merberg, D.,  
 Treacy, M., Spaulding, V. and Agostino, M.J.  
 Secreter proteins and polynucleotides encoding them  
 Patent: JP 2002503955-A 12 05-FEB-2002;  
 GENETICS INSTITUTE INC  
 PN JP 2002503955-A/12  
 PD 05-FEB-2002  
 PF 20-MAR-1998 JP 1998545874  
 PR 21-MAR-1997 US 08/822167, 19-MAR-1998 US 09/044466 PI  
 KENNETH JACOBS, JOHN M MCCOY, EDWARD R LAVALLIE, LISA A RACIE, PI  
 DAVID MERBERG,  
 PI MAURICE TREACY, VIKKI SPAULDING, MICHAEL J AGOSTINO PC  
 C12N15/12, C07K14/47, A61K38/17

```

CC Strandedness: Single;
CC Topology: Linear;
CC /desc="Oligonucleotide", Location/Qualifiers.
FH Key Location/Qualifiers
FEATURES
    source
        1..29
            /organism="Chlamydia sp."
            /mol_type="genomic DNA"
            /db_xref="taxon:35827"

Query Match
Best Local Similarity 1.5%; Score 28; DB 1; Length 29;
Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 295 GATTGGCACTCTCGTTGACTGTTGGA 323
Db 29 GATTGGCACTCTCGTTGACTGTTGNA 1

RESULT 2
AR562157/c
LOCUS AR562157 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 33 from patent US 6759215.
ACCESSION AR562157
VERSION AR562157.1 GI:53976020
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 33 06-JUL-2004;
FEATURES
    source
        1..20
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match
Best Local Similarity 1.0%; Score 18.4; DB 1; Length 20;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1832 CTGAAAAAATAAAAAAAAAA 1851
Db 20 CTAAAAAATAAAAAAAAAA 1

RESULT 3
AR562158/c
LOCUS AR562158 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 34 from patent US 6759215.
ACCESSION AR562158
VERSION AR562158.1 GI:53976021
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 34 06-JUL-2004;
FEATURES
    source
        1..20
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match
Best Local Similarity 1.0%; Score 18; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAATAAAAAAAAAA 1851
Db 19 GAAAAAATAAAAAAAAAA 2

RESULT 4
A69549/c
LOCUS A69549 23 bp DNA linear PAT 07-MAY-1999
DEFINITION Sequence 11 from Patent WO9805762.
ACCESSION A69549
VERSION A69549.1 GI:4774190
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 23)
AUTHORS Fischer,S. and Kohnert,U.
TITLE PLASMINOGEN ACTIVATOR CAPABLE OF BEING ACTIVATED BY THROMBIN
JOURNAL Patent: WO 9805762-A 11 12-FEB-1998;
FEATURES
    Location/Qualifiers
        source
            1..23
                /organism="unidentified"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32644"

Query Match
Best Local Similarity 1.0%; Score 17.8; DB 1; Length 23;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1263 ATGAGCCTCTCGAGCCCTC 1283
Db 22 ATGAGCCTCTCGAGCGCTC 2

RESULT 5
AR528447/c
LOCUS AR528447 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 85 from patent US 6723897.
ACCESSION AR528447
VERSION AR528447.1 GI:53916512
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Brown,S.M., Elich,T.D., Heck,G.R., Kishore,G.M., Logusch,B.W.,
Logusch,S.J., Piller,K.J., Rao,S., Ream,J.E. and Baerson,S.R.
TITLE Methods for controlling gibberellin levels
JOURNAL Patent: US 6723897-A 85 20-APR-2004;
FEATURES
    Location/Qualifiers
        source
            1..19
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.9%; Score 17.2; DB 1; Length 19;
Matches 17; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1834 GAAAAAATAAAAAAAAAA 1851
Db 19 BAAAAAATAAAAAAAAAA 2

RESULT 6
AR541350/c
LOCUS AR541350 19 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 15 from patent US 6737520.
ACCESSION AR541350
VERSION AR541350.1 GI:53932997
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.

```

TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry  
JOURNAL Patent: US 6737520-A 15 18-MAY-2004;  
FEATURES Location/Qualifiers  
source 1. 19  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 44;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 7  
AR541351/c  
LOCUS AR541351 19 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 16 from patent US 6737520.  
ACCESSION AR541351  
VERSION AR541351.1 GI:53932998  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Manoharan,M. and Mohan,V.  
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry  
JOURNAL Patent: US 6737520-A 16 18-MAY-2004;  
FEATURES Location/Qualifiers  
source 1. 19  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 44;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 8  
AR541352/c  
LOCUS AR541352 19 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 17 from patent US 6737520.  
ACCESSION AR541352  
VERSION AR541352.1 GI:53932999  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Manoharan,M. and Mohan,V.  
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry  
JOURNAL Patent: US 6737520-A 17 18-MAY-2004;  
FEATURES Location/Qualifiers  
source 1. 19  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 44;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 19 AAAAAAAAAAAAAAAAAA 3

TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry  
JOURNAL Patent: US 6737520-A 15 18-MAY-2004;  
FEATURES Location/Qualifiers  
source 1. 19  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 44;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 9  
AR541353/c  
LOCUS AR541353 19 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 18 from patent US 6737520.  
ACCESSION AR541353  
VERSION AR541353.1 GI:53933000  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Manoharan,M. and Mohan,V.  
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry  
JOURNAL Patent: US 6737520-A 18 18-MAY-2004;  
FEATURES Location/Qualifiers  
source 1. 19  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 44;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 10  
AR541361/c  
LOCUS AR541361 19 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 26 from patent US 6737520.  
ACCESSION AR541361  
VERSION AR541361.1 GI:53933008  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Manoharan,M. and Mohan,V.  
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry  
JOURNAL Patent: US 6737520-A 26 18-MAY-2004;  
FEATURES Location/Qualifiers  
source 1. 19  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 44;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 11  
AR532682  
LOCUS AR532682 20 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 55 from patent US 6730269.  
ACCESSION AR532682  
VERSION AR532682.1 GI:53922053  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J., Elghariani,R. and Taton,T.A.

TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor

JOURNAL Patent: US 6730269-A 55 04-MAY-2004;

FEATURES source 1. .20 /organism="unknown" /mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 49; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||

Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 12

AR559396

LOCUS AR559396 20 bp DNA linear PAT 08-OCT-2004

DEFINITION Sequence 55 from patent US 6750016.

ACCESSION AR559396

VERSION AR559396.1 GI:53968812

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Mirkin,C.A., Letsinger,R.L. and Park,S.-J.

TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor

JOURNAL Patent: US 6750016-A 55 15-JUN-2004;

FEATURES source 1. .20 /organism="unknown" /mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 49; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||

Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 13

AR559411

LOCUS AR559411 20 bp DNA linear PAT 08-OCT-2004

DEFINITION Sequence 70 from patent US 6750016.

ACCESSION AR559411

VERSION AR559411.1 GI:53968827

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Mirkin,C.A., Letsinger,R.L. and Park,S.-J.

TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor

JOURNAL Patent: US 6750016-A 70 15-JUN-2004;

FEATURES source 1. .20 /organism="unknown" /mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 49; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||

Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 14

AR561993

LOCUS AR561993 20 bp DNA linear PAT 08-OCT-2004

DEFINITION Sequence 55 from patent US 6759199.

ACCESSION AR561993

VERSION AR561993.1 GI:53975645

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J., Elghanian,R. and Taton,T.A.

TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor

JOURNAL Patent: US 6759199-A 55 06-JUL-2004;

FEATURES source 1. .20 /organism="unknown" /mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 49; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||

Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 15

AR562156/c

LOCUS AR562156 20 bp DNA linear PAT 08-OCT-2004

DEFINITION Sequence 32 from patent US 6759215.

ACCESSION AR562156

VERSION AR562156.1 GI:53976019

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Zsebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.

TITLE Method of preparing human stem cell factor polypeptide

JOURNAL Patent: US 6759215-A 32 06-JUL-2004;

FEATURES source 1. .20 /organism="unknown" /mol\_type="genomic DNA"

Query Match 0.9%; Score 17; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 49; Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
|||||

Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 16

AR565165

LOCUS AR565165 20 bp DNA linear PAT 08-OCT-2004

DEFINITION Sequence 55 from patent US 6767702.

ACCESSION AR565165

VERSION AR565165.1 GI:53981003

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J., Elghanian,R., Taton,T.A., Garimella,V. and Li,Z.



TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor  
JOURNAL Patent: US 6767702-A 55 27-JUL-2004;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.9%; Score 17; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 49;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1835 AAAAAAAAAAAAAA 1851  
Db 1 AAAAAAAAAAAAAA 17  
RESULT 17  
LOCUS AR292366/c 18 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 4101 from patent US 6537751.  
ACCESSION AR292366  
VERSION AR292366.1 GI:31679650  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.  
TITLE Balleic markers for use in constructing a high density disequilibrium map of the human genome  
JOURNAL Patent: US 6537751-A 4101 25-MAR-2003;  
FEATURES Location/Qualifiers  
source 1..18  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 94.4%; Pred. No. 51;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 730 CCATCTACAGTCCTCACA 747  
Db 18 CCATCTACATTCCTCACA 1  
RESULT 18  
LOCUS CQ882062 20 bp DNA linear PAT 11-OCT-2004  
DEFINITION Sequence 3 from Patent WO2004083232.  
ACCESSION CQ882062  
VERSION CQ882062.1 GI:54034772  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Pettipher,R.  
TITLE Receptor proteins  
JOURNAL Patent: WO 2004083232-A 3 30-SEP-2004;  
JOURNAL Oxagen Limited (GB)  
FEATURES Location/Qualifiers  
source 1..20  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="PRIMER/OLIGONUCLEOTIDE"  
Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 62;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1411 ACACCATGACTGTCATGG 1428

Db 2 ACACCGTGAAGTCATGG 19  
RESULT 19  
LOCUS AR312535/c 20 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 3072 from patent US 6559294.  
ACCESSION AR312535  
VERSION AR312535.1 GI:31705961  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A., Sankaran,B. and Fletcher,L.D.  
TITLE Chlamydia pneumoniae polynucleotides and uses thereof  
JOURNAL Patent: US 6559294-A 3072 06-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 62;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1612 TCATCTTCAAAGCAGCAC 1629  
Db 19 TCATCTTCAAAGCAGCAC 2  
RESULT 20  
LOCUS DOGVWFB/c 20 bp DNA linear STS 11-APR-1996  
DEFINITION Canis familiaris von Willebrand's factor (VWF) STS DNA, 3' primer, sequence tagged site.  
ACCESSION L77431  
VERSION L77431.1 GI:1261792  
KEYWORDS STS; PCR identification; PCR primer; sequence tagged site; universal mammalian STS; von Willebrand factor.  
SOURCE Canis familiaris (dog)  
ORGANISM Canis familiaris  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Mammalia; Euthera; Carnivora; Fissipedia; Canidae; Canis.  
TITLE Buckyvota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Ventrals; P.J.; Brouillette,J.A.; Yuzbasiyan-Gurkan,V. and Brewer,G.J.  
JOURNAL Gene-specific universal mammalian sequence-tagged sites: application to the canine genome  
COMMENT Unpublished (1996)  
Original source text: Canis familiaris DNA.  
Gene-specific universal mammalian sequence-tagged site for VWF. Primer for the 3' end is in exon 47. Human product is 650 bp.  
Canine product is 650 bp.  
PCR conditions: 1 min, 94 C, 2 min, 57 C, 3 min, 72 C, 35 cycles.  
FEATURES Location/Qualifiers  
source 1..20  
/organism="Canis familiaris"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9615"  
primer\_bind 1..20  
/note="PCR primer binding site"  
STS 1..20  
/evidence="experimental"  
Query Match 0.9%; Score 16.4; DB 1; Length 20;  
Best Local Similarity 94.4%; Pred. No. 62;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1333 GGATCCAGCTGAGTGC 1350  
Db 20 GGATTCAGCTGAGTGC 3

```
RESULT 21
LOCUS AR084578 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 67 from patent US 5981185.
ACCESSION AR084578
VERSION AR084578.1 GI:10011349
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 67 09-NOV-1999;
FEATURES
source Location/Qualifiers
1..21
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred.No.73;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 28 GCCGCTCCGTCGCCGCCGTC 48
| | | | | | | | | | | | | | | | | | | |
Db 1 GCCGCGCGCGCGCGCGCGCC 1

RESULT 22
LOCUS AR084582/c 21 bp DNA linear PAT 01-SEP-2000
DEFINITION Sequence 71 from patent US 5981185.
ACCESSION AR084582
VERSION AR084582.1 GI:10011353
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE Oligonucleotide repeat arrays
JOURNAL Patent: US 5981185-A 71 09-NOV-1999;
FEATURES
source Location/Qualifiers
1..21
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred.No.73;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 28 GCCGCTCCGTCGCCGCCGTC 48
| | | | | | | | | | | | | | | | | | | |
Db 1 GCCGCGCGCGCGCGCGCGCC 21

RESULT 23
LOCUS AR093142/c 21 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 11 from patent US 5998596.
ACCESSION AR093142
VERSION AR093142.1 GI:10019894
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Bergan,R. and Neckers,L.
TITLE Inhibition of protein kinase activity by aptameric action of oligonucleotides
JOURNAL Patent: US 5998596-A 11 07-DEC-1999;

RESULT 24
LOCUS AR526824 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 32 from patent US 6723506.
ACCESSION AR526824
VERSION AR526824.1 GI:53913647
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Fletcher,J.A. and Kroll,T.G.
TITLE Method of identifying PAX8-PPAR gamma-nucleic acid molecules
JOURNAL Patent: US 6723506-A 32 20-APR-2004;
FEATURES
source Location/Qualifiers
1..21
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred.No.73;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 886 ACCCAGATCTGATTCCTTCA 906
| | | | | | | | | | | | | | | | | | | |
Db 1 ACCCAGAAAGCGATTCCTTCA 21

RESULT 25
LOCUS AX922788 21 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1128 from Patent WO02068649.
ACCESSION AX922788
VERSION AX922788.1 GI:40215778
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 other sequences; artificial sequences.
AUTHORS
JOURNAL Patent: WO 02068649-A 1128 06-SEP-2002;
Curagen Corporation (US)
FEATURES
source Location/Qualifiers
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: Ag712 Reverse"
Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred.No.73;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGCTGTT 1461
| | | | | | | | | | | | | | | | | | | |
Db 1 TGAATGTTGCTGCTGCTGTT 21

RESULT 26
```

AR561628  
LOCUS AR561628 16 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 1 from patent US 6756492.  
ACCESSION AR561628  
VERSION AR561628.1 GI:53974736  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Beier, M. and Honeiseil, J.  
TITLE Nucleoside derivatives with photo-unstable protective groups  
JOURNAL Patent: US 6756492-A 1 29-JUN-2004;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.9%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 48;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1835 AAAAAAAAAAAAAA 1850  
Db 1 AAAAAAAAAAAAAA 16  
RESULT 27  
AR561693/c  
LOCUS AR561693 16 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 9 from patent US 6759039.  
ACCESSION AR561693  
VERSION AR561693.1 GI:53974843  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Tsang, W.-G., Zheng, T. and Huang, C.J.  
TITLE Culturing pancreatic stem cells having a specified, intermediate stage of development  
JOURNAL Patent: US 6759039-A 9 06-JUL-2004;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.9%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 48;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1835 AAAAAAAAAAAAAA 1850  
Db 16 AAAAAAAAAAAAAA 1  
RESULT 28  
AX129261/c  
LOCUS AX129261 19 bp DNA linear PAT 15-MAY-2001  
DEFINITION Sequence 479 from Patent WO0130362.  
ACCESSION AX129261  
VERSION AX129261.1 GI:14135566  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Robbins, J.M. and Tritz, R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 479 03-MAY-2001;  
IMMUSOL, INC. (US)

AR561628  
LOCUS AR561628 16 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 1 from patent US 6756492.  
ACCESSION AR561628  
VERSION AR561628.1 GI:53974736  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Beier, M. and Honeiseil, J.  
TITLE Nucleoside derivatives with photo-unstable protective groups  
JOURNAL Patent: US 6756492-A 1 29-JUN-2004;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.9%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 48;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1835 AAAAAAAAAAAAAA 1850  
Db 1 AAAAAAAAAAAAAA 16  
RESULT 27  
AR561693/c  
LOCUS AR561693 16 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 9 from patent US 6759039.  
ACCESSION AR561693  
VERSION AR561693.1 GI:53974843  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Tsang, W.-G., Zheng, T. and Huang, C.J.  
TITLE Culturing pancreatic stem cells having a specified, intermediate stage of development  
JOURNAL Patent: US 6759039-A 9 06-JUL-2004;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.9%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 48;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1835 AAAAAAAAAAAAAA 1850  
Db 16 AAAAAAAAAAAAAA 1  
RESULT 28  
AX129261/c  
LOCUS AX129261 19 bp DNA linear PAT 15-MAY-2001  
DEFINITION Sequence 479 from Patent WO0130362.  
ACCESSION AX129261  
VERSION AX129261.1 GI:14135566  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Robbins, J.M. and Tritz, R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 479 03-MAY-2001;  
IMMUSOL, INC. (US)

FEATURES  
source  
1. .19  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Cdk4 ribozyme binding site"  
Query Match 0.9%; Score 16; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 66;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1095 TGGACTGCAGAGAAC 1110  
Db 19 TGGACTGCAGAGAAC 4  
RESULT 29  
AR241724/c  
LOCUS AR241724 19 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 12 from patent US 6472154.  
ACCESSION AR241724  
VERSION AR241724.1 GI:27287536  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 19)  
AUTHORS Garner, H.R., Wren, J.D., Minna, J.D. and Fondon, J.W. III.  
TITLE Polymorphic repeats in human genes  
JOURNAL Patent: US 6472154-A 12 29-OCT-2002;  
FEATURES  
source  
1. .19  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 71;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1516 AGAAACAGTAAGAAAGAAA 1534  
Db 19 AGAAAGAAAGAAAGAAA 1  
RESULT 30  
AX131832/c  
LOCUS AX131832 19 bp DNA linear PAT 15-MAY-2001  
DEFINITION Sequence 3050 from Patent WO0130362.  
ACCESSION AX131832  
VERSION AX131832.1 GI:14138137  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Robbins, J.M. and Tritz, R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 3050 03-MAY-2001;  
IMMUSOL, INC. (US)  
FEATURES  
source  
1. .19  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Cyclin A1 ribozyme binding site"  
Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 71;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 436 GGGAGAGGGGAGAGAAATC 454

```

Db      19  GCGAGAGGAGATGAATC 1
|||||
AX131833      19 bp      DNA      linear      PAT 15-MAY-2001
LOCUS
DEFINITION   Sequence 3051 from Patent WO0130362.
ACCESSION   AX131833
VERSION      AX131833.1  GI:14138138
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Robbins,J.M. and Tritz,R.
TITLE       Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL     Patent: WO 0130362-A 3051 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES     Location/Qualifiers
             source
               1..19
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
               /notes="Cyclin A1 ribozyme binding site"
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      434  CTGGGAGAGGGGAGAGAA 452
|||||
Db      19  CTGGGAGAGGAGAGATGAA 1

RESULT 32
BD272150
LOCUS
DEFINITION   Nucleic acid sequences to proteins involved in isoprenoid
synthesis.
ACCESSION   BD272150
VERSION      BD272150.1  GI:33081918
KEYWORDS     JP 2002541851-A/7.
SOURCE       synthetic construct
ORGANISM     other sequences; artificial sequences.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Kishore,G.M., Boronat,A. and Campos,N.
TITLE       Nucleic acid sequences to proteins involved in isoprenoid synthesis
JOURNAL     Patent: JP 2002541851-A 7 10-DEC-2002;
CALGENE LLC
COMMENT      OS Artificial Sequence
PN JP 2002541851-A/7
PD 10-DEC-2002
PF 14-APR-2000 JP 2000612468
PR 15-APR-1999 US 60/129899,30-JUL-1999 US 60/146461 PI
GANESH M KISHORE,ALBERT BORONAT,NARSISKO CAMPOS PC
C12N15/09,A01H5/00,C12N5/10//C12N9/90,C12N15/00,C12N5/00 CC
Synthetic Oligonucleotide
FH Key      Location/Qualifiers
FT source   1..20
             /organism='Artificial Sequence'.
FEATURES     Location/Qualifiers
             source
               1..20
               /organism="synthetic construct"
               /mol_type="genomic DNA"
               /db_xref="taxon:32630"
Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db      19  GCGAGAGGAGAGATGAATC 1
|||||
AX131833      19 bp      DNA      linear      PAT 15-MAY-2001
LOCUS
DEFINITION   Sequence 3051 from Patent WO0130362.
ACCESSION   AX131833
VERSION      AX131833.1  GI:14138138
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Robbins,J.M. and Tritz,R.
TITLE       Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL     Patent: WO 0130362-A 3051 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES     Location/Qualifiers
             source
               1..19
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
               /notes="Cyclin A1 ribozyme binding site"
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      434  CTGGGAGAGGGGAGAGAA 452
|||||
Db      19  CTGGGAGAGGAGAGATGAA 1

RESULT 31
AX131833/c
LOCUS
DEFINITION   Sequence 3051 from Patent WO0130362.
ACCESSION   AX131833
VERSION      AX131833.1  GI:14138138
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Robbins,J.M. and Tritz,R.
TITLE       Ribozyme therapy for the treatment of proliferative skin and eye
diseases
JOURNAL     Patent: WO 0130362-A 3051 03-MAY-2001;
IMMUSOL, INC. (US)
FEATURES     Location/Qualifiers
             source
               1..19
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"
               /notes="Cyclin A1 ribozyme binding site"
Query Match      0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1244  GGCATCATCGAGGAGGTT 1262
|||||
Db      1  GGCATCTGCTGGAGGAGTT 19
|||||

RESULT 33
I15679
LOCUS
DEFINITION   Sequence 16 from patent US 5470719.
ACCESSION   I15679
VERSION      I15679.1  GI:1250587
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Meng,S.-Y., Morris,C.F. and Tsai,L.B.
TITLE       Modified OmpA signal sequence for enhanced secretion of
polypeptides
JOURNAL     Patent: US 5470719-A 16 28-NOV-1995;
FEATURES     Location/Qualifiers
             source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1680  TGATTTCTAGAAAAAGGAAT 1698
|||||
Db      2  TGATTTCTAGAGAGGAAT 20
|||||

RESULT 34
I36684
LOCUS
DEFINITION   Sequence 16 from patent US 5608036.
ACCESSION   I36684
VERSION      I36684.1  GI:2086509
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Meng,S.-Y., Morris,C.F. and Tsai,L.B.
TITLE       Enhanced secretion of polypeptides
JOURNAL     Patent: US 5608036-A 16 04-MAR-1997;
FEATURES     Location/Qualifiers
             source
               1..20
               /organism="unknown"
               /mol_type="unassigned DNA"
Query Match      0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 78;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1680  TGATTTCTAGAAAAAGGAAT 1698
|||||
Db      2  TGATTTCTAGAGAGGAAT 20
|||||

RESULT 35
AR315632/c
LOCUS
DEFINITION   Sequence 6169 from patent US 6559294.
ACCESSION   AR315632
VERSION      AR315632.1  GI:31709058
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.

```

REFERENCE 1 (bases 1 to 20)  
AUTHORS Griffais,R., Hotseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,  
Sankaran,B. and Fletcher,L.D.  
TITLE Chlamydia pneumoniae polynucleotides and uses thereof  
JOURNAL Patent: US 6559294-A 6169 06-MAY-2003;  
FEATURES Location/Qualifiers  
source  
1..20  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 78;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1440 ATGAATGTTGCTGCTGCTG 1458  
Db 19 ATGATTGTTGCTGCTGCG 1

RESULT 36  
LOCUS AX040095 20 bp DNA linear PAT 18-NOV-2000  
DEFINITION Sequence 8 from Patent WO0063389.  
ACCESSION AX040095  
VERSION AX040095.1 GI:11230056  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.

REFERENCE 1  
AUTHORS Kishore,G.M., Boronat,A., Bhat,B.G. and Rangwala,S.H.  
TITLE Nucleic acid sequences to proteins involved in isoprenoid synthesis  
JOURNAL Patent: WO 0063389-A 8 26-OCT-2000;  
Calgene LLC (US)  
FEATURES Location/Qualifiers  
source  
1..20  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Synthetic Oligonucleotide"

Query Match 0.9%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 78;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1244 GGCCATCATGCGAGGTT 1262  
Db 1 GGCCATGCTGGAGGTT 19

RESULT 37  
LOCUS AX956227/c 20 bp DNA linear PAT 08-JAN-2004  
DEFINITION Sequence 134 from Patent WO03093505.  
ACCESSION AX956227  
VERSION AX956227.1 GI:40784753  
KEYWORDS Mus musculus (house mouse).  
SOURCE Mus musculus (house mouse).

REFERENCE 1  
AUTHORS Mouthon,F., Nouvel,V. and Deslys,J.P.  
TITLE Method for determining the presence of an unconventional transmissible agent responsible for transmissible subacute spongiform encephalopathy  
JOURNAL Patent: WO 03093505-A 134 13-NOV-2003;  
COMMISSARIAT A L'ENERGIE ATOMIQUE (FR)  
FEATURES Location/Qualifiers  
source  
1..20  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"

REFERENCE 1 (bases 1 to 21)  
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.  
TITLE Oligonucleotide repeat arrays  
JOURNAL Patent: US 5981185-A 52 09-NOV-1999;  
FEATURES Location/Qualifiers  
source  
1..21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 85;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTTCGTCGCCGCCG 46  
Db 3 GCCGCGCGCGCGCGCGCG 21

RESULT 39  
LOCUS AR084566 21 bp DNA linear PAT 01-SEP-2000  
DEFINITION Sequence 55 from patent US 5981185.  
ACCESSION AR084566  
VERSION AR084566.1 GI:10011337  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.  
TITLE Oligonucleotide repeat arrays  
JOURNAL Patent: US 5981185-A 55 09-NOV-1999;  
FEATURES Location/Qualifiers  
source  
1..21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 85;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTTCGTCGCCGCCG 46  
Db 2 GCCGCGCGCGCGCGCGCG 20

RESULT 40  
LOCUS AR084567/c 21 bp DNA linear PAT 01-SEP-2000  
DEFINITION Sequence 56 from patent US 5981185.  
ACCESSION AR084567  
VERSION AR084567.1 GI:10011338

/db\_xref="taxon:10090"

Query Match 0.9%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 78;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1240 CCAGGCGCATCATGAGGA 1258  
Db 20 CCAGGGCTATCATGAGGA 2

RESULT 38  
LOCUS AR084563 21 bp DNA linear PAT 01-SEP-2000  
DEFINITION Sequence 52 from patent US 5981185.  
ACCESSION AR084563  
VERSION AR084563.1 GI:10011334  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.  
TITLE Oligonucleotide repeat arrays  
JOURNAL Patent: US 5981185-A 52 09-NOV-1999;  
FEATURES Location/Qualifiers  
source  
1..21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 85;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTTCGTCGCCGCCG 46  
Db 3 GCCGCGCGCGCGCGCGCG 21

RESULT 39  
LOCUS AR084566 21 bp DNA linear PAT 01-SEP-2000  
DEFINITION Sequence 55 from patent US 5981185.  
ACCESSION AR084566  
VERSION AR084566.1 GI:10011337  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.  
TITLE Oligonucleotide repeat arrays  
JOURNAL Patent: US 5981185-A 55 09-NOV-1999;  
FEATURES Location/Qualifiers  
source  
1..21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
Best Local Similarity 89.5%; Pred. No. 85;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTTCGTCGCCGCCG 46  
Db 2 GCCGCGCGCGCGCGCGCG 20

RESULT 40  
LOCUS AR084567/c 21 bp DNA linear PAT 01-SEP-2000  
DEFINITION Sequence 56 from patent US 5981185.  
ACCESSION AR084567  
VERSION AR084567.1 GI:10011338

```
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
JOURNAL    Patent: US 5981185-A 56 09-NOV-1999;
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGCCG 46
Db 19 GCCGCCGCCGCCGCCGCCG 1

RESULT 41
LOCUS      AR084579/c
DEFINITION Sequence 68 from patent US 5981185.
ACCESSION  AR084579
VERSION    AR084579.1 GI:10011350
KEYWORDS   Unknown.
ORGANISM   Unclassified.
REFERENCE   1 (bases 1 to 21)
AUTHORS    Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
TITLE      Oligonucleotide repeat arrays
JOURNAL    Patent: US 5981185-A 68 09-NOV-1999;
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGCCG 46
Db 19 GCCGCCGCCGCCGCCGCCG 1

RESULT 42
LOCUS      CQ830490
DEFINITION Sequence 2 from Patent WO2004055153.
ACCESSION  CQ830490
VERSION    CQ830490.1 GI:50250830
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE   1
AUTHORS    Schluesener,H. and Wendel,H.P.
TITLE      Devices coated with substances that mediate the adhesion of
            biological material
JOURNAL    Patent: WO 2004055153-A 2 01-JUL-2004;
            Eberhard-Karls-Universitaet Tuebingen (DE)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Nukleotidsequenz"

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGCCG 46
Db 20 GCCGCCGCCGCCGCCGCCG 2

RESULT 43
LOCUS      CQ830491/c
DEFINITION Sequence 3 from Patent WO2004055153.
ACCESSION  CQ830491
VERSION    CQ830491.1 GI:50250831
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE   1
AUTHORS    Schluesener,H. and Wendel,H.P.
TITLE      Devices coated with substances that mediate the adhesion of
            biological material
JOURNAL    Patent: WO 2004055153-A 3 01-JUL-2004;
            Eberhard-Karls-Universitaet Tuebingen (DE)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Nukleotidsequenz"

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGCCG 46
Db 20 GCCGCCGCCGCCGCCGCCG 2

RESULT 44
LOCUS      CQ830492/c
DEFINITION Sequence 4 from Patent WO2004055153.
ACCESSION  CQ830492
VERSION    CQ830492.1 GI:50250832
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE   1
AUTHORS    Schluesener,H. and Wendel,H.P.
TITLE      Devices coated with substances that mediate the adhesion of
            biological material
JOURNAL    Patent: WO 2004055153-A 4 01-JUL-2004;
            Eberhard-Karls-Universitaet Tuebingen (DE)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Nukleotidsequenz"

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGCCG 46
Db 19 GCCGCCGCCGCCGCCGCCG 1
```

```

RESULT 45
LOCUS      AX203496                      21 bp    DNA          linear          PAT 30-AUG-2001
DEFINITION Sequence 126 from Patent WO0153520.
ACCESSION  AX203496
VERSION     AX203496.1  GI:15392907
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Cullen,P. and Seedorf,U.
TITLE      Gene chip for neonate screening
JOURNAL    Patent: WO 0153520-A 126 26-JUL-2001;
           Cullen, Paul (DE) ; Seedorf, Udo (DE)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 197 TGAAGAAATAAAGAGAA 215
Db 3 TGAAGAAATTAACGAGNA 21

RESULT 46
LOCUS      BD056667/c                    21 bp    DNA          linear          PAT 27-AUG-2002
DEFINITION Method to diagnose and treat pathological conditions resulting from
ACCESSION  BD056667
VERSION     BD056667.1  GI:22602273
KEYWORDS   JP 2001508291-A/124.
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1. (bases 1 to 21)
AUTHORS    Lifton,R.P. and Simon,D.B.
TITLE      Method to diagnose and treat pathological conditions resulting from
           deficient ion transport
JOURNAL    Patent: JP 2001508291-A 124 26-JUN-2001;
           YALE UNIVERSITY
COMMENT    OS Artificial Sequence
           PN JP 2001508291-A/124
           PD 26-JUN-2001
           PF 19-DEC-1997 JP 1998530123
           PR 31-DEC-1996 US 08/778052
           PI RICHARD P LIFTON,DAVID B SIMON
           PC C12N15/09,C07K14/435,C07K16/00,C12N1/15,C12N1/19,C12N1/21, PC
           C12N5/10,
           PC C12P21/02,C12Q1/68,G01N33/53,C12N15/00,C12N5/00 CC Primer
           for analysis of human ROMK gene
FH Key Location/Qualifiers
   source
     1..21
       /organism="synthetic construct"
       /mol_type="genomic DNA"
       /db_xref="taxon:32630"
Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 85;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 961 GTGGACATCTGGACGCTG 979
Db 21 GTGGACATCTGGACACGG 3

RESULT 47
LOCUS      AX725153                      17 bp    DNA          linear          PAT 08-MAY-2003
DEFINITION Sequence 2840 from Patent WO03025176.
ACCESSION  AX725153
VERSION     AX725153.1  GI:30504496
KEYWORDS   Mus musculus (house mouse)
SOURCE     Mus musculus
ORGANISM   Mus musculus
REFERENCE  1
AUTHORS    Telerman,A., Amson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL    Patent: WO 03025176-A 2840 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Mus musculus"
                /mol_type="unassigned DNA"
                /db_xref="taxon:10090"
Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 68;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1428 GATCCAAAGCAGATGAA 1444
Db 1 GATCCAAATCAGATGAA 17

RESULT 48
LOCUS      AX727863/c                    17 bp    DNA          linear          PAT 08-MAY-2003
DEFINITION Sequence 5550 from Patent WO03025176.
ACCESSION  AX727863
VERSION     AX727863.1  GI:30507206
KEYWORDS   Mus musculus (house mouse)
SOURCE     Mus musculus
ORGANISM   Mus musculus
REFERENCE  1
AUTHORS    Telerman,A., Amson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
           reversion, apoptosis and/or virus resistance and their use as
           medicines
JOURNAL    Patent: WO 03025176-A 5550 27-MAR-2003;
           Molecular Engines Laboratories (FR)
FEATURES   Location/Qualifiers
            source
              1..17
                /organism="Mus musculus"
                /mol_type="unassigned DNA"
                /db_xref="taxon:10090"
Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 68;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1040 CTCACCTTATTAAAGATC 1056
Db 17 CTCGCTTATTAAAGATC 1

RESULT 49
LOCUS      AX733002/c                    17 bp    DNA          linear          PAT 08-MAY-2003
DEFINITION Sequence 4636 from Patent WO03025175.
ACCESSION  AX733002
VERSION     AX733002.1  GI:30512345

```

```
KEYWORDS      Homo sapiens (human)
SOURCE
ORGANISM      Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Teitelman,A., Anson,R. and Tuijinder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
               reversion, apoptosis and/or virus resistance and their use as
               medicines
JOURNAL      Patent: WO 03025175-A 4636 27-MAR-2003;
               Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 68;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      832 TGCTTCTCTATGGGATC 848
Db      17 TGCTTCTCTTGGGATC 1
|||||
|

RESULT 50
LOCUS      A67588      18 bp      DNA      linear      PAT 05-MAY-1999
DEFINITION Sequence 8 from Patent WO9744485.
ACCESSION  A67588
VERSION     A67588.1 GI:4756451
KEYWORDS   unidentified
SOURCE      unidentified
ORGANISM    unidentified
REFERENCE   1 (bases 1 to 18)
AUTHORS     Goodfellow,P.N.
TITLE       METHODS FOR IDENTIFYING A MUTATION IN A GENE OF INTEREST
JOURNAL     Patent: WO 9744485-A 8 27-NOV-1997;
               HEXAGEN TECHNOLOGY LIMITED (GB)
FEATURES
source
1. .18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      30 CGCTCCGTCGCGCCG 46
Db      18 CGCGCGCTCGCGCCG 2
|||||
|

RESULT 51
LOCUS      AR035168      18 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 28 from patent US 5971730.
ACCESSION  AR035168
VERSION     AR035168.1 GI:5951836
KEYWORDS   Unknown.
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Brzezinski,R., Dery,C.V. and Beaulieu,C.
TITLE       Thermostable xylanase DNA, protein and methods of use
JOURNAL     Patent: US 5871730-A 28 16-FEB-1999;
               Location/Qualifiers
FEATURES
source
1. .18

KEYWORDS      Homo sapiens (human)
SOURCE
ORGANISM      Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Teitelman,A., Anson,R. and Tuijinder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
               reversion, apoptosis and/or virus resistance and their use as
               medicines
JOURNAL      Patent: WO 03025175-A 4636 27-MAR-2003;
               Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 68;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      832 TGCTTCTCTATGGGATC 848
Db      17 TGCTTCTCTTGGGATC 1
|||||
|

RESULT 52
LOCUS      AR089726/c      18 bp      DNA      linear      PAT 07-SEP-2000
DEFINITION Sequence 8 from patent US 5994075.
ACCESSION  AR089726
VERSION     AR089726.1 GI:10016481
KEYWORDS   Unknown.
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Goodfellow,P.N.
TITLE       Methods for identifying a mutation in a gene of interest without a
               phenotypic guide
JOURNAL     Patent: US 5994075-A 8 30-NOV-1999;
               Location/Qualifiers
FEATURES
source
1. .18
/organism="unassigned DNA"
/mol_type="unassigned DNA"

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      30 CGCTCCGTCGCGCCG 46
Db      18 CGCGCGCTCGCGCCG 2
|||||
|

RESULT 53
LOCUS      CQ786327      18 bp      DNA      linear      PAT 24-MAR-2004
DEFINITION Sequence 135 from Patent WO2004020668.
ACCESSION  CQ786327
VERSION     CQ786327.1 GI:45721429
KEYWORDS   synthetic construct
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Nakamura,Y. and Katagiri,T.
TITLE       Method for treating synovial sarcoma
JOURNAL     Patent: WO 2004020668-A 135 11-MAR-2004;
               Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)
FEATURES
source
1. .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: synthetic oligonucleotide"

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      336 GGCTCAAGAACCTAGA 352
Db      1 GGCTCCATGAACCTAGA 17
|||||
|
```



```
RESULT 54
AR340812          18 bp      DNA      linear      PAT 17-AUG-2003
LOCUS
DEFINITION      Sequence 8 from patent US 6573069.
ACCESSION      AR340812
VERSION        AR340812.1 GI:33732655
KEYWORDS
SOURCE
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 18)
AUTHORS      Holloway,J.L., Gao,Z. and Whitmore,T.E.
TITLE        Crib protein ZMSE1
JOURNAL      Patent: US 6573069-A 8 03-JUN-2003;
FEATURES
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      714 TCCGTGGCCTCCTTCTC 730
      |||||
Db      1 TCCGCGGCCTCCTTCTC 17

RESULT 55
AX141245          18 bp      DNA      linear      PAT 31-MAY-2001
LOCUS
DEFINITION      Sequence 8 from Patent WO0134803.
ACCESSION      AX141245
VERSION        AX141245.1 GI:14281481
KEYWORDS
SOURCE
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE      1
AUTHORS      Holloway,J.L., Gao,Z. and Whitmore,T.E.
TITLE        Crib protein zmsel
JOURNAL      Patent: WO 0134803-A 8 17-MAY-2001;
FEATURES
Location/Qualifiers
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide primer ZC18860"

Query Match      0.8%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 75;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      714 TCCGTGGCCTCCTTCTC 730
      |||||
Db      1 TCCGCGGCCTCCTTCTC 17

RESULT 56
BD142414          20 bp      DNA      linear      PAT 18-SEP-2002
LOCUS
DEFINITION      Method of culturing mesenchymal stem cells.
ACCESSION      BD142414
VERSION        BD142414.1 GI:23237359
KEYWORDS      WO 0222788-A/11.
SOURCE
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Kato,Y., Tsutsumi,S. and Shimazu,A.
TITLE        Method of culturing mesenchymal stem cells
JOURNAL      Patent: WO 0222788-A 11 21-MAR-2002;

YUKIO KATO,SHINICHI TSUTSUMI,ATSUSHI SHIMAZU
OS      Artificial Sequence
PN      WO 0222788-A/11
PD      21-MAR-2002
PF      12-SEP-2001 WO 2001JP007914
PR      12-SEP-2000 JP 00P 276971
PI      YUKIO KATO,SHINICHI TSUTSUMI,ATSUSHI SHIMAZU
PC      C12N5/06,C12N5/02//C12N5/06,C12R1:91), (C12N5/02,C12R1:91) CC
PCR primer
PH      Key      Location/Qualifiers
FT      source      1..20
          /organism="Artificial Sequence".
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 91;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1403 CCACGGAGACCATGA 1419
      |||||
Db      1 CCACGGAGACCATGA 17

RESULT 57
AR315566          20 bp      DNA      linear      PAT 12-JUN-2003
LOCUS
DEFINITION      Sequence 6103 from patent US 6559294.
ACCESSION      AR315566
VERSION        AR315566.1 GI:31708992
KEYWORDS
SOURCE
ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 20)
AUTHORS      Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,
Sankaran,B. and Fletcher,L.D.
TITLE        Chlamydia pneumoniae polynucleotides and uses thereof
JOURNAL      Patent: US 6559294-A 6103 06-MAY-2003;
FEATURES
Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 91;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      150 TGCTCTGGGAAGCTAT 166
      |||||
Db      2 TGCTCTGGGAAGCTAT 18

RESULT 58
AX149057          20 bp      DNA      linear      PAT 08-JUN-2001
LOCUS
DEFINITION      Sequence 259 from Patent WO0136625.
ACCESSION      AX149057
VERSION        AX149057.1 GI:14347581
KEYWORDS
SOURCE
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE      1
AUTHORS      Wright,J.A., Young,A.H. and Dugourd,D.
TITLE        Antisense oligonucleotide sequences derived from groel and groes as
inhibitors of microorganisms
JOURNAL      Patent: WO 0136625-A 259 25-MAY-2001;
GeneSense Technologies Inc. (CA)
FEATURES
Location/Qualifiers
```

```
source 1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Antisense oligonucleotide"

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 91;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1445 TGTGTGCTGCTGCTTT 1461
|||||
Db 2 TGTGTGCTGCTGCTTT 18

RESULT 59
AX554362
LOCUS AX554362
DEFINITION Sequence 49 from Patent WO244403.
ACCESSION AX554362
VERSION AX554362.1 GI:25998178
KEYWORDS
ORGANISM synthetic construct
SOURCE other sequences; artificial sequences.
REFERENCE
1 White, J.H.
AUTHORS Markers for testing analogs of vitamin d and therapeutical uses
TITLE Patent: WO 0244403-A 49 06-JUN-2002;
JOURNAL MCGILL UNIVERSITY (CA)
FEATURES
source 1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="primer"

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 91;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1272 CTCGAGCCCTCAATAT 1288
|||||
Db 3 CTCGAGCCCTCAATAT 19

RESULT 60
AR121539/c
LOCUS AR121539
DEFINITION Sequence 75 from patent US 6159734.
ACCESSION AR121539
VERSION AR121539.1 GI:14105115
KEYWORDS
ORGANISM Unknown.
SOURCE Unclassified.
REFERENCE
1 (bases 1 to 20)
AUTHORS McKay, R., Borchers, A.H. and Baker, B.F.
TITLE Antisense modulation of peroxisome proliferator-activated receptor
gamma expression
JOURNAL Patent: US 6159734-A 75 12-DEC-2000;
FEATURES
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 887 CCCAGATACCTGATTCCTCA 906
|||||
Db 20 CCCAGAAAGCGATTCCTCA 1

source 1. .20 bp DNA linear PAT 16-MAY-2001
AR121992
Sequence 11 from patent US 6160203.
LOCUS AR121992
DEFINITION
ACCESSION AR121992
VERSION AR121992.1 GI:14105568
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
1 (bases 1 to 20)
AUTHORS Ferri, S. and Toguri, T.
TITLE DNA strands coding for glycerol-e-phosphate acyltransferase
JOURNAL Patent: US 6160203-A 11 12-DEC-2000;
FEATURES
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1480 TTGTTGCAGACATGGAGAA 1499
|||||
Db 1 TTGTTGCAGAAATGGAAGAA 20

RESULT 62
CQ786367
LOCUS CQ786367
DEFINITION Sequence 175 from Patent WO2004020668.
ACCESSION CQ786367
VERSION CQ786367.1 GI:45721468
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1 Nakamura, Y. and Katagiri, T.
AUTHORS Method for treating synovial sarcoma
TITLE Patent: WO 2004020668-A 175 11-MAR-2004;
JOURNAL Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)
FEATURES
source 1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Description of Artificial Sequence: synthetic oligonucleotide"

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 720 GCCTCCTTCTCCATCTACAG 739
|||||
Db 1 GTCCCTTCTCCATCTCCAG 20

RESULT 63
CQ796907/c
LOCUS CQ796907
DEFINITION Sequence 21 from Patent WO2004026902.
ACCESSION CQ796907
VERSION CQ796907.1 GI:46408533
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1 other sequences; artificial sequences.
```

AUTHORS Kuernsteiner,H. and Friedlin,B.  
TITLE Process for production of cephalosporin c  
PATENT: WO 2004026902-A 21 01-APR-2004;  
SANDOZ GMBH (AT)  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="oligonucleotide primer"  
Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 99;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 381 CTGCAGCAAGATGGCTGGA 400  
Db 20 CTGGAGCAGGTGAGCTGGA 1  
RESULT 64  
183426/c  
LOCUS 183426 20 bp DNA linear PAT 10-AUG-1998  
DEFINITION Sequence 7 from patent US 5714318.  
ACCESSION 183426  
VERSION 183426.1 GI:3406956  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Sagner,G., Kessler,C., Blum,H. and Domdey,H.  
TITLE Simultaneous sequencing of nucleic acids  
JOURNAL Patent: US 5714318-A 7 03-FEB-1998;  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 99;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 620 CCAACCTTACATCACTACT 639  
Db 20 CCAACCTTACATTACTTCT 1  
RESULT 65  
AR182885/c  
LOCUS AR182885 20 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 57 from patent US 6339068.  
ACCESSION AR182885  
VERSION AR182885.1 GI:20226092  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Krieg,A.M., Davis,H.L., Wu,T. and Schorr,J.  
TITLE Vectors and methods for immunization or therapeutic protocols  
JOURNAL Patent: US 6339068-A 57 15-JAN-2002;  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 99;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 29 CCGCTCCGTCGCGCGCTC 48  
||||| ||| |||||||

Db 20 CCGCGCGCGCGCGCGGCC 1  
RESULT 66  
AR313757  
LOCUS AR313757 20 bp DNA linear PAT 12-JUN-2003  
DEFINITION Sequence 4294 from patent US 6559294.  
ACCESSION AR313757  
VERSION AR313757.1 GI:31707183  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Griffais,R., Hoiseth,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,  
Sankaran,B. and Fletcher,L.D.  
TITLE Chlamydia pneumoniae polynucleotides and uses thereof  
JOURNAL Patent: US 6559294-A 4294 06-MAY-2003;  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 99;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1428 GATCCGAACGATGAATGT 1447  
Db 1 GCTCCGAACGATGAATGT 20  
RESULT 67  
AR429256  
LOCUS AR429256 20 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 10 from patent US 6642370.  
ACCESSION AR429256  
VERSION AR429256.1 GI:40189415  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Wise,C.A.  
TITLE Genetic marker for autoimmune disorder  
JOURNAL Patent: US 6642370-A 10 04-NOV-2003;  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 99;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 989 GCAGGGTGCCATGGATGATG 1008  
Db 1 GCAGGTGTCAAGATGATG 20  
RESULT 68  
AX104051/c  
LOCUS AX104051 20 bp DNA linear PAT 30-APR-2001  
DEFINITION Sequence 243 from Patent WO0122972.  
ACCESSION AX104051  
VERSION AX104051.1 GI:13920248  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.  
AUTHORS Krieg,A.M., Schetter,C. and Vollmer,J.C.  
TITLE Immunostimulatory nucleic acids

```
JOURNAL Patent: WO 012972-A 243 05-APR-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) ; Coley Pharmaceutical
GmbH (DE)
FEATURES
  source      Location/Qualifiers
              1..20
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CGCCTCCGTCGCCGCCGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 69
AX298435/c
LOCUS AX298435 20 bp DNA linear PAT 26-NOV-2001
DEFINITION Sequence 69 from Patent WO0183749.
ACCESSION AX298435
VERSION AX298435.1 GI:17128425
KEYWORDS Mus sp.
SOURCE Mus sp.
ORGANISM Mus sp.
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE Li,X., Ohmen,J.D., Reed,D.R., Ross,D. and Tordoff,M.G.
JOURNAL Gene and sequence variation associated with sensing carbohydrate
compounds and other sweeteners
Patent: WO 0183749-A 69 08-NOV-2001;
WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
(US)
FEATURES
  source      Location/Qualifiers
              1..20
              /organism="Mus sp."
              /mol_type="unassigned DNA"
              /db_xref="taxon:10095"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 685 AGGTGGGGCTTTGGCATCT 704
Db 20 AGGTGAGGGTTTGGCTTCT 1

RESULT 70
AX355382/c
LOCUS AX355382 20 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 410 from Patent WO0197843.
ACCESSION AX355382
VERSION AX355382.1 GI:18620050
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Weiner,G. and Hartmann,G.
TITLE Methods for enhancing antibody-induced cell lysis and treating
cancer
JOURNAL Patent: WO 0197843-A 410 27-DEC-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES
  source      Location/Qualifiers
              1..20
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"

/note="Synthetic oligonucleotide-phosphodiester backbone"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CGCCTCCGTCGCCGCCGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 71
AX458688/c
LOCUS AX458688 20 bp DNA linear PAT 08-JUL-2002
DEFINITION Sequence 5 from Patent WO0246462.
ACCESSION AX458688
VERSION AX458688.1 GI:21725352
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Greaves,D., Price,S. and Watkins,H.
TITLE Functional genetic variants
JOURNAL Patent: WO 0246462-A 5 13-JUN-2002;
Isis Innovation Limited (GB)
FEATURES
  source      Location/Qualifiers
              1..20
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Amplification Primer"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 384 CAGCAGATGGCTGGAGAA 403
Db 20 CAGCAGAGGCGACTGGAGAA 1

RESULT 72
AX547104/c
LOCUS AX547104 20 bp DNA linear PAT 01-MAR-2003
DEFINITION Sequence 243 from Patent WO02053141.
ACCESSION AX547104
VERSION AX547104.1 GI:25812248
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Bratzler,R.L.
TITLE Inhibition of angiogenesis by nucleic acids
JOURNAL Patent: WO 02053141-A 243 11-JUL-2002;
Coley Pharmaceutical Group, Inc. (US)
FEATURES
  source      Location/Qualifiers
              1..20
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Synthetic Sequence"

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CGCCTCCGTCGCCGCCGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1
```

RESULT 75	BD088317	LOCUS	BD088317	20 bp	DNA	linear	PAT 27-AUG-2002												
DEFINITION	A method of arraying genome clone.																		
ACCESSION	BD088317	VERSION	BD088317.1	GI:22633927															
KEYWORDS	JP 2001321190-A/561.																		
SOURCE	synthetic construct																		
ORGANISM	other sequences; artificial sequences.																		
REFERENCE	1 (bases 1 to 20)																		
AUTHORS	Soeda,E.																		
TITLE	A method of arraying genome clone																		
JOURNAL	Patent: JP 2001321190-A 561 20-NOV-2001;																		
COMMENT	THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA GENOTECHS																		
	OS	Artificial Sequence																	
	PN	JP 2001321190-A/561																	
	PD	20-NOV-2001																	
	PF	12-MAR-2001	JP 2001068285																
	PI	EIICHI SOEDA																	
	PC	C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566,PC C12N15/00.																	
	PC	C12N15/00																	
	CC	Description of Artificial Sequence:Synthetic DNA	PH	Key															
		Location/Qualifiers																	
	FT	source	1..20																
	FT	Location/Qualifiers	/organism='Artificial Sequence'.																
FEATURES	source																		
		1..20																	
		/organism="synthetic construct"																	
		/mol_type="genomic DNA"																	
		/db_xref="taxon:32630"																	
	Query Match	0.8%;	Score 15.2;	DB 1;	Length 20;														
	Best Local Similarity	85.0%;	Pred. No. 99;																
	Matches	17;	Conservative	0;	Mismatches	3;	Indels 0; Gaps 0;												
Qy	1789	TTCCACTTTAAAGTAAACA 1808																	
Db	1	TTCCACTTTTGAAGCAACA 20																	
RESULT 76	AB068428	LOCUS	AB068428	20 bp	DNA	linear	SYN 21-MAY-2003												
DEFINITION	Synthetic construct DNA, forward primer for human STS sts-SGC34104 at lp36.																		
ACCESSION	AB068428	VERSION	AB068428.1	GI:15129232															
KEYWORDS	synthetic construct																		
SOURCE	synthetic construct																		
ORGANISM	other sequences; artificial sequences.																		
REFERENCE	1																		
AUTHORS	Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K., Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H., Morohashi,A., Ohira,M., Nakagawa,A., Liu,S., Hoshi,M., Horii,A. and Soeda,E.																		
TITLE	A BAC-based STS-content map spanning a 35-Mb region of human chromosome lp35-p36																		
JOURNAL	Genomics 74 (1), 55-70 (2001)																		
MEDLINE	21269192																		
PUBMED	11374902																		
REFERENCE	2 (bases 1 to 20)																		
AUTHORS	Horii,A.																		
TITLE	Direct Submission																		
JOURNAL	Submitted (04-AUG-2001) Akira Horii, Tohoku University School of Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi 980-8575, Japan [E-mail:horii@mail.cc.tohoku.ac.jp, Tel:81-22-717-8042, Fax:81-22-717-8047]																		

```
source          1. .20
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
misc_feature    1. .20
                /notes="forward primer for human STS sts-SGC34104 at 1p36
                sts-SGC34104 obtained from clones B99P18, B345C23, B275J8,
                Human BAC library RPCI-11"

Query Match    0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 99;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1789 TTCCACTTTAAAGTAAACA 1808
Db      ||||||| |||||
        1 TTCCACTTTGCAAGCAACA 20

RESULT 77
LOCUS AX129260/c 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 478 from Patent WO0130362.
ACCESSION AX129260
VERSION AX129260.1 GI:14135565
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
        diseases
JOURNAL Patent: WO 0130362-A 478 03-MAY-2001;
        IMMUSOL, INC. (US)
FEATURES
source 1. .19
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
        /notes="Cdk4 ribozyme binding site"

Query Match    0.8%; Score 15; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1096 GGACTGCAGAGAAGAC 1110
Db      ||||||| |||||
        19 GGACTGCAGAGAAGAC 5

RESULT 78
LOCUS AR107613 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 53 from patent US 6110664.
ACCESSION AR107613
VERSION AR107613.1 GI:12823100
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowser,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 53 29-AUG-2000;
        Location/Qualifiers
FEATURES
source 1. .20
        /organism="unassigned DNA"

Query Match    0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
Db      ||||||| |||||
        3 TTGCTGCTGCTGTTT 17

RESULT 81
LOCUS AR107616 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 56 from patent US 6110664.
ACCESSION AR107616
VERSION AR107616.1 GI:12823103
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowser,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 56 29-AUG-2000;
        Location/Qualifiers
FEATURES
source 1 (bases 1 to 20)
        /organism="unassigned DNA"

Query Match    0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1447 TTGCTGCTGCTGTTT 1461
Db      ||||||| |||||
        1 TTGCTGCTGCTGTTT 15

RESULT 79
LOCUS AR107614 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 54 from patent US 6110664.
ACCESSION AR107614
VERSION AR107614.1 GI:12823101
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowser,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 54 29-AUG-2000;
        Location/Qualifiers
FEATURES
source 1. .20
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match    0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
Db      ||||||| |||||
        2 TTGCTGCTGCTGTTT 16

RESULT 80
LOCUS AR107615 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 55 from patent US 6110664.
ACCESSION AR107615
VERSION AR107615.1 GI:12823102
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowser,L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 55 29-AUG-2000;
        Location/Qualifiers
FEATURES
source 1. .20
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match    0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGTTT 1461
Db      ||||||| |||||
        3 TTGCTGCTGCTGTTT 17

RESULT 81
LOCUS AR107616 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 56 from patent US 6110664.
ACCESSION AR107616
VERSION AR107616.1 GI:12823103
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
```

```

AUTHORS      Cowsert, L.M.
TITLE        Antisense inhibition of G-alpha-S1 expression
JOURNAL      Patent: US 6110664-A 56 29-AUG-2000;
FEATURES     Location/Qualifiers
source       1..20
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 4 TTGCTGCTGCTGTTT 18

RESULT 82
AR107617 LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 57 from patent US 6110664.
ACCESSION AR107617
VERSION AR107617.1 GI:12823104
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsert, L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 57 29-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
       /organism="unknown"
       /mol_type="unassigned DNA"

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 5 TTGCTGCTGCTGTTT 19

RESULT 83
AR107618 LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 58 from patent US 6110664.
ACCESSION AR107618
VERSION AR107618.1 GI:12823105
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cowsert, L.M.
TITLE Antisense inhibition of G-alpha-S1 expression
JOURNAL Patent: US 6110664-A 58 29-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
       /organism="unknown"
       /mol_type="unassigned DNA"

Query Match      0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1447 TTGCTGCTGCTGTTT 1461
Db 6 TTGCTGCTGCTGTTT 20

RESULT 84
I15672 LOCUS 19 bp DNA linear PAT 02-APR-1996
DEFINITION Sequence 9 from patent US 5470719.
ACCESSION I15672
VERSION I15672.1 GI:1250580
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Meng, S.-Y., Morris, C.F. and Tsai, L.B.
TITLE Modified OmpA signal sequence for enhanced secretion of
JOURNAL polypeptides
FEATURES Patent: US 5470719-A 9 28-NOV-1995;
       Location/Qualifiers
       source 1..19
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAGGAA 1697
Db 2 TGATTCTAGAAAGGAGGAA 19

RESULT 85
I36677 LOCUS 19 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 9 from patent US 5608036.
ACCESSION I36677
VERSION I36677.1 GI:2086502
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Meng, S.-Y., Morris, C.F. and Tsai, L.B.
TITLE Enhanced secretion of polypeptides
JOURNAL Patent: US 5608036-A 9 04-MAR-1997;
FEATURES Location/Qualifiers
source 1..19
       /organism="unknown"
       /mol_type="unassigned DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1680 TGATTCTAGAAAAGGAA 1697
Db 2 TGATTCTAGAAAGGAGGAA 19

RESULT 86
AR295153 LOCUS 19 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 6888 from patent US 6537751.
ACCESSION AR295153
VERSION AR295153.1 GI:31682437
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Cohen, D., Chumakov, I. and Blumenfeld, M.
TITLE Biallelic markers for use in constructing a high density
JOURNAL disequilibrium map of the human genome
FEATURES Patent: US 6537751-A 6888 25-MAR-2003;
       Location/Qualifiers

```

```

source      1. .19
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 GTTGTCTTCTATGTTGTT 1484
    ||| ||||| |||||
Db 19 GTTCTCTTCTATGTTGTT 2

RESULT 87
AR295404/c
LOCUS      AR295404      19 bp      DNA      linear      PAT 12-JUN-2003
DEFINITION Sequence 7139 from patent US 6537751.
ACCESSION AR295404
VERSION AR295404.1 GI:31682688
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
        disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 7139 25-MAR-2003;
FEATURES
    Location/Qualifiers
    source      1. .19
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1629 CTCTATTTCATGCTTCT 1646
    ||| ||||| |||||
Db 19 CTCTCTTCTTGCTTCT 2

RESULT 88
AR533334/c
LOCUS      AR533334      19 bp      DNA      linear      PAT 08-OCT-2004
DEFINITION Sequence 19 from patent US 6730500.
ACCESSION AR533334
VERSION AR533334.1 GI:53922962
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Lok,S.
TITLE Methods for generating a continuous nucleotide sequence from
        noncontiguous nucleotide sequences
JOURNAL Patent: US 6730500-A 19 04-MAY-2004;
FEATURES
    Location/Qualifiers
    source      1. .19
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGAGACTCTG 1082
    ||| ||||| |||||
Db 19 CTCCCATAGAGACTCTG 2

RESULT 89
AX131510/c
LOCUS      AX131510      19 bp      DNA      linear      PAT 08-JUN-2001
DEFINITION Sequence 371 from Patent WO0136625.
ACCESSION AX149169
VERSION AX149169.1 GI:14347693
KEYWORDS
SOURCE
ORGANISM

```

---

```

LOCUS      AX131510      19 bp      DNA      linear      PAT 15-MAY-2001
DEFINITION Sequence 2728 from Patent WO0130362.
ACCESSION AX131510
VERSION AX131510.1 GI:14137815
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
        diseases
JOURNAL Patent: WO 0130362-A 2728 03-MAY-2001;
FEATURES
    Location/Qualifiers
    source      1. .19
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
                /note="Cyclin G1 ribozyme binding site"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1326 AACTTTGGATCCAGCT 1343
    ||| ||||| |||||
Db 18 AACATTTGGATACAGCT 1

RESULT 90
AX132341/c
LOCUS      AX132341      19 bp      DNA      linear      PAT 15-MAY-2001
DEFINITION Sequence 3559 from Patent WO0130362.
ACCESSION AX132341
VERSION AX132341.1 GI:14138646
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
        diseases
JOURNAL Patent: WO 0130362-A 3559 03-MAY-2001;
FEATURES
    Location/Qualifiers
    source      1. .19
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
                /note="Cdc25 hs ribozyme binding site"

Query Match      0.8%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 963 GGACATCTGGACAGCTGG 980
    ||| ||||| |||||
Db 19 GGACATCTGGACAGACGG 2

RESULT 91
AX149169/c
LOCUS      AX149169      19 bp      DNA      linear      PAT 08-JUN-2001
DEFINITION Sequence 371 from Patent WO0136625.
ACCESSION AX149169
VERSION AX149169.1 GI:14347693
KEYWORDS
SOURCE
ORGANISM

```



ORGANISM  
Eukaryotes  
Amniota  
Mammalia  
Primates  
Catarrhini  
Hominoidea  
Hominidae  
Homo  
1

REFERENCE  
Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
Myosin-like gene expressed in human heart and muscle  
Patent: WO 0192524-A 8365 06-DEC-2001.  
Aeomica, Inc. (US)

FEATURES  
Location/Qualifiers

Query Match  
Best Local  
Matches

QY 1065 CGTCAAAGAGGACTC 1080  
Db 16 CGTCCACAGAGGACTC 1

RESULT 96  
AR327069 17 bp RNA PAT 17-AUG-2003  
LOCUS Sequence 4471 from patent US 6566127.  
DEFINITION AR327069  
ACCESSION AR327069  
VERSION AR327069.1 GI:33712877  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Favco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions  
related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 4471 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1204 TACCCACTGGCGTCGA 1219  
Db 2 TACCCACTGGCGACGA 17

RESULT 97  
AR464687 17 bp DNA PAT 20-FEB-2004  
LOCUS Sequence 8364 from patent US 6686188.  
DEFINITION AR464687  
ACCESSION AR464687  
VERSION AR464687.1 GI:42699744  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and  
Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed  
predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8364 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 395 GCTGGAGAAAGTTCAC 410  
Db 2 GCTGGAGAAAGTGCAC 17

RESULT 98  
AR464688 17 bp DNA PAT 20-FEB-2004  
LOCUS Sequence 8365 from patent US 6686188.  
DEFINITION AR464688  
ACCESSION AR464688  
VERSION AR464688.1 GI:42699745  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.

Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and  
Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed  
predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8365 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 395 GCTGGAGAAAGTTCAC 410  
Db 1 GCTGGAGAAAGTGCAC 16

RESULT 99  
AR466353/c 17 bp DNA PAT 20-FEB-2004  
LOCUS Sequence 10030 from patent US 6686188.  
DEFINITION AR466353  
ACCESSION AR466353  
VERSION AR466353.1 GI:42701410  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and  
Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed  
predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10030 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CGTCAAAGAGGACTC 1080  
Db 17 CGTCCACAGAGGACTC 2

RESULT 100  
AR466354/c 17 bp DNA PAT 20-FEB-2004  
LOCUS Sequence 10031 from patent US 6686188.  
DEFINITION AR466354  
ACCESSION AR466354  
VERSION AR466354.1 GI:42701411  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and  
Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed  
predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 10031 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGAGGACTC 1080  
Db 16 CGTCCACAGAGGACTC 1

## RESULT 101

AX218292 17 bp RNA linear PAT 07-SEP-2001  
LOCUS Sequence 3734 from Patent WO0159103.  
DEFINITION AX218292  
ACCESSION AX218292  
VERSION AX218292.1 GI:15528353  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.

REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J., and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 3734 16-AUG-2001;  
RBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)

FEATURES  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/notes="Nucleic Acid"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 AAATAAAGAGAGAAAT 217  
Db 1 AAATAAAGAGAGAAAT 16

## RESULT 102

AX579784/c 17 bp RNA linear PAT 10-JAN-2003  
LOCUS Sequence 1622 from Patent WO0211674.  
DEFINITION AX579784  
ACCESSION AX579784  
VERSION AX579784.1 GI:27648986  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E. and Grupe, A.  
TITLE Method and reagent for the inhibition of calcium activated chloride channel-1 (clca-1)  
JOURNAL Patent: WO 0211674-A 1622 14-FEB-2002;  
RBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);  
Thompson, James (US)

FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1152 GTAATATTTCCAACT 1167  
Db 16 GTAATATTTCCATCT 1

## RESULT 103

AX722986/c 17 bp DNA linear PAT 08-MAY-2003  
LOCUS Sequence 673 from Patent WO03025176.  
DEFINITION AX722986  
ACCESSION AX722986  
VERSION AX722986.1 GI:30423487  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus

REFERENCE 1  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025176-A 673 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 968 TCTGGACAGCTGGAT 983  
Db 17 TCTGGATAGCTGGAT 2

## RESULT 104

AX723927 17 bp DNA linear PAT 08-MAY-2003  
LOCUS Sequence 1614 from Patent WO03025176.  
DEFINITION AX723927  
ACCESSION AX723927  
VERSION AX723927.1 GI:30503270  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus

REFERENCE 1  
AUTHORS Telerman, A., Amson, R. and Tuijnder, M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025176-A 1614 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source  
1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1558 ATCTGGGTCTGCAAC 1573  
Db 2 ATCTGGGTCTGCAAC 17

## RESULT 105

AX724619 17 bp DNA linear PAT 08-MAY-2003  
LOCUS Sequence 2306 from Patent WO03025176.  
DEFINITION AX724619  
ACCESSION AX724619

AX724619.1	GI:30503962
VERSION	Mus musculus (house mouse)
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1 Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines Patent: WO 03025176-A 2306 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
AUTHORS	1..17
TITLE	/organism="Mus musculus" /mol_type="unassigned DNA" /db_xref="taxon:10090"
JOURNAL	Patient: WO 03025176-A 2306 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
FEATURES	source
Query Match	0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity	93.8%; Pred. No. 1e+02;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	492 ATCTGCGTTCGGCA 507
Db	2 ATCTGCGTTCGGCA 17
RESULT 106	
AX725224/c	
LOCUS	Sequence 2911 from Patent WO03025176. linear PAT 08-MAY-2003
DEFINITION	Sequence 2911 from Patent WO03025176.
ACCESSION	AX725224
VERSION	AX725224.1 GI:30504567
KEYWORDS	Mus musculus (house mouse)
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1 Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines Patent: WO 03025176-A 2911 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
AUTHORS	1..17
TITLE	/organism="Mus musculus" /mol_type="unassigned DNA" /db_xref="taxon:10090"
JOURNAL	Patient: WO 03025176-A 2911 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
FEATURES	source
Query Match	0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity	93.8%; Pred. No. 1e+02;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	1041 TCATTATTAAGATC 1056
Db	16 TCATTATTAAGATC 1
RESULT 107	
AX726651/c	
LOCUS	Sequence 4338 from Patent WO03025176. linear PAT 08-MAY-2003
DEFINITION	Sequence 4338 from Patent WO03025176.
ACCESSION	AX726651
VERSION	AX726651.1 GI:30505994
KEYWORDS	Mus musculus (house mouse)
SOURCE	Mus musculus
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE	1 Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines Patent: WO 03025176-A 4338 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
AUTHORS	1..17
TITLE	/organism="Mus musculus" /mol_type="unassigned DNA" /db_xref="taxon:10090"
JOURNAL	Patient: WO 03025176-A 4338 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
FEATURES	source
Query Match	0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity	93.8%; Pred. No. 1e+02;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	920 GATCACTGGGAGCAA 935
Db	1 GATCACTGGGAGAAA 16
RESULT 109	
AX736376	
LOCUS	Sequence 1966 from Patent WO03025177. linear PAT 08-MAY-2003
DEFINITION	Sequence 1966 from Patent WO03025177.
ACCESSION	AX736376
VERSION	AX736376.1 GI:30515653
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 1966 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
AUTHORS	1..17
TITLE	/organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
JOURNAL	Patient: WO 03025177-A 1142 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
FEATURES	source
Query Match	0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity	93.8%; Pred. No. 1e+02;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	920 GATCACTGGGAGCAA 935
Db	1 GATCACTGGGAGAAA 16
RESULT 109	
AX736376	
LOCUS	Sequence 1966 from Patent WO03025177. linear PAT 08-MAY-2003
DEFINITION	Sequence 1966 from Patent WO03025177.
ACCESSION	AX736376
VERSION	AX736376.1 GI:30515653
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 1966 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
AUTHORS	1..17
TITLE	/organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
JOURNAL	Patient: WO 03025177-A 1142 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
FEATURES	source
Query Match	0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity	93.8%; Pred. No. 1e+02;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	920 GATCACTGGGAGCAA 935
Db	1 GATCACTGGGAGAAA 16
RESULT 109	
AX736376	
LOCUS	Sequence 1966 from Patent WO03025177. linear PAT 08-MAY-2003
DEFINITION	Sequence 1966 from Patent WO03025177.
ACCESSION	AX736376
VERSION	AX736376.1 GI:30515653
KEYWORDS	Homo sapiens (human)
SOURCE	Homo sapiens
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1 Telerman,A., Amson,R. and Tuijnder,M. Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments Patent: WO 03025177-A 1966 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
AUTHORS	1..17
TITLE	/organism="Homo sapiens" /mol_type="unassigned DNA" /db_xref="taxon:9606"
JOURNAL	Patient: WO 03025177-A 1142 27-MAR-2003; Molecular Engines Laboratories (FR) Location/Qualifiers
FEATURES	source
Query Match	0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity	93.8%; Pred. No. 1e+02;
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	920 GATCACTGGGAGCAA 935
Db	1 GATCACTGGGAGAAA 16
RESULT 109	
AX736376	
LOCUS	Sequence 1966 from Patent WO03025177. linear PAT 08-MAY-

```
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1376 ATCAAGTATTCTTC 1391
Db 2 ATCAAGTATTCTTC 17

RESULT 110
LOCUS AR164526 18 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 17 from patent US 6274147.
ACCESSION AR164526
VERSION AR164526.1 GI:16237580
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Vakharia,V.N. and Yao,K.
TITLE Method for generating nonpathogenic infectious pancreatic necrosis
JOURNAL virus (IPNV) from synthetic RNA transcripts
PUBLISHED Patent: US 6274147-A 17 14-AUG-2001;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 450 GAATCAGCTGTGATGC 465
Db 3 GAATCAGCTGTGATGC 18

RESULT 111
LOCUS AX133011/c 18 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 4229 from Patent WO0130362.
ACCESSION AX133011
VERSION AX133011.1 GI:14139321
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
JOURNAL diseases
PUBLISHED Patent: WO 0130362-A 4229 03-MAY-2001;
FEATURES
source
1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/notes="Hammerhead ribozyme recognition site for cdc 2
kinase"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1376 ATCAAGTATTCTTC 1391
```

```
Db 16 ATCAAGTATTCTTC 1

RESULT 112
LOCUS AX327131 18 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 327 from Patent WO0178894.
ACCESSION AX327131
VERSION AX327131.1 GI:18097843
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Keith,T.
TITLE Novel human gene relating to respiratory diseases, obesity, and
JOURNAL inflammatory bowel disease
PUBLISHED Patent: WO 0178894-A 327 25-OCT-2001;
Genome Therapeutics Corp. (US)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Primer"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 453 TCAGCTGTGATGCTGG 468
Db 3 TCAGCTGTGCTGCTGG 18

RESULT 113
LOCUS AX697910 18 bp DNA linear PAT 02-APR-2003
DEFINITION Sequence 29 from Patent EP1283272.
ACCESSION AX697910
VERSION AX697910.1 GI:29498975
KEYWORDS Human immunodeficiency virus
SOURCE Human immunodeficiency virus
ORGANISM Human immunodeficiency virus
REFERENCE 1
AUTHORS Kemp,S., Vingerhoets,J.H. and Michiels,L.E.
TITLE Methods and means for assessing HIV envelope inhibitor therapy
JOURNAL Patent: EP 1283272-A 29 12-FEB-2003;
Tibotec Pharmaceuticals Ltd. (IE)
FEATURES
source
1..18
/organism="Human immunodeficiency virus"
/mol_type="unassigned DNA"
/db_xref="taxon:12721"

Query Match
Best Local Similarity 0.8%; Score 14.4; DB 1; Length 18;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1104 GAAGAACAAGGTGGAG 1119
Db 18 GAAGAACAAGGTGGAG 3

RESULT 114
LOCUS AX131834/c 19 bp DNA linear PAT 15-MAY-2001
DEFINITION Sequence 3052 from Patent WO0130362.
ACCESSION AX131834
VERSION AX131834.1 GI:14138139
```

KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Robbins,J.M. and Tritz,R.  
TITLE Ribozyme therapy for the treatment of proliferative skin and eye diseases  
JOURNAL Patent: WO 0130362-A 3052 03-MAY-2001;  
IMMUSOL, INC. (US)  
FEATURES source  
1..19  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
/note="Cyclin A1 ribozyme binding site"  
Query Match 0.8%; Score 14.4; DB 1; Length 19;  
Best Local Similarity 93.8%; Pred. No. 1.1e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 433 ACTGGAGAGGGGAGA 448  
DB 17 ACTGGAGAGGAGAGA 2  
|||||  
RESULT 115  
LOCUS I81221 17 bp DNA linear PAT 10-JUN-1998  
DEFINITION Sequence 5 from patent US 5710023.  
ACCESSION I81221  
VERSION I81221.1 GI:3209511  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Collins,M., Donaldson,D., Fitz,L., Neben,T., Whitters,M. and Wood,C.  
TITLE IL-13 cytokine receptor chain  
JOURNAL Patent: US 5710023-A 5 20-JAN-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.2; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.1e+02;  
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 1343 TGGAGTCCTGGAGCCA 1359  
DB 17 TGGAGYGMVTGGAGYSM 1  
|||||  
RESULT 116  
LOCUS AR438875 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 5 from patent US 6664227.  
ACCESSION AR438875  
VERSION AR438875.1 GI:42663882  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Wynn,T.A., Chiaromonte,M.G., Collins,M., Donaldson,D., Fitz,L., Neben,T., Whitters,M.J. and Wood,C.  
TITLE Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains  
JOURNAL Patent: US 6664227-A 5 16-DEC-2003;  
FEATURES Location/Qualifiers

source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 14.2; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.1e+02;  
Matches 11; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 1343 TGGAGTCCTGGAGCCA 1359  
DB 17 TGGAGYGMVTGGAGYSM 1  
|||||  
RESULT 117  
LOCUS AR322168 15 bp DNA linear PAT 17-AUG-2003  
DEFINITION Sequence 19 from patent US 6566061.  
ACCESSION AR322168  
VERSION AR322168.1 GI:33707712  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Philibert,R.A., Ginns,E.I. and Delisi,L.  
TITLE Identification of polymorphisms in the PCTG4 region of Xq13  
JOURNAL Patent: US 6566061-A 19 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..15  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 14; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 94;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1445 TGTTGCTGCTGCTG 1458  
DB 14 TGTTGCTGCTGCTG 1  
|||||  
RESULT 118  
LOCUS CQ617850 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 2590 from Patent WO0192524.  
ACCESSION CQ617850  
VERSION CQ617850.1 GI:41668068  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 2590 06-DEC-2001;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 990 CAGGGTGCCCATGGA 1003  
DB 4 CAGGGTGCCCATGGA 17  
|||||

```

RESULT 119
LOCUS      CQ617851
DEFINITION Sequence 2591 from Patent WO0192524.
ACCESSION  CQ617851
VERSION     CQ617851.1 GI:41668069
KEYWORDS   Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 2591 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      990 CAGGGTGCCATGGA 1003
Db      3 CAGGGTGCCATGGA 16
|||||
|

RESULT 120
LOCUS      CQ617852
DEFINITION Sequence 2592 from Patent WO0192524.
ACCESSION  CQ617852
VERSION     CQ617852.1 GI:41668070
KEYWORDS   Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 2592 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      990 CAGGGTGCCATGGA 1003
Db      3 CAGGGTGCCATGGA 16
|||||
|

RESULT 121
LOCUS      CQ617853
DEFINITION Sequence 2593 from Patent WO0192524.
ACCESSION  CQ617853
VERSION     CQ617853.1 GI:41668071
KEYWORDS   Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 2593 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      990 CAGGGTGCCATGGA 1003
Db      2 CAGGGTGCCATGGA 15
|||||
|

RESULT 122
LOCUS      AR458913
DEFINITION Sequence 2590 from patent US 6686188.
ACCESSION  AR458913
VERSION     AR458913.1 GI:42693970
KEYWORDS   Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
            1 (bases 1 to 17)
            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 2590 03-FEB-2004;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      990 CAGGGTGCCATGGA 1003
Db      4 CAGGGTGCCATGGA 17
|||||
|

RESULT 123
LOCUS      AR458914
DEFINITION Sequence 2591 from patent US 6686188.
ACCESSION  AR458914
VERSION     AR458914.1 GI:42693971
KEYWORDS   Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
            1 (bases 1 to 17)
            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 2591 03-FEB-2004;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 2593 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES   source
            1..17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      990 CAGGGTGCCATGGA 1003
Db      1 CAGGGTGCCATGGA 14
|||||
|

RESULT 122
LOCUS      AR458913
DEFINITION Sequence 2590 from patent US 6686188.
ACCESSION  AR458913
VERSION     AR458913.1 GI:42693970
KEYWORDS   Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
            1 (bases 1 to 17)
            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 2590 03-FEB-2004;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      990 CAGGGTGCCATGGA 1003
Db      4 CAGGGTGCCATGGA 17
|||||
|

RESULT 123
LOCUS      AR458914
DEFINITION Sequence 2591 from patent US 6686188.
ACCESSION  AR458914
VERSION     AR458914.1 GI:42693971
KEYWORDS   Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
            1 (bases 1 to 17)
            Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and
            Shannon, M.E.
TITLE       Polynucleotide encoding a human myosin-like polypeptide expressed
            predominantly in heart and muscle
JOURNAL     Patent: US 6686188-A 2591 03-FEB-2004;
            Location/Qualifiers
FEATURES   source
            1..17
            /organism="unknown"
            /mol_type="genomic DNA"

```

Query Match Best Local Similarity 0.8%; Score 14; DB 1; Length 17; Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Sequence 2937 from Patent EP1281758. AX217415 VERSION AX217415.1 GI:15527476 KEYWORDS synthetic construct SOURCE other sequences; artificial sequences.
Qy	990 CAGGGTGCCATGGA 1003       3 CAGGGTGCCATGGA 16	synthetic construct synthetic construct other sequences; artificial sequences.
Db		
RESULT 124		
LOCUS AR458915	17 bp DNA linear PAT 20-FEB-2004	
DEFINITION Sequence 2592 from patent US 6886188.		
ACCESSION AR458915		
VERSION AR458915.1 GI:42693972		
KEYWORDS Unknown.		
SOURCE Unknown.		
ORGANISM Unclassified.		
REFERENCE 1 (bases 1 to 17)		
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.		
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle		
JOURNAL Patent: US 6886188-A 2592 03-FEB-2004;		
FEATURES Location/Qualifiers		
source	1..17	/organism="unknown"
		/mol_type="genomic DNA"
Query Match Best Local Similarity 0.8%; Score 14; DB 1; Length 17; Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Score 14; DB 1; Length 17; Pred. No. 1.2e+02; Mismatches 0; Indels 0; Gaps 0;
Qy	990 CAGGGTGCCATGGA 1003       2 CAGGGTGCCATGGA 15	
Db		
RESULT 125		
LOCUS AR458916	17 bp DNA linear PAT 20-FEB-2004	
DEFINITION Sequence 2593 from patent US 6886188.		
ACCESSION AR458916		
VERSION AR458916.1 GI:42693973		
KEYWORDS Unknown.		
SOURCE Unknown.		
ORGANISM Unclassified.		
REFERENCE 1 (bases 1 to 17)		
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.		
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle		
JOURNAL Patent: US 6886188-A 2593 03-FEB-2004;		
FEATURES Location/Qualifiers		
source	1..17	/organism="unknown"
		/mol_type="genomic DNA"
Query Match Best Local Similarity 0.8%; Score 14; DB 1; Length 17; Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Score 14; DB 1; Length 17; Pred. No. 1.2e+02; Mismatches 0; Indels 0; Gaps 0;
Qy	990 CAGGGTGCCATGGA 1003       1 CAGGGTGCCATGGA 14	
Db		
RESULT 126		
LOCUS AX217415	17 bp RNA linear PAT 07-SEP-2001	
DEFINITION Sequence 835 from Patent EP1281758.		
ACCESSION AX217415		
VERSION AX217415.1 GI:15527476		
KEYWORDS synthetic construct		
SOURCE other sequences; artificial sequences.		
ORGANISM Homo sapiens (human)		
REFERENCE 1		
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.		
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression		
JOURNAL Patent: WO 0159103-A 2857 16-AUG-2001;		
FEATURES Location/Qualifiers		
source	1..17	/organism="synthetic construct"
		/mol_type="unassigned RNA"
		/db_xref="taxon:32630"
		/note="Nucleic Acid"
Query Match Best Local Similarity 0.8%; Score 14; DB 1; Length 17; Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Score 14; DB 1; Length 17; Pred. No. 1.2e+02; Mismatches 0; Indels 0; Gaps 0;
Qy	201 GAATAAAGAAGA 214       4 GAATAAAGAAGA 17	
Db		
RESULT 127		
LOCUS AX688102/C	17 bp DNA linear PAT 31-MAR-2003	
DEFINITION Sequence 834 from Patent EP1281758.		
ACCESSION AX688102		
VERSION AX688102.1 GI:29410800		
KEYWORDS Homo sapiens (human)		
SOURCE Homo sapiens		
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.		
REFERENCE 1		
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.		
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12		
JOURNAL Patent: EP 1281758-A 834 05-FEB-2003;		
FEATURES Location/Qualifiers		
source	1..17	/organism="Homo sapiens"
		/mol_type="unassigned DNA"
		/db_xref="taxon:9606"
Query Match Best Local Similarity 0.8%; Score 14; DB 1; Length 17; Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Score 14; DB 1; Length 17; Pred. No. 1.2e+02; Mismatches 0; Indels 0; Gaps 0;
Qy	1236 AAGGCCAGGCCAT 1249       17 AAGGCCAGGCCAT 4	
Db		
RESULT 128		
LOCUS AX688103/C	17 bp DNA linear PAT 31-MAR-2003	
DEFINITION Sequence 835 from Patent EP1281758.		
ACCESSION AX688103		
VERSION AX688103.1 GI:29410801		
KEYWORDS Homo sapiens (human)		
SOURCE Homo sapiens		
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.		



```
REFERENCE
1  Shannon,M., Gu,Y. and Nguyen,C.T.
   TITLE
   Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
   mdz12
JOURNAL
Patent: EP 1281758-A 835 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249
Db 16 AAGGCCAGGGCCAT 3

RESULT 129
AX688104/c
LOCUS AX688104 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 836 from Patent EP1281758.
ACCESSION AX688104
VERSION AX688104.1 GI:29410802
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1  Shannon,M., Gu,Y. and Nguyen,C.T.
   AUTHORS
   TITLE
   Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
   mdz12
JOURNAL
Patent: EP 1281758-A 836 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249
Db 15 AAGGCCAGGGCCAT 2

RESULT 130
AX688105/c
LOCUS AX688105 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 837 from Patent EP1281758.
ACCESSION AX688105
VERSION AX688105.1 GI:29410803
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1  Shannon,M., Gu,Y. and Nguyen,C.T.
   AUTHORS
   TITLE
   Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
   mdz12
JOURNAL
Patent: EP 1281758-A 837 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/mol_type="Homo sapiens"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249
Db 16 AAGGCCAGGGCCAT 3

RESULT 132
AX753818/c
LOCUS AX753818 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 165 from Patent WO03037931.
ACCESSION AX753818
VERSION AX753818.1 GI:32166515
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1  Shannon,M. and Phan,T.
   AUTHORS
   TITLE
   Human angiomotin-like protein 1
   JOURNAL
   Patent: WO 03037931-A 165 08-MAY-2003;
   Amergham Biosciences SV Corp. (US)
FEATURES
source
1. .17
/mol_type="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1445 TGTTCGTGCTGCTG 1458
Db 1445 TGTTCGTGCTGCTG 1458
```

```

Db      17  TGTGTGCTGCTGCTG  4

RESULT 133
AX753819/c
LOCUS      17 bp      DNA      linear      PAT 23-JUN-2003
DEFINITION Sequence 166 from Patent WO03037931.
ACCESSION  AX753819
VERSION     AX753819.1  GI:32166516
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Shannon,M. and Phan,T.
TITLE      Human angiomotin-like protein 1
JOURNAL    Patent: WO 03037931-A 166 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1445  TGTGTGCTGCTGCTG 1458
Db      16  TGTGTGCTGCTGCTG  3

RESULT 134
AX753820/c
LOCUS      17 bp      DNA      linear      PAT 23-JUN-2003
DEFINITION Sequence 167 from Patent WO03037931.
ACCESSION  AX753820
VERSION     AX753820.1  GI:32166517
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Shannon,M. and Phan,T.
TITLE      Human angiomotin-like protein 1
JOURNAL    Patent: WO 03037931-A 167 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1445  TGTGTGCTGCTGCTG 1458
Db      16  TGTGTGCTGCTGCTG  3

RESULT 135
AX753821/c
LOCUS      17 bp      DNA      linear      PAT 23-JUN-2003
DEFINITION Sequence 168 from Patent WO03037931.
ACCESSION  AX753821
VERSION     AX753821.1  GI:32166518
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Shannon,M. and Phan,T.
TITLE      Human angiomotin-like protein 1
JOURNAL    Patent: WO 03037931-A 183 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1445  TGTGTGCTGCTGCTG 1458
Db      15  TGTGTGCTGCTGCTG  2

RESULT 137
AX753836
LOCUS      17 bp      DNA      linear      PAT 23-JUN-2003
DEFINITION Sequence 183 from Patent WO03037931.
ACCESSION  AX753836
VERSION     AX753836.1  GI:32166533
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Shannon,M. and Phan,T.
TITLE      Human angiomotin-like protein 1
JOURNAL    Patent: WO 03037931-A 183 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      662  GCAGGGGGCGGTGG 675
Db      4   GCAGGGGGCGGTGG  17

RESULT 136
AX753835
LOCUS      17 bp      DNA      linear      PAT 23-JUN-2003
DEFINITION Sequence 182 from Patent WO03037931.
ACCESSION  AX753835
VERSION     AX753835.1  GI:32166532
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Shannon,M. and Phan,T.
TITLE      Human angiomotin-like protein 1
JOURNAL    Patent: WO 03037931-A 182 08-MAY-2003;
            Amersham Biosciences SV Corp. (US)
FEATURES   source
            1. .17
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      662  GCAGGGGGCGGTGG 675
Db      4   GCAGGGGGCGGTGG  17

```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
  0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 3 GCAGGGGCGGTGG 16

RESULT 138
LOCUS AX753837
DEFINITION Sequence 184 from Patent WO03037931.
ACCESSION AX753837
VERSION AX753837.1 GI:32166534
KEYWORDS
ORGANISM Homo sapiens (human)
REFERENCE
  1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiomin-like protein 1
JOURNAL Patent: WO 03037931-A 184 08-MAY-2003;
  Amersham Biosciences SV Corp. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 2 GCAGGGGCGGTGG 15

RESULT 139
LOCUS AX753838
DEFINITION Sequence 185 from Patent WO03037931.
ACCESSION AX753838
VERSION AX753838.1 GI:32166535
KEYWORDS
ORGANISM Homo sapiens (human)
REFERENCE
  1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiomin-like protein 1
JOURNAL Patent: WO 03037931-A 185 08-MAY-2003;
  Amersham Biosciences SV Corp. (US)
FEATURES
  source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match
  0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 662 GCAGGGGCGGTGG 675
Db 1 GCAGGGGCGGTGG 14

/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
  0.8%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGACAGAT 285
Db 1 AGCCGAGACAGAT 14

RESULT 140
LOCUS I66351
DEFINITION Sequence 10 from patent US 5670330.
ACCESSION I66351
VERSION I66351.1 GI:2724328
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
  1 (bases 1 to 18)
  Sonenberg, N., Katze, M.G., Roy, S., Koromilas, A.E. and Barber, G.H.
  Anti-tumor agent assay using PKR
  JOURNAL Patent: US 5670330-A 10 23-SEP-1997;
  Location/Qualifiers
    source
      1..18
      /organism="unknown"
      /mol_type="unassigned DNA"

Query Match
  0.8%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 272 AGCCGAGACAGAT 285
Db 1 AGCCGAGACAGAT 14

RESULT 141
LOCUS AR564469
DEFINITION Sequence 1 from patent US 6759580.
ACCESSION AR564469
VERSION AR564469.1 GI:53979879
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
  1 (bases 1 to 18)
  Cunyngnam, C.T.
  TITLE Inbred maize line PH87H
  JOURNAL Patent: US 6759580-A 1 06-JUL-2004;
  Location/Qualifiers
    source
      1..18
      /organism="unknown"
      /mol_type="genomic DNA"

Query Match
  0.8%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1084 GGCTGGTCTCTGG 1097
Db 4 GGCTGGTCTCTGG 17

RESULT 142
LOCUS AR168820/C
DEFINITION Sequence 46 from patent US 6288042.
ACCESSION AR168820
VERSION AR168820.1 GI:17904939
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
  1 (bases 1 to 17)
  Rando, R.F., Ojwang, J.O., Hogan, M.E., Wallace, T.L. and Cossum, P.A.
  Anti-viral guanosine-rich tetrad forming oligonucleotides
  JOURNAL Patent: US 6288042-A 46 11-SEP-2001;
  Location/Qualifiers
    source
      1..17
```

```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCTCCCTCCACCAC 1721
Db 17 CCCACCCACCACCAC 1

RESULT 143
BD198938/c
LOCUS          17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION     Method and reagent for treating diseases or conditions concerning
                molecule participating in vasculogenic response.
ACCESSION      BD198938.1 GI:33008708
VERSION        JP 2002509721-A/1964.
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens

REFERENCE
AUTHORS        Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE          Method and reagent for treating diseases or conditions concerning
                molecule participating in vasculogenic response
JOURNAL        Patent: JP 2002509721-A 1964 02-APR-2002;
                RIBOZYME PHARMACEUTICALS INC
COMMENT        OS Homo sapiens (human)
                PN JP 2002509721-A/1964
                PD 02-APR-2002
                PF 24-MAR-1999 JP 2000541291
                PR 27-MAR-1998 US 60/079678
                PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
                PJ JAMES A MCSWIGGEN
                PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
                PC A61P29/00,
                PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
                CC Method and reagent for treating diseases or conditions CC
                CC concerning molecule
                CC participating in vasculogenic response
                FH Key Location/Qualifiers
                FT source 1..17 /organism='Homo sapiens (human)'.

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 202 AAATAAAGAGAAATAG 218
Db 17 AAATAAAGAGAAATAG 1

RESULT 145
LOCUS          17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION     Sequence 1536 from Patent WO0192524.
ACCESSION      CQ616796
VERSION        CQ616796.1 GI:41667014
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens

REFERENCE
AUTHORS        Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
                Shannon,M.E.
TITLE          Myosin-like gene expressed in human heart and muscle
JOURNAL        Patent: WO 0192524-A 1536 06-DEC-2001;
                Aeomica, Inc. (US)
COMMENT        OS Homo sapiens (human)
                PN JP 2002509721-A/4348
                PD 02-APR-2002
                PF 24-MAR-1999 JP 2000541291
                PR 27-MAR-1998 US 60/079678
                PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
                PJ JAMES A MCSWIGGEN
                PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
                PC A61P29/00,
                PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
                CC Method and reagent for treating diseases or conditions CC
                CC concerning molecule
                CC participating in vasculogenic response
                FH Key Location/Qualifiers
                FT source 1..17 /organism='Homo sapiens (human)'.

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 203 AATAAAGAGAAATAG 219
Db 17 AGTAATAGAGAAATAG 1

RESULT 144
BD201322/c
LOCUS          17 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION     Method and reagent for treating diseases or conditions concerning
                molecule participating in vasculogenic response.
ACCESSION      BD201322.1 GI:33011092
VERSION        JP 2002509721-A/4348.
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens

```

```

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 17)
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
Patent: JP 2002509721-A 4348 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
OS Homo sapiens (human)
PN JP 2002509721-A/4348
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
PJ JAMES A MCSWIGGEN
PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
PC A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17 /organism='Homo sapiens (human)'.

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 202 AAATAAAGAGAAATAG 218
Db 17 AAATAAAGAGAAATAG 1

RESULT 145
LOCUS          17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION     Sequence 1536 from Patent WO0192524.
ACCESSION      CQ616796
VERSION        CQ616796.1 GI:41667014
KEYWORDS       Homo sapiens (human)
SOURCE         Homo sapiens
ORGANISM       Homo sapiens

REFERENCE
AUTHORS        Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
                Shannon,M.E.
TITLE          Myosin-like gene expressed in human heart and muscle
JOURNAL        Patent: WO 0192524-A 1536 06-DEC-2001;
                Aeomica, Inc. (US)
COMMENT        OS Homo sapiens (human)
                PN JP 2002509721-A/4348
                PD 02-APR-2002
                PF 24-MAR-1999 JP 2000541291
                PR 27-MAR-1998 US 60/079678
                PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COESHOTT,
                PJ JAMES A MCSWIGGEN
                PC C12N15/09,A61K31/7088,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
                PC A61P29/00,
                PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
                CC Method and reagent for treating diseases or conditions CC
                CC concerning molecule
                CC participating in vasculogenic response
                FH Key Location/Qualifiers
                FT source 1..17 /organism='Homo sapiens (human)'.

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1081 TCGGGCTGGTCTCTGG 1097
Db 1 TCGGGCTGGTCTCTGG 17

```

```

RESULT 146
LOCUS      CQ616797      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 1537 from Patent WO0192524.
ACCESSION  CQ616797
VERSION     CQ616797.1  GI:41667015
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 1537 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1082 GCGGCTGGTCTCTGGA 1098
Db 1 GGGGCTGGTCCCTGGA 17

RESULT 147
LOCUS      CQ623620      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8360 from Patent WO0192524.
ACCESSION  CQ623620
VERSION     CQ623620.1  GI:41673838
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8360 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 390 GATGGCTGGAGAAAGT 406
Db 1 GAGGAGCTGGAGAAAGT 17

RESULT 148
LOCUS      CQ623623      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 8363 from Patent WO0192524.
ACCESSION  CQ623623
VERSION     CQ623623.1  GI:41673841
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens

```

```

REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 8363 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 393 GGGCTGGAGAAAGTTCA 409
Db 1 GAGCTGGAGAAAGTGCA 17

RESULT 149
LOCUS      CQ624832/c      17 bp      DNA      linear      PAT 02-FEB-2004
DEFINITION Sequence 9572 from Patent WO0192524.
ACCESSION  CQ624832
VERSION     CQ624832.1  GI:41675050
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE       Myosin-like gene expressed in human heart and muscle
JOURNAL     Patent: WO 0192524-A 9572 06-DEC-2001;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source          1..17
                        /organism="Homo sapiens"
                        /mol_type="unassigned DNA"
                        /db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 969 CTCGACAGCTGGGATGT 985
Db 17 CTCGACAGCGGGATGT 1

RESULT 150
LOCUS      AR188676      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION Sequence 4164 from patent US 6346398.
ACCESSION  AR188676
VERSION     AR188676.1  GI:20234641
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Favco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE       Method and reagent for the treatment of diseases or conditions
            related to levels of vascular endothelial growth factor receptor
            Patent: US 6346398-A 4164 12-FEB-2002;
            Aeomica, Inc. (US)
FEATURES    Location/Qualifiers
            source          1..17
                        /organism="unknown"

```

/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583  
|||||  
Db 1 CTGCAACTTTGGAAAC 17

RESULT 151  
ARI88677

LOCUS ARI88677 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 4165 from patent US 6346398.  
ACCESSION ARI88677  
VERSION ARI88677.1 GI:20234642  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 4165 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCACACTTTGGAAACT 1584  
|||||  
Db 1 TGCACACTTTGGAAACT 17

RESULT 152  
ARI88762/c

LOCUS ARI88762 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 4250 from patent US 6346398.  
ACCESSION ARI88762  
VERSION ARI88762.1 GI:20234727  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 4250 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 AAGGTAATATTCCAA 1165  
|||||  
Db 17 AAGGTAATATTCCCA 1

RESULT 153  
ARI90246

LOCUS ARI90246 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 5734 from patent US 6346398.

ACCESSION ARI90246  
VERSION ARI90246.1 GI:20236211  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 5734 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583  
|||||  
Db 1 CTGCAACTTTGGAAAC 17

RESULT 154  
ARI90247

LOCUS ARI90247 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 5735 from patent US 6346398.  
ACCESSION ARI90247  
VERSION ARI90247.1 GI:20236212  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 5735 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCACACTTTGGAAACT 1584  
|||||  
Db 1 TGCACACTTTGGAAACT 17

RESULT 155  
ARI90332/c

LOCUS ARI90332 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 5820 from patent US 6346398.  
ACCESSION ARI90332  
VERSION ARI90332.1 GI:20236297  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 5820 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 AAGTAATATTTCCAA 1165  
Db 17 AAGGAAATATTTCCCA 1

RESULT 156  
AR192330/c AR192330 17 bp DNA linear PAT 20-APR-2002  
LOCUS Sequence 7818 from patent US 6346398.  
DEFINITION AR192330.  
ACCESSION AR192330.  
VERSION AR192330.1 GI:20238295  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 7818 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAATAAAAAA 1851  
Db 17 AAACAATAAAAAA 1

RESULT 157  
AR192331/c AR192331 17 bp DNA linear PAT 20-APR-2002  
LOCUS Sequence 7819 from patent US 6346398.  
DEFINITION AR192331  
ACCESSION AR192331  
VERSION AR192331.1 GI:20238296  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6346398-A 7819 12-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAATAAAAAA 1851  
Db 17 AAACAATAAAAAA 1

RESULT 158  
AR200289/c AR200289 17 bp DNA linear PAT 20-APR-2002  
LOCUS Sequence 46 from patent US 6355785.  
DEFINITION AR200289  
ACCESSION AR200289

VERSION AR200289.1 GI:20250363  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Rando,R.F., Fennewald,S., Zendequi,J.G., Ojwang,J.O., Hogan,M.B., Pommer,Y. and Mazumder,A.  
TITLE Guanosine-rich oligonucleotide integrase inhibitors  
JOURNAL Patent: US 6355785-A 46 12-MAR-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACCAC 1721  
Db 17 CCCACCACCCACCAC 1

RESULT 159  
AR262421/c AR262421 17 bp DNA linear PAT 29-JAN-2003  
LOCUS Sequence 46 from patent US 6323185.  
DEFINITION AR262421  
ACCESSION AR262421  
VERSION AR262421.1 GI:28073852  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Rando,R.F., Fennewald,S., Zendequi,J.G., Ojwang,J.O. and Hogan,M.B.  
TITLE Anti-viral guanosine-rich oligonucleotides and method of treating HIV  
JOURNAL Patent: US 6323185-A 46 27-NOV-2001;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1705 CCCCTCCCTCCACCAC 1721  
Db 17 CCCACCACCCACCAC 1

RESULT 160  
AR324529 AR324529 17 bp RNA linear PAT 17-AUG-2003  
LOCUS Sequence 1931 from patent US 6566127.  
DEFINITION AR324529  
ACCESSION AR324529  
VERSION AR324529.1 GI:33710337  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 1931 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned RNA"

```
Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583
Db 1 CTGCAAAATTGGAAACC 17

RESULT 161
AR324530
LOCUS AR324530 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 1932 from patent US 6566127.
ACCESSION AR324530
VERSION AR324530.1 GI:33710338
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 1932 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCAACTTTGGAAACT 1584
Db 1 TGCAAAATTGGAAACCT 17

RESULT 162
AR324615/c
LOCUS AR324615 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2017 from patent US 6566127.
ACCESSION AR324615
VERSION AR324615.1 GI:33710423
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2017 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 AAGGTAAATATTCCAA 1165
Db 17 AAGGAAAATATTCCCA 1

RESULT 163
AR325211
LOCUS AR325211 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2613 from patent US 6566127.
ACCESSION AR325211
VERSION AR325211.1 GI:33711019

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1567 CTGCAACTTTGGAAAC 1583
Db 1 CTGCAAAATTGGAAACC 17

RESULT 164
AR325212
LOCUS AR325212 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2614 from patent US 6566127.
ACCESSION AR325212
VERSION AR325212.1 GI:33711020
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2614 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCAACTTTGGAAACT 1584
Db 1 TGCAAGTTTGGAAACCT 17

RESULT 165
AR326200/c
LOCUS AR326200 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3602 from patent US 6566127.
ACCESSION AR326200
VERSION AR326200.1 GI:33712008
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3602 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCAACTTTGGAAACT 1584
Db 1 TGCAAGTTTGGAAACCT 17

RESULT 166
AR326200/c
LOCUS AR326200 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 3602 from patent US 6566127.
ACCESSION AR326200
VERSION AR326200.1 GI:33712008
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 3602 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```



Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 17 AAACAAACAAACAAAA 1

RESULT 166  
AR326201/c  
LOCUS AR326201 17 bp RNA linear PAT 17-AUG-2003  
DEFINITION Sequence 3603 from patent US 6566127.  
ACCESSION AR326201  
VERSION AR326201.1 GI:33712009  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 3603 20-MAY-2003;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 17 AAACAAACAAACAAAA 1

RESULT 167  
AR328859/c  
LOCUS AR328859 17 bp RNA linear PAT 17-AUG-2003  
DEFINITION Sequence 6261 from patent US 6566127.  
ACCESSION AR328859  
VERSION AR328859.1 GI:33714667  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 6261 20-MAY-2003;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851  
Db 17 AAACAAACAAACAAAA 1

RESULT 168  
AR402091  
LOCUS AR402091 17 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 431 from patent US 6623962.  
ACCESSION AR402091  
VERSION AR402091.1 GI:40149541  
KEYWORDS

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.  
TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors  
JOURNAL Patent: US 6623962-A 431 23-SEP-2003;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 174 AATGGCATCTCTAAGAG 190  
Db 1 AATGGCATCTTTAAGG 17

RESULT 169  
AR457859  
LOCUS AR457859 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 1536 from patent US 6686188.  
ACCESSION AR457859  
VERSION AR457859.1 GI:42692916  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 1536 03-FEB-2004;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1081 TGGGGCTGTGCTCTGG 1097  
Db 1 TGGGGCTGTGCTCTGG 17

RESULT 170  
AR457860  
LOCUS AR457860 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 1537 from patent US 6686188.  
ACCESSION AR457860  
VERSION AR457860.1 GI:42692917  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 1537 03-FEB-2004;  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1082 GCGGCTGGTGCTCTGGA 1098  
Db 1 GGGGCTGGTGCTCTGGA 17

RESULT 171  
AR464683  
LOCUS AR464683 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8360 from patent US 6686188.  
ACCESSION AR464683  
VERSION AR464683.1 GI:42699740  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8360 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 GATGGCTGGAGAAAGT 406  
Db 1 GAGGAGCTGGAGAAAGT 17

RESULT 172  
AR464686  
LOCUS AR464686 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8363 from patent US 6686188.  
ACCESSION AR464686  
VERSION AR464686.1 GI:42699743  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8363 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 393 GGGCTGGAGAAAGTTCA 409  
Db 1 GAGCTGGAGAAAGTTCA 17

RESULT 173  
AR465895/c  
LOCUS AR465895/c 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 9572 from patent US 6686188.

ACCESSION AR465895  
VERSION AR465895.1 GI:42700952  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 9572 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTGCAGCTGGGATGT 985  
Db 17 CTCGACAGCGGGATGT 1

RESULT 174  
AX217108  
LOCUS AX217108 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 2550 from Patent WO0159103.  
ACCESSION AX217108  
VERSION AX217108.1 GI:15527169  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 2550 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAAGAGAAAT 217  
Db 1 GGAATAAGAGAGAAAT 17

RESULT 175  
AX226648/c  
LOCUS AX226648/c 17 bp RNA linear PAT 10-SEP-2001  
DEFINITION Sequence 20 from Patent WO0157206.  
ACCESSION AX226648  
VERSION AX226648.1 GI:15555789  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Fattaey, A.R., Jarvis, T., McSwiggen, J., Boehr, R.N. and Holman, P.S.  
TITLE Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme

```

JOURNAL Patent: WO 0157206-A 20 09-AUG-2001;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US) ; Fattaey, Ali R. (US)
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1654 TCTTCTTGATCTTC 1670
Db 17 TCTTCTTAATTTTC 1

RESULT 176
AX255600/c
LOCUS AX255600 17 bp RNA linear PAT 10-OCT-2001
DEFINITION Sequence 21 from Patent WO0170982.
ACCESSION AX255600
VERSION AX255600.1 GI:16074656
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Beger,C., Barber,J. and Wong-Staal,F.
TITLE Brca-1 regulators and methods of use
JOURNAL Patent: WO 0170982-A 21 27-SEP-2001;
Immusol Incorporated (US) ; Beger, Carmela (DE)
FEATURES
source
1. .17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1468 TTGTTTCTATGTGTT 1484
Db 17 TTGATTCTAATGTGTT 1

RESULT 177
AX421858/c
LOCUS AX421858 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 194 from Patent WO0188124.
ACCESSION AX421858
VERSION AX421858.1 GI:21525240
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 194 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1118 AGTTGGTGCCTTCCAGT 1134
Db 17 AGTTGGTGAATTCAGT 1

RESULT 178
AX423222/c
LOCUS AX423222 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1558 from Patent WO0188124.
ACCESSION AX423222
VERSION AX423222.1 GI:21526604
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1558 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 30 CGCTCCGTCGCGCGCG 46
Db 17 CGCGCGCGTCGCGCGCG 1

RESULT 179
AX423319/c
LOCUS AX423319 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1655 from Patent WO0188124.
ACCESSION AX423319
VERSION AX423319.1 GI:21526701
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1655 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1120 TTGGTGCCTTCCAGTAT 1136
Db 17 TTGGTGAATTCAGTAT 1

RESULT 180
AX475498

```

LOCUS AX475498 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 719 from Patent WO224750.  
ACCESSION AX475498  
VERSION AX475498.1 GI:22214783  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 719 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1414 CCATGACTGTCAGGAT 1430  
|||||  
Db 1 CCAGGACTGTCAGGGAT 17  
RESULT 181  
AX502944/c  
LOCUS AX502944 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 4251 from Patent EP1229046.  
ACCESSION AX502944  
VERSION AX502944.1 GI:23385237  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 4251 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 65 ATTATCTTAACAGAAA 81  
|||||  
Db 17 AATATCATACACAGAAA 1  
RESULT 182  
AX578360/c  
LOCUS AX578360 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 198 from Patent WO0211674.  
ACCESSION AX578360  
VERSION AX578360.1 GI:27647562  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.

and Grupe, A.  
TITLE Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
JOURNAL Patent: WO 0211674-A 198 14-FEB-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);  
Thompson, James (US)  
FEATURES  
source 1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1722 ATAGAATCAACATATGG 1738  
|||||  
Db 17 ATAGAATCAACATGTG 1  
RESULT 183  
AX578426  
LOCUS AX578426 17 bp RNA linear PAT 10-JAN-2003  
DEFINITION Sequence 264 from Patent WO0211674.  
ACCESSION AX578426  
VERSION AX578426.1 GI:27647628  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.  
and Grupe, A.  
TITLE Method and reagent for the inhibition of calcium activated chloride  
channel-1 (clca-1)  
JOURNAL Patent: WO 0211674-A 264 14-FEB-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US); Syntex (U.S.A.) LLC (US);  
Thompson, James (US)  
FEATURES  
source 1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 210 GAAGAAATAGCCAGCTG 226  
|||||  
Db 1 GAAGAAATATCCCACTG 17  
RESULT 184  
AX615236  
LOCUS AX615236 17 bp DNA linear PAT 20-FEB-2003  
DEFINITION Sequence 43 from Patent EP1262488.  
ACCESSION AX615236  
VERSION AX615236.1 GI:28446135  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Gu, Y. and Nguyen, C.T.  
TITLE Human lcc1-domain containing protein  
JOURNAL Patent: EP 1262488-A 43 04-DEC-2002;  
Aeomica, Inc. (US)  
FEATURES  
source 1. .17  
Location/Qualifiers

```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1518 AACACAGTAAGAAAGAAA 1534
Db 1 AACACAGAAAGAAAAA 17

RESULT 185
AX615237
LOCUS AX615237 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 44 from Patent EP1262488.
ACCESSION AX615237
VERSION AX615237.1 GI:28446136
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gu, Y. and Nguyen, C.T.
AUTHORS Human lcel-domain containing protein
TITLE Human lcel-domain containing protein
JOURNAL Patent: EP 1262488-A 44 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1519 AACAGTAAGAAAGAAC 1535
Db 1 AACAGAAAGAAAAAAC 17

RESULT 186
AX648875/c
LOCUS AX648875 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 715 from Patent EP1273660.
ACCESSION AX648875
VERSION AX648875.1 GI:29151693
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gu, Y.
AUTHORS Human sodium-hydrogen exchanger like protein 1
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 715 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 911 TGTAGCAGAGATCACTG 927
Db 17 TGTAGCAGACATCAGTG 1

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 911 TGTAGCAGAGATCACTG 927
Db 17 TGTAGCAGACATCAGTG 1

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Mus musculus (house mouse)

RESULT 187
AX648876/c
LOCUS AX648876 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 716 from Patent EP1273660.
ACCESSION AX648876
VERSION AX648876.1 GI:29151694
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gu, Y.
AUTHORS Human sodium-hydrogen exchanger like protein 1
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 716 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 910 CTGTAGCAGAGATCACT 926
Db 17 CTGTAGCAGACATCAGT 1

RESULT 188
AX693083
LOCUS AX693083 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 5815 from Patent EP1281758.
ACCESSION AX693083
VERSION AX693083.1 GI:29416047
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Shannon, M., Gu, Y. and Nguyen, C.T.
AUTHORS Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
TITLE mdz12
JOURNAL Patent: EP 1281758-A 5815 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1102 CAGAAGAACAAAGGTGGA 1118
Db 1 CAGCAGAACAAATGTGGA 17

RESULT 189
AX724533/c
LOCUS AX724533 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2220 from Patent WO03025176.
ACCESSION AX724533
VERSION AX724533.1 GI:30503876
KEYWORDS
SOURCE Mus musculus (house mouse)
```

ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1  
REFERENCE  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025176-A 2220 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 438 GAGAGGGGAGAGATC 454  
Db 17 GTGAGGGGAGAGATC 1  
RESULT 190  
AX728002/c  
LOCUS AX728002  
DEFINITION Sequence 5689 from Patent WO03025176.  
ACCESSION AX728002  
VERSION AX728002.1 GI:30507345  
KEYWORDS Mus musculus (house mouse)  
SOURCE  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1  
REFERENCE  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025176-A 5689 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1040 CTCACCTATTAAAGATC 1056  
Db 17 CTCCTTTATTAAAGATC 1  
RESULT 191  
AX730762  
LOCUS AX730762  
DEFINITION Sequence 2396 from Patent WO03025175.  
ACCESSION AX730762  
VERSION AX730762.1 GI:30510105  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as

medicines  
JOURNAL Patent: WO 03025175-A 2396 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1827 GATCTCTGAAAAAAA 1843  
Db 1 GATCTCTGAAAAAATAA 17  
RESULT 192  
AX734915  
LOCUS AX734915  
DEFINITION Sequence 505 from Patent WO03025177.  
ACCESSION AX734915  
VERSION AX734915.1 GI:30514192  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 505 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 231 GATGTTGCTAAAGCAAT 247  
Db 1 GATCTTGCTACAGCAAT 17  
RESULT 193  
AX736157  
LOCUS AX736157  
DEFINITION Sequence 1747 from Patent WO03025177.  
ACCESSION AX736157  
VERSION AX736157.1 GI:30515434  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments  
JOURNAL Patent: WO 03025177-A 1747 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"

```

/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1827 GATCTCTGAAAAAAA 1843
|||||
Db 1 GATCTCTTAAATAAAA 17

RESULT 194
AX736485/c
LOCUS AX736485 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2075 from Patent WO03025177.
ACCESSION AX736485
VERSION AX736485.1 GI:30515773
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 2075 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 GGTGTTCACTTTTATC 145
|||||
Db 17 GGTTTCACTTTGATC 1

RESULT 195
AX737865
LOCUS AX737865 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 3455 from Patent WO03025177.
ACCESSION AX737865
VERSION AX737865.1 GI:30517153
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 3455 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 845 GATCAAAATGTCATTC 861
|||||
Db 1 GATCAAAATGTCATTC 17

RESULT 196
AX783722/c
LOCUS AX783722 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2053 from Patent WO03050284.
ACCESSION AX783722
VERSION AX783722.1 GI:32951571
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2053 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 511 GCATTGGACTCTCTCA 527
|||||
Db 17 GCATTGGACTCTCTCA 1

RESULT 197
BD067591
LOCUS BD067591 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067591
VERSION BD067591.1 GI:22613194
KEYWORDS JP 2001511003-A/431.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 431 07-AUG-2001;
RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
PN JP 2001511003-A/431
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHR, AKHTAR, PATRICIA FELL, JAMES A MCSWIGGEN PC
C12N/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions
related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
1..17
FT source /organism="unidentified"
/db_xref="taxon:32644"
FEATURES
source Location/Qualifiers
1..17
/organism="unidentified"
/mol_type="genomic RNA"
/db_xref="taxon:32644"

```

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 174 AATGGCATCTCTAAGAG 190  
|||||  
Db 1 AATGGCATCTTTAAGG 17

RESULT 198  
A14295/c  
LOCUS A14295 18 bp DNA linear PAT 05-OCT-1994  
DEFINITION oligonucleotide.  
ACCESSION A14295  
VERSION A14295.1 GI:640787  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 18)  
AUTHORS  
JOURNAL Patent: GB 2068971-A 40 19-AUG-1981;  
FEATURES  
source Location/Qualifiers  
1..18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 190 GGACTTTTGAAGAAATA 206  
|||||  
Db 17 GGATTATGAAGAAATA 1

RESULT 199  
A18146  
LOCUS A18146 18 bp DNA linear PAT 22-APR-1994  
DEFINITION Probe specific for region corresponding to amino acids 56 to 61 of HLA-B\*2703 alpha 1 domain seq ID No:12.  
ACCESSION A18146  
VERSION A18146.1 GI:513201  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 18)  
AUTHORS  
JOURNAL PROCESS FOR AMPLIFYING NUCLEIC ACID  
TITLE Patent: WO 9207956-A 14 14-MAY-1992;  
FEATURES  
source Location/Qualifiers  
1..18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 504 GGCAGCAGCATTTGGAC 520  
|||||  
Db 2 GGCGGAGCATTTGGAC 18

RESULT 200  
A65728/c  
LOCUS A65728 18 bp DNA linear PAT 29-MAR-1999  
DEFINITION Sequence 9 from Patent WO9735973.  
ACCESSION A65728  
VERSION A65728.1 GI:4531347

KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.

REFERENCE 1  
AUTHORS Lenzen, G., Pietri-Rouxel, F., Drumare, Marie-Francoise and Strosberg, A. D.  
TITLE CANINE beta 2- AND beta 3-ADRENERGIC RECEPTORS AND USE THEREOF  
JOURNAL Patent: WO 9735973-A 9 02-OCT-1997;  
COMMENT Other publication FR 2746813 19971003.  
FEATURES  
source Location/Qualifiers  
1..18  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 721 CCTCCTTCTCCATCTAC 737  
|||||  
Db 18 CCTCGCTCTCTCTAC 2

RESULT 201  
A67594/c  
LOCUS A67594 18 bp DNA linear PAT 05-MAY-1999  
DEFINITION Sequence 14 from Patent WO9744485.  
ACCESSION A67594  
VERSION A67594.1 GI:4756457  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.

REFERENCE 1 (bases 1 to 18)  
AUTHORS Goodfellow, P. N.  
TITLE METHODS FOR IDENTIFYING A MUTATION IN A GENE OF INTEREST  
JOURNAL Patent: WO 9744485-A 14 27-NOV-1997;  
FEATURES  
source Location/Qualifiers  
1..18  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCGCGCTCGTCGCGC 44  
|||||  
Db 17 GCGCGCGCGCGCGC 1

RESULT 202  
AR049397  
LOCUS AR049397 18 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 12 from patent US 5824515.  
ACCESSION AR049397  
VERSION AR049397.1 GI:6005436  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
unclassified.

REFERENCE 1 (bases 1 to 18)  
AUTHORS Hill, A. Vivian, Sinton.  
TITLE Process for amplifying nucleic acid  
JOURNAL Patent: US 5824515-A 12 20-OCT-1998;  
FEATURES  
source Location/Qualifiers  
1..18  
/organism="unknown"



RESULT	205
AR072949	
LOCUS	AR072949      18 bp      DNA      linear      PAT 28-AUG-2000
DEFINITION	Sequence 31 from patent US 5948672.
ACCESSION	AR072949
VERSION	AR072949.1    GI:9999712



SOURCE  
ORGANISM synthetic construct  
REFERENCE synthetic construct  
AUTHORS other sequences; artificial sequences.  
1  
Rasmussen, P., Frandsen, N.M., Nyborg, M., Rasmussen, F.W., Hamzavi, R.,  
Nielsen, P.E. and Kj Ruliff, S.R.  
TITLE Modified pna molecules  
JOURNAL Patent: WO 2004024757-A 9 25-MAR-2004;  
Santaris Pharma A/S (DK)  
FEATURES Location/Qualifiers  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Novel sequence"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 332 GAGTGGCTCCAGAAC 348  
Db 18 GAGTGGCTCCGAGAGC 2

RESULT 212  
CQ807790/c  
LOCUS 18 bp DNA linear PAT 10-MAY-2004  
DEFINITION Sequence 1240 from Patent WO2004035803.  
ACCESSION CQ807790  
VERSION CQ807790.1 GI:4713184  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS other sequences; artificial sequences.  
1  
Foekens, J., Harbeck, N., Koenig, T., Maier, S., Martens, J., Model, F.,  
Nimmrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M.P. and  
Marx, A.  
TITLE Method and nucleic acids for the improved treatment of breast cell.  
JOURNAL proliferative disorders  
Patent: WO 2004035803-A 1240 29-APR-2004;  
Epigenomics AG (DE)  
FEATURES Location/Qualifiers  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Detection oligonucleotide for ING4"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1617 TTCAAGCACAACCTCTA 1633  
Db 18 TTCAAAACACATCTCTA 2

RESULT 213  
CQ876358/c  
LOCUS 18 bp DNA linear PAT 04-OCT-2004  
DEFINITION Sequence 208 from Patent WO2004065583.  
ACCESSION CQ876358  
VERSION CQ876358.1 GI:53789962  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS other sequences; artificial sequences.  
1  
Cobleigh, M.A., Shak, S., Baker, J.B. and Cronin, M.T.  
TITLE Gene expression markers for breast cancer prognosis  
JOURNAL Patent: WO 2004065583-A 208 05-AUG-2004;

Genomic Health, Inc. (US); Rush University Medical Center (US)  
FEATURES Location/Qualifiers  
source  
1. .18  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="probe"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 673 TGGAGCTGCCAAGGTG 689  
Db 17 TGGCAGCTGCCAGGTG 1

RESULT 214  
E29787/c  
LOCUS 18 bp DNA linear PAT 18-JUN-2001  
DEFINITION Method for discriminating and detecting human coagulation factor V  
gene polymorphism.  
ACCESSION E29787  
VERSION E29787.1 GI:13016883  
KEYWORDS JP 1999313676-A/34.  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Takashi, F., Shigetoshi, K., Makoto, H. and Keizo, S.  
TITLE Method for discriminating and detecting human coagulation factor V  
gene polymorphism  
JOURNAL Patent: JP 1999313676-A 34 16-NOV-1999;  
OTSUKA PHARMACEUT CO LTD  
COMMENT OS Unidentified  
PN JP 1999313676-A/34  
PD 16-NOV-1999  
PF 30-APR-1998 JP 1998120217  
PR  
PI TAKASHI FUKUI, SHIGETOSHI KINOSHITA, MAKOTO HASHIZUME, PI  
KEIZO SUGIMACHI  
PC C12N15/09, C12Q1/68, C12N15/00  
CC Strandedness: Single;  
CC Topology: Linear;  
FH Key Location/Qualifiers  
FT source 1.18  
FT Location/Qualifiers  
source  
1. .18  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1685 CTAGAAAGGATCAT 1701  
Db 18 CTAGAAAGGATGAT 2

RESULT 215  
I21931  
LOCUS 18 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 12 from patent US 5525492.  
ACCESSION I21931  
VERSION I21931.1 GI:1602285  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)



AUTHORS Griffiths,A.D., Hoogenboom,H.R.J.M., Marks,J.D., McCafferty,J.,  
Winter,G.P. and Grigg,G.W.  
TITLE Production of anti-self bodies from antibody segment repertoires  
and displayed on phage  
JOURNAL Patent: US 6582915-A 14 24-JUN-2003;  
FEATURES Location/Qualifiers  
source  
1..18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGGTGGGAAGA 811  
|||||  
Db 2 TGTATTACTGTGCAAGA 18  
|||||

RESULT 221  
AR4353533  
LOCUS AR4353533 18 bp DNA linear PAT 17-AUG-2003  
DEFINITION Sequence 14 from patent US 6593081.  
ACCESSION AR4353533  
VERSION AR4353533.1 GI:33759523  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Griffiths,A.D., Hoogenboom,H.R.J.M., Marks,J.D., McCafferty,J.,  
Winter,G.P. and Grigg,G.W.  
TITLE Production of anti-self antibodies from antibody segment  
repertoires and displayed on phage  
JOURNAL Patent: US 6593081-A 14 15-JUL-2003;  
FEATURES Location/Qualifiers  
source  
1..18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 795 TGTATTACGGTGGGAAGA 811  
|||||  
Db 2 TGTATTACTGTGCAAGA 18  
|||||

RESULT 222  
AR442110/c  
LOCUS AR442110 18 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 9 from patent US 6670124.  
ACCESSION AR442110  
VERSION AR442110.1 GI:42669367  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Chow,R. and Tonai,R.  
TITLE High throughput methods of HLA typing  
JOURNAL Patent: US 6670124-A 9 30-DEC-2003;  
FEATURES Location/Qualifiers  
source  
1..18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAAGATGGGCTG 398  
|||||

Db 17 TGCAGCACGAGGGGCTG 1  
|||||

RESULT 223  
AR442224/c  
LOCUS AR442224 18 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 125 from patent US 6670124.  
ACCESSION AR442224  
VERSION AR442224.1 GI:42669481  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Chow,R. and Tonai,R.  
TITLE High throughput methods of HLA typing  
JOURNAL Patent: US 6670124-A 125 30-DEC-2003;  
FEATURES Location/Qualifiers  
source  
1..18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 382 TGCAGCAAGATGGGCTG 398  
|||||  
Db 17 TGCAGCACGAGGGGCTG 1  
|||||

RESULT 224  
AR493061  
LOCUS AR493061 18 bp DNA linear PAT 15-MAY-2004  
DEFINITION Sequence 93 from patent US 6720137.  
ACCESSION AR493061  
VERSION AR493061.1 GI:47264447  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Roder,M., Plaschke,J. and Ganai,M.  
TITLE Microsatellite markers for plants of the species Triticum aestivum  
and Tribe triticeae and the use of said markers  
JOURNAL Patent: US 6720137-A 93 13-APR-2004;  
FEATURES Location/Qualifiers  
source  
1..18  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1696 AATCATTTCTCCCTCCC 1712  
|||||  
Db 2 AATCATTTCTCCCTCCC 18  
|||||

RESULT 225  
AX092726/c  
LOCUS AX092726 18 bp DNA linear PAT 21-MAR-2001  
DEFINITION Sequence 138 from Patent WO0115676.  
ACCESSION AX092726  
VERSION AX092726.1 GI:13444783  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS Hayden,M.R., Brooks-Wilson,A.R., Pimstone,S.N. and Clee,S.M.  
 TITLE Compositions and methods for modulating hdl cholesterol and triglyceride levels  
 JOURNAL University of British Columbia (CA) ; Xenon Genetics Inc. (CA)  
 FEATURES Location/Qualifiers

source  
 1..18  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1641 CTTTCTGTTATTCTT 1657  
 ||||| ||||| |||||  
 Db 18 CTTTCTGATTCTCTT 2

RESULT 226  
 AX113887  
 LOCUS AX113887 18 bp DNA linear PAT 01-MAY-2001  
 DEFINITION Sequence 35 from Patent WO0127330.  
 ACCESSION AX113887  
 VERSION AX113887.1 GI:13940067  
 KEYWORDS  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 other sequences; artificial sequences.

REFERENCE 1  
 AUTHORS Ahuja,S., Gonzalez,E. and Mummidu,S.  
 TITLE Screening for disease susceptibility by genotyping the ccr5 and ccr2 genes  
 JOURNAL Patent: WO 0127330-A 35 19-APR-2001;  
 Board of Regents, The University of Texas System (US)

FEATURES  
 source  
 1..18  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="Synthetic oligonucleotide"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1506 CCTAGGTCCTAGAACCA 1522  
 ||||| ||||| |||||  
 Db 1 CCTGGGTCCTAGAAATCA 17

RESULT 227  
 AX326905  
 LOCUS AX326905 18 bp DNA linear PAT 07-JAN-2002  
 DEFINITION Sequence 101 from Patent WO0178894.  
 ACCESSION AX326905  
 VERSION AX326905.1 GI:18097616  
 KEYWORDS  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 other sequences; artificial sequences.

REFERENCE 1  
 AUTHORS Keith,T.  
 TITLE Novel human gene relating to respiratory diseases, obesity, and inflammatory bowel disease  
 JOURNAL Patent: WO 0178894-A 101 25-OCT-2001;  
 Genome Therapeutics Corp. (US)

FEATURES  
 source  
 1..18  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"

/note="Primer"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1101 GCAGAGACACAGGTGG 1117  
 ||||| ||||| |||||  
 Db 2 GCAGAGGACCAAGGTGG 18

RESULT 228  
 AX378472/c  
 LOCUS AX378472 18 bp DNA linear PAT 18-MAR-2002  
 DEFINITION Sequence 261 from Patent WO0206525.  
 ACCESSION AX378472  
 VERSION AX378472.1 GI:19574325  
 KEYWORDS  
 SOURCE Homo sapiens (human)

ORGANISM  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
 AUTHORS Cohen,D., Blumenfeld,M., Chumakov,I., Abderrahim,H. and Bihain,B.  
 TITLE Obesity associated biallelic marker maps  
 JOURNAL Patent: WO 0206525-A 261 24-JAN-2002;  
 GENSET (FR)

FEATURES  
 Location/Qualifiers  
 source  
 1..18  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

primer\_bind

1..18  
 /note="upstream amplification primer 99-32166 for SEQ 90"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 224 CTGTGAGATGTTGCTA 240  
 ||||| ||||| |||||  
 Db 17 CTGTGAAGATGATGCTA 1

RESULT 229  
 AX699211  
 LOCUS AX699211 18 bp DNA linear PAT 29-MAY-2003  
 DEFINITION Sequence 152 from Patent WO03000727.  
 ACCESSION AX699211  
 VERSION AX699211.1 GI:29499861  
 KEYWORDS  
 SOURCE synthetic construct  
 ORGANISM synthetic construct  
 other sequences; artificial sequences.

REFERENCE 1  
 AUTHORS Zhang,Y., Moffatt,M., Cookson,W. and Tinsley,J.O.  
 TITLE Atopy  
 JOURNAL Patent: WO 03000727-A 152 03-JAN-2003;  
 ISIS INNOVATION LIMITED (GB)

FEATURES  
 Location/Qualifiers  
 source  
 1..18  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="Primer"

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 939 CCAGAACAGGTGTACT 955  
 ||||| ||||| |||||  
 Db 1 CCTGAACAGGCTGTACT 17

```

RESULT 230
AX785466
LOCUS AX785466 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 77 from Patent WO03050301.
ACCESSION AX785466
VERSION AX785466.1 GI:32953086
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gurling,H.M.
TITLE Susceptibility locus for schizophrenia
JOURNAL Patent: WO 03050301-A 77 19-JUN-2003;
Gurling, Hugh Malcolm Douglas (GB)
FEATURES
source
1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1514 CTAGAACAGTAAGAAA 1530
|||||
DB 1 CTAGTAAAGTAAGAAA 17

RESULT 231
AX959634/c
LOCUS AX959634 18 bp DNA linear PAT 14-JAN-2004
DEFINITION Sequence 17 from Patent EP1369125.
ACCESSION AX959634
VERSION AX959634.1 GI:40879989
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Attie,K.M., Carlsson,L.M., Gesundheit,N. and Goddard,A.
TITLE Treatment of partial growth hormone insensitivity syndrome
JOURNAL Patent: EP 1369125-A 17 10-DEC-2003;
Genentech, Inc. (US)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 264 TATGTTAAAGCCCGAGAA 280
|||||
DB 17 TAAGGTTAAAGCCCGAGCA 1

RESULT 232
BD002174/c
LOCUS BD002174 18 bp DNA linear PAT 31-JAN-2002
DEFINITION Remedy of partial growth hormone insensible syndrome.
ACCESSION BD002174
VERSION BD002174.1 GI:18630135
KEYWORDS
SOURCE JP 2000226334-A/9.
synthetic construct
ORGANISM other sequences; artificial sequences.

```

```

REFERENCE 1 (bases 1 to 18)
Kenneth,A., S.C.L.M., Nail,G. and Audley,G.
TITLE Remedy of partial growth hormone insensible syndrome
JOURNAL Patent: JP 2000226334-A 9 15-AUG-2000;
GENETIC INC
COMMENT OS Artificial Sequence
PN JP 2000226334-A/9
PD 15-AUG-2000
PF 07-JAN-2000 JP 2000001444
PR 07-APR-1994 US 08/224982
PI ATI KENNETH, CARLSSON LENA M S, GESANDORAITO NAIL, GODDARD AUDLEY
PC A61K38/27,A61P3/00,A61P5/02,A61P43/00//C07K14/65,C12N15/09 CC
FH Key Location/Qualifiers
FT source 1..18
/organism="Artificial Sequence".
FEATURES
source
1..18
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 264 TATGTTAAAGCCCGAGAA 280
|||||
DB 17 TAAGGTTAAAGCCCGAGCA 1

RESULT 233
BD002275
LOCUS BD002275 18 bp DNA linear PAT 31-JAN-2002
DEFINITION Cellulase preparation comprising endoglucanase.
ACCESSION BD002275
VERSION BD002275.1 GI:18630236
KEYWORDS JP 2000217583-A/28.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gurete,R., Moller,M.J., Martin,S. and Ananto,P.S.
TITLE Cellulase preparation comprising endoglucanase
JOURNAL Patent: JP 2000217583-A 28 08-AUG-2000;
NOVO NORDISK A/S
COMMENT OS Artificial Sequence
PN JP 2000217583-A/28
PD 08-AUG-2000
PF 22-DEC-1999 JP 1999365341
PR 09-MAY-1990 DK 1159/90,22-APR-1991 DK 0736/91 PI
RASMUSSEN GURETE,MIKKJELSEN JAN MOLLER,SCHREIN MARTIN, PI PATKUL
SHAMKANTO ANANTO
PC C12N15/09,C11D3/386,C12N1/15,C12N1/19,C12N9/42,C12S3/04, PC
D06M16/00//
PD 22-DEC-1999
CC D21H11/20,(C12N9/42,C12R1:645),C12N15/00
FH Key Location/Qualifiers
FT source 1..18
/organism="Artificial Sequence".
FEATURES
source
1..18
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 633 AACTACTCAAGGACGGT 649
|||||
DB 1 AGCTTCTCAAGGACGGT 17

```

```

RESULT 234
BD010879
LOCUS          BD010879          18 bp    DNA          linear          PAT 31-JAN-2002
DEFINITION     Cellulase preparation containing endoglucanase.
ACCESSION      BD010879
VERSION        BD010879.1 GI:18639252
KEYWORDS       JP 2001057894-A/28.
SOURCE         synthetic construct
ORGANISM       other sequences: artificial sequences.
REFERENCE      1 (bases 1 to 18)
AUTHORS        Rasmussen,G., Mikkelsen,J.M., Schilein,M., Patkar,S.A., Hagen,F.,
                Miland,H.K. and Hallstrop,S.
TITLE          Cellulase preparation containing endoglucanase
JOURNAL        Patent: JP 2001057894-A 28 06-MAR-2001;
                NOVO NORDISK AS
COMMENT        OS Artificial Sequence
                PN JP 2001057894-A/28
                PD 06-MAR-2001
                PF 06-JUL-2000 JP 2000205757
                PR 09-MAY-1990 DK 1159/90,22-APR-1991 DK 0736/91 PI
                GURETE RASMUSSEN JAN MOLLER MIKKJELSEN MARTIN SCHILEIN, PI
                SHAMKANT ANANT PATKAR,FRED HAGEN,HUORT KARSTEN MILAND, PI SVEND
                HALLSTROP
PC             C12N15/09,C11D3/386,C12N1/15,C12N1/19,C12N9/24,D06M16/00// PC
                (C12N15/09,C12R1/77),(C12N15/09,C12R1/645),(C12N9/24,PC
C12R1/865),
PC             C12N9/24,C12R1/885),(C12N9/24,C12R1/78),(C12N9/24,C12R1/69),
PC             (C12N9/24,C12R1/695),C12N15/00,(C12N15/00,C12R1/77),(C12N15/00,PC
C12R1/645)
CC             Key Location/Qualifiers
FH             source 1..18
FT             /organism='Artificial Sequence'.
FEATURES       source
                1..18
                Location/Qualifiers
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"

Query Match    0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY             633 AACTACTCAAGGACGGT 649
Db             1 AGCTTCTCAAGGACGGT 17

RESULT 235
BD244856
LOCUS          BD244856          15 bp    DNA          linear          PAT 17-JUL-2003
DEFINITION     Oligonucleotide primer capable of making the non-specific double
                strand formation unstable.
ACCESSION      BD244856
VERSION        BD244856.1 GI:33054626
KEYWORDS       JP 2002532063-A/1.
SOURCE         synthetic construct
ORGANISM       other sequences: artificial sequences.
REFERENCE      1 (bases 1 to 15)
AUTHORS        Pelletier,J. and Das,M.
TITLE          Oligonucleotide primer capable of making the non-specific double
                strand formation unstable
JOURNAL        Patent: JP 2002532063-A 1 02-OCT-2002;
                MCGILL UNIVERSITY
COMMENT        OS Artificial Sequence
                PN JP 2002532063-A/1
                PD 02-OCT-2002
                PF 06-OCT-1999 JP 2000574722

PR             07-OCT-1998 CA 2246623
PI             JERRY PELLETIER,MANJULA DAS
PC             C12N15/09,C12Q1/68,C12N15/00
CC             Description of Artificial Sequence: synthetic oligonucleotide
FH             Key Location/Qualifiers
FT             source 1..15
                /organism='Artificial Sequence'.
FEATURES       source
                1..15
                Location/Qualifiers
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"

Query Match    0.7%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY             1835 AAAAAAAAAAAAAA 1849
                ||||| |||||
Db             1 AAAAAAAAAAAAAA 15

RESULT 236
AR328438/c
LOCUS          AR328438          16 bp    RNA          linear          PAT 17-AUG-2003
DEFINITION     Sequence 5840 from patent US 6566127.
ACCESSION      AR328438
VERSION        AR328438.1 GI:33714246
KEYWORDS       Unknown.
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 16)
AUTHORS        Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE          Method and reagent for the treatment of diseases or conditions
                related to levels of vascular endothelial growth factor receptor
JOURNAL        Patent: US 6566127-A 5840 20-MAY-2003;
FEATURES       source
                1..16
                Location/Qualifiers
                /organism="unknown"
                /mol_type="unassigned RNA"

Query Match    0.7%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY             1281 CTCATATCACTCAG 1295
                ||||| |||||
Db             16 CTCACATCACTCAG 2

RESULT 237
AX928000/c
LOCUS          AX928000          16 bp    DNA          linear          PAT 19-DEC-2003
DEFINITION     Sequence 86 from Patent WO03085110.
ACCESSION      AX928000
VERSION        AX928000.1 GI:40251008
KEYWORDS       synthetic construct
SOURCE         synthetic construct
ORGANISM       other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Thruw,C.A., h G.A.M. and Kristjansen,P.E.
TITLE          Oligomeric compounds for the modulation hif-lalpha expression
JOURNAL        Patent: WO 03085110-A 86 16-OCT-2003;
                Curson A/S (DK)
FEATURES       source
                1..16
                Location/Qualifiers
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Description of Artificial Sequence:antisense
                oligonucleotide to human HIF-1a"

```



Query Match 0.7%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.3e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 399 GAGAAAGTTACCTG 413  
Db 15 GACAAAGTTACCTG 1  
|||||

RESULT 238  
AR168840/c  
LOCUS AR168840 17 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 66 from patent US 6288042.  
ACCESSION AR168840  
VERSION AR168840.1 GI:17904970  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.  
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides  
JOURNAL Patent: US 6288042-A 66 11-SEP-2001;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCGNCCACCACCAC 1  
|||||

RESULT 239  
AR168847/c  
LOCUS AR168847 17 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 73 from patent US 6288042.  
ACCESSION AR168847  
VERSION AR168847.1 GI:17904981  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.  
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides  
JOURNAL Patent: US 6288042-A 73 11-SEP-2001;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCGNCCACCACCAC 1  
|||||

RESULT 240  
AR168850/c  
LOCUS AR168850 17 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 76 from patent US 6288042.  
ACCESSION AR168850  
VERSION AR168850.1 GI:17904985  
KEYWORDS

SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.  
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides  
JOURNAL Patent: US 6288042-A 76 11-SEP-2001;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCGNCCACCACCAC 1  
|||||

RESULT 241  
AR168851/c  
LOCUS AR168851 17 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 77 from patent US 6288042.  
ACCESSION AR168851  
VERSION AR168851.1 GI:17904987  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.  
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides  
JOURNAL Patent: US 6288042-A 77 11-SEP-2001;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1706 CCTCTCCCTCCACCAC 1721  
Db 16 CCGNCCACCACCAC 1  
|||||

RESULT 242  
BD198937/c  
LOCUS BD198937 17 bp RNA linear PAT 17-JUL-2003  
DEFINITION Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response.  
ACCESSION BD198937  
VERSION BD198937.1 GI:33008707  
KEYWORDS JP 2002509721-A/1963.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.  
TITLE Method and reagent for treating diseases or conditions concerning molecule participating in vasculogenic response  
JOURNAL Patent: JP 2002509721-A 1963 02-APR-2002;  
COMMENT RIBOZYME PHARMACEUTICALS INC  
OS Homo sapiens (human)  
PN JP 2002509721-A/1963  
PD 02-APR-2002.  
PF 24-MAR-1999 JP 2000541291  
PR 27-MAR-1998 US 60/079678  
PI PAMELA A PAVCO, ELISABETH ROBERTS, THALE JARVIS, CLAIRE COESHOTT,

```

PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7125,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism="Homo sapiens (human)".

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 205 TAAAGAAGAAATAG 219
DB 17 TAATAGAAGAAATAG 3

RESULT 243
BD201049/c
LOCUS
DEFINITION
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION
BD201049.1 GI:33010819
VERSION
JP 2002509721-A/4075.
KEYWORDS
Homo sapiens (human)
SOURCE
Homo sapiens
ORGANISM
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Favco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
JOURNAL
Patent: JP 2002509721-A 4075 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Homo sapiens (human)
PN JP 2002509721-A/4075
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COSSHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism="Homo sapiens (human)".

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1642 TTTCGTGTTATCT 1656
DB 16 TTTCGTGTTATCT 2

RESULT 244
BD201115/c
LOCUS
DEFINITION
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response.
ACCESSION
BD201115
VERSION
BD201115.1 GI:33010885
KEYWORDS
JP 2002509721-A/4141.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Pavco,P.A., Roberts,E., Jarvis,T., Coeshott,C. and Mcswiggen,J.A.
TITLE
Method and reagent for treating diseases or conditions concerning
molecule participating in vasculogenic response
JOURNAL
Patent: JP 2002509721-A 4141 02-APR-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Homo sapiens (human)
PN JP 2002509721-A/4141
PD 02-APR-2002
PF 24-MAR-1999 JP 2000541291
PR 27-MAR-1998 US 60/079678
PI PAMELA A PAVCO,ELISABETH ROBERTS,THALE JARVIS,CLAIRE COSSHOTT,
PI JAMES A MCSWIGGEN
PC
C12N15/09,A61K31/7088,A61K48/00,A61P3/10,A61P17/06, PC
A61P29/00,
PC A61P35/00,A61P43/00,C12N5/10,C12N9/00//A61K35/76,C12N15/00, PC
C12N5/00
CC Method and reagent for treating diseases or conditions CC
CC concerning molecule
CC participating in vasculogenic response
FH Key Location/Qualifiers
FT source 1..17
FT /organism="Homo sapiens (human)".

FEATURES
source
1..17
/organism="Homo sapiens"
/mol_type="genomic RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 239 TAAAGCAATCAAA 253
DB 15 TAAAGCAAGCATCAA 1

RESULT 245
BD254875/c
LOCUS
DEFINITION
Regulation of repressor genes using nucleic acid molecules.
ACCESSION
BD254875
VERSION
BD254875.1 GI:33064645
KEYWORDS
JP 2002541795-A/2668.
SOURCE
unidentified
ORGANISM
unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS
Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE
Regulation of repressor genes using nucleic acid molecules
JOURNAL
Patent: JP 2002541795-A 2668 10-DEC-2002;
RIBOZYME PHARMACEUTICALS INC
COMMENT
OS Eukaryote
PN JP 2002541795-A/2668

```

PD 10-DEC-2002  
PF 11-APR-2000 JP 2000611654  
PI 12-APR-1999 US 60/129390  
C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC  
C12P21/02,  
PC  
C12P21/02, C12P21/02/A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC  
C12R1:91),  
PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,  
PC A61K37/02,  
PC (C12N5/00, C12R1:91)  
CC Regulation of repressor genes using nucleic acid molecules FH  
Key  
FT source 1. .17  
Location/Qualifiers  
/organism="Eukaryote".  
FEATURES  
source  
1. .17  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 594 GCAAGAGGGAAGATT 608  
Db 17 GGAAGAGGGAAGATT 3  
RESULT 246  
CQ616798  
LOCUS 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 1538 from Patent WO0192524.  
ACCESSION CQ616798  
VERSION CQ616798.1 GI:41667016  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 1538 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1084 GGCTGGTGGCTCTGGA 1098  
Db 2 GGCTGGTGGCTCTGGA 16  
RESULT 247  
CQ616799  
LOCUS 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 1539 from Patent WO0192524.  
ACCESSION CQ616799  
VERSION CQ616799.1 GI:41667017  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 1539 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1084 GGCTGGTGGCTCTGGA 1098  
Db 1 GGCTGGTGGCTCTGGA 15  
RESULT 248  
CQ623626  
LOCUS 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 8366 from Patent WO0192524.  
ACCESSION CQ623626  
VERSION CQ623626.1 GI:41673844  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8366 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 396 CTGGAGAAAGTTCAC 410  
Db 1 CTGGAGAAAGTTCAC 15  
RESULT 249  
CQ623847  
LOCUS 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 8587 from Patent WO0192524.  
ACCESSION CQ623847  
VERSION CQ623847.1 GI:41674065  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8587 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17

[illegible]

```

VERSION      E32474.1  GI:13026726
KEYWORDS     JP 1999123092-A/5.
SOURCE       unclassified
ORGANISM     unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Motoo,Y., Kenji,S., Nobuo,H., Akiko,F. and Kaoru,M.
TITLE        Novel vascular smooth muscle cell growth factor
JOURNAL      Patent: JP 1999123092-A 5 11-MAY-1999;
              KYOWA HAKKO KOGYO CO LTD
COMMENT      OS Unidentified
              PN JP 1999123092-A/5
              PD 11-MAY-1999
              PF 11-AUG-1998 JP 1998226905
              PR
              PI MOTOO YAMAZAKI, KENJI SHIBATA, NOBUO HANAI, AKIKO FURUYA, PI
              KAORU MIYAMOTO
              PC C12N15/09,A61K38/22,A61K38/22,C07K14/52,C07K16/24,C12N5/10, PC
              C12P21/02//
              PC
              A61K39/395,C12P21/08,G01N33/53,G01N33/577,(C12P21/02,C12R1:91), PC
              C12N15/00,
              PC A61K37/24,A61K37/24,C12N5/00
              CC Strandedness: Single;
              CC Topology: Linear;
              FH Key
              FT source
              FT Location/Qualifiers
              FT /organism='Unidentified'.
              FT Location/Qualifiers
              FT 1..17
              /organism='unidentified'
              /mol_type='genomic DNA'
              /db_xref='taxon:32644'

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1384 ATTCTTCTTCCATC 1398
Db 17 ATTCCTCTTCCATC 3

RESULT 255
AR188763/c
LOCUS        AR188763      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION   Sequence 4251 from patent US 6346398.
ACCESSION    AR188763
VERSION      AR188763.1  GI:20234728
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 4251 12-FEB-2002;
FEATURES     Location/Qualifiers
              source
              1..17
              /organism='unknown'
              /mol_type='unassigned DNA'

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1149 AAGGTAATATTTCC 1163
Db 15 AAGGAAATATTTCC 1

RESULT 256
AR188763/c
LOCUS        AR188763      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION   Sequence 4251 from patent US 6346398.
ACCESSION    AR188763
VERSION      AR188763.1  GI:20234728
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 4251 12-FEB-2002;
FEATURES     Location/Qualifiers
              source
              1..17
              /organism='unknown'
              /mol_type='unassigned DNA'

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1149 AAGGTAATATTTCC 1163
Db 15 AAGGAAATATTTCC 1

RESULT 256

```

```

AR190333/c
LOCUS        AR190333      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION   Sequence 5821 from patent US 6346398.
ACCESSION    AR190333
VERSION      AR190333.1  GI:20236298
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE        Method and reagent for the treatment of diseases or conditions
              related to levels of vascular endothelial growth factor receptor
JOURNAL      Patent: US 6346398-A 5821 12-FEB-2002;
FEATURES     Location/Qualifiers
              source
              1..17
              /organism='unknown'
              /mol_type='unassigned DNA'

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1149 AAGGTAATATTTCC 1163
Db 15 AAGGAAATATTTCC 1

RESULT 257
AR200309/c
LOCUS        AR200309      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION   Sequence 66 from patent US 6355785.
ACCESSION    AR200309
VERSION      AR200309.1  GI:20250383
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Rando,R.F., Fennewald,S., Zengdeui,J.G., Ojwang,J.O., Hogan,M.E.,
              Pommer,y. and Mazumder,A.
TITLE        Guanosine-rich oligonucleotide integrase inhibitors
JOURNAL      Patent: US 6355785-A 66 12-MAR-2002;
FEATURES     Location/Qualifiers
              source
              1..17
              /organism='unknown'
              /mol_type='unassigned DNA'

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACAC 1721
Db 16 CCCNCCACCCACAC 1

RESULT 258
AR200316/c
LOCUS        AR200316      17 bp      DNA      linear      PAT 20-APR-2002
DEFINITION   Sequence 73 from patent US 6355785.
ACCESSION    AR200316
VERSION      AR200316.1  GI:20250390
KEYWORDS     Unknown.
SOURCE       Unknown.
ORGANISM     Unclassified.
REFERENCE     1 (bases 1 to 17)
AUTHORS      Rando,R.F., Fennewald,S., Zengdeui,J.G., Ojwang,J.O., Hogan,M.E.,
              Pommer,y. and Mazumder,A.
TITLE        Guanosine-rich oligonucleotide integrase inhibitors
JOURNAL      Patent: US 6355785-A 73 12-MAR-2002;
FEATURES     Location/Qualifiers

```



```
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCACCCNCCACCAC 1

RESULT 264
AR262451/c
LOCUS AR262451 Sequence 77 from patent US 6323185. 17 bp DNA linear PAT 29-JAN-2003
DEFINITION AR262451
ACCESSION AR262451
VERSION AR262451.1 GI:28073882
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Fennwald,S., Zendegeui,J.G., Oiwang,J.O. and Hogan,M.B.
TITLE Anti-viral guanosine-rich oligonucleotides and method of treating HIV
JOURNAL Patent: US 6323185-A 77 27-NOV-2001;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1706 CCCTCCCTCCACCAC 1721
Db 16 CCCNCCACCACCAC 1

RESULT 265
AR324616/c
LOCUS AR324616 Sequence 2018 from patent US 6566127. 17 bp RNA linear PAT 17-AUG-2003
DEFINITION AR324616
ACCESSION AR324616
VERSION AR324616.1 GI:33710424
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwigen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2018 20-MAY-2003;
FEATURES Location/Qualifiers
source 1..17
/mol_type="unassigned RNA"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1149 AAGTAAATATTTC 1163
Db 15 AAGGAAATATTTC 1

RESULT 266
AR457861
LOCUS AR457861 Sequence 1538 from patent US 6686188. 17 bp DNA linear PAT 20-FEB-2004
DEFINITION AR457861
ACCESSION AR457861
VERSION AR457861.1 GI:42692918
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1538 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1084 GGCTGGTGCTCTCGA 1098
Db 2 GGCTGGTGCTCTCGA 16

RESULT 267
AR457862
LOCUS AR457862 Sequence 1539 from patent US 6686188. 17 bp DNA linear PAT 20-FEB-2004
DEFINITION AR457862
ACCESSION AR457862
VERSION AR457862.1 GI:42692919
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 1539 03-FEB-2004;
FEATURES Location/Qualifiers
source 1..17
/mol_type="genomic DNA"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1084 GGCTGGTGCTCTCGA 1098
Db 1 GGCTGGTGCTCTCGA 15

RESULT 268
AR464689
LOCUS AR464689 Sequence 8366 from patent US 6686188. 17 bp DNA linear PAT 20-FEB-2004
DEFINITION AR464689
ACCESSION AR464689
VERSION AR464689.1 GI:42699746
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8366 03-FEB-2004;
```

```
FEATURES             Location/Qualifiers
     source             1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 396 CTCGAGAAAGTTTCAC 410
Db 1 CTCGAGAAAGTGCAC 15

RESULT 269
LOCUS AR464910
DEFINITION Sequence 8587 from patent US 6686188.
ACCESSION AR464910
VERSION AR464910.1 GI:42699967
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8587 03-FEB-2004;
FEATURES             Location/Qualifiers
     source             1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACCAAGG 1114
Db 3 TGCAGAAGCAACAGG 17

RESULT 270
LOCUS AR464911
DEFINITION Sequence 8588 from patent US 6686188.
ACCESSION AR464911
VERSION AR464911.1 GI:42699968
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8588 03-FEB-2004;
FEATURES             Location/Qualifiers
     source             1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACCAAGG 1114
Db 2 TGCAGAAGCAACAGG 16

RESULT 271
LOCUS AR464912
DEFINITION Sequence 8589 from patent US 6686188.
ACCESSION AR464912
VERSION AR464912.1 GI:42699969
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 8589 03-FEB-2004;
FEATURES             Location/Qualifiers
     source             1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1100 TGCAGAAGACCAAGG 1114
Db 1 TGCAGAAGCAACAGG 15

RESULT 272
LOCUS AR466352/c
DEFINITION Sequence 10029 from patent US 6686188.
ACCESSION AR466352
VERSION AR466352.1 GI:42701409
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10029 03-FEB-2004;
FEATURES             Location/Qualifiers
     source             1..17
                        /organism="unknown"
                        /mol_type="genomic DNA"

Query Match
Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1066 GTCCAAAGAGGACTC 1080
Db 17 GTCCACAGAGGACTC 3

RESULT 273
LOCUS AR466355/c
DEFINITION Sequence 10032 from patent US 6686188.
ACCESSION AR466355
VERSION AR466355.1 GI:42701412
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
```



Shannon, M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 10032 03-FEB-2004;  
JOURNAL Location/Qualifiers  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGACT 1079  
Db 15 CGTCCACAGAGACT 1

RESULT 274  
AX475031/c  
LOCUS  
DEFINITION Sequence 418 from patent US 6692917.  
ACCESSION AR475031  
VERSION AR475031.1  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
1 (bases 1 to 17)  
Unclassified.  
AUTHORS Neri, B.P., Hall, J.G., Lyamichev, V. and Smith, L.M.  
TITLE Systems and methods for invasive cleavage reaction on dendrimers  
JOURNAL Patent: US 6692917-A 418 17-FEB-2004;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 566 CGATGAAGCTGCAGAG 580  
Db 16 CGATGACCTGCAGAG 2

RESULT 275  
AX183650/c  
LOCUS  
DEFINITION Sequence 1403 from Patent WO0142511.  
ACCESSION AX183650  
VERSION AX183650.1  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Daly, M., Hudson, T.J., Lander, E.S., Rioux, J. and Siminovitch, K.  
TITLE Ibd-related polymorphisms  
JOURNAL Patent: WO 0142511-A 1403 14-JUN-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Ellipsis  
Biotherapeutics Corporation (CA)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Shannon, M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 10032 03-FEB-2004;  
JOURNAL Location/Qualifiers  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1065 CGTCCAAAGAGACT 1079  
Db 15 CGTCCACAGAGACT 1

RESULT 274  
AX475031/c  
LOCUS  
DEFINITION Sequence 418 from patent US 6692917.  
ACCESSION AR475031  
VERSION AR475031.1  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE  
1 (bases 1 to 17)  
Unclassified.  
AUTHORS Neri, B.P., Hall, J.G., Lyamichev, V. and Smith, L.M.  
TITLE Systems and methods for invasive cleavage reaction on dendrimers  
JOURNAL Patent: US 6692917-A 418 17-FEB-2004;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 566 CGATGAAGCTGCAGAG 580  
Db 16 CGATGACCTGCAGAG 2

RESULT 275  
AX183650/c  
LOCUS  
DEFINITION Sequence 1403 from Patent WO0142511.  
ACCESSION AX183650  
VERSION AX183650.1  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Daly, M., Hudson, T.J., Lander, E.S., Rioux, J. and Siminovitch, K.  
TITLE Ibd-related polymorphisms  
JOURNAL Patent: WO 0142511-A 1403 14-JUN-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Ellipsis  
Biotherapeutics Corporation (CA)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 94 AAAAAAATGAATTCCT 109  
Db 17 AAAAAAANGAATTCAT 2

RESULT 276  
AX217109  
LOCUS  
DEFINITION Sequence 2551 from Patent WO0159103.  
ACCESSION AX217109  
VERSION AX217109.1  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE  
1  
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 2551 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 203 AATAAAGAGAGAAAT 217  
Db 2 AATAAAGAGAGAAAT 16

RESULT 277  
AX264296  
LOCUS  
DEFINITION Sequence 1687 from Patent WO0173002.  
ACCESSION AX264296  
VERSION AX264296.1  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 1687 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 198 GAAGAAATAAAGAA 212  
Db 2 GCAGAAATAAAGAA 16

RESULT 278  
AX264297/c  
LOCUS  
DEFINITION Sequence 1687 from Patent WO0173002.  
ACCESSION AX264297  
VERSION AX264297.1  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 1687 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 198 GAAGAAATAAAGAA 212  
Db 2 GCAGAAATAAAGAA 16

RESULT 278  
AX264297/c  
LOCUS  
DEFINITION Sequence 1687 from Patent WO0173002.  
ACCESSION AX264297  
VERSION AX264297.1  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 1687 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

DEFINITION Sequence 1688 from Patent WO0173002.  
ACCESSION AX264297  
VERSION AX264297.1 GI:16513096  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kniec,E.B., Gamper,H.B. and Rice,M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
Patent: WO 0173002-A 1688 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 198 GAAGAAATATAAGAA 212  
Db 16 GCAGAAATAAAGAA 2  
RESULT 279  
AX502942/c  
LOCUS AX502942 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 4249 from Patent EPI229046.  
ACCESSION AX502942  
VERSION AX502942.1 GI:23385235  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhan,J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 4249 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 67 TATCTTAACAAGAA 81  
Db 17 TATCATAACAAGAA 3  
RESULT 280  
AX502943/c  
LOCUS AX502943 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 4250 from Patent EPI229046.  
ACCESSION AX502943  
VERSION AX502943.1 GI:23385236  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhan,J.

TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 4250 07-AUG-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 67 TATCTTAACAAGAA 81  
Db 16 TATCATAACAAGAA 2  
RESULT 281  
AX532149/c  
LOCUS AX532149 17 bp DNA linear PAT 22-NOV-2002  
DEFINITION Sequence 1658 from Patent EPI239051.  
ACCESSION AX532149  
VERSION AX532149.1 GI:25256083  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M.  
TITLE Human posh-like protein 1  
JOURNAL Patent: EP 1239051-A 1658 11-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1497 GAAATGCTGCCTAGG 1511  
Db 17 GAAATGCTGCCTGG 3  
RESULT 282  
AX532150/c  
LOCUS AX532150 17 bp DNA linear PAT 22-NOV-2002  
DEFINITION Sequence 1659 from Patent EPI239051.  
ACCESSION AX532150  
VERSION AX532150.1 GI:25256085  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M.  
TITLE Human posh-like protein 1  
JOURNAL Patent: EP 1239051-A 1659 11-SEP-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1497 GAAATGCTGCCTAGG 1511  
Db 17 GAAATGCTGCCTGG 3

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1497 GAAATGCTGCCTAGG 1511

Db 16 GAAATGCTGCCTGG 2

RESULT 283

AX532151/c

LOCUS

DEFINITION

AX532151

ACCESSION

AX532151

VERSION

AX532151.1

KEYWORDS

GI:25256087

ORGANISM

Homo sapiens (human)

REFERENCE

Shannon, M.

Human poah-like protein 1

Patent: EP 1239051-A 1660 11-SEP-2002;

Acemica, Inc. (US)

FEATURES

source

1. .17

/organism="Homo sapiens"

/mol\_type="unassigned DNA"

/db\_xref="taxon:9606"

Query Match

Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1497 GAAATGCTGCCTAGG 1511

Db 15 GAAATGCTGCCTGG 1

RESULT 284

AX579422/c

LOCUS

DEFINITION

AX579422

ACCESSION

AX579422

VERSION

AX579422.1

KEYWORDS

GI:27648624

ORGANISM

Homo sapiens (human)

REFERENCE

Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.

Method and reagent for the inhibition of calcium activated chloride

channel-1 (clca-1)

Patent: WO 0211674-A 1260 14-FEB-2002;

RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;

Thompson, James (US)

FEATURES

source

1. .17

/organism="Homo sapiens"

/mol\_type="unassigned RNA"

/db\_xref="taxon:9606"

Query Match

Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 ATGAATCAACATAT 1736

Db 16 ATGAATCAACATGT 2

RESULT 285

AX579854/c

LOCUS

DEFINITION

AX579854

ACCESSION

AX579854

VERSION

AX579854.1

KEYWORDS

GI:27649056

ORGANISM

Homo sapiens (human)

REFERENCE

Thompson, J., Mcswiggen, J., Mckenzie, T., Ayers, D., Szymkowski, D.E.

Method and reagent for the inhibition of calcium activated chloride

channel-1 (clca-1)

Patent: WO 0211674-A 1692 14-FEB-2002;

RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;

Thompson, James (US)

FEATURES

source

1. .17

/organism="Homo sapiens"

/mol\_type="unassigned RNA"

/db\_xref="taxon:9606"

Query Match

Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1722 ATGAATCAACATAT 1736

Db 15 ATGAATCAACATGT 1

RESULT 286

AX648877/c

LOCUS

DEFINITION

AX648877

ACCESSION

AX648877

VERSION

AX648877.1

KEYWORDS

GI:29151695

ORGANISM

Homo sapiens (human)

REFERENCE

Gu, Y.

Human sodium-hydrogen exchanger like protein 1

Patent: EP 1273660-A 717 08-JAN-2003;

Acemica, Inc. (US)

FEATURES

source

1. .17

/organism="Homo sapiens"

/mol\_type="unassigned DNA"

/db\_xref="taxon:9606"

Query Match

Best Local Similarity 0.7%; Score 13.4; DB 1; Length 17;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 910 CTGTAGCAGATCA 924

Db 16 CTGTAGCAGATCA 2

RESULT 287

AX648878/c

LOCUS

DEFINITION

AX648878

ACCESSION

AX648878

VERSION

AX648878.1

KEYWORDS

GI:29151696

ORGANISM

Homo sapiens (human)

SOURCE

Homo sapiens

```
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gu, Y.
TITLE        Human sodium-hydrogen exchanger like protein 1
JOURNAL      Patent: EP 1273660-A 718 08-JAN-2003;
              Aeomica, Inc. (US)
FEATURES
  source     1. .17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      910 CTGTAGCAGAGATCA 924
        |||||
Db      15 CTGTAGCAGACATCA 1

RESULT 288
AX648913
LOCUS      AX648913              17 bp      DNA      linear      PAT 22-MAR-2003
DEFINITION Sequence 753 from Patent EP1273660.
ACCESSION  AX648913
VERSION     AX648913.1 GI:29151731
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gu, Y.
TITLE        Human sodium-hydrogen exchanger like protein 1
JOURNAL      Patent: EP 1273660-A 753 08-JAN-2003;
              Aeomica, Inc. (US)
FEATURES
  source     1. .17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      563 TTTCGATGAACTGCA 577
        |||||
Db      3 TTTCATGAACTGCA 17

RESULT 289
AX648914
LOCUS      AX648914              17 bp      DNA      linear      PAT 22-MAR-2003
DEFINITION Sequence 754 from Patent EP1273660.
ACCESSION  AX648914
VERSION     AX648914.1 GI:29151732
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gu, Y.
TITLE        Human sodium-hydrogen exchanger like protein 1
JOURNAL      Patent: EP 1273660-A 754 08-JAN-2003;
              Aeomica, Inc. (US)
FEATURES
  source     1. .17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Telerman, A., Amson, R. and Tuijinder, M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or resistance to viruses and their use as
              medicines
JOURNAL      Patent: WO 03004526-A 782 16-JAN-2003;
              Molecular Engines Laboratories (FR)
FEATURES
  source     1. .17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1248 ATCATGAGGAGGTT 1262
        |||||
Db      2 ATCATGAGAGGTT 16
```

```
/db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      563 TTTCGATGAACTGCA 577
        |||||
Db      2 TTTCATGAACTGCA 16

RESULT 290
AX648915
LOCUS      AX648915              17 bp      DNA      linear      PAT 22-MAR-2003
DEFINITION Sequence 755 from Patent EP1273660.
ACCESSION  AX648915
VERSION     AX648915.1 GI:29151733
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gu, Y.
TITLE        Human sodium-hydrogen exchanger like protein 1
JOURNAL      Patent: EP 1273660-A 755 08-JAN-2003;
              Aeomica, Inc. (US)
FEATURES
  source     1. .17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      563 TTTCGATGAACTGCA 577
        |||||
Db      1 TTTCATGAACTGCA 15

RESULT 291
AX672337
LOCUS      AX672337              17 bp      DNA      linear      PAT 27-MAR-2003
DEFINITION Sequence 782 from Patent WO03004526.
ACCESSION  AX672337
VERSION     AX672337.1 GI:29330685
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Telerman, A., Amson, R. and Tuijinder, M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or resistance to viruses and their use as
              medicines
JOURNAL      Patent: WO 03004526-A 782 16-JAN-2003;
              Molecular Engines Laboratories (FR)
FEATURES
  source     1. .17
             /organism="Homo sapiens"
             /mol_type="unassigned DNA"
             /db_xref="taxon:9606"

Query Match      0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1248 ATCATGAGGAGGTT 1262
        |||||
Db      2 ATCATGAGAGGTT 16
```

<hr/>					
VERSION	AX723876.1 GI:30503219				
KEYWORDS					
SOURCE	Mus musculus (house mouse)				
ORGANISM	Mus musculus				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus;				
AUTHORS	Telerman,A., Anson,R. and Tuijnder,M.				
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines				
JOURNAL	Patent: WO 03025176-A 1563 27-MAR-2003;				
FEATURES	Molecular Engines Laboratories (FR) Location/Qualifiers 1..17 /organism="Mus musculus" /mol_type="unassigned DNA" /db_xref="taxon:10090"				
<hr/>					
Query Match	0.7%; Score 13.4; DB 1; Length 17;				
Best Local Similarity	93.3%; Pred. No. 1.5e+02;				
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
<hr/>					
Qy	1831 TCTGAAAAA AAAA 1845				
Db	 3 TCTGAAGAAAAAA 17				
<hr/>					
RESULT 295	PAT 08-MAY-2003				
AX725443/C	linear				
LOCUS	AX725443 17 bp DNA				
DEFINITION	Sequence 3130 from Patent W003025176.				
ACCESSION	AX725443				
VERSION	AX725443.1 GI:30504786				
KEYWORDS					
SOURCE	Mus musculus (house mouse)				
ORGANISM	Mus musculus				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus;				
AUTHORS	Telerman,A., Anson,R. and Tuijnder,M.				
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines				
JOURNAL	Patent: WO 03025176-A 3130 27-MAR-2003;				
FEATURES	Molecular Engines Laboratories (FR) Location/Qualifiers 1..17 /organism="Mus musculus" /mol_type="unassigned DNA" /db_xref="taxon:10090"				
<hr/>					
Query Match	0.7%; Score 13.4; DB 1; Length 17;				
Best Local Similarity	93.3%; Pred. No. 1.5e+02;				
Matches	14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;				
<hr/>					
Qy	440 GAGGGGAGAAGATC 454				
Db	 15 GAGGGGAGAAGATC 1				
<hr/>					
RESULT 296	PAT 08-MAY-2003				
AX725734/C	linear				
LOCUS	AX725734 17 bp DNA				
DEFINITION	Sequence 3421 from Patent W003025176.				
ACCESSION	AX725734				
VERSION	AX725734.1 GI:30505077				
KEYWORDS					
SOURCE	Mus musculus (house mouse)				
ORGANISM	Mus musculus				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus;				
1					

```

AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 3421 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
source       1..17
              /organism="Mus musculus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:10090"
Query Match  0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 178 GCATCTCTTAAGAGA 192
Db 17 GCATCTCTACAGA 3

RESULT 297
AX727363
LOCUS        AX727363
DEFINITION   Sequence 5050 from Patent WO03025176.
ACCESSION   AX727363
VERSION      AX727363.1 GI:30506706
KEYWORDS     Mus musculus (house mouse)
SOURCE       Mus musculus
ORGANISM     Mus musculus
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 5050 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
source       1..17
              /organism="Mus musculus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:10090"
Query Match  0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1831 TCTGAAAAAAAAA 1845
Db 3 TCTGAAAAAAAAA 17

RESULT 298
AX731151/c
LOCUS        AX731151
DEFINITION   Sequence 2785 from Patent WO03025175.
ACCESSION   AX731151
VERSION      AX731151.1 GI:30510494
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025175-A 2785 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers

AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025176-A 3421 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
source       1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match  0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 437 GGAGAGGGGAGAGA 451
Db 17 GGAGAGGGGAGAGA 3

RESULT 299
AX731593
LOCUS        AX731593
DEFINITION   Sequence 3227 from Patent WO03025175.
ACCESSION   AX731593
VERSION      AX731593.1 GI:30510936
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025175-A 3227 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
source       1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match  0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1248 ATCATGGAGAGGTT 1262
Db 2 ATCATGGAGAGGTT 16

RESULT 300
AX732448
LOCUS        AX732448
DEFINITION   Sequence 4082 from Patent WO03025175.
ACCESSION   AX732448
VERSION      AX732448.1 GI:30511791
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025175-A 4082 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
source       1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match  0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1248 ATCATGGAGAGGTT 1262
Db 2 ATCATGGAGAGGTT 16

RESULT 300
AX732448
LOCUS        AX732448
DEFINITION   Sequence 4082 from Patent WO03025175.
ACCESSION   AX732448
VERSION      AX732448.1 GI:30511791
KEYWORDS     Homo sapiens (human)
SOURCE       Homo sapiens
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Telerman,A., Anson,R. and Tuijnder,M.
TITLE        Sequences involved in phenomena of tumour suppression, tumour
              reversion, apoptosis and/or virus resistance and their use as
              medicines
JOURNAL      Patent: WO 03025175-A 4082 27-MAR-2003;
              Molecular Engines Laboratories (FR)
FEATURES     Location/Qualifiers
source       1..17
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match  0.7%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1248 ATCATGGAGAGGTT 1262
Db 2 ATCATGGAGAGGTT 16
```

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1831 TCTGAAAAA 1845  
Db 3 TCTGAAAAA 17

RESULT 301  
AX733113  
LOCUS AX733113 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 4747 from Patent WO03025175.  
ACCESSION AX733113  
VERSION AX733113.1 GI:30512456  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 4747 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1704 TCCCTCCCTCCAC 1718  
Db 3 TCCCTCCCTCCAC 17

RESULT 302  
AX734098  
LOCUS AX734098 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 5732 from Patent WO03025175.  
ACCESSION AX734098  
VERSION AX734098.1 GI:30513441  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 5732 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1704 TCCCTCCCTCCAC 1718  
Db 3 TCCCTCCCTCCAC 17

RESULT 303  
AX734177  
LOCUS AX734177 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 5811 from Patent WO03025175.  
ACCESSION AX734177  
VERSION AX734177.1 GI:30513520  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 5811 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1704 TCCCTCCCTCCAC 1718  
Db 3 TCCCTCCCTCCAC 17

RESULT 304  
AX734975  
LOCUS AX734975 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 565 from Patent WO03025177.  
ACCESSION AX734975  
VERSION AX734975.1 GI:30514252  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or resistance to viruses and the use  
thereof as medicaments

JOURNAL Patent: WO 03025177-A 565 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1831 TCTGAAAAA 1845  
Db 3 TCTGAAAAA 17

RESULT 305  
AX736940  
LOCUS AX736940 17 bp DNA linear PAT 08-MAY-2003  
DEFINITION Sequence 2530 from Patent WO03025177.  
ACCESSION AX736940  
VERSION AX736940.1 GI:30516228  
KEYWORDS







LOCUS AX783723 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Sequence 2054 from Patent WO03050284.  
ACCESSION AX783723  
VERSION AX783723.1 GI:32951572  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Guo,J.  
TITLE Human prostate cancer candidate protein 1  
JOURNAL Patent: WO 03050284-A 2054 19-JUN-2003;  
Amersham Biosciences (SV) Corp. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 511 GCATTGGGACTCTC 525  
Db 16 GCATTGGGACTCTC 2  
RESULT 315  
AX783724/c  
LOCUS AX783724 17 bp DNA linear PAT 17-JUL-2003  
DEFINITION Sequence 2055 from Patent WO03050284.  
ACCESSION AX783724  
VERSION AX783724.1 GI:32951573  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Guo,J.  
TITLE Human prostate cancer candidate protein 1  
JOURNAL Patent: WO 03050284-A 2055 19-JUN-2003;  
Amersham Biosciences (SV) Corp. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13.4; DB 1; Length 17;  
Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 511 GCATTGGGACTCTC 525  
Db 15 GCATTGGGACTCTC 1  
RESULT 316  
AR165194/c  
LOCUS AR165194 15 bp DNA linear PAT 17-OCT-2001  
DEFINITION Sequence 8 from patent US 6274708.  
ACCESSION AR165194  
VERSION AR165194.1 GI:16238662  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Hilton,D.James.  
TITLE Mouse interleukin-11 receptor

JOURNAL Patent: US 6274708-A 8 14-AUG-2001;  
FEATURES  
source  
1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.7%; Score 13.2; DB 1; Length 15;  
Best Local Similarity 80.0%; Pred. No. 1.3e+02;  
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
QY 1343 TGGAGTGCCTGGAGC 1357  
Db 15 TGGAGYGCNTGGAGY 1  
RESULT 317  
AR056166/c  
LOCUS AR056166 15 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 370 from patent US 5837542.  
ACCESSION AR056166  
VERSION AR056166.1 GI:5981743  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.  
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes  
JOURNAL Patent: US 5837542-A 370 17-NOV-1998;  
FEATURES  
source  
1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1829 TCTCTGAAAAAAA 1841  
Db 13 TCTCTGAAAAAAA 1  
RESULT 318  
AR113924/c  
LOCUS AR113924 15 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 370 from patent US 6132967.  
ACCESSION AR113924  
VERSION AR113924.1 GI:14094246  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.  
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)  
JOURNAL Patent: US 6132967-A 370 17-OCT-2000;  
FEATURES  
source  
1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1829 TCTCTGAAAAAAA 1841  
Db 13 TCTCTGAAAAAAA 1

```

RESULT 319
BD268106/c
LOCUS
DEFINITION
  BD268106
  15 bp DNA linear PAT 17-JUL-2003
  Stabilized biologically active peptides, and identification,
  synthesis and utilization methods.
ACCESSION
  BD268106
  1 GI:33077874
  16
  JP 2002534059-A/16
  synthetic construct
  synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1 (bases 1 to 15)
  Altman,E.
  Stabilized biologically active peptides, and identification,
  synthesis and utilization methods
  Patent: JP 2002534059-A 16 15-OCT-2002;
  THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
  OS Artificial Sequence
  PN JP 2002534059-A/16
  PD 15-OCT-2002
  PF 12-OCT-1999 JP 2000576003
  PR 13-OCT-1998 US 60/104013,14-DEC-1998 US 60/112150 PT
  ELLIOT ALTMAN
  PC C12N15/09,A61K38/00,A61K47/48,A61P31/04,C07K5/075,C07K5/097,
  C07K14/47,
  PC C12N1/11,C12N1/21,C12N5/10,C12Q1/02/(C12N1/21,C12R1:19), PC
  (C12N1/21,C12R1:46), (C12N1/21,C12R1:44), (C12Q1/02,C12R1:19), PC
  (C12Q1/02,C12R1:46), (C12Q1/02,C12R1:44), (C12Q1/02,C12R1:01), PC
  C12N15/00,
  PC C12N5/00,A61K37/02
  CC Description of Artificial Sequence: primer fragment FH Key
  FT source
  FT Location/Qualifiers
  1 (bases 1 to 15)
  /organism="Artificial Sequence".
  FEATURES
  source
  Query Match 0.7%; Score 13; DB 1; Length 15;
  Best Local Similarity 100.0%; Pred. No. 1.4e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  Qy 475 GAATTCATAGAT 487
  Db 15 GAATTCATAGAT 3
  RESULT 320
  BD268107/c
  LOCUS
  DEFINITION
    BD268107
    15 bp DNA linear PAT 17-JUL-2003
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods.
  ACCESSION
    BD268107
    1 GI:33077875
    17
    JP 2002534059-A/17
    synthetic construct
    synthetic construct
    other sequences; artificial sequences.
  REFERENCE
    1 (bases 1 to 15)
    Altman,E.
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods
    Patent: JP 2002534059-A 17 15-OCT-2002;
    THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
    OS Artificial Sequence
    PN JP 2002534059-A/17
    PD 15-OCT-2002
    PF 12-OCT-1999 JP 2000576003
    PR 13-OCT-1998 US 60/104013,14-DEC-1998 US 60/112150 PT
    ELLIOT ALTMAN
  
```

```

PC C12N15/09,A61K38/00,A61K47/48,A61P31/04,C07K5/075,C07K5/097,
PC C07K14/47,
PC C12N1/11,C12N1/21,C12N5/10,C12Q1/02/(C12N1/21,C12R1:19), PC
(C12N1/21,C12R1:46), (C12N1/21,C12R1:44), (C12Q1/02,C12R1:19), PC
(C12Q1/02,C12R1:46), (C12Q1/02,C12R1:44), (C12Q1/02,C12R1:01), PC
C12N15/00,
PC C12N5/00,A61K37/02
CC Description of Artificial Sequence: primer fragment FH Key
FT source
FT Location/Qualifiers
  1 (bases 1 to 15)
  /organism="Artificial Sequence".
  FEATURES
  source
  Query Match 0.7%; Score 13; DB 1; Length 15;
  Best Local Similarity 100.0%; Pred. No. 1.4e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  Qy 475 GAATTCATAGAT 487
  Db 15 GAATTCATAGAT 3
  RESULT 321
  BD268108/c
  LOCUS
  DEFINITION
    BD268108
    15 bp DNA linear PAT 17-JUL-2003
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods.
  ACCESSION
    BD268108
    1 GI:33077876
    18
    JP 2002534059-A/18
    synthetic construct
    synthetic construct
    other sequences; artificial sequences.
  REFERENCE
    1 (bases 1 to 15)
    Altman,E.
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods
    Patent: JP 2002534059-A 18 15-OCT-2002;
    THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
    OS Artificial Sequence
    PN JP 2002534059-A/18
    PD 15-OCT-2002
    PF 12-OCT-1999 JP 2000576003
    PR 13-OCT-1998 US 60/104013,14-DEC-1998 US 60/112150 PT
    ELLIOT ALTMAN
  PC C12N15/09,A61K38/00,A61K47/48,A61P31/04,C07K5/075,C07K5/097,
  C07K14/47,
  PC C12N1/11,C12N1/21,C12N5/10,C12Q1/02/(C12N1/21,C12R1:19), PC
  (C12N1/21,C12R1:46), (C12N1/21,C12R1:44), (C12Q1/02,C12R1:19), PC
  (C12Q1/02,C12R1:46), (C12Q1/02,C12R1:44), (C12Q1/02,C12R1:01), PC
  C12N15/00,
  PC C12N5/00,A61K37/02
  CC Description of Artificial Sequence: primer fragment FH Key
  FT source
  FT Location/Qualifiers
  1 (bases 1 to 15)
  /organism="Artificial Sequence".
  FEATURES
  source
  Query Match 0.7%; Score 13; DB 1; Length 15;
  Best Local Similarity 100.0%; Pred. No. 1.4e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
  Qy 475 GAATTCATAGAT 487
  Db 15 GAATTCATAGAT 3
  RESULT 322
  BD268109/c
  LOCUS
  DEFINITION
    BD268109
    15 bp DNA linear PAT 17-JUL-2003
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods.
  ACCESSION
    BD268109
    1 GI:33077877
    19
    JP 2002534059-A/19
    synthetic construct
    synthetic construct
    other sequences; artificial sequences.
  REFERENCE
    1 (bases 1 to 15)
    Altman,E.
    Stabilized biologically active peptides, and identification,
    synthesis and utilization methods
    Patent: JP 2002534059-A 19 15-OCT-2002;
    THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
    OS Artificial Sequence
    PN JP 2002534059-A/19
    PD 15-OCT-2002
    PF 12-OCT-1999 JP 2000576003
    PR 13-OCT-1998 US 60/104013,14-DEC-1998 US 60/112150 PT
    ELLIOT ALTMAN
  
```

RESULT 322  
AX633215/c  
LOCUS AX633215 15 bp RNA linear PAT 21-FEB-2003  
DEFINITION Sequence 354 from Patent EP1260586.  
ACCESSION AX633215  
VERSION AX633215.1 GI:28468829  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1  
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Drenzo,A., Karpelisky,A., Draper,K.G., Kislich,K., Matulic-Adamic,J., Meswigen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Woolf,T.  
TITLE Method and reagent for inhibiting the expression of disease related genes  
JOURNAL Patent: EP 1260586-A 354 27-NOV-2002;  
RIBOZYME PHARMACEUTICALS, INC. (US)  
FEATURES  
source  
1. .15  
/organism="unidentified"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32644"  
Query Match 0.7%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1829 TCCTCGAAAAAA 1841  
DB 13 TCCTCGAAAAAA 1  
RESULT 323  
LOCUS A11765 16 bp DNA linear PAT 27-NOV-1993  
DEFINITION Nucleotide sequence 4 from patent number EP0228018.  
ACCESSION A11765  
VERSION A11765.1 GI:489383  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Habermann,P. and Muellner,H.  
TITLE GM-CSF protein, its derivatives, preparation of such proteins and their use  
JOURNAL Patent: EP 0228018-A 4 08-JUL-1987;  
HOECHST AKTIENGESELLSCHAFT  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
Query Match 0.7%; Score 13; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 992 GGGTGCCATGGAT 1004  
DB 1 GGGTGCCATGGAT 13  
RESULT 324  
AX252970  
LOCUS AX252970 16 bp DNA linear PAT 05-OCT-2001  
DEFINITION Sequence 13 from Patent WO0168900.  
ACCESSION AX252970

VERSION AX252970.1 GI:15986224  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Walcher,M., Wagner,M. and Snaidr,J.  
TITLE Method for specifically detecting microorganisms by polymerase chain reaction  
JOURNAL Patent: WO 0168900-A 13 20-SEP-2001;  
Vermicon AG (DE)  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Beschreibung der kunstlichen Sequenz: Oligonukleotidprimer"  
Query Match 0.7%; Score 13; DB 1; Length 16;  
Best Local Similarity 86.7%; Pred. No. 1.5e+02;  
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1444 ATGTTGCTGCTGCTG 1458  
DB 2 AGGTGCTGCTGCTG 16  
RESULT 325  
LOCUS ARI68848/c 17 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 74 from patent US 6288042.  
ACCESSION ARI68848  
VERSION ARI68848.1 GI:17904982  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.  
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides  
JOURNAL Patent: US 6288042-A 74 11-SEP-2001;  
FEATURES  
source  
1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 81.2%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 1706 CCTCTCCTCCACCAC 1721  
DB 16 CCCNCCNCCNCCAC 1  
RESULT 326  
LOCUS ARI68852/c 17 bp DNA linear PAT 17-DEC-2001  
DEFINITION Sequence 78 from patent US 6288042.  
ACCESSION ARI68852  
VERSION ARI68852.1 GI:17904988  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Rando,R.F., Ojwaug,J.O., Hogan,M.E., Wallace,T.L. and Cossum,P.A.  
TITLE Anti-viral guanosine-rich tetrad forming oligonucleotides  
JOURNAL Patent: US 6288042-A 78 11-SEP-2001;  
FEATURES  
source  
1. .17  
/organism="unknown"

COMMENT	OS	Eukaryote
	PN	JP 2002541795-A/2667
	PD	10-DEC-2002

Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 012524-A 2594 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 991 AGGTCGTCATGGA 1003
Db 1 AGGTCGTCATGGA 13

RESULT 331
AR200317/c
LOCUS AR200317 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 74 from patent US 6355785.
ACCESSION AR200317
VERSION AR200317.1 GI:20250391
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Fennewald,S., Zendequi,J.G., Ojwang,J.O., Hogan,M.E.,
Pommier,Y. and Mazumder,A.
TITLE Guanosine-rich oligonucleotide integrase inhibitors
JOURNAL Patent: US 6355785-A 74 12-MAR-2002;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACAC 1721
Db 16 CCNCNCCNCCNCCAC 1

RESULT 332
AR200321/c
LOCUS AR200321 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 78 from patent US 6355785.
ACCESSION AR200321
VERSION AR200321.1 GI:20250395
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Fennewald,S., Zendequi,J.G., Ojwang,J.O., Hogan,M.E.,
Pommier,Y. and Mazumder,A.
TITLE Guanosine-rich oligonucleotide integrase inhibitors
JOURNAL Patent: US 6355785-A 74 12-MAR-2002;
FEATURES
source Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACAC 1721
Db 16 CCNCNCCNCCNCCAC 1

RESULT 333
AR200321/c
LOCUS AR200321 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 78 from patent US 6355785.
ACCESSION AR200321
VERSION AR200321.1 GI:20250395
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Fennewald,S., Zendequi,J.G., Ojwang,J.O. and Hogan,M.E.
TITLE Anti-viral guanosine-rich oligonucleotides and method of treating
JOURNAL Patent: US 6323185-A 74 27-NOV-2001;
HIV
FEATURES
source Location/Qualifiers
1..17
/organism="genomic DNA"
/mol_type="genomic DNA"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACAC 1721
Db 16 CCNCNCCNCCNCCAC 1

RESULT 334
AR262452/c
LOCUS AR262452 17 bp DNA linear PAT 29-JAN-2003
DEFINITION Sequence 78 from patent US 6323185.
ACCESSION AR262452
VERSION AR262452.1 GI:28073883
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Fennewald,S., Zendequi,J.G., Ojwang,J.O. and Hogan,M.E.
TITLE Anti-viral guanosine-rich oligonucleotides and method of treating
JOURNAL Patent: US 6323185-A 74 27-NOV-2001;
HIV
FEATURES
source Location/Qualifiers
1..17
/organism="genomic DNA"
/mol_type="genomic DNA"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACAC 1721
Db 16 CCNCNCCNCCNCCAC 1

RESULT 335
AR365612/c
LOCUS AR365612 17 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 19 from patent US 5514566.
ACCESSION AR365612
VERSION AR365612.1 GI:34429443
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Fennewald,S., Zendequi,J.G., Ojwang,J.O. and Hogan,M.E.
TITLE Anti-viral guanosine-rich oligonucleotides and method of treating
JOURNAL Patent: US 5514566-A 78 12-MAR-2002;
HIV
FEATURES
source Location/Qualifiers
1..17
/organism="genomic DNA"
/mol_type="genomic DNA"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACAC 1721
Db 16 CCNCNCCNCCNCCAC 1

RESULT 335
AR365612/c
LOCUS AR365612 17 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 19 from patent US 5514566.
ACCESSION AR365612
VERSION AR365612.1 GI:34429443
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Rando,R.F., Fennewald,S., Zendequi,J.G., Ojwang,J.O. and Hogan,M.E.
TITLE Anti-viral guanosine-rich oligonucleotides and method of treating
JOURNAL Patent: US 5514566-A 78 12-MAR-2002;
HIV
FEATURES
source Location/Qualifiers
1..17
/organism="genomic DNA"
/mol_type="genomic DNA"
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1706 CCTCTCCTCCACAC 1721
Db 16 CCNCNCCNCCNCCAC 1
```

Unclassified.  
1 (bases 1 to 17)  
AUTHORS Fiddes,J.C. and Abraham,J.A.  
TITLE Methods of producing recombinant fibroblast growth factors  
JOURNAL Patent: US 5514566-A 19 07-MAY-1996;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1329 TTTTGGATCCCAAG 1341  
Db 14 TTTTGGATCCCAAG 2

RESULT 336  
AR401993  
LOCUS AR401993 17 bp DNA linear PAT 18-DEC-2003  
DEFINITION Sequence 333 from patent US 6623962.  
ACCESSION AR401993  
VERSION AR401993.1 GI:40149443  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.  
TITLE Enzymatic nucleic acid treatment of diseases of conditions related to levels of epidermal growth factor receptors  
JOURNAL Patent: US 6623962-A 333 23-SEP-2003;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1330 TTTTGGATCCCAAGC 1342  
Db 2 TTTTGGATCCCAAGC 14

RESULT 337  
AR458912  
LOCUS AR458912 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 2589 from patent US 6686188.  
ACCESSION AR458912  
VERSION AR458912.1 GI:42693969  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 2589 03-FEB-2004;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 990 CAGGTGCCATGG 1002  
Db 5 CAGGTGCCATGG 17

RESULT 338  
AR458917  
LOCUS AR458917 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 2594 from patent US 6686188.  
ACCESSION AR458917  
VERSION AR458917.1 GI:42693974  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 2594 03-FEB-2004;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 991 AGGTGCCATGGA 1003  
Db 1 AGGTGCCATGGA 13

RESULT 339  
AR482819  
LOCUS AR482819 17 bp DNA linear PAT 14-MAY-2004  
DEFINITION Sequence 265 from patent US 6703228.  
ACCESSION AR482819  
VERSION AR482819.1 GI:47245342  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Landers,J., Jordan,B., Housman,D.E. and Charest,A.  
TITLE Methods and products related to genotyping and DNA analysis  
JOURNAL Patent: US 6703228-A 265 09-MAR-2004;  
FEATURES Location/Qualifiers  
source  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1594 ATAACAATTCAT 1606  
Db 5 ATAACAATTCAT 17

RESULT 340  
AX422454/c  
LOCUS AX422454 17 bp RNA linear PAT 18-JUN-2002  
DEFINITION Sequence 790 from Patent WO0188124.  
ACCESSION AX422454  
VERSION AX422454.1 GI:21525836  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 790 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 GTTGGTGCCTTCC 1131
DB 14 GTTGGTGCCTTCC 2

RESULT 341
AX423117/c
LOCUS
Sequence 1453 from Patent WO0188124.
DEFINITION
AX423117
ACCESSION
AX423117.1 GI:21526499
VERSION
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 1453 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 GTTGGTGCCTTCC 1131
DB 16 GTTGGTGCCTTCC 4

RESULT 342
AX423564/c
LOCUS
Sequence 1900 from Patent WO0188124.
DEFINITION
AX423564
ACCESSION
AX423564.1 GI:21526946
VERSION
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE
Method and reagent for the inhibition of erg
JOURNAL
Patent: WO 0188124-A 1900 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source
1. .17

```

```

/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 GTTGGTGCCTTCC 1131
DB 17 GTTGGTGCCTTCC 5

RESULT 343
AX578184/c
LOCUS
Sequence 22 from Patent WO0211674.
DEFINITION
AX578184
ACCESSION
AX578184.1 GI:27647386
VERSION
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Thompson,J., Mcswiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL
Patent: WO 0211674-A 22 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1152 GTAAATATTTCCTCA 1164
DB 14 GTAAATATTTCCTCA 2

RESULT 344
AX578361/c
LOCUS
Sequence 199 from Patent WO0211674.
DEFINITION
AX578361
ACCESSION
AX578361.1 GI:27647563
VERSION
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
1
Thompson,J., Mcswiggen,J., McKenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.
TITLE
Method and reagent for the inhibition of calcium activated chloride
channel-1 (clca-1)
JOURNAL
Patent: WO 0211674-A 199 14-FEB-2002;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;
Thompson, James (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;

```



Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1722 ATAGATCAACAT 1734  
Db 13 ATAGATCAACAT 1

RESULT 345  
AX688101/c  
LOCUS AX688101 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 833 from Patent EP1281758.  
ACCESSION AX688101  
VERSION AX688101.1 GI:29410799

KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
AUTHORS Shannon, M., Gu, Y., and Nguyen, C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12

JOURNAL Patent: EP 1281758-A 833 05-FEB-2003;

FEATURES  
source Aecomica, Inc. (US)

1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1237 AGGCCAGGCCAT 1249  
Db 17 AGGCCAGGCCAT 5

RESULT 346  
AX688106/c  
LOCUS AX688106 17 bp DNA linear PAT 31-MAR-2003  
DEFINITION Sequence 838 from Patent EP1281758.  
ACCESSION AX688106

VERSION AX688106.1 GI:29410804

KEYWORDS Homo sapiens (human)

SOURCE Homo sapiens

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
AUTHORS Shannon, M., Gu, Y., and Nguyen, C.T.

TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12

JOURNAL Patent: EP 1281758-A 838 05-FEB-2003;

FEATURES  
source Aecomica, Inc. (US)

1. .17  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1236 AAGCCAGGCCA 1248  
Db 13 AAGCCAGGCCA 1

RESULT 347

AX723059

LOCUS

DEFINITION Sequence 746 from Patent WO03025176.

ACCESSION AX723059

VERSION AX723059.1 GI:30423560

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

AUTHORS Telerman, A., Anson, R., and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as

medicines

Patent: WO 03025176-A 746 27-MAR-2003;

JOURNAL Molecular Engines Laboratories (FR)

FEATURES

source

1. .17

Location/Qualifiers

/organism="Mus musculus"

/mol\_type="unassigned DNA"

/db\_xref="taxon:10090"

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1281 CTCATATCACTC 1293

Db 4 CTCATATCACTC 16

RESULT 348

AX724771

LOCUS

DEFINITION Sequence 2458 from Patent WO03025176.

ACCESSION AX724771

VERSION AX724771.1 GI:30504114

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

AUTHORS Telerman, A., Anson, R., and Tuijinder, M.

TITLE Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as

medicines

Patent: WO 03025176-A 2458 27-MAR-2003;

JOURNAL Molecular Engines Laboratories (FR)

FEATURES

source

1. .17

Location/Qualifiers

/organism="Mus musculus"

/mol\_type="unassigned DNA"

/db\_xref="taxon:10090"

Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 845 GATCAAAATGTC 857

Db 1 GATCAAAATGTC 13

RESULT 349

AX726794/c

LOCUS

DEFINITION Sequence 4481 from Patent WO03025176.

ACCESSION AX726794

VERSION AX726794.1 GI:30506137

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1  
REFERENCE  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025176-A 4481 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1. .17  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 466 TGGAGCCAGAAAT 478  
Db 17 TGGAGCCAGAAAT 5  
RESULT 350  
LOCUS AX729200  
DEFINITION Sequence 834 from Patent WO03025175.  
ACCESSION AX729200  
VERSION AX729200.1 GI:30508543  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 834 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 630 ATCAACTACTCAA 642  
Db 2 ATCAACTACTCAA 14  
RESULT 351  
LOCUS AX731823/c  
DEFINITION Sequence 3457 from Patent WO03025175.  
ACCESSION AX731823  
VERSION AX731823.1 GI:30511166  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as

medicines  
JOURNAL Patent: WO 03025175-A 3457 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1429 ATCCAAAGCAGAT 1441  
Db 14 ATCCAAAGCAGAT 2  
RESULT 352  
LOCUS AX732282/c  
DEFINITION Sequence 3916 from Patent WO03025175.  
ACCESSION AX732282  
VERSION AX732282.1 GI:305111625  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 3916 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1677 CTCTGATTCTAGA 1689  
Db 15 CTCTGATTCTAGA 3  
RESULT 353  
LOCUS AX732330  
DEFINITION Sequence 3964 from Patent WO03025175.  
ACCESSION AX732330  
VERSION AX732330.1 GI:305111673  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.  
TITLE Sequences involved in phenomena of tumour suppression, tumour  
reversion, apoptosis and/or virus resistance and their use as  
medicines  
JOURNAL Patent: WO 03025175-A 3964 27-MAR-2003;  
Molecular Engines Laboratories (FR)  
FEATURES  
source 1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"

```
/db_xref="taxon:9606"

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 845 GATCAAAATTGTC 857
    |||||
Db 1 GATCAAAATTGTC 13

RESULT 354
AX732492      AX732492      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS      Sequence 4126 from Patent WO03025175.
DEFINITION      AX732492
ACCESSION      AX732492
VERSION      AX732492.1 GI:30511835
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Telleran,A., Amson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
JOURNAL      reversion, apoptosis and/or virus resistance and their use as
Molecular      medicines
Patent: WO 03025175-A 4126 27-MAR-2003;
Molecular      Engines Laboratories (FR)
FEATURES
source      Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 967 ATCTGGACAGCTG 979
    |||||
Db 2 ATCTGGACAGCTG 14

RESULT 355
AX739518      AX739518      17 bp      DNA      linear      PAT 08-MAY-2003
LOCUS      Sequence 5108 from Patent WO03025177.
DEFINITION      AX739518
ACCESSION      AX739518
VERSION      AX739518.1 GI:30518815
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Telleran,A., Amson,R. and Tuijnder,M.
TITLE      Sequences involved in phenomena of tumour suppression, tumour
JOURNAL      reversion, apoptosis and/or resistance to viruses and the use
Molecular      thereof as medicaments
Patent: WO 03025177-A 5108 27-MAR-2003;
Molecular      Engines Laboratories (FR)
FEATURES
source      Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 203 AATAAAGAAGAA 215
    |||||
Db 1 AATAAAGAAGAA 17

RESULT 356
AX753817      AX753817      17 bp      DNA      linear      PAT 23-JUN-2003
LOCUS      Sequence 164 from Patent WO03037931.
DEFINITION      AX753817
ACCESSION      AX753817
VERSION      AX753817.1 GI:32166514
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Shannon,M. and Phan,T.
TITLE      Human angiomotin-like protein 1
JOURNAL      Patent: WO 03037931-A 164 08-MAY-2003;
Amersham      Biosciences SV Corp. (US)
FEATURES
source      Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1446 GTTGCTGCTGCTG 1458
    |||||
Db 17 GTTGCTGCTGCTG 5

RESULT 357
AX753822      AX753822      17 bp      DNA      linear      PAT 23-JUN-2003
LOCUS      Sequence 169 from Patent WO03037931.
DEFINITION      AX753822
ACCESSION      AX753822
VERSION      AX753822.1 GI:32166519
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS      Shannon,M. and Phan,T.
TITLE      Human angiomotin-like protein 1
JOURNAL      Patent: WO 03037931-A 169 08-MAY-2003;
Amersham      Biosciences SV Corp. (US)
FEATURES
source      Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGTGCTGCTGCT 1457
    |||||
Db 13 TGTGTGCTGCTGCT 1

RESULT 358
AX753834      AX753834      17 bp      DNA      linear      PAT 23-JUN-2003
LOCUS      Sequence 181 from Patent WO03037931.
DEFINITION      AX753834
ACCESSION      AX753834
VERSION      AX753834.1 GI:32166531
KEYWORDS
```

SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M. and Phan,T.  
TITLE Human angiomotin-like protein 1  
JOURNAL Patent: WO 03037931-A 181 08-MAY-2003;  
Amerham Biosciences SV Corp. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 662 GCAGGGGGCGGTG 674  
Db 5 GCAGGGGGCGGTG 17  
RESULT 359  
AX753839  
LOCUS AX753839 17 bp DNA linear PAT 23-JUN-2003  
DEFINITION Sequence 186 from Patent WO03037931.  
ACCESSION AX753839  
VERSION AX753839.1 GI:32166536  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Shannon,M. and Phan,T.  
TITLE Human angiomotin-like protein 1  
JOURNAL Patent: WO 03037931-A 186 08-MAY-2003;  
Amerham Biosciences SV Corp. (US)  
FEATURES  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 663 CAGGGGGCGGTG 675  
Db 1 CAGGGGGCGGTG 13  
RESULT 360  
AX757635  
LOCUS AX757635 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 956 from Patent WO03040369.  
ACCESSION AX757635  
VERSION AX757635.1 GI:32252251  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Telesman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 956 15-MAY-2003;  
Molecular Engines Laboratories (FR)  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Thompson,S.A. and Abraham,J.A.  
TITLE High-level expression of basic fibroblast growth factors having the same N-terminals  
JOURNAL Patent: JP 2001169793-A 9 26-JUN-2001;  
SCIOS INC  
COMMENT OS Unidentified  
PN JP 2001169793-A/9  
PD 26-JUN-2001  
PF 20-NOV-2000 JP 2000353649  
PR 29-MAR-1990 US 501206  
PI STEWART A THOMPSON,JUDITH A ABRAHAM  
PC C12N15/09,C07K14/50,C12N15/00  
CC Strandedness: Single;  
CC Topology: Linear;  
CC High-level expression of basic fibroblast growth factors CC having the same  
CC N-terminals Location/Qualifiers  
FH Key 1. .17  
FT source Location/Qualifiers  
1. .17  
/organism="Unidentified".  
1. .17  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"  
Query Match 0.7%; Score 13; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1329 TTTTGATCAAG 1341  
Db 14 TTTTGATCAAG 2  
RESULT 362  
BD067493  
LOCUS BD067493 17 bp RNA linear PAT 27-AUG-2002  
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors.  
ACCESSION BD067493  
VERSION BD067493.1 GI:22613096  
KEYWORDS JP 2001511003-A/333.  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.

```

REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and Mcswiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
        to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 333 07-AUG-2001;
        RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
COMMENT OS Unidentified
        PN JP 2001511003-A/333
        PD 07-AUG-2001
        PR 14-JAN-1998 JP 1998532913
        SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
        C12N9/00,C07K14/71
        CC Strandedness: Single;
        CC Topology: Linear;
        CC Enzymatic nucleic acid treatment of diseases or conditions CC
        CC levels of epidermal growth factor receptors
        FH Key Location/Qualifiers
        FT source 1..17
        FT /organism='Unidentified'.
FEATURES source
        Location/Qualifiers
        1..17
        /organism='unidentified'
        /mol_type='genomic RNA'
        /db_xref='taxon:32644'
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1330 TTTGGATCCCAAGC 1342
Db 2 TTTGGATCCCAAGC 14
RESULT 363
LOCUS BD104092 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104092.1 GI:22649666
KEYWORDS WO 0192572-A/196.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
        Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 196 06-DEC-2001;
        NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
        KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
        NISHIDA
COMMENT OS Artificial Sequence
        PN WO 0192572-A/196
        PD 06-DEC-2001
        PR 01-JUN-2001 WO 2001JP004662
        PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
        MATSUMURA,
        PI SHOGO MORIYA,MICHIO NISHIDA
        PC C1201/68,C12M1/00,C12N15/09,G01N33/53
        CC Description of Artificial Sequence:capture
        FH Key Location/Qualifiers
        FT source 1..17
        FT /organism='Artificial Sequence'.
FEATURES source
        Location/Qualifiers
        1..17
        /organism='synthetic construct'
        /mol_type='genomic DNA'
        /db_xref='taxon:32630'
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 33 CTCGGTCGCGGCC 45
Db 16 CTCGGTCGCGGCC 4
RESULT 365
LOCUS AX724533 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2220 from Patent WO03025176.
ACCESSION AX724533
KEYWORDS AX724533.1 GI:30503876
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
        Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or virus resistance and their use as
        medicines
JOURNAL Patent: WO 03025176-A 2220 27-MAR-2003;
        Molecular Engines Laboratories (FR)

```

```

Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 33 CTCGGTCGCGGCC 45
Db 15 CTCGGTCGCGGCC 3
RESULT 364
LOCUS BD104594/c
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104594
KEYWORDS BD104594.1 GI:22650168
        WO 0192572-A/698.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 17)
AUTHORS Inoko,H., Kagiya,T., Ichihara,T., Matsumura,Y., Moriya,S. and
        Nishida,M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 698 06-DEC-2001;
        NISSHINBO INDUSTRIES INC,SYSTEM RESEARCH INC,HIDETOSHI INOKO, TAEKO
        KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
        NISHIDA
COMMENT OS Artificial Sequence
        PN WO 0192572-A/698
        PD 06-DEC-2001
        PR 01-JUN-2001 WO 2001JP004662
        PI HIDETOSHI INOKO,TAEKO KAGIYA,TATSUO ICHIHARA,YOSHIYUKI PI
        MATSUMURA,
        PI SHOGO MORIYA,MICHIO NISHIDA
        PC C1201/68,C12M1/00,C12N15/09,G01N33/53
        CC Description of Artificial Sequence:capture
        FH Key Location/Qualifiers
        FT source 1..17
        FT /organism='Artificial Sequence'.
FEATURES source
        Location/Qualifiers
        1..17
        /organism='synthetic construct'
        /mol_type='genomic DNA'
        /db_xref='taxon:32630'
Query Match 0.7%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 33 CTCGGTCGCGGCC 45
Db 16 CTCGGTCGCGGCC 4
RESULT 365
LOCUS AX724533 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 2220 from Patent WO03025176.
ACCESSION AX724533
KEYWORDS AX724533.1 GI:30503876
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
        Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
        Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
        reversion, apoptosis and/or virus resistance and their use as
        medicines
JOURNAL Patent: WO 03025176-A 2220 27-MAR-2003;
        Molecular Engines Laboratories (FR)

```

```

FEATURES
  source      Location/Qualifiers
    1..17     /organism="Mus musculus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:10090"

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1697 ATCATCTCCCTCCCTCC 1712
Db 2 ATCTTCTCCCTCCAC 17

RESULT 366
LOCUS AR365612 17 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 19 from patent US 5514566.
ACCESSION AR365612
VERSION AR365612.1 GI:34429443
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Fiddes,J.C. and Abraham,J.A.
TITLE Methods of producing recombinant fibroblast growth factors
JOURNAL Patent: US 5514566-A 19 07-MAY-1996;
FEATURES
  source      Location/Qualifiers
    1..17     /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1424 CATGGATCCAAAGCAG 1439
Db 2 CTTGGATCCAAACAG 17

RESULT 367
AR401993/c
LOCUS AR401993 17 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 333 from patent US 6623962.
ACCESSION AR401993
VERSION AR401993.1 GI:40149443
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: US 6623962-A 333 23-SEP-2003;
FEATURES
  source      Location/Qualifiers
    1..17     /organism="unknown"
              /mol_type="genomic DNA"

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1421 TGTCTGGATCCCAAG 1436
Db 16 TGGCTTGGATCCCAAG 1

RESULT 368

```

---

```

BD015242
LOCUS BD015242 17 bp DNA linear PAT 27-AUG-2002
DEFINITION High-level expression of basic fibroblast growth factors having the
same N-terminals.
ACCESSION BD015242
VERSION BD015242.1 GI:22556049
KEYWORDS JP 2001169793-A/9.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Thompson,S.A. and Abraham,J.A.
TITLE High-level expression of basic fibroblast growth factors having the
same N-terminals
JOURNAL Patent: JP 2001169793-A 9 26-JUN-2001;
COMMENT SCIOS INC
OS Unidentified
PN JP 2001169793-A/9
PD 26-JUN-2001
PF 20-NOV-2000 JP 2000353649
PR 29-MAR-1990 US 501206
PI STEWART A THOMPSON,JUDITH A ABRAHAM
PC C12N15/09,C07K14/50,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC High-level expression of basic fibroblast growth factors CC
CC N-terminals having the same
CC N-terminals
FH Key Location/Qualifiers
FT source 1..17 /organism='Unidentified'.
FEATURES
  source      Location/Qualifiers
    1..17     /organism="unidentified"
              /mol_type="genomic DNA"
              /db_xref="taxon:32644"

Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1424 CATGGATCCAAAGCAG 1439
Db 2 CTTGGATCCAAACAG 17

RESULT 369
BD067493/c
LOCUS BD067493 17 bp RNA linear PAT 27-AUG-2002
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors.
ACCESSION BD067493
VERSION BD067493.1 GI:22613096
KEYWORDS JP 2001511003-A/333.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Akhtar,S., Fell,P. and McSwiggen,J.A.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related
to levels of epidermal growth factor receptors
JOURNAL Patent: JP 2001511003-A 333 07-AUG-2001;
COMMENT RIBOZYME PHARMACEUTICALS INC,ASTON UNIV
OS Unidentified
PN JP 2001511003-A/333
PD 07-AUG-2001
PF 14-JAN-1998 JP 1998532913
PR 31-JAN-1997 US 60/036476,04-DEC-1997 US 08/985162 PI
SAGHIR AKHTAR,PATRICIA FELL,JAMES A MCSWIGGEN PC
C12N9/00,C07K14/71
CC Strandedness: Single;
CC Topology: Linear;
CC Enzymatic nucleic acid treatment of diseases or conditions CC

```

```

related to
CC levels of epidermal growth factor receptors
FH Key Location/Qualifiers
FT source 1..17
FT /organism='Unidentified'.
FEATURES
    source      Location/Qualifiers
    1..17
    /organism="unidentified"
    /mol_type="genomic RNA"
    /db_xref="taxon:32644"
Query Match      0.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1421 TGTCTGGATCCAAAG 1436
    |||||||
Db 16 TGGCTTGGATCCAAAG 1
Search completed: July 12, 2005, 10:37:31
Job time : 8 secs

```

**THIS PAGE BLANK (USPTO)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 12, 2005, 10:40:04 ; Search time 9 Seconds  
(without alignments)  
3.379 Million cell updates/sec

Title: US-09-745-763-35  
Perfect score: 1851  
Sequence: 1 GGCTAGCGCGAGCTTAGT.....CTGCAAAAAAAAAAAAAAAAAA 1851

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 448 seqs, 8214 residues

Total number of hits satisfying chosen parameters: 896

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 448 summaries

Database : rng35.seq.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	28	1.5	29	1 AAV82789	Probe used to isol
C 2	28	1.5	29	1 ABQ92088	Human polynucleoti
C 3	26	1.4	26	1 AAZ58336	Human peptidase NA
C 4	26	1.4	26	1 AAZ58335	Human peptidase NA
C 5	25	1.4	25	1 AAZ58343	Human peptidase NA
C 6	24	1.3	24	1 AAZ58344	Human peptidase NA
C 7	19.2	1.0	24	1 ABA01588	Human neuroprotein
C 8	19.2	1.0	24	1 ABL55122	Human Myb protein
C 9	18	1.0	24	1 ADR44221	Caenorhabditis ele
C 10	17.4	0.9	21	1 ADD14311	Human src biomarke
C 11	17.2	0.9	22	1 ADS13095	Oligo dt PCR prime
C 12	17	0.9	18	1 ADR32355	Rat KDR cytosolic
C 13	17	0.9	18	1 ADR57967	Nucleotide #4 for
C 14	17	0.9	19	1 ADR82260	Hepatitis C virus
C 15	17	0.9	19	1 ADR82257	Hepatitis C virus
C 16	17	0.9	19	1 ADR82261	Hepatitis C virus
C 17	17	0.9	19	1 ADR82258	Hepatitis C virus
C 18	17	0.9	19	1 ADR82256	Hepatitis C virus
C 19	17	0.9	19	1 ADR82259	Hepatitis C virus
C 20	17	0.9	20	1 ADR69805	Micro-channel mole
C 21	16.8	0.9	20	1 ADR23158	Acyl-coenzyme A sy
C 22	16.8	0.9	21	1 AAV25611	Primer for PTI-1 b
C 23	16.4	0.9	18	1 AAZ69745	Human biallelic ma
C 24	16.4	0.9	20	1 AAV01232	Von Willebrand's f
C 25	16.4	0.9	20	1 AAX93746	PCR primer used to
C 26	16.4	0.9	20	1 ADS75311	PCR primer CCRL2 P
C 27	16.2	0.9	21	1 AAZ44349	Protein kinase inh
C 28	16.2	0.9	21	1 AAH76301	Human PPARgamma cD
C 29	16.2	0.9	21	1 ABK99279	Hepatitis C virus
C 30	16.2	0.9	21	1 ADI17592	Reverse PCR primer
C 31	16.2	0.9	21	1 ADN42680	Human NOV37 RTQ-PC
C 32	16.2	0.9	21	1 ADS82520	RT-PCR primer for
C 33	16	0.9	19	1 AAA82893	cdk4 ribozyme bind

Cell-cycle depende  
Hepatitis C virus  
Primer BRL367. Sy  
Cyclin A1 ribozyme  
Cyclin A1 ribozyme  
Cyclin A1 ribozyme  
Cyclin A1 ribozyme  
Caenorhabditis ele  
EST polymorphic DN  
Human TGFb-R sRNA  
Human TGFb-R trans  
Plant gene polymor  
Human glucose-6-ph  
PCR primer used in  
PCR primer used to  
PCR primer for nuc  
D-1-deoxyxylulose  
Human endometrium  
Arabidopsis dmr RA  
Mouse interferon B  
Human OKL38 3' spl  
Murine plasma glut  
Chimeric phosphoro  
Chimeric phosphoro  
PCR primer used to  
Human brain natriu  
Acyl-coenzyme A sy  
Acyl-coenzyme A sy  
Human ROMK gene ex  
Human CFTR gene as  
Human G-protein co  
Device with substa  
Device with substa  
Device with substa  
Aromatase siRNA se  
Oestrogen receptor  
WNV inozyme subatr  
WNV minus strand A  
WNV minus strand A  
Tumour suppression  
HBV hammerhead rib  
Murine oligonucleo  
Murine oligonucleo  
Hepatitis B virus  
Silkworm juvenile  
Human single nucle  
Streptomyces sp. d  
PCR primer D-R use  
Murine Sox3 gene P  
PCR primer D-R use  
Human zmsel mappin  
Human zmsel mappin  
Endothelin 3 (Syx)  
Allele A oligo #2,  
Allele A oligo #1,  
Rat Atrial naturer  
Rat Atrial naturer  
Rat gene specific  
Rat RT-PCR primer  
Mitogen activated  
Mitogen activated  
Protein tyrosine p  
Rat ANP gene speci  
Hv 18-specific ol  
PCR primer used to  
Streptococcus pyog  
VRP gene specific  
Fibroblast growth  
Vpr-driven constru  
rpoB gene oligomer  
Human HIF-1 antise  
Acyl-coenzyme A sy  
Acyl-coenzyme A sy  
Multiplex vector 1

107	15.2	0.8	20	1	AAQ92495	Spinach glycerol-3	180	15	0.8	20	1	AAA94503	Antisense oligonuc
108	15.2	0.8	20	1	AAT61766	Primer for Atase c	181	15	0.8	20	1	AAA94505	Antisense oligonuc
109	15.2	0.8	20	1	AAV47686	Unmethylated CpG d	182	15	0.8	20	1	AAA94506	Antisense oligonuc
110	15.2	0.8	20	1	AAV74243	CpG-N motif O-ODN	183	15	0.8	20	1	AAA94508	Antisense oligonuc
111	15.2	0.8	20	1	AAZ02802	PCR primer used to	184	15	0.8	20	1	AB285199	Human oligonucleot
112	15.2	0.8	20	1	AAZ04579	PCR primer used to	185	15	0.8	20	1	AB285565	Human oligonucleot
113	15.2	0.8	20	1	AAZ94968	PCR primer used to	186	15	0.8	20	1	ABD21429	Human transglutami
114	15.2	0.8	20	1	AAZ60081	Forward PCR primer	187	15	0.8	20	1	ABD21795	Human transglutami
115	15.2	0.8	20	1	AAZ60557	Human fra-1 mRNA a	188	15	0.8	20	1	ADF11714	Set 2 left PCR pri
116	15.2	0.8	20	1	AAF75307	Mouse inducible NO	189	14.8	0.8	18	1	AAF85699	Multiple repeated
117	15.2	0.8	20	1	AAF99116	Immunostimulatory	190	14.8	0.8	18	1	ADQ26654	Synthetic leader s
118	15.2	0.8	20	1	AAZ08746	Human PD-ABC form	191	14.8	0.8	18	1	ADQ26616	Synthetic leader s
119	15.2	0.8	20	1	AAZ08837	Human PD-ABC form	192	14.8	0.8	18	1	ADQ26622	Synthetic leader s
120	15.2	0.8	20	1	AAZ23716	Human PPARgamma an	193	14.8	0.8	18	1	ADQ26692	Synthetic leader s
121	15.2	0.8	20	1	ASZ97459	Murine SAC1 Gene-s	194	14.8	0.8	19	1	AAA85973	Cdc25 hs ribozyme
122	15.2	0.8	20	1	ABS77759	Angiogenesis inhib	195	14.8	0.8	19	1	AAA85142	Cyclin G1 ribozyme
123	15.2	0.8	20	1	ABL39008	Immunostimulatory	196	14.8	0.8	19	1	AAZ72532	Human biallelic ma
124	15.2	0.8	20	1	ABN86471	Human MMP-2 1306T	197	14.8	0.8	19	1	AAZ72783	Human biallelic ma
125	15.2	0.8	20	1	ABL43517	Human chromosome 1	198	14.8	0.8	19	1	AH56723	S. aureus groE ope
126	15.2	0.8	20	1	ABT13053	Human apolipoprote	199	14.8	0.8	19	1	AH60304	Cyclin G1 ribozyme
127	15.2	0.8	20	1	ABN80988	Mouse caspase 7 ph	200	14.8	0.8	19	1	AH61135	Cdc25 hs ribozyme
128	15.2	0.8	20	1	ABK47992	Human MIP-3 beta R	201	14.8	0.8	19	1	ADJ94210	Human MYOC gene mu
129	15.2	0.8	20	1	ACD99549	Immunostimulatory	202	14.8	0.8	19	1	ADM70255	Plant gene polymor
130	15.2	0.8	20	1	ADB36618	Immunostimulatory	203	14.8	0.8	19	1	ADM86893	Example nucleotide
131	15.2	0.8	20	1	ADD24338	CD2 binding protei	204	14.8	0.8	19	1	ADR80686	Human apolipoprote
132	15.2	0.8	20	1	AAD63540	Human CD2BF1 cDNA	205	14.8	0.8	19	1	ADR81197	Hepatitis C virus
133	15.2	0.8	20	1	ABZ90044	Human oligonucleot	206	14.8	0.8	19	1	ABL78028	Human apolipoprote
134	15.2	0.8	20	1	ABZ89607	Human oligonucleot	207	14.4	0.8	16	1	ABL57076	Molecular beacon t
135	15.2	0.8	20	1	ABZ90469	Human oligonucleot	208	14.4	0.8	16	1	AAD57846	Target oligonucleo
136	15.2	0.8	20	1	ABZ82795	Mouse HSL chimeric	209	14.4	0.8	16	1	ADF23332	Binding partner sc
137	15.2	0.8	20	1	ABD26699	N35316-derived oli	210	14.4	0.8	16	1	ADS15827	Control probe targ
138	15.2	0.8	20	1	ABD26274	AA398883-derived o	211	14.4	0.8	17	1	AAZ25490	Oestrogen receptor
139	15.2	0.8	20	1	ABD25837	AI085559-derived o	212	14.4	0.8	17	1	AAZ25488	Oestrogen receptor
140	15.2	0.8	20	1	ADH41329	Human ovarian spec	213	14.4	0.8	17	1	AAZ25596	Oestrogen receptor
141	15.2	0.8	20	1	ADH18272	2'-MOE gapmer anti	214	14.4	0.8	17	1	ABX03734	Human CD20 Ambery
142	15.2	0.8	20	1	ADH18846	2'-MOE gapmer anti	215	14.4	0.8	17	1	ABN10039	Human GDMPLP-1 17-m
143	15.2	0.8	20	1	ADH18638	Human apolipoprote	216	14.4	0.8	17	1	ABN08373	Human GDMPLP-1 17-m
144	15.2	0.8	20	1	ADJ31845	Human apolipoprote	217	14.4	0.8	17	1	ABN10038	Human GDMPLP-1 17-m
145	15.2	0.8	20	1	ADK43211	Antisense 2'-MOE g	218	14.4	0.8	17	1	ABN08372	Human GDMPLP-1 17-m
146	15.2	0.8	20	1	ADK43334	Human PTPRA DNA ta	219	14.4	0.8	17	1	ABX57251	Human CUCAL Gene e
147	15.2	0.8	20	1	ADJ24885	Human endothelial	220	14.4	0.8	17	1	ACN01676	WNV inozyme substr
148	15.2	0.8	20	1	ADJ241174	Human endothelial	221	14.4	0.8	17	1	ACN13699	WNV minus strand D
149	15.2	0.8	20	1	ADK79679	Chimeric phosphoro	222	14.4	0.8	17	1	ACN12456	WNV minus strand Z
150	15.2	0.8	20	1	ADK75648	Chimeric phosphoro	223	14.4	0.8	17	1	ACN01677	WNV inozyme substr
151	15.2	0.8	20	1	ADK75704	Chimeric phosphoro	224	14.4	0.8	17	1	ACN15154	WNV minus strand A
152	15.2	0.8	20	1	ADK70098	Plant gene polymor	225	14.4	0.8	17	1	ABZ61174	Human K-Ras DNazym
153	15.2	0.8	20	1	ADL91774	Sequencing primer	226	14.4	0.8	17	1	ACD50766	HBV hammerhead rib
154	15.2	0.8	20	1	ADM41705	Murine SAC1 DNA PC	227	14.4	0.8	17	1	ACD63373	HCV minus strand D
155	15.2	0.8	20	1	ADM15799	Human IGFBP-1 reve	228	14.4	0.8	17	1	ACD59296	HCV DNazyme substr
156	15.2	0.8	20	1	ADO01532	Chimeric phosphoro	229	14.4	0.8	17	1	ACD59612	HCV DNazyme substr
157	15.2	0.8	20	1	ADP79070	Chimeric phosphoro	230	14.4	0.8	17	1	ACD50768	HBV hammerhead rib
158	15.2	0.8	20	1	ADN40102	Human selenoprotei	231	14.4	0.8	17	1	ACC65059	Murine oligonucleo
159	15.2	0.8	20	1	ADN40132	Human selenoprotei	232	14.4	0.8	17	1	ACC63426	Murine oligonucleo
160	15.2	0.8	20	1	ADN30177	Hepatocyte growth	233	14.4	0.8	17	1	ACC64367	Murine oligonucleo
161	15.2	0.8	20	1	ADN30248	Hepatocyte growth	234	14.4	0.8	17	1	ACC65664	Murine oligonucleo
162	15.2	0.8	20	1	ADN31637	Human equine syn	235	14.4	0.8	17	1	ACC67091	Murine oligonucleo
163	15.2	0.8	20	1	ADO33179	Human apolipoprote	236	14.4	0.8	17	1	ADJ48639	Human tumour suppr
164	15.2	0.8	20	1	ADO33387	Antisense 2'-MOE g	237	14.4	0.8	17	1	ADJ49463	Hepatitis B virus
165	15.2	0.8	20	1	ADO33432	Phosphodiester dou	238	14.4	0.8	17	1	ADM58131	Hepatitis B virus
166	15.2	0.8	20	1	ADO32813	Antisense 2'-MOE g	239	14.4	0.8	17	1	ADM58133	HCV DNazyme substr
167	15.2	0.8	20	1	ADP68918	Human DRK2 antise	240	14.4	0.8	17	1	ADJ84168	HCV DNazyme substr
168	15.2	0.8	20	1	ADP68974	Human DRK2 antise	241	14.4	0.8	17	1	ADJ86043	HCV DNazyme substr
169	15.2	0.8	20	1	ADQ13711	DMD region PCR pri	242	14.4	0.8	17	1	ADR27062	Human single nucle
170	15.2	0.8	20	1	ADQ32216	Human nestin rever	243	14.4	0.8	17	1	ACN73128	Human GDMPLP-1 prob
171	15.2	0.8	20	1	ADT79911	Human squalene syn	244	14.4	0.8	17	1	ACN71463	Human GDMPLP-1 prob
172	15	0.8	15	1	AAZ59263	Human NR8 gene pro	245	14.4	0.8	17	1	ACN73129	Human GDMPLP-1 prob
173	15	0.8	15	1	ADQ81798	Oligonucleotide sy	246	14.4	0.8	17	1	ACN71462	Human GDMPLP-1 prob
174	15	0.8	17	1	ABZ61173	Human K-Ras DNazym	247	14.4	0.8	18	1	AAZ25403	Infectious pancrea
175	15	0.8	18	1	ADF13436	Cdc42-interacting	248	14.4	0.8	18	1	AAA10847	G-alpha-i1 antisen
176	15	0.8	19	1	AAA82892	cdk4 ribozyme bind	249	14.4	0.8	18	1	AAA86639	Cdc 2 kinase hamme
177	15	0.8	19	1	AAH58054	Cell-cycle depende	250	14.4	0.8	18	1	AAA58514	PCR primer used to
178	15	0.8	20	1	AAA94507	Antisense oligonuc	251	14.4	0.8	18	1	AH61805	Cdc 2 kinase hamme
179	15	0.8	20	1	AAA94504	Antisense oligonuc	252	14.4	0.8	18	1	ABZ72355	Gene 216 polymorph

c 253 14.4 0.8 18 1 AAD40167 Cauliflower mosaic  
 c 254 14.4 0.8 18 1 AAD40589 HIV-1 LTR lucifera  
 c 255 14.4 0.8 18 1 ABX75208 Human 216 gene all  
 c 256 14.4 0.8 18 1 ABZ81757 Huntington's disea  
 c 257 14.4 0.8 18 1 ACC70479 Mouse DNA gp41 seque  
 c 258 14.4 0.8 18 1 ADD94304 HIV DNA gp41 seque  
 c 259 14.4 0.8 18 1 ADH71082 Human Vbeta micros  
 c 260 14.4 0.8 18 1 ADJ36936 Gene 216 related a  
 c 261 14.4 0.8 18 1 ADL81514 Gene 216 ASO prime  
 c 262 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 263 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 264 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 265 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 266 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 267 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 268 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 269 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 270 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 271 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 272 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 273 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 274 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 275 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 276 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 277 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 278 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 279 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 280 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 281 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 282 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 283 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 284 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 285 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 286 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 287 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 288 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 289 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 290 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 291 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 292 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 293 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 294 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 295 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 296 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 297 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 298 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 299 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 300 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 301 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 302 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 303 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 304 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 305 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 306 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 307 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 308 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 309 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 310 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 311 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 312 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 313 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 314 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 315 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 316 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 317 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 318 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 319 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 320 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 321 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 322 14.4 0.8 19 1 AAD85466 Cyclin A1 ribozyme  
 c 323 13.8 0.7 18 1 AAD85466 Cyclin A1 ribozyme  
 c 324 13.8 0.7 18 1 AAD85466 Cyclin A1 ribozyme  
 c 325 13.8 0.7 18 1 AAD85466 Cyclin A1 ribozyme

c 326 13.8 0.7 17 1 AAX71500 Human KDR VEGF rec  
 c 327 13.8 0.7 17 1 AAX75068 Mouse flt-1 VEGF r  
 c 328 13.8 0.7 17 1 AAX71415 Human KDR VEGF rec  
 c 329 13.8 0.7 17 1 AAX72984 Mouse flk-1 VEGF r  
 c 330 13.8 0.7 17 1 AAX73070 Mouse flk-1 VEGF r  
 c 331 13.8 0.7 17 1 AAX72985 Mouse flt-1 VEGF r  
 c 332 13.8 0.7 17 1 AAX75069 Mouse flt-1 VEGF r  
 c 333 13.8 0.7 17 1 AAX71414 Human KDR VEGF rec  
 c 334 13.8 0.7 17 1 AAX71414 Human KDR VEGF rec  
 c 335 13.8 0.7 17 1 AAX7651 Human EGF-R target  
 c 336 13.8 0.7 17 1 AAX79245 Oligonucleotide #3  
 c 337 13.8 0.7 17 1 AAX79245 Integrin alpha 6 s  
 c 338 13.8 0.7 17 1 AAX18738 Human TIE-2 substra  
 c 339 13.8 0.7 17 1 AAX25595 Oestrogen receptor  
 c 340 13.8 0.7 17 1 AAX25180 Oestrogen receptor  
 c 341 13.8 0.7 17 1 AAX94595 Human Chk1 ribozym  
 c 342 13.8 0.7 17 1 AAK02550 Human NOGO Ambery  
 c 343 13.8 0.7 17 1 AAS6748 BRL ribozyme seque  
 c 344 13.8 0.7 17 1 AAF83171 Probe PN(n)T used  
 c 345 13.8 0.7 17 1 AABN01544 Human GMMLP-1 17-m  
 c 346 13.8 0.7 17 1 AABN09580 Human GMMLP-1 17-m  
 c 347 13.8 0.7 17 1 AABN08368 Human GMMLP-1 17-m  
 c 348 13.8 0.7 17 1 AABN08371 Human GMMLP-1 17-m  
 c 349 13.8 0.7 17 1 AABN01545 Human GMMLP-1 17-m  
 c 350 13.8 0.7 17 1 AABQ63943 Human KTM1a portin  
 c 351 13.8 0.7 17 1 AABV83005 Human HTPL scannin  
 c 352 13.8 0.7 17 1 AABK17547 Human ERG hammerhe  
 c 353 13.8 0.7 17 1 AABK19008 Human ERG DNzyme  
 c 354 13.8 0.7 17 1 AABK18911 Human ERG DNzyme  
 c 355 13.8 0.7 17 1 AAD41868 ON-21 oligonucleot  
 c 356 13.8 0.7 17 1 AABK55893 Human CLCA1 gene e  
 c 357 13.8 0.7 17 1 AABK55827 Human CLCA1 gene e  
 c 358 13.8 0.7 17 1 ACN01678 WNV Inozyme substra  
 c 359 13.8 0.7 17 1 ACN13432 WNV minus strand Z  
 c 360 13.8 0.7 17 1 ACN03066 WNV Inozyme substra  
 c 361 13.8 0.7 17 1 ACN03066 WNV Inozyme substra  
 c 362 13.8 0.7 17 1 ACN03119 WNV Inozyme substra  
 c 363 13.8 0.7 17 1 ACN15153 WNV minus strand A  
 c 364 13.8 0.7 17 1 ACN00195 WNV Hammerhead Rib  
 c 365 13.8 0.7 17 1 ABT36759 Tumour suppression  
 c 366 13.8 0.7 17 1 ADB04829 Human MD212 scanni  
 c 367 13.8 0.7 17 1 ABZ61368 Human H-Ras DNzyme  
 c 368 13.8 0.7 17 1 ACDS9841 HCV minus strand D  
 c 369 13.8 0.7 17 1 ACDS9841 HCV DNzyme substra  
 c 370 13.8 0.7 17 1 ACC64973 Murine oligonucleo  
 c 371 13.8 0.7 17 1 ACC68442 Murine oligonucleo  
 c 372 13.8 0.7 17 1 ADC04228 Human Na/H exchang  
 c 373 13.8 0.7 17 1 ADF64149 Human PCP1 DNA fr  
 c 374 13.8 0.7 17 1 ADG38381 Anti-HIV L-DNA #48  
 c 375 13.8 0.7 17 1 ADI48002 Human tumour suppr  
 c 376 13.8 0.7 17 1 ADI49572 Human tumour suppr  
 c 377 13.8 0.7 17 1 ADI49244 Human tumour suppr  
 c 378 13.8 0.7 17 1 ADI50952 Human tumour suppr  
 c 379 13.8 0.7 17 1 ADI50952 Human IL4-R oligon  
 c 380 13.8 0.7 17 1 ADL49803 Human PKR substra  
 c 381 13.8 0.7 17 1 ADL46473 Human ADG46473  
 c 382 13.8 0.7 17 1 ADL47007 Human NOGO recepto  
 c 383 13.8 0.7 17 1 ADL49254 Human PKR substra  
 c 384 13.8 0.7 17 1 ABD30412 Human IL4-R derive  
 c 385 13.8 0.7 17 1 ADJ59200 Oligonucleotide as  
 c 386 13.8 0.7 17 1 ADI84285 HCV DNzyme substra  
 c 387 13.8 0.7 17 1 ADI85895 HCV DNzyme substra  
 c 388 13.8 0.7 17 1 ADO46690 Human oligonucleot  
 c 389 13.8 0.7 17 1 ACN64635 Human GMMLP-1 prob  
 c 390 13.8 0.7 17 1 ACN71461 Human GMMLP-1 prob  
 c 391 13.8 0.7 17 1 ACN72670 Human GMMLP-1 prob  
 c 392 13.8 0.7 17 1 ACN64634 Human GMMLP-1 prob  
 c 393 13.8 0.7 17 1 ACN71458 Human GMMLP-1 prob  
 c 394 13.8 0.7 18 1 AAQ20007 Oligonucleotide #3  
 c 395 13.8 0.7 18 1 AAQ24901 Human leukocyte an  
 c 396 13.8 0.7 18 1 AAQ42926 Primer CDRBACK. S  
 c 397 13.8 0.7 18 1 AAQ70349 Antisense oligonuc  
 c 398 13.8 0.7 18 1 AAX15196 Triple helix formi

c 326 13.8 0.7 17 1 AAX71500 Human KDR VEGF rec  
 c 327 13.8 0.7 17 1 AAX75068 Mouse flt-1 VEGF r  
 c 328 13.8 0.7 17 1 AAX71415 Human KDR VEGF rec  
 c 329 13.8 0.7 17 1 AAX72984 Mouse flk-1 VEGF r  
 c 330 13.8 0.7 17 1 AAX73070 Mouse flk-1 VEGF r  
 c 331 13.8 0.7 17 1 AAX72985 Mouse flt-1 VEGF r  
 c 332 13.8 0.7 17 1 AAX75069 Mouse flt-1 VEGF r  
 c 333 13.8 0.7 17 1 AAX71414 Human KDR VEGF rec  
 c 334 13.8 0.7 17 1 AAX71414 Human KDR VEGF rec  
 c 335 13.8 0.7 17 1 AAX7651 Human EGF-R target  
 c 336 13.8 0.7 17 1 AAX79245 Oligonucleotide #3  
 c 337 13.8 0.7 17 1 AAX79245 Integrin alpha 6 s  
 c 338 13.8 0.7 17 1 AAX18738 Human TIE-2 substra  
 c 339 13.8 0.7 17 1 AAX25595 Oestrogen receptor  
 c 340 13.8 0.7 17 1 AAX25180 Oestrogen receptor  
 c 341 13.8 0.7 17 1 AAX94595 Human Chk1 ribozym  
 c 342 13.8 0.7 17 1 AAK02550 Human NOGO Ambery  
 c 343 13.8 0.7 17 1 AAS6748 BRL ribozyme seque  
 c 344 13.8 0.7 17 1 AAF83171 Probe PN(n)T used  
 c 345 13.8 0.7 17 1 AABN01544 Human GMMLP-1 17-m  
 c 346 13.8 0.7 17 1 AABN09580 Human GMMLP-1 17-m  
 c 347 13.8 0.7 17 1 AABN08368 Human GMMLP-1 17-m  
 c 348 13.8 0.7 17 1 AABN08371 Human GMMLP-1 17-m  
 c 349 13.8 0.7 17 1 AABN01545 Human GMMLP-1 17-m  
 c 350 13.8 0.7 17 1 AABQ63943 Human KTM1a portin  
 c 351 13.8 0.7 17 1 AABV83005 Human HTPL scannin  
 c 352 13.8 0.7 17 1 AABK17547 Human ERG hammerhe  
 c 353 13.8 0.7 17 1 AABK19008 Human ERG DNzyme  
 c 354 13.8 0.7 17 1 AABK18911 Human ERG DNzyme  
 c 355 13.8 0.7 17 1 AAD41868 ON-21 oligonucleot  
 c 356 13.8 0.7 17 1 AABK55893 Human CLCA1 gene e  
 c 357 13.8 0.7 17 1 AABK55827 Human CLCA1 gene e  
 c 358 13.8 0.7 17 1 ACN01678 WNV Inozyme substra  
 c 359 13.8 0.7 17 1 ACN13432 WNV minus strand Z  
 c 360 13.8 0.7 17 1 ACN03066 WNV Inozyme substra  
 c 361 13.8 0.7 17 1 ACN03066 WNV Inozyme substra  
 c 362 13.8 0.7 17 1 ACN03119 WNV Inozyme substra  
 c 363 13.8 0.7 17 1 ACN15153 WNV minus strand A  
 c 364 13.8 0.7 17 1 ACN00195 WNV Hammerhead Rib  
 c 365 13.8 0.7 17 1 ABT36759 Tumour suppression  
 c 366 13.8 0.7 17 1 ADB04829 Human MD212 scanni  
 c 367 13.8 0.7 17 1 ABZ61368 Human H-Ras DNzyme  
 c 368 13.8 0.7 17 1 ACDS9841 HCV minus strand D  
 c 369 13.8 0.7 17 1 ACDS9841 HCV DNzyme substra  
 c 370 13.8 0.7 17 1 ACC64973 Murine oligonucleo  
 c 371 13.8 0.7 17 1 ACC68442 Murine oligonucleo  
 c 372 13.8 0.7 17 1 ADC04228 Human Na/H exchang  
 c 373 13.8 0.7 17 1 ADF64149 Human PCP1 DNA fr  
 c 374 13.8 0.7 17 1 ADG38381 Anti-HIV L-DNA #48  
 c 375 13.8 0.7 17 1 ADI48002 Human tumour suppr  
 c 376 13.8 0.7 17 1 ADI49572 Human tumour suppr  
 c 377 13.8 0.7 17 1 ADI49244 Human tumour suppr  
 c 378 13.8 0.7 17 1 ADI50952 Human tumour suppr  
 c 379 13.8 0.7 17 1 ADI50952 Human IL4-R oligon  
 c 380 13.8 0.7 17 1 ADL49803 Human PKR substra  
 c 381 13.8 0.7 17 1 ADL46473 Human ADG46473  
 c 382 13.8 0.7 17 1 ADL47007 Human NOGO recepto  
 c 383 13.8 0.7 17 1 ADL49254 Human PKR substra  
 c 384 13.8 0.7 17 1 ABD30412 Human IL4-R derive  
 c 385 13.8 0.7 17 1 ADJ59200 Oligonucleotide as  
 c 386 13.8 0.7 17 1 ADI84285 HCV DNzyme substra  
 c 387 13.8 0.7 17 1 ADI85895 HCV DNzyme substra  
 c 388 13.8 0.7 17 1 ADO46690 Human oligonucleot  
 c 389 13.8 0.7 17 1 ACN64635 Human GMMLP-1 prob  
 c 390 13.8 0.7 17 1 ACN71461 Human GMMLP-1 prob  
 c 391 13.8 0.7 17 1 ACN72670 Human GMMLP-1 prob  
 c 392 13.8 0.7 17 1 ACN64634 Human GMMLP-1 prob  
 c 393 13.8 0.7 17 1 ACN71458 Human GMMLP-1 prob  
 c 394 13.8 0.7 18 1 AAQ20007 Oligonucleotide #3  
 c 395 13.8 0.7 18 1 AAQ24901 Human leukocyte an  
 c 396 13.8 0.7 18 1 AAQ42926 Primer CDRBACK. S  
 c 397 13.8 0.7 18 1 AAQ70349 Antisense oligonuc  
 c 398 13.8 0.7 18 1 AAX15196 Triple helix formi

399 13.8 0.7 18 1 AAT77597 Wheat microsattelli  
 C 400 13.8 0.7 18 1 AAV10476 Canine beta-3 adre  
 C 401 13.8 0.7 18 1 AAV16014 PCR primer G-R use  
 C 402 13.8 0.7 18 1 AAV33800 Human growth hormo  
 C 403 13.8 0.7 18 1 AAZ31824 Human G-alpha-13 a  
 C 404 13.8 0.7 18 1 AAZ39664 Human Vch aggregat  
 C 405 13.8 0.7 18 1 AAZ43273 Murine Sox3 gene p  
 C 406 13.8 0.7 18 1 AAZ05258 PCR primer G-R use  
 C 407 13.8 0.7 18 1 AAF26702 Human Smad7 phosph  
 C 408 13.8 0.7 18 1 AAF92967 Wild type sequence  
 C 409 13.8 0.7 18 1 ABZ72129 Gene 216 SSCP dete  
 C 410 13.8 0.7 18 1 ABK41013 Human obesity-asso  
 C 411 13.8 0.7 18 1 ABS97456 Human diazepam bin  
 C 412 13.8 0.7 18 1 ABS66015 Mycobacterium dete  
 C 413 13.8 0.7 18 1 ABS66019 Mycobacterium intr  
 C 414 13.8 0.7 18 1 AAD34959 Human SDF1 gene am  
 C 415 13.8 0.7 18 1 ABK98126 Triple helix formi  
 C 416 13.8 0.7 18 1 ABX74982 Human gene 216 pol  
 C 417 13.8 0.7 18 1 ADA27361 Human microsattelli  
 C 418 13.8 0.7 18 1 AAL60043 Human GH-1 gene am  
 C 419 13.8 0.7 18 1 AAL60014 Human GH-1 gene am  
 C 420 13.8 0.7 18 1 ADEI3307 HLA class I allele  
 C 421 13.8 0.7 18 1 ADEI3393 HLA class I allele  
 C 422 13.8 0.7 18 1 ADF13036 Human PCM1 exon 33  
 C 423 13.8 0.7 18 1 ADF78408 Chromosomal abnorm  
 C 424 13.8 0.7 18 1 ADG70285 CILDB exon 12 and  
 C 425 13.8 0.7 18 1 ADG73179 Pseudomonas syring  
 C 426 13.8 0.7 18 1 ADH42989 Lower PCR primer u  
 C 427 13.8 0.7 18 1 ADH53213 Human APC (adenoma  
 C 428 13.8 0.7 18 1 ADL12235 Pseudomonas syring  
 C 429 13.8 0.7 18 1 ADM07244 PCR primer 2 used  
 C 430 13.8 0.7 18 1 ADM07236 PCR primer 2 used  
 C 431 13.8 0.7 18 1 ADU36710 Human gene 216 SNP  
 C 432 13.8 0.7 18 1 ADL09243 HLA locus-specific  
 C 433 13.8 0.7 18 1 ADL09357 HLA locus-specific  
 C 434 13.8 0.7 18 1 ADL61289 Gene 216 SSCP prim  
 C 435 13.8 0.7 18 1 ADM76352 NEPHA gene transcr  
 C 436 13.8 0.7 18 1 ADM76353 NEPHA gene transcr  
 C 437 13.8 0.7 18 1 ADM06884 Mouse Hnf4 exon 8/  
 C 438 13.8 0.7 18 1 ADO26612 Synthetic leader s  
 C 439 13.8 0.7 18 1 ADO26628 Synthetic leader s  
 C 440 13.8 0.7 18 1 ADP27776 PCR primer to ampl  
 C 441 13.8 0.7 18 1 ADP08680 Extend primer 17 u  
 C 442 13.8 0.7 18 1 ADQ78196 PCR primer used to  
 C 443 13.8 0.7 18 1 ADP84638 Human breast-speci  
 C 444 13.8 0.7 18 1 ADR00170 EGFR PCR reverse p  
 C 445 13.8 0.7 18 1 ADS0224 Oligonucleotide of  
 C 446 13.8 0.7 18 1 ADR97984 Human APC DNA frag  
 C 447 13.8 0.7 18 1 ADS08668 Human APC oligonuc  
 C 448 13.6 0.7 15 1 AAS95939 Human CALM1 gene a

## ALIGNMENTS

RESULT 1  
 AAV82789/c  
 ID AAV82789 standard; DNA; 29 BP.  
 XX  
 AC AAV82789;  
 XX  
 AC  
 XX  
 DT 25-FEB-1999 (first entry)  
 XX  
 DE Probe used to isolate clone bu45\_2 (V82779).  
 XX  
 KW Secreted protein; nutritional activity; immune stimulating; vaccine;  
 KW suppressing activity; haematopoiesis regulating activity;  
 KW tissue growth activity; activin; inhibin activity; chemotaxis;  
 KW chemokinetic activity; haemostasis; thrombolytic activity; receptor;  
 KW ligand; anti-inflammatory; cadherin; tumour invasion suppressor;  
 KW tumour inhibition; gene therapy; probe; ss.  
 XX  
 OS Synthetic.

OS Homo sapiens.  
 XX  
 PN WO9842739-A2.  
 XX  
 PD 01-OCT-1998.  
 XX  
 PF 20-MAR-1998; 98WO-US005653.  
 XX  
 PR 21-MAR-1997; 97US-00822167.  
 PR 19-MAR-1998; 98US-00044466.  
 XX  
 PA (GEM ) GENETICS INST INC.  
 XX  
 PI Jacobs K, McCoy JM, Lavallie ER, Racie LA, Merberg D, Treacy M;  
 PI Spaulding V, Agostino MJ;  
 XX  
 DR WPI; 1998-609890/51.  
 XX  
 PT New polynucleotides encoding secreted human proteins - derived from human  
 PT foetal brain, adult brain, foetal kidney, placenta or adult pineal gland  
 PT cDNA libraries.  
 XX  
 PS Disclosure; Page 90; 113pp; English.  
 XX  
 CC Probes AAV82788-97 were used to isolate clones encoding secreted  
 CC proteins. The polynucleotides and their secreted proteins are predicted  
 CC to have biological activities which would make them suitable for  
 CC treating, preventing or ameliorating medical conditions in humans and  
 CC animals, although no supporting data is given. Suggested activities  
 CC include nutritional activity, immune stimulating (e.g. as vaccines) or  
 CC suppressing activity, haematopoiesis regulating activity, tissue growth  
 CC activity, activin/inhibin activity, chemotactic/chemokinetic activity,  
 CC haemostatic and thrombolytic activity, receptor/ligand activity, anti-  
 CC inflammatory activity, cadherin/tumour invasion suppressor activity, and  
 CC tumour inhibition activity (no data is given in the specification to  
 CC support these activities). The polynucleotide is also stated to be useful  
 CC for gene therapy  
 XX  
 SQ Sequence 29 BP; 11 A; 8 C; 4 G; 5 T; 0 U; 1 Other;  
 Query Match 1.5%; Score 28; DB 1; Length 29;  
 Best Local Similarity 96.6%; Pred. No. 0.91;  
 Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 OY 295 GATTGGCACTTCTGGTTGATCTGTTGGA 323  
 DB 29 GATTGGCACTTCTGGTTGATCTGTTGNA 1  
 RESULT 2  
 ABQ92088/c  
 ID ABQ92088 standard; DNA; 29 BP.  
 XX  
 AC ABQ92088;  
 XX  
 AC  
 XX  
 DT 04-OCT-2002 (first entry)  
 XX  
 DE Human polynucleotide related probe SEQ ID NO 85.  
 XX  
 KW Human; cytostatic; antirheumatic; antiarthritic; vulnery; analgesic;  
 KW antiinflammatory; antibacterial; immunosuppressive; antiparkinsonian;  
 KW neuroprotective; nootropic; osteopathic; haemostatic; vasotropic;  
 KW antiulcer; fungicide; antidiabetic; antiasthmatic; antiallergic;  
 KW immunostimulant; antiparasitic; secreted protein; transmembrane protein;  
 KW cytokine; cell proliferation; cell differentiation; autoimmune disease;  
 KW stem cell; growth factor; nervous system disease; neuropathy;  
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;  
 KW osteoporosis; severe combined immunodeficiency; SCID; infection;  
 KW multiple sclerosis; rheumatoid arthritis; gene therapy; probe; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2002065394-A1.

XX 30-MAY-2002.  
XX  
XX  
XX 22-DEC-2000; 2000US-00745763.  
XX  
XX 18-MAR-1998; 98US-00040963.  
XX  
XX (JACO/) JACOBS K.  
XX (MCCO/) MCCOY J M.  
XX (LAVA/) LAVALLIE E R.  
XX (COLL/) COLLINS-RACIE L A.  
XX (EVAN/) EVANS C.  
XX (MERB/) MERBERG D.  
XX (TREA/) TREACY M.  
XX (SPAU/) SPAULDING V.  
XX  
XX Jacobs K, McCoy JM, Lavallie ER, Collins-Racie LA, Evans C;  
XX Merberg D, Treacy M, Spaulding V;  
XX WPI; 2002-582343/62.  
XX  
XX Novel secreted or transmembrane protein and polynucleotide encoding the  
XX protein, useful for diagnosis and treatment of neurological disorders,  
XX cancer, autoimmune diseases, bone disorders and lung or liver fibrosis.  
XX  
XX Disclosure; Page 128; 284pp; English.  
XX  
XX The invention relates to human secreted or transmembrane protein (I),  
XX their fragments and is encoded by specific complementary deoxyribonucleic  
XX acid (cDNA) inserts (II), where the protein is substantially free from  
XX other mammalian proteins. (I) are useful for preventing, treating or  
XX ameliorating a medical condition, especially immunological treatment or  
XX prevention of tumours. (I) exhibits activity relating to angiogenesis,  
XX cytokine cell proliferation, cell differentiation, antiinflammatory,  
XX stem cell growth factor activity and activin or inhibin-related  
XX activities. (I) can be used to manipulate stem cells in culture to give  
XX rise to neuroepithelial cells that can be used to augment or replace  
XX cells damaged by illness, autoimmune disease, accidental damage or  
XX genetic disorders. (I) induces the proliferation of neural cells and  
XX regeneration of nerve and brain tissue and is useful for the treatment of  
XX central and peripheral nervous system diseases and neuropathies, such as  
XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic  
XX lateral sclerosis. (I) is involved in chemotactic or chemokinetic  
XX activity, regulation of haematopoiesis and is useful for treating myeloid  
XX or lymphoid cell disorders, platelet disorders such as thrombocytopaenia  
XX and for regeneration of bone, cartilage, tendon, ligament and/or nerve  
XX tissue growth and in tissue repair, healing of burns, incisions, ulcers,  
XX for treating osteoporosis, osteoarthritis, bone degenerative disorders or  
XX periodontal disease. (I) is also useful for gut protection or  
XX regeneration and treatment of lung or liver fibrosis, and disorders including  
XX in various tissues, various immune deficiencies and disorders including  
XX severe combined immunodeficiency (SCID), bacterial or fungal infections,  
XX autoimmune disorders e.g. multiple sclerosis, rheumatoid arthritis,  
XX diabetes mellitus, myasthenia gravis, allergic reactions and conditions,  
XX such as asthma or other respiratory problems. (II) is useful to express  
XX recombinant protein, as markers for tissues in which the corresponding  
XX protein is preferentially expressed and in gene therapy. The present  
XX sequence is that of a probe used in the isolation of polynucleotides of  
XX the invention  
XX  
XX Sequence 29 BP; 11 A; 8 C; 4 G; 5 T; 0 U; 1 Other;  
XX  
XX Query Match 1.5%; Score 28; DB 1; Length 29;  
XX Best Local Similarity 96.6%; Pred. No. 0.91;  
XX Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
XX 295 GATTGGCACTTCTGGTTGATCTGTGGA 323  
XX |||||||  
XX 29 GATTGGCACTTCTGGTTGATCTGTGNA 1  
XX  
XX RESULT 3  
XX AAZ58336/c

AAZ58336 standard; cDNA; 26 BP.  
AAZ58336;  
08-MAY-2000 (first entry)  
Human peptidase NAALAD-ase IV PCR primer NAALD4AP4.  
NAALAD-ase IV; N-acetylated alpha-linked acidic dipeptidase; human;  
prostate cancer; neurodegenerative disease; Alzheimer's disease;  
schizophrenia; ALS; Parkinson's disease; peripheral neuropathy;  
Huntington's disease; acute brain injury; multiple sclerosis;  
peripheral nerve trauma; ischaemia; dementia; gene therapy; diagnosis;  
nootropic; neuroprotective; neuroleptic; antiparkinsonian;  
anticongulsant; vasotropic; PCR primer; ss.  
Homo sapiens.  
WO200004157-A2.  
27-JAN-2000.  
14-JUL-1999; 99WO-GB002241.  
14-JUL-1998; 98GB-00015284.  
(JANC ) JANSSEN PHARM NV.  
Pangalos M, Neefs JEFM, Peeters DCG;  
WPI; 2000-182424/16.  
New human N-acetylated alpha-linked acidic dipeptidases for treating  
neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's  
disease.  
Disclosure; Page 27; 95pp; English.  
The present sequence is that of primer NAALD4AP4 used in the PCR  
amplification of full-length human N-acetylated alpha-linked acidic  
dipeptidase IV (NAALAD-ase IV) cDNA (see AAZ58333). cDNA from human  
hippocampus was as template. The invention provides human NAALAD-ase L,  
II and IV polypeptides, cDNAs, antisense nucleic acids, vectors, host  
cells, transgenic organisms, antagonists and agonists. These are useful  
for treating neural disorders such as Alzheimer's disease, schizophrenia,  
ALS, Parkinson's disease, peripheral neuropathy, Huntington's disease,  
acute brain injury, multiple sclerosis, exposure to neurotoxins,  
peripheral nerve trauma, ischaemia or dementia (claimed). Nucleic acids  
can also be used for gene therapy and for genetic screening of  
predisposition to disorders associated with NAALAD-ase  
Sequence 26 BP; 7 A; 6 C; 7 G; 6 T; 0 U; 0 Other;  
Query Match 1.4%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 1.9;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1563 GGGTCTGCACTTTGGAAACTCTC 1588  
|||  
Db 26 GGGTCTGCACTTTGGAAACTCTC 1  
RESULT 4  
AAZ58335  
ID AAZ58335 standard; cDNA; 26 BP.  
XX  
XX AAZ58335;  
XX AC  
XX 08-MAY-2000 (first entry)  
XX  
XX Human peptidase NAALAD-ase IV PCR primer NAALD4SP2.  
XX NAALAD-ase IV; N-acetylated alpha-linked acidic dipeptidase; human;

KW prostate cancer; neurodegenerative disease; Alzheimer's disease;  
 KW schizophrenia; ALS; Parkinson's disease; peripheral neuropathy;  
 KW Huntington's disease; acute brain injury; multiple sclerosis;  
 KW peripheral nerve trauma; ischaemia; dementia; gene therapy; diagnosis;  
 KW neurotropic; neuroprotective; neuroleptic; antiparkinsonian;  
 KW anticonvulsant; vasotropic; PCR primer; ss.  
 OS Homo sapiens.  
 XX WO200004157-A2.  
 PN 27-JAN-2000.  
 XX 14-JUL-1999; 99WO-GB002241.  
 PF 14-JUL-1998; 98GB-00015284.  
 PR (JANC ) JANSSEN PHARM NV.  
 XX Pangalos M, Neefs JEFM, Peeters DCG;  
 PI WPI; 2000-182424/16.  
 DR New human N-acetylated alpha-linked acidic dipeptidases for treating  
 XX neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's  
 PT disease.  
 PT Disclosure; Page 27; 95pp; English.  
 PS The present sequence is that of primer NAALD4SP2 used in the PCR  
 CC amplification of full-length human N-acetylated alpha-linked acidic  
 CC dipeptidase IV (NAALAD-ase IV) cDNA (see AAZ58313). cDNA from human  
 CC hippocampus was as template. The invention provides human NAALAD-ase L,  
 CC II and IV polypeptides, cDNAs, antisense nucleic acids, vectors, host  
 CC cells, transgenic organisms, antagonists and agonists. These are useful  
 CC for treating neural disorders such as Alzheimer's disease, schizophrenia,  
 CC ALS, Parkinson's disease, peripheral neuropathy, Huntington's disease,  
 CC acute brain injury, multiple sclerosis, exposure to neurotoxins,  
 CC peripheral nerve trauma, ischaemia or dementia (claimed). Nucleic acids  
 CC can also be used for gene therapy and for genetic screening of  
 CC predisposition to disorders associated with NAALAD-ase  
 XX  
 SQ Sequence 26 BP; 6 A; 9 C; 5 G; 6 T; 0 U; 0 Other;  
 Query Match 1.4%; Score 26; DB 1; Length 26;  
 Best Local Similarity 100.0%; Pred. No. 1.9;  
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 45 CGTCAGAGCGCCCTATCAGATTATC 70  
 DB 1 CGTCAGAGCGCCCTATCAGATTATC 26  
 RESULT 5  
 AAZ58343  
 ID AAZ58343 standard; cDNA; 25 BP.  
 XX AAZ58343;  
 AC 08-MAY-2000 (first entry)  
 XX Human peptidase NAALAD-ase IV PCR primer NAALD4SI.  
 DE NAALAD-ase IV; N-acetylated alpha-linked acidic dipeptidase; human;  
 KW prostate cancer; neurodegenerative disease; Alzheimer's disease;  
 KW schizophrenia; ALS; Parkinson's disease; peripheral neuropathy;  
 KW Huntington's disease; acute brain injury; multiple sclerosis;  
 KW peripheral nerve trauma; ischaemia; dementia; gene therapy; diagnosis;  
 KW neurotropic; neuroprotective; neuroleptic; antiparkinsonian;  
 KW anticonvulsant; vasotropic; PCR primer; ss.  
 OS Homo sapiens.

PN WO200004157-A2.  
 XX 27-JAN-2000.  
 XX 14-JUL-1999; 99WO-GB002241.  
 PF 14-JUL-1998; 98GB-00015284.  
 PR (JANC ) JANSSEN PHARM NV.  
 XX Pangalos M, Neefs JEFM, Peeters DCG;  
 PI WPI; 2000-182424/16.  
 DR New human N-acetylated alpha-linked acidic dipeptidases for treating  
 XX neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's  
 PT disease.  
 PT Disclosure; Page 33; 95pp; English.  
 PS The present sequence is that of primer NAALD4S1 used in the RT-PCR  
 CC amplification of human N-acetylated alpha-linked acidic dipeptidase IV  
 CC (NAALAD-ase IV) cDNA (see AAZ58313) for use in gene expression studies.  
 CC The invention provides human NAALAD-ase L, II and IV polypeptides, cDNAs,  
 CC antisense nucleic acids, vectors, host cells, transgenic organisms,  
 CC antagonists and agonists. These are useful for treating neural disorders  
 CC such as Alzheimer's disease, schizophrenia, ALS, Parkinson's disease,  
 CC peripheral neuropathy, Huntington's disease, acute brain injury, multiple  
 CC sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or  
 CC dementia  
 XX  
 SQ Sequence 25 BP; 8 A; 2 C; 11 G; 4 T; 0 U; 0 Other;  
 Query Match 1.4%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 2.7;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1101 GCAGAGAACACAGGTGGAGTTGGTG 1125  
 DB 1 GCAGAGAACACAGGTGGAGTTGGTG 25  
 RESULT 6  
 AAZ58344/C  
 ID AAZ58344 standard; cDNA; 24 BP.  
 XX AAZ58344;  
 AC 08-MAY-2000 (first entry)  
 XX Human peptidase NAALAD-ase IV PCR primer NAALD4AS1.  
 DE NAALAD-ase IV; N-acetylated alpha-linked acidic dipeptidase; human;  
 KW prostate cancer; neurodegenerative disease; Alzheimer's disease;  
 KW schizophrenia; ALS; Parkinson's disease; peripheral neuropathy;  
 KW Huntington's disease; acute brain injury; multiple sclerosis;  
 KW peripheral nerve trauma; ischaemia; dementia; gene therapy; diagnosis;  
 KW neurotropic; neuroprotective; neuroleptic; antiparkinsonian;  
 KW anticonvulsant; vasotropic; PCR primer; ss.  
 OS Homo sapiens.  
 XX WO200004157-A2.  
 PN 27-JAN-2000.  
 XX 14-JUL-1999; 99WO-GB002241.  
 PF 14-JUL-1998; 98GB-00015284.  
 PR (JANC ) JANSSEN PHARM NV.  
 XX Pangalos M, Neefs JEFM, Peeters DCG;  
 PI

XX WPI; 2000-182424/16.  
 XX New human N-acetylated alpha-linked acidic dipeptidases for treating  
 PT neural disorders e.g. Alzheimer's disease, schizophrenia and Parkinson's  
 PT disease.  
 XX Disclosure; Page 33; 95pp; English.  
 XX  
 XX The present sequence is that of primer NAALD4AS1 used in the RT-PCR  
 CC amplification of human N-acetylated alpha-linked acidic dipeptidase IV  
 CC (NAALAD-ase IV) cDNA (see AA258313) for use in gene expression studies.  
 CC The invention provides human NAALAD-ase L, II and IV polypeptides, cDNAs,  
 CC antisense nucleic acids, vectors, host cells, transgenic organisms,  
 CC antagonists and agonists. These are useful for treating neural disorders  
 CC such as Alzheimer's disease, schizophrenia, ALS, Parkinson's disease,  
 CC peripheral neuropathy, Huntington's disease, acute brain injury, multiple  
 CC sclerosis, exposure to neurotoxins, peripheral nerve trauma, ischaemia or  
 CC dementia  
 XX  
 XX Sequence 24 BP; 5 A; 5 C; 7 G; 7 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.3%; Score 24; DB 1; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 4;  
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1414 CCATGACTGTCATGATCCAAAGC 1437  
 DB 24 CCATGACTGTCATGATCCAAAGC 1  
 |||||  
 RESULT 7  
 ABA01588  
 ID ABA01588 standard; DNA; 24 BP.  
 XX  
 AC ABA01588;  
 XX  
 XX 31-JAN-2002 (first entry)  
 DT  
 XX Human neuroproteins Y 11 PCR primer 2 SEQ ID NO:4.  
 DE  
 XX Human; neuroproteins Y 11; cytostatic; virucidal; immunomodulatory;  
 KW anti-inflammatory; haemostatic; cardiant; gene therapy; diagnosis;  
 KW malignant tumour; haemopathy; human immunodeficiency virus;  
 KW HIV infection; immunological disease; inflammation; angiocardopathy;  
 KW developmental disorder; PCR primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200175020-A2.  
 XX  
 XX 11-OCT-2001.  
 PD  
 XX 19-MAR-2001; 2001WO-CN000358.  
 PF  
 XX 22-MAR-2000; 2000CN-00115045.  
 PR  
 XX (BIOW-) BLOWDOWN GENE DEV INC SHANGHAI.  
 PA  
 XX Mao Y, Xie Y;  
 PI  
 XX WPI; 2002-025842/03.  
 DR  
 XX Human neuroproteins Y 11 and encoded polynucleotide, used in diagnosis and  
 PT treatment of malignant tumors, hemopathy, human immunodeficiency virus  
 PT infection, immunological diseases and inflammation.  
 PT  
 XX Example 2; Page 12; 33pp; Chinese.  
 PS  
 XX The present invention describes the human neuroproteins Y 11 protein.  
 CC Human neuroproteins Y 11 has cytostatic, virucidal, immunomodulatory,  
 CC anti-inflammatory, haemostatic and cardiant activities and can be used in  
 CC gene therapy. The human neuroproteins Y 11 protein and its encoding

CC polynucleotide can be used in the diagnosis and treatment of malignant  
 CC tumour, haemopathy, human immunodeficiency virus (HIV) infection,  
 CC immunological diseases, various inflammations, angiocardopathy and  
 CC developmental disorders. The present sequence represents a PCR primer for  
 CC human neuroprotein Y 11 which is used in an example from the present  
 CC invention  
 XX  
 XX Sequence 24 BP; 0 A; 4 C; 9 G; 11 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.0%; Score 19.2; DB 1; Length 24;  
 Best Local Similarity 87.5%; Pred. No. 30;  
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1446 GTTGCTGCTGCTGTTGGGCTGTT 1469  
 DB 1 GTTGCTGCTGCTGTTGGGCTGTT 24  
 |||||  
 RESULT 8  
 ABL55122  
 ID ABL55122 standard; DNA; 24 BP.  
 XX  
 AC ABL55122;  
 XX  
 XX 31-MAY-2002 (first entry)  
 DT  
 XX Human Myb protein 32 RT-PCR primer, SEQ ID NO:3.  
 DE  
 XX Human; Myb protein 32; recombinant production; cancer; HIV infection;  
 KW human immunodeficiency virus; gene therapy; cytostatic; anti-HIV;  
 KW reverse transcription-PCR; RT-PCR; primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN CN1325886-A.  
 XX  
 XX 12-DEC-2001.  
 PD  
 XX 26-MAY-2000; 2000CN-00115890.  
 PF  
 XX 26-MAY-2000; 2000CN-00115890.  
 PR  
 XX (BODE-) BODE GENE DEV CO LTD SHANGHAI.  
 PA  
 XX Mao Y, Xie Y;  
 PI  
 XX WPI; 2002-196654/26.  
 DR  
 XX Polypeptide-human Myb protein 32 and polynucleotide for coding it, useful  
 PT for treating cancer, and HIV infection.  
 PT  
 XX Example 2; Page 17 (Disclosure); 33pp; Chinese.  
 PS  
 XX The invention relates to human Myb protein 32 (AAM49156) and to nucleic  
 CC acids encoding it (ABL55121). The protein has a molecular weight of 32  
 CC kD. The invention also relates to a method for the recombinant production  
 CC of the protein, an antagonist of the protein, and the use of the protein,  
 CC gene and antagonist in therapeutic applications. Myb protein 32 can be  
 CC used in the treatment of a variety of diseases such as cancer and HIV  
 CC (human immunodeficiency virus) infection. Sequences ABL55122-ABL55123  
 CC represent reverse transcription-PCR (RT-PCR) primers used in an  
 CC exemplification of the invention to isolate human Myb protein 32 cDNA  
 XX  
 XX Sequence 24 BP; 2 A; 12 C; 9 G; 1 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.0%; Score 19.2; DB 1; Length 24;  
 Best Local Similarity 87.5%; Pred. No. 30;  
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 25 GGAGCCGCTTCGTCGCCGCCGTC 48  
 DB 1 GGAGCAGCCGCCGCCGCCGTC 24  
 |||||





Qy 1834 GAAAAAAAAAAAAA 1851

```

OS Unidentified.
XX
XX WO2004072302-A1.
XX
XX
XX PD 26-AUG-2004.
XX
XX
XX PF 13-FEB-2004; 2004WO-JP001588.
XX
XX PF 14-FEB-2003; 2003JP-00037212.
XX
XX (PALM-) PALMA BEEZ RES INST CO LTD.
XX
XX PA Usui M, Fujikawa T;
XX
XX WPI; 2004-642306/62.
XX
XX
XX PT Signal amplification method for detecting expressed gene, by using
XX reverse transcription reaction and self-assembly reaction of
XX oligonucleotide probes.
XX
XX PS Disclosure; SEQ ID NO 4; 27pp; Japanese.
XX
XX
XX CC The invention relates to a signal amplification method (M1) for detecting
XX expressed gene using reverse transcription reaction and a self-assembly
XX reaction of forming a self assembly of oligonucleotide probes, thus
XX improving detection sensitivity of the expressed gene in a DNA chip. (M1)
XX is useful for signal amplification method (M1) for detecting expressed
XX gene (claimed). (M1) improves detection sensitivity of the expressed gene
XX in a DNA chip (claimed). (M1) does not require use of expensive enzymes
XX and enables detection corresponding to the original RNA length or
XX expression amount because of using neither linear amplification nor PCR.
XX This sequence corresponds to a nucleotide used in the method of the
XX invention.
XX
XX SQ Sequence 18 BP; 0 A; 0 C; 0 G; 18 T; 0 U; 0 Other;

Query Match 0.9%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 18 AAAAAAAAAAAAAAAAAA 2

RESULT 14
ADR82260/c
ID ADR82260 standard; DNA; 19 BP.
XX
XX AC ADR82260;
XX
XX DT 16-DEC-2004 (first entry)
XX
XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6759.
XX
XX KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX coronary artery disease; CAD; coronary heart disease; CHD;
XX atherosclerosis; hepatic glucose production;
XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX colon cancer; lung cancer; neurological disease; Huntington disease;
XX spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX
XX OS Hepatitis C virus.
XX
XX PN WO2004080406-A2.
XX
XX PD 23-SEP-2004.
XX
XX PF 08-MAR-2004; 2004WO-US007070.
XX
107-MAR-2003; 2003US-0452682P.
12-MAR-2003; 2003US-0454265P.
13-MAR-2003; 2003US-0454962P.
14-APR-2003; 2003US-0455050P.
17-APR-2003; 2003US-0462894P.
25-APR-2003; 2003US-0463772P.
25-APR-2003; 2003US-0465665P.
25-APR-2003; 2003US-0465802P.
09-MAY-2003; 2003US-0469612P.
08-AUG-2003; 2003US-0493986P.
11-AUG-2003; 2003US-0494597P.
26-SEP-2003; 2003US-0506341P.
09-OCT-2003; 2003US-0510246P.
10-OCT-2003; 2003US-0510318P.
07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
XX
XX PI Manoharan M, Bumcrot D;
XX
XX DR WPI; 2004-677362/66.
XX
XX
XX PT Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX PS Example 5; SEQ ID NO 6759; 378pp; English.
XX
XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a hepatitis C virus (HCV) antisense oligonucleotide that can
XX be used to control HCV gene expression.
XX
XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 0.9%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851
Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 15
ADR82257/c
ID ADR82257 standard; DNA; 19 BP.
XX
XX AC ADR82257;

```

XX 16-DEC-2004 (first entry)  
 XX Hepatitis C virus (HCV) oligonucleotide seqid 6756.  
 XX  
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
 KW cytosatic; anticonvulsant; nootropic; muscula; anti-HIV;  
 KW RNA interference; iRNA; antisense technology; lipid metabolism;  
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
 KW coronary artery disease; CAD; coronary heart disease; CHD;  
 KW atherosclerosis; hepatic glucose production;  
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
 KW colon cancer; lung cancer; neurological disease; Huntington disease;  
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
 XX  
 OS Hepatitis C virus.  
 XX  
 XX WO2004080406-A2.  
 XX  
 XX 23-SEP-2004.  
 XX  
 XX 08-MAR-2004; 2004WO-US007070.  
 XX  
 XX 07-MAR-2003; 2003US-0452682P.  
 XX 12-MAR-2003; 2003US-0454265P.  
 XX 13-MAR-2003; 2003US-0454962P.  
 XX 13-MAR-2003; 2003US-0455050P.  
 XX 14-APR-2003; 2003US-0462894P.  
 XX 17-APR-2003; 2003US-0463772P.  
 XX 25-APR-2003; 2003US-0465665P.  
 XX 25-APR-2003; 2003US-0465802P.  
 XX 09-MAY-2003; 2003US-0469612P.  
 XX 08-AUG-2003; 2003US-0493986P.  
 XX 11-AUG-2003; 2003US-0494597P.  
 XX 26-SEP-2003; 2003US-0506341P.  
 XX 09-OCT-2003; 2003US-0510246P.  
 XX 10-OCT-2003; 2003US-0510318P.  
 XX 07-NOV-2003; 2003US-0518453P.  
 XX  
 PA (ALNY-) ALNYLAM PHARM.  
 XX  
 XX Manoharan M, Bumcrot D;  
 XX WPI; 2004-677362/66.  
 XX  
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
 XX disease, diabetes, cancer or neurological disease, comprises sense  
 XX sequence and antisense sequence which has specific modifications.  
 XX  
 XX Example 5; SEQ ID NO 6756; 378pp; English.  
 XX  
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a  
 XX sense sequence and an antisense sequence, where the sense sequences have  
 XX one or more asymmetrical 2'-O alkyl modifications, the antisense  
 XX sequences have one or more asymmetrical phosphorothioate modifications  
 XX and the antisense sequence targets a human gene sequence. Also described  
 XX are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
 XX levels or glucose-6-phosphatase levels in a subject; producing (I);  
 XX stabilising (I), involves selecting a sequence with activity and  
 XX introducing one or more asymmetrical modification in the sequence, where  
 XX the modification decreases nuclease sensitivity while not decreasing its  
 XX activity; a kit comprising (I) and instruction for its use; and a device  
 XX that can be dispense or administer a composition comprising (I). (I) is  
 XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
 XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
 XX The subject is suffering from a disorder characterised by elevated or  
 XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
 XX levels of cholesterol, and/or dysregulation of lipid metabolism. The  
 XX disorder is chosen from the HDL/LDL cholesterol imbalance,  
 XX dyslipidaemias, hypercholesterolaemia, statin-resistant  
 XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
 XX disease (CHD) and atherosclerosis. (I) is administered to a subject to  
 XX inhibit hepatic glucose production or for treating glucose-metabolism-

CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
 CC lung cancer), neurological disease (e.g., Huntington disease or  
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
 CC be used to control HCV gene expression.  
 XX  
 XX Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
 XX  
 XX Query Match 0.9%; Score 17; DB 1; Length 19;  
 XX Best Local Similarity 100.0%; Pred. No. 57;  
 XX Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 XX  
 Qy 1835 AAAAAAAAAAAAAA 1851  
 Db |||||  
 19 AAAAAAAAAAAAAA 3  
 XX  
 XX RESULT 16  
 XX ADR82261/c  
 XX ID ADR82261 standard; DNA; 19 BP.  
 XX  
 XX AC ADR82261;  
 XX  
 XX 16-DEC-2004 (first entry)  
 XX  
 XX Hepatitis C virus (HCV) oligonucleotide seqid 6760.  
 XX  
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
 KW cytosatic; anticonvulsant; nootropic; muscula; anti-HIV;  
 KW RNA interference; iRNA; antisense technology; lipid metabolism;  
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
 KW coronary artery disease; CAD; coronary heart disease; CHD;  
 KW atherosclerosis; hepatic glucose production;  
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
 KW colon cancer; lung cancer; neurological disease; Huntington disease;  
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
 XX  
 OS Hepatitis C virus.  
 XX  
 XX WO2004080406-A2.  
 XX  
 XX 23-SEP-2004.  
 XX  
 XX 08-MAR-2004; 2004WO-US007070.  
 XX  
 XX 07-MAR-2003; 2003US-0452682P.  
 XX 12-MAR-2003; 2003US-0454265P.  
 XX 13-MAR-2003; 2003US-0454962P.  
 XX 13-MAR-2003; 2003US-0454962P.  
 XX 13-MAR-2003; 2003US-0455050P.  
 XX 14-APR-2003; 2003US-0462894P.  
 XX 17-APR-2003; 2003US-0463772P.  
 XX 25-APR-2003; 2003US-0465665P.  
 XX 25-APR-2003; 2003US-0465802P.  
 XX 09-MAY-2003; 2003US-0469612P.  
 XX 08-AUG-2003; 2003US-0493986P.  
 XX 11-AUG-2003; 2003US-0494597P.  
 XX 26-SEP-2003; 2003US-0506341P.  
 XX 09-OCT-2003; 2003US-0510246P.  
 XX 10-OCT-2003; 2003US-0510318P.  
 XX 07-NOV-2003; 2003US-0518453P.  
 XX  
 PA (ALNY-) ALNYLAM PHARM.  
 XX  
 XX Manoharan M, Bumcrot D;  
 XX WPI; 2004-677362/66.  
 XX  
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
 XX disease, diabetes, cancer or neurological disease, comprises sense  
 XX sequence and antisense sequence which has specific modifications.  
 XX  
 XX Example 5; SEQ ID NO 6760; 378pp; English.  
 XX  
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a  
 XX sense sequence and an antisense sequence, where the sense sequences have  
 XX one or more asymmetrical 2'-O alkyl modifications, the antisense  
 XX sequences have one or more asymmetrical phosphorothioate modifications  
 XX and the antisense sequence targets a human gene sequence. Also described  
 XX are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
 XX levels or glucose-6-phosphatase levels in a subject; producing (I);  
 XX stabilising (I), involves selecting a sequence with activity and  
 XX introducing one or more asymmetrical modification in the sequence, where  
 XX the modification decreases nuclease sensitivity while not decreasing its  
 XX activity; a kit comprising (I) and instruction for its use; and a device  
 XX that can be dispense or administer a composition comprising (I). (I) is  
 XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
 XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
 XX The subject is suffering from a disorder characterised by elevated or  
 XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
 XX levels of cholesterol, and/or dysregulation of lipid metabolism. The  
 XX disorder is chosen from the HDL/LDL cholesterol imbalance,  
 XX dyslipidaemias, hypercholesterolaemia, statin-resistant  
 XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
 XX disease (CHD) and atherosclerosis. (I) is administered to a subject to  
 XX inhibit hepatic glucose production or for treating glucose-metabolism-

XX The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 57;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1835 AAAAAAAAAAAAAAAAAA 1851  
DB 19 AAAAAAAAAAAAAAAAAA 3  
  
RESULT 17  
ADR82258/c  
ID ADR82258 standard; DNA; 19 BP.  
XX AC ADR82258;  
XX  
XX 16-DEC-2004 (first entry)  
DE Hepatitis C virus (HCV) oligonucleotide seqid 6757.  
XX  
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
OS Hepatitis C virus.  
XX  
XX WO2004080406-A2.  
XX  
XX 23-SEP-2004.  
XX  
XX 08-MAR-2004; 2004WO-US007070.  
XX  
XX 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.

PR 14-APR-2003; 2003US-0462894P.  
PR 17-APR-2003; 2003US-0463772P.  
PR 25-APR-2003; 2003US-0465665P.  
PR 25-APR-2003; 2003US-0465802P.  
PR 09-MAY-2003; 2003US-0469612P.  
PR 08-AUG-2003; 2003US-0493986P.  
PR 11-AUG-2003; 2003US-0494597P.  
PR 26-SEP-2003; 2003US-0506341P.  
PR 09-OCT-2003; 2003US-0510246P.  
PR 10-OCT-2003; 2003US-0510318P.  
PR 07-NOV-2003; 2003US-0518453P.  
XX (ALNY-) ALNYLAM PHARM.  
XX  
XX Manoharan M, Bumcrot D;  
PI WPI; 2004-677362/66.  
XX  
XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
PT disease, diabetes, cancer or neurological disease, comprises sense  
PT sequence and antisense sequence which has specific modifications.  
XX  
PS Example 5; SEQ ID NO 6757; 378pp; English.  
XX  
XX The invention describes a RNA interference (iRNA) agent (I) comprising a  
CC sense sequence and an antisense sequence, where the sense sequences have  
CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
CC sequences have one or more asymmetrical phosphorothioate modifications  
CC and the antisense sequence targets a human gene sequence. Also described  
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
CC stabilising (I), involves selecting a sequence with activity and  
CC introducing one or more asymmetrical modification in the sequence, where  
CC the modification decreases nuclease sensitivity while not decreasing its  
CC activity; a kit comprising (I) and instruction for its use; and a device  
CC that can be dispense or administer a composition comprising (I). (I) is  
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
CC The subject is suffering from a disorder characterised by elevated or  
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
CC inhibit hepatic glucose production or for treating glucose-metabolism-  
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
CC lung cancer), neurological disease (e.g., Huntington disease or  
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
CC be used to control HCV gene expression.  
XX  
SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 17; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 57;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1835 AAAAAAAAAAAAAAAAAA 1851  
DB 19 AAAAAAAAAAAAAAAAAA 3  
  
RESULT 18  
ADR82256/c  
ID ADR82256 standard; DNA; 19 BP.  
XX AC ADR82256;  
XX  
XX 16-DEC-2004 (first entry)  
DE Hepatitis C virus (HCV) oligonucleotide seqid 6755.  
XX  
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;  
KW RNA interference; iRNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
OS Hepatitis C virus.  
XX  
XX WO2004080406-A2.  
XX  
XX 23-SEP-2004.  
XX  
XX 08-MAR-2004; 2004WO-US007070.  
XX  
XX 07-MAR-2003; 2003US-0452682P.  
PR 12-MAR-2003; 2003US-0454265P.  
PR 13-MAR-2003; 2003US-0454962P.  
PR 13-MAR-2003; 2003US-0455050P.



CC sequences have one or more asymmetrical phosphorothioate modifications  
 CC and the antisense sequence targets a human gene sequence. Also described  
 CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100  
 CC levels or glucose-6-phosphate levels in a subject; producing (I);  
 CC stabilising (I), involves selecting a sequence with activity and  
 CC introducing one or more asymmetrical modification in the sequence, where  
 CC the modification decreases nuclease sensitivity while not decreasing its  
 CC activity; a kit comprising (I) and instruction for its use; and a device  
 CC that can be dispense or administer a composition comprising (I). (I) is  
 CC useful for reducing apoB-100 levels or glucose-6-phosphate levels. (MI)  
 CC is useful for reducing apoB-100 levels or glucose-6-phosphate levels. (MI)  
 CC The subject is suffering from a disorder characterised by elevated or  
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
 CC inhibit hepatic glucose production or for treating glucose-metabolism-  
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
 CC lung cancer), neurological disease (e.g., Huntington disease or  
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
 CC be used to control HCV gene expression.

XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 17; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 57;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
 Db 19 AAAAAAAAAAAAAAAAAA 3

RESULT 20  
 AD69805  
 ID ADR69805 standard; DNA; 20 BP.  
 AC ADR69805;  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Micro-channel molecule isolation related Adenine oligo.  
 XX  
 KW molecule isolation; micro-channel; molecular weight; micro flow path;  
 KW polymer compound; flow behaviour; non turbulent flow; ss.  
 XX Unidentified.  
 OS  
 XX WO2004076038-A1.  
 PN  
 XX 10-SEP-2004.  
 XX  
 PF 18-FEB-2004; 2004WO-JP001814.  
 XX  
 PR 18-FEB-2003; 2003JP-00039870.  
 XX  
 XX (NAAD-) NAT INST ADVANCED IND SCI & TECHNOLOGY.  
 PA  
 PI Yamashita K, Maeda H, Shimizu H, Miyazaki M, Nakamura H;  
 PI Yamaguchi Y;  
 XX  
 XX WPI; 2004-661906/64.  
 XX  
 PT Isolating molecules e.g., DNA, by introducing solution with two types of  
 PT solute molecules into micro flow path to form non turbulent flow,  
 PT providing physical action to molecule causing difference in flow  
 PT behavior, separating molecules.  
 XX  
 XX Example 3; Page 7; 19pp; Japanese.

XX  
 CC The invention relates to a novel method for isolating molecules using a  
 CC micro-channel. The molecules are isolated by introducing a mixed solution  
 CC having two types of solute molecules differing in molecular weight into a  
 CC micro flow path, to form a non turbulent flow, and providing physical  
 CC action to the molecules by changing the flow state, thus causing  
 CC different behaviours among different solute molecules, where the  
 CC different behaviour enables uneven distribution of specific kinds of  
 CC molecules in the flow path, causing separation of the molecules. The  
 CC invention further comprises: molecule separation apparatus, comprising a  
 CC substrate with a micro flow path, having one or more curved portions, a  
 CC sample intake unit at one side and a sample removal opening at the other  
 CC side, and a physical property detection sensor arranged inside the curved  
 CC portion or outside the curved portion. The method is useful for isolating  
 CC molecules, e.g. polymer compounds, DNA or proteins. The method enables  
 CC simple and efficient separation of molecules by utilising specific flow  
 CC behaviour in a non turbulent flow, in a micro flow path, where a large  
 CC number of samples can be processed. This polynucleotide sequence  
 CC represents an oligo used in the exemplification of the invention.

XX SQ Sequence 20 BP; 20 A; 0 C; 0 G; 0 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 17; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 60;  
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAAAAAA 1851  
 Db 1 AAAAAAAAAAAAAAAAAA 17

RESULT 21  
 ADK23158  
 ID ADK23158 standard; DNA; 20 BP.  
 XX  
 AC ADK23158;  
 XX  
 DT 18-NOV-2004 (first entry)  
 XX  
 DE Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #3235.  
 XX  
 KW acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;  
 KW metabolic syndrome X; cardiovascular disorder; cancer; infection;  
 KW inflammation; tumour; antisense; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO2004016749-A2.  
 XX  
 PD 26-FEB-2004.  
 XX  
 PF 14-AUG-2003; 2003WO-US025389.  
 XX  
 PR 14-AUG-2002; 2002US-0403591P.  
 XX  
 XX (PHAA ) PHARMACIA CORP.  
 PA  
 XX Ross SA;  
 PI  
 XX WPI; 2004-203782/19.  
 XX  
 PT New antisense compounds targeted to nucleic acid molecules encoding acyl-  
 PT coenzyme A synthetase 1 (ACS1), useful for treating diseases or  
 PT conditions associated with aberrant expression of ACS1, e.g. diabetes,  
 PT obesity or cancer.  
 XX  
 XX Claim 3; SEQ ID NO 3235; 940pp; English.  
 PS  
 CC The invention relates to an antisense compound targeted to a nucleic acid  
 CC molecule encoding acyl-coenzyme A synthetase 1 (ACS1). The antisense  
 CC compound specifically hybridises with and inhibits the expression of  
 CC ACS1. The antisense oligonucleotides or compounds are useful for  
 CC inhibiting the expression of acyl-coenzyme A synthetase 1 (ACS1), and for

CC treating diseases or conditions associated with aberrant expression of  
CC ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular  
CC disorder or cancer. The antisense compounds are also useful as research  
CC reagents and kits, or in diagnostic, therapeutic and prophylactic  
CC applications, e.g. to prevent or delay infection, inflammation or tumour  
CC formation. The present sequence represents an acyl-coenzyme A synthetase  
CC 1, ACS1, antisense oligonucleotide.

XX Sequence 20 BP; 2 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 85;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1463 GGCTGTTGTTCTTATGTTG 1482

Db 1 GGCTGTTGTTCTGATGATG 20

## RESULT 22

AAV25611/c  
ID AAV25611 standard; DNA; 21 BP.

XX AC AAV25611;

XX DT 16-JUL-1998 (first entry)

XX DE Primer for PTI-1 bridge region.

XX KW PCR primer; bridge region; prostate tumour inducing gene; PCI-1;  
XX KW detection; cancer cell; carcinoma cell; metastatic prostate cancer;  
XX KW late stage prostate cancer; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO9810098-A1.

XX PD 12-MAR-1998.

XX PF 05-SEP-1997; 97WO-US015645.

XX PR 06-SEP-1996; 96US-00708208.

XX PA (UYCO) UNIV COLUMBIA NEW YORK.

XX PI Fisher PB;

XX DR WPI; 1998-193641/17.

XX PT Detection of prostate tumour inducing gene using specific primers -  
XX PT useful for detection of cancer cells.

XX PS Claim 11; Page 32; 43pp; English.

XX CC The present sequence is a primer for the bridge region of the prostate  
XX CC tumour inducing gene, PCI-1. The primer was used in the development of a  
XX CC novel method for the detection of cancer cells, comprising the detection  
XX CC of PCI-1 expression. The method can be used to detect carcinoma cells or  
XX CC prostate, breast, colon or lung cancer cells, and determine whether a  
XX CC subject has metastatic or late stage prostate cancer

XX SQ Sequence 21 BP; 10 A; 7 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 89;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1441 TGAATGTTGCTGCTGCTTT 1460

Db 20 TGATGTTGCTGCTGCTTT 1

## RESULT 23

AAZ69745/c  
ID AAZ69745 standard; DNA; 18 BP.

XX AC AAZ69745;

XX DT 10-SEP-2001 (first entry)

XX DE Human biallelic marker upstream amplification primer SEQ ID NO:4101.

XX KW Human genome; biallelic marker; high density disequilibrium map;  
XX KW genomic map; haplotype; phenotype; polymorphic base; genotyping;  
XX KW haplotyping; hybridisation; identification; characterisation;  
XX KW amplification; single nucleotide polymorphism; SNP; PCR primer;  
XX KW diagnosis; ss.

XX OS Homo sapiens.

XX PN WO9954500-A2.

XX PD 28-OCT-1999.

XX PF 21-APR-1999; 99WO-IB000822.

XX PR 21-APR-1998; 98US-0082614P.

XX PR 23-NOV-1998; 98US-0109732P.

XX PA (GEST) GENSET.

XX PI Cohen D, Blumenfeld M, Chumakov I;

XX DR WPI; 2000-013267/01.

XX PT Novel biallelic markers used to construct a high density disequilibrium  
XX PT map of the human genome.

XX PS Claim 8; Page 1105; 2745pp; English.

XX CC AAZ65654 to AAZ69578 represent human biallelic markers from the present  
XX CC invention, which contain a polymorphic base at position 24 of their  
XX CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification  
XX CC primers for the biallelic markers. The biallelic markers of the invention  
XX CC have a variety of uses: they can be used for high density mapping of the  
XX CC human genome, and in complex association studies and haplotyping studies  
XX CC which are useful in determining the genetic basis for disease states.  
XX CC Compositions and methods of the invention can also be useful for the  
XX CC identification of the targets for the development of pharmaceutical  
XX CC agents and diagnostic methods, as well as the characterisation of the  
XX CC differential efficacious responses to and side effects from  
XX CC pharmaceutical agents acting on a disease as well as other treatment.  
XX CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and  
XX CC 3367, are not actually given a sequence in the Sequence Listing from the  
XX CC present invention

XX SQ Sequence 18 BP; 5 A; 0 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 18;  
Best Local Similarity 94.4%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 730 CCATCTACAGTCTCTCACA 747

Db 18 CCATCTACATTCCTCACA 1

## RESULT 24

AAV01232/c  
ID AAV01232 standard; DNA; 20 BP.

XX AC AAV01232;

XX DT 23-MAR-1998 (first entry)

XX XX

DE Von Willebrand's factor PCR primer for universal mammalian STS's.  
 XX PCR primer; polymerase chain reaction; amplification; UM-STS;  
 KW universal mammalian sequence tagged site; genomic map; clone; ss.  
 XX Synthetic.  
 XX WO9731012-A1.  
 XX 28-AUG-1997.  
 XX 18-FEB-1997; 97WO-US002403.  
 XX 22-FEB-1996; 96US-0012061P.  
 XX (UNMI ) UNIV MICHIGAN.  
 XX (UNMS ) UNIV MICHIGAN STATE.  
 XX Brewer GJ, Venta PJ, Yuzbasiyan-Gurkan V;  
 XX WPI; 1997-435083/40.  
 XX New oligonucleotide primers amplifying gene regions conserved among  
 PT mammals - useful for developing genomic maps, isolating clones and making  
 PT cross-species comparisons.  
 XX Claim 1; Page 11; 26pp; English.  
 XX The present sequence represents a specifically claimed oligonucleotide  
 CC PCR primer. The oligonucleotide can be used for polymerase chain reaction  
 CC (PCR) amplification of DNA, specifically regions of specific genes that  
 CC are conserved among mammalian species, i.e. pairs of oligonucleotides  
 CC from the present specification represent universal mammalian sequence-  
 CC tagged site (UM-STS) primers. The primers are used to develop genomic  
 CC maps, to isolate clones from libraries, to make cross-species comparisons  
 CC and to develop additional genetic markers. UM-STS allow genomic  
 CC comparisons to be made between more species  
 XX Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;  
 SQ Query Match 0.9%; Score 16.4; DB 1; Length 20;  
 Best Local Similarity 94.4%; Pred. No. 77;  
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1333 GGATCCAAAGCTGGAGTCC 1350  
 Db |||||  
 20 GGATTCGAAGCTGGAGTCC 3  
 RESULT 25  
 AAX93746/c  
 ID AAX93746 standard; DNA; 20 BP.  
 XX AC AAX93746;  
 XX 13-SEP-1999 (first entry)  
 XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.  
 XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;  
 KW neutralising epitope; PCR primer; ss.  
 XX Synthetic.  
 OS Chlamydophila pneumoniae.  
 XX WO9927105-A2.  
 XX 03-JUN-1999.  
 XX 20-NOV-1998; 98WO-IB001890.  
 XX 21-NOV-1997; 97FR-00014673.

PR 04-NOV-1998; 98US-0107078P.  
 XX (GEST ) GENSET.  
 PA Griffais R;  
 PI WPI; 1999-357842/30.  
 DR Genome sequence of Chlamydia pneumoniae.  
 XX Page 1615; Disclosure; 1912pp; English.  
 XX AAX91991-X97517 represent PCR primers used to amplify open reading frames  
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae  
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as  
 CC pneumonia and bronchitis and is thought to be a contributing factor in  
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
 CC frames of the C. pneumoniae genome (see AAY34584- AAY35875) can be used  
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
 CC nucleotides sequences can also be used as immunogenic compositions,  
 CC especially where the vector directs the expression of a neutralising  
 CC epitope of C. pneumoniae  
 XX Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;  
 SQ Query Match 0.9%; Score 16.4; DB 1; Length 20;  
 Best Local Similarity 94.4%; Pred. No. 77;  
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1612 TCATCTTCAAGCACAAC 1629  
 Db |||||  
 19 TCATCTTCAAGCAGCAGC 2  
 RESULT 26  
 ADS75311  
 ID ADS75311 standard; DNA; 20 BP.  
 XX AC ADS75311;  
 XX 16-DEC-2004 (first entry)  
 XX PCR primer CCRL2 P1v2 F used to amplify a human CCRL2 DNA SNP region.  
 XX PCR; ss; inflammatory bowel disease; IBD; ulcerative colitis; CCRL2;  
 KW GPCR receptor; chemokine (C-C motif) receptor-like 2; HCR; gene therapy;  
 KW antiinflammatory; primer.  
 XX Homo sapiens.  
 XX WO2004083232-A2.  
 XX 30-SEP-2004.  
 XX 18-MAR-2004; 2004WO-GB001159.  
 XX 20-MAR-2003; 2003GB-00006428.  
 XX (OXAG-) OXAGEN LTD.  
 PA Pettipher R;  
 PI WPI; 2004-728453/71.  
 XX Determining whether an individual is predisposed to inflammatory bowel  
 XX disease (i.e. ulcerative colitis) comprises identifying whether the  
 PT individual has a polymorphism in the CCRL2 polynucleotide or protein.  
 XX Example 2; Page 28; 60pp; English.  
 XX This invention relates to a novel method for determining whether an  
 CC individual is predisposed to inflammatory bowel disease (IBD), preferably



CC to ulcerative colitis. Specifically, it refers to the identification of  
 CC single nucleotide polymorphisms (SNPs) in the CCR12 polynucleotide or  
 CC encoded protein thereof, where CCR12 refers to the GPCR receptor  
 CC chemokine (C-C motif) receptor-like 2 protein that is also known as HCR.  
 CC The present invention describes methods for preventing or treating IBD,  
 CC as well as diagnosing a predisposition to the disease by use of probes,  
 CC primers and antibodies that can detect and amplify the CCR12 SNP regions.  
 CC Furthermore, it provides a screening assay for agents that can be used to  
 CC identify individuals with a genetic predisposition and in turn be used  
 CC for gene therapy purposes. The pharmaceutical compositions derived  
 CC thereof exhibit an antiinflammatory activity. This oligonucleotide  
 CC sequence is a PCR primer used to amplify a human CCR12 DNA SNP region of  
 CC the invention.

XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.4; DB 1; Length 20;  
 Best Local Similarity 94.4%; Pred. No. 77;  
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1411 ACACCATGACTGTCATGG 1428  
 Db 2 ACACCGTACTGTCATGG 19

RESULT 27  
 AAZ44349/C  
 ID AAZ44349 standard; DNA; 21 BP.

XX AAZ44349;

XX 04-APR-2000 (first entry)

XX Protein kinase inhibiting primer #11.

XX Antimicrobial; cytostatic; immunosuppressive; protein kinase;  
 KW prophylactic; therapy; treatment; cancer; autoimmune disease;  
 KW pathogenic microorganism; primer; ss.

XX Unidentified.

XX US5998596-A.

XX 07-DEC-1999.

XX 04-APR-1995; 95US-00416214.

XX 04-APR-1995; 95US-00416214.

XX (USSH ) US DEPT HEALTH & HUMAN SERVICES.

XX Bergan R, Neckers L;

XX WPI; 2000-104623/09.

XX Oligonucleotides inhibiting protein kinase, useful for treating diseases  
 PT such as cancer and autoimmune disease.

XX Example 3; Col 27-28; 26pp; English.

XX This invention describes novel purified aptameric oligonucleotides which  
 CC have antimicrobial, cytostatic and immunosuppressive activity. The  
 CC oligonucleotides are useful for binding to and preventing or inhibiting  
 CC the biological function of a protein kinase or a target molecule and for  
 CC detecting the presence or absence of a target molecule in biological  
 CC samples. The oligonucleotides are also useful for prophylactic and  
 CC therapeutic treatment of diseases such as cancer, autoimmune diseases and  
 CC diseases caused by pathogenic microorganisms. This sequence represents a  
 CC primer used in the method of the invention

XX Sequence 21 BP; 0 A; 7 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.2; DB 1; Length 21;

Best Local Similarity 85.7%; Pred. No. 88;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 28 GCGCCCTCCGTCGCGCGCGTC 48  
 Db 21 GCGCCGCGCGCGCGCGCGCC 1

RESULT 28

AAH76301

ID AAH76301 standard; DNA; 21 BP.

XX AAH76301;

XX 29-OCT-2001 (first entry)

XX Human PPARGamma cDNA amplifying 5' primer.

XX PAX8-PPARGamma; oncogene; cytostatic; PAX8; PPARGamma; cancer;  
 KW follicular carcinoma; PAX8e7-PPARGammae1; human; PCR primer; ss.

XX Homo sapiens.

XX WO200152789-A2.

XX 26-JUL-2001.

XX 18-JAN-2001; 2001WO-US001664.

XX 20-JAN-2000; 2000US-0177109P.

XX 14-AUG-2000; 2000US-0225079P.

XX (BGHM ) BRIGHAM & WOMENS HOSPITAL INC.

XX Kroll TG, Fletcher JA;

XX WPI; 2001-514487/56.

XX New PAX8-PPARc1 oncogene and oncoprotein, useful for detecting and  
 PT treating certain tumors or cancers, e.g. follicular carcinoma.

XX Example; Page 141; 145pp; English.

XX The invention relates to an oncogene designated PAX8-PPARGamma that  
 CC contains a PAX8 coding region fused to PPARGamma coding region. The PAX8  
 CC -PPARGamma polypeptides can be expressed by standard recombinant  
 CC methodology. A PPARGamma ligand or agent is useful for treating a subject  
 CC having a disorder characterized by the presence of a PAX8-PPARGamma,  
 CC where the disorder is cancer, e.g. follicular carcinoma. The PAX8-  
 CC PPARGamma molecules are also useful for providing nucleotide and amino  
 CC acid sequences useful for detecting the above disease. The present  
 CC sequence represents a PCR primer for amplifying PPARGamma cDNA

XX Sequence 21 BP; 7 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 16.2; DB 1; Length 21;  
 Best Local Similarity 85.7%; Pred. No. 88;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 886 ACCAGATGATGATTCCTTCA 906  
 Db 1 ACCAGAGAAGCGATTCCTTCA 21

RESULT 29

ABK99279

ID ABK99279 standard; RNA; 21 BP.

XX ABK99279;

XX 21-OCT-2002 (first entry)

XX Hepatitis C virus (HCV) NS5B replicase RNA synthesis template #9.

XX Hepatitis C virus; HCV; NS5B replicase; ss; RNA polymerase.  
KW Synthetic.  
XX  
XX US2002064771-A1.  
XX  
XX 30-MAY-2002.  
XX  
XX 06-APR-2001; 2001US-00828034.  
XX  
XX 07-APR-2000; 2000US-0195852P.  
XX  
XX (ZHONG/) ZHONG W.  
PA (HONG/) HONG Z.  
PA (FERRARI/) FERRARI E.  
XX  
XX Zhong W, Hong Z, Ferrari E;  
XX WPI; 2002-582330/62.  
XX  
XX Novel replicase complex comprising hepatitis C virus NS5B replicase, a 3'  
PT nucleotide-long template to which a 2 nucleotide-long primer is annealed,  
PT and template and primer which do not form a stable duplex in the absence  
PT of HCV NS5B.  
XX  
XX Example; Page 6; 17pp; English.  
XX  
XX The invention relates to a replicase complex comprising a hepatitis C  
CC virus (HCV) NS5B replicase protein, a linear nucleic acid template and a  
CC complementary nucleic acid primer which is annealed to the 3' terminus of  
CC the template, where the template is at least three nucleotides and the  
CC primer is two or three nucleotides, and the template and primer do not  
CC form a stable duplex in solution in the absence of the HCV NS5B protein.  
CC The complex is useful for detecting HCV replicase activity and permits  
CC establishment of sensitive RNA-dependent RNA polymerase assays to screen  
CC and evaluate antiviral inhibitors and to improve the specificity and  
CC efficacy of the inhibitors. The complex is also useful in the development  
CC of a reliable system for determining kinetic and thermodynamic constants  
CC of HCV NS5B-catalysed nucleotide incorporation and investigation of  
CC mechanistic inhibitors for mis-incorporation or chain termination.  
CC Specifically, the short RNA template and primer pairs are useful in  
CC screening assays which are used for determining kinetic, thermodynamic  
CC and mechanistic properties of NS5B replication and ultimately in the  
CC development of inhibitors of NS5B. Newly identified inhibitors of  
CC replicase activity may be used for developing anti-HCV pharmaceuticals.  
CC Sequences ABK99271-ABK99296 represent HCV NS5B replicase RNA synthesis  
CC templates  
XX  
XX Sequence 21 BP; 0 A; 14 C; 7 G; 0 T; 0 U; 0 Other;  
SQ  
Query Match 0.94; Score 16.2; DB 1; Length 21;  
Best Local Similarity 85.74; Pred. No. 88;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
Qy 28 GCGGCTTCGTCGCGCGCTC 48  
Db 1 GCGGCGCGCGCGCGCGCC 21  
RESULT 30  
AD117592  
ID AD117592 standard; DNA; 21 BP.  
XX  
XX AD117592;  
XX  
XX 15-APR-2004 (first entry)  
DT  
DE Reverse PCR primer used to amplify human NOVX DNA SeqID1128.  
XX  
XX PCR; ss; NOVX; metabolic disorder; diabetes; anorexia; cancer;  
KW cardiovascular; infectious; neurodegenerative; immune;  
KW haematopoietic disease; dyslipidaemia; anorectic; virucide; nootropic;

antiinflammatory; neuroprotective; antilipaeamic; anabolic; cardiant;  
KW neurogenesis; wound healing; angiogenesis; chromosome mapping;  
KW tissue typing; preventive medicine; pharmacogenomic; primer; human.  
XX  
XX Homo sapiens.  
XX WO200268649-A2.  
XX  
XX 06-SEP-2002.  
XX  
XX 31-JAN-2002; 2002WO-US002785.  
XX  
XX 31-JAN-2001; 2001US-0265395P.  
XX 31-JAN-2001; 2001US-0265412P.  
XX 31-JAN-2001; 2001US-0265514P.  
XX 31-JAN-2001; 2001US-0265517P.  
XX 02-FEB-2001; 2001US-0266406P.  
XX 05-FEB-2001; 2001US-0266767P.  
XX 07-FEB-2001; 2001US-0266975P.  
XX 07-FEB-2001; 2001US-0267057P.  
XX 08-FEB-2001; 2001US-0267459P.  
XX 09-FEB-2001; 2001US-0267823P.  
XX 15-FEB-2001; 2001US-0268974P.  
XX 26-FEB-2001; 2001US-0271664P.  
XX 27-FEB-2001; 2001US-0271839P.  
XX 27-FEB-2001; 2001US-0271855P.  
XX 02-MAR-2001; 2001US-0272788P.  
XX 02-MAR-2001; 2001US-0273046P.  
XX 14-MAR-2001; 2001US-0275925P.  
XX 14-MAR-2001; 2001US-0275947P.  
XX 14-MAR-2001; 2001US-0275950P.  
XX 14-MAR-2001; 2001US-0275989P.  
XX 15-MAR-2001; 2001US-0276448P.  
XX 16-MAR-2001; 2001US-0276450P.  
XX 16-MAR-2001; 2001US-0276397P.  
XX 16-MAR-2001; 2001US-0276768P.  
XX 20-MAR-2001; 2001US-0278652P.  
XX 26-MAR-2001; 2001US-0278775P.  
XX 26-MAR-2001; 2001US-0278778P.  
XX 29-MAR-2001; 2001US-0279882P.  
XX 29-MAR-2001; 2001US-0279884P.  
XX 30-MAR-2001; 2001US-0280147P.  
XX 11-APR-2001; 2001US-0282992P.  
XX 11-APR-2001; 2001US-0283083P.  
XX 20-APR-2001; 2001US-0285133P.  
XX 23-APR-2001; 2001US-0285749P.  
XX 03-MAY-2001; 2001US-0288327P.  
XX 03-MAY-2001; 2001US-0288504P.  
XX 29-MAY-2001; 2001US-0294047P.  
XX 30-MAY-2001; 2001US-0294473P.  
XX 08-JUN-2001; 2001US-0296864P.  
XX 18-JUN-2001; 2001US-0298959P.  
XX 19-JUN-2001; 2001US-0299324P.  
XX 13-AUG-2001; 2001US-0312020P.  
XX 16-AUG-2001; 2001US-0312889P.  
XX 16-AUG-2001; 2001US-0312908P.  
XX 21-AUG-2001; 2001US-0313390P.  
XX 28-AUG-2001; 2001US-0315470P.  
XX 31-AUG-2001; 2001US-0316447P.  
XX 07-SEP-2001; 2001US-0318115P.  
XX 07-SEP-2001; 2001US-0318118P.  
XX 12-SEP-2001; 2001US-0318740P.  
XX 19-SEP-2001; 2001US-0323379P.  
XX 18-OCT-2001; 2001US-0330245P.  
XX 18-OCT-2001; 2001US-0330308P.  
XX 14-NOV-2001; 2001US-0332701P.  
XX  
XX (CURA-) CURAGEN CORP.  
XX  
XX Tchernev VT, Spytek KA, Zerhusen BD, Patturajan M, Shimkets RA;  
PI Li L, Gangolli EA, Padigar M, Anderson DM, Rastelli L, Miller CE;  
PI Gerlach VL, Taupier RJ, Gusev VY, Colman SD, Wolenc AR, Pena CEA;  
PI Furtak K, Grosse WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CE;

XX WPI; 2002-706998/76.  
 XX New NOVX polypeptides and nucleic acids, useful for preventing or  
 PT treating NOVX-associated disorders, e.g. cancer, cardiomyopathy, atherosclerosis, or diabetes, and in chromosome mapping, tissue typing or  
 PT pharmacogenomics.  
 XX  
 PS Example 2; SEQ ID NO 1128; 1498pp; English.  
 XX  
 CC This invention relates to a novel nucleic acids, and encoded polypeptides  
 CC thereof, which have properties related to the stimulation of biochemical  
 CC or physiological responses in a cell, tissue, organ or organism.  
 CC Specifically, it refers to the use of biologically active fragments for  
 CC diagnostic and prognostic assays and furthermore in the treatment of  
 CC diverse pathological conditions. The present invention describes novel  
 CC human and murine NOVX proteins, as well as methods to modulate their  
 CC expression using antisense oligos, ribozymes and peptide nucleic acids.  
 CC The polypeptides, nucleic acid molecules and antibodies are useful in the  
 CC manufacture of a medicament for treating metabolic disorders, diabetes,  
 CC anorexia, cancer, cardiovascular, infectious, neurodegenerative, immune  
 CC and haematopoietic diseases as well as various dyslipidaemias.  
 CC Accordingly, these molecules have many activities including anorectic,  
 CC virucide, nootropic, antiinflammatory, neuroprotective, antilipaeamic,  
 CC anabolic and cardiatic. Furthermore, they are useful in screening assays  
 CC to identify small molecules that modulate or inhibit, for example,  
 CC neurogenesis, wound healing and angiogenesis. The nucleic acids are also  
 CC used as in chromosome mapping, tissue typing, preventive medicine and  
 CC pharmacogenomics. This oligonucleotide is a PCR primer used to amplify  
 CC human NOVX DNA of the invention.  
 XX  
 SQ Sequence 21 BP; 2 A; 4 C; 6 G; 9 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 16.2; DB 1; Length 21;  
 Best Local Similarity 85.7%; Pred. No. 88;  
 Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Oy 1441 TGAATGTTGCTGCTGCTGTTT 1461  
 |||||  
 Db 1 TGGATGTTGCTGCTACTGCTCT 21  
 |||||  
 RESULT 31  
 ADN42680  
 ID ADN42680 standard; DNA; 21 BP.  
 XX  
 AC ADN42680;  
 XX  
 DT 17-JUN-2004 (first entry)  
 XX  
 DE Human NOV37 RTQ-PCR reverse primer #6.  
 XX  
 KW Human; sg; NOVX; cancer; diabetes; cardiomyopathy; atherosclerosis; PCR;  
 KW primer; RTQ PCR; real time quantitative PCR.  
 XX  
 OS Homo sapiens.  
 XX  
 XN US2004033493-A1.  
 XX  
 PD 19-FEB-2004.  
 XX  
 PF 31-JAN-2002; 2002US-00072012.  
 XX  
 PR 31-JAN-2001; 2001US-0265395P.  
 PR 31-JAN-2001; 2001US-0265412P.  
 PR 31-JAN-2001; 2001US-0265514P.  
 PR 31-JAN-2001; 2001US-0265517P.  
 PR 02-FEB-2001; 2001US-0266406P.  
 PR 05-FEB-2001; 2001US-0266767P.  
 PR 07-FEB-2001; 2001US-0266975P.  
 PR 07-FEB-2001; 2001US-0267057P.  
 PR 08-FEB-2001; 2001US-0267459P.  
 PR 09-FEB-2001; 2001US-0267823P.

PR 15-FEB-2001; 2001US-0268974P.  
 PR 26-FEB-2001; 2001US-0271664P.  
 PR 27-FEB-2001; 2001US-0271839P.  
 PR 27-FEB-2001; 2001US-0271855P.  
 PR 02-MAR-2001; 2001US-0272788P.  
 PR 02-MAR-2001; 2001US-0273046P.  
 PR 14-MAR-2001; 2001US-0275925P.  
 PR 14-MAR-2001; 2001US-0275947P.  
 PR 14-MAR-2001; 2001US-0275950P.  
 PR 14-MAR-2001; 2001US-0275989P.  
 PR 15-MAR-2001; 2001US-0276448P.  
 PR 15-MAR-2001; 2001US-0276450P.  
 PR 16-MAR-2001; 2001US-0276397P.  
 PR 16-MAR-2001; 2001US-0276768P.  
 PR 20-MAR-2001; 2001US-0278652P.  
 PR 26-MAR-2001; 2001US-0278775P.  
 PR 26-MAR-2001; 2001US-0278778P.  
 PR 29-MAR-2001; 2001US-0279882P.  
 PR 29-MAR-2001; 2001US-0279884P.  
 PR 30-MAR-2001; 2001US-0280147P.  
 PR 11-APR-2001; 2001US-0282992P.  
 PR 11-APR-2001; 2001US-0283083P.  
 PR 20-APR-2001; 2001US-0285133P.  
 PR 23-APR-2001; 2001US-0285749P.  
 PR 03-MAY-2001; 2001US-0288327P.  
 PR 03-MAY-2001; 2001US-0288504P.  
 PR 29-MAY-2001; 2001US-0294047P.  
 PR 30-MAY-2001; 2001US-0294473P.  
 PR 08-JUN-2001; 2001US-0296964P.  
 PR 18-JUN-2001; 2001US-0298959P.  
 PR 19-JUN-2001; 2001US-0299324P.  
 PR 13-AUG-2001; 2001US-0312020P.  
 PR 16-AUG-2001; 2001US-0312889P.  
 PR 16-AUG-2001; 2001US-0312908P.  
 PR 21-AUG-2001; 2001US-0313930P.  
 PR 28-AUG-2001; 2001US-0315470P.  
 PR 31-AUG-2001; 2001US-0316447P.  
 PR 07-SEP-2001; 2001US-0318115P.  
 PR 07-SEP-2001; 2001US-0318118P.  
 PR 12-SEP-2001; 2001US-0318740P.  
 PR 18-SEP-2001; 2001US-0323379P.  
 PR 18-OCT-2001; 2001US-0330245P.  
 PR 18-OCT-2001; 2001US-0330308P.  
 PR 14-NOV-2001; 2001US-0332701P.  
 XX  
 XX (TCHE/) TCHERNEV V T.  
 PA (SPYT/) SPYTEK K A.  
 PA (ZERH/) ZERHUSEN B D.  
 PA (PATT/) PATTURAJAN M.  
 PA (SHIM/) SHINKETS R A.  
 PA (LILL/) LI L.  
 PA (GANG/) GANGOLLI E A.  
 PA (PADI/) PADIGARU M.  
 PA (ANDE/) ANDERSON D W.  
 PA (RAST/) RASTELLI L.  
 PA (MILL/) MILLER C E.  
 PA (GERL/) GERLACH V.  
 PA (TAUP/) TAUPIER R J.  
 PA (GUSE/) GUSEV V Y.  
 PA (COLM/) COLMAN S D.  
 PA (WOLE/) WOLENC A R.  
 PA (PENA/) PENNA C E A.  
 PA (FURT/) FURTAK K.  
 PA (GROS/) GROSSE W M.  
 PA (ALSO/) ALSOBROOK J P.  
 PA (LEPL/) LEPLY D M.  
 PA (RIEG/) RIEGER D K.  
 PA (BURG/) BURGESS C E.  
 XX  
 PI Tchernev VT, Spytek KA, Zerhusen BD, Patturajan M, Shinkets RA;  
 PI Li L, Gangolli EA, Padigar M, Anderson DW, Rastelli L, Miller CE;  
 PI Gerlach V, Taupier RJ, Colman SD, Wolenc AR, Pena CEA;  
 PI Furtak K, Grosse WM, Alsobrook JP, Lepley DM, Rieger DK, Burgess CE;

```

XX DR WPI; 2004-180039/17.
XX
XX PT Isolated NOVX polypeptides and polynucleotides, useful for preventing
XX PT diagnosing and/or treating cancer, diabetes, cardiomyopathy and
XX PT atherosclerosis.
XX
XX PS Example 2; SEQ ID NO 1128; 1309pp; English.
XX
XX CC The invention relates isolated 162 NOVX polypeptides (NOV1-NOV99,
XX CC including splice variants) and the nucleic acids (NA) that encode them.
XX CC Also included are the mature NOVX proteins (NA) and their encoding
XX CC polynucleotides), a vector comprising NOVX NA, a cell comprising the
XX CC vector, an antibody that binds immunospecifically to NOVX, determining
XX CC the presence or amount of NOVX in a sample, determining the presence or
XX CC amount of NOVX NA in a sample, identifying an agent that binds to NOVX,
XX CC modulating the activity of NOVX, treating or preventing a NOVX-associated
XX CC disorder, determining the presence of or predisposition to a disease
XX CC associated with altered levels of NOVX and treating a pathological state
XX CC in a mammal comprising administering a polypeptide which is at least 95%
XX CC identical to NOVX (or fragment). NOVX and NA may be used in the
XX CC prevention, treatment and diagnosis of diseases associated with
XX CC inappropriate expression and activity of NOVX (e.g. cancer, diabetes,
XX CC cardiomyopathy and/or atherosclerosis). The anti-NOVX antibodies and
XX CC antagonists may also be used to down regulate expression and activity of
XX CC NOVX. The anti-NOVX antibodies may also be used as diagnostic agents for
XX CC detecting the presence of NOVX in samples (e.g. by enzyme linked
XX CC immunosorbant assay (ELISA). The agents and methods may be used in this
XX CC way to prevent, diagnose and treat cancer, diabetes, cardiomyopathy
XX CC and/or atherosclerosis. The present sequence is a real time quantitative
XX CC PCR (RTQ PCR) primer for tissue specific expression studies for a NOVX
XX CC gene.
XX
XX SQ Sequence 21 BP; 2 A; 4 C; 6 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 88;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1441 TGAATGTTGCTGCTGCTGTTT 1461
Db 1 TGGATGTTGCTGCTACTGCTCT 21
|||||
|||||

RESULT 32
ADS82520/c
ID ADS82520 standard; DNA; 21 BP.
XX
XX AC ADS82520;
XX
XX DT 16-DEC-2004 (first entry)
XX
XX DE RT-PCR primer for detection of human MLC-2v expression.
XX
XX KW Cardiomyocyte; embryonic stem cell; differentiation; cell therapy;
XX KW gene therapy; myocardial infarction model; cardiant; human; MLC-2v;
XX KW reverse transcription-PCR; RT-PCR; primer; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2004081205-A1.
XX
XX PD 23-SEP-2004.
XX
XX PF 11-MAR-2004; 2004WO-AU000302.
XX
XX PR 11-MAR-2003; 2003AU-00901099.
XX
XX PA (ESCE-) ES CELL INT PTE LTD.
XX PA (NEON-) NETHERLANDS INST ONTWIKKELINGSBIOLOGIE.
XX PA (IPOR-) IP ORGANISERS PTY LTD.
XX
XX PI Mummery CL, Doeveandans PAFM, Tertoolen LGJ;

```

---

```

XX DR WPI; 2004-677542/66.
XX
XX PT Inducing cardiomyocyte differentiation of a human embryonic stem (hES)
XX PT cell, useful for restoring cardiac function, comprises co-culturing the
XX PT hES cell with a cell excreting cardiomyocyte differentiation inducing
XX PT factor.
XX
XX PS Disclosure; SEQ ID NO 7; 46pp; English.
XX
XX CC The invention provides a method for inducing the differentiation of human
XX CC embryonic stem (hES) cells to cardiomyocytes. It involves co-culturing
XX CC the hES cells with a cell excreting at least one cardiomyocyte
XX CC differentiation-inducing factor, or with an extracellular medium, under
XX CC conditions that induce differentiation. A suitable cell line for the co-
XX CC culture is the mouse visceral-endoderm-like END-2 cell line or the HepG2
XX CC liver parenchymal cell line. Treating or preventing a cardiac disease or
XX CC condition comprises introducing an isolated differentiated cardiomyocyte
XX CC and/or a cell capable of differentiating into a cardiomyocyte cell when
XX CC treated, into a cardiac tissue of a subject. The isolated cardiomyocyte
XX CC is transplanted into damaged cardiac tissue of a subject for restoration
XX CC of cardiac function. The differentiated cardiomyocyte resembles a human
XX CC foetal ventricular, atrial cell or pacemaker cell in culture. The
XX CC cardiomyocytes provide a myocardial infarction model for the study of
XX CC human cardiac disease and for testing the ability to restore cardiac
XX CC function. They can also be used for testing drugs, for transplantation,
XX CC cell therapy or gene therapy. The method was demonstrated by determining
XX CC the expression of cardiac-specific ion channels and stem cell or
XX CC sarcomere markers in undifferentiated hES cells and in differentiating
XX CC cells 8 and 15 days after initiation of co-culture with END-2 cells. The
XX CC present sequence is that of an RT-PCR (reverse transcription-PCR) primer
XX CC for MLC-2v. MLC-2v expression became detectable by RT-PCR during the
XX CC course of the co-culture. Transcripts for MLC-2v were also detected in
XX CC non-beating, myocyte-like areas.
XX
XX SQ Sequence 21 BP; 4 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.9%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 88;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1106 AGAACAAAGGTGGAGTTGGTGC 1126
Db 21 AGAACACGTTGGAGTTGGCGC 1
|||||
|||||

RESULT 33
AAA82893/c
ID AAA82893 standard; DNA; 19 BP.
XX
XX AC AAA82893;
XX
XX DT 04-DEC-2000 (first entry)
XX
XX DE cdk4 ribozyme binding site #74.
XX
XX KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX
XX OS Mammalia.
XX
XX PN WO200032765-A2.
XX
XX PD 08-JUN-2000.
XX
XX PF 06-DEC-1999; 99WO-US028772.
XX
XX PR 04-DEC-1998; 98US-0110954P.
XX
XX PA (IMMU-) IMMUSOL INC.
XX
XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.

```

XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
PT PCNA and Cyclin B1.  
XX  
XX Disclosure; Page 53; 109pp; English.  
XX  
XX The present invention relates to a hairpin or hammerhead ribozyme,  
CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
CC Representative examples of ribozyme recognition sites are given in  
CC AA02415 to AA086787. The ribozyme of the invention is useful for  
CC inhibiting restenosis by introduction of the ribozyme into cells. The  
CC ribozyme is resistant to endonuclease activity and hence is efficient in  
CC restenosis treatment  
XX  
XX Sequence 19 BP; 4 A; 5 C; 4 G; 6 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 16; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 85;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1095 TGGACTGCAGAGAAC 1110  
Db 19 TGGACTGCAGAGAAC 4  
RESULT 34  
AAH58055/c  
ID AAH58055 standard; DNA; 19 BP.  
XX  
XX AC AAH58055;  
XX  
XX DT 10-SEP-2001 (first entry)  
XX  
XX DE Cell-cycle dependent kinase cdk4 ribozyme binding site SEQ ID NO:479.  
XX  
XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
KW recognition site; target; ribozyme binding site; eye disease; vulnary;  
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;  
KW antisticking; ophthalmological; keratolytic; gene therapy; viral wart;  
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
KW sickle cell retinopathy; ss.  
XX  
XX OS Homo sapiens.  
XX OS Synthetic.  
XX  
XX PN WO200130362-A2.  
XX  
XX PD 03-MAY-2001.  
XX  
XX PF 26-OCT-2000; 2000WO-US029500.  
XX  
XX PF 26-OCT-1999; 99US-0161532P.  
XX  
XX PF (IMMU-) IMMUSOL INC.  
XX  
XX PF Robbins JM, Tritz R;  
XX  
XX PF WPI; 2001-300427/31.  
XX  
XX PF Treating proliferative skin or eye diseases and scarring, using ribozymes  
PT that cleave RNA encoding cytokines involved in inflammation, matrix  
PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
XX  
XX PS Example 1; Page 106; 408pp; English.  
XX  
XX The present invention describes a method for treating a proliferative  
CC skin or eye disease and scarring. The method involves administering a

CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
CC dependent kinase, growth factor or a reductase, or administering a  
CC nucleic acid molecule (II) comprising a promoter operably linked to a  
CC nucleic acid segment encoding (I). (I) can have antiproliferative,  
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisticking,  
CC ophthalmological, vulnary, keratolytic and virucide activities, and  
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
CC also be used for treating proliferative eye diseases such as diabetic  
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
CC prematurity and retinal detachment, and for treating and preventing  
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
CC scar. AAH57577 to AAH62099 represent sequences used in the  
CC exemplification of the present invention  
XX  
XX Sequence 19 BP; 4 A; 5 C; 4 G; 6 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 16; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 85;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1095 TGGACTGCAGAGAAC 1110  
Db 19 TGGACTGCAGAGAAC 4  
RESULT 35  
ADR81681/c  
ID ADR81681 standard; DNA; 19 BP.  
XX  
XX AC ADR81681;  
XX  
XX DT 16-DEC-2004 (first entry)  
XX  
XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6180.  
XX  
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
KW cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;  
KW RNA interference; RNA; antisense technology; lipid metabolism;  
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
KW coronary artery disease; CAD; coronary heart disease; CHD;  
KW atherosclerosis; hepatic glucose production;  
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
KW colon cancer; lung cancer; neurological disease; Huntington disease;  
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.  
XX  
XX OS Hepatitis C virus.  
XX  
XX PN WO2004080406-A2.  
XX  
XX PD 23-SEP-2004.  
XX  
XX PF 08-MAR-2004; 2004WO-US007070.  
XX  
XX PF 07-MAR-2003; 2003US-0452682P.  
XX  
XX PF 12-MAR-2003; 2003US-0454265P.  
XX  
XX PF 13-MAR-2003; 2003US-0454962P.  
XX  
XX PF 14-APR-2003; 2003US-0455050P.  
XX  
XX PF 17-APR-2003; 2003US-0462894P.  
XX  
XX PF 25-APR-2003; 2003US-0463772P.  
XX  
XX PF 25-APR-2003; 2003US-0465665P.  
XX  
XX PF 25-APR-2003; 2003US-0465802P.  
XX  
XX PF 09-MAY-2003; 2003US-0469612P.  
XX  
XX PF 08-AUG-2003; 2003US-0493986P.  
XX  
XX PF 11-AUG-2003; 2003US-0494597P.  
XX  
XX PF 26-SEP-2003; 2003US-0506341P.  
XX  
XX PF 09-OCT-2003; 2003US-0510246P.  
XX  
XX PF 10-OCT-2003; 2003US-0510318P.  
XX  
XX PF 07-NOV-2003; 2003US-0518453P.  
XX

```

PA (ALNY-) ALNYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
XX WPI; 2004-677362/66.
XX
DR Interference RNA agent useful for treating dyalipidemiae, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sense and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 6180; 378bp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
CC be used to control HCV gene expression.
XX
XX Sequence 19 BP; 0 A; 0 C; 2 G; 17 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1850
DB 19 AAAAAAAAAAAAAA 4

RESULT 36
AAZ22510
ID AAZ22510 standard; DNA; 19 BP.
XX
AC AAZ22510;
XX
XX 02-DEC-1999 (first entry)
DT
DE
DE Primer BRL367.
XX
XX Internal Transcribed Spacer; ITS; fungus; yeast; fermentation; assay;
KW PCR; microorganism; wine-making; commercial; primer; ss.
XX
XX Synthetic.
OS Dekkera sp.
XX
XX WO9946405-A1.
PN
XX
XX 16-SEP-1999.
PD
XX
XX 11-MAR-1999; 99WO-US004251.
PF

11-MAR-1998; 98US-00037990.
(GALL-) GALLO WINERY E & J.
Engel SR, Descenzo RA, Morenzoni RA, Ireian NA;
WPI; 1999-551425/46.
New isolated fungal and yeast nucleic acids, used for identifying
different fermentation-related microorganisms, particularly in wine
fermentation cultures.
Claim 5; Page 46; 52pp; English.
This is one of the primers, used to identify Dekkera sp. This invention
is directed to the identification of different fermentation-related
microorganisms, particularly those involved in the production of wine.
The invention utilizes a polymerase chain reaction (PCR) based diagnostic
assay of DNA sequences located in the Internal Transcribed Spacer (ITS)
region of the ribosomal RNA gene. Ribosomal genes are suitable for use as
molecular probe targets because of their high copy number. Non
transcribed and transcribed spacer sequences associated with ribosomal
genes are usually poorly conserved and, thus, are advantageously used as
target sequences for the detection of recent evolutionary divergence.
Fungal rRNA genes are organized in units. Each unit encodes mature
subunits of 18S, 5.8S and 28S rRNA. The ITS region lies between the 18S
and 28S rRNA genes and contains two variable non-coding spacers (ITS1 and
ITS2) and the 5.8S rRNA gene
Sequence 19 BP; 5 A; 8 C; 0 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 92;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1696 AATCATTTCCCTCCCTC 1714
DB 1 AATCATTTCCCTCCCTC 19

RESULT 37
AAA85465/c
ID AAA85465 standard; DNA; 19 BP.
XX
AC AAA85465;
XX
XX 04-DEC-2000 (first entry)
DT
DE
DE Cyclin A1 ribozyme binding site #87.
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
OS Mammalia.
XX
XX WO200032765-A2.
PN
XX
XX 08-JUN-2000.
PD
XX
XX 06-DEC-1999; 99WO-US028772.
PF
XX
XX 04-DEC-1998; 98US-0110954P.
PR
XX
XX (IMMU-) IMMUSOL INC.
PA
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
PI
XX
XX WPI; 2000-412314/35.
DR
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
PT PCNA and Cyclin B1.
PT
XX

```

PS Disclosure; Page 92; 109pp; English.

XX The present invention relates to a hairpin or hammerhead ribozyme, designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

CC Representative examples of ribozyme recognition sites are given in AA82415 to AA86787. The ribozyme of the invention is useful for inhibiting restenosis by introduction of the ribozyme into cells. The ribozyme is resistant to endonuclease activity and hence is efficient in restenosis treatment

XX Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

SQ Query Match 0.9%; Score 15.8; DB 1; Length 19; Best Local Similarity 89.5%; Pred. No. 92; Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 434 CTGGGAGGGGAGAGAA 452  
|||||

Db 19 CTGGGAGGGGAGAGATGAA 1  
|||||

RESULT 38  
AA85464/C

ID AAA85464 standard; DNA; 19 BP.

XX AAA85464;

XX 04-DEC-2000 (first entry)

XX Cyclin A1 ribozyme binding site #86.

DE Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.

XX Mammalia.

XX WO200032765-A2.

XX 08-JUN-2000.

XX 06-DEC-1999; 99WO-US028772.

XX 04-DEC-1998; 98US-0110954P.

XX (IMMU-) IMMUSOL INC.

XX Tritz R, Welch PJ, Barber JR, Robbins JM;

XX WPI; 2000-412314/35.

XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1, PCNA and Cyclin B1.

XX Disclosure; Page 92; 109pp; English.

XX The present invention relates to a hairpin or hammerhead ribozyme, designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.

CC Representative examples of ribozyme recognition sites are given in AA82415 to AA86787. The ribozyme of the invention is useful for inhibiting restenosis by introduction of the ribozyme into cells. The ribozyme is resistant to endonuclease activity and hence is efficient in restenosis treatment

XX Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

SQ Query Match 0.9%; Score 15.8; DB 1; Length 19; Best Local Similarity 89.5%; Pred. No. 92; Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 436 GGGAGAGGGGAGAGAAATC 454  
|||||

Db 19 GGGAGAGGGGAGAGATGAAATC 1  
|||||

RESULT 39  
AAH60627/C

ID AAH60627 standard; DNA; 19 BP.

XX AAH60627;

XX 10-SEP-2001 (first entry)

XX Cyclin A1 ribozyme binding site SEQ ID NO:3051.

DE Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme; recognition site; target; ribozyme binding site; eye disease; vulnary; proliferative disease; skin disease; psoriasis; diabetic retinopathy; cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP; matrix metalloproteinase; growth factor; reductase; scarring; cytostatic; antipsoriatic; dermatological; keratolytic; antidiabetic; virucide; antisickling; ophthalmological; keratolytic; gene therapy; viral wart; atopic dermatitis; actinic keratosis; squamous cell carcinoma; basal cell carcinoma; seboreic wart; vitreoretinopathy; scar; sickle cell retinopathy; ss.

XX Homo sapiens.

OS Synthetic.

XX WO200130362-A2.

XX 03-MAY-2001.

XX 26-OCT-2000; 2000WO-US029500.

XX 26-OCT-1999; 99US-0161532P.

XX (IMMU-) IMMUSOL INC.

XX Robbins JM, Tritz R;

XX WPI; 2001-300427/31.

XX Treating proliferative skin or eye diseases and scarring, using ribozymes that cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, growth factors and cell-cycle dependent kinases.

XX Example 1; Page 293; 408pp; English.

XX The present invention describes a method for treating a proliferative skin or eye disease and scarring. The method involves administering a ribozyme (I) which cleaves RNA encoding a cytokine involved in inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle dependent kinase, growth factor or a reductase, or administering a nucleic acid molecule (II) comprising a promoter operably linked to a nucleic acid segment encoding (I). (I) can have antipsoriatic, dermatological, vulnary, keratolytic and virucide activities, and cleaves RNA encoding cytokine involved in inflammation. (I) can be used in gene therapy. (I) and (II) are useful for treating proliferative skin diseases such as psoriasis, atopic dermatitis, actinic keratosis, squamous or basal cell carcinoma and viral or seboreic wart. They can also be used for treating proliferative eye diseases such as diabetic retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of prematurity and retinal detachment, and for treating and preventing scarring such as keloid, adhesion and hypertrophic or hypertrophic burn scar. AAH57577 to AAH62099 represent sequences used in the exemplification of the present invention

XX Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

SQ Query Match 0.9%; Score 15.8; DB 1; Length 19; Best Local Similarity 89.5%; Pred. No. 92; Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	434	CTGGAGAGGGAGAGAA	452	Matches	17;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
Db	19	CTGGAGAGGAGAGATGAA	1										
RESULT 40													
AAH60626/c													
ID	AAH60626	standard; DNA; 19 BP.											
XX	AC	AAH60626;											
XX	DT	10-SEP-2001	(first entry)										
XX	DE	Cyclin A1 ribozyme binding site SEQ ID NO:3050.											
XX	KW	Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;											
XX	KW	recognition site; target; ribozyme binding site; eye disease; vulnery;											
XX	KW	proliferative disease; skin disease; psoriasis; diabetic retinopathy;											
XX	KW	cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;											
XX	KW	matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;											
XX	KW	antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;											
XX	KW	antisickling; ophthalmological; keratolytic; gene therapy; viral wart;											
XX	KW	atopic dermatitis; actinic keratosis; squamous cell carcinoma;											
XX	KW	basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;											
XX	KW	sickle cell retinopathy; ss.											
OS	XX	Homo sapiens.											
OS	XX	Synthetic.											
XX	PN	WO200130362-A2.											
XX	PD	03-MAY-2001.											
XX	PF	26-OCT-2000; 2000WO-US029500.											
XX	PR	26-OCT-1999; 99US-0161532P.											
XX	PA	(IMMU-) IMMUSOL INC.											
XX	PI	Robbins JM, Tritz R;											
XX	DR	WPI; 2001-300427/31.											
XX	PT	Treating proliferative skin or eye diseases and scarring, using ribozymes											
XX	PT	that cleave RNA encoding cytokines involved in inflammation, matrix											
XX	PT	metalloproteinases, growth factors and cell-cycle dependent kinases.											
XX	PS	Example 1; Page 293; 408pp; English.											
XX	CC	The present invention describes a method for treating a proliferative											
XX	CC	skin or eye disease and scarring. The method involves administering a											
XX	CC	ribozyme (I) which cleaves RNA encoding a cytokine involved in											
XX	CC	inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle											
XX	CC	dependent kinase, growth factor or a reductase, or administering a											
XX	CC	nucleic acid molecule (II) comprising a promoter operably linked to a											
XX	CC	nucleic acid segment encoding (I). (I) can have antipsoriatic,											
XX	CC	dermatological, cycostatic, antiseborrheic, antidiabetic, antisickling,											
XX	CC	ophthalmological, vulnery, keratolytic and virucide activities, and											
XX	CC	cleaves RNA encoding cytokine involved in inflammation. (I) can be used											
XX	CC	in gene therapy. (I) and (II) are useful for treating proliferative skin											
XX	CC	diseases such as psoriasis, atopic dermatitis, actinic keratosis,											
XX	CC	squamous or basal cell carcinoma and viral or seboreic wart. They can											
XX	CC	also be used for treating proliferative eye diseases such as diabetic											
XX	CC	retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of											
XX	CC	prematurity and retinal detachment, and for treating and preventing											
XX	CC	scarring such as keloid, adhesion and hypertrophic or hypertrophic burn											
XX	CC	scar. AAH57577 to AAH62099 represent sequences used in the											
XX	CC	exemplification of the present invention											
XX	XX	Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;											
Query Match		0.9%; Score 15.8; DB 1; Length 19;											
Best Local Similarity		89.5%; Pred. No. 92;											

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
 Best Local Similarity 89.5%; Pred. No. 92;



Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1517 GAAACAGTAAAGAAAGAAC 1535  
||||| ||||| ||||| |||||  
Db 19 GAAACAGCAAGAAAGAAC 1

RESULT 42  
ID ABX79687 standard; cDNA; 19 BP.  
XX  
AC ABX79687;  
XX  
DT 17-APR-2003 (first entry)  
XX  
DE EST polymorphic DNA repeat polynucleotide #12.  
XX  
KW EST; expressed sequence tag; ss; polymorphic repeat; tandem repeat;  
KW Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;  
KW Haw River syndrome; Huntington's disease; fragile-X syndrome;  
KW Friedrich's ataxia; myotonic dystrophy; hyperandrogenaemia;  
KW spinal atrophy; bulbar atrophy; spinocerebellar ataxia.  
XX  
OS Homo sapiens.  
XX  
FN US6472154-B1.  
XX  
PD 29-OCT-2002.  
XX  
PF 31-DEC-1999; 99US-00475947.  
XX  
PR 31-DEC-1999; 99US-00475947.  
XX  
PA (TEXA ) UNIV TEXAS SYSTEM.  
XX  
PI Garner HR, Wren JD, Minna JD, Fondon JW;  
XX  
DR WPI; 2003-208818/20.  
XX  
PT Identifying a candidate polymorphic repeat within a coding sequence, for  
PT understanding or treating genetic disease, comprises detecting tandem  
PT repeats in a target coding sequence and scoring the repeats for  
PT polymorphic probability.  
XX  
PS Example; Col 175; 588pp; English.  
XX  
CC The invention discloses a method for identifying a candidate polymorphic  
CC repeat within a coding sequence (expressed sequence tag, EST), which  
CC comprises detecting tandem repeats in a target coding sequence, scoring  
CC the repeats for polymorphic probability and generating a dataset  
CC correlating the repeats with polymorphic probability to identify a  
CC candidate polymorphic repeat. The computational methods (polymorphic  
CC marker prediction of ubiquitous simple sequences, POMPOUS, and Rep-X) are  
CC useful for identifying and detecting candidate polymorphic repeats in  
CC human genes, which can be used to understand, treat or eliminate genetic  
CC diseases, predispositions or adverse drug-treatment reactions. Examples  
CC of diseases linked to nucleotide repeats are Machado-Joseph, Haw River  
CC syndrome, Huntington's disease, fragile-X syndrome, Friedrich's ataxia,  
CC myotonic dystrophy, hyperandrogenaemia, spinal and bulbar atrophy and  
CC spinocerebellar ataxia. The sequences presented in ABX79676-ABX80022 are  
CC the polymorphic repeats identified for a search of human ESTs  
XX  
SQ Sequence 19 BP; 0 A; 4 C; 0 G; 15 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 92;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1516 AGAACACGTAAAGAAAGAA 1534  
||||| ||||| ||||| |||||  
Db 19 AGAACAAAGAAAGAAAGAA 1

RESULT 43  
ID ADJ66298 standard; RNA; 19 BP.  
XX  
AC ADJ66298;  
XX  
DT 06-MAY-2004 (first entry)  
XX  
DE Human TGFb-R siRNA lower strand, SEQ ID NO:136.  
XX  
KW RNA interference; short interfering nucleic acid; siRNA;  
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;  
KW short hairpin RNA; shRNA; expression modulation; gene therapy;  
KW drug screening; diagnosis; therapeutic target identification;  
KW pharmacogenomics; gene function analysis; gene mapping; human;  
KW antidiabetic; nephrotropic; hepatotropic; cytostatic;  
KW transforming growth factor beta receptor; TGFb; TGFb-R;  
KW diabetic nephropathy; chronic liver disease; pulmonary fibrosis; ss.  
XX  
OS Homo sapiens.  
XX  
FN WO2003070197-A2.  
XX  
PD 28-AUG-2003.  
XX  
PF 11-FEB-2003; 2003WO-US007273.  
XX  
PR 20-FEB-2002; 2002US-0358580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 12-NOV-2002; 2002US-0425559P.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Mcswiggen J, Beigelman L;  
XX  
DR WPI; 2003-697557/66.  
XX  
PT New short interfering nucleic acid, useful e.g. for treatment and  
PT diagnosis of diabetic nephropathy, which downregulates expression of the  
PT transforming growth factor-beta receptor gene.  
XX  
PS Example 3; SEQ ID NO 136; 137pp; English.  
XX  
CC The invention relates to short interfering nucleic acids (siNA) which  
CC downregulate expression of the human transforming growth factor beta  
CC (TGFb) receptor (TGFb-R) gene by RNA interference. The siNAs may or may  
CC not comprise ribonucleotides and may be double or single stranded. They  
CC further comprise sense and antisense regions, or alternatively are  
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.  
CC Specifically, the siNAs include short interfering RNA (siRNA), double-  
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs  
CC can be unmodified or chemically modified, can contain  
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a  
CC vector or enzymatically synthesised. The invention also relates to kits  
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes  
CC of siNA; and vectors that express siNA. The siNAs are used to modulate  
CC expression of the TGFb-R gene in cells, tissue explants or organisms  
CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the  
CC treatment of a variety of conditions. They may be used for treating  
CC diabetic nephropathy, chronic liver disease or pulmonary fibrosis. The  
CC siNAs are also useful for drug screening, diagnosis, therapeutic target  
CC identification and validation, genetic engineering, pharmacogenomics,  
CC studying gene function, and gene mapping (e.g., of single nucleotide  
CC polymorphisms). The present sequence represents the lower strand of a  
CC human TGFb-R-targeted double-stranded siNA.  
XX  
SQ Sequence 19 BP; 0 A; 12 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
 Best Local Similarity 89.5%; Pred. No. 92;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCGTCGCCGCCG 46  
 ||||| ||||| ||||| ||||| |||||  
 Db 1 GCCGCTCGTCGCCGCCG 19

RESULT 44  
 ADJ66170/c  
 ID ADJ66170 standard; RNA; 19 BP.  
 XX AC ADJ66170;  
 XX DT 06-MAY-2004 (first entry)  
 XX DE Human TGFb-R transcript target sequence/siNA upper strand, SEQ ID NO:8.  
 XX KW RNA interference; short interfering nucleic acid; siNA;  
 XX KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;  
 KW short hairpin RNA; shRNA; expression modulation; gene therapy;  
 KW drug screening; diagnosis; therapeutic target identification;  
 KW pharmacogenomics; gene function analysis; gene mapping; human;  
 KW antidiabetic; nephrotropic; hepatotropic; cytostatic;  
 KW transforming growth factor beta receptor; TGFb; TGFb-R;  
 KW diabetic nephropathy; chronic liver disease; pulmonary fibrosis;  
 KW target sequence; ss.  
 XX OS Homo sapiens.  
 XX PN WO2003070197-A2.  
 XX PD 28-AUG-2003.  
 XX PF 11-FEB-2003; 2003WO-US007273.  
 XX PR 20-FEB-2002; 2002US-0358580P.  
 PR 11-MAR-2002; 2002US-0363124P.  
 PR 06-JUN-2002; 2002US-0386782P.  
 PR 29-AUG-2002; 2002US-0406784P.  
 PR 05-SEP-2002; 2002US-0408378P.  
 PR 03-SEP-2002; 2002US-0409293P.  
 PR 12-NOV-2002; 2002US-0425559P.  
 PR 15-JAN-2003; 2003US-0440129P.  
 XX PA (RIBO-) RIBOZYME PHARM INC.  
 XX PI Mcswiggen J, Beigelman L;  
 XX WPI; 2003-697557/66.  
 XX New short interfering nucleic acid, useful e.g. for treatment and  
 diagnosis of diabetic nephropathy, which downregulates expression of the  
 transforming growth factor-beta receptor gene.  
 XX Example 3; SEQ ID NO 8; 137bp; English.  
 XX The invention relates to short interfering nucleic acids (siNA) which  
 downregulate expression of the human transforming growth factor beta  
 (TGFb) receptor (TGFb-R) gene by RNA interference. The siNAs may or may  
 not comprise ribonucleotides and may be double or single stranded. They  
 further comprise sense and antisense regions, or alternatively are  
 assembled from a sense oligonucleotide and an antisense oligonucleotide.  
 CC Specifically, the siNAs include short interfering RNA (siRNA), double-  
 stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs  
 can be unmodified or chemically modified, can contain  
 CC deoxyribonucleotides, and can be chemically synthesized, expressed from a  
 vector or enzymatically synthesized. The invention also relates to kits  
 CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes  
 CC of siNA; and vectors that express siNA. The siNAs are used to modulate  
 expression of the TGFb-R gene in cells, tissue explants or organisms

CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the  
 CC treatment of a variety of conditions. They may be used for treating  
 CC diabetic nephropathy, chronic liver disease or pulmonary fibrosis. The  
 CC siNAs are also useful for drug screening, diagnosis, therapeutic target  
 CC identification and validation, genetic engineering, pharmacogenomics,  
 CC studying gene function, and gene mapping (e.g., of single nucleotide  
 CC polymorphisms). The present sequence represents the upper strand of a  
 CC human TGFb-R targeted double-stranded siNA, which is identical to the  
 CC TGFb-R transcript target sequence.  
 XX  
 XX Sequence 19 BP; 0 A; 7 C; 12 G; 0 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 15.8; DB 1; Length 19;  
 Best Local Similarity 89.5%; Pred. No. 92;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCTCGTCGCCGCCG 46  
 ||||| ||||| ||||| ||||| |||||  
 Db 19 GCCGCTCGTCGCCGCCG 1

RESULT 45  
 ADM70256/c  
 ID ADM70256 standard; DNA; 19 BP.  
 XX AC ADM70256;  
 XX DT 03-JUN-2004 (first entry)  
 XX DE Plant gene polymorphism marker related primer, SEQ ID 1135.  
 XX KW Primer; variation mapping; mutation mapping; plant;  
 KW gene polymorphism marker; ss.  
 XX OS Synthetic.  
 XX PN JP2003289885-A.  
 XX PD 14-OCT-2003.  
 XX PF 31-JAN-2003; 2003JP-00024620.  
 XX PR 01-FEB-2002; 2002JP-00025338.  
 XX PA (RIKA ) RIKAGAKU KENKYUSHO.  
 PA (SAIM-) SAI MEDIA KK.  
 PA (MATS/) MATSUI M.  
 PA (NAKA/) NAKAZAWA M.  
 XX WPI; 2004-126231/13.  
 XX A primer set and method useful for mapping at least the  
 PT variation/mutation part of a plant gene using a gene polymorphism marker.  
 XX Claim 7; SEQ ID NO 1135; 120pp; Japanese.  
 XX The present invention relates to a primer set and method for mapping at  
 CC least the variation/mutation part of a plant gene using a gene  
 CC polymorphism marker. A mutation site of the plant gene is mapped by  
 CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is  
 CC prepared from a plant homozygously having a mutation to be an object of  
 CC the mapping; (b) A forward primer 1 containing a base corresponding to  
 CC the gene polymorphic maker of one ecotype plant, a forward primer 2  
 CC containing a base corresponding to the genetic polymorphism of the other  
 CC ecotype plant and a reverse primer 3 based on the base sequence common  
 CC with both the ecotype plants are prepared; (c) two kinds of  
 CC oligonucleotides emitting fluorescence of different colors when the  
 CC genetic polymorphism marker is detected are prepared; (d) an  
 CC amplification reaction of the genomic DNA is carried out in the presence  
 CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)  
 CC the fluorescence intensity emitted from the resultant reactional product  
 CC is detected and (f) the position on the genome of the mutation site is  
 CC determined from the results of detection. The present sequence is a

```

CC primer, used to illustrate the invention.
XX Sequence 19 BP; 3 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
SQ
    Query Match      0.9%; Score 15.8; DB 1; Length 19;
    Best Local Similarity 89.5%; Pred. No. 92;
    Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
    QY 594 GCAAGAGGGAAGATTGGT 612
    DB 19 GCAGAGGGAACATGGTG 1
    RESULT 45
    ID ADR80868/c
    XX ADR80868 standard; DNA; 19 BP.
    AC ADR80868;
    DT 16-DEC-2004 (first entry)
    DE Human glucose-6-phosphatase oligonucleotide seqid 5367.
    KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
    KW cycostatic; anticongulant; nootropic; muscular; anti-HIV;
    KW RNA interference; iRNA; antisense technology; lipid metabolism;
    KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
    KW coronary artery disease; CAD; coronary heart disease; CHD;
    KW atherosclerosis; hepatic glucose production;
    KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
    KW colon cancer; lung cancer; neurological disease; Huntington disease;
    KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.
    OS Homo sapiens.
    XX WO2004080406-A2.
    PN 23-SEP-2004.
    PD
    PP 08-MAR-2004; 2004WO-US007070.
    XX 07-MAR-2003; 2003US-0452682P.
    PR 12-MAR-2003; 2003US-0454265P.
    PR 13-MAR-2003; 2003US-0454962P.
    PR 13-MAR-2003; 2003US-0455050P.
    PR 14-APR-2003; 2003US-0462894P.
    PR 17-APR-2003; 2003US-0483772P.
    PR 25-APR-2003; 2003US-0465665P.
    PR 25-APR-2003; 2003US-0465802P.
    PR 09-MAY-2003; 2003US-0469612P.
    PR 11-AUG-2003; 2003US-0491986P.
    PR 26-SEP-2003; 2003US-0494597P.
    PR 26-SEP-2003; 2003US-0506341P.
    PR 09-OCT-2003; 2003US-0510246P.
    PR 10-OCT-2003; 2003US-0510318P.
    PR 07-NOV-2003; 2003US-0518453P.
    XX (ALNY-) ALNYLAM PHARM.
    XX Manoharan M, Bumcrot D;
    FI WPI; 2004-677362/66.
    DR
    XX Interference RNA agent useful for treating dyslipidemias, coronary artery
    PT disease, diabetes, cancer or neurological disease, comprises sense
    PT sequence and antisense sequence which has specific modifications.
    XX
    PS Example 5; SEQ ID NO 5367; 378pp; English.
    XX
    CC The invention describes a RNA interference (iRNA) agent (I) comprising a
    CC sense sequence and an antisense sequence, where the sense sequences have
    CC one or more asymmetrical 2'-O alkyl modifications, the antisense
    CC sequences have one or more asymmetrical phosphorothioate modifications
    CC

```

and the antisense sequence targets a human gene sequence. Also described are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100 levels or glucose-6-phosphatase levels in a subject; producing (I), stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apoB-100, elevated or otherwise unwanted levels of cholesterol, and/or dysregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidaemias, hypercholesterolaemia, statin-resistant hypercholesterolaemia, coronary artery disease (CAD), coronary heart disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a human glucose-6-phosphatase antisense oligonucleotide that can be used to control glucose-6-phosphatase gene expression.

Sequence 19 BP; 1 A; 1 C; 2 G; 15 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 92;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1832 CTGAAAAAAGAAAAA 1850  
DB 19 CTCAAAAAAGAAAAA 1

RESULT 47  
AAT05353  
ID AAT05353 standard; CDNA; 20 BP.  
XX  
AC AAT05353;  
XX  
DT 09-MAY-1996 (first entry)  
XX  
DE PCR primer used in the construction of vector pCFM1656/BDNFopt3.  
XX  
KW BDNF; neurotrophic factor; neurotrophin; NT-3; NT-4; nerve growth;  
KW signal peptide; NGF peptide; methionine; ss.  
XX  
OS Homo sapiens.  
XX  
PN W09525743-A1.  
XX  
PD 28-SEP-1995.  
XX  
PP 16-MAR-1995; 95WO-US003175.  
XX  
PR 18-MAR-1994; 94US-00215138.  
XX  
PA (AMGE-) AMGEN INC.  
XX  
PI Meng S, Morris CF, Tsai LB;  
XX  
XX WPI; 1995-344586/44.  
XX  
PT Signal peptide sequences - useful for improving secretion efficacy of  
PT nerve growth factor peptide(s).  
XX  
PS Example 2; Page 32; 59pp; English.  
XX  
CC Human nerve growth factor signal peptide-encoding cDNAs can be used to  
CC enhance the amount of peptides secreted from host cells. By using  
CC indirect expression techniques host cells can be made to express NGF

CC peptides without an amino terminal methionine (Met-less NGF peptides),  
 CC vectors used in these techniques include pCFM1656/BDNFopt3 and  
 CC pCFM1656/NT-3opt3. AAT05350-54 are PCR primers used in the construction  
 CC of these vectors. Signal peptides useful in this invention include those  
 CC of neurotrophin-3, neurotrophin-4, BDNF and NGF  
 XX  
 SQ Sequence 20 BP; 7 A; 1 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 98;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1680 TGATTCTAGAAAAGGNAAT 1698  
 |||||  
 2 TGATTCTAGAAAGGGAAT 20

Db  
 AAX96843/C  
 AAX96843 standard; DNA; 20 BP.  
 AC  
 AAX96843;  
 XX  
 DT 13-SEP-1999 (first entry)  
 XX  
 DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.  
 XX  
 KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;  
 KW neutralising epitope; PCR primer; ss.  
 XX  
 OS Synthetic.  
 OS Chlamydia pneumoniae.  
 XX  
 PN WO9927105-A2.  
 XX  
 PD 03-JUN-1999.  
 XX  
 PF 20-NOV-1998; 98WO-IB001890.  
 XX  
 PR 21-NOV-1997; 97FR-00014673.  
 PR 04-NOV-1998; 98US-0107078P.  
 XX  
 PA (BEST ) GENSET.  
 XX  
 PI Griffais R;  
 XX  
 DR WPI; 1999-357842/30.  
 XX  
 PT Genome sequence of Chlamydia pneumoniae.  
 PS  
 PS Page 1857; Disclosure; 1912pp; English.  
 CC  
 CC AAX91991-X97517 represent PCR primers used to amplify open reading frames  
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae  
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as  
 CC pneumonia and bronchitis and is thought to be a contributing factor in  
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
 CC frames of the C. pneumoniae genome (see AAX34584-AAX35879) can be used  
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
 CC nucleotide sequences can also be used as immunogenic compositions,  
 CC especially where the vector directs the expression of a neutralising  
 CC epitope of C. pneumoniae  
 XX  
 SQ Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 98;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1440 ATGAATGTTGCTGCTGCTG 1458  
 |||||

Db  
 19 ATGATTGTTGCTGCTGCG 1  
 RESULT 49  
 AAX15575  
 ID AAX15575 standard; DNA; 20 BP.  
 XX  
 AC AAX15575;  
 XX  
 DT 06-MAY-1999 (first entry)  
 XX  
 DE PCR primer for nucleic acid encoding IFN-beta.  
 XX  
 KW Origin binding protein Binding site III sequence; HSV-1; HSV-2;  
 KW viral infection; viral reactivation; interferon regulatory factor-1;  
 KW IRF-1; TIS7; interferon-alpha; IFN-alpha; IFN-beta; PCR primer; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9901464-A1.  
 XX  
 PD 14-JAN-1999.  
 XX  
 PF 01-JUL-1998; 98WO-US013733.  
 XX  
 PR 03-JUL-1997; 97US-0051633P.  
 PR 01-AUG-1997; 97US-0054515P.  
 PR 01-APR-1998; 98US-0080352P.  
 XX  
 PA (SMIK ) SMITHKLINE BEECHAM CORP.  
 PA (WIST-) WISTAR INST.  
 XX  
 PI Berger SL, Fraser NW, Leary JJ, Tal-Singer R;  
 XX  
 DR WPI; 1999-105992/09.  
 XX  
 PT Treating viral infection or reactivation, particularly Herpesvirus -  
 PT using compounds which modulate interferon pathways.  
 XX  
 PS Example 6; Page 41; 40pp; English.  
 CC  
 CC PCR primers AAX15571-90 were used to amplify TIS7A, TIS7B, interferon-  
 CC beta (IFN-beta), IFN-alpha, IFN-alpha/beta, interferon regulatory factor  
 CC -1 (IRF-1), IRF-2, tumour necrosis factor (TNF)-alpha, beta-actin or  
 CC cyclophilin, in the course of the invention. The specification describes  
 CC a method for treating viral infection or reactivation. The method  
 CC comprises contacting an individual with a compound which is an antagonist  
 CC of the reaction between the origin binding protein Binding site III  
 CC sequence from Herpes simplex virus (HSV)-1 and HSV-2 and IRF-1.  
 CC Alternatively, the compound lowers the level of IRF-1, TIS7, IFN-alpha,  
 CC or IFN-beta. The method can be used to treat viral reactivation in HSV  
 XX  
 SQ Sequence 20 BP; 11 A; 1 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 98;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 AGAAGCAAGGAGGAGGATT 608  
 |||||  
 2 AAAAGCAAGGAGGAGGATT 20

Db  
 RESULT 50  
 AAC65462  
 ID AAC65462 standard; DNA; 20 BP.  
 XX  
 AC AAC65462;  
 XX  
 DT 12-FEB-2001 (first entry)  
 XX  
 DE D-1-deoxyxylulose 5-phosphate reductoisomerase PCR primer DXR-GSP3.  
 XX

KW D-1-deoxyxylulose 5-phosphate reductoisomerase; dxr;  
 KW secondary metabolite; tocopherol; nutrition; cancer; cardiac disease;  
 KW cataract; neurodegeneration; PCR primer; ss.  
 OS Arabidopsis sp.  
 XX WO2000063389-A1.  
 PN 26-OCT-2000.  
 XX 14-APR-2000; 2000WO-US010367.  
 PF 15-APR-1999; 99US-0129899P.  
 XX 30-JUL-1999; 99US-0146461P.  
 PR (CALJ ) CALGENE LLC.  
 XX Kishore GM, Boronot A, Bhat BG, Rangwala SH;  
 FI WPI; 2000-672739/65.  
 DR New nucleic acid encoding 1-deoxy-D-xylulose-5-phosphate reducto-  
 PT isomerase, useful for altering production of isoprenoid compounds in  
 PT plants.  
 XX Example 3; Page 25; 45pp; English.  
 PS The present invention describes the D-1-deoxyxylulose 5-phosphate  
 XX reductoisomerase (dxr) enzyme and its coding sequence from Arabidopsis.  
 CC This protein is involved in the production of isoprenoids in the cell,  
 CC which in turn affects the production of secondary metabolites such as  
 CC tocopherols. These are important in mammalian nutrition, and are known  
 CC antioxidants, protecting against cardiac disease, cancer, cataracts,  
 CC retinopathy, Alzheimer's disease and neurodegeneration, and having  
 CC beneficial effects on the symptoms of arthritis. The gene and protein of  
 CC the invention can be used to increase the production of dxr in plants and  
 CC thus increase the amount of tocopherols they produce  
 XX Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;  
 SQ Query Match 0.9%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 98;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1244 GCCCATCATGCGAGGAGTT 1262  
 DB 1 GCCCATGCTGGAGGAGTT 19  
 RESULT 51  
 AAH24585  
 ID AAH24585 standard; DNA; 20 BP.  
 XX AAH24585;  
 AC 07-AUG-2001 (first entry)  
 DT Human endometrium cDNA clone 1-9-SP6 PCR primer #1.  
 XX Human; endometrium  
 XX Human; endometrium; gynaecological; cytostatic; gene therapy;  
 KW peptide therapy; endometriosis; gene expression; drug screening;  
 KW PCR primer; ss.  
 XX Homo sapiens.  
 OS WO200132920-A2.  
 PN 10-MAY-2001.  
 XX 03-NOV-2000; 2000WO-GB004228.  
 PF 03-NOV-1999; 99GB-00026074.  
 XX 03-NOV-1999; 99GB-00026076.

PR 03-NOV-1999; 99GB-00026079.  
 PR 03-NOV-1999; 99GB-00026081.  
 XX (METR-) METRIS THERAPEUTICS LTD.  
 PA Pappa H, Lnenicek M;  
 PI WPI; 2001-328804/34.  
 DR Screening for a gene or gene product associated with endometriosis, for  
 XX diagnosing or treating endometriosis, comprises selecting a gene whose  
 XX level of expression differs between healthy and diseased endometrium  
 XX tissues.  
 PS Example; Fig 3; 106pp; English.  
 XX The invention relates to a method for screening for a gene or gene  
 CC product associated with endometriosis. The method comprises comparing the  
 CC pattern of gene expression in a diseased endometrium tissue from a  
 CC patient suffering from endometriosis to the pattern of gene expression in  
 CC healthy endometrium tissue from the same patient, and selecting a gene  
 CC whose level of expression differs between healthy and diseased tissues.  
 CC The gene, gene product and their antagonists and agonists are useful in  
 CC the manufacture of a medicament for diagnosing or treating endometriosis.  
 CC The method is useful for screening genes or gene products that are  
 CC implicated in endometriosis. It is particularly useful in diagnosing  
 CC endometriosis, as well as for screening agents for treating  
 CC endometriosis. Prior methods of diagnosing endometriosis are more  
 CC difficult to perform and are more expensive, normally involving surgery.  
 CC The present method allows the disease to be diagnosed and treated at  
 CC earlier stage. The present sequence was used in a reverse transcription  
 CC polymerase chain reaction (RT-PCR) procedure to validate the results of  
 CC differential gene expression studies. It was used to amplify human  
 CC endometrium cDNA encoding elongation factor-1  
 XX Sequence 20 BP; 1 A; 3 C; 7 G; 9 T; 0 U; 0 Other;  
 SQ Query Match 0.9%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 98;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1441 TGAATGTTGCTGCTGCTGT 1459  
 DB 2 TGATTGTTGCTGCTGCTGT 20  
 RESULT 52  
 ABX14278  
 ID ABX14278 standard; DNA; 20 BP.  
 XX ABX14278;  
 AC 26-FEB-2003 (first entry)  
 DT Arabidopsis dxr RACE PCR primer DXR-GSP3.  
 XX Plant; ss; 1-deoxy-D-xylulose 5-phosphate reductoisomerase; dxr;  
 KW isoprenoid; disease resistance; tocopherol; antioxidant; PCR; primer;  
 KW free radical damage; cardiac disease; cancer; cataract; retinopathy;  
 KW Alzheimer's disease; arthritis; neurodegeneration; anti-aging;  
 KW carotenoid; monoterpene; diterpene; plastoquinone; RACE;  
 KW rapid amplification of cDNA ends.  
 XX Arabidopsis thaliana.  
 OS US2002108148-A1.  
 XX 08-AUG-2002.  
 PD 13-NOV-2001; 2001US-00987025.  
 XX 15-APR-1999; 99US-0129899P.  
 PR 30-JUL-1999; 99US-0146461P.

```

PR 14-APR-2000; 2000US-00549787.
XX (BORO/) BORONAT A.
PA (CAMP/) CAMPOS N.
PA (KISH/) KISHORE G M.
XX
PI Boronat A, Campos N, Kishore GM;
XX WPI; 2003-066660/06.
DR
XX
XX New nucleic acid sequence encoding 1-deoxy-D-xylulose 5-phosphate
PT reductoisomerase from an eukaryotic source, useful for altering
PT isoprenoid content and composition, and modulating disease resistance in
PT plants.
XX
XX Example 3; Page 9; 19pp; English.
XX
XX The invention relates to an isolated nucleic acid sequence encoding 1-
CC deoxy-D-xylulose 5-phosphate reductoisomerase (DXR) from a eukaryotic
CC source, or the Arabidopsis (At) dxr gene sequence appearing as AX14272
CC encoding the DXR protein appearing as ABG72671, a polynucleotide
CC comprising a sequence which is 70-95% identical to Arabidopsis dxr, a
CC polynucleotide which hybridizes to dxr or its fragment, or a complement
CC of dxr. Also include are: (1) a DNA construct comprising as operably
CC associated components in the 5'-3' direction of transcription, a promoter
CC functional in a plant cell, At dxr and a transcriptional termination
CC sequence; (2) a host cell comprising the construct; (3) a plant
CC comprising the host cell; and (4) producing an isoprenoid compound of
CC interest in a plant, by obtaining a transformed plant, the plant having
CC and expressing in its genome, a primary construct comprising At dxr
CC operably linked to a transcriptional initiation region functional in a
CC plant cell, and at least one secondary construct comprising a DNA
CC sequence encoding a protein involved in the production of a particular
CC isoprenoid operably linked to a transcriptional initiation region
CC functional in a plant cell. The DNA construct is useful for altering
CC (increasing or decreasing) the isoprenoid content in a plant, where dxr
CC is in sense or antisense orientation, and also for increasing the non-
CC mevalonate isoprenoid biosynthetic flux in cell from a host plant. The
CC DNA construct is also useful for modulating disease resistance in a
CC plant. The modified plant is useful for producing isoprenoids such as
CC tocopherol (useful as an antioxidant and protecting mammalian cells from
CC free radical damage and therefore useful in treatment of cardiac disease,
CC cancer, cataracts, retinopathy, Alzheimer's disease, arthritis,
CC neurodegeneration and in anti-aging treatments), carotenoid, monoterpene,
CC diterpene, or plastoquinone. Dxr is useful for producing plants or plant
CC parts including leaves, stems, roots, reproductive and seed with a
CC modified content of tocopherols. The present sequence is a RACE (rapid
CC amplification of cDNA ends) PCR primer used to isolate At dxr cDNA
XX
SQ Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1244 GCCCATCGAGGAGGTT 1262
DB 1 GCCCATCGAGGAGGTT 19
RESULT 53
ADD07277
ID ADD07277 standard; DNA; 20 BP.
XX
XX ADD07277;
AC
XX
XX 01-JAN-2004 (first entry)
DT
XX
XX Mouse interferon Beta RT-PCR primer #1.
DE
XX
XX PCR; ss; interferon regulatory factor; IRF-1; IRF-2; herpes; antiviral;
KW transcription factor; virucide; vaccine; interferon; mouse; primer;
KW differential display; RT-PCR; reverse transcriptase PCR.
XX

```

---

```

XX OS
XX Mus musculus.
XX US2003104356-A1.
XX
XX 05-JUN-2003.
XX
XX 26-MAR-2002; 2002US-00108164.
XX
XX 22-NOV-1999; 99US-00424348.
XX (SMIK ) SMITHKLINE BEECHAM CORP.
XX
XX Berger SL;
XX
XX WPI; 2003-801223/75.
XX
XX Treating infection or reactivation caused by Herpes virus comprises using
XX antagonist of Herpes Simplex virus polynucleotide sequence and interferon
XX regulatory factor-1.
XX
XX Claim 5; SEQ ID NO 125; 53pp; English.
XX
XX The invention relates to treating viral infection or reactivation
XX comprising contacting an individual with an antagonist of the interaction
XX between a Herpes Simplex virus (HSV) polynucleotide sequence appearing as
XX ADD07153 and interferon regulatory factor-1 (IRF-1, a transcription
XX factor of the interferon regulatory pathway). Also included are an
XX isolated HSV polynucleotide comprising ADD07153, a composition comprising
XX a HSV polypeptide involved in viral infection or reactivation, screening
XX for compounds capable of inhibiting specific binding of IRF-1 to a
XX polynucleotide, screening for compounds capable of inhibiting specific
XX binding of IRF-1 to IRF-1:IRF-BP (undefined) complex, a compound capable
XX of agonising or antagonising any compound in IRF-1 and/or interferon
XX genetic regulatory pathway and a composition for comprising an HSV IRF-1
XX binding site consensus sequence. The method is useful for treating
XX infection or reactivation caused by Herpes virus, e.g., HSV-1 or HSV-2
XX infections and for cytomegalovirus, Epstein Barr virus and zoster virus
XX antiviral vaccines. An experiment was performed where cDNA from the
XX infection. The HSV polypeptide and polynucleotides may also be useful as
XX transgenimal ganglia of mice infected with HSV was isolated by
XX differential display reverse transcriptase PCR (DDRT-PCR). The present
XX sequence is an RT-PCR primer from an interferon pathway protein (or
XX control) used to amplify specific cDNA from the DDRT-PCR isolated
XX products.
XX
SQ Sequence 20 BP; 11 A; 1 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 590 AGAAGCAAGAGGAGATT 608
DB 2 AAAAGCAAGAGGAGATT 20
RESULT 54
ADL88498/c
ID ADL88498 standard; DNA; 20 BP.
XX
XX ADL88498;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Human OKL38 3' splice acceptor region #2.
XX
XX human; ds; OKL38; cell differentiation; cell proliferation;
KW tumorigenesis; cancer; tumour; liver cancer; kidney cancer;
KW prostate cancer; testis cancer; bladder cancer; lung cancer;
XX breast cancer.
XX
XX Homo sapiens.
XX

```

XX PN US2003166519-A1.  
 XX XX 04-SEP-2003.  
 XX PF 22-MAR-2001; 2001US-00815453.  
 XX PR 24-MAY-2000; 2000AU-00007732.  
 XX PR 25-MAY-2000; 2000GB-00012820.  
 XX PR 15-AUG-2000; 2000AU-00009470.  
 XX XX  
 XX PA (NACA-) NAT CANCER CENT SINGAPORE PTE LTD.  
 XX XX  
 XX PI Huynh TH;  
 XX XX WPI; 2003-898095/82.  
 XX XX  
 XX PT New polypeptide designated OKL38 useful to modulate cell differentiation  
 XX PT and proliferation and to diagnose, prevent or treat cancer particularly  
 XX PT of the breast, or of the liver, kidney, prostate, testis, bladder or  
 XX PT lung.  
 XX XX  
 XX PS Disclosure; Fig 11; 64pp; English.  
 XX XX  
 XX CC The invention relates to a biologically active fragment of a polypeptide  
 XX CC designated OKL38. The invention is used to modulate cell differentiation,  
 XX CC cell proliferation or tumourigenesis and to diagnose, prevent or treat  
 XX CC cancer or tumour, particularly of the liver, kidney, prostate, testis,  
 XX CC bladder, lung, or more specifically of the breast. The present sequence  
 XX CC represents a human OKL38 3' splice acceptor region.  
 XX XX  
 XX SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 98;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 564 TTCGATGAACCTGCAGAGAA 582  
 DB 19 TTCGATGGACTGCAGGGAA 1  
 RESULT 55  
 ADF08405/C  
 ID ADF08405 standard; DNA; 20 BP.  
 AC ADF08405;  
 XX DT 12-FEB-2004 (first entry)  
 XX DE Murine plasma glutamate carboxypeptidase PCR primer, SEQ ID 134.  
 XX KW Murine; subacute transmissible spongiform encephalopathy; ESST; PCR;  
 XX KW primer; ss; plasma glutamate carboxypeptidase.  
 XX OS Mus musculus.  
 XX XX FR2839081-A1.  
 XX PN 31-OCT-2003.  
 XX PF 29-APR-2002; 2002FR-00005392.  
 XX PR 29-APR-2002; 2002FR-00005392.  
 XX XX (COMS ) COMMISSARIAT ENERGIE ATOMIQUE.  
 XX PI Mouthon F, Nouvel V, Deslys JP;  
 XX XX WPI; 2004-045747/05.  
 XX XX  
 XX PT Identifying genes having altered expression level in presence of non-  
 XX PT conventional transmissible agent, e.g. prion, useful for diagnosis and

PT drug screening.  
 XX Claim 15; SEQ ID NO 134; 100pp; French.  
 XX CC  
 CC The present invention relates to a method for identifying genes (I) the  
 CC expression level of which, in cells or tissues, is correlated with  
 CC presence/absence of a non-conventional transmissible agent (A),  
 CC particularly the normal or pathological form of a prion protein (PrP).  
 CC The method comprises: applying the RDA (representational difference  
 CC analysis) method to total and/or messenger RNA from cells or tissues  
 CC infected by (A) and/or PrP; identifying partial mRNA sequences (Y) for  
 CC which expression is increased or reduced, relative to non-infected cells  
 CC or tissues; screening databases of genes and/or cDNA, obtained from the  
 CC same cells or tissues to identify genes that correspond to Y; optionally,  
 CC confirming under- or over-expression of the identified genes, e.g. by  
 CC reverse transcription PCR, using primers having sequences deduced from  
 CC step (c); and optionally, identifying, from the selected sequences, those  
 CC for which expression levels are returned to normal after treatment with  
 CC an agent able to reverse the phenotype of infected cells to normal. The  
 CC method is useful for measuring gene expression and to detect agents that  
 CC cause subacute transmissible spongiform encephalopathy (ESST) in humans  
 CC or animals and to screen for agents that can delay, stop or inhibit  
 CC development of ESST. The present sequence was used to illustrate the  
 CC invention.  
 XX SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 15.8; DB 1; Length 20;  
 Best Local Similarity 89.5%; Pred. No. 98;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1240 CCAGGGCCATCATCGAGGA 1258  
 DB 20 CCAGGGCTATCATCGAGGA 2  
 RESULT 56  
 ADF75647  
 ID ADF75647 standard; DNA; 20 BP.  
 XX AC ADF75647;  
 XX DT 20-MAY-2004 (first entry)  
 XX DE Chimeric phosphorothioate oligonucleotide to target Nav1.3 #2981.  
 XX KW Nav1.3; Analgesic; Nootropic; Neuroprotective; post-herpetic neuralgia;  
 XX KW diabetic neuropathy; arthritic pain; migraine headache;  
 XX KW infantile epilepsy; ataxia; ss.  
 XX OS Synthetic.  
 XX XX WO2004016754-A2.  
 XX PN 26-FEB-2004.  
 XX PF 14-AUG-2003; 2003WO-US025465.  
 XX PR 14-AUG-2002; 2002US-0403416P.  
 XX XX (PHAA ) PHARMACIA CORP..  
 XX PA Roberts SL;  
 XX PI WPI; 2004-203785/19.  
 XX DR New antisense compound targeted to a nucleic acid molecule encoding  
 XX PT Nav1.3, useful for treating a disease or condition associated  
 XX PT with Nav1.3, e.g. pain, seizure disorder such as childhood seizure  
 XX PT disorder, or ataxia.  
 XX PS Claim 4; SEQ ID NO 2981; 417pp; English.  
 XX XX

The present invention relates to an antiseize compound targeted to a nucleic acid molecule encoding Nav1.3, where the antiseize compound specifically hybridizes with and inhibits the expression of Nav1.3. The compound and composition are useful for treating a disease or condition associated with Nav1.3, e.g. pain including but not limited to neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain, diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain, pain from burns, migraine headache, cluster headache, mild-to-moderate headache; seizure disorder such as childhood seizure disorder, including but not limited to neonatal or infantile epilepsy or ataxia. The present



Db 2 TCTGGTGATGAGGCTGAC 20

RESULT 59  
ADQ82155/c  
ID ADQ82155 standard; DNA; 20 BP.  
XX  
AC ADQ82155;  
XX  
DT 21-OCT-2004 (first entry)  
XX  
DE Human brain natriuretic peptide gene PCR primer #1.  
XX  
KW cardiovascular; endocrine; SHOX; PCR; primer; ss; natriuretic peptide;  
KW short stature; growth protein; cardiovascular disease;  
KW short stature homeobox-containing gene.  
XX  
OS Homo sapiens.  
XX  
FN WO2004062555-A2.  
XX  
PD 29-JUL-2004.  
XX  
PF 12-JAN-2004; 2004WO-EP000134.  
XX  
PR 13-JAN-2003; 2003EP-00000728.  
XX  
PA (RAPP/) RAPPOLD-HOERBRAND G.  
XX  
PI Rappold-Hoerbrand G, Haacker B;  
XX  
DR WPI; 2004-544028/52.  
XX  
PT Use of natriuretic peptide in combination with a growth protein, e.g.  
PT Short stature Homeobox-containing gene (SHOX) protein for preparing  
PT pharmaceutical compositions for treating short stature in a subject or  
PT cardiovascular diseases.  
XX  
PS Example 5; Page 19; 36pp; English.  
XX  
CC The present invention relates to the use of a natriuretic peptide (atrial  
CC natriuretic peptide, ANP or brain natriuretic peptide, BNP) in  
CC combination with a growth protein, e.g. Short stature Homeobox-containing  
CC gene (SHOX) protein for the preparation of pharmaceutical compositions  
CC for the treatment of short stature in a subject being suspected of having  
CC a genetic defect in the SHOX gene or for treatment of patients with  
CC cardiovascular diseases. The natriuretic peptide (ANP or BNP) in  
CC combination with a growth protein, e.g. SHOX protein is useful for the  
CC preparation of pharmaceutical compositions for the treatment of short  
CC stature in a subject being suspected of having a genetic defect in the  
CC SHOX gene or for treatment of patients with cardiovascular diseases. It  
CC is also useful for the preparation of pharmaceutical compositions for  
CC stimulating or increasing human growth or for treating patients with  
CC idiopathic short stature, patients with Turner syndrome, or patients with  
CC Leri-Weill syndrome. The present sequence is a PCR primer used in the  
CC exemplification of the invention.  
XX  
SQ Sequence 20 BP; 1 A; 6 C; 3 G; 10 T; 0 U; 0 Other;  
Query Match 0.9%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 98;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 157 GGAAAGCTATATGCAAGAA 175  
DB 19 GGAAAGCCAGATGCAAGAA 1  
RESULT 60  
ADK23151  
ID ADK23151 standard; DNA; 20 BP.  
XX  
AC ADK23151;  
XX

XX 18-NOV-2004 (first entry)  
DT  
XX  
DE Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #3228.  
XX  
KW acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;  
KW metabolic syndrome X; cardiovascular disorder; cancer; infection;  
KW inflammation; tumour; antisense; ss.  
XX  
OS Synthetic.  
XX  
FN WO2004016749-A2.  
XX  
PD 26-FEB-2004.  
XX  
PF 14-AUG-2003; 2003WO-US025389.  
XX  
PR 14-AUG-2002; 2002US-0403591P.  
XX  
PA (PHAA ) PHARMACIA CORP.  
XX  
PI Ross SA;  
XX  
DR WPI; 2004-203782/19.  
XX  
PT New antisense compounds targeted to nucleic acid molecules encoding acyl-  
PT coenzyme A synthetase 1 (ACS1), useful for treating diseases or  
PT conditions associated with aberrant expression of ACS1, e.g. diabetes,  
PT obesity or cancer.  
XX  
PS Claim 3; SEQ ID NO 3228; 940pp; English.  
XX  
CC The invention relates to an antisense compound targeted to a nucleic acid  
CC molecule encoding acyl-coenzyme A synthetase 1 (ACS1). The antisense  
CC compound specifically hybridises with and inhibits the expression of  
CC ACS1. The antisense oligonucleotides or compounds are useful for  
CC inhibiting the expression of acyl-coenzyme A synthetase 1 (ACS1), and for  
CC treating diseases or conditions associated with aberrant expression of  
CC ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular  
CC disorder or cancer. The antisense compounds are also useful as research  
CC reagents and kits, or in diagnostic, therapeutic and prophylactic  
CC applications, e.g. to prevent or delay infection, inflammation or tumour  
CC formation. The present sequence represents an acyl-coenzyme A synthetase  
CC 1, ACS1, antisense oligonucleotide.  
XX  
SQ Sequence 20 BP; 2 A; 3 C; 6 G; 9 T; 0 U; 0 Other;  
Query Match 0.9%; Score 15.8; DB 1; Length 20;  
Best Local Similarity 89.5%; Pred. No. 98;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1464 GCTGTGTTTCTTATGTTG 1482  
DB 1 GCTGTGTTTCTTATGTTG 19  
RESULT 61  
ADK22897  
ID ADK22897 standard; DNA; 20 BP.  
XX  
AC ADK22897;  
XX  
DT 18-NOV-2004 (first entry)  
XX  
DE Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #2974.  
XX  
KW acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;  
KW metabolic syndrome X; cardiovascular disorder; cancer; infection;  
KW inflammation; tumour; antisense; ss.  
XX  
OS Synthetic.  
XX  
FN WO2004016749-A2.

```

XX PD 26-FEB-2004.
XX PF 14-AUG-2003; 2003WO-US025389.
XX PR 14-AUG-2002; 2002US-0403591P.
XX PA (PHAA ) PHARMACIA CORP.
XX PI Ross SA;
XX XX WPI; 2004-203782/19.
XX XX New antisense compounds targeted to nucleic acid molecules encoding acyl-
PT coenzyme A synthetase 1 (ACSL1), useful for treating diseases or
PT conditions associated with aberrant expression of ACS1, e.g. diabetes,
PT obesity or cancer.
XX Claim 3; SEQ ID NO 2974; 940pp; English.
XX The invention relates to an antisense compound targeted to a nucleic acid
CC molecule encoding acyl-coenzyme A synthetase 1 (ACSL1). The antisense
CC compound specifically hybridises with and inhibits the expression of
CC ACS1. The antisense oligonucleotides or compounds are useful for
CC inhibiting the expression of acyl-coenzyme A synthetase 1 (ACSL1), and for
CC treating diseases or conditions associated with aberrant expression of
CC ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular
CC disorder or cancer. The antisense compounds are also useful as research
CC reagents and kits, or in diagnostic, therapeutic and prophylactic
CC applications, e.g. to prevent or delay infection, inflammation or tumour
CC formation. The present sequence represents an acyl-coenzyme A synthetase
CC 1, ACS1, antisense oligonucleotide.
XX SQ Sequence 20 BP; 3 A; 2 C; 6 G; 9 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 98;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1463 GGCTGTGTTCTTCTATGTT 1481
Db 2 GGCTGTGTTCTCTGATGAT 20

RESULT 62
AAV45742/c
ID AAV45742 standard; DNA; 21 BP.
XX AC AAV45742;
XX DT 21-DEC-1998 (first entry)
XX DE Human ROMK gene exon 5 reverse primer hROMKex5A.
XX KW ATP-sensitive K+ channel; ROMK; human; Bartter's syndrome; ion transport;
XX hypokalaemic alkalosis; hypercalciuria; nephrocalcinosis; diagnosis;
XX therapy; SSCP; primer; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9829431-A1.
XX PD 09-JUL-1998.
XX PF 19-DEC-1997; 97WO-US023553.
XX PR 31-DEC-1996; 96US-00778052.
XX PA (UYYA ) UNIV YALE.
XX PI Lifton RP, Simon DB;
XX XX This invention describes a novel nucleotide support (A; gene chip) which

```

---

```

DR XX WPI; 1998-388029/33.
PT Thiazide sensitive cotransporter and ATP sensitive potassium channel
PT genes - useful for developing products for the diagnosis and treatment of
PT ion transport disorders, e.g. Gitelman's Syndrome or Bartter's Syndrome.
XX Example 3; Page 76; 105pp; English.
XX Primers hROMKex5A forward and reverse (see AAV45741 and AAV45742,
CC respectively) are designed to amplify exon 5 of the human ROMK gene that
CC codes for ATP-sensitive potassium channel protein ROMK. The forward
CC primer is located within an intron of the gene, and the reverse primer
CC within exon 5. 8. 11 Sets of specific primers (see AAV45733-54) were used
CC for SSCP analysis of ROMK. Amplified products were analysed for molecular
CC variants by electrophoresis, and identified variants were sequenced.
CC Mutations in ROMK were demonstrated to cause Bartter's syndrome.
CC Identification of the molecular basis of Bartter's syndrome allows for
CC the genetic diagnosis of this disorder. The invention provides products
CC and methods useful for diagnosis and treatment of Bartter's syndrome and
CC other ion transport disorders
XX SQ Sequence 21 BP; 4 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 961 GTGGACATCTGGACAGCTG 979
Db 21 GTGGACATCTGGACACGG 3

RESULT 63
AAH48999
ID AAH48999 standard; DNA; 21 BP.
XX AC AAH48999;
XX DT 12-NOV-2001 (first entry)
XX DE Human CFTR gene associated primer #54.
XX KW Neonate screening; prenatal screening; gene chip; diagnosis;
XX phenylketonuria; maple syrup disease; galactosemia; homocysteinuria;
XX medium-chain acyl-CoA-dehydrogenase deficiency; biotinidase deficiency;
XX familial hypercholesterolemia; familial defective apolipoprotein-B;
XX cystic fibrosis; Marfan syndrome; Smith-Lemli-Opitz syndrome;
XX androgenital syndrome; ss.
XX OS Homo sapiens.
XX PN WO200153520-A2.
XX PD 26-JUL-2001.
XX PF 09-JAN-2001; 2001WO-BE000139.
XX PR 21-JAN-2000; 2000DE-01002446.
XX PA (CULL/) CULLEN P.
XX PA (SEED/) SEEDORF U.
XX PI Cullen P, Seedorf U;
XX DR WPI; 2001-457616/49.
XX DNA chip, useful for neonatal or prenatal screening for many genetic
PT diseases simultaneously, carries oligonucleotides complementary to
PT phenotypically relevant reference sequences.
XX Claim 4; Page 49; 101pp; German.
XX This invention describes a novel nucleotide support (A; gene chip) which

```

CC carries a selection of oligonucleotides (I) that are identical, or  
 CC complementary, to segments of reference sequences relevant to at least  
 CC two genetically determined phenotypes. (A) are used for simultaneous  
 CC diagnosis of at least two of the following diseases: phenylketonuria  
 CC (maple syrup disease), galactosemia, homocysteinuria, biotinidase  
 CC deficiency, medium-chain acyl-CoA-dehydrogenase deficiency, familial  
 CC hypercholesterolemia, familial defective apolipoprotein-B, cystic  
 CC fibrosis, Marfan syndrome, Smith-Lemli-Opitz syndrome and androgenital  
 CC syndrome. Specifically they are used in neonatal or prenatal diagnosis.  
 CC (A) require a relatively small number of separate hybridization regions  
 CC (about 500 for testing for 21 specified disorders), so can be used for  
 CC simultaneous testing for many diseases. Testing is quick, inexpensive,  
 CC reliable and more sensitive than current physiological methods. AHA48968-  
 CC AHA489166 represent oligonucleotides used to illustrate the method of the  
 CC invention

XX SQ Sequence 21 BP; 12 A; 1 C; 5 G; 3 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 15.8; DB 1; Length 21;  
 Best Local Similarity 89.5%; Pred. No. 1e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 197 TGAAGAAATAAAGAGAA 215  
 Db 3 TGAAGAAATAAAGAGAA 21

RESULT 64  
 ADE34513  
 ID ADE34513 standard; DNA; 21 BP.  
 XX AC ADE34513;  
 XX DT 29-JAN-2004 (first entry)  
 XX DE Human G-protein coupled receptor related primer #SEQ ID 133.  
 KW Cytostatic; antiinflammatory; hepatotropic; nephrotropic; dermatological;  
 KW antiarthritic; antiasthmatic; antidiabetic; hypotensive; antiulcer;  
 KW antilipemic; antiarteriosclerotic; nootropic; neuroprotective; anorectic;  
 KW immunomodulator; uropathic; antiinfertility; G-protein coupled receptor;  
 KW GPCR; GPCR185; GPCR186; GPCR187; GPCR188; GPCR189; GPCR222; GPCR223;  
 KW hepatitis; nephritis; dermatitis; pancreatitis; rheumatoid arthritis;  
 KW osteoarthritis; atopic dermatitis; asthma; diabetes; hypertension;  
 KW inflammatory bowel disease; gastric ulcer; arteriosclerosis;  
 KW hyperlipemia; Alzheimer's disease; dementia; obesity; pulmonary fibrosis;  
 KW renal fibrosis; immune deficiency; infertility; urinary blockage; cancer;  
 KW PCR; primer; ss.

XX OS Homo sapiens.  
 XX PN WO2003078632-A1.  
 XX PD 25-SEP-2003.  
 XX PF 14-MAR-2003; 2003WO-JP003050.  
 XX PR 15-MAR-2002; 2002JP-00071567.  
 XX PR 14-MAY-2002; 2002JP-00138013.  
 XX PR 28-FEB-2003; 2003JP-00054663.  
 XX PA (NISR) JAPAN TOBACCO INC.  
 XX PI Watanabe H, Nozaki Y;  
 XX DR WPI; 2003-722435/68.  
 XX PT G-protein coupled receptor proteins, genes encoding them and antibodies  
 XX recognizing them for treatment and diagnosis of cancer, inflammatory and  
 XX gastrointestinal disorders.  
 XX PS Example; SEQ ID NO 133; 274pp; Japanese.

CC The invention relates to G-protein coupled receptor proteins of human  
 CC origin. These proteins include GPCR185, GPCR186, GPCR187, GPCR188,  
 CC GPCR189, GPCR222 and GPCR223. Proteins of the invention are used in the  
 CC treatment and prevention of diseases associated with inflammation,  
 CC angiogenesis and tissue neogenesis, including hepatitis, nephritis,  
 CC dermatitis, pancreatitis, rheumatoid arthritis, osteoarthritis, atopic  
 CC dermatitis, asthma, diabetes, hypertension, inflammatory bowel disease,  
 CC gastric ulcer, arteriosclerosis, hyperlipemia, Alzheimer's disease,  
 CC dementia, obesity, pulmonary fibrosis, renal fibrosis, immune deficiency,  
 CC infertility, urinary blockage and cancer (such as cancer of the brain,  
 CC neck, tongue, lung, breast, pancreas, stomach, colon, duodenum, prostate,  
 CC bladder, ovary, womb or rectum). Primers of the invention are devised and  
 CC synthesised based on G-protein coupled receptor consensus sequences and  
 CC used for 5'-RACE (rapid amplification of cDNA ends) and 3'-RACE  
 CC amplification of human cDNA derived from adrenal and visual cortex RNA.  
 CC Sequences given in ADE34534-ADE34533 represent human G-protein coupled  
 CC receptor proteins, genes encoding them, and primers for the amplification  
 CC of these sequences.

XX SQ Sequence 21 BP; 8 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.8; DB 1; Length 21;  
 Best Local Similarity 89.5%; Pred. No. 1e+02;  
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1355 AGCCAGTCTACTTGATGAC 1373  
 Db 2 AGCCAGTACTTGATGAC 20

RESULT 65  
 ADQ30709/c  
 ID ADQ30709 standard; DNA; 21 BP.  
 XX AC ADQ30709;  
 XX DT 23-SEP-2004 (first entry)  
 XX DE Device with substance to aid adhesion of biological material aptamer #3.  
 KW aptamer; ss; implant; biological material adhesion; bioreactor.  
 XX OS Synthetic.

XX PN WO2004055153-A2.  
 XX PD 01-JUL-2004.  
 XX PF 10-DEC-2003; 2003WO-EP013989.  
 XX PR 17-DEC-2002; 2002DE-01058924.  
 XX PA (UYTU-) UNIV TUEBINGEN EBERHARD-KARLS.  
 XX PI Schluesener H, Wendel H;  
 XX DR WPI; 2004-517421/49.

XX PT Device coated with aptamers for binding specific biological materials,  
 XX useful e.g. as stent or component of extracorporeal circulation system,  
 XX also new aptamers specific for endothelial precursor cells.

XX PS Claim 15; SEQ ID NO 3; 31pp; German.

XX CC The present invention relates to a device that has at least one surface  
 CC that contacts tissue and/or liquids of the human or animal body and is at  
 CC least partly coated with a substance that mediates binding of biological  
 CC materials. The new feature is that this substance is an aptamer. The  
 CC device is particularly an implant, e.g. a stent, vascular prosthesis,  
 CC heart valve, joint etc., but may also be a component of an extracorporeal  
 CC circulation system, a nanomaterial for tissue engineering and vascular  
 CC surgery, a catheter, contact lens, storage device for blood etc., also a  
 CC bioreactor for isolation and culture of selected cell types, for

```

CC production of substances or for growing organ replacements. The present
CC sequence is an aptamer suitable for use in the device of the invention.
XX
SQ Sequence 21 BP; 0 A; 7 C; 14 G; 0 T; 0 U; 0 Other;

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGCCG 46
Db 20 GCCGCCGCCGCCGCCGCCG 2

RESULT 66
ADQ30710/c
ID ADQ30710 standard; DNA; 21 BP.
XX
AC ADQ30710;
XX
DT 23-SEP-2004 (first entry)
XX
DE Device with substance to aid adhesion of biological material aptamer #4.
XX
KW aptamer; ss; implant; biological material adhesion; bioreactor.
XX
OS Synthetic.
XX
PN WO2004055153-A2.
XX
PD 01-JUL-2004.
XX
PF 10-DEC-2003; 2003WO-EP013989.
XX
PR 17-DEC-2002; 2002DE-01058924.
XX
PA (UYTU-) UNIV TUEBINGEN EBERHARD-KARLS.
XX
PI Schluesener H, Wendel H;
XX
DR WPI; 2004-517421/49.
XX
PT Device coated with aptamers for binding specific biological materials,
PT useful e.g. as stent or component of extracorporeal circulation system,
PT also new aptamers specific for endothelial precursor cells.
XX
PS Claim 15; SEQ ID NO 4; 31pp; German.
XX
CC The present invention relates to a device that has at least one surface
CC that contacts tissue and/or liquids of the human or animal body and is at
CC least partly coated with a substance that mediates binding of biological
CC materials. The new feature is that this substance is an aptamer. The
CC device is particularly an implant, e.g. a stent, vascular prosthesis,
CC heart valve, joint etc., but may also be a component of an extracorporeal
CC circulation system, a nanomaterial for tissue engineering and vascular
CC surgery, a catheter, contact lens, storage device for blood etc., also a
CC bioreactor for isolation and culture of selected cell types, for
CC production of substances or for growing organ replacements. The present
CC sequence is an aptamer suitable for use in the device of the invention.
XX
SQ Sequence 21 BP; 0 A; 7 C; 14 G; 0 T; 0 U; 0 Other;

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGCCG 46
Db 19 GCCGCCGCCGCCGCCGCCG 1

RESULT 67
ADQ30708

```

```

ID ADQ30708 standard; DNA; 21 BP.
XX
AC ADQ30708;
XX
DT 23-SEP-2004 (first entry)
XX
DE Device with substance to aid adhesion of biological material aptamer #2.
XX
KW aptamer; ss; implant; biological material adhesion; bioreactor.
XX
OS Synthetic.
XX
PN WO2004055153-A2.
XX
PD 01-JUL-2004.
XX
PF 10-DEC-2003; 2003WO-EP013989.
XX
PR 17-DEC-2002; 2002DE-01058924.
XX
PA (UYTU-) UNIV TUEBINGEN EBERHARD-KARLS.
XX
PI Schluesener H, Wendel H;
XX
DR WPI; 2004-517421/49.
XX
PT Device coated with aptamers for binding specific biological materials,
PT useful e.g. as stent or component of extracorporeal circulation system,
PT also new aptamers specific for endothelial precursor cells.
XX
PS Claim 15; SEQ ID NO 2; 31pp; German.
XX
CC The present invention relates to a device that has at least one surface
CC that contacts tissue and/or liquids of the human or animal body and is at
CC least partly coated with a substance that mediates binding of biological
CC materials. The new feature is that this substance is an aptamer. The
CC device is particularly an implant, e.g. a stent, vascular prosthesis,
CC heart valve, joint etc., but may also be a component of an extracorporeal
CC circulation system, a nanomaterial for tissue engineering and vascular
CC surgery, a catheter, contact lens, storage device for blood etc., also a
CC bioreactor for isolation and culture of selected cell types, for
CC production of substances or for growing organ replacements. The present
CC sequence is an aptamer suitable for use in the device of the invention.
XX
SQ Sequence 21 BP; 0 A; 14 C; 7 G; 0 T; 0 U; 0 Other;

Query Match      0.9%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 GCCGCCTCCGTCGCCGCCG 46
Db 3 GCCGCCGCCGCCGCCGCCG 21

RESULT 68
ADQ92979
ID ADQ92979 standard; RNA; 21 BP.
XX
AC ADQ92979;
XX
DT 21-OCT-2004 (first entry)
XX
DE Aromatase siRNA sense strand, SEQ ID 555.
XX
KW Endocrine; Antiseborrheic; Dermatological; Depilatory; RNA interference;
KW small interfering RNA; siRNA;
KW androgen signal transduction pathway protein;
KW androgen signal transduction; aromatase; hair loss;
KW hyperandrogenic condition; androgenic alopecia; male pattern alopecia;
KW acne vulgaris; seborrhea; female hirsutism; prostatic hypertrophy; ds.
XX
OS Synthetic.

```

XX FH Key Location/Qualifiers  
 XX misc\_feature 20..21  
 XX /\*tag= a  
 XX /note= "2 deoxynucleotide overhang"  
 XX  
 XX WO2004063331-A2.  
 XX  
 XX 29-JUL-2004.  
 XX  
 XX 05-JAN-2004; 2004WO-US000128.  
 XX  
 XX 03-JAN-2003; 2003US-0437842P.  
 XX  
 XX (GENC-) GENCIA CORP.  
 XX  
 XX Kahn S;  
 XX  
 XX WPI; 2004-561892/54.  
 XX  
 XX Inhibitory nucleic acid that inhibits expression of an androgen signal transduction pathway protein useful for treating hair loss, comprises a double stranded RNA having a partial sequence encoding a pathway protein in one strand.  
 XX  
 XX Claim 11; Page 50; 92pp; English.  
 XX  
 XX The present invention relates to novel small interfering RNAs (siRNAs), comprising a double stranded RNA, where one strand comprises a partial nucleic acid sequence of an androgen signal transduction pathway protein, and where the double-stranded RNA inhibits translation of mRNA encoding the nucleic acid sequence of the androgen signal transduction pathway protein thereby blocking the androgen signal transduction pathway. The androgen signal transduction pathway protein is chosen from isozymes I and II of 5-alpha reductase (ADQ92435 and ADQ92516), the androgen receptor (ADQ92571), aromatase (ADQ92896), 3-alpha-hydroxysteroiddehydrogenase (ADQ93182), 3-beta-hydroxysteroiddehydrogenase (ADQ93360), 3-beta-hydroxysteroiddehydrogenase-4-5-isomerase (ADQ93541), 17-beta-hydroxysteroiddehydrogenase (ADQ93722), and steroid sulfatase (ADQ93770). The siRNAs of the invention are useful for reducing hair loss in a mammal which involves contacting several mammal's hair cells with the siRNA, where the siRNA interferes with the translation of mRNA of the androgen signal transduction protein. The siRNAs are useful for treating hyperandrogenic conditions of androgenic alopecia, including male pattern alopecia, acne vulgaris, seborrhea, and female hirsutism and prostatic hypertrophy. The present sequence is the sense strand for one such siRNA of the invention.  
 XX  
 XX SQ Sequence 21 BP; 5 A; 4 C; 6 G; 2 T; 4 U; 0 Other;  
 Query Match 0.9%; Score 15.8; DB 1; Length 21;  
 Best Local Similarity 73.7%; Pred. No. 1e+02; Indels 0; Gaps 0;  
 Matches 14; Conservative 3; Mismatches 2;  
 Qy 965 ACATCTGGACAGCTGGGAT 983  
 |||||:|||||:|||||  
 Db 2 ACAUCUGGACAGGUUGAT 20  
 RESULT 69  
 AAA25489  
 ID AAA25489 standard; DNA; 17 BP.  
 XX  
 XX AC AAA25489;  
 XX  
 XX 19-JUL-2000 (first entry)  
 XX  
 XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1987.  
 DE  
 DE Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
 KW  
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
 KW gene expression modification; cancer; phosphorothioate; endonuclease;  
 KW

XX anticancer; breast cancer; endometrium cancer; ss.  
 XX Homo sapiens.  
 XX WO9954459-A2.  
 XX  
 XX 28-OCT-1999.  
 XX  
 XX 19-APR-1999; 99WO-US008547.  
 XX  
 XX 20-APR-1998; 98US-0082404P.  
 XX  
 XX 23-JUN-1998; 98US-00103636.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX  
 XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
 XX Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
 XX Matulic-Adamic J;  
 XX  
 XX WPI; 2000-013248/01.  
 XX  
 XX New nucleic acids that interact, and optionally cleave, target sequences, used to treat cancer.  
 XX  
 XX Claim 77; Page 81; 148pp; English.  
 XX  
 XX The present invention describes nucleic acids (A) that interact stably with a target sequence and contain at least one phosphorodithioate link, having endonuclease activity. (A), and more generally any catalytic nucleic acid (A') that modulates expression of the oestrogen receptor gene, are used to treat cancer (particularly of breast or endometrium), or in vivo or by transforming cells ex vivo and implanting treated cells, or for other conditions associated with levels of oestrogen receptor. Because of the high selectivity for targeted RNA (A) can also be used to correlate inhibition of gene expression with alterations in phenotype, particularly for identification of therapeutic targets, and as research reagents (for RNA, in the same way that restriction endonucleases are used with DNA). The combination of modifications in (A) improves resistance to nucleases, binding affinity and/or activity. AAA23503 to AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and AAA25993 to AAA26107 to AAA26218 represent their corresponding target sequences. AAA26219 to AAA26271 represent other ribozyme sequences and antisense oligonucleotides used in the exemplification of the present invention  
 XX  
 XX SQ Sequence 17 BP; 5 A; 4 C; 1 G; 7 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 96;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1323 ATCAACTTTTGGATCCA 1339  
 |||||:|||||:|||||  
 Db 1 ATCAACTTTTGGATCCA 17  
 RESULT 70  
 ACN03148  
 ID ACN03148 standard; RNA; 17 BP.  
 XX  
 XX AC ACN03148;  
 XX  
 XX 22-APR-2004 (first entry)  
 XX  
 XX WNV Inozyme substrate SEQ ID NO 3151.  
 XX  
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;  
 KW Amberzyme; Zinzyme; ss.

```

XX OS West Nile Virus.
XX PN WO200268637-A2.
XX PD 06-SEP-2002.
XX PF 19-OCT-2001; 2001WO-US048350.
XX PR 20-OCT-2000; 2000US-0242411P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswiggen JA;
XX DR WPI; 2002-706994/76.
XX XX
XX XX New nucleic acid molecule that modulates replication of West Nile Virus
XX PT (WNV), useful for treating a condition related to WNV infection e.g.
XX PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX XX
XX PS Claim 23; SEQ ID NO 3151; 495pp; English.
XX XX
XX CC The invention relates to nucleic acid molecules that modulate replication
XX CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC treating a condition related to WNV infection e.g. pancreatitis,
XX CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC molecule is selected from the group of ribozymes consisting of
XX CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX CC nucleic acid molecules further comprise at least five ribose residues, at
XX CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX CC in the specification. The present sequence is that of a nucleic acid
XX CC molecule of the invention
XX XX
XX SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
XX
Query Match 0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 96;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1239 GCCAGGGCCCATCTGGA 1255
DB 1 GCCAGGGCCCAUCAUGA 17
|||||||:|:|
1 GCCAGGGCCCAUCAUGA 17

RESULT 71
ACN03149
ID ACN03149 standard; RNA; 17 BP.
XX ACN03149;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Inozyme substrate SEQ ID NO 3152.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX PD 06-SEP-2002.
XX
XX PF 19-OCT-2001; 2001WO-US048350.
XX PR 20-OCT-2000; 2000US-0242411P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PI Blatt L, Mcswiggen JA;
XX DR WPI; 2002-706994/76.
XX XX
XX XX New nucleic acid molecule that modulates replication of West Nile Virus
XX PT (WNV), useful for treating a condition related to WNV infection e.g.
XX PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX XX
XX PS Claim 23; SEQ ID NO 3151; 495pp; English.
XX XX
XX CC The invention relates to nucleic acid molecules that modulate replication
XX CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX CC treating a condition related to WNV infection e.g. pancreatitis,
XX CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX CC molecule is selected from the group of ribozymes consisting of
XX CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX CC nucleic acid molecules further comprise at least five ribose residues, at
XX CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX CC least three of the 5' terminal nucleotides and a 3' end modification of a
XX CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX CC in the specification. The present sequence is that of a nucleic acid
XX CC molecule of the invention
XX XX
XX SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;
XX
Query Match 0.8%; Score 15.4; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 96;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1239 GCCAGGGCCCATCTGGA 1255
DB 1 GCCAGGGCCCAUCAUGA 17
|||||||:|:|
1 GCCAGGGCCCAUCAUGA 17

RESULT 72
ACN14350/c
ID ACN14350 standard; RNA; 17 BP.
XX ACN14350;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV minus strand Amberzyme substrate SEQ ID NO 14353.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX PD 06-SEP-2002.
XX
XX PF 19-OCT-2001; 2001WO-US048350.
XX PR 20-OCT-2000; 2000US-0242411P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.

```

XX PI Blatt L, Mcswiggen JA;  
 XX DR WPI; 2002-706994/76.  
 XX PT New nucleic acid molecule that modulates replication of West Nile Virus  
 PT (WNV), useful for treating a condition related to WNV infection e.g.  
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX PS Claim 23; SEQ ID NO 14353; 495pp; English.  
 XX CC The invention relates to nucleic acid molecules that modulate replication  
 CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 CC treating a condition related to WNV infection e.g. pancreatitis,  
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 CC molecule is selected from the group of ribozymes consisting of  
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
 CC nucleic acid molecules further comprise at least five ribose residues, at  
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 CC in the specification. The present sequence is that of a nucleic acid  
 CC molecule of the invention  
 XX SQ  
 XX Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 96;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1239 GCCAGGGCCATCATGGA 1255  
 DB 17 GCCAGGGCCATCATGGA 1  
 RESULT 73  
 ABT38999/c  
 ID ABT38999 standard; DNA; 17 BP.  
 XX AC ABT38999;  
 XX DT 12-JUN-2003 (first entry)  
 XX DE Tumour suppression related human fukutin oligo SEQ ID No 4636.  
 XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; protein chip; gene therapy; tumour suppression;  
 KW human fukutin; ds.  
 XX OS Homo sapiens.  
 XX FN WO2003025175-A2.  
 XX PD 27-MAR-2003.  
 XX PF 17-SEP-2002; 2002WO-IB004208.  
 XX PR 17-SEP-2001; 2001FR-00011978.  
 XX PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX PI Telerman A, Amson R, Tuijnder M;  
 XX DR WPI; 2003-313353/30.  
 XX PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX PS Disclosure; Page 576; 720pp; French.

XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,  
 CC given in the specification, a sequence containing at least 15 consecutive  
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
 CC hybridizes to them under highly stringent conditions, or the complement  
 CC of any of them, or the corresponding RNA. The novel isolated nucleic  
 CC acids of the invention are useful as probes and primers for detecting,  
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
 CC component of a gene chip, in vitro as (anti)sense reagents, and for  
 CC production of recombinant polypeptides. Any of the nucleic acids,  
 CC polypeptides, vectors containing the nucleic acids, cells containing the  
 CC vector or antibodies directed against the polypeptides are useful for  
 CC preparation of pharmaceuticals for prevention and/or treatment of viral  
 CC diseases that are characterised by development of tumours or cell  
 CC degeneration, specifically cancer but also Alzheimer's disease and  
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
 CC patient samples is useful for diagnosis and/or prognosis of these  
 CC diseases. The polypeptides can also be used to generate antibodies, and  
 CC both the polypeptide and antibodies are useful as components of protein  
 CC chips. The nucleic acid sequences of the invention can be used in gene  
 CC therapy. This polynucleotide sequence represents a tumour suppression  
 CC related human fukutin oligonucleotide of the invention  
 XX SQ  
 XX Sequence 17 BP; 7 A; 5 C; 4 G; 1 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 96;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 832 TGGCTTCTCATGGGATC 848  
 DB 17 TGGCTTCTCATGGGATC 1  
 RESULT 74  
 ACDS0767/c  
 ID ACDS0767 standard; RNA; 17 BP.  
 XX AC ACDS0767;  
 XX DT 23-SEP-2003 (first entry)  
 XX DE HBV hammerhead ribozyme substrate sequence #233.  
 XX KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
 KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 XX OS Hepatitis B virus.  
 XX FN WO200281494-A1.  
 XX PD 17-OCT-2002.  
 XX PF 26-MAR-2002; 2002WO-US009187.  
 XX PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT)/ BLAT L.  
 PA (MACE)/ MACEJAK D.  
 PA (MCSW)/ MCSWIGGEN J.  
 PA (MORR)/ MORRISSEY D.

PA (PAVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 XX  
 PI Blatt L, Macejak D, Mcawiggen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;  
 XX  
 DR WPI; 2003-229207/22.  
 XX  
 XX Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
 PT infection.  
 PT  
 XX  
 PS Example 1; Page 140; 387pp; English.  
 XX  
 CC The present invention relates to nucleic acid molecules which modulate  
 CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
 CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
 CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
 CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
 CC DNA. The nucleic acids may be used to modulate the expression of HBV  
 CC genes and HBV viral replication. Also disclosed is a method for screening  
 CC compounds and/or potential therapies directed against HBV, and compounds  
 CC that modulate the expression and/or replication of HCV. The compounds and  
 CC methods of the invention are useful for the treatment of degenerative and  
 CC disease states related to HBV and HCV infection, replication and gene  
 CC expression such as cirrhosis, liver failure, and hepatocellular  
 CC carcinoma. The present sequence represents a substrate for one of the HBV  
 CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberyzyme sequences  
 CC disclosed in the present invention  
 XX  
 SQ Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 96;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 529 AAGGCATTACAGCAGAA 545  
 Db 17 AAGGCATTAAAGCAGAA 1  
 |||||  
 RESULT 75  
 ACC68303/c  
 ID ACC68303 standard; DNA; 17 BP.  
 XX  
 AC ACC68303;  
 XX  
 XX 01-JUL-2003 (first entry)  
 DT  
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 5550.  
 XX  
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; ss.  
 XX  
 OS Mus musculus.  
 XX  
 PN WO2003025176-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004210.  
 XX  
 PR 17-SEP-2001; 2001FR-00011979.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-333167/31.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 363; 738pp; French.  
 XX  
 CC The present invention relates to murine oligonucleotides (ACC62754-  
 CC ACC68806), which are associated with tumour suppression, tumour  
 CC reversion, apoptosis and virus resistance. The oligonucleotides are  
 CC useful as (1) as probes and primers for detecting, identifying,  
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
 CC recombinant polypeptides. The oligonucleotides are useful for preparation  
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia  
 XX  
 SQ Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 96;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 529 AAGGCATTACAGCAGAA 545  
 Db 17 AAGGCATTAAAGCAGAA 1  
 |||||  
 RESULT 75  
 ACC68303/c  
 ID ACC68303 standard; DNA; 17 BP.  
 XX  
 AC ACC68303;  
 XX  
 XX 01-JUL-2003 (first entry)  
 DT  
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2840.  
 XX  
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; ss.  
 XX  
 OS Mus musculus.  
 XX  
 PN WO2003025176-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004210.  
 XX  
 PR 17-SEP-2001; 2001FR-00011979.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-333167/31.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 363; 738pp; French.  
 XX  
 CC The present invention relates to murine oligonucleotides (ACC62754-  
 CC ACC68806), which are associated with tumour suppression, tumour  
 CC reversion, apoptosis and virus resistance. The oligonucleotides are  
 CC useful as (1) as probes and primers for detecting, identifying,

PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-333167/31.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 679; 738pp; French.  
 XX  
 CC The present invention relates to murine oligonucleotides (ACC62754-  
 CC ACC68806), which are associated with tumour suppression, tumour  
 CC reversion, apoptosis and virus resistance. The oligonucleotides are  
 CC useful as (1) as probes and primers for detecting, identifying,  
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
 CC recombinant polypeptides. The oligonucleotides are useful for preparation  
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia  
 XX  
 SQ Sequence 17 BP; 6 A; 2 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 96;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1040 CTCGCTTATTAAGATC 1056  
 Db 17 CTCGCTTATTAAGATC 1  
 |||||  
 RESULT 76  
 ACC65593  
 ID ACC65593 standard; DNA; 17 BP.  
 XX  
 AC ACC65593;  
 XX  
 XX 01-JUL-2003 (first entry)  
 DT  
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2840.  
 XX  
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;  
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;  
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;  
 KW schizophrenia; ss.  
 XX  
 OS Mus musculus.  
 XX  
 PN WO2003025176-A2.  
 XX  
 PD 27-MAR-2003.  
 XX  
 PF 17-SEP-2002; 2002WO-IB004210.  
 XX  
 PR 17-SEP-2001; 2001FR-00011979.  
 XX  
 PA (MOLE-) MOLECULAR ENGINES LAB.  
 XX  
 PI Telerman A, Amson R, Tuijnder M;  
 XX  
 DR WPI; 2003-333167/31.  
 XX  
 PT New isolated nucleic acid, useful for treating viral diseases associated  
 PT with tumors and cell degeneration, also related polypeptides, antibodies  
 PT and transfected cells.  
 XX  
 PS Disclosure; Page 363; 738pp; French.  
 XX  
 CC The present invention relates to murine oligonucleotides (ACC62754-  
 CC ACC68806), which are associated with tumour suppression, tumour  
 CC reversion, apoptosis and virus resistance. The oligonucleotides are  
 CC useful as (1) as probes and primers for detecting, identifying,



CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of  
 CC recombinant polypeptides. The oligonucleotides are useful for preparation  
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
 CC are characterised by development of tumours or cell degeneration,  
 CC specifically cancer but also Alzheimer's disease and schizophrenia

XX Sequence 17 BP; 8 A; 3 C; 3 G; 3 T; 0 U; 0 Other;  
 SQ Query Match 0.8%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 96;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1428 GATCAAGCAGATGAA 1444  
 |||||  
 Db 1 GATCAAGCAGATGAA 17

RESULT 77  
 ADM58132/C  
 ID ADM58132 standard; RNA; 17 BP.

XX AC ADM58132;

XX DT 03-JUN-2004 (first entry)

XX DE Hepatitis B virus (HBV) RNA target sequence #266.

XX KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;  
 KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;  
 KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;  
 KW virucide; hepatotropic; antiinflammatory; cytostatic.

XX OS Hepatitis B virus.

XX PN US2004054156-A1.

XX PD 18-MAR-2004.

XX PF 15-JAN-2003; 2003US-00342902.

XX PR 14-MAY-1992; 92US-00882712.

XX PR 07-FEB-1994; 94US-00193627.

XX PR 08-NOV-1999; 99US-00436430.

XX PR 20-MAR-2000; 2000US-00531025.

XX PR 09-AUG-2000; 2000US-00636385.

XX PR 24-OCT-2000; 2000US-00696347.

XX PR 08-JUN-2001; 2001US-00877478.

XX PA (DRAP/) DRAPER K.

XX PA (BLAT/) BLATT L.

XX PA (MCSW/) MCSWIGGEN J A.

XX PA (MORR/) MORRISSEY D.

XX PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;

XX PS WPI; 2004-247781/23.

XX PT Novel enzymatic nucleic acid molecule such as DNazymes and inozymes  
 PT specifically cleaving RNA derived from hepatitis B virus and comprising  
 PT one or more binding arms, useful for treating hepatitis and cirrhosis.

XX PS Disclosure; SEQ ID NO 266; 122pp; English.  
 XX CC The invention relates to an enzymatic nucleic acid molecule that  
 CC specifically cleaves RNA derived from hepatitis B virus (HBV) and  
 CC comprising one or more binding arms, without requiring the presence of a  
 CC 2'-OH group within the molecule for activity. The nucleic acids are  
 CC useful for treating hepatitis B virus infection, hepatitis,  
 CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in  
 CC combination with other therapies such as lamivudine and interferons. The  
 CC nucleic acids are useful as diagnostic tools to examine genetic drift and  
 CC mutations within diseased cells, for detecting the presence of HBV RNA in

CC a cell, for the study of RNA and for down-regulating gene expression of  
 CC target genes in bacterial, fungal, viral, plant or mammalian cells. This  
 CC sequence represents an HBV RNA target sequence, used in the scope of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 17;  
 Best Local Similarity 94.1%; Pred. No. 96;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 529 AAGCATTACAGCAGAA 545  
 |||||  
 Db 17 AAGCATTAAAGCAGAA 1

RESULT 78  
 ADR05333/C

XX ID ADR05333 standard; DNA; 17 BP.

XX AC ADR05333;

XX DT 21-OCT-2004 (first entry)

XX DE Silkorm juvenile hormone acid transmethylease cDNA PCR primer FP1.

XX KW ss; primer; insect repellent; insect attractant;  
 KW reproductive maturation regulator; imago; diapause inducer;  
 KW diapause inhibitor; larva; transformation regulator; pupa;  
 KW juvenile hormone acid transmethylease; silkworm; Bombyx mori;  
 KW Drosophila melanogaster; mosquito; Anopheles gambia; Spodoptera litura;  
 KW Helicoverpa armigera; molting; transformation; diapause; blastogenesis;  
 KW polymorphism; arthropod; cotton bollworm; PCR primer.

XX OS Bombyx mori.

XX PN WO2004065604-A1.

XX PD 05-AUG-2004.

XX PF 20-JAN-2003; 2003WO-JP000415.

XX PR 20-JAN-2003; 2003WO-JP000415.

XX PA (NAG-) NAT AGRIC RES ORG JAPAN.

XX PI Shinoda T, Itoyama K, Hamamura T;

XX PS WPI; 2004-580727/56.

XX PT New DNA encoding protein having juvenile-hormone acid transmethylease  
 PT activity, useful for screening for a compound controlling the expression  
 PT level of juvenile-hormone acid transmethylease DNA.

XX PS Example 1; SEQ ID NO 11; 118pp; Japanese.

XX CC The invention relates to a DNA (I) encoding a protein (II) having  
 CC juvenile-hormone acid transmethylease activity selected from the DNA from  
 CC silkworm (Bombyx mori), Drosophila melanogaster, mosquito (Anopheles  
 CC gambiae), Spodoptera litura and Helicoverpa armigera, their encoded  
 CC proteins (S2), DNAs (D2) that hybridize under stringent conditions with  
 CC the nucleic acids or an amino acid sequence (S3) comprising any one of  
 CC (S2) in which one or more amino acids are substituted, deleted, inserted  
 CC and/or added. (I) is useful for screening a compound that controls the  
 CC expression level of (I), and as a controlling agent of molting and  
 CC transformation, reproductive, diapause, blastogenesis, action,  
 CC polymorphism or lifetime of arthropod. (II) is useful for screening a  
 CC compound having binding affinity with respect to (II), which involves  
 CC contacting test compound with (II), detecting the binding of (II) with  
 CC test compound, and selecting the compound that binds with (II). (II) is  
 CC useful for screening a compound that controls the activity of (II), which  
 CC involves contacting test compound with (II), measuring the activity of

CC (II), and selecting the compound that decreases or increases the activity  
CC of (II), based on comparison of the activity of (II) in absence of test  
CC compound. (II) is useful for manufacturing activated juvenile hormone.  
CC This sequence corresponds to a PCR primer used to amplify and isolate the  
CC transmethylease cDNA from the silkworm *Bombyx mori*.

Query Match	0.8%	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	94.1%;	Pred. No. 96;		
Matches 16;	Conservative	0;	Mismatches 1;	Indels 0;
Gaps	0;			

Qy 1834 GAAAAAAAAAAAAAAAAA 1850  
Dy 17 GAAAAAAAAAAAAAAAAA 1

RESULT 79  
ADR27061  
ID ADR27061 standard; DNA: 17 BP.

04-NOV-2004 (first entry)

DE Human single nucleotide polymorphism detection primer #151.

KW as; primer; single nucleotide polymorphism; SNP; diagnosis;  
 KW disease association; linkage analysis; autoimmune disease;  
 KW rheumatoid arthritis; diabetes; multiple sclerosis;  
 KW systemic lupus erythematosus; inflammatory bowel disease; psoriasis;  
 KW thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;  
 KW glomerulonephritis; Graves' disease; myocarditis; Sjogren disease;  
 KW primary systemic vasculitis; genotyping; gene therapy; PCR primer.

xx Homo sapiens.

AA  
PN  
WO2004067779-A2.

PD 12-AUG-2004.

30-JAN-2004: 2004WO-US002652.

30-JAN-2003: 2003US-0443566P.

PR 25-APR-2003; 2003US-0465241P.

PR 13-NOV-2003; 2003US-0519270P.

PA (APPL-) APPLERA CORP.

PI Cargill M, Begovich AB, Car

DR WPI; 2004-594223/57.

PT New single nucleotide polymorphisms (SNPs) associated with rheuma

PT developing RA or oth

**XX**

The invention relates to an isolated nucleic acid molecule comprising at least 8 contiguous nucleotides where one of the nucleotides is a single nucleotide polymorphism (SNP) selected from any one of the nucleotide sequences of SEQ ID Nos:1-669 and 1339-49582, or their complements. The SNPs are useful as targets for the design of diagnostic reagents and the development of therapeutic agents, as well as for disease association and linkage analysis. In particular, the SNPs are useful for identifying an individual who is at an increased or decreased risk for developing an autoimmune disease such as rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel diseases, psoriasis, thyroiditis, celiac disease, pernicious anaemia,

asthma, vitiligo, glomerulonephritis, Graves' disease, myocarditis, Sjogren disease, or primary systemic vasculitis. Methods associated with the SNPs are useful for early detection of the disease, for providing clinically important information for the prevention and/or treatment of the autoimmune diseases particularly rheumatoid arthritis, and for screening and selecting therapeutic agents. The SNPs are useful for human identification applications. The genes containing the SNPs are useful for treating the diseases defined above. The nucleic acid molecules are useful as hybridization probes for genotyping SNPs in messenger RNA, cDNA, genomic DNA, and genomic clones. The nucleic acid molecules are useful for constructing host cells expressing a part or all of the nucleic acid molecules and variant peptides, for constructing transgenic animals, for assaying or screening drugs that modulate nucleic acid expression, or for gene therapy in patients whose cells have aberrant gene expression. This sequence corresponds to a PCR primer which hybridises to the nucleic acids of the invention to amplify the SNP containing region. (Note: SEQ ID NOS 1-49582 are claimed and stated as being provided in the specification, however these sequences are not provided in the printed specification).

SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match	0.8%	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	94.1%	Pred. No. 96;		

428 ACCCCACTGGGAGAGGG 444  
Ov

Db  
1 ACTCCACTGGGAGAGGG 17

RESULT 80

AAX22509

ID AAX22509 standard; RNA; 18 BP.

AC AAX22509:

25-MAR-2003 (revised)

DT 21-MAY-1999 (first entry)

DE Streptomyces sp. dac gene RBS RNA fragment.

xylanase; acidophilic; thermostable; XYL I; XYL II; plant biomass;  
KW  
hemicellulase; beta-1,4 bond; xylosic chain; xylan; D-xylose; paper;  
KW  
mulp; chlorine bleaching; feed; beta-glucan; cellulose; lignin; ds;  
KW

Strep. omvces sp.

US5871730-A.

16-FEB-1999

29-III-1994: 94US-00282197.

XX  
PR 29-III.-1994. 94IIS-00282197.XX  
PA (ITVSH ) INTV SHEPPROCKE

XX  
PT Beaulieu C Przeziński R Nerv CV:

XX  
DB WPT: 1996-141348/14.

XX New acidophilic and thermostable xylanase enzymes from *Actinomadura* sp.  
PT  
PT FC7 - useful for treating plant biomass, especially paper and wood pulp,  
PT to degrade hemicellulose and hydrolyse xylan.  
PT

Example 7: Fig 7: 60pp: English.

XX CC This invention describes the use of novel acidophilic and thermostable  
CC xylanase enzymes (XYL I and XYL II) from *Actinomadura* sp. FC7 which  
CC retain their activity under harsh industrial conditions (e.g. high  
CC temperature or wide pH ranges) and may be secreted by recombinant host  
CC cells, to treat plant biomass. Xylanases XYL I and XYL II are part of

CC large group of hemicellulase enzymes and function by cutting the beta-1,4  
 CC bonds within the xylosic chain of xylan (a polymer of D-xylose residues  
 CC that is a major constituent of hemicellulose). This means that they may  
 CC be used in the paper and pulp industry to improve the efficiency of the  
 CC bleaching process by degrading the structure of the material. XYL I and  
 CC XYL II may also be used to treat feed, by degrading a substrate with a  
 CC high beta-glucan or cellulose content. XYL I and XYL II retain their  
 CC activity at high temperatures (e.g. 70 deg. C) and at low pHs (e.g. 4.0).  
 CC conditions which tend to denature most known xylanases. Enzymes that  
 CC remain active in these conditions may be used in industrial processes  
 CC that are carried out at high temperature and low pH to speed up other,  
 CC non-enzymatic reactions, minimising costs, energy requirements, and the  
 CC risk of pollution, (e.g. enzymes XYL I and XYL II can be used to  
 CC facilitate chlorine bleaching of paper pulp which is carried out in hot,  
 CC acidic conditions). Pretreatment with XYL I and XYL II, allows the  
 CC bleaching agents to penetrate better, to remove lignin from the pulp and  
 CC 'bleach' the colouration from it. This means smaller quantities of the  
 CC agents can be used to produce the same or a better result. Also,  
 CC disrupting the structure aids water drainage. NOTE: This patent is an  
 CC equivalent to FI9503640. (Updated on 25-MAR-2003 to correct DR field.)  
 CC  
 SQ Sequence 18 BP; 7 A; 2 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
 Best Local Similarity 82.4%; Pred. No. 1e+02;  
 Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 443 GGGAGAGAGAACTGCTG 459  
 Db 2 GGGAGAGAGAACTGCTG 18

RESULT 81  
 AA16008/C  
 ID AA16008 standard; DNA; 18 BP.  
 XX  
 AC AA16008;  
 XX  
 XX  
 DT 21-MAY-1998 (first entry)  
 XX  
 DE PCR primer D-R used to identify Sox-3 gene mutations in mice.  
 XX  
 XX Mutation; Sox-3; ENU mutagenesis; mutational screening; recessive;  
 KW single strand conformation polymorphism; SSCP; phenotypic alteration;  
 KW PCR primer; amplify; ss.  
 XX  
 XX Synthetic.  
 OS Mus sp.  
 XX WO9744485-A1.  
 XX  
 XX 27-NOV-1997.  
 XX  
 PF 16-MAY-1997; 97WO-GB001354.  
 XX  
 PR 17-MAY-1996; 96GB-00010355.  
 XX  
 XX (HEXA-) HEXAGEN TECHNOLOGY LTD.  
 PA  
 XX Goodfellow PN;  
 XX  
 XX WPI; 1998-018536/02.  
 XX  
 XX Identification of mutation(s) in genes of interest - without prior  
 PT observation of phenotypic alteration in the mutated organism or cell.  
 XX  
 PS Example 4; Page 41; 66pp; English.  
 XX  
 XX PCR primers AA16001-18 were used to identify mutations in Sox-3 using  
 CC the method of the invention. The primers are located throughout the gene  
 CC and are unique to Sox-3. The method comprises testing a nucleic acid  
 CC sample from a mutated organism for a mutation in a gene of interest  
 CC without the prior observation of a phenotypic alteration in the mutated

CC organism resulting from the mutation. Sox-3 is a member of the Sox gene  
 CC family, a family of about 20 genes which all encode a "HMG" box, which is  
 CC a DNA-binding domain. Mice were mutagenised using ENU mutagenesis. The  
 CC mutagenised mice were tested by PCR with each primer set and fluorescent  
 CC single strand conformation polymorphism (SSCP), which identifies mice  
 CC carrying mutations in Sox-3. The method provides mutational screening  
 CC based on genomic and genetic techniques rather than on phenotypic  
 CC observation. The method identifies and characterises genes via  
 CC mutagenesis to identify genes encoding products which may have  
 CC therapeutic benefit. The method also identifies the presence of mutations  
 CC in a gene which do not rely solely upon prior matching of a gene with a  
 CC disease. Heterozygotic organisms can also be screened to identify those  
 CC carrying a mutation in a copy of a gene of interest even though the gene  
 CC may be recessive and therefore causes no phenotypic alteration  
 XX  
 SQ Sequence 18 BP; 1 A; 6 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
 Best Local Similarity 94.1%; Pred. No. 1e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 CGCCTCGTCGCGCGCG 46  
 Db 18 CGCCTCGTCGCGCGCG 2

RESULT 82  
 AA43267/C  
 ID AA43267 standard; DNA; 18 BP.  
 XX  
 AC AA43267;  
 XX  
 XX 11-FEB-2000 (first entry)  
 DT  
 XX  
 DE Murine Sox3 gene PCR primer 8.  
 XX  
 XX Screening; mutation; treatment; disease; drug discovery; PCR primer; ss.  
 XX Mus musculus.  
 OS  
 XX US5994075-A.  
 PN  
 XX 30-NOV-1999.  
 PD  
 XX 16-MAY-1997; 97US-00857946.  
 PF  
 XX 17-MAY-1996; 96US-0017824P.  
 PR  
 XX (HEXA-) HEXAGEN TECHNOLOGY LTD.  
 XX  
 XX Goodfellow PN;  
 XX  
 XX WPI; 2000-038255/03.  
 DR  
 XX  
 XX Identifying a mutation in a gene of interest in an organism useful for  
 PT identifying genes encoding products which may have therapeutic benefits.  
 XX  
 XX Example 5; Col 63-64; 70pp; English.  
 XX  
 XX This invention describes a novel mutational screening method based on  
 CC genomic and genetic techniques to identify and characterize a mutation in  
 CC a gene of interest without first selecting a phenotypic characteristic.  
 CC The screening methods are useful for identifying genes encoding products  
 CC which may have therapeutic benefit for treating human or animal diseases.  
 CC The method can be used for the DNA mutation screening of a class or a  
 CC family of genes providing a rapid assay for identifying mutant genes. The  
 CC methods produce organisms which can be used for drug discovery e.g.  
 CC providing a model for the study and treatment of a disease state, allow  
 CC in vitro assessment of drug activity and interbreeding of mutants which  
 CC allow investigation of gene interactions in the overall phenotype. A  
 CC range of phenotypes associated with different mutations, and specified  
 CC mutations in a gene of interest can be determined. The method can be  
 CC adapted to screen for a mutation in two or more genes of interest in an

CC organism. The methods allow mutations in a gene of interest to be  
 CC identified without having to rely on matching a gene with a disease.  
 CC AAZ43260-Z43421 represent PCR primers used in the method of the invention

XX SQ Sequence 18 BP; 1 A; 6 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
 Best Local Similarity 94.1%; Pred. No. 1e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 CGCCTCGTCGCGCGCG 46  
 |||||  
 Db 18 CGCGCGCGTCGCGCGCG 2

RESULT 83  
 AAA05252/c  
 ID AAA05252 standard; DNA; 18 BP.  
 XX AC AAA05252;  
 XX DT 19-MAY-2000 (first entry)  
 XX DE PCR primer D-R used in Sox-3 amplicon generation.  
 XX KW PCR primer; Sox-2; Sox-3; T gene; Tyrosinase; MGF; Sry; c-kit; Tryp-1;  
 KW Pax-6; mutation detection; therapeutic target identification; mouse;  
 KW mast cell growth factor; ss.  
 XX OS Mus sp.  
 XX PN US6015670-A.  
 XX PD 18-JAN-2000.  
 XX PF 14-NOV-1997; 97US-00970740.  
 XX PR 17-MAY-1996; 96US-0017824P.  
 PR 16-MAY-1997; 97US-00857946.  
 XX (HEXA-) HEXAGEN TECHNOLOGY LTD.  
 XX Goodfellow PN;  
 XX WPI; 2000-181139/16.  
 XX Detecting mutations in selected genes, useful e.g. for identifying  
 PT therapeutic targets or products, by analyzing DNA in mutated embryonic  
 PT stem cells without phenotypic characterization.  
 XX Example 5; Col 31; 66pp; English.

XX PCR primers AAA05245-A05406 are used to generate amplicons from the mouse  
 CC Sox-3 gene, Sox-2 gene, T gene, tyrosinase gene, Tryp-1 gene, Sry gene,  
 CC MGF (mast cell growth factor) gene, c-kit gene, and the Pax-6 gene. The  
 CC primers are used in a method for the identification of a mutation in a  
 CC selected gene in a tissue without the prior observation of a phenotypic  
 CC alteration in the mutated organism or cell. The method is used to  
 CC identify mutations in a selected gene that encode products of potential  
 CC therapeutic activity or that are potential targets, particularly where  
 CC the gene of interest has been identified as a candidate gene by  
 CC positional cloning. Other applications are determining functions of genes  
 CC ; detecting the range of phenotypes associated with different mutations  
 CC in a particular gene and identification of particular mutations. Animals  
 CC containing an identified mutation are used as models for studying  
 CC diseases or their treatment, and cells from them for in vitro assessment  
 CC of drug action. Interbreeding of mutant mice is used to investigate  
 CC genetic interaction in the overall phenotype

XX SQ Sequence 18 BP; 1 A; 6 C; 11 G; 0 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 18;  
 Best Local Similarity 94.1%; Pred. No. 1e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 30 CGCCTCGTCGCGCGCG 46  
 |||||  
 Db 18 CGCGCGCGTCGCGCGCG 2

RESULT 84  
 AAA05675  
 ID AAA05675 standard; DNA; 18 BP.  
 XX AC AAA05675;  
 XX DT 31-JUL-2001 (first entry)  
 XX DE Human zmsel mapping antisense PCR primer.

XX KW Human; zmsel protein; Cdc42/Rac interactive binding protein; CRIB;  
 KW Wiskott-Aldrich Syndrome; cancer; tumour; invasion; metastasis; asthma;  
 KW digestion; actin polymerisation; cytoskeletal reorganisation; arthritis;  
 KW testicular function; muscle inflammation; inflammatory bowel disease;  
 KW diverticulitis; male infertility; male contraceptive agent; myocarditis;  
 KW spermatogenesis; sperm capacitation; reperfusion ischaemia; psoriasis;  
 KW melanoma; atherosclerosis; pelvic inflammatory disease; PID; eczema;  
 KW scleroderma; cytostatic; vasotropic; dermatological; gene therapy;  
 KW PCR primer; ss.  
 XX OS Homo sapiens.  
 XX PN WO200134803-A2.  
 XX PD 17-MAY-2001.  
 XX PF 09-NOV-2000; 2000WO-US030945.  
 XX PR 10-NOV-1999; 99US-00438564.  
 XX (ZYMO) ZYMOGENETICS INC.  
 XX PI Holloway JL, Gao Z, Whitmore TE;  
 XX WPI; 2001-335928/35.

XX Novel human CRIB protein, zmsel and polynucleotide encoding the protein,  
 PT for detecting human chromosomal abnormalities and for treating cancer,  
 PT cardiovascular and inflammatory conditions.

XX Example 3; Page 126; 132pp; English.

XX The present invention relates to DNA and protein for zmsel, a novel human  
 CC Cdc42/Rac interactive binding (CRIB) protein. CRIB proteins are  
 CC implicated in human disease such as Wiskott-Aldrich Syndrome. Zmsel  
 CC metastasis, gene transcription, contractility of various tissues, actin  
 CC polymerisation and cytoskeletal reorganisation, digestion, testicular  
 CC function and fertility. Zmsel sequence and its modulators are useful for  
 CC treating cancer, inflammatory heart or cardiovascular conditions, muscle  
 CC inflammation, inflammation during and after surgery, arthritis, asthma,  
 CC inflammatory bowel diseases or diverticulitis, myocarditis, scleroderma,  
 CC atherosclerosis, pelvic inflammatory disease (PID), eczema and other  
 CC inflammatory diseases, male infertility or as male contraceptive agents  
 CC and for modulating spermatogenesis and sperm capacitation. zmsel and anti  
 CC -zmsel antibodies are useful in diagnosing inflammatory diseases, such as  
 CC reperfusion ischaemia, psoriasis, arthritis, melanoma and other  
 CC inflammatory diseases, male reproductive cancers such as prostate and  
 CC testicular cancers. Zmsel polynucleotide sequences are useful as probes  
 CC or primers for detecting human chromosomal abnormalities. zmsel sequence  
 CC is used in gene therapy. The present sequence is an antisense PCR primer  
 CC used for mapping human zmsel sequence

XX SQ Sequence 18 BP; 1 A; 9 C; 3 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 18;

Best Local Similarity 94.1%; Pred. No. 1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 714 TCCGTGGCTCCTTCTC 730  
DB 1 TCCGGGGCTCTTCTC 17

RESULT 85  
ADBA9435  
ID ADB49435 standard; DNA; 18 BP.  
AC ADB49435;  
XX  
DT 04-DEC-2003 (first entry)  
DE Human Zmsel PCR primer ZC18860.  
XX  
KW primer; human; ss; PCR; Zmsel; wound healing; anti-bacterial; anti-viral;  
KW inflammation; asthma; arthritis; diverticulitis; cancer;  
KW vasoconstriction; heart inflammation; immunogenic.  
XX  
OS Homo sapiens.  
XX  
FN US6573069-B1.  
XX  
PD 03-JUN-2003.  
XX  
PF 09-NOV-2000; 2000US-00710794.  
XX  
PR 10-NOV-1999; 99US-0164685P.  
XX  
PA (ZYMO) ZYMOGENETICS INC.  
XX  
PI Holloway JL, Gao Z, Whitmore TE;  
XX  
DR WPI; 2003-764570/72.  
XX  
XX New isolated polynucleotide encoding Zmsel polypeptide having a Cdc42/Rac  
PT interactive binding (CRIB) motif, useful for diagnosing and treating  
PT cancer and inflammatory conditions.  
XX  
PS Example 3; Col 77-78; 55pp; English.  
XX  
XX The invention relates to an isolated polynucleotide encoding a Zmsel  
CC polypeptide. Cells expressing the nucleic acid are useful for producing  
CC polypeptides. The nucleic acid is useful as probes or primers to clone 5'  
CC non-coding regions of Zmsel gene. The nucleic acid is also useful for  
CC detecting allelic differences between diseased or non-diseased  
CC individuals at the Zmsel chromosomal locus. The Zmsel polypeptides are  
CC useful as research reagents and as an amino acid source for cell culture.  
CC The Zmsel present in heart and skeletal muscle are useful in promoting  
CC wound healing effects and exhibits anti-bacterial or anti-viral effects.  
CC The Zmsel polypeptides are useful for treating inflammatory conditions  
CC such as asthma, arthritis, diverticulitis. The Zmsel polypeptide is  
CC useful for treating cancer, vasoconstriction, heart inflammation. The  
CC Zmsel polypeptide is useful as an immunogen to elicit an immune response  
CC in an animal. The Zmsel polypeptide is useful for diagnosing cancer. The  
CC present sequence represents a human Zmsel PCR primer.  
XX  
SQ Sequence 18 BP; 1 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 714 TCCGTGGCTCCTTCTC 730  
DB 1 TCCGGGGCTCTTCTC 17

RESULT 86  
ADL91734

Best Local Similarity 94.1%; Pred. No. 1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 336 GGCTCCCAAGAACCTAGA 352  
DB 1 GGCTCCATGAACTAGA 17

RESULT 87  
ADS16437  
ID ADS16437 standard; DNA; 18 BP.  
XX  
AC ADS16437;  
XX  
DT 02-DEC-2004 (first entry)

ADL91734 standard; DNA; 18 BP.  
ADL91734;  
03-JUN-2004 (first entry)  
Endothelin 3 (SYX 3) antisense S-oligonucleotide, SEQ ID NO:135.  
Synovial sarcoma; SYX; sarcoma-associated gene; drug screening;  
Frizzled homologue 10; FZD10-associated disease; colorectal cancer;  
gastric cancer; chronic myeloid leukaemia; acute myeloid leukaemia;  
FZD10 antibody; diagnosis; prognosis; prevention; cytostatic;  
gene therapy; antisense oligonucleotide; ss.  
Homo sapiens.  
WO2004020668-A2.  
11-MAR-2004.  
21-AUG-2003; 2003WO-JP010591.  
30-AUG-2002; 2002US-0407506P.  
11-JUL-2003; 2003US-0486195P.  
(ONCO-) ONCOTHERAPY SCI INC.  
(UVTY) UNIV TOKYO.  
Nakamura Y, Katagiri T;  
WPI; 2004-239208/22.  
Use of a compound or composition for diagnosing, treating or preventing  
synovial sarcoma or a disease associated with Frizzled homologue 10, e.g.  
colorectal cancer, gastric cancer, chronic myeloid leukemia or acute  
myeloid leukemia.  
Example 4; SEQ ID NO 135; 143pp; English.  
The invention relates to the use of a compound or composition for  
diagnosing, prognosing, treating or preventing synovial sarcoma or a  
Frizzled homologue 10 (FZD10)-associated disease in a patient. The  
invention encompasses the use of sarcoma-associated genes designated SYX  
1-26 or their encoded proteins in diagnosing of synovial sarcoma and in  
screening for compounds for treating or preventing this condition; and  
the use of antibodies specific for FZD10 (FZD10 is also referred to as  
SYX 1 in the specification) for diagnosing, treating or preventing FZD10-  
associated diseases. The compound, composition and methods of the  
invention are useful for diagnosing, treating or preventing synovial  
sarcoma or FZD10-associated diseases, such as colorectal cancer, gastric  
cancer, chronic myeloid leukemia or acute myeloid leukemia. Sequences  
ADL91688-ADL91751 represent antisense and control S-oligonucleotides used  
in a study of antisense-mediated inhibition of the expression of synovial  
sarcoma-associated genes.  
Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;  
Best Local Similarity 94.1%; Pred. No. 1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 336 GGCTCCCAAGAACCTAGA 352  
DB 1 GGCTCCATGAACTAGA 17

RESULT 87  
ADS16437  
ID ADS16437 standard; DNA; 18 BP.  
XX  
AC ADS16437;  
XX  
DT 02-DEC-2004 (first entry)

XX DE Allele A oligo #2, used in polynucleotide sequence detection.

XX KW Single nucleotide polymorphism; SNP; genotyping; ss.

XX OS Synthetic.

XX PN US2004175704-A1.

XX PD 09-SEP-2004.

XX XX 12-MAY-2003; 2003US-00436231.

XX PF 06-MAR-2003; 2003US-0452481P.

XX PR (STRA-) STRATAGENE.

XX PA Sorge JA, Firmin A;

XX PI WPI; 2004-642120/62.

XX DR Determining polynucleotide sequence differences by amplifying

XX PT polynucleotide in presence of labeled nucleotide and detecting variation

XX PT based on incorporation frequency of labeled nucleotide compared to known

XX PT reference frequency.

XX XX Disclosure; SEQ ID NO 2; 52pp; English.

XX PS The invention relates to compositions, kits and methods for detecting

XX CC polynucleotide sequence differences. The method involves amplifying the

XX CC polynucleotide of interest in the presence of a labelled nucleotide and

XX CC detecting variation based on incorporation frequency of labelled

XX CC nucleotide compared to known reference frequency. The method is useful

XX CC for determining a sequence difference such as a single nucleotide

XX CC polymorphism (SNP) or a tandem repeat, between a region of interest in a

XX CC polynucleotide and a reference sequence. It is useful for determining the

XX CC presence of a mutation in a region of interest in a polynucleotide and is

XX CC also useful for genotyping. The present sequence is an allelic

XX CC oligonucleotide used in polynucleotide sequence detection.

XX SQ Sequence 18 BP; 0 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

XX Query Match 0.8%; Score 15.4; DB 1; Length 18;

XX Best Local Similarity 94.1%; Pred. No. 1e+02;

XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1445 TGTTCGTCTGCTGCTTT 1461

DB 2 TGTTCGTCTGCTGCTTT 18

RESULT 88

ADSL6436/c

ID ADS16436 standard; DNA; 18 BP.

XX AC ADS16436;

XX XX 02-DEC-2004 (first entry)

XX DE Allele A oligo #1, used in polynucleotide sequence detection.

XX KW Single nucleotide polymorphism ; SNP; genotyping; ss.

XX OS Unidentified.

XX PN US2004175704-A1.

XX XX 09-SEP-2004.

XX PF 12-MAY-2003; 2003US-00436231.

XX PR 06-MAR-2003; 2003US-0452481P.

XX DR

PA (STRA-) STRATAGENE.

XX Sorge JA, Firmin A;

XX PI WPI; 2004-642120/62.

XX DR Determining polynucleotide sequence differences by amplifying

XX PT polynucleotide in presence of labeled nucleotide and detecting variation

XX PT based on incorporation frequency of labeled nucleotide compared to known

XX PT reference frequency.

XX XX Disclosure; SEQ ID NO 1; 52pp; English.

XX PS The invention relates to compositions, kits and methods for detecting

XX CC polynucleotide sequence differences. The method involves amplifying the

XX CC polynucleotide of interest in the presence of a labelled nucleotide and

XX CC detecting variation based on incorporation frequency of labelled

XX CC nucleotide compared to known reference frequency. The method is useful

XX CC for determining a sequence difference such as a single nucleotide

XX CC polymorphism (SNP) or a tandem repeat, between a region of interest in a

XX CC polynucleotide and a reference sequence. It is useful for determining the

XX CC presence of a mutation in a region of interest in a polynucleotide and is

XX CC also useful for genotyping. The present sequence is an allelic

XX CC oligonucleotide used in polynucleotide sequence detection.

XX SQ Sequence 18 BP; 8 A; 5 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 18;

Best Local Similarity 94.1%; Pred. No. 1e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1445 TGTTCGTCTGCTGCTTT 1461

DB 17 TGTTCGTCTGCTGCTTT 1

RESULT 89

ABK10366

ID ABK10366 standard; DNA; 19 BP.

XX AC ABK10366;

XX XX 21-MAY-2002 (first entry)

XX DT Rat Atrial naturetic factor RT-PCR primer #1.

XX DE

XX KW Vascular inflammation; cardiac tissue damage; inflammatory response;

XX KW inflammation-related disorder; trauma induced inflammation;

XX KW surgically induced inflammation; bacterial induced inflammation;

XX KW viral induced inflammation; cardiovascular disorder; atherosclerosis;

XX KW coronary artery disease; aneurysm; arteriosclerosis; angina;

XX KW myocardial infarction; embolism; stroke; thrombosis; Kawasaki disease;

XX KW vascular plaque inflammation; vascular plaque rupture; calcification;

XX KW vascular calcification; valvar calcification; PCR; primer; ss;

XX KW aldosterone blocker.

XX OS Rattus sp.

XX XX WO200209683-A2.

XX PN 07-FEB-2002.

XX PD

XX XX 26-JUL-2001; 2001WO-US023520.

XX PF

XX XX 27-JUL-2000; 2000US-0221358P.

XX PR 12-JAN-2001; 2001US-0261352P.

XX XX (PHAA ) PHARMACIA CORP.

XX PA

XX XX Rocha R, Zack MD, McMahon EG;

XX PI WPI; 2002-195909/25.

XX DR

XX XX

PT Treating or preventing an inflammation-related disorder e.g. coronary  
PT artery disease, aneurysm, arteriosclerosis and myocardial infarction,  
PT comprises treatment with an aldosterone blocker.  
PS  
XX Example 18; Page 111; 210pp; English.  
XX  
CC The invention relates to treating or preventing an inflammation-related  
CC disorder comprises treatment with an aldosterone blocker or its salts.  
CC Rats were treated with aldosterone in the presence of salt to induce  
CC vascular inflammation and cardiac tissue damage. The damage induced by  
CC the treatment was preceded by an inflammatory response characterised by  
CC upregulation of proinflammatory molecules. Administration of eplerenone  
CC markedly attenuated this initial vascular inflammatory response and  
CC subsequent myocardial infarction. The aldosterone blocker is used for  
CC treating or preventing inflammation-related disorders (occurring in  
CC tissue or organs), such as trauma induced inflammation, surgically  
CC induced inflammation, bacterial induced inflammation or viral induced  
CC inflammation, e.g. cardiovascular disorders (e.g. coronary artery  
CC disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial  
CC infarction, embolism, stroke, thrombosis, angina, vascular plaque  
CC inflammation, vascular plaque rupture, Kawasaki disease, calcification  
CC (e.g. vascular calcification and valvar calcification) and inflammation  
CC or cardiovascular disorder which occurs in whole or in part in the  
CC kidney, brain or heart. The present sequence is an RT-PCR (reverse  
CC transcriptase PCR) primer for a rat gene encoding a molecule involved in  
CC regulation of inflammation whose expression may be altered by  
CC administration of an aldosterone blocker  
XX  
SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY . 718 TGGGCTCTCTTCCATC 734  
DB ||| ||||| ||||| |||||  
1 TGGGCTCTCTTCCATC 17  
RESULT 90  
ABA95109  
ID ABA95109 standard; DNA; 19 BP.  
AC ABA95109;  
XX  
XX 20-MAY-2002 (first entry)  
DE ANP gene specific forward primer.  
XX  
XX Aldosterone; cyclooxygenase-2; cardiovascular; eplerenone; cardiant;  
KW vasotrophic; antiarteriosclerotic; cerebroprotective; thrombolytic; rat;  
KW antianginal; antiinflammatory; vulnerable; antibacterial; virucide; ss;  
KW nephrotropic; atrial natriuretic factor; ANP; PCR primer.  
XX  
OS Rattus sp.  
XX  
XX WO200209759-A2.  
FN  
XX 07-FEB-2002.  
PD  
XX  
XX 26-JUL-2001; 2001WO-US023601.  
PF  
XX  
XX 27-JUL-2000; 2000US-0221364P.  
PR  
XX 12-JAN-2001; 2001US-0261497P.  
PR  
XX (PHAA ) PHARMACIA CORP.  
FA  
XX Rocha R, Zack MD, McMahon EG;  
PI  
XX WPI; 2002-227077/28.  
XX  
XX Method for treating or preventing inflammation-related cardiovascular  
PT disorders comprises administration of an aldosterone antagonist and

PT cyclooxygenase-2 inhibitor combination.  
XX Example 18; Page 160; 273pp; English.  
XX  
CC The invention provides a method for treating or preventing an  
CC inflammation-related cardiovascular disorder. The method involves  
CC administration of an aldosterone antagonist and cyclooxygenase-2  
CC inhibitor combination or their salts. The method is used to treat or  
CC prevent inflammation-related cardiovascular disorders in the heart  
CC kidney and/or brain, e.g. coronary artery disease, aneurysm, embolism,  
CC arteriosclerosis, atherosclerosis, myocardial infarction, thrombosis,  
CC stroke, angina, vascular plaque inflammation, vascular plaque rupture,  
CC Kawasaki disease, vascular or valvar calcification, trauma-, surgically-,  
CC bacterial- or viral-induced inflammation. The use of eplerenone in  
CC conjunction with the aldosterone receptor antagonist markedly attenuates  
CC the initial vascular inflammatory response and subsequent myocardial  
CC injury. Sequences ABA95108-138 represent TaqMan primers and probes  
CC designed from known sequences of rat genes such as transforming growth  
CC factor beta 1 (TGFbeta1), atrial natriuretic factor (ANP), collagen I and  
CC III, cyclooxygenase-2 (COX-2), osteopontin, monocyte chemoattractant  
CC protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), vascular  
CC adhesion molecule-1 (VCAM-1) and a reference cyclophilin, used in the  
CC course of the invention  
XX  
SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 15.4; DB 1; Length 19;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 718 TGGGCTCTCTTCCATC 734  
DB ||| ||||| ||||| |||||  
1 TGGGCTCTCTTCCATC 17  
RESULT 91  
ADC18700  
ID ADC18700 standard; DNA; 19 BP.  
AC ADC18700;  
XX  
XX 18-DEC-2003 (first entry)  
DT  
XX  
XX Rat RT-PCR primer 2 used for amplification of ANP gene.  
DE  
XX  
XX aldosterone receptor antagonist; non-steroidal anti-inflammatory drug;  
KW NSAID; cardiovascular disorder; inflammation; prostaglandin production;  
KW anti-inflammatory drug; ulcer;  
KW human arachidonic acid/prostaglandin pathway; cyclooxygenase; COX; COX-2;  
KW prostaglandin G/H synthase II; combination therapy; cardiovascular-gen;  
KW hypotensive; cardiant; antiarteriosclerotic; thrombolytic;  
KW cerebroprotective; antianginal; vasotropic; antiinflammatory;  
KW immunomodulator; dermatological; hypertension; heart failure;  
KW coronary artery disease; aneurysm; arteriosclerosis; atherosclerosis;  
KW myocardial infarction; embolism; stroke; thrombosis; angina;  
KW vascular plaque inflammation; vascular plaque rupture; Kawasaki disease;  
KW calcification; inflammation-related disorder; ss; rat;  
KW atrial natriuretic factor; ANP; RT-PCR; reverse transcription PCR; PCR;  
KW primer.  
XX  
XX Rattus sp.  
OS  
XX  
XX WO2003063908-A1.  
PN  
XX 07-AUG-2003.  
PD  
XX  
XX 30-JAN-2003; 2003WO-US002923.  
PF  
XX  
XX 30-JAN-2002; 2002US-0353008P.  
PR  
XX (PHAA ) PHARMACIA CORP.  
PA  
XX McMahon EG, Rocha R;  
PI





XX OS Synthetic.  
 XX PN WO2003072590-A1.  
 XX PD 04-SEP-2003.  
 XX PF 28-JAN-2003; 2003WO-US002510.  
 XX PR 20-FEB-2002; 2002US-0358580P.  
 XX PR 11-MAR-2002; 2002US-0363124P.  
 XX PR 06-JUN-2002; 2002US-0385782P.  
 XX PR 29-AUG-2002; 2002US-0406784P.  
 XX PR 05-SEP-2002; 2002US-0408378P.  
 XX PR 09-SEP-2002; 2002US-0409293P.  
 XX PR 15-JAN-2003; 2003US-0440129P.  
 XX PA (SIRN-) SIRNA THERAPEUTICS INC.  
 XX PI Mcawiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;  
 XX WPI; 2003-689980/65.  
 XX DR New short interfering nucleic acid, useful e.g. for treatment and  
 XX PT diagnosis of cancer, downregulates expression of mitogen-activated  
 XX PT protein kinase genes.  
 XX Example 3; SEQ ID NO 998; 164pp; English.  
 XX PS The present invention describes a short interfering nucleic acid (siRNA)  
 XX CC that downregulates expression of a mitogen-activated protein kinase  
 XX CC (MAPK) genes by RNA interference. Also described: (1) a method for  
 XX CC modulating expression of MAPK genes in cells, tissue explants or  
 XX CC organisms by introduction of siRNA; (2) kits for in vitro or in vivo  
 XX CC delivery of siRNA; (3) conjugates and/or complexes of siRNA; and (4)  
 XX CC vectors that express siRNA and cells containing these vectors. MAPK siRNAs  
 XX CC have cytostatic, anorectic, antidiabetic, antiinflammatory,  
 XX CC antiarthritic, immunosuppressive, antibacterial, antirheumatic,  
 XX CC antiatheritic, antipsoriatic and gastrointestinal activities. The MAPK  
 XX CC siRNAs can be used to modulate the expression of MAPK genes, in cells,  
 XX CC tissue explants or organisms, e.g. for treating obesity; diabetes types I  
 XX CC and II; a wide range of tumors, and inflammatory diseases (asthma,  
 XX CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel  
 XX CC disease). They can also be used for drug screening; diagnosis; target  
 XX CC identification and validation; genetic engineering; pharmacogenomics;  
 XX CC studying gene function and gene mapping (e.g. of single-nucleotide  
 XX CC polymorphisms). The present sequence represents a MAPK siRNA which is used  
 XX CC in the exemplification of the present invention.  
 XX SQ Sequence 19 BP; 9 A; 1 C; 8 G; 0 T; 1 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 19;  
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;  
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 1103 AGAAGACACAGGTGGAG 1119  
 ||||| ||||| |||||  
 Db 3 AGAAGACACAGGTGGAG 19  
 RESULT 94  
 ADH01808/c  
 ID ADH01808 standard; RNA; 19 BP.  
 XX AC ADH01808;  
 XX 11-MAR-2004 (first entry)  
 DT Protein tyrosine phosphatase siRNA sequence, SEQ ID No 420.  
 DE small interfering RNA; siRNA; protein tyrosine phosphatase; PTP; PTP1B;  
 KW insulin receptor protein phosphorylation; Jak2; antidiabetic; anorectic;  
 KW antiinflammatory; neuroprotective; cytostatic; immunosuppressive;

KW antimicrobial; gene therapy; ss; siRNA.  
 XX Unidentified.  
 XX OS WO2003099227-A2.  
 XX PN 04-DEC-2003.  
 XX PD 23-MAY-2003; 2003WO-US016651.  
 XX PF 23-MAY-2002; 2002US-0383249P.  
 XX PR 14-APR-2003; 2003US-0462942P.  
 XX XX (CEPT-) CEPTYR INC.  
 XX PI Lewis SP, Klinghoffer R, Wilson LK;  
 XX WPI; 2004-035036/03.  
 XX DR New small interfering polynucleotide that modulates protein tyrosine  
 XX PT phosphatase (PTP)1B polypeptide signal transduction, useful for treating  
 XX PT disorders associated with altered PTP1B signal transduction, e.g.  
 XX PT diabetes or cancer.  
 XX Example 3; SEQ ID NO 420; 234pp; English.  
 XX PS The invention relates to a novel isolated small interfering RNA (siRNA)  
 XX CC polynucleotide, comprising at least one nucleotide sequence from any of  
 XX CC the 20 fully defined sequences given in the specification. The invention  
 XX CC further relates to: a pharmaceutical composition comprising a new siRNA  
 XX CC polynucleotide and a physiological carrier; a recombinant nucleic acid  
 XX CC construct, comprising a polynucleotide that is capable of directing  
 XX CC transcription of an siRNA; a host cell transformed or transfected with  
 XX CC the above recombinant nucleic acid construct; a method for interfering  
 XX CC with expression of a protein tyrosine phosphatase (PTP)1B polypeptide, or  
 XX CC its variant; a method for identifying a component of a PTP1B signal  
 XX CC transduction pathway; a method for modulating an insulin receptor protein  
 XX CC phosphorylation state in a cell; a method for altering a Jak2 protein  
 XX CC associated disorder. The siRNA has the following activities:  
 XX CC antidiabetic, anorectic, antiinflammatory, neuroprotective, cytostatic,  
 XX CC immunosuppressive, and antimicrobial. The novel siRNA polynucleotides can  
 XX CC be used in gene therapy to treat disorders. The composition and methods  
 XX CC are useful in treating disorders associated with PTP1B-mediated signal  
 XX CC transduction, such as diabetes, obesity, hyperglycaemia-induced  
 XX CC apoptosis, inflammation, neurodegenerative disorders, cancer, autoimmune  
 XX CC diseases or infection. This polynucleotide sequence represents an siRNA  
 XX CC used for modulating the signal transduction of a protein tyrosine  
 XX CC phosphatase of the invention.  
 XX SQ Sequence 19 BP; 6 A; 0 C; 9 G; 0 T; 4 U; 0 Other;  
 Query Match 0.8%; Score 15.4; DB 1; Length 19;  
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 722 CTCCTTCTCCATCTACA 738  
 ||||| ||||| |||||  
 Db 17 CTCCTTCTCCATCTCCA 1  
 RESULT 95  
 ADO52023  
 ID ADO52023 standard; DNA; 19 BP.  
 XX AC ADO52023;  
 XX 15-JUL-2004 (first entry)  
 DT Rat ANP gene specific forward RT-PCR primer.  
 DE Inflammation-related disorder; aldosterone blocker; inflammation;  
 KW cardiac remodeling; myocarditis; cardiomyopathy; vasculitis;

KW Behcet's disease; PCR; primer; rat; atrial natriuretic factor; ANP; ss.  
 XX Rattus sp.  
 XX US2004037806-A1.  
 PN XX  
 XX 26-FEB-2004.  
 PD XX  
 XX 24-JAN-2003; 2003US-00350964.  
 PF XX  
 XX 25-JAN-2002; 2002US-0351851P.  
 PR XX  
 XX (PHAA ) PHARMACIA CORP.  
 PA XX  
 XX Rocha R, Zack MD;  
 PI XX  
 XX WPI; 2004-280243/26.  
 XX  
 XX Preventing or treating an inflammation-related disorder such as  
 PT cardiomyopathy, comprises using an aldosterone blocker to alter  
 PT expression products, e.g., IL-8, involved in the regulation of  
 PT inflammation or cardiac remodeling.  
 XX  
 XX Example 18; Page 36; 109pp; English.  
 PS  
 XX The invention relates to a method for preventing or treating an  
 CC inflammation-related disorder which involves administering a  
 CC therapeutically-effective amount of an aldosterone blocker to alter the  
 CC expression of one or more expression products involved, directly or  
 CC indirectly, in the regulation of inflammation or cardiac remodeling in  
 CC the subject. The method is useful to treat an inflammation-related  
 CC disorder such as myocarditis, cardiomyopathy, vasculitis and Behcet's  
 CC disease. The present sequence is a TagMan RT-PCR primer specific for rat  
 CC atrial natriuretic factor (ANP) gene. This sequence is used to illustrate  
 CC the method of the invention.  
 XX  
 XX Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.8%; Score 15.4; DB 1; Length 19;  
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 718 TGGCTCTCTTCATC 734  
 Db |||||  
 1 TGGCTCTCTTCATC 17  
 RESULT 96  
 AAQ87040/C  
 ID AAQ87040 standard; DNA; 20 BP.  
 XX  
 XX AAQ87040;  
 AC  
 XX 12-JAN-1996 (first entry)  
 DT  
 XX HPV 18-specific oligonucleotide 96-19.  
 DE  
 XX probe; hybridisation; human papilloma virus; HPV; detection; riboprobe;  
 KW diagnosis; ss.  
 KW  
 XX Synthetic.  
 OS  
 XX WO9511316-A1.  
 PN  
 XX 27-APR-1995.  
 PD  
 XX 19-OCT-1994; 94WO-US012044.  
 PF  
 XX 22-OCT-1993; 93US-00141711.  
 PR  
 XX (AMGE-) AMGEN INC.  
 PA  
 XX Martin FH, Jacobsen FW, Green CL;  
 PI

XX WPI; 1995-193795/25.  
 DR  
 XX Detection of target nucleic acid sequence in biological samples - using a  
 PT labelled riboprobe which hybridises to target nucleic acid for use in  
 PT medical diagnostics, forensics, and research.  
 PT  
 XX Example 1; Page 59; 75pp; English.  
 PS  
 XX HPV 18 often integrates into the human genome, as opposed to remaining in  
 CC episomal form. DNA was isolated from HeLa cells known to contain  
 CC integrated subgenomic HPV 18 HindIII fragments. HPV 18-specific  
 CC oligonucleotides AAQ87038-9 were added to filters contg. the HPV 18 DNA.  
 CC Duplicate filters were probed also with AAQ87040-41. Plaques giving  
 CC clearly duplicated signals were pulled, purified and grown up. Clones  
 CC contg. portions of the HPV 18 genome were obt'd. and verified. DNA was  
 CC prep'd. for the prodn. of riboprobes to be used in the methods of the  
 CC invention. Riboprobes improve the detection limits of nucleic acid  
 CC hybridisation. The detection methods using riboprobes can be used in  
 CC medical diagnostics, forensics and molecular biology research  
 XX  
 XX Sequence 20 BP; 9 A; 1 C; 4 G; 6 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.8%; Score 15.4; DB 1; Length 20;  
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1673 AATTCTCTGATTCTAGA 1689  
 Db |||||  
 17 AATTCTCTGATTCTAGA 1  
 RESULT 97  
 AAAX96777  
 ID AAAX96777 standard; DNA; 20 BP.  
 XX  
 XX AAAX96777;  
 AC  
 XX 13-SEP-1999 (first entry)  
 DT  
 XX PCR primer used to amplify an ORF of Chlamydia pneumoniae.  
 DE  
 XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;  
 KW neutralising epitope; PCR primer; ss.  
 KW  
 XX Synthetic.  
 OS  
 XX Chlamydoiphila pneumoniae.  
 OS  
 XX WO9927105-A2.  
 PN  
 XX 03-JUN-1999.  
 PD  
 XX 20-NOV-1998; 98WO-IB001890.  
 PF  
 XX 21-NOV-1997; 97FR-00014673.  
 PR  
 XX 04-NOV-1998; 98US-0107078P.  
 XX  
 XX (GEST ) GENSET.  
 PA  
 XX Griffais R;  
 PI  
 XX WPI; 1999-357842/30.  
 DR  
 XX Genome sequence of Chlamydia pneumoniae.  
 PT  
 XX Page 1852; Disclosure; 1912pp; English.  
 PS  
 XX AAAX91991-X97517 represent PCR primers used to amplify open reading frames  
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae  
 CC (see AAAX91990). C. pneumoniae causes respiratory disease such as  
 CC pneumonia and bronchitis and is thought to be a contributing factor in  
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema

CC nodum or pharyngitis. The polypeptides encoded by the open reading  
 CC frames of the C. pneumoniae genome (see AA34584- AA35879) can be used  
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
 CC nucleotide sequences can also be used as immunogenic compositions.  
 CC especially where the vector directs the expression of a neutralising  
 CC epitope of C. pneumoniae

XX Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;  
 SQ Query Match 0.8%; Score 15.4; DB 1; Length 20;  
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 150 TGCTCTGGGAAGCTAT 166  
 |||||  
 Db 2 TGCTCTGGGAACCTAT 18

RESULT 98  
 AAH56611  
 ID AAH56611 standard; DNA; 20 BP.  
 AC AAH56611;  
 XX  
 DT 06-SEP-2001 (first entry)  
 DE Streptococcus pyogenes groEL antisense oligonucleotide SEQ ID NO:259.

XX Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;  
 KW microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;  
 KW Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;  
 KW antibacterial; antiviral; antiproliferative; antisense therapy;  
 KW microbial infection; ss.  
 XX Streptococcus pyogenes.

OS WO20013625-A2.  
 XX 25-MAY-2001.  
 PN 20-NOV-2000; 2000WO-CA001347.  
 XX 18-NOV-1999; 99US-0166249P.  
 PR (GENE-) GENESENSE TECHNOLOGIES INC.  
 XX Wright JA, Young AH, Dugourd D;  
 PI WPI; 2001-355633/37.  
 XX

XX Novel antisense compounds targeting nucleic acid encoding groEL or groES  
 XX gene of microorganism, which hybridize with and inhibit expression of the  
 XX genes, useful to inhibit growth of microorganism having the genes.

PS Claim 3; Page 48; 110pp; English.

XX The present invention specifically claims AAH56368 to AAH56832 which are  
 CC antisense oligonucleotides to nucleotide sequences encoding groE. More  
 CC generally, antisense compounds (I) comprising antisense oligonucleotides  
 CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat  
 CC shock protein (HSP) 60) (GL) and groES (HSP10) (GS) gene from a  
 CC microorganism, where the antisense compound is complementary to GL or GS  
 CC of a microorganism and specifically hybridises with and inhibits the  
 CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral and  
 CC antiproliferative activities, and can be used in antisense therapy and  
 CC for inhibition of expression of groES or groEL. (I) are useful for  
 CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are  
 CC also useful for inhibiting the growth of a microorganism, or inhibiting  
 CC the expression of GL or GS gene in a microorganism (a bacterial cell or a  
 CC virus) having a GL or GS gene which involves administering to the  
 CC microorganism or to a cell infected with the microorganism, (I). (I) are  
 CC also useful for treating a mammalian pathological condition mediated by  
 CC the microorganisms which involves identifying a eukaryotic organism

CC having a pathological condition mediated by microorganisms having a GL or  
 CC GS gene and administering (I) such that the growth of microorganism is  
 CC inhibited. The antisense compounds are utilised for diagnostics,  
 CC therapeutics, prophylaxis and as research reagents and kits, e.g., to  
 CC prevent or delay microbial infections in humans. They are also useful as  
 CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854  
 CC represent PCR primers for groE sequences which are used in the  
 CC exemplification of the present invention. AAH56855 to AAH56870 represent  
 CC groE nucleotide sequence given in the present invention

XX Sequence 20 BP; 1 A; 4 C; 5 G; 10 T; 0 U; 0 Other;  
 SQ Query Match 0.8%; Score 15.4; DB 1; Length 20;  
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1445 TGTTGCTGCTGCTGTTT 1461  
 |||||  
 Db 2 TGTTGCTGCTGCTGTTT 18

RESULT 99  
 AAD41550  
 ID AAD41550 standard; DNA; 20 BP.  
 XX  
 AC AAD41550;  
 XX  
 DT 30-OCT-2002 (first entry)  
 DE VRP gene specific reverse RT-PCR primer.

XX Marker; vitamin D analogue; antiproliferative; cancer; osteodystrophy;  
 DE multiple sclerosis; osteoporosis; osteomalacia; hyperparathyroidism;  
 KW genoprotective; epidermal wound; chemoprotective; DNA repair mechanism;  
 KW cystostatic; psoriasis; neuroprotective; vulnerary; RT-PCR; primer; ss.  
 XX Unidentified.

OS WO200244403-A2.

XX 06-JUN-2002.

XX 28-NOV-2001; 2001WO-CA001689.

XX 29-NOV-2000; 2000US-0253746P.

XX 02-MAY-2001; 2001US-0287729P.

XX (UYMC-) UNIV MCGILL.

XX White JH;

XX WPI; 2002-537458/57.

XX Novel marker for testing analogs of vitamin D expected to be effective in  
 XX reducing aberrant activity of vitamin D-responsive cell, comprises gene  
 XX pertinent to action of vitamin D for testing the analogs.

PS Example 2; Page 48; 89pp; English.

XX The invention relates to a marker for testing analogues of vitamin D  
 CC expected to be effective in reducing aberrant activity of vitamin D-  
 CC responsive cell, comprises at least one gene pertinent to the action of  
 CC vitamin D for testing the analogues and determining analogues capable of  
 CC regulating the gene, and is indicative of a chemopreventive or  
 CC chemotherapeutic agent. The invention is useful for testing analogues of  
 CC vitamin D expected to be effective in reducing aberrant activity of  
 CC vitamin D-responsive cell or for testing analogues of vitamin D suspected  
 CC to have antiproliferative activity. The invention is useful for reducing  
 CC aberrant activity of vitamin D-responsive cell, and for treating a  
 CC disorder characterised by an aberrant activity of vitamin D-responsive  
 CC cell, where the disorder is selected from cancer, psoriasis, multiple  
 CC sclerosis, osteoporosis, osteodystrophy, osteomalacia and  
 CC hyperparathyroidism. The invention is useful for identifying regulated

CC target genes correlated with the antiproliferative effect of vitamin D  
CC and its analogues. The invention is useful for protecting against in vivo  
CC DNA damage, for inducing in vivo DNA repair mechanisms in a mammal, or  
CC for reducing or preventing DNA damage to the skin of a mammal, preferably  
CC human. The invention is useful as a genoprotective or chemoprotective  
CC agent. The invention is useful as a marker for the activity of DNA repair  
CC mechanisms. The invention is useful for testing compounds susceptible of  
CC inhibiting an enzyme which metabolises 1,25-dihydroxyvitamin D3. The  
CC invention is useful for treating epidermal wounds. The present sequence  
CC is VPR gene specific RT-PCR primer  
XX  
SQ Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1272 CTCGAGCCCTCAATAT 1288  
DB 3 CTCGAGCCCTCACTAT 19

RESULT 100  
ABK49323  
ID ABK49323 standard; DNA; 20 BP.

XX ABK49323;

DT 15-JUL-2002 (first entry)

DE Fibroblast growth factor-related RT-PCR primer #11.

KW Mesenchymal stem cell; proliferation potency; fibroblast growth factor;  
KW FGF; pluripotency; transplantation; cartilage; bone tissue; primer; ss;  
KW RT-PCR; reverse transcriptase; osteopathic.

OS Mammalia.

XX W020022798-Al.

XX 21-MAR-2002.

XX 12-SEP-2001; 2001WO-JP007914.

XX 12-SEP-2000; 2000JP-00276971.

XX (KATO/) KATO Y.

XX Kato Y, Teutsumi S, Shimazu A;

XX WPI; 2002-362342/39.

XX Culturing mesenchymal stem cells in large quantity by adding fibroblast  
PT growth factor to medium to stimulate their proliferation potency while  
PT maintaining pluripotency to prolong life, application in transplantation.

PS Example 6; Page 13; 34pp; Japanese.

XX The invention relates to a method of culturing mammalian mesenchymal stem  
CC cells by adding to a medium, a substance that can stimulate proliferation  
CC potency of these cells (such as fibroblast growth factor (FGF)) while  
CC maintaining pluripotency. With this method, large quantities of  
CC mesenchymal stem cells can be cultured over at least 30 generations. The  
CC method is useful for culturing mesenchymal stem cells for transplantation  
CC into cartilage and bone tissues. This sequence represents a reverse  
CC transcriptase PCR (RT-PCR) primer used in the scope of the invention

XX Sequence 20 BP; 7 A; 7 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1403 CCACGAGACACCATGA 1419  
DB 1 CCACGAGACACCATGA 17

RESULT 101

ACA97216

ID ACA97216 standard; DNA; 20 BP.

XX ACA97216;

XX 11-AUG-2003 (first entry)

XX Vpr-driven construct associated primer #49.

DE PCR; primer; Vpr; ss; immune response; immunocompromise; HIV; cancer;  
KW gene therapy.

XX Unidentified.

XX US2003017137-A1.

XX 23-JAN-2003.

XX 22-JUL-1998; 98US-00120286.

XX 22-JUL-1998; 98US-00120286.

XX (ALFI/) ALFIERI C.

XX (TANN/) TANNER J.

XX (ROUX/) ROUX P.

XX Alfieri C, Tanner J, Roux P;

XX WPI; 2003-438926/41.

XX Novel DNA or RNA construct for increasing immune response of warm-blooded  
PT animal, has Vpr activated promoter, DNA segment encoding interleukin 2  
PT and secretory DNA encoding signal peptide functional in mammary cells.

XX Disclosure; Page 17; 28pp; English.

XX The invention relates to a DNA or RNA construct capable of expressing  
CC interleukin (IL)-2 in a warm-blooded animal or biological preparation,  
CC comprising a Vpr activated promoter, a transcribable DNA segment coding  
CC for IL-2 and a secretory DNA encoding for a signal peptide functional in  
CC mammary cells and operably linked between the promoter and the DNA  
CC segment to facilitate secretion of IL-2. The construct is useful for  
CC increasing the immune response of a warm-blooded animal or biological  
CC preparation, by introducing the construct in stem cells, antigen  
CC presenting cells or immune cell leukocytes, fibroblasts and epithelial  
CC cells, of the warm-blooded animal or biological preparation to obtain a  
CC transfected cell populations and administering a pharmaceutically  
CC effective amount of the transfected cell populations to the warm-blooded  
CC animal or biological preparation. The warm-blooded animal is an  
CC immunocompromised patient. The method is useful for stimulating immune  
CC response in immunocompromised patients affected with HIV, cancer and  
CC other immunocompromised patients. The present sequence represents a Vpr-  
CC driven construct associated primer. Note: The present sequence is  
CC displayed in the sequence listing but no further reference is made to it  
CC in the specification

XX Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 20;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1272 CTCGAGCCCTCAATAT 1288

DB 3 CTCGAGCCCTCACTAT 19

```

RESULT 102
AAL54397/c
ID AAL54397 standard; DNA; 20 BP.
XX
XX
AC AAL54397;
XX
DT 03-APR-2003 (first entry)
XX
DE rpoB gene oligomer probe SEQ ID No 14.
XX
XX Mycobacterium tuberculosis; non-tuberculosis Mycobacterium; MOTT;
KW anti-tuberculosis drug; rpoB gene; probe; ss.
XX
XX Mycobacterium abscessus.
OS
XX
XX WO2003008645-A1.
XX
XX 30-JAN-2003.
XX
XX 23-JUL-2001; 2001WO-KR001253.
XX
XX 19-JUL-2001; 2001KR-00043450.
XX
XX (XENI-) XENISS LIFE SCI CO LTD.
XX
XX Lee H, Bang HE, Cho S, Bai G, Kim S;
XX
XX WPI; 2003-221853/21.
XX
XX Identifying Mycobacterium tuberculosis and non-tuberculosis Mycobacterium
PT (MOTT) and detecting resistance or susceptibility to an anti-tuberculosis
PT drug, comprises amplifying a fragment in the rpoB gene.
XX
XX Claim 4; Page 7; 45pp; English.
XX
XX The invention relates to a novel method for identifying Mycobacterium
CC tuberculosis and non-tuberculosis Mycobacterium (MOTT) and detecting the
CC resistance or susceptibility of M. tuberculosis, obtained by mutation of
CC the rpoB gene to an anti-tuberculosis drug by amplifying a 531 base pair
CC fragment in the rpoB gene by a polymerase chain reaction. The method, a
CC kit and oligomer probes are useful for identifying M. tuberculosis and
CC MOTTs and for detecting their resistance or susceptibility obtained by
CC mutation of the rpoB gene. New primers are useful for amplifying a 531 bp
CC fragment in the rpoB gene by PCR. This polynucleotide sequence represents
CC an oligomer probe used for targeting Mycobacterium of the invention
XX
XX Sequence 20 BP; 8 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 126 GGTGGTGTTCACCTTTT 142
Db |||||||
17 GGTGGTGTTCACCTTTT 1

RESULT 103
ADQ88767
ID ADQ88767 standard; DNA; 20 BP.
XX
XX ADQ88767;
AC
XX
DT 21-OCT-2004 (first entry)
XX
DE Human HIF-1 antisense oligonucleotide RX-0063.
XX
XX RX-0047; RX-0149; human; hypoxia inducible factor; HIF-1; cytotoxicity;
KW cancer; infection; inflammation; tumour formation; ss;
KW antisense oligonucleotide; antisense technology; RX-0158; RX-0063.
XX
XX Homo sapiens.
OS
XX

```

---

```

PN US2004152655-A1.
XX
XX 05-AUG-2004.
XX
XX 28-JAN-2004; 2004US-00766185.
XX
XX 31-JAN-2003; 2003US-0444367P.
XX
XX (YOON/) YOON H.
PA (MAOL/) MAO L.
PA (LEEY/) LEE Y B.
PA (AHNC/) AHN C.
PA (JIAN/) JIANG X.
XX
XX Yoon H, Mao L, Lee YB, Ahn C, Jiang X;
PI
XX
XX WPI; 2004-561492/54.
XX
XX New RX-0047 and RX-0149 antisense oligonucleotide compounds targeted to a
PT nucleic acid molecule encoding human hypoxia inducible factor (HIF-1),
PT useful for inhibiting expression of HIF-1 and inducing cytotoxicity in
PT several cancer cells.
XX
XX Example 4; SEQ ID NO 47; 35pp; English.
XX
XX The invention describes a compound, RX-0047 or RX-0149 targeted to a
CC nucleic acid molecule encoding human hypoxia inducible factor (HIF-1),
CC where the oligonucleotide compound inhibits the expression of human HIF-
CC 1. Also described are: a method of inhibiting the expression of HIF-1 in
CC human cells or tissues; and a method of inducing cytotoxicity in a cancer
CC cell. Specifically claimed are RX-0047 and RX-0149 compounds having a
CC fully defined sequence comprising 20 bp (SEQ ID NO. 2, 5',
CC aatgagccaccagtgcacaa 3' and SEQ ID NO. 4, 5' ggagctaacatctccaagtc 3',
CC respectively). The compounds are useful for inhibiting the expression of
CC HIF-1 and inducing the cytotoxicity in several cancer cells. The
CC antisense compounds are also useful for preventing or delaying infection,
CC inflammation, or tumour formation. This sequence represents a human HIF-1
CC antisense oligonucleotide.
XX
XX Sequence 20 BP; 8 A; 3 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1134 TATTATCAGTTACACAA 1150
Db |||||||
4 TAATATCAGTTACACAA 20

RESULT 104
ADK23065
ID ADK23065 standard; DNA; 20 BP.
XX
XX ADK23065;
AC
XX
DT 18-NOV-2004 (first entry)
XX
DE Acyl-coenzyme A synthetase 1, ACS1, antisense oligonucleotide #3142.
XX
XX acyl-coenzyme A synthetase 1; ACS1; diabetes; obesity;
KW metabolic syndrome X; cardiovascular disorder; cancer; infection;
KW inflammation; tumour; antisense; ss.
XX
XX Synthetic.
OS
XX
XX WO2004016749-A2.
XX
XX 26-FEB-2004.
XX
XX 14-AUG-2003; 2003WO-US025389.
XX
XX 14-AUG-2002; 2002US-0403591P.
XX

```

```

XX PA (PHAA ) PHARMACIA CORP.
XX PI Ross SA;
XX DR WPI; 2004-203782/19.
XX PT New antisense compounds targeted to nucleic acid molecules encoding acyl-
XX PT coenzyme A synthetase 1 (ACSL1), useful for treating diseases or
XX PT conditions associated with aberrant expression of ACS1, e.g. diabetes,
XX PT obesity or cancer.
XX PS Claim 3; SEQ ID NO 3142; 940pp; English.
XX CC The invention relates to an antisense compound targeted to a nucleic acid
XX CC molecule encoding acyl-coenzyme A synthetase 1 (ACSL1). The antisense
XX CC compound specifically hybridises with and inhibits the expression of
XX CC ACS1. The antisense oligonucleotides or compounds are useful for
XX CC inhibiting the expression of acyl-coenzyme A synthetase 1 (ACSL1), and for
XX CC treating diseases or conditions associated with aberrant expression of
XX CC ACS1, e.g. diabetes, obesity, metabolic syndrome X, cardiovascular
XX CC disorder or cancer. The antisense compounds are also useful as research
XX CC reagents and kits, or in diagnostic, therapeutic and prophylactic
XX CC applications, e.g. to prevent or delay infection, inflammation or tumour
XX CC formation. The present sequence represents an acyl-coenzyme A synthetase
XX CC 1, ACS1, antisense oligonucleotide.
XX SQ Sequence 20 BP; 3 A; 3 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1463 GGCTGTGTTCTTATG 1479
Db 4 GGCTGTGTTCTGATG 20

RESULT 105
AAQ54138/c
ID AAQ54138 standard; DNA; 20 BP.
XX AC AAQ54138;
XX DT 25-MAR-2003 (revised)
XX DT 15-JUN-1994 (first entry)
XX DE Multiplex vector 19 primer Plex 19E.
XX KW Simultaneous sequencing; ss.
XX OS Synthetic.
XX PN WO9324654-A1.
XX PD 09-DEC-1993.
XX PF 01-JUN-1993; 93WO-BP001376.
XX PR 02-JUN-1992; 92DE-04218152.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Sagner G, Blum H, Domdey H;
XX DR WPI; 1993-405842/50.
XX PT Simultaneously sequencing many nucleic acid fragments - by cloning in
XX PT vector after attachment of double strands adaptors, and sequencing
XX PT selected clones, for high cloning efficiency with only one vector.
XX PS Example 3; Page 23; 47pp; German.
XX CC The sequence is that of a primer, plex 19E, which was used in the
XX CC sequencing of Multiplex vector 19 as part of a method of simultaneously
XX CC sequencing nucleic acids. (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 20 BP; 6 A; 0 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 620 CCAACCTTACATCACTACT 639
||||| ||||| ||||| |||

```

```

Db      20 CCAACCCCTACATTAACTTCT 1
RESULT 107
AAQ92495
ID AAQ92495 standard; DNA; 20 BP.
AC AAQ92495;
XX
XX
DT 12-JAN-1996 (first entry)
XX
DE Spinach glycerol-3-phosphate acyltransferase gene PCR primer.
XX
XX Glycerol-3-phosphate acyltransferase; cold resistance; transgenic; plant;
KW spinach; ss.
XX
XX Synthetic.
XX
XX WO9514094-A1.
XX
XX 26-MAY-1995.
XX
XX 18-NOV-1994; 94WO-JP001956.
XX
XX 19-NOV-1993; 93JP-00314212.
XX
XX (KIRI ) KIRIN BEER KK.
XX
XX Nishizawa O, Toguri T;
PI
XX WPI; 1995-200384/26.
XX
XX Glycerol-3-phosphate acyltransferase gene from spinach - useful for
PT generating cold-resistant transgenic plants.
XX
XX Example 2; Page 18; 49pp; Japanese.
XX
XX AAQ92495-Q92499 and AAQ93859 are PCR primers used for the isolation and
CC amplification of DNA coding for spinach glycerol-3-phosphate
CC acyltransferase (AAQ92494). This DNA can be incorporated into cold-
CC sensitive transgenic plants to increase their resistance to low
CC temperatures
XX
XX Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1480 TTGTTGCAGACATGGAAGAA 1499
      ||| ||||| ||||| |||||
Db      1 TTGCTGCAGGAATGGAAGAA 20

RESULT 108
AAAT61766
ID AAAT61766 standard; DNA; 20 BP.
XX
XX AAAT61766;
AC
XX
XX 08-OCT-1997 (first entry)
DT
XX
DE Primer for Atase coding sequence amplification.
XX
XX primer; PCR; polymerase chain reaction; glycerol-3-phosphate; Atase;
KW acyltransferase; chimera; Atase; pumpkin; spinach; Spinacia oleracea;
KW Cucurbita moschata; enhanced substrate specificity; unsaturated;
KW fatty acid; transgenic plant; membrane lipid; phosphatidylglycerol;
KW cold resistance; ss.
XX
XX Synthetic.
OS
XX WO9705246-A1.
PN

```

---

```

XX
PD 13-FEB-1997.
XX
XX 03-JUL-1996; 96WO-JP001844.
XX
XX 27-JUL-1995; 95JP-00192123.
XX
XX (KIRI ) KIRIN BEER KK.
XX
XX Ferri S, Toguri T;
PI
XX WPI; 1997-145684/13.
XX
XX Chimeric gene coding for glycerol-3-phosphate acyltransferase - combines
PT parts of spinach and pumpkin genes, and imparts greater cold resistance
PT to plants transformed with it.
XX
XX Disclosure; Page 14; 53pp; Japanese.
XX
XX AAT61766-71 are primers used to amplify glycerol-3-phosphate acyl-
CC transferase (Atase) gene sequences from spinach (Spinacea oleracea) and
CC pumpkin (Cucurbita moschata). New chimeric Atase genes, are based on the
CC pumpkin Atase gene, where part of the sequence (between defined
CC restriction points) is replaced with the corresponding sequence from the
CC spinach Atase gene. The encoded chimeric enzyme has enhanced substrate
CC specificity for unsaturated fatty acids. The DNA can be inserted into a
CC suitable vector, which can be used to transform plants, enabling them to
CC produce membrane lipid phosphatidylglycerol with a higher unsaturated
CC content. Plants, e.g. tobacco, tomato, rice, maize, potato, banana,
CC melon, barley, etc., transformed with the chimeric DNA have improved cold
CC resistance
XX
XX Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1480 TTGTTGCAGACATGGAAGAA 1499
      ||| ||||| ||||| |||||
Db      1 TTGCTGCAGGAATGGAAGAA 20

RESULT 109
AAV47686/C
ID AAV47686 standard; DNA; 20 BP.
XX
XX AAV47686;
AC
XX
XX 20-NOV-1998 (first entry)
DT
XX
DE Unmethylated CpG dinucleotide.2001.
XX
XX Unmethylated CpG dinucleotide; immune response; bacterial meningitis;
KW natural killer cell activation; NK cell; Th2 response; neonatal sepsis;
KW pulmonary disorder; asthma; environmentally induced airway disease;
KW bacterial infection; endotoxaemia; therapy; cystic fibrosis;
KW inflammatory bowel disease; ss.
XX
XX Synthetic.
OS
XX WO9837919-A1.
XX
XX 03-SEP-1998.
XX
XX 25-FEB-1998; 98WO-US003678.
XX
XX 28-FEB-1997; 97US-0039405P.
XX
XX (IOWA ) UNIV IOWA RES FOUND.
PA
XX Schwartz DA, Krieg AM;
PI
XX

```

```

DR WPI; 1998-480941/41.
XX
PT Use of nucleic acids containing an unmethylated CpG - for treating a
PT subject having or at risk of having an acute decrement in air flow or
PT inhibiting an inflammatory response.
XX
PS Claim 35; Page 27; 65pp; English.
XX
CC This sequence represents an unmethylated CpG dinucleotide, and can be
CC used in the method of the invention. The method is for treating a subject
CC having, or at risk of having an acute decrement in air flow, comprising
CC administering a nucleic acid sequence containing at least one
CC unmethylated CpG. The nucleic acids containing an unmethylated CpG
CC dinucleotide affect an immune response in a subject by activating natural
CC killer cells (NK) or redirecting a subject's immune response from a Th2
CC to a Th1 response by inducing monocytic and other cells to produce Th1
CC cytokines. They can be used to treat pulmonary disorders having an
CC immunologic component, such as asthma or environmentally induced airway
CC disease. They can also be used to treat diseases associated with Gram-
CC positive bacterial infections or endotoxaemia including bacterial
CC meningitis, neonatal sepsis, cystic fibrosis, inflammatory bowel disease
CC and liver cirrhosis, Gram-negative pneumonia, Gram-negative abdominal
CC abscesses, haemorrhagic shock, disseminated intravascular coagulation, or
CC an inflammatory response to lipopolysaccharide
XX
SQ Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCTCCGTCGCGCGGTC 48
DB 20 CCGCGCGCGCGCGCGGCC 1

RESULT 110
AAV74243/c
ID AAV74243 standard; DNA; 20 BP.
AC AAV74243;
XX
DT 20-MAR-2003 (revised)
DT 15-MAR-1999 (first entry)
XX
XX CpG-N motif O-ODN 2001 DNA.
XX
XX CpG-N motif; immunostimulation; antigen; CpG-S motif; immunisation; ODN;
XX viral antigen; bacterial antigen; parasite; therapeutic; growth factor;
XX toxin; tumour suppressor; cytokine; apoptotic protein; interferon;
XX hormone; clotting factor; ligand; receptor; oligodeoxynucleotide; ss.
XX
XX Synthetic.
XX
XX W09852581-A1.
XX
XX 26-NOV-1998.
XX
XX 20-MAY-1998; 98WO-US010408.
XX
XX 20-MAY-1997; 97US-0047209P.
XX 20-MAY-1997; 97US-0047233P.
XX
XX (OTTA-) OTTAWA CIVIC HOSPITAL LOEB RES INST.
PA (IOWA) UNIV IOWA RES FOUND.
PA (QIAG-) QIAGEN GMBH.
XX
XX Davis HL, Krieg AM, Schorr J, Wu T;
XX WPI; 1999-059712/05.
XX
XX Use of neutralising CpG and stimulating CpG motifs in DNA vectors - for
XX enhancing the immunostimulatory effect of an antigen or enhancing the
PT
expression of a therapeutic polypeptide.
XX
PS Example 1; Page 64; 109pp; English.
XX
CC AAV74237-V74253 are oligodeoxynucleotide (ODN) primers used to describe a
CC method for enhancing the immunostimulatory effect of an antigen encoded
CC by nucleic acid contained in a nucleic acid construct. The method
CC involves determining the CpG-N and CpG-S motifs present in the construct,
CC removing neutralising CpG (CpG-N) motifs and optionally inserting a
CC stimulatory CpG (CpG-S) motifs in the construct, thereby producing a
CC nucleic acid construct having enhanced immunostimulatory efficacy. The
CC method can be used for immunisation against viral antigens, e.g. from
CC hepatitis B virus (HBV), bacterial antigens or an antigen derived from a
CC parasite. They can also be used for expression of a therapeutic
CC polypeptide, e.g. growth factors, toxins, tumour suppressors, cytokines,
CC apoptotic proteins, interferons, hormones, clotting factors, ligands and
CC receptors. (Updated on 20-MAR-2003 to correct PA field.)
XX
SQ Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCTCCGTCGCGCGGTC 48
DB 20 CCGCGCGCGCGCGCGGCC 1

RESULT 111
AAZ02802
ID AAZ02802 standard; DNA; 20 BP.
XX
XX AAZ02802;
XX
XX 07-OCT-1999 (first entry)
XX
XX PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
XX Vaccine; eye disease; conventional trachoma; nonendemic trachoma;
XX paratrachoma; inclusion conjunctivitis; genital disease; perithenitis;
XX nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
XX bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
XX Synthetic.
XX
XX Chlamydia trachomatis.
XX
XX W09928475-A2.
XX
XX 10-JUN-1999.
XX
XX 27-NOV-1998; 98WO-IB001939.
XX
XX 28-NOV-1997; 97FR-00015041.
XX 17-DEC-1997; 97FR-00016034.
XX 04-NOV-1998; 98US-0107077P.
XX
XX (GEST) GENSET.
XX
XX Griffais R;
XX
XX WPI; 1999-371125/31.
XX
XX Genome sequence of Chlamydia trachomatis.
PT
XX Disclosure; Page 1554; 1755pp; English.
XX
XX PCR primers AAZ01426-Z06209 were used to amplify open reading frames
XX (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
XX encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
XX against Chlamydia trachomatis. Antisense and ribozyme sequences can also
XX be used to control growth of the microorganism. Chlamydia trachomatis is
XX responsible for a large number of diseases, e.g. eye diseases such as

```



CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion  
 CC conjunctivitis; genital diseases such as nongonococcal urethritis,  
 CC epididymitis, cervicitis, salpingitis, perihepatitis, Bartholinitis;  
 CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.  
 CC The polypeptides of the invention may be of use in treating these  
 CC diseases  
 XX

SQ Sequence 20 BP; 1 A; 9 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1756 GCATTTCTTTATATACACCTC 1775

Db 1 GCATTTCTTTCTCTCCCTC 20

RESULT 112

AAZ04579

ID AAZ04579 standard; DNA; 20 BP.

AC AAZ04579;

XX

DT 07-OCT-1999 (first entry)

XX

DE PCR primer used to amplify an ORF of Chlamydia trachomatis.

XX

KW Vaccine; eye disease; conventional trachoma; nonendemic trachoma;  
 KW paratrachoma; inclusion conjunctivitis; genital disease; perihepatitis;  
 KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;  
 KW Bartholinitis; pneumopathy; venereal lymphogranulomatosis; ss.

XX

OS Synthetic.

OS Chlamydia trachomatis.

XX

PN WO9928475-A2.

XX

PD 10-JUN-1999.

XX

PF 27-NOV-1998; 98WO-IB001939.

XX

PR 28-NOV-1997; 97FR-00015041.

XX

PR 17-DEC-1997; 97FR-00016034.

XX

PR 04-NOV-1998; 98US-0107077P.

XX

PA (GEST ) GENSET.

XX

PI Griffiths R;

XX

DR WPI; 1999-371125/31.

XX

PT Genome sequence of Chlamydia trachomatis.

XX

PS Disclosure; Page 1700; 1755pp; English.

XX

CC PCR primers AAZ01426-206209 were used to amplify open reading frames  
 CC (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs  
 CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines  
 CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also  
 CC be used to control growth of the microorganism. Chlamydia trachomatis is  
 CC responsible for a large number of diseases, e.g. eye diseases such as  
 CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion  
 CC conjunctivitis; genital diseases such as nongonococcal urethritis,  
 CC epididymitis, cervicitis, salpingitis, perihepatitis, Bartholinitis;  
 CC pneumopathy in breast feeding infants; and venereal lymphogranulomatosis.  
 CC The polypeptides of the invention may be of use in treating these  
 CC diseases  
 XX

SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1414 CCATGACTGTCATGATCCA 1433

Db 1 CCACGACTGTCATGATCCA 20

RESULT 113

AAZ94968

ID AAZ94968 standard; DNA; 20 BP.

XX

AC AAZ94968;

XX

DT 13-SEP-1999 (first entry)

XX

DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.

XX

KW Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;  
 KW sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;  
 KW neutralising epitope; PCR primer; ss.

XX

OS Synthetic.

OS Chlamydia pneumoniae.

XX

PN WO9927105-A2.

XX

PD 03-JUN-1999.

XX

PF 20-NOV-1998; 98WO-IB001890.

XX

PR 21-NOV-1997; 97FR-00014673.

XX

PR 04-NOV-1998; 98US-0107078P.

XX

PA (GEST ) GENSET.

XX

PI Griffiths R;

XX

DR WPI; 1999-357842/30.

XX

PT Genome sequence of Chlamydia pneumoniae.

XX

PS Page 1711; Disclosure; 1912pp; English.

XX

CC AAX91991-X97517 represent PCR primers used to amplify open reading frames  
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae  
 CC (see AAX91990). C. pneumoniae causes respiratory disease such as  
 CC pneumonia and bronchitis and is thought to be a contributing factor in  
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema  
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading  
 CC frames of the C. pneumoniae genome (see AAY34584-AAY35879) can be used  
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae  
 CC nucleotides sequences can also be used as immunogenic compositions,  
 CC especially where the vector directs the expression of a neutralising  
 CC epitope of C. pneumoniae  
 XX

SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1428 GATCCAAAGCAGATGAATG 1447

Db 1 GCTCCGACCAGATGAATGT 20

RESULT 114

AAZ60081

ID AAZ60081 standard; DNA; 20 BP.

XX

AC AAZ60081;

XX

DT 25-APR-2000 (first entry)

```

XX Forward PCR primer +25/MIP-3beta used to amplify MIP-3beta ORF.
DE
XX
XX Chemokine; PCR primer; macrophage inflammation protein 3beta;
KW dendritic cell; disease treatment; MIP-3beta; infection; cancer; allergy;
KW immune response initiation; autoimmune disease; tissue rejection; ss.
XX
OS Homo sapiens.
XX
XX EP974357-A1.
PN
XX
XX 26-JAN-2000.
PD
XX
XX 16-JUL-1998; 98EP-00401799.
PF
XX
XX 16-JUL-1998; 98EP-00401799.
PR
XX
XX (SCHE ) SCHERING-PLOUGH.
PA
XX
XX Caux C, Vanbervliet B, Lebecque S, Vicari A, Dieu M;
PI WPI; 2000-118300/11.
XX
XX Use of chemokines capable of directing migration of dendritic cells,
DR useful for treating microbial infections, cancer and autoimmune diseases.
XX
XX Disclosure; Col 13; 16pp; English.
PS
XX
XX This sequence represents a PCR primer used to amplify the chemokine
CC macrophage inflammation protein 3 beta (MIP 3beta) coding sequence. The
CC PCR product is used in the analysis of dendritic cell response to
CC different chemokines. The invention relates to the use of chemokines
CC which are capable of directing dendritic cells, in the manufacture of a
CC medicament for the treatment of a disease state. Methods are included for
CC treating diseases by facilitating or inhibiting the migration or
CC activation of antigen-presenting dendritic cells. The chemokines can be
CC used to initiate, amplify or modulate an immune response. The chemokines
CC are useful for the treatment of disease states e.g. a bacterial, viral,
CC fungal or parasitic infection, cancer (especially melanoma), breast,
CC pancreatic, colon, lung, glioma, hepatocellular, endometrial, gastric,
CC intestinal, renal, prostate, thyroid, ovarian, testicular, liver, head
CC and neck, colorectal, oesophagus, stomach, eye, bladder, glioblastoma and
CC metastatic carcinomas), autoimmune disease, tissue rejection or an
CC allergy
XX
XX Sequence 20 BP; 1 A; 6 C; 5 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1083 CGGCTGGTGTCTGGACTGC 1102
Db 1 CTGCTGGTCTCTGGACTTC 20

RESULT 115
AAC60557
ID AAC60557 standard; DNA; 20 BP.
XX
XX AAC60557;
AC
XX
XX 31-JAN-2001 (first entry)
DT
XX
XX Human fra-1 mRNA antisense oligonucleotide ISIS 109048.
DE
XX
XX Human; fra-1; antisense oligonucleotide; phosphorothioate; cytostatic;
KW antiinflammatory; 2'-methoxyethyl wing; 2'-MOE wing; infection; cancer;
KW ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX

PN US6124133-A.
XX
XX 26-SEP-2000.
PD
XX
XX 15-OCT-1999; 99US-00418641.
PF
XX
XX 15-OCT-1999; 99US-00418641.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Taylor JK, Cowsett LM;
PI WPI; 2000-601552/57.
XX
XX Novel antisense compound 8-30 nucleobases in length targeted to human fra
PT -1 and which specifically hybridizes with and inhibits the expression of
PT human fra-1, useful for modulating the expression of fra-1 in cells.
XX
XX Claim 3; Col 41; 38pp; English.
PS
XX
XX The present sequence is one of a large number of antisense
CC oligonucleotides which are targeted to nucleic acids encoding fra-1. The
CC sequences may be oligodeoxyribonucleotides or chimeric oligonucleotides
CC containing a central gap region consisting of ten 2'-deoxynucleotides,
CC which is flanked on both sides by 2'-methoxyethyl (2'-MOE) wings. The
CC oligonucleotides have a phosphorothioate backbone and the cytidine
CC residues in the 2'-MOE wings are 5-methylcytidines. The fra-1 antisense
CC oligonucleotides are useful for inhibiting the expression of fra-1 in
CC human cells or tissues. They can be used for diagnostics, therapeutics,
CC prophylaxis and as research reagents and in kits. Use of the antisense
CC compounds may also be useful prophylactically, e.g. to prevent or delay
CC infection, inflammation or tumour formation
XX
XX Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1270 TGTCTGAGCCCTCAATATC 1289
Db 1 TTCTGAGCTCTCAATATC 20

RESULT 116
AAH75307/C
ID AAH75307 standard; DNA; 20 BP.
XX
XX AAH75307;
AC
XX
XX 02-OCT-2001 (first entry)
DT
XX
XX Mouse inducible NOS antisense oligonucleotide SEQ ID NO 151.
DE
XX
XX Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
KW modulate expression; immunomodulator; antidiabetic; cardiovascular;
KW cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
KW 2'-O-methoxyethyl; phosphorothioate; mouse; ss.
XX
XX Mus sp.
OS
XX
XX Key Location/Qualifiers
FT modified_base 1..20 a
FT /mod_base= OTHER
FT /notes="phosphorothioate backbone, 5' and 3' five
FT nucleotide 2'-MOE (2'-O-methoxyethyl) wings, all cytidine
FT residues are 5-methylcytidines and a deoxy gap"
XX
XX WO200152902-A1.
PN
XX
XX 26-JUL-2001.
PD
XX
XX
XX

```

```

PF 15-JAN-2001; 2001WO-US001381.
XX
XX
PR 24-JAN-2000; 2000US-00490208.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Bennett CF, Dean NM, Cowseert LM;
XX
XX
DR WPI; 2001-465340/50.
XX
XX
PT New antisense oligonucleotides for modulating the expression of inducible
PT nitric oxide synthase in cells or tissues, particularly useful for
PT treating e.g. immunological, cardiovascular or neurological disorders, or
PT ischemia.
XX
XX
PS Example 17; Page 87; 144pp; English.
XX
XX
CC The invention relates to antisense compounds, especially
CC oligonucleotides, which are targeted to a nucleic acid encoding inducible
CC nitric oxide synthase and which specifically hybridize to and modulate
CC expression of inducible nitric oxide synthase. The antisense compounds
CC have immunomodulator, antidiabetic, cardiovascular, cardiant,
CC neuroprotective, disorder and vasotropic activity. The antisense
CC oligonucleotides are useful for inhibiting the expression of inducible
CC nitric oxide synthase in cells or tissues. In particular, the antisense
CC oligonucleotides are useful for treating diseases or disorders associated
CC with inducible nitric oxide synthase, e.g. diabetes, immunological
CC disorder, cardiovascular disorder, neurological disorder or
CC ischaemia/reperfusion injury. The antisense oligonucleotides are also
CC useful for research and diagnostics. The present sequence is that of an
CC antisense 2'-O-methoxyethyl gapper oligonucleotide with a
CC phosphorothioate backbone, a central "gap" region of ten nucleotides
CC flanked by five nucleotide 2'-MOE (2'-methoxyethyl) wings and 5-
CC methylcytidine residues throughout the oligonucleotide. The antisense
CC oligonucleotide is targeted to mouse inducible nitric oxide synthase (NOS)
XX mRNA (AAH47974)
XX
XX
SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 385 ACAGATGGCTGGAGAA 404
Db 20 ACCAAGATGGCTGGAGAA 1

RESULT 117
AAF99116/c
ID AAF99116 standard; DNA; 20 BP.
XX
XX
AC AAF99116;
XX
XX
DT 12-JUN-2001 (first entry)
DE Immunostimulatory nucleic acid #232.
XX
XX
KW vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
KW immunostimulatory; tumour; viral infection; bacterial infection;
KW fungal infection; parasitic infection; cancer; asthma;
KW infectious disease; allergy; immune deficiency; phosphorothioate; ss.
XX
XX
OS Synthetic.
XX
XX
PN WO200122972-A2.
XX
XX
PD 05-APR-2001.
XX
XX
PF 25-SEP-2000; 2000WO-US026393.
XX
XX
PR 25-SEP-1999; 99US-0156113P.
PR 27-SEP-1999; 99US-0156135P.

23-AUG-2000; 2000US-0227436P.
(IOWA ) UNIV IOWA RES FOUND.
(COLE-) COLEY PHARM GMBH.
Krieg AM, Schetter C, Vollmer J;
WPI; 2001-273485/28.
Vaccinating against tumors, infectious diseases, allergies and asthma
using immunostimulatory Py-rich and TG nucleic acids.
Claim 101; Page 43; 338pp; English.
The present invention relates to a method for stimulating an immune
response. The method comprises administering an immunostimulatory nucleic
acid to a non-rodent subject in sufficient quantity to stimulate an
immune response. The present sequence is one such immunostimulatory
nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
(py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
against tumour antigens, viral antigens (e.g. herpesviridae, retroviridae
and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
haemophilus, campylobacter, clostridium, Escherichia coli and/or
staphylococcus), fungal antigens and/or parasitic antigens. The method is
also useful for preventing cancer, asthma, infectious disease, allergy or
immune deficiency. The present sequence can also be used to redirect a
Th2 to a Th1 immune response and to activate immune cells. Note: the
present sequence may have a phosphorothioate backbone
Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCTTCCTCGCGCGCGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 118
AAS08746
ID AAS08746 standard; DNA; 20 BP.
XX
XX
AC AAS08746;
XX
XX
DT 26-SEP-2001 (first entry)
DE Human PD-ABC form 1 DNA exon 14 3' splice site.
XX
XX
KW PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
KW peripheral blood leukocyte; bone marrow; lymph node; dyalipidemia;
KW cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
KW epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
KW familial high-density lipoprotein deficiency; fatty liver disease;
KW atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
KW alcoholism; retinal degeneration; hypertension; vascular disease.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200153490-A1.
XX
XX
PD 26-JUL-2001.
XX
XX
PF 23-JAN-2001; 2001WO-US002191.
XX
XX
PR 24-JAN-2000; 2000US-0177889P.
PR 30-JUN-2000; 2000US-0215405P.
XX
XX
PA (WARN ) WARNER LAMBERT CO.
XX
XX
PI Johns MA, Tafuri SR, Wang M;
XX

```

```

DR WPI; 2001-442259/47.
XX
PT New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
PT of dyplipidemia, epilepsy and diseases related to abnormal calcium flux.
XX
PS Disclosure; Page 37; 77pp; English.
XX
CC The sequence represents a splice site within a DNA molecule encoding
CC human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
CC 19p13.3 and is expressed in various tissues including spleen, thymus,
CC peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
CC molecules and proteins are used to diagnose and treat cardiovascular
CC disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
CC related to abnormal calcium flux, coronary artery disease, Tangier's
CC disease, familial high-density lipoprotein deficiency, atherosclerosis,
CC diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
CC retinal degeneration, hypertension and vascular disease. The sequences
CC are also used in drug screening assays
XX
SQ Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 36 CGTGGCGCGGTGAGACCG 55
Db 1 CGTGGCGCGGTGAGACCG 20

RESULT 119
AAS08837
ID AAS08837 standard; DNA; 20 BP.
XX
AC AAS08837;
XX
DT 26-SEP-2001 (first entry)
XX
DE Human PD-ABC form 2 DNA exon 14 3' splice site.
XX
KW PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
KW peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
KW cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
KW epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
KW familial high-density lipoprotein deficiency; fatty liver disease;
KW atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
KW alcoholism; retinal degeneration; hypertension; vascular disease.
XX
OS Homo sapiens.
XX
PN W0200153490-A1.
XX
PD 26-JUL-2001.
XX
PF 23-JAN-2001; 2001WO-US002191.
XX
PR 24-JAN-2000; 2000US-0177889P.
XX
PR 30-JUN-2000; 2000US-0215405P.
XX
PA (WARN ) WARNER LAMBERT CO.
XX
PI Johns MA, Tafuri SR, Wang M;
XX
WPI; 2001-442259/47.
XX
DR New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
DR of dyplipidemia, epilepsy and diseases related to abnormal calcium flux.
XX
PS Disclosure; Page 39; 77pp; English.
XX
CC The sequence represents a splice site within a DNA molecule encoding
CC human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
CC 19p13.3 and is expressed in various tissues including spleen, thymus,
XX
SQ Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 36 CGTGGCGCGGTGAGACCG 55
Db 1 CGTGGCGCGGTGAGACCG 20

RESULT 120
AAF23716/C
ID AAF23716 standard; DNA; 20 BP.
XX
AC AAF23716;
XX
DT 27-MAR-2001 (first entry)
XX
DE Human PPARGgamma antisense oligonucleotide ISIS# 106034.
XX
KW Cytostatic; antiinflammatory; antisense oligonucleotide; PPARGgamma;
KW peroxisome proliferator-activated receptor gamma; transcription factor;
KW nuclear hormone receptor; human; infection; inflammation; tumour;
KW phosphorothioate; 2-methoxyethyl wing; ss.
XX
OS Homo sapiens.
XX
PN US6159734-A.
XX
PD 12-DEC-2000.
XX
PF 18-JAN-2000; 2000US-00484345.
XX
PR 18-JAN-2000; 2000US-00484345.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI McKay R, Baker BF, Borchers AH;
XX
WPI; 2001-070112/08.
XX
PT Novel antisense compounds capable of modulating expression of peroxisome
PT proliferator-activated receptor gamma useful for diagnosis, prophylaxis
PT and treatment of diseases associated with expression of the receptor.
XX
PS Example 15; Col 43-44; 40pp; English.
XX
CC Peroxisome proliferator-activated receptors (PPARs) are members of the
CC nuclear hormone receptor subfamily of transcription factors. The present
CC invention relates to antisense oligonucleotides, targeted to a nucleic
CC acid molecule encoding human PPARGgamma, which specifically hybridises
CC with and inhibits the expression of human PPARGgamma. The present sequence
CC is one such antisense oligonucleotide. The oligonucleotides of the
CC present invention can be used in the diagnosis and treatment of diseases
CC associated with the expression of PPARGgamma, e.g. to prevent or delay
CC infection, inflammation or tumour formation. Note: the present sequence
CC may have a phosphorothioate backbone and 2'-O-(2-methoxyethyl) (2-MOE)
CC wings
XX
SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;

CC peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
CC molecules and proteins are used to diagnose and treat cardiovascular
CC disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
CC related to abnormal calcium flux, coronary artery disease, Tangier's
CC disease, familial high-density lipoprotein deficiency, atherosclerosis,
CC diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
CC retinal degeneration, hypertension and vascular disease. The sequences
CC are also used in drug screening assays
XX
SQ Sequence 20 BP; 2 A; 6 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 36 CGTGGCGCGGTGAGACCG 55
Db 1 CGTGGCGCGGTGAGACCG 20

```

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 887 CCCAGATCTGATTCCTTCA 906

Db 20 CCCAGAGCGGATTCCTCA 1

RESULT 121

AAS97459/c

ID AAS97459 standard; DNA; 20 BP.

XX AC

XX AAS97459;

XX DT

XX 12-MAR-2002 (first entry)

XX DE

XX Murine SAC1 gene-specific oligonucleotide PCR primer #64.

XX KW

XX Human; mouse; SAC1; carbohydrate; sweetener; ethanol; alcoholism; ss;  
obesity; diabetes; transgenic embryo; body tissue; body fluid; pancreas;  
blood; tongue; PCR primer; anorectic; antidiabetic; gene therapy;  
protein replacement therapy.

XX KW

XX OS

XX Mus sp.

XX PN

XX WO200183749-A2.

XX PD

XX 08-NOV-2001.

XX PF

XX 25-APR-2001; 2001WO-US013387.

XX PR

XX 28-APR-2000; 2000US-0200794P.

XX PR

XX 28-JUL-2000; 2000US-0221419P.

XX PR

XX 10-NOV-2000; 2000US-0247443P.

XX PA

XX (WARN ) WARNER LAMBERT CO.

XX PA

XX (MONE-) MONELL CHEM SENSES CENT.

XX PI

XX Bachmanov AA, Beauchamp GK, Chatterjee A, De Jong PJ, Li S, Li X;

XX PI

XX Ohmen JD, Reed DR, Ross D, Tordoff MG;

XX DR

XX WPI; 2002-075162/10.

XX PT

XX Novel isolated polypeptide comprising variant form of mouse or human SAC1

XX PT

XX polypeptide, and is associated with altered preference for carbohydrates

XX PT

XX or other sweeteners, useful for preventing obesity, diabetes, alcoholism.

XX XX

XX Claim 14; Page 76; 239pp; English.

XX PS

XX The invention relates to an isolated polypeptide, comprising a variant

XX CC

XX form of mouse or human SAC1 polypeptide. The variant form is associated

XX CC

XX with altered preference for carbohydrates, other sweeteners or ethanol.

XX CC

XX The polypeptide and its associated DNA sequence can be produced by

XX CC

XX recombinant techniques and is useful for preventing obesity, diabetes or

XX CC

XX alcoholism associated with SAC1 expression. The sequences are useful in

XX CC

XX screening for drugs and sweeteners. Recombinant cell lines and transgenic

XX CC

XX embryos may be used in screening for and identifying agents that induce

XX CC

XX or repress function of SAC1. Predisposition to diabetes, obesity or

XX CC

XX alcoholism can be ascertained by testing any fluid or tissue of a human

XX CC

XX (such as blood, pancreas or tongue) for sequence variations of the SAC1

XX CC

XX gene. A sequence variation of the SAC1 locus may indicate a

XX CC

XX predisposition to diabetes, obesity and/or alcoholism and may provide a

XX CC

XX diagnostic mark. The polynucleotide can be detected in a biological

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 685 AGGTGGGGCTTGGCATCT 704

Db 20 CCCAGAGCGGATTCCTCA 1

RESULT 123

ABL39008/c

ID ABL39008 standard; DNA; 20 BP.

XX AC

XX ABL39008;

XX DT

XX 13-DEC-2002 (first entry)

XX DE

XX Angiogenesis inhibitory oligonucleotide #243.

XX KW

XX Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;

XX KW

XX tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;

XX KW

XX diabetic retinopathy; retinopathy of prematurity; macular degeneration;

XX KW

XX corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;

XX KW

XX rubeosis; Osler-Weber Syndrome; myocardial angiogenesis;

XX KW

XX plaque neovascularisation; telangiectasia; haemophilic joint;

XX KW

XX angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;

XX KW

XX scleroderma; hypertrophic scar.

XX OS

XX Synthetic.

XX PN

XX WO200253141-A2.

XX PD

XX 11-JUL-2002.

XX PF

XX 14-DEC-2001; 2001WO-US048458.

XX PR

XX 14-DEC-2000; 2000US-0255534P.

XX PR

XX (COLE-) COLEY PHARM GROUP INC.

XX PA

XX Bratzler RL;

XX PI

XX WPI; 2002-566690/60.

XX DR

XX Inhibiting angiogenesis in a subject, involves administering at least one

XX XX

XX antiangiogenic nucleic acid molecule to the subject.

XX PT

XX Claim 2; Page 23; 276pp; English.

XX PS

XX The invention relates to inhibiting angiogenesis in a subject, comprising

XX CC

XX administering at least one antiangiogenic nucleic acid molecule. Also

XX CC

XX included is a kit comprising a first container housing the antiangiogenic

XX CC

XX nucleic acids, and instructions for administering them to a subject

Db 20 AGGTGAGGGTTTGGCTTCT 1

RESULT 122

ABS77759/c

ID ABS77759 standard; DNA; 20 BP.

XX AC

XX ABS77759;

XX DT

XX 13-DEC-2002 (first entry)

XX DE

XX Angiogenesis inhibitory oligonucleotide #243.

XX KW

XX Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;

XX KW

XX tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;

XX KW

XX diabetic retinopathy; retinopathy of prematurity; macular degeneration;

XX KW

XX corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;

XX KW

XX rubeosis; Osler-Weber Syndrome; myocardial angiogenesis;

XX KW

XX plaque neovascularisation; telangiectasia; haemophilic joint;

XX KW

XX angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;

XX KW

XX scleroderma; hypertrophic scar.

XX OS

XX Synthetic.

XX PN

XX WO200253141-A2.

XX PD

XX 11-JUL-2002.

XX PF

XX 14-DEC-2001; 2001WO-US048458.

XX PR

XX 14-DEC-2000; 2000US-0255534P.

XX PR

XX (COLE-) COLEY PHARM GROUP INC.

XX PA

XX Bratzler RL;

XX PI

XX WPI; 2002-566690/60.

XX DR

XX Inhibiting angiogenesis in a subject, involves administering at least one

XX XX

XX antiangiogenic nucleic acid molecule to the subject.

XX PT

XX Claim 2; Page 23; 276pp; English.

XX PS

XX The invention relates to inhibiting angiogenesis in a subject, comprising

XX CC

XX administering at least one antiangiogenic nucleic acid molecule. Also

XX CC

XX included is a kit comprising a first container housing the antiangiogenic

XX CC

XX nucleic acids, and instructions for administering them to a subject

XX CC

XX having a condition characterised by unwanted angiogenesis. The method is

XX CC

XX useful for inhibiting angiogenesis associated with solid tumour growth,

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCTCCGTCGCGCGGTC 48

Db 20 CCGCGCGCGCGCGCGGCC 1

RESULT 123

ABL39008/c

ID ABL39008 standard; DNA; 20 BP.

XX AC

XX ABL39008;

XX DT

XX 13-DEC-2002 (first entry)

XX DE

XX Angiogenesis inhibitory oligonucleotide #243.

XX KW

XX Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;

XX KW

XX tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;

XX KW

XX diabetic retinopathy; retinopathy of prematurity; macular degeneration;

XX KW

XX corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;

XX KW

XX rubeosis; Osler-Weber Syndrome; myocardial angiogenesis;

XX KW

XX plaque neovascularisation; telangiectasia; haemophilic joint;

XX KW

XX angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;

XX KW

XX scleroderma; hypertrophic scar.

XX OS

XX Synthetic.

XX PN

XX WO200253141-A2.

XX PD

XX 11-JUL-2002.

XX PF

XX 14-DEC-2001; 2001WO-US048458.

XX PR

XX 14-DEC-2000; 2000US-0255534P.

XX PR

XX (COLE-) COLEY PHARM GROUP INC.

XX PA

XX Bratzler RL;

XX PI

XX WPI; 2002-566690/60.

XX DR

XX Inhibiting angiogenesis in a subject, involves administering at least one

XX XX

XX antiangiogenic nucleic acid molecule to the subject.

XX PT

XX Claim 2; Page 23; 276pp; English.

XX PS

XX The invention relates to inhibiting angiogenesis in a subject, comprising

XX CC

XX administering at least one antiangiogenic nucleic acid molecule. Also

XX CC

XX included is a kit comprising a first container housing the antiangiogenic

XX CC

XX nucleic acids, and instructions for administering them to a subject

```
XX AC ABL39008;
XX DT 16-APR-2002 (first entry)
XX DE Immunostimulatory nucleic acid SEQ ID NO: 410.
XX KW Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
XX KW angiogenesis; metastasis; cytostatic; ss.
XX OS Synthetic.
XX PN WO200197843-A2.
XX PD 27-DEC-2001.
XX XX 22-JUN-2001; 2001WO-US020154.
XX PF 22-JUN-2000; 2000US-0213346P.
XX PR (IOWA ) UNIV IOWA RES FOUND.
XX PA
XX PI Weiner G, Hartmann G;
XX DR WPI; 2002-154611/20.
XX XX Treating or preventing cancer, such as basal cell carcinoma, comprises
PT administering immunostimulatory nucleic acids that induce expression of
PT cell surface antigens and antibodies to a subject having or at risk of
PT developing cancer.
XX PS Disclosure; Page 199; 312pp; English.
XX XX The present invention relates to methods for treating or preventing
CC cancer, involving administering to a subject having or at risk of
CC developing cancer immunostimulatory nucleic acids that induce expression
CC of cell surface antigens and antibodies. The methods are useful for
CC treating or preventing cancer such as basal cell carcinoma, bladder
CC cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC breast cancer, cervical cancer, colon and rectum cancer, connective
CC tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx
CC cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC present sequence is an immunostimulatory oligonucleotide described in the
CC exemplification of the invention
XX SQ Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 124
ABN86471/C
ID AEN86471 standard; DNA; 20 BP.
XX AC AEN86471;
XX XX 21-OCT-2002 (first entry)
XX DE Human MMP-2 1306T allele polymorphism genotyping primer BG-1.
XX KW Matrix metalloproteinase-2; MMP-2; myocardial infarction; restenosis;
XX KW thromboembolism; atherosclerosis; arthritis; cancer; tumour; allele;
XX KW polymorphism; PCR; primer; ss.

XX AC ABL39008;
XX DT 16-APR-2002 (first entry)
XX DE Immunostimulatory nucleic acid SEQ ID NO: 410.
XX KW Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
XX KW angiogenesis; metastasis; cytostatic; ss.
XX OS Synthetic.
XX PN WO200197843-A2.
XX PD 27-DEC-2001.
XX XX 22-JUN-2001; 2001WO-US020154.
XX PF 22-JUN-2000; 2000US-0213346P.
XX PR (IOWA ) UNIV IOWA RES FOUND.
XX PA
XX PI Weiner G, Hartmann G;
XX DR WPI; 2002-154611/20.
XX XX Treating or preventing cancer, such as basal cell carcinoma, comprises
PT administering immunostimulatory nucleic acids that induce expression of
PT cell surface antigens and antibodies to a subject having or at risk of
PT developing cancer.
XX PS Disclosure; Page 199; 312pp; English.
XX XX The present invention relates to methods for treating or preventing
CC cancer, involving administering to a subject having or at risk of
CC developing cancer immunostimulatory nucleic acids that induce expression
CC of cell surface antigens and antibodies. The methods are useful for
CC treating or preventing cancer such as basal cell carcinoma, bladder
CC cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC breast cancer, cervical cancer, colon and rectum cancer, connective
CC tissue cancer, oesophageal cancer, eye cancer, kidney cancer, larynx
CC cancer, leukaemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC present sequence is an immunostimulatory oligonucleotide described in the
CC exemplification of the invention
XX SQ Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 29 CCGCCTCCGTCGCGCGGTC 48
Db 20 CCGCGCGCGCGCGCGCGCC 1

RESULT 124
ABN86471/C
ID AEN86471 standard; DNA; 20 BP.
XX AC AEN86471;
XX XX 21-OCT-2002 (first entry)
XX DE Human MMP-2 1306T allele polymorphism genotyping primer BG-1.
XX KW Matrix metalloproteinase-2; MMP-2; myocardial infarction; restenosis;
XX KW thromboembolism; atherosclerosis; arthritis; cancer; tumour; allele;
XX KW polymorphism; PCR; primer; ss.

OS Homo sapiens.
XX WO200246462-A2.
XX PD 13-JUN-2002.
XX XX 04-DEC-2001; 2001WO-GB005365.
XX PF 07-DEC-2000; 2000GB-00029864.
XX PR 05-OCT-2001; 2001GB-00024013.
XX XX (ISIS-) ISIS INNOVATION LTD.
XX PI Greaves DR, Price S, Watkins H;
XX DR WPI; 2002-590539/63.
XX XX Assessing individual for predisposition to disease in which matrix
PT metalloproteinase-2 plays role, involves determining nucleotide at a site
PT of matrix metalloproteinase-2 polymorphism associated with such disease.
XX PS Disclosure; Page 18; 32pp; English.
XX XX The invention relates to assessing an individual for predisposition to a
CC disease in which matrix metalloproteinase-2 (MMP-2) plays a role. The
CC method involves determining the nucleotide at a site of MMP-2
CC polymorphism associated with such disease. The method is useful for
CC assessing predisposition to a disease or prognosis and/or prevention of
CC the disease in an individual, and in the profiling and assessment of
CC individuals for medical treatment, especially clinical trial. The MMP-2
CC diseases include myocardial infarction, thromboembolism, abdominal aortic
CC aneurysm, and other consequences of atherosclerosis, restenosis,
CC arthritis, cancer caused by both metastatic and non-metastatic tumours,
CC obstructive pulmonary disease, emphysema, hepatic fibrosis and other
CC diseases involving fibrosis. The present sequence represents a PCR primer
CC for genotyping the MMP-2 C-1306T allele polymorphism
XX SQ Sequence 20 BP; 1 A; 7 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 384 CAGCAGATGGGCTGGAGAA 403
Db 20 CAGCAGAGGCGACTGGAGAA 1

RESULT 125
ABL43517
ID ABL43517 standard; DNA; 20 BP.
XX AC ABL43517;
XX XX 11-APR-2002 (first entry)
XX DE Human chromosome 1p36-35 PCR primer SEQ ID NO:561.
XX KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
XX KW PCR primer; ss.
XX OS Homo sapiens.
XX PN JP2001321190-A.
XX PD 20-NOV-2001.
XX XX 12-MAR-2001; 2001JP-00068285.
XX PF 10-MAR-2000; 2000JP-00066716.
XX XX (RIKA ) RIKAGAKU KENKYUSHO.
XX PA (GENO-) GENOTEX YG.
```

XX WPI; 2002-144136/19.  
 XX Arraying genome clones.  
 XX Claim 4; Page 15; 528pp; Japanese.  
 XX The present invention describes a method of arraying genome clones. The  
 CC method comprises: (a) clones of the genomic libraries contained in  
 CC multiwell plates numbered for discrimination are mixed in each of the  
 CC multiwell plates; (b) a primer designed based on the chromosome marker  
 CC sequence is added to the mixture to carry out an amplification reaction;  
 CC (c) a signal corresponding to the marker is detected from the resultant  
 CC amplified product to specify the discrimination Nos. of the multiwell  
 CC plates containing the clones having said marker sequence; (d) the order  
 CC of the markers is changed so that the same discrimination Nos. succeed to  
 CC the maximum in the specified discrimination Nos. to array the multiwell  
 CC plates; (e) the clones in the multiwell plates of the specified  
 CC discrimination Nos. are mixed respectively in each wells of longitudinal  
 CC and lateral directions; (f) the mixed clones are cultured and the  
 CC resultant cultures are amplified by using the above primer; (g) signals  
 CC are detected from the amplified products; (h) the clones in the multiwell  
 CC plates are specified from the detected result; and (i) the clones are  
 CC reconstituted as the positions on the chromosome and arrayed. The  
 CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent  
 CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634  
 CC represent PCR primers for human chromosome 21q22.1, which are  
 CC specifically claimed for use in the present invention  
 XX  
 XX Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1789 TTCACCTTTAAAGTAACA 1808  
 DB 1 TTCACCTTTGCAAGCAACA 20  
 RESULT 126  
 ABL13053  
 ID ABL13053 standard; DNA; 20 BP.  
 XX  
 XX ABL13053;  
 AC  
 XX  
 DT 30-JAN-2003 (first entry)  
 XX  
 XX Human apolipoprotein A-IV PCR primer (SNP specific) #19.  
 DE  
 XX  
 XX Human; PCR; primer; ss; gene therapy; single nucleotide polymorphism;  
 KW cytochrome C oxidase subunit VIB; COX6B; high serum cholesterol; GPI-1;  
 KW N-acetylglucosaminyl transferase component; cardiovascular disease; HDL;  
 KW glycosylphosphatidylinositol-1; SNP; low serum high density lipoprotein.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200272604-A2.  
 PN  
 XX  
 PD 19-SEP-2002.  
 XX  
 XX 05-MAR-2002; 2002WO-US006728.  
 XX  
 XX 09-MAR-2001; 2001US-00802640.  
 XX  
 XX (SEQU-) SEQUENOM INC.  
 XX  
 XX Braun A, Bansal A, Kleya PW;  
 XX  
 XX WPI; 2002-750478/81.  
 XX  
 XX Detecting the presence or absence of an allelic variant of a polymorphic  
 FT region of COX6B and/or GPI-1 gene, useful for detecting a predisposition

PT to high serum cholesterol, low serum HDL and cardiovascular disease.  
 XX  
 PS Disclosure; Page 32; 199pp; English.  
 XX  
 CC The invention comprises methods of detecting the presence or absence of  
 CC at least one allelic variant of a polymorphic region of a gene associated  
 CC with cardiovascular disease. The invention specifically relates to  
 CC detecting the region of a cytochrome C oxidase subunit VIB (COX6B) gene  
 CC that is associated with high serum cholesterol, or the region of the N-  
 CC acetylglucosaminyl transferase component glycosylphosphatidylinositol-1  
 CC (GPI-1) gene that is associated with low serum high density lipoprotein  
 CC (HDL). The methods of the invention are useful for detecting a  
 CC predisposition to high serum cholesterol, low serum HDL and  
 CC cardiovascular disease. The methods are also useful for elucidating  
 CC pathological pathways, developing diagnostic assays and new drug  
 CC therapies for such disorders. The present DNA sequence represents a PCR  
 CC primer used to amplify a human gene that is associated with high serum  
 CC cholesterol, low serum HDL and/or cardiovascular disease  
 XX  
 SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1265 GAGCCTGCTGCAGCCCTCA 1284  
 DB 1 GTGACTTCTGCAGCCCTCA 20  
 RESULT 127  
 ABL80988  
 ID ABL80988 standard; DNA; 20 BP.  
 XX  
 XX ABL80988;  
 AC  
 XX  
 DT 15-JUL-2002 (first entry)  
 XX  
 XX Mouse caspase 7 phosphorothioate oligonucleotide SEQ ID NO:166.  
 DE  
 XX  
 KW Caspase 7; antisense modulation; antiinflammatory; cytostatic;  
 KW antisense therapy; caspase 7 inhibitor; inflammatory condition;  
 KW hyperproliferative disorder; cancer; bone metabolism; infection;  
 KW cholesterol disorder; inflammation; tumour; phosphorothioate; ss.  
 XX  
 OS Mus musculus.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate linkages"  
 FT modified\_base 1..5  
 FT /\*tag= b  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) wing"  
 FT modified\_base 16..20  
 FT /\*tag= c  
 FT /mod\_base= OTHER  
 FT /note= "2'-methoxyethyl (2'-MOE) wing"  
 XX  
 XX WO200222640-A1.  
 PN  
 XX  
 XX 21-MAR-2002.  
 PD  
 XX  
 XX 10-SEP-2001; 2001WO-US028232.  
 XX  
 XX 11-SEP-2000; 2000US-00659860.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Zhang H, Watt AT;  
 XX

DR WPI; 2002-404806/43.

XX Novel antisense compounds targeted to nucleic acids encoding caspase 7,

PT for modulating gene expression and treating diseases associated with

PT expression of caspase 7 in humans.

XX

PS Example 16; Page 89; 138pp; English.

XX

CC The present invention describes a compound (I) 8-50 nucleobases in length

CC targeted to a nucleic acid molecule encoding caspase 7, which

CC specifically hybridises with and inhibits the expression of caspase 7.

CC (I) has antiinflammatory and cytostatic activities, and can be used in

CC antisense therapy and as an inhibitor of caspase 7 expression. (I) is

CC useful for inhibiting the expression of caspase 7 in human cells or

CC tissues, and for treating a human having a disease or condition

CC associated with caspase 7 including inflammatory condition,

CC hyperproliferative disorder (cancer), or bone metabolism or cholesterol

CC disorder. (I) is useful for diagnostics, therapeutics, prophylaxis and as

CC research reagent and kits. (I) is useful prophylactically to prevent or

CC delay infection, inflammation or tumour formation. The present sequence

CC represent a mouse caspase 7 inhibiting chimeric phosphorothioate

CC oligonucleotide having 2'-MOE wings and a deoxy gap, which is used in an

CC example from the present invention

XX

SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1528 AAGGAACGTTTCATGCTT 1547

DB 1 AAGGAACCTTTTCATGCTT 20

RESULT 128

ABK47992

ID ABK47992 standard; DNA; 20 BP.

XX

AC ABK47992;

DT 02-JUL-2002 (first entry)

XX

DE Human MIP-3 beta RT-PCR primer +25/MIP-3 beta.

XX

KW Human; chemokine; MCP-4; hMCP-4; ss; 6CKine; dendritic cell; renal;

KW autoimmune disease; tissue rejection; allergy; cancer; hepatocellular;

KW melanoma; breast; pancreas; colon; glioma; endometrium; intestine; lung;

KW prostate; thyroid; ovary; testis; liver; head; neck; colorectal; bladder;

KW oesophagus; stomach; eye; glioblastoma; gastric; metastatic carcinoma;

KW immunosuppressive; antiallergic; cytostatic; rectum; RT-PCR; primer;

KW reverse transcriptase; macrophage inflammatory protein 3 beta;

KW MIP-3 beta.

XX

OS Homo sapiens.

XX

PN US2002034494-A1.

XX

PD 21-MAR-2002.

XX

PF 24-JAN-2001; 2001US-00768917.

XX

PR 24-JAN-2001; 2001US-00768917.

XX

PA (VICA/) VICARI A P.

PA (CAUX/) CAUX C.

PA (LAFa/) LAFACE D.

XX

PI Vicari AP, Caux C, Laface D;

XX

DR WPI; 2002-351086/38.

XX

PT Using chemokine MCP-4 or 6CKine to attract dendritic cells to the site of

PT an antigen is useful to treat disease states, particularly autoimmune

PT disease, tissue rejection, allergy and cancer.

XX

PS Example; Page 7; 29pp; English.

XX

CC The invention relates to a method for enhancing an immune response in a

CC mammal, comprising administering chemokine MCP-4 or 6CKine or their

CC biologically active fragments. The chemokines are capable of directing

CC the migration of dendritic cells to manufacture a medicament for a

CC disease state. The invention is used to treat disease states, including

CC an autoimmune disease, tissue rejection or an allergy, or a cancer,

CC particularly melanoma, breast, pancreatic, colon, lung, glioma,

CC hepatocellular, endometrial, gastric, intestinal, renal, prostate,

CC thyroid, ovarian, testicular, liver, head and neck, colorectal,

CC oesophagus, stomach, eye or bladder cancer, glioblastoma or metastatic

CC carcinoma. This sequence represents an RT-PCR primer for macrophage

CC inflammatory protein 3 beta (MIP-3 beta), used in analysis of

CC responsiveness to chemokines

XX

SQ Sequence 20 BP; 1 A; 6 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1083 CGGCTGGTCTCTGGACTGC 1102

DB 1 CTGCTGGTCTCTGGACTTC 20

RESULT 129

ACD99549/c

ID ACD99549 standard; DNA; 20 BP.

XX

AC ACD99549;

DT 25-SEP-2003 (first entry)

XX

DE Immunostimulatory nucleic acid #235.

XX

KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;

KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;

KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;

KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.

XX

OS Synthetic.

XX

PN US2003050268-A1.

XX

PD 13-MAR-2003.

XX

PF 29-MAR-2002; 2002US-00112653.

XX

PR 29-MAR-2001; 2001US-0279642P.

XX

PA (KRIE/) KRIEG A M.

PA (BERG/) BERG D J.

XX

PI Krieg AM, Berg DJ;

XX

DR WPI; 2003-521815/49.

XX

PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,

PT allergic contact dermatitis, latex dermatitis or inflammatory bowel

PT disease by administering an immunostimulatory nucleic acid.

XX

PS Disclosure; Page 15; 229pp; English.

XX

CC The invention describes a method of treating non-allergic inflammatory

CC disease comprising administering to a subject having or at risk of

CC developing a non-allergic inflammatory disease an immunostimulatory

CC nucleic acid for prevention or treatment of the disease. The method is

CC useful for treating non-allergic inflammatory diseases, such as



CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or  
 CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.  
 CC This sequence represents an immunostimulatory nucleic acid  
 XX  
 SQ Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTCGCGCGTC 48  
 ||||| ||||| ||||| |||||  
 Db 20 CCGCGCGCGCGCGCGCC 1

## RESULT 130

ADB36618/c  
 ID ADB36618 standard; DNA; 20 BP.

AC ADB36618;

DT 04-DEC-2003 (first entry)

DE Immunostimulatory nucleic acid #232.

XX ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;  
 KW hypo-responsive subject; immunostimulatory.  
 XX Synthetic.

OS

XX US2003087848-A1.

FN

XX 08-MAY-2003.

XX 02-FEB-2001; 2001US-00776479.

XX 03-FEB-2000; 2000US-0179991P.

XX (BRAT/) BRATZLER R L.

PA (PETE/) PETERSEN D M.

PA (FOUR/) FOURON Y.

XX Bratzler RL, Petersen DM, Fouron Y;

XX WPI; 2003-657977/62.

XX Treating and/or preventing allergy or asthma using an immunostimulatory  
 PT nucleic acid alone or in combination with an asthma/allergy medicament.  
 XX Disclosure; Page 8; 221pp; English.

XX The invention relates to a method of treating or preventing allergy or  
 CC asthma which comprises administering to a subject a poly-G nucleic acid  
 CC in an aerosol formulation. The methods and compositions of the present  
 CC invention are useful for diagnosing and/or treating asthma and allergy  
 CC especially in a hypo-responsive subject. The present sequence represents  
 CC an immunostimulatory nucleic acid of the invention.

XX Sequence 20 BP; 0 A; 6 C; 14 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 29 CCGCCTCGTCGCGCGTC 48  
 ||||| ||||| ||||| |||||  
 Db 20 CCGCGCGCGCGCGCC 1

## RESULT 131

ADD24338

ID ADD24338 standard; DNA; 20 BP.

XX

AC

ADD24338;

DT 15-JAN-2004 (first entry)

DE CD2 binding protein 1 (CD2BP1) primer #7.

XX human; CD2 binding protein; CD2BP1; genetic marker; autoimmune disorder;  
 KW PAPA syndrome; familial recurrent arthritis; FRA syndrome; ss; PCR;  
 KW primer.

XX Homo sapiens.

OS US2003104404-A1.

XX 05-JUN-2003.

XX 04-FEB-2002; 2002US-00067076.

XX 08-NOV-2000; 2000US-00710693.

PR 01-MAY-2001; 2001US-0287893P.

XX (WISE/) WISE C A.

XX Wise CA;

XX WPI; 2003-801229/75.

XX Novel isolated nucleic acid molecule useful as genetic markers for  
 PT autoimmune disorder such as PAPA syndrome.

XX Example 2; SEQ ID NO 10; 22pp; English.

XX The invention relates to an isolated nucleic acid molecule where the  
 CC molecule encodes CD2 binding protein (CD2BP1). The nucleic acid is useful  
 CC as genetic markers for autoimmune disorder such as PAPA syndrome which is  
 CC a combination of familial recurrent arthritis (FRA) syndrome and PAPA  
 CC syndrome. The present sequence is used in the exemplification of the  
 CC present invention.

XX Sequence 20 BP; 5 A; 2 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 989 GCAGGTGTCAGGATGATG 1008

Db 1 GCAGGTGTCAGGATGATG 20

## RESULT 132

AAD63540

ID AAD63540 standard; DNA; 20 BP.

XX AAD63540;

XX 12-FEB-2004 (first entry)

XX Human CD2BP1 cDNA amplifying PCR primer, CD2BP1-4F.

XX Human; CD2 binding protein; CD2BP1; familial recurrent arthritis; FRA;  
 KW CD2BP1 mediated disorder; PCR; primer; ss.

XX Homo sapiens.

OS US6642370-B1.

XX 04-NOV-2003.

XX 08-NOV-2000; 2000US-00710693.

XX 08-NOV-2000; 2000US-00710693.

XX

```
PA (TEXA-) TEXAS SCOTTISH RITE HOSPITAL.
XX
XX Wise CA;
XX
XX WPI; 2003-851363/79.
XX
XX New nucleic acid encoding CD2 binding protein CD2BP1, useful for
XX producing antibodies, in diagnostic assays or identifying cellular or
XX extracellular gene products involved in the regulation of a CD2BP1
XX mediated disorder.
XX
XX Example 2; Col 22; Opp; English.
XX
XX The present invention relates to the identification of a gene encoding
XX CD2 binding protein, CD2BP1 as the inherited factor associated with
XX familial recurrent arthritis (FRA). Particularly mutant alleles of CD2BP1
XX are identified as a causative factor in FRA. Nucleic acid molecules of
XX the invention are used for the production of antibodies, in diagnostic
XX assays or for the identification of other cellular or extracellular gene
XX products involved in the regulation of CD2BP1 mediated disorders
XX including FRA. The present sequence is a PCR primer used to amplify human
XX CD2BP1 cDNA
XX
XX Sequence 20 BP; 5 A; 2 C; 8 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 989 GCAGGTGGCCATGGATGATG 1008
DB 1 GCAGTGTGTCAGGATGATG 20
|||||
RESULT 133
ID ABZ90044 standard; DNA; 20 BP.
XX
XX ABZ90044;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiqunone.
XX
PS Disclosure; SEQ ID NO 5286; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiqunone. A composition of the invention
XX has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX immunosuppressive, and cytostatic activity. The composition may have a
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels
XX of, or reducing sensitivity to adenosine, reducing levels of ubiqunone or
XX receptor, producing bronchodilation, increasing levels of ubiqunone or
XX lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX lung inflammation, lung allergies, or a respiratory disease or condition.
XX Note: The sequence data for this patent is not represented in the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 8 A; 1 C; 2 G; 9 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1672 AAATCTCTGATTCAGAAA 1691
DB 1 AAATTTTGATTCATATAA 20
|||||
RESULT 134
ID ABZ89607/c standard; DNA; 20 BP.
XX
XX ABZ89607;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiqunone.
XX
```

PS Disclosure; SEQ ID NO 4849; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequences

XX

XX Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;

XX

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred.No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 888 CCAGTACTGATTCCTTCAA 907

Db 20 CCAAAATATGTCCTTCAA 1

RESULT 135

ABZ90469/C

ID ABZ90469 standard; DNA; 20 BP.

AC ABZ90469;

XX

XX 17-OCT-2003 (first entry)

XX Human oligonucleotide sequence.

XX

XX Human; antisense; lung dysfunction; nasal airway dysfunction;

XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

XX antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX lung inflammation; respiratory disease; ds.

XX

XX Homo sapiens.

OS

XX

XX WO200285308-A2.

PN

XX

XX 31-OCT-2002.

PD

XX

XX 23-APR-2002; 2002WO-US013135.

PF

XX

XX 24-APR-2001; 2001US-0286137P.

PR

XX

XX (EPIG-) EPIGENESIS PHARM INC.

PA

XX

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI

XX

XX Miller S, Tang L, Shahabuddin S;

PI

XX

XX WPI; 2003-229219/22.

DR

XX

XX Pharmaceutical composition for treating ailments associated with impaired

XX respiration, has oligo(s) antisense to specific gene(s) or its

XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

XX ubiquinone.

XX

PS Disclosure; SEQ ID NO 5711; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published\_pct\_sequences

XX

XX Sequence 20 BP; 2 A; 1 C; 4 G; 13 T; 0 U; 0 Other;

XX

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred.No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1518 AAACAGTAAGAAAGAAACGT 1537

Db 20 AAACACTAAGAAACAAACAT 1

RESULT 136

ABZ82795

ID ABZ82795 standard; DNA; 20 BP.

AC ABZ82795;

XX

XX 14-MAY-2003 (first entry)

XX Mouse HSL chimeric phosphorothioate oligonucleotide SEQ ID NO:184.

XX

XX Hormone-sensitive lipase; antisense oligonucleotide; inhibitor; obesity;

XX phosphorothioate; antidiabetic; anorectic; cytostatic; antisense therapy;

XX abnormal metabolic condition; hyperlipidaemia; type 2 diabetes; cancer;

XX hyperproliferative disorder; mouse; ss.

XX

XX Mus musculus.

OS

XX

XX Synthetic.

XX

XX Key Location/Qualifiers

FT modified\_base 1..20

FT /\*tag= a

FT /mod\_base= OTHER

FT /note= "phosphorothioate linkages"

FT modified\_base 1..5

FT /\*tag= b

FT /mod\_base= OTHER

FT /note= "2'-O-methoxyethyl (2'-MOE) wing"

FT modified\_base 16..20

FT /\*tag= c

FT /mod\_base= OTHER

FT /note= "2'-O-methoxyethyl (2'-MOE) wing"

XX

XX WO2003010139-A2.

PN

XX

XX 06-FEB-2003.

PD

XX

XX 15-JUL-2002; 2002WO-US022672.

PF

XX

XX 26-JUL-2001; 2001US-00915814.

PR

```

XX (ISIS-) ISIS PHARM INC.
XX Butler MM, Watt AT, Freier SM, Wyatt JR;
XX WPI; 2003-239411/23.
XX
XX New antisense oligonucleotides targeted against nucleic acids encoding
XX hormone-sensitive lipase, useful for treating abnormal metabolic
XX condition, e.g. hyperlipidemia and obesity, or a hyperproliferative
XX disorder, e.g. cancer.
XX
XX Example 17; Page 93; 167pp; English.
XX
XX The present invention describes a compound (I) 8-50 nucleobases in length
XX targeted to a nucleic acid molecule encoding a hormone-sensitive lipase
XX (HSL) or a splice variant of HSL. The compound specifically hybridizes
XX with and inhibits the expression of HSL or a splice variant of HSL, or
XX specifically hybridizes with at least an 8-nucleobase portion of an
XX active site on a nucleic acid molecule encoding HSL. (I) have anorectic,
XX antidiabetic and cytostatic activities, and can be used in antisense
XX therapy. (I) is useful for treating an animal, particularly human,
XX suspected of having an abnormal metabolic condition such as obesity,
XX hyperlipidaemia, type 2 diabetes, a hyperproliferative disorder such as
XX cancer (e.g. pituitary, colorectal, breast, testicular, pulmonary or
XX epithelial cancer). (I) is also useful in modulating blood glucose
XX levels, particularly plasma or serum glucose levels, in a diabetic
XX animal. The present sequence represents a mouse hormone-sensitive lipase
XX chimeric phosphorothioate antisense oligonucleotide, which is used in an
XX example from the present invention
XX
XX Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 524 TCCAGAGGCGATTACAGCAG 543
DB 1 TCCAGAGGCTTTCCAGAG 20
XX
RESULT 137
ABD26699/C
XX ABD26699 standard; DNA; 20 BP.
XX AC ABD26699;
XX
XX 29-JUL-2004 (first entry)
XX
XX N35316-derived oligonucleotide SEQ ID 5711.
XX
Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX

```

---

```

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 5711; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 2 A; 1 C; 4 G; 13 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1518 AAACACTAAGAAAGAACGT 1537
DB 20 AAACACTAAGAAACAACAT 1
XX
RESULT 138
ABD26274
XX ID ABD26274 standard; DNA; 20 BP.
XX AC ABD26274;
XX
XX 29-JUL-2004 (first entry)
XX
XX AA398883-derived oligonucleotide SEQ ID 5286.
XX
Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX

```

OS Homo sapiens.  
 XX WO200285309-A2.  
 PN 31-OCT-2002.  
 PD 23-APR-2002; 2002WO-US013143.  
 XX 24-APR-2001; 2001US-0286036P.  
 XX (EPIG-) EPIGENESIS PHARM INC.  
 XX  
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
 PI Miller S, Tang L, Shahabuddin S;  
 XX WPI; 2003-093058/08.  
 XX  
 XX Pharmaceutical composition for treating asthma, has antisense  
 PT oligonucleotide containing less percentage of adenosine, targeted to  
 PT nucleic acids associated with lung airway or lung dysfunction, and  
 PT bronchodilating agent.  
 XX  
 PS Claim 15; SEQ ID NO 5286; 763pp; English.  
 XX  
 XX This invention describes a novel composition (a) a first active agent,  
 CC comprising oligonucleotides, effective for alleviating  
 CC bronchoconstriction, respiratory tract inflammation, allergies and  
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,  
 CC surfactant depletion or hyposecretion, when administered to a mammal. The  
 CC oligonucleotides are derived from a gene encoding or regulating  
 CC expression of a target polypeptide associated with lung airway or lung  
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.  
 CC The invention also describes a kit, that comprises: (a) a delivery  
 CC device, in separate containers, (b) the oligonucleotides, (c)  
 CC instructions for adding a carrier and for use of the kit. The composition  
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,  
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a  
 CC beta-adrenergic agonist. The composition is useful for preventing or  
 CC treating a respiratory, lung or malignant disease. The administered  
 CC composition comprises oligo and is administered to reduce the production  
 CC or availability, or to increase the degradation of the target mRNA or to  
 CC reduce the amount of target polypeptide present in the lungs. The  
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung  
 CC inflammation, allergies, asthma, impeded respiration, respiratory  
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary  
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.  
 CC The reduced adenosine content of the anti-sense oligos corresponding to  
 CC thymidines present in the target RNA serves to prevent the breakdown of  
 CC the oligonucleotides into products that free adenosine into the system  
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to  
 CC prevent any unwanted effects due to it  
 XX  
 SQ Sequence 20 BP; 8 A; 1 C; 2 G; 9 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 1672 AAATTCTCTGATTCAGAAA 1691  
 Db 1 AAATTTTGTGATTCATATAA 20  
 RESULT 139  
 ABD25837/c  
 ID ABD25837 standard; DNA; 20 BP.  
 XX  
 AC ABD25837;  
 XX  
 DT 29-JUL-2004 (first entry)

XX DE  
 XX  
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;  
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;  
 KW surfactant depletion; anti-allergic; antiinflammatory; antiasthmatic;  
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;  
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;  
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;  
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;  
 KW pulmonary transplantation rejection; ss; primer.  
 XX  
 XX Homo sapiens.  
 OS  
 WO200285309-A2.  
 PN  
 31-OCT-2002.  
 PD  
 23-APR-2002; 2002WO-US013143.  
 XX  
 24-APR-2001; 2001US-0286036P.  
 XX  
 (EPIG-) EPIGENESIS PHARM INC.  
 XX  
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
 PI Miller S, Tang L, Shahabuddin S;  
 XX WPI; 2003-093058/08.  
 XX  
 XX Pharmaceutical composition for treating asthma, has antisense  
 PT oligonucleotide containing less percentage of adenosine, targeted to  
 PT nucleic acids associated with lung airway or lung dysfunction, and  
 PT bronchodilating agent.  
 XX  
 PS Claim 15; SEQ ID NO 4849; 763pp; English.  
 XX  
 XX This invention describes a novel composition (a) a first active agent,  
 CC comprising oligonucleotides, effective for alleviating  
 CC bronchoconstriction, respiratory tract inflammation, allergies and  
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,  
 CC surfactant depletion or hyposecretion, when administered to a mammal. The  
 CC oligonucleotides are derived from a gene encoding or regulating  
 CC expression of a target polypeptide associated with lung airway or lung  
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.  
 CC The invention also describes a kit, that comprises: (a) a delivery  
 CC device, in separate containers, (b) the oligonucleotides, (c)  
 CC instructions for adding a carrier and for use of the kit. The composition  
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,  
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a  
 CC beta-adrenergic agonist. The composition is useful for preventing or  
 CC treating a respiratory, lung or malignant disease. The administered  
 CC composition comprises oligo and is administered to reduce the production  
 CC or availability, or to increase the degradation of the target mRNA or to  
 CC reduce the amount of target polypeptide present in the lungs. The  
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung  
 CC inflammation, allergies, asthma, impeded respiration, respiratory  
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary  
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.  
 CC The reduced adenosine content of the anti-sense oligos corresponding to  
 CC thymidines present in the target RNA serves to prevent the breakdown of  
 CC the oligonucleotides into products that free adenosine into the system  
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to  
 CC prevent any unwanted effects due to it  
 XX  
 SQ Sequence 20 BP; 7 A; 2 C; 5 G; 6 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY      888 CCAGATACCTGATTCCTTCAA 907
Db      ||||| ||||| ||||| ||||| |||||
        20 CCAATATTGCTTCCTTCAA 1

RESULT 140
ADH1329/c
ID      ADH1329 standard; DNA; 20 BP.
XX
AC      ADH1329;
XX
DT      11-MAR-2004 (first entry)
XX
DE      Human ovarian specific gene (OSG) PCR primer #2.
XX
KW      human; ovarian specific gene; OSG; gynaecologic cancer; PCR; ss; primer.
XX
OS      Homo sapiens.
XX
PN      US2003096238-A1.
XX
PD      22-MAY-2003.
XX
PF      17-AUG-2001; 2001US-00932419.
XX
PR      17-AUG-2000; 2000US-0225857P.
XX
PA      (SALC/) SALCEDA S.
PA      (CAFF/) CAFFERKEY R.
XX
PI      Salceda S, Cafferkey R;
XX
XX      WPI; 2004-096548/10.
XX
PT      New ovarian specific gene, useful for diagnosing metastasis, staging and
PT      for treating gynecologic cancer in a patient, and for identifying
PT      potential therapeutic agents for use in imaging and treating gynecologic
PT      cancers.
XX
PS      Example; SEQ ID NO 5; 35pp; English.
XX
CC      The invention comprises a human the DNA sequence of an ovarian specific
CC      gene (OSG) and the encoded protein. The DNA and protein sequences of the
CC      invention are useful for diagnosing, monitoring and treating gynaecologic
CC      cancer. The DNA and protein sequences are also useful for imaging a
CC      gynaecologic cancer. The present DNA sequence represents a PCR primer
CC      that was used in an example of the invention.
XX
XX      Sequence 20 BP; 9 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1445 TGTTGCTGCTGCTGTTGGG 1464
Db      ||||| ||||| ||||| ||||| |||||
        20 TCTTGATGCTGCTGTTTCGG 1

RESULT 141
ADH18272/c
ID      ADH18272 standard; DNA; 20 BP.
XX
AC      ADH18272;
XX
DT      11-MAR-2004 (first entry)
XX
DE      2'-MOE gapmer antisense oligo targeted to human Apob DNA 1 - SEQ ID 261.
XX
KW      apolipoprotein B; Apob; antiarteriosclerotic; cardiant; antidiabetic;
KW      anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW      diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW      antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;
KW      human; ss.
XX
OS      Oryctolagus cuniculus.
XX
PN      WO2003097662-A1.
XX
PD      27-NOV-2003.
XX
PF      15-MAY-2003; 2003WO-US015493.
XX

```

```

KW      human; ss.
XX
OS      Homo sapiens.
XX
PN      WO2003097662-A1.
PD      27-NOV-2003.
XX
PF      15-MAY-2003; 2003WO-US015493.
XX
PR      15-MAY-2002; 2002US-00147196.
PR      13-NOV-2002; 2002US-0426324P.
XX
PA      (ISIS-) ISIS PHARM INC.
XX
PI      Crooke RM, Graham MJ;
XX
XX      WPI; 2004-022840/02.
XX
PT      New antisense compound, useful for preparing a composition for treating
PT      abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT      2, obesity, hyperlipidemia or cardiovascular disease.
XX
PS      Claim 1; SEQ ID NO 261; 405pp; English.
XX
CC      The invention relates to a novel antisense compound targeted to a nucleic
CC      acid molecule encoding human apolipoprotein B (Apob) which specifically
CC      hybridises with and inhibits the expression of human apolipoprotein B.
CC      The compound of the invention demonstrates antiarteriosclerotic,
CC      cardiant, antidiabetic and anorectic activities and may be useful for
CC      preparing a composition for treating abnormal lipid or cholesterol
CC      metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC      cardiovascular disease. Furthermore, the compound has gene therapy
CC      applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC      MOE) gapmer antisense oligo of the invention which has 2'-MOE 'wings', a
CC      phosphorothioate backbone throughout and in which all cytidine residues
CC      are 5-methylcytidines.
XX
XX      Sequence 20 BP; 6 A; 1 C; 4 G; 9 T; 0 U; 0 Other;

Query Match      0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      780 AAAAAATCCACAGCCCTGTAT 799
Db      ||||| ||||| ||||| ||||| |||||
        20 AAAAAATCCAAACTGCCTATAT 1

RESULT 142
ADH18846
ID      ADH18846 standard; DNA; 20 BP.
XX
AC      ADH18846;
XX
DT      11-MAR-2004 (first entry)
XX
DE      2'-MOE gapmer antisense oligo targeted to rabbit Apob DNA - SEQ ID 835.
XX
KW      apolipoprotein B; Apob; antiarteriosclerotic; cardiant; antidiabetic;
KW      anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW      diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW      antisense; 2'-O-methoxyethyl gapmer; phosphorothioate backbone; 2'-MOE;
KW      human; ss.
XX
OS      Oryctolagus cuniculus.
XX
PN      WO2003097662-A1.
XX
PD      27-NOV-2003.
XX
PF      15-MAY-2003; 2003WO-US015493.
XX

```

```

PR 15-MAY-2002; 2002US-00147196.
PR 13-NOV-2002; 2002US-0426324P.
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke RM, Graham MJ;
PI
XX
XX WPI; 2004-022840/02.
DR
XX
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidemia or cardiovascular disease.
XX
XX Claim 1; SEQ ID NO 935; 405pp; English.
XX
XX The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC MOE) gapmer antisense oligo of the invention which has 2'-MOE "wings", a
CC phosphorothioate backbone throughout and in which all cytidine residues
CC are 5-methylcytidines.
XX
XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 167 ATGCAAGATCGCATCTCTA 186
Db 1 ATGGAAGACTGCACGCTCTA 20
||||| ||||| ||||| |||||
||||| ||||| ||||| |||||

RESULT 143
ADH18638
ID ADH18638 standard; DNA; 20 BP.
XX
XX ADH18638;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX Human apolipoprotein B antisense inhibition target DNA - SEQ ID 627.
DE
XX apolipoprotein B; ApoB; antiarteriosclerotic; cardiant; antidiabetic;
KW anorectic; lipid; cholesterol metabolism; atherosclerosis;
KW diabetes Type 2; obesity; hyperlipidaemia; cardiovascular; gene therapy;
KW antisense inhibition target; human; ds.
XX
XX Homo sapiens.
OS
XX WO2003097662-A1.
XX
XX 27-NOV-2003.
XX
XX 15-MAY-2003; 2003WO-US015493.
XX
XX 15-MAY-2002; 2002US-00147196.
PR
XX 13-NOV-2002; 2002US-0426324P.
PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke RM, Graham MJ;
PI
XX
XX WPI; 2004-022840/02.
DR
XX
XX New antisense compound, useful for preparing a composition for treating
PT abnormal lipid or cholesterol metabolism, atherosclerosis, diabetes Type
PT 2, obesity, hyperlipidemia or cardiovascular disease.
XX
XX Claim 1; SEQ ID NO 935; 405pp; English.
XX
XX The invention relates to a novel antisense compound targeted to a nucleic
CC acid molecule encoding human apolipoprotein B (ApoB) which specifically
CC hybridises with and inhibits the expression of human apolipoprotein B.
CC The compound of the invention demonstrates antiarteriosclerotic,
CC cardiant, antidiabetic and anorectic activities and may be useful for
CC preparing a composition for treating abnormal lipid or cholesterol
CC metabolism, atherosclerosis, diabetes Type 2, obesity, hyperlipidaemia or
CC cardiovascular disease. Furthermore, the compound has gene therapy
CC applications. The current sequence is that of the 2'-O-methoxyethyl (2'-
CC MOE) gapmer antisense oligo of the invention which has 2'-MOE "wings", a
CC phosphorothioate backbone throughout and in which all cytidine residues
CC are 5-methylcytidines.
XX
XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 167 ATGCAAGATCGCATCTCTA 186
Db 1 ATGGAAGACTGCACGCTCTA 20
||||| ||||| ||||| |||||
||||| ||||| ||||| |||||

RESULT 144
ADJ31845/C
ID ADJ31845 standard; DNA; 20 BP.
XX
XX ADJ31845;
AC
XX
XX 22-APR-2004 (first entry)
DT
XX
XX Human splicing factor R/S-rich 10 antisense oligonucleotide ISIS #156237.
DE
XX Splicing factor R/S-rich 10; hyperproliferative disorder; infection;
KW inflammation; tumour formation; therapy; human; antisense; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone: All cytidines are 5'-
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'- methoxyethyl (2'- MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'- methoxyethyl (2'- MOE) nucleotides"
XX
XX US2003232977-A1.
XX
XX 18-DEC-2003.
XX
XX 17-JUN-2002; 2002US-00175499.
XX
XX 17-JUN-2002; 2002US-00175499.
PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Dobie KW, Myers SJ;
PI
XX
XX WPI; 2004-081292/08.
DR
XX
XX New compound targeted to a nucleic acid molecule encoding splicing factor
PT R/S-rich 10, useful in treating hyperproliferative disorder or disease
PT

```

PT involving cellular development and in preventing infection, inflammation  
 PT or tumor formation.

XX Example 15; SEQ ID NO 39; 46pp; English.

XX The present invention is directed to antisense compounds which are  
 CC targeted to nucleic acid encoding splicing factor R/S-rich 10 and which  
 CC modulate the expression of splicing factor R/S-rich 10. The invention is  
 CC useful for treating a disease or condition associated with splicing  
 CC factor R/S-rich 10 such as hyperproliferative disorder and which involves  
 CC cellular development and in preventing infection, inflammation and tumour  
 CC formation. The present sequence is human splicing factor R/S-rich 10  
 CC antisense oligonucleotide.

XX Sequence 20 BP; 6 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1411 ACACATGATGTCATGGAT 1430  
 Db 20 ACACATGATGTCATGGAT 1

RESULT 145

ID ADK43211/c  
 AC ADK43211; standard; DNA; 20 BP.

XX AC ADK43211;

DT 06-MAY-2004 (first entry)

XX Antisense 2'-MOE gapmer oligo targeted to human PTPRA - SEQ ID 35.

XX PTPRA; protein tyrosine phosphatase, receptor type alpha;  
 KW LCA-related phosphatase; LRP; HLP; HPTPA; PTPRL2; RPTPA; cytosolic;  
 KW hyperproliferative disorder; metabolic; antisense; ss; human;  
 KW 2'-MOE wing; 2'-methoxyethyl gapmer; phosphorothioate backbone.

XX Homo sapiens.

XX Key Location/Qualifiers

PH modified\_base 1..20

FT /\*cag= a

FT /mod\_base= OTHER

FT /note= "OTHER = Bases 1-5 and 16-20 comprise 2'-  
 methoxyethyl (2'-MOE) wings. Phosphorothioate backbone  
 throughout. All cytidines are 5-methylcytidines"

XX WO2004011623-A2.

PN

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

CC alpha, LCA-related phosphatase; LRP; HLP; HPTPA; PTPRL2; RPTPA) and  
 CC inhibits the expression of PTPRA. The compound of the invention  
 CC demonstrates cytostatic activities and may be useful for treating a  
 CC disease or condition associated with PTPRA, such as a hyperproliferative  
 CC disorder or metabolic disorder, as well as in research and diagnostics  
 CC for modulating the expression of PTPRA. The current sequence is that of  
 CC an antisense 2'-MOE (2'-methoxyethyl) gapmer oligonucleotide which was  
 CC targeted to human PTPRA of the invention.

XX Sequence 20 BP; 6 A; 2 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 888 CCAGATGATGTCCTCA 907

Db 20 CCAGATGATGATACAA 1

RESULT 146

ID ADK43334

AC ADK43334 standard; DNA; 20 BP.

XX AC ADK43334;

DT 06-MAY-2004 (first entry)

XX Human PTPRA DNA targeted for antisense therapy - SEQ ID 158.

XX PTPRA; protein tyrosine phosphatase, receptor type alpha;  
 KW LCA-related phosphatase; LRP; HLP; HPTPA; PTPRL2; RPTPA; cytosolic;  
 KW hyperproliferative disorder; metabolic; antisense target; human; ds.

XX Homo sapiens.

XX WO2004011623-A2.

XX 05-FEB-2004.

XX 31-JUL-2003; 2003WO-US023972.

XX 31-JUL-2002; 2002US-00210556.

XX (ISIS-) ISIS PHARM INC.

XX Cowsett LM, Freier SM, Dobie KW;

XX WPI; 2004-143851/14.

XX New compounds, particularly antisense oligonucleotides targeted to a  
 PT nucleic acid encoding protein tyrosine phosphatase receptor type alpha  
 PT (PTPRA), useful for treating hyperproliferative or metabolic disorder.

XX Example 16; SEQ ID NO 158; 289pp; English.

XX The invention relates to a novel compound 8-80 nucleobases in length  
 CC which is targeted to and specifically hybridises with a nucleic acid  
 CC molecule encoding PTPRA (protein tyrosine phosphatase, receptor type  
 CC alpha, LCA-related phosphatase; LRP; HLP; HPTPA; PTPRL2; RPTPA) and  
 CC inhibits the expression of PTPRA. The compound of the invention  
 CC demonstrates cytostatic activities and may be useful for treating a  
 CC disease or condition associated with PTPRA, such as a hyperproliferative  
 CC disorder or metabolic disorder, as well as in research and diagnostics  
 CC for modulating the expression of PTPRA. The current sequence is that of a  
 CC human PTPRA DNA of the invention which was targeted for antisense  
 CC therapy.

XX Sequence 20 BP; 7 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.2e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;



```

QY 888 CCAGATCTGATCTCTTCAA 907
DB 1 CCAGATCTGATCTATCA 20

RESULT 147
ADJ24885
ID ADJ24885 standard; DNA; 20 BP.
XX
AC ADJ24885;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human endothelial lipase antisense oligonucleotide, SEQ ID 3283.
XX
KW Antilipemic; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
KW Human; Endothelial Lipase; dyslipidaemia; high density lipoprotein; HDL;
KW cardiovascular disorder; metabolic syndrome X; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "This oligonucleotide has a phosphorothioate
FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
FT and 3' ends, which are 4 nucleotides in length. Also all
FT cytidine residues are 5-methylcytidines"
XX
PN WO2004009541-A2.
XX
PD 29-JAN-2004.
XX
PF 18-JUL-2003; 2003WO-US022410.
XX
PR 19-JUL-2002; 2002US-0397106P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Bhat BG;
XX
WPI; 2004-132912/13.
XX
PT New antisense oligonucleotide for modulating endothelial lipase
PT expression, for diagnosing, preventing or treating e.g. dyslipidemia, low
PT high density lipoprotein or cardiovascular disorders.
XX
PS Claim 3; SEQ ID NO 3283; 1007pp; English.
XX
CC The present invention relates to antisense oligonucleotides (ADJ21603-
CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
CC with and inhibits the expression of EL. The antisense oligonucleotides
CC are useful for modulating the expression of endothelial lipase in cells
CC or tissues to treat diseases associated with EL expression, such as
CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
CC used for diagnostics, prophylaxis, or as research reagents or kits.
XX
SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 319 TTGACCCAGACTGAGTGGC 338
DB 1 TTGTACCACTGAGAGGC 20

RESULT 149
ADK79679
ID ADK79679 standard; DNA; 20 BP.
XX
AC ADK79679;
XX
XX

```



PI Roberds SL;  
 DR WPI; 2004-203785/19.  
 XX  
 XX New antisense compound targeted to a nucleic acid molecule encoding  
 PT Navi1.3, useful for treating a disease or condition associated  
 PT with Navi1.3, e.g. pain, seizure disorder such as childhood seizure  
 PT disorder, or ataxia.  
 XX  
 XX Claim 4; SEQ ID NO 3038; 417pp; English.  
 PS  
 XX The present invention relates to an antisense compound targeted to a  
 CC nucleic acid molecule encoding Navi1.3, where the antisense compound  
 CC specifically hybridizes with and inhibits the expression of Navi1.3. The  
 CC compound and composition are useful for treating a disease or condition  
 CC associated with Navi1.3, e.g. pain including but not limited to  
 CC neuropathic pain, post-herpetic neuralgia, chronic pain, lower back pain,  
 CC diabetic neuropathy, trigeminal neuropathy, arthritic pain, acute pain,  
 CC pain from burns, migraine headache, cluster headache, mild-to-moderate  
 CC headache; seizure disorder such as childhood seizure disorder, including  
 CC but not limited to neonatal or infantile epilepsy; or ataxia. The present  
 CC sequence represents a chimeric phosphorothioate oligonucleotide with  
 CC 2'WOE wings and a deoxy gap. Used during the antisense inhibition of  
 CC human Navi1.3 expression, the oligonucleotides are designed to target  
 CC different regions of the human Navi1.3 RNA.  
 XX  
 SQ Sequence 20 BP; 14 A; 1 C; 2 G; 3 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 85 AACTGCAATATAAATGAAA 104  
 DB 1 AAATGCAATATAAATGAAA 20  
 RESULT 152  
 ADM70098/C  
 ID ADM70098 standard; DNA; 20 BP.  
 XX  
 AC ADM70098;  
 XX  
 DT 03-JUN-2004 (first entry)  
 XX  
 DE Plant gene polymorphism marker related primer, SEQ ID 977.  
 XX  
 KW Primer; variation mapping; mutation mapping; plant;  
 KW gene polymorphism marker; ss.  
 XX  
 OS Synthetic.  
 XX  
 XX JP2003289885-A.  
 XX  
 XX 14-OCT-2003.  
 XX  
 XX 31-JAN-2003; 2003JP-00024620.  
 XX  
 XX 01-FEB-2002; 2002JP-00025338.  
 XX  
 XX (RIKA) RIKAGAKU KENKYUSHO.  
 XX (SAIM-) SAI MEDIA KK.  
 XX (MATS/) MATSUI M.  
 XX (NAKA/) NAKAZAWA M.  
 XX  
 XX WPI; 2004-126231/13.  
 XX  
 XX A primer set and method useful for mapping at least the  
 PT variation/mutation part of a plant gene using a gene polymorphism marker.  
 PT  
 XX Claim 7; SEQ ID NO 977; 120pp; Japanese.  
 PS  
 XX The present invention relates to a primer set and method for mapping at

CC least the variation/mutation part of a plant gene using a gene  
 CC polymorphism marker. A mutation site of the plant gene is mapped by  
 CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is  
 CC prepared from a plant homozygously having a mutation to be an object of  
 CC the mapping; (b) A forward primer 1 containing a base corresponding to  
 CC the gene polymorphic maker of one ecotype plant, a forward primer 2  
 CC containing a base corresponding to the genetic polymorphism of the other  
 CC ecotype plant and a reverse primer 3 based on the base sequence common  
 CC with both the ecotype plants are prepared; (c) two kinds of  
 CC oligonucleotides emitting fluorescence of different colors when the  
 CC genetic polymorphism marker is detected are prepared; (d) an  
 CC amplification reaction of the genomic DNA is carried out in the presence  
 CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)  
 CC the fluorescence intensity emitted from the resultant reaction product  
 CC is detected and (f) the position on the genome of the mutation site is  
 CC determined from the results of detection. The present sequence is a  
 CC primer, used to illustrate the invention.  
 XX  
 SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 784 TTCCAACAGCGCTGTATTACG 803  
 DB 20 TTCCAACAGCGCTGTATTATG 1  
 RESULT 153  
 ADL91774  
 ID ADL91774 standard; DNA; 20 BP.  
 XX  
 AC ADL91774;  
 XX  
 DT 03-JUN-2004 (first entry)  
 XX  
 DE Sequencing primer SEQ ID NO:175 for sequencing FZD10 constructs.  
 XX  
 KW Synovial sarcoma; SYX; sarcoma-associated gene; drug screening;  
 KW Frizzled homologue 10; FZD10-associated disease; colorectal cancer;  
 KW gastric cancer; chronic myeloid leukaemia; acute myeloid leukaemia;  
 KW FZD10 antibody; diagnosis; prognosis; prevention; cytostatic;  
 KW gene therapy; sequencing; primer; ss.  
 XX  
 OS Unidentified.  
 XX  
 XX WO2004020668-A2.  
 XX  
 XX 11-MAR-2004.  
 XX  
 XX 21-AUG-2003; 2003WO-JP010591.  
 XX  
 XX 30-AUG-2002; 2002US-0407506P.  
 XX  
 XX 11-JUL-2003; 2003US-0486195P.  
 XX  
 XX (ONCO-) ONCOTHERAPY SCI INC.  
 XX (UYTY) UNIV TOKYO.  
 XX  
 XX Nakamura Y, Katagiri T;  
 XX WPI; 2004-239208/22.  
 XX  
 XX Use of a compound or composition for diagnosing, treating or preventing  
 PT synovial sarcoma or a disease associated with Frizzled homologue 10, e.g.  
 PT colorectal cancer, gastric cancer, chronic myeloid leukemia or acute  
 -PT myeloid leukemia.  
 XX  
 XX Example 8; SEQ ID NO 175; 143pp; English.  
 PS  
 XX The invention relates to the use of a compound or composition for  
 CC diagnosing, prognosing, treating or preventing synovial sarcoma or a  
 CC Frizzled homologue 10 (FZD10)-associated disease in a patient. The

CC invention encompasses the use of sarcoma-associated genes designated SYX  
 CC 1-26 or their encoded proteins in diagnosing of synovial sarcoma and in  
 CC screening for compounds for treating or preventing this condition; and  
 CC the use of antibodies specific for FZD10 (FZD10 is also referred to as  
 CC SYX 1 in the specification) for diagnosing, treating or preventing FZD10-  
 CC associated diseases. The compound, composition and methods of the  
 CC invention are useful for diagnosing, treating or preventing synovial  
 CC sarcoma or FZD10-associated diseases, such as colorectal cancer, gastric  
 CC cancer, chronic myeloid leukaemia or acute myeloid leukaemia. The present  
 CC sequence represents a primer used in sequencing FZD10 constructs in an  
 CC example of the invention.

XX Sequence 20 BP; 2 A; 10 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 720 GCTCTCTTCTCCATCTACAG 739

Db | | | | | | | | | | | | | | | | | | | |  
 1 GTCCCTCTCCATCTCCAG 20

RESULT 154

ADM41705/C  
 ID ADM41705 standard; DNA; 20 BP.

XX AC ADM41705;

XX DT 17-JUN-2004 (first entry)

XX DE Cephalosporin C biosynthetic protein cefD1 and cefD2 gene PCR primer.

XX KW Cephalosporin C; antibiotic; cefD1; cefD2; PCR; primer; ss.

XX OS Acromonium chrysogenum.

XX PN W02004026902-A1.

XX PD 01-APR-2004.

XX PF 16-SEP-2003; 2003WO-EP010289.

XX PR 17-SEP-2002; 2002AT-00001397.

XX PA (SANO ) SANDOZ GMBH.

XX PI Kuernsteiner H, Friedlin E;

XX DR WPI; 2004-295383/27.

XX PT Novel Acromonium chrysogenum protein useful in synthetic or semi-  
 PT synthetic production of cephalosporin C or its derivatives with  
 PT antibiotic properties.

XX PS Example 7; SEQ ID NO 21; 43pp; English.

XX CC The present sequence is that of primer PCR7r. This was used, with primer  
 CC PCR7f ADM41704, in an example from the invention to confirm  
 CC transformation of Acromonium chrysogenum strain CEF-67605 with a plasmid  
 CC carrying the A. chrysogenum cefD1 and cefD2 genes ADM41690. The primers  
 CC amplify a 9001 bp DNA fragment. It is an object of the present invention  
 CC to provide a nucleic acid ADM41686-ADM41688 and vectors which code for a  
 CC new protein ADM41685 of A. chrysogenum, and which can be used for  
 CC transformation of an A. chrysogenum host cell such that the host cell is  
 CC capable of producing cephalosporin C in good yield. The vector may  
 CC additionally include the cefD1 and cefD2 genes.

XX SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 381 CTGCACGACATCGGCTGGA 400  
 ||| ||||| ||| |||||  
 Db 20 CTGGAGCAAGGTGAGCTGGA 1

RESULT 155

ADM15799/C  
 ID ADM15799 standard; DNA; 20 BP.

XX AC ADM15799;

XX DT 15-JUL-2004 (first entry)

XX DE Murine SAC1 DNA PCR primer #64.

XX KW Mouse; SAC1; PCR; ss; carbohydrate; sweetener; ethanol; obesity;  
 KW diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;  
 KW primer.

XX OS Mus musculus.

XX PN US2004081964-A1.

XX PD 29-APR-2004.

XX PF 25-OCT-2002; 2002US-00280183.

XX PR 25-OCT-2002; 2002US-00280183.

XX PA (BACH/) BACHMANOV A A.

XX PA (BEAU/) BEAUCHAMP G K.

XX PA (LISS/) LI S.

XX PA (LIXX/) LI X.

XX PA (REED/) REED D R.

XX PA (TORD/) TORDOFF M G.

XX PA (ROSS/) ROSS D A.

XX PA (OHMA/) OHMAN J D.

XX PA (CHAI/) CHATTERJEE A.

XX PA (DJON/) DE JONG P J.

XX PI Bachmanov AA, Beauchamp GK, Li S, Li X, Reed DR, Tordoff MG;

XX PI Ross DA, Ohman JD, Chatterjee A, De Jong PJ;

XX XX WPI; 2004-340133/31.

XX PT New isolated polynucleotides for sensing carbohydrates, other sweeteners,  
 PT or ethanol, useful for screening drugs for inhibition or restoration of  
 PT gene function as antidiabetic, antiobesity or antialcohol consumption  
 PT therapies.

XX PS Example 12; SEQ ID NO 69; 148pp; English.

XX CC The invention relates to SAC1 polypeptides and the polynucleotides  
 CC encoding them. The polynucleotides contain a variation associated with  
 CC sensing carbohydrates, other sweeteners or ethanol. The invention also  
 CC relates to a method for analysing a biomolecule in a biological sample,  
 CC comprising altering SAC1 activity in the sample and measuring the  
 CC activity, a method for analysing a polynucleotide in a biological sample,  
 CC comprising contacting a polynucleotide in a biological sample with a  
 CC probe where the probe hybridises to a SAC1 polynucleotide to form a  
 CC hybridisation complex and detecting the hybridisation complex, a method  
 CC of identifying susceptibility to obesity or diabetes comprising comparing  
 CC the nucleotide sequence of the suspected SAC1 allele with a wild type  
 CC nucleotide sequence, where the difference between the suspected allele  
 CC and the wild-type sequence identifies a sequence variation of the SAC1  
 CC nucleotide sequence, and a method of treating or preventing obesity,  
 CC diabetes or alcoholism associated with expression of SAC1, comprising  
 CC administering to a subject a pharmaceutical composition and a transgenic  
 CC animal that carries an altered SAC1 allele. The methods and compositions  
 CC of the invention are useful for screening drugs for inhibition or  
 CC restoration of gene function as antidiabetic, antiobesity or antialcohol  
 CC consumption therapies and for identifying sweeteners and alcohols. This

CC sequence represents a PCR primer used to amplify murine SAC1 DNA of the  
 CC invention.  
 XX  
 SQ Sequence 20 BP; 8 A; 8 C; 2 G; 2 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 685 AGGTGGGGCTTTGGCATCT 704  
 ||||| ||||| ||||| |||||  
 Db 20 AGGTGAGGGTTTGGCTTCT 1  
 RESULT 156  
 ADO01532/c  
 ID ADO01532 standard; DNA; 20 BP.  
 XX  
 AC ADO01532;  
 XX  
 DT 29-JUL-2004 (first entry)  
 XX Human IGFBP-1 reverse transcription PCR primer.  
 DE  
 XX liver regeneration; quinazolinone derivative; hepatotropic;  
 KW antiinflammatory; insulin like growth factor binding protein;  
 KW IGFBP-1 gene expression modulator; IGFBP-3 gene expression modulator;  
 KW liver fibrosis; cirrhotic liver; partial hepatectomy;  
 KW signal transduction pathway; hepatocyte growth factor;  
 KW reverse transcription; PCR; RT-PCR; primer; human; IGFBP-1; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN WO2004039308-A2.  
 XX  
 PD 13-MAY-2004.  
 XX  
 PF 30-OCT-2003; 2003WO-IL000900.  
 XX  
 PR 31-OCT-2002; 2002US-0422487P.  
 XX  
 XX (ISRA ) ISRAEL MIN AGRIC.  
 PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.  
 PA (COLL-) COLLAGARD BIOPHARMACEUTICALS LTD.  
 XX  
 PI Pines M, Nagler A, Yarkoni S;  
 XX  
 DR WPI; 2004-390189/36.  
 XX  
 PT Use of a composition comprising quinazolinone derivatives for the  
 PT improvement of liver regeneration e.g. cirrhosis.  
 XX  
 PS Example; Page 27; 49pp; English.  
 XX  
 CC The present invention describes a method for the improvement of liver  
 CC regeneration. The method comprises administration of a composition (I)  
 CC comprising quinazolinone derivatives (A) and their salts. (I) has  
 CC hepatotropic and antiinflammatory activities, and can be used in insulin  
 CC like growth factor binding protein 1 (IGFBP-1) gene expression modulators  
 CC and IGFBP-3 gene expression modulators. (I) is useful for treating or  
 CC preventing pathological processes, related to toxin (particularly  
 CC thioacetamide (TAA)) induced alterations in gene expression and  
 CC alterations in gene expression of at least one of IGFBP-1, IGFBP-3,  
 CC protein related lamda-1 (PRL-1) protein tyrosine phosphatase 411  
 CC (PTP41), apolipoprotein A IV precursor, phosphatidylinositol 3-kinase  
 CC p85-alpha subunit, mitogen activated protein kinase p38, Proteasome  
 CC component C8, epidermal fatty acid-binding protein, peripheral myelin  
 CC protein (PMP) (PMP-22/SR13), proliferation cell nuclear antigen,  
 CC Proteasome activator rP28 subunit alpha, c-K-ras 2b proto-oncogene,  
 CC alcohol sulfotransferase (ST2) A (ST2A2) (Probable alcohol  
 CC sulfotransferase), tissue inhibitor of metalloproteinase (MMP) 2 (TIMP-2)  
 CC metalloproteinase inhibitor 2 (Precursor), MMP-3 or MMP-13 (preferably

CC IGFBP-1 or IGFBP-3)) during fibrotic processes (particularly liver  
 CC fibrosis). (I) is also useful for improving the capacity of a cirrhotic  
 CC liver to regenerate following partial hepatectomy, by inducing gene  
 CC expression (of at least one gene of IGFBP-1, PRL-1, MMP-3 or MMP-13) or  
 CC by affecting the molecules in the signal transduction pathway of  
 CC hepatocyte growth factor. (I) is also useful for increasing the amount of  
 CC biologically active IGF-1. The present sequence represents a reverse  
 CC transcription PCR (RT-PCR) primer for human IGFBP-1, which is used in an  
 CC example from the present invention.  
 XX  
 SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 QY 219 GCCAGCTGTGGAGATGTTC 238  
 ||||| ||||| ||||| |||||  
 Db 20 GCTACCTGTGGTGATGTTC 1  
 RESULT 157  
 ADP79070  
 ID ADP79070 standard; DNA; 20 BP.  
 XX  
 AC ADP79070;  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Chimeric phosphorothioate oligonucleotide #2869.  
 XX  
 KW GFAT; Antidiabetic; Cardiant;  
 KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;  
 KW reperfusion; ss.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..4  
 FT /\*tag= a  
 FT /mod\_base= other  
 FT /note= "2-methoxyethyl wing"  
 FT modified\_base 17..20  
 FT /\*tag= b  
 FT /mod\_base= other  
 FT /note= "2-methoxyethyl wing"  
 XX  
 PN WO2004035763-A2.  
 XX  
 PD 29-APR-2004.  
 XX  
 PF 02-OCT-2003; 2003WO-US033332.  
 XX  
 PR 17-OCT-2002; 2002US-0419268P.  
 XX  
 XX (PHAA ) PHARMACIA CORP.  
 XX  
 XX Broschat KO, Crosby SD;  
 XX  
 DR WPI; 2004-348453/32.  
 XX  
 CC New compounds, particularly antisense oligonucleotides targeted to a  
 CC nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase  
 CC (GFAT), for treating diabetes, a cardiovascular or neurologic disorder,  
 CC ischemia/reperfusion injury.  
 XX  
 PS Claim 4; SEQ ID NO 2869; 175pp; English.  
 XX  
 CC The present invention relates to a compound which specifically hybridizes  
 CC with a nucleic acid molecule encoding GFAT, and inhibits the expression  
 CC of GFAT. Specifically claimed are antisense oligonucleotides capable of  
 CC modulating the expression of GFAT, and which comprise any of the 3063  
 CC sequences of 20 base pairs, given in the specification. The compound,

CC composition and methods are useful for treating a disease or condition  
 CC associated with GFAT, such as a disease or condition, e.g. diabetes, a  
 CC cardiovascular or neurological disorder, ischemia/reperfusion injury.  
 CC They are also useful in research and diagnostics for modulating the  
 CC expression of GFAT. The present sequence represents a chimeric  
 CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these  
 CC oligonucleotides inhibit human GFAT expression.

XX  
 SQ Sequence 20 BP; 8 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 845 GATCAAAATTGTCATTTCAGC 864  
 ||| ||| ||||| |||||  
 Db 1 GATAAAATATGTCATTTCAGC 20

RESULT 158  
 ADN40102/c  
 ID ADN40102 standard; DNA; 20 BP.  
 XX  
 AC ADN40102;  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Human selenoprotein W DNA, antisense oligonucleotide #20.  
 XX  
 KW Antisense therapy; human; selenoprotein W; metabolic disorder;  
 KW autoimmune disorder; reproductive disorder; developmental disorder;  
 KW immunosuppressive; gynaecological; phosphorothioate; ss.  
 XX  
 OS Homo sapiens.

XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "This oligonucleotide has a phosphorothioate  
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'  
 FT and 3' ends, which are 5 nucleotides in length at each  
 FT end. All cytidine residues are 5-methylcytidines"  
 XX  
 PN US2004101849-A1.  
 XX  
 PD 27-MAY-2004.  
 XX  
 PF 21-NOV-2002; 2002US-00303326.  
 XX  
 PR 21-NOV-2002; 2002US-00303326.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Bennett CF, Dean NM, Dobie KW;  
 XX  
 DR WPI; 2004-399678/37.

XX  
 PT New antisense oligonucleotides for modulating selenoprotein W expression,  
 PT useful for diagnosing, preventing or treating conditions associated with  
 PT aberrant selenoprotein W expression e.g. metabolic disorders.  
 XX  
 PS Example 15; SEQ ID NO 30; 34pp; English.

XX  
 CC The present invention relates to antisense compounds targeted to a  
 CC nucleic acid encoding human selenoprotein W. The antisense compound  
 CC comprises an antisense oligonucleotide that specifically hybridises with  
 CC the nucleic acid and inhibits the expression of selenoprotein W. The  
 CC antisense oligonucleotide is a chimeric oligonucleotide. The antisense  
 CC oligonucleotide comprises at least one modified internucleoside linkage,  
 CC preferably a phosphorothioate linkage. It also comprises at least one  
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar  
 CC moiety. The antisense oligonucleotide further comprises at least one  
 CC modified nucleobase, preferably a 5-methylcytosine. The antisense  
 CC oligonucleotides are useful for the treatment of diseases such as  
 CC metabolic disorders, autoimmune disorders, reproductive disorders, and  
 CC developmental disorders. The present sequence represents a human  
 CC selenoprotein W DNA target sequence for an antisense oligonucleotide.

XX  
 SQ Sequence 20 BP; 8 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

CC modified nucleobase, preferably a 5-methylcytosine. The antisense  
 CC oligonucleotides are useful for the treatment of diseases such as  
 CC metabolic disorders, autoimmune disorders, reproductive disorders, and  
 CC developmental disorders. The present sequence represents an antisense  
 CC oligonucleotide used in the examples of the present invention.

XX  
 SQ Sequence 20 BP; 2 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 37 GTCGCGCGCTCAGAGCCGC 56  
 ||| ||||| ||||| |||||  
 Db 20 GTGCGCGCATCAAGCCGC 1

RESULT 159  
 ADN40132  
 ID ADN40132 standard; DNA; 20 BP.  
 XX  
 AC ADN40132;  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Human selenoprotein W DNA target sequence #13.  
 XX  
 KW Antisense therapy; human; selenoprotein W; metabolic disorder;  
 KW autoimmune disorder; reproductive disorder; developmental disorder;  
 KW immunosuppressive; gynaecological; ds.  
 XX  
 OS Homo sapiens.

XX  
 PN US2004101849-A1.  
 XX  
 PD 27-MAY-2004.  
 XX  
 PF 21-NOV-2002; 2002US-00303326.  
 XX  
 PR 21-NOV-2002; 2002US-00303326.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Bennett CF, Dean NM, Dobie KW;  
 XX  
 DR WPI; 2004-399678/37.

XX  
 PT New antisense oligonucleotides for modulating selenoprotein W expression,  
 PT useful for diagnosing, preventing or treating conditions associated with  
 PT aberrant selenoprotein W expression e.g. metabolic disorders.  
 XX  
 PS Example 15; SEQ ID NO 60; 34pp; English.

XX  
 CC The present invention relates to antisense compounds targeted to a  
 CC nucleic acid encoding human selenoprotein W. The antisense compound  
 CC comprises an antisense oligonucleotide that specifically hybridises with  
 CC the nucleic acid and inhibits the expression of selenoprotein W. The  
 CC antisense oligonucleotide is a chimeric oligonucleotide. The antisense  
 CC oligonucleotide comprises at least one modified internucleoside linkage,  
 CC preferably a phosphorothioate linkage. It also comprises at least one  
 CC modified sugar moiety, preferably a 2'-O-methoxyethyl (2'-MOE) sugar  
 CC moiety. The antisense oligonucleotide further comprises at least one  
 CC modified nucleobase, preferably a 5-methylcytosine. The antisense  
 CC oligonucleotides are useful for the treatment of diseases such as  
 CC metabolic disorders, autoimmune disorders, reproductive disorders, and  
 CC developmental disorders. The present sequence represents a human  
 CC selenoprotein W DNA target sequence for an antisense oligonucleotide.

XX  
 SQ Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 37 GTGCGCGCGTCAGAGCGGC 56  
Best Local Similarity 0.8%; Score 15.2; DB 1; Length 20;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Db 1 GTGCGCGCGCATCAAGCGGC 20

RESULT 160  
ADN30177/c  
ID ADN30177 standard; DNA; 20 BP.  
AC ADN30177;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Hepatocyte growth factor receptor antisense oligonucleotide #9.  
XX  
KW cytostatic; hepatocyte growth factor receptor;  
KW hyperproliferative disorder; antisense technology; human;  
KW antisense oligonucleotide; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= Phosphorothioate backbone. All cytidines  
FT are 5-methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"  
FT modified\_base 15..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"  
XX  
PN US2004102622-A1.  
XX  
PD 27-MAY-2004.  
XX  
PF 23-NOV-2002; 2002US-00304019.  
XX  
PR 23-NOV-2002; 2002US-00304019.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Dean NM, Bennett CF, Dobie KW;  
XX  
DR WPI; 2004-399741/37.  
XX  
PT New compound targeted to a nucleic acid molecule encoding hepatocyte  
PT growth factor receptor, useful in diagnosing and treating  
PT hyperproliferative disorder.  
XX  
PS Example 15; SEQ ID NO 23; 116pp; English.  
XX  
CC The invention describes a new compound 8-80 nucleobases in length  
CC targeted to a nucleic acid molecule encoding hepatocyte growth factor  
CC receptor, where the compound specifically hybridises with the nucleic  
CC acid molecule encoding hepatocyte growth factor receptor comprising a  
CC sequence of 4586 bp (SEQ ID NO: 4) and inhibits the expression of  
CC hepatocyte growth factor receptor. Also described are: a method of  
CC inhibiting the expression of hepatocyte growth factor receptor in cells  
CC or tissues; screening for a modulator of hepatocyte growth factor  
CC receptor; a diagnostic method for identifying a disease state; a kit or  
CC assay device comprising the compound; and treating an animal having a  
CC disease or condition associated with hepatocyte growth factor receptor.  
CC The compound and methods are useful in diagnosing and treating  
CC hyperproliferative disorder. This sequence represents a human hepatocyte  
CC growth factor receptor antisense oligonucleotide.  
XX  
SQ Sequence 20 BP; 9 A; 1 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No: 1.2e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1664 TACTTCCAAATCTCTGAT 1693  
Db 20 TCCTTCCAAATACTTGTAT 1

RESULT 161  
ADN30248  
ID ADN30248 standard; DNA; 20 BP.  
XX  
AC ADN30248;  
XX  
DT 12-AUG-2004 (first entry)  
XX  
DE Hepatocyte growth factor receptor antisense oligonucleotide #80.  
XX  
KW cytostatic; hepatocyte growth factor receptor;  
KW hyperproliferative disorder; antisense technology; human;  
KW antisense oligonucleotide; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= Phosphorothioate backbone. All cytidines  
FT are 5-methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"  
FT modified\_base 15..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"  
XX  
PN US2004102622-A1.  
XX  
PD 27-MAY-2004.  
XX  
PF 23-NOV-2002; 2002US-00304019.  
XX  
PR 23-NOV-2002; 2002US-00304019.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Dean NM, Bennett CF, Dobie KW;  
XX  
DR WPI; 2004-399741/37.  
XX  
PT New compound targeted to a nucleic acid molecule encoding hepatocyte  
PT growth factor receptor, useful in diagnosing and treating  
PT hyperproliferative disorder.  
XX  
PS Example 15; SEQ ID NO 94; 116pp; English.  
XX  
CC The invention describes a new compound 8-80 nucleobases in length  
CC targeted to a nucleic acid molecule encoding hepatocyte growth factor  
CC receptor, where the compound specifically hybridises with the nucleic  
CC acid molecule encoding hepatocyte growth factor receptor comprising a  
CC sequence of 4586 bp (SEQ ID NO: 4) and inhibits the expression of  
CC hepatocyte growth factor receptor. Also described are: a method of  
CC inhibiting the expression of hepatocyte growth factor receptor in cells  
CC or tissues; screening for a modulator of hepatocyte growth factor  
CC receptor; a diagnostic method for identifying a disease state; a kit or  
CC assay device comprising the compound; and treating an animal having a  
CC disease or condition associated with hepatocyte growth factor receptor.  
CC The compound and methods are useful in diagnosing and treating  
CC hyperproliferative disorder. This sequence represents a human hepatocyte  
CC growth factor receptor antisense oligonucleotide.  
XX  
SQ Sequence 20 BP; 9 A; 1 C; 5 G; 5 T; 0 U; 0 Other;





CC lipid or cholesterol metabolism. The compound may be useful for  
 CC decreasing circulating lipoprotein levels, triglyceride levels,  
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase  
 CC reactants and chylomicrons and thus may be utilised during treatment of  
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,  
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's  
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,  
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,  
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,  
 CC diabetes, obesity and atherosclerosis. The current sequence is that of a  
 CC human apolipoprotein B (ApoB) antisense therapy target DNA of the  
 CC invention. The human ApoB gene is located at chromosome 2p23-2p24.  
 XX  
 XX Sequence 20 BP; 9 A; 4 C; 1 G; 6 T; 0 U; 0 Other;  
 Qy Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Db 780 AAAATTCCAAAGCTGTAT 799  
 1 AAAATTCCAAAGCTGTAT 20  
 RESULT 164  
 ADO33387  
 ID ADO33387 standard; DNA; 20 BP.  
 AC ADO33387;  
 XX  
 XX 12-AUG-2004 (first entry)  
 DE Antisense 2'-MOE gapmer oligo targeted to rabbit ApoB - SEQ 835.  
 XX  
 KW apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;  
 KW antilipaeamic; antidiabetic; anorectic; cardiac; vasotropic; hypotensive;  
 KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;  
 KW neuroprotective; nontropic; lipid; cholesterol metabolism;  
 KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;  
 KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;  
 KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;  
 KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;  
 KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;  
 KW obesity; atherosclerosis; antisense; 2'-MOE gapmer; 2'-methoxyethyl wing;  
 KW phosphorothioate backbone; rabbit; ss.  
 XX  
 OS Oryctolagus cuniculus.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "OTHER = Phosphorothioate backbone, bases 1-5 and  
 FT 16-20, 2'-MOE wing bases, all cytidine residues are 5-  
 FT methylcytidines"  
 XX  
 XX WO2004044181-A2.  
 XX 27-MAY-2004.  
 XX  
 XX 13-NOV-2003; 2003WO-US036411.  
 XX  
 XX 13-NOV-2002; 2002US-0426234P.  
 XX 15-MAY-2003; 2003WO-US015493.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;  
 XX WPI; 2004-420321/39.  
 XX  
 XX Antisense oligonucleotide compound that inhibits expression of mRNA  
 XX encoding human apolipoprotein B, useful for treating hyperlipidemia,  
 FT

PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's  
 PT syndrome.  
 XX  
 XX Example 42; SEQ ID NO 835; 483pp; English.  
 PS  
 CC The invention relates to a novel antisense compound where the compound  
 CC hybridises to and inhibits expression of mRNA encoding human  
 CC apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%  
 CC confluent HepG2 cells in culture at a concentration of 150 nM. The  
 CC compound of the invention demonstrates cardiovascular,  
 CC antiarteriosclerotic, antilipaeamic, antidiabetic, anorectic, cardiac,  
 CC endocrine, hypotensive, anabolic, eating disorder-related, cytostatic,  
 CC neuroprotective, neuroprotective and nontropic activities and may  
 CC be useful for inhibiting the expression of apolipoprotein B in cells or  
 CC tissues in vivo in order to address a condition associated with abnormal  
 CC lipid or cholesterol metabolism. The compound may be useful for  
 CC decreasing circulating lipoprotein levels, triglyceride levels,  
 CC cholesterol levels, lipid levels, fatty acid levels, acute phase  
 CC reactants and chylomicrons and thus may be utilised during treatment of  
 CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,  
 CC cardiovascular disorders, Von Gierke's disease, lipodystrophy, Cushing's  
 CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,  
 CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,  
 CC impotence, obstructive liver disease, Alzheimer's disease, dementia,  
 CC diabetes, obesity and atherosclerosis. The current sequence is that of an  
 CC antisense 2'-MOE (2'-methoxyethyl) gapmer oligo of the invention which is  
 CC targeted to rabbit ApoB.  
 XX  
 XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;  
 Qy Query Match 0.8%; Score 15.2; DB 1; Length 20;  
 Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
 Db 167 ATGCAGAAATGGCATCTCTA 186  
 1 ATGCAGAAATGGCATCTCTA 20  
 RESULT 165  
 ADO33432/C  
 ID ADO33432 standard; RNA; 20 BP.  
 XX  
 XX ADO33432;  
 XX  
 XX 12-AUG-2004 (first entry)  
 DE  
 XX Phosphodiester double-stranded RNA targeted to human ApoB - SEQ ID 880.  
 DE  
 KW apolipoprotein B; ApoB; cardiovascular; antiarteriosclerotic;  
 KW antilipaeamic; antidiabetic; anorectic; cardiac; vasotropic; hypotensive;  
 KW anabolic; eating disorder; cytostatic; endocrine; vasotropic;  
 KW neuroprotective; nontropic; lipid; cholesterol metabolism;  
 KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;  
 KW Von Gierke's disease; lipodystrophy; Cushing's syndrome;  
 KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;  
 KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;  
 KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;  
 KW obesity; atherosclerosis; human; chromosome 2p23-2p24; ds;  
 KW phosphodiester backbone.  
 XX  
 XX Homo sapiens.  
 OS  
 XX  
 XX Key Location/Qualifiers  
 FT modified\_base 1..20  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "OTHER = Phosphodiester backbone"  
 XX  
 XX WO2004044181-A2.  
 XX 27-MAY-2004.  
 XX

```

PF 13-NOV-2003; 2003WO-US036411.
XX
XX
PR 13-NOV-2002; 2002US-0426234P.
PR 15-MAY-2003; 2003WO-US015493.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
XX
XX WPI; 2004-420321/39.
XX
XX Antisense oligonucleotide compound that inhibits expression of mRNA
PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
PT syndrome.
XX
XX Example 60; SEQ ID NO 880; 483pp; English.
XX
XX The invention relates to a novel antisense compound where the compound
PS hybridises to and inhibits expression of mRNA encoding human
XX apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
CC compound of the invention demonstrates cardiovascular,
CC antidiabetic, anorectic, antidiabetic, anorectic, cardiant,
CC endocrine, vasotropic, neuroprotective and neurotropic activities and may
CC be useful for inhibiting the expression of apolipoprotein B in cells or
CC tissues in vivo in order to address a condition associated with abnormal
CC lipid or cholesterol metabolism. The compound may be useful for
CC decreasing circulating lipoprotein levels, triglyceride levels,
CC cholesterol levels, lipid levels, fatty acid levels, acute phase
CC reactants and chylomicrons and thus may be utilised during treatment of
CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
CC cardiovascular disorders, von Gierke's disease, lipodystrophy, Cushing's
CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
CC diabetes, obesity and atherosclerosis. The current sequence is that of a
CC phosphodiester double-stranded RNA of the invention which is targeted to
CC human ApoB RNA.
XX
XX Sequence 20 BP; 3 A; 6 C; 5 G; 0 T; 6 U; 0 Other;
XX
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 941 AGAACAGGTTGTACTGGTCA 960
DB 20 AGAACAGGCGAGTCTGGTCA 1
RESULT 166
AD032813/C
ID ADO32813 standard; DNA; 20 BP.
XX
XX ADO32813;
XX
XX 12-AUG-2004 (first entry)
XX
XX Antisense 2'-MOE gapmer oligo targeted to human ApoB RNA - SEQ 261.
XX
XX apolipoprotein B; ApoB; cardiovascular; antidiabetic; anorectic;
KW antilipemic; antidiabetic; anorectic; cardiant; vasotropic; hypotensive;
KW anabolic; eating disorder; cytostatic; endocrine; endocrine; vasotropic;
KW neuroprotective; neurotropic; lipid; cholesterol metabolism;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW von Gierke's disease; lipodystrophy; Cushing's syndrome;
KW sexual ateliotic dwarfism; hyperthyroidism; hypertension;
KW anorexia nervosa; Werner's syndrome; hepatoma; multiple myeloma; uraemia;
KW impotence; obstructive liver disease; Alzheimer's; dementia; diabetes;
KW obesity; atherosclerosis; antisense; 2'-MOE gapmer; 2'-methoxyethyl wing;
KW phosphorothioate backbone; human; chromosome 2p23-2p24; ss.

```

---

```

XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER = Phosphorothioate backbone, bases 1-5 and
FT 16-20 2'-MOE wing bases, all cytidine residues are 5-
FT methylcytidines"
XX
XX WO2004044181-A2.
XX
XX 27-MAY-2004.
XX
XX 13-NOV-2003; 2003WO-US036411.
XX
XX 13-NOV-2002; 2002US-0426234P.
PR 15-MAY-2003; 2003WO-US015493.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Crooke R, Graham M, Lemonidis-Tarbet K, Dobie KW;
XX WPI; 2004-420321/39.
XX
XX Antisense oligonucleotide compound that inhibits expression of mRNA
PT encoding human apolipoprotein B, useful for treating hyperlipidemia,
PT diabetes, obesity, von Gierke's disease, lipodystrophies, Cushing's
PT syndrome.
XX
XX Example 29; SEQ ID NO 261; 483pp; English.
XX
XX The invention relates to a novel antisense compound where the compound
CC hybridises to and inhibits expression of mRNA encoding human
XX apolipoprotein B (ApoB) after 16-24 hours by at least 30% in 80%
CC confluent HepG2 cells in culture at a concentration of 150 nM. The
CC compound of the invention demonstrates cardiovascular,
CC antidiabetic, anorectic, antilipemic, antidiabetic, anorectic, cardiant,
CC vasotropic, hypotensive, anabolic, eating disorder-related, cytostatic,
CC endocrine, vasotropic, neuroprotective and neurotropic activities and may
CC be useful for inhibiting the expression of apolipoprotein B in cells or
CC tissues in vivo in order to address a condition associated with abnormal
CC lipid or cholesterol metabolism. The compound may be useful for
CC decreasing circulating lipoprotein levels, triglyceride levels,
CC cholesterol levels, lipid levels, fatty acid levels, acute phase
CC reactants and chylomicrons and thus may be utilised during treatment of
CC hyperlipoproteinaemia, hyperlipidaemia, hypercholesterolaemia,
CC cardiovascular disorders, von Gierke's disease, lipodystrophy, Cushing's
CC syndrome, sexual ateliotic dwarfism, hyperthyroidism, hypertension,
CC anorexia nervosa, Werner's syndrome, hepatoma, multiple myeloma, uraemia,
CC impotence, obstructive liver disease, Alzheimer's disease, dementia,
CC diabetes, obesity and atherosclerosis. The current sequence is that of an
CC antisense 2'-MOE (2'-methoxyethyl) gapmer oligo of the invention which is
CC targeted to human ApoB RNA.
XX
XX Sequence 20 BP; 6 A; 1 C; 4 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 780 AAAATTCACAGCCTGTAT 799
DB 20 AAAATTCACAGCCTGTAT 1
RESULT 167
ADP68918/C
ID ADP68918 standard; DNA; 20 BP.
XX
XX ADP68918;
XX

```

DT 09-SEP-2004 (first entry)  
DE Human DRK2 antisense oligonucleotide ISIS224163.  
XX  
KW Human; ss; antisense; DRK2;  
KW death-associated protein kinase-rel. apoptosis-inducing protein kinase;  
KW serine/threonine kinase 17B; STK17B; apoptosis; degenerative disorder;  
KW neurological disorder; Alzheimer's disease; Parkinson's disease;  
KW Amyotrophic lateral sclerosis; ALS; retinitis pigmentosa;  
KW blood cell disorder; cancer; autoimmune disorder; viral infection;  
KW gene therapy; hyperproliferative disorder; chromosome 2.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..20  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone and all cytidines are 5  
FT -methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl residue"  
FT modified\_base 16..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "2'-methoxyethyl residue"  
XX  
XX US2004115645-A1.  
XX  
XX 17-JUN-2004.  
XX  
XX 12-DEC-2002; 2002US-00318819.  
XX  
XX 12-DEC-2002; 2002US-00318819.  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Bennett CF, Dobie KW;  
XX WPI; 2004-449384/42.  
XX  
XX New oligonucleotide compound that inhibits expression of DRK2, useful  
XX for preparing a composition for treating hyperproliferative disorder,  
XX e.g., cancer.  
XX  
XX Example 15; SEQ ID NO 64; 87pp; English.  
XX  
XX The invention relates to a new compound (e.g. an antisense  
XX oligonucleotide), having a sequence comprising 8-80 bp targeted to a  
XX nucleic acid encoding DRK2 (death-associated protein kinase-related  
XX apoptosis-inducing protein kinase 2, also known as serine/threonine  
XX kinase 17B, STK17B), specifically hybridizes with the nucleic acid  
XX encoding DRK2 (appearing as ADP68859 and representing bases 58695-149492  
XX of human chromosome 2) and inhibits expression of DRK2. Also included  
XX are inhibiting the expression of DRK2 in cells or tissues, screening for  
XX a modulator of DRK2, a diagnostic method for identifying a disease  
XX state, a kit or assay device comprising the compound and treating an  
XX animal having a disease or condition associated with DRK2. The  
XX oligonucleotide compound is useful for preparing a composition for  
XX treating hyperproliferative disorders, degenerative disorders,  
XX neurological disorders, Alzheimer's disease, Parkinson's disease,  
XX Amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, blood cell  
XX disorders, cancer, autoimmune disorders and viral infection. The present  
XX sequence represents an antisense oligonucleotide targeting DRK2.  
XX  
XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 15.2; DB 1; Length 20;  
XX Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 501 CTTGGCAGCAGCATTTGGAC 520  
Db ||||| ||||| |||||  
20 CTTGGCTACAGCAGTGGAC 1  
RESULT 168  
ADP68974  
ID ADP68974 standard; DNA; 20 BP.  
AC ADP68974;  
XX  
XX 09-SEP-2004 (first entry)  
DT XX  
DE Human DRK2 antisense target region #36.  
XX  
XX Human; ds; antisense; DRK2;  
KW death-associated protein kinase-rel. apoptosis-inducing protein kinase;  
KW serine/threonine kinase 17B; STK17B; apoptosis; degenerative disorder;  
KW neurological disorder; Alzheimer's disease; Parkinson's disease;  
KW Amyotrophic lateral sclerosis; ALS; retinitis pigmentosa;  
KW blood cell disorder; cancer; autoimmune disorder; viral infection;  
KW gene therapy; hyperproliferative disorder; chromosome 2.  
XX  
XX Homo sapiens.  
OS  
XX US2004115645-A1.  
XX  
XX 17-JUN-2004.  
XX  
XX 12-DEC-2002; 2002US-00318819.  
XX  
XX 12-DEC-2002; 2002US-00318819.  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Bennett CF, Dobie KW;  
XX WPI; 2004-449384/42.  
XX  
XX New oligonucleotide compound that inhibits expression of DRK2, useful  
XX for preparing a composition for treating hyperproliferative disorder,  
XX e.g., cancer.  
XX  
XX Example 15; SEQ ID NO 120; 87pp; English.  
XX  
XX The invention relates to a new compound (e.g. an antisense  
XX oligonucleotide), having a sequence comprising 8-80 bp targeted to a  
XX nucleic acid encoding DRK2 (death-associated protein kinase-related  
XX apoptosis-inducing protein kinase 2, also known as serine/threonine  
XX kinase 17B, STK17B), specifically hybridizes with the nucleic acid  
XX encoding DRK2 (appearing as ADP68859 and representing bases 58695-149492  
XX of human chromosome 2) and inhibits expression of DRK2. Also included  
XX are inhibiting the expression of DRK2 in cells or tissues, screening for  
XX a modulator of DRK2, a diagnostic method for identifying a disease  
XX state, a kit or assay device comprising the compound and treating an  
XX animal having a disease or condition associated with DRK2. The  
XX oligonucleotide compound is useful for preparing a composition for  
XX treating hyperproliferative disorders, degenerative disorders,  
XX neurological disorders, Alzheimer's disease, Parkinson's disease,  
XX Amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, blood cell  
XX disorders, cancer, autoimmune disorders and viral infection. The present  
XX sequence represents a target region for the antisense oligonucleotides,  
XX from the DRK2 genomic DNA.  
XX  
XX Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 15.2; DB 1; Length 20;  
XX Best Local Similarity 85.0%; Pred. No. 1.2e+02;  
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 501 CTTGGCAGCAGCATTTGGAC 520  
Db ||||| ||||| |||||  
1 CTTGGCTACAGCAGTGGAC 20

```
RESULT 169
ADQ13711
ID ADQ13711 standard; DNA; 20 BP.
XX
XX
AC ADQ13711;
XX
XX
DT 07-OCT-2004 (first entry)
DE
DE DMD region PCR primer, SEQ ID 106.
XX
XX Human; SCAIP; dystrophin; Duchenne Muscular Dystrophy; DMD;
KW Becker Muscular Dystrophy; BMD; PCR; primer; ss;
KW Single Condition Amplification/ Internal Primer.
XX
XX Homo sapiens.
OS
XX
XX WO2004058985-A2.
PN
XX
XX 15-JUL-2004.
PD
XX
XX 17-DEC-2003; 2003WO-US040278.
PF
XX
XX 17-DEC-2002; 2002US-0433774P.
PR
XX
XX (UTAH ) UNIV UTAH RES FOUND.
PA
XX
XX Flanigan KM, Weiss RB, Dunn DM, Von Niederhausern A;
PI
XX
XX WPI; 2004-525893/50.
DR
XX
XX Characterizing a nucleic acid region, useful for detecting genetic
PT mutations in any large multi-exon gene e.g., those indicating
PT dystrophinopathy, comprises using a Single Condition
PT Amplification/Internal Primer (SCAIP) sequencing method.
XX
XX
XX Example 1; Page 31; 174pp; English.
PS
XX
XX The present invention relates to a Single Condition Amplification/
CC Internal Primer (SCAIP) sequencing method for direct sequence analysis of
CC large multi-exon genes from genomic DNA samples and identifying mutations
CC in multi-exon genes e.g. the dystrophin gene, CAPN3 gene and DYSF gene.
CC Mutations in the dystrophin gene result in both Duchenne Muscular
CC Dystrophy (DMD) and Becker Muscular Dystrophy (BMD). Mutations in the
CC CAPN3 gene, encoding calpain (calcium-activated neutral protease) result
CC in limb-girdle muscular dystrophy type 2A (LGMD2A) and mutations in the
CC DYSF gene, encoding dysferlin, result in limb-girdle muscular dystrophy
CC type 2B (LGMD2B). The method comprises bringing into contact in each of
CC the reaction chambers an amplicon from a different one of the
CC amplification reactions and one or more internal sequencing primers
CC corresponding to the amplicon and analysing the sequences of the
CC amplicons. The method allows for the rapid, accurate, and economical
CC analysis of any large multi-exon gene. The method is useful in detecting
CC genetic mutations in any large multi-exon gene. It is also useful for the
CC identification and analysis of specific individual genomic mutations
CC including deletions, point mutations, or its combinations. Gene complexes
CC with multiple exons/introns spanning large genomic regions. The present
CC sequence is a PCR primer, used in the method of the invention.
XX
XX Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 445 GAGAGAAATCAGCTGTGATG 464
DB 1 GAGAGAAATCAGCTGGCTG 20
RESULT 170
ADR32216
ID ADR32216 standard; DNA; 20 BP.
XX
XX
AC ADR32216;
XX
XX
DT 18-NOV-2004 (first entry)
DE
DE Human nestin reverse RT-PCR primer, SEQ ID NO:8.
XX
XX Human; salivary gland; stem cell; hSGSC; CD49f-positive; differentiation;
KW liver; pancreas; nestin-positive cell; albumin-positive cell;
KW insulin-positive cell; glucagon-positive cell; organ regeneration;
KW organ transplant; hepatotropic; nestin; reverse transcription-PCR;
KW expression analysis; RT-PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX
XX WO2004074465-A1.
PN
XX
XX 02-SEP-2004.
PD
XX
XX 20-FEB-2004; 2004WO-JP002002.
PF
XX
XX 20-FEB-2003; 2003JP-00043339.
PR
XX
XX (BIOS-) BIOS RES INST INC.
PA
XX
XX (ENDO/) ENDO F.
PA
XX
XX Endo F, Okumura K, Nakamura K;
PI
XX
XX WPI; 2004-642513/62.
DR
XX
XX New isolated human stem cell from a salivary gland, capable of
PT differentiating into a nestin-positive and albumin-positive cell, insulin
PT positive and glucagon-positive cell, for use in the regeneration of
PT liver.
XX
XX Example 3; SEQ ID NO 8; 28pp; Japanese.
PS
XX
XX The invention relates to an isolated CD49f-positive adult human salivary
CC gland stem cell (hSGSC) which is capable of differentiating into cells
CC characteristic of various organs such as the liver or pancreas when
CC cultured in vitro. Specifically, the hSGSCs are capable of
CC differentiating into nestin-positive and albumin-positive cells, insulin-
CC positive cells or glucagon-positive cells. The invention also relates to
CC the differentiated cells produced from hSGSCs; methods of inducing
CC differentiation of hSGSCs into nestin-positive/albumin positive, insulin-
CC positive or glucagon-positive cells by in vitro culture in the presence
CC of a fibroblast growth factor, epithelial cell growth factor and
CC leukaemia inhibitory factor; and a method of isolating hSGSCs from human
CC salivary gland and culturing them in the presence of epithelial cell
CC growth factor. The hSGSCs can be used to regenerate human liver and
CC pancreas. The regenerated organs eliminate transplant rejection, as the
CC stem cells used to produce the organs are taken from the patient.
CC Sequences ADR32209-ADR32230 represent reverse transcription-PCR (RT-PCR)
CC primers used to analyse gene expression in hSGSCs in an example of the
CC invention.
XX
XX Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 926 TGGGAGCAAAATTCGAGAC 945
DB 1 TGGGAGCAAAAGATCCAAGAC 20
RESULT 171
ADT79911/c
ID ADT79911 standard; cDNA; 20 BP.
XX
XX
AC ADT79911;
```



```
PS Example 9; SEQ ID NO 13; 77pp; English.
XX
CC The present invention relates to a method for the synthesis of at least
CC two different oligonucleotides, which involves providing a solid support
CC comprising anchor groups that are protected by at least two orthogonal
CC protective groups, removing one of the protective groups from the anchor
CC groups, synthesizing an oligonucleotide on the deprotected anchor groups,
CC capping the synthesized oligonucleotide, repeating these steps until all
CC of anchor groups are deprotected, and cleaving the synthesized
CC oligonucleotides. The method can be used for the synthesis of at least
CC two different oligonucleotides, in the field of nucleotide chemistry, in
CC applying the required pairs of oligonucleotide primers, several probes at
CC a time, duplexed nuclei acid fragments (including PCR, sequencing,
CC multiplexed genotyping, cloning and RNA interference), for applying to
CC any known methods for the solid phase synthesis of oligonucleotides
CC (including phosphoramidite chemistry, H-phosphonate chemistry,
CC phosphotriester chemistry, or any other synthetic chemistry used to
CC prepare oligonucleotides on solid supports). The present sequence is a
CC polynucleotide used to demonstrate the method of the invention.
XX
SQ Sequence 15 BP; 0 A; 0 C; 0 G; 15 T; 0 U; 0 Other;
    Query Match      0.8%; Score 15; DB 1; Length 15;
    Best Local Similarity 100.0%; Pred. No. 98;
    Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1849
Db 15 AAAAAAAAAAAAAA 1

RESULT 174
ABZ61173/c
ID ABZ61173 standard; RNA; 17 BP.
XX
AC ABZ61173;
XX
DT 21-MAR-2003 (first entry)
XX
DE Human K-Ras DNzyme substrate #1285.
XX
KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO200297114-A2.
XX
PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016940.
XX
PR 29-MAY-2001; 2001US-0294140P.
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI McSwiggen J;
XX
XX WPI; 2003-140484/13.
XX
XX Novel short interfering RNA and enzymatic nucleic acid useful for
XX treating cancer, modulates the expression of a nucleic acid encoding
XX HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX Claim 58; Page 109; 185pp; English.
XX
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
XX acid molecule or an enzymatic nucleic acid molecule, that modulates
XX expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX human immunodeficiency virus (HIV) or a component of HIV. The nucleic
```

```
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ5989 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66595 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 7 A; 4 C; 3 G; 0 T; 3 U; 0 Other;
    Query Match      0.8%; Score 15; DB 1; Length 17;
    Best Local Similarity 100.0%; Pred. No. 1.1e+02;
    Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 AATGTTGCTGCTGCT 1457
Db 16 AATGTTGCTGCTGCT 2

RESULT 175
ADF13436
ID ADF13436 standard; DNA; 18 BP.
XX
AC ADF13436;
XX
DT 12-FEB-2004 (first entry)
XX
DE Cdc42-interacting protein 4 (CIP4), BaySNP 5002, PCR primer #2.
XX
KW Cardiant; antiarteriosclerotic; vasotropic; cerebroprotective;
KW hypotensive; gene therapy; human; Cdc42-interacting protein 4; CIP4; PCR;
KW primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003072813-A2.
XX
PD 04-SEP-2003.
XX
PF 14-FEB-2003; 2003WO-EF001514.
XX
PR 27-FEB-2002; 2002EP-00004258.
XX
PA (FARB ) BAYER AG.
XX
PI Stropp U, Schwes S, Kallabis H;
XX
XX WPI; 2003-712738/67.
XX
XX New isolated polynucleotide encoded by a phenotype-associated gene,
XX useful for prognosticating statin therapy response, and diagnosing or
XX treating cardiovascular diseases, such as hypertension, myocardial
XX infarction and stroke.
XX
XX Example 1; Page 68; 182pp; English.
XX
XX The present invention relates to human phenotype-associated (PA) genes (I
XX ; ADF1307-ADF13386) which contain a Single Nucleotide Polymorphism
XX (SNP). The SNP is given in the sequence as a variant nucleotide. Also
XX claimed are methods for screening for agents which regulate the activity
XX of a PA gene and reagents that modulate the activity of a PA polypeptide
XX or a polynucleotide where the reagent is identified by the screening
XX methods. The methods and compositions of the present invention are useful
XX for prognosticating, diagnosing and treating cardiovascular diseases,
XX such as atherosclerosis, hypertension, restenosis, arterial inflammation,
XX myocardial infarction and stroke. The present sequence is a PCR primer,
XX used in the examples from the invention.
XX
SQ Sequence 18 BP; 8 A; 2 C; 7 G; 1 T; 0 U; 0 Other;
    Query Match      0.8%; Score 15; DB 1; Length 18;
    Best Local Similarity 100.0%; Pred. No. 1.2e+02;
```

Matches 15; \_Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1103 AGAAGACAAAGGTGG 1117  
 |||||  
 Db 4 AGAAGACAAAGGTGG 18

RESULT 176  
 AAH58054/c  
 ID AAH58054 standard; DNA; 19 BP.  
 AC AAH58054;  
 XX  
 XX  
 DT 04-DEC-2000 (first entry)  
 DE  
 DE cdk4 ribozyme binding site #73.  
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
 OS Mammalia.  
 XX  
 XX WO200032765-A2.  
 XX  
 XX PD 08-JUN-2000.  
 XX  
 XX PF 06-DEC-1999; 99WO-US028772.  
 XX  
 XX PR 04-DEC-1998; 98US-0110954P.  
 XX  
 XX PA (IMMU-) IMMUSOL INC.  
 XX  
 XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;  
 XX  
 XX DR WPI; 2000-412314/35.  
 XX  
 XX PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
 PT PCNA and Cyclin B1.  
 XX  
 XX PS Disclosure; Page 53; 109pp; English.  
 XX  
 XX CC The present invention relates to a hairpin or hammerhead ribozyme,  
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
 CC Representative examples of ribozyme recognition sites are given in  
 CC AAH58054 to AAH58057. The ribozyme of the invention is useful for  
 CC inhibiting restenosis by introduction of the ribozyme into cells. The  
 CC ribozyme is resistant to endonuclease activity and hence is efficient in  
 CC restenosis treatment  
 XX  
 XX SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1096 GGACTGCAGAGAAGAC 1110  
 |||||  
 Db 19 GGACTGCAGAGAAGAC 5

RESULT 177  
 AAH58054/c  
 ID AAH58054 standard; DNA; 19 BP.  
 AC AAH58054;  
 XX  
 XX  
 DT 10-SEP-2001 (first entry)  
 DE  
 DE Cell-cycle dependent kinase cdk4 ribozyme binding site SEQ ID NO:478.  
 XX  
 XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
 KW recognition site; target; ribozyme binding site; eye disease; vulnerary;

KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytotatic;  
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW antiscaling; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.  
 XX  
 XX OS Homo sapiens.  
 XX  
 XX OS Synthetic.  
 XX  
 XX PN WO200130362-A2.  
 XX  
 XX PD 03-MAY-2001.  
 XX  
 XX PF 26-OCT-2000; 2000WO-US029500.  
 XX  
 XX PR 26-OCT-1999; 99US-0161532P.  
 XX  
 XX PA (IMMU-) IMMUSOL INC.  
 XX  
 XX PI Robbins JM, Tritz R;  
 XX  
 XX DR WPI; 2001-300427/31.  
 XX  
 XX PT Treating proliferative skin or eye diseases and scarring, using ribozymes  
 PT that cleave RNA encoding cytokines involved in inflammation, matrix  
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
 XX  
 XX PS Example 1; Page 106; 408pp; English.  
 XX  
 XX CC The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
 CC dermatological, cytotatic, antiseborrheic, antidiabetic, antiscaling,  
 CC ophthalmological, vulnerary, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
 CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention  
 XX  
 XX SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 15; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1096 GGACTGCAGAGAAGAC 1110  
 |||||  
 Db 19 GGACTGCAGAGAAGAC 5

RESULT 178  
 AAH58054/c  
 ID AAH58054 standard; DNA; 20 BP.  
 AC AAH58054;  
 XX  
 XX  
 DT 09-JAN-2001 (first entry)  
 DE  
 DE Antisense oligonucleotide #20946 targeted to human G-alpha-S1.





```

AC AAA94503;
XX 09-JAN-2001 (first entry)
XX
XX Antisense oligonucleotide #20942 targeted to human G-alpha-S1.
XX
XX G-alpha-S1; infection; inflammation; tumour; antisense; human;
KW phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
KW Gs-alpha short form; ss.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /mod_base= OTHER
XX /note= "Optionally the internucleotide linkages are
XX phosphorothioate"
XX modified_base 1..5
XX /mod_base= OTHER
XX /note= "Optionally the nucleotides are 2'-methoxyethyl
XX and cytidine residues are 5-methylcytidines"
XX modified_base 16..20
XX /mod_base= OTHER
XX /note= "Optionally the nucleotides are 2'-methoxyethyl
XX and cytidine residues are 5-methylcytidines"
XX
XX US6110664-A.
XX
XX 29-AUG-2000.
XX
XX 25-JUN-1999; 99US-00344914.
XX
XX 25-JUN-1999; 99US-00344914.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowser LM;
XX
XX WPI; 2000-586346/55.
XX
XX New antisense compounds for modulating the expression of G-alpha-S1,
XX especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
XX prevent or delay infection, inflammation or tumor formation.
XX
XX Claim 3; Col 39; 37pp; English.
XX
XX The present invention relates to antisense compounds 8-30 bases long
XX targeted to a coding region, a stop codon, or a 3' untranslated region of
XX human G-alpha-S1 (see AAA9451). The antisense compounds specifically
XX hybridize with and inhibit the expression of human G-alpha-S1. The
XX antisense compounds are useful for diagnostics, therapeutics and
XX prophylaxis, e.g. to prevent or delay infection, inflammation or tumour
XX formation. Particularly, the antisense oligonucleotides are useful for
XX treating humans prone to a disease or condition associated with
XX expression of G-alpha-S1. The present sequence an antisense
XX oligonucleotide targeted to the 3' untranslated region of human G-alpha-
XX S1
XX
XX Sequence 20 BP; 1 A; 3 C; 4 G; 12 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 15; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 1.3e+02;
XX Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1447 TTGCTGCTGCTGTTT 1461
XX 1 TTGCTGCTGCTGTTT 15
XX
XX RESULT 181

```

```
RESULT 182
AAA94506
ID AAA94506 standard; DNA; 20 BP.
XX
AC AAA94506;
XX
DT 09-JAN-2001 (first entry)
XX
DE Antisense oligonucleotide #20945 targeted to human G-alpha-S1.
XX
KW G-alpha-S1; infection; inflammation; tumour; antisense; human;
KW phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
KW Gs-alpha short form; ss.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Optionally the internucleotide linkages are
FT phosphorothioate"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
XX
PN US6110664-A.
XX
PD 29-AUG-2000.
XX
PF 25-JUN-1999; 99US-00344914.
XX
PR 25-JUN-1999; 99US-00344914.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowsert LM;
XX
WPI; 2000-586346/55.
XX
PT New antisense compounds for modulating the expression of G-alpha-S1,
PT especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
PT prevent or delay infection, inflammation or tumor formation.
XX
PS Claim 3; Col 39; 37pp; English.
XX
CC The present invention relates to antisense compounds 8-30 bases long
CC targeted to a coding region, a stop codon, or a 3' untranslated region of
CC human G-alpha-S1 (see AAA94451). The antisense compounds specifically
CC hybridize with and inhibit the expression of human G-alpha-S1. The
CC antisense compounds are useful for diagnostics, therapeutics and
CC prophylaxis, e.g. to prevent or delay infection, inflammation or tumour
CC formation. Particularly, the antisense oligonucleotides are useful for
CC treating humans prone to a disease or condition associated with
CC expression of G-alpha-S1. The present sequence an antisense
CC oligonucleotide targeted to the 3' untranslated region of human G-alpha-
CC S1
XX
SQ Sequence 20 BP; 1 A; 3 C; 5 G; 11 T; 0 U; 0 Other;
Query Match 0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1447 TTGCTGCTGCTGTTT 1461
Db |||||
4 TTGCTGCTGCTGTTT 18

RESULT 183
AAA94508
ID AAA94508 standard; DNA; 20 BP.
XX
AC AAA94508;
XX
DT 09-JAN-2001 (first entry)
XX
DE Antisense oligonucleotide #20947 targeted to human G-alpha-S1.
XX
KW G-alpha-S1; infection; inflammation; tumour; antisense; human;
KW phosphorothioate; 2'-methoxyethyl; MOE; 5-methylcytidine;
KW Gs-alpha short form; ss.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Optionally the internucleotide linkages are
FT phosphorothioate"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Optionally the nucleotides are 2'-methoxyethyl
FT and cytidine residues are 5-methylcytidines"
XX
PN US6110664-A.
XX
PD 29-AUG-2000.
XX
PF 25-JUN-1999; 99US-00344914.
XX
PR 25-JUN-1999; 99US-00344914.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cowsert LM;
XX
WPI; 2000-586346/55.
XX
PT New antisense compounds for modulating the expression of G-alpha-S1,
PT especially useful for diagnostics, therapeutics and prophylaxis, e.g. to
PT prevent or delay infection, inflammation or tumor formation.
XX
PS Claim 3; Col 39; 37pp; English.
XX
CC The present invention relates to antisense compounds 8-30 bases long
CC targeted to a coding region, a stop codon, or a 3' untranslated region of
CC human G-alpha-S1 (see AAA94451). The antisense compounds specifically
CC hybridize with and inhibit the expression of human G-alpha-S1. The
CC antisense compounds are useful for diagnostics, therapeutics and
CC prophylaxis, e.g. to prevent or delay infection, inflammation or tumour
CC formation. Particularly, the antisense oligonucleotides are useful for
CC treating humans prone to a disease or condition associated with
CC expression of G-alpha-S1. The present sequence an antisense
CC oligonucleotide targeted to the 3' untranslated region of human G-alpha-
CC S1
XX
SQ Sequence 20 BP; 0 A; 3 C; 5 G; 12 T; 0 U; 0 Other;
Query Match 0.8%; Score 15; DB 1; Length 20;
```

```

Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1447 TTGCTGCTGCTGCTTT 1461
DB 6 TTGCTGCTGCTGCTTT 20

RESULT 184
ABZ85199
ID ABZ85199 standard; DNA; 20 BP.
XX
AC ABZ85199;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 441; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosstatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 8 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 775 TGCCCAAAATTCCAA 789
DB 4 TGCCCAAAATTCCAA 18

RESULT 185
ABZ85565/C
ID ABZ85565 standard; DNA; 20 BP.
XX
AC ABZ85565;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Claim 15; SEQ ID NO 807; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosstatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 0 C; 13 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 20;

```

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1704 TCCCTCCCTCCAC 1718
Db 20 TCCCTCCCTCCAC 6
|||||

RESULT 186
ABD21429
ID ABD21429 standard; DNA; 20 BP.
AC ABD21429;
XX
XX 29-JUL-2004 (first entry)
DT
XX
DE Human transglutaminase-derived oligo SEQ ID 441.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX
XX WO200285309-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013143.
PF
XX
XX 24-APR-2001; 2001US-0286036P.
PR
XX
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 441; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
```

```
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 8 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 775 TGCCCAAAATTCAA 789
Db 4 TGCCCAAAATTCAA 18
|||||

RESULT 187
ABD21795/C
ID ABD21795 standard; DNA; 20 BP.
XX
XX ABD21795;
AC
XX
XX 29-JUL-2004 (first entry)
DT
XX
XX Human stannocalcin-derived oligo SEQ ID 807.
DE
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX
XX WO200285309-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013143.
PF
XX
XX 24-APR-2001; 2001US-0286036P.
PR
XX
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 807; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
```

CC instructions for adding a carrier and for use of the kit. The composition  
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,  
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a  
 CC beta-adrenergic agonist. The composition is useful for preventing or  
 CC treating a respiratory, lung or malignant disease. The administered  
 CC composition comprises oligo and is administered to reduce the production  
 CC or availability, or to increase the degradation of the target mRNA or to  
 CC reduce the amount of target polypeptide present in the lungs. The  
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung  
 CC inflammation, allergies and/or surfactant hypoproduction are associated  
 CC with a disease or condition such as pulmonary vasoconstriction,  
 CC inflammation, allergies, asthma, impeded respiration, respiratory  
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary  
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.  
 CC The reduced adenosine content of the anti-sense oligos corresponding to  
 CC thymidines present in the target RNA serves to prevent the breakdown of  
 CC the oligonucleotides into products that free adenosine into the system  
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to  
 CC prevent any unwanted effects due to it  
 CC  
 CC Sequence 20 BP; 5 A; 0 C; 13 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1704 TCCCTCCTCCAC 1718  
 |||||  
 Db 20 TCCCTCCTCCAC 6

RESULT 188  
 ADP11714  
 ID ADP11714 standard; DNA; 20 BP.  
 XX  
 AC ADP11714;  
 XX  
 DT 12-AUG-2004 (first entry)  
 XX  
 DE Set 2 left PCR primer for marker probe #66.  
 XX  
 KW transplant rejection; immune system; rheumatoid arthritis; lupus;  
 KW inflammatory bowel disease; multiple sclerosis; HIV; AIDS; ss; primer.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004042346-A2.  
 XX  
 PD 21-MAY-2004.  
 XX  
 PF 24-APR-2003; 2003WO-US012946.  
 XX  
 PR 24-APR-2002; 2002US-00131831.  
 PR 20-DEC-2002; 2002US-00325899.  
 XX  
 PA (EXPR-) EXPRESSION DIAGNOSTICS INC.  
 XX  
 PI Wohlgenuth J, Fry K, Woodward R, Ly N, Prentice J, Morris M;  
 PI Rosenberg S;  
 XX  
 DR WPI; 2004-400724/37.  
 XX  
 PT Diagnosing or monitoring transplant rejection, e.g. heart, kidney, liver,  
 PT pancreas, pancreatic islet, lung, bone marrow or stem cell transplant  
 PT rejection, in an individual, comprises detecting the expression level of  
 PT the genes.  
 XX  
 PS Claim 58; SEQ ID NO 1723; 1762pp; English.  
 XX  
 CC The present invention relates to diagnosing or monitoring transplant  
 CC rejection, e.g. cardiac or kidney transplant rejection, in an individual  
 CC comprises detecting the expression level of one or more genes. The

CC methods, system and kits are useful in diagnosing or monitoring  
 CC transplant rejection, e.g. heart, kidney, liver, pancreas, pancreatic  
 CC islet, lung, bone marrow or stem cell transplant rejection,  
 CC xenotransplant rejection or mechanical organ replacement rejection, in an  
 CC individual. The method is also useful in assessing the immune status of  
 CC diseases that involve the immune system, e.g. rheumatoid arthritis,  
 CC lupus, inflammatory bowel diseases, multiple sclerosis, HIV/AIDS or  
 CC viral, bacterial or fungal infection. The present sequence represents a  
 CC primer for a 50 mer oligonucleotide marker for diagnosis and monitoring  
 CC of allograft rejection and other disorders.

Qy Sequence 20 BP; 2 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 15; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1448 TGCTGCTGCTGTTTG 1462  
 |||||  
 Db 6 TGCTGCTGCTGTTTG 20

RESULT 189  
 AAP85699/c  
 ID AAP85699 standard; DNA; 18 BP.  
 XX  
 AC AAP85699;  
 XX  
 DT 13-JUL-2001 (first entry)  
 XX  
 DE Multiple repeated heat process PCR related oligonucleotide #3.  
 XX  
 KW Multiple repeated heat circulation; polymerase chain reaction; PCR;  
 KW target DNA production; DNA synthesis; ds.  
 XX  
 OS Unidentified.  
 XX  
 PN CN1278558-A.  
 XX  
 PD 03-JAN-2001.  
 XX  
 PF 22-JUN-1999; 99CN-00114949.  
 XX  
 PR 22-JUN-1999; 99CN-00114949.  
 XX  
 PA (XIAQ/) XIA Q.  
 XX  
 PI Xia Q;  
 XX  
 DR WPI; 2001-245741/26.  
 XX  
 PT Asynchronous chain-extending polymerase chain reaction for producing lots  
 PT of target DNA fragments, comprises a multiple repeated heat circulation  
 PT process.  
 XX  
 PS Disclosure; Page 3; 4pp; Chinese.  
 XX  
 CC The present invention relates to a kind of two chains asynchronously-  
 CC elongated DNA amplification technology in vitro, which is characterized  
 CC by that firstly, a pair of specific primers is synthesized according to  
 CC the target DNA sequence to be amplified, then a repetitive sequence  
 CC complementary oligo-repetitive sequence of 3' target DNA chain whose tail  
 CC end is modified and elongation vitality is lost, then the oligo-  
 CC repetitive sequence, chain primer, heat-resisting DNA polymerase, dNTP  
 CC substrate, template DNA, magnesium ion, polymerase chain reaction (PCR)  
 CC buffer solution and ultra-pure water are mixed uniformly and made into a  
 CC reaction system. The reaction system then undergoes the processes of high  
 CC -temp., low-temp., medium-low temp., medium-temp. and repeated heat  
 CC circulation treatment in the heat-circulating instrument to obtain  
 CC million copies of specific target DNA fragments. The invention adopts a  
 CC multiple repeated heat circulation process, so that it can produce lots  
 CC of target DNA fragments. The present sequence was used in the

```
CC      exemplification of the invention
XX
SQ      Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      29 CCGCCCTCCGTCGCCGCCG 46
Db      18 CCGCCCGCCGCCGCCG 1

RESULT 190
ADO26654/c
ID      ADO26654 standard; DNA; 18 BP.
XX
AC      ADO26654;
XX
DT      12-AUG-2004 (first entry)
XX
DE      Synthetic leader sequence encoding DNA SEQ ID NO:47.
XX
KW      phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX
OS      Synthetic.
XX
FN      WO2004042059-A1.
XX
PD      21-MAY-2004.
XX
PF      10-NOV-2003; 2003WO-AU001487.
XX
PR      08-NOV-2002; 2002US-0425163P.
XX
PA      (UYQU ) UNIV QUEENSLAND.
XX
PI      Frazer IH;
XX
DR      WPI; 2004-411519/38.
DR      P-PSDB; ADO26655.
XX
CC      Constructing synthetic polynucleotide for modulating the quality of a
PT      selected phenotype displayed by an organism comprises replacing a first
PT      codon with a synonymous codon to construct the synthetic polynucleotide.
XX
PS      Example 1; SEQ ID NO 47; 86pp; English.
XX
CC      The present invention describes a method for constructing a synthetic
CC      polynucleotide from which a polypeptide is producible to confer a
CC      selected phenotype to an organism of interest or part in a different
CC      quality than that conferred by a parent polynucleotide that encodes the
CC      same polypeptide. The method comprises: (a) selecting a first codon of
CC      the parent polynucleotide for replacement with a synonymous codon, where
CC      the synonymous codon is selected on the basis that it exhibits a
CC      different phenotypic preference than the first codon in a comparison of
CC      phenotypic preferences in test organisms or parts, where the test
CC      organism are selected from organisms of the same species as the organism
CC      of interest and organisms that are related to the organisms of interest;
CC      and (b) replacing the first codon with the synonymous codon to construct
CC      the synthetic polynucleotide. Also described: (1) a method for
CC      determining the phenotypic preference of a first codon in an organism of
CC      interest or its parts; (2) a synthetic polynucleotide constructed from
CC      the method above; (3) an organism of interest or part containing a
CC      synthetic polynucleotide constructed from the method above; (4) an
CC      organism of interest or part containing a synthetic construct that
CC      comprises a regulatory polynucleotide operably linked to a tandem repeat
CC      of a first codon fused in frame with a reporter polynucleotide that
CC      encodes a reporter protein, which produces, or is predicted to produce a
CC      selected phenotype or a phenotype of the same class as the selected
CC      phenotype in the organism or part; (5) a method of modulating the quality
CC      of a selected phenotype that is displayed by an organism of interest or
CC      part and that results from the expression of a parent polynucleotide that
CC      encodes the polypeptide; (6) a method of enhancing the quality of a
CC      selected phenotype that is displayed by an organism of interest or part
CC      and that results from the expression of a parent polynucleotide that
CC      encodes the polypeptide; and (7) a method of reducing the quality of a
CC      selected phenotype that is displayed by an organism of interest or part
CC      and that results from the expression of a parent polynucleotide that
CC      encodes the polypeptide. The method is useful for constructing a
CC      synthetic polynucleotide from which a polypeptide is producible to confer
CC      a selected phenotype to an organism of interest or part in a different
CC      quality than that conferred by a parent polynucleotide that encodes the
CC      same polypeptide. It is useful for modulating the quality of a selected
CC      phenotype displayed by an organism or part. The present sequence encodes
CC      a synthetic leader sequence, which is used in an example from the present
CC      invention.
XX
SQ      Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

Query Match      0.8%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 GCCTGCTCCGTCGCCGCC 45
Db      18 GCCTGCTCCGTCGCCGCC 1

RESULT 191
ADO26616
ID      ADO26616 standard; DNA; 18 BP.
XX
AC      ADO26616;
XX
DT      12-AUG-2004 (first entry)
XX
DE      Synthetic leader sequence encoding DNA SEQ ID NO:9.
XX
KW      phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX
OS      Synthetic.
XX
FN      WO2004042059-A1.
XX
PD      21-MAY-2004.
XX
PF      10-NOV-2003; 2003WO-AU001487.
XX
PR      08-NOV-2002; 2002US-0425163P.
XX
PA      (UYQU ) UNIV QUEENSLAND.
XX
PI      Frazer IH;
XX
DR      WPI; 2004-411519/38.
DR      P-PSDB; ADO26617.
XX
CC      Constructing synthetic polynucleotide for modulating the quality of a
PT      selected phenotype displayed by an organism comprises replacing a first
PT      codon with a synonymous codon to construct the synthetic polynucleotide.
XX
PS      Example 1; SEQ ID NO 9; 86pp; English.
XX
CC      The present invention describes a method for constructing a synthetic
CC      polynucleotide from which a polypeptide is producible to confer a
CC      selected phenotype to an organism of interest or part in a different
CC      quality than that conferred by a parent polynucleotide that encodes the
CC      same polypeptide. The method comprises: (a) selecting a first codon of
CC      the parent polynucleotide for replacement with a synonymous codon, where
CC      the synonymous codon is selected on the basis that it exhibits a
CC      different phenotypic preference than the first codon in a comparison of
CC      phenotypic preferences in test organisms or parts, where the test
CC      organism are selected from organisms of the same species as the organism
CC      of interest and organisms that are related to the organisms of interest;
CC      and (b) replacing the first codon with the synonymous codon to construct
```

CC the synthetic polynucleotide. Also described: (1) a method for  
 CC determining the phenotypic preference of a first codon in an organism of  
 CC interest or its parts; (2) a synthetic polynucleotide constructed from  
 CC the method above; (3) an organism of interest or part containing a  
 CC synthetic polynucleotide constructed from the method above; (4) an  
 CC organism of interest or part containing a synthetic construct that  
 CC comprises a regulatory polynucleotide operably linked to a tandem repeat  
 CC of a first codon fused in frame with a reporter polynucleotide that  
 CC encodes a reporter protein, which produces, or is predicted to produce a  
 CC selected phenotype or a phenotype of the same class as the selected  
 CC phenotype in the organism or part; (5) a method of modulating the quality  
 CC of a selected phenotype that is displayed by an organism of interest or  
 CC part and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; (6) a method of enhancing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; and (7) a method of reducing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide. The method is useful for constructing a  
 CC synthetic polynucleotide from which a polypeptide is producible to confer  
 CC a selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. It is useful for modulating the quality of a selected  
 CC phenotype displayed by an organism or part. The present sequence encodes  
 CC a synthetic leader sequence, which is used in an example from the present  
 CC invention.

XX Sequence 18 BP; 0 A; 12 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
 Best Local Similarity 88.9%; Pred. NO. 1.3e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 GCCGCTCCGTCGCGCC 45

Db 1 GCCGCGCGCGCGCGCC 18

RESULT 192

ADO26622/C

ID ADO26622 standard; DNA; 18 BP.

XX ADO26622;

XX 12-AUG-2004 (first entry)

DE Synthetic leader sequence encoding DNA SEQ ID NO:15.

XX phenotype; phenotypic preference; phenotype modulation; leader; ds.

OS Synthetic.

XX WO2004042059-A1.

XX 21-MAY-2004.

XX 10-NOV-2003; 2003WO-AU001487.

XX 08-NOV-2002; 2002US-0425163P.

XX (UYQU ) UNIV QUEBENSISLAND.

XX Frazer IH;

XX WPI; 2004-411519/38.

XX P-PSDB; ADO26623.

XX Constructing synthetic polynucleotide for modulating the quality of a  
 XX selected phenotype displayed by an organism comprises replacing a first  
 XX codon with a synonymous codon to construct the synthetic polynucleotide.

XX Example 1; SEQ ID NO 15; 86pp; English.

PS

xx

CC The present invention describes a method for constructing a synthetic  
 CC polynucleotide from which a polypeptide is producible to confer a  
 CC selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. The method comprises: (a) selecting a first codon of  
 CC the parent polynucleotide for replacement with a synonymous codon, where  
 CC the synonymous codon is selected on the basis that it exhibits a  
 CC different phenotypic preference than the first codon in a comparison of  
 CC phenotypic preferences in test organisms or parts, where the test  
 CC organism are selected from organisms of the same species as the organism  
 CC of interest and organisms that are related to the organisms of interest;  
 CC and (b) replacing the first codon with the synonymous codon to construct  
 CC the synthetic polynucleotide. Also described: (1) a method for  
 CC determining the phenotypic preference of a first codon in an organism of  
 CC interest or its parts; (2) a synthetic polynucleotide constructed from  
 CC the method above; (3) an organism of interest or part containing a  
 CC synthetic polynucleotide constructed from the method above; (4) an  
 CC organism of interest or part containing a synthetic construct that  
 CC comprises a regulatory polynucleotide operably linked to a tandem repeat  
 CC of a first codon fused in frame with a reporter polynucleotide that  
 CC encodes a reporter protein, which produces, or is predicted to produce a  
 CC selected phenotype or a phenotype of the same class as the selected  
 CC phenotype in the organism or part; (5) a method of modulating the quality  
 CC of a selected phenotype that is displayed by an organism of interest or  
 CC part and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; (6) a method of enhancing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide. The method is useful for constructing a  
 CC synthetic polynucleotide from which a polypeptide is producible to confer  
 CC a selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. It is useful for modulating the quality of a selected  
 CC phenotype displayed by an organism or part. The present sequence encodes  
 CC a synthetic leader sequence, which is used in an example from the present  
 CC invention.

XX Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 18;  
 Best Local Similarity 88.9%; Pred. No. 1.3e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 29 CCGCTCCGTCGCGCGC 46

Db 18 CCGCGCGCGCGCGCGC 1

RESULT 193

ADO26692

ID ADO26692 standard; DNA; 18 BP.

XX ADO26692;

XX 12-AUG-2004 (first entry)

XX Synthetic leader sequence encoding DNA SEQ ID NO:85.

DE phenotype; phenotypic preference; phenotype modulation; leader; ds.

XX Synthetic.

XX WO2004042059-A1.

XX 21-MAY-2004.

XX 10-NOV-2003; 2003WO-AU001487.

XX 08-NOV-2002; 2002US-0425163P.

XX PA (UYQU ) UNIV QUEENSLAND.  
 XX PI Frazer IH;  
 XX DR WPI; 2004-411519/38.  
 XX DR P-PSDB; ADO26693.  
 XX PT Constructing synthetic polynucleotide for modulating the quality of a  
 PT selected phenotype displayed by an organism comprises replacing a first  
 PT codon with a synonymous codon to construct the synthetic polynucleotide.  
 XX PS Example 1; SEQ ID NO 85; 86pp; English.  
 XX CC The present invention describes a method for constructing a synthetic  
 CC polynucleotide from which a polypeptide is producible to confer a  
 CC selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. The method comprises: (a) selecting a first codon of  
 CC the parent polynucleotide for replacement with a synonymous codon, where  
 CC the synonymous codon is selected on the basis that it exhibits a  
 CC different phenotypic preference than the first codon in a comparison of  
 CC phenotypic preferences in test organisms or parts, where the test  
 CC organism are selected from organisms of the same species as the organism  
 CC of interest and organisms that are related to the organisms of interest;  
 CC and (b) replacing the first codon with the synonymous codon to construct  
 CC the synthetic polynucleotide. Also described: (1) a method for  
 CC determining the phenotypic preference of a first codon in an organism of  
 CC interest or its parts; (2) a synthetic polynucleotide constructed from  
 CC the method above; (3) an organism or interest or part containing a  
 CC synthetic polynucleotide constructed from the method above; (4) an  
 CC organism or interest or part containing a synthetic construct that  
 CC comprises a regulatory polynucleotide operably linked to a tandem repeat  
 CC of a first codon fused in frame with a reporter polynucleotide that  
 CC encodes a reporter protein, which produces, or is predicted to produce a  
 CC selected phenotype or a phenotype of the same class as the selected  
 CC phenotype in the organism or part; (5) a method of modulating the quality  
 CC of a selected phenotype that is displayed by an organism of interest or  
 CC part and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; (6) a method of enhancing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; and (7) a method of reducing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide. The method is useful for constructing a  
 CC synthetic polynucleotide from which a polypeptide is producible to confer  
 CC a selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. It is useful for modulating the quality of a selected  
 CC phenotype displayed by an organism or part. The present sequence encodes  
 CC a synthetic leader sequence, which is used in an example from the present  
 CC invention.  
 XX SQ Sequence 18 BP; 0 A; 12 C; 6 G; 0 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 18;  
 Best Local Similarity 88.9%; Pred. No. 1.3e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 29 CCGCCTCCGCGCGCG 46  
 DB 1 CCGCGCGCGCGCGCG 18  
 RESULT 194  
 AAA85973/C  
 ID AAA85973 standard; DNA; 19 BP.  
 XX AAA85973;  
 AC  
 XX  
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;  
 DT 04-DEC-2000 (first entry)  
 XX WPI; 2000-412314/35.

DE Cdc 25 hs ribozyme binding site #81.  
 XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
 XX Mammalia.  
 OS  
 PN WO200032765-A2.  
 XX 08-JUN-2000.  
 PD  
 XX 06-DEC-1999; 99WO-US028772.  
 PF  
 XX 04-DEC-1998; 98US-0110954P.  
 PR  
 XX (IMMU-) IMMUSOL INC.  
 PA  
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;  
 PI  
 XX WPI; 2000-412314/35.  
 DR  
 XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
 PT PCNA and Cyclin B1.  
 PT  
 XX Disclosure; Page 100; 109pp; English.  
 PS  
 XX The present invention relates to a hairpin or hammerhead ribozyme,  
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
 CC Representative examples of ribozyme recognition sites are given in  
 CC AAA82415 to AAA86787. The ribozyme of the invention is useful for  
 CC inhibiting restenosis by introduction of the ribozyme into cells. The  
 CC ribozyme is resistant to endonuclease activity and hence is efficient in  
 CC restenosis treatment  
 CC  
 XX SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 963 GGACATCTGGACAGCTGG 980  
 DB 19 GGACATCTGGACAGCG 2  
 RESULT 195  
 AAA85142/c  
 ID AAA85142 standard; DNA; 19 BP.  
 XX  
 AC AAA85142;  
 XX  
 XX 04-DEC-2000 (first entry)  
 DT  
 XX Cyclin G1 ribozyme binding site #167.  
 DE  
 XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
 XX Mammalia.  
 OS  
 PN WO200032765-A2.  
 XX 08-JUN-2000.  
 PD  
 XX 06-DEC-1999; 99WO-US028772.  
 PF  
 XX 04-DEC-1998; 98US-0110954P.  
 PR  
 XX (IMMU-) IMMUSOL INC.  
 PA  
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;  
 PI  
 XX WPI; 2000-412314/35.  
 DR





SQ Sequence 19 BP; 11 A; 1 C; 7 G; 0 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1629 CTCATTTCATGCTTCT 1646  
DB 19 CTCCTTCTGCTTCT 2

RESULT 198  
AAH56723/C  
ID AAH56723 standard; DNA; 19 BP.  
XX AC AAH56723;  
DT 06-SEP-2001 (first entry)  
XX S. aureus groE operon antisense oligonucleotide SEQ ID NO:371.  
DE Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;  
XX Microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;  
KW Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;  
KW antibacterial; antiviral; antiproliferative; antisense therapy;  
XX microbial infection; ss.  
XX Staphylococcus aureus.  
XX WO200136625-A2.  
XX 25-MAY-2001.  
XX 20-NOV-2000; 2000WO-CA001347.  
XX 18-NOV-1999; 99US-0166249P.  
XX (GENE-) GENESENSE TECHNOLOGIES INC.  
XX Wright JA, Young AH, Dugourd D;  
XX WPI; 2001-355633/37.  
XX Novel antisense compounds targeting nucleic acid encoding groEL or groES  
PT Gene of microorganism, which hybridize with and inhibit expression of the  
PT genes, useful to inhibit growth of microorganism having the genes.  
XX Claim 3; Page 51; 110pp; English.  
XX The present invention specifically claims AAH56368 to AAH56832 which are  
CC antisense oligonucleotides to nucleotide sequences encoding groE. More  
CC generally, antisense compounds (I) comprising antisense oligonucleotides  
CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat  
CC shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a  
CC microorganism, where the antisense compound is complementary to GL or GS  
CC of a microorganism and specifically hybridizes with and inhibits the  
CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral and  
CC antiproliferative activities, and can be used in antisense therapy and  
CC for inhibition of expression of groE or groEL. (II) are useful for  
CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are  
CC also useful for inhibiting the growth of a microorganism, or inhibiting  
CC the expression of GL or GS gene in a microorganism (a bacterial cell or a  
CC virus) having a GL or GS gene which involves administering to the  
CC microorganism or to a cell infected with the microorganism, (I). (I) are  
CC also useful for treating a mammalian pathological condition mediated by  
CC the microorganisms which involves identifying a eukaryotic organism  
CC having a pathological condition mediated by microorganisms having a GL or  
CC GS gene and administering (I) such that the growth of microorganism is  
CC inhibited. The antisense compounds are utilised for diagnostics,  
CC therapeutics, prophylaxis and as research reagents and kits, e.g., to  
CC prevent or delay microbial infections in humans. They are also useful as  
CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854  
CC represent PCR primers for groE sequences which are used in the

CC exemplification of the present invention. AAH56855 to AAH56870 represent  
CC groE nucleotide sequence given in the present invention  
XX SQ Sequence 19 BP; 5 A; 2 C; 0 G; 12 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.8; DB 1; Length 19;  
Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 88 TCGAAAAAAATGAAAT 105  
DB 18 TGAATAATAAATGAAAT 1

RESULT 199  
AAH60304/C  
ID AAH60304 standard; DNA; 19 BP.  
XX AC AAH60304;  
DT 10-SEP-2001 (first entry)  
XX Cyclin G1 ribozyme binding site SEQ ID NO:2728.  
DE Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
XX recognition site; target; ribozyme binding site; eye disease; vulnery;  
KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
KW antiskinning; ophthalmological; keratolytic; gene therapy; viral wart;  
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
KW sickle cell retinopathy; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX WO200130362-A2.  
XX 03-MAY-2001.  
XX 26-OCT-2000; 2000WO-US029500.  
XX 26-OCT-1999; 99US-0161532P.  
XX (IMMU-) IMMUSOL INC.  
XX Robbins JM, Tritz R;  
XX WPI; 2001-300427/31.  
XX Treating proliferative skin or eye diseases and scarring, using ribozymes  
PT that cleave RNA encoding cytokines involved in inflammation, matrix  
PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
XX Example 1; Page 270; 408pp; English.  
XX The present invention describes a method for treating a proliferative  
CC skin or eye disease and scarring. The method involves administering a  
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
CC dependent kinase, growth factor or a reductase, or administering a  
CC nucleic acid molecule (II) comprising a promoter operably linked to a  
CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiskinning,  
CC ophthalmological, vulnery, keratolytic and virucide activities, and  
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
CC in gene therapy. (II) and (II) are useful for treating proliferative skin  
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
CC also be used for treating proliferative eye diseases such as diabetic  
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of

CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloïd, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 19 BP; 5 A; 3 C; 3 G; 8 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1326 AACTTTGGATCAAGCT 1343  
 Db 18 AACATTGGATCAAGCT 1  
 RESULT 200  
 AAH61135/C  
 ID AAH61135 standard; DNA; 19 BP.  
 XX  
 AC AAH61135;  
 DT 10-SEP-2001 (first entry)  
 DE Cdc25 hs ribozyme binding site SEQ ID NO:3559.  
 XX  
 KW Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
 KW recognition site; target; ribozyme binding site; eye disease; vulnary;  
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;  
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW anticikling; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 OS  
 XX WO200130362-A2.  
 PN  
 XX 03-MAY-2001.  
 PD  
 XX  
 XX 26-OCT-2000; 2000WO-US029500.  
 PF  
 XX 26-OCT-1999; 99US-0161532P.  
 PR  
 XX (IMMU-) IMMUSOL INC.  
 PA  
 XX Robbins JM, Tritz R;  
 PI  
 XX WPI; 2001-300427/31.  
 DR  
 XX  
 XX Treating proliferative skin or eye diseases and scarring, using ribozymes  
 PT that cleave RNA encoding cytokines involved in inflammation, matrix  
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
 XX  
 XX Example 1; Page 330; 408pp; English.  
 PS  
 XX The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, anticikling,  
 CC ophthalmological, vulnary, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can

CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloïd, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 963 GGACATCTGGACAGCTGG 980  
 Db 19 GGACATCTGGACAGCG 2

RESULT 201  
 ADJ94210/C  
 ID ADJ94210 standard; DNA; 19 BP.  
 XX  
 AC ADJ94210;  
 DT 06-MAY-2004 (first entry)  
 DE Human MYOC gene mutation detection primer M-SRL3.  
 DE  
 XX glaucoma; detection; mutation; MYOC; primer; ss.  
 KW  
 XX Homo sapiens.  
 OS  
 XX WO2003083108-A1.  
 PN  
 XX 09-OCT-2003.  
 PD  
 XX  
 XX 19-MAR-2003; 2003WO-JP003307.  
 PF  
 XX 29-MAR-2002; 2002JP-00093443.  
 PR  
 XX (SYSM-) SYSMEX CORP.  
 PA  
 XX Asano K, Takahata T, Numada S, Masago A, Kouchi Y;  
 PI  
 XX WPI; 2003-804059/75.  
 DR  
 XX Examining genes to assess the risk of the onset of glaucoma by detecting  
 PT mutations in the MYOC gene or the region upstream from it.  
 PT  
 XX Example 1; SEQ ID NO 24; 42pp; Japanese.  
 PS  
 XX The invention relates to a method of examining genes to assess the risk  
 CC of the onset of glaucoma comprising detection of at least two mutations  
 CC in the glaucoma related gene encoding region and/or a region upstream  
 CC from it. The glaucoma related gene is preferably the MYOC gene. The  
 CC method is useful for the prevention or early detection of glaucoma. This  
 CC sequence corresponds to a PCR primer used to detect mutations in the  
 CC human MYOC gene (ADJ94187).  
 XX  
 SQ Sequence 19 BP; 8 A; 4 C; 2 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1017 GCCTTTATATCATCGGAA 1034  
 Db 19 GCCTTTATTTAATGGAA 2

RESULT 202  
 ADM70255/C  
 ID ADM70255 standard; DNA; 19 BP.

XX AC ADM70255;  
 XX DT 03-JUN-2004 (first entry)  
 XX DE Plant gene polymorphism marker related primer, SEQ ID 1134.  
 XX KW Primer; variation mapping; mutation mapping; plant;  
 XX OS gene polymorphism marker; ss.  
 XX OS Synthetic.  
 XX PN JP2003289885-A.  
 XX PD 14-OCT-2003.  
 XX PF 31-JAN-2003; 2003JP-00024620.  
 XX PR 01-FEB-2002; 2002JP-00025338.  
 XX PA (RIKA ) RIKAGAKU KENKYUSHO.  
 XX PA (SAIM-) SAI MEDIA KK.  
 XX PA (MATS/) MATSUI M.  
 XX PA (NAKA/) NAKAZAWA M.  
 XX DR WPI; 2004-126231/13.  
 XX PT A primer set and method useful for mapping at least the  
 XX PT variation/mutation part of a plant gene using a gene polymorphism marker.  
 XX PS Claim 7; SEQ ID NO 1134; 120pp; Japanese.  
 XX CC The present invention relates to a primer set and method for mapping at  
 CC least the variation/mutation part of a plant gene using a gene  
 CC polymorphism marker. A mutation site of the plant gene is mapped by  
 CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is  
 CC prepared from a plant homozously having a mutation to be an object of  
 CC the mapping; (b) A forward primer 1 containing a base corresponding to  
 CC the gene polymorphic maker of one ecotype plant, a forward primer 2  
 CC containing a base corresponding to the genetic polymorphism of the other  
 CC ecotype plant and a reverse primer 3 based on the base sequence common  
 CC with both the ecotype plants are prepared; (c) two kinds of  
 CC oligonucleotides emitting fluorescence of different colors when the  
 CC genetic polymorphism marker is detected are prepared; (d) an  
 CC amplification reaction of the genomic DNA is carried out in the presence  
 CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)  
 CC the fluorescence intensity emitted from the resultant reactional product  
 CC is detected and (f) the position on the genome of the mutation site is  
 CC determined from the results of detection. The present sequence is a  
 CC primer, used to illustrate the invention.  
 XX SQ Sequence 19 BP; 3 A; 7 C; 2 G; 7 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 595 CAAGAGGGAAGATTGTTG 612  
 Db 18 CAAGAGGGAACATTGGTG 1  
 RESULT 203  
 ADM88693/c  
 ID ADM88693 standard; DNA; 19 BP.  
 XX AC ADM88693;  
 XX DT 15-JUL-2004 (first entry)  
 XX DE Example nucleotide sequence #14 used in nucleic acid synthesis method.  
 XX KW Nucleic acid synthesis; continuous nucleotide sequence; exon;

KW gene expression; protein synthesis; gene function; ss.  
 XX Synthetic.  
 XX PN US6730500-B1.  
 XX PD 04-MAY-2004.  
 XX PF 23-AUG-2001; 2001US-009380077.  
 XX PR 30-AUG-2000; 2000US-0229109P.  
 XX PR 20-DEC-2000; 2000US-0257079P.  
 XX PA (ZYMO ) ZYMOGENETICS INC.  
 XX PI Lok S;  
 XX WPI; 2004-354680/33.  
 XX PT Producing nucleic acid that comprises continuous nucleotide sequence to  
 XX PT produce protein, by amplifying nucleotide sequences using primer pairs,  
 XX PT cleaving amplified products with restriction endonuclease, and ligating  
 XX PT cleaved fragments.  
 XX PS Disclosure; SEQ ID NO 19; 17pp; English.  
 XX CC The present invention relates to a method for producing nucleic acid  
 CC molecules that comprise continuous nucleotide sequences capable of being  
 CC transcribed and translated to produce a protein of interest. The method  
 CC comprises amplifying two nucleotide sequences from a single nucleic acid  
 CC template using primer pairs, cleaving amplified products with a class IIS  
 CC restriction endonuclease to produce nucleic acid fragments, and ligating  
 CC cleaved nucleic acid fragments to produce a nucleic acid comprising a  
 CC continuous nucleotide sequence. The nucleic acid molecule template is  
 CC chosen from genomic DNA, cDNA, vector DNA and chemically-synthesized  
 CC nucleic acid molecule. In the method, each of the amplified products  
 CC comprises at least a portion of an exon. One or more of the amplified  
 CC products comprises at least a portion of an exon, and at least one of the  
 CC amplified products comprises a nucleotide sequence capable of controlling  
 CC gene expression. In the method, one primer of each primer pair is  
 CC partially complementary to the antisense strand of the 5' end of an exon,  
 CC where the other primer of each primer pair is partially complementary to  
 CC the sense strand of the 3'-end of the exon. One of the amplified products  
 CC comprises at least one mutation of the nucleotide sequence, which resides  
 CC in the corresponding nucleic acid molecule template, where at least one  
 CC mutation resides in an amino acid encoding sequence. The act of  
 CC amplification is performed using PCR. The method of the invention is  
 CC useful for producing a nucleic acid molecule that comprises a continuous  
 CC nucleotide sequence capable of being transcribed and transplanted to  
 CC produce a protein of interest. The method is useful for restoring gene  
 CC function rendered inactive by naturally occurring mutations to produce  
 CC proteins with useful functions, or for producing polypeptides having  
 CC value in industry, therapeutics, diagnostics or research. The method is  
 CC an improved method for producing nucleic acid molecules that encode a  
 CC protein of interest. The present DNA sequence is used in the  
 CC exemplification of the method of the invention.  
 XX SQ Sequence 19 BP; 5 A; 5 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1065 CGTCCAAAGAGGACTCTG 1082  
 Db 19 CTTCATAGAGGACTCTG 2  
 RESULT 204  
 ADR80686/c  
 ID ADR80686 standard; DNA; 19 BP.  
 XX AC ADR80686;

XX 16-DEC-2004 (first entry)  
 XX Human apolipoprotein B (ApoB) oligonucleotide seqid 5183.  
 XX  
 XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
 KW cytosstatic; anticonvulsant; nootropic; muscula; anti-HIV;  
 KW RNA interference; iRNA; antisense technology; lipid metabolism;  
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
 KW coronary artery disease; CAD; coronary heart disease; CHD;  
 KW atherosclerosis; hepatic glucose production;  
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
 KW colon cancer; lung cancer; neurological disease; Huntington disease;  
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.  
 XX  
 XX Homo sapiens.  
 XX  
 XX W02004080406-A2.  
 XX  
 XX 23-SEP-2004.  
 XX  
 XX 08-MAR-2004; 2004WO-US007070.  
 XX  
 XX 07-MAR-2003; 2003US-0452682P.  
 XX 12-MAR-2003; 2003US-0454265P.  
 XX 13-MAR-2003; 2003US-0454962P.  
 XX 13-MAR-2003; 2003US-0455050P.  
 XX 14-APR-2003; 2003US-0462894P.  
 XX 17-APR-2003; 2003US-0463772P.  
 XX 25-APR-2003; 2003US-0465665P.  
 XX 25-APR-2003; 2003US-0465802P.  
 XX 09-MAY-2003; 2003US-0469612P.  
 XX 08-AUG-2003; 2003US-0493986P.  
 XX 11-AUG-2003; 2003US-0494597P.  
 XX 26-SEP-2003; 2003US-0506341P.  
 XX 09-OCT-2003; 2003US-0510246P.  
 XX 10-OCT-2003; 2003US-0510318P.  
 XX 07-NOV-2003; 2003US-0518453P.  
 XX  
 XX (ALNY-) ALNYLAM PHARM.  
 XX  
 XX Manoharan M, Bumcrot D;  
 XX WPI; 2004-677362/66.  
 XX  
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
 PT disease, diabetes, cancer or neurological disease, comprises sense  
 PT sequence and antisense sequence which has specific modifications.  
 XX  
 XX Example 5; SEQ ID NO 5183; 378pp; English.  
 XX  
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a  
 CC sense sequence and an antisense sequence, where the sense sequences have  
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
 CC sequences have one or more asymmetrical phosphorothioate modifications  
 CC and the antisense sequence targets a human gene sequence. Also described  
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
 CC stabilising (I), involves selecting a sequence with activity and  
 CC introducing one or more asymmetrical modification in the sequence, where  
 CC the modification decreases nuclease sensitivity while not decreasing its  
 CC activity; a kit comprising (I) and instruction for its use; and a device  
 CC that can be dispense or administer a composition comprising (I). (I) is  
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
 CC The subject is suffering from a disorder characterised by elevated or  
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
 CC inhibit hepatic glucose production or for treating glucose-metabolism-

CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
 CC lung cancer), neurological disease (e.g., Huntington disease or  
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that  
 CC can be used to control ApoB gene expression.

XX Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.4e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 400 AGAAAGTTCACCTGGAGC 417

Db 19 AGTAAGTTCTCTGGAGC 2

RESULT 205

ADR81197

ID ADR81197 standard; DNA; 19 BP.

XX ADR81197;

XX 16-DEC-2004 (first entry)

DE Hepatitis C virus (HCV) oligonucleotide seqid 5696.

KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;  
 KW cytosstatic; anticonvulsant; nootropic; muscula; anti-HIV;  
 KW RNA interference; iRNA; antisense technology; lipid metabolism;  
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
 KW coronary artery disease; CAD; coronary heart disease; CHD;  
 KW atherosclerosis; hepatic glucose production;  
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
 KW colon cancer; lung cancer; neurological disease; Huntington disease;  
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.

OS Hepatitis C virus.

XX W02004080406-A2.

XX 23-SEP-2004.

XX 08-MAR-2004; 2004WO-US007070.

XX 07-MAR-2003; 2003US-0452682P.

XX 12-MAR-2003; 2003US-0454265P.

XX 13-MAR-2003; 2003US-0454962P.

XX 13-MAR-2003; 2003US-0455050P.

XX 14-APR-2003; 2003US-0462894P.

XX 17-APR-2003; 2003US-0463772P.

XX 25-APR-2003; 2003US-0465665P.

XX 25-APR-2003; 2003US-0465802P.

XX 09-MAY-2003; 2003US-0469612P.

XX 08-AUG-2003; 2003US-0493986P.

XX 11-AUG-2003; 2003US-0494597P.

XX 26-SEP-2003; 2003US-0506341P.

XX 09-OCT-2003; 2003US-0510246P.

XX 10-OCT-2003; 2003US-0510318P.

XX 07-NOV-2003; 2003US-0518453P.

XX (ALNY-) ALNYLAM PHARM.

XX Manoharan M, Bumcrot D;

XX WPI; 2004-677362/66.

XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
 PT disease, diabetes, cancer or neurological disease, comprises sense  
 PT sequence and antisense sequence which has specific modifications.

XX Example 5; SEQ ID NO 5696; 378pp; English.

XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a  
 CC sense sequence and an antisense sequence, where the sense sequences have  
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
 CC sequences have one or more asymmetrical phosphorothioate modifications  
 CC and the antisense sequence targets a human gene sequence. Also described  
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
 CC stabilising (I), involves selecting a sequence with activity and  
 CC introducing one or more asymmetrical modification in the sequence, where  
 CC the modification decreases nuclease sensitivity while not decreasing its  
 CC activity; a kit comprising (I) and instruction for its use; and a device  
 CC that can be dispense or administer a composition comprising (I). (I) is  
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
 CC The subject is suffering from a disorder characterised by elevated or  
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
 CC inhibit hepatic glucose production or for treating glucose-metabolism-  
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
 CC lung cancer), neurological disease (e.g., Huntington disease or  
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can  
 CC be used to control HCV gene expression.  
 XX SQ Sequence 19 BP; 8 A; 7 C; 3 G; 1 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 374 CCAAAACCTGCACGACA 391  
 Db 2 CGAAACCTGCACGACA 19  
 RESULT 206  
 ADR78028/C  
 ID ADR78028 standard; DNA; 19 BP.  
 AC ADR78028;  
 XX 16-DEC-2004 (first entry)  
 DE Human apolipoprotein B (apoB) oligonucleotide seqid 2513.  
 XX antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;  
 KW cytosstatic; anticonvulsant; nootropic; muscula; anti-HIV;  
 KW RNA interference; iRNA; antisense technology; lipid metabolism;  
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;  
 KW coronary artery disease; CAD; coronary heart disease; CHD;  
 KW atherosclerosis; hepatic glucose production;  
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;  
 KW colon cancer; lung cancer; neurological disease; Huntington disease;  
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.  
 OS Homo sapiens.  
 XX WO2004080406-A2.  
 XX 23-SEP-2004.  
 XX 08-MAR-2004; 2004WO-US0007070.  
 XX 07-MAR-2003; 2003US-0452682P.  
 PR 12-MAR-2003; 2003US-0454265P.  
 PR 13-MAR-2003; 2003US-0454962P.  
 PR 13-MAR-2003; 2003US-0455050P.

PR 14-APR-2003; 2003US-0462894P.  
 PR 17-APR-2003; 2003US-0463772P.  
 PR 25-APR-2003; 2003US-0465665P.  
 PR 25-APR-2003; 2003US-0465802P.  
 PR 09-MAY-2003; 2003US-049312P.  
 PR 08-AUG-2003; 2003US-0493186P.  
 PR 11-AUG-2003; 2003US-0494597P.  
 PR 26-SEP-2003; 2003US-0506341P.  
 PR 09-OCT-2003; 2003US-0510246P.  
 PR 10-OCT-2003; 2003US-0510318P.  
 PR 07-NOV-2003; 2003US-0518453P.  
 XX (ALNY-) ALNYLAM PHARM.  
 XX Manoharan M, Bumrot D;  
 PI WPI; 2004-677362/66.  
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery  
 PT disease, diabetes, cancer or neurological disease, comprises sense  
 PT sequence and antisense sequence which has specific modifications.  
 XX Example 5; SEQ ID NO 2513; 378pp; English.  
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a  
 CC sense sequence and an antisense sequence where the sense sequences have  
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense  
 CC sequences have one or more asymmetrical phosphorothioate modifications  
 CC and the antisense sequence targets a human gene sequence. Also described  
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100  
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);  
 CC stabilising (I), involves selecting a sequence with activity and  
 CC introducing one or more asymmetrical modification in the sequence, where  
 CC the modification decreases nuclease sensitivity while not decreasing its  
 CC activity; a kit comprising (I) and instruction for its use; and a device  
 CC that can be dispense or administer a composition comprising (I). (I) is  
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)  
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.  
 CC The subject is suffering from a disorder characterised by elevated or  
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted  
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The  
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,  
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant  
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart  
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to  
 CC inhibit hepatic glucose production or for treating glucose-metabolism-  
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for  
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or  
 CC lung cancer), neurological disease (e.g., Huntington disease or  
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence  
 CC represents a human apolipoprotein B (apoB) antisense oligonucleotide that  
 CC can be used to control apoB gene expression.  
 XX SQ Sequence 19 BP; 5 A; 5 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.8; DB 1; Length 19;  
 Best Local Similarity 88.9%; Pred. No. 1.4e+02;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 400 AGAAAGTTCACCTGGAGC 417  
 Db 19 AGTAACTTCTCTGGAGC 2  
 RESULT 207  
 ABL57076  
 ID ABL57076 standard; DNA; 16 BP.  
 XX ABL57076;  
 AC ABL57076;  
 XX 22-JUL-2002 (first entry)  
 XX Molecular beacon target sequence (single mismatch).  
 DE

XX KW Molecular beacon; fluorophore; nanoparticle; nucleic acid detection; ss.  
 XX OS Synthetic.  
 XX FH Key Location/Qualifiers  
 FT misc\_feature 9  
 FT /\*tag= a  
 FT /note= "mismatch site"  
 XX WO200218951-A2.  
 XX 07-MAR-2002.  
 XX 29-AUG-2001; 2001WO-US041941.  
 XX 29-AUG-2000; 2000US-0228728P.  
 XX 30-MAR-2001; 2001US-0280350P.  
 XX (UVRQ ) UNIV ROCKEFELLER.  
 XX Dubertret B, Calame M, Libchaber A;  
 XX WPI; 2002-404569/43.  
 XX Sensitive detecting proximity changes in a system that utilizes an  
 PT interacting fluorophore and quencher, for high sensitivity applications,  
 PT involves utilizing a metal surface as quencher.  
 XX Example 3; Page 30; 62pp; English.  
 XX The present sequence is that of a single mismatch target sequence for a  
 CC molecular beacon comprising an oligonucleotide probe (see ABL57069)  
 CC covalently attached at the 3' end to fluorescent dye and at the 5' end to  
 CC a nanoparticle. In the native state, the probe forms a hairpin  
 CC conformation with hybridised termini. The proximity of the fluorophore  
 CC and quencher (gold nanoparticle) in the molecular beacon results in  
 CC little or no detectable fluorescence. Upon hybridisation of the central  
 CC complementary stretch of the probe to a target sequence, such as the  
 CC present sequence, the hairpin undergoes a conformational change resulting  
 CC in an increase in fluorescence, the extent of which is proportional to  
 CC the amount of target sequence present. Experiments with the present  
 CC sequence and a perfectly-matched target (see ABL57071) showed that  
 CC hybridisation was very specific to the matched target. The invention  
 CC relates generally to the use of metal surface quenchers such as particles  
 CC or films for high sensitivity applications in, for example, detection and  
 CC diagnostic systems  
 XX Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 16;  
 Best Local Similarity 93.8%; Pred. No. 1.3e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1834 GAAAAAAAAAAAAA 1849  
 Db 1 GAAAAAAAACAAAAAA 16  
 RESULT 208  
 AAD57846  
 ID AAD57846 standard; DNA; 16 BP.  
 XX AC AAD57846;  
 XX 20-NOV-2003 (first entry)  
 XX Target oligonucleotide #3 used in nonlinear optical technique.  
 DE Nonlinear optical technique; screening; ss.  
 KW Unidentified.  
 XX OS

PN WO2003064991-A2.  
 PD 07-AUG-2003.  
 XX 17-JUL-2002; 2002WO-US022681.  
 XX 17-JUL-2001; 2001US-0306040P.  
 PR 23-OCT-2001; 2001US-0347821P.  
 PR 06-FEB-2002; 2002US-0354668P.  
 XX (SALA/) SALAFSKY J S.  
 XX Salafsky JS;  
 PI WPI; 2003-646172/61.  
 DR Screening candidate binding partner(s) for binding to test molecule by  
 PT applying external force field to sample in homogeneous phase,  
 PT illuminating sample with light beam(s) at fundamental frequencies, and  
 PT measuring physical properties.  
 XX Disclosure; Fig 20-B; 146pp; English.  
 XX The present invention relates to a method for detecting interactions  
 CC between biological components using a nonlinear optical technique. The  
 CC invention is used for screening candidate binding partner(s) for binding  
 CC to test molecule. It can also be used to detect changes in orientation or  
 CC conformation of the probe and/or target. The present sequence is a target  
 CC oligonucleotide used in nonlinear optical technique  
 XX Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 16;  
 Best Local Similarity 93.8%; Pred. No. 1.3e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1834 GAAAAAAAAAAAAA 1849  
 Db 1 GAAAAAAAACAAAAAA 16  
 RESULT 209  
 ADF23332  
 ID ADF23332 standard; DNA; 16 BP.  
 XX AC ADF23332;  
 XX 12-FEB-2004 (first entry)  
 XX Binding partner screening method molecular beacon analogue #3.  
 DE binding partner screening; light beam; nonlinear optical light beam; ss;  
 KW molecular beacon analogue.  
 XX Synthetic.  
 OS US2003148391-A1.  
 XX 07-AUG-2003.  
 XX 06-JUN-2002; 2002US-00164915.  
 XX 24-JAN-2002; 2002US-0351879P.  
 PR 06-FEB-2002; 2002US-0354668P.  
 PR 06-FEB-2002; 2002US-0354679P.  
 PR 05-MAR-2002; 2002US-0362003P.  
 XX (SALA/) SALAFSKY J S.  
 XX Salafsky JS;  
 PI WPI; 2003-897567/82.  
 XX

PT Screening of candidate binding partners for binding to test molecule  
PT comprises illuminating sample with light beams and measuring physical  
PT properties of nonlinear optical light beam emanating from sample.  
XX  
PS Disclosure; SEQ ID NO 3; 58pp; English.  
XX  
CC The invention describes screening a candidate binding partner by  
CC illuminating the sample with light beams at fundamental frequencies to  
CC binding partners, and measuring physical properties of a nonlinear  
CC optical light beam emanating from sample. On binding to the test molecule  
CC the properties change relative to that in absence of exposure of the test  
CC molecule. The invention is used in the screening of candidate binding  
CC partners for binding to test molecule. This sequence represents a  
CC molecular beacon analogue, an exemplary test molecule of the invention.  
XX  
SQ Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1834 GAAAAAAAAAAAAA 1849  
| | | | | | | | | |  
DB 1 GAAAAAAAAAAAAA 16  
RESULT 210  
ADSL5827  
ID ADSL5827 standard; DNA; 16 BP. .  
XX  
AC ADSL5827;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Control probe targeted to labelled/bound oligo in binding analysis.  
XX  
KW binding; sequence detection; reaction kinetics; ss; probe.  
XX  
OS Synthetic.  
XX  
PN DE10307801-A1.  
XX  
PD 09-SEP-2004.  
XX  
PF 24-FEB-2003; 2003DE-01007801.  
XX  
PR 24-FEB-2003; 2003DE-01007801.  
XX  
PA (ADVA-) ADVALYTIX AG.  
XX  
PI Kirchner R, Gauer C;  
XX  
DR WPI; 2004-654186/64.  
XX  
PT Analyzing binding between macromolecules, useful for detecting nucleic  
PT acids by hybridization, where a labeled detector molecule is immobilized  
PT and becomes fluorescent only after specific binding.  
XX  
PS Example; Page 6; 11pp; German.  
XX  
CC The invention relates to a novel analytical method for examining binding  
CC events between first and second macromolecules. The method comprises  
CC preparing a surface on which a fluorescently-labelled first macromolecule  
CC is bound and which is at least partly fitted with a fluorescence-  
CC suppressing layer. A sample liquid containing the second macromolecule is  
CC applied and fluorescence is measured. The first macromolecule has a  
CC secondary structure such that its fluorescence is suppressed by the  
CC suppressing layer when it is not specifically bound to the second  
CC macromolecule, but fluorescence is not suppressed when the two  
CC macromolecules are specifically bound. The method of the invention may be  
CC used to detect hybridisation of RNA or, particularly DNA, especially for  
CC detecting the presence of particular sequences in samples, but also for  
CC studying reaction kinetics. The method allows the use of molecular

CC beacons that are simple to prepare or synthesise, particularly because  
CC they do not require incorporation of a quencher. The current sequence is  
CC that of the control probe of the invention which is targeted to the  
CC fluorescent-labelled and bound DNA oligonucleotide in the binding  
CC analysis method.  
XX  
SQ Sequence 16 BP; 14 A; 1 C; 1 G; 0 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 16;  
Best Local Similarity 93.8%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1834 GAAAAAAAAAAAAA 1849  
| | | | | | | | | |  
DB 1 GAAAAAAAAAAAAA 16  
RESULT 211  
AAA25490  
ID AAA25490 standard; DNA; 17 BP.  
XX  
AC AAA25490;  
XX  
DT 19-JUL-2000 (first entry)  
XX  
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1988.  
XX  
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9954459-A2.  
XX  
PD 28-OCT-1999.  
XX  
PF 19-APR-1999; 99WO-US008547.  
XX  
PR 20-APR-1998; 98US-0082404P.  
XX  
PR 23-JUN-1998; 98US-00103636.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
XX  
PI Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
PI Matulic-Adamic J;  
XX  
DR WPI; 2000-013248/01.  
XX  
PT New nucleic acids that interact, and optionally cleave, target sequences,  
PT used to treat cancer.  
XX  
PS Claim 77; Page 81; 148pp; English.  
XX  
CC The present invention describes nucleic acids (A) that interact stably  
CC with a target sequence and contain at least one phosphorodithioate  
CC link, having endonuclease activity. (A), and more generally any catalytic  
CC nucleic acid (A') that modulates expression of the oestrogen receptor  
CC gene, are used to treat cancer (particularly of breast or endometrium),  
CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
CC for other conditions associated with levels of oestrogen receptor.  
CC Because of the high selectivity for targeted RNA, (A) can also be used to  
CC correlate inhibition of gene expression with alterations in phenotype,  
CC particularly for identification of therapeutic targets, and as research  
CC reagents (for RNA, in the same way that restriction endonucleases are  
CC used with DNA). The combination of modifications in (A) improves  
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
CC AAA24748 to AAA25992 represent their corresponding target sequences.  
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
CC sequences, and AAA26107 to AAA26218 represent their corresponding target



sequences. AAA26219 to AAA26271 represent other ribozyme sequences and antisense oligonucleotides used in the exemplification of the present invention

CC Sequence 17 BP; 4 A; 5 C; 1 G; 7 T; 0 U; 0 Other;  
XX Query Match 0.8%; Score 14.4; DB 1; Length 17;  
CC Best Local Similarity 93.8%; Pred. NO. 1.4e+02;  
CC Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
SQ

Qy 1324 TCAACTTTTGGATCCA 1339  
Db 1 TCAACTTTTGGATCCA 16

RESULT 212  
AAA25488  
ID AAA25488 standard; DNA; 17 BP.  
XX AC  
XX AAA25488;  
XX DT  
XX 19-JUL-2000 (first entry)  
XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1986.  
DE Oestrogen receptor; c-ras; k-ras; bcl-2; ribozyme; cleavage;  
XX hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX Homo sapiens.  
OS  
XX WO9954459-A2.  
FN  
XX 28-OCT-1999.  
PD  
XX 19-APR-1999; 99WO-US008547.  
PF  
XX 20-APR-1998; 98US-0082404P.  
PR  
XX 23-JUN-1998; 98US-00103636.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
PI Matulic-Adamic J;  
XX  
XX WPI; 2000-013248/01.  
DR  
XX New nucleic acids that interact, and optionally cleave, target sequences, used to treat cancer.  
PT  
XX Claim 77; Page 81; 148pp; English.  
PS  
XX The present invention describes nucleic acids (A) that interact stably with a target sequence and contain at least one phosphorodithioate link, having endonuclease activity. (A), and more generally any catalytic nucleic acid (A') that modulates expression of the oestrogen receptor gene, are used to treat cancer (particularly of breast or endometrium), in vivo or by transforming cells ex vivo and implanting treated cells, or for other conditions associated with levels of oestrogen receptor. CC Because of the high selectivity for targeted RNA, (A) can also be used to correlate inhibition of gene expression with alterations in phenotype, CC particularly for identification of therapeutic targets, and as research reagents (for RNA, in the same way that restriction endonucleases are used with DNA). The combination of modifications in (A) improves CC resistance to nucleases, binding affinity and/or activity. AAA23503 to CC AAA24748 represent oestrogen receptor hammerhead ribozyme sequences, and CC AAA25993 to AAA25992 represent their corresponding target sequences. CC AAA26219 to AAA26271 represent other ribozyme sequences and antisense oligonucleotides used in the exemplification of the present

invention

CC Sequence 17 BP; 4 A; 4 C; 1 G; 8 T; 0 U; 0 Other;  
XX Query Match 0.8%; Score 14.4; DB 1; Length 17;  
CC Best Local Similarity 93.8%; Pred. NO. 1.4e+02;  
CC Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
SQ

Qy 1323 ATCAACTTTTGGATCC 1338  
Db 2 ATCAACTTTTGGATCC 17

RESULT 213  
AAA25596  
ID AAA25596 standard; DNA; 17 BP.  
XX AC  
XX AAA25596;  
XX DT  
XX 19-JUL-2000 (first entry)  
XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2094.  
DE Oestrogen receptor; c-ras; k-ras; bcl-2; ribozyme; cleavage;  
XX hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX Homo sapiens.  
OS  
XX WO9954459-A2.  
FN  
XX 28-OCT-1999.  
PD  
XX 19-APR-1999; 99WO-US008547.  
PF  
XX 20-APR-1998; 98US-0082404P.  
PR  
XX 23-JUN-1998; 98US-00103636.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
PI Matulic-Adamic J;  
XX  
XX WPI; 2000-013248/01.  
DR  
XX New nucleic acids that interact, and optionally cleave, target sequences, used to treat cancer.  
PT  
XX Claim 77; Page 84; 148pp; English.  
PS  
XX The present invention describes nucleic acids (A) that interact stably with a target sequence and contain at least one phosphorodithioate link, having endonuclease activity. (A), and more generally any catalytic nucleic acid (A') that modulates expression of the oestrogen receptor gene, are used to treat cancer (particularly of breast or endometrium), in vivo or by transforming cells ex vivo and implanting treated cells, or for other conditions associated with levels of oestrogen receptor. CC Because of the high selectivity for targeted RNA, (A) can also be used to correlate inhibition of gene expression with alterations in phenotype, CC particularly for identification of therapeutic targets, and as research reagents (for RNA, in the same way that restriction endonucleases are used with DNA). The combination of modifications in (A) improves CC resistance to nucleases, binding affinity and/or activity. AAA23503 to CC AAA24748 represent oestrogen receptor hammerhead ribozyme sequences, and CC AAA25993 to AAA25992 represent their corresponding target sequences. CC AAA26219 to AAA26271 represent other ribozyme sequences and antisense oligonucleotides used in the exemplification of the present

SQ Sequence 17 BP; 6 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1569 GCAACTTGGAAACT 1584  
 |||||  
 Db 2 GCAACTTGGAAACT 17

RESULT 214  
 ABK03734  
 ID ABK03734 standard; RNA; 17 BP.  
 AC ABK03734;  
 XX  
 DT 12-MAR-2002 (first entry)  
 XX  
 DE Human CD20 Antibody #83.  
 XX  
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
 KW cerebroprotective; neuroprotective; antiparkinsonian;  
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KW DNazyme; inozyme; G-cleaver; ambryzyme; zinzyme; lymphoma; leukaemia;  
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;  
 KW inflammatory arthropathy; central nervous system injury;  
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KW Parkinson's disease; ataxia; Huntington's disease;  
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 PN WO200159103-A2.  
 XX  
 PD 16-AUG-2001.  
 XX  
 PF 09-FEB-2001; 2001WO-US004273.  
 XX  
 PR 11-FEB-2000; 2000US-0181297P.  
 PR 28-FEB-2000; 2000US-0185516P.  
 PR 06-MAR-2000; 2000US-0187128P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (CHOW/) CHOWRIRA B W.  
 XX  
 PI Blatt L, Mcswiggen J, Chowrira BM;  
 XX WPI; 2001-607195/69.  
 XX  
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 PT central nervous system injury.  
 XX  
 PS Claim 30; Page 168; 200pp; English.  
 XX  
 CC The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule  
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an ambryzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of

CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is an ambryzyme molecule of the invention  
 XX  
 SQ Sequence 17 BP; 11 A; 0 C; 4 G; 0 T; 2 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 81.2%; Pred. No. 1.4e+02;  
 Matches 13; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 202 AAATRAAAGAGAAT 217  
 |||||  
 Db 1 AAATRAAAGAGAAGU 16

RESULT 215  
 ABN10039/C  
 ID ABN10039 standard; DNA; 17 BP.  
 XX  
 AC ABN10039;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10031.  
 XX  
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 OS  
 PN WO200192524-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 25-MAY-2001; 2001WO-US016981.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234587P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 XX  
 PA (AEOM-) AEOMICA INC.



PD 06-DEC-2001.  
XX 25-MAY-2001; 2001WO-US016981.  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX (AEOM-) AEOMICA INC.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX Disclosure; SEQ ID NO 10030; 214pp; English.  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX Sequence 17 BP; 2 A; 4 C; 7 G; 4 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1065 CGTCCAAAGAGGACTC 1080  
DB 17 CGTCCACAGAGGACTC 2  
RESULT 218  
ABN08372  
ID ABN08372 standard; DNA; 17 BP.  
XX AC ABN08372;  
XX 29-MAY-2002 (first entry)  
DT

Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8364.  
Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
skeletal muscle disorder; amplicon; screening; ss.  
Homo sapiens.  
WO200192524-A2.  
06-DEC-2001.  
25-MAY-2001; 2001WO-US016981.  
26-MAY-2000; 2000US-0207456P.  
21-SEP-2000; 2000US-0234687P.  
27-SEP-2000; 2000US-0236359P.  
04-OCT-2000; 2000GB-00024263.  
30-JAN-2001; 2001WO-US000661.  
30-JAN-2001; 2001WO-US000662.  
30-JAN-2001; 2001WO-US000663.  
30-JAN-2001; 2001WO-US000664.  
30-JAN-2001; 2001WO-US000665.  
30-JAN-2001; 2001WO-US000666.  
30-JAN-2001; 2001WO-US000667.  
30-JAN-2001; 2001WO-US000668.  
30-JAN-2001; 2001WO-US000669.  
05-FEB-2001; 2001US-0266860P.  
(AEOM-) AEOMICA INC.  
Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
WPI; 2002-179446/23.  
New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
or as specific biomolecule capture probes for surface-enhanced laser  
desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
Disclosure; SEQ ID NO 8364; 214pp; English.  
The present invention describes a human genome-derived myosin-like  
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
nucleic acids can be used as probes to detect, characterise and quantify  
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
provide initial substrates for the recombinant engineering of hGDMPLP-1  
protein variants having desired phenotypic improvements, and for  
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
used as immunogens to raise antibodies that specifically recognise hGDMPLP  
-1 proteins, as standards in assays used to determine the concentration  
and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
capture probes for surface-enhanced laser desorption/ionisation, as  
therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
production, and in vaccines or for replacement therapy. The  
polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
disorder associated with the expression of hGDMPLP-1, in particular heart  
and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
The present sequence represents an oligomer used in the screening of the  
hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
The sequence data for this patent did not form part of the printed  
specification, but was obtained in electronic format directly from WIPO  
at ftp.wipo.int/pub/published\_pct\_sequence  
Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 395 GCTGGAGAAAGTTTCA 410



DT 22-APR-2004 (first entry)  
 XX WNV minus strand DNazyme substrate SEQ ID NO 13702.  
 DE  
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 PN  
 XX 06-SEP-2002.  
 PD  
 XX 19-OCT-2001; 2001WO-US048350.  
 XX  
 PF 20-OCT-2000; 2000US-0242411P.  
 XX  
 PR (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 XX Blatt L, Mcswiggen JA;  
 PI  
 XX WPI; 2002-706994/76.  
 DR  
 XX New nucleic acid molecule that modulates replication of West Nile Virus  
 XX (WNV), useful for treating a condition related to WNV infection e.g.  
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 XX Claim 23; SEQ ID NO 13702; 495pp; English.  
 PS  
 XX The invention relates to nucleic acid molecules that modulate replication  
 XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 CC treating a condition related to WNV infection e.g. pancreatitis,  
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 CC molecule is selected from the group of ribozymes consisting of  
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
 CC nucleic acid molecules further comprise at least five ribose residues, at  
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 CC in the specification. The present sequence is that of a nucleic acid  
 CC molecule of the invention  
 XX  
 SQ Sequence 17 BP; 3 A; 5 C; 5 G; 0 T; 4 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1241 CAGGGCCATCATGGAG 1256  
 DB |||||  
 17 CAGGGCCATCATGGAG 2  
 RESULT 222  
 ACN12456/c  
 ID ACN12456 standard; RNA; 17 BP.  
 XX  
 AC ACN12456;  
 XX  
 XX 22-APR-2004 (first entry)  
 DT  
 XX WNV minus strand Zinzyme substrate SEQ ID NO 12459.  
 DE  
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 PN  
 XX 06-SEP-2002.  
 PD  
 XX 19-OCT-2001; 2001WO-US048350.  
 PF  
 XX 20-OCT-2000; 2000US-0242411P.  
 PR  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX  
 XX Blatt L, Mcswiggen JA;  
 PI  
 XX WPI; 2002-706994/76.  
 DR  
 XX New nucleic acid molecule that modulates replication of West Nile Virus  
 XX (WNV), useful for treating a condition related to WNV infection e.g.  
 PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 XX Claim 23; SEQ ID NO 12459; 495pp; English.  
 PS  
 XX The invention relates to nucleic acid molecules that modulate replication  
 XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 CC treating a condition related to WNV infection e.g. pancreatitis,  
 CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 CC molecule is selected from the group of ribozymes consisting of  
 CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
 CC nucleic acid molecules further comprise at least five ribose residues, at  
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 CC in the specification. The present sequence is that of a nucleic acid  
 CC molecule of the invention  
 XX  
 SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1239 GCCAGGGCCATCATGG 1254  
 DB |||||  
 16 GCCAGGGCCATCATTTG 1  
 RESULT 223  
 ACN01677/c  
 ID ACN01677 standard; RNA; 17 BP.  
 XX  
 AC ACN01677;  
 XX  
 XX 22-APR-2004 (first entry)  
 DT  
 XX WNV Inozyme substrate SEQ ID NO 1667.  
 DE  
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 KW Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 PN

PD 06-SEP-2002.  
 XX 19-OCT-2001; 2001WO-US048350.  
 XX 20-OCT-2000; 2000US-0242411P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 XX Blatt L, Mcswiggen JA;  
 PI Claim 23; SEQ ID NO 1667; 495pp; English.  
 XX  
 DR WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 XX Claim 23; SEQ ID NO 1667; 495pp; English.  
 XX  
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX  
 SQ Sequence 17 BP; 4 A; 5 C; 5 G; 0 T; 3 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Oy 328 GACTGAGTGGCTCCAA 343  
 Db 16 GCCTGAGTGGCTCCAA 1  
 RESULT 224  
 ACN15154  
 ID ACN15154 standard; RNA; 17 BP.  
 XX ACN15154;  
 XX  
 DT 22-APR-2004 (first entry)  
 XX  
 XX WNV minus strand Amberzyme substrate SEQ ID NO 15157.  
 DE  
 XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.  
 XX  
 OS West Nile Virus.  
 XX  
 XX WO200268637-A2.  
 XX  
 XX 06-SEP-2002.  
 XX  
 XX 19-OCT-2001; 2001WO-US048350.  
 XX  
 XX 20-OCT-2000; 2000US-0242411P.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 PI Blatt L, Mcswiggen JA;  
 XX WPI; 2002-706994/76.  
 XX  
 XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 PT  
 XX Claim 23; SEQ ID NO 15157; 495pp; English.  
 XX  
 XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention  
 XX  
 SQ Sequence 17 BP; 3 A; 6 C; 5 G; 0 T; 3 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 75.0%; Pred. No. 1.4e+02;  
 Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
 Oy 328 GACTGAGTGGCTCCAA 343  
 Db 1 GCCUGAGUGGCUCCAA 16  
 RESULT 225  
 ABZ61174/C  
 ID ABZ61174 standard; RNA; 17 BP.  
 XX ABZ61174;  
 AC  
 XX  
 DT 21-MAR-2003 (first entry)  
 XX  
 XX Human K-Ras DNazyme substrate #1286.  
 DE  
 XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras; enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV; anti-rheumatic; cancer; AIDS; ss.  
 KW  
 KW  
 OS Homo sapiens.  
 XX  
 XX WO200297114-A2.  
 XX  
 XX 05-DEC-2002.  
 XX  
 XX 29-MAY-2002; 2002WO-US016940.  
 XX  
 XX 29-MAY-2001; 2001US-0294140P.  
 PR 06-JUN-2001; 2001US-0296249P.  
 PR 10-SEP-2001; 2001US-0318471P.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX Mcswiggen J;  
 PI  
 XX WPI; 2003-140484/13.  
 XX  
 XX Novel short interfering RNA and enzymatic nucleic acid useful for treating cancer, modulates the expression of a nucleic acid encoding

PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
 XX  
 PS Claim 58; Page 109; 185pp; English.  
 XX  
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic acid molecule or an enzymatic nucleic acid molecule, that modulates expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras, human immunodeficiency virus (HIV) or a component of HIV. The nucleic acid molecule of the invention has cytostatic, anti-HIV, and anti-rheumatic activity. The nucleic acid molecules are useful for reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are also useful for treating breast, ovarian, colorectal, lung, prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences shown in AB259889 - AB262216, AB264544 - AB265531, AB266520 - AB266524, CC AB266530 - AB266585 represent substrate/target sequences for the human CC ribozymes of the invention  
 XX  
 SQ Sequence 17 BP; 8 A; 4 C; 2 G; 0 T; 3 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1440 ATGAATGTTGCTGCTG 1455  
 Db 16 ATTAATGTTGCTGCTG 1  
 XX  
 RESULT 226  
 ACD50766/c  
 ID ACD50766 standard; RNA; 17 BP.  
 XX  
 AC ACD50766;  
 XX  
 DT 23-SEP-2003 (first entry)  
 XX  
 DE HBV hammerhead ribozyme substrate sequence #232.  
 XX  
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;  
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 XX  
 OS Hepatitis B virus.  
 XX  
 PN WO200281494-A1.  
 XX  
 PD 17-OCT-2002.  
 XX  
 XX 26-MAR-2002; 2002WO-US009187.  
 XX  
 PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.  
 PA (BLAT/) BLATT L.  
 PA (NACE/) MACEJAK D.  
 PA (NCNW/) MCSWIGGEN J.  
 PA (MORR/) MORRISSEY D.  
 PA (PVC/) PAVCO P.  
 PA (LEEP/) LEE P.  
 PA (DRAP/) DRAPER K.  
 PA (ROBE/) ROBERTS E.  
 XX  
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
 PI Draper K, Roberts E;

XX  
 DR WPI; 2003-229207/22.  
 XX  
 PT Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus infection.  
 XX  
 PS Example 1; Page 140; 387pp; English.  
 XX  
 CC The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of Hepatitis C virus (HCV) or Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes, inozymes, zinzyms, amberyne, and G-cleaver ribozymes. Also disclosed are nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences, as well as oligonucleotides that specifically bind the Enhancer I region of HBV DNA. The nucleic acids may be used to modulate the expression of HBV genes and HBV viral replication. Also disclosed is a method for screening compounds and/or potential therapies directed against HBV, and compounds that modulate the expression and/or replication of HCV. The compounds and methods of the invention are useful for the treatment of degenerative and disease states related to HBV and HCV infection, replication and gene expression such as cirrhosis, liver failure, and hepatocellular carcinoma. The present sequence represents a substrate for one of the HBV ribozyme, inozyme, G-cleaver, zinzyme, DNzyme or amberyne sequences disclosed in the present invention  
 XX  
 SQ Sequence 17 BP; 3 A; 4 C; 2 G; 0 T; 8 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 530 AGGCATTACAGCAGAA 545  
 Db 17 AGGCATTAAAGCAGAA 2  
 XX  
 RESULT 227  
 ACD63373  
 ID ACD63373 standard; RNA; 17 BP.  
 XX  
 AC ACD63373;  
 XX  
 DT 30-SEP-2003 (first entry)  
 XX  
 DE HCV minus strand DNzyme substrate sequence #1012.  
 XX  
 KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
 KW RNA stability; RNA expression; RNA synthesis; antisense;  
 KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;  
 KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
 KW HBV reverse transcriptase; Enhancer I region; viral replication;  
 KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
 KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
 KW virucide; antiinflammatory; substrate; ss.  
 XX  
 OS Hepatitis C virus.  
 XX  
 PN WO200281494-A1.  
 XX  
 PD 17-OCT-2002.  
 XX  
 XX 26-MAR-2002; 2002WO-US009187.  
 XX  
 PR 26-MAR-2001; 2001US-00817879.  
 PR 08-JUN-2001; 2001US-00877478.  
 PR 08-JUN-2001; 2001US-0296876P.  
 PR 24-OCT-2001; 2001US-0335059P.  
 PR 05-DEC-2001; 2001US-0337055P.  
 XX  
 PA (RIBO-) RIBOZYME PHARM INC.



PA (BLAT/) BLATT L.  
PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
PI WPI; 2003-229207/22.  
XX  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
XX  
XX Claim 1; Page 293; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
CC inozymes, zinczymes, amberyzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV, and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNazyme or minus strand DNazyme sequences disclosed in the present  
CC invention  
XX  
XX Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;  
SQ  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 75.0%; Pred. No. 1.4e+02;  
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;  
OY 1005 GATGCGGTGGAGCCT 1020  
DB ||:||||:||||:  
2 GAUGGGGUGGAGCCU 17  
RESULT 228  
ACD59296/C  
ID ACD59296 standard; RNA; 17 BP.  
XX  
XX ACD59296;  
XX  
XX 24-SEP-2003 (first entry)  
XX  
XX HCV DNazyme substrate sequence #1266.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
XX RNA stability; RNA expression; RNA synthesis; antisense;  
XX enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinczyme;  
XX amberyzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
XX HBV reverse transcriptase; Enhancer I region; viral replication;  
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
XX virucide; antiinflammatory; substrate; ss.  
XX  
XX Hepatitis C virus.  
OS  
XX  
XX WO200281494-A1.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
XX RNA stability; RNA expression; RNA synthesis; antisense;

PD 17-OCT-2002.  
XX  
XX 26-MAR-2002; 2002WO-US009187.  
XX  
XX 26-MAR-2001; 2001US-00817879.  
PR 08-JUN-2001; 2001US-00877478.  
PR 08-JUN-2001; 2001US-0296876P.  
PR 24-OCT-2001; 2001US-0335059P.  
PR 05-DEC-2001; 2001US-0337055P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
PI WPI; 2003-229207/22.  
XX  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
XX  
XX Claim 1; Page 256; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
CC inozymes, zinczymes, amberyzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV, and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNazyme or minus strand DNazyme sequences disclosed in the present  
CC invention  
XX  
XX Sequence 17 BP; 3 A; 10 C; 2 G; 0 T; 2 U; 0 Other;  
SQ  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
OY 1005 GATGCGGTGGAGCCT 1020  
DB |||||:|||||||  
17 GATGGGGGTGGAGCCT 2  
RESULT 229  
ACD59612/C  
ID ACD59612 standard; RNA; 17 BP.  
XX  
XX ACD59612;  
XX  
XX 24-SEP-2003 (first entry)  
XX  
XX HCV DNazyme substrate sequence #1414.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
XX RNA stability; RNA expression; RNA synthesis; antisense;

KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; HCV infection; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX  
OS Hepatitis C virus.  
XX  
XX WO200281494-A1.  
XX  
XX 17-OCT-2002.  
XX  
XX 26-MAR-2002; 2002WO-US009187.  
XX  
XX 26-MAR-2001; 2001US-00817879.  
XX  
XX 08-JUN-2001; 2001US-00877478.  
XX  
XX 08-JUN-2001; 2001US-0296876P.  
XX  
XX 24-OCT-2001; 2001US-0335059P.  
XX  
XX 05-DEC-2001; 2001US-0337055P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX (BLAT/) BLATT L.  
XX  
XX (NACE/) MACEJAK D.  
XX  
XX (MCSW/) MCSWIGGEN J.  
XX  
XX (MORR/) MORRISSEY D.  
XX  
XX (PAVC/) PAVCO P.  
XX  
XX (LEEP/) LEE P.  
XX  
XX (DRAP/) DRAPER K.  
XX  
XX (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
XX Draper K, Roberts E;  
XX WPI; 2003-229207/22.  
XX  
XX Novel compound useful for treating cirrhosis, liver failure,  
XX hepatocellular carcinoma, or condition associated with hepatitis C virus  
XX infection.  
XX  
XX Claim 1; Page 259; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
XX and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
XX transcriptase and/or HBV reverse transcriptase primer sequences, as well  
XX as oligonucleotides that specifically bind the Enhancer I region of HBV  
XX DNA. The nucleic acids may be used to modulate the expression of HBV  
XX genes and HBV viral replication. Also disclosed is a method for screening  
XX compounds and/or potential therapies directed against HBV, and compounds  
XX that modulate the expression and/or replication of HCV. The compounds and  
XX methods of the invention are useful for the treatment of degenerative and  
XX disease states related to HBV and HCV infection, replication and gene  
XX expression such as cirrhosis, liver failure, and hepatocellular  
XX carcinoma. The present sequence represents a substrate for one of the HCV  
XX DNazyme or minus strand DNazyme sequences disclosed in the present  
XX invention  
XX  
XX Sequence 17 BP; 4 A; 9 C; 2 G; 0 T; 2 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 14.4; DB 1; Length 17;  
XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
XX QY 1173 CTGGTGATGAGGCTG 1188  
XX Db 16 CTGGTGATGAGGCTG 1  
XX  
XX RESULT 230

ACD50768/c  
ID ACD50768 standard; RNA; 17 BP.  
XX  
AC ACD50768;  
XX  
XX 23-SEP-2003 (first entry)  
XX  
XX HBV hammerhead ribozyme substrate sequence #234.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
XX RNA stability; RNA expression; RNA synthesis; antisense;  
XX enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
XX HBV reverse transcriptase; Enhancer I region; viral replication;  
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
XX virucide; antiinflammatory; substrate; ss.  
XX  
OS Hepatitis B virus.  
XX  
XX WO200281494-A1.  
XX  
XX 17-OCT-2002.  
XX  
XX 26-MAR-2002; 2002WO-US009187.  
XX  
XX 26-MAR-2001; 2001US-00817879.  
XX  
XX 08-JUN-2001; 2001US-00877478.  
XX  
XX 08-JUN-2001; 2001US-0296876P.  
XX  
XX 24-OCT-2001; 2001US-0335059P.  
XX  
XX 05-DEC-2001; 2001US-0337055P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX (BLAT/) BLATT L.  
XX  
XX (NACE/) MACEJAK D.  
XX  
XX (MCSW/) MCSWIGGEN J.  
XX  
XX (MORR/) MORRISSEY D.  
XX  
XX (PAVC/) PAVCO P.  
XX  
XX (LEEP/) LEE P.  
XX  
XX (DRAP/) DRAPER K.  
XX  
XX (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
XX Draper K, Roberts E;  
XX WPI; 2003-229207/22.  
XX  
XX Novel compound useful for treating cirrhosis, liver failure,  
XX hepatocellular carcinoma, or condition associated with hepatitis C virus  
XX infection.  
XX  
XX Example 1; Page 140; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
XX Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
XX and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
XX inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
XX are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
XX transcriptase and/or HBV reverse transcriptase primer sequences, as well  
XX as oligonucleotides that specifically bind the Enhancer I region of HBV  
XX DNA. The nucleic acids may be used to modulate the expression of HBV  
XX genes and HBV viral replication. Also disclosed is a method for screening  
XX compounds and/or potential therapies directed against HBV, and compounds  
XX that modulate the expression and/or replication of HCV. The compounds and  
XX methods of the invention are useful for the treatment of degenerative and  
XX disease states related to HBV and HCV infection, replication and gene  
XX expression such as cirrhosis, liver failure, and hepatocellular  
XX carcinoma. The present sequence represents a substrate for one of the HBV  
XX ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberzyme sequences  
XX disclosed in the present invention  
XX  
XX Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;

```

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 529 AAGCATTACAGCAGA 544
DB 16 AAGGCATTAAAGCAGA 1

RESULT 231
ACC65059
ID ACC65059 standard; DNA; 17 BP.
XX
AC ACC65059;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2306.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004210.
XX
PR 17-SEP-2001; 2001FR-00011979.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-333167/31.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 300; 738pp; French.
XX
CC The present invention relates to murine oligonucleotides (ACC62754-
CC ACC6806), which are associated with tumour suppression, tumour
CC reversion, apoptosis and virus resistance. The oligonucleotides are
CC useful as (1) as probes and primers for detecting, identifying,
CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
CC recombinant polypeptides. The oligonucleotides are useful for preparation
CC of pharmaceuticals for prevention and/or treatment of viral diseases that
CC are characterised by development of tumours or cell degeneration,
CC specifically cancer but also Alzheimer's disease and schizophrenia
XX
SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 492 ATCTGGGTCTTGCCA 507
DB 2 ATCTGGGTCTTGCCA 17

RESULT 232
ACC63426/C
ID ACC63426 standard; DNA; 17 BP.
XX

```

---

```

ACC63426;
01-JUL-2003 (first entry)
Murine oligonucleotide associated with tumour suppression, SEQ ID 673.
Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
tumour suppression; tumour reversion; apoptosis; virus resistance;
viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
schizophrenia; ss.
Mus musculus.
WO2003025176-A2.
27-MAR-2003.
17-SEP-2002; 2002WO-IB004210.
17-SEP-2001; 2001FR-00011979.
(MOLE-) MOLECULAR ENGINES LAB.
Telerman A, Amson R, Tuijnder M;
WPI; 2003-333167/31.
New isolated nucleic acid, useful for treating viral diseases associated
with tumors and cell degeneration, also related polypeptides, antibodies
and transfected cells.
Disclosure; Page 109; 738pp; French.
The present invention relates to murine oligonucleotides (ACC62754-
ACC6806), which are associated with tumour suppression, tumour
reversion, apoptosis and virus resistance. The oligonucleotides are
useful as (1) as probes and primers for detecting, identifying,
quantifying and/or amplifying nucleic acid, e.g. as one component of a
gene chip; in vitro as (anti)sense reagents; and (2) for production of a
recombinant polypeptides. The oligonucleotides are useful for preparation
of pharmaceuticals for prevention and/or treatment of viral diseases that
are characterised by development of tumours or cell degeneration,
specifically cancer but also Alzheimer's disease and schizophrenia
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match          0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 968 TCTGGACAGCTGGGAT 983
DB 17 TCTGGATAGCTGGGAT 2

RESULT 233
ACC64367
ID ACC64367 standard; DNA; 17 BP.
XX
AC ACC64367;
XX
DT 01-JUL-2003 (first entry)
XX
DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1614.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; ss.
XX
OS Mus musculus.
XX
PN WO2003025176-A2.

```

```

XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 219; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia
XX SQ Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1558 ATCTGGGTCTGCAAC 1573
Db 2 ATCTGGGTCTGCAAC 17

RESULT 234
ACC65664/C
ID ACC65664 standard; DNA; 17 BP.
XX AC ACC65664;
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 2911.
XX KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 538; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia
XX SQ Sequence 17 BP; 6 A; 1 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1041 TCACATTATTAAAGATC 1056
Db 16 TCACATTATTACAGATC 1

RESULT 235
ACC67091/C
ID ACC67091 standard; DNA; 17 BP.
XX AC ACC67091;
XX DT 01-JUL-2003 (first entry)
XX DE Murine oligonucleotide associated with tumour suppression, SEQ ID 4338.
XX KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; murine;
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; ss.
XX OS Mus musculus.
XX PN WO2003025176-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB004210.
XX PR 17-SEP-2001; 2001FR-00011979.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-333167/31.
XX OS New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; Page 538; 738pp; French.
XX CC The present invention relates to murine oligonucleotides (ACC62754-
XX CC ACC68806), which are associated with tumour suppression, tumour
XX CC reversion, apoptosis and virus resistance. The oligonucleotides are
XX CC useful as (1) as probes and primers for detecting, identifying,
XX CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
XX CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
XX CC recombinant polypeptides. The oligonucleotides are useful for preparation
XX CC of pharmaceuticals for prevention and/or treatment of viral diseases that
XX CC are characterised by development of tumours or cell degeneration,
XX CC specifically cancer but also Alzheimer's disease and schizophrenia

```

CC specifically cancer but also Alzheimer's disease and schizophrenia  
 XX Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;  
 SQ

Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 CTTCTGGCCAGGAATC 1560  
 DB 16 CTTCTGGCCAGGATC 1

## RESULT 236

ADI48639  
 ID ADI48639 standard; DNA; 17 BP.

XX  
 AC ADI48639;

XX 15-APR-2004 (first entry)

XX Human tumour suppression/reversion-related DNA sequence SeqID1142.

XX tumour suppression; tumour reversion; apoptosis; virus resistance;  
 XX cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;  
 KW primer; PCR; gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

XX WO2003025177-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004523.

XX 17-SEP-2001; 2001FR-00011980.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated  
 XX with tumors and cell degeneration, also related polypeptides, antibodies  
 XX and transfected cells.

XX Disclosure; SEQ ID NO 1142; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved  
 XX in the phenomena of tumour suppression, tumour reversion, apoptosis  
 XX and/or resistance to viruses. The invention may be useful for the  
 XX development of compounds with a cytostatic, virucide, neuroprotective,  
 XX neurotropic or neuroleptic activity. The DNA sequences may be useful as  
 XX probes and primers for detecting, identifying, quantifying and/or  
 XX amplifying nucleic acid, for example as one component of a gene chip, in  
 XX vitro as antisense reagents and for production of recombinant  
 XX polypeptides. The invention may therefore be useful for preparation of  
 XX pharmaceuticals for prevention and/or treatment of viral diseases that  
 XX are characterised by development of tumours or cell degeneration,  
 XX specifically cancer but also Alzheimer's disease and schizophrenia. The  
 XX present sequence is that of a nucleic acid sequence of the invention.  
 XX Note: The sequence data for this patent did not form part of the printed  
 XX specification, but was obtained in electronic format directly from WIPO  
 XX at ftp.wipo.int/pub/publishedpct\_sequences

XX Sequence 17 BP; 8 A; 2 C; 5 G; 2 T; 0 U; 0 Other;

## Query Match

Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 920 GATCACTGGGAGCAAA 935  
 DB 1 GATCACTGGGAGAAA 16

## RESULT 237

ADI49463  
 ID ADI49463 standard; DNA; 17 BP.

XX  
 AC ADI49463;

XX 15-APR-2004 (first entry)

XX Human tumour suppression/reversion-related DNA sequence SeqID1366.

XX tumour suppression; tumour reversion; apoptosis; virus resistance;  
 XX cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;  
 KW primer; PCR; gene chip; antisense; viral disease; tumour;  
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX Homo sapiens.

XX WO2003025177-A2.

XX 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004523.

XX 17-SEP-2001; 2001FR-00011980.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313354/30.

XX New isolated nucleic acid, useful for treating viral diseases associated  
 XX with tumors and cell degeneration, also related polypeptides, antibodies  
 XX and transfected cells.

XX Disclosure; SEQ ID NO 1966; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved  
 XX in the phenomena of tumour suppression, tumour reversion, apoptosis  
 XX and/or resistance to viruses. The invention may be useful for the  
 XX development of compounds with a cytostatic, virucide, neuroprotective,  
 XX neurotropic or neuroleptic activity. The DNA sequences may be useful as  
 XX probes and primers for detecting, identifying, quantifying and/or  
 XX amplifying nucleic acid, for example as one component of a gene chip, in  
 XX vitro as antisense reagents and for production of recombinant  
 XX polypeptides. The invention may therefore be useful for preparation of  
 XX pharmaceuticals for prevention and/or treatment of viral diseases that  
 XX are characterised by development of tumours or cell degeneration,  
 XX specifically cancer but also Alzheimer's disease and schizophrenia. The  
 XX present sequence is that of a nucleic acid sequence of the invention.  
 XX Note: The sequence data for this patent did not form part of the printed  
 XX specification, but was obtained in electronic format directly from WIPO  
 XX at ftp.wipo.int/pub/publishedpct\_sequences

XX Sequence 17 BP; 4 A; 4 C; 2 G; 7 T; 0 U; 0 Other;

## Query Match

Best Local Similarity 0.8%; Score 14.4; DB 1; Length 17;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1376 ATCAAGTATTCTTC 1391

DB 2 ATCAAGTATTCTTC 17

## RESULT 238

ADM58131/c  
 ID ADM58131 standard; RNA; 17 BP.

```

XX AC ADM58131;
XX DT 03-JUN-2004 (first entry)
XX DE Hepatitis B virus (HBV) RNA target sequence #265.
XX KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
XX KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
XX KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
XX KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX OS Hepatitis B virus.
XX PN US2004054156-A1.
XX PD 18-MAR-2004.
XX PF 15-JAN-2003; 2003US-00342902.
XX PR 14-MAY-1992; 92US-00882712.
XX PR 07-FEB-1994; 94US-00193627.
XX PR 08-NOV-1999; 99US-00436430.
XX PR 20-MAR-2000; 2000US-00531025.
XX PR 09-AUG-2000; 2000US-00636385.
XX PR 24-OCT-2000; 2000US-00696347.
XX PR 08-JUN-2001; 2001US-00877478.
XX PA (DRAP/) DRAPER K.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PA (MORR/) MORRISSEY D.
XX PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX DR WPI; 2004-247781/23.
XX PT Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX PT specifically cleaving RNA derived from hepatitis B virus and comprising
XX PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX PS Disclosure; SEQ ID NO 265; 122pp; English.
XX CC The invention relates to an enzymatic nucleic acid molecule that
XX CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX CC comprising one or more binding arms, without requiring the presence of a
XX CC 2'-OH group within the molecule for activity. The nucleic acids are
XX CC useful for treating hepatitis B virus infection, hepatitis,
XX CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX CC combination with other therapies such as lamivudine and interferons. The
XX CC nucleic acids are useful as diagnostic tools to examine genetic drift and
XX CC mutations within diseased cells, for detecting the presence of HBV RNA in
XX CC a cell, for the study of RNA and for down-regulating gene expression of
XX CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX CC sequence represents an HBV RNA target sequence, used in the scope of the
XX CC invention. Note: The sequence data for this patent is also available in
XX CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 17 BP; 3 A; 4 C; 2 G; 0 T; 8 U; 0 Other;
    Query Match 0.8%; Score 14.4; DB 1; Length 17;
    Best Local Similarity 93.8%; Pred. No. 1.4e+02;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 530 AGGCATTACAGCAA 545
    |||||
DB 17 AGGCATTAAAGCAGAA 2

```

```

RESULT 239
ADM58133/c
ID ADM58133 standard; RNA; 17 BP.
XX
AC

```

```

AC ADM58133;
XX DT 03-JUN-2004 (first entry)
XX DE Hepatitis B virus (HBV) RNA target sequence #267.
XX KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;
XX KW Hepatitis B virus infection; hepatitis; hepatocellular carcinoma;
XX KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;
XX KW virucide; hepatotropic; antiinflammatory; cytostatic.
XX OS Hepatitis B virus.
XX PN US2004054156-A1.
XX PD 18-MAR-2004.
XX PF 15-JAN-2003; 2003US-00342902.
XX PR 14-MAY-1992; 92US-00882712.
XX PR 07-FEB-1994; 94US-00193627.
XX PR 08-NOV-1999; 99US-00436430.
XX PR 20-MAR-2000; 2000US-00531025.
XX PR 09-AUG-2000; 2000US-00636385.
XX PR 24-OCT-2000; 2000US-00696347.
XX PR 08-JUN-2001; 2001US-00877478.
XX PA (DRAP/) DRAPER K.
XX PA (BLAT/) BLATT L.
XX PA (MCSW/) MCSWIGGEN J A.
XX PA (MORR/) MORRISSEY D.
XX PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;
XX DR WPI; 2004-247781/23.
XX PT Novel enzymatic nucleic acid molecule such as DNazymes and inozymes
XX PT specifically cleaving RNA derived from hepatitis B virus and comprising
XX PT one or more binding arms, useful for treating hepatitis and cirrhosis.
XX PS Disclosure; SEQ ID NO 267; 122pp; English.
XX CC The invention relates to an enzymatic nucleic acid molecule that
XX CC specifically cleaves RNA derived from hepatitis B virus (HBV) and
XX CC comprising one or more binding arms, without requiring the presence of a
XX CC 2'-OH group within the molecule for activity. The nucleic acids are
XX CC useful for treating hepatitis B virus infection, hepatitis,
XX CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in
XX CC combination with other therapies such as lamivudine and interferons. The
XX CC nucleic acids are useful as diagnostic tools to examine genetic drift and
XX CC mutations within diseased cells, for detecting the presence of HBV RNA in
XX CC a cell, for the study of RNA and for down-regulating gene expression of
XX CC target genes in bacterial, fungal, viral, plant or mammalian cells. This
XX CC sequence represents an HBV RNA target sequence, used in the scope of the
XX CC invention. Note: The sequence data for this patent is also available in
XX CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX SQ Sequence 17 BP; 2 A; 4 C; 2 G; 0 T; 9 U; 0 Other;
    Query Match 0.8%; Score 14.4; DB 1; Length 17;
    Best Local Similarity 93.8%; Pred. No. 1.4e+02;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 529 AGGCATTACAGCAGA 544
    |||||
DB 16 AGGCATTAAAGCAGA 1

```

```

RESULT 240
ADI84168/c
ID ADI84168 standard; RNA; 17 BP.
XX
AC ADI84168;

```

```

XX 03-JUN-2004 (first entry)
XX HCV DNazyme substrate sequence #1414.
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX HCV infection; type I interferon; DNazyme.
XX
XX Hepatitis C virus.
XX
XX US2003125270-A1.
XX
XX 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
XX (PAVC/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1414; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX the binding arms of the enzymatic nucleic acid molecule comprises
XX sequences complementary to any of the defined substrate sequences given
XX in the specification. The nucleic acid molecule may be administered for
XX the treatment of HCV infections, especially in combination with type I
XX interferons. The present sequence represents a HCV DNazyme substrate
XX sequence.
XX
XX Sequence 17 BP; 4 A; 9 C; 2 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;
XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX Qy 1173 CTGGTGATGGAGTCTG 1188
XX Db 16 CTGGTGATGGAGGCTG 1
XX
XX RESULT 241
XX ADI86043
XX ID ADI86043 standard; RNA; 17 BP.
XX
XX AC ADI86043;
XX
XX 03-JUN-2004 (first entry)
XX
XX HCV DNazyme substrate sequence #3289.
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
XX HCV infection; type I interferon; DNazyme.
XX
XX Hepatitis C virus.
XX
XX US2003125270-A1.
XX
XX 03-JUL-2003.
XX

```

```

PF 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
XX (PAVC/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 3289; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX the binding arms of the enzymatic nucleic acid molecule comprises
XX sequences complementary to any of the defined substrate sequences given
XX in the specification. The nucleic acid molecule may be administered for
XX the treatment of HCV infections, especially in combination with type I
XX interferons. The present sequence represents a HCV DNazyme substrate
XX sequence.
XX
XX Sequence 17 BP; 2 A; 3 C; 9 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 0.8%; Score 14.4; DB 1; Length 17;
XX Best Local Similarity 75.0%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
XX
XX Qy 1005 GATGGCGGTGGAGCCT 1020
XX Db 2 GAUGGGGGUGGAGCCU 17
XX
XX RESULT 242
XX ADR27062
XX ID ADR27062 standard; DNA; 17 BP.
XX
XX AC ADR27062;
XX
XX 04-NOV-2004 (first entry)
XX
XX Human single nucleotide polymorphism detection primer #152.
XX
XX ss; primer; single nucleotide polymorphism; SNP; diagnosis;
XX disease association; linkage analysis; autoimmune disease;
XX rheumatoid arthritis; diabetes; multiple sclerosis;
XX systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
XX thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;
XX glomerulonephritis; Graves' disease; myocarditis; Sjogren disease;
XX primary systemic vasculitis; genotyping; gene therapy; PCR primer.
XX
XX Homo sapiens.
XX
XX WO2004067779-A2.
XX
XX 12-AUG-2004.
XX
XX 30-JAN-2004; 2004WO-US002652.
XX
XX 30-JAN-2003; 2003US-0443566P.
XX 18-MAR-2003; 2003US-0455444P.
XX 25-APR-2003; 2003US-0465241P.
XX 15-AUG-2003; 2003US-0495115P.
XX 13-NOV-2003; 2003US-0519270P.
XX
XX (APPL-) APPLERA CORP.

```





KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 XX skeletal muscle function.  
 XX Homo sapiens.  
 XX US2004137589-A1.  
 XX 15-JUL-2004.  
 XX 26-NOV-2003; 2003US-00723361.  
 XX 26-MAY-2000; 2000US-0207456P.  
 XX 21-SEP-2000; 2000US-0234687P.  
 XX 27-SEP-2000; 2000US-0236359P.  
 XX 04-OCT-2000; 2000GB-00024263.  
 XX 30-JAN-2001; 2001WO-US000661.  
 XX 30-JAN-2001; 2001WO-US000662.  
 XX 30-JAN-2001; 2001WO-US000663.  
 XX 30-JAN-2001; 2001WO-US000664.  
 XX 30-JAN-2001; 2001WO-US000665.  
 XX 30-JAN-2001; 2001WO-US000666.  
 XX 30-JAN-2001; 2001WO-US000667.  
 XX 30-JAN-2001; 2001WO-US000668.  
 XX 30-JAN-2001; 2001WO-US000669.  
 XX 05-FEB-2001; 2001WO-US000670.  
 XX 25-MAY-2001; 2001US-0266860P.  
 XX 25-MAY-2001; 2001US-00866108.  
 XX (GUY/) GU Y.  
 XX (JIY/) JI Y.  
 XX (PENN/) PENN S G.  
 XX (HANZ/) HANZEL D K.  
 XX (RANK/) RANK D.  
 XX (CHEN/) CHEN W.  
 XX (SHAN/) SHANNON M E.  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 XX WPI; 2004-533378/51.  
 XX Novel myosin-like protein-1, useful for treating or preventing disorder  
 XX associated with decreased expression or activity of human genome-derived  
 XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 XX function.  
 XX Disclosure; SEQ ID NO 8365; Opp; English.  
 XX The invention relates to a novel polypeptide (I) comprising a sequence  
 XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
 XX defined in the specification, a fragment of at least 8 amino acids of  
 XX (S1), 95% deviation from (S1) which are conservative substitutions, and  
 XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
 XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 XX pharmaceutical composition of the invention is useful for treating or  
 XX preventing a disorder associated with decreased expression or activity of  
 XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 XX The present sequence represents a 17-mer nucleotide, used in the  
 XX invention for scanning the sequence represented in ACN63103  
 XX  
 XX Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;  
 XX  
 XX Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 395 GCTGGAGAAAGTTTCAC 410  
 Db 1 GCTGGAGAAAGTGCAC 16  
 RESULT 245  
 ACN73129/C  
 ID ACN73129 standard; DNA; 17 BP.

XX ACN73129;  
 XX 02-DEC-2004 (first entry)  
 XX Human GDMPLP-1 probe SEQ ID NO:10031.  
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 XX skeletal muscle function.  
 XX Homo sapiens.  
 XX US2004137589-A1.  
 XX 15-JUL-2004.  
 XX 26-NOV-2003; 2003US-00723361.  
 XX 26-MAY-2000; 2000US-0207456P.  
 XX 21-SEP-2000; 2000US-0234687P.  
 XX 27-SEP-2000; 2000US-0236359P.  
 XX 04-OCT-2000; 2000GB-00024263.  
 XX 30-JAN-2001; 2001WO-US000661.  
 XX 30-JAN-2001; 2001WO-US000662.  
 XX 30-JAN-2001; 2001WO-US000663.  
 XX 30-JAN-2001; 2001WO-US000664.  
 XX 30-JAN-2001; 2001WO-US000665.  
 XX 30-JAN-2001; 2001WO-US000666.  
 XX 30-JAN-2001; 2001WO-US000667.  
 XX 30-JAN-2001; 2001WO-US000668.  
 XX 30-JAN-2001; 2001WO-US000669.  
 XX 05-FEB-2001; 2001WO-US000670.  
 XX 25-MAY-2001; 2001US-0266860P.  
 XX 25-MAY-2001; 2001US-00866108.  
 XX (GUY/) GU Y.  
 XX (JIY/) JI Y.  
 XX (PENN/) PENN S G.  
 XX (HANZ/) HANZEL D K.  
 XX (RANK/) RANK D.  
 XX (CHEN/) CHEN W.  
 XX (SHAN/) SHANNON M E.  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 XX WPI; 2004-533378/51.  
 XX Novel myosin-like protein-1, useful for treating or preventing disorder  
 XX associated with decreased expression or activity of human genome-derived  
 XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 XX function.  
 XX Disclosure; SEQ ID NO 10031; Opp; English.  
 XX The invention relates to a novel polypeptide (I) comprising a sequence  
 XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
 XX defined in the specification, a fragment of at least 8 amino acids of  
 XX (S1), 95% deviation from (S1) which are conservative substitutions, and  
 XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
 XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 XX pharmaceutical composition of the invention is useful for treating or  
 XX preventing a disorder associated with decreased expression or activity of  
 XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 XX The present sequence represents a 17-mer nucleotide, used in the  
 XX invention for scanning the sequence represented in ACN63103  
 XX  
 XX Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;  
 XX  
 XX Query Match 0.8%; Score 14.4; DB 1; Length 17;  
 XX Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
 XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 CGTCCAAAGAGGACTC 1080  
Db 16 CGTCCACAGAGGACTC 1

RESULT 246  
ACN71462  
ID ACN71462 standard; DNA; 17 BP.  
XX AC ACN71462;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPL-1 probe SEQ ID NO:8364.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPL-1;  
KW hGDMPL-1 agonist hGDMPL antagonist; hGDMPL inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
XX Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PEN/) PEN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEW/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
XX  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
XX Disclosure; SEQ ID NO 8364; Opp; English.  
XX  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPL-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 68% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPL-1, or as an inhibitor of hGDMPL-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPL-1, such as a disorder of heart and/or skeletal muscle function.  
CC  
CC The present sequence represents a 17-mer nucleotide, used in the

CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 6 A; 3 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 0.8%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.4e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 395 GCTGGAGAAAGTTTCAC 410  
Db 2 GCTGGAGAAAGTGCAC 17

RESULT 247  
AAZ25403  
ID AAZ25403 standard; DNA; 18 BP.  
XX  
AC AAZ25403;  
XX  
DT 16-DEC-1999 (first entry)  
XX  
DE Infectious pancreatic necrosis virus PCR primer #5.  
XX  
KW Infectious pancreatic necrosis virus; IPNV; strain West Buxton;  
KW strain SP; segment A; segment B; nonpathogenic; Birnaviridae family;  
KW infection; live attenuated vaccine; aquaculture industry; Rainbow trout;  
KW Brook trout; Atlantic salmon; PCR primer; ss.  
XX  
OS Synthetic.  
OS Infectious pancreatic necrosis virus.  
XX  
PN WO9950419-A2.  
XX  
PD 07-OCT-1999.  
XX  
PF 31-MAR-1999; 99WO-US004285.  
XX  
PR 31-MAR-1998; 98US-0080178P.  
XX  
PA (UYMA-) UNIV MARYLAND BIOTECHNOLOGY INST.  
XX  
PI Vakharia VN, Yao K;  
XX WPI; 1999-591321/50.  
XX  
XX Preparing nonpathogenic infectious pancreatic necrosis virus, IPNV,  
PT useful for producing attenuated virus for vaccines useful in the  
PT aquaculture industry.  
XX  
XX Example 1; Page 35; 63pp; English.  
XX  
XX A method has been developed for preparing nonpathogenic, infectious  
CC pancreatic necrosis virus (IPNV). The method comprises: 1) preparing cDNA  
CC containing the IPNV genome segments A and B where A is modified to  
CC prevent expression of an arginine-rich non-structural (NS) protein; 2)  
CC transcribing the cDNA to produce RNA; 3) incubating the host cells in a  
CC culture medium; and 4) isolating live IPNV from the culture medium. The  
CC method is useful to produce live nonpathogenic IPNV, useful to study  
CC viral pathogenesis and for the production of live, nonpathogenic IPNV  
CC vaccines, since it was demonstrated that the NS protein-deficient virus  
CC could replicate but did not invoke a pathological response in hosts.  
CC Combination vaccines may also be produced by combining the IPNV with  
CC bacterial antigens (especially from gram negative bacteria e.g. Aeromonas  
CC salmonicida) and/or antigens from aquatic viruses other than Birnaviruses  
CC (the family to which IPNV belongs) e.g. infectious haematopoietic  
CC necrosis virus. The method may also be used to generate a nonpathogenic  
CC chimeric virus when the cDNA of segment A encodes epitopic determinants  
CC from at least two different IPNV strains. IPNV causes a highly contagious  
CC and destructive disease of juvenile Rainbow and Brook trout and Atlantic  
CC salmon (e.g. highly virulent strains can cause more than 90 % mortality  
CC in hatchery stocks less than 4 months old and survivors can remain  
CC lifelong carriers and reservoirs of infection); IPNV is therefore a  
CC pathogen of major economic importance to the aquaculture industry. The

CC present sequence represents an IPNV PCR primer used in an example from  
 CC the present invention  
 XX  
 SQ Sequence 18 BP; 4 A; 3 C; 6 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 450 GAATCAGCTGTGATGC 465  
 ||||| |||||  
 Db 3 GAATCAGCTGTGATGC 18

RESULT 248  
 AAA10847/C  
 ID AAA10847 standard; DNA; 18 BP.  
 XX  
 AC AAA10847;  
 XX  
 DT 14-JUL-2000 (first entry)  
 XX  
 DE G-alpha-i1 antisense oligonucleotide ISIS# 25748.  
 XX  
 KW G-alpha-i1; G protein; adenyl cyclase hormonal inhibition; tumour;  
 KW plasma membrane regulation; antisense composition; treatment; prevent;  
 KW delay; infection; inflammation; tumour formation; research; diagnose; ss.  
 XX  
 OS Synthetic.  
 XX  
 XX US6046321-A.  
 XX  
 XX 04-APR-2000.  
 XX  
 XX 09-APR-1999; 99US-00289377.  
 XX  
 PR 09-APR-1999; 99US-00289377.  
 XX  
 XX (ISIS-) ISIS PHARM INC.  
 XX  
 XX Cowser LM;  
 XX  
 DR WPI; 2000-292434/25.  
 XX  
 XX New antisense compounds targeting nucleic acids encoding human G-alpha-i1  
 PT useful for modulating G-alpha-i1 expression and for treating diseases  
 PT associated with G-alpha-i1 expression.  
 XX  
 XX Example 15; Col 38; 31pp; English.  
 XX  
 XX Human G-alpha-i1 is a member of the Gi subfamily of G proteins which is  
 CC involved in hormonal inhibition of adenylyl cyclase and in the regulation  
 CC of plasma membrane enzymes. The expression of G-alpha-i1 is altered in  
 CC some tumours. The present sequence is a G-alpha-i1 antisense  
 CC oligonucleotide, which can be used to inhibit the expression of human G-  
 CC alpha-i1. The invention relates to antisense oligonucleotides represented  
 CC in AAA10814-A10853, which can be used in the treatment of diseases or  
 CC condition associated with the expression of G-alpha-i1 by modulating the  
 CC expression of G-alpha-i1 in cells or tissues. The antisense compositions  
 CC may also be used prophylactically, e.g. to prevent or delay infection,  
 CC inflammation, or tumour formation. Furthermore, the antisense  
 CC oligonucleotides may also be useful in research and diagnostics, e.g. in  
 CC detecting nucleic acids encoding G-alpha-i1 by conjugation of an enzyme  
 CC to the oligonucleotide, or radiolabelling the oligonucleotide. Kits using  
 CC such detection means for detecting the level of G-alpha-i1 in the sample  
 CC may also be prepared. Antisense oligonucleotides, which are able to  
 CC inhibit specific gene expression, are often used to elucidate the  
 CC function of particular genes. These antisense compounds are also used to  
 CC distinguish between functions of various members of a biological pathway

SQ Sequence 18 BP; 3 A; 5 C; 1 G; 9 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 807 GAAGATGCAGAAATGA 822  
 ||||| |||||  
 Db 16 GAAGATGCAGAAATGA 1

RESULT 249  
 AAA86639/C  
 ID AAA86639 standard; DNA; 18 BP.  
 XX  
 AC AAA86639;  
 XX  
 DT 04-DEC-2000 (first entry)  
 XX  
 DE Cdc 2 kinase hammerhead ribozyme recogniton site #70.  
 XX  
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.  
 XX  
 OS Mammalia.  
 XX  
 XX WO200032765-A2.  
 XX  
 XX 08-JUN-2000.  
 XX  
 PF 06-DEC-1999; 99WO-US028772.  
 XX  
 XX 04-DEC-1998; 98US-0110954P.  
 XX  
 XX (IMMU-) IMMUSOL INC.  
 XX  
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;  
 XX  
 DR WPI; 2000-412314/35.  
 XX  
 XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves  
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,  
 PT PCNA and Cyclin B1.  
 XX  
 XX Example 1; Page 19; 109pp; English.  
 XX  
 XX The present invention relates to a hairpin or hammerhead ribozyme,  
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase  
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.  
 CC Representative examples of ribozyme recognition sites are given in  
 CC AAA82415 to AAA86787. The ribozyme of the invention is useful for  
 CC inhibiting restenosis by introduction of the ribozyme into cells. The  
 CC ribozyme is resistant to endonuclease activity and hence is efficient in  
 CC restenosis treatment

SQ Sequence 18 BP; 7 A; 2 C; 4 G; 5 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 1376 ATACAGTATTCTTC 1391  
 ||||| |||||  
 Db 16 ATCCAGTATTCTTC 1

RESULT 250  
 AAA58514/C  
 ID AAA58514 standard; DNA; 18 BP.  
 XX  
 AC AAA58514;  
 XX  
 XX 20-OCT-2000 (first entry)  
 XX  
 DE PCR primer used to amplify bleomycin (BLM) gene cluster ORF28.  
 XX  
 KW BLM gene cluster; bleomycin gene cluster; polyketide metabolite;

KW bleomycin; bleomycin analogue; holo-carrier protein; thiazolidine;  
 KW thiazoline; bithiazoline; microbial metabolite; sugar; PCR primer; ss.  
 OS Streptomyces verticillus.  
 XX WO200040704-A1.  
 XX 13-JUL-2000.  
 XX 06-JAN-2000; 2000WO-US000445.  
 XX 06-JAN-1999; 99US-0115435P.  
 PR 05-FEB-1999; 99US-0118848P.  
 PR 05-JAN-2000; 2000US-00477962.  
 XX (REGC ) UNIV CALIFORNIA.  
 PA Shen B, Du L, Sanchez C, Chen M, Edwards DJ;  
 PI WPI; 2000-465974/40.  
 DR New bleomycin gene cluster components useful for peptide and/or  
 PT polyketide metabolites, especially bleomycin, production and for  
 PT chemically modifying biological molecules.  
 XX Disclosure; Page 22; 162pp; English.  
 XX PCR primers AA58474-A58541 were used to amplify open reading frames  
 CC (ORFs) 8 to 41 of the BLM (Bleomycin) gene cluster. The proteins encoded  
 CC by the gene cluster are useful for producing peptides and/or polyketide  
 CC metabolites, especially bleomycin or bleomycin analogues. They are also  
 CC useful for chemically modifying biological molecules to produce branched  
 CC methyl groups, and for coupling amino acids and fatty acids. They may be  
 CC reacted with an apo-carrier protein and coenzyme A to produce a holo-  
 CC carrier protein. The BLM gene cluster or catalytic domains can be used  
 CC individually or collectively to produce thiazolidine, thiazoline,  
 CC bithiazoline and bithiazoline-containing microbial metabolites. The BLM  
 CC gene cluster may also be used to produce sugars  
 XX Sequence 18 BP; 6 A; 5 C; 5 G; 2 T; 0 U; 0 Other;  
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1292 TCAGTCTCTGAGCCAT 1307  
 DB ||||| ||||| |||||  
 16 TCAGTCTCTGTGCCAT 1  
 RESULT 251  
 AAH61805/c  
 ID AAH61805 standard; DNA; 18 BP.  
 XX AC AAH61805;  
 XX DT 10-SEP-2001 (first entry)  
 XX Cdc 2 kinase hammerhead ribozyme recognition site SEQ ID NO:4229.  
 XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;  
 KW recognition site; target; ribozyme binding site; eye disease; vulnery;  
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;  
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;  
 KW matrix metalloproteinase; growth factor; reductase; scarring; cyrostatic;  
 KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;  
 KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;  
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;  
 KW sickle cell retinopathy; ss.  
 XX Homo sapiens.  
 OS Synthetic.

XX WO200130362-A2.  
 XX 03-MAY-2001.  
 XX 26-OCT-2000; 2000WO-US029500.  
 XX 26-OCT-1999; 99US-0161532P.  
 XX (IMMU-) IMMUSOL INC.  
 XX Robbins JM, Tritz R;  
 XX WPI; 2001-300427/31.  
 XX Treating proliferative skin or eye diseases and scarring, using ribozymes  
 PT that cleave RNA encoding cytokines involved in inflammation, matrix  
 PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
 XX Disclosure; Page 381; 408pp; English.  
 XX The present invention describes a method for treating a proliferative  
 CC skin or eye disease and scarring. The method involves administering a  
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
 CC dependent kinase, growth factor or a reductase, or administering a  
 CC nucleic acid molecule (II) comprising a promoter operably linked to a  
 CC nucleic acid segment encoding (I). (I) can have antipsoriatic,  
 CC dermatological, cyrostatic, antiseborrheic, antidiabetic, antisickling,  
 CC ophthalmological, vulnery, keratolytic and virucide activities, and  
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
 CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
 CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
 CC also be used for treating proliferative eye diseases such as diabetic  
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
 CC prematurity and retinal detachment, and for treating and preventing  
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
 CC scar. AAH57577 to AAH62099 represent sequences used in the  
 CC exemplification of the present invention  
 XX Sequence 18 BP; 7 A; 2 C; 4 G; 5 T; 0 U; 0 Other;  
 SQ Query Match 0.8%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 1376 ATACAAGTATTCTTC 1391  
 DB ||||| ||||| |||||  
 16 ATCCAAGTATTCTTC 1  
 RESULT 252  
 ABZ72355  
 ID ABZ72355 standard; DNA; 18 BP.  
 XX AC ABZ72355;  
 XX DT 03-APR-2003 (first entry)  
 XX Gene 216 polymorphism genotyping A50 primer SEQ ID NO 327.  
 XX Human; Gene 216; chromosome 20p13-p12; antiaesthatic; anorectic;  
 KW antiinflammatory; gastrointestinal; gene therapy; vaccine; asthma;  
 KW obesity; inflammatory bowel disease; primer; ss.  
 OS Synthetic.  
 XX WO200178894-A2.  
 XX 25-OCT-2001.  
 XX 13-APR-2001; 2001WO-US012245.

```
XX 13-APR-2000; 2000US-00548797.
XX (GENO-) GENOME THERAPEUTICS CORP.
XX Keith T;
XX WPI; 2001-639428/73.
XX Isolated genes (Gene 216) from human chromosome 20p13-p12 and the
XX proteins they encode, useful for the prevention, diagnosis and treatment
XX of asthma, obesity and inflammatory bowel disease.
XX Example 11; Page 156; 520pp; English.
XX The invention relates to isolated genes (Gene 216) from human chromosome
XX 20p13-p12 and the proteins they encode. The nucleic acids and proteins
XX associated with inappropriate Gene 216 expression. For example, the
XX nucleic acids (or vectors) and proteins may be used to treat disorders
XX associated with decreased expression by rectifying mutations or deletions
XX in a patient's genome that affect the activity of gene 216 by expressing
XX inactive proteins or to supplement the patients own production of Gene
XX 216 proteins. Additionally, the nucleic acids may be used to produce the
XX secreted Gene 216 protein, by inserting the nucleic acids into a host
XX cell and culturing the cell to express the protein. The nucleic acids and
XX complementary sequences may also be used as DNA probes in diagnostic
XX assays to detect and quantitate the presence of similar nucleic acid
XX sequences in samples and therefore which patients may be in need of
XX restorative therapy. The Gene 216 protein may also be used as antigens in
XX the production of antibodies against Gene 216 and in assays to identify
XX modulators of Gene 216 expression and activity. The anti-Gene 216
XX antibodies and antagonists may also be used to down regulate expression
XX and activity. The anti-Gene 216 antibodies may also be used as diagnostic
XX agents for detecting the presence of Gene 216 proteins in samples (e.g.
XX by enzyme linked immunosorbant assay or ELISA). Disorders that may be
XX prevented, diagnosed and/or treated by the above methods include, for
XX example asthma, obesity and inflammatory bowel disease. The present
XX sequence is that of a Gene 216 related primer used in examples of the
XX invention. The primers are used in the physical mapping of the gene
XX (ABZ72067-ABZ72088), polymorphism identification using single strand
XX conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184),
XX sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362)
XX
XX Sequence 18 BP; 1 A; 3 C; 9 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. NO. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 453 TCAGCTGTGATGCTGG 468
Db 3 TCAGCTGTGCTGGTGG 18
|||||
RESULT 253
AAD40167/c
ID AAD40167 standard; DNA; 18 BP.
XX AAD40167;
XX
XX 22-OCT-2002 (first entry)
XX Cauliflower mosaic virus 35S promoter target DNA.
XX Identification; production; DNA binding protein; gene construct;
XX target gene regulator; therapeutic; gene; ds.
XX Cauliflower mosaic virus.
XX WO200240632-A2.
XX 23-MAY-2002.
```

```
XX 16-NOV-2001; 2001WO-US043107.
XX 17-NOV-2000; 2000US-0249546P.
XX (WISE/) WISE J G.
XX (FROM/) FROMKNECHT K.
XX Wise JG, Fromknecht K;
XX WPI; 2002-500212/53.
XX Deriving DNA binding protein sequence binding to target regulatory
XX sequence comprises selecting sequence for protein, mutating it, and
XX providing to cell having reporter/separator gene and screening for gene
XX expression.
XX Example 2; Fig 4; 90pp; English.
XX The invention relates to methods for identification and production of new
XX DNA binding proteins that up or down regulate the expression of pre-
XX determined target genes. Such genes include DNA sequences that encode
XX proteins that regulate such target genes as well as gene constructs and
XX biological materials that contain such DNA binding proteins and/or their
XX DNA sequences. The method is useful for deriving a gene sequence of a new
XX DNA binding protein that can bind to a target regulatory sequence where
XX the gene sequence derived is useful as a tool for controlling gene
XX expression and as therapeutics. The present sequence is Cauliflower
XX mosaic virus 35S promoter target DNA used to illustrate the method of the
XX invention
XX Sequence 18 BP; 7 A; 2 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.8%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. NO. 1.5e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 97 AAATGAATTCCTTAT 112
Db 16 AAATGAATTCCTTAT 1
|||||
RESULT 254
AAD40589/c
ID AAD40589 standard; DNA; 18 BP.
XX AAD40589;
XX
XX 30-OCT-2002 (first entry)
XX HIV-1 LTR luciferase reporter gene mutant fragment, A7.
XX Human immunodeficiency virus; HIV; infection; transcriptional repressor;
XX ORF18; brain; polymorphonuclear blood mononucleocyte; neuronal injury;
XX CD4+ T cell; antiretroviral; mononuclear phagocyte; MP; macrophage;
XX gene therapy; anti-HIV; mutant; ds.
XX Human immunodeficiency virus 1.
XX Synthetic.
XX WO200235981-A2.
XX 10-MAY-2002.
XX 06-NOV-2001; 2001WO-US044336.
XX 06-NOV-2000; 2000US-0246331P.
XX 06-APR-2001; 2001US-00828648.
XX (UNYNE-) UNIV NEBRASKA.
XX Ikezu T, Leisman G, Carlson KA, Gendelman HE;
XX
```

DR WPI; 2002-519218/55.

XX New truncated OTK18 transcriptional repressor protein, useful for

PT treating human immunodeficiency virus infection and for identifying OTK18

PT expression in a biological sample.

XX

XX Example 2; Fig 11A; 96pp; English.

PS

XX The invention relates to methods and compositions for the treatment of

XX human immunodeficiency virus (HIV) infection. The invention also relates

CC to OTK18 transcriptional repressor protein and its corresponding nucleic

CC acid. An antibody to OTK18 is useful for identifying OTK18 expression in

CC a biological sample (e.g. polymorphonuclear blood mononuclear cells, brain

CC tissue, macrophages and CD4+ T cells). OTK18 is used for treating HIV

CC infection. It is useful for screening molecules that modulate or affect

CC its activity. Its antibody is useful for identifying multinuclear giant

CC cells in HIV encephalitic brains or immune activated mononuclear

CC phagocytes (MP) in the brains, for fluorescent activated cell sorting

CC (FACS) analysis of peripheral blood cells to evaluate the antiretroviral

CC reaction of MP and for immunoprecipitating proteins from a sample

CC containing a mixture of proteins and other biological molecules. OTK18

CC molecules are useful in the treatment and diagnosis of HIV infection, as

CC research tools to identify the control of gene expression in response to

CC HIV infection and subsequent neuronal injury. OTK18 DNA is useful in gene

CC therapy. The present sequence is HIV-1 LTR luciferase reporter gene

CC derived mutant DNA fragment used to illustrate the method of the

CC invention

XX

SQ Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 956 GGTCAGTGGACATCTG 971

Db 16 GGTCAGTGGATATCTG 1

RESULT 255

ID ABX75208

XX ABX75208 standard; DNA; 18 BP.

XX

AC ABX75208;

XX

XX 25-MAR-2003 (first entry)

DT

DE Human 216 gene allele specific oligonucleotide probe #39.

XX

XX Human; mouse; ss; probe; gene 216; antiasthmatic; antiinflammatory;

KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;

KW gene therapy; respiratory disease; asthma; obesity;

KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;

KW adult respiratory distress syndrome; inflammatory bowel syndrome.

XX

OS Homo sapiens.

XX

XX WO200283077-A2.

PN

XX 24-OCT-2002.

XX

XX 15-APR-2002; 2002WO-US012063.

PF

XX 13-APR-2001; 2001US-00834597.

PR

XX 13-APR-2001; 2001WO-US012245.

PR

XX (SCHE ) SCHERING CORP.

PA

XX (GENO-) GENOME THERAPEUTICS CORP.

PA

XX Keith T, Little RD, Van Eerdewegh P, Dupuis J, Del Mastro RG;

PI Simon J, Allen K, Pandit S;

PI

XX WPI; 2003-092960/08.

DR

XX New isolated gene 216 nucleic acids, useful for diagnosing, preventing or

PT treating a disorder, such as asthma, bronchial hyper-responsiveness,

PT chronic obstructive pulmonary disease, obesity or inflammatory bowel

PT syndrome.

XX

XX Example 10; Page 166; 650pp; English.

PS

XX This invention relates to a novel isolated nucleic acid, gene 216,

CC identified from human chromosome 20p13-p12. The invention also discloses

CC regions of the 216 gene that contain single nucleotide polymorphisms

CC (SNP's) which may be used as markers for disease susceptibility or

CC severity. The nucleotides of the invention may have antiasthmatic,

CC antiinflammatory or anorectic activities and may be used in gene therapy.

CC The nucleic acids, antibodies or its fragments are useful for diagnosing,

CC preventing or treating a disorder, such as respiratory diseases (e.g.

CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary

CC disease or adult respiratory distress syndrome), obesity, or inflammatory

CC bowel syndrome. The nucleic acids are also useful for identifying

CC increased susceptibility of a subject to the disorders mentioned. The

CC nucleic acids can also be used as primers and templates for the

CC recombinant production of disorder-associated peptides or polypeptides,

CC for chromosome and gene mapping, or for tissue distribution studies. The

CC present sequence represents a gene 216 specific oligonucleotide probe

CC used in the scope of the invention

XX

SQ Sequence 18 BP; 1 A; 3 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 453 TCAGCTGTGATCTGG 468

Db 3 TCAGCTGTGCTGCTGG 18

RESULT 256

ID ABZ81757/C

XX ABZ81757 standard; DNA; 18 BP.

XX

AC ABZ81757;

XX

XX 11-JUN-2003 (first entry)

DT

DE Huntington's disease exon 1 triplet repeat sequence.

XX

XX Huntington's disease; nootropic; anticonvulsant; huntingtin; human;

KW gene therapy; ss.

XX

OS Homo sapiens.

XX

XX WO2003013437-A2.

PN

XX 20-FEB-2003.

PD

XX 07-AUG-2002; 2002WO-US025352.

PF

XX 07-AUG-2001; 2001US-0310757P.

PR

XX 08-AUG-2001; 2001US-0310770P.

PR

XX 04-DEC-2001; 2001US-0310889P.

PR

XX (UYDE ) UNIV DELAWARE.

PA

XX Kmiec EB, Parekh-Olmedo H;

PI

XX WPI; 2003-256478/25.

DR

XX New single stranded oligonucleotides comprising a DNA domain having at

PT least one mismatch with respect to the genetic sequence of the

PT Huntington's disease gene to be altered, useful for treating or

PT preventing Huntington's disease.

SQ Sequence 18 BP; 1 A; 9 C; 0 G; 8 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 93.8%; Pred. No. 1.5e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0

QY 1104 GAAGAACAAAGTGGAG 1119  
 ||||| |||||  
 Db 18 GAAGAACAAAGTGGAG 3

RESULT 258  
 ADD94304  
 ID ADD94304 standard; DNA; 18 BP.  
 XX AC ADD94304;  
 AC  
 XX 29-JAN-2004 (first entry)  
 DT  
 XX  
 XX Mouse HUI77/HUIV26 antibody related PCR primer SeqID189.  
 XX grafted antibody; complementarity determining region; CDR; light CDR;  
 KW heavy CDR; cryptic collagen epitope; solid tumour;  
 KW new blood vessel growth; angiogenesis; tumour growth; cytostatic;  
 KW collagen agonist; collagen antagonist; cancer metastasis;  
 KW anti-cryptic collagen; HUI77; HUIV26; mouse; murine; PCR; primer; ss;  
 KW heavy chain.  
 XX  
 XX Mus musculus.  
 OS  
 XX WO2003046204-A2.  
 PN  
 XX 05-JUN-2003.  
 PD  
 XX  
 XX 26-NOV-2002; 2002WO-US038147.  
 PF  
 XX 26-NOV-2001; 2001US-00995529.  
 PR  
 XX 06-DEC-2001; 2001US-00011250.  
 PR  
 XX (CELL-) CELL MATRIX INC.  
 PA  
 XX  
 XX Watking JD, Huse WD, Tang Y, Broek D, Brooks PC;  
 PI WPI; 2003-513649/48.  
 XX  
 XX New cryptic collagen antibody with one or more complementarity  
 PT determining regions, useful for diagnosing and treating disorders  
 PT associated with angiogenesis, tumor growth and/or cancer metastasis.  
 PT  
 XX Example 1; SEQ ID NO 189; 232pp; English.  
 PS  
 XX This invention relates to a novel grafted antibody or its functional  
 CC fragment comprising one or more complementarity determining regions  
 CC (CDRs) of a defined light CDR and a heavy CDR with at least one amino  
 CC acid (aa) substitution where the antibody has specific binding activity  
 CC for a cryptic collagen epitope. The growth of all solid tumours requires  
 CC new blood vessel growth, angiogenesis, inhibition of which is an approach  
 CC to limiting tumour growth. The invention may allow development of  
 CC therapeutics with a cytostatic activity as a collagen agonist or  
 CC antagonist. The invention is useful for diagnosing and treating disorders  
 CC associated with angiogenesis, tumour growth and/or cancer metastasis. The  
 CC present sequence is that of a mutagenic PCR primer for amplification of  
 CC the sequence encoding the light chain of mouse HUI77 or HUIV26 antibodies  
 CC and used in the exemplification of the invention.  
 CC  
 XX

SQ Sequence 18 BP; 0 A; 3 C; 4 G; 7 T; 0 U; 4 Other;  
 Query Match 0.8%; Score 14.4; DB 1; Length 18;  
 Best Local Similarity 75.0%; Pred. No. 1.5e+02;  
 Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0

QY 1444 ATGTTGCTGCTGTGT 1459  
 :||:|||||||:

Db 1 RTRTCTGCTGCTRT 16

RESULT 259  
ADH71082/c  
ID ADH71082 standard; DNA; 18 BP.  
XX  
XX  
AC ADH71082;  
XX  
XX  
XX 25-MAR-2004 (first entry)  
XX  
XX Human Vbeta microsatellite primer #25.  
XX  
XX human; T-cell associated disease; Vbeta; autoimmune disease;  
KW degenerative nervous system disease; graft versus host disease;  
KW hypersensitivity disease; infectious disease; neoplastic disease;  
KW Addison's disease; atrophic gastritis;  
KW degenerative nervous system disease; multiple sclerosis;  
KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;  
KW allergy; type II hypersensitivity; Goodpasture's syndrome;  
KW type IV hypersensitivity; leprosy; infectious disease; viral infection;  
KW HIV; fungal infection; Candida; parasitic infection; schistosoma;  
KW filaria; bacterial infection; Mycobacterium; neoplastic disease;  
KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;  
KW breast cancer; ss; primer; microsatellite.  
XX  
XX Homo sapiens.  
XX  
XX US2002150891-A1.  
XX  
XX 17-OCT-2002.  
XX  
XX 05-MAR-1999; 99US-00263959.  
XX  
XX 19-SEP-1994; 94US-00309335.  
XX 19-SEP-1995; 95US-00531241.  
XX  
XX (HOOD/) HOOD L E.  
XX (HOWE/) ROWEN L.  
XX  
XX Hood LE, Rowen L;  
XX  
XX WPI; 2004-059052/06.  
XX  
XX Kit for diagnosing and treating T-cell associated diseases e.g.  
PT autoimmune, degenerative nervous system and infectious disease, comprises  
PT nucleic acid primers specifically priming and allowing amplification of a  
PT Vbeta gene.  
XX  
XX Disclosure; SEQ ID NO 1276; 164pp; English.  
XX  
XX The invention relates to a kit for diagnosing and treating T-cell  
XX associated diseases which comprises a panel of nucleic acid primers  
XX specifically priming and allowing amplification of each Vbeta gene,  
XX VbetapNA or cDNA. The kit is useful for diagnosing organ transplant  
XX rejection and diagnosing and treating T-cell associated diseases  
XX including autoimmune diseases, degenerative nervous system diseases,  
XX graft versus host disease, hypersensitivity diseases, infectious diseases  
XX and neoplastic diseases. Autoimmune diseases include Addison's disease,  
XX atrophic gastritis. Degenerative nervous system diseases include multiple  
XX sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type  
XX I hypersensitivities such as contact with allergens that lead to  
XX allergies, type II hypersensitivities such as those present in  
XX Goodpasture's syndrome and type IV hypersensitivities such as those  
XX manifested in leprosy. Infectious diseases include viral infections  
XX caused by viruses such as HIV, fungal infections such as those caused by  
XX the yeast genus Candida, parasitic infections such as those caused by  
XX schistosomes, filaria and bacterial infections such as those caused by  
XX Mycobacterium. Neoplastic diseases include lymphoproliferative diseases  
XX such as leukaemias, lymphomas and cancers such as cancer of the brain,  
XX breast. The present sequence represents a Vbeta microsatellite primer.  
XX  
XX Sequence 18 BP; 3 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.5e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1335 ATCCAAAGCTGGAGTGC 1350  
DB 17 ATCCAGGCTGGAGTGC 2  
||||| |||||||  
RESULT 260  
ADJ36936  
ID ADJ36936 standard; DNA; 18 BP.  
XX  
XX ADJ36936;  
AC  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE Gene 216 related allele specific oligonucleotide seq id 327.  
XX  
KW antiasthmatic; respiratory; gene therapy; asthma;  
KW bronchial hyperresponsiveness; atopy; chronic obstructive lung disease;  
KW adult respiratory distress syndrome; obesity; inflammatory bowel disease;  
KW human; gene 216; single nucleotide polymorphism; SNP;  
KW allele specific oligonucleotide; ASO; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX US2004002470-A1.  
PN  
XX  
XX 01-JAN-2004.  
PD  
XX  
XX 17-OCT-2002; 2002US-00277216.  
PF  
XX  
XX 13-APR-2000; 2000US-00548797.  
PR 13-APR-2001; 2001US-00834597.  
PR 19-APR-2002; 2002US-00126022.  
XX  
XX (KEIT/) KEITH T.  
XX (LITT/) LITTLE R D.  
XX (VEER/) VAN EERDEWEGH P.  
XX (DUPU/) DUPUIS J.  
XX (DMAS/) DEL MASTRO R G.  
XX (SIMO/) SIMON J.  
XX (ALLE/) ALLEN K.  
XX (PAND/) PANDIT S.  
XX  
XX Keith T, Little RD, Eerdewegh PV, Dupuis J, Del Mastro RG;  
PI Simon J, Allen K, Pandit S;  
XX  
XX WPI; 2004-061675/06.  
DR  
XX  
XX Gene 216 nucleic acid, useful for preparing a composition for treating  
PT disorders e.g., asthma, bronchial hyperresponsiveness, atopy, chronic  
PT obstructive lung disease and adult respiratory distress syndrome.  
XX  
XX Example 11A; SEQ ID NO 327; 441pp; English.  
PS  
XX  
XX The invention describes a new isolated nucleic acid comprising a fully  
XX defined sequence having 23574 bp or at least its 50 or 15 contiguous  
XX nucleotides and includes: allele G of single nucleotide polymorphism  
XX (SNP) AB+2; allele G of SNP BC+1; and allele C of SNP BC+2. The invention  
XX describes identifying increased susceptibility to a disorder comprising  
XX asthma, bronchial hyperresponsiveness, atopy, chronic obstructive lung  
XX disease and adult respiratory distress syndrome in a subject comprising  
XX testing a biological sample obtained from a subject for the presence of  
XX at least one allele or haplotype given in the specification, where the  
XX presence identifies an increased susceptibility to the disorder. The  
XX nucleic acid is useful for preparing a composition for treating disorders  
XX comprising asthma, bronchial hyperresponsiveness, atopy, chronic  
XX obstructive lung disease and adult respiratory distress syndrome. This  
XX sequence represents an allele specific oligonucleotide used in the  
XX polymorphism genotyping of human gene 216 single nucleotide



QY 453 TCAGCTGTGATGCTGG 468

KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;  
KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;  
KW basal cell carcinoma; seboreic wart; vitreoretinopathy; scar;  
KW sickle cell retinopathy; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX W0200130362-A2.  
PN  
XX  
XX 03-MAY-2001.  
XX  
XX 26-OCT-2000; 2000WO-US029500.  
XX  
XX 26-OCT-1999; 99US-0161532P.  
XX (IMMU-) IMMUSOL INC.  
XX PA  
XX Robbins JM, Tritz R;  
PI  
XX WPI; 2001-300427/31.  
DR  
XX  
XX Treating proliferative skin or eye diseases and scarring, using ribozymes  
PT that cleave RNA encoding cytokines involved in inflammation, matrix  
PT metalloproteinases, growth factors and cell-cycle dependent kinases.  
XX  
XX Example 1; Page 294; 408pp; English.  
XX  
XX The present invention describes a method for treating a proliferative  
CC skin or eye disease and scarring. The method involves administering a  
CC ribozyme (I) which cleaves RNA encoding a cytokine involved in  
CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle  
CC dependent kinase, growth factor or a reductase, or administering a  
CC nucleic acid molecule (II) comprising a promoter operably linked to a  
CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,  
CC ophthalmological, vulnary, keratolytic and virucide activities, and  
CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used  
CC in gene therapy. (I) and (II) are useful for treating proliferative skin  
CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,  
CC squamous or basal cell carcinoma and viral or seborrheic wart. They can  
CC also be used for treating proliferative eye diseases such as diabetic  
CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of  
CC prematurity and retinal detachment, and for treating and preventing  
CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn  
CC scar. AAH57577 to AAH62099 represent sequences used in the  
CC exemplification of the present invention  
XX  
SQ Sequence 19 BP; 2 A; 9 C; 1 G; 7 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 19;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 433 ACTGGGAGAGGGGAGA 448  
Db |||||  
17 ACTGGGAGAGGGGAGA 2  
  
RESULT 264  
ADF54045/C  
ID ADF54045 standard; RNA; 19 BP.  
XX  
AC ADF54045;  
XX  
XX 12-FEB-2004 (first entry)  
DT  
XX Human GAB2 short interfering nucleic acid upper sequence SEQ ID NO:118.  
DE  
XX RNA interference; short interfering nucleic acid; siRNA;  
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;  
KW short hairpin RNA; shRNA; expression modulation; gene therapy;  
KW drug screening; diagnosis; therapeutic target identification;

KW pharmacogenomics; gene function analysis; gene mapping; human;  
KW GRB2-associated binding protein; GAB2; cancer; inflammation; allergy;  
KW chromosome 11; cytostatic; antiinflammatory; antiallergic;  
KW target sequence; ss.  
XX  
XX Synthetic.  
OS Homo sapiens.  
XX W02003070903-A2.  
PN  
XX  
XX 28-AUG-2003.  
XX  
XX 18-FEB-2003; 2003WO-US004909.  
XX  
XX 20-FEB-2002; 2002US-0358580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX PA  
XX Mcswiggen J, Beigelman L, Usman N;  
PI  
XX WPI; 2003-697611/66.  
DR  
XX  
XX New short interfering nucleic acid, useful e.g. for treatment and  
PT diagnosis of cancer, downregulates expression of the GRB2-associated  
PT binding protein gene.  
XX  
XX Example 3; SEQ ID NO 118; 140pp; English.  
XX  
XX The present invention relates to short interfering nucleic acids (siNA)  
CC which downregulate expression of the human GRB2-associated binding  
CC protein (GAB2) gene by RNA interference. The siNAs may or may not  
CC comprise ribonucleotides and may be double or single stranded. They  
CC further comprise sense and antisense regions, or alternatively are  
CC assembled from a sense oligonucleotide and an antisense oligonucleotide.  
CC Specifically, the siNAs include short interfering RNA (siRNA), double-  
CC stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs  
CC can be unmodified or chemically modified, can contain  
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a  
CC vector or enzymatically synthesised. The invention also relates to kits  
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes  
CC of siNA; and vectors that express siNA. The siNAs are used to modulate  
CC expression of the GAB2 gene in cells, tissue explants or organisms (e.g.,  
CC by ex vivo gene therapy), or in grafts and transplants for the treatment  
CC of a variety of conditions. They may be used for treating cancer.  
CC inflammation and allergies. The siNAs are also useful for drug screening,  
CC diagnosis, therapeutic target identification and validation, genetic  
CC engineering, pharmacogenomics, studying gene function, and gene mapping  
CC (e.g., of single nucleotide polymorphisms). The human GAB2 gene is  
CC located on chromosome 11, more specifically to region 11q13.4. The human  
CC GAB2 siNAs have cytostatic, antiinflammatory and antiallergic activities.  
CC The present sequence represents the upper strand of a human GAB2-targeted  
CC double-stranded siNA, which is identical to the GAB2 transcript target  
CC sequence.  
XX  
SQ Sequence 19 BP; 3 A; 8 C; 4 G; 0 T; 4 U; 0 Other;  
  
Query Match 0.8%; Score 14.4; DB 1; Length 19;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 219 GCCAGCTGTGGAGATG 234  
Db |||||  
16 GCCAGCTGTGGAGATG 1  
  
RESULT 265  
ADF54381







PS Example 5; Page 30; 71pp; English.

XX A method for treating airway disease in a subject has been produced,

CC which involves the topical administration of an essentially adenosine

CC free antisense oligonucleotide (ON) to the airway epithelium of the

CC subject. The present sequence is an antisense oligonucleotide specific

CC for the human IL4 receptor. The method can be used to treat airway

CC diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary

CC disease, bronchitis and other airway diseases characterised by an

CC inflammatory response. By eliminating adenosine from the antisense ON,

CC its liberatory upon antisense degradation is prevented, thereby

CC preventing adenosine-induced bronchoconstriction in patients with hyper-

CC reactive airways

XX

SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 14;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GTGGGGGCTTTGGC 700

Db 1 GTGGGGGCTTTGGC 14

RESULT 272

AAAX54005

ID AAAX54005 standard; DNA; 14 BP.

XX

AC AAAX54005;

XX

DT 05-JUL-1999 (first entry)

XX

DE Human IL-4 receptor antisense oligonucleotide fragment.

XX

KW Antisense oligonucleotide; multiple target; antisense treatment;

KW impaired respiration; inflammation; lung disease;

KW pulmonary vasoconstriction; inflammation; allergic rhinitis;

KW acute asthma; allergy; asthma; impeded respiration;

KW respiratory distress syndrome; pain; cystic fibrosis;

KW chronic obstructive pulmonary disease; emphysema;

KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;

KW colon cancer; breast cancer; lung cancer; pancreatic cancer;

KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;

KW prostate cancer; ss.

XX

OS Synthetic.

OS

XX

PN WO9913886-A1.

XX

PD 25-MAR-1999.

XX

XX 17-SEP-1998; 98WO-US019419.

XX

XX 17-SEP-1997; 97US-0059160P.

PR

PR 09-JUN-1998; 98US-00093972.

XX

XX (UYEC-) UNIV EAST CAROLINA.

PA

XX

XX Nyce JW;

PI

XX

XX WPI; 1999-229400/19.

DR

XX

XX New antisense oligonucleotides used in treatment of, e.g. pulmonary

PT vasoconstriction.

PT

XX Disclosure; Page 49; 120pp; English.

PS

XX The specification describes antisense oligonucleotides (AAAX52869-X55271)

CC directed against at least 2 mRNAs selected from target genes, coding and

CC non-coding regions of RNAs corresponding to target genes, gene initiation

CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-

CC end and the juxta-section between coding and non-coding regions and all

CC

CC segments of RNAs encoding proteins associated with one or more diseases,

CC conditions or mixtures. The antisense oligonucleotides may be derived

CC from sequences AAAX5272-74. These multiple target oligonucleotides

CC (specifically AAAX5180-271) can be used for the antisense treatment of

CC diseases and conditions. Typical diseases and conditions are those

CC associated with impaired respiration and inflammation, including lung

CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,

CC acute asthma, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,

CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary

CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.

CC colon cancer, breast cancer, lung cancer, pancreatic cancer,

CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as

CC well as all types of cancers which may metastasize or have metastasized

CC to the lungs, including breast and prostate cancer

XX

SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 14;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GTGGGGGCTTTGGC 700

Db 1 GTGGGGGCTTTGGC 14

RESULT 273

AAAX33449

ID AAAX33449 standard; DNA; 14 BP.

XX

AC AAAX33449;

XX

DT 28-JUL-2000 (first entry)

XX

DE Low adenosine antisense oligonucleotide SEQ ID NO:1138.

XX

KW Human; adenosine receptor; low adenosine antisense oligonucleotide;

KW phosphorothioate; impaired respiration; inflammation; allergy;

KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;

KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;

KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;

KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;

KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;

KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.

XX

OS Homo sapiens.

OS

XX

PN WO200009525-A2.

XX

PD 24-FEB-2000.

XX

XX 03-AUG-1999; 99WO-US017712.

PF

XX 03-AUG-1998; 98US-0095212P.

PR

XX (UYEC-) UNIV EAST CAROLINA.

PA

XX

XX Nyce JW;

PI

XX

XX WPI; 2000-205971/18.

DR

XX

XX New antisense oligonucleotides useful for treating e.g. pulmonary

PT vasoconstriction, inflammation, allergies, asthma, hypertension,

PT bronchitis, emphysema, respiratory distress syndrome, ischemia or

PT cancers.

PT

XX Claim 18; Page 407; 1343pp; English.

PS

XX The present invention describes a new composition comprising an antisense

CC oligonucleotide (ON) with low adenosine (up to 15%), which targets

CC nucleic acids involved in bronchoconstriction, allergies, and/or

CC inflammation. The ON can have antiinflammatory, antiallergic,

CC

CC antiasthmatic, cytostatic and analgesic activities. The compositions are  
 CC useful for the treatment of diseases associated with inflammation,  
 CC impaired airways, including lung disease and diseases whose secondary  
 CC effects afflict the lungs of a subject. They can be used for treating  
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,  
 CC impeded respiration, respiratory distress syndrome, pain, cystic  
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive  
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,  
 CC carcinomas, and cancers which may metastasise to the lungs, including  
 CC breast and prostate cancer. The reduction of the adenosine content of the  
 CC ONS reduces side effects. The A-containing ONS break down with the  
 CC release of deoxyadenosine which activates adenosine receptors causing  
 CC bronchoconstriction and inflammation. AAA33313 to AAA35312 represent the  
 CC nucleotide sequences given in the sequence listing from the present  
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185  
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ  
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to  
 CC AAA33992) are specifically claimed ONS from the present invention. N.B.  
 CC Sequences given in the disclosure of the present invention do not match  
 CC up with their corresponding SEQ ID NO: sequences given in the sequence  
 CC listing  
 XX  
 SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 14;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GTGGGGGCTTTGGC 700  
 Db 1 GTGGGGGCTTTGGC 14

## RESULT 274

AAF19571 ID AAF19571 standard; DNA; 14 BP.

XX AAF19571;

AC AAF19571;

DT 14-MAR-2001 (first entry)

XX Human IL4 receptor polynucleotide fragment #1138.

DE Low adenosine antisense oligonucleotide; phosphorothioate; allergy;  
 XX human; airway disorder; bronchoconstriction; lung inflammation;  
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;  
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;  
 KW respiratory obstruction; pulmonary vasoconstriction; impeded respiration;  
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;  
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;  
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
 KW cancer; ss.

XX Homo sapiens.

XX WO2000062736-A2.

XX 26-OCT-2000.

XX 24-MAR-2000; 2000WO-US008020.

XX 06-APR-1999; 99US-0127958P.

XX (UYEC-) UNIV EAST CAROLINA.

PA (NYCE/) NYCE J W.

XX Nyce JW;

XX WPI; 2000-679539/66.

XX Low adenosine (A) content antisense oligonucleotides which do not trigger  
 PT adenosine receptors during metabolism, useful e.g. for treating cancers

PT and respiratory obstructions.  
 XX Claim 14; Page 208; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense  
 CC oligonucleotides and compositions (I) comprising them. In the antisense  
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.  
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,  
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.  
 CC The antisense oligonucleotides and (I) can be used to down-regulate the  
 CC expression and or activity of target polypeptides associated with  
 CC lung/respiratory disorders and malignancies, such as stimulating and  
 CC activating peptide factors and transmitters, transcription factors,  
 CC immunoglobulins and antibodies, antibody receptors, cytokines and  
 CC chemokines, endogenously produced specific and non-specific enzymes,  
 CC binding proteins, adhesion molecules and their receptors, cytokine and  
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
 CC nervous system (CNS) and peripheral nervous and non-nervous system  
 CC receptors, CNS and peripheral nervous and non-nervous system peptide  
 CC transmitters, defensins, growth factors, vasoactive peptides and  
 CC receptors, binding proteins and malignancy associated proteins. The  
 CC antisense oligonucleotides may be used in this way to treat disorders  
 CC including respiratory obstruction (especially pulmonary obstruction  
 CC and/or bronchoconstriction) and/or lung inflammation, allergies) and/or  
 CC surfactant hypoproduction which are associated with a disease or  
 CC condition selected from pulmonary vasoconstriction, inflammation,  
 CC allergies, asthma, impeded respiration, respiratory distress syndrome  
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
 CC fragments and antisense oligonucleotides used in the exemplification of  
 CC the present invention  
 XX

SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 14;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GTGGGGGCTTTGGC 700

Db 1 GTGGGGGCTTTGGC 14

## RESULT 275

ABZ95265 ID ABZ95265 standard; DNA; 14 BP.

XX ABZ95265;

AC ABZ95265;

DT 17-OCT-2003 (first entry)

XX Human IL-4 receptor antisense fragment no.1129.

DE Human; antisense; lung dysfunction; nasal airway dysfunction;  
 XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;  
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;  
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
 KW lung inflammation; respiratory disease; da.

XX Homo sapiens.

XX WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (SPIG-) EPIGENESIS PHARM INC.

```

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.
XX PS Disclosure; SEQ ID NO 10507; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense, which has a
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antiinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antiinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine or
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 687 GTGGGGCGCTTTGGC 700
Db 1 GTGGGGCGCTTTGGC 14

RESULT 276
ABD19234
ID ABD19234 standard; DNA; 14 BP.
AC ABD19234;
XX
XX DT 29-JUL-2004 (first entry)
XX
XX DE Human IL4 receptor DNA fragment 1129.
XX
XX KW Human; antisense: bronchoconstriction; allergy; hyposecretion; pain;
XX KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX KW surfactant depletion; antiasthmatic; antiinflammatory; antiasthmatic;
XX KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX KW pulmonary transplantation rejection; db.
XX
XX OS Homo sapiens.
XX
XX PN WO200285309-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013143.
XX
XX PR 24-APR-2001; 2001US-0286036P.
XX

```

---

```

XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX DR Pharmaceutical composition for treating asthma, has antisense
XX PT oligonucleotide containing less percentage of adenosine, targeted to
XX PT nucleic acids associated with lung airway or lung dysfunction, and
XX PT bronchodilating agent.
XX
XX PS Claim 15; SEQ ID NO 10507; 763pp; English.
XX
XX CC This invention describes a novel composition (a) a first active agent,
XX CC comprising oligonucleotides, effective for alleviating
XX CC bronchoconstriction, respiratory tract inflammation, allergies and
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
XX CC oligonucleotides are derived from a gene encoding or regulating or
XX CC expression of a target polypeptide associated with lung airway or lung
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX CC The invention also describes a kit, that comprises: (a) a delivery
XX CC device, in separate containers, (b) the oligonucleotides, (c)
XX CC instructions for adding a carrier and for use of the kit. The composition
XX CC of the invention has antiasthmatic, antiinflammatory, antiasthmatic,
XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX CC beta-adrenergic agonist. The composition is useful for preventing or
XX CC treating a respiratory, lung or malignant disease. The administered
XX CC composition comprises oligo and is administered to reduce the production
XX CC or availability, or to increase the degradation of the target mRNA or to
XX CC reduce the amount of target polypeptide present in the lungs. The
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
XX CC inflammation, allergies and/or surfactant hypoproduction are associated
XX CC with a disease or condition such as pulmonary vasoconstriction,
XX CC inflammation, allergies, asthma, impeded respiration, respiratory
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
XX CC Transplantation rejection, pulmonary infections, bronchitis or cancer.
XX CC The reduced adenosine content of the anti-sense oligos corresponding to
XX CC thymidines present in the target RNA serves to prevent the breakdown of
XX CC the oligonucleotides into products that free adenosine into the system
XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX CC prevent any unwanted effects due to it.
XX SQ Sequence 14 BP; 0 A; 2 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 687 GTGGGGCGCTTTGGC 700
Db 1 GTGGGGCGCTTTGGC 14

RESULT 277
AAZ90832
ID AAZ90832 standard; DNA; 15 BP.
XX
XX AC AAZ90832;
XX
XX DT 24-MAY-2000 (first entry)
XX
XX DE Human NR8 gene probe #60.
XX
XX KW Haemopoietin receptor family; NR8; antibody; diagnosis;
XX KW blood formation disorder; fusion protein; probe; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO967290-A1.
XX

```



```

XX 29-DEC-1999.
XX
XX
XX PF 23-JUN-1999; 99WO-JP003351.
XX
XX PR 24-JUN-1998; 98JP-00214720.
XX PR 19-OCT-1998; 98JP-00297409.
XX
XX PA (CHUS ) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
XX PI Nomura H, Maeda M;
XX
XX DR WPI; 2000-116933/10.
XX
XX PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX PT formation disorders.
XX
XX PS Example 1; Page 40; 176pp; Japanese.
XX
XX CC The invention relates to the isolation of sequences encoding human
XX CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
XX CC were initially searched for comparison on a nucleic acid database with
XX CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
XX CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
XX CC Z90925 represent specific examples of probe sequences used in the search.
XX CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
XX CC formation disorders. Compounds identified as binding to the proteins are
XX CC used for the treatment of such disorders
XX
XX SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAG 1356
Db 1 TGGAGTGCCTGGAG 14

RESULT 278
AAZ59267
ID AAZ59267 standard; DNA; 15 BP.
AC AAZ59267;
XX
XX DT 24-MAY-2000 (first entry)
XX
XX DE Human NR8 gene probe #10.
XX
XX KW Haemopoietin receptor family; NR8; antibody; diagnosis;
XX KW blood formation disorder; fusion protein; probe; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO9967290-A1.
XX
XX PD 29-DEC-1999.
XX
XX PF 23-JUN-1999; 99WO-JP003351.
XX
XX PR 24-JUN-1998; 98JP-00214720.
XX PR 19-OCT-1998; 98JP-00297409.
XX
XX PA (CHUS ) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
XX PI Nomura H, Maeda M;
XX
XX DR WPI; 2000-116933/10.
XX
XX PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX PT formation disorders.
XX
XX PS Example 1; Page 40; 176pp; Japanese.
XX
XX CC The invention relates to the isolation of sequences encoding human
XX CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
XX CC were initially searched for comparison on a nucleic acid database with
XX CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
XX CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
XX CC Z90925 represent specific examples of probe sequences used in the search.
XX CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
XX CC formation disorders. Compounds identified as binding to the proteins are
XX CC used for the treatment of such disorders
XX
XX SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAG 1356
Db 1 TGGAGTGCCTGGAG 14

RESULT 278
AAZ59267
ID AAZ59267 standard; DNA; 15 BP.
AC AAZ59267;
XX
XX DT 24-MAY-2000 (first entry)
XX
XX DE Human NR8 gene probe #10.
XX
XX KW Haemopoietin receptor family; NR8; antibody; diagnosis;
XX KW blood formation disorder; fusion protein; probe; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO9967290-A1.
XX
XX PD 29-DEC-1999.
XX
XX PF 23-JUN-1999; 99WO-JP003351.
XX
XX PR 24-JUN-1998; 98JP-00214720.
XX PR 19-OCT-1998; 98JP-00297409.
XX
XX PA (CHUS ) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
XX PI Nomura H, Maeda M;
XX
XX DR WPI; 2000-116933/10.
XX
XX PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX PT formation disorders.
XX
XX PS Example 1; Page 40; 176pp; Japanese.
XX
XX CC The invention relates to the isolation of sequences encoding human
XX CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
XX CC were initially searched for comparison on a nucleic acid database with
XX CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
XX CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
XX CC Z90925 represent specific examples of probe sequences used in the search.
XX CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
XX CC formation disorders. Compounds identified as binding to the proteins are
XX CC used for the treatment of such disorders
XX
XX SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;

```

```

PS Example 1; Page 38; 176pp; Japanese.
XX
XX CC The invention relates to the isolation of sequences encoding human
XX CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
XX CC were initially searched for comparison on a nucleic acid database with
XX CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
XX CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
XX CC Z90925 represent specific examples of probe sequences used in the search.
XX CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
XX CC formation disorders. Compounds identified as binding to the proteins are
XX CC used for the treatment of such disorders
XX
XX SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1343 TGGAGTGCCTGGAG 1356
Db 1 TGGAGTGCCTGGAG 14

RESULT 279
AAZ90877
ID AAZ90877 standard; DNA; 15 BP.
AC AAZ90877;
XX
XX DT 24-MAY-2000 (first entry)
XX
XX DE Human NR8 gene probe #105.
XX
XX KW Haemopoietin receptor family; NR8; antibody; diagnosis;
XX KW blood formation disorder; fusion protein; probe; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO9967290-A1.
XX
XX PD 29-DEC-1999.
XX
XX PF 23-JUN-1999; 99WO-JP003351.
XX
XX PR 24-JUN-1998; 98JP-00214720.
XX PR 19-OCT-1998; 98JP-00297409.
XX
XX PA (CHUS ) CHUGAI RES INST MOLECULAR MEDICINE INC.
XX
XX PI Nomura H, Maeda M;
XX
XX DR WPI; 2000-116933/10.
XX
XX PT Hemopoietin receptor protein family NR8 used for diagnosis of blood
XX PT formation disorders.
XX
XX PS Example 1; Page 43; 176pp; Japanese.
XX
XX CC The invention relates to the isolation of sequences encoding human
XX CC haemopoietin receptor protein family NR8 genes. The NR8 family sequences
XX CC were initially searched for comparison on a nucleic acid database with
XX CC the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid
XX CC sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-
XX CC Z90925 represent specific examples of probe sequences used in the search.
XX CC Antibodies to the NR8 family proteins are used for the diagnosis of blood
XX CC formation disorders. Compounds identified as binding to the proteins are
XX CC used for the treatment of such disorders
XX
XX SQ Sequence 15 BP; 2 A; 2 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1343 TGGAGTGCCTGGAG 1356  
 Db 1 TGGAGTGCCTGGAG 14

RESULT 280  
 AAZ90872  
 ID AAZ90872 standard; DNA; 15 BP.  
 XX AC AAZ90872;  
 XX AC (first entry)  
 DT 24-MAY-2000 (first entry)  
 XX Human NR8 gene probe #100.  
 DE Haemopoietin receptor family; NR8; antibody; diagnosis;  
 KW blood formation disorder; fusion protein; probe; ss.  
 KW Homo sapiens.  
 XX WO9967290-A1.  
 XX 29-DEC-1999.  
 XX 23-JUN-1999; 99WO-JP003351.  
 XX 24-JUN-1998; 98JP-00214720.  
 XX 19-OCT-1998; 98JP-00297409.  
 PA (CHUS ) CHUGAI RES INST MOLECULAR MEDICINE INC.  
 XX Nomura H, Maeda M;  
 PI WPI; 2000-116933/10.  
 DR Hemopoietin receptor protein family NR8 used for diagnosis of blood  
 PT formation disorders.  
 XX Example 1; Page 42; 176pp; Japanese.

The invention relates to the isolation of sequences encoding human  
 haemopoietin receptor protein family NR8 genes. The NR8 family sequences  
 were initially searched for comparison on a nucleic acid database with  
 the nucleic acid probe sequence TGGAGYNNNTGGAGY encoding the amino acid  
 sequence Trp-Ser-Xaa-Trp-Ser. The sequences AAZ59258-Z59300 and AAZ90816-  
 Z90925 represent specific examples of probe sequences used in the search.  
 CC Antibodies to the NR8 family proteins are used for the diagnosis of blood  
 CC formation disorders. Compounds identified as binding to the proteins are  
 CC used for the treatment of such disorders

QY 1343 TGGAGTGCCTGGAG 1356  
 Db 1 TGGAGTGCCTGGAG 14

RESULT 281  
 ABK98169/c  
 ID ABK98169 standard; DNA; 15 BP.  
 XX AC ABK98169;  
 XX 07-OCT-2002 (first entry)  
 DT Triple helix forming associated oligonucleotide #39.  
 DE Triple-helix formation; purine-rich target sequence; double-helix DNA;  
 KW Triple-helix formation; purine-rich target sequence; double-helix DNA;

QY 1835 AAAAAAAAAAAAAA 1849  
 Db 15 AAAAAAAAAAAAAA 1

RESULT 282  
 ABK98187/c  
 ID ABK98187 standard; DNA; 15 BP.  
 XX AC ABK98187;  
 XX 07-OCT-2002 (first entry)  
 DT Triple helix forming associated oligonucleotide #51.

gene expression; regulatory sequence; pathogenic double-stranded DNA;  
 pathogenic bacteria; virus; replication; virulence; cancer;  
 oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.  
 Synthetic.  
 US6403302-B1.  
 11-JUN-2002.  
 16-DEC-1993; 93US-00168920.  
 17-SEP-1992; 92US-00946976.  
 (CALY ) CALIFORNIA INST OF TECHNOLOGY.  
 Dervan PB, Beal PA;  
 WPI; 2002-536030/57.  
 A triple-helix comprising a double helical nucleic acid (DHNA) and an  
 oligonucleotide which binds in parallel and antiparallel orientation,  
 respectively, for targeting sequences on alternate strands of DHNA to  
 control gene expression.  
 Example 6; Fig 20A; 108pp; English.

The present invention relates to methods and oligonucleotides for forming  
 a triple-helix comprising a double helical nucleic acid comprising first  
 and second substantially complementary strands, and an oligonucleotide  
 bound to a purine-rich target sequence within the double helical nucleic  
 acid, where the oligonucleotide binds in a parallel and antiparallel  
 orientation, respectively, to target sequences on alternate strands of  
 the double helical nucleic acid. The method has therapeutic applications,  
 where gene expression is controlled by selective triple-helix formation,  
 within expression regulatory sequences of a target gene. The  
 oligonucleotides can be used to form triple-helices, and are useful to  
 detect the presence or absence of specific sequences within genomic DNA  
 for diagnostic and therapeutic purposes. The oligonucleotides can be  
 selected to specifically bind to pathogenic bacteria or viruses for  
 specific sequences required by pathogenic bacteria or viruses for  
 replication or virulence, reducing their pathogenicity. Alternatively,  
 the oligonucleotide can be chosen to target a unique sequence of the  
 pathogen which is not found in the genome of pathogen's host. The  
 oligonucleotides can be used in cancer treatment by way of triple-helix  
 suppression of specific oncogenes including those of endogenous or viral  
 origin. Such therapeutic oligonucleotides are capable of forming triple-  
 helices with such sequences in cancerous cells containing the activated  
 oncogene, so preferentially killing or repressing the cancer causing  
 cell. The present sequence represents an oligonucleotide used in the  
 methods of the present invention

Query Match 0.8%; Score 14; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;

KW Triple-helix formation; purine-rich target sequence; double-helix DNA;  
 KW gene expression; regulatory sequence; pathogenic double-stranded DNA;  
 KW pathogenic bacteria; virus; replication; virulence; cancer;  
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.  
 XX  
 OS Synthetic.  
 PN US6403302-B1.  
 XX  
 PD 11-JUN-2002.  
 XX  
 PF 16-DEC-1993; 93US-00168920.  
 XX  
 PR 17-SEP-1992; 92US-00946976.  
 XX  
 XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.  
 XX  
 XX Dervan PB, Beal PA;  
 XX  
 DR WPI; 2002-536030/57.  
 XX  
 XX A triple-helix comprising a double helical nucleic acid (DHNA) and an  
 XX oligonucleotide which binds in parallel and antiparallel orientation,  
 XX respectively, for targeting sequences on alternate strands of DHNA to  
 XX control gene expression.  
 PS Example 7; Fig 24A; 108pp; English.  
 XX  
 XX The present invention relates to methods and oligonucleotides for forming  
 XX a triple-helix comprising a double helical nucleic acid comprising first  
 XX and second substantially complementary strands, and an oligonucleotide  
 XX bound to a purine-rich target sequence within the double helical nucleic  
 XX acid, where the oligonucleotide binds in a parallel and antiparallel  
 XX orientation, respectively, to target sequences on alternate strands of  
 XX the double helical nucleic acid. The method has therapeutic applications,  
 XX where gene expression is controlled by selective triple-helix formation  
 XX within expression regulatory sequences of a target gene. The  
 XX oligonucleotides can be used to form triple-helices, and are useful to  
 XX detect the presence or absence of specific sequences within genomic DNA  
 XX for diagnostic and therapeutic purposes. The oligonucleotides can be  
 XX selected to specifically bind to pathogenic double-stranded DNA including  
 XX specific sequences required by pathogenic bacteria or viruses for  
 XX replication or virulence, reducing their pathogenicity. Alternatively,  
 XX the oligonucleotide can be chosen to target a unique sequence of the  
 XX pathogen which is not found in the genome of pathogen's host. The  
 XX oligonucleotides can be used in cancer treatment by way of triple-helix  
 XX suppression of specific oncogenes including those of endogenous or viral  
 XX origin. Such therapeutic oligonucleotides are capable of forming triple-  
 XX helices with such sequences in cancerous cells containing the activated  
 XX oncogene, so preferentially killing or repressing the cancer causing  
 XX cell. The present sequence represents an oligonucleotide used in the  
 XX methods of the present invention  
 XX  
 SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;  
 Query Match 0.8%; Score 14; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1835 AAAAAAAAAAAAAA 1849  
 Db 15 AAAAAAAAAAAAAA 1  
 RESULT 283  
 ABK98168/C  
 ID ABK98168 standard; DNA; 15 BP.  
 XX  
 XX AC ABK98168;  
 XX  
 DT 07-OCT-2002 (first entry)  
 XX  
 DE Triple helix forming associated oligonucleotide #38.

XX  
 KW Triple-helix formation; purine-rich target sequence; double-helix DNA;  
 KW gene expression; regulatory sequence; pathogenic double-stranded DNA;  
 KW pathogenic bacteria; virus; replication; virulence; cancer;  
 KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.  
 XX  
 OS Synthetic.  
 PN US6403302-B1.  
 XX  
 PD 11-JUN-2002.  
 XX  
 PF 16-DEC-1993; 93US-00168920.  
 XX  
 PR 17-SEP-1992; 92US-00946976.  
 XX  
 XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.  
 XX  
 XX Dervan PB, Beal PA;  
 XX  
 DR WPI; 2002-536030/57.  
 XX  
 XX A triple-helix comprising a double helical nucleic acid (DHNA) and an  
 XX oligonucleotide which binds in parallel and antiparallel orientation,  
 XX respectively, for targeting sequences on alternate strands of DHNA to  
 XX control gene expression.  
 PS Example 6; Fig 20A; 108pp; English.  
 XX  
 XX The present invention relates to methods and oligonucleotides for forming  
 XX a triple-helix comprising a double helical nucleic acid comprising first  
 XX and second substantially complementary strands, and an oligonucleotide  
 XX bound to a purine-rich target sequence within the double helical nucleic  
 XX acid, where the oligonucleotide binds in a parallel and antiparallel  
 XX orientation, respectively, to target sequences on alternate strands of  
 XX the double helical nucleic acid. The method has therapeutic applications,  
 XX where gene expression is controlled by selective triple-helix formation  
 XX within expression regulatory sequences of a target gene. The  
 XX oligonucleotides can be used to form triple-helices, and are useful to  
 XX detect the presence or absence of specific sequences within genomic DNA  
 XX for diagnostic and therapeutic purposes. The oligonucleotides can be  
 XX selected to specifically bind to pathogenic double-stranded DNA including  
 XX specific sequences required by pathogenic bacteria or viruses for  
 XX replication or virulence, reducing their pathogenicity. Alternatively,  
 XX the oligonucleotide can be chosen to target a unique sequence of the  
 XX pathogen which is not found in the genome of pathogen's host. The  
 XX oligonucleotides can be used in cancer treatment by way of triple-helix  
 XX suppression of specific oncogenes including those of endogenous or viral  
 XX origin. Such therapeutic oligonucleotides are capable of forming triple-  
 XX helices with such sequences in cancerous cells containing the activated  
 XX oncogene, so preferentially killing or repressing the cancer causing  
 XX cell. The present sequence represents an oligonucleotide used in the  
 XX methods of the present invention  
 XX  
 SQ Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;  
 Query Match 0.8%; Score 14; DB 1; Length 15;  
 Best Local Similarity 93.3%; Pred. No. 1.5e+02;  
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 Qy 1835 AAAAAAAAAAAAAA 1849  
 Db 15 AAAAAAAAAAAAAA 1  
 RESULT 284  
 ABK98167/C  
 ID ABK98167 standard; DNA; 15 BP.  
 XX  
 XX AC ABK98167;  
 XX  
 DT 07-OCT-2002 (first entry)  
 XX  
 DE Triple helix forming associated oligonucleotide #38.

```
DE Triple helix forming associated oligonucleotide #37.
XX
XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW pathogenic bacteria; virus; replication; virulence; cancer;
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
OS Synthetic.
XX
XX US6403302-B1.
XX
XX 11-JUN-2002.
XX
XX 16-DEC-1993; 93US-00168920.
XX
XX 17-SEP-1992; 92US-00946976.
XX
XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX
XX Dervan PB, Beal PA;
XX
XX WPI; 2002-536030/57.
XX
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT oligonucleotide which binds in parallel and antiparallel orientation,
PT respectively, for targetting sequences on alternate strands of DHNA to
PT control gene expression.
XX
XX Example 6; Fig 20A; 108pp; English.
XX
XX The present invention relates to methods and oligonucleotides for forming
CC a triple-helix comprising a double helical nucleic acid comprising first
CC and second substantially complementary strands, and an oligonucleotide
CC bound to a purine-rich target sequence within the double helical nucleic
CC acid, where the oligonucleotide binds in a parallel and antiparallel
CC orientation, respectively, to target sequences on alternate strands of
CC the double helical nucleic acid. The method has therapeutic applications,
CC where gene expression is controlled by selective triple-helix formation
CC within expression regulatory sequences of a target gene. The
CC oligonucleotides can be used to form triple-helices, and are useful to
CC detect the presence or absence of specific sequences within genomic DNA
CC for diagnostic and therapeutic purposes. The oligonucleotides can be
CC selected to specifically bind to pathogenic double-stranded DNA including
CC specific sequences required by pathogenic bacteria or viruses for
CC replication or virulence, reducing their pathogenicity. Alternatively,
CC the oligonucleotide can be chosen to target a unique sequence of the
CC pathogen which is not found in the genome of pathogen's host. The
CC oligonucleotides can be used in cancer treatment by way of triple-helix
CC suppression of specific oncogenes including those of endogenous or viral
CC origin. Such therapeutic oligonucleotides are capable of forming triple-
CC helices with such sequences in cancerous cells containing the activated
CC oncogene, so preferentially killing or repressing the cancer causing
CC cell. The present sequence represents an oligonucleotide used in the
CC methods of the present invention
XX
XX Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAAAAAA 1849
DB 15 AAAAAAAAAAAAAA 1
RESULT 285
ABK98186/c
ID ABK98186 standard; DNA; 15 BP.
XX
AC ABK98186;
XX
XX 07-OCT-2002 (first entry)
DT
Triple helix forming associated oligonucleotide #30.
XX
XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW pathogenic bacteria; virus; replication; virulence; cancer;
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
OS Synthetic.
XX
XX US6403302-B1.
XX
XX 11-JUN-2002.
XX
XX 16-DEC-1993; 93US-00168920.
XX
XX 17-SEP-1992; 92US-00946976.
XX
XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX
XX Dervan PB, Beal PA;
XX
XX WPI; 2002-536030/57.
XX
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT oligonucleotide which binds in parallel and antiparallel orientation,
PT respectively, for targetting sequences on alternate strands of DHNA to
PT control gene expression.
XX
XX Example 7; Fig 24A; 108pp; English.
XX
XX The present invention relates to methods and oligonucleotides for forming
CC a triple-helix comprising a double helical nucleic acid comprising first
CC and second substantially complementary strands, and an oligonucleotide
CC bound to a purine-rich target sequence within the double helical nucleic
CC acid, where the oligonucleotide binds in a parallel and antiparallel
CC orientation, respectively, to target sequences on alternate strands of
CC the double helical nucleic acid. The method has therapeutic applications,
CC where gene expression is controlled by selective triple-helix formation
CC within expression regulatory sequences of a target gene. The
CC oligonucleotides can be used to form triple-helices, and are useful to
CC detect the presence or absence of specific sequences within genomic DNA
CC for diagnostic and therapeutic purposes. The oligonucleotides can be
CC selected to specifically bind to pathogenic double-stranded DNA including
CC specific sequences required by pathogenic bacteria or viruses for
CC replication or virulence, reducing their pathogenicity. Alternatively,
CC the oligonucleotide can be chosen to target a unique sequence of the
CC pathogen which is not found in the genome of pathogen's host. The
CC oligonucleotides can be used in cancer treatment by way of triple-helix
CC suppression of specific oncogenes including those of endogenous or viral
CC origin. Such therapeutic oligonucleotides are capable of forming triple-
CC helices with such sequences in cancerous cells containing the activated
CC oncogene, so preferentially killing or repressing the cancer causing
CC cell. The present sequence represents an oligonucleotide used in the
CC methods of the present invention
XX
XX Sequence 15 BP; 0 A; 0 C; 0 G; 14 T; 0 U; 1 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1835 AAAAAAAAAAAAAA 1849
DB 15 AAAAAAAAAAAAAA 1
RESULT 286
ADR36131
ID ADR36131 standard; DNA; 16 BP.
XX
AC ADR36131;
XX
XX
```

DT	04-NOV-2004	(first entry)
XX		
DE	Human nicking agent DNA containing BstNBI restriction site #2551.	
XX		
KW	ss; nicking agent; assay panel; diagnosis; expression pattern;	
KW	DNA fingerprinting; nosocomial infection; microbiological assay;	
XX	bacterial contamination; genome mapping; bioremediation.	
XX		
OS	Homo sapiens.	
XX		
PN	W02004067765-A2.	
XX		
PD	12-AUG-2004.	
XX		
XX	29-JAN-2004; 2004WO-US002720.	
XX		
PR	29-JAN-2003; 2003US-0443811P.	
XX		
PA	(KECK-) KECK GRADUATE INST.	
XX		
PI	Van Ness J, Galas DJ, Van Ness LK;	
XX		
DR	WPI; 2004-581010/56.	
XX		
PT	Identifying nucleic acid sample source, useful for identifying bacterial	
PT	strains involved in nosocomial infections, comprises treating the nucleic	
PT	acid sample with components comprising a nicking agent under nicking	
PT	conditions.	
XX		
PS	Example 3; Page 105-219; 238pp; English.	
XX		
CC	The invention relates to a method of treating a nucleic acid sample with	
CC	components under nicking conditions, where the components comprise a	
CC	nicking agent, and the conditions cause the nicking agent to nick the	
CC	nucleic acid sample to thus produce a family of initiating	
CC	oligonucleotide fragments, and subjecting one or more members of the	
CC	family of initiating oligonucleotide fragments to a characterization	
CC	process to thus provide results. The method is useful for creating an	
CC	assay panel of diagnostic oligonucleotides that can identify any organism	
CC	or individual. The method is useful for characterizing other DNA	
CC	molecules e.g., cDNA, and for characterizing cDNA expression patterns.	
CC	The method, kit or composition is useful for identifying the source	
CC	organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,	
CC	non-human animal or human. The method is particularly useful for rapidly	
CC	fingerprinting DNA to identifying prokaryotic and eukaryotic species,	
CC	subspecies, and especially strains or individuals of the subspecies. It	
CC	is especially useful for identifying different bacterial strains involved	
CC	in e.g., nosocomial infections. Furthermore, the method is useful for	
CC	diagnosing bacterial disease in plants and humans, monitoring for	
CC	bacterial content and/or contamination in the environment, monitoring	
CC	food for bacterial contamination, monitoring manufacturing processes for	
CC	bacterial contamination, monitoring quality assurance/quality control of	
CC	laboratory tests involving microbiological assays, tracing bacterial	
CC	contamination and/or outbreaks of bacterial infections, genome mapping,	
CC	monitoring bioremediation sites, and for monitoring agricultural sites	
CC	for test crops, bacteria and recombinant molecules. Sequences ADR33581-	
CC	ADR337496 correspond to target nucleic acids containing an NBstNBI	
CC	restriction site and used in the method of the invention.	
XX		
SQ	Sequence 16 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 1 Other;	
	Query Match 0.8%; Score 14; DB 1; Length 16;	
	Best Local Similarity 87.5%; Pred. No. 1.6e+02;	
	Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;	
QY	381 CTCGACGACAGATGGGC 396	
	:	
Db	1 STACACGACAGATGGGC 16	
RESULT 287		
ADR36132		
ID	ADR36132 standard; DNA; 16 BP.	

XX  
AC ADR36132;  
XX  
XX 04-NOV-2004 (first entry)  
XX  
XX Human nicking agent DNA containing *Bst*NI restriction site #2552.  
XX  
XX ss; nicking agent; assay panel; diagnosis; expression pattern;  
XX DNA fingerprinting; nosocomial infection; microbiological assay;  
XX bacterial contamination; genome mapping; bioremediation.  
XX  
XX Homo sapiens.  
XX  
XX WO2004067765-A2.  
XX  
XX 12-AUG-2004.  
XX  
XX 29-JAN-2004; 2004WO-US002720.  
XX  
XX 29-JAN-2003; 2003US-0443811P.  
XX  
XX (KECK-) KECK GRADUATE INST.  
XX  
XX Van Ness J, Galas DJ, Van Ness LK;  
XX  
XX WPT; 2004-581010/56.  
XX  
XX Identifying nucleic acid sample source, useful for identifying bacterial  
XX strains involved in nosocomial infections, comprises treating the nucleic  
XX acid sample with components comprising a nicking agent under nicking  
XX conditions.  
XX  
XX Example 3; Page 105-219; 238pp; English.  
XX  
XX The invention relates to a method of treating a nucleic acid sample with  
XX components under nicking conditions, where the components comprise a  
XX nicking agent, and the conditions cause the nicking agent to nick the  
XX nucleic acid sample to thus produce a family of initiating  
XX oligonucleotide fragments, and subjecting one or more members of the  
XX family of initiating oligonucleotide fragments to a characterization  
XX process to thus provide results. The method is useful for creating an  
XX assay panel of diagnostic oligonucleotides that can identify any organism  
XX or individual. The method is useful for characterizing other DNA  
XX molecules e.g., cDNA, and for characterizing cDNA expression patterns.  
XX The method, kit or composition is useful for identifying the source  
XX organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,  
XX non-human animal or human. The method is particularly useful for rapidly  
XX fingerprinting DNA to identifying prokaryotic and eukaryotic species, It  
XX is especially useful for identifying different bacterial strains involved  
XX in e.g., nosocomial infections. Furthermore, the method is useful for  
XX diagnosing bacterial disease in plants and humans, monitoring for  
XX bacterial content and/or contamination in the environment, monitoring  
XX food for bacterial contamination, monitoring manufacturing processes for  
XX bacterial contamination, monitoring quality assurance/quality control of  
XX laboratory tests involving microbiological assays, tracing bacterial  
XX contamination and/or outbreaks of bacterial infections, genome mapping,  
XX monitoring bioremediation sites, and for monitoring agricultural sites  
XX for test crops, bacteria and recombinant molecules. Sequences ADR33581-  
XX ADR37496 correspond to target nucleic acids containing an *Nbs*NI  
XX restriction site and used in the method of the invention.  
XX  
XX Sequence 16 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 1 Other;

```

Query Match      0.88;   Score 14;   DB 1;   Length 16;
Best Local Similarity 87.5%;   Pred. No. 1.6e+02;
Matches 14;   Conservative 1;   Mismatches 1;   Indels 0;   Gaps 0;

Qy      381  CTGCAGCAAGATGGGC 396
          : |||||
Db       1  STACAGCAAGATGGGC 16

```

```
RESULT 288
ADR36130
ID  ADR36130 standard; DNA; 16 BP.
XX
AC  ADR36130;
XX
DT  04-NOV-2004 (first entry)
XX
DE  Human nicking agent DNA containing BstNBI restriction site #2550.
XX
XX  ss; nicking agent; assay panel; diagnosis; expression pattern;
XX  DNA fingerprinting; nosocomial infection; microbiological assay;
XX  bacterial contamination; genome mapping; bioremediation.
XX
OS  Homo sapiens.
XX
XX  WO2004067765-A2.
XX
XX  12-AUG-2004.
XX
XX  29-JAN-2004; 2004WO-US002720.
XX
XX  29-JAN-2003; 2003US-0443811P.
XX
XX  (KECK-) KECK GRADUATE INST.
XX
XX  Van Ness J, Galas DJ, Van Ness LK;
XX  WPI; 2004-581010/56.
XX
XX  Identifying nucleic acid sample source, useful for identifying bacterial
XX  strains involved in nosocomial infections, comprises treating the nucleic
XX  acid sample with components comprising a nicking agent under nicking
XX  conditions.
XX
XX  Example 3; Page 105-219; 238pp; English.
XX
XX  The invention relates to a method of treating a nucleic acid sample with
XX  components under nicking conditions, where the components comprise a
XX  nicking agent, and the conditions cause the nicking agent to nick the
XX  nucleic acid sample to thus produce a family of initiating
XX  oligonucleotide fragments, and subjecting one or more members of the
XX  family of initiating oligonucleotide fragments to a characterization
XX  process to thus provide results. The method is useful for creating an
XX  assay panel of diagnostic oligonucleotides that can identify any organism
XX  or individual. The method is useful for characterizing other DNA
XX  molecules e.g., cDNA, and for characterizing cDNA expression patterns.
XX  The method, kit or composition is useful for identifying the source
XX  organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,
XX  non-human animal or human. The method is particularly useful for rapidly
XX  fingerprinting DNA to identifying prokaryotic and eukaryotic species,
XX  subspecies, and especially strains or individuals of the subspecies. It
XX  is especially useful for identifying different bacterial strains involved
XX  in e.g., nosocomial infections. Furthermore, the method is useful for
XX  diagnosing bacterial disease in plants and humans, monitoring for
XX  bacterial content and/or contamination in the environment, monitoring
XX  food for bacterial contamination, monitoring manufacturing processes for
XX  bacterial contamination, monitoring quality assurance/quality control of
XX  laboratory tests involving microbiological assays, tracing bacterial
XX  contamination and/or outbreaks of bacterial infections, genome mapping,
XX  monitoring bioremediation sites, and for monitoring agricultural sites
XX  for test crops, bacteria and recombinant molecules. Sequences ADR33581-
XX  ADR37496 correspond to target nucleic acids containing an NBstNBI
XX  restriction site and used in the method of the invention.
XX
XX  Sequence 16 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 1 Other;
XX
XX  Query Match 0.8%; Score 14; DB 1; Length 16;
XX  Best Local Similarity 87.5%; Pred. No. 1.6e+02;
XX  Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX  381 CTGCAGCAAGATGGGC 396
XX  : |||||||||
```

Db 1 STACAGCAAGATGGGC 16

RESULT 289  
ADR36129  
ID ADR36129 standard; DNA; 16 BP.  
XX  
AC ADR36129;  
XX  
DT 04-NOV-2004 (first entry)  
XX  
DE Human nicking agent DNA containing BstNBI restriction site #2549.  
XX  
XX ss; nicking agent; assay panel; diagnosis; expression pattern;  
XX DNA fingerprinting; nosocomial infection; microbiological assay;  
XX bacterial contamination; genome mapping; bioremediation.  
XX  
OS Homo sapiens.  
XX  
XX WO2004067765-A2.  
XX  
XX 12-AUG-2004.  
XX  
XX 29-JAN-2004; 2004WO-US002720.  
XX  
XX 29-JAN-2003; 2003US-0443811P.  
XX  
XX (KECK-) KECK GRADUATE INST.  
XX  
XX Van Ness J, Galas DJ, Van Ness LK;  
XX WPI; 2004-581010/56.  
XX  
XX Identifying nucleic acid sample source, useful for identifying bacterial  
XX strains involved in nosocomial infections, comprises treating the nucleic  
XX acid sample with components comprising a nicking agent under nicking  
XX conditions.  
XX  
XX Example 3; Page 105-219; 238pp; English.  
XX  
XX The invention relates to a method of treating a nucleic acid sample with  
XX components under nicking conditions, where the components comprise a  
XX nicking agent, and the conditions cause the nicking agent to nick the  
XX nucleic acid sample to thus produce a family of initiating  
XX oligonucleotide fragments, and subjecting one or more members of the  
XX family of initiating oligonucleotide fragments to a characterization  
XX process to thus provide results. The method is useful for creating an  
XX assay panel of diagnostic oligonucleotides that can identify any organism  
XX or individual. The method is useful for characterizing other DNA  
XX molecules e.g., cDNA, and for characterizing cDNA expression patterns.  
XX The method, kit or composition is useful for identifying the source  
XX organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,  
XX non-human animal or human. The method is particularly useful for rapidly  
XX fingerprinting DNA to identifying prokaryotic and eukaryotic species,  
XX subspecies, and especially strains or individuals of the subspecies. It  
XX is especially useful for identifying different bacterial strains involved  
XX in e.g., nosocomial infections. Furthermore, the method is useful for  
XX diagnosing bacterial disease in plants and humans, monitoring for  
XX bacterial content and/or contamination in the environment, monitoring  
XX food for bacterial contamination, monitoring manufacturing processes for  
XX bacterial contamination, monitoring quality assurance/quality control of  
XX laboratory tests involving microbiological assays, tracing bacterial  
XX contamination and/or outbreaks of bacterial infections, genome mapping,  
XX monitoring bioremediation sites, and for monitoring agricultural sites  
XX for test crops, bacteria and recombinant molecules. Sequences ADR33581-  
XX ADR37496 correspond to target nucleic acids containing an NBstNBI  
XX restriction site and used in the method of the invention.  
XX  
XX Sequence 16 BP; 5 A; 3 C; 5 G; 2 T; 0 U; 1 Other;  
XX  
XX Query Match 0.8%; Score 14; DB 1; Length 16;  
XX Best Local Similarity 87.5%; Pred. No. 1.6e+02;  
XX Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 381 CTGACGCAAGATGGGC 396  
 :|||||||  
 Db 1 STACAGCAAGATGGGC 16

RESULT 290  
 ABK02857  
 ID ABK02857 standard; RNA; 17 BP.  
 XX  
 AC ABK02857;  
 XX  
 DT 12-MAR-2002 (first entry)  
 XX  
 DE Human CD20 Hammerhead ribozyme #156.  
 XX  
 KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
 KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
 KW DNzyme; inozyme; G-cleaver; amberzyme; zincyme; lymphoma; leukaemia;  
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
 KW inflammatory arthropathy; central nervous system injury;  
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
 KW Parkinson's disease; ataxia; Huntington's disease;  
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 XX WO200159103-A2.  
 XX  
 XX 16-AUG-2001.  
 XX  
 XX 09-FEB-2001; 2001WO-US004273.  
 XX  
 XX 11-FEB-2000; 2000US-0181797P.  
 PR 28-FEB-2000; 2000US-0185516P.  
 PR 06-MAR-2000; 2000US-0187128P.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC..  
 PA (BLATZ) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (CHOW/) CHOWRIRA B M.  
 XX  
 PI Blatt L, Mcswiggen J, Chowrira BM;  
 XX WPI; 2001-607195/69.  
 XX  
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 XX central nervous system injury.  
 XX  
 PS Claim 30; Page 142; 200pp; English.  
 XX  
 XX The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule  
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
 CC an amberzyme (cleaving RNA with an MGN triplet), a zincyme (cleaving RNA  
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic

CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is a hammerhead ribozyme of the invention  
 XX  
 SQ Sequence 17 BP; 11 A; 0 C; 3 G; 0 T; 3 U; 0 Other;  
 Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 92.9%; Pred. No. 1.7e+02;  
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 Qy 201 GAAATAAAGAAGA 214  
 Db 4 GAAATAAAGAAGA 17  
 |||||  
 |||||

RESULT 291  
 ABN02598  
 ID ABN02598 standard; DNA; 17 BP.  
 XX  
 AC ABN02598;  
 XX  
 DT 29-MAY-2002 (first entry)  
 XX  
 DE Human GDMPL-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2590.  
 XX  
 KW Human; genome-derived myosin-like protein 1; GDMPL-1; hGDMPL-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200192524-A2.  
 XX  
 XX 06-DEC-2001.  
 XX  
 XX 25-MAY-2001; 2001WO-US016981.  
 XX  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 03-FEB-2001; 2001US-0266860P.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 PI WPI; 2002-179446/23.  
 XX  
 XX New polypeptide, for raising antibodies that recognize hGDMPL-1 proteins,

PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 XX  
 XX Disclosure; SEQ ID NO 2590; 214pp; English.  
 XX  
 XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 990 CAGGGTGCCATGGA 1003  
 Db |||||  
 4 CAGGGTGCCATGGA 17  
 RESULT 292  
 ABN02601  
 ID ABN02601 standard; DNA; 17 BP.  
 AC  
 AC ABN02601;  
 XX  
 XX 29-MAY-2002 (first entry)  
 DT  
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2593.  
 DE  
 XX Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 XX WO200192524-A2.  
 PN  
 XX 06-DEC-2001.  
 PD  
 XX 25-MAY-2001; 2001WO-US016981.  
 XX  
 XX 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.  
 PR 30-JAN-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0268660P.  
 XX  
 XX (AEOM-) AEOMICA INC.  
 XX  
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;  
 XX  
 XX WPI; 2002-179446/23.  
 DR  
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 PT or as specific biomolecule capture probes for surface-enhanced laser  
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 PT  
 XX Disclosure; SEQ ID NO 2593; 214pp; English.  
 XX  
 XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX  
 SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 990 CAGGGTGCCATGGA 1003  
 Db |||||  
 1 CAGGGTGCCATGGA 14  
 RESULT 293  
 ABN02599  
 ID ABN02599 standard; DNA; 17 BP.  
 AC  
 AC ABN02599;  
 XX  
 XX 29-MAY-2002 (first entry)  
 DT  
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2591.  
 DE  
 XX Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;  
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 KW skeletal muscle disorder; amplicon; screening; ss.  
 XX  
 XX Homo sapiens.  
 OS  
 XX WO200192524-A2.  
 PN  
 XX 06-DEC-2001.  
 PD  
 XX 25-MAY-2001; 2001WO-US016981.  
 PF 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.



PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001US-0266860P.  
XX (ABOM-) ABOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX or as specific biomolecule capture probes for surface-enhanced laser  
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 2591; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX nucleic acids can be used as probes to detect, characterise and quantify  
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX protein variants having desired phenotypic improvements, and for  
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX -1 proteins, as standards in assays used to determine the concentration  
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX capture probes for surface-enhanced laser desorption ionisation, as  
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX production, and in vaccines or for replacement therapy. The  
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
XX disorder associated with the expression of hGDMPLP-1, in particular heart  
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
XX The present sequence represents an oligomer used in the screening of the  
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
XX The sequence data for this patent did not form part of the printed  
XX specification, but was obtained in electronic format directly from WIPO  
XX at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 14; DB 1; Length 17;  
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 990 CAGGGTGCCATGGA 1003  
XX  
XX DB 3 CAGGGTGCCATGGA 16  
XX  
XX RESULT 294  
XX ABN02600  
XX ID ABN02600 standard; DNA; 17 BP.  
XX  
XX AC ABN02600;  
XX  
XX XX  
XX DT 29-MAY-2002 (first entry)  
XX  
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2592.  
XX  
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

KW skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 05-FEB-2001; 2001US-0266860P.  
XX (ABOM-) ABOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX or as specific biomolecule capture probes for surface-enhanced laser  
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 2592; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX nucleic acids can be used as probes to detect, characterise and quantify  
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX protein variants having desired phenotypic improvements, and for  
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX -1 proteins, as standards in assays used to determine the concentration  
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX capture probes for surface-enhanced laser desorption ionisation, as  
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX production, and in vaccines or for replacement therapy. The  
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
XX disorder associated with the expression of hGDMPLP-1, in particular heart  
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
XX The present sequence represents an oligomer used in the screening of the  
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
XX The sequence data for this patent did not form part of the printed  
XX specification, but was obtained in electronic format directly from WIPO  
XX at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 14; DB 1; Length 17;  
XX Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
XX Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 990 CAGGGTGCCATGGA 1003  
XX  
XX DB 2 CAGGGTGCCATGGA 15  
XX  
XX RESULT 295

[illegible]

XX OS West Nile Virus.  
 XX PN WO200268637-A2.  
 XX PD 06-SEP-2002.  
 XX PF 19-OCT-2001; 2001WO-US048350.  
 XX PR 20-OCT-2000; 2000US-0242411P.  
 XX PA (RIBO-) RIBOZYME PHARM INC.  
 XX PA (BLAT/) BLATT L.  
 XX PA (MCSW/) MCSWIGGEN J A.  
 XX PI Blatt L, Mcswiggen JA;  
 XX XX WPI; 2002-706994/76.  
 XX DR  
 XX CC New nucleic acid molecule that modulates replication of West Nile Virus  
 XX CC (WNV), useful for treating a condition related to WNV infection e.g.  
 XX CC pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX PS Claim 23; SEQ ID NO 3637; 495pp; English.  
 XX CC The invention relates to nucleic acid molecules that modulate replication  
 XX CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 XX CC treating a condition related to WNV infection e.g. pancreatitis,  
 XX CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 XX CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 XX CC molecule is selected from the group of ribozymes consisting of  
 XX CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
 XX CC nucleic acid molecules further comprise at least five ribose residues, at  
 XX CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 XX CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 XX CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 XX CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 XX CC in the specification. The present sequence is that of a nucleic acid  
 XX CC molecule of the invention  
 XX SQ Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;  
 Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 330 CTGAGTGGCTCCAA 343  
 Db 17 CTGAGTGGCTCCAA 4  
 RESULT 298  
 ACN04524  
 ID ACN04524 standard; RNA; 17 BP.  
 XX AC  
 XX ACN04524;  
 XX AC  
 XX DT 22-APR-2004 (first entry)  
 XX DE WNV Zinzyme substrate SEQ ID NO 4527.  
 XX OS WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 XX KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 XX KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 XX KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 XX KW Amberzyme; Zinzyme; ss.  
 XX OS West Nile Virus.  
 XX OS WO200268637-A2.  
 XX PN  
 XX XX 06-SEP-2002.

PF 19-OCT-2001; 2001WO-US048350.  
 XX PR 20-OCT-2000; 2000US-0242411P.  
 XX XX (RIBO-) RIBOZYME PHARM INC.  
 XX PA (BLAT/) BLATT L.  
 XX PA (MCSW/) MCSWIGGEN J A.  
 XX XX Blatt L, Mcswiggen JA;  
 XX XX WPI; 2002-706994/76.  
 XX DR  
 XX CC New nucleic acid molecule that modulates replication of West Nile Virus  
 XX CC (WNV), useful for treating a condition related to WNV infection e.g.  
 XX CC pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
 XX PS Claim 23; SEQ ID NO 4527; 495pp; English.  
 XX CC The invention relates to nucleic acid molecules that modulate replication  
 XX CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
 XX CC treating a condition related to WNV infection e.g. pancreatitis,  
 XX CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
 XX CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
 XX CC molecule is selected from the group of ribozymes consisting of  
 XX CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
 XX CC nucleic acid molecules further comprise at least five ribose residues, at  
 XX CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 XX CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 XX CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 XX CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
 XX CC in the specification. The present sequence is that of a nucleic acid  
 XX CC molecule of the invention  
 XX SQ Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
 Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 85.7%; Pred. No. 1.7e+02;  
 Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
 QY 1239 GCCAGGGCCATCAT 1252  
 Db 3 GCCAGGGCCCAUCAU 16  
 RESULT 299  
 ACN0921/c  
 ID ACN0921 standard; RNA; 17 BP.  
 XX AC  
 XX ACN0921;  
 XX AC  
 XX DT 22-APR-2004 (first entry)  
 XX DE WNV minus strand Inozyme substrate SEQ ID NO 9924.  
 XX OS WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
 XX KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
 XX KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
 XX KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
 XX KW Amberzyme; Zinzyme; ss.  
 XX OS West Nile Virus.  
 XX OS WO200268637-A2.  
 XX PN  
 XX XX 06-SEP-2002.  
 XX PF 19-OCT-2001; 2001WO-US048350.  
 XX PR 20-OCT-2000; 2000US-0242411P.  
 XX XX (RIBO-) RIBOZYME PHARM INC.  
 XX PA (BLAT/) BLATT L.  
 XX PA (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;  
PI WPI; 2002-706994/76.  
XX  
XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
XX Claim 23; SEQ ID NO 9924; 495pp; English.  
XX  
XX The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
XX Sequence 17 BP; 4 A; 4 C; 6 G; 0 T; 3 U; 0 Other;  
SQ

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. NO. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1239 GCCAGGGCCATCAT 1252  
DB 14 GCCAGGGCCATCAT 1

RESULT 300  
ABT39396/C  
ID ABT39396 standard; DNA; 17 BP.  
XX  
XX AC ABT39396;  
DT  
DT 12-JUN-2003 (first entry)  
XX  
XX Tumour suppression related human fukutin oligo SEQ ID No 5033.  
DE  
XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
XX Homo sapiens.  
OS  
XX WO2003025175-A2.  
PN  
XX 27-MAR-2003.  
PD  
XX 17-SEP-2002; 2002WO-IB004208.  
PF  
XX 17-SEP-2001; 2001FR-00011978.  
PR  
XX (MOLE-) MOLECULAR ENGINES LAB.  
PA  
XX Telerman A, Amson R, Tuijnder M;  
PI WPI; 2003-313353/30.  
XX  
XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
XX Disclosure; Page 622; 720pp; French.  
PS

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,  
CC given in the specification, a sequence containing at least 15 consecutive  
CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
CC hybridizes to them under highly stringent conditions, or the complement  
CC of any of them, or the corresponding RNA. The novel isolated nucleic  
CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (antisense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
XX Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;  
SQ

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. NO. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 189 AGGACTTTTGAAGA 202  
DB 16 AGGACTTTTGAAGA 3

RESULT 301  
ADA99846/C  
ID ADA99846 standard; DNA; 17 BP.  
XX  
XX AC ADA99846;  
DT  
DT 20-NOV-2003 (first entry)  
XX  
XX Human MDZ3 scanning oligonucleotide SEQ ID 835.  
DE  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MDZ3; MDZ4; MDZ7; MDZ12; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
XX Homo sapiens.  
OS  
XX EP1281758-A2.  
PN  
XX 05-FEB-2003.  
PD  
XX 30-JUL-2002; 2002EP-00016874.  
PF  
XX 02-AUG-2001; 2001US-00922181.  
PR  
XX (AEOM-) AEOMICA INC.  
PA  
XX Shannon M, Gu Y, Nguyen C;  
PI WPI; 2003-423107/40.  
DR  
XX New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MDZ3,  
PT MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
XX Example 8; SEQ ID NO 835; 103pp; English.  
PS  
XX

CC The present invention relates to novel human zinc finger-containing  
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
 CC or in manufacturing a medicament for treating or preventing a disorder  
 CC associated with decreased or increased expression or activity of MD23,  
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
 CC acids and proteins are also useful for diagnosing or monitoring a disease  
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
 CC acids can also be used as probes to detect and characterize gross  
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
 CC useful in constructing microarrays for measuring gene expression. The  
 CC proteins are useful as therapeutic agents for gene therapy or as  
 CC vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249  
 Db 16 AAGGCCAGGGCCAT 3  
 |||||

RESULT 302  
 ADA99847/C  
 ID ADA99847 standard; DNA; 17 BP.  
 AC ADA99847;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human MD23 scanning oligonucleotide SEQ ID 836.  
 XX  
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
 KW developmental disorder; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EP1281758-A2.  
 XX  
 PD 05-FEB-2003.  
 XX  
 PF 30-JUL-2002; 2002EP-00016874.  
 XX  
 PR 02-AUG-2001; 2001US-00922181.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Shannon M, Gu Y, Nguyen C;  
 XX  
 DR WPI; 2003-423107/40.  
 XX  
 PT New zinc finger-containing proteins and nucleic acids, useful in  
 PT manufacturing a medicament for treating or preventing a disorder  
 PT associated with decreased or increased expression or activity of MD23,  
 PT MD24, MD27 or MD212, e.g. cancer.  
 XX  
 PS Example 8; SEQ ID NO 836; 103pp; English.  
 XX  
 CC The present invention relates to novel human zinc finger-containing  
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
 CC or in manufacturing a medicament for treating or preventing a disorder  
 CC associated with decreased or increased expression or activity of MD23,  
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic

CC acids and proteins are also useful for diagnosing or monitoring a disease  
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
 CC acids can also be used as probes to detect and characterize gross  
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
 CC useful in constructing microarrays for measuring gene expression. The  
 CC proteins are useful as therapeutic agents for gene therapy or as  
 CC vaccines. The present sequence was used to illustrate the invention.

XX Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1236 AAGGCCAGGGCCAT 1249  
 Db 15 AAGGCCAGGGCCAT 2  
 |||||

RESULT 303  
 ADA99845/C  
 ID ADA99845 standard; DNA; 17 BP.  
 XX  
 AC ADA99845;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human MD23 scanning oligonucleotide SEQ ID 834.  
 XX  
 KW Cytostatic; immunostimulant; gene therapy; vaccine; human;  
 KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
 KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
 KW developmental disorder; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN EP1281758-A2.  
 XX  
 PD 05-FEB-2003.  
 XX  
 PF 30-JUL-2002; 2002EP-00016874.  
 XX  
 PR 02-AUG-2001; 2001US-00922181.  
 XX  
 PA (AEOM-) AEOMICA INC.  
 XX  
 PI Shannon M, Gu Y, Nguyen C;  
 XX  
 DR WPI; 2003-423107/40.  
 XX  
 PT New zinc finger-containing proteins and nucleic acids, useful in  
 PT manufacturing a medicament for treating or preventing a disorder  
 PT associated with decreased or increased expression or activity of MD23,  
 PT MD24, MD27 or MD212, e.g. cancer.  
 XX  
 PS Example 8; SEQ ID NO 834; 103pp; English.  
 XX  
 CC The present invention relates to novel human zinc finger-containing  
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
 CC or in manufacturing a medicament for treating or preventing a disorder  
 CC associated with decreased or increased expression or activity of MD23,  
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
 CC acids and proteins are also useful for diagnosing or monitoring a disease  
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
 CC acids can also be used as probes to detect and characterize gross  
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
 CC useful in constructing microarrays for measuring gene expression. The  
 CC proteins are useful as therapeutic agents for gene therapy or as  
 CC vaccines. The present sequence was used to illustrate the invention.

```
SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1236 AAGCCAGGGCCCAT 1249
Db |||||||||||
17 AAGCCAGGGCCCAT 4

RESULT 304
ADA99848/c
ID ADA99848 standard; DNA; 17 BP.
XX AC ADA99848;
XX XX
DT 20-NOV-2003 (first entry)
XX XX
DE Human MD23 scanning oligonucleotide SEQ ID 837.
XX XX
KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
KW developmental disorder; ss.
XX XX
OS Homo sapiens.
XX XX
PN EP1281758-A2.
XX XX
PD 05-FEB-2003.
XX XX
PF 30-JUL-2002; 2002EP-00016874.
XX XX
PR 02-AUG-2001; 2001US-00922181.
XX XX
PA (AEOM-) AEOMICA INC.
XX XX
PI Shannon M, Gu Y, Nguyen C;
XX XX
WPI; 2003-423107/40.
XX XX
DR New zinc finger-containing proteins and nucleic acids, useful in
PT manufacturing a medicament for treating or preventing a disorder
PT associated with decreased or increased expression or activity of MD23,
PT MD24, MD27 or MD212, e.g. cancer.
XX XX
PS Example 8; SEQ ID NO 837; 103pp; English.
XX XX
CC The present invention relates to novel human zinc finger-containing
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
CC or in manufacturing a medicament for treating or preventing a disorder,
CC associated with decreased or increased expression or activity of MD23,
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
CC acids and proteins are also useful for diagnosing or monitoring a disease
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
CC acids can also be used as probes to detect and characterize gross
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
CC useful in constructing microarrays for measuring gene expression. The
CC proteins are useful as therapeutic agents for gene therapy or as
CC vaccines. The present sequence was used to illustrate the invention.
XX XX
SQ Sequence 17 BP; 1 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1236 AAGCCAGGGCCCAT 1249
Db |||||||||||

SQ Sequence 17 BP; 2 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1445 TGTTCGTGCTGCTG 1458
Db |||||||||||
17 TGTTCGTGCTGCTG 4

RESULT 306
ADC37833
ID ADC37833 standard; DNA; 17 BP.
XX AC ADC37833;
XX XX
DT 18-DEC-2003 (first entry)
XX XX
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:182.
XX XX
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
KW AMLP1a; ss.
XX XX
OS Synthetic.
```



Best Local Similarity 100.0%; Pred. No. 1.7e+02; Mismatches 0; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458  
Db 15 TGTGCTGCTGCTG 2

RESULT 309  
ADC37817/c  
ID ADC37817 standard; DNA; 17 BP.  
XX AC ADC37817;  
XX XX  
DT 18-DEC-2003 (first entry)  
XX XX  
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:166.  
XX XX  
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;  
KW AMLP1a; ss.  
XX Synthetic.  
OS Homo sapiens.  
XX PN WO2003037931-A2.  
XX PD 08-MAY-2003.  
XX PF 01-NOV-2002; 2002WO-US035129.  
XX PR 01-NOV-2001; 2001US-0334773P.  
XX DT 18-DEC-2003 (first entry)  
XX XX  
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:166.  
XX XX  
KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;  
KW AMLP1a; ss.  
XX Synthetic.  
OS Homo sapiens.  
XX PN WO2003037931-A2.  
XX PD 08-MAY-2003.  
XX PF 01-NOV-2002; 2002WO-US035129.  
XX PR 01-NOV-2001; 2001US-0334773P.  
XX PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
XX PI Shannon M, Phan T;  
XX WPI; 2003-430501/40.  
XX New isolated nucleic acid molecule encoding a human angiominotin-like protein, useful for treating or preventing a disorder associated with decreased or increased expression or activity of AMLP1.  
XX Example 2; SEQ ID NO 166; 172pp; English.  
XX CC The present invention describes the human angiominotin-like protein 1 (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and compositions of the present invention can be used for treating or preventing a disorder associated with decreased or increased expression or activity of AMLP1. The present sequence represents a scanning CC oligonucleotide for human AMLP1a, which is used in an example from the CC present invention.  
XX SQ Sequence 17 BP; 6 A; 5 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02; Mismatches 0; Indels 0; Gaps 0;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458  
Db 16 TGTGCTGCTGCTG 3

RESULT 310  
ADC37819/c  
ID ADC37819 standard; DNA; 17 BP.  
XX AC ADC37819;  
XX XX  
DT 18-DEC-2003 (first entry)  
XX XX  
DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:168.

XX human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;  
KW AMLP1a; ss.  
XX Synthetic.  
OS Homo sapiens.  
XX PN WO2003037931-A2.  
XX PD 08-MAY-2003.  
XX PF 01-NOV-2002; 2002WO-US035129.  
XX PR 01-NOV-2001; 2001US-0334773P.  
XX PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
XX PI Shannon M, Phan T;  
XX WPI; 2003-430501/40.  
XX New isolated nucleic acid molecule encoding a human angiominotin-like protein, useful for treating or preventing a disorder associated with decreased or increased expression or activity of AMLP1.  
XX Example 2; SEQ ID NO 168; 172pp; English.  
XX CC The present invention describes the human angiominotin-like protein 1 (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and compositions of the present invention can be used for treating or preventing a disorder associated with decreased or increased expression or activity of AMLP1. The present sequence represents a scanning CC oligonucleotide for human AMLP1a, which is used in an example from the CC present invention.  
XX SQ Sequence 17 BP; 7 A; 6 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02; Mismatches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 TGTGCTGCTGCTG 1458  
Db 14 TGTGCTGCTGCTG 1

RESULT 311  
ADC37834  
ID ADC37834 standard; DNA; 17 BP.  
XX AC ADC37834;  
XX DT 18-DEC-2003 (first entry)  
XX DE Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:183.  
XX KW human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;  
KW AMLP1a; ss.  
XX Synthetic.  
OS Homo sapiens.  
XX PN WO2003037931-A2.  
XX PD 08-MAY-2003.  
XX PF 01-NOV-2002; 2002WO-US035129.  
XX PR 01-NOV-2001; 2001US-0334773P.  
XX PA (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
XX XX



PI Shannon M, Phan T;  
XX WPI; 2003-430501/40.  
XX  
XX New isolated nucleic acid molecule encoding a human angiomotin-like  
PT protein, useful for treating or preventing a disorder associated with  
PT decreased or increased expression or activity of AMLP1.  
XX  
XX Example 2; SEQ ID NO 183; 172pp; English.  
XX  
XX The present invention describes the human angiomotin-like protein 1  
CC (AMLp1). human AMLp1 has cytostatic activity, and can be used in gene  
CC therapy. The AMLp1 protein, nucleic acid molecules, antibodies, and  
CC compositions of the present invention can be used for treating or  
CC preventing a disorder associated with decreased or increased expression  
CC or activity of AMLP1. The present sequence represents a scanning  
CC oligonucleotide for human AMLP1a, which is used in an example from the  
CC present invention.  
XX  
XX Sequence 17 BP; 2 A; 3 C; 11 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 662 GCAGGGGCGGTGG 675  
DB 3 GCAGGGGCGGTGG 16  
RESULT 312  
ADC37836  
ID ADC37836 standard; DNA; 17 BP.  
XX  
XX ADC37836;  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:185.  
XX  
XX human; angiomotin-like protein 1; AMLP1; cytostatic; gene therapy;  
KW AMLP1a; ss.  
XX  
XX Synthetic.  
OS Homo sapiens.  
XX  
XX WO2003037931-A2.  
XX  
XX 08-MAY-2003.  
XX  
XX 01-NOV-2002; 2002WO-US035129.  
XX  
XX 01-NOV-2001; 2001US-0334773P.  
XX  
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.  
XX  
XX Shannon M, Phan T;  
XX  
XX WPI; 2003-430501/40.  
XX  
XX New isolated nucleic acid molecule encoding a human angiomotin-like  
PT protein, useful for treating or preventing a disorder associated with  
PT decreased or increased expression or activity of AMLP1.  
XX  
XX Example 2; SEQ ID NO 185; 172pp; English.  
XX  
XX The present invention describes the human angiomotin-like protein 1  
CC (AMLp1). human AMLP1 has cytostatic activity, and can be used in gene  
CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and  
CC compositions of the present invention can be used for treating or  
CC preventing a disorder associated with decreased or increased expression  
CC or activity of AMLP1. The present sequence represents a scanning  
CC oligonucleotide for human AMLP1a, which is used in an example from the

CC present invention.  
XX  
XX Sequence 17 BP; 1 A; 4 C; 11 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
OY 662 GCAGGGGCGGTGG 675  
DB 1 GCAGGGGCGGTGG 14  
RESULT 313  
ADL49810  
ID ADL49810 standard; RNA; 17 BP.  
XX  
XX ADL49810;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX Human PKR substrate sequence #924.  
XX  
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
XX Unidentified.  
XX  
XX WO200281628-A2.  
XX  
XX 17-OCT-2002.  
XX  
XX 03-APR-2002; 2002WO-US010512.  
XX  
XX 05-APR-2001; 2001US-00827395.  
XX  
XX 29-MAY-2001; 2001US-029412P.  
XX  
XX 28-AUG-2001; 2001US-0315315P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
XX  
XX WPI; 2003-058513/05.  
XX  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
XX Claim 59; SEQ ID NO 3343; 317pp; English.  
XX  
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human PKR

```
CC  substrate sequence.
XX
SQ  Sequence 17 BP; 7 A; 4 C; 4 G; 0 T; 2 U; 0 Other;

Query Match      0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY  272 AGCCCGAGACAGAT 285
Db   |||||
     4 AGCCCGAGACAGAU 17

RESULT 314
ADL50678
ID  ADL50678 standard; RNA; 17 BP.
XX
AC  ADL50678;
XX
DT  20-MAY-2004 (first entry)
XX
DE  Human PKR substrate sequence #1792.
XX
KW  antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW  prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW  protein kinase PKR; cerebrovascular accident;
KW  central nervous system injury; CNS injury; spinal cord injury; cancer;
KW  melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW  restenosis; asthma; Crohn's disease; diabetes; obesity;
KW  autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW  graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KW  allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW  substrate; ds.
XX
OS  Unidentified.
XX
PN  WO200281628-A2.
XX
PD  17-OCT-2002.
XX
PF  03-APR-2002; 2002WO-US010512.
XX
PR  05-APR-2001; 2001US-00827395.
PR  28-MAY-2001; 2001US-0294412P.
PR  28-AUG-2001; 2001US-0315315P.
XX
PA  (RIBO-) RIBOZYME PHARM INC.
XX
PI  Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;
XX
DR  WPI; 2003-058513/05.
XX
PT  Novel enzymatic nucleic acid that down-regulates expression of neurite
PT  growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT  protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS  Claim 59; SEQ ID NO 4211; 317pp; English.
XX
CC  The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC  that down regulate the expression or inhibit the function of a receptor
CC  for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC  IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC  invention are useful for treating: cerebrovascular accident, central
CC  nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC  lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC  restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC  disease, lupus, multiple sclerosis, transplant/graft rejection,
CC  ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC  conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC  nucleic acids of the invention are also useful for down-regulating the
CC  expression of a target gene and as a diagnostic tool to examine genetic
CC  drifts and mutations within diseased cells or to detect the presence of a
CC  target RNA in a cell. The present RNA sequence represents a human PKR
```

CC substrate sequence.  
 XX Sequence 17 BP; 6 A; 5 C; 3 G; 0 T; 3 U; 0 Other;  
 SQ Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 92.9%; Pred. No. 1.7e+02;  
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 272 AGCCGAGACAGAT 285  
 DB 1 AGCCGAGACAGAU 14  
 RESULT 316  
 ACN65689  
 ID ACN65689 standard; DNA; 17 BP.  
 XX  
 XX ACN65689;  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Human GDMPLP-1 probe SEQ ID NO:2591.  
 XX  
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004137589-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 26-NOV-2003; 2003US-00723361.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 PR 25-MAY-2001; 2001US-00866108.  
 XX  
 PA (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 XX WPI; 2004-533378/51.  
 XX  
 PT Novel myosin-like protein-1, useful for treating or preventing disorder  
 PT associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 PT function.  
 XX  
 PS Disclosure; SEQ ID NO 2591; Opp; English.  
 XX  
 XX The invention relates to a novel polypeptide (I) comprising a sequence  
 CC (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully

CC defined in the specification, a fragment of at least 8 amino acids of  
 CC (SI), 95% deviation from (SI) which are conservative substitutions, and  
 CC 65% identity to (SI). A polypeptide of the invention acts as a agonist or  
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
 CC pharmaceutical composition of the invention is useful for treating or  
 CC preventing a disorder associated with decreased expression or activity of  
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
 CC The present sequence represents a 17-mer nucleotide, used in the  
 CC invention for scanning the sequence represented in ACN63102  
 XX  
 SQ Sequence 17 BP; 3 A; 4 C; 7 G; 3 T; 0 U; 0 Other;  
 Query Match 0.8%; Score 14; DB 1; Length 17;  
 Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 990 CAGGGTCCCATGGA 1003  
 DB 3 CAGGGTCCCATGGA 16  
 RESULT 317  
 ACN65688  
 ID ACN65688 standard; DNA; 17 BP.  
 XX  
 XX ACN65688;  
 XX  
 DT 02-DEC-2004 (first entry)  
 XX  
 DE Human GDMPLP-1 probe SEQ ID NO:2590.  
 XX  
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
 KW skeletal muscle function.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2004137589-A1.  
 XX  
 PD 15-JUL-2004.  
 XX  
 PF 26-NOV-2003; 2003US-00723361.  
 XX  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 PR 30-JAN-2001; 2001WO-US000661.  
 PR 30-JAN-2001; 2001WO-US000662.  
 PR 30-JAN-2001; 2001WO-US000663.  
 PR 30-JAN-2001; 2001WO-US000664.  
 PR 30-JAN-2001; 2001WO-US000665.  
 PR 30-JAN-2001; 2001WO-US000666.  
 PR 30-JAN-2001; 2001WO-US000667.  
 PR 30-JAN-2001; 2001WO-US000668.  
 PR 30-JAN-2001; 2001WO-US000669.  
 PR 05-FEB-2001; 2001WO-US000670.  
 PR 05-FEB-2001; 2001US-0266860P.  
 PR 25-MAY-2001; 2001US-00866108.  
 XX  
 PA (GUY/) GU Y.  
 PA (JIY/) JI Y.  
 PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 XX WPI; 2004-533378/51.  
 XX  
 PT Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.

XX  
PS Disclosure; SEQ ID NO 2590; Opp; English.

XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63102

XX  
SQ Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003  
|||||

Db 4 CAGGGTGCCATGGA 17

RESULT 318  
ACN65690

ID ACN65690 standard; DNA; 17 BP.

XX  
AC ACN65690;

XX  
DT 02-DEC-2004 (first entry)

XX  
DE Human GDMLP-1 probe SEQ ID NO:2592.

XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.

XX  
OS Homo sapiens.

XX  
PN US2004137589-A1.

XX  
PD 15-JUL-2004.

XX  
PF 26-NOV-2003; 2003US-00723361.

XX  
PR 26-MAY-2000; 2000US-0207456P.

XX  
PR 21-SEP-2000; 2000US-0234687P.

XX  
PR 27-SEP-2000; 2000US-0236359P.

XX  
PR 04-OCT-2000; 2000GB-00024263.

XX  
PR 30-JAN-2001; 2001WO-US000661.

XX  
PR 30-JAN-2001; 2001WO-US000662.

XX  
PR 30-JAN-2001; 2001WO-US000663.

XX  
PR 30-JAN-2001; 2001WO-US000664.

XX  
PR 30-JAN-2001; 2001WO-US000665.

XX  
PR 30-JAN-2001; 2001WO-US000666.

XX  
PR 30-JAN-2001; 2001WO-US000667.

XX  
PR 30-JAN-2001; 2001WO-US000668.

XX  
PR 30-JAN-2001; 2001WO-US000669.

XX  
PR 25-MAY-2001; 2001US-00866108.

XX  
PA (GUY)/ GU Y.

XX  
PA (JIY)/ JI Y.

XX  
PA (PENN)/ PENN S G.

XX  
PA (HANZ)/ HANZEL D K.

XX  
PA (RANK)/ RANK D.

PA (CHEN/) CHEN W.

PA (SHAN/) SHANNON M E.

XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX  
XX WPI; 2004-533378/51.

XX  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
XX associated with decreased expression or activity of human genome-derived  
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
XX function.

XX  
PS Disclosure; SEQ ID NO 2592; Opp; English.

XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63102

XX  
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 990 CAGGGTGCCATGGA 1003  
|||||

Db 2 CAGGGTGCCATGGA 15

RESULT 319  
ACN65691

ID ACN65691 standard; DNA; 17 BP.

XX  
AC ACN65691;

XX  
DT 02-DEC-2004 (first entry)

XX  
DE Human GDMLP-1 probe SEQ ID NO:2593.

XX  
KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.

XX  
OS Homo sapiens.

XX  
PN US2004137589-A1.

XX  
PD 15-JUL-2004.

XX  
PF 26-NOV-2003; 2003US-00723361.

XX  
PR 26-MAY-2000; 2000US-0207456P.

XX  
PR 21-SEP-2000; 2000US-0234687P.

XX  
PR 27-SEP-2000; 2000US-0236359P.

XX  
PR 04-OCT-2000; 2000GB-00024263.

XX  
PR 30-JAN-2001; 2001WO-US000661.

XX  
PR 30-JAN-2001; 2001WO-US000662.

XX  
PR 30-JAN-2001; 2001WO-US000663.

XX  
PR 30-JAN-2001; 2001WO-US000664.

XX  
PR 30-JAN-2001; 2001WO-US000665.

XX  
PR 30-JAN-2001; 2001WO-US000666.

XX  
PR 30-JAN-2001; 2001WO-US000667.

XX  
PR 30-JAN-2001; 2001WO-US000668.

XX  
PR 30-JAN-2001; 2001WO-US000669.

XX  
PR 30-JAN-2001; 2001WO-US000670.

```

PR 05-FEB-2001; 2001US-0266860P.
XX 25-MAY-2001; 2001US-00866108.
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 2593; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGMLP-1, or as an inhibitor of hGMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 4 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 950 CAGGTGTCATGGA 1003
DB 1 CAGGTGTCATGGA 14
RESULT 320
AAV01069
ID AAV01069 standard; DNA; 18 BP.
XX
XX AAV01069;
XX
XX 30-MAR-1998 (first entry)
XX
XX Primer R8 for human PKR gene.
XX
XX Human; PKR; double stranded RNA-activated protein kinase; neoplasm;
XX cell growth; differentiation; tumour suppressor; tumorigenesis; primer;
XX PCR; amplification; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX US5670330-A.
XX
XX 23-SEP-1997.
XX
XX 25-OCT-1993; 93US-00143219.
XX
XX 29-SEP-1992; 92US-00953681.
XX
XX 22-OCT-1993; 93US-00141244.
XX
XX (UYMC-) UNIV MCGILL.
XX (UNIW) UNIV WASHINGTON.
XX

```

---

```

XX Roy S, Barber GH, Koromillas AE, Sonenberg N, Katze MG;
XX WPI; 1997-479453/44.
XX
XX Screening method for identifying anti-tumour agents.- based on an
PT increase in the activity of a double stranded RNA-activated protein
PT kinase.
XX
XX Disclosure; Col 37; 41pp; English.
XX
XX The primers AAV01061-V01071 were used to PCR amplify the gene encoding
CC the human PKR protein (AAV01060), a double stranded RNA-activated protein
CC kinase. The protein can be used in a screening method for identifying
CC anti-tumour agents by measuring PKR activity in a system before and after
CC adding a test agent, where an increase in PKR activity indicates that the
CC agent is an anti-tumour agent, especially useful for the prevention
CC and/or treatment of neoplasms. PKR is an interferon-inducible cytoplasmic
CC Ser-Thr specific protein kinase which can also be activated by double
CC stranded RNA. PKR is active in cell growth and differentiation by
CC regulating protein synthesis, and thus has been suggested to function as
CC a tumour suppressor. The screening system may also include a further
CC protein which inhibits PKR activity thereby inducing tumourigenesis. An
CC example of such a protein is the P58 protein, a cellular 58 kD protein
CC purified from influenza-infected cells (see AAW36140)
XX
XX Sequence 18 BP; 6 A; 5 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 272 AGCCGAGAACAGAT 285
DB 1 AGCCGAGAACAGAT 14
RESULT 321
ADQ25637
ID ADQ25637 standard; DNA; 18 BP.
XX
XX ADQ25637;
XX
XX 23-SEP-2004 (first entry)
XX
XX L primer used to detect SSR profiles of inbred maize line PH87H #1.
XX
XX PH87H; maize inbred line; herbicide resistance; transgenic; food;
XX livestock feed; primer; plant; SSR; simple sequence repeat; maize; ss.
XX
XX Zea mays.
XX
XX US6759580-B1.
XX
XX 06-JUL-2004.
XX
XX 15-OCT-2002; 2002US-00271065.
XX
XX 28-JAN-2002; 2002US-0352291P.
XX
XX (PION-) PIONEER HI-BRED INT INC.
XX
XX Cunnyngham CT;
XX
XX WPI; 2004-497138/47.
XX
XX New seed of maize inbred line designated PH87H, useful for producing
PT first generation F1 maize hybrids with superior characteristics (e.g.,
PT herbicide resistance) and as human food, livestock feed or as raw
PT material in industry.
XX
XX Disclosure; SEQ ID NO 1; 28pp; English.
XX

```

CC The present invention provides a seed of maize inbred line, designated  
 CC PH87H. The invention is useful for producing first generation F1 maize  
 CC hybrids with superior characteristics (e.g., herbicide resistance). The  
 CC seed of inbred maize line PH87H, the plant produced from it, hybrid seed  
 CC and various parts of the hybrid maize plant and transgenic versions are  
 CC used as human food, livestock feed and as a raw material in industry. The  
 CC present sequence is a primer used to detect unique simple sequence repeat  
 CC (SSR) profiles for PH1279122 locus of inbred maize line PH87H. This  
 CC sequence is used in the invention.

XX SQ Sequence 18 BP; 2 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1084 GGCTGGTCTGG 1097  
 |||||  
 Db 4 GGCTGGTCTGG 17

RESULT 322  
 ADR74179/c  
 ID ADR74179 standard; DNA; 18 BP.  
 XX AC ADR74179;  
 XX DT 16-DEC-2004 (first entry)  
 XX DE Allele specific primer A for human MI-associated marker hCV25627205.  
 XX KW Human; ss; PCR; primer; SNP; single nucleotide polymorphism;  
 KW myocardial infarction; allele specific primer.  
 XX OS Homo sapiens.  
 XX PN WO2004081187-A2.  
 XX PD 23-SEP-2004.  
 XX PF 10-MAR-2004; 2004WO-US007141.  
 XX PR 10-MAR-2003; 2003US-0453135P.  
 XX PR 30-APR-2003; 2003US-0466412P.  
 XX PA (APPL-) APPLERA CORP.  
 XX PI Cargill M, Devlin JJ, Iakoubova O, Shiffman D;  
 XX WPI; 2004-677537/66.  
 XX PT Identifying an individual who has altered risk for developing myocardial  
 PT infarction comprises detecting single nucleotide polymorphism (SNP), in  
 PT the individual's nucleic acids.  
 XX PS Claim 19; SEQ ID NO 44004; 139pp; English.  
 XX CC The invention relates to identifying an individual who has altered risk  
 CC for developing myocardial infarction comprises detecting single  
 CC nucleotide polymorphism (SNP) in any one of the 4336 nucleotide  
 CC sequences (not given in the specification), in the individual's nucleic  
 CC acids, where the presence of the SNP is correlated with an altered risk  
 CC for myocardial infarction in the individual. Also included are an  
 CC isolated nucleic acid molecule comprising at least 8 contiguous  
 CC nucleotides where one of the nucleotides is an SNP as cited above, or  
 CC their complement), an isolated polypeptide comprising an amino acid  
 CC sequence selected from any of the 696 amino acid sequences not defined in  
 CC the specification, an antibody that specifically binds to the polypeptide  
 CC (or its antigen-binding fragment), an amplified polynucleotide containing  
 CC the SNP as cited (where the amplified polynucleotide is between about 16  
 CC and about 1,000 nucleotides in length), an isolated polynucleotide which  
 CC specifically hybridises to a nucleic acid molecule containing the SNP, a  
 CC kit for detecting SNP in a nucleic acid, detecting SNP in a nucleic acid

CC molecule, detecting a variant polypeptide and identifying an agent useful  
 CC in therapeutically or prophylactically treating myocardial infarction.  
 CC The detection step of the method is carried out by a process selected  
 CC from allele-specific probe hybridisation, allele-specific primer  
 CC extension, allele-specific amplification, sequencing, 5' nuclease  
 CC digestion, molecular beacon assay, oligonucleotide ligation assay, size  
 CC analysis, and single-stranded conformation polymorphism. The method is  
 CC useful for identifying an individual who has altered risk for developing  
 CC myocardial infarction. The present sequence is an allele specific PCR  
 CC primer used to amplify an SNP-containing region from a myocardial  
 CC infarction-associated marker gene. NOTE: SEQ IDs 1-43787 are not shown in  
 CC the specification and are not available from WIPO. These sequence are  
 CC contained on a CD-R named CL001509CDR which has not been supplied with  
 CC the specification.

XX SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 14; DB 1; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1221 TTCACCTGGCAGTGA 1234  
 |||||  
 Db 16 TTCACCTGGCAGTGA 3

RESULT 323  
 AAQ20006/c  
 ID AAQ20006 standard; DNA; 17 BP.  
 XX AC AAQ20006;  
 XX DT 01-APR-1992 (first entry)  
 XX DE Oligonucleotide #2 able to covalently cross-link to target DNA.  
 XX KW deoxyribonucleic acid; major groove; ethanoamino group;  
 KW aziridinylcytosine; cross-linking group; ss.  
 XX OS Synthetic.  
 XX FH Key Location/Qualifiers  
 FT modified\_base 8 /\*tag= b  
 FT /\*mod\_base= m5c  
 FT modified\_base 14 /\*tag= c  
 FT /\*mod\_base= m5c  
 FT modified\_base 17 /\*tag= a  
 FT /\*mod\_base= OTHER  
 FT /\*note= "N4N4-ethanocytosine"  
 XX PN W09118997-A.  
 XX PD 12-DEC-1991.  
 XX PF 25-MAY-1990; 90US-00529346.  
 XX PR 25-MAY-1990; 90US-00529346.  
 XX PR 14-JAN-1991; 91US-00640654.  
 XX PA (GILB-) GILEAD SCIE INC.  
 XX PI Matteucci MD, Krawczyk S;  
 XX WPI; 1992-007480/01.  
 XX PT New sequence-specific non-photo-activated crosslinking agents - bind to  
 PT the major groove of duplex DNA and are esp. useful for treating latent  
 PT infections e.g. HIV.  
 XX PS Example 2; Page 20; 42pp; English.

XX The 3' end of this oligonucleotide carries 1,3-propanediol. The oligo is  
 CC one of four oligonucleotides which were designed to specifically bind and  
 CC cross-link to the duplex target sequence AAQ20004. Oligo #2 has the  
 CC covalent cross-linking group, i.e. N4N4-ethanocytosine, at its 3' end. An  
 CC assay for crosslinked triple helix showed considerable reaction with  
 CC Oligo #2 and with Oligo #1 (see AAQ20005) which has the crosslinking  
 CC group at the 5' end. The most complete reaction was seen with Oligo #3  
 CC (see AAQ20007) having N4N4-ethanocytosine at both the 5' and 3' termini.  
 CC A control oligo with no cross-linking group showed no reaction. The half-  
 CC life of the cross-linking reaction for Oligo #2 was ca. 1 hr (1 microm);  
 CC Oligo #1 showed a rate four times slower. See also AAQ20008  
 XX Sequence 17 BP; 0 A; 3 C; 0 G; 14 T; 0 U; 0 Other;  
 SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 1834 GAAAAAAGAAAAA 1850  
 DB 17 GAAGAAAAAGAAAAA 1  
 RESULT 324  
 ID AAQ79246/c  
 XX AAQ79246 standard; DNA; 17 BP.  
 AC AAQ79246;  
 XX 25-MAR-2003 (revised)  
 DT 18-JUL-1995 (first entry)  
 DT XX  
 DE Guanosine rich oligonucleotide used to treat viral infection.  
 XX  
 XX Guanosine; tetrad; inhibition; replication; virus; treatment; therapy;  
 KW infection; herpes simplex virus; human papilloma virus;  
 KW Epstein-Barr virus; HIV; adenovirus; respiratory syncytial virus;  
 KW hepatitis B virus; human cytomegalovirus; ss.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT misc\_feature 17  
 FT /\*tag= a  
 FT /mod base  
 FT /note= "Propanolamine group attached to this base."  
 XX  
 XX W09425037-A1.  
 XX  
 XX 10-NOV-1994.  
 XX  
 XX 25-APR-1994; 94WO-US004529.  
 XX  
 XX 23-APR-1993; 93US-00053027.  
 XX 28-OCT-1993; 93US-00145704.  
 XX  
 XX (TRIP-) TRIPLEX PHARM CORP.  
 XX (BAYU ) BAYLOR COLLEGE MEDICINE.  
 XX  
 XX Rando RF, Fennwald S, Zengdegi JG, Ojwang JO, Hogan ME;  
 XX WPI; 1994-357890/44.  
 XX  
 XX Oligo-nucleotide(s) rich in guanosine which form guanosine tetrads - used  
 XX to treat viral infections, e.g. herpes-virus and HIV.  
 XX  
 XX Claim 41; Page 68; 101pp; English.  
 XX  
 XX The oligonucleotides (See AAQ79201-52) can be used to treat viral  
 CC infections. The oligonucleotides inhibit viral replication by forming  
 CC guanosine tetrads which form a stabilised 3D structure. Preferred  
 CC oligonucleotides contain at least 2 runs of at least 2 guanosine bases

CC and may be capped at the 3' terminus with a modifier selected from  
 CC polyamine, poly-L-lysine, cholesterol and propanolamine. They may also  
 CC have a modified phosphodiester linkage or be modified to contain a  
 CC phosphorothioate linkage. They are used to treat infections with viruses  
 CC such as herpes simplex virus, human papilloma virus, Epstein-Barr virus,  
 CC HIV, adenovirus, respiratory syncytial virus, hepatitis B virus or human  
 CC cytomegalovirus. (Updated on 25-MAR-2003 to correct PN field.)  
 XX Sequence 17 BP; 0 A; 0 C; 13 G; 4 T; 0 U; 0 Other;  
 SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 OY 1705 CCCCTCCCTCCACCAC 1721  
 DB 17 CCCACCACCCACCAC 1  
 RESULT 325  
 ID AAT51663/c  
 XX AAT51663 standard; DNA; 17 BP.  
 AC AAT51663;  
 XX 12-NOV-1997 (first entry)  
 DT XX  
 DE Viral integrase inhibiting oligonucleotide.  
 XX  
 XX Human immunodeficiency virus; HIV; Epstein Barr virus; EBV;  
 KW herpes simplex virus; HSV; human papilloma virus; HPV; adenovirus;  
 KW respiratory syncytial virus; RSV; cytomegalovirus; CMV; hepatitis B;  
 KW integrase inhibition; guanosine tetrad; ss.  
 XX  
 OS Synthetic.  
 XX  
 XX W09703997-A1.  
 XX 06-FEB-1997.  
 XX  
 XX 17-JUL-1996; 96WO-US011786.  
 XX  
 XX 19-JUL-1995; 95US-0001505P.  
 XX 23-OCT-1995; 95US-00535168.  
 XX 19-MAR-1996; 96US-0013688P.  
 XX 25-MAR-1996; 96US-0014007P.  
 XX 17-APR-1996; 96US-0015714P.  
 XX 23-APR-1996; 96US-0016271P.  
 XX  
 XX (ARON-) ARONEX PHARM INC.  
 XX  
 XX Rando RF, Fennwald S, Zengdegi JG, Ojwang JO, Hogan ME;  
 XX Pommer Y, Mazumder A;  
 XX WPI; 1997-132569/12.  
 XX  
 XX Oligo-nucleotide(s) capable of forming guanosine tetrads - inhibit viral  
 XX enzyme responsible for integrating viral nucleic acid into the host  
 XX genome.  
 XX  
 XX Claim 3; Page 166; 245pp; English.  
 XX  
 XX AAT51619-T51698 are oligonucleotides used to inhibit the production of  
 CC viruses within a host cell. The oligonucleotides may form guanosine  
 CC tetrads (structures formed of eight hydrogen bonds by coordination of the  
 CC four oxygen atoms of guanine with alkali cations believed to bind to the  
 CC centre of a quadruplex, and by strong stacking interactions) and are used  
 CC to prevent the integration of viral nucleic acid into a host genome. The  
 CC oligonucleotides inhibit functioning of the integrase enzyme and hence  
 CC prevent viral infection. Viral infections that may be treated include  
 CC human immunodeficiency virus (HIV), Epstein Barr virus (EBV), herpes  
 CC simplex virus (HSV), human papilloma virus (HPV), adenovirus, respiratory  
 CC syncytial virus (RSV), cytomegalovirus (CMV) and hepatitis B virus (HBV),

```
CC especially HIV-1 infection
XX
SQ Sequence 17 BP; 0 A; 0 C; 13 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCCTCCCTCCACAC 1721
Db 17 CCCACCCACCCACAC 1

RESULT 326
AAAX71500/c
ID AAX71500 standard; RNA; 17 BP.
XX
AC AAX71500;
XX
DT 28-JUL-1999 (first entry)
DE
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #512.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; Kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR ) CHIRON CORP.
XX
PI Pavco P, Meswigen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 112; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 AAGGTAATATTTCCAA 1165
Db 17 AAGGAAATATTTCCCA 1

RESULT 327
AAAX75068/c
ID AAX75068 standard; RNA; 17 BP.
XX
AC AAX75068;
XX
DT 28-JUL-1999 (first entry)
DE
DE Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #596.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; Kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Mus sp.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (CHIR ) CHIRON CORP.
XX
PI Pavco P, Meswigen J, Stinchcomb D, Escobedo J;
XX
DR WPI; 1997-259017/23.
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
PS Claim 4; Page 173; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 0 A; 0 C; 2 G; 0 T; 15 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAATAAAAAA 1851
Db 17 AAACAAAAAACAATAA 1

RESULT 328
AAAX71415
ID AAX71415 standard; RNA; 17 BP.
XX
AC AAX71415;
XX
DT 28-JUL-1999 (first entry)
DE
DE Human KDR VEGF receptor hammerhead ribozyme substrate #427.
```





XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA

PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,

PT rheumatoid arthritis, etc., in a human patient.

XX Claim 4; Page 138; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate the

CC synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be

CC treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAX67275 to AAX75752 represent specific examples

CC of nucleic acid molecules from the present invention

XX

SQ Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 AAGGTAATATTTCCAA 1165

DB 17 AAGGAAAATATTTCCCA 1

RESULT 331

AAX72985

ID AAX72985 standard; RNA; 17 BP.

XX AAX72985;

AC

XX 28-JUL-1999 (first entry)

DT

XX Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #418.

DE

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;

KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;

KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;

KW foetal liver kinase 1; ss.

XX

OS Mus sp.

XX

XX W09715662-A2.

PN

XX 01-MAY-1997.

PD

XX 25-OCT-1996; 96WO-US017480.

PP

XX 26-OCT-1995; 95US-0005974P.

XX

PR 11-JAN-1996; 96US-00584040.

XX

XX (RIBO-) RIBOZYME PHARM INC.

PA (CHIR ) CHIRON CORP.

PA

XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

PI

XX WPI; 1997-259017/23.

DR

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA

PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,

PT rheumatoid arthritis, etc., in a human patient.

XX

XX Claim 4; Page 136; 218pp; English.

PS

XX The present invention describes nucleic acid molecules which modulate the

CC synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be

CC treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAX67275 to AAX75752 represent specific examples

CC of nucleic acid molecules from the present invention

XX

SQ Sequence 17 BP; 5 A; 3 C; 4 G; 0 T; 5 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 1.8e+02;

Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1568 TGCACCTTTGGAAACT 1584

DB 1 UGCAAGUUGGAAACCU 17

RESULT 332

AAX75069/C

ID AAX75069 standard; RNA; 17 BP.

XX AAX75069;

AC

XX 28-JUL-1999 (first entry)

DT

XX Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #597.

DE

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;

KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;

KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;

KW foetal liver kinase 1; ss.

XX

OS Mus sp.

XX

XX W09715662-A2.

PN

XX 01-MAY-1997.

PD

XX 25-OCT-1996; 96WO-US017480.

PP

XX 26-OCT-1995; 95US-0005974P.

XX

PR 11-JAN-1996; 96US-00584040.

XX

XX (RIBO-) RIBOZYME PHARM INC.

PA (CHIR ) CHIRON CORP.

PA

XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

PI

XX WPI; 1997-259017/23.

DR

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA

PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,

PT rheumatoid arthritis, etc., in a human patient.

XX

XX Claim 4; Page 173; 218pp; English.

PS

XX The present invention describes nucleic acid molecules which modulate the

CC synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be

CC treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAX67275 to AAX75752 represent specific examples

CC of nucleic acid molecules from the present invention

XX

SQ Sequence 17 BP; 0 A; 0 C; 2 G; 0 T; 15 U; 0 Other;

```

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1835 AAAAAAAAAAAAAAAAAA 1851
    ||||| ||||| |||||
Db 17 AAAAAAAAAACAAAAA 1

RESULT 333
AAX71414
ID AAX71414 standard; RNA; 17 BP.
XX
AC AAX71414;
XX
DT 28-JUL-1999 (first entry)
XX
DE Human KDR VEGF receptor hammerhead ribozyme substrate #426.
XX
KW Vascular endothelial growth factor receptor; VEGF receptor; flk-1;
KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW foetal liver kinase 1; ss.
XX
OS Homo sapiens.
XX
PN WO9715662-A2.
XX
PD 01-MAY-1997.
XX
PF 25-OCT-1996; 96WO-US017480.
XX
PR 26-OCT-1995; 95US-0005974P.
XX
PR 11-JAN-1996; 96US-00584040.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PA (CHIR ) CHIRON CORP.
XX
PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX
PI WPI, 1997-259017/23.
XX
DR
XX
PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX
XX
PS Claim 4; Page 110; 218pp; English.
XX
CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX
SQ Sequence 17 BP; 6 A; 4 C; 3 G; 0 T; 4 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1567 CTGCAACTTTCGAAAC 1583
    ||||| :|||
Db 1 CUGCAAAUUGGAAACC 17

RESULT 334
AAX97651
ID AAX97651 standard; RNA; 17 BP.
XX
AC AAX97651;
XX
DT 17-MAR-1999 (first entry)
XX
DE Human EGF-R target sequence nucleotide position 3744.
XX
KW Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW cancer; genetic drift; detection; mutation; ss.
XX
OS Homo sapiens.
XX
PN WO9833893-A2.
XX
PD 06-AUG-1998.
XX
PF 14-JAN-1998; 98WO-US000730.
XX
PR 31-JAN-1997; 97US-0036476P.
XX
PR 04-DEC-1997; 97US-00985162.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (UYAS-) UNIV ASTON.
XX
PI Akhtar S, Pell P, Mcswiggen JA;
XX
PI WPI, 1998-437449/37.
XX
DR
XX
PT Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT growth factor receptor, useful for inhibiting cell proliferation and for
PT treating cancers.
XX
XX
PS Claim 5; Page 77; 109pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules (NAMS)
CC which specifically cleave RNA derived from an epidermal growth factor
CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC represent specifically claimed target sequence from human EGF-R. AAV98044
CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
CC hairpin ribozymes respectively for human EGF-R. The NAMS are useful for
CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC expression levels e.g. to inhibit cell proliferation in the prevention or
CC treatment of cancers. The NAMS can also be used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of EGF-R RNA in a cell
XX
SQ Sequence 17 BP; 5 A; 2 C; 5 G; 0 T; 5 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 174 AATGGCATCTCTAAGAG 190
    ||||| :|||
Db 1 AAUGCAUUCUUAAGGG 17

RESULT 335
AAX79245/C
ID AAX79245 standard; DNA; 17 BP.
XX
AC AAX79245;
XX
DT 21-OCT-2004 (revised)
DT 31-AUG-1999 (first entry)
XX
DE Oligonucleotide #38 forms an intramolecular stacked tetrad structure.
XX
KW Column; box; stacked tetrad; inhibition; replication; pathophysiological;
KW herpes simplex virus; HSV; human papilloma virus; Epstein Barr Virus;
KW HPV; EBV; HIV; human immunodeficiency virus; adenovirus; RSV; HBV; HCMV;

```

KW respiratory syncytial virus; hepatitis B virus; human cytomegalovirus;  
 KW human T-cell leukaemia virus; HTLV; ss.  
 XX Synthetic.  
 XX Key Location/Qualifiers  
 XX misc\_structure 1. .17  
 FT /\*tag= a  
 FT /note= "forms intramolecular stacked tetrad or 3D  
 FT columnar box structure"  
 FT modified\_base 1. .17  
 FT /\*tag= b  
 FT /mod\_base= optionally contains phosphodiester  
 FT internucleotide linkages  
 XX WO9833807-A1.  
 XX 06-AUG-1998. 98WO-US001974.  
 XX 03-FEB-1998; 98WO-US001974.  
 XX 04-FEB-1997; 97US-0037374P.  
 PR 09-DEC-1997; 97US-00987574.  
 XX (ARON-) ARONEX PHARM INC.  
 PA Rando RF, Ojwang JO, Hogan ME, Wallace TL, Cossum PA;  
 PI WPI; 1998-446809/38.  
 XX New guanosine-rich tetrad forming oligonucleotide(s) - used for  
 PT inhibiting virus replication for treating e.g. herpes simplex, papilloma,  
 PT HIV, adenovirus or hepatitis B virus infection.  
 XX Disclosure; Page 147; 140pp; English.  
 PS Sequences AAX79210-X79275 represent oligonucleotides (ON) which are able  
 CC to form a columnar box or "stacked tetrad" structure by intramolecular  
 CC internucleotide binding. The ONs are used to inhibit the replication of  
 CC viruses. They are able to suppress virus production for prolonged periods  
 CC after an initial short treatment regimen. They can be used for treating  
 CC pathophysiological states caused by viruses such as herpes simplex virus,  
 CC human papilloma virus, Epstein Barr Virus, HIV, adenovirus, respiratory  
 CC syncytial virus, hepatitis B virus, human cytomegalovirus and HTLV I and  
 CC II  
 CC Revised record issued on 21-OCT-2004 : Correction to feature table key  
 XX Sequence 17 BP; 0 A; 0 C; 13 G; 4 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1705 CCCCTCCCTCCACCAC 1721  
 DB 17 CCCACCACCCACCAC 1  
 RESULT 336  
 AAA21122/c  
 ID AAA21122 standard; RNA; 17 BP.  
 XX AAA21122;  
 AC  
 XX 19-JUN-2000 (first entry)  
 XX Integrin alpha 6 subunit substrate sequence SEQ ID NO:4348.  
 DE  
 XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytostatic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;

KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX Homo sapiens.  
 OS  
 XX WO9950403-A2.  
 PN 07-OCT-1999.  
 XX 24-MAR-1999; 99WO-US006507.  
 PF 27-MAR-1998; 98US-0079678P.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
 PI WPI; 1999-591315/50.  
 XX Novel ribozymes for modulating the synthesis, expression and/or stability  
 PT of an mRNA encoding an angiogenic factors.  
 XX Claim 55; Page 188; 305pp; English.  
 PS The present invention describes enzymatic nucleic acid molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT.  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3  
 XX Sequence 17 BP; 1 A; 2 C; 0 G; 0 T; 14 U; 0 Other;  
 SQ  
 Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 202 AAATAAAGAGAAATA 218  
 DB 17 AAAGAAAGAGAAATA 1  
 RESULT 337  
 AAA18738/c  
 ID AAA18738 standard; RNA; 17 BP.  
 XX AAA18738;  
 AC  
 XX 19-JUN-2000 (first entry)  
 XX Human TIE-2 substrate sequence SEQ ID NO:1964.  
 DE

XX Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;  
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;  
 KW hammerhead ribozyme; angiogenic factor; cytotstatic; antidiabetic;  
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;  
 KW dermatological; RNA cleavage; cancer; diabetic retinopathy; arthritis;  
 KW age related macular degeneration; inflammation; neovascular glaucoma;  
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;  
 KW tuberos scleriosis; pot-wine stain; Sturge Weber syndrome;  
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.  
 XX Homo sapiens.  
 OS  
 XX  
 XX WO9950403-A2.  
 PN  
 XX  
 XX 07-OCT-1999.  
 PD  
 XX  
 XX 24-MAR-1999; 99WO-US006507.  
 PF  
 XX  
 XX 27-MAR-1998; 98US-0079678P.  
 PR  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX  
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;  
 PI WPI; 1999-591315/50.  
 DR  
 XX  
 XX Novel ribozymes for modulating the synthesis, expression and/or stability  
 PT of an mRNA encoding an angiogenic factors.  
 PT  
 XX  
 XX Claim 56; Page 114; 305pp; English.  
 FS  
 XX  
 XX The present invention describes enzymatic nucleic acid molecules with RNA  
 CC cleaving activity, which specifically cleave RNA encoded by an aryl  
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3  
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to  
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,  
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their  
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to  
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086  
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;  
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme  
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and  
 CC AAA21596 to AAA21688 represent their corresponding target sequences;  
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence  
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to  
 CC AAA23422 represent their corresponding target sequences. The ribozymes of  
 CC the invention are used for modulating the synthesis, expression and/or  
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,  
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are  
 CC especially used to treat cancer, diabetic retinopathy, age related  
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as  
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,  
 CC angiofibroma of tuberos scleriosis, pot-wine stains, Sturge Weber  
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,  
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,  
 CC integrin subunit alpha-6, or integrin subunit beta-3  
 XX  
 XX Sequence 17 BP; 3 A; 4 C; 0 G; 0 T; 10 U; 0 Other;  
 SQ  
 Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 203 AATAAAGCAAGAAATAG 219  
 DB 17 AGTAATAGCAAGAAATAG 1  
 RESULT 338  
 AAA25595  
 ID AAA25595 standard; DNA; 17 BP.  
 XX

AC  
 XX  
 XX 19-JUL-2000 (first entry)  
 DT  
 XX  
 XX Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2093.  
 DE  
 XX  
 XX Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
 KW gene expression modification; cancer; phosphorothioate; endonuclease;  
 KW anticancer; breast cancer; endometrium cancer; ss.  
 KW  
 OS  
 XX Homo sapiens.  
 OS  
 XX WO9954459-A2.  
 PN  
 XX  
 XX 28-OCT-1999.  
 PD  
 XX  
 XX 19-APR-1999; 99WO-US008547.  
 PF  
 XX  
 XX 20-APR-1998; 98US-0082404P.  
 PR  
 XX  
 XX 23-JUN-1998; 98US-00103636.  
 PR  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 PA  
 XX  
 XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;  
 PI Matulic-Adamic J;  
 PI  
 XX  
 XX WPI; 2000-013248/01.  
 DR  
 XX  
 XX New nucleic acids that interact, and optionally cleave, target sequences,  
 PT used to treat cancer.  
 PT  
 XX  
 XX Claim 77; Page 84; 148pp; English.  
 PS  
 XX  
 XX The present invention describes nucleic acids (A) that interact stably  
 CC with a target sequence and contain at least one phosphorodithioate  
 CC link, having endonuclease activity. (A), and more generally any catalytic  
 CC nucleic acid (A') that modulates expression of the oestrogen receptor  
 CC gene, are used to treat cancer (particularly of breast or endometrium),  
 CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
 CC for other conditions associated with levels of oestrogen receptor.  
 CC Because of the high selectivity for targeted RNA, (A) can also be used to  
 CC correlate inhibition of gene expression with alterations in phenotype,  
 CC particularly for identification of therapeutic targets, and as research  
 CC reagents (for RNA, in the same way that restriction endonucleases are  
 CC used with DNA). The combination of modifications in (A) improves  
 CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
 CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
 CC AAA24748 to AAA25992 represent their corresponding target sequences.  
 CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
 CC sequences, and AAA26107 to AAA26218 represent their corresponding target  
 CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and  
 CC antisense oligonucleotides used in the exemplification of the present  
 CC invention  
 XX  
 XX Sequence 17 BP; 6 A; 4 C; 3 G; 4 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1567 CTGCAACTTTGGAAAC 1583  
 DB 1 CAGCACTTTGGAATC 17  
 RESULT 339  
 AAA25180/c  
 ID AAA25180 standard; DNA; 17 BP.  
 XX  
 XX AAA25180;  
 AC  
 XX

DT 19-JUL-2000 (first entry)  
DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1678.  
XX  
XX  
KW Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;  
KW gene expression modification; cancer; phosphorothioate; endonuclease;  
KW anticancer; breast cancer; endometrium cancer; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO9954459-A2.  
XX  
XX 28-OCT-1999.  
XX  
XX 19-APR-1999; 99WO-US008547.  
XX  
XX 20-APR-1998; 98US-0082404P.  
XX  
XX 23-JUN-1998; 98US-00103636.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Thompson JD, Beigelman L, Mcswiggen JA, Karpeisky A, Bellon L;  
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeberli P;  
PI Matulic-Adamic J;  
XX  
XX WPI; 2000-013248/01.  
XX  
XX New nucleic acids that interact, and optionally cleave, target sequences,  
XX used to treat cancer.  
XX  
XX Claim 77; Page 71; 149pp; English.  
XX  
XX The present invention describes nucleic acids (A) that interact stably  
CC with a target sequence and contain at least one phosphorodi(thioate  
CC link, having endonuclease activity. (A), and more generally any catalytic  
CC nucleic acid (A') that modulates expression of the oestrogen receptor  
CC gene, are used to treat cancer (particularly of breast or endometrium),  
CC in vivo or by transforming cells ex vivo and implanting treated cells, or  
CC for other conditions associated with levels of oestrogen receptor.  
CC Because of the high selectivity for targeted RNA, (A) can also be used to  
CC correlate inhibition of gene expression with alterations in phenotype,  
CC particularly for identification of therapeutic targets, and as research  
CC reagents (for RNA, in the same way that restriction endonucleases are  
CC used with DNA). The combination of modifications in (A) improves  
CC resistance to nucleases, binding affinity and/or activity. AAA23503 to  
CC AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and  
CC AAA24748 to AAA25992 represent their corresponding target sequences.  
CC AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme  
CC sequences, and AAA26107 to AAA26218 represent their corresponding target  
CC sequences. AAA26219 to AAA26271 represent other ribozyme sequences and  
CC antisense oligonucleotides used in the exemplification of the present  
XX invention  
XX  
XX Sequence 17 BP; 1 A; 0 C; 1 G; 15 T; 0 U; 0 Other;  
SQ

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1835 AAAAAAAAAAAAAA 1851  
DB 17 AAAAAAAAAACAAAA 1

RESULT 340  
AAH94595/c  
ID AAH94595 standard; RNA; 17 BP.  
XX  
XX AAH94595;  
AC  
XX 09-OCT-2001 (first entry)  
DT  
XX

DE Human Chk1 ribozyme substrate SEQ ID NO: 20.  
XX  
KW Human; checkpoint kinase-1; Chk1; antisense; ribozyme; gene therapy;  
KW RNA cleavage; cancer; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO200157206-A2.  
XX  
XX 09-AUG-2001.  
XX  
XX 02-FEB-2001; 2001WO-US003504.  
XX  
XX 03-FEB-2000; 2000US-0179983P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX (FATT/) FATTAEY A R.  
XX  
XX Fattaey AR, Jarvis T, Mcswiggen J, Boohar RN, Holman PS;  
XX  
XX WPI; 2001-496922/54.  
XX  
XX Novel nucleic acid molecule e.g., ribozymes or antisense nucleic acid  
XX molecules, which downregulates expression of a checkpoint kinase-1 gene,  
XX useful for treating colorectal, lung, breast or prostate cancers.  
XX  
XX Claim 4; Page 52; 115pp; English.  
XX  
XX The present invention provides nucleic acid molecules capable of  
CC downregulating the expression of the human checkpoint kinase-1 (Chk1)  
CC gene. These may be antisense or ribozyme sequences, and are useful in the  
CC treatment of diseases associated with conditions affected by Chk1 levels,  
CC including cancer. The present sequence is an oligonucleotide described in  
CC the exemplification of the invention  
XX  
XX Sequence 17 BP; 11 A; 0 C; 3 G; 0 T; 3 U; 0 Other;  
SQ

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1654 TCTTCTTGATCTTTC 1670  
DB 17 TCTTCTTAATATTTTC 1

RESULT 341  
ABK02550  
ID ABK02550 standard; RNA; 17 BP.  
XX  
XX ABK02550;  
AC  
XX  
XX 12-MAR-2002 (first entry)  
DT  
XX  
XX Human NOGO Amberzyme #222.  
XX  
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
XX Homo sapiens.  
XX  
XX Synthetic.  
XX  
XX WO200159103-A2.  
XX  
XX

XX PD 16-AUG-2001.  
 XX PF 09-FEB-2001; 2001WO-US004273.  
 XX PR 11-FEB-2000; 2000US-0181797P.  
 XX PR 28-FEB-2000; 2000US-0185516P.  
 XX PR 06-MAR-2000; 2000US-0187128P.  
 XX PA (RIBO-) RIBOZYME PHARM INC.  
 XX PA (BLAT/) BLATT L.  
 XX PA (MCSW/) MCSWIGGEN J.  
 XX PA (CHOW/) CHOWRIRA B M.  
 XX PI Blatt L, Mcswiggen J, Chowrira BM;  
 XX DR WPI; 2001-607195/69.  
 XX PR Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
 PT constructs, which down regulate expression of a CD20 gene or neurite  
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
 PT central nervous system injury.  
 XX PS Claim 88; Page 135; 200pp; English.  
 XX CC The invention relates to a nucleic acid molecule which down regulates  
 CC expression of a CD20 gene and a nucleic acid molecule which down  
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
 CC DNzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule  
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr  
 CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
 CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA  
 CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
 CC the cell and treat a patient having a condition associated with the level  
 CC of CD20. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOGO-  
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
 CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
 CC cell and treat a patient having a condition associated with the level of  
 CC NOGO. The treatment may further comprise the use of one or more  
 CC therapies. In particular, the NOGO-targetting nucleic acid may be used to  
 CC treat central nervous system (CNS) injury and cerebrovascular accident  
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
 CC disease, muscular dystrophy, and/or other neurodegenerative disease  
 CC states which respond to the modulation of NOGO expression. The present  
 CC sequence is an amberyzyme molecule of the invention  
 XX SQ Sequence 17 BP; 10 A; 0 C; 5 G; 0 T; 2 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 76.5%; Pred. No. 1.8e+02;  
 Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;  
 Qy 201 GAAATAAAGGAAGAAAT 217  
 Db 1 GGAUUAAGGAAGAAU 17  
 RESULT 342  
 AAS56748/C  
 ID AAS56748 standard; RNA; 17 BP.  
 XX AC AAS56748;  
 16-JAN-2002 (first entry)  
 BR1 ribozyme sequence tag RNA #17.  
 Human; BRCA-1 regulator; ribozyme; BR1; RNA target recognition; probe;  
 cytosatic; RNA cleavage; tumour suppressor; PCR primer; CHLR2; AF6; BR2;  
 inhibitor dominant negative 4; breast basic conserved protein 1; BNC1;  
 BR3; ID4; cancer; proliferative disorder; tumour proliferation; ss.  
 Homo sapiens.  
 WO200170982-A2.  
 27-SEP-2001.  
 23-MAR-2001; 2001WO-US009559.  
 23-MAR-2000; 2000US-00536058.  
 (IMMU-) IMMUSOL INC.  
 (BEGE/) BEGER C.  
 Beger C, Barber J, Wong-Staal F;  
 WPI; 2001-611503/70.  
 Novel polypeptides that are the regulators of BRCA-1, useful for treating  
 cancer and diagnosing the presence of neoplastic cells in biological  
 sample.  
 Disclosure; Page 20; 97pp; English.  
 Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators,  
 ribozyme target recognition RNA sequences, DNA fragments encoding the RNA  
 and primers used in the methods of the invention. Hybridisation of  
 ribozymes to their targets results in cleavage of the RNA target. The  
 ribozymes can be used to cleave regulators of the tumour suppressor BRCA-  
 1, resulting in upregulation or downregulation of BRCA-1 in a cell. The  
 mRNA targets include those encoding the BRCA-1 regulator BR1, inhibitor  
 dominant negative 4 (ID4), breast basic conserved protein 1 (BBC1),  
 CHLR2, AF6, BR2 and BR3. Regulation of BRCA-1 is useful for treating and  
 diagnosing cancer and other proliferative disorders. The severity of an  
 incidence of cancer can be lessened by regulating tumour proliferation  
 through modulation of BRCA-1 expression. The sequences of the invention  
 are useful in the development of anti-cancer drugs  
 SQ Sequence 17 BP; 10 A; 3 C; 1 G; 0 T; 3 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 1468 TTGTTTCTTATGTTGTT 1484  
 Db 17 TTGATTCATAATGTTGTT 1  
 RESULT 343  
 AAF83171  
 ID AAF83171 standard; DNA; 17 BP.  
 XX AC AAF83171;  
 XX DT 09-JUL-2001 (first entry)  
 XX DE Probe PN(n)T used in detection by allele specific extension.  
 XX KW Immobilisation; chemical; biological; polynucleotide amplification;  
 XX KW nucleic acid detection; probe; hybridisation; PCR primer; ss.  
 XX OS Synthetic.  
 XX





XX OS Homo sapiens.  
 XX PN WO200192524-A2.  
 XX PD 06-DEC-2001.  
 XX PF 25-MAY-2001; 2001WO-US016981.  
 XX PR 26-MAY-2000; 2000US-0207456P.  
 XX PR 21-SEP-2000; 2000US-0234687P.  
 XX PR 27-SEP-2000; 2000US-0236359P.  
 XX PR 04-OCT-2000; 2000GB-00024263.  
 XX PR 30-JAN-2001; 2001WO-US000661.  
 XX PR 30-JAN-2001; 2001WO-US000662.  
 XX PR 30-JAN-2001; 2001WO-US000663.  
 XX PR 30-JAN-2001; 2001WO-US000664.  
 XX PR 30-JAN-2001; 2001WO-US000665.  
 XX PR 30-JAN-2001; 2001WO-US000666.  
 XX PR 30-JAN-2001; 2001WO-US000667.  
 XX PR 30-JAN-2001; 2001WO-US000668.  
 XX PR 30-JAN-2001; 2001WO-US000669.  
 XX PR 30-JAN-2001; 2001WO-US000670.  
 XX PR 05-FEB-2001; 2001US-0266860P.  
 XX PA (AEOM-) AEOMICA INC.  
 XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 XX PX WPI; 2002-179446/23.  
 XX PR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 XX PT or as specific biomolecule capture probes for surface-enhanced laser  
 XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 XX PS Disclosure; SEQ ID NO 9572; 214pp; English.  
 XX XX The present invention describes a human genome-derived myosin-like  
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 CC nucleic acids can be used as probes to detect, characterise and quantify  
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
 CC protein variants having desired phenotypic improvements, and for  
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 CC -1 proteins, as standards in assays used to determine the concentration  
 CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 CC capture probes for surface-enhanced laser desorption ionisation, as  
 CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 CC production, and in vaccines or for replacement therapy. The  
 CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 CC disorder associated with the expression of hGDMPLP-1, in particular heart  
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 CC The present sequence represents an oligomer used in the screening of the  
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequence  
 XX SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;  
 XX  
 XX Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 XX Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 XX  
 XX Qy 969 CTGCACACGCTGGGATGT 985  
 XX Db 17 CTCGACACGCGGGATGT 1  
 XX  
 XX RESULT 346  
 XX ABN08368

ABN08368 standard; DNA; 17 BP.  
 ABN08368;  
 29-MAY-2002 (first entry)  
 Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8360.  
 Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
 muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
 skeletal muscle disorder; amplicon; screening; ss.  
 Homo sapiens.  
 WO200192524-A2.  
 06-DEC-2001.  
 25-MAY-2001; 2001WO-US016981.  
 26-MAY-2000; 2000US-0207456P.  
 21-SEP-2000; 2000US-0234687P.  
 27-SEP-2000; 2000US-0236359P.  
 04-OCT-2000; 2000GB-00024263.  
 30-JAN-2001; 2001WO-US000661.  
 30-JAN-2001; 2001WO-US000662.  
 30-JAN-2001; 2001WO-US000663.  
 30-JAN-2001; 2001WO-US000664.  
 30-JAN-2001; 2001WO-US000665.  
 30-JAN-2001; 2001WO-US000666.  
 30-JAN-2001; 2001WO-US000667.  
 30-JAN-2001; 2001WO-US000668.  
 30-JAN-2001; 2001WO-US000669.  
 30-JAN-2001; 2001WO-US000670.  
 05-FEB-2001; 2001US-0266860P.  
 (AEOM-) AEOMICA INC.  
 Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
 WPI; 2002-179446/23.  
 New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
 or as specific biomolecule capture probes for surface-enhanced laser  
 desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
 Disclosure; SEQ ID NO 8360; 214pp; English.  
 The present invention describes a human genome-derived myosin-like  
 protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
 nucleic acids can be used as probes to detect, characterise and quantify  
 hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
 provide initial substrates for the recombinant engineering of hGDMPLP-1  
 protein variants having desired phenotypic improvements, and for  
 expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
 used as immunogens to raise antibodies that specifically recognise hGDMPLP  
 -1 proteins, as standards in assays used to determine the concentration  
 and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
 capture probes for surface-enhanced laser desorption ionisation, as  
 therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
 production, and in vaccines or for replacement therapy. The  
 polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
 disorder associated with the expression of hGDMPLP-1, in particular heart  
 and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
 The present sequence represents an oligomer used in the screening of the  
 hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
 The sequence data for this patent did not form part of the printed  
 specification, but was obtained in electronic format directly from WIPO  
 at ftp.wipo.int/pub/published\_pct\_sequence  
 Sequence 17 BP; 6 A; 1 C; 8 G; 2 T; 0 U; 0 Other;

```
Query Match          0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 390 GATGGCTGGAGAAAGT 406
   ||| ||| ||| ||| |||
Db 1 GAGGAGCTGGAGAAAGT 17

RESULT 347
ABN08371
ID ABN08371 standard; DNA; 17 BP.
AC ABN08371;
XX
XX
DT 29-MAY-2002 (first entry)
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8363.
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 8363; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
```

```
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1 in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 6 A; 2 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match          0.7%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.8e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 393 GGGCTGGAGAAAGTTCA 409
XX   ||| ||| ||| ||| |||
XX Db 1 GAGCTGGAGAAAGTTCA 17

RESULT 348
ABN01545
ID ABN01545 standard; DNA; 17 BP.
XX
XX AC ABN01545;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1537.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 1537; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
```

nucleic acids can be used as probes to detect, characterise and quantify hGDMPL-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPL-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPL-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPL-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPL proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPL-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPL-1 may be used for diagnosing a disorder associated with the expression of hGDMPL-1, in particular heart and skeletal muscle disorders. hGDMPL-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPL-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at [ftp.wipo.int/pub/published\\_pct\\_sequence](http://ftp.wipo.int/pub/published_pct_sequence)

DR	WPI; 2002-479509/51.
XX	
PT	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
PT	acids encoding the protein, useful for treating subjects having defects
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
PT	e.g., liver or bone.
XX	
XX	Example 2; Page 243; 418pp; English.
PS	
XX	
CC	The invention relates to a novel isolated nucleic acid encoding human
CC	KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the
CC	invention has cytostatic activity. The nucleotide may have a use in gene
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC	monitor a disease caused by altered expression of human KTOM1.
CC	Compositions comprising the nucleic acids, proteins or antibodies may be
CC	used to treat subjects having defects in KTOM1 which can manifest as
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta,
CC	function. The sequence represents a probe used in the invention to scan
CC	the nt 1-1001 portion of human KTOM1a (AB063232)
XX	
XX	Sequence 17 BP; 4 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
SQ	

XX PS Example 2; Page 621; 718pp; English.

XX CC The present invention relates to human testis expressed Patched like protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL has two isoforms, with a few single base pair differences between the two. One of the single base pair changes introduces a premature stop codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL shares an overall structure organisation with the Patched protein. The shared structural features strongly imply that HTPL plays a role similar to that of Patched, and is a potential tumour suppressor. HTPL is important in regulating male germ cell development, and the HTPL gene was mapped to human chromosome 10p12.1. HTPL and its coding sequence are useful for diagnosing a disorder caused by mutation in HTPL, and in therapy and manufacture of a medicament for treatment or prevention of such disorder associated with decreased expression or activity of human HTPL. Such disorders include disorders of testis, or adrenal, adult and foetal liver, bone marrow, brain, kidney, lung, placenta, prostate, skeletal muscle or colon function. HTPL proteins and nucleic acids are clinically useful diagnostic markers and potential therapeutic agents for male infertility and cancer. The present oligonucleotide was used in an example from the invention

XX SQ Sequence 17 BP; 3 A; 1 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 65 ATTATCTTAACAAGAAA 81  
 DB 17 AATATCATACAGAAA 1  
 ||||| ||||| ||||| |||||

RESULT 351  
 ABK17547/c  
 ID ABK17547 standard; RNA; 17 BP.  
 XX AC ABK17547;  
 XX 09-APR-2002 (first entry)  
 XX Human ERG hammerhead ribozyme target sequence, Seq ID No 194.

XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;  
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
 KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;  
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;  
 KW amberzyme.

XX OS Homo sapiens.  
 XX WO200188124-A2.  
 XX 22-NOV-2001.  
 XX 16-MAY-2001; 2001WO-US015866.  
 XX 16-MAY-2000; 2000US-00572021.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX (GLAX) GLAXO GROUP LTD.  
 XX Jarvis T, Von Carlowitz I, Mcswiggen-JA, McLaughlin F, Randi AM;  
 XX WPI; 2002-082995/11.

XX Novel polynucleotide which down regulates expression of Ets-related gene,  
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,  
 PT

PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
 XX Claim 4; Page 62; 149pp; English.  
 XX The invention relates to a nucleic acid molecule (I) which down regulates expression of an Ets-related gene (ERG). (I) is useful for treating conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma, tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for treating a patient having a condition associated with the level of ERG, by contacting cells of the patient with (I) under conditions suitable for the treatment. The method comprises the use of one or more therapies under conditions suitable for the treatment. Leukaemia or tumour angiogenesis is treated by administering (I) to the patient in conjunction with one or more of other therapies such as radiation or chemotherapy treatment. (I) is useful for reducing ERG activity in a cell, by contacting the cell with (I). (I) is useful for cleaving RNA of ERG gene, by contacting (I) with RNA, in the presence of a divalent cation such as Mg<sup>2+</sup>. (I) is useful for diagnosis of conditions and diseases related to the expression of ERG, and as diagnostic tool to examine genetic drift and mutations within diseased cells or to detect the presence of ERG RNA in a cell. (I) is useful for specifically targeting genes that share homology with ERG gene or ERG fusion genes. ABK17547-ABK22719 represent nucleic acids, including antisense and enzymatic nucleic acid molecules which regulate expression of ERG, and related PCR primers of the invention

XX SQ Sequence 17 BP; 6 A; 5 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1118 AGTTGGTGCTTCCAGT 1134  
 DB 17 AGTTGGTGAATCCAGT 1  
 ||||| ||||| ||||| |||||

RESULT 352  
 ABK19008/c  
 ID ABK19008 standard; RNA; 17 BP.  
 XX AC ABK19008;  
 XX 09-APR-2002 (first entry)  
 XX Human ERG DNAzyme target sequence Seq ID No 1655.

XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;  
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
 KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;  
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;  
 KW amberzyme.

XX OS Homo sapiens.  
 XX WO200188124-A2.  
 XX 22-NOV-2001.  
 XX 16-MAY-2001; 2001WO-US015866.  
 XX 16-MAY-2000; 2000US-00572021.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX (GLAX) GLAXO GROUP LTD.

XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;  
 XX WPI; 2002-082995/11.  
 XX Novel polynucleotide which down regulates expression of Ets-related gene,  
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,  
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
 XX Claim 4; Page 106; 149pp; English.  
 XX The invention relates to a nucleic acid molecule (I) which down regulates  
 CC expression of an Ets-related gene (ERG). (I) is useful for treating  
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,  
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
 CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge  
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu  
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
 CC treating a patient having a condition associated with the level of ERG,  
 CC by contacting cells of the patient with (I) under conditions suitable for  
 CC the treatment. The method comprises the use of one or more therapies  
 CC under conditions suitable for the treatment. Leukaemia or tumour  
 CC angiogenesis is treated by administering (I) to the patient in  
 CC conjunction with one or more of other therapies such as radiation or  
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and  
 CC diseases related to the expression of ERG, and as diagnostic tool to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of ERG RNA in a cell. (I) is useful for specifically  
 CC targeting genes that share homology with ERG gene or ERG fusion genes.  
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
 CC enzymatic nucleic acid molecules, which regulate expression of ERG, and  
 CC related PCR primers of the invention  
 XX Sequence 17 BP; 7 A; 4 C; 2 G; 0 T; 4 U; 0 Other;  
 SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1120 TTGGTGCTTCCAGTAT 1136  
 ||||| |||||  
 Db 17 TTGGTGAATTCAGTAT 1  
 RESULT 353  
 ID ABK18911/c  
 XX ABK18911 standard; RNA; 17 BP.  
 XX AC ABK18911;  
 XX 09-APR-2002 (first entry)  
 XX Human ERG DNase target sequence Seq ID No 1558.  
 XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;  
 KW ophthalmological; antiarthritis; antipsoriatic; virucide; osteopathic;  
 KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
 KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;  
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNase; inozyme;  
 KW amberyze.  
 XX Homo sapiens.  
 XX WO200188124-A2.  
 XX 22-NOV-2001.

XX 16-MAY-2001; 2001WO-US015866.  
 XX 16-MAY-2000; 2000US-00572021.  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX (GLAX) GLAXO GROUP LTD.  
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;  
 XX WPI; 2002-082995/11.  
 XX Novel polynucleotide which down regulates expression of Ets-related gene,  
 PT useful for treating cancer, diabetic retinopathy, macular degeneration,  
 PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
 XX Claim 4; Page 105; 149pp; English.  
 XX The invention relates to a nucleic acid molecule (I) which down regulates  
 CC expression of an Ets-related gene (ERG). (I) is useful for treating  
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca  
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
 CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge  
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu  
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
 CC treating a patient having a condition associated with the level of ERG,  
 CC by contacting cells of the patient with (I) under conditions suitable for  
 CC the treatment. The method comprises the use of one or more therapies  
 CC under conditions suitable for the treatment. Leukaemia or tumour  
 CC angiogenesis is treated by administering (I) to the patient in  
 CC conjunction with one or more of other therapies such as radiation or  
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and  
 CC diseases related to the expression of ERG, and as diagnostic tool to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of ERG RNA in a cell. (I) is useful for specifically  
 CC targeting genes that share homology with ERG gene or ERG fusion genes.  
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
 CC related PCR primers of the invention  
 XX Sequence 17 BP; 1 A; 7 C; 9 G; 0 T; 0 U; 0 Other;  
 SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 30 CGCCTCGTCGCGCGCG 46  
 ||||| ||||| |||||  
 Db 17 CGCGCGTCGCGCGCG 1  
 RESULT 354  
 ID AAD41868/c  
 XX AAD41868 standard; RNA; 17 BP.  
 XX AC AAD41868;  
 XX 30-OCT-2002 (first entry)  
 XX ON-21 oligonucleotide used in the exemplification of the invention.  
 XX Antisense therapy; infection; cardiovascular disorder; immune reaction;  
 KW gene therapy; virucide; cytostatic; antibacterial; antiinflammatory;  
 KW cancer; cardiant; ss.  
 XX Unidentified.  
 XX Key Location/Qualifiers  
 XX modified\_base 2.5

```
FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "5-(1-propynyl)-2'-deoxyuridine; This base is
FT FT given as N in the sequence shown as SEQ ID NO: 15 in the
FT FT sequence listing"
FT FT 6
FT FT modified_base
FT FT
FT FT /*tag= b
FT FT /mod_base= OTHER
FT FT /note= "5-methyl-2'-deoxycytidine; This base is given as
FT FT N in the sequence shown as SEQ ID NO: 15 in the sequence
FT FT listing"
FT FT 7. .8
FT FT modified_base
FT FT
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "5-(1-propynyl)-2'-deoxyuridine; This base is
FT FT given as N in the sequence shown as SEQ ID NO: 15 in the
FT FT sequence listing"
FT FT 9
FT FT modified_base
FT FT
FT FT /*tag= d
FT FT /mod_base= OTHER
FT FT /note= "5-methyl-2'-deoxycytidine; This base is given as
FT FT N in the sequence shown as SEQ ID NO: 15 in the sequence
FT FT listing"
FT FT 11. .16
FT FT modified_base
FT FT
FT FT /*tag= e
FT FT /mod_base= OTHER
FT FT /note= "5-(1-propynyl)-2'-deoxyuridine; This base is
FT FT given as N in the sequence shown as SEQ ID NO: 15 in the
FT FT sequence listing"
FT FT 17
FT FT modified_base
FT FT
FT FT /*tag= f
FT FT /mod_base= OTHER
FT FT /note= "5-methyl-2'-deoxycytidine; This base is given as
FT FT N in the sequence shown as SEQ ID NO: 15 in the sequence
FT FT listing"
FT FT 18. .19
FT FT modified_base
FT FT
FT FT /*tag= g
FT FT /mod_base= OTHER
FT FT /note= "5-(1-propynyl)-2'-deoxyuridine; This base is
FT FT given as N in the sequence shown as SEQ ID NO: 15 in the
FT FT sequence listing"
FT FT 20
FT FT modified_base
FT FT
FT FT /*tag= h
FT FT /mod_base= OTHER
FT FT /note= "5-methyl-2'-deoxycytidine; This base is given as
FT FT N in the sequence shown as SEQ ID NO: 15 in the sequence
FT FT listing"
FT FT
FT FT US6380368-B1.
FT FT
FT FT 30-APR-2002.
FT FT
FT FT 12-FEB-1996; 96US-00599738.
FT FT
FT FT 26-NOV-1991; 91US-00799824.
FT FT 25-AUG-1992; 92US-00935444.
FT FT 23-OCT-1992; 92US-00965941.
FT FT 25-NOV-1992; 92US-00976103.
FT FT 14-NOV-1994; 94US-00338352.
FT FT
FT FT (ISIS-) ISIS PHARM INC.
FT FT
FT FT Froehler B, Wagner R, Mattencchi M, Jones RJ, Gutierrez AJ;
FT FT Pudlo J;
FT FT
FT FT WPI; 2002-535437/57.
FT FT
FT FT New oligomers useful for binding to DNA duplex target sequence and for
FT FT treating e.g. diseases caused by viruses and inflammatory conditions
FT FT comprise at least three 3'-5' linked nucleosides.
FT FT
FT FT Example 6; Col 41-42; 106pp; English.
FT FT
XX XX
```

```
CC The present invention relates to novel oligomers which have enhanced
CC ability with respect to forming duplexes or triplexes. The oligomers
CC comprise at least three 3'-5' linked nucleosides or their salts. At least
CC one internucleoside linkage is not a phosphodiester linkage and at least
CC one nucleoside comprises a base. Sequences of the invention are useful
CC for binding to a DNA duplex target sequence via either CT or GT triplex
CC helix binding motif and in antisense therapies. They are also used for
CC treating diseases caused by viruses and for diagnostic applications to
CC detect viral infections, bacterial infections and diseases such as
CC cancers. The oligomers are also used as primers, in the treatment of
CC pathological conditions associated with inflammatory conditions,
CC cardiovascular disorders, immune reactions and bacterial infections and
CC for modulating target gene expression. They are also useful in gene
CC therapy. The present sequence is an oligonucleotide used in the
CC exemplification of the invention
XX
SQ Sequence 17 BP; 2 A; 3 C; 0 G; 0 T; 12 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 90 GAAAAAAATGAAATT 106
Db 17 GAAGAAAAATGAAAT 1
RESULT 355
ABK55893
ID ABK55893 standard; RNA; 17 BP.
XX
AC ABK55893;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #264.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
XX WO200211674-A2.
XX
XX 14-FEB-2002.
XX
XX 09-AUG-2001; 2001WO-US024970.
XX
XX 09-AUG-2000; 2000US-0224383P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (SYNT ) SYNTEX USA LLC.
XX
XX (THOM/) THOMPSON J.
XX
XX Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX Grupe A;
XX
XX WPI; 2002-217145/27.
XX
XX Enzymatic polynucleotide that down regulates expression of chloride
XX channel calcium activated gene, useful for treating Chronic obstructive
XX pulmonary disease (COPD), chronic bronchitis and asthma.
XX
XX Claim 4; Page 57; 152pp; English.
XX
XX The invention relates to enzymatic nucleic acid molecules that down
XX regulate expression of chloride channel calcium activated 1 (CLCA1) genes
XX by cleaving RNA derived from the genes. The nucleic acid sequences are
XX useful as pharmaceutical agents for treating conditions such as chronic
XX obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX
```

CC fibrosis, obstructive bowel syndrome and any other diseases or conditions  
 CC that are related to or will respond to the levels of CLCA1 in a cell or  
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,  
 CC hence, are useful for treatment of a patient having a condition  
 CC associated with the level of CLCA1, where the invention further comprises  
 CC the use of one or more therapies under conditions suitable for the  
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The  
 CC nucleic acids of the invention are also used as diagnostic tools to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of CLCA1 RNA in a cell. This sequence represents an  
 CC enzymatic nucleic acid molecule of the invention

XX Sequence 17 BP; 8 A; 3 C; 3 G; 0 T; 3 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 1.8e+02;

Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Oy 210 GAAGAAATAGCCAGCTG 226

|||||:|||||:

Db 1 GAAGAAUAUCCACUG 17

RESULT 356

ABK5827/c

ID ABK5827 standard; RNA; 17 BP.

XX AC

XX AC

XX ABK5827;

XX DT

XX 02-JUL-2002 (first entry)

XX DE

XX Human CLCA1 gene enzymatic nucleic acid #198.

XX KW

XX Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;

XX KW

XX antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;

XX KW

XX chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;

XX KW

XX oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;

XX KW

XX acetylcysteine.

XX OS

XX Homo sapiens.

XX XX

XX WO200211674-A2.

XX XX

XX 14-FEB-2002.

XX XX

XX 09-AUG-2001; 2001WO-US024970.

XX XX

XX 09-AUG-2000; 2000US-0224383P.

XX XX

XX (RIBO-) RIBOZYME PHARM INC.

XX PA

XX (SYNT ) SYNTEX USA LLC.

XX PA

XX (THOM/) THOMPSON J.

XX XX

XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;

XX PI

XX Grupe A;

XX XX

XX WPI; 2002-217145/27.

XX DR

XX Enzymatic polynucleotide that down regulates expression of chloride

XX PT

XX channel calcium activated gene, useful for treating Chronic obstructive

XX PT

XX pulmonary disease (COPD), chronic bronchitis and asthma.

XX XX

XX Claim 4; Page 56; 152pp; English.

XX PS

XX The invention relates to enzymatic nucleic acid molecules that down

XX CC

XX regulate expression of chloride channel calcium activated 1 (CLCA1) genes

XX CC

XX by cleaving RNA derived from the genes. The nucleic acid sequences are

CC hence, are useful for treatment of a patient having a condition  
 CC associated with the level of CLCA1, where the invention further comprises  
 CC the use of one or more therapies under conditions suitable for the  
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,  
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The  
 CC nucleic acids of the invention are also used as diagnostic tools to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of CLCA1 RNA in a cell. This sequence represents an  
 CC enzymatic nucleic acid molecule of the invention

XX Sequence 17 BP; 5 A; 3 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1722 ATAGAATCAACATATGG 1738

|||||:|||||:

Db 17 ATAGAATCAACATGTTG 1

RESULT 357

ACN01678/c

ID ACN01678 standard; RNA; 17 BP.

XX AC

XX AC

XX ACN01678;

XX DT

XX 22-APR-2004 (first entry)

XX XX

XX MNV Inozyme substrate SEQ ID NO 1668.

XX DE

XX MNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

XX KW

XX virucide; neuroprotective; antibacterial; replication; pancreatitis;

XX KW

XX encephalitis; myocarditis; meningitis; infection; hepatitis;

XX KW

XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;

XX KW

XX Amberzyme; Zinzyme; ss.

XX OS

XX West Nile Virus.

XX PN

XX WO200268637-A2.

XX XX

XX 06-SEP-2002.

XX PD

XX 19-OCT-2001; 2001WO-US048350.

XX XX

XX 20-OCT-2000; 2000US-0242411P.

XX PR

XX (RIBO-) RIBOZYME PHARM INC.

XX PA

XX (BLAT/) BLATT L.

XX PA

XX (MCSW/) MCSWIGGEN J A.

XX PA

XX Blatt L, Mcswiggen JA;

XX PI

XX WPI; 2002-706994/76.

XX DR

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX PT

XX (WNV), useful for treating a condition related to WNV infection e.g.

XX PT

XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX XX

XX Claim 23; SEQ ID NO 1668; 495pp; English.

XX PS

XX The invention relates to nucleic acid molecules that modulate replication

XX CC

XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for

XX CC

XX treating a condition related to WNV infection e.g. pancreatitis,

XX CC

XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

XX CC

XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of  
 CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The  
 CC nucleic acid molecules further comprise at least five ribose residues, at  
 CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
 CC least three of the 5' terminal nucleotides and a 3' end modification of a  
 CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
 CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention

XX Sequence 17 BP; 4 A; 5 C; 7 G; 0 T; 1 U; 0 Other;

SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 325 CCAGACTGAGTGCTCC 341

DB 17 CCTGCTGAGTGCTCC 1

RESULT 358

ACN13432

ID ACN13432 standard; RNA; 17 BP.

XX AC ACN13432;

DT 22-APR-2004 (first entry)

XX WNV minus strand Zinzyme substrate SEQ ID NO 13435.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;  
XX encephalitis; myocarditis; meningitis; infection; hepatitis;  
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
XX Amberzyme; Zinzyme; ss.

OS West Nile Virus.

XX WO200268637-A2.

PD 06-SEP-2002.

PF 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus  
XX (WNV), useful for treating a condition related to WNV infection e.g.  
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 13435; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication  
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
XX treating a condition related to WNV infection e.g. pancreatitis,  
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
XX molecule is selected from the group of ribozymes consisting of  
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
XX nucleic acid molecules further comprise at least five ribose residues, at  
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
XX least three of the 5' terminal nucleotides and a 3' end modification of a  
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
XX in the specification. The present sequence is that of a nucleic acid  
XX molecule of the invention

SQ Sequence 17 BP; 2 A; 6 C; 5 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 70.6%; Pred. No. 1.8e+02;

Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 326 CAGACTGAGTGCTCCA 342

DB 1 CUGCCUGAGUGGUCCA 17

RESULT 359

ACN03066

ID ACN03066 standard; RNA; 17 BP.

XX AC ACN03066;

DT 22-APR-2004 (first entry)

XX WNV Inozyme substrate SEQ ID NO 3069.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;  
XX encephalitis; myocarditis; meningitis; infection; hepatitis;  
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
XX Amberzyme; Zinzyme; ss.

OS West Nile Virus.

XX WO200268637-A2.

PD 06-SEP-2002.

PF 19-OCT-2001; 2001WO-US048350.

PR 20-OCT-2000; 2000US-0242411P.

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX Blatt L, Mcswiggen JA;

XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus  
XX (WNV), useful for treating a condition related to WNV infection e.g.  
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PS Claim 23; SEQ ID NO 3069; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication  
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
XX treating a condition related to WNV infection e.g. pancreatitis,  
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
XX molecule is selected from the group of ribozymes consisting of  
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
XX nucleic acid molecules further comprise at least five ribose residues, at  
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
XX least three of the 5' terminal nucleotides and a 3' end modification of a  
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
XX in the specification. The present sequence is that of a nucleic acid  
XX molecule of the invention

SQ Sequence 17 BP; 9 A; 1 C; 4 G; 0 T; 3 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 70.6%; Pred. No. 1.8e+02;

Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 473 AGCAATTCATAGTAG 489

DB 1 AGGAUUUCAUAGAAAG 17



```

RESULT 360
ACN04090/c
ID ACN04090 standard; RNA; 17 BP.
XX
AC ACN04090;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV Zinzyme substrate SEQ ID NO 4093.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
FN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 4093; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 4 A; 4 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 937 ATCCAGACAGGTTGTA 953
Db 17 ATCCAGACAGGTTGTA 1
RESULT 361
ACN03719
ID ACN03719 standard; RNA; 17 BP.
XX
AC ACN03719;
XX
DT 22-APR-2004 (first entry)

```

```

XX WNV Zinzyme substrate SEQ ID NO 3722.
DE
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyme; ss.
XX
OS West Nile Virus.
XX
FN WO200268637-A2.
XX
PD 06-SEP-2002.
XX
PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
PI Blatt L, Mcswiggen JA;
XX
DR WPI; 2002-706994/76.
XX
PT New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
PS Claim 23; SEQ ID NO 3722; 495pp; English.
XX
CC The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.8e+02;
Matches 13; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
Oy 503 TGGCAGCAGCATTGGGA 519
Db 1 UGGAAGCAGCAUUGGCA 17
RESULT 362
ACN15153
ID ACN15153 standard; RNA; 17 BP.
XX
AC ACN15153;
XX
DT 22-APR-2004 (first entry)
XX
DE WNV minus strand Amberzyme substrate SEQ ID NO 15156.
XX
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;

```



XX WPI; 2003-313353/30.  
XX  
XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
PT  
XX  
XX Disclosure; Page 313; 720pp; French.  
XX  
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,  
CC given in the specification, a sequence containing at least 15 consecutive  
CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that  
CC hybridizes to them under highly stringent conditions, or the complement  
CC of any of them, or the corresponding RNA. The novel isolated nucleic  
CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterized by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
XX Sequence 17 BP; 9 A; 1 C; 3 G; 4 T; 0 U; 0 Other;  
SQ

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Oy 1827 GATCTCTGAAAAA 1843  
Db 1 GATCTGTGAAAAATAA 17  
|||||  
1 GATCTGTGAAAAATAA 17

RESULT 365  
ADB04829  
ID ADB04829 standard; DNA; 17 BP.  
XX  
XX ADB04829;  
AC  
XX  
XX 20-NOV-2003 (first entry)  
DT  
XX  
XX Human MD212 scanning oligonucleotide SEQ ID 5815.  
DE  
XX  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
KW zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;  
KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
KW developmental disorder; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX EPI281758-A2.  
PN  
XX  
XX 05-FEB-2003.  
PD  
XX  
XX 30-JUL-2002; 2002EP-00016874.  
PF  
XX  
XX 02-AUG-2001; 2001US-00922181.  
PR  
XX  
XX (AEOM-) AEOMICA INC.  
PA  
XX  
XX Shannon M, Gu Y, Nguyen C;  
PI  
XX  
XX WPI; 2003-423107/40.  
DR

XX New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MD23,  
PT MD24, MD27 or MD212, e.g. cancer.  
XX  
XX Example 8; SEQ ID NO 5815; 103pp; English.  
XX  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MD23  
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
XX Sequence 17 BP; 7 A; 3 C; 5 G; 2 T; 0 U; 0 Other;  
SQ

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Oy 1102 CAGAGAACCAAGGTGGA 1118  
Db 1 CAGCAGAACCAATGTGGA 17  
|||||  
1 CAGCAGAACCAATGTGGA 17

RESULT 366  
ABZ61368/C  
ID ABZ61368 standard; RNA; 17 BP.  
XX  
XX ABZ61368;  
AC  
XX  
XX 21-MAR-2003 (first entry)  
DT  
XX  
XX Human H-Ras DNase target #159.  
DE  
XX  
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;  
KW anti-rheumatic; cancer; AIDS; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200297114-A2.  
PN  
XX  
XX 05-DEC-2002.  
PD  
XX  
XX 29-MAY-2002; 2002WO-US016840.  
PF  
XX  
XX 29-MAY-2001; 2001US-0294140P.  
PR  
XX  
XX 06-JUN-2001; 2001US-0296249P.  
PR  
XX  
XX 10-SEP-2001; 2001US-0318471P.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Mcswiggen J;  
PI  
XX  
XX WPI; 2003-140484/13.  
DR  
XX  
XX Novel short interfering RNA and enzymatic nucleic acid useful for  
PT treating cancer, modulates the expression of a nucleic acid encoding  
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
XX  
XX Claim 58; Page 114; 185pp; English.  
XX

CC The invention relates to a novel short interfering RNA (siRNA) nucleic acid molecule or an enzymatic nucleic acid molecule, that modulates expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras, human immunodeficiency virus (HIV) or a component of HIV. The nucleic acid molecule of the invention has cytostatic, anti-HIV, and anti-rheumatic activity. The nucleic acid molecules are useful for reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are also useful for treating breast, ovarian, colorectal, lung, prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target sequences for the human CC ribozymes of the invention

XX  
SQ Sequence 17 BP; 0 A; 6 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCCTCGTCCGCCGCG 46  
DB 17 CGCGCGCGCGCGCGCG 1

RESULT 367  
ACD63057  
ID ACD63057 standard; RNA; 17 BP.  
XX  
AC ACD63057;  
XX  
DT 24-SEP-2003 (first entry)  
XX  
DE HCV minus strand DNAzyme substrate sequence #864.  
XX  
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO200281494-A1.  
XX  
PD 17-OCT-2002.  
XX  
PF 26-MAR-2002; 2002WO-US009187.  
XX  
PR 26-MAR-2001; 2001US-00817879.  
PR 08-JUN-2001; 2001US-00877478.  
PR 08-JUN-2001; 2001US-0296876P.  
PR 24-OCT-2001; 2001US-0335059P.  
PR 05-DEC-2001; 2001US-0337055P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
XX  
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
XX  
DR WPI; 2003-229207/22.  
XX  
PT Novel compound useful for treating cirrhosis, liver failure,

PT hepatocellular carcinoma, or condition associated with hepatitis C virus infection.

PT  
XX  
PS Claim 1; Page 290; 387pp; English.

XX  
CC The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of Hepatitis C virus (HCV) or Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes, inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed are nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences, as well as oligonucleotides that specifically bind the Enhancer I region of HBV DNA. The nucleic acids may be used to modulate the expression of HBV genes and HBV viral replication. Also disclosed is a method for screenings compounds and/or potential therapies directed against HBV, and compounds that modulate the expression and/or replication of HCV. The compounds and methods of the invention are useful for the treatment of degenerative and disease states related to HBV and HCV infection, replication and gene expression such as cirrhosis, liver failure, and hepatocellular carcinoma. The present sequence represents a substrate for one of the HCV DNAzyme or minus strand DNAzyme sequences disclosed in the present invention

XX  
SQ Sequence 17 BP; 2 A; 2 C; 9 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 1.8e+02;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1171 GTCGTGGTGGAGTCT 1187  
DB 1 GGCUGGUGAUGGAGGCU 17

RESULT 368  
ACD59841  
ID ACD59841 standard; RNA; 17 BP.  
XX  
AC ACD59841;  
XX  
DT 24-SEP-2003 (first entry)  
XX  
DE HCV DNAzyme substrate sequence #1531.  
XX  
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO200281494-A1.  
XX  
PD 17-OCT-2002.  
XX  
PF 26-MAR-2002; 2002WO-US009187.  
XX  
PR 26-MAR-2001; 2001US-00817879.  
PR 08-JUN-2001; 2001US-00877478.  
PR 08-JUN-2001; 2001US-0296876P.  
PR 24-OCT-2001; 2001US-0335059P.  
PR 05-DEC-2001; 2001US-0337055P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
XX  
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
XX  
DR WPI; 2003-229207/22.  
XX  
PT Novel compound useful for treating cirrhosis, liver failure,



CC quantifying and/or amplifying nucleic acid, e.g. as one component of a  
CC gene chip; in vitro as (antisense reagents; and (2) for production of  
CC recombinant polypeptides. The oligonucleotides are useful for preparation  
CC of pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia  
XX  
SQ Sequence 17 BP; 8 A; 1 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1040 CTCACCTATTAAAGATC 1056  
||| ||||| ||||| |||||  
DB 17 CTCCTTTTATTAAAGATC 1

RESULT 371  
ADC04228/c  
ID ADC04228 standard; DNA; 17 BP.  
XX AC ADC04228;  
XX AC  
XX 18-DEC-2003 (first entry)  
DT  
DE Human Na/H exchanger-like protein 1 gene oligonucleotide #675.  
XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;  
KW NHELP1; passive replacement therapy; vaccine; diagnosis.  
XX Homo sapiens.  
XX EP1273660-A2.  
PN  
XX 08-JAN-2003.  
XX  
XX 25-JAN-2002; 2002EP-00001160.  
XX  
PR 30-JAN-2001; 2001WO-US000666.  
PR 23-MAY-2001; 2001US-00864761.  
PR 21-DEC-2001; 2001US-0343331P.  
XX  
XX (AEOM-) AEOMICA INC.  
PA  
XX Gu Y;  
XX WPI; 2003-302724/30.  
XX  
XX New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a  
PT passive replacement therapy or as a vaccine for treating or preventing  
PT disorders associated with aberrant expression or activity of human  
PT NHELP1.  
XX  
XX Example 2; SEQ ID NO 715; 468pp; English.

XX The invention relates to a nucleic acid molecule which encodes a Na+/H+  
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1  
CC polypeptide, an antibody against the protein or its antigen-binding  
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1  
CC polypeptide and an agonist are particularly useful for manufacturing a  
CC medicament for treating or preventing a disorder associated with  
CC decreased expression or activity of human NHELP1. The antibody or its  
CC antigen-binding fragment, and an antagonist, are useful for manufacturing  
CC a medicament for treating or preventing a disorder associated with  
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid  
CC or protein is useful as passive replacement therapy, as a vaccine, or in  
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide  
CC spanning the sequence of the human NHELP1 gene (ADC03514).  
XX  
SQ Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 911 TGTAGCAGAGATCACTG 927  
||||| ||||| ||||| |||||  
DB 17 TGTAGCAGAGATCACTG 1

RESULT 372  
ADC04229/c  
ID ADC04229 standard; DNA; 17 BP.  
XX AC ADC04229;  
XX AC  
XX 18-DEC-2003 (first entry)  
DT  
DE Human Na/H exchanger-like protein 1 gene oligonucleotide #676.  
XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;  
KW NHELP1; passive replacement therapy; vaccine; diagnosis.  
XX Homo sapiens.  
XX EP1273660-A2.  
PN  
XX 08-JAN-2003.  
XX  
XX 25-JAN-2002; 2002EP-00001160.  
XX  
PR 30-JAN-2001; 2001WO-US000666.  
PR 23-MAY-2001; 2001US-00864761.  
PR 21-DEC-2001; 2001US-0343331P.  
XX  
XX (AEOM-) AEOMICA INC.  
PA  
XX Gu Y;  
XX WPI; 2003-302724/30.  
XX  
XX New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a  
PT passive replacement therapy or as a vaccine for treating or preventing  
PT disorders associated with aberrant expression or activity of human  
PT NHELP1.  
XX  
XX Example 2; SEQ ID NO 716; 468pp; English.

XX The invention relates to a nucleic acid molecule which encodes a Na+/H+  
CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1  
CC polypeptide, an antibody against the protein or its antigen-binding  
CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1  
CC polypeptide and an agonist are particularly useful for manufacturing a  
CC medicament for treating or preventing a disorder associated with  
CC decreased expression or activity of human NHELP1. The antibody or its  
CC antigen-binding fragment, and an antagonist, are useful for manufacturing  
CC a medicament for treating or preventing a disorder associated with  
CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid  
CC or protein is useful as passive replacement therapy, as a vaccine, or in  
CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide  
CC spanning the sequence of the human NHELP1 gene (ADC03514).  
XX  
SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 910 CTGTAGCAGAGATCACT 926  
||||| ||||| ||||| |||||  
DB 17 CTGTAGCAGAGATCACT 1

RESULT 373  
ADF64149/c

```

ID ADF64149 standard; DNA; 17 BP.
XX AC
XX ADF64149;
XX DT
XX 12-FEB-2004 (first entry)
XX DE
XX Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2053.
XX KW
XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
XX KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX KW human; ss; probe.
XX OS
XX Homo sapiens.
XX PN
XX WO2003050284-A1.
XX PD
XX 19-JUN-2003.
XX PF
XX 22-NOV-2002; 2002WO-US037506.
XX PR
XX 10-DEC-2001; 2001US-0339764P.
XX PA
XX (AMSH ) AMERSHAM BIOSCIENCES SV CORP.
XX PI
XX Guo J;
XX DR
XX WPI; 2003-532916/50.
XX KW
XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
XX PT composition for treating or preventing a disorder associated with
XX PT decreased or increased expression or activity of PCCP1 e.g., tumor.
XX XX
XX Example 2; SEQ ID NO 2053; 164pp; English.
XX CC
XX The invention relates to a novel isolated nucleic acid that encodes a
XX CC protein with a chromatin organisation modifier (CHROMO) domain. The
XX CC polynucleotide of the invention demonstrates cytostatic activity and may
XX CC be useful for preparing a composition for treating or preventing a
XX CC disorder associated with decreased or increased expression or activity of
XX CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
XX CC during gene therapy and vaccine production procedures. The current
XX CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
XX CC directed probe of the invention. Note: The current sequence is not shown
XX CC within the specification per se but was retrieved from the Wipoweb
XX CC database.
XX SQ
XX Sequence 17 BP; 6 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 511 GCATTGGGACTCTCCCA 527
Db ||||| ||||| ||||| |||||
17 GCATTGGGACTCTCTTA 1

RESULT 374
ADG38381/C
ID ADG38381 standard; DNA; 17 BP.
XX AC
XX ADG38381;
XX DT
XX 26-FEB-2004 (first entry)
XX DE
XX Anti-HIV L-DNA #48.
XX KW
XX L-DNA; ss; anti-HIV; antiviral; AIDS; acquired immunodeficiency syndrome;
XX KW guanine tetrad; viral disease.
XX OS
XX Synthetic.
XX PN
XX JP2003204793-A.

XX 22-JUL-2003.
XX PD
XX 15-JAN-2002; 2002JP-00006108.
XX PF
XX 15-JAN-2002; 2002JP-00006108.
XX PR
XX (TAKE ) TAKEDA CHEM IND LTD.
XX PA
XX WPI; 2003-807784/76.
XX DR
XX Novel L-DNA or its salt forming guanine tetrad(s), useful as prophylactic
XX PT or therapeutic agent for viral disease e.g., human immunodeficiency
XX PT virus.
XX PT
XX Disclosure; SEQ ID NO 48; 22pp; Japanese.
XX PS
XX The invention relates to L-DNA or its salt forming guanine tetrad(s). L-
XX CC DNA means DNA whose sugar moiety in L-deoxyribose rather than the normal
XX CC D-deoxyribose. Also included are an antiviral agent containing L-DNA, and
XX CC a prophylactic or therapeutic agent for the viral disease, containing L-
XX CC DNA. The L-DNA is useful as a prophylactic or therapeutic agent of viral
XX CC disease (e.g. AIDS, acquired immunodeficiency syndrome) caused by e.g.,
XX CC human immunodeficiency virus. L-DNA has an excellent antiviral activity,
XX CC is less toxic and chemically stable. The present sequence is an L-DNA
XX CC oligonucleotide of the invention.
XX SQ
XX Sequence 17 BP; 0 A; 0 C; 13 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1705 CCCCTCCCTCCACCAC 1721
Db ||||| ||||| ||||| |||||
17 CCCACCACCCACCACCAC 1

RESULT 375
AD148002
ID AD148002 standard; DNA; 17 BP.
XX AC
XX AD148002;
XX DT
XX 15-APR-2004 (first entry)
XX DE
XX Human tumour suppression/reversion-related DNA sequence SeqID505.
XX KW
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW cytostatic; viricide; neuroprotective; nootropic; neuroleptic; probe;
XX KW primer; PCR; gene chip; antisense; viral disease; tumour;
XX KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX OS
XX Homo sapiens.
XX PN
XX WO2003025177-A2.
XX PD
XX 27-MAR-2003.
XX PF
XX 17-SEP-2002; 2002WO-IB004523.
XX PR
XX 17-SEP-2001; 2001FR-00011980.
XX PA
XX (MOLE-) MOLESCULAR ENGINES LAB.
XX PI
XX Telerman A, Amson R, Tuijnder M;
XX DR
XX WPI; 2003-313354/30.
XX KW
XX New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PT
XX
```

PS Disclosure; SEQ ID NO 505; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC neurotropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, identifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration. The

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct\_sequences

XX

SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 231 GATGTTGCTAAGCAAT 247

DB 1 GATCTTGCTACAGCAAT 17

|||||

RESULT 376

ADI49572/c

ID ADI49572 standard; DNA; 17 BP.

XX

AC ADI49572;

DT 15-APR-2004 (first entry)

XX

DE Human tumour suppression/reversion-related DNA sequence SeqID2075.

XX

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX

OS Homo sapiens.

XX

PN WO2003025177-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004523.

XX

PR 17-SEP-2001; 2001PR-00011980.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijnder M;

XX

WPI; 2003-313354/30.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; SEQ ID NO 2075; 30pp; French.

XX

CC This invention relates to novel isolated nucleic acid sequences involved

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC neurotropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, identifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration. The

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct\_sequences

XX

SQ Sequence 17 BP; 5 A; 4 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 231 GATGTTGCTAAGCAAT 247

DB 1 GATCTTGCTACAGCAAT 17

|||||

RESULT 377

ADI49244

ID ADI49244 standard; DNA; 17 BP.

XX

AC ADI49244;

DT 15-APR-2004 (first entry)

XX

DE Human tumour suppression/reversion-related DNA sequence SeqID1747.

XX

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW cytostatic; virucide; neuroprotective; neurotropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX

OS Homo sapiens.

XX

PN WO2003025177-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004523.

XX

PR 17-SEP-2001; 2001PR-00011980.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijnder M;

XX

WPI; 2003-313354/30.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

XX

PS Disclosure; SEQ ID NO 1747; 30pp; French.

XX

CC This invention relates to novel isolated nucleic acid sequences involved

CC in the phenomena of tumour suppression, tumour reversion, apoptosis

CC and/or resistance to viruses. The invention may be useful for the

CC development of compounds with a cytostatic, virucide, neuroprotective,

CC neurotropic or neuroleptic activity. The DNA sequences may be useful as

CC probes and primers for detecting, identifying, quantifying and/or

CC amplifying nucleic acid, for example as one component of a gene chip, in

CC vitro as antisense reagents and for production of recombinant

CC polypeptides. The invention may therefore be useful for preparation of

CC pharmaceuticals for prevention and/or treatment of viral diseases that

CC are characterised by development of tumours or cell degeneration. The

CC specifically cancer but also Alzheimer's disease and schizophrenia. The

CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/publishedpct\_sequences

XX

SQ Sequence 17 BP; 8 A; 4 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.8e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 129 GGTGTTCACTTTTATC 145

DB 17 GGTGTTCACTTTTGATC 1

|||||



CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences

XX Sequence 17 BP; 9 A; 2 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1827 GATCTCTGAAAAA 1843

DB 1 GATCTCTTAAATAAAA 17

RESULT 378

ADIS0952

ID ADIS0952 standard; DNA; 17 BP.

XX

AC ADIS0952;

XX

DT 15-APR-2004 (first entry)

XX

DE Human tumour suppression/reversion-related DNA sequence SeqID3455.

XX

KW tumour suppression; tumour reversion; apoptosis; virus resistance;

KW cytosolic; virucide; neuroprotective; neurotropic; neuroleptic; probe;

KW primer; PCR; gene chip; antisense; viral disease; tumour;

KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.

XX

OS Homo sapiens.

XX

PN WO2003025177-A2.

XX

PD 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004523.

XX

PR 17-SEP-2001; 2001FR-00011980.

XX

PA (MOLE-) MOLECULAR ENGINES LAB.

XX

PI Telerman A, Amson R, Tuijnder M;

XX

DR WPI; 2003-313354/30.

XX

PT New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.

XX

PS Disclosure; SEQ ID NO 3455; 30pp; French.

XX

CC This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, identifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.

CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences

XX

XX

XX

SQ Sequence 17 BP; 5 A; 3 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 GATCAAAATGTCATTC 861

DB 1 GATCAAAATGTCCTGC 17

RESULT 379

ABZ97381/C

ID ABZ97381 standard; DNA; 17 BP.

XX

AC ABZ97381;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human IL4-R oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;  
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;  
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

PT Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiquinone.

XX

PS Disclosure; SEQ ID NO 12623; 872pp; English.

XX

CC The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antiinflammatory steroid and ubiquinone. A composition of the invention  
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,  
CC immunosuppressive, and cytostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or  
CC preventing a respiratory, lung or malignant disease or condition, also  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC antiinflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences

XX

SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1342 CTGGAGTGCCTGGAGCC 1358  
 |||||  
 Db 17 CTGGAGTGCCTGGAGCC 1

## RESULT 380

ADL49803  
 ID ADL49803 standard; RNA; 17 BP.

XX AC ADL49803;  
 XX DT 20-MAY-2004 (first entry)  
 XX DE Human PKR substrate sequence #917.

XX antisenase oligonucleotide; neurite growth inhibitor; NOGO;  
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 KW protein kinase PKR; cerebrovascular accident;  
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
 KW substrate; ds.

XX OS Unidentified.

XX PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PS Claim 59; SEQ ID NO 3336; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 CC that down regulate the expression or inhibit the function of a receptor  
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 CC invention are useful for treating: cerebrovascular accident, central  
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 CC nucleic acids of the invention are also useful for down-regulating the  
 CC expression of a target gene and as a diagnostic tool to examine genetic  
 CC drifts and mutations within diseased cells or to detect the presence of a  
 CC target RNA in a cell. The present RNA sequence represents a human PKR  
 CC substrate sequence.

XX SQ Sequence 17 BP; 8 A; 3 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 70.6%; Pred. No. 1.8e+02;  
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1823 GGAAGATCTCTGAAAAA 1839  
 |||||  
 Db 1 GUAACAUCUCUGAAAAA 17

## RESULT 381

ADL46473/C  
 ID ADL46473 standard; RNA; 17 BP.

XX AC ADL46473;

XX DT 20-MAY-2004 (first entry)

XX DE Human NOGO receptor hammerhead ribozyme substrate sequence #6.

XX antisenase oligonucleotide; neurite growth inhibitor; NOGO;  
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
 KW protein kinase PKR; cerebrovascular accident;  
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
 KW allergy; asthma; allergic rhinitis; atopic dermatitis;  
 KW NOGO receptor hammerhead ribozyme; substrate; ds.

XX OS Unidentified.

XX PN WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite

PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or

PT protein kinase PKR genes, for treating cancer and inflammatory disease.

PS Claim 9; SEQ ID NO 6; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
 CC that down regulate the expression or inhibit the function of a receptor  
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
 CC invention are useful for treating: cerebrovascular accident, central  
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,  
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
 CC nucleic acids of the invention are also useful for down-regulating the  
 CC expression of a target gene and as a diagnostic tool to examine genetic  
 CC drifts and mutations within diseased cells or to detect the presence of a  
 CC target RNA in a cell. The present RNA sequence represents a human NOGO  
 CC receptor hammerhead ribozyme substrate sequence.

XX SQ Sequence 17 BP; 3 A; 7 C; 3 G; 0 T; 4 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

OY 382 TGCAGCAAGATGGGCTG 398
Db 17 TGCAGGAAGATGCGCTG 1

RESULT 382
ADL47007
ID ADL47007 standard; RNA; 17 BP.
XX
AC ADL47007;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor inozyme substrate sequence #440.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor inozyme; substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fossnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 540; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human NOGO
CC receptor inozyme substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 3 C; 8 G; 0 T; 4 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 1085 GCTGGTCTCTGGACTG 1101
Db 1 GCUGGUGCUGGACAG 17

RESULT 383
ADL49254
ID ADL49254 standard; RNA; 17 BP.
XX
AC ADL49254;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #368.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.
XX
OS Unidentified.
XX
PN WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fossnaugh K;
XX
DR WPI; 2003-058513/05.
XX
PT Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2787; 317pp; English.
XX
CC The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 3 C; 2 G; 0 T; 5 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

```

QY 1822 TGAAGATCTCTGAAAA 1938  
Db :|||:|:|||||  
1 UGUACAUCUCUGAAAA 17

RESULT 384  
ABD30412/C  
ID ABD30412 standard; DNA; 17 BP.  
XX AC ABD30412;  
DT 29-JUL-2004 (first entry)  
XX Human IL4-R derived oligonucleotide SEQ ID 12623.  
DE Human; antisease; bronchoconstriction; allergy; hyposecretion; pain;  
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;  
KW surfactant depletion; antiallergic; anti-inflammatory; antiasthmatic;  
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;  
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;  
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;  
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;  
XX pulmonary transplantation rejection; ss; primer.  
XX Homo sapiens.  
OS  
XX WO200285309-A2.  
PN  
XX 31-OCT-2002.  
PD  
XX 23-APR-2002; 2002WO-US013143.  
PF  
XX 24-APR-2001; 2001US-0286036P.  
PR  
XX (EPIG-) EPIGENESIS PHARM INC.  
PA  
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahabuddin S;  
PI WPI; 2003-093058/08.  
DR  
XX Pharmaceutical composition for treating asthma, has antisense  
XX oligonucleotide containing less percentage of adenosine, targeted to  
XX nucleic acids associated with lung airway or lung dysfunction, and  
XX bronchodilating agent.  
PS  
XX Claim 15; SEQ ID NO 12623; 763pp; English.  
XX  
XX This invention describes a novel composition (a) a first active agent,  
XX comprising oligonucleotides, effective for alleviating  
XX bronchoconstriction, respiratory tract inflammation, allergies and  
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,  
XX surfactant depletion or hyposecretion, when administered to a mammal. The  
XX oligonucleotides are derived from a gene encoding or regulating  
XX expression of a target polypeptide associated with lung airway or lung  
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.  
XX The invention also describes a kit, that comprises: (a) a delivery  
XX device, in separate containers, (b) the oligonucleotides, (c)  
XX instructions for adding a carrier and for use of the kit. The composition  
XX of the invention has antiallergic, anti-inflammatory, antiasthmatic,  
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a  
XX beta-adrenergic agonist. The composition is useful for preventing or  
XX treating a respiratory, lung or malignant disease. The administered  
XX composition comprises oligo and is administered to reduce the production  
XX or availability, or to increase the degradation of the target mRNA or to  
XX reduce the amount of target polypeptide present in the lungs. The  
XX pulmonary obstruction, and/or bronchoconstriction and/or lung  
XX inflammation, allergies and/or surfactant hypoproduction are associated  
XX with a disease or condition such as pulmonary vasoconstriction,  
XX inflammation, allergies, asthma, impeded respiration, respiratory  
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary  
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.  
CC The reduced adenosine content of the anti-sense oligos corresponding to  
CC thymidines present in the target RNA serves to prevent the breakdown of  
CC the oligonucleotides into products that free adenosine into the system  
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to  
CC prevent any unwanted effects due to it  
XX  
SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1342 CTGGAGTGCCTGGAGCC 1358  
Db 17 CTGGAGTGCCTGGAGCC 1  
  
RESULT 385  
ADJ59200/C  
ID ADJ59200 standard; DNA; 17 BP.  
XX AC ADJ59200;  
XX 06-MAY-2004 (first entry)  
DT  
XX Oligonucleotide associated to IL 4R #55.  
DE  
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;  
KW airway inflammation; allergy; asthma; impeded respiration;  
KW cystic fibrosis; acute respiratory distress syndrome;  
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;  
KW ss.  
OS  
XX Homo sapiens.  
XX WO2004011613-A2.  
PN  
XX 05-FEB-2004.  
PD  
XX 25-JUL-2003; 2003WO-US023509.  
PF  
XX 29-JUL-2002; 2002US-0399076P.  
PR  
XX (EPIG-) EPIGENESIS PHARM INC.  
PA  
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;  
PI Shahabuddin S, Lu H, Cong H;  
PI WPI; 2004-203534/19.  
DR  
XX Novel single or multiple target oligonucleotide anti-sense to e.g.  
XX initiation codons and introns of respiratory disease-relevant genes e.g.,  
XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory  
XX disease e.g., asthma.  
XX  
XX Claim 2; SEQ ID NO 56; 85pp; English.  
PS  
XX The present invention relates to an oligonucleotide anti-sense to e.g.,  
XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-  
XX end of nucleic acid target comprising gene(s) chosen from e.g.  
XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the  
XX oligonucleotide and optionally surfactant operatively linked to the  
XX oligonucleotide. The method is useful for preventing or treating a  
XX respiratory or lung disease, which involves administering to the airways  
XX of a subject an effective amount of an inhibitor. The oligonucleotide is  
XX useful for production of a medicament for the prevention and/or treatment  
XX of a respiratory or lung disease. The respiratory or lung disease is  
XX chosen from airway inflammation, allergy(ies), asthma, impeded  
XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases  
XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome  
XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway  
XX obstruction. The present sequence represents an oligonucleotide of the



KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;  
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;  
KW acute respiratory distress syndrome; pulmonary hypertension;  
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.  
XX  
OS Homo sapiens.  
XX  
XX US2004049022-A1.  
XX  
XX 11-MAR-2004.  
XX  
XX 25-JUL-2003; 2003US-00627930.  
XX  
XX 23-APR-2002; 2002WO-US013135.  
PR  
PR 23-APR-2002; 2002WO-US013143.  
XX  
XX (NYCE/) NYCE J W.  
PA (SAND/) SANDRASAGRA A.  
PA (TANG/) TANG L.  
PA (AGUI/) AGUILAR D.  
PA (MILL/) MILLER S.  
PA (SHAH/) SHAHABUDDIN S.  
PA (LUHH/) LU H.  
PA (CONG/) CONG H.  
XX  
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;  
PI Shahabuddin S, Lu H, Cong H;  
XX  
XX WPI; 2004-293804/27.  
XX  
XX Novel single or multiple target oligonucleotide anti-sense to e.g.  
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,  
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.  
PT asthma.  
XX  
XX Claim 2; SEQ ID NO 56; 174pp; English.  
XX  
XX The invention relates to oligonucleotides anti-sense to an initiation  
CC codon, coding region, 5' or 3' intron-exon junction, intron or region  
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target  
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)  
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,  
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention  
CC also relates to a method of screening a candidate compound that binds to  
CC one or more nucleic acid target(s) or expressed product(s), for the  
CC prevention and/or treatment of a respiratory or lung disease. The  
CC oligonucleotides are useful for reducing or inhibiting expression of a  
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,  
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,  
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are  
CC useful for preventing or treating a respiratory or lung disease. The  
CC respiratory or lung disease is associated with hyper-responsiveness to  
CC and/or increased levels of, adenosine and/or levels of adenosine A  
CC receptor(s), and/or asthma and/or lung allergies associated with  
CC inflammation or an inflammatory disease. The respiratory or lung disease  
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,  
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),  
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary  
CC hypertension, lung inflammation, bronchitis, airway obstruction or  
CC bronchoconstriction. This sequence represents an oligonucleotide of the  
CC invention.  
XX  
XX Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;  
SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1342 CTGGAGTGCTGGAGCC 1358  
|||||  
Db 17 CTGGAGTGAGTGAGCC 1

RESULT 389  
ACN64635  
ID ACN64635 standard; DNA; 17 BP.  
XX  
XX ACN64635;  
XX  
XX 02-DEC-2004 (first entry)  
XX  
XX Human GDMPLP-1 probe SEQ ID NO:1537.  
DE  
XX  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
XX Homo sapiens.  
XX  
XX US2004137589-A1.  
PN  
XX  
PD 15-JUL-2004.  
XX  
XX 26-NOV-2003; 2003US-00723361.  
PF  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR  
XX 21-SEP-2000; 2000US-0234687P.  
PR  
XX 27-SEP-2000; 2000US-0236359P.  
PR  
XX 04-OCT-2000; 2000GB-00024263.  
PR  
XX 30-JAN-2001; 2001WO-US000661.  
PR  
XX 30-JAN-2001; 2001WO-US000662.  
PR  
XX 30-JAN-2001; 2001WO-US000663.  
PR  
XX 30-JAN-2001; 2001WO-US000664.  
PR  
XX 30-JAN-2001; 2001WO-US000665.  
PR  
XX 30-JAN-2001; 2001WO-US000666.  
PR  
XX 30-JAN-2001; 2001WO-US000667.  
PR  
XX 30-JAN-2001; 2001WO-US000668.  
PR  
XX 30-JAN-2001; 2001WO-US000669.  
PR  
XX 05-FEB-2001; 2001WO-US000670.  
PR  
XX 25-MAY-2001; 2001US-0266860P.  
PR  
XX (GUY/) GU Y.  
PA (JIYY/) JI Y.  
PA (PENNY/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
WPI; 2004-533378/51.  
XX  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
XX associated with decreased expression or activity of human genome-derived  
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
XX function.  
XX  
XX Disclosure; SEQ ID NO 1537; Opp; English.  
PS  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
XX defined in the specification, a fragment of at least 8 amino acids of  
XX (S1); 95% deviation from (S1) which are conservative substitutions, and  
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
XX pharmaceutical composition of the invention is useful for treating or  
XX preventing a disorder associated with decreased expression or activity of  
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
XX The present sequence represents a 17-mer nucleotide, used in the  
XX invention for scanning the sequence represented in ACN63102  
XX  
XX Sequence 17 BP; 1 A; 4 C; 9 G; 3 T; 0 U; 0 Other;  
SQ Query Match 0.7%; Score 13.8; DB 1; Length 17;

Disclosure; SEQ ID NO 9572; Opp; English.

```

XX CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX SQ Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 CTGGACAGCTGGGATGT 985
Db 17 CTGGACAGCGGGGATGT 1

RESULT 392
ACN64634
ID ACN64634 standard; DNA; 17 BP.
XX AC ACN64634;
XX DT 02-DEC-2004 (first entry)
XX DE Human GDMLP-1 probe SEQ ID NO:1536.
XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX KW skeletal muscle function.
XX OS Homo sapiens.
XX PN US2004137589-A1.
XX PD 15-JUL-2004.
XX PF 26-NOV-2003; 2003US-00723361.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PR 25-MAY-2001; 2001US-00866108.
XX PA (GUY/) GU Y.
XX PA (JIY/) JI Y.
XX PA (PENN/) PENN S G.
XX PA (HANZ/) HANZEL D K.
XX PA (RANK/) RANK D.
XX PA (CHEN/) CHEN W.
XX PA (SHAN/) SHANNON M E.
XX GU Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI PI
XX XX

```

---

```

DR WPI; 2004-533378/51.
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX PS Disclosure; SEQ ID NO 1536; Opp; English.
XX CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX SQ Sequence 17 BP; 0 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.8e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1081 TCGGCTGCTGCTCTGG 1097
Db 1 TCGGCTGCTGCTCTGG 17

RESULT 393
ACN71458
ID ACN71458 standard; DNA; 17 BP.
XX AC ACN71458;
XX DT 02-DEC-2004 (first entry)
XX DE Human GDMLP-1 probe SEQ ID NO:8360.
XX KW Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX KW skeletal muscle function.
XX OS Homo sapiens.
XX PN US2004137589-A1.
XX PD 15-JUL-2004.
XX PF 26-NOV-2003; 2003US-00723361.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PR 25-MAY-2001; 2001US-00866108.
XX PA (GUY/) GU Y.
XX PA (JIY/) JI Y.

```



PA (PENN/) PENN S G.  
 PA (HANZ/) HANZEL D K.  
 PA (RANK/) RANK D.  
 PA (CHEN/) CHEN W.  
 PA (SHAN/) SHANNON M E.  
 XX  
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
 XX WPI; 2004-533378/51.  
 DR  
 XX Novel myosin-like protein-1, useful for treating or preventing disorder  
 XX associated with decreased expression or activity of human genome-derived  
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
 PT function.  
 XX  
 XX Disclosure; SEQ ID NO 8360; Opp; English.  
 PS  
 CC The invention relates to a novel polypeptide (I) comprising a sequence  
 CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
 CC defined in the specification, a fragment of at least 8 amino acids of  
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
 CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
 CC pharmaceutical composition of the invention is useful for treating or  
 CC preventing a disorder associated with decreased expression or activity of  
 CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
 CC The present sequence represents a 17-mer nucleotide, used in the  
 CC invention for scanning the sequence represented in ACN63103  
 XX  
 SQ Sequence 17 BP; 6 A; 1 C; 8 G; 2 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 390 GATGGCTGGAGAAAGT 406  
 ||| ||||| ||||| |||||  
 Db 1 GAGGAGCTGGAGAAAGT 17  
 RESULT 394  
 AAQ20007/c  
 ID AAQ20007 standard; DNA; 18 BP.  
 XX  
 AC AAQ20007;  
 XX  
 DT 01-APR-1992 (first entry)  
 XX  
 DE Oligonucleotide #3 able to covalently cross-link to target DNA.  
 XX  
 KW deoxyribonucleic acid; major groove; ethanocino group;  
 KW aziridinylcytosine; cross-linking group; ss.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "N4N4-ethanocytosine"  
 FT modified\_base 9  
 FT /\*tag= b  
 FT /mod\_base= m5c  
 FT modified\_base 15  
 FT /\*tag= c  
 FT /mod\_base= m5c  
 FT modified\_base 18  
 FT /\*tag= da  
 FT /mod\_base= OTHER  
 FT /note= "N4N4-ethanocytosine"  
 XX  
 FN W09118997-A.  
 XX

PD 12-DEC-1991.  
 XX  
 PF 25-MAY-1990; 90US-00529346.  
 XX  
 PR 25-MAY-1990; 90US-00529346.  
 PR 14-JAN-1991; 91US-00640654.  
 XX  
 PA (GILE-) GILEAD SCIE INC.  
 XX  
 PI Matteucci MD, Krawczyk S;  
 XX WPI; 1992-007480/01.  
 DR  
 XX New sequence-specific non-photo-activated crosslinking agents - bind to  
 PT the major groove of duplex DNA and are esp. useful for treating latent  
 PT infections e.g. HIV.  
 XX  
 XX Example 2; Page 21; 42pp; English.  
 PS  
 CC The 3' end of this oligonucleotide carries 1,3-propanediol. The oligo is  
 CC one of four oligonucleotides which were designed to specifically bind and  
 CC cross-link to the duplex target sequence AAQ20004. Oligo #3 has a  
 CC covalent cross-linking group, i.e. N4N4-ethanocytosine, at its 5'- and 3'-  
 CC ends. An assay for crosslinked triple helix showed the most complete  
 CC reaction with Oligo #3. A control oligo with no cross-linking group  
 CC showed no reaction while Oligos #1 (see AAQ20005) and #2 (AAQ20006) with  
 CC the crosslinking group at the 5' and 3' ends, respectively, showed  
 CC considerable reaction. An oligonucleotide with N4N4-ethanocytosine within  
 CC its sequence (see AAQ20008) showed less effective binding  
 XX  
 SQ Sequence 18 BP; 0 A; 4 C; 0 G; 14 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 1834 GAAAAAAGAAAAA 1850  
 ||| ||||| ||||| |||||  
 Db 18 GAAGAAAAAGAAAAA 2  
 RESULT 395  
 AAQ24901  
 ID AAQ24901 standard; DNA; 18 BP.  
 XX  
 AC AAQ24901;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 19-NOV-1992 (first entry)  
 XX  
 DE Human leukocyte antigen probe.  
 XX  
 KW HLA; polymerase chain reaction; inflammatory arthropathy; susceptibility;  
 KW arthritis; arthritis related diseases; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN W09207956-A1.  
 XX  
 PD 14-MAY-1992.  
 XX  
 PF 05-NOV-1991; 91WO-GB001935.  
 XX  
 PR 05-NOV-1990; 90GB-00024005.  
 PR  
 PA (BRBI-) BRITISH BIO-TECHNOLOGY LTD.  
 XX  
 PI Hill AV;  
 XX WPI; 1992-183691/22.  
 DR  
 XX PCR amplification of nucleic acids using buffer soln. and chelating agent  
 PT - for detecting HLA class I alleles for determining susceptibility to

PT arthritis etc.  
XX  
PS Disclosure; Page 14; 52pp; English.  
XX  
CC The sequence is that of a probe which hybridises to one of the human  
CC leukocyte antigen (HLA) sequences in the primer extension products (or  
CC strands) produced during PCR amplification of the HLA class I alleles. It  
CC is specific for the sequence encoding amino acids 56-61 of the alpha 1  
CC domain of HLA-B. It can be used in the detection and/or identification of  
CC an HLA sequence that may be indicative of a patients susceptibility to  
CC inflammatory arthropathy such as arthritis and arthritis related  
CC diseases. Such diseases include reactive arthritis, rheumatoid arthritis,  
CC Reiter's syndrome, uveitis, viral arthritis, psoriatic arthropathy, gouty  
CC arthritis, septic arthritis, erythema nodosum, Henoch-Schloelein purpura  
CC and esp. ankylosing spondylitis. See also AAQ24895-Q24902. (Updated on 25  
CC -MAR-2003 to correct PN field.)  
XX  
SQ Sequence 18 BP; 3 A; 4 C; 9 G; 2 T; 0 U; 0 Other;  
Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 504 GGCAGCAGCATTTGGGAC 520  
Db 2 GGCAGCAGCATTTGGGAC 18  
RESULT 396  
AAQ42926  
ID AAQ42926 standard; DNA; 18 BP.  
XX AC AAQ42926;  
XX  
DT 25-MAR-2003 (revised)  
DT 11-OCT-1993 (first entry)  
XX  
DE Primer CDRBACK.  
XX  
KW Polymerase chain reaction; PCR; amplify; primer; D-segment; variable;  
KW heavy; domain; VH; region; J-segment; human; germline; back primers;  
KW cloning; vector; PHEN1-V3; Vlamda3; light; chain; scFv; BSA; CDR3;  
KW thyroglobulin; ss.  
XX  
OS Synthetic.  
XX  
XX WO9311236-A1.  
XX  
XX 10-JUN-1993.  
XX  
XX 02-DEC-1992; 92WO-GB002240.  
XX  
XX 02-DEC-1991; 91GB-00025579.  
XX 02-DEC-1991; 91GB-00025582.  
XX 24-MAR-1992; 92GB-00006318.  
XX 24-MAR-1992; 92GB-00006372.  
XX 23-SEP-1992; 92WO-GB001755.  
XX  
XX (MEDI-) MEDICAL RES COUNCIL.  
XX (CAME-) CAMBRIDGE ANTIBODY TECHNOLOGY.  
XX  
XX Griffiths AD, Hoogenboom HRJM, Marks JD, McCafferty J, Winter GP;  
XX Gri99 GW;  
XX  
XX WPI; 1993-197055/24.  
XX  
XX Prodn. of anti-self antibodies - using replicating genetic display  
XX packages, i.e. AB repertoires displayed on phage.  
XX  
XX Disclosure; Page 80; 95pp; English.  
XX  
XX The sequences given in AAQ42925-26 are primers which were used in to  
CC analyse the CDR3 length of thyroglobulin binding clones (see also

CC AAQ42923-24). In thyroglobulin binding clones a CDR3 length of 10  
CC residues was found. (Updated on 25-MAR-2003 to correct PN field.)  
XX  
SQ Sequence 18 BP; 5 A; 2 C; 5 G; 6 T; 0 U; 0 Other;  
Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 795 TGTATTACGTTGGAGA 811  
Db 2 TGTATTACGTTGGAGA 18  
RESULT 397  
AAQ70349/c  
ID AAQ70349 standard; DNA; 18 BP.  
XX AC AAQ70349;  
XX  
DT 25-MAR-2003 (revised)  
DT 15-FEB-1995 (first entry)  
XX  
DE Antisense oligonucleotide for mouse FGF.  
XX  
KW Fibroblast growth factor; hybridisation; laser procedures;  
KW vascular smooth muscle cell; proliferation; SMC; vascular stenosis;  
KW post angioplasty restenosis; atherosclerosis; cardiac hypertrophy;  
KW organ transplant; ss.  
XX  
OS Synthetic.  
XX  
XX WO9415945-A1.  
XX  
XX 21-JUL-1994.  
XX  
XX 28-DEC-1993; 93WO-US012600.  
XX  
XX 31-DEC-1992; 92US-00999706.  
XX  
XX (TEXA-) TEXAS BIOTECHNOLOGY CORP.  
XX  
XX Denner LA, Rege AA, Dixon RA;  
XX  
XX WPI; 1994-249123/30.  
XX  
XX New anti-sense polynucleotide(s) to fibroblast growth factor receptor -  
XX used for inhibiting vascular smooth muscle cell proliferation, partic.  
XX for treating restenosis.  
XX  
XX Claim 3; Page 9; 53pp; English.  
XX  
XX The sequence is an antisense molecule directed against position -6 to  
XX +12, relative to the start codon of the gene for mouse fibroblast growth  
XX factor 1. The polynucleotide can be used for inhibiting vascular smooth  
XX muscle cell proliferation and for treating a disease e.g. vascular  
XX stenosis, post angioplasty restenosis, atherectomy, atherosclerosis,  
XX atrial venous shunt failure, cardiac hypertrophy, vascular surgery and  
XX organ transplant. See also AAQ70333-60. (Updated on 25-MAR-2003 to  
XX correct PN field.)  
XX  
SQ Sequence 18 BP; 4 A; 10 C; 2 G; 2 T; 0 U; 0 Other;  
Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 977 CTGGGATGTTGGGCGAG 993  
Db 17 CTGGGATGTTGGGCTGG 1  
RESULT 398

```

AA15196/c
ID  AA15196 standard; DNA; 18 BP.
XX
AC  AA15196;
XX
DT  25-MAR-2003 (revised)
DT  28-APR-1999 (first entry)
XX
DE  XX
XX  Triple helix forming oligonucleotide.
XX
XX  Double-stranded DNA; triple helix; quinoline;
KW  quinazoline-based structure; hydrogen bonding; ss.
XX
OS  Synthetic.
XX
PN  WO9623777-A1.
XX
XX  08-AUG-1996.
XX
PF  29-JAN-1996; 96WO-US001473.
XX
PR  01-FEB-1995; 95US-00384324.
XX
XX  (UYNE-) UNIV NEBRASKA.
XX
PI  Gold BI;
XX
XX  WPI; 1996-371338/37.
XX
XX  New subst. quinoline and quinazoline cpds. - are monomers for triple
PT  helix-forming oligonucleotide analogues useful e.g. for treating tumours
PT  or viral infection.
XX
XX  Disclosure; Fig 1; 102pp; English.
XX
XX  The present sequence represents a triple helix forming oligonucleotide
CC  that form a triple helix with the double-stranded DNA sequence described
CC  in AA15195. The specification describes novel monomeric compositions
CC  which are substituted quinoline or quinazoline-based structures capable
CC  of hydrogen bonding specifically with interstrand purine-pyrimidine pairs
CC  in a double stranded Watson-Crick DNA molecule to form a triple-helix.
CC  (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ  Sequence 18 BP; 0 A; 3 C; 0 G; 15 T; 0 U; 0 Other;
    Query Match      0.7%; Score 13.8; DB 1; Length 18;
    Best Local Similarity 88.2%; Pred. No. 1.9e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  1834 GAAAAAAGAAAAA 1850
DB  17 GAAAAAAGAAAAA 1

RESULT 399
AA177597
ID  AA177597 standard; DNA; 18 BP.
XX
AC  AA177597;
XX
DT  11-SEP-1997 (first entry)
XX
XX  Wheat microsatellite WMS155 left primer.
XX
XX  Microsatellite marker; hypervariable genomic fragment; Triticum aestivum;
KW  wheat; Triticaceae; sequence tagged site; STS; primer; PCR; amplify;
KW  polymorphism; genetic analysis; hexaploid; tetraploid; mapping; ss.
XX
OS  Synthetic.
XX
XX  DE19525284-A1.
XX
XX  02-JAN-1997.
XX
XX  28-JUN-1995; 95DE-01025284.
XX
XX  28-JUN-1995; 95DE-01025284.
XX
PA  (PFLA-) INST PFLANZENGENETIK & KULTURPFLANZENFOR.
XX
PI  Roeder M, Plaschke J, Ganai M;
XX
XX  WPI; 1997-053731/06.
XX
XX  Primers for STS microsatellite markers for wheat and related species -
PT  useful for genetic mapping, analysis and labelling etc. of wheat.
XX
XX  Claim 5; Page 7; 8pp; German.
XX
XX  Microsatellite markers based on hypervariable genomic fragments, from
CC  Triticum aestivum (wheat) or the tribe Triticaceae, consist of a sequence
CC  tagged site (STS), defined by 2 specific primers (of mean size 17-23
CC  bases) that flank a microsatellite sequence at both ends, which can be
CC  amplified to polymorphisms (PCR products of different sizes). The
CC  microsatellites are n-fold tandem repeats (n = 10 or more) of di-, tri-
CC  or tetra-nucleotide sequences, combination microsatellite sequences or an
CC  imperfect sequence in which individual bases are mutated. The
CC  microsatellite markers can be used for genetic analysis of hexaploid and
CC  tetraploid forms of wheat and for genetic mapping or labelling of
CC  monogenic and polygenic properties, and for their selection; for
CC  analysing relationships and identifying varieties; and for evaluating
CC  varietal purity, hybrid identification and plant growth. The markers can
CC  differentiate between almost all European wheat lines and show a higher
CC  degree of DNA polymorphism than known probes for the wheat genome. They
CC  can be detected by PCR, so large numbers of samples can be analysed
CC  easily (e.g. several hundred per day). Microsatellite marker-related
CC  polymorphisms are stably inherited so can also serve as genetic markers.
CC  AAT77003-22 and AAT77355-716 are primer pairs that define the
CC  microsatellite markers. WMS155 has a CT type repeat
XX
SQ  Sequence 18 BP; 3 A; 10 C; 0 G; 5 T; 0 U; 0 Other;
    Query Match      0.7%; Score 13.8; DB 1; Length 18;
    Best Local Similarity 88.2%; Pred. No. 1.9e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  1696 AATCATTTCCCTCC 1712
DB  2 AATCATTTCCCTCC 18

RESULT 400
AAV30476/c
ID  AAV30476 standard; DNA; 18 BP.
XX
XX  AAV30476;
XX
XX  14-OCT-1998 (first entry)
XX
XX  Canine beta-3 adrenergic receptor antisense primer 1263.
XX
XX  Canine; beta-adrenergic receptor; brown adipose tissue; probe; human;
KW  hybridisation; ligand; primer; ss.
XX
OS  Synthetic.
OS  Canis familiaris.
XX
XX  WO9735973-A2.
XX
XX  02-OCT-1997.
XX
XX  26-MAR-1997; 97WO-FR000537.
XX
XX  26-MAR-1996; 96FR-00003730.
XX
XX  (VETI-) VETIGEN.

```

XX Lenzen G, Pietri-Rouxel P, Drumare M, Strosberg AD;  
 XX WPI; 1998-032136/03.  
 XX Canine beta 2 and beta 3 adrenergic receptors and coding sequences -  
 PT useful for identifying specific ligands and (ant)agonists to develop  
 PT specific treatments for obesity in dogs.  
 XX Claim 17; Page 49; 79pp; French.  
 XX Primers AAV30470-V30490 were used for sequencing the coding region of the  
 CC canine beta 3-adrenergic receptor (RA-Ca-b3) gene (AAV30469). RA-Ca-b3  
 CC has been implicated in obesity and obesity-related metabolic disorders  
 CC e.g. diabetes. The canine version of RA-Ca-b3 can be used to develop  
 CC treatments specific for dogs. The sequence can also be used in  
 CC differential screening for ligands for RA-Ca-b3 as compared to the beta-2  
 CC adrenergic receptor (AAW44932)  
 XX Sequence 18 BP; 6 A; 1 C; 10 G; 1 T; 0 U; 0 Other;  
 SQ Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 721 CCTCCTTCTCCATCTAC 737  
 DB ||||| ||||| |||||  
 18 CCTCCGCTCTCCTTCTAC 2  
 RESULT 401  
 AAV16014/C  
 ID AAV16014 standard; DNA; 18 BP.  
 XX AAV16014;  
 AC AAV16014;  
 XX 21-MAY-1998 (first entry)  
 DT PCR primer G-R used to identify Sox-3 gene mutations in mice.  
 XX Mutation; Sox-3; ENU mutagenesis; mutational screening; recessive;  
 KW single strand conformation polymorphism; SSCP; phenotypic alteration;  
 KW PCR primer; amplify; ss.  
 XX Synthetic.  
 OS Mus sp.  
 XX WO9744485-A1.  
 PN 27-NOV-1997.  
 PD 16-MAY-1997; 97WO-GB001354.  
 PF 17-MAY-1996; 96GB-00010355.  
 PR (HEXA-) HEXAGEN TECHNOLOGY LTD.  
 XX Goodfellow PN;  
 PI WPI; 1998-018536/02.  
 XX Identification of mutation(s) in genes of interest - without prior  
 PT observation of phenotypic alteration in the mutated organism or cell.  
 XX Example 4; Page 41; 66pp; English.  
 XX PCR primers AAV16001-18 were used to identify mutations in Sox-3 using  
 CC the method of the invention. The primers are located throughout the gene  
 CC and are unique to Sox-3. The method comprises testing a nucleic acid  
 CC sample from a mutated organism for a mutation in a gene of interest  
 CC without the prior observation of a phenotypic alteration in the mutated  
 CC organism resulting from the mutation. Sox-3 is a member of the Sox gene  
 CC family, a family of about 20 genes which all encode a "HMG" box, which is

CC a DNA-binding domain. Mice were mutagenised using ENU mutagenesis. The  
 CC mutagenised mice were tested by PCR with each primer set and fluorescent  
 CC single strand conformation polymorphism (SSCP), which identifies mice  
 CC carrying mutations in Sox-3. The method provides mutational screening  
 CC based on genomic and genetic techniques rather than on phenotypic  
 CC observation. The method identifies and characterises genes via  
 CC mutagenesis to identify genes encoding products which may have  
 CC therapeutic benefit. The method also identifies the presence of mutations  
 CC in a gene which do not rely solely upon prior matching of a gene with a  
 CC disease. Heterozygotic organisms can also be screened to identify those  
 CC carrying a mutation in a copy of a gene of interest even though the gene  
 CC may be recessive and therefore causes no phenotypic alteration  
 XX Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;  
 SQ Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 28 GCGGCTCGTGGCGC 44  
 DB ||||| ||||| |||||  
 17 GCGGCGCGCGCGCGC 1  
 RESULT 402  
 AAV3800/C  
 ID AAV3800 standard; DNA; 18 BP.  
 XX AAV3800;  
 AC AAV3800;  
 XX 30-DEC-1998 (first entry)  
 DT Human growth hormone receptor exon 2 DNA primer 101.  
 DE Growth hormone receptor; GHR; idiopathic short stature; ISS; GH;  
 XX partial growth hormone insensitivity syndrome; GHIS; growth hormone;  
 KW insulin-like growth factor I; IGF-I; growth hormone binding protein;  
 KW laron syndrome; PCR; primer; amplification; ss.  
 XX Synthetic.  
 OS Homo sapiens.  
 XX US5824642-A.  
 PN 20-OCT-1998.  
 PD 06-JUN-1995; 95US-00468580.  
 PF 07-APR-1994; 94US-00224982.  
 PR 24-MAR-1995; 95US-00410452.  
 XX (GETH ) GENENTECH INC.  
 PA Gesundheit N, Goddard A, Attie K, Carlsson LMS;  
 XX WPI; 1998-582593/49.  
 PT Treatment of non growth hormone dependent short stature - comprises  
 PT administration of growth factor and/or insulin-like growth factor I.  
 XX Example 4; Col 27-28; 57pp; English.  
 XX Primers 101 and 102 (AAV3801) were used to amplify the human growth  
 CC hormone receptor exon 2 coding region and its flanking splice sites. The  
 CC PCR product was used in the method of the invention. The invention  
 CC provides a method for increasing the growth rate of a patient having  
 CC partial growth hormone insensitivity syndrome (GHIS) comprising of  
 CC administering growth hormone (GH) and/or insulin-like growth factor I  
 CC (IGF-I). The patients chosen had a height of less than -2 standard  
 CC deviations below normal for age and sex, had a serum level of high-  
 CC affinity GH-binding protein of at least 2 standard deviations below  
 CC normal levels, had a mean or maximum stimulated serum GH level that was  
 CC at least normal, and did not have Laron syndrome

```

XX SQ Sequence 18 BP; 2 A; 5 C; 4 G; 7 T; 0 U; 0 Other;
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 264 TATGGTAAAGCCAGAA 280
DB 17 TAAGGTAAGCCAGCA 1

RESULT 403
AAZ31824
ID AAZ31824 standard; DNA; 18 BP.
XX AC AAZ31824;
XX DT 24-JAN-2000 (first entry)
XX DE Human G-alpha-13 antisense inhibitor ISIS# 20773.
XX KW G-alpha-13; human; inhibitor; cancer; antisense compound; therapy; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN US981732-A.
XX PD 09-NOV-1999.
XX PF 04-DEC-1998; 98US-00205860.
XX PR 04-DEC-1998; 98US-00205860.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Cowser LM;
XX DR WPI; 1999-633376/54.
XX PT Antisense compound inhibiting expression of human G-alpha-13.
XX PS Claim 11; Col 39; 38pp; English.
XX CC This sequence represents an antisense inhibitor of the invention, and
CC inhibits the expression of the human G-alpha-13 protein. The antisense
CC compounds of the invention are of 8 to 30 nucleobases in length, that
CC inhibits the expression of the human G-alpha-13. The antisense compound
CC is useful for treating an animal, particularly humans, having or being
CC prone to a disease or condition associated with the expression of G-alpha
CC -13, such as cancer
XX SQ Sequence 18 BP; 5 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1778 AAAACATTTGTTCCAC 1794
DB 2 AAACCTTTGTTCCAC 18

RESULT 404
AAZ39664/C
ID AAZ39664 standard; DNA; 18 BP.
XX AC AAZ39664;
XX DT 28-FEB-2000 (first entry)
XX DE Human vth aggregation factor gene specific FPCR-SSCP primer.

```

```

XX KW Gene polymorphism; human; vth aggregation factor; genetic diagnosis;
XX KW diabetes; FPCR; SSCP; fluorescence-based polymerase chain reaction;
XX KW single strand conformation polymorphism; PCR primer; ss.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN JP11313676-A.
XX PD 16-NOV-1999.
XX PF 30-APR-1998; 98JP-00120217.
XX PR 30-APR-1998; 98JP-00120217.
XX PA (SAKA ) OTSUKA PHARM CO LTD.
XX DR WPI; 2000-057352/05.
XX KW Discrimination of human V aggregation factor gene polymorphism.
XX PS Disclosure; Page 10; 34pp; Japanese.
XX CC The invention provides a method for the discrimination of the gene
XX CC polymorphism of human vth aggregation factor, where one of the following
XX CC (1) to (6)) residues/nucleotides in the aggregation gene is discriminated
XX CC in the patient to be tested: (1) residue 495: guanine (G) or adenine (A),
XX CC (2) residue 642: (G) or thymine (T), (3) residue 2663: (G) or (A), (4)
XX CC residue 2763: (G) or (A), (5) residue 2863: (A) or (G), (6) residue 5112:
XX CC (A) or (G). The method is useful in the genetic diagnosis of a diabetes
XX CC patient. The method uses FPCR-SSCP (fluorescence-based polymerase chain
XX CC reaction-single strand conformation polymorphism) for analyzing DNA
XX CC samples for polymorphisms. Sequences AAZ39632-717 represent primers used
XX CC for the FPCR-SSCP analysis of the human vth aggregation factor gene
XX SQ Sequence 18 BP; 3 A; 5 C; 2 G; 8 T; 0 U; 0 Other;
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1685 CTAGAAAAGGAATCAT 1701
DB 18 CTAGAAAAGGAATGAT 2

RESULT 405
AAZ43273/C
ID AAZ43273 standard; DNA; 18 BP.
XX AC AAZ43273;
XX DT 11-FEB-2000 (first entry)
XX DE Murine Sox3 gene PCR primer 14.
XX KW Screening; mutation; treatment; disease; drug discovery; PCR primer; ss.
XX OS Mus musculus.
XX PN US5994075-A.
XX PD 30-NOV-1999.
XX PF 16-MAY-1997; 97US-00857946.
XX PR 17-MAY-1996; 96US-0017824P.
XX PA (HEXA-) HEXAGEN TECHNOLOGY LTD.
XX PI Goodfellow PN;
XX

```

```

DR WPI; 2000-038255/03.
XX Identifying a mutation in a gene of interest in an organism useful for
PT identifying genes encoding products which may have therapeutic benefits.
PS Example 5; Col 65-66; 70pp; English.
XX
XX This invention describes a novel mutational screening method based on
CC genomic and genetic techniques to identify and characterize a mutation in
CC a gene of interest without first selecting a phenotypic characteristic.
CC The screening methods are useful for identifying genes encoding products
CC which may have therapeutic benefit for treating human or animal diseases.
CC The method can be used for the DNA mutation screening of a class or a
CC family of genes providing a rapid assay for identifying mutant genes. The
CC methods produce organisms which can be used for drug discovery e.g.
CC providing a model for the study and treatment of a disease state, allow
CC in vitro assessment of drug activity and interbreeding of mutants which
CC allow investigation of gene interactions in the overall phenotype. A
CC range of phenotypes associated with different mutations, and specified
CC mutations in a gene of interest can be determined. The method can be
CC adapted to screen for a mutation in two or more genes of interest in an
CC organism. The methods allow mutations in a gene of interest to be
CC identified without having to rely on matching a gene with a disease.
CC AAZ43260-Z43421 represent PCR primers used in the method of the invention
XX
XX Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 28 GCCGCTCTCCGTCGCCGC 44
DB 17 GCCGCGCGCGCGCGCGC 1
RESULT 406
AAZ05258/C
ID AAA05258 standard; DNA; 18 BP.
AC AAA05258;
XX 19-MAY-2000 (first entry)
DT PCR primer G-R used in Sox-3 amplicon generation.
DE
XX PCR primer; Sox-2; Sox-3; T gene; Tyrosinase; MGF; Sry; c-kit; Tryp-1;
KW Pax-6; mutation detection; therapeutic target identification; mouse;
KW mast cell growth factor; ss.
XX Mus sp.
OS
XX US6015670-A.
PN
XX 18-JAN-2000.
PD
XX 14-NOV-1997; 97US-00970740.
PF
XX 17-MAY-1996; 96US-0017824P.
PR
XX 16-MAY-1997; 97US-00857946.
PR
XX (HEXA-) HEXAGEN TECHNOLOGY LTD.
PA
XX Goodfellow PN;
XX WPI; 2000-181139/16.
XX
XX Detecting mutations in selected genes, useful e.g. for identifying
PT therapeutic targets or products, by analysing DNA in mutated embryonic
PT stem cells without phenotypic characterization.
XX
XX Example 5; Col 31; 66pp; English.
XX

```

---

```

CC PCR primers AAA05245-A05406 are used to generate amplicons from the mouse
CC Sox-3 gene, Sox-2 gene, T gene, tyrosinase gene, Tryp-1 gene, Sry gene,
CC MGF (mast cell growth factor) gene, c-kit gene, and the Pax-6 gene. The
CC primers are used in a method for the identification of a mutation in a
CC selected gene in a tissue without the prior observation of a phenotypic
CC alteration in the mutated organism or cell. The method is used to
CC identify mutations in a selected gene that encode products of potential
CC therapeutic activity or that are potential targets, particularly where
CC the gene of interest has been identified as a candidate gene by
CC positional cloning. Other applications are determining functions of genes
CC detecting the range of phenotypes associated with different mutations
CC in a particular gene and identification of particular mutations. Animals
CC containing an identified mutation are used as models for studying
CC diseases or their treatment, and cells from them for in vitro assessment
CC of drug action. Interbreeding of mutant mice is used to investigate
CC genetic interaction in the overall phenotype
XX
XX Sequence 18 BP; 0 A; 7 C; 11 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 28 GCCGCTCTCCGTCGCCGC 44
DB 17 GCCGCGCGCGCGCGCGC 1
RESULT 407
AAF26702
ID AAF26702 standard; DNA; 18 BP.
XX AAF26702;
AC AAF26702;
XX 09-SEP-2004 (revised)
DT 02-APR-2001 (first entry)
DT
XX Human Smad7 phosphorothioate antisense oligonucleotide SEQ ID NO:45.
DE
XX Human; Smad7; antisense oligonucleotide; phosphorothioate; inhibition;
KW antiinflammatory; cytostatic; infection; inflammation; tumour formation;
KW ss.
XX Homo sapiens.
OS Unidentified.
XX
XX Key Location/Qualifiers
FH modified_base 1..18
FT /tag= a
FT /mod_base
FT /note= "phosphorothioate linkages"
FT
XX US6159697-A.
PN
XX 12-DEC-2000.
PD
XX 09-JAN-2000; 2000US-00487444.
PF
XX 09-JAN-2000; 2000US-00487444.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Monia BP, Cowser LM;
PI
XX WPI; 2001-070108/08.
XX
XX Antisense compound capable of inhibiting the expression of human Smad7,
PT useful for preventing or delaying infection, inflammation or tumor
PT formation.
XX
XX Example 15; Col 41; 33pp; English.
XX
XX The present invention describes an antisense compound (I) of up to 30
XX

```

The invention relates to isolated genes (Gene 216) from human chromosome 20p13-p12 and the proteins they encode. The nucleic acids and proteins may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate Gene 216 expression. For example, the nucleic acids (or vectors) and proteins may be used to treat disorders associated with decreased expression by rectifying mutations or deletions in a patient's genome that affect the activity of gene 216 by expressing inactive proteins or to supplement the patients own production of Gene 216 proteins. Additionally, the nucleic acids may be used to produce the secreted Gene 216 protein, by inserting the nucleic acids into a host cell and culturing the cell to express the protein. The nucleic acids and complementary sequences may also be used as DNA probes in diagnostic assays to detect and quantitate the presence of similar nucleic acid sequences in samples and therefore which patients may be in need of restorative therapy. The Gene 216 protein may also be used as antigens in the production of antibodies against Gene 216 and in assays to identify modulators of Gene 216 expression and activity. The anti-Gene 216 antibodies and antagonists may also be used to down regulate expression and activity. The anti-Gene 216 antibodies may also be used as diagnostic agents for detecting the presence of Gene 216 proteins in samples (e.g. by enzyme linked immunosorbant assay or ELISA). Disorders that may be prevented, diagnosed and/or treated by the above methods include, for example asthma, obesity and inflammatory bowel disease. The present sequence is that of a Gene 216 related primer used in examples of the invention. The primers are used in the physical mapping of the gene

CC (ABZ72067-ABZ72088), polymorphism identification using single strand  
 CC conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184),  
 CC sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362)  
 XX  
 SQ Sequence 18 BP; 5 A; 2 C; 10 G; 1 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 1101 GCAGAGCAACAGGTGG 1117  
 Db 2 GCAGAGGAGCAAGGTGG 18  
 RESULT 410  
 ID ABK41013/C  
 AC ABK41013;  
 XX 21-MAY-2002 (first entry)  
 DT Human obesity-associated biallelic marker upstream PCR primer #90.  
 DE Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;  
 KW drug response; hyperuricaemia; digestive pathology; hypertension; cancer;  
 KW hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;  
 KW insulin disorder; atherosclerotic disease; cardiac insufficiency; primer.  
 XX Homo sapiens.  
 OS  
 XX W0200206525-A2.  
 PN 24-JAN-2002.  
 PD 28-JUN-2001; 2001WO-IB001477.  
 PF 18-JUL-2000; 2000US-0219704P.  
 PR (GEST ) GENSET.  
 XX Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;  
 PI WPI; 2002-155043/20.  
 DR Set of novel map-related biallelic markers, preferably located on obesity  
 PT disorder-associated chromosomal regions on chromosomes 3, 10 and 19,  
 PT useful, for e.g. detecting statistical correlations between marker allele  
 PT and a phenotype.  
 XX Example 2; Page 246; 31pp; English.  
 CC The invention relates to a set of novel map-related biallelic markers,  
 CC preferably located on obesity disorder-associated chromosomal regions on  
 CC chromosomes 3, 10 and 19. The markers are useful for genotyping or  
 CC estimating the frequency of an allele in a population, for detecting an  
 CC association between a genotype or haplotype and a phenotype, e.g. a  
 CC disease involving drug responses, obesity or disorders related to  
 CC obesity, such as hyperuricaemia, digestive pathology, hepatic function  
 CC disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,  
 CC insulin disorders, atherosclerotic disease and cardiac insufficiency. The  
 CC markers are useful for detecting a statistical correlation between a  
 CC biallelic marker allele and a phenotype and/or between a biallelic marker  
 CC haplotype and a phenotype. This sequence represents a PCR primer used to  
 CC amplify a human obesity-associated biallelic marker  
 XX Sequence 18 BP; 5 A; 5 C; 3 G; 5 T; 0 U; 0 Other;  
 SQ Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 224 CTGTGGAGATGTTGCTA 240  
 Db 17 CTGTGAAGATGATGCTA 1  
 RESULT 411  
 ABS97456  
 ID ABS97456 standard; DNA; 18 BP.  
 XX  
 AC ABS97456;  
 XX 23-DEC-2002 (first entry)  
 DT Human diazepam binding inhibitor (DBI) gene PCR Primer #6.  
 DE Human; ss; primer; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1; PCR;  
 KW cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002B1; LTF;  
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;  
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;  
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;  
 KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;  
 KW glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;  
 KW HMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;  
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoxidoreductase 2; SOD;  
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;  
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;  
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;  
 KW multidrug resistance associated protein 3; cancer; prostate;  
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;  
 KW altered drug metabolism; cardiovascular function; colorectal tumour;  
 KW central nervous system; pulmonary; immunological.  
 XX Homo sapiens.  
 OS  
 XX W0200257410-A2.  
 PN 25-JUL-2002.  
 PD 28-NOV-2001; 2001WO-US044838.  
 PF 28-NOV-2000; 2000US-00724389.  
 PR (DNAS-) DNA SCI LAB INC.  
 XX Guida M, Hall J;  
 PI WPI; 2002-698522/75.  
 DR Isolated nucleic acid molecules having polymorphisms in known human genes  
 PT e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers  
 PT for locating, identifying and characterizing the genes responsible for  
 PT disorder-related traits.  
 XX Example 9; Page 115; 714pp; English.  
 PS This invention relates to the sequence of an isolated nucleic acid  
 CC molecule comprising at least one base variation from that of a known  
 CC human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),  
 CC cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADRB1),  
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator  
 CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding  
 CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating  
 CC protein (FLAP), glutathione-S-transferase 12 (GSTI2), histamine-N-methyl  
 CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),  
 CC sulfoxidoreductase 2 (SOD), kallikrein 2 (KLK2), nicotinamide -N-methyl  
 CC transferase (HMT), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl  
 CC transferase (UGT2B4), urokinase receptor (uPA), multidrug resistance 1  
 CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3  
 CC (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic  
 CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.  
 CC The polymorphisms in the human genes cited in the invention are useful as  
 CC genetic linkage markers for locating and characterising the genes that



CC are responsible for specific traits within the genome and eventually  
 CC identifying the genes responsible for a variety of disorder-related  
 CC traits as a result of their e.g., overexpression, constitutive  
 CC expression, mutation or underexpression, which may be used in diagnosing  
 CC and/or treating the disorders. The nucleic acid molecules comprising the  
 CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,  
 CC ARNT, EPHX2, GSTI2, NNMT, NOD2, NR1I2, STM, UGT2B4, UGT2B15, AHR,  
 CC MDR1 and/or MDR3 are useful for screening individuals for altered drug  
 CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,  
 CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for  
 CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are  
 CC used to screen for altered cardiovascular function, in COX2 for altered  
 CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central  
 CC nervous system function, in FLAP and HNMT for altered pulmonary,  
 CC immunological or haematological function, in KLK2 for altered serine  
 CC protease activity in the prostate, in LTF for altered immunological or  
 CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and  
 CC peripheral nervous system function. The present sequence represents a PCR  
 CC primer used to amplify the sequences of the invention

SQ Sequence 18 BP; 6 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 411 CTGGAGCCAGTCAGAAAT 427  
 |||||  
 Db 1 CTGGAGACACTGAGAAAT 17

## RESULT 412

ABS66015  
 ID ABS66015 standard; DNA; 18 BP.

AC ABS66015;

DT 15-NOV-2002 (first entry)

DE Mycobacterium intracellulare detection primer #2.

KW Microbe detection; Legionella; Pseudomonas aeruginosa; Mycobacterium;  
 KW Burkholderia cepacia; Escherichia coli; Acinetobacter; Acanthamoeba;  
 KW Cryptosporidium parvum; PCR; primer; ss.

XX Mycobacterium.

XX JP2002223766-A.

XX 13-AUG-2002.

PD 31-JAN-2001; 2001JP-00023742.

PR 31-JAN-2001; 2001JP-00023742.

XX (RAKA-) RAKAN KK.

PA (GIFU-) GIFU DAIGAKUCHO.

DR WPI; 2002-649521/70.

XX Detection of a microbe and a primer set for the detection.

PS Claim 4; Page 5; 25pp; Japanese.

XX The invention relates to a method for detection of a microbe by  
 CC amplifying the gene of the microbe belonging to a specified range of  
 CC classification by polymerase chain reaction (PCR) using a primer  
 CC targeting the gene of the microbe. A primer set for the detection of a  
 CC microbe is included for the detection of Legionella spp, Pseudomonas  
 CC aeruginosa, Burkholderia cepacia, Escherichia coli, Acinetobacter  
 CC Mycobacterium, Acanthamoeba, Cryptosporidium parvum groups. ABS66002-  
 CC ABS66053 represent primers used to detect the microbes of the invention

SQ Sequence 18 BP; 2 A; 9 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 725 CTTCTCCATCTACAGTC 741  
 |||||  
 Db 2 CTTCTCCACCTACCGTC 18

## RESULT 413

ABS66019  
 ID ABS66019 standard; DNA; 18 BP.

AC ABS66019;

DT 15-NOV-2002 (first entry)

DE Mycobacterium intracellulare detection primer #2.

KW Microbe detection; Legionella; Pseudomonas aeruginosa; Mycobacterium;  
 KW Burkholderia cepacia; Escherichia coli; Acinetobacter; Acanthamoeba;  
 KW Cryptosporidium parvum; PCR; primer; ss.

XX Mycobacterium intracellulare.

XX JP2002223766-A.

XX 13-AUG-2002.

PD 31-JAN-2001; 2001JP-00023742.

PR 31-JAN-2001; 2001JP-00023742.

XX (RAKA-) RAKAN KK.

PA (GIFU-) GIFU DAIGAKUCHO.

DR WPI; 2002-649521/70.

XX Detection of a microbe and a primer set for the detection.

PS Claim 4; Page 5; 25pp; Japanese.

XX The invention relates to a method for detection of a microbe by  
 CC amplifying the gene of the microbe belonging to a specified range of  
 CC classification by polymerase chain reaction (PCR) using a primer  
 CC targeting the gene of the microbe. A primer set for the detection of a  
 CC microbe is included for the detection of Legionella spp, Pseudomonas  
 CC aeruginosa, Burkholderia cepacia, Escherichia coli, Acinetobacter,  
 CC Mycobacterium, Acanthamoeba, Cryptosporidium parvum groups. ABS66002-  
 CC ABS66053 represent primers used to detect the microbes of the invention

SQ Sequence 18 BP; 2 A; 9 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 725 CTTCTCCATCTACAGTC 741  
 |||||  
 Db 2 CTTCTCCACCTACCGTC 18

## RESULT 414

AAD34959  
 ID AAD34959 standard; DNA; 18 BP.

AC AAD34959;

DT 16-JUL-2002 (first entry)

DE Human SDF1 gene amplifying forward PCR primer.

```

XX Human; CCR2; SDF1; Factor V; MTHFR; Factor XIII; CCR5; detection; PCR;
KW primer; ss.
XX
XX Homo sapiens.
OS
XX US2002037507-A1.
PN
XX 28-MAR-2002.
XX
XX 14-DEC-2000; 2000US-00736863.
XX
XX 16-DEC-1999; 99US-0171126P.
XX
XX (WALK/) WALKERPEACH C R.
PA (HUX/) HU X.
PA
XX Walkerpeach CR, Hu X;
XX
XX WPI; 2002-329124/36.
XX
XX Polynucleotide primers and probes useful for single base substitutions in
PT the human CCR2, SDF1, Factor V, MTHFR, Factor XIII genes, and a 32-bp
PT deletion in the human CCR5 gene by polymerase chain reaction.
XX
XX Claim 1; Page 12; 41pp; English.
XX
XX The invention relates to sequence-specific polynucleotide probes, pairs
CC of probes, the design of pairs of probes in relation to the strands of
CC target nucleic acid and coordinate sequence-specific pairs of primers,
CC for the detection of four single base substitutions in the human CCR2,
CC SDF1, Factor V, MTHFR, Factor XIII genes, and a 32-bp deletion in the
CC human CCR5 gene. The polynucleotides of the invention are used for the
CC detection of four single base substitutions in the human CCR2, SDF1,
CC Factor V, MTHFR, Factor XIII genes, and a 32-bp deletion in the human
CC CCR5 gene. The present sequence is a PCR primer used for target
CC amplification and detection of human SDF1 gene
XX
XX Sequence 18 BP; 3 A; 10 C; 0 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 722 CTCCTTCTCCATCACA 738
DB 1 CCCCTTCTCCATCACA 17
RESULT 415
ABK98126/c
ID ABK98126 standard; DNA; 18 BP.
XX
XX AC ABK98126;
XX
XX 07-OCT-2002 (first entry)
XX
XX Triple helix forming associated oligonucleotide #15.
XX
XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW pathogenic bacteria; virus; replication; virulence; cancer;
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
XX Synthetic.
XX
XX OS US6403302-B1.
XX
XX PN 11-JUN-2002.
XX
XX 16-DEC-1993; 93US-00168920.
XX
XX 17-SEP-1992; 92US-00946976.
XX

```

```

XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.
PA
XX Dervan PB, Beal PA;
XX
XX WPI; 2002-536030/57.
XX
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT oligonucleotide which binds in parallel and antiparallel orientation,
PT respectively, for targeting sequences on alternate strands of DHNA to
PT control gene expression.
XX
XX Example 7; Col 41; 108pp; English.
XX
XX The present invention relates to methods and oligonucleotides for forming
CC a triple-helix comprising a double helical nucleic acid comprising first
CC and second substantially complementary strands, and an oligonucleotide
CC bound to a purine-rich target sequence within the double helical nucleic
CC acid, where the oligonucleotide binds in a parallel and antiparallel
CC orientation, respectively, to target sequences on alternate strands of
CC the double helical nucleic acid. The method has therapeutic applications,
CC where gene expression is controlled by selective triple-helix formation
CC within expression regulatory sequences of a target gene. The
CC oligonucleotides can be used to form triple-helices, and are useful to
CC detect the presence or absence of specific sequences within genomic DNA
CC for diagnostic and therapeutic purposes. The oligonucleotides can be
CC selected to specifically bind to pathogenic double-stranded DNA including
CC specific sequences required by pathogenic bacteria or viruses for
CC replication or virulence, reducing their pathogenicity. Alternatively,
CC the oligonucleotide can be chosen to target a unique sequence of the
CC pathogen which is not found in the genome of pathogen's host. The
CC oligonucleotides can be used in cancer treatment by way of triple-helix
CC suppression of specific oncogenes including those of endogenous or viral
CC origin. Such therapeutic oligonucleotides are capable of forming triple-
CC helices with such sequences in cancerous cells containing the activated
CC oncogene, so preferentially killing or repressing the cancer causing
CC cell. The present sequence represents an oligonucleotide used in the
CC methods of the present invention
XX
XX Sequence 18 BP; 0 A; 2 C; 0 G; 14 T; 0 U; 2 Other;
SQ
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 1.9e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
QY 1834 GAAAAAAGAAAAA 1850
DB 17 GAAAAAAGAAAAA 1
RESULT 416
ABX74982
ID ABX74982 standard; DNA; 18 BP.
XX
XX AC ABX74982;
XX
XX 25-MAR-2003 (first entry)
XX
XX Human gene 216 polymorphism detection PCR primer #39.
XX
XX Human; mouse; ss; primer; Gene 216; antiasthmatic; antiinflammatory;
KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
KW gene therapy; respiratory disease; asthma; obesity; PCR;
KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
KW adult respiratory distress syndrome; inflammatory bowel syndrome.
XX
XX OS Homo sapiens.
XX
XX PN WO200283077-A2.
XX
XX 24-OCT-2002.
XX
XX 15-APR-2002; 2002WO-US012063.
XX

```

```
XX 13-APR-2001; 2001US-00834597.
PR 13-APR-2001; 2001WO-US012245.
XX (SCHE ) SCHERING CORP.
PA (GENO-) GENOME THERAPEUTICS CORP.
XX Keith T, Little RD, Van Berdewegh P, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX WPI; 2003-092960/08.
DR
XX New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
PT treating a disorder, such as asthma, bronchial hyper-responsiveness,
PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
PT syndrome.
XX Example 10; Page 155; 650pp; English.
PS
XX This invention relates to a novel isolated nucleic acid, gene 216,
CC identified from human chromosome 20p13-p12. The invention also discloses
CC regions of the 216 gene that contain single nucleotide polymorphisms
CC (SNP's) which may be used as markers for disease susceptibility or
CC severity. The nucleotides of the invention may have antiasthmatic,
CC antiinflammatory or anorectic activities and may be used in gene therapy.
CC The nucleic acids, antibodies or its fragments are useful for diagnosing,
CC preventing or treating a disorder, such as respiratory diseases (e.g.
CC asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
CC disease or adult respiratory distress syndrome), obesity, or inflammatory
CC bowel syndrome. The nucleic acids are also useful for identifying
CC increased susceptibility of a subject to the disorders mentioned. The
CC nucleic acids can also be used as primers and templates for the
CC recombinant production of disorder-associated peptides or polypeptides,
CC for chromosome and gene mapping, or for tissue distribution studies. The
CC present sequence represents a gene 216 specific PCR primer used in the
CC scope of the invention
XX
SQ Sequence 18 BP; 5 A; 2 C; 10 G; 1 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 1101 GCAGAAGAACAAAGGTGG 1117
||||| |||||
Db 2 GCAGAGGAGCAAGGTGG 18
RESULT 417
ADA27361/c
ID ADA27361 standard; DNA; 18 BP.
XX
XX ADA27361;
AC
XX 20-NOV-2003 (first entry)
DT
XX Human microsatellite repeat M2_3_8.
DE
XX ds; HLA-related research; HLA class II-associated disease;
KW transplantation matching; recombination hot spot identification;
KW linkage disequilibrium study; human; microsatellite.
XX
XX Homo sapiens.
OS
XX US2003108940-A1.
PN
XX 12-JUN-2003.
PD
XX 06-DEC-2002; 2002US-00314405.
PF
XX 15-NOV-2000; 2000US-00713616.
XX
XX (INOK/) INOKO H.
PA
```

```
XX Inoko H, Tamiya G, Matsuzaka Y;
PI WPI; 2003-616782/58.
DR
XX New oligonucleotide primer capable of specifically hybridizing to a DNA
PT having the sequence of the flanking regions of a microsatellite (e.g.
PT M249), useful for HLA-related research, e.g. transplantation matching.
XX Example 2; Page 5; 20pp; English.
PS
XX The invention relates to an oligonucleotide primer capable of
CC specifically hybridizing to a DNA having the sequence of the flanking
CC regions of a microsatellite selected from M2-4-9, M2-2-9, M2-2-12, M2-3-
CC 11, M2-2-20, M2-2-21, M2-2-23, M2-2-24, M2-4-25, M2-4-26, M2-2-
CC 29, M2-2-32, M2-4-32, M2-4-37, M2-3-22, M2-3-36, M2-5-11, M2-2-
CC 46, and M2-2-48. The primer is useful for determining the number of
CC repeat units of the microsatellite cited above. The primer is useful in
CC HLA-related research, such as genetic mapping of HLA class II-associated
CC diseases, transplantation matching, population genetics, and
CC identification of recombination hot spots as well as linkage
CC disequilibrium studies. The present sequence represents the human
CC microsatellite repeat M2_3_8.
XX
SQ Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 30 CGCTCCGTCGCGCGCG 46
||||| |||||
Db 18 CGCGCGCGCGCGCGCG 2
RESULT 418
AAL60043/c
ID AAL60043 standard; DNA; 18 BP.
XX
XX AAL60043;
AC
XX 27-AUG-2003 (first entry)
DT
XX Human GH-1 gene amplifying PCR primer, CRV156.5a1.
DE
XX Human; growth hormone 1; GH-1; single nucleotide polymorphism; SNP;
KW gene therapy; PCR; primer; ss.
KW
XX Homo sapiens.
OS
XX WO2003042226-A2.
PN
XX 22-MAY-2003.
PD
XX 07-NOV-2002; 2002WO-US035719.
PF
XX 09-NOV-2001; 2001US-0347448P.
PR
XX (PHAA ) PHARMACIA & UPJOHN CO.
PA
XX Wood LS, Wagner S, Parodi LA;
PI WPI; 2003-449555/42.
XX
XX New growth hormone 1 (GH-1) diagnostic polynucleotide, useful as markers
PT for the analysis of a disease, or of susceptibility to drug treatment for
PT GH-1 dysfunction or other diseases.
XX Example 2; Page 30; 74pp; English.
PS
XX The invention relates to growth hormone 1 (GH-1) gene including single
CC nucleotide polymorphisms (SNP). The GH-1 diagnostic polynucleotide is
CC useful as markers for the analysis of a disease, of susceptibility to
CC
```

RESULT 420:

PA (STEM-) STEM-CYTE INC.  
 XX Chow R, Tonai R;  
 XX WPI; 2003-874916/81.  
 XX Identifying class I or II Human Leukocyte Antigen genotypes using  
 PT hybridization and amplification assays.  
 XX Claim 7; SEQ ID NO 9; 66pp; English.  
 XX The invention relates to a method of identifying a class I or II Human  
 CC Leukocyte Antigen (HLA) genotype of a subject using hybridisation and  
 CC amplification assay. The method is used for determining the HLA genotype  
 CC of a subject. The present sequence represents a HLA class I allele  
 XX specific primer.  
 XX  
 SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 382 TGCAGCAAGATGGGCTG 398  
 Db 17 TGCAGCACGAGGGGCTG 1  
 RESULT 422  
 ADF13036  
 ID ADF13036 standard; DNA; 18 BP.  
 XX  
 AC ADF13036;  
 XX  
 DT 12-FEB-2004 (first entry)  
 XX  
 DE Human PCMI exon 33 splice donor fragment.  
 XX  
 KW schizophrénia; chromosome 8p21-22; pericentriolar material 1; PCMI;  
 KW marker; microsatellite repeat; NT 000501 contig; polymorphic marker;  
 KW linkage disequilibrium; D8S261; D8S2615; D8S2616;  
 KW single nucleotide polymorphism; SNP; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003050301-A2.  
 XX  
 PD 19-JUN-2003.  
 XX  
 PF 12-DEC-2002; 2002WO-GB005630.  
 XX  
 PR 12-DEC-2001; 2001GB-00029758.  
 XX  
 PA (GURL/) GURLING H M D.  
 XX  
 PI Gurling HMD;  
 XX  
 XX WPI; 2003-532919/50.  
 XX  
 XX Determining the susceptibility of an individual to a neuropsychiatric  
 PT disorder (e.g. schizophrénia) or diagnosing or prognosing the disorder  
 PT comprises using a pericentriolar material 1 marker in the chromosomal  
 PT region 8p21-22.  
 XX  
 XX Claim 9; Fig 6; 108pp; English.  
 XX  
 XX This invention describes a novel method of determining the susceptibility  
 CC to or diagnosis of schizophrénia comprising using a marker located in the  
 CC chromosomal region 8p21-22. The method involves determining the presence  
 CC or absence in a test sample of a pericentriolar material 1 (PCMI) marker  
 CC which is selected from any of the microsatellite repeats present in the  
 CC NT 000501 contig on chromosome 8p21-22 or a polymorphic marker which is  
 CC in linkage disequilibrium with the chromosome. The PCMI marker is

CC preferably D8S261, D8S2615 or D8S2616 and lies within the PCMI gene. The  
 CC novel method involves assessing two or more of the PCMI markers single  
 CC nucleotide polymorphisms (SNPs). The PCMI gene is amplified, particularly  
 CC within the intronic sequence 3' to exon 4, in exon 4, or in the intronic  
 CC sequence 5' of exon 5. The PCMI marker is assessed by strand conformation  
 CC polymorphic marker analysis, heteroduplex analysis or restriction  
 CC fragment length polymorphism (RFLP) analysis. Schizophrenia therapy  
 CC comprises screening an individual for a genetic predisposition to  
 CC schizophrénia, where the predisposition is correlated with the PCMI  
 CC marker and if a predisposition is identified, providing therapeutic  
 CC treatment for the individual. Alternatively, the method comprises  
 CC administering to a patient a substance that modulates the expression from  
 CC the PCMI gene or a gene located within 1000 base of the PCMI locus. This  
 CC sequence represents the human PCMI exon 33 splice donor region.  
 XX  
 SQ Sequence 18 BP; 10 A; 1 C; 3 G; 4 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 1514 CTAGAAACAGTAAGAA 1530  
 Db 1 CTAGTAAAGTAAGAA 17  
 RESULT 423  
 ADF78408  
 ID ADF78408 standard; DNA; 18 BP.  
 XX  
 AC ADF78408;  
 XX  
 DT 26-FEB-2004 (first entry)  
 XX  
 DE Chromosomal abnormality detection-related APC small deletion DNA 154.  
 XX  
 KW chromosomal abnormality; maternal locus; genetic disorder; foetus;  
 KW mutation; translocation; transversion; monosomy; trisomy; trisomy 21;  
 KW chromosome 21; Down's Syndrome; aneuploidies; chromosome deletion;  
 KW chromosome addition; chromosome amplification; chromosome translocation;  
 KW chromosome rearrangement; single nucleotide polymorphism detection;  
 KW SNP detection; pregnant female; APC; adenomatous polyposis coli; ds.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003074723-A2.  
 XX  
 PD 12-SEP-2003.  
 XX  
 PF 28-FEB-2003; 2003WO-US0006198.  
 XX  
 PR 01-MAR-2002; 2002US-0360232P.  
 PR 11-MAR-2002; 2002US-00093618.  
 PR 08-MAY-2002; 2002US-0378354P.  
 XX  
 PA (DHALL/) DHALLAN R.  
 XX  
 XX Dhallan R;  
 XX  
 XX WPI; 2003-845073/78.  
 XX  
 XX Detection of chromosomal abnormalities e.g. Down's Syndrome, non-  
 PT invasively in a fetus, comprises forming a ratio of amounts of alleles at  
 PT a locus of interest and a different heterozygous locus.  
 XX  
 XX Example 7; Page 163; 164pp; English.  
 PS  
 XX This invention relates to a novel method of detecting chromosomal  
 CC abnormalities by determining the sequence of alleles of a locus of  
 CC interest from template DNA, determining which alleles are present and  
 CC comparing to amounts of alleles at a different, selected heterozygous  
 CC locus (for example on another chromosome or a maternal locus); relative  
 CC amounts are expressed as a ratio indicating presence or absence of the

CC abnormality. The method is useful for the detection of genetic disorders,  
 CC especially in a fetus, including chromosomal abnormalities and  
 CC mutations, for example translocations, transversions, monosomes,  
 CC trisomies (for example trisomy 21 in which an additional copy of  
 CC chromosome 21 results in Down's Syndrome) and other aneuploidies,  
 CC deletions, additions, amplifications, translocations and rearrangements.  
 CC It can be used to detect any alterations in a gene sequence, especially  
 CC single nucleotide polymorphisms (SNPs), and may be used to detect  
 CC numerous abnormalities simultaneously, for example if several SNPs are  
 CC associated with a particular disease. The method provides a rapid, non-  
 CC invasive method for determining the sequence of DNA from a fetus using a  
 CC sample from a pregnant female, for example to detect genetic disorders as  
 CC above or to determine if a fetus is a carrier of a disease or  
 CC predisposed to a disease.

SQ Sequence 18 BP; 12 A; 0 C; 3 G; 3 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAGAGAGAAAT 217  
 Db 1 GAAATAAAGAGAGAAAT 17  
 |||||

RESULT 424  
 ADG70285  
 ID ADG70285 standard; DNA; 18 BP.

XX AC ADG70285;

XX DT 11-MAR-2004 (first entry)

DE CELLD8 exon 12 and ANGE exon 3 SNP identification primer #101.

XX ANGE; CELLD8; CELLD7; ANGE-CLLD8; ANGE-CLLD7; CELLD7-CLLD8;

KW ANGE-CLLD8-CLLD7; anti-allergic; antiasthmatic; dermatological;

KW antipyretic; antiinflammatory; gene therapy; IGE-mediated disease;

KW primer; ss.

XX Unidentified.

XX PN W02003000727-A2.

XX PD 03-JAN-2003.

XX XX 21-JUN-2002; 2002WO-GB002859.

XX XX 21-JUN-2001; 2001GB-00015211.

PR 21-JUN-2001; 2001GB-00015212.

PR 21-JUN-2001; 2001GB-00015213.

XX (ISIS-) ISIS INNOVATIONS LTD.

XX PI Zhang Y, Moffatt M, Cookson W, Tinsley J;

XX WPI; 2003-201405/19.

PT New nucleic acid sequence comprising an ANGE, CELLD8 or CELLD7 mRNA, or  
 PT their hybrid, useful for screening agents for treating IGE-mediated  
 PT diseases, e.g. asthma, atopy, hay fever, eczema, atopic dermatitis, or  
 PT allergic rhinitis.

XX Disclosure; Page 408; 429pp; English.

XX The invention relates to a novel isolated or recombinant nucleic acid  
 CC sequence comprising an ANGE, CELLD8 or CELLD7 mRNA, or ANGE-CLLD8, ANGE-  
 CC CELLD7, CELLD7-CLLD8, or ANGE-CLLD8-CLLD7 hybrid mRNA sequence, its  
 CC complement, homologue or fragment. The novel nucleic acid sequences have  
 CC the following activities: anti-allergic, antiasthmatic, dermatological,  
 CC antipyretic, and antiinflammatory. The nucleic acids of the invention may  
 CC be used in gene therapy to treat disorders. The nucleic acid sequences

CC are useful for screening agents that inhibit or enhance activity of an  
 CC ANGE, CELLD8 or CELLD7 gene. The agent or antibody is useful for treating  
 CC IGE-mediated diseases, such as asthma, atopy, hay fever, eczema, atopic  
 CC dermatitis, allergic rhinitis or non-atopic asthma. The antibody is  
 CC useful in an assay detecting or measuring the polypeptide in the sample.  
 CC The host cell is useful for producing, regulating and analyzing the  
 CC polypeptide. The splice variant of ANGE, CELLD8, or CELLD7 is useful for  
 CC diagnosing an IGE-mediated disease, atopy, a form of atopic disease or  
 CC non-atopic asthma, or predicting the severity, or predisposition to a  
 CC disease. This polynucleotide sequence represents a primer used in the  
 CC exemplification of the invention.

SQ Sequence 18 BP; 4 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 939 CCAGAACAGGTTGTACT 955

Db 1 CCTGAACAGGCTGTACT 17  
 |||||

RESULT 425  
 ADG73179/c  
 ID ADG73179 standard; DNA; 18 BP.

XX AC ADG73179;

XX DT 11-MAR-2004 (first entry)

DE Pseudomonas syringae pv. tomato DC3000 Avr gene PCR primer #14.

XX Avr; Hop; transgenic plant; disease resistance; cancer; bacteria;

KW metabolic pathway; eukaryotic cell death; programmed cell death;

KW cytotatic; PCR; primer; ss.

XX Pseudomonas syringae; pv. tomato str. DC3000.

XX US2003204868-A1.

XX 30-OCT-2003.

XX PF 12-FEB-2003; 2003US-00365742.

XX 12-FEB-2002; 2002US-0356408P.

PR 10-MAY-2002; 2002US-0380185P.

XX (COLL/) COLLIER A.

PA (ALFA/) ALFANO J R.

PA (CART/) CARTINHOOR S W.

PA (SCHN/) SCHNEIDER D J.

XX (TANG/) TANG X.

XX Collmer A, Alfano JR, Cartinhour SW, Schneider DJ, Tang X;

XX WPI; 2003-875735/81.

XX New nucleic acid, useful in imparting disease resistance to a plant or in  
 PT preparing a composition for treating cancer.

XX Example; SEQ ID NO 173; 209pp; English.

XX The present invention relates to the isolation of Pseudomonas syringae  
 CC pv. tomato DC3000 Avr/Hop proteins, and the polynucleotide sequences  
 CC encoding them. Also disclosed are expression vectors, host cells, and  
 CC transgenic plants comprising polynucleotide sequences of the invention.  
 CC The polynucleotide and polypeptide sequences are useful in imparting  
 CC disease resistance to a plant or in preparing a composition for treating  
 CC cancer. The sequences may also be used to make a plant hypersusceptible  
 CC to colonisation by nonpathogenic bacteria, modify a metabolic pathway in  
 CC a cell, cause eukaryotic cell death, and inhibit programmed cell death.  
 CC The present sequence represents a PCR primer used in the examples of the

CC present invention.

XX Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 13.8; DB 1; Length 18;

XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1416 ATGACTGTCATGGATCC 1432

Db ||| ||||| ||||| |||||

18 ACGATTGTCATGGATCC 2

RESULT 426

ADH42989

ID ADH42989 standard; DNA; 18 BP.

XX

AC ADH42989;

XX

DT 25-MAR-2004 (first entry)

XX

DE Lower PCR primer used for RT-PCR analysis of human PC 5/6.

XX

XX Primer; 5S; RT-PCR; reverse transcriptase; proprotein convertase 5/6;

KW PC 5/6; uterus; serine proteinase; implantation; fertilised egg; embryo;

KW pregnancy; fertile period; early pregnancy; inhibiting fertility;

KW fertility; contraceptive; antisense gene therapy; uterine receptivity;

KW fertility-related condition; infertility; luteal phase defect; abortion;

KW parturition; isoform.

XX

OS Synthetic.

XX

XX WO2003011328-A1.

XX

XX 13-FEB-2003.

XX

XX 31-JUL-2002; 2002WO-AU001020.

XX

XX 31-JUL-2001; 2001AU-00006730.

XX

XX (PRIN-) PRINCE HENRY'S INST MEDICAL RES.

XX

XX Nie G, Salomonson LA, Findlay JK;

XX

XX WPI; 2003-248116/24.

XX

XX Promoting fertility of a female mammal comprises stimulating the activity

XX of proprotein convertase 5/6 enzyme in the uterus of the female mammal.

XX

XX Example 13; SEQ ID NO 51; 99pp; English.

XX

XX The invention discloses a method for promoting the fertility of a female

XX mammal comprising stimulating the activity of proprotein convertase 5/6

XX (PC 5/6) in the uterus of a female mammal. PC 5/6 (a serine proteinase)

XX is believed to be useful in promoting the implantation of the fertilised

XX egg in the uterus, development of the embryo and maintenance of

XX pregnancy. Also claimed are methods for detecting a fertile period in a

XX female mammal by measuring the activity of or detecting the presence of

XX PC 5/6 in a biological sample from the mammal; detecting whether the

XX uterus of a female mammal is in a receptive state by detecting the

XX presence or absence of PC 5/6 in a biological sample from the mammal, or

XX its presence in increased amounts at a particular stage of the cycle

XX compared with another stage; detecting an early pregnancy by detecting

XX the presence of PC 5/6 activity or an increase of PC 5/6 above the level

XX in the non-pregnant state in a biological sample from the mammal;

XX inhibiting fertility in a female mammal by administering a PC 5/6

XX antagonist to a female mammal; screening for compounds which can modulate

XX PC 5/6 activity, by assessing the ability of a candidate compound to

XX increase or decrease PC 5/6 activity; identifying molecules necessary for

XX implantation by testing a candidate molecule for the ability to promote

XX the conversion of protein precursors cleavable by PC 5/6 into mature

XX proteins; a nucleic acid molecule encoding an isoform of PC 5/6 and a

XX protein having PC 5/6 activity encoded by a nucleic acid molecule. The

XX

CC method is used for promoting fertility of a female mammal. The PC 5/6

CC enzyme is a useful in controlling fertility (e.g. as a contraceptive and

CC antisense gene therapy), monitoring early pregnancy, for detecting

CC uterine receptivity, promoting the implantation of the fertilised egg in

CC the uterus, development of embryo and maintenance of pregnancy, and in

CC diagnosing fertility-related conditions (e.g. infertility due to luteal

CC phase defect, early abortion or early parturition). The sequence

CC presented is a reverse transcriptase PCR (RT-PCR) primer which was used

CC for semi-quantitative detection of human PC 5/6 cDNA expression in the

CC edometrium with ADH42973.

XX

XX Sequence 18 BP; 3 A; 9 C; 2 G; 4 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 13.8; DB 1; Length 18;

XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 509 CAGCATTGGGACTCTCCTC 525

Db ||||| ||||| |||||

2 CAGCATTGGGACTCTCCTC 18

RESULT 427

ADH53213

ID ADH53213 standard; DNA; 18 BP.

XX

AC ADH53213;

XX

DT 25-MAR-2004 (first entry)

XX

DE Human APC (adenomatous polyposis coli) DNA fragment 150.

XX

XX sequence determination; recognition site; restriction endonuclease;

KW human; APC; adenomatous polyposis coli; chromosome 5q21-22;

KW colorectal cancer; ds.

XX

XX Homo sapiens.

XX

XX WO2003074740-A1.

XX

XX 12-SEP-2003.

XX

XX 28-FEB-2003; 2003WO-US006376.

XX

XX 01-MAR-2002; 2002US-0360232P.

XX

XX 11-MAR-2002; 2002US-00093618.

XX

XX 08-MAY-2002; 2002US-0378354P.

XX

XX (DHALL/) DHALLAN R.

XX

XX Dhallan R;

XX

XX WPI; 2003-756772/71.

XX

XX Determining a sequence of a locus of interest comprises replicating a

XX region of DNA comprising a locus of interest from a template

XX polynucleotide by using a first and a second primer.

XX

XX Example 5; Page 140; 190pp; English.

XX

XX The invention relates to a novel method for determining the sequence of a

XX locus of interest which comprises replicating a region of DNA comprising

XX a locus of interest from a template polynucleotide by using a first and a

XX second primer where the second primer contains a sequence that generates

XX a recognition site for a restriction enzyme such that digestion with the

XX restriction enzyme generates a 5' overhang containing the locus of

XX interest. The method may be useful for determining the sequences of

XX multiple loci of interest concurrently and for determining the sequence

XX of a mutant allele in the presence of a normal allele. The current

XX sequence is that of the human APC (adenomatous polyposis coli) DNA

XX fragment of the invention which is located on chromosome 5q21-22 and in

XX which mutations are associated with colorectal cancer.

XX

SQ Sequence 18 BP; 12 A; 0 C; 3 G; 3 T; 0 U; 0 Other;  
Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 201 GAAATAAAGAGAAAT 217  
DB 1 GAAATAAAGAGAAAGAT 17  
RESULT 428  
ADL12235/c  
ID ADL12235 standard; DNA; 18 BP.  
XX  
AC ADL12235;  
DT 06-MAY-2004 (first entry)  
XX Pseudomonas syringae anti-cancer gene primer #46.  
XX cytostatic; gene therapy; Avr; Hop; cancer; primer; ss.  
XX Pseudomonas syringae; pv tomato DC3000.  
XX W02003068930-A2.  
XX 21-AUG-2003.  
XX 12-FEB-2003; 2003WO-US004450.  
XX 12-FEB-2002; 2002US-0356408P.  
XX 10-MAY-2002; 2002US-0380185P.  
XX (CORR ) CORNELL RES FOUND INC.  
PA (USDA ) US SEC OF AGRIC.  
PA (UYNE-) UNIV NEBRASKA.  
PA (UNIV ) UNIV KANSAS STATE RES FOUND.  
XX Collmer A, Alfano JR, Cartinhour SW, Schneider DU, Tang X;  
PI WPI; 2003-679632/64.  
XX New nucleic acid molecule, useful for preparing a composition for  
PT treating cancer.  
XX Disclosure; SEQ ID NO 173; 284pp; English.  
XX The invention relates to novel Pseudomonas Avr and Hop genes, a sequence  
CC that hybridizes with these sequences under stringency conditions  
CC comprising a hybridization medium that includes 0.9 x saline sodium  
CC citrate (SSC) buffer at a temperature of 42 deg C. The nucleic acid  
CC molecule is useful for preparing a composition for treating cancer. This  
CC sequence corresponds to a PCR to isolate and amplify one of the genes of  
CC the invention.  
XX Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 U; 0 Other;  
SQ Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1416 ATGACTGTCATGGATCC 1432  
DB 18 ACGATTGTCATGGATCC 2  
RESULT 429  
ADM07244  
ID ADM07244 standard; DNA; 18 BP.  
XX  
AC ADM07244;  
XX

DT 20-MAY-2004 (first entry)  
XX PCR primer 2 used to graft murine 15A2 DNA into canine gp 2 light chain.  
XX canine; dog; heavy; immunoglobulin; antibody light chain variable domain;  
KW antiallergic; allergy; IgE; gene therapy; PCR; primer; ss; group 2;  
KW murine; mouse; 15A2; CDR grafting; complementarity determining region.  
XX Canis familiaris.  
OS Mus sp.  
XX W02003060080-A2.  
XX 24-JUL-2003.  
XX 20-DEC-2002; 2002WO-US041362.  
XX 21-DEC-2001; 2001US-0344874P.  
XX (IDEX-) IDEXX LAB INC.  
XX Krah ER, Guo H, Aiyappa A, Lawton R;  
PI WPI; 2003-598521/56.  
XX New canine heavy and light chain variable domain polypeptides, useful for  
PT treating canine allergy.  
XX Example 5; Page 46; 130pp; English.  
XX The invention relates to a novel canine heavy or light chain variable  
CC domain polypeptide. The protein of the invention demonstrates  
CC antiallergic activity and may be useful for treating canine allergy.  
CC possibly via gene therapy. The current sequence is that of an PCR primer  
CC which was used in the exemplification of the invention.  
XX Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;  
SQ Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1069 CAAAGAGGACTCTGGCG 1085  
DB 1 CTAAGAGCACTCTGGCG 17  
RESULT 430  
ADM07236  
ID ADM07236 standard; DNA; 18 BP.  
XX ADM07236;  
AC ADM07236;  
XX 20-MAY-2004 (first entry)  
XX PCR primer 2 used to amplify canine lambda constant domain DNA.  
DE canine; dog; heavy; immunoglobulin; antibody light chain variable domain;  
XX antiallergic; allergy; IgG; gene therapy; PCR; primer; ss;  
KW lambda constant domain.  
XX Canis familiaris.  
OS W02003060080-A2.  
XX 24-JUL-2003.  
XX 20-DEC-2002; 2002WO-US041362.  
XX 21-DEC-2001; 2001US-0344874P.  
XX (IDEX-) IDEXX LAB INC.  
XX



PI Krah ER, Guo H, Aiyappa A, Lawton R;  
 XX WPI; 2003-598521/56.  
 DR  
 XX  
 PT New canine heavy and light chain variable domain polypeptides, useful for  
 XX treating canine allergy.  
 PT  
 XX  
 PS Example 2; Page 43; 130pp; English.  
 XX  
 CC The invention relates to a novel canine heavy or light chain variable  
 CC domain polypeptide. The protein of the invention demonstrates  
 CC antiallergic activity and may be useful for treating canine allergy,  
 CC possibly via gene therapy. The current sequence is that of an PCR primer  
 CC which was used in the exemplification of the invention.  
 XX  
 XX  
 SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 1069 CAAAGAGGACTCTGCGG 1085  
 Db 1 CTAAGAGCACTCTGCGG 17  
 ||||| |||||  
 RESULT 431  
 ADJ36710  
 ID ADJ36710 standard; DNA; 18 BP.  
 XX  
 AC ADJ36710;  
 XX  
 XX 22-APR-2004 (first entry)  
 XX  
 XX Human gene 216 SNP detection primer seq id 101.  
 DE  
 XX  
 XX antiasthmatic; respiratory; gene therapy; asthma;  
 KW bronchial hyperresponsiveness; atopy; chronic obstructive lung disease;  
 KW adult respiratory distress syndrome; obesity; inflammatory bowel disease;  
 KW human; gene 216; single nucleotide polymorphism; SNP; PCR; primer; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2004002470-A1.  
 FN  
 XX  
 XX 01-JAN-2004.  
 PD  
 XX  
 XX 17-OCT-2002; 2002US-00277216.  
 PF  
 XX  
 XX 13-APR-2000; 2000US-00548797.  
 PR  
 XX  
 XX 13-APR-2001; 2001US-00834597.  
 PR  
 XX  
 XX 19-APR-2002; 2002US-00126022.  
 PR  
 XX  
 XX (KEIT/) KEITH T.  
 PA (LITT/) LITTLE R D.  
 PA (VEER/) VAN EERDEWEGH P.  
 PA (DUPU/) DUPUIS J.  
 PA (DMAS/) DEL MASTRO R G.  
 PA (SIMO/) SIMON J.  
 PA (ALLE/) ALLEN K.  
 PA (PAND/) PANDIT S.  
 XX  
 XX Keith T, Little RD, Eerdegwegh PV, Dupuis J, Del Mastro RG;  
 PI Simon J, Allen K, Pandit S;  
 PI  
 XX  
 XX WPI; 2004-061675/06.  
 DR  
 XX  
 XX Gene 216 nucleic acid, useful for preparing a composition for treating  
 PT disorders e.g., asthma, bronchial hyperresponsiveness, atopy, chronic  
 PT obstructive lung disease and adult respiratory distress syndrome.  
 PT  
 XX  
 XX Example 10; SEQ ID NO 101; 441pp; English.  
 PS  
 XX

CC The invention describes a new isolated nucleic acid comprising a fully  
 CC defined sequence having 23574 bp or at least its 50 or 15 contiguous  
 CC nucleotides and includes: allele G of single nucleotide polymorphism  
 CC (SNP) AB+2; allele G of SNP BC+1; and allele C of SNP BC+2. The invention  
 CC describes identifying increased susceptibility to a disorder comprising  
 CC asthma, bronchial hyperresponsiveness, atopy, chronic obstructive lung  
 CC disease and adult respiratory distress syndrome in a subject comprising  
 CC testing a biological sample obtained from a subject for the presence of  
 CC at least one allele or haplotype given in the specification, where the  
 CC presence identifies an increased susceptibility to the disorder. The  
 CC nucleic acid is useful for preparing a composition for treating disorders  
 CC comprising asthma, bronchial hyperresponsiveness, atopy, chronic  
 CC obstructive lung disease and adult respiratory distress syndrome. This  
 CC sequence represents a primer used to detect single nucleotide  
 CC polymorphisms in the human gene 216.  
 XX  
 XX  
 SQ Sequence 18 BP; 5 A; 2 C; 10 G; 1 T; 0 U; 0 Other;  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 Qy 1101 GCAGAGGACCAAGGTGG 1117  
 Db 2 GCAGAGGACCAAGGTGG 18  
 ||||| |||||  
 RESULT 432  
 ADL09243/C  
 ID ADL09243 standard; DNA; 18 BP.  
 XX  
 AC ADL09243;  
 XX  
 XX 06-MAY-2004 (first entry)  
 XX  
 XX HLA locus-specific capture oligonucleotide #9.  
 DE  
 XX  
 XX ss; primer; human leukocyte antigen; HLA; HLA genotyping; human; PCR.  
 KW  
 KW Homo sapiens.  
 OS  
 XX  
 XX US6670124-B1.  
 FN  
 XX  
 XX 30-DEC-2003.  
 PD  
 XX  
 XX 20-DEC-2000; 2000US-00747391.  
 PF  
 XX  
 XX 20-DEC-1999; 99US-0172768P.  
 PR  
 XX  
 XX (STEM-) STEMCYTE INC.  
 PA  
 XX  
 XX Chow R, Tonai R;  
 PI  
 XX  
 XX WPI; 2004-068584/07.  
 DR  
 XX  
 XX Identifying an HLA genotype of a subject by hybridizing the amplification  
 XX products with an HLA locus-specific capture oligonucleotide and detecting  
 XX the detectable complexes to identify the HLA genotype of the subject.  
 PT  
 XX  
 XX Example 1; SEQ ID NO 9; 68pp; English.  
 PS  
 XX  
 XX The invention describes a method of identifying a human leukocyte antigen  
 CC (HLA) genotype of a subject comprising: obtaining a sample comprising a  
 CC template nucleic acid from the subject; amplifying the template nucleic  
 CC acid with HLA allele-specific forward primers and HLA allele-specific  
 CC reverse primers to form amplification products; hybridising the  
 CC amplification products with an HLA locus-specific capture oligonucleotide  
 CC ; and detecting the detectable complexes to identify the HLA genotype of  
 CC the subject. The present sequence represents one of 276 HLA locus-  
 CC specific capture oligonucleotides of the invention.  
 CC  
 XX  
 XX Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

```
Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 TGCAGCAAGATGGGCTG 398
Db 17 TGCAGCACGAGGGGCTG 1

RESULT 433
ADL09357/c
ID ADL09357 standard; DNA; 18 BP.
XX
AC ADL09357;
XX
DT 06-MAY-2004 (first entry)
XX
DE HLA locus-specific capture oligonucleotide #123.
XX
KW ss; primer; human leukocyte antigen; HLA; HLA genotyping; human; PCR.
XX
OS Homo sapiens.
XX
PN US6670124-B1.
XX
PD 30-DEC-2003.
XX
PF 20-DEC-2000; 2000US-00747391.
XX
PR 20-DEC-1999; 99US-0172768P.
XX
PA (STEM-) STEM-CYTE INC.
XX
PI Chow R, Tonai R;
XX
DR WPI; 2004-068584/07.
XX
PT Identifying an HLA genotype of a subject by hybridizing the amplification
PT products with an HLA locus-specific capture oligonucleotide and detecting
PT the detectable complexes to identify the HLA genotype of the subject.
XX
PS Example 1; SEQ ID NO 125; 68pp; English.
XX
CC The invention describes a method of identifying a human leukocyte antigen
CC (HLA) genotype of a subject comprising: obtaining a sample comprising a
CC template nucleic acid from the subject; amplifying the template nucleic
CC acid with HLA allele-specific forward primers and HLA allele-specific
CC reverse primers to form amplification products; hybridising the
CC amplification products with an HLA locus-specific capture oligonucleotide
CC ; and detecting the detectable complexes to identify the HLA genotype of
CC the subject. The present sequence represents one of 276 HLA locus-
CC specific capture oligonucleotides of the invention.
XX
SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 TGCAGCAAGATGGGCTG 398
Db 17 TGCAGCACGAGGGGCTG 1

RESULT 434
ADL81289
ID ADL81289 standard; DNA; 18 BP.
XX
AC ADL81289;
XX
DT 20-MAY-2004 (first entry)
XX
DE Gene 216 SSCP primer #39.

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 382 TGCAGCAAGATGGGCTG 398
Db 17 TGCAGCACGAGGGGCTG 1

RESULT 435
ADM76352
ID ADM76352 standard; DNA; 18 BP.
XX
AC ADM76352;
XX
DT 03-JUN-2004 (first entry)
XX
DE NEPHA gene transcriptional control region Pax-8 binding site.
XX
KW Human; NEPHA; ephrin receptor; brain; chromosome 1; apoptosis;
KW drug screening; antisense therapy; gene therapy; cancer; tumour;
KW lung cancer; ovarian cancer; breast cancer; cervical cancer;
KW prostate cancer; bladder cancer; stomach cancer; colorectal cancer;
KW cytostatic; transcriptional control region; promoter;
KW transcription factor binding site; ds.
XX
OS Homo sapiens.
XX
```

```
XX
KW asthma; bronchial hyperresponsiveness; obesity;
XX inflammatory bowel disease; human; gene 216; ss; primer.
XX
OS Homo sapiens.
XX
PN US2004023215-A1.
XX
PD 05-FEB-2004.
XX
PF 19-APR-2002; 2002US-00126022.
XX
PR 13-APR-1999; 99US-0129391P.
PR 13-APR-2000; 2000US-00548797.
PR 13-APR-2001; 2001US-00834597.
XX
PA (KEIT/) KEITH T.
PA (LITT/) LITTLE R D.
PA (BERD/) EERDEWEGH P V.
PA (DUPU/) DUPUIS J.
PA (DMAS/) DEL MASTRO R G.
PA (SIMO/) SIMON J.
PA (ALLE/) ALLEN K.
PA (PAND/) PANDIT S.
XX
PI Keith T, Little RD, Eerdewegh PV, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX
DR WPI; 2004-142647/14.
XX
PT New isolated nucleic acid molecules useful for diagnosing or treating
PT asthma or bronchial hyperresponsiveness, or other diseases such as
PT obesity or inflammatory bowel disease.
XX
PS Example 10; SEQ ID NO 101; 485pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule, or a set of
CC nucleic acid molecules each given in the specification. The composition
CC and methods are useful in diagnosing or treating asthma or bronchial
CC hyperresponsiveness, and other diseases such as obesity or inflammatory
CC bowel disease. The present sequence is used in the exemplification of the
CC present invention.
XX
SQ Sequence 18 BP; 5 A; 2 C; 10 G; 1 T; 0 U; 0 Other;

Query Match      0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1101 GCAGAGACACAGGTGG 1117
Db 2 GCAGAGGACAGAGGTGG 18

RESULT 435
ADM76352
ID ADM76352 standard; DNA; 18 BP.
XX
AC ADM76352;
XX
DT 03-JUN-2004 (first entry)
XX
DE NEPHA gene transcriptional control region Pax-8 binding site.
XX
KW Human; NEPHA; ephrin receptor; brain; chromosome 1; apoptosis;
KW drug screening; antisense therapy; gene therapy; cancer; tumour;
KW lung cancer; ovarian cancer; breast cancer; cervical cancer;
KW prostate cancer; bladder cancer; stomach cancer; colorectal cancer;
KW cytostatic; transcriptional control region; promoter;
KW transcription factor binding site; ds.
XX
OS Homo sapiens.
XX
```

```

PN JP2003289876-A.
XX 14-OCT-2003.
XX
XX 05-APR-2002; 2002JP-00103497.
XX
XX 05-APR-2002; 2002JP-00103497.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX WPI; 2004-038434/04.
XX
XX Novel antisense oligonucleotide useful as anticancer agent for preventing
XX cancer e.g. lung cancer, stomach cancer, breast cancer.
XX
XX Example 2; Page 28; 38pp; Japanese.
XX
XX The invention relates to antisense oligonucleotides (ADM76030 and
XX ADM76031) targeted to the human NEPHA gene (ADM76029), which encodes a
XX novel brain-derived ephrin receptor (ADM76028). The NEPHA protein has
XX 50.7% homology to the human EphA7 ephrin receptor and its gene is located
XX on chromosome 1. Ephrin receptors are overexpressed in various cancers
XX and it has been found that inhibition of NEPHA expression promotes
XX apoptosis. The invention also relates to the NEPHA transcriptional
XX control (promoter) region (ADM76037); recombinant vectors and host cells
XX comprising the NEPHA promoter operably linked to a reporter gene; a
XX method of screening for compounds which inhibit or activate transcription
XX of the NEPHA gene; and pharmaceutical compositions comprising an
XX antisense oligonucleotide or a transcriptional inhibitor or activator.
XX The antisense oligonucleotides and modulators of NEPHA transcription are
XX useful for inducing apoptosis for the treatment and/or prevention of
XX cancers in which NEPHA is overexpressed such as lung cancer, ovarian
XX cancer, breast cancer, cervical cancer, prostate cancer, bladder cancer,
XX stomach cancer and colorectal cancer. Sequences ADM76038-ADM76371
XX represent transcription factor binding sites within the transcriptional
XX control region of the NEPHA gene.
XX
XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 993 GGTGCCATGGATGATGG 1009
XX Db 1 GTTCCCATGGATGATGG 17
XX
XX RESULT 436
XX ADM76353
XX ID ADM76353 standard; DNA; 18 BP.
XX
XX AC ADM76353;
XX
XX XX 03-JUN-2004 (first entry)
XX
XX NEPHA gene transcriptional control region Pax-8 binding site.
XX
XX Human; NEPHA; ephrin receptor; brain; chromosome 1; apoptosis;
XX drug screening; antisense therapy; gene therapy; cancer; tumour;
XX lung cancer; ovarian cancer; breast cancer; cervical cancer;
XX prostate cancer; bladder cancer; stomach cancer; colorectal cancer;
XX cytostatic; transcriptional control region; promoter;
XX transcription factor binding site; ds.
XX
XX OS Homo sapiens.
XX
XX JP2003289876-A.
XX
XX 14-OCT-2003.
XX
XX 05-APR-2002; 2002JP-00103497.
XX
XX

```

```

PR 05-APR-2002; 2002JP-00103497.
XX
XX (TAKE ) TAKEDA CHEM IND LTD.
XX
XX WPI; 2004-038434/04.
XX
XX Novel antisense oligonucleotide useful as anticancer agent for preventing
XX cancer e.g. lung cancer, stomach cancer, breast cancer.
XX
XX Example 2; Page 28; 38pp; Japanese.
XX
XX The invention relates to antisense oligonucleotides (ADM76030 and
XX ADM76031) targeted to the human NEPHA gene (ADM76029), which encodes a
XX novel brain-derived ephrin receptor (ADM76028). The NEPHA protein has
XX 50.7% homology to the human EphA7 ephrin receptor and its gene is located
XX on chromosome 1. Ephrin receptors are overexpressed in various cancers
XX and it has been found that inhibition of NEPHA expression promotes
XX apoptosis. The invention also relates to the NEPHA transcriptional
XX control (promoter) region (ADM76037); recombinant vectors and host cells
XX comprising the NEPHA promoter operably linked to a reporter gene; a
XX method of screening for compounds which inhibit or activate transcription
XX of the NEPHA gene; and pharmaceutical compositions comprising an
XX antisense oligonucleotide or a transcriptional inhibitor or activator.
XX The antisense oligonucleotides and modulators of NEPHA transcription are
XX useful for inducing apoptosis for the treatment and/or prevention of
XX cancers in which NEPHA is overexpressed such as lung cancer, ovarian
XX cancer, breast cancer, cervical cancer, prostate cancer, bladder cancer,
XX stomach cancer and colorectal cancer. Sequences ADM76038-ADM76371
XX represent transcription factor binding sites within the transcriptional
XX control region of the NEPHA gene.
XX
XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 13.8; DB 1; Length 18;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 993 GGTGCCATGGATGATGG 1009
XX Db 1 GTTCCCATGGATGATGG 17
XX
XX RESULT 437
XX ADM06884/C
XX ID ADM06884 standard; DNA; 18 BP.
XX
XX AC ADM06884;
XX
XX XX 17-JUN-2004 (first entry)
XX
XX Mouse Hnf4 exon 8/10 reverse RT-PCR primer.
XX
XX Glycosylated PNA monomer; peptide nucleic acid; PNA; antisense;
XX targeting; uptake; cell-specific; tissue-specific;
XX pharmacokinetic behaviour; infection; bacterial; viral; protozoal;
XX fungal; cancer; metabolic disease; cardiovascular disease;
XX autoimmune disorder; immunological disorder; disinfectant; antibacterial;
XX virucide; protozoacide; fungicide; cytostatic; immunosuppressive; mouse;
XX murine; hepatocyte nuclear factor 4alpha; Hnf4; splice pattern;
XX exon skipping; reverse transcription-PCR; RT-PCR; primer; ss.
XX
XX OS Mus sp.
XX
XX WO2004024757-A2.
XX
XX 25-MAR-2004.
XX
XX 11-SEP-2003; 2003WO-DK000588.
XX
XX 11-SEP-2002; 2002DK-00001334.
XX
XX 19-NOV-2002; 2002DK-00001786.
XX
XX 20-DEC-2002; 2002DK-00001956.
XX
XX 16-APR-2003; 2003DK-00000600.
XX

```

```

XX PA (SANT-) SANTARIS PHARMA AS.
XX PI Rasmussen P, Frandsen NM, Nyborg M, Rasmussen FW, Hamzavi R;
XX PI Nielsen PE, Kjaerulff S;
XX DR WPI; 2004-329446/30.
XX PT Novel modified peptide nucleic acid monomer, useful for treating
XX PT bacterial, viral, and fungal infections, cancer and cardiovascular
XX PT disease.
XX PS Example 65; Page 84; 112pp; English.
XX CC The invention relates to glycosylated peptide nucleic acid (PNA)
XX CC monomers. The glycosylated PNA monomers may be incorporated into
XX CC antisense PNA oligomers to improve the cell and/or organ-specific uptake
XX CC of PNAs and hence their pharmacokinetic behaviour. The PNA monomers and
XX CC PNA oligomers constructed using them are useful in the treatment or
XX CC prevention of bacterial, viral, protozoal and fungal infections, cancer,
XX CC metabolic diseases, cardiovascular diseases, autoimmune and immunological
XX CC disorders. They are also useful for disinfecting non-living objects, such
XX CC as tools used in surgery and dentistry and equipment used in
XX CC slaughterhouses, in the dairy industry, and in the hair and beauty
XX CC industries. In an example of the invention, mice were treated with
XX CC glycosylated PNA oligomers (ADM06878-ADM06879) which alter the splice
XX CC pattern of Hnf4 (hepatocyte nuclear factor 4alpha) pre-mRNA. Sequences
XX CC ADM06880-ADM06884 represent reverse transcription-PCR (RT-PCR) primers
XX CC used to analyse Hnf4 mRNA from tissue samples from the mice to determine
XX CC whether exons had been skipped.
XX SQ Sequence 18 BP; 2 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 332 GAGTGGCTCCAGAAC 348
Db 18 GAGTGGCTCCGAGAGC 2

RESULT 438
ADO26612/C
XX AC ADO26612;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic leader sequence encoding DNA SEQ ID NO:5.
XX KW phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX OS Synthetic.
XX PN WO2004042059-A1.
XX PD 21-MAY-2004.
XX PF 10-NOV-2003; 2003WO-AU001487.
XX PR 08-NOV-2002; 2002US-0425163P.
XX PA (UYQU ) UNIV QUEENSLAND.
XX PI Frazer IH;
XX DR WPI; 2004-411519/38.
XX DR P-PSDB; ADO26613.
XX PT Constructing synthetic polynucleotide for modulating the quality of a
XX PT selected phenotype displayed by an organism comprises replacing a first

```

---

```

PT codon with a synonymous codon to construct the synthetic polynucleotide.
XX Example 1; SEQ ID NO 5; 86pp; English.
XX PS The present invention describes a method for constructing a synthetic
XX CC polynucleotide from which a polypeptide is producible to confer a
XX CC selected phenotype to an organism of interest or part in a different
XX CC quality than that conferred by a parent polynucleotide that encodes the
XX CC same polypeptide. The method comprises: (a) selecting a first codon of
XX CC the parent polynucleotide for replacement with a synonymous codon, where
XX CC the synonymous codon is selected on the basis that it exhibits a
XX CC different phenotypic preference than the first codon in a comparison of
XX CC phenotypic preferences in test organisms or parts, where the test
XX CC organism are selected from organisms of the same species as the organism
XX CC of interest and organisms that are related to the organisms of interest;
XX CC and (b) replacing the first codon with the synonymous codon to construct
XX CC the synthetic polynucleotide. Also described: (1) a method for
XX CC determining the phenotypic preference of a first codon in an organism of
XX CC interest or its parts; (2) a synthetic polynucleotide constructed from
XX CC the method above; (3) an organism of interest or part containing a
XX CC synthetic polynucleotide constructed from the method above; (4) an
XX CC organism of interest or part containing a synthetic construct that
XX CC comprises a regulatory polynucleotide operably linked to a tandem repeat
XX CC of a first codon fused in frame with a reporter polynucleotide that
XX CC encodes a reporter protein, which produces, or is predicted to produce a
XX CC selected phenotype or a phenotype of the same class as the selected
XX CC phenotype in the organism or part; (5) a method of modulating the quality
XX CC of a selected phenotype that is displayed by an organism of interest or
XX CC part and that results from the expression of a parent polynucleotide that
XX CC encodes the polypeptide; (6) a method of enhancing the quality of a
XX CC selected phenotype that is displayed by an organism of interest or part
XX CC and that results from the expression of a parent polynucleotide that
XX CC encodes the polypeptide; and (7) a method of reducing the quality of a
XX CC selected phenotype that is displayed by an organism of interest or part
XX CC and that results from the expression of a parent polynucleotide that
XX CC encodes the polypeptide. The method is useful for constructing a
XX CC synthetic polynucleotide from which a polypeptide is producible to confer
XX CC a selected phenotype to an organism of interest or part in a different
XX CC quality than that conferred by a parent polynucleotide that encodes the
XX CC same polypeptide. It is useful for modulating the quality of a selected
XX CC phenotype displayed by an organism or part. The present sequence encodes
XX CC a synthetic leader sequence, which is used in an example from the present
XX CC invention.
XX SQ Sequence 18 BP; 0 A; 6 C; 12 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 CGCTCCGTCGCGCGCG 46
Db 18 CGCGCGCGCGCGCGCG 2

RESULT 439
ADO26628
XX ID ADO26628 standard; DNA; 18 BP.
XX AC ADO26628;
XX DT 12-AUG-2004 (first entry)
XX DE Synthetic leader sequence encoding DNA SEQ ID NO:21.
XX KW phenotype; phenotypic preference; phenotype modulation; leader; ds.
XX OS Synthetic.
XX PN WO2004042059-A1.
XX PD 21-MAY-2004.
XX PT

```

PF 10-NOV-2003; 2003WO-AU001487.  
 XX 08-NOV-2002; 2002US-0425163P.  
 PR (UYQU ) UNIV QUEENSLAND.  
 XX Frazer IH;  
 XX WPI; 2004-411519/38.  
 XX P-PSDB; ADO26629.  
 XX  
 XX Constructing synthetic polynucleotide for modulating the quality of a  
 PT selected phenotype displayed by an organism comprises replacing a first  
 PT codon with a synonymous codon to construct the synthetic polynucleotide.  
 XX  
 XX Example 1; SEQ ID NO 21; 86pp; English.  
 PS  
 XX The present invention describes a method for constructing a synthetic  
 CC polynucleotide from which a polypeptide is producible to confer a  
 CC selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. The method comprises: (a) selecting a first codon of  
 CC the parent polynucleotide for replacement with a synonymous codon, where  
 CC the synonymous codon is selected on the basis that it exhibits a  
 CC different phenotypic preference than the first codon in a comparison of  
 CC phenotypic preferences in test organisms or parts, where the test  
 CC organism are selected from organisms of the same species as the organism  
 CC of interest and organisms that are related to the organisms of interest;  
 CC and (b) replacing the first codon with the synonymous codon to construct  
 CC the synthetic polynucleotide. Also described: (1) a method for  
 CC determining the phenotypic preference of a first codon in an organism of  
 CC interest or its parts; (2) a synthetic polynucleotide constructed from  
 CC the method above; (3) an organism of interest or part containing a  
 CC synthetic polynucleotide constructed from the method above; (4) an  
 CC organism of interest or part containing a synthetic construct that  
 CC comprises a regulatory polynucleotide operably linked to a tandem repeat  
 CC of a first codon fused in frame with a reporter polynucleotide that  
 CC encodes a reporter protein, which produces, or is predicted to produce a  
 CC selected phenotype or a phenotype of the same class as the selected  
 CC phenotype in the organism or part; (5) a method of modulating the quality  
 CC of a selected phenotype that is displayed by an organism of interest or  
 CC part and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; (6) a method of enhancing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; and (7) a method of reducing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide. The method is useful for constructing a  
 CC synthetic polynucleotide from which a polypeptide is producible to confer  
 CC a selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. It is useful for modulating the quality of a selected  
 CC phenotype displayed by an organism or part. The present sequence encodes  
 CC a synthetic leader sequence, which is used in an example from the present  
 XX invention.  
 XX  
 XX Sequence 18 BP; 0 A; 12 C; 6 G; 0 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 30 CGCCTCCGTCGCCGCCG 46  
 Db 1 CGCCGCCGCCGCCGCCG 17  
 RESULT 440  
 ADP27776/C  
 ID ADP27776 standard; DNA; 18 BP.  
 XX  
 AC ADP27776;  
 10-NOV-2003; 2003WO-AU001487.  
 XX 08-NOV-2002; 2002US-0425163P.  
 PR (UYQU ) UNIV QUEENSLAND.  
 XX Frazer IH;  
 XX WPI; 2004-411519/38.  
 XX P-PSDB; ADO26629.  
 XX  
 XX Constructing synthetic polynucleotide for modulating the quality of a  
 PT selected phenotype displayed by an organism comprises replacing a first  
 PT codon with a synonymous codon to construct the synthetic polynucleotide.  
 XX  
 XX Example 1; SEQ ID NO 21; 86pp; English.  
 PS  
 XX The present invention describes a method for constructing a synthetic  
 CC polynucleotide from which a polypeptide is producible to confer a  
 CC selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. The method comprises: (a) selecting a first codon of  
 CC the parent polynucleotide for replacement with a synonymous codon, where  
 CC the synonymous codon is selected on the basis that it exhibits a  
 CC different phenotypic preference than the first codon in a comparison of  
 CC phenotypic preferences in test organisms or parts, where the test  
 CC organism are selected from organisms of the same species as the organism  
 CC of interest and organisms that are related to the organisms of interest;  
 CC and (b) replacing the first codon with the synonymous codon to construct  
 CC the synthetic polynucleotide. Also described: (1) a method for  
 CC determining the phenotypic preference of a first codon in an organism of  
 CC interest or its parts; (2) a synthetic polynucleotide constructed from  
 CC the method above; (3) an organism of interest or part containing a  
 CC synthetic polynucleotide constructed from the method above; (4) an  
 CC organism of interest or part containing a synthetic construct that  
 CC comprises a regulatory polynucleotide operably linked to a tandem repeat  
 CC of a first codon fused in frame with a reporter polynucleotide that  
 CC encodes a reporter protein, which produces, or is predicted to produce a  
 CC selected phenotype or a phenotype of the same class as the selected  
 CC phenotype in the organism or part; (5) a method of modulating the quality  
 CC of a selected phenotype that is displayed by an organism of interest or  
 CC part and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; (6) a method of enhancing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide; and (7) a method of reducing the quality of a  
 CC selected phenotype that is displayed by an organism of interest or part  
 CC and that results from the expression of a parent polynucleotide that  
 CC encodes the polypeptide. The method is useful for constructing a  
 CC synthetic polynucleotide from which a polypeptide is producible to confer  
 CC a selected phenotype to an organism of interest or part in a different  
 CC quality than that conferred by a parent polynucleotide that encodes the  
 CC same polypeptide. It is useful for modulating the quality of a selected  
 CC phenotype displayed by an organism or part. The present sequence encodes  
 CC a synthetic leader sequence, which is used in an example from the present  
 XX invention.  
 XX  
 XX Sequence 18 BP; 0 A; 12 C; 6 G; 0 T; 0 U; 0 Other;  
 SQ  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 30 CGCCTCCGTCGCCGCCG 46  
 Db 1 CGCCGCCGCCGCCGCCG 17  
 RESULT 440  
 ADP27776/C  
 ID ADP27776 standard; DNA; 18 BP.  
 XX  
 AC ADP27776;  
 26-AUG-2004 (first entry)  
 PCR primer to amplify a human cancer prognostic marker DNA SeqID 213.  
 human; primer; PCR; prognostic marker; EGFR;  
 epidermal growth factor receptor; cancer; gene expression profiling;  
 microarray; head and neck cancer; colon cancer; metastatic spread;  
 neoplastic disease; ss.  
 Homo sapiens.  
 W02004046386-A1.  
 03-JUN-2004.  
 14-NOV-2003; 2003WO-US036777.  
 15-NOV-2002; 2002US-0427090P.  
 (GENO-) GENOMIC HEALTH INC.  
 (VALL-) VALL HEBRON UNIV HOSPITAL.  
 Baker JB, Cronin MT, Shak S, Baselga J;  
 WPI; 2004-420643/39.  
 Prognosing a patient with EGFR-expressing colon cancer comprises  
 subjecting a sample comprising EGFR-expressing cancer cells to  
 quantitative analysis of the expression level of the RNA transcript of at  
 least one gene e.g., CD44v3.  
 Claim 54; SEQ ID NO 213; 113pp; English.  
 This invention relates to a novel method concerning prognostic markers  
 associated with EGFR (epidermal growth factor receptor) positive cancer.  
 Specifically, it refers to a gene expression profiling method that can  
 provide a prediction as to whether a patient is likely to respond well to  
 treatment with an EGFR inhibitor. The present invention describes the  
 quantitative analysis of the expression level of the RNA transcript of at  
 least one gene selected from the group of CD44v3, CD44v6, DR5, GR01,  
 KRT17, LAMC2 or their products thereof. It further provides a cDNA  
 microarray containing named genes that represent prognostic transcripts  
 which are useful for determining whether a patient diagnosed with an EGFR  
 -expressing head or neck cancer or colon cancer exhibits elevated or  
 decreased expression levels of these genes compared to normal. As such,  
 these methods are also useful for prognosing or predicting the likelihood  
 of cancer-attributable death or progression, including recurrence and  
 metastatic spread of a neoplastic disease, as well as drug resistance.  
 This oligonucleotide sequence is a PCR primer used to amplify a human PCR  
 amplicon DNA sequence used as a prognostic cancer marker, given in an  
 exemplification of the invention.  
 Query Match 0.7%; Score 13.8; DB 1; Length 18;  
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 673 TGAAGCTGCCAAGGTG 689  
 Db 17 TGGCAGCTGCCCAGGTG 1  
 RESULT 441  
 ADP08680/C  
 ID ADP08680 standard; DNA; 18 BP.  
 XX  
 AC ADP08680;  
 XX 26-AUG-2004 (first entry)  
 DE Extend primer 17 used to genotype human glycoprotein VI polymorphism.

```

XX breast cancer; cytostatic; gene therapy; human; platelet glycoprotein VI;
KW GP6; GPIV; GPIV; chromosome 19q13.4; ss; PCR; primer; SNP;
KW single nucleotide polymorphism.
XX Homo sapiens.
XX OS
XX WO2004047767-A2.
XX PN
XX PD
XX 10-JUN-2004.
XX XX
XX .25-NOV-2003; 2003WO-US037966.
XX PF
XX 25-NOV-2002; 2002US-0429136P.
XX PR
XX 24-JUL-2003; 2003US-0490234P.
XX XX
XX (SEQU-) SEQUENOM INC.
XX PA
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX PI
XX WPI; 2004-441082/41.
XX DR
XX Identifying a subject at risk of breast cancer by detecting the presence
XX PT or absence of one or more nucleotide polymorphic variations, useful for
XX PT diagnosing, preventing and/or treating breast cancer.
XX XX
XX Example 3; Page 82; 286pp; English.
XX PS
XX The invention relates to a novel method for identifying a subject at risk
XX CC of breast cancer which comprises detecting the presence or absence of one
XX CC or more polymorphic variations associated with breast cancer in a nucleic
XX CC acid sample from a subject. The method of the invention has cytostatic
XX CC applications and may be useful for identifying a risk of breast cancer,
XX CC as well as therapeutic and prophylactic treatments that specifically
XX CC target breast cancer, such as gene therapy. The current sequence is that
XX CC of an extend primer of the invention which was used to genotype single
XX CC nucleotide polymorphisms within human glycoprotein VI (platelet) (GP6;
XX CC GPIV/GPIV) DNA which is located at chromosomal position 19q13.4.
XX CC
XX Sequence 18 BP; 3 A; 3 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 910 CTGTAGCAGATCACT 926
Db ||| ||||| |||||
18 CTGAAGCAGACATCACT 2

RESULT 442
ADQ78196/c
ID ADQ78196 standard; DNA; 18 BP.
XX AC
XX ADQ78196;
XX AC
XX 09-SEP-2004 (first entry)
XX DT
XX PCR primer used to amplify cancer related genes for biochip SeqID 878.
XX DE
XX mini-sequencing; Cpg island; methylation specific PCR; MSP;
XX KW multiplex MSP PCR; cancer; PCR; primer; ss; microarray chip.
XX KW
XX Unidentified.
XX OS
XX KR2003069752-A.
XX PN
XX 27-AUG-2003.
XX PD
XX 07-MAY-2002; 2002KR-00025108.
XX PF
XX 20-FEB-2002; 2002KR-00009132.
XX PR
XX XX

(PA (GOOD-) GOODGENE INC.
XX Choi HI, Bom TH, Jun BI, Kim OH, Mun UC, Oh MY, Song MG;
XX PI
XX WPI; 2004-095256/10.
XX DR
XX Minisequencing type oligonucleotide chip for detecting methylation of
XX PT promoter CpG islands of multiple genes, useful for detecting cancer.
XX PT
XX Claim 13; SEQ ID NO 878; 248pp; Korean.
XX PS
XX This invention relates to a novel mini-sequencing type DNA
XX CC oligonucleotide chip. Specifically, it refers to a chip that is useful
XX CC for detecting methylation of promoter CpG islands occurring in multiple
XX CC genes. The present invention describes using oligonucleotide primers to
XX CC determine the position of a target gene and promoter CpG islands, this
XX CC constitutes treating DNA of the target gene with sodium bisulfite in
XX CC order to carry out methylation specific (MSP) PCR or multiplex MSP PCR to
XX CC amplify the sodium bisulfite treated DNA and sequencing the PCR product
XX CC to confirm the hypomethylation site of the promoter CpG islands of
XX CC multiple genes. Accordingly, the chip comprises primer sequences designed
XX CC from these PCR products that have amine linkers of 12 carbons attached to
XX CC the 5'-terminal, which are spotted onto the glass slide coated with 3-
XX CC aminopropyltrimethoxylan and 1,4-diisothiocyanate using an array robot.
XX CC The resulting minisequencing chip is useful for detecting cancer, thereby
XX CC accurately and rapidly detecting methylation of CpG islands of multiple
XX CC genes. This oligonucleotide sequence is a PCR primer given in an
XX CC exemplification of the invention.
XX CC
XX Sequence 18 BP; 1 A; 0 C; 1 G; 16 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1835 AAAAAAAAAAAAAA 1851
Db ||||| ||||| |||||
18 AAAAAACAAATAAAAA 2

RESULT 443
ADP84638
ID ADP84638 standard; DNA; 18 BP.
XX AC
XX ADP84638;
XX AC
XX 09-SEP-2004 (first entry)
XX DT
XX Human breast-specific gene-related PCR primer #4.
XX DE
XX human; breast-specific protein; breast cancer; PCR; primer; ss.
XX KW
XX Homo sapiens.
XX OS
XX WO2004053077-A2.
XX PN
XX 24-JUN-2004.
XX PD
XX 05-DEC-2003; 2003WO-US038815.
XX PF
XX 05-DEC-2002; 2002US-0431123P.
XX PR
XX (DIAD-) DIADEXUS INC.
XX PA
XX Macina RA, Turner LR, Sun Y, Chen H, Rodriguez M;
XX PI
XX WPI; 2004-468848/44.
XX DR
XX New breast specific nucleic acid molecules and polypeptides useful for
XX PT diagnosing, preventing or treating breast cancer, for producing
XX PT transgenic animals or cells, or for research purposes.
XX PT
XX Example 2b; SEQ ID NO 237; 521pp; English.
XX PS

```

XX The invention comprises the amino acid and coding sequences of human  
CC breast-specific proteins. The DNA and protein sequences of the invention  
CC are useful for the diagnosis, treatment and prevention of breast cancer.  
CC The present DNA sequence represents a PCR primer that was used in an  
CC example of the invention.  
XX Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Oy 680 TGCCAAGGTGGGGCTT 696  
Db 2 TGCCAAGGTGGCAGCTT 18  
RESULT 444  
AD000170/C  
ID ADR00170 standard; DNA; 18 BP.  
XX AC ADR00170;  
XX 21-OCT-2004 (first entry)  
DT EGFR PCR reverse primer, SEQ ID 208.  
XX DE Breast cancer; human; ss; PCR; primer; EGFR.  
XX KW Homo sapiens.  
XX OS WO2004065583-A2.  
XX PN 05-AUG-2004.  
XX PD 14-JAN-2004; 2004WO-US000985.  
XX PF 15-JAN-2003; 2003US-0440861P.  
XX PR (GENO-) GENOMIC HEALTH INC.  
XX PA (UTRU-) UNIV RUSH MEDICAL CENT.  
XX PI Cobleigh MA, Shak S, Baker JB, Cronin MT;  
XX WPI; 2004-593480/57.  
XX DR Predicting likelihood of long-term survival of a breast cancer patient  
XX PT without the recurrence of breast cancer by determining the expression  
XX PT level of prognostic RNA transcripts or their expression products in a  
XX PT breast cancer tissue sample.  
XX PS Claim 33; SEQ ID NO 208; 125pp; English.  
XX CC The present invention relates to a method for predicting the likelihood  
CC of long-term survival of a breast cancer patient without the recurrence  
CC of breast cancer. The method comprises determining the expression level  
CC of one or more prognostic RNA transcripts or their expression products in  
CC a breast cancer tissue sample obtained from the patient. The prognostic  
CC RNA transcript is the transcript of one or more genes, e.g. TP53BP2,  
CC GRB7, PR, CD68, Bcl2, KRT14, IRS1, CTSL, ESR1, Chk1, IGFBP2, BAG1,  
CC CEGP1, STK15, GSTM1, FHIT, RIZ1, AIB1, SURV, BBC3, IGFBP2, p27, GATA3,  
CC ZNF217, EGFR, CD9, MYBL2, HIF1alpha, p52, ErbB3, TOP2B, MDM2, RAD51C,  
CC KRT19, TS, Her2, KLK10, beta-Catenin, gamma-Catenin, MCM2, PI3KC2A, IGFB1,  
CC TBP, CNB1, FBX05, or DR5, where expression of one or more of GRB7, CD68,  
CC CTSL, Chk1, AIB1, CNB1, MCM2, FBX05, Her2, STK15, SURV, EGFR, MYBL2,  
CC HIF1alpha, or TS indicates a decreased likelihood of long-term survival  
CC without breast cancer recurrence, and where the expression of one or more  
CC of TP53BP2, PR, Bcl2, KRT14, ESR1, IGFBP2, BAG1, CEGP1, KLK10, beta-  
CC Catenin, gamma-Catenin, DR5, PI3KCA2, RAD51C, GSTM1, FHIT, RIZ1, BBC3,  
CC TBP, p27, IRS1, IGFB1, GATA3, ZNF217, CD9, p52, ErbB3, TOP2B, MDM2, IGFB1,  
CC or KRT19 indicates an increased likelihood of long-term survival without  
CC breast cancer recurrence. The present sequence is a PCR primer used to

CC amplify one such prognostic gene of the invention.  
XX Sequence 18 BP; 4 A; 7 C; 5 G; 2 T; 0 U; 0 Other;  
SQ  
Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Oy 673 TGGGAAGCTGCCAAGGTG 689  
Db 17 TGGCAGCTGCCCAGGTG 1  
RESULT 445  
ADS90224/C  
ID ADS90224 standard; DNA; 18 BP.  
XX AC ADS90224;  
XX 18-NOV-2004 (first entry)  
DT Oligonucleotide of the invention SEQ ID NO:1240.  
XX DE ss; cell proliferative disorder; breast; methylation; cytostatic;  
XX KW gene therapy; single nucleotide polymorphism; SNP.  
XX OS Unidentified.  
XX PN WO2004035803-A2.  
XX PD 29-APR-2004.  
XX PF 01-OCT-2003; 2003WO-EP010881..  
XX PR 01-OCT-2002; 2002DE-01045779.  
XX PR 07-JAN-2003; 2003DE-01000096.  
XX PR 17-APR-2003; 2003DE-01017955.  
XX PA (SPIG-) EPIGENOMICS AG.  
XX PI Foekens J, Harbeck N, Koenig T, Maier S, Martens J, Model P;  
XX PI Nimmrich I, Rujan T, Schmitt A, Schmitt M, Look MP, Marx A;  
XX WPI; 2004-348468/32.  
XX DR Predicting responsiveness of a subject with breast cell proliferative  
XX PT disorder, useful for treating or differentiating breast cell  
XX PT proliferative disorders comprises analyzing methylation pattern of a  
XX PT genomic DNA from the subject.  
XX PS Disclosure; SEQ ID NO 1240; 104pp; English.  
XX CC The invention relates to a novel method for predicting the responsiveness  
CC of a subject with a cell proliferative disorder of the breast tissues to  
CC a therapy comprising analysing the methylation pattern of a target  
CC nucleic acid by contacting at least one of the target nucleic acids in a  
CC biological sample obtained from the subject prior to or during treatment.  
CC The method of the invention has cytostatic activity, and may have a use  
CC in gene therapy. The set of oligonucleotides comprising at least two of  
CC the oligomers are useful for detecting the cytosine methylation state  
CC and/or single nucleotide polymorphisms (SNPs) within the sequences. The  
CC methods, nucleic acid, oligonucleotide, and kit are useful for the  
CC treatment, characterization, classification and/or differentiation, of  
CC breast cell proliferative disorders. The method is also useful for  
CC predicting the responsiveness of a subject with a cell proliferative  
CC disorder of the breast tissues to a therapy. The present sequence is used  
CC in the exemplification of the invention.  
XX SQ Sequence 18 BP; 5 A; 0 C; 5 G; 8 T; 0 U; 0 Other;  
XX CC  
Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1617 TTCAAGCACAACCTCTA 1633  
Db 18 TTCAAAACACATCTCTA 2

RESULT 446  
ADR97984  
ID ADR97984 standard; DNA; 18 BP.  
XX ADR97984;  
DT 02-DEC-2004 (first entry)  
XX Human APC DNA fragment containing deletion at codon 1306.  
DE db; chromosomal abnormality; detection; foetus; translocation;  
XX transversion; monosomy; trisomy; aneuploidy; deletion; addition;  
KW amplification; prenatal diagnosis; SNP; single nucleotide polymorphism;  
KW human; chromosome 5q21-22; adenomatous polyposis coli; mutation.  
XX

OS Homo sapiens.  
OS Synthetic.  
XX WO2004079011-A1.  
XX 16-SEP-2004.  
XX 29-AUG-2003; 2003WO-US027308.  
XX 28-FEB-2003; 2003WO-US006198.  
XX (RAVG-) RAVGEN INC.  
XX Dhallan R;  
XX WPI; 2004-677127/66.  
XX Detecting a chromosomal abnormality, e.g. translocations, transversions,  
PT monosomes, trisomies, aneuploidies, deletions, or arrangements, comprises  
PT determining the sequence of alleles of a locus of interest in the sample  
PT from template DNA.  
XX Example 7; Page 155; 429pp; English.  
XX

This invention describes a novel method for detecting a chromosomal  
CC abnormality in a sample which comprises determining the sequence of  
CC alleles of a locus of interest in a sample from template DNA where  
CC determining the sequence of the alleles comprises amplifying the locus of  
CC interest, hybridising the amplified loci to GeneChip array, washing  
CC GeneChip array, staining the GeneChip array with detectable reagents, and  
CC scanning GeneChip array. The amplification method is self-sustained  
CC sequence reaction, ligase chain reaction, rapid amplification of cDNA  
CC ends, PCR and ligase chain reaction, Q-beta phage amplification, strand  
CC displacement amplification, or splice overlap extension PCR, preferably  
CC PCR. The determination of the sequence of the alleles comprises  
CC amplifying the locus of interest, fragmenting the amplicon, hybridising  
CC fragmented amplicons to CodeLink Arrays, extension reaction to  
CC incorporate a nucleotide and detecting incorporated nucleotides. The  
CC amplicon fragmentation is by exonuclease digestion. Detecting a  
CC chromosomal abnormality in a sample comprises determining the sequence of  
CC alleles of a locus of interest from template DNA, where determining the  
CC determination of the sequence of the alleles may also be done by  
CC amplifying the locus of interest, dephosphorylation of the unused  
CC reagents, in vitro transcription reaction of the products, RNase A  
CC cleavage of the products, mixing the products with CleanResin,  
CC transferring products to SpectroCHIP, and analysing the SpectroCHIP. The  
CC dephosphorylation reaction is with shrimp alkaline phosphatase.  
CC Alternatively, the determination of the sequence of the alleles comprises  
CC amplifying the locus of interest, dephosphorylation of the unused  
CC reagents, hybridising a primer to the locus of interest, incorporating a  
CC nucleotide, mixing the products with CleanResin, transferring products to

CC SpectroCHIP, and analysing the SpectroCHIP. The hybridisation of primer  
CC is adjacent to the locus of interest. The determination of the sequence  
CC of the alleles may also comprise amplifying the locus of interest,  
CC treating the products with exonuclease, single stranded DNA is annealed  
CC to an oligonucleotide, incorporating a nucleotide using the annealed  
CC template and primer, and detecting the incorporated nucleotide. The  
CC method is useful for detecting a chromosomal abnormality in a sample.  
CC Specifically, the method is useful for detecting chromosomal  
CC abnormalities in a fetus including translocations, transversions,  
CC monosomes, trisomies, and other aneuploidies, deletions, additions,  
CC amplifications, and arrangements. The method of the invention can also be  
CC used for prenatal diagnosis. This sequence represents a fragment of the  
CC human adenomatous polyposis coli (APC) gene which contains a nucleotide  
CC deletion.  
XX

SQ Sequence 18 BP; 12 A; 0 C; 3 G; 3 T; 0 U; 0 Other;  
Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 201 GAAATAAAAGAGAAAT 217  
Db 1 GAAATAAAAGAGAAAGAT 17

RESULT 447  
ADS08668  
ID ADS08668 standard; DNA; 18 BP.  
XX ADS08668;  
XX 02-DEC-2004 (first entry)  
XX Human DNA oligonucleotide #157.  
XX Human; nucleic acid detection; cell lysis; chromosomal abnormality;  
KW cancer; carcinoma; bladder; breast; bronchus; colon; kidney; liver; lung;  
KW oesophagus; gall bladder; ovary; pancreas; stomach; cervix; thyroid;  
KW prostate; skin; small cell lung cancer; squamous cell carcinoma;  
KW leukaemia; lymphoma; myelodysplastic syndrome; fibrosarcoma;  
KW rhabdomyosarcoma; astrocytoma; neuroblastoma; glioma; schwannoma;  
KW melanoma; seminoma; teratocarcinoma; osteosarcoma; ds.  
XX Homo sapiens.  
OS Synthetic.  
XX WO2004078994-A2.  
XX 16-SEP-2004.  
XX 01-MAR-2004; 2004WO-US006337.  
XX 28-FEB-2003; 2003WO-US006198.  
XX (RAVG-) RAVGEN INC.  
XX Dhallan R;  
XX WPI; 2004-662434/64.  
XX Detecting presence or absence of nucleic acid, containing mutation,  
PT involves isolating nucleic acid from sample containing cell lysis  
PT inhibitor, and detecting presence or absence of nucleic acid.  
XX Example 7; Page 164; 440pp; English.  
XX The invention relates to a method for detecting a nucleic acid, involving  
CC isolating a nucleic acid from a sample, where an agent that impedes cell  
CC lysis was added to the sample, and detecting the presence or absence of  
CC the nucleic acid. The invention also relates to a method for detecting  
CC chromosomal abnormalities in a DNA sample and determining the sequence of  
CC foetal DNA from a sample of a pregnant female. The nucleic acid contains



at least one mutation chosen from a single point mutation, multiple point mutations, an insertion, a frameshift, a truncation, a deletion, a duplication and a transversion. The method is useful for detecting a nucleic acid in a sample obtained from a source chosen from bacteria, viruses, fungi, mycobacteria, protozoa, molds, yeasts, plants, humans, non-humans, multi-cellular parasites, animals and archaeobacteria. The method is useful for detecting, diagnosing or monitoring a disease such as cancer chosen from carcinoma of the bladder, breast, bronchus, colon, kidney, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate and skin, small cell lung cancer, squamous cell carcinoma, haematopoietic tumours of lymphoid lineage, leukaemia, acute lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, Burkett's lymphoma, haematopoietic tumours of myeloid lineage, acute and chronic myelogenous leukaemias, myelodysplastic syndrome and promyelocytic leukaemia, tumours of mesenchymal origin, fibrosarcoma and rhabdomyosarcoma, tumours of the central and peripheral nervous system, astrocytoma, neuroblastoma, glioma and schwannomas, melanoma, seminoma, teratocarcinoma and osteosarcoma. The method is also useful for monitoring response to treatment chosen from surgery, radiation, lifestyle change, dietary protocol and supplementary and administration of a drug. The drug is chosen from chemotherapeutic agents, anti-bacterial agents, anti-viral agents, anti-fungal agents, targeted-cancer drugs, cytotoxic agents, cytostatic agents and anti-proliferative agents. This sequence represents a DNA oligonucleotide used in the scope of the invention.

Sequence 18 BP; 12 A; 0 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 13.8; DB 1; Length 18;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 201 GAAATAAAGAGAAAT 217  
DB 1 GAAATAAAGAGAAAT 17  
|||||

# RESULT 448

AAS95939

ID AAS95939 standard; DNA; 15 BP.

AC AAS95939;

DT 26-FEB-2002 (first entry)

DE Human CALM1 gene allele-specific oligonucleotide #48.

XX Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;

KW haplotyping; SCYA3; Alzheimer's disease; drug screening;

KW calcium-dependent signal transduction; PCR primer; ss.

XX Homo sapiens.

XX WO200179218-A2.

XX 25-OCT-2001.

XX 09-APR-2001; 2001WO-US011509.

XX 12-APR-2000; 2000US-0196340P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;

XX WPI; 2002-049190/06.

XX New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in  
PT expressing CALM1 protein for use in screening for candidate drugs to  
PT treat diseases related to CALM1 activity such as Alzheimer's disease.

PS Claim 15; Page 13; 82pp; English.

XX

CC The invention relates to an isolated polynucleotide comprising a sequence  
CC selected from a polymorphic variant of calmodulin 1 (CALM1). The  
CC polymorphic variant comprises an CALM1 isogene defined by a haplotype  
CC selected from haplotypes 1-21 given in the specification. The  
CC polymorphisms are useful for studying the biological function of CALM1 as  
CC well as in identifying drugs targeting this protein for the treatment of  
CC a disorder related to its abnormal expression or function. The  
CC polymorphic variants may also be used in screening for compounds  
CC targeting CALM1 to treat a specific condition or disease predicted to be  
CC associated with CALM1 activity. Establishing CALM1 haplotype or haplotype  
CC pair of an individual is useful for improving the efficiency and  
CC reliability of several steps in the discovery and development of drugs  
CC for treating diseases associated with SCYA3 activity, e.g. Alzheimer's  
CC disease and diseases involving defects in calcium-dependent signal  
CC transduction. Haplotyping the CALM1 gene in an individual is also useful  
CC in the design of clinical trials of candidate drugs for treating a  
CC specific condition or disease predicted to be associated with CALM1  
CC activity. AAS95892-AAS96018 represent human CALM1 allele-specific  
CC oligonucleotides and PCR primers of the invention  
XX

Sequence 15 BP; 1 A; 3 C; 10 G; 0 T; 0 U; 1 Other;

Query Match 0.7%; Score 13.6; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.7e+02;

Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 661 CGCAGGGGGCGGTG 674

DB 2 CGCAGGGGGCGGTG 15

Search completed: July 12, 2005, 10:40:15

Job time : 11 secs

**THIS PAGE BLANK (USPTO)**